{"columns":["registry_id","brief_title","acronym","overall_status","study_type","phases","allocation","masking","enrollment","conditions","interventions","lead_sponsor","start_date","primary_completion_date","has_results","primary_outcomes","reference_pmids","document_urls","ipd_sharing","secondary_ids"],"rows":[["NCT06885736","LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy","LEAN-PREP","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","232","Obesity","BEHAVIORAL:Resistance exercise; DIETARY_SUPPLEMENT:Protein Intake","Dasman Diabetes Institute","2025-08-07","2029-08-30","FALSE","MRI measured quadriceps cross sectional area (CSA) [From enrollment (at baseline) to the end of treatment at 6 months.]","BACKGROUND:28698222; BACKGROUND:19927027; BACKGROUND:33951361; BACKGROUND:22777332; BACKGROUND:21540423; BACKGROUND:37330638; DERIVED:42020128",null,"YES",null],["NCT00672399","Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","70","Healthy Subjects","DRUG:exenatide; DRUG:Moxifloxacin; DRUG:Placebo","AstraZeneca","2008-04","2008-07","FALSE","Comparison of exenatide's effect on QT interval when compared to placebo [single doses - measurements at 1, 2, 3, 4, 5.5 and 10 hours after dosing]",null,null,null,null],["NCT01429506","Efficacy of Laparoscopic Sleeve Gastrectomy and Intensive Medical Management in Obese Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","30","Diabetes Mellitus; Obesity","PROCEDURE:Sleeve gastrectomy; DRUG:Intensive medical management","Post Graduate Institute of Medical Education and Research, Chandigarh","2011-01","2012-08","FALSE","weight loss [6 months]",null,null,null,null],["NCT07861100","A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity","AMBIENCE","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","8500","Cardiovascular Risk; Obesity","DRUG:Zenagamtide; DRUG:Placebo","Novo Nordisk A/S","2026-10-26","2030-09-16","FALSE","Time from randomization to first occurrence of a 4-point (P) composite major adverse cardiovascular events (MACE) endpoint consisting of: Cardiovascular (CV) death, Non-fatal MI, Non-fatal stroke, HF hospitalization or urgent HF visit [From baseline (week 0) to up to 203 weeks or longer]",null,null,"YES","OTHER:U1111-1335-0048; OTHER:2026-525182-53"],["NCT07605247","Tirzepatide in the Treatment of Endometrial Cancer","TREAT-EC","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2",null,"NONE","30","Endometrial Cancer","DRUG:Tirzepatide; DEVICE:LNG-IUD plus tirzepatide","Rutgers, The State University of New Jersey","2026-06-01","2028-01","FALSE","Quality of Life Quality of life will be measured through PROMs at the time points listed below for explorative purposes. [● Screening (day -30 to Week 0) ● 3 months (Visit 4, Week 12) ● 6 months (Visit 7, Week 24) ● 9 months (Visit 10, Week 36)]",null,null,null,null],["NCT06901648","A Study of HS-20094 in Patients With T2DM",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","275","Type 2 Diabetes","DRUG:HS-20094; DRUG:Dulaglutide; DRUG:Palcebo","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2024-02-06","2025-03-07","FALSE","The change of HbA1c in the patients [From baseline to week 32]",null,null,null,null],["NCT07468552","Trial of Tirzepatide for the Treatment of Cannabis Use Disorder",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","100","Cannabis Use Disorder","DRUG:Tirzepatide; DRUG:Placebo","National Institute on Drug Abuse (NIDA)","2026-11-15","2028-03-15","FALSE","Maximum Tolerated Dose (MTD) [24 weeks (Treatment Phase)] | Days of Abstinence [24 weeks (Treatment Phase)]",null,null,"UNDECIDED",null],["NCT06269107","A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)","COMBINE 4","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","485","Type 2 Diabetes","DRUG:IcoSema; DRUG:Insulin glargine","Novo Nordisk A/S","2024-02-15","2025-05-27","FALSE","Change in glycated haemoglobin (HbA1c) [From baseline (week 0) to week 40]","DERIVED:42594928",null,"YES","OTHER:U1111-1283-8648; OTHER:2022-502484-38-00"],["NCT02717858","A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","52","Metabolism and Nutrition Disorder; Obesity","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2016-03-16","2017-02-27","FALSE","Maximum postprandial gallbladder ejection fraction (GBEFmax) [At 12 weeks (visit 9)]","RESULT:29892986",null,null,"EUDRACT_NUMBER:2014-004772-38; OTHER:U1111-1163-4641; NIH:2014"],["NCT07326111","A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese","PERIODS","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","198","Polycystic Ovary Syndrome (PCOS); Obesity & Overweight","DRUG:Tirzepatide as an adjunct to lifestyle intervention; DRUG:Placebo as an adjunct to lifestyle intervention","University of Bonn","2025-12-09","2028-12","FALSE","Improvement of ovarian dysfunction as defined by menstrual irregularity in overweight or obesity-related PCOS [At 72 weeks after randomization] | Key Secondary - Improvement of ovarian dysfunction as defined by ovulation frequency in overweight or obesity-related PCOS [Within 24 weeks after completed dose titration]",null,null,"YES","CTIS:2024-515982-32-00"],["NCT00254800","The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy Females",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","38","Type 2 Diabetes Mellitus","DRUG:ethinyl estradiol and levonorgestrel; exenatide","AstraZeneca","2005-11","2006-08","FALSE","Assessment of Pharmacokinetics profile of exenatide measured by AUC and Cmax [Day 8 and Day 22 of each treatment period hours of sampling: Predose, 0.5, 1,1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6,8, 10, 12, 16, 24, 48]","DERIVED:22429273",null,null,null],["NCT00775684","Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","47","Pre-diabetes; Type 2 Diabetes","DRUG:Exenatide; DRUG:Sitagliptin; DRUG:Glimepiride","University of Pennsylvania","2008-10","2012-11","TRUE","Effect on Functional Beta-cell Mass as Determined by Change in ß-cell Secretory Capacity at 6 Months (μU/ml) [Baseline and 6 months] | Effect on Functional Beta-cell Mass as Determined by Change in ß-cell Secretory Capacity at 6 Months (pg/mL) [Baseline and 6 months]","BACKGROUND:9727886; BACKGROUND:7589820; BACKGROUND:12502499; BACKGROUND:16505537; BACKGROUND:11549624; BACKGROUND:15249997; BACKGROUND:6384269",null,"NO",null],["NCT07760948","HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide","PRESERVE-HMB","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","90","Type 2 Diabetes Mellitus (T2DM); Sarcopenia; Obesity; Muscle Loss; Older Adults","DIETARY_SUPPLEMENT:Calcium-HMB Plus Vitamin D3; OTHER:Matching placebo","Vanderbilt University Medical Center","2026-12-01","2029-11-30","FALSE","Change in Appendicular Lean Mass [Baseline to month 6]",null,null,"YES","OTHER_GRANT:9-26-ICTS-1434"],["NCT06478563","A Research Study Looking at Different Oral Formulations and the Effect of Food Intake on How the Medicine NNC0487-0111 Behaves in the Body of Participants Living With Overweight or Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","SINGLE","133","Obesity; Overweight","DRUG:NNC0487-0111 (formulation D); DRUG:NNC0487-0111 (formulation C)","Novo Nordisk A/S","2024-06-27","2025-06-05","FALSE","Phase A: The area under the NNC0487-0111 plasma concentration-time curve during a dosing interval at steady state [From pre-dose to after dosing on days 21, 42, 63, 84, 105 and 126]",null,null,"YES","OTHER:U1111-1300-3720"],["NCT03985384","Semaglutide Treatment On Coronary Progression","STOP","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","140","Type 2 Diabetes; Coronary Artery Disease","DRUG:Semaglutide 2 MG/1.5 ML Subcutaneous Solution; DRUG:Placebo","Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","2019-04-30","2022-12-27","FALSE","Rate of change in non-calcified plaque volume [12 months]",null,null,null,null],["NCT05254158","A Research Study of How NNC0174-0833 Behaves in Chinese Volunteers Who Are Normal Weight, Overweight or With Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","24","Overweight and Obesity","DRUG:NNC0174 0833","Novo Nordisk A/S","2022-03-03","2022-09-07","FALSE","AUC0-∞, NNC0174-0833: The area under the NNC0174-0833 plasma concentration-time curve from time 0 to infinity after a single dose [From pre-dose (Day 1) to Visit 7 (Day 36)]",null,null,"YES","OTHER:U1111-1247-7538"],["NCT07845578","A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body Weight",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","60","Obesity; Overweight","DRUG:Semaglutide; DRUG:Placebo semaglutide; DRUG:Paracetamol","Novo Nordisk A/S","2026-09-25","2027-09-11","FALSE","AUC,para: The area under the paracetamol plasma concentration-time curve following a standardised meal [Day 177]",null,null,"YES","OTHER:U1111-1335-9563; OTHER:2026-526083-20"],["NCT02443155","A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","308","Diabetes; Diabetes Mellitus, Type 1","DRUG:NNC0114-0006; DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2015-11-10","2018-08-31","TRUE","Area Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Tolerance Test (MMTT) Stimulated C-peptide at Week 54 Relative to Baseline [0 - 4 hours post-dose on week 0 and week 54]","RESULT:33662334","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/55/NCT02443155/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/55/NCT02443155/SAP_001.pdf",null,"EUDRACT_NUMBER:2014-001215-39; OTHER:U1111-1154-7172; REGISTRY:REec-2015-1768; NIH:2014"],["NCT00516048","An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","NON_RANDOMIZED","NONE","58","Type 2 Diabetes Mellitus","DRUG:exenatide","AstraZeneca","2007-08","2008-04","TRUE","Treatment-emergent Antibody Status (Maximum Titer Level Experienced) [24 weeks] | Incidence of Potentially Immune-related Treatment-emergent Adverse Events [24 weeks]",null,null,null,null],["NCT07855133","A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1",null,"NONE","60","Overweight; Obesity; Type 2 Diabetes","DRUG:Semaglutide; DRUG:Zenagamtide","Novo Nordisk A/S","2026-09-30","2028-09-06","FALSE","Number of treatment emergent adverse events (TEAE) [From first administration of zenagamtide day 1 to day 57]",null,null,"YES","OTHER:U1111-1335-9523"],["NCT03645408","The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers",null,"TERMINATED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","8","Alcohol Use Disorder","DRUG:Exenatide; OTHER:Sham injection","Boston Medical Center","2019-05-02","2021-07-01","TRUE","Alcohol Consumption [2 hours]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/08/NCT03645408/Prot_SAP_000.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/08/NCT03645408/ICF_001.pdf","NO","NIH:R21AA027332-01"],["NCT04666987","A Research Study Looking at Long-term Blood Sugar Control in People With Type 2 Diabetes Being Treated With Xultophy® in a Real-world Setting in Italy",null,"COMPLETED","OBSERVATIONAL",null,null,null,"359","Diabetes Mellitus, Type 2","DRUG:Insulin degludec and liraglutide (IDegLira)","Novo Nordisk A/S","2020-10-21","2022-12-30","FALSE","Change in Glycated Haemoglobin (HbA1c) [From baseline (V0, month 0) to 6 months after initiation.]",null,null,"YES","OTHER:U1111-1253-1809"],["NCT05616052","Comparison of Body Weight Change Through Different Smeglutide Administration Methods",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","80","Weight Change, Body","DRUG:Semaglutide","Huashan Hospital","2022-12-01","2023-12-01","FALSE","weight change in kilograms [16 weeks]","BACKGROUND:34097869; BACKGROUND:10702749; BACKGROUND:28266779",null,"NO",null],["NCT06423599","Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure","FIT-HF","RECRUITING","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","SINGLE","100","Heart Failure With Reduced Ejection Fraction; Obesity; Weight Loss; Chronic Heart Failure","DRUG:Semaglutide Injectable Product; DIETARY_SUPPLEMENT:Calorie-restricted diet","Jens D Hove, MD,PHD","2024-04-30","2027-12-30","FALSE","Peak oxygen uptake [The patients will be examined after 0, 16 and 52 weeks]",null,null,"NO","CTIS:2023-503753-35-01; NIH:2023"],["NCT00039013","Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","336","Diabetes Mellitus, Type 2","DRUG:AC2993; DRUG:Placebo","AstraZeneca","2002-03","2003-06","FALSE","Change in HbA1c (glycosylated hemoglobin) from baseline to study termination (Week 30) [Baseline (Day 1), Week 30]","RESULT:15855572; RESULT:16776749; DERIVED:22913891; DERIVED:22236356",null,null,null],["NCT01687582","Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients",null,"COMPLETED","INTERVENTIONAL",null,null,"NONE","10","Type 2 Diabetes; Psoriasis","DRUG:GLP-1 analog","Cliniques universitaires Saint-Luc- Université Catholique de Louvain","2012-01","2012-12","FALSE","Improvement of PASI score [4 to 6 months]","BACKGROUND:22227407; BACKGROUND:21744074",null,null,null],["NCT03357380","A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","67","Hepatobiliary Disorders; Non-alcoholic Fatty Liver Disease","DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2017-11-28","2020-03-20","FALSE","Change in liver stiffness (kPa) assessed by magnetic resonance elastography (MRE) [Up to day -20, week 48]","RESULT:34570916; DERIVED:33006125",null,"YES","REGISTRY:2017-001193-42; OTHER:U1111-1194-3900; NIH:2017"],["NCT02690883","Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","92","Diabetic Nephropathies","DRUG:Exenatide; DRUG:Lispro","Nanfang Hospital, Southern Medical University","2016-04-08","2019-12-13","FALSE","the percentage change of 24h-UAER(urinary albumin excretion rates) from baseline at Week 24 [from baseline at Week 24]","BACKGROUND:17276798; BACKGROUND:25342915; BACKGROUND:16825327; BACKGROUND:24147203; BACKGROUND:18280439; BACKGROUND:24456114; BACKGROUND:8366922; BACKGROUND:25501571; BACKGROUND:23176216; BACKGROUND:17360951; BACKGROUND:24556697; BACKGROUND:22687869; BACKGROUND:24064677; BACKGROUND:18456920; BACKGROUND:24639403; DERIVED:39963952",null,"UNDECIDED",null],["NCT02016846","Liraglutide Efficacy on Glucocorticoid Induced Hyperglycemia in Patients High Risk for Diabetes",null,"UNKNOWN","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","36","Glucocorticoid Induced Hyperglycemia","DRUG:Liraglutide; DRUG:Placebo","Rabin Medical Center","2014-01","2015-01","FALSE","Glucose levels 2 hours after 75 gr OGTT [6 weeks]",null,null,null,null],["NCT05478603","A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","24","Hepatic Impairment; Healthy Volunteers","DRUG:PF-07081532","Pfizer","2022-08-01","2023-04-05","TRUE","Maximum Plasma Concentration (Cmax) of PF-07081532 [At 0 (prior to dose), 0.5, 1, 2, 4, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96, 120, and 144 hours post dose on Day 1] | Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-07081532 [At 0 (prior to dose), 0.5, 1, 2, 4, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96, 120, and 144 hours post dose on Day 1] | Area Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PF-07081532 [At 0 (prior to dose), 0.5, 1, 2, 4, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96, 120, and 144 hours post dose on Day 1] | Fraction of Unbound Drug in Plasma (Fu) of PF-07081532 [At 0 (prior to dose), 0.5, 1, 2, 4, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96, 120, and 144 hours post dose on Day 1] | Unbound Cmax (Cmax,u) of PF-07081532 [At 0 (prior to dose), 0.5, 1, 2, 4, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96, 120, and 144 hours post dose on Day 1] | Unbound AUCinf (AUCinf,u) of PF-07081532 [At 0 (prior to dose), 0.5, 1, 2, 4, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96, 120, and 144 hours post dose on Day 1] | Unbound AUClast (AUClast,u) of PF-07081532 [At 0 (prior to dose), 0.5, 1, 2, 4, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96, 120, and 144 hours post dose on Day 1]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/03/NCT05478603/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/03/NCT05478603/SAP_001.pdf","NO",null],["NCT06980623","Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction",null,"ACTIVE_NOT_RECRUITING","OBSERVATIONAL",null,null,null,"26000","Type 2 Diabetes; Heart Failure","DRUG:Tirzepatide; DRUG:Semaglutide","Brigham and Women's Hospital","2025-01-01","2025-11-30","FALSE","Hospitalization for heart failure and all-cause mortality [From treatment initiation to end of follow up, up to 48 months.]",null,null,null,null],["NCT05473286","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice","PIONEER REAL","WITHDRAWN","OBSERVATIONAL",null,null,null,"0","Diabetes Mellitus, Type 2","DRUG:Oral Semaglutide","Novo Nordisk A/S","2022-09-30","2024-05-16","FALSE","Change in Glycated haemoglobin (HbA1c ) [From baseline (week 0) to End of Study visit (V3) (week 34-44)]",null,null,"YES",null],["NCT04091373","A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","36","Type 2 Diabetes Mellitus","COMBINATION_PRODUCT:cotadutide multidose pen injection","MedImmune LLC","2019-09-27","2020-03-06","FALSE","Area under the plasma concentration time curve [48 hours]",null,null,"YES",null],["NCT06588283","Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight","TOGETHER-PsO","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","281","Psoriasis; Obesity","DRUG:Ixekizumab; DRUG:Tirzepatide","Eli Lilly and Company","2024-09-30","2026-01-08","FALSE","Percentage of Participants Who Simultaneously Achieved Psoriasis Area and Severity Index (PASI) 100 and At Least 10% Weight Reduction [Baseline to Week 36]","DERIVED:42139049",null,"YES","OTHER:I1F-MC-RHDC"],["NCT05413369","iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","582","Type 2 Diabetes Mellitus","DRUG:Insulin glargine/Lixisenatide; DRUG:IDegAsp; DRUG:Metformin; DRUG:SGLT2 inhibitor","Sanofi","2022-07-07","2023-10-20","TRUE","Change in HbA1c From Baseline to Week 24: Non-Inferiority Analysis [Baseline, Week 24]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/69/NCT05413369/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/69/NCT05413369/SAP_001.pdf","YES","REGISTRY:U1111-1267-2772"],["NCT06965413","A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity","GYMINDA","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","285","Obesity; Overweight; Overweight With One Weight Related Comorbidity","DRUG:RO7204239; DRUG:RO7204239 Matching Placebo; DRUG:Tirzepatide","Hoffmann-La Roche","2025-05-05","2026-09-03","FALSE","Percent Change From Baseline in Body Weight [Baseline, Week 48]",null,null,"YES","REGISTRY:2024-519561-22-00"],["NCT06354660","Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","537","Diabetes Type 2","DRUG:Retatrutide; DRUG:Placebo","Eli Lilly and Company","2024-04-10","2026-01-22","FALSE","Change from Baseline in Hemoglobin A1c (HbA1c) (%) [Baseline, Week 40]","DERIVED:42250575",null,"YES","OTHER:J1I-MC-GZBY"],["NCT04938388","Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care",null,"TERMINATED","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","12","Diabetes Mellitus, Type 2; Glucose Metabolism Disorders (Including Diabetes Mellitus)","DRUG:Semaglutide Pill; DIETARY_SUPPLEMENT:Fresh organic vegetables","Sansum Diabetes Research Institute","2022-01-29","2023-02-16","FALSE","HbA1c < 7.0% [At 50 weeks]",null,null,null,null],["NCT03962010","A Phase 2, 12-Week, Double-Blind, Efficacy and Safety of GX-G6 in Patients With Uncontrolled Type 2 Diabetes Mellitus",null,"UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","78","Type 2 Diabetes Mellitus","DRUG:GX-G6; DRUG:Control","Genexine, Inc.","2019-06-01","2022-06-01","FALSE","Change in HbA1c [Week 12]",null,null,"UNDECIDED",null],["NCT05087342","Latino Semaglutide Study","LSS","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","119","Obesity; Obesity; Drug; Overweight or Obesity; Weight Loss; Weight Loss Trajectory; Weight, Body","DRUG:Semaglutide 2.4mg; DRUG:Placebo","Loma Linda University","2022-12-13","2024-05-29","FALSE","Assessment of weight loss. [Change between baseline and final study visit, seven months post baseline.]",null,null,null,null],["NCT01782261","Incretin Effect on the Immunological Phenotype",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","15","Type 1 Diabetes","DRUG:Liraglutide; DRUG:Saxagliptin","Medical University of Graz","2012-02","2015-02","FALSE","Increase of regulatory FOXP3+ T cells [4 weeks]",null,null,"NO","EUDRACT_NUMBER:2011-006300-12"],["NCT05046873","A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","16","Diabetes Mellitus, Type 2","DRUG:Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL; DRUG:semaglutide 1.34 mg/mL (placebo); DRUG:Semaglutide 1.34 mg/mL; DRUG:NNC0480-0389 A 10 mg/mL","Novo Nordisk A/S","2021-09-06","2022-01-05","FALSE","AUC0-∞,sema,SD: Area under the semaglutide plasma concentration-time curve after a single dose [From baseline (visit 2/12, day 1, pre-dose) until completion of the assessment period (visit 11/21, day 36)] | AUC0-∞,NNC0480-0389,SD: Area under the NNC0480-0389 plasma concentration-time curve after a single dose [From baseline (visit 2/12, day 1, pre-dose) until completion of the assessment period (visit 11/21, day 36)]",null,null,"YES","OTHER:U1111-1266-0502; EUDRACT_NUMBER:2021-001397-36"],["NCT06801015","Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","30","Obesity","DRUG:Semaglutide; DRUG:Tirzepatide; DRUG:Placebo","Mayo Clinic","2025-10-01","2028-01-31","FALSE","Gastric emptying of solids T1/2 min, that is time for half meal to empty from stomach [Measurement at baseline, after 16 and 24 weeks' treatment, and at 28 weeks (off treatment for 4 weeks)] | Body weight [Measurement at baseline, after 16 and 24 weeks' treatment, and at 28 weeks (off treatment for 4 weeks)]",null,null,"NO",null],["NCT03353350","Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise","AMPLITUDE-M","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","406","Type 2 Diabetes Mellitus","DRUG:efpeglenatide (SAR439977); DRUG:placebo","Hanmi Pharmaceutical Company Limited","2017-12-05","2020-01-29","TRUE","Change in Glycated Hemoglobin (HbA1c) (%) [Baseline to Week 30]","DERIVED:35671039","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/50/NCT03353350/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/50/NCT03353350/SAP_001.pdf","NO","OTHER:2016-001857-42; OTHER:U1111-1182-1806; NIH:2016"],["NCT00579150","Exenatide Pregnancy Registry - Type 2 Diabetes in Pregnancy","Exenatide","TERMINATED","OBSERVATIONAL",null,null,null,"7","Birth Defects; Type 2 Diabetes; Preterm Birth",null,"AstraZeneca","2009-01","2016-04","FALSE","Primary Outcome [For each group, primary outcome measure will be assessed among all births, including major birth defects identified during the postnatal period and up to infant age 12 months.]",null,null,null,"OTHER:BCA401"],["NCT03444584","Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","49","Type 2 Diabetes Mellitus","DRUG:MEDI0382; DRUG:Placebo; DRUG:Dapaglifozin; DRUG:Metformin","MedImmune LLC","2018-05-08","2018-12-06","TRUE","Change From Baseline to Day 28 in Plasma Glucose Area Under the Concentration Time-curve From Time 0 to 4 Hours (AUC0-4hrs) as Measured by Mixed-meal Tolerance Test (MMTT) [Zero minutes before and 15, 30, 45, 60, 90, 120, 180, and 240 minutes after consumption of the standardised meal on Day -1 (Baseline) and Day 28] | Percent Change From Baseline to Day 28 in Plasma Glucose AUC0-4hrs as Measured by MMTT [Zero minutes before and 15, 30, 45, 60, 90, 120, 180, and 240 minutes after consumption of the standardised meal on Day -1 (Baseline) and Day 28]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/84/NCT03444584/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/84/NCT03444584/SAP_001.pdf","UNDECIDED","EUDRACT_NUMBER:2017-002817-78; NIH:2017"],["NCT02685852","Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","11","Hyperinsulinemic Hypoglycemia","DRUG:Exenatide; DRUG:Acarbose; DRUG:Exenatide Placebo; DRUG:Acarbose Placebo","University of Minnesota","2016-02","2019-07-22","FALSE","Glucose area under the curve (AUC) following treatment for each 4-hour test period [During the 4-hour test period] | Presence of hypoglycemia [15, 30, 45, 60, 90, 120, 180 and 240 minutes]",null,null,null,null],["NCT04469855","Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®",null,"COMPLETED","OBSERVATIONAL",null,null,null,"3217","Diabetes Mellitus, Type 2","DRUG:semaglutide","Novo Nordisk A/S","2020-07-27","2025-05-12","FALSE","Number of adverse events (AEs) [From baseline (day 0) to end of study (month 36)]",null,null,"YES","OTHER:U1111-1187-9072"],["NCT03987308","Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients",null,"RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","115","Type 2 Diabetic Patients; T2DM (Type 2 Diabetes Mellitus); T2DM","DRUG:Beinaglutide; DRUG:Insulin aspart","Beijing Hospital","2019-07-02","2025-09","FALSE","The proportion of subjects achieving HbA1c <7.0%, no weight increase (≤0 kg), and no hypoglycemia (blood glucose ≤3.9 mmol/L or severe hypoglycemia) after 8 weeks of treatment. [From baseline to the end of treatment at 8 week]",null,null,"NO",null],["NCT05920889","Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies","GALLOP","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","140","Stroke; Stroke, Acute; Stroke, Ischemic; Brain Diseases","DRUG:Semaglutide","Chinese University of Hong Kong","2023-08-01","2024-10-25","FALSE","Change of Modified Rankin Score [Day 90] | Composite Safety Outcome [Day 90]","DERIVED:41392086",null,"NO",null],["NCT06431308","Nutritional Therapy to Incretin-based Anti-obesity Medications in the Management of Gastrointestinal Adverse Events",null,"RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","120","Obesity; Drug","BEHAVIORAL:nutritional intervention","Ariel University","2025-01-30","2026-02-01","FALSE","Gastrointestinal symptoms assessment [Baseline and at the end of the study period (20 weeks)] | Defecation texture [Baseline and at the end of the study period (20 weeks)] | Bowel Movement (BM) frequency [Baseline and at the end of the study period (20 weeks)] | Participants gastrointestinal symptoms report [Baseline, at the end of the study period (20 weeks) and weekly until 20 weeks (for subjective GI symptoms report only)]",null,null,null,null],["NCT07654374","A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","1100","Obesity; Overweight; Chronic Weight Management; Type2 Diabetes Mellitus","DRUG:aleniglipron; DRUG:Placebo","Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics","2026-07-17","2028-09","FALSE","Percent change in body weight from Baseline [Baseline and week 76]",null,null,"YES",null],["NCT07627074","Weight Loss in Adults Using Semaglutide (Real-world Study)",null,"COMPLETED","OBSERVATIONAL",null,null,null,"237211","Overweight; Obesity","DRUG:Semaglutide","Novo Nordisk A/S","2026-05-12","2026-06-15","FALSE","Change in body weight [From index date (day 0) to week 68 (day 476)] | Proportion of individuals achieving a clinically meaningful weight loss [From index date (day 0) to week 68 (day 476)]",null,null,"YES","OTHER:U1111-1338-2016"],["NCT01517555","Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","18","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo; DRUG:paracetamol","Novo Nordisk A/S","2006-10","2007-05","FALSE","Area under the curve of paracetamol [] | Area under the curve of post prandial plasma glucose []","RESULT:21792552; RESULT:21340616; RESULT:23551925; RESULT:26225223",null,null,"EUDRACT_NUMBER:2006-000561-10"],["NCT03987919","A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes","SURPASS-2","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","1879","Type 2 Diabetes","DRUG:Tirzepatide; DRUG:Semaglutide","Eli Lilly and Company","2019-07-30","2021-01-28","TRUE","Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) [Baseline, Week 40]","DERIVED:39531161; DERIVED:38777128; DERIVED:37668888; DERIVED:37526908; DERIVED:37415503; DERIVED:37000390; DERIVED:35489606; DERIVED:35210595; DERIVED:34170647","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/19/NCT03987919/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/19/NCT03987919/SAP_001.pdf","YES","OTHER:I8F-MC-GPGL; EUDRACT_NUMBER:2018-004422-29; NIH:2018"],["NCT05268627","Endoscopic Ultrasound Guided Gastric Botulinum Toxin Injections Versus Glucagon Like Peptide 1 Receptor Agonist in Weight Loss",null,"UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","38","Obesity","DRUG:Liraglutide","Mansoura University","2022-01-27","2023-01-27","FALSE","weight loss [1 year] | Body mass index [1 year] | waist circumference [1 year] | hip circumference [1 year]",null,null,"UNDECIDED",null],["NCT06338553","GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab","GLP-TEP","RECRUITING","INTERVENTIONAL","EARLY_PHASE1","RANDOMIZED","QUADRUPLE","24","Type 1 Diabetes","DRUG:Semaglutide (Rybelsus®); DRUG:Placebo","Vanderbilt University Medical Center","2024-06-12","2027-03","FALSE","Investigate the impact of GLP-1Ra on postprandial glycemia in a pilot study [During the MMTT in which the participant is randomly selected to receive semaglutide (Rybelsus®), glucose level will be checked at timepoints -30, -15, 0, 10, 20, 30, 60, 90, 120, 150, 180, and 240 minutes] | Study the impact of GLP-1Ra on the disposition index (DI) in a pilot study [Based on the glucose and insulin readings obtained at timepoints -30, -15, 0, 10, 20, 30, 60, 90, 120, 150, 180, and 240 min and calculated approximately 1 month following completion of the MMTT once insulin levels in plasma are resulted.] | Determine the impact of GLP-1Ra on endothelial function in a pilot study [During the last 30 minutes of each MMTT, between the 210 and 240 timepoints] | Determine how much GLP-1Ra monotherapy therapy changes the disposition index (DI) in a pilot study of early stage 3 T1DM. [During the MMTT in which the participant is randomly selected to receive semaglutide (Rybelsus®), glucose level will be checked at timepoints -30, -15, 0, 10, 20, 30, 60, 90, 120, 150, 180, and 240 minutes]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/53/NCT06338553/Prot_004.pdf","YES","NIH:R01DK139322"],["NCT02288273","Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","239","Type 2 Diabetes","DRUG:Bydureon; DRUG:Placebo","AstraZeneca","2014-12","2015-08","TRUE","Change in 24-hour Mean Weighted Glucose [Day 27/28]",null,null,null,null],["NCT01077505","An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","16","Diabetes Mellitus, Type 2","BIOLOGICAL:albiglutide; DRUG:Oral contraceptive (Brevicon)","GlaxoSmithKline","2010-03-15","2010-11-24","FALSE","AUC0-24 of norethindrone and ethinyl estradiol after OC alone in Period 1 and after OC with albiglutide in Period 2. [Day 21]","BACKGROUND:23322139; DERIVED:25387217",null,"YES",null],["NCT07557953","A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","120","Overweight; Obesity","DRUG:Cagrilintide; DRUG:Placebo Cagrilintide","Novo Nordisk A/S","2026-04-30","2027-04-13","FALSE","Relative change in total energy intake across ad libitum breakfast, lunch, evening meal and snack box [From baseline (Day 2) to end of treatment (Day 127)]",null,null,"YES","OTHER:U1111-1325-8810; OTHER:2025-524206-15; NIH:2025"],["NCT05691712","A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes","SURPASS-CN-INS","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","257","Diabetes Type 2; Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Disease; Endocrine System Diseases","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2023-02-05","2024-07-01","TRUE","Mean Change From Baseline in HbA1c (Tirzepatide 10 or 15 Milligram [mg]) [Baseline, Week 40]","DERIVED:41167231","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/12/NCT05691712/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/12/NCT05691712/SAP_001.pdf","YES","OTHER:I8F-MC-GPIM"],["NCT03929744","A Study of LY3502970 in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","133","Healthy","DRUG:LY3502970; DRUG:Placebo; DRUG:Atorvastatin; DRUG:Simvastatin; DRUG:Midazolam","Eli Lilly and Company","2019-06-12","2020-11-02","TRUE","Parts A and B: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug [Baseline through Follow-up (up to Day 42)]","DERIVED:38402332","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/44/NCT03929744/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/44/NCT03929744/SAP_001.pdf","NO","OTHER:J2A-MC-GZGA"],["NCT07446998","Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss","PLATEAU","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","239","Obesity & Overweight; Mobility Disability; HOMA-IR","DRUG:Enobosarm; DRUG:Semaglutide (Wegovy) weekly injection","Veru Inc.","2026-03-26","2027-10","FALSE","To determine the effect of enobosarm in combination with semaglutide on total body weight compared to semaglutide alone. [Day 476]",null,null,"NO","OTHER:U1111-1343-2062"],["NCT03757130","Multiple Ascending Dose Study of AMG 598 in Adults With Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","50","Obesity","DRUG:AMG 598; DRUG:Placebo; DRUG:Liraglutide","Amgen","2018-11-26","2019-12-16","TRUE","Number of Participants With Treatment-emergent Adverse Events [207 days] | Number of Participants With TEAEs Due to Laboratory, Electrocardiogram, and Vital Sign Findings [207 days]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/30/NCT03757130/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/30/NCT03757130/SAP_001.pdf","YES",null],["NCT02953665","Safety and Efficacy of Liraglutide in Parkinson's Disease",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","63","Parkinson Disease","DRUG:Liraglutide; DRUG:Placebo","Cedars-Sinai Medical Center","2017-04-03","2022-08-03","TRUE","Change in Unified Parkinson's Disease Rating Scale (UPDRS Part III Motor Examination) During \"OFF\" Time From Baseline to the End of Double-Blind Maintenance Period [From Baseline (Week 0) to end of Maintenance Period (up to 54 weeks)] | Change in the Non-Motor Symptoms Scale (NMSS) Total Score From Baseline to the End of the Double-Blind Maintenance Period [From Baseline (Week 0) to the End of Maintenance Period (up to Week 54)] | Change in the Mattis Dementia Rating Scale (DRS-2) From Baseline to the End of Double-Blind Maintenance Period [From Baseline (Week 0) to the end of Maintenance Period (up to 54 weeks)]","DERIVED:31958096","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/65/NCT02953665/Prot_SAP_000.pdf","NO",null],["NCT05040087","Changing the Natural History of Type 2 Diabetes (\"CHANGE\" Study)","CHANGE","ACTIVE_NOT_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","127","Type 2 Diabetes","OTHER:Intensification of diabetes medication based largely on HbA1c levels; OTHER:Intensification of diabetes medication based on glucose levels","Foundation for Atlanta Veterans Education and Research, Inc.","2021-09-01","2026-12-31","FALSE","EFFECT SIZE [2.75 years (includes 3 month washout)] | β-CELL FUNCTION - PRIMARY OUTCOME #2a [2.75 years (includes 3 month washout)] | β-CELL FUNCTION - PRIMARY OUTCOME #2b [2.75 years (includes 3 month washout)] | β-CELL FUNCTION - PRIMARY OUTCOME #2c. [2.75 years (includes 3 month washout)]","RESULT:25249668","Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/87/NCT05040087/ICF_000.pdf","YES","NIH:1R01DK127083-01A1"],["NCT03878706","The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination",null,"RECRUITING","OBSERVATIONAL",null,null,null,"240","Diabetes Mellitus, Type 2",null,"University of Athens","2017-11-03","2026-12-31","FALSE","Comparison of Global Longitudinal Strain (GLS) difference among treatment groups. [12 months]","RESULT:25869408; RESULT:26696682; RESULT:24144654; RESULT:21430088; RESULT:26371721; RESULT:24323912; RESULT:27299675; RESULT:26180105; RESULT:27295427; RESULT:26378978; RESULT:27651331; RESULT:10029125; RESULT:10421594; RESULT:11641288; RESULT:11358934; RESULT:11742883; RESULT:3965165; RESULT:8403292; RESULT:18497732; RESULT:20139923; RESULT:25660150; RESULT:28096045; RESULT:27787699; RESULT:32133741; DERIVED:42226732; DERIVED:40008510; DERIVED:32326806",null,"UNDECIDED",null],["NCT02660736","Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","59","Diabetes Mellitus, Type 2","DRUG:Albiglutide Liquid Auto-injector; DRUG:Albiglutide Lyophilized DCC Pen Injector; DRUG:Placebo Liquid Auto-injector; DRUG:Placebo Lyophilized DCC Pen injector","GlaxoSmithKline","2016-02","2016-08","FALSE","Area under the plasma concentration-time curve (AUC) from 0 to the last measurable concentration (AUC 0-t) for albiglutide in session 1 and 2 [Predose (0), 24, 48, 72, 96, 120, 216, 312, 480, 672, and 840 hours post-dose in both sessions 1 and 2] | AUC from 0 to infinity (AUC [0-inf]) for albiglutide in session 1 and 2 [Predose (0), 24, 48, 72, 96, 120, 216, 312, 480, 672, and 840 hours post-dose in both sessions 1 and 2] | Peak plasma concentration (Cmax) for albiglutide in session 1 and 2 [Predose (0), 24, 48, 72, 96, 120, 216, 312, 480, 672, and 840 hours post-dose in both sessions 1 and 2]","DERIVED:30063297",null,null,null],["NCT01965509","A PK/PD Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","120","Type 2 Diabetes","DRUG:PEX168 or placebo","Jiangsu HengRui Medicine Co., Ltd.","2012-05","2013-08","FALSE","To assess HbA1C levels after treatment [12 weeks]",null,null,null,null],["NCT06352892","A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","20","Obesity","DRUG:Maridebart Cafraglutide","Amgen","2024-04-25","2024-08-27","FALSE","Maximum Observed Plasma Concentration (Cmax) of Maridebart Cafraglutide [Up to approximately 120 days] | Area Under the Plasma Concentration-time Curve (AUC) from Time Zero to the Last Quantifiable Concentration (AUClast) of Maridebart Cafraglutide [Up to approximately 120 days] | AUC from Time Zero Extrapolated to Infinity (AUCinf) of Maridebart Cafraglutide [Up to approximately 120 days]",null,null,"YES",null],["NCT04384081","A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","SINGLE","37","Healthy","DRUG:BI 456906; DRUG:Placebo","Boehringer Ingelheim","2020-06-01","2020-11-17","FALSE","Cumulative percentage (%) of subjects withdrawn from up-titration by dose escalation scheme. [up to 113 days]",null,null,"NO",null],["NCT06946628","New Triple Therapy in Newly Diagnosed Type 2 Diabetes",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","296","Diabetes Mellitus","DRUG:Group A (triple combination therapy group); DRUG:Group B (standard therapy group)","Sun Yat-sen University","2025-06-01","2028-12-31","FALSE","Diabetic remission rate [6 months after discontinuation of medication]",null,null,"NO",null],["NCT03466021","Effects of Liraglutide in Chronic Obstructive Pulmonary Disease",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","40","Pulmonary Disease, Chronic Obstructive","DRUG:Liraglutide; DRUG:Placebo","Claus Bogh Juhl","2018-01-01","2020-05-31","FALSE","Transition Dyspnea Index (TDI) [40 weeks]","DERIVED:38902794",null,null,null],["NCT07481630","A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain","AMAZE 5","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","400","Obesity; Knee Osteoarthritis (OA)","DRUG:NNC0487-0111; DRUG:Placebo (matched to NNC0487-0111 )","Novo Nordisk A/S","2026-04-13","2028-08-14","FALSE","Relative change in body weight [From baseline (week 0) to (week 80)] | Change in WOMAC Osteoarthritis Index NRS 3.1 (24-hour) (WOMAC) pain score [From baseline (week 0) to (week 80)]",null,null,"YES","OTHER:U1111-1313-6585; OTHER:2024-520444-42"],["NCT03959865","GLP-1 REceptor Agonists and Real World EvIdeNce","GLP-1REWIN","UNKNOWN","OBSERVATIONAL",null,null,null,"6000","Type 2 Diabetes","DRUG:Long-acting GLP-1RA; DRUG:Short-acting GLP-1RA; DRUG:Human-based GLP-1RA; DRUG:Exendin-based GLP-1RA; DRUG:Fixed ratio BI/GLP-1RA combination; DRUG:Flexible BI/GLP-1RA combination","University of Padova","2018-12-19","2019-02-11","FALSE","HbA1c [3-12 months]","BACKGROUND:19444259; BACKGROUND:29221659; BACKGROUND:30291106; BACKGROUND:27717195; BACKGROUND:27717130; DERIVED:31364233",null,"NO",null],["NCT06292065","Gastric Ultrasound To Assess Gastric Contents In Patients On Semaglutide Therapy","GUST","COMPLETED","INTERVENTIONAL",null,null,"NONE","88","Gastroparesis","DIAGNOSTIC_TEST:Point-of-care gastric ultrasound","Nils Vlaeminck","2024-04-16","2025-05-31","FALSE","Prevalence of full stomach [Immediately preoperatively]",null,null,"NO",null],["NCT07165028","A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","SINGLE","4500","Metabolic Dysfunction-Associated Steatotic Liver Disease","DRUG:Tirzepatide; DRUG:Retatrutide; DRUG:Placebo","Eli Lilly and Company","2025-10-15","2030-08","FALSE","Time to First Occurrence of Any Component of the Composite Endpoint for Major Adverse Liver Outcomes (MALO) [Baseline up to Study Completion (about 224 weeks)]",null,null,"YES","CTIS:2025-522674-36-00; OTHER:N1T-MC-MALO; OTHER:N1T-MC-TZ01; OTHER:N1T-MC-RT01; NIH:2025"],["NCT00937079","Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients",null,"COMPLETED","OBSERVATIONAL",null,null,null,"30","Hyperinsulinism; Hypoglycemia; Insulinoma","OTHER:111In-exendin-4 imaging","University Hospital, Basel, Switzerland","2007-11","2011-12","FALSE","Detection of insulinomas, cure rate [one year]","RESULT:18703486; RESULT:19820010",null,null,null],["NCT04269642","SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease",null,"UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","99","Early Parkinson's Disease","DRUG:PT320 2.0mg Placebo; DRUG:PT320 2.0 mg; DRUG:PT320 2.5 mg","Peptron, Inc.","2020-03-19","2021-09-29","FALSE","Change of MDS-UPDRS part 3 score [48 week]",null,null,"NO",null],["NCT06649773","The Experiment of Noiiglutide Injection in Type 2 Diabetes Patients",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","137","Type 2 Diabetes","DRUG:Noiiglutide Injection; DRUG:Noiiglutide Placebo","Jiangsu HengRui Medicine Co., Ltd.","2024-11-06","2025-05-28","FALSE","Changes in glycated hemoglobin (HbA1c) relative to baseline at week 24 in SHR20004 compared to placebo. [Week 26]",null,null,"UNDECIDED",null],["NCT01452451","Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","72","Diabetes Mellitus","DRUG:HM11260C; DRUG:Placebo","Hanmi Pharmaceutical Company Limited","2011-12","2013-06","FALSE","Number of subjects with adverse events as a measure of safety and tolerability [Up to 106 days]",null,null,null,null],["NCT01324505","Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","43","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:placebo; DRUG:Microgyn®","Novo Nordisk A/S","2011-03","2012-01","FALSE","Area under the ethinylestradiol concentration-time curve [in the 24 hour dosing interval] | Area under the levonorgestrel concentration-time curve [in the 24 hour dosing interval]",null,null,null,"OTHER:U1111-1119-2214; EUDRACT_NUMBER:2010-022435-11"],["NCT05708859","Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT","T-PLAQUE","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","120","Type II Diabetes; Atherosclerosis","DRUG:Tirzepatide; DRUG:Placebo","Matthew J. Budoff","2024-01-02","2025-12","FALSE","Reduction of total non-calcified coronary plaque volume [12 months]",null,null,null,null],["NCT07043361","Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipidogram- Role of Baseline Vitamin D Levels","Semaglutide","COMPLETED","OBSERVATIONAL",null,null,null,"5300","Metabolic Disease","DRUG:semaglutide","Hillel Yaffe Medical Center","2023-12-18","2024-12-21","FALSE","relative weight loss measured by BMI [12 months from semaglutide initiation] | glycemic control using Hgb1C [12 months from semaglutide initiation] | lipid control using LDL and TG [12 months from semaglutide initiation]","BACKGROUND:34861016; BACKGROUND:33964002; BACKGROUND:36151309; BACKGROUND:35044569; BACKGROUND:35532859; BACKGROUND:33567185; BACKGROUND:27186364; BACKGROUND:25944304; BACKGROUND:27321586; BACKGROUND:24824430; BACKGROUND:35174649; BACKGROUND:24655583; BACKGROUND:30604598; BACKGROUND:15637289; BACKGROUND:31344685; BACKGROUND:31336940; BACKGROUND:30442233","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/61/NCT07043361/Prot_SAP_001.pdf","NO","OTHER_GRANT:Non applicable"],["NCT01342042","The Safety,Preliminary Pharmacodynamics and Pharmacokinetics Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus","SPPS","UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","36","Type 2 Diabetes","BIOLOGICAL:rExenatide-4","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","2011-03","2011-12","FALSE","To compare treatment arms in terms of change from baseline to endpoint in HbA1c [12 Weeks]","DERIVED:28932995",null,null,null],["NCT05444569","A Study of LY3537021 in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","47","Healthy","DRUG:LY3537021; DRUG:Liraglutide; DRUG:Placebo","Eli Lilly and Company","2022-08-08","2023-02-24","FALSE","Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline up to Week 22]",null,null,"NO","OTHER:J2R-MC-YAAC"],["NCT04126603","Impact of Semaglutide on CD34+ EPC and Fat Derived MSC",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","10","Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Placebos","Sabyasachi Sen","2019-08-01","2023-10-25","TRUE","CD34+ Endothelial Progenitor Cell Number (EPC) Per Mononuclear Cells (MNC) Ratio [First Visit at Baseline and Last Visit at 24 weeks] | CD34+ Endothelial Progenitor Cell Migration (EPC) Against Serum SDF1a Gradient [First Visit at Baseline and Last Visit at 24 weeks] | Gene Expression of CD34+ Endothelial Progenitor Cell Number [First Visit at Baseline and Last Visit at 24 weeks] | CD34+ Endothelial Cell Colony Formation Unit (CFU) [First Visit at Baseline and Last Visit at 24 weeks]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/03/NCT04126603/Prot_SAP_002.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/03/NCT04126603/ICF_003.pdf",null,null],["NCT01940770","Specific Clinical Experience Investigation for Long-term Use of Bydureon.",null,"COMPLETED","OBSERVATIONAL",null,null,null,"1137","Type 2 Diabetes",null,"AstraZeneca","2013-10-18","2019-11-29","FALSE","Adverse event incidence [3 years]",null,null,"NO","REGISTRY:EUPAS18608"],["NCT07064486","A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","152","Type 2 Diabetes (T2DM)","DRUG:BGM0504; DRUG:Semaglutide","BrightGene Bio-Medical Technology Co., Ltd.","2025-07-04","2027-04-30","FALSE","Change From Baseline in Hemoglobin A1c (HbA1c) [Week 0 to Week 24]",null,null,null,null],["NCT00856986","The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","987","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:insulin detemir; DRUG:metformin","Novo Nordisk A/S","2009-03","2010-04","TRUE","Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. [Week 0 (Randomisation), week 26]","RESULT:22584132; RESULT:23746555; RESULT:25504028",null,null,"EUDRACT_NUMBER:2007-005317-19"],["NCT02541734","Effect of Gelofusine on GLP1-receptor Imaging","GLP1-EX-GELO","COMPLETED","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","NONE","12","Diabetes Mellitus, Non-Insulin-Dependent; Diabetes Mellitus","DRUG:Gelofusine; RADIATION:111In-exendin 4 SPECT/CT; DRUG:Placebo","Radboud University Medical Center","2015-08","2017-05","FALSE","Renal uptake as measured by uptake of 111In-exendin-4 on SPECT images and without co-infusion of Gelofusine. [up to 8 months]",null,null,null,"EUDRACT_NUMBER:2014-003006-33; NIH:2014"],["NCT07855900","SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","NON_RANDOMIZED","NONE","350","Obesity","COMBINATION_PRODUCT:Survodutide","Boehringer Ingelheim","2026-11-07","2028-06-25","FALSE","Percent change in body weight from baseline to Week 52 [At baseline and Week 52]",null,null,"YES","REGISTRY:U1111-1339-5379; REGISTRY:2026-527093-36-00"],["NCT07255209","A Study of IBI362 in Chinese Adolescents With Obesity or Overweight",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","180","Adolescents With Obesity or Overweight With Weight-Related Comorbidities","DRUG:Placebo; DRUG:IBI362","Innovent Biologics (Suzhou) Co. Ltd.","2025-12-29","2027-10-31","FALSE","Percent Change from Baseline in BMI [Week 32]",null,null,null,null],["NCT06762600","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","102","Overweight or Obesity","DRUG:HRS-4729 injection; DRUG:HRS-4729 injection placebo; DRUG:HRS9531 injection; DRUG:HRS9531 injection placebo; DRUG:Acetaminophen","Fujian Shengdi Pharmaceutical Co., Ltd.","2025-01-16","2026-03-12","FALSE","Adverse events (AEs) [Screening period up to day 43.]",null,null,"UNDECIDED",null],["NCT00823992","A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","305","Diabetes Mellitus Type 2","DRUG:placebo; DRUG:taspoglutide","Hoffmann-La Roche","2009-01","2010-05","FALSE","Absolute change from baseline in HbA1c [24 weeks]",null,null,null,"OTHER:2008-005809-20; NIH:2008"],["NCT07091734","Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024","TILT-2024","RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","32","Lipodystrophy, Partial","DRUG:Tirzepatide; DRUG:Usual care medications","University of Michigan","2025-09-08","2029-09","FALSE","Change in Body Mass Index (BMI) from baseline in Group A (Tirzepatide-treated) versus Group B (control) at 24 weeks [Baseline, 24 weeks] | Change in Hemoglobin A1c from baseline in Group A (Tirzepatide-treated) versus Group B (control) at 24 weeks [Baseline, 24 weeks]",null,null,"YES",null],["NCT07668336","A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes","ACHIEVE-PEDS","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","170","Diabetes Mellitus, Type 2","DRUG:Orforglipron; DRUG:Dulaglutide","Eli Lilly and Company","2026-09","2030-03","FALSE","Change from Baseline in Hemoglobin A1c (HbA1c) [Baseline, Week 40]",null,null,"YES","OTHER:J2A-MC-GZGY; CTIS:2025-524811-35-00; NIH:2025"],["NCT02879409","HbA1c Variability in Type II Diabetes",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","150","Diabetes Mellitus Type 2","DRUG:Metformin; DRUG:Gliclazide; DRUG:Sitagliptin; DRUG:Liraglutide; DRUG:Pioglitazone; DRUG:Dapagliflozin; DRUG:human insulin","Weill Cornell Medical College in Qatar","2016-11","2023-10-01","FALSE","Determination of the variability of HbA1c (by measurement of standard deviation of HbA1c) between the 2 diabetes treatment thresholds [24-30 months]","BACKGROUND:8366922; BACKGROUND:19549736; BACKGROUND:19672575; BACKGROUND:16801566; BACKGROUND:18539917; BACKGROUND:9742976; BACKGROUND:9742977; BACKGROUND:9732337; BACKGROUND:18539916; BACKGROUND:19092145; BACKGROUND:16004665; BACKGROUND:19246588; BACKGROUND:18040661; BACKGROUND:19651819; BACKGROUND:19496962; BACKGROUND:22580991; BACKGROUND:24812434; BACKGROUND:12020338; BACKGROUND:18784091; BACKGROUND:17490424; BACKGROUND:8455366; BACKGROUND:10938048; BACKGROUND:9886743; BACKGROUND:15921524; BACKGROUND:25538321; BACKGROUND:14694008; BACKGROUND:7997705; BACKGROUND:15189396; BACKGROUND:2106931",null,"NO","OTHER_GRANT:NPRP: 8-315-3-065; OTHER:14-00058; OTHER:15103/15"],["NCT07284511","A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar","TZP","RECRUITING","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","NONE","105","Type 1 Diabetes; Type 1 Diabetes Mellitus; T1D; T1DM; T1DM - Type 1 Diabetes Mellitus","DRUG:Tirzepatide; DEVICE:Tandem Control-IQ Automated Insulin Delivery System (with Dexcom G7 CGM); BEHAVIORAL:Carbohydrate Counting; BEHAVIORAL:No Meal Announcement","McGill University Health Centre/Research Institute of the McGill University Health Centre","2026-05-19","2028-01","FALSE","Daytime Time-in-Range [During the final 6 weeks of the study]","BACKGROUND:27633186; BACKGROUND:11126230; BACKGROUND:29747423; BACKGROUND:21346182; BACKGROUND:27118163; BACKGROUND:34170647; BACKGROUND:39745353; BACKGROUND:39794615; BACKGROUND:29246950; BACKGROUND:31539622; BACKGROUND:31189511; BACKGROUND:27295427; BACKGROUND:34047449; BACKGROUND:38743306; BACKGROUND:39601745; BACKGROUND:35733769; BACKGROUND:27621531; BACKGROUND:18252903; BACKGROUND:37017916; BACKGROUND:30657336; BACKGROUND:31902063",null,"YES",null],["NCT06734312","MAINTAIN (Mucosal AblatIoN Therapy After INcretins)","MAINTAIN","RECRUITING","INTERVENTIONAL",null,null,"NONE","20","Obesity and Obesity-related Medical Conditions; Obesity and Overweight; Obesity Prevention; Obesity Recidivism; GLP-1; Ablation Techniques","DEVICE:Gastric Fundal Mucosal Ablation (GFMA)","Dr. Christopher McGowan","2025-01-01","2026-06","FALSE","Percent Change in Total Body Weight Loss (TBWL) from Baseline [12 months]","BACKGROUND:29476845; BACKGROUND:35441470; BACKGROUND:37445623",null,"UNDECIDED",null],["NCT06777238","A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise","Optimum 1","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","274","Type 2 Diabetes Mellitus (T2DM)","DRUG:GZR18; DRUG:Placebo","Gan & Lee Pharmaceuticals.","2025-01-16","2026-08-07","FALSE","Primary Outcome Measure [Baseline, Week 44]",null,null,"NO",null],["NCT07154238","Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.","OUTSTEP-1","ENROLLING_BY_INVITATION","OBSERVATIONAL",null,null,null,"2546","Obesity","OTHER:No treatment given","Novo Nordisk A/S","2025-09-26","2026-09-30","FALSE","Description of characteristics, including clinical, demographic and physical characteristics, among individuals initiated on injectable semaglutide for weight management [At the time of survey response (Day 1)] | Description of the experience of individuals initiated on injectable semaglutide for weight management through personal perception of physical and mental health and self-reported QoL [At the time of survey response (Day 1)] | Individual-reported change in BMI since initiation [At the time of survey response (Day 1)] | Individual-reported achievement of weight loss goal [At the time of survey response (Day 1)] | Individual-reported change in weight since initiation [At the time of survey response (Day 1)] | Individual-reported changes in daily life since initiation on injectable semaglutide [At the time of survey response (Day 1)]",null,null,"YES","OTHER:U1111-1314-6149"],["NCT05352815","A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec","COMBINE 1","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","1291","Diabetes Mellitus, Type 2","DRUG:IcoSema; DRUG:Insulin icodec","Novo Nordisk A/S","2022-06-01","2024-03-19","TRUE","Change in Glycated Haemoglobin (HbA1c) [Baseline (Week 0), Week 52]","DERIVED:42557064; DERIVED:42306490; DERIVED:40482671","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/15/NCT05352815/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/15/NCT05352815/SAP_001.pdf","YES","OTHER:U1111-1260-8259; EUDRACT_NUMBER:2020-005281-34"],["NCT03672604","A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects","NLY01-H1","COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","96","Safety and Tolerability in Healthy Volunteers","DRUG:NLY01","Neuraly, Inc.","2018-09-19","2019-07-30","FALSE","Treatment-Related Adverse Events [Day 1 through Day 29 (Part A) or Day 57 (Part B)]","BACKGROUND:29892066; DERIVED:30957581",null,"NO",null],["NCT00763815","GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone","GETGOAL-P","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","484","Diabetes Mellitus Type 2","DRUG:Lixisenatide (AVE0010); DRUG:Placebo; DEVICE:Pen auto-injector; DRUG:Pioglitazone; DRUG:Metformin","Sanofi","2008-09","2011-06","TRUE","Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 [Baseline, Week 24]","RESULT:23627775",null,null,"OTHER:EudraCT: 2007-005884-92"],["NCT03191396","Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes","SUSTAIN 10","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","577","Diabetes; Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Liraglutide","Novo Nordisk A/S","2017-06-27","2018-07-09","TRUE","Change in HbA1c [Week 0, week 30]","RESULT:31539622; DERIVED:32193837","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/96/NCT03191396/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/96/NCT03191396/SAP_001.pdf","YES","REGISTRY:2016-004965-22; OTHER:U1111-1190-5868; NIH:2016"],["NCT05714683","Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea",null,"NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"600","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2027-01-31","2027-08-30","FALSE","Number (Incidence) of adverse events (AEs) [From baseline (week 0) to 26 weeks]",null,null,"YES","OTHER:U1111-1243-9500"],["NCT06571383","STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE4",null,"NONE","500","Obesity","DRUG:Semaglutide","Novo Nordisk A/S","2024-09-17","2028-11-15","FALSE","Maintenance of Body Mass Index (BMI) below obesity threshold [From 1.5 years to 3 years]",null,null,"YES","OTHER:U1111-1295-4799; OTHER:2023-508055-40; NIH:2023"],["NCT01836523","The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes","ADJUNCT ONE™","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","1398","Diabetes; Diabetes Mellitus, Type 1","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2013-11","2015-06","TRUE","Change From Baseline in HbA1c (Glycosylated Haemoglobin) [Week 0, week 52] | Change From Baseline in Body Weight [Week 0, week 52] | Change From Baseline in Total Daily Insulin Dose [Week 0, week 52]","RESULT:27506222; DERIVED:39717993; DERIVED:34463425",null,null,"EUDRACT_NUMBER:2012-003580-21; OTHER:U1111-1133-0590"],["NCT02423824","Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists","COGDYS-GLP1","COMPLETED","INTERVENTIONAL","PHASE3","NON_RANDOMIZED","NONE","21","Bipolar Disorder; Major Depressive Disorder","BIOLOGICAL:Liraglutide","University Health Network, Toronto","2015-05","2016-04","FALSE","Executive function [4 weeks]",null,null,null,null],["NCT02467920","Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","349","Type 2 Diabetes Mellitus","DRUG:glargine + exenatide; DRUG:aspart 30","Huazhong University of Science and Technology","2015-08","2017-12","FALSE","the absolute change in HbA1c from baseline to 24-week endpoint of basal insulin glargine combination with exenatide bid vs. switching to aspart30 in type 2 diabetic patients inadequately controlled on premixed human insulin and metformin. [from baseline to 24-week endpoint]",null,null,null,null],["NCT07638592","Tirzepatide-Based Prehabilitation Before Elective Ventral and Incisional Hernia Repair in Patients With Obesity",null,"COMPLETED","OBSERVATIONAL",null,null,null,"91","Obese Adults; Hernia Abdominal Wall; Prehabilitation","DRUG:Tirzepatide prehabilitation","Azienda Sanitaria Locale Napoli 2 Nord","2025-01-01","2026-06-01","FALSE","Feasibility of tirzepatide-based prehabilitation [16 weeks (from initiation of prehabilitation to surgery)]",null,null,"NO",null],["NCT03167411","Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","20","Type2 Diabetes Mellitus","DRUG:Bexagliflozin; DRUG:Exenatide Injection","Theracos","2017-05-24","2017-06-29","TRUE","Cmax (Maximum Observed Plasma Concentration) [Up to 48 hrs] | Tmax (Time of Maximum Observed Plasma Concentration) [Up to 48 hrs] | T1/2 (Apparent Terminal Elimination Half-life) [Up to 48 hrs] | AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity) [Up to 48 hrs]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/11/NCT03167411/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/11/NCT03167411/SAP_001.pdf","NO",null],["NCT04387201","GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response",null,"COMPLETED","INTERVENTIONAL","PHASE4","NON_RANDOMIZED","NONE","23","Glucose Intolerance; Overweight and Obesity; Drug Effect; Adiposity","DRUG:Cyanocobalamin; DRUG:Dulaglutide","The University of Texas Health Science Center, Houston","2020-05-15","2023-10-06","TRUE","Cytokine Interleukin-6 (IL-6) Messenger Ribonucleic Acid (mRNA) Level (From Adipose Tissue) [6 weeks after start of each intervention] | Uncoupling Protein 1 (UCP1) Messenger Ribonucleic Acid (mRNA) Level (From Adipose Tissue) [6 weeks after start of each intervention] | Signal Transducer and Activator of Transcription 3 (STAT3) Band Intensity/Western Blot (From Adipose Tissue) [6 weeks after start of each intervention]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/01/NCT04387201/Prot_SAP_001.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/01/NCT04387201/ICF_002.pdf","YES","NIH:R21DK122234"],["NCT04325581","Laparocopic Sleeve Gastrectomy With or Without Liraglutide in Obese Patients",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","16","Weight Loss","DRUG:Liraglutide 6 MG/ML; DRUG:Placebos","Post Graduate Institute of Medical Education and Research, Chandigarh","2016-08-01","2018-12-31","FALSE","Incretin change [baseline and at 6weeks and 6months after laparoscopic sleeve gastrectomy] | Changes in indices of insulin resistance [baseline and at 6weeks and 6months after laparoscopic sleeve gastrectomy] | Change in pancreatic steatosis [baseline and 6months after laparoscopic sleeve gastrectomy]",null,null,null,null],["NCT04839237","The Effect and the Pharmacogenomics Study of Liraglutide in Obese Patients",null,"WITHDRAWN","INTERVENTIONAL","PHASE2","NON_RANDOMIZED","NONE","0","Obesity","DRUG:Liraglutide; DRUG:Liraglutide;metformin","Xiangya Hospital of Central South University","2017-12-01","2020-12-01","FALSE","Weight Change at 3 months [baseline and 3 months] | Genotype [baseline]",null,null,null,null],["NCT07087795","A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","96","Diabetes Mellitus, Type 1","DRUG:NNC0194-0499; DRUG:Placebo; DRUG:Semaglutide","Novo Nordisk A/S","2025-07-01","2026-09-12","FALSE","Part A: Change in time in range (TIR) 3.9-10.0 mmol/L (70-80 mg/dL) [From baseline (day -14 - -1) to day 36-49 / day 106-119] | Part B: Change in time in range (TIR) 3.9-10.0 mmol/L (70-80 mg/dL) [From baseline (day -14 - -1) to day 92-105 / day 162-175]",null,null,"YES","OTHER:U1111-1315-5122; OTHER:2024-519533-38"],["NCT07027969","Metabolic Surgery for Atrial Fibrillation Elimination","METSAFE","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","100","Atrial Fibrillation; Obesity and Obesity-related Medical Conditions","PROCEDURE:Roux-en-Y Gastric Bypass or Sleeve Gastrectomy; DRUG:Anti-Obesity Medication (AOM) treatment","Ali Aminian","2026-11-01","2029-12-31","FALSE","Relative change in total duration of being in atrial fibrillation (AF) [First 52 weeks of the study]",null,null,"NO",null],["NCT07797101","Body-weight Reduction Effect on Portal Hypertension in Compensated Cirrhosis","B-REACH","NOT_YET_RECRUITING","INTERVENTIONAL",null,null,"NONE","50","Cirrhosis; Portal Hypertension; Fatty Liver Disease; GLP-1","DRUG:Mazdutide injection","The Second Affiliated Hospital of Chongqing Medical University","2026-09-01","2029-05-31","FALSE","Percentage Change in Hepatic Venous Pressure Gradient (HVPG) from Baseline [Baseline (screening, Day -14 to -1) to Week 16 (End of Treatment, Day 112 ± 3 days)]",null,null,"NO",null],["NCT07423481","Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity","SEMAFOLLOW","NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"3000","Obesity & Overweight","OTHER:SEMAFOLLOW questionnaire","Nantes University Hospital","2026-10-01","2027-07-01","FALSE","Describe weight changes during the follow-up period according to patient characteristics. [Baseline]",null,null,"UNDECIDED","OTHER:2026-A00299-42"],["NCT06500429","A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","120","Overweight and Obesity; Healthy","DRUG:NG101; DRUG:Placebo; DRUG:Semaglutide Injectable Product","Neurogastrx, Inc.","2024-06-24","2024-09-04","FALSE","Duration of GI-related adverse events [96 hours following GLP-1 agonist injection] | Severity of GI-related adverse events [96 hours following GLP-1 agonist injection]",null,null,"NO",null],["NCT02608853","Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants",null,"COMPLETED","OBSERVATIONAL",null,null,null,"9999","Diabetes; Diabetes Mellitus, Type 2","OTHER:No treatment given","Novo Nordisk A/S","2015-01","2015-01","FALSE","Incidence of all malignant neoplasms [Follow-up is defined as the period following the date of the qualifying prescription or diagnosis (01 Jan 2008 at the earliest) and will vary depending on when this date occurs. The follow-up study period ends on 31 Dec 2013 (in total up to 6 years)]",null,null,null,"OTHER:U1111-1173-7000"],["NCT04572165","Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data",null,"COMPLETED","OBSERVATIONAL",null,null,null,"194928","Diabetes Mellitus, Type 2","DRUG:Ozempic®; DRUG:Active Comparator; DRUG:Rybelsus®","Novo Nordisk A/S","2021-01-26","2025-11-25","FALSE","Occurrence of first time malignant neoplasm of pancreas [From when semaglutide entered the market in Denmark, Sweden, and Norway (Q3/Q4 2018) until December 31, 2023]",null,null,"YES","OTHER:U1111-1214-6228; REGISTRY:EUPAS37258"],["NCT07567001","A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity","HF-POLARIS","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","5610","Obesity; Heart Failure","DRUG:NNC0487-0111; DRUG:Placebo","Novo Nordisk A/S","2026-05-11","2029-07-23","FALSE","Time to first occurrence of a composite Heart Failure (HF) endpoint consisting of cardiovascular (CV) death [From baseline (week 0) to 165 weeks] | Time to first occurrence of a composite HF endpoint consisting of HF hospitalisation or urgent HF visit [From baseline (week 0) to 165 weeks]",null,null,"YES","OTHER:U1111-1328-2701; OTHER:2025-523717-29; NIH:2025"],["NCT01507389","Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","24","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2006-03","2006-06","FALSE","Area under the Curve (0-infinity) []",null,null,null,"EUDRACT_NUMBER:2005-003027-38; NIH:2005"],["NCT06351748","Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)","SCHOLAR","COMPLETED","OBSERVATIONAL",null,null,null,"34238","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2024-01-02","2024-03-29","FALSE","Change in Haemoglobin A1c (HbA1c) level [From baseline (3 months prior to or on the index date) to 6 months] | Change in HbA1c level [From baseline (3 months prior to or on the index date) to 6 months] | Proportion of participants achieving HbA1c less than (<) 7.0% [At 6 months]","DERIVED:42803912; DERIVED:41848818",null,"YES","OTHER:U1111-1296-3151"],["NCT01785043","Differences in Endothelial Function Amongst Sitagliptin and Liraglutide Users","LAED001","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","13","DIABETES Mellitus Type 2 Not Well Controlled","DRUG:Liraglutide; DRUG:Sitagliptin","Anna Cruceta","2013-03","2014-03","FALSE","Assess the effects on endothelial function of a three month treatment with Liraglutide compared to Sitagliptin. [3months]",null,null,null,null],["NCT07090343","Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement","REVERSE-TAVR","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","826","Aortic Stenosis; Heart Failure","DRUG:Wegovy ®; DRUG:Placebo","Leiden University Medical Center","2026-04-01","2030-09-01","FALSE","CV death, non-fatal myocardial infarction, non-fatal stroke, and hospitalization for HF [From randomization through 12 and 27 months]","BACKGROUND:27633186; BACKGROUND:39222642",null,"NO",null],["NCT07868835","Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","560","Weight Loss","DRUG:VK2735; DRUG:Placebo comparator","Viking Therapeutics, Inc.","2026-10-15","2028-07","FALSE","Percentage change in body weight for participants receiving VK2735 orally once daily [68 weeks]",null,null,"NO",null],["NCT06548490","GLP-1R Agonist Treatment for Opioid Use Disorder",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","200","Opioid Use Disorder; Opioid Abuse and Addiction; Narcotic-Related Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorder; Opioid","DRUG:Semaglutide Pen Injector; DRUG:Placebo","Milton S. Hershey Medical Center","2025-01-27","2027-04-30","FALSE","Number of participants being abstinent from illicit and nonprescribed opioids. [Study week 2] | Number of participants being abstinent from illicit and nonprescribed opioids. [Study week 3] | Number of participants being abstinent from illicit and nonprescribed opioids. [Study week 4] | Number of participants being abstinent from illicit and nonprescribed opioids. [Study week 5] | Number of participants being abstinent from illicit and nonprescribed opioids. [Study week 6] | Number of participants being abstinent from illicit and nonprescribed opioids. [Study week 7] | Number of participants being abstinent from illicit and nonprescribed opioids. [Study week 8] | Number of participants being abstinent from illicit and nonprescribed opioids. [Study week 9] | Number of participants being abstinent from illicit and nonprescribed opioids. [Study week 10] | Number of participants being abstinent from illicit and nonprescribed opioids. [Study week 11] | Number of participants being abstinent from illicit and nonprescribed opioids. [Study week 12] | Number of participants being abstinent from illicit and nonprescribed opioids. [Study week 13]","DERIVED:41168808; DERIVED:40502777",null,"NO","NIH:UH3DA050325"],["NCT05340868","Genetics of the Acute Response to Oral Semaglutide","GAROS","RECRUITING","INTERVENTIONAL",null,null,"NONE","1000","PreDiabetes; Prediabetic State; Obesity","DRUG:Semaglutide Pill","Medical University of Bialystok","2022-09-01","2025-12-31","FALSE","Glycemic measures - change in HbA1c (%) [1 and 3 months] | Body composition - change in body weight (kg) [1 and 3 months]",null,null,"YES",null],["NCT07586150","Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)","LIFETRAIN","NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","140","Severe Mental Illness; Depression / Major Depressive Disorder; Bipolar Disorder (BD); Schizophrenia","DRUG:Semaglutide (SEMA); BEHAVIORAL:Exercise module; BEHAVIORAL:Anti-inflammatory diet module; BEHAVIORAL:Sleep intervention module; BEHAVIORAL:Social prescribing module; DEVICE:Closed-loop transcranial alternating current stimulation (CL-tACS); BEHAVIORAL:Structured lifestyle psychoeducation; DEVICE:Sham CL-tACS","Ludwig-Maximilians - University of Munich","2028-10","2030-07","FALSE","Change in Short Form 36 Health Survey (SF-36) Mental Component Summary (MCS) score [Baseline to Month 3]",null,null,"UNDECIDED","OTHER:U1111-1340-3272"],["NCT04520490","Brain Activation and Satiety in Children 2","BASIC2","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","63","Childhood Obesity","BEHAVIORAL:Family Based Behavioral Treatment; DRUG:Exenatide 2 mg [Bydureon]; DRUG:Placebo","Seattle Children's Hospital","2021-01-28","2025-08-21","FALSE","Change of BMI z-score [Change from drug treatment randomization at week 8 of family-based behavioral treatment (FBT) to end of combined intervention (FBT + drug) at week 24 of FBT]",null,null,"NO",null],["NCT06118008","A Study of HS-20094 in T2DM Participants",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","54","Type 2 Diabetes","DRUG:HS-20094 5mg; DRUG:HS-20094 10mg; DRUG:HS-20094 15mg; DRUG:HS-20094 20mg","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2023-05-31","2024-01-04","FALSE","Incidence of adverse event (AE), serious adverse event (SAE), AE leading to study discontinuation, AE severity and relation with study drug [From Baseline to Day 57.] | The number of participants with changes of laboratory tests blood routine, urine routine, blood biochemistry, coagulation function [From Baseline to Day 57] | The changes ECG examination assessed by PR, R-R, QRS and QTcF [From Baseline to Day 57] | The changes in Blood pressure [From Baseline to Day 57] | Pulse rate [From Baseline to Day 57] | Respiratory rate [From Baseline to Day 57] | Temperature [From Baseline to Day 57]",null,null,"NO",null],["NCT02187250","PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","45","PCOS; Obesity","DRUG:metformin; DRUG:liraglutide; DRUG:roflumilast","University Medical Centre Ljubljana","2014-03","2014-06","FALSE","The main outcome was change in body weight. [Patient's body weight was mesured at the base point and every four weeks during 12 weeks of clinical trial.]","DERIVED:26032655",null,null,null],["NCT07492563","Safety and Effectiveness of Tirzepatide in Patients With Obesity at Hospital de Clínicas, Paraguay",null,"NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"300","Obesity; Type 2 Diabetes Mellitus; Overweight With Comorbidities","DRUG:Tirzepatide (T.G.)","LABORATORIOS INDUFAR","2026-03","2026-10","FALSE","Incidence of Adverse Events [12 months]",null,null,"UNDECIDED",null],["NCT06497049","Open Randomized Study of Comparative Pharmacokinetics and Biosimilarity of GP40221 (GEROPHARM LLC, Russia) and Ozempic®.",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","120","Pharmacokinetics; Safety Issues; Bioequivalence","DRUG:GP40221; DRUG:ozempic","Geropharm","2023-06-30","2024-05-05","FALSE","AUC 0-t [-60, -30, 0 minutes and 2, 4, 8, 10, 12, 16, 24, 36, 48, 60, 72, 96, 144, 192, 240, 288 hours after injection] | Cmax [-60, -30, 0 minutes and 2, 4, 8, 10, 12, 16, 24, 36, 48, 60, 72, 96, 144, 192, 240, 288 hours after injection]",null,null,null,null],["NCT02404376","COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial","COMBAT-MI","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","378","ST Elevation Acute Myocardial Infarction","DRUG:Exenatide; OTHER:Remote Ischemic Conditioning (RIC); DRUG:Placebo","Hospital Universitari Vall d'Hebron Research Institute","2016-03","2019-08","FALSE","Myocardial Infarct Size [3-7 days after pPCI]","BACKGROUND:21920963; RESULT:20189026; RESULT:25240548; RESULT:25449504; DERIVED:37106099",null,null,null],["NCT01966978","The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study","SIMPLE","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","157","Diabetes Mellitus, Type 2; Diabetes","DRUG:Metformin; DRUG:Detemir; DRUG:Liraglutide; DRUG:Insulin Aspart","University of Texas Southwestern Medical Center","2014-11","2017-12","TRUE","Mean Change From Randomization in A1c at Week 26 [Baseline and Week 26]","DERIVED:31803482","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/78/NCT01966978/Prot_SAP_000.pdf",null,null],["NCT05218915","Basal Plus GLP1-ra on Glycemic Variability in CKD",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","95","Diabetes Mellitus; Diabetic Kidney Disease","DRUG:Dulaglutide; DRUG:Insulin Degludec; DEVICE:Continuous glucose monitor","Elaine Chow","2022-01-28","2024-10-30","FALSE","Glycemic variability [16 weeks]",null,null,"NO",null],["NCT01237119","Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis","LEAN","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","52","Nonalcoholic Steatohepatitis","DRUG:Liraglutide; OTHER:Liraglutide-placebo","University of Birmingham","2010-08","2014-07","FALSE","Liver Histological improvement [48 weeks]","BACKGROUND:24189085; RESULT:26608256; RESULT:26394161",null,null,"REGISTRY:ISRCTN85774727"],["NCT07713992","Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","72","Type 2 Diabetes Mellitus (T2DM); Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus","DRUG:Mazdutide(Dual GLP-1R/GCGR Agonist); DRUG:Semaglutide (1 Mg Dose)","Tianjin Medical University","2026-09-15","2027-12-31","FALSE","Absolute change in liver fat content measured by MRI-PDFF [Baseline, Week 16, Week 32] | Absolute change in liver fat content measured by liver transient elastography [Baseline, Week 16, Week 32]","BACKGROUND:28733905; BACKGROUND:34713962; BACKGROUND:20957001; BACKGROUND:31405212; BACKGROUND:23999198; BACKGROUND:40802944; BACKGROUND:34310013; BACKGROUND:33880754; BACKGROUND:40491239; BACKGROUND:39431379; BACKGROUND:29221645; BACKGROUND:18726585; BACKGROUND:35013484; BACKGROUND:31604171; BACKGROUND:39809974",null,"NO",null],["NCT03923114","Imaging Pituitary ActiVation by Exendin","iPAVE","COMPLETED","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","20","Diabetes Mellitus, Type 2","RADIATION:Ga-68-NODAGA-exendin-4 PET/CT","Radboud University Medical Center","2019-05-23","2024-04-03","FALSE","Pituitary uptake of Ga-68-NODAGA-exendin [1.5 year]",null,null,"NO",null],["NCT01791465","Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults",null,"TERMINATED","INTERVENTIONAL","PHASE4",null,"NONE","6","Human Immunodeficiency Virus Infection; Diabetes Mellitus","DRUG:extended-release exenatide","Vanderbilt University","2013-03","2014-12","TRUE","Serum Highly-sensitive C-reactive Protein (hsCRP) Levels at Baseline and 16 Weeks [baseline and 16 weeks] | Serum Interleukin 6 (IL-6) at Levels at Baseline and 16 Weeks [baseline and 16 weeks]",null,null,"NO","NIH:P30AI054999"],["NCT04311411","A Study of Tirzepatide in Overweight and Very Overweight Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","114","Obesity; Overweight","DRUG:Tirzepatide; DRUG:Placebo; DRUG:Liraglutide","Eli Lilly and Company","2020-08-24","2022-12-16","TRUE","Change From Baseline in Calorie Intake in Participants Receiving Tirzepatide or Placebo at Week 3 [Baseline, Week 3]","DERIVED:40555748","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/11/NCT04311411/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/11/NCT04311411/SAP_001.pdf","NO","OTHER:I8F-MC-GPHH"],["NCT06565871","A Study of HRS9531 Injection in Obese Subjects With Obstructive Sleep Apnea",null,"UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","108","Weight Management","DRUG:HRS9531 Injection; DRUG:Placebo Injection","Fujian Shengdi Pharmaceutical Co., Ltd.","2024-08","2025-12","FALSE","Percentage change from baseline in body weight [Baseline,32week]",null,null,"UNDECIDED",null],["NCT06672172","A Study of HRS-7535 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Diet and Exercise","OUTSTAND-1","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","284","Type 2 Diabetes","DRUG:HRS-7535 tablet; DRUG:HRS-7535 placebo tablet","Shandong Suncadia Medicine Co., Ltd.","2024-09-25","2025-11-13","FALSE","Change from baseline in HbA1c at 32 weeks of treatment [at 32 weeks]","DERIVED:42811187",null,"UNDECIDED",null],["NCT07173712","Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","324","Type 2 Diabetes","DRUG:CSII; DRUG:Insulin glargine /lixisenatide Fixed Ratio Combination; DRUG:Insulin Degludec and Insulin Aspart Injection; DRUG:Insulin Glargine (HOE901 - U300); DRUG:Metformin","Yanbing Li","2026-03-15","2027-06-30","FALSE","Proportion of subjects with optimal glycemic control [24 weeks]",null,null,null,null],["NCT01789957","Extension Study for 2993-112",null,"COMPLETED","INTERVENTIONAL","PHASE3",null,"NONE","225","Type 2 Diabetes Mellitus","DRUG:AC2993","AstraZeneca","2002-09","2004-06","FALSE","Change in HbA1c from Day 1 of Protocol 2993-112 to Week 52 (or termination) [Day 1 of study 2993-112 through extension study termination (up to Week 52)] | Change in body weight from Day 1 of Protocol 2993-112 to Week 52 (or termination) [Day 1 of study 2993-112 through extension study termination (up to Week 52)]",null,null,null,null],["NCT06099067","Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)","HARRP","COMPLETED","OBSERVATIONAL",null,null,null,"239990","Type 2 Diabetes Mellitus","DRUG:Canagliflozin; DRUG:DPP4 inhibitor; DRUG:Liraglutide; DRUG:Saxagliptin; DRUG:2nd generation Sulfonylurea","AstraZeneca","2020-05-15","2023-08-31","FALSE","3-point MACE [Follow up begins the day after drug initiation for the three investigated studies [a median of 134-167 days]]",null,null,"YES",null],["NCT03018665","A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","200","Diabetes Mellitus, Type 2","DRUG:Exenatide; DRUG:BIAsp30; DRUG:Metformin","The First Hospital of Jilin University","2017-02","2021-12","FALSE","Rate of Inducing Diabetes Remission [At the end of 12-week treatment] | Change of Rate of Maintaining Diabetes Remission [3,6,12,24,36 months after 12-week treatment] | Time of Maintaining Diabetes Remission [up to 36 months after 12-week treatment]",null,null,null,null],["NCT06925334","A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus","TLI vs PMI","ENROLLING_BY_INVITATION","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","170","Type 2 Diabetic Patients","DRUG:Degludec insulin","Beijing Tsinghua Chang Gung Hospital","2024-05-20","2025-12-31","FALSE","Time to blood glucose compliance [From the time of enrollment and signing of informed consent, the program started when blood glucose was controlled at 7.5 mmol/l for 14 days]",null,null,"NO",null],["NCT04624672","Treatment of GLP-1 for Diabetic Bariatric Patients","NOVO-GLP1","TERMINATED","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","3","Diabetes Mellitus, Type 2","DRUG:Semaglutide (1 Mg Dose); DRUG:Placebo","Geisinger Clinic","2021-08-25","2022-07-18","TRUE","RATE OF PARTIAL REMISSION OF DIABETES [11 months]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/72/NCT04624672/Prot_SAP_000.pdf","NO","OTHER:U1111-1242-4068"],["NCT06987695","Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease","MARITIME-3-J","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","279","Obesity Disease","DRUG:Maridebart cafraglutide; DRUG:Placebo","Amgen","2025-06-13","2027-04-27","FALSE","Percent Change From Baseline in Body Weight at Week 72 [Baseline and Week 72] | Participants Achieving ≥ 5% Reduction in Body Weight From Baseline at Week 72 [Baseline and Week 72]",null,null,"YES",null],["NCT03745937","A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","20","Type 2 Diabetes Mellitus","DRUG:MEDI0382; DRUG:Placebo","MedImmune LLC","2019-01-07","2019-05-28","TRUE","Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) Through the End of the Up-titration Period [Baseline (Day -1) through Day 56 (end of Up-titration period)] | Number of Participants With TEAEs and TESAEs Through the End of the Follow-up Period [Baseline (Day-1) through 28 days post last dose (end of follow-up period; approximately up to 5 months)] | Number of Participants With Abnormal Electrocardiograms (ECGs) Reported as TEAEs Through the End of the Up-titration Period [Baseline (Day -1) through Day 56 (end of Up-titration period)] | Number of Participants With Abnormal ECGs Reported as TEAEs Through the End of the Follow-up Period [Baseline (Day-1) through 28 days post last dose (end of follow-up period; approximately up to 5 months)] | Number of Participants With Abnormal Vital Signs Reported as TEAEs Through the End of the Up-titration Period [Baseline (Day -1) through Day 56 (end of Up-titration period)] | Number of Participants With Abnormal Vital Signs Reported as TEAEs Through the End of the Follow-up Period [Baseline (Day-1) through 28 days post last dose (end of follow-up period; approximately up to 5 months)] | Number of Participants With Abnormal Physical Examinations Reported as TEAEs Through the End of the Up-titration Period [Baseline (Day -1) through Day 56 (end of Up-titration period)] | Number of Participants With Abnormal Physical Examinations Reported as TEAEs Through the End of the Follow-up Period [Baseline (Day-1) through 28 days post last dose (end of follow-up period; approximately up to 5 months)] | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs Through the End of the Up-titration Period [Baseline (Day -1) through Day 56 (end of Up-titration period)] | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs Through the End of the Follow-up Period [Baseline (Day-1) through 28 days post last dose (end of follow-up period; approximately up to 5 months)]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/37/NCT03745937/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/37/NCT03745937/SAP_001.pdf",null,null],["NCT07184086","A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","80","Obesity","DRUG:CagriSema (Cagrilintide B + semaglutide I); BEHAVIORAL:Low Energy Diet","Novo Nordisk A/S","2025-09-26","2027-10-12","FALSE","Change in sleeping metabolic rate (SMR) [Baseline (Week 0) to Week 20]",null,null,"YES","OTHER:U1111-1316-8299"],["NCT07092605","Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures",null,"ENROLLING_BY_INVITATION","INTERVENTIONAL","EARLY_PHASE1","RANDOMIZED","SINGLE","150","Longevity; Quality of Life; Mood; Inflammation; Immune Health; Pain Management; Weight Management; Alertness","DRUG:GLP-1; DRUG:Placebo","AgelessRx","2024-11-01","2025-11-01","FALSE","Change in self-reported pain levels in participants microdosing GLP1s [6 months] | Concentration of complete blood cells, as a measure of immunological health, in participants microdosing GLP1s [6 months] | Concentration of basic metabolites (cholesterol, glucose, creatinine, sodium, potassium), as a measure of immunological health, in participants microdosing GLP1s [6 months] | Change in mood in participants microdosing GLP1s [6 months] | Change in heart rate variability in participants microdosing GLP1s [6 months] | Changes in sleep patterns in participants microdosing GLP1s [6 months] | Change in frequency of physical activity in participants microdosing GLP1s [6 months]","BACKGROUND:31680842; BACKGROUND:27633186; BACKGROUND:29617641","Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/05/NCT07092605/ICF_000.pdf",null,null],["NCT00333151","Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes","LEAD-4","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","576","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:rosiglitazone; DRUG:metformin","Novo Nordisk A/S","2006-05","2007-08","FALSE","HbA1c [after 26 weeks of treatment]","BACKGROUND:21450987; RESULT:19245711; RESULT:19289857; RESULT:19491536; RESULT:19878259; RESULT:22055210; RESULT:22193143; RESULT:21883806; RESULT:22862847; RESULT:23010561; RESULT:23186975; RESULT:25504028; RESULT:26936426; DERIVED:24561125; DERIVED:21209033",null,null,null],["NCT05702931","Semaglutide Treatment for Hyperglycaemia After Renal Transplantation","Sema-RTx","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","104","Hyperglycemia; Renal Transplant Complication Primary Non-Function; Diabetes","DRUG:Semaglutide 14 MG [Rybelsus]; DRUG:Placebo","Copenhagen University Hospital, Rigshospitalet","2024-09-19","2027-12","FALSE","Mean sensor glucose (mmol/L) [14 weeks]",null,null,null,null],["NCT05444153","Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity","PIONEER START","WITHDRAWN","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","0","Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Empagliflozin","Novo Nordisk A/S","2022-10-06","2024-10-02","FALSE","Participants acheiving glycated haemoglobin (HbA1c) less than (<) 7 percentage (%) (Yes/No) [At week 104] | Participants acheiving body weight reduction greater than or equal to (>=) 5% (Yes/No) [At week 104]",null,null,"YES","OTHER:U1111-1270-0763; EUDRACT_NUMBER:2021-005396-39"],["NCT06792422","A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma","ABSALON","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","126","Primary Open Angle Glaucoma (POAG); Open-Angle Glaucoma; Glaucoma","DRUG:Oral semaglutide; DRUG:Placebo","Glostrup University Hospital, Copenhagen","2025-01","2028-08","FALSE","Photopic negative response of the electroretinogram after 6 months [From baseline to month 6.]",null,null,"NO","OTHER_GRANT:NNF22OC0079544; CTIS:2024-518510-87-00"],["NCT06559722","A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes",null,"UNKNOWN","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","510","Type 2 Diabetes","DRUG:Insulin Degludec/liraglutide Injection; DRUG:XULTOPHY®","Tonghua Dongbao Pharmaceutical Co.,Ltd","2024-08","2025-10","FALSE","Change from baseline in HbA1c after 26 weeks of treatment [Baseline, Week 26]",null,null,null,null],["NCT07528027","Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","648","Hypertension With Overweight or Obesity","DRUG:HRS-7535; DRUG:Placebo","Shandong Suncadia Medicine Co., Ltd.","2026-05-29","2027-12","FALSE","Change in SBP relative to baseline at Week 24 [at Week 24]",null,null,"UNDECIDED",null],["NCT06734273","Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","EARLY_PHASE1","RANDOMIZED","NONE","42","Obesity and Obesity-related Medical Conditions","DRUG:Mounjaro; PROCEDURE:Sleeve Gastrectomy","Nicholas Skertich","2025-03-10","2027-09","FALSE","Weight Loss [12 months after surgery]",null,null,"YES",null],["NCT01408888","A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","29","Diabetes Mellitus, Type 2","BIOLOGICAL:LY2189265; DRUG:Sitagliptin","Eli Lilly and Company","2011-08","2012-04","TRUE","Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Sitagliptin [Predose and up to 24 hours postdose on Day 4, Day 6, and Day 13 of Treatment 2] | Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Sitagliptin [Predose and up to 24 hours postdose on Day 4, Day 6, and Day 13 of Treatment 2]",null,null,null,"OTHER:H9X-MC-GBDW"],["NCT03018028","Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes","PIONEER 9","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","243","Diabetes; Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Placebo; DRUG:Liraglutide","Novo Nordisk A/S","2017-01-10","2018-01-09","TRUE","Change in HbA1c (Week 26) [Week 0, week 26]","DERIVED:32998732; DERIVED:32333875; DERIVED:32267058; DERIVED:31903692","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/28/NCT03018028/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/28/NCT03018028/SAP_001.pdf","YES","OTHER:U1111-1181-4048; OTHER:JapicCTI-173489"],["NCT06054698","Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","61","Overweight or Obesity","DRUG:HRS9531 injection; DRUG:HRS9531 injection Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2023-10-16","2024-09-09","FALSE","Percentage change in body weight [Week 0, Week 36]",null,null,"UNDECIDED",null],["NCT05803421","A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk","ACHIEVE-4","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","2749","Type 2 Diabetes; Obesity; Overweight or Obesity; Overweight; Cardiovascular Diseases; Chronic Kidney Disease","DRUG:Orforglipron; DRUG:Insulin Glargine","Eli Lilly and Company","2023-04-03","2026-03-16","FALSE","Time to First Occurrence of Any Major Adverse Cardiovascular Event (MACE-4) [Myocardial Infarction (MI), Stroke, Hospitalization for Unstable Angina, or Cardiovascular (CV) Death] [Baseline to End of the Study (Approximate Maximum 104 Weeks)]","DERIVED:42815506",null,"YES","OTHER:J2A-MC-GZGS; OTHER:2022-502833-25-00; OTHER:U1111-1285-6821"],["NCT05606471","Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets","SemVLCD","UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","45","Type 2 Diabetes Mellitus in Obese","DRUG:Semaglutide Pen Injector [Ozempic]; DIETARY_SUPPLEMENT:Very-low Calorie Diet","University of Nottingham","2021-09-15","2023-07-28","FALSE","Muscle protein synthesis rate [6 weeks] | Muscle protein breakdown rate [6 weeks]","DERIVED:41850248",null,"NO",null],["NCT06171152","Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues",null,"SUSPENDED","INTERVENTIONAL","EARLY_PHASE1","RANDOMIZED","NONE","30","Multiple Sclerosis; Long COVID; Long Covid19; Obese; Obesity; Obesity, Morbid; Acute Leukemia in Remission","DRUG:Liraglutide Pen Injector [Saxenda]; OTHER:Medication Diary","University of Chicago","2024-01-26","2027-06-01","FALSE","Change from Baseline in Serum Brain Derived Neurotrophic Factor (BDNF) after 8 Weeks [8 weeks]",null,null,"YES",null],["NCT07265752","Tirzepatide for the Treatment of Cannabis Use Disorder",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","6","Cannabis Use Disorder","DRUG:Tirzepatide; DRUG:Placebo","Brigham and Women's Hospital","2027-03-01","2028-06-30","FALSE","Cue-Induced Craving [5 weeks]",null,null,"NO",null],["NCT02113332","Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","124","Type 2 Diabetes Mellitus","DRUG:Liraglutide; DRUG:Placebo","Vastra Gotaland Region","2013-01","2014-08","FALSE","Change in HbA1c from baseline to week 24. [Baseline, week 24]","BACKGROUND:20042772; BACKGROUND:19820278; BACKGROUND:9742976; BACKGROUND:20092585; BACKGROUND:20417856; BACKGROUND:22015237; BACKGROUND:22613745; BACKGROUND:15855602; DERIVED:25175385",null,null,"EUDRACT_NUMBER:2012-001941-42"],["NCT06671821","Long-term Efficacy and Safety of HRS-7535 Tablets in Obese Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE2","NON_RANDOMIZED","NONE","81","Chronic Weight Management","DRUG:HRS-7535","Shandong Suncadia Medicine Co., Ltd.","2024-11-20","2025-08-15","FALSE","Number of participants with Treatment-emergent Adverse Event(AE) [During the 32-week open-label extension treatment period]",null,null,"UNDECIDED",null],["NCT07139548","A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","600","T2DM","DRUG:RAY1225; DRUG:Semaglutide","Guangdong Raynovent Biotech Co., Ltd","2025-08-31","2026-12-01","FALSE","Change From Baseline in Hemoglobin A1c (HbA1c) (6 mg and 9 mg) [Baseline,36 Week]",null,null,"UNDECIDED",null],["NCT03985293","A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","412","Diabetes Mellitus, Type 2","DRUG:Placebo; DRUG:PF-06882961","Pfizer","2019-10-15","2021-06-08","TRUE","Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 16 [Baseline, Week 16]","DERIVED:37213102","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/93/NCT03985293/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/93/NCT03985293/SAP_001.pdf","YES","EUDRACT_NUMBER:2019-000218-12; NIH:2019"],["NCT05610800","Exenatide for Smoking Cessation and Prevention of Weight Gain",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","140","Smoking Cessation; Weight Gain","DRUG:Exenatide 2 milligram (mg) Injection; DRUG:Placebo; DRUG:Nicotine patch; BEHAVIORAL:Smoking Cessation Counseling","The University of Texas Health Science Center, Houston","2022-12-07","2025-11-07","FALSE","Percentage of participants with 4-week continuous abstinence at 12 weeks post-target quit day as assessed by self-report timeline followback (TLFB) and verified by breath carbon monoxide (CO) level [Week 15] | Weight change in kilograms at 12 weeks post-target quit day [Baseline, Week 15]","DERIVED:38663460; DERIVED:37316311",null,"NO",null],["NCT07845994","SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years","SEMAFORCRANIO","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","50","Craniopharyngioma, Child","DRUG:Semaglutide (Wegovy) weekly injection; DRUG:Placebo weekly Injection","University Hospital, Angers","2026-11","2031-02","FALSE","Change in BMI SD score (according to french references) at 40 weeks [40 weeks] | Change in BMI SD score (according to french references) at 80 weeks [80 weeks]",null,null,"UNDECIDED","CTIS:2024-511114-20-00"],["NCT05780905","Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes",null,"RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","50","Diabetes Mellitus, Type 2; Stroke (CVA) or Transient Ischemic Attack","DRUG:Semaglutide Auto-Injector; OTHER:Placebo","University of Washington","2024-01-11","2026-03-31","FALSE","Intracranial blood flow (IBF) [Approximately 12 Months] | bloodbrain barrier Ktrans [Approximately 12 Months]",null,null,null,"OTHER_GRANT:U1111-1271-3352"],["NCT07571005","AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea","AMAZE 3","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","300","Obesity; Overweight; Obstructive Sleep Apnoea","DRUG:NNC0487-0111; DRUG:Placebo (matched to NNC0487-0111)","Novo Nordisk A/S","2026-05-05","2028-07-12","FALSE","Relative change in body weight [From baseline (week 0) to (week 80)] | Change in apnoea-hypopnoea index (AHI) [From baseline (week 0) to (week 80)]",null,null,"YES","OTHER:U1111-1313-6359; OTHER:2024-520442-36"],["NCT06354101","The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.",null,"WITHDRAWN","OBSERVATIONAL",null,null,null,"0","Metabolic Health","DRUG:Tirzepatide; DRUG:Semaglutide","CorEvitas","2023-07-01","2023-07-01","FALSE","Main Objective of Registry [Up to 10 years]",null,null,"NO",null],["NCT03208881","Ultrasound Assessment of the Adventitia, Extra-media (EMT) and Veia Jugularis Interna Thickness",null,"UNKNOWN","OBSERVATIONAL",null,null,null,"80","Osteoarthritis, Obesity","DIETARY_SUPPLEMENT:Dietary Supplement: Intensive dietary intervention","Henrik Gudbergsen","2017-07-15","2019-01","FALSE","Change in the mean thickness of adventitia, extra-media thickness (EMT), and vena jugularis interna assessed in mm [Week -8 to 0]",null,null,null,null],["NCT01468181","A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3","NON_RANDOMIZED","NONE","394","Type 2 Diabetes Mellitus","DRUG:LY2189265; DRUG:Sulfonylureas (SU); DRUG:Biguanides (BG); DRUG:alpha-glucosidase inhibitor (a-GI); DRUG:Thiazolidinedione (TZD); DRUG:Glinides","Eli Lilly and Company","2011-11","2013-12","TRUE","Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) [Baseline through 52 Weeks] | Percentage of Participants With Hypoglycemic Episodes [Baseline through 52 Weeks]",null,null,null,"OTHER:H9X-JE-GBDQ"],["NCT06263595","Semaglutide and Preoperative Residual Gastric Volumes",null,"COMPLETED","OBSERVATIONAL",null,null,null,"94","Pulmonary Aspiration","DEVICE:gastric antral sonography","University of Calgary","2024-05-31","2025-05-16","FALSE","Number of participants presenting with a full stomach [Measured in the preoperative holding area]",null,null,"NO",null],["NCT01432405","Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","24","Type 2 Diabetes Mellitus","DRUG:Exenatide; DRUG:Pioglitazone","Baylor College of Medicine","2007-06","2008-07","TRUE","Hepatic Fat [one year]","DERIVED:21956711",null,null,null],["NCT01098539","A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","507","Diabetes Mellitus, Type 2","BIOLOGICAL:albiglutide; DRUG:sitagliptin","GlaxoSmithKline","2010-05","2012-11","TRUE","Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 [Baseline; Week 26]","DERIVED:39963952; DERIVED:25387217",null,"YES",null],["NCT07871799","ELITE: Deep Profiling and Algorithmic Polytherapy to Map Individual Response in Healthy Aging","ELITE","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","31","Healthy Aging","DIETARY_SUPPLEMENT:AgeBiotics AB-01; DIETARY_SUPPLEMENT:AgeBiotics AB-02; DRUG:Metformin; DRUG:semaglutide; DRUG:empagliflozin","Sheba Medical Center","2025-11-17","2026-02-25","FALSE","Change From Baseline in Muscular-Immune-Cognitive Composite (MIC-C) Score at Week 8 [Baseline to Week 8]",null,null,"NO","REGISTRY:MOH_2026-07-21_016947; REGISTRY:ISRCTN84791030"],["NCT07590219","Use of Liraglutide in Children Aged 6 to 12 Years With Severe Obesity",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","30","Severe Obesity; Cardiovascular Function; Liraglutide; Childhood Obesity; Echocardiography; Speckle Tracking","DRUG:Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml","University of Sao Paulo General Hospital","2024-03-30","2027-04","FALSE","Change in Body Mass Index (BMI) [6 months]","BACKGROUND:27295427; BACKGROUND:36322838; BACKGROUND:32233338; BACKGROUND:29055731; BACKGROUND:31963569; BACKGROUND:23449553; BACKGROUND:23302619; BACKGROUND:28359099; BACKGROUND:19875556; BACKGROUND:8610077; BACKGROUND:9614255; BACKGROUND:38438626",null,null,null],["NCT07845500","A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","660","Obesity; Overweight and/or Obesity; Overweight; Treatment Of Obesity","DRUG:Semaglutide; DRUG:Tirzepatide; DRUG:Berobenatide","Pfizer","2026-10-01","2028-02-16","FALSE","Percent change from baseline in body weight [Baseline, Week 32]",null,null,"YES",null],["NCT07734311","A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","360","Knee Osteoarthritis; Obesity","DRUG:Ecnoglutide Injection; DRUG:placebo with matching volume","Hangzhou Sciwind Biosciences Co., Ltd.","2026-08-03","2028-05-31","FALSE","Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score [Baseline, week 68] | Percentage Change in Body Weight [Baseline, week 68]",null,null,"NO",null],["NCT03856632","Liraglutide Effect in Atrial Fibrillation","LEAF","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","60","Atrial Fibrillation","DRUG:Liraglutide; OTHER:RFM; DRUG:Anti Arrhythmics; PROCEDURE:Afib Catheter Ablation","University of Miami","2019-03-18","2026-12-31","FALSE","Change in size of Left Atrial Epicardial Adipose Tissue (LAEAT) [Baseline, 3 months (prior to ablation)]","DERIVED:42159524",null,"NO",null],["NCT02870231","Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","187","Metabolism and Nutrition Disorder; Obesity","DRUG:NNC9204-0530; DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2016-08-18","2017-09-03","FALSE","Number of treatment emergent adverse events [Day 1-112]",null,null,"YES","OTHER:U1111-1175-7040"],["NCT05788965","Semaglutide in CFRD",null,"COMPLETED","INTERVENTIONAL","PHASE2; PHASE3",null,"NONE","8","Cystic Fibrosis; Cystic Fibrosis-related Diabetes","DRUG:Semaglutide","University of Minnesota","2023-10-16","2024-12-23","TRUE","Weight [12 weeks] | BMI (kg/m2) [12 weeks]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/65/NCT05788965/Prot_SAP_000.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/65/NCT05788965/ICF_001.pdf","UNDECIDED",null],["NCT01744236","SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","70","Type 2 Diabetes","DRUG:Liraglutide; DRUG:Sitagliptin; DRUG:Exenatide; DRUG:Liraglutide placebo; DRUG:Sitagliptin placebo; DRUG:Exenatide placebo; DRUG:L-NMMA","Amsterdam UMC, location VUmc","2013-04","2015-08","FALSE","Changes from baseline following infusion of GLP-1RA (acute effects) and the changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on resting heart rate variability, as derived from electrocardiographic measurements. [12 weeks] | Changes from baseline following infusion of GLP-1RA (acute effects) and the changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on Glomerular Filtration Rate, measured by the inulin-clearance technique. [12 weeks] | Changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on pancreatic exocrine function, measured as fecal Elastase-1. [12 weeks]","DERIVED:33429063; DERIVED:27627981; DERIVED:27585605; DERIVED:27451030; DERIVED:27038451; DERIVED:26586327",null,null,"OTHER:U1111-1130-8248; EUDRACT_NUMBER:2012-003256-36"],["NCT01652729","Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus","DURATION-NEO-2","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","365","Diabetes Type 2","DRUG:Exenatide once weekly suspension; DRUG:Sitagliptin; DRUG:Placebo","AstraZeneca","2013-02","2014-04","TRUE","Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28 [Baseline to Week 28]","DERIVED:32306296; DERIVED:28205322",null,null,"OTHER:MB001-004"],["NCT01515592","Safety and Tolerability of Liraglutide in Healthy Japanese Male Volunteers",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","24","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2006-01","2006-04","FALSE","Adverse events [] | Body weight [] | Antibody against liraglutide []","RESULT:18541123",null,null,null],["NCT06972472","A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","600","Obesity; Overweight; Type 2 Diabetes","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2025-05-19","2027-08","FALSE","Change from Baseline in Hemoglobin A1c (HbA1c) [Baseline, Week 40]",null,null,"YES","CTIS:2025-521098-14-00; OTHER:J2A-MC-GZP2; OTHER:J2A-MC-GZPO; NIH:2025"],["NCT03041792","Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","61","Obesity","DRUG:Liraglutide; OTHER:Placebo","Pfizer","2017-02-20","2018-01-16","TRUE","Change From Baseline (Visit 3) in Mean Energy Intake During Ad Libitum Lunches at Visits 4 and 5 [Visit 3, Visit 4 and Visit 5]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/92/NCT03041792/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/92/NCT03041792/SAP_001.pdf","NO",null],["NCT05322200","The POST-ACS Study",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","140","Diabetes Mellitus; Acute Coronary Syndrome; Coronary Artery Disease","RADIATION:A computerized tomography (CT) coronary angiogram; PROCEDURE:Vicorder (Skidmore medical, UK); OTHER:Blood tests for inflammation and oxidative stress markers","Swansea Bay University Health Board","2022-08-31","2024-04-28","FALSE","Compare the regression of vulnerable coronary plaque (necrotic core) assessed using histologically validated \"Plaque Maps\" derived from CT Coronary angiography in patients with raised HbA1c admitted with ACS and treated with oral Semaglutide or placebo. [12 months]",null,null,"NO",null],["NCT04007107","A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","103","Healthy Volunteers Diabetes Mellitus, Type 2; Healthy Volunteers Overweight; Healthy Volunteers Obesity","DRUG:Semaglutide (administered by DV3396 pen); DRUG:Semaglutide (administered by PDS290 pen)","Novo Nordisk A/S","2019-06-27","2019-07-28","TRUE","Intensity of Injection Site Pain [After 1 minute of each injection (Day 1)]","DERIVED:35434913","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/07/NCT04007107/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/07/NCT04007107/SAP_001.pdf","YES","REGISTRY:2019-002284-10; OTHER:U1111-1233-9590; NIH:2019"],["NCT06982846","A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","80","Type 2 Diabetes Mellitus","DRUG:Retatrutide; DRUG:Placebo","Eli Lilly and Company","2025-06-06","2026-05-04","FALSE","Time-to-Event of Recovery of Plasma Glucose (PG) Concentration from 48 Milligram per Deciliter (48 mg/dL) to 70 mg/dL (tPG_nadir-70 mg/dL) [Within 60 minutes after nadir]",null,null,"NO","OTHER:J1I-MC-GZQF; CTIS:2024-518471-63-00"],["NCT06568731","A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","23","Obesity","DRUG:Danuglipron","Pfizer","2024-08-23","2024-12-18","FALSE","Steady-state area under the concentration-time profile from time zero to 24 hours (AUC24) for danuglipron [Predose to 24 hours post danuglipron administration] | Steady-state maximum observed concentration (Cmax) for danuglipron [Predose to 24 hours post danuglipron administration] | Steady-state time to reach maximum observed concentration (Tmax) for danuglipron [Predose to 24 hours post danuglipron administration]",null,null,"NO","REGISTRY:NCT06568731"],["NCT05622045","Does Personality Predict Patient Adherence, Health Behaviors, and Weight Loss Outcomes During the Latino Crossover Semaglutide Study (LCSS)? (Story-LCSS Project)","StoryLCSS","ACTIVE_NOT_RECRUITING","OBSERVATIONAL",null,null,null,"59","Obesity; Body Weight Changes","BEHAVIORAL:Voice data","Loma Linda University","2023-02-01","2024-05-29","FALSE","Predicted patient weight change success [The voice data measurement will take place at baseline and take about 10-15 minutes for collection to take place.] | Clinician predictions [The clinician judgement will be measured during the second month of the subject's weight loss study.] | Predicated patient calorie intake [The voice data measurement will take place during the subject's initial clinic visit and take about 10-15 minutes for collection to take place.] | Predicated patient physical activity level [The voice data measurement will take at baseline and take about 10-15 minutes for collection to take place.]","BACKGROUND:27826445; BACKGROUND:26444382; BACKGROUND:34585130; BACKGROUND:33472547; BACKGROUND:23537492; BACKGROUND:26807008; BACKGROUND:33567185",null,"UNDECIDED",null],["NCT07840729","Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","90","Valid MeSH Conditiongs","DRUG:JMT206 injection; COMBINATION_PRODUCT:Semaglutide injection; DRUG:Placebo injection","Shanghai JMT-Bio Inc.","2026-10-20","2027-02-28","FALSE","Incidence of Adverse Events (AE) assessed by CTCAE v6.0 [Baseline through week 19]",null,null,null,null],["NCT01658501","Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","593","Type 2 Diabetes Mellitus","DRUG:50 mg PB1023; DRUG:70 mg PB1023; DRUG:100 mg PB1023; DRUG:Placebo (0.9% Sodium Chloride); DRUG:Victoza®; OTHER:Diet and Exercise; DRUG:Metformin; DRUG:Sulfonylurea; DRUG:Metformin and Sulfonylurea","PhaseBio Pharmaceuticals Inc.","2012-07","2013-07","FALSE","Evaluation of dose response of Glymera as measured as the change from baseline in HbA1c after 20 weeks of dosing with Glymera compared to placebo and active comparator [Baseline and 20 weeks]",null,null,null,null],["NCT03884075","Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)",null,"RECRUITING","INTERVENTIONAL","PHASE2","NON_RANDOMIZED","NONE","104","Non-Alcoholic Steatohepatitis; Non-Alcoholic Fatty Liver Disease","DRUG:Semaglutide","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","2019-07-24","2027-09-03","FALSE","Histological Improvement [30 weeks] | Clinical Improvement [30 weeks] | Change in hepatic gene expression [2 hours after an oral 75g glucose load]",null,null,"YES","OTHER:19-DK-0072"],["NCT06345066","A Study of LY3841136 in Overweight and Obese Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","96","Obesity; Overweight","DRUG:Tirzepatide; DRUG:LY3841136; DRUG:Placebo","Eli Lilly and Company","2024-04-03","2025-09-29","FALSE","Number of participants with one or more Treatment Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration [Baseline up to 42 weeks]",null,null,"NO","OTHER:J3R-MC-YDAC"],["NCT00637273","A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","514","Type 2 Diabetes Mellitus","DRUG:exenatide once weekly; DRUG:sitagliptin; DRUG:pioglitazone; DRUG:placebo tablet; DRUG:placebo once weekly","AstraZeneca","2008-01","2009-02","TRUE","Change in HbA1c From Baseline to Week 26 [Day 1, Week 26]","DERIVED:32306296; DERIVED:23748507; DERIVED:23748506; DERIVED:23522121; DERIVED:23039868; DERIVED:22236356; DERIVED:21434995; DERIVED:20580422",null,null,null],["NCT07671391","A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese Participants",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","60","Obesity Adult Onset","DRUG:LAE102 +Tirzepatide; DRUG:LAE102 placebo,+Tirzepatide","Shanghai Zhongshan Hospital","2026-08","2027-07","FALSE","The percentage change in lean body mass [24 weeks]",null,null,"NO",null],["NCT07502508","Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","60","Type 2 Diabetes","DRUG:icovamenib 100 mg; DRUG:Placebo","Biomea Fusion Inc.","2026-04-30","2027-06","FALSE","To demonstrate that icovamenib 100 mg once daily for 12 weeks is superior to placebo for glycemic control [26 weeks]",null,null,"NO",null],["NCT01499108","Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes","Liratime","COMPLETED","INTERVENTIONAL","PHASE4",null,"NONE","32","Type 2 Diabetes","DRUG:liraglutide","Peter Rossing","2012-08","2013-07","FALSE","Change in ambulatory blood pressure [50 days]","DERIVED:25935863",null,null,null],["NCT05071417","Effect Of Semaglutide In Coronary Atheroma Plaque","SEPLA","UNKNOWN","INTERVENTIONAL","PHASE3",null,"NONE","120","Atheroscleroses, Coronary","DRUG:Semaglutide","Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León","2021-11","2024-12","FALSE","Plaque burden modification assessed by coronary CT and plaque quantification [18 months]",null,null,"UNDECIDED",null],["NCT01484873","Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor",null,"COMPLETED","INTERVENTIONAL","PHASE2",null,"NONE","10","Obesity; Overweight; Craniopharyngioma","DRUG:Exenatide","Vanderbilt University Medical Center","2012-06","2015-03","TRUE","Body Weight (kg) [baseline, 50 weeks]","RESULT:27133664",null,"NO",null],["NCT06250946","Efficacy and Safety of HRS-7535 Tablets in Obese Subjects .",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","235","Overweight and Obesity","DRUG:HRS-7535;Placebo; DRUG:Placebo","Shandong Suncadia Medicine Co., Ltd.","2024-02-23","2025-01-22","FALSE","Percent change in body weight from baseline at Week 26 [Week 26]","DERIVED:42331800",null,"UNDECIDED",null],["NCT06629688","Semaglutide and Intestinal Iron Absorption",null,"COMPLETED","INTERVENTIONAL",null,null,"NONE","51","Diabetes Mellitus Type 2; Iron Absorption","DRUG:semaglutide","University Hospital Dubrava","2023-11-01","2024-04-01","FALSE","General objective [10 weeks]",null,null,"UNDECIDED",null],["NCT00395746","Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","264","Diabetes; Diabetes Mellitus, Type 2","DRUG:sulfonylurea; DRUG:liraglutide","Novo Nordisk A/S","2006-10","2007-10","TRUE","Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment [after 24 weeks of treatment]","RESULT:24843595; RESULT:20380655; RESULT:23010561; RESULT:25504028; DERIVED:21450987; DERIVED:21209033",null,null,"REGISTRY:JapicCTI-060324"],["NCT07400588","Aleniglipron Phase 2 in Type 2 Diabetes Mellitus","GSBR-1290","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","58","Obese; Obesity; Obesity Type 2 Diabetes Mellitus; Weight Loss","DRUG:Aleniglipron; DRUG:Placebo","Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics","2025-12-01","2026-09","FALSE","Incidence, severity and relationship of AEs/SAEs [Baseline to week 31] | Assessment of vital signs [Baseline to week 31] | Assessment of laboratory measures [Baseline to week 31] | Assessment of Electrocardiograms (ECG) [Baseline to week 31]",null,null,"YES",null],["NCT01722227","Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes",null,"WITHDRAWN","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","0","Type 1 Diabetes","DRUG:Liraglutide; DRUG:Placebo","University at Buffalo","2012-11","2017-11","FALSE","Mean weekly blood glucose concentrations. [3 Months]",null,null,null,"OTHER_GRANT:1-12-CT-20"],["NCT06937203","A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus",null,"RECRUITING","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","QUADRUPLE","150","Obesity; Diabetes Mellitus, Type 2","DRUG:ARO-ALK7; DRUG:Placebo","Arrowhead Pharmaceuticals","2025-05-09","2027-02","FALSE","Number of Participants with Treatment-Emergent Adverse Events (TEAEs) [Up to Day 253 End of Study (EOS)]",null,null,null,null],["NCT04889183","SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes","SMART","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","125","Obesity; Albuminuria","DRUG:Semaglutide; DRUG:Placebo","University Medical Center Groningen","2022-03-14","2024-05-28","FALSE","Change from baseline to week 24 in urinary albumin:creatinine ratio (UACR) [Week 1 to week 24]","DERIVED:42308057; DERIVED:39455729",null,"UNDECIDED","EUDRACT_NUMBER:2021-001247-27"],["NCT07540754","A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function",null,"RECRUITING","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","24","Diabetes Mellitus; Weight Loss","DRUG:HRS9531 Injection","Fujian Shengdi Pharmaceutical Co., Ltd.","2026-05-26","2027-01","FALSE","Maximum concentration (Cmax) [Post-dose from Day 1 to Day 29.] | The area under the concentration-time curve to the last measurable concentration (AUClast) [Post-dose from Day 1 to Day 29.] | The area under the concentration-time curve extrapolated to infinity (AUCinf) [Post-dose from Day 1 to Day 29.]",null,null,"UNDECIDED",null],["NCT01847313","The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","20","Diabetic Kidney Disease","DRUG:Liraglutide","Karl Neff","2013-04","2015-11","TRUE","MCP-1:Creatinine Ratio in Urine [Up to 26 weeks]","BACKGROUND:22608055; BACKGROUND:23173142; BACKGROUND:15664230; BACKGROUND:21537349; BACKGROUND:22969168; BACKGROUND:21975753; BACKGROUND:21744074; BACKGROUND:19238145; BACKGROUND:19585513; BACKGROUND:16374426; BACKGROUND:14675042; BACKGROUND:17631861; BACKGROUND:19587356; BACKGROUND:17167242; BACKGROUND:16177002; BACKGROUND:16231067; BACKGROUND:18487229; BACKGROUND:21253697; BACKGROUND:22691169; BACKGROUND:21206136; BACKGROUND:20622169; BACKGROUND:22517736; BACKGROUND:20856686; BACKGROUND:20002084; DERIVED:39963952",null,null,null],["NCT05726227","A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight","STEP Young","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","212","Obesity","DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2023-07-07","2025-10-15","FALSE","Group Kids: Change in body mass index (BMI) [From baseline (week 0) to week 68]",null,null,"YES","OTHER:U1111-1266-3808; EUDRACT_NUMBER:2022-502922-41"],["NCT03482024","A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","45","Renal Insufficiency; End Stage Renal Disease","DRUG:Tirzepatide","Eli Lilly and Company","2018-03-30","2019-08-19","TRUE","Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Tlast (AUC[0-tlast]) [Predose, 8hours(h), 12h, 24h, 48h, 72h, 96h, 168h, 336h postdose] | PK: Maximum Concentration of Tirzepatide [Predose, 8hours(h), 12h, 24h, 48h, 72h, 96h, 168h, 336h postdose] | PK: Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Infinity (AUC[0-inf]) [Predose, 8hours(h), 12h, 24h, 48h, 72h, 96h, 168h, 336h postdose]","DERIVED:33778934","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/24/NCT03482024/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/24/NCT03482024/SAP_001.pdf","NO","OTHER:I8F-MC-GPGG"],["NCT04057261","Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease","Lirabolic","WITHDRAWN","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","0","Type 2 Diabetes; Cardiovascular Diseases","DRUG:Liraglutide Pen Injector [Victoza]; DRUG:Placebo","RWTH Aachen University","2020-11","2022-08","FALSE","Changes in the metabolomics profile (fold changes) between Liraglutide treatment group and placebo group after 1 and 3 months [3 month]",null,null,null,null],["NCT07213466","Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder","OBOE-Mayo","RECRUITING","INTERVENTIONAL","PHASE4","NON_RANDOMIZED","NONE","100","Bipolar I Disorder; Bipolar II Disorder; Schizo Affective Disorder; Obesity; Weight Loss; GLP - 1","BEHAVIORAL:Group Therapy Program; DRUG:semaglutide; DRUG:Phentermine-Topiramate; DRUG:naltrexone and bupropion (combination)","Mayo Clinic","2026-01-19","2028-02-01","FALSE","Describe the distribution of obesity phenotypes (hungry brain, hungry gut, emotional hunger and slow burn) in patients with BD and obesity, with the goal of identifying predominant phenotype patterns within this clinical population. [From enrollment through the end of the 20-week intervention.]",null,null,"NO",null],["NCT05051566","A Multiple Dose Study of LY3502970 in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","SINGLE","26","Healthy","DRUG:LY3502970; DRUG:Esomeprazole","Eli Lilly and Company","2021-09-16","2022-04-04","TRUE","Part A: PK: Maximum Observed Concentration (Cmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation [Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)] | Part A: PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours Post-Dose (AUC(0-24)) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation [Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)] | Part A: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation [Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)] | Part B: PK: Maximum Observed Concentration (Cmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation [Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)] | Part B: PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours Post-dose (AUC(0-24)) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation [Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)] | Part B: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation [Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/66/NCT05051566/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/66/NCT05051566/SAP_001.pdf","NO","OTHER:J2A-MC-GZGD; OTHER:QSC202755; EUDRACT_NUMBER:2020-005750-15"],["NCT07269756","A Study to Evaluate the Drug Interactions of HRS-7535 With Acetaminophen, Digoxin, Rosuvastatin, and Omeprazole in Obese or Overweight Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","40","Obesity; Overweight","DRUG:HRS-7535 Tablets; DRUG:Paracetamol Tablets; DRUG:Digoxin Tablets; DRUG:Rosuvastatin Calcium Tablets; DRUG:Omeprazole Enteric-coated Capsules","Shandong Suncadia Medicine Co., Ltd.","2025-12-07","2026-03-08","FALSE","Maximum concentration (Cmax) [63 days.] | Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-last) [63 days.] | Area under the concentration-time curve from time zero to infinity (AUC0-inf) [63 days.]",null,null,"UNDECIDED",null],["NCT07754461","A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","600","Type 2 Diabetes","DRUG:Placebo; DRUG:Survodutide","Boehringer Ingelheim","2026-08-24","2028-01-17","FALSE","Absolute change in glycosylated haemoglobin A1c (HbA1c) (%) from baseline to Week 41 [At baseline and Week 41.]",null,null,"YES",null],["NCT06737042","Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","326","Obesity and Overweight","DRUG:GZR18; DRUG:Tirzepatide","Gan and Lee Pharmaceuticals, USA","2025-02-24","2026-02-27","FALSE","Primary Objective [36 weeks]",null,null,null,null],["NCT02127541","New Imaging Procedure for the Localisation of Insulinoma",null,"COMPLETED","INTERVENTIONAL",null,null,"SINGLE","52","Endogenous Hyperinsulinaemic Hypoglycaemia","OTHER:Ga -exendin PET/CT, In- exendin SPECT/CT, MRI","University Hospital, Basel, Switzerland","2014-01-06","2017-11","FALSE","Measuring Tumour to Background Ratio [4 years] | Measuring the accuracy of the Tumour-Localisation of 68-DOTA-Exendin-4 PET/CT and 111 In-DOTA-exendin-4 SPECT/CT. [4 years]","BACKGROUND:18703486; BACKGROUND:19820010; BACKGROUND:20860517; BACKGROUND:24622317; DERIVED:31298706; DERIVED:30449018; DERIVED:30054698",null,null,null],["NCT07284979","Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes","KaiNETIC-3","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","1270","Obesity","DRUG:Ribupatide; DRUG:Semaglutide; DRUG:Placebo","Kailera","2025-12-30","2028-03","FALSE","Percent Change From Baseline in Body Weight at Week 76 [Baseline, Week 76]",null,null,"NO","CTIS:2025-523511-11-00; NIH:2025"],["NCT04952779","Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea",null,"COMPLETED","OBSERVATIONAL",null,null,null,"750","Diabetes Mellitus, Type 2","DRUG:Xultophy® (insulin degludec/liraglutide)","Novo Nordisk A/S","2021-06-02","2024-12-15","FALSE","Incidence of Adverse Events (AEs) by preferred term [baseline (Visit1, 0 week) to 26 weeks]",null,null,"YES","OTHER:1111-1211-7084"],["NCT01324388","A Study of the Effect of LY2189265 on Two Blood Pressure Drugs",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","SINGLE","51","Diabetes Mellitus, Type 2","BIOLOGICAL:LY2189265; DRUG:Metoprolol; DRUG:Lisinopril; DRUG:Placebo","Eli Lilly and Company","2011-03","2011-08","TRUE","Pharmacokinetics, Area Under the Concentration Curve (AUC) of Lisinopril [Day -1, Day 3, Day 24 of Part 1] | Pharmacokinetics, Maximum Concentration (Cmax) of Lisinopril [Day -1, Day 3, Day 24 in Part 1] | Mean, 24-hour Heart Rate (Collected by Ambulatory Blood Pressure Monitoring [ABPM]) in Response to Co-administration of LY2189265 and Metoprolol [Day -1, Day 4, Day 7 of Treatment 2 in Part 2] | Mean, 24-hour Blood Pressure (Collected by Ambulatory Blood Pressure Monitoring [ABPM]) in Response to Co-administration of LY2189265 and Metoprolol [Day -1, Day 4, Day 7 of Treatment 2 in Part 2]",null,null,null,"OTHER:H9X-MC-GBCO"],["NCT07444073","Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock",null,"NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"440","Aging; Obesity & Overweight","OTHER:Not applicable. This is an observational study.","National University of Singapore","2026-06-01","2026-12-31","FALSE","LinAge2 Biological Age [Baseline and 6 months]","BACKGROUND:38898237",null,"UNDECIDED",null],["NCT07220642","Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide","RENEW 1","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","300","Obesity; Overweight","DRUG:Cagrilintide; DRUG:Placebo","Novo Nordisk A/S","2025-11-05","2027-05-11","FALSE","Relative change in body weight [From baseline (week 0) to end of treatment (week 64)]",null,null,"YES","OTHER:U1111-1314-8906; OTHER:2024-519530-24"],["NCT06339086","Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes",null,"UNKNOWN","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","478","Type 2 Diabetes Mellitus","DRUG:Semaglutide Injection; DRUG:Semaglutide Injection(Ozempic®); DRUG:Metformin","Chengdu Brilliant Pharmaceutical Co., Ltd.","2024-04","2025-08-30","FALSE","Change in HbA1c [Week 32]",null,null,"NO",null],["NCT02811484","Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes","Dexlar","WITHDRAWN","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","0","Diabetes Mellitus, Type 2","DRUG:Exenatide-LAR plus Dapagliflozin placebo; DRUG:Exenatide-LAR plus Dapagliflozin; DRUG:Insulin Titration; BEHAVIORAL:Behavioral Therapy","Weill Medical College of Cornell University","2016-06","2018-06","FALSE","Change in HbA1c [baseline, 24 weeks]",null,null,"NO",null],["NCT07430332","GLP-1 RA for Stage 1 Type 1 Diabetes",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","15","Stage 1 Diabetes Mellitus, Type 1","DRUG:Semaglutide; DRUG:Placebo","Children's Hospital Medical Center, Cincinnati","2027-09-01","2029-06-01","FALSE","C-peptide area under the curve [12 months] | C-peptide area under the curve (AUC) [12 months]","BACKGROUND:36084852; BACKGROUND:33662334",null,"NO",null],["NCT01695109","The Influence of Liraglutide on the Reward Properties of Food: an fMRI Study on Healthy Volunteers",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","16","Healthy Human Male Subjects","DRUG:Liraglutide; DRUG:Placebo","Medical University of Vienna","2010-11","2012-02","FALSE","Food intake at an ad libitum buffet [day 4] | fMRI activity in the brain [day 4]",null,null,null,null],["NCT07423247","Tirzepatide (Spartina) in Obese Kidney Transplant Recipients",null,"RECRUITING","INTERVENTIONAL","PHASE4",null,"NONE","30","Tirzepatide","DRUG:Tirzepatide","Shahid Beheshti University of Medical Sciences","2026-01-01","2026-07","FALSE","Percent Change in Body Weight From Baseline at Week 24 [Baseline to Week 24] | Incidence of Gastrointestinal Adverse Events [Baseline to Week 24 (monthly assessment)] | Change in Serum Creatinine [Baseline to Week 24]",null,null,"NO",null],["NCT05984238","A Trial to Evaluate Safety, Feasibility and Efficacy of Endoscopic Duodenal PEF Therapy","EMINENT-2","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","QUADRUPLE","33","Diabetes Mellitus, Type 2","DEVICE:PEF therapy using the Endogenex Device; DRUG:Semaglutide, 1.0 mg/mL; OTHER:Sham procedure","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","2023-08-03","2025-03-21","FALSE","Incidence rate of procedure-related SAEs, UADEs, SADEs, AESIs [safety] [24 weeks] | Percentage of patients off insulin at 24 weeks [efficacy] [24 weeks]","DERIVED:40007651; DERIVED:38579730",null,"NO",null],["NCT07720271","AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight","AMAZE 9","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","950","Overweight; Obesity","DRUG:zenagamtide; DRUG:Placebo","Novo Nordisk A/S","2026-08-31","2028-06-27","FALSE","Relative change in body weight [From baseline (week 0) to (week 76)]",null,null,"YES","OTHER:U1111-1313-7267"],["NCT05786521","Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","20","Aging; Diabetes Mellitus, Type 2; PreDiabetes; Overweight and Obesity","DRUG:Semaglutide Injectable Product; BEHAVIORAL:Lifestyle Counseling","The University of Texas Health Science Center at San Antonio","2023-04-01","2024-05-20","TRUE","Lean Body Mass Change [Baseline to 20 weeks]","DERIVED:39269759","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/21/NCT05786521/Prot_SAP_002.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/21/NCT05786521/ICF_000.pdf","NO","NIH:5P30AG044271-08"],["NCT07368855","GLP-1 Medicines and Mental Health Changes",null,"COMPLETED","INTERVENTIONAL",null,null,"NONE","90","Obesity; Depression; GLP-1","DRUG:GLP-1","University of California, San Diego","2024-05-01","2025-07-01","FALSE","Beck Depression Inventory-2 [Six months]",null,null,"NO",null],["NCT07253285","A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","460","Overweight; Obesity","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo cagrilintide; DRUG:Placebo semaglutide","Novo Nordisk A/S","2026-01-08","2030-03-20","FALSE","Relative change in body mass index (BMI) [Baseline (week 0), week 68]",null,null,"YES","OTHER:U1111-1299-4751; OTHER:2023-509176-42; NIH:2023"],["NCT07373834","Tirzepatide and Muscle Outcomes in Obesity","TIRMO","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","30","Obesity (Disorder)","DRUG:Tirzepatide; DRUG:Placebo","University Medical Centre Ljubljana","2026-01","2026-12","FALSE","Change in Body Mass and Composition [Baseline to Week 24] | Change in Quadriceps Muscle Strength [Baseline to Week 24]",null,null,"YES",null],["NCT01508806","Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","30","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2005-08","2006-03","FALSE","Area under the Curve (AUC) []","RESULT:20002084",null,null,null],["NCT06468748","The Effects of Semaglutide on Body Composition and Performance in Military Personnel",null,"WITHDRAWN","INTERVENTIONAL","PHASE4",null,"NONE","0","Obesity","DRUG:Semaglutide","United States Army Research Institute of Environmental Medicine","2024-08-01","2025-03-27","FALSE","Weight Loss [24 weeks] | Body composition [24 weeks] | Physical Performance [24 weeks]",null,null,"NO",null],["NCT06780449","A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","400","Obesity","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo cagrilintide; DRUG:Placebo semaglutide","Novo Nordisk A/S","2025-02-10","2028-08-28","FALSE","Relative change in body weight [From baseline (week 0) to week 104]",null,null,"YES","OTHER:U1111-1304-7430; OTHER:2024-512144-39"],["NCT00873223","Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","33","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:insulin detemir","Novo Nordisk A/S","2009-03","2009-09","FALSE","Insulin detemir pharmacokinetics with and without liraglutide administration [at approx. 12 weeks (including screening, washout and evaluation period)]","RESULT:21114606",null,null,null],["NCT04881110","Liraglutide and Peripheral Artery Disease","STARDUST","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","60","Type 2 Diabetes; Peripheral Arterial Disease","DRUG:Liraglutide; OTHER:Control","University of Campania Luigi Vanvitelli","2021-02-01","2022-12-31","TRUE","Peripheral Transcutaneous Oxygen Pressure [6 months]","RESULT:36812501; DERIVED:38470420","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/10/NCT04881110/Prot_000.pdf","NO",null],["NCT07503210","AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss","AMAZE 12","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","606","Obesity","DRUG:NNC0487-0111; DRUG:Placebo (matched to NNC0487-0111)","Novo Nordisk A/S","2026-04-21","2028-06-06","FALSE","Relative change in body weight [From week 40 to week 92]",null,null,"YES","OTHER:U1111-1327-1477; OTHER:2025-523804-62; NIH:2025"],["NCT07382180","Real-World Tirzepatide Therapy in Post-Bariatric Weight Regain and Preoperative Obesity Patients","TIR-REAL","COMPLETED","OBSERVATIONAL",null,null,null,"254","Obesity & Overweight; Weight Regain; Obesity, Morbid","DRUG:Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physician","Azienda Sanitaria Locale Napoli 2 Nord","2025-02-01","2026-01-18","FALSE","Percentage Total Body Weight Loss (%TBWL) [From baseline (initiation of tirzepatide therapy) to 6 months of treatment]",null,null,"NO",null],["NCT02229227","Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","814","Diabetes Mellitus, Type 2","DRUG:Albiglutide; DRUG:Insulin Glargine and Insulin Lispro","GlaxoSmithKline","2014-11-21","2017-07-24","TRUE","Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 [Baseline (Day -1) and Week 26]","BACKGROUND:32694215","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/27/NCT02229227/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/27/NCT02229227/SAP_001.pdf","YES","EUDRACT_NUMBER:2014-001821-34; NIH:2014"],["NCT01147250","Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)","ELIXA","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","6068","Acute Coronary Syndrome","DRUG:Lixisenatide (AVE0010); DRUG:Placebo","Sanofi","2010-06","2015-02","TRUE","Time to First Occurence of Primary CV Event: CV Death, Non-Fatal MI, Non-Fatal Stroke or Hospitalization for Unstable Angina [From randomization up to the end of study (median follow-up of 25 months)]","BACKGROUND:25965710; RESULT:26630143; DERIVED:39963952; DERIVED:36546588; DERIVED:35817031; DERIVED:33046070; DERIVED:32212368; DERIVED:30648112; DERIVED:30292589; DERIVED:29693361; DERIVED:28554908; DERIVED:23537041",null,null,"EUDRACT_NUMBER:2009-012852-26; OTHER:U1111-1116-5558; NIH:2009"],["NCT02229396","Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","695","Diabetes Mellitus","DRUG:Exantide with Dapagliflozin; DRUG:Exentide; DRUG:Dapagliflozin","AstraZeneca","2014-09-04","2016-04-26","TRUE","Change in HbA1c From Baseline to Week 28 [Baseline to Week 28]","DERIVED:32816874; DERIVED:32306296; DERIVED:30082326; DERIVED:27651331",null,null,"EUDRACT_NUMBER:2014-003503-29; NIH:2014"],["NCT06383390","The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","10000","Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD)","DRUG:Retatrutide; DRUG:Placebo","Eli Lilly and Company","2024-04-30","2029-02","FALSE","Time to First Occurrence of Composite Endpoints [Randomization up to Study Completion (Approximate 248 Weeks)] | Time to First Occurrence of Composite Endpoint of End Stage Kidney Disease (ESKD), ≥ 40% Sustained Decline in Estimated Glomerular Filtration Rate (eGFR), CV Death or Renal Death [Randomization up to Study Completion (Approximate 248 Weeks)]","DERIVED:41160422",null,"YES","OTHER:J1I-MC-GZBO; OTHER:2023-508630-34-00; NIH:2023"],["NCT04426474","A Study of LY3502970 in Participants With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","68","Diabetes Mellitus, Type 2","DRUG:LY3502970; DRUG:Placebo","Eli Lilly and Company","2020-10-08","2021-07-12","TRUE","Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug [Baseline through Follow-up (up to Day 105)]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/74/NCT04426474/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/74/NCT04426474/SAP_001.pdf","NO","OTHER:J2A-MC-GZGC; EUDRACT_NUMBER:2020-000125-86"],["NCT01618162","The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy","DUAL™IV","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","435","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide; DRUG:placebo","Novo Nordisk A/S","2012-08-29","2013-10-23","TRUE","Change in Glycosylated Haemoglobin (HbA1c) [Week 0, Week 26]","BACKGROUND:28332144; RESULT:27589252; DERIVED:39963952",null,null,"EUDRACT_NUMBER:2012-000140-97; OTHER:U1111-1126-9776"],["NCT02909933","Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","30","Polycystic Ovary Syndrome; Obesity","DRUG:liraglutide; DRUG:metformin and liraglutide","University Medical Centre Ljubljana","2015-07","2015-10","FALSE","The main outcome was change in body weight. [Patient's body weight was measured at the base point and after 12 weeks of clinical trial.]","DERIVED:28143456",null,"NO",null],["NCT05129891","A Research Study Looking at New Protein-based Tablets in Healthy Male Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","384","Healthy Volunteers; High Blood Cholesterol Levels; Type 2 Diabetes","DRUG:Semaglutide D; DRUG:Semaglutide G; DRUG:Semaglutide H; DRUG:Semaglutide I; DRUG:NNC0385-0434 B; DRUG:NNC0385-0434 C; DRUG:NNC0385-0434 D; DRUG:NNC0385-0434 E","Novo Nordisk A/S","2021-11-03","2023-02-26","FALSE","AUC0-24h,API,day10; area under the API plasma concentration-time curve from 0 to 24 hours after the 10th dose [From pre-dose PK sample (0 hours) at day 10 to PK sample 24 hours after dose administration]",null,null,"YES","OTHER:U1111-1266-0672; EUDRACT_NUMBER:2021-001452-34"],["NCT03724981","A Study Comparing the Dulaglutide Pen and the Semaglutide Pen",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","312","Diabetes Mellitus, Type 2","DRUG:Dulaglutide Pen; DRUG:Semaglutide Pen","Eli Lilly and Company","2018-10-18","2019-04-12","TRUE","Participant Preference Between 2 Injection Devices Based on Global Preference Item [Day 1]","BACKGROUND:31646727","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/81/NCT03724981/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/81/NCT03724981/SAP_001.pdf","YES","OTHER:H9X-MC-B021"],["NCT07727473","Preoperative Semaglutide Prior to Radical Prostatectomy",null,"NOT_YET_RECRUITING","INTERVENTIONAL","EARLY_PHASE1",null,"NONE","20","Prostate Cancer","DRUG:Semaglutide 2.4 mg","Banner Health","2026-07","2028-05","FALSE","Change in Caspase-3 (CC3) activation between baseline biopsy and radical prostatectomy specimen [Baseline (pre-treatment biopsy) through radical prostatectomy, assessed up to 6 months] | Change in Ki-67 proliferative index between baseline biopsy and radical prostatectomy specimen [Baseline through radical prostatectomy, assessed up to 6 months] | Change in Gleason score from biopsy to prostatectomy specimen [Baseline biopsy through radical prostatectomy specimen collection, assessed up to 6 months] | Change in Decipher genomic score in prostate tumor tissue [Baseline biopsy through radical prostatectomy specimen collection, assessed up to 6 months]",null,null,"NO",null],["NCT05813795","A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","664","Weight Management","DRUG:Ecnoglutide Low Dosage; DRUG:Ecnoglutide Medium Dosage; DRUG:Ecnoglutide High Dosage; DRUG:Placebo","Hangzhou Sciwind Biosciences Co., Ltd.","2023-04-05","2024-06-20","FALSE","Percent change in body weight from baseline [Week 40] | Proportion of subjects with weight loss ≥5% from baseline [Week 40]","DERIVED:40555243",null,"NO",null],["NCT02752412","Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs","LIXILAN JP-L","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","513","Type 2 Diabetes Mellitus","DRUG:Insulin glargine/Lixisenatide (HOE901/AVE0010); DRUG:Insulin glargine U100 (HOE901); DRUG:Metformin","Sanofi","2016-05-17","2018-10-04","FALSE","Change from baseline in HbA1c [Baseline, 26 weeks]","RESULT:32072742",null,null,"OTHER:U1111-1176-8378"],["NCT07687667","Effects of GLP-1RAs on Fertility Outcomes in Obese Women With PCOS",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","406","Polycystic Ovary Syndrome (PCOS); Obesity; Infertility, Female","DRUG:GLP-1 receptor agonist; DRUG:Metformin","Peking University Third Hospital","2026-07","2028-12","FALSE","Ongoing Pregnancy Rate [First cycle of IVF/ICSI-ET (the first frozen-thawed embryo transfer cycle if all embryos are cryopreserved after oocyte retrieval)]",null,null,"UNDECIDED",null],["NCT03882970","A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes","SURPASS-3","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","1444","Type 2 Diabetes Mellitus","DRUG:Tirzepatide; DRUG:Insulin Degludec","Eli Lilly and Company","2019-04-01","2020-12-11","TRUE","Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) [Baseline, Week 52]","DERIVED:42576670; DERIVED:40318682; DERIVED:39531161; DERIVED:38528819; DERIVED:37668888; DERIVED:37526908; DERIVED:37000390; DERIVED:35468325; DERIVED:35468321; DERIVED:35210595; DERIVED:34370970","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/70/NCT03882970/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/70/NCT03882970/SAP_001.pdf","YES","OTHER:I8F-MC-GPGH; EUDRACT_NUMBER:2018-003422-84; NIH:2018"],["NCT06461039","A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become Pregnant",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","43","Obesity","DRUG:NNC0487-0111 A; DRUG:NNC0487-0111 C; DRUG:Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC); DRUG:Acetaminophen - 500 mg/15 ml","Novo Nordisk A/S","2024-06-14","2025-03-16","FALSE","The area under the ethinylestradiol plasma concentration time curve at steady state [Day 8 and Day 193] | The area under the levonorgestrel plasma concentration time curve at steady state [Day 8 and Day 193]",null,null,"YES","OTHER:U1111-1300-3685"],["NCT01469351","Identifying Potential Effects of Liraglutide on Degenerative Changes",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","QUADRUPLE","34","Alzheimers Disease","DRUG:Liraglutide; DRUG:non-active study drug","University of Aarhus","2012-01","2013-04","FALSE","PIB PET scan [PIB PET-scan at baseline and after 26 weeks]","BACKGROUND:19573562; BACKGROUND:17544131; BACKGROUND:19519314; BACKGROUND:12925848; DERIVED:27871675; DERIVED:27252647; DERIVED:23158895",null,null,null],["NCT05086445","A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","62","Diabetes Mellitus, Type 2","DRUG:LY3502970; DRUG:Placebo","Eli Lilly and Company","2021-11-12","2022-09-05","TRUE","Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline Through Follow-Up (Up To Week 15)]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/45/NCT05086445/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/45/NCT05086445/SAP_001.pdf","NO","OTHER:J2A-JE-GZGB"],["NCT02967757","In-market Utilisation of Liraglutide Used for Weight Management in Europe",null,"COMPLETED","OBSERVATIONAL",null,null,null,"316","Metabolism and Nutrition Disorder; Obesity","DRUG:liraglutide","Novo Nordisk A/S","2016-12-22","2019-05-28","FALSE","Number of patients with BMI above or equal to 30 kg/m^2 [Less than 6 months before date of first prescription] | Number of patients with BMI above or equal to 27kg/m^2 and below 30 kg/m^2 and 1 or more comorbidity [Less than 6 months before date of first prescription] | Number of patients with above or equal to 27 kg/m^2 and below 30 kg/m^2 and no comorbidities [Less than 6 months before date of first prescription] | Number of patients with BMI below 27 kg/m^2 [Less than 6 months before date of first prescription] | Number of patients with BMI not measured [Within 6 months before date of the first prescription]","RESULT:36514273",null,null,"OTHER:U1111-1185-3661; REGISTRY:EUPAS16225"],["NCT05700877","Screening and Intervention for Subclinical Coronary Artery Disease in Patients With Type 2 Diabetes","STENO INTEN-CT","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","7300","Type 2 Diabetes; Cardiovascular Diseases","OTHER:CAC-based treatment strategy; OTHER:Standard treatment","Per Løgstrup Poulsen","2023-01-12","2029-01-01","FALSE","Rates of a composite cardiovascular endpoint [Event-driven, expected mean follow-up of 5 years]","DERIVED:41401988","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/77/NCT05700877/Prot_000.pdf","YES",null],["NCT03600480","A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","96","Obesity; Overweight","DRUG:NNC0174-0833; DRUG:Semaglutide; DRUG:Placebo (NNC0174-0833)","Novo Nordisk A/S","2018-07-25","2020-06-12","FALSE","Number of treatment emergent adverse events (TEAEs) [From first administration of NNC0174-0833 (Day 1) to completion of the post-treatment follow-up (Day 176)]","RESULT:33894838",null,"YES","OTHER:U1111-1203-6796"],["NCT07801820","Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","240","Type 2 Diabetes Mellitus (T2DM)","DRUG:MWN109 1; DRUG:MWN109 2; DRUG:MWN109 3; DRUG:MWN109 4; DRUG:Placebo; DRUG:Semaglutide Tablets","Shanghai Minwei Biotechnology Co., Ltd","2026-06-23","2027-03","FALSE","Change in Glycated Hemoglobin (HbA1c) from Baseline at Week 20 Compared to Placebo [Baseline, Week 20]",null,null,"NO",null],["NCT07668388","A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","300","Diabetes Mellitus, Type 2","DRUG:UBT251; DRUG:UBT251 Placebo; DRUG:Semaglutide; DRUG:Semaglutide Placebo","Novo Nordisk A/S","2026-06-22","2027-10-04","FALSE","UBT251: Change in glycated haemoglobin (HbA1c) [From baseline (week 0) to 12 weeks on a given maintenance dose (week 16, 28 and 40)]",null,null,"YES","OTHER:U1111-1329-7014; OTHER:2026-525465-42"],["NCT06937060","Effect of Semaglutide in Patients With Psoriasis and Obesity","SEMPSO","RECRUITING","INTERVENTIONAL","PHASE3",null,"NONE","14","Psoriasis (PsO); Obesity and Overweight","BIOLOGICAL:semaglutide","The University of Hong Kong","2025-03-20","2026-07-31","FALSE","Change in mean Psoriasis Area and Severity Index (PASI) before and after semaglutide treatment. [36 weeks]",null,null,null,null],["NCT06604624","Semaglutide in Treatment of Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","SINGLE","462","Weight Management","DRUG:HD1916; DRUG:semaglutide","CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","2024-09-20","2025-08-27","FALSE","Relative percentage change in body weight from baseline at 44 weeks of treatment [Baseline through Week44]",null,null,null,null],["NCT07485062","Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes","MOTIVATE","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","164","Type 2 Diabetes; Cognitive Decline in Older Adults","DRUG:semaglutide; BEHAVIORAL:Moderate-Intensity Resistance Exercise; BEHAVIORAL:Balance and Tone (BAT) Exercise","Western University, Canada","2026-09-01","2029-05-01","FALSE","Trail Making Test (TMT) Part A and B [Baseline (Week 0), Midpoint (Week 16), Endpoint (Week 32)]",null,null,"NO","OTHER_GRANT:528313"],["NCT07627191","GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer",null,"RECRUITING","INTERVENTIONAL","EARLY_PHASE1","NON_RANDOMIZED","NONE","30","Pancreatic Cancer; Colorectal Cancer; Hepatocellular Carcinoma","DRUG:GLP1-RA (semaglutide)","University of Arizona","2026-10-10","2028-06-30","FALSE","Incidence of Treatment Emergent Adverse Events [Safety] attributed to GLP1-RA and/or its interaction with chemotherapy [Up to 6 months or at time of disease progression, whichever comes first]",null,null,"NO",null],["NCT07597018","A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","234","Obesity; Overweight","DRUG:Cagrilintide D; DRUG:Cagrilintide B and placebo semaglutide I","Novo Nordisk A/S","2026-05-18","2027-05-28","FALSE","AUC,ss: area under the total cagrilintide concentration-time curve at steady state after 5th dosing of cagrilintide s.c. [Day 113 (pre-dose) to Day 120 (post-dose)] | Cmax,ss: maximum concentration of total cagrilintide at steady state after 5th dosing of cagrilintide s.c. [Day 113 (pre-dose) to Day 120 (post-dose)]",null,null,"YES","OTHER:U1111-1314-9337; OTHER:2025-521384-12; NIH:2025"],["NCT02077946","A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden",null,"COMPLETED","OBSERVATIONAL",null,null,null,"1059","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:sitagliptin","Novo Nordisk A/S","2014-02-10","2014-09-03","FALSE","Percent (%) of patients achieving at least 1 %-point HbA1c (glycosylated haemoglobin) reduction [Day 0, Day 180]","BACKGROUND:27216947",null,null,"OTHER:U1111-1151-9632"],["NCT07527195","Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)","RASMUS","RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","100","Obesity","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo cagrilintide; DRUG:Placebo semaglutide","Novo Nordisk A/S","2026-04-10","2028-04-28","FALSE","Change in insulin-stimulated fluorodeoxyglucose (FDG) uptake in skeletal muscle [Baseline to Week 51]",null,null,"YES","OTHER:U1111-1321-8655; OTHER:2025-522920-28; NIH:2025"],["NCT05520775","Semaglutide for Alcohol Use Disorder",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","48","Alcohol Use Disorder; Cigarette Smoking","DRUG:Semaglutide; DRUG:Sham/placebo","University of North Carolina, Chapel Hill","2022-09-02","2024-04-12","TRUE","Change in Alcohol Consumed [Baseline (Week 0) to post-medication (Week 8)] | Change in Breath Alcohol Concentration [Baseline (Week 0) to post-medication (Week 8)]","DERIVED:39937469","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/75/NCT05520775/Prot_SAP_001.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/75/NCT05520775/ICF_003.pdf","YES","NIH:R21AA026931-02"],["NCT07225686","Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy","MARITIME-OSA-1","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","250","Obesity; Obstructive Sleep Apnea","DRUG:Maridebart cafraglutide; DRUG:Placebo","Amgen","2025-12-19","2027-08-20","FALSE","Change in Apnea-Hypopnea Index (AHI) from baseline at week 52 [At week 52]",null,null,"YES",null],["NCT07073053","The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","60","Glucagon-Like Peptide-1 Receptor Agonists; Type 2 Diabetes; Coronary Arterial Disease (CAD)","DRUG:Semaglutide 1.0 mg; DRUG:Semaglutide 0.5 mg","Taipei Veterans General Hospital, Taiwan","2025-10-01","2028-07-31","FALSE","change of Time-in-range (%) [From enrollment to the end of treatment at 24 weeks] | change of HbA1c [From enrollment to the end of treatment at 24 weeks] | change of Flow-Mediated Dilatation (FMD) [From enrollment to the end of treatment at 24 weeks]",null,null,"NO",null],["NCT02931383","Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance","US-LOSEIT-II","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","150","Osteoarthritis; Obesity","DRUG:Liraglutide 3 mg (Saxenda); DRUG:Liraglutide 3 mg placebo","Henrik Gudbergsen","2016-11","2019-02","FALSE","Change in the degree of inflammation in the knee-joint (Greyscale-score) [Week 0 to 52]",null,null,null,null],["NCT07734870","Tirzepatide for Treatment of CCCA",null,"RECRUITING","INTERVENTIONAL","PHASE2",null,"NONE","20","Central Centrifugal Cicatricial Alopecia (CCCA)","DRUG:Tirzepatide","Johns Hopkins University","2026-09-15","2028-05-25","FALSE","Change in Central Centrifugal Cicatricial Alopecia Clinical Activity Tool Score [Baseline, 3 months, 6 months] | Change in Scalp Gene-Expression Profiles [Baseline, 6 months]","BACKGROUND:40771443; BACKGROUND:29282458; BACKGROUND:38856224; BACKGROUND:39230880; BACKGROUND:33378699; BACKGROUND:29913259; BACKGROUND:35007355; BACKGROUND:33609590; BACKGROUND:24680004",null,"NO",null],["NCT06640972","Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","68","Triglycerides; Weight Gain Trajectory; Cholesterol, Elevated","DRUG:RDX-002; DRUG:Placebo","Response Pharmaceuticals","2024-09-27","2025-01-04","TRUE","Incremental Postprandial Triglycerides (TG) [12 weeks]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/72/NCT06640972/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/72/NCT06640972/SAP_001.pdf",null,null],["NCT07200622","Oral Semaglutide in Patients With Alzheimer's Disease",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","60","Alzheimer Disease","DRUG:Semaglutide (Rybelsus®); DRUG:Placebo","Imperial College London","2025-09-25","2027-12-31","FALSE","To evaluate the safety and tolerability of oral semaglutide in an AD population. [Adverse events monitoring: Baseline; Weeks 4, 8, 26, 39, 52]",null,null,"UNDECIDED",null],["NCT07220629","Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)","RESOLVE-2","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","82","Obesity","DRUG:NT-0796; DRUG:Placebo","Rezera (formerly NodThera Limited)","2025-10-02","2026-08-21","FALSE","Assess the safety and tolerability of NT-0796 as an adjunct to semaglutide in participants with obesity by assessing AEs and SAEs, symptoms of nausea and vomiting, clinical laboratory parameters, vital signs and ECGs. [Baseline to Week 24]",null,null,null,null],["NCT06154486","Evaluation of Gastric Content of Volunteers Fasting and Using Semaglutide: an Observational and Cross-sectional Study",null,"COMPLETED","OBSERVATIONAL",null,null,null,"30","Pneumonia, Aspiration; Anesthesia","DRUG:semaglutide use","Hospital Israelita Albert Einstein","2023-06-19","2023-06-19","FALSE","prevalence of full stomach after fasting for at least 8 hours [1 day]","BACKGROUND:34268675; BACKGROUND:28958851; BACKGROUND:33403167; BACKGROUND:34019629; BACKGROUND:28045707; BACKGROUND:29624530; BACKGROUND:19512861; BACKGROUND:25951832; BACKGROUND:3896910",null,"UNDECIDED",null],["NCT01018173","A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","2118","Diabetes Mellitus Type 2","DRUG:placebo; DRUG:taspoglutide","Hoffmann-La Roche","2010-01","2011-01","FALSE","Time to cardiovascular composite primary endpoints [event-driven, cardiovascular assessments weeks 1,4,12 and every 3 to 4 months thereafter]",null,null,null,"OTHER:2009-014986-22; NIH:2009"],["NCT01226966","Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes","EVIDENCE","COMPLETED","OBSERVATIONAL",null,null,null,"3152","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2010-09","2013-11","FALSE","Percentage of patients still in liraglutide treatment and having a HbA1c (glycosylated haemoglobin) value below 7.0% [Month 24]","RESULT:26424330; RESULT:28138803",null,null,"OTHER:U1111-1116-2722"],["NCT06739122","A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)",null,"RECRUITING","INTERVENTIONAL","PHASE3",null,"NONE","55","Type 2 Diabetes","DRUG:Dulaglutide","Eli Lilly and Company","2025-01-10","2027-12","FALSE","Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration [Baseline through Week 26]",null,null,"YES","OTHER:H9X-MC-GBGS"],["NCT07424430","Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes","SEMA-CKM","COMPLETED","OBSERVATIONAL",null,null,null,"3392","Diabetes (DM); Type 2 Diabetes; Obesity (Disorder)","DRUG:Semaglutide (SEMA)","LMC Diabetes & Endocrinology Ltd.","2026-02-20","2026-09-28","FALSE","Change in HbA1c- 3 Years [Baseline to 3 Years]",null,null,"NO",null],["NCT05938712","The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients","HALLMARK","RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","20","Kidney Transplant Recipients","DRUG:Dapagliflozin 10 MG; DRUG:Semaglutide, 1.0 mg/mL","University Health Network, Toronto","2023-10-24","2027-10-01","FALSE","Proximal tubular natriuresis with combination therapy [From baseline to combination therapy end (24 weeks)] | Proximal tubular natriuresis with monotherapy [From baseline to monotherapy end (12 weeks)]",null,null,"NO",null],["NCT05348122","A Study of TG103 Injection in Type 2 Diabetes Subjects",null,"UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","SINGLE","240","Type 2 Diabetes Mellitus","DRUG:TG103,Q2W; DRUG:TG103,QW; DRUG:Placebo,Q2W; DRUG:Placebo,QW; DRUG:Dulaglutide,QW","CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","2022-06-15","2023-11-01","FALSE","Changes in glycosylated hemoglobin (HbA1c) from baseline to week 17 [Baseline through Day 113]",null,null,"NO",null],["NCT07731256","Semaglutide for Low Back Pain",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","250","Lower Back Pain; Obesity (BMI>30); Chronic Lower Back Pain; glp1 Agonist","DRUG:Semaglutide (administered by PDS290 pen-injector); DRUG:Placebo (administered by PDS290 pen-injector)","Washington University School of Medicine","2027-02-01","2031-01-01","FALSE","BPI-SF Pain Severity Scale [Baseline, up to 52 weeks]","BACKGROUND:32520773; BACKGROUND:34051018; BACKGROUND:37385275; BACKGROUND:28192789; BACKGROUND:35507483; BACKGROUND:8080219; BACKGROUND:40016636; BACKGROUND:39301951; BACKGROUND:39808758; BACKGROUND:20007994; BACKGROUND:27537761; BACKGROUND:39833406; BACKGROUND:39476345; BACKGROUND:39476339; BACKGROUND:37351564; BACKGROUND:36662529; BACKGROUND:31797139; BACKGROUND:35606809; BACKGROUND:32125402; BACKGROUND:29573870; BACKGROUND:37273833",null,"YES",null],["NCT07302802","Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice",null,"RECRUITING","OBSERVATIONAL",null,null,null,"70","Monogenic Obesity","DRUG:Semaglutide (administered by PDS290 pen-injector)","Prof. Dr. Martin Wabitsch","2025-12-01","2028-06","FALSE","Proportion of participants achieving ≥10% BMI reduction from baseline (week 0) to week 68. [68 weeks]","BACKGROUND:34291582; BACKGROUND:33205056; BACKGROUND:35528826; BACKGROUND:34097736; BACKGROUND:28377240",null,"NO",null],["NCT02602600","Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis","GAP","COMPLETED","INTERVENTIONAL","PHASE4",null,"NONE","33","Microvascular Angina","DRUG:Liraglutide","Eva Prescott","2015-11-19","2017-04-18","FALSE","Change from baseline in Coronary Flow Reserve [Assessed at baseline, week 4 and week 18] | Change from baseline in Angina Symptoms [Assessed at baseline, week 4 and week 18]","RESULT:20220183; RESULT:21911339; RESULT:16720691; RESULT:19433695; RESULT:20579539; RESULT:11320360; RESULT:17314342; RESULT:24705387; RESULT:24563437; RESULT:24855202; RESULT:15313949; RESULT:18427132; RESULT:19151200; RESULT:22496084; RESULT:23868944; RESULT:24503784; RESULT:20075143; RESULT:21586690; RESULT:21561896; RESULT:14981009; RESULT:25896352; RESULT:25082954; DERIVED:30773266",null,null,null],["NCT01593137","A Long-term Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes","ADELANTE","WITHDRAWN","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","0","Type 2 Diabetes","DRUG:Liraglutide + metformin; DRUG:Glimepiride + metformin","Fundación Fernández-Cruz","2012-05","2013-12","FALSE","assess the effect of treatment with liraglutide compared to glimepiride, as add-on to metformin, for one year on circulating levels of EPCs in patients with type 2 diabetes poorly controlled. [1 year]",null,null,null,"EUDRACT_NUMBER:2012-000311-87"],["NCT03068065","Antidiabetic Effects on Intrahepatic Fat",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","87","Non-Alcoholic Fatty Liver Disease; Type2 Diabetes","DRUG:Liraglutide; DRUG:Metformin; DRUG:Gliclazide","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","2014-05","2014-11","FALSE","Intrahepatic fat [-7±3days; 168±3days]",null,null,"UNDECIDED",null],["NCT03175211","Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male Volunteers",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","SINGLE","20","Healthy","DRUG:BI 456906; DRUG:Placebo","Boehringer Ingelheim","2017-06-30","2018-02-19","FALSE","[N (%)] of subjects with drug-related adverse events. [Up to 672 hours]","DERIVED:36527386",null,null,"EUDRACT_NUMBER:2017-000295-29; NIH:2017"],["NCT02472236","Evaluate the Pharmacokinetics of Digoxin When Coadministered With PEX168 in Healthy Adult Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","16","Healthy","DRUG:PEX168; DRUG:Digoxin","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2015-06-08","2015-09-24","FALSE","Composite measure the plasma concentrations of Digoxin. [Baseline to Day44]",null,null,null,null],["NCT02081118","Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","209","Type 2 Diabetes","DRUG:HM11260C; DRUG:Placebo","Hanmi Pharmaceutical Company Limited","2014-02","2015-03","FALSE","Change in baseline in glycosylated haemoglobin (HbA1c) at 16 weeks [Up to day 155]",null,null,null,null],["NCT04702516","The Effect of Semaglutide on Bone Turnover in Patients With Increased Risk of Bone Fracture",null,"UNKNOWN","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","QUADRUPLE","64","Osteopenia","DRUG:Ozempic; DRUG:Placebo","Morten Frost","2021-03-24","2022-08-31","FALSE","Procollagen type 1 N-terminal propeptide (P1NP) [Baseline and 52 weeks]","DERIVED:38737002",null,null,"EUDRACT_NUMBER:2020-000616-29; OTHER_GRANT:0052699; OTHER_GRANT:18/51856; OTHER_GRANT:A35844"],["NCT06485089","Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers",null,"COMPLETED","OBSERVATIONAL",null,null,null,"25","Obesity; Breast Cancer Risk","DRUG:tirzepatide","University of Kansas Medical Center","2024-09-14","2026-03-25","FALSE","Feasibility of design as assessed by accrual rate of 1 or more per month over 12 months [12 months] | Completion rate of 70% or more [6 months]",null,null,"NO",null],["NCT06184568","A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","349","Type 2 Diabetes; Obesity","DRUG:IBI362; DRUG:Semaglutide","Innovent Biologics (Suzhou) Co. Ltd.","2024-02-29","2025-09-17","FALSE","Proportion of subjects who achieve composite endpoint of HbA1c <7.0% and ≥10% weight loss [Week 32]",null,null,null,null],["NCT06182891","Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","300","Type 2 Diabetic Nephropathy","DRUG:Dulaglutide Injection","The Affiliated Hospital of Xuzhou Medical University","2021-10-30","2023-06-30","FALSE","Evaluation of the urinary albumin-to-creatinine ratio [3,6 and 12 months after dulaglutide injection treatment] | Evaluation of the biomarkers of the epithelial-mesenchymal transition process [3,6 and 12 months after dulaglutide injection treatment]","DERIVED:39963952",null,"NO",null],["NCT02860923","Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy","CRANIOEXE","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","42","Craniopharyngiomas; Hypothalamic Obesity","DRUG:Exenatide; DRUG:Placebo","University Hospital, Bordeaux","2017-01-11","2018-06-30","FALSE","Compare body weight change thanks to weighing machine [baseline and 6 months]","RESULT:38450721",null,"NO","EUDRACT_NUMBER:2013-004755-21"],["NCT06536023","This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","36","Adolescents With Obesity","DRUG:IBI362; DRUG:IBI362 placebo","Innovent Biologics (Suzhou) Co. Ltd.","2024-08-30","2025-07-22","FALSE","Incidence of adverse events and serious adverse events [up to week 20]",null,null,"NO",null],["NCT04083820","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)","SURE FRANCE","COMPLETED","OBSERVATIONAL",null,null,null,"521","Diabetes Mellitus, Type 2","DRUG:semaglutide","Novo Nordisk A/S","2019-09-16","2021-09-27","FALSE","Change in Glycated Haemoglobin A1c (HbA1c) [Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38)]","BACKGROUND:36869853",null,"YES","OTHER:U1111-1222-5620"],["NCT03015220","Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes","PIONEER 10","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","458","Diabetes; Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Dulaglutide","Novo Nordisk A/S","2017-01-10","2018-07-12","TRUE","Number of Treatment-emergent Adverse Events (TEAEs) [Weeks 0-57]","RESULT:33460016; RESULT:32333876; DERIVED:32998732; DERIVED:32267058; DERIVED:31903692","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/20/NCT03015220/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/20/NCT03015220/SAP_001.pdf","YES","OTHER:U1111-1181-4133; OTHER:JapicCTI-173485"],["NCT02920190","Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat",null,"WITHDRAWN","INTERVENTIONAL","PHASE4",null,"NONE","0","Monoclonal Gammopathies; Overweight; Obesity","DRUG:Liraglutide","University of Miami","2020-09-01","2021-09-01","FALSE","Change in Epicardial Fat Thickness [Baseline, 12 months]",null,null,"NO",null],["NCT05360147","Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","SINGLE","30","Type 2 Diabetes Mellitus","DRUG:Liraglutide; DRUG:Oral antidiabetic drugs: Metformin, Sulfonylureas (2nd generation), Thiazolidinediones, α-Glucosidase inhibitors, and Glinides","Third Military Medical University","2021-01-20","2021-04-20","FALSE","Changes in cognitive function from baseline to 12 weeks [0 week, 12 week]",null,null,null,null],["NCT05333835","A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes",null,"UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","455","Type 2 Diabetes","DRUG:HR17031 injection; DRUG:INS068 injection; DRUG:SHR20004 injection","Jiangsu HengRui Medicine Co., Ltd.","2022-07-08","2024-03-30","FALSE","Mean Change From Baseline in HbA1c at Week 26 [at Week 26]",null,null,"UNDECIDED",null],["NCT02773355","Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients",null,"COMPLETED","OBSERVATIONAL",null,null,null,"27","Obesity","DRUG:liraglutide 3.0 mg","Novo Nordisk A/S","2016-05-16","2021-11-30","FALSE","Frequency of pancreatitis [Year 0-3]",null,null,null,"OTHER:U1111-1170-6497"],["NCT02162550","Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","148","Type 2 Diabetes","DRUG:Bydureon; DRUG:placebo","Phoenix VA Health Care System","2014-06","2019-04","FALSE","Change in carotid plaque volume [18 months]","DERIVED:33495294",null,"NO",null],["NCT02168491","Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin","LixiBIT","COMPLETED","INTERVENTIONAL","PHASE3",null,"NONE","10","Type 2 Diabetes Mellitus","DRUG:Lixisenatide; DRUG:Insulin glargine","Medical University of Vienna","2014-11","2015-07","TRUE","Change in HbA1c From Baseline to End [12 weeks]","DERIVED:28357772",null,null,"EUDRACT_NUMBER:2013-005334-37"],["NCT00614120","Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","929","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo; DRUG:glimepiride; DRUG:metformin","Novo Nordisk A/S","2008-01","2009-02","TRUE","Change in Glycosylated Haemoglobin A1c (HbA1c) [week 0, week 16]","RESULT:21114607; RESULT:23010561; RESULT:25504028; RESULT:25684604; DERIVED:21450987",null,null,null],["NCT04904913","A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","328","Overweight/ Obesity","DRUG:IBI362; OTHER:placebo","Innovent Biologics (Suzhou) Co. Ltd.","2021-06-08","2023-03-29","FALSE","Percent Change from Baseline in Body Weight [Baseline ,week 24]","DERIVED:41875890; DERIVED:38092790",null,null,null],["NCT01654120","Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","37","Diabetes Mellitus, Type II","DRUG:Liraglutide; DRUG:Insulin","Mountain Diabetes and Endocrine Center","2011-12","2013-11","FALSE","Change from baseline in HbA1c at six months [baseline and six months]",null,null,null,null],["NCT07588438","Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay.","REAL-TIRZEPY","RECRUITING","INTERVENTIONAL","PHASE4","NON_RANDOMIZED","NONE","160","Obesity; Diabetes Mellitus, Type 2","DRUG:Tirzepatide (LIPOLESS de Laboratorio de Productos Eticos C.E.I.S.A.)","Las Rías Medical Center","2026-07-27","2027-08-10","FALSE","Mean Percent Change From Baseline in Body Weight at 52 Weeks. [Baseline and 52 weeks.] | Mean Change From Baseline in Glycated Hemoglobin (HbA1c) at 52 Weeks. [Baseline and 52 weeks.] | Number of Participants With Treatment-Emergent Adverse Events (TEAEs). [Through week 52.]",null,null,"NO",null],["NCT03235050","A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","834","Diabetes Mellitus, Type 2","DRUG:MEDI0382 low dose; DRUG:MEDI0382 mid dose; DRUG:MEDI0382 high dose; DRUG:Placebo; DRUG:Liraglutide","AstraZeneca","2017-08-02","2018-05-03","TRUE","Change in HbA1c [From baseline to 14 weeks] | Percent Change in Body Weight [From baseline to 14 weeks]","DERIVED:34016612","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/50/NCT03235050/Prot_002.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/50/NCT03235050/SAP_003.pdf",null,null],["NCT06836284","The Evira Study: Additional Support During Obesity Treatment",null,"RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","40","Childhood Obesity; Treatment Adherence","DEVICE:Digi-physical treatment tool, Evira; DRUG:Obesity medication with liraglutide or semaglutide","Karolinska Institutet","2026-02-13","2027-04-01","FALSE","Change in BMI SDS [From start of treatment to six months follow-up]",null,null,"UNDECIDED",null],["NCT07223593","Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease","ATTAIN-PAD","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","1205","Peripheral Arterial Disease","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2025-10-31","2028-06","FALSE","Percent Change from Baseline in Maximum Walking Distance [Baseline, Week 52]",null,null,"YES","CTIS:2025-523283-21-00; OTHER:J2A-MC-GZPR; NIH:2025"],["NCT01733758","A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","494","Diabetes Mellitus, Type 2","DRUG:Albiglutide 30 mg weekly; DRUG:Albiglutide 50 mg weekly; DRUG:Placebo; DRUG:Liraglutide 0.9 mg daily","GlaxoSmithKline","2013-02","2014-06","TRUE","Model-adjusted Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 [Baseline and Week 24] | Mean HbA1c at Baseline, Week 24, and Change From Baseline at Week 24 [Baseline and Week 24]",null,null,"YES",null],["NCT01208649","Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH)",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","13","Nonalcoholic Fatty Liver Disease","DRUG:Exenatide","Ruhr University of Bochum","2008-07","2010-09","FALSE","histological activity of NASH (steatosis, necroinflammation, ballooning) [24 weeks]",null,null,null,null],["NCT05813912","A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3",null,"NONE","148","Diabetes Mellitus, Type 2","DRUG:Insulin Icodec; DRUG:Semaglutide","Novo Nordisk A/S","2023-09-22","2025-04-14","TRUE","Change in Glycated Haemoglobin (HbA1c) [Baseline (Week 26), Week 52]","DERIVED:42387310","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/12/NCT05813912/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/12/NCT05813912/SAP_001.pdf","YES","EUDRACT_NUMBER:2022-002847-24; OTHER:U1111-1281-4752"],["NCT02507128","Effects of Glucagon Like Peptide-1 on No-reflow",null,"UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","190","Acute ST-segment Elevation Myocardial Infarction","DRUG:liraglutide; DRUG:placebo","Chen Wei Ren, MD","2015-07","2016-07","FALSE","a change in the prevalence of no-reflow [immediately after PCI]","BACKGROUND:12517460; BACKGROUND:11997276; BACKGROUND:19021281; BACKGROUND:23506504; BACKGROUND:19195607",null,null,null],["NCT05746039","Feasibility of Semaglutide in Advanced Lung Disease",null,"RECRUITING","INTERVENTIONAL","PHASE1; PHASE2",null,"NONE","8","Obesity; Interstitial Lung Disease; Chronic Obstructive Pulmonary Disease; Sarcoidosis, Pulmonary; Pulmonary Hypertension","DRUG:Semaglutide Pen Injector","University of Pennsylvania","2024-01-29","2027-12-28","FALSE","Tolerability [12 weeks]",null,null,"NO",null],["NCT07651319","Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease",null,"RECRUITING","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","QUADRUPLE","30","Alzheimer Dementia (AD)","DRUG:IL-2 (Aldesleukin); DRUG:Semaglutide Plus IL-2; DRUG:Placebo","The Methodist Hospital Research Institute","2026-09-01","2029-06","FALSE","Safety and the tolerability of IL-2 plus Semaglutide in AD patients [6 months treatment phase]",null,null,"NO",null],["NCT05882045","A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease","TRIUMPH-3","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","1946","Obesity; Cardiovascular Diseases","DRUG:Retatrutide; DRUG:Placebo","Eli Lilly and Company","2023-05-30","2026-04-16","FALSE","Percent Change from Baseline in Body Weight [Baseline, Week 80]",null,null,"YES","OTHER:J1I-MC-GZBM; OTHER:2023-503659-88-00; NIH:2023"],["NCT05897372","Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study","WP3","TERMINATED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","1","Diabetic Kidney Disease","DRUG:ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib","Iain Bressendorff","2023-08-01","2024-09-23","FALSE","urine albumin/creatinin-ratio (UACR) reduction to less than 50% of baseline [after 9 months of treatment]",null,null,"NO",null],["NCT02752828","Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan","LIXILAN JP-O2","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","521","Type 2 Diabetes Mellitus","DRUG:Insulin glargine/lixisenatide (HOE901/AVE0010); DRUG:Insulin glargine (HOE901); DRUG:Oral anti-diabetic drugs","Sanofi","2016-05-23","2018-03-12","FALSE","Change from baseline in HbA1c [Baseline, 26 weeks]","RESULT:32291880",null,null,"OTHER:U1111-1176-8450"],["NCT00082381","Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","551","Diabetes Mellitus, Type 2","DRUG:Exenatide (AC2993); DRUG:Insulin glargine","AstraZeneca","2003-06","2008-07","TRUE","Change in Glycosylated Hemoglobin (HbA1c) [Baseline, week 26]","RESULT:16230722; DERIVED:22913891; DERIVED:22236356",null,null,null],["NCT07815067","A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With Overweight or Obesity",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","320","Overweight; Obesity","DRUG:Zenagamtide injection; DRUG:Zenagamtide tablet","Novo Nordisk A/S","2026-09-07","2028-06-12","FALSE","AUC, zenagamtide, steady state (ss): area under the zenagamtide plasma concentration-time curve during a dosing interval at steady state [From 0 (pre-dose) up to Day 196 and Day 224]",null,null,"YES","OTHER:U1111-1316-5947; OTHER:2025-521383-35; NIH:2025"],["NCT06005012","Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM","SAMARA","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","120","Fibrosis, Liver; Type 2 Diabetes Mellitus in Obese; Non-Alcoholic Fatty Liver Disease","DRUG:Semaglutide; DRUG:Placebo","University of California, San Diego","2023-07-25","2026-12-31","FALSE","Change in fibrosis due to NAFLD [52 weeks]",null,null,null,null],["NCT06900075","Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Q2W in T2D Patients",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","88","Type 2 Diabetes","DRUG:Efsubaglutide Alfa 3mg Q2W and 1mg QW; DRUG:Efsubaglutide Alfa 1mg QW and 3mg Q2W","Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","2025-07-30","2026-01-30","FALSE","Time in range (TIR) [6-8 weeks]",null,null,null,null],["NCT04259801","First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","152","Healthy Volunteers; Overweight; Obesity; Diabetes Mellitus, Type 2","DRUG:NNC0480-0389; DRUG:Semaglutide; DRUG:Placebo (NNC0480-0389); DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2020-02-17","2022-03-16","FALSE","Number of treatment emergent adverse events (TEAE) in Part 1 [From time of dosing (day 1) until completion of follow-up visit (day 71)] | Number of treatment emergent adverse events (TEAE) in Part 2 [From first combination dosing (day 57) until completion of follow-up visit (day 148)]",null,null,"YES","REGISTRY:2019-002857-44; OTHER:U1111-1236-4114; NIH:2019"],["NCT05073692","Comparison of Type 2 Diabetes Pharmacotherapy Regimens","ON TARGET DM","COMPLETED","OBSERVATIONAL",null,null,null,"241981","Type 2 Diabetes Mellitus; Cardiovascular Diseases","DRUG:SU; DRUG:DPP4; DRUG:SGLT2i; DRUG:GLP-1RA; DRUG:SGLT2i or GLP-1RA; DRUG:Linagliptin (DPP4); DRUG:Exenatide (GLP-1RA); DRUG:Liraglutide (GLP-1RA); DRUG:Empagliflozin (SGLT2i); DRUG:Glimepiride (SU); DRUG:Glipizide (SU); DRUG:Glimepiride (SU) or Glipizide (SU); DRUG:SU or DPP4 (excluding saxagliptin and alogliptin); DRUG:Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)","Kaiser Permanente","2021-07-01","2024-12-31","TRUE","Incidence of 3-point Major Adverse Cardiovascular Events (MACE) [2.5 years]","BACKGROUND:38488777; RESULT:38745886; RESULT:40734551; RESULT:41091469","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/92/NCT05073692/Prot_SAP_000.pdf","NO",null],["NCT07535307","Investigating How NNC0487-0111 Regulates Insulin of Adults With Type 2 Diabetes",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","80","Diabetes Mellitus","DRUG:NNC0487-0111; DRUG:Placebo","Novo Nordisk A/S","2026-04-10","2027-11-11","FALSE","Change in M-value in Hyperinsulinaemic euglycaemic clamp (HEC) [Baseline to week 40]",null,null,"YES","OTHER:U1111-1320-4780; OTHER:2025-521595-55; NIH:2025"],["NCT05556512","A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity","SURMOUNT-MMO","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","15374","Obesity; Overweight","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2022-10-11","2027-10","FALSE","Time to First Occurrence of Any Component Event of Composite (All-Cause Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Coronary Revascularization, or Heart Failure Events) [Up to 5 Years]","DERIVED:41589430",null,"YES","OTHER:I8F-MC-GPIJ; OTHER:2022-501744-15-00"],["NCT06370728","A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","30","Healthy","DRUG:Orforglipron; DRUG:Carbamazepine","Eli Lilly and Company","2024-05-06","2024-07-23","TRUE","Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-∞]) of Orforglipron [Day 1 (Predose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours post-dose); Day 15 (Predose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours post-dose)] | PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of Orforglipron [Day 1 (Predose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours post-dose); Day 15 (Predose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours post-dose)] | PK: Maximum Observed Concentration (Cmax) of Orforglipron [Day 1 (Predose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours post-dose); Day 15 (Predose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours post-dose)]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/28/NCT06370728/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/28/NCT06370728/SAP_001.pdf","NO","OTHER:J2A-MC-GZPJ"],["NCT05153590","A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland",null,"COMPLETED","OBSERVATIONAL",null,null,null,"269","Obesity or Overweight","DRUG:Saxenda®","Novo Nordisk A/S","2021-12-03","2022-04-15","FALSE","Relative change in body weight greater than or equal to 5% (lower BMI with weight related comorbidities) or greater than or equal to 7% (higher BMI) in reimbursed setting (yes/no) [From Baseline (Week 0) to Week 16] | Relative change in body weight greater than or equal to 5%, conditionally to relative change greater than or equal to 5% or greater than or equal to 7% at Week 16 in reimbursed setting(yes/no) [From Week 16 to Month 10]",null,null,"YES","OTHER:U1111-1263-5715"],["NCT07272343","The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes",null,"RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","100","Type 2 Diabetes Mellitus (T2DM); Semaglutide; Caloric Restriction","DRUG:semaglutide; BEHAVIORAL:caloric restriction","Second Affiliated Hospital of Nanchang University","2023-02-10","2026-06-30","FALSE","HbA1c [From enrollment to the end of treatment at 12 weeks] | FPG [From enrollment to the end of treatment at 12 weeks] | 2hPG [From enrollment to the end of treatment at 12 weeks]",null,null,"NO",null],["NCT07859176","Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric Surgery",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","100","Morbid Obesity","DRUG:Semaglutide weekly injection; DRUG:Placebo","General Committee of Teaching Hospitals and Institutes, Egypt","2026-10","2028-04","FALSE","Percentage change in body weight [Baseline till 18 months]",null,null,"YES",null],["NCT04102189","A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","201","Overweight; Obesity","DRUG:Semaglutide; OTHER:Placebo","Novo Nordisk A/S","2019-10-07","2022-03-25","TRUE","Change in Body Mass Index (BMI) (Percentage [%]) [Baseline (week 0), week 68]","RESULT:36322838; DERIVED:37196421; DERIVED:36534451; DERIVED:35797460","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/89/NCT04102189/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/89/NCT04102189/SAP_001.pdf","YES","OTHER:U1111-1215-7560; EUDRACT_NUMBER:2018-002431-18; NIH:2018"],["NCT05482789","Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes",null,"RECRUITING","INTERVENTIONAL","PHASE4",null,"NONE","13","Gestational Diabetes","DRUG:Exenatide","Maisa N. Feghali, MD","2023-04-12","2025-12-31","FALSE","Area Under the Plasma Concentration Versus Time Curve (AUC) of glucose [Baseline and 1 week later]",null,null,"NO",null],["NCT07697391","AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes","AI-LIFE-T2D-OB","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","285","Obesity; Diabetes Mellitus, Type 2","BEHAVIORAL:AI-Assisted Intensive Lifestyle Intervention; DRUG:Tirzepatide; BEHAVIORAL:Standard Lifestyle Management","The First Affiliated Hospital of Anhui Medical University","2026-07-20","2027-10-31","FALSE","Percent Change in Body Weight From Baseline to Week 52 [Baseline to Week 52]",null,null,"NO","OTHER:MR-34-26-044995"],["NCT06792955","The Evaluation of Bioequivalence Between a Single-dose Pen and a Multi-dose Pen of HRS9531 Injection Solution",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","120","Overweight/Obesity","DRUG:HRS9531 injection","Fujian Shengdi Pharmaceutical Co., Ltd.","2025-02-11","2025-06-06","FALSE","The maximum plasma concentration (Cmax) [Post-dose at day 1 to day 43.] | Area under the concentration curve from time 0 to the last quantifiable concentration (AUClast) [Post-dose at day 1 to day 43.] | Area under the concentration curve from time 0 to extrapolated infinite time (AUCinf) [Post-dose at day 1 to day 43.]",null,null,"UNDECIDED",null],["NCT06659718","Emulation of the SOUL Diabetes Trial in Healthcare Claims",null,"COMPLETED","OBSERVATIONAL",null,null,null,"43650","Diabetes Mellitus, Type 2","DRUG:Oral semaglutide; DRUG:Sitagliptin","Brigham and Women's Hospital","2024-10-24","2025-02-13","FALSE","Major adverse cardiac event (MACE), including myocardial infarction, stroke and all cause death [Through study completion (1 day after cohort entry date until the first of outcome or censoring)]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/18/NCT06659718/Prot_SAP_003.pdf",null,null],["NCT04094415","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice","SURE ITALY","COMPLETED","OBSERVATIONAL",null,null,null,"581","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2019-10-28","2021-07-28","FALSE","Change in Glycated Haemoglobin A1c (HbA1c) (measured in percent) [Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)] | Change in HbA1c (measured in mmol/mol) [Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)]","BACKGROUND:36789682",null,"YES","OTHER:U1111-1233-2023"],["NCT05459285","A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","68","Type 2 Diabetes","BIOLOGICAL:14028 injection; BIOLOGICAL:dulaglutide injection","Sunshine Lake Pharma Co., Ltd.","2022-05-31","2022-07-02","FALSE","Maximum (peak) plasma drug concentration(Cmax) [0 hour (pre-dose,within 30mins) to 384 hours after administration] | Area under the plasma concentration-time curve from time zero to ∞ (AUC0-∞) [0 hour (pre-dose, within 30mins) to infinity]","BACKGROUND:26507721; BACKGROUND:21251179; BACKGROUND:21251178; BACKGROUND:28357715; DERIVED:38651744",null,"NO",null],["NCT05536804","A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes","TREASURE-CKD","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","134","Overweight; Obesity; Chronic Kidney Disease; Type 2 Diabetes; T2D","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2023-02-08","2026-07-06","FALSE","Percent Change from Baseline in Renal Sinus Fat Content (MRI) [Baseline, Week 52]","DERIVED:40512543; DERIVED:39963952",null,"YES","OTHER:I8F-MC-GPIG; EUDRACT_NUMBER:2021-005273-47; OTHER:2023-506082-60-00; NIH:2023"],["NCT01573806","Pharmacology of Exenatide in Pediatric Sepsis","PEPS","WITHDRAWN","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","QUADRUPLE","0","Septic Shock; Inflammation; Glucose Homeostasis; Organ Dysfunction; Health-related Quality of Life","DRUG:Exenatide; DRUG:Exenatide vehicle","Seattle Children's Hospital","2012-10","2014-10","FALSE","Exenatide associated adverse event occurence [From PICU admission to PICU discharge, an average interval of 7.5 days] | Exenatide pharmacokinetics: Area under the exenatide concentration curve for 4 subcutaneous exenatide injections administered every 12 hours. [48 hours following the first exenatide dose]","BACKGROUND:20215542; BACKGROUND:20701787; BACKGROUND:19446153; BACKGROUND:20228679",null,null,null],["NCT06611904","The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria",null,"UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","NONE","60","Urine Albumin (UAlb); Glycocalyx; Arterial Stiffness","DRUG:Dulaglutide; DRUG:DPP-4 Inhibitors","Attikon Hospital","2018-02-01","2022-02-05","FALSE","UACR [4 and 12 months] | PWV [4 and 12 months] | PBR [4 and 12 months] | GLS [4 and 12 months]","RESULT:31284526; RESULT:29310645; DERIVED:39768420",null,"UNDECIDED",null],["NCT01937598","Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","16","Type 2 Diabetes","DRUG:Placebo; OTHER:Mixed meal test; DRUG:Liraglutide; DRUG:Sitagliptin","Michael A. Nauck","2013-08","2014-04","TRUE","Incremental Area Under the Plasma Glucose (BG) Concentration-time Profile (AUC) [0 to 300 min post mixed meal test]",null,null,"UNDECIDED","EUDRACT_NUMBER:2013-001764-35"],["NCT07717814","A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","154","Overweight and Obesity","DRUG:AMG 133 (frozen liquid); DRUG:AMG 133 (liquid)","Amgen","2024-11-26","2025-05-22","FALSE","Maximum Observed Concentration (Cmax) of AMG 133 [Up to Day 120] | Area Under the Concentration-time Curve (AUC) From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of AMG 133 [Up to Day 120] | AUC From Time 0 Extrapolated to Infinity (AUCinf) of AMG 133 [Up to Day 120]",null,null,"YES",null],["NCT02846233","Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","22","Type 2 Diabetes Mellitus","DRUG:GLP1 receptor agonist; DRUG:basal insulin; DRUG:SGLT2 inhibitor; DRUG:Metformin","University of California, San Francisco","2016-08","2018-12","TRUE","Change in A1c at the End of Study Period [16 weeks (from baseline to end of study at 16 weeks)]","BACKGROUND:27222560; BACKGROUND:26731084; BACKGROUND:25011946","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/33/NCT02846233/Prot_SAP_000.pdf","NO",null],["NCT02042664","Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics",null,"COMPLETED","INTERVENTIONAL","PHASE3","NON_RANDOMIZED","NONE","44","Obesity; Diabetes","DRUG:BYETTA treatment; DRUG:Metformine","Assistance Publique Hopitaux De Marseille","2011-01","2015-01","FALSE","intracardiac triglyceride [3 years]","RESULT:27106272; DERIVED:37424866",null,null,"OTHER:2010-14"],["NCT05762471","Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","TRIPLE","142","Overweight or Obesity; Type2 Diabetes Mellitus","DRUG:GSBR-1290; DRUG:Placebo","Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics","2023-01-09","2024-04-11","FALSE","Incidence, severity and relationship of AE/SAE, vital signs, laboratory measures and ECG to assess safety and tolerability of multiple oral doses of GSBR-1290 in HOV and T2DM [42 days]",null,null,"YES",null],["NCT06825793","Semaglutide's Weight Loss Effects in Obesity",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","56","Obesity","DRUG:Semaglutide Subcutaneous Injection","Beijing Chao Yang Hospital","2025-02-20","2026-12-31","FALSE","Body weight [Weight changes will be measured at the following time points: before treatment, and at weeks 4, 8, 12, 16, 20, 24, and 28 after treatment] | Gut microbiota [Gut microtioba will be measured at the following time points: before treatment, and at weeks 4, 8, 12, 16, 20, 24, and 28 after treatment]",null,null,null,null],["NCT02200991","Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","136","Type 2 Diabetes Mellitus","DRUG:LIXISENATIDE AVE0010; DRUG:Sitagliptin; DRUG:Insulin glargine HOE901","Sanofi","2014-08","2015-11","FALSE","Change from baseline in postprandial plasma glucose at Day 29 after a standardized breakfast [Day 29 after first intake of investigational product]","DERIVED:28345162",null,null,"OTHER:U1111-1159-5323"],["NCT04383197","Exercise and GLP-1 RA on Insulin Secretion","EXISECRET","UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","NONE","30","Type 2 Diabetes","BEHAVIORAL:Endurance exercise training; DRUG:Semaglutide","University of Copenhagen","2019-12-10","2021-08","FALSE","Insulin secretion [Change from baseline insulin secretion after Exercise intervention(12 weeks).] | Insulin secretion [Change from baseline insulin secretion after 3 months of therapeutic semaglutide treatment] | Insulin secretion [Change from baseline insulin secretion after 3 months of combined exercise and therapeutic semaglutide treatment]","DERIVED:37265222",null,"NO",null],["NCT04190160","Quality of Life and Fixed-ratio Combination of Insulin Degludec and Liraglutide (iDegLira)","XETD2","COMPLETED","INTERVENTIONAL",null,null,"NONE","35","Type2 Diabetes","DRUG:IDegLira","Stefano Rizza","2018-11-19","2019-11-22","FALSE","Self reported quality of Life (CASP-19) [6 months] | The Diabetes Treatment Satisfaction (DTSQ) [6 months]",null,null,null,null],["NCT00620282","The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","49","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo; DRUG:glimepiride","Novo Nordisk A/S","2008-02","2010-05","TRUE","Change in Acetylcholine (ACh)-Mediated Forearm Blood Flow (FBF) [week 0, week 12]","RESULT:23010561; RESULT:25212693; RESULT:25504028",null,null,null],["NCT03940742","A Study of Tirzepatide in Participants With Impaired Liver Function",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","32","Hepatic Insufficiency","DRUG:Tirzepatide","Eli Lilly and Company","2019-07-22","2020-09-22","TRUE","Pharmacokinetics (PK): Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC[0-∞]) of Tirzepatide [Predose, 8, 12, 24, 48, 72, 96, 168 and 336 post dose] | PK: Maximum Observed Drug Concentration (Cmax) of Tirzepatide [Predose, 8, 12, 24, 48, 72, 96, 168 and 336 post dose]","DERIVED:35674880","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/42/NCT03940742/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/42/NCT03940742/SAP_001.pdf","NO","OTHER:I8F-MC-GPGQ"],["NCT07458269","Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","264","Obesity","DRUG:Ribupatide; DRUG:Placebo","Kailera","2026-03-04","2027-05","FALSE","Percent Change From Baseline in Body Weight at Week 48 [Baseline, Week 48]",null,null,"NO",null],["NCT02344641","Efficacy and Mechanism of Exenatide on Improving Heart Function in Type 2 Diabetes With Heart Failure Patients",null,"UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","NONE","234","Type 2 Diabetes Mellitus; Heart Failure","DRUG:Exenatide","Chinese Academy of Medical Sciences, Fuwai Hospital","2015-01","2016-12","FALSE","The change in plasma NT-proBNP level after using exenatide for 4 weeks [4 weeks]",null,null,null,null],["NCT06318442","The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced Diabetes",null,"RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","QUADRUPLE","60","Steroid-Induced Diabetes; Steroid Induced Hyperglycemia","DRUG:Semaglutide Oral Product; DRUG:Metformin Oral Tablet; DRUG:Placebo","Imperial College London","2024-05-15","2027-06-01","FALSE","Difference in Glucose tolerance [Through study completion, on day 7 dexamethasone and study medication]",null,null,null,null],["NCT01777282","A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","374","Diabetes Mellitus","DRUG:Albiglutide; DRUG:Sulfonylurea; DRUG:Biguanide; DRUG:Glinide; DRUG:Thiazolidinedione; DRUG:Alpha-glucosidase inhibitor","GlaxoSmithKline","2013-02-23","2015-01-27","TRUE","Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) [From Baseline through Week 52] | Number of Participants With Any Hypoglycemic Event [From Baseline through Week 52]","DERIVED:27852119",null,"YES",null],["NCT07508020","A Research Study Looking at How NNC0487-0111 Affects Food Intake, Appetite and Metabolism After Meals in People With Obesity",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","120","Obesity","DRUG:NNC0487-0111; DRUG:Placebo (matched to NNC0487-0111)","Novo Nordisk A/S","2026-03-30","2028-01-19","FALSE","Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 126 [From Baseline to Day 126] | Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 182 [From Baseline to Day 182] | Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 238 [From Baseline to Day 238]",null,null,"YES","OTHER:U1111-1319-9246; OTHER:2025-521393-34; NIH:2025"],["NCT06422624","A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human Subjects",null,"UNKNOWN","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","14","Diabetes Mellitus, Type 2","DRUG:Semaglutide Extended-release for Injectable Suspension, 1 mg; DRUG:Semaglutide Extended-release for Injectable Suspension, 4 mg; DRUG:Semaglutide Extended-release for Injectable Suspension, 8 mg","Bostal Drug Delivery Co., Ltd","2024-08","2024-11","FALSE","Cmax [From time zero up to the last time point with measurable concentration] | AUC0-t [From time zero up to the last time point with measurable concentration] | AUC0-inf [From time zero up to the last time point with measurable concentration]",null,null,null,null],["NCT07119450","The Study of [14C] GZR18",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","6","Overweight; Obese; Obesity","DRUG:GZR18 injection、[14C]GZR18 injection","Gan & Lee Pharmaceuticals.","2025-05-07","2025-08-13","FALSE","Primary Outcome Measure [Through study completion, an average of 1 year]",null,null,null,null],["NCT01783717","Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage",null,"UNKNOWN","INTERVENTIONAL",null,null,"NONE","10","Hypothalamic Obesity; Diabetes Mellitus","DRUG:Exenatide","Huashan Hospital","2012-12","2015-01","FALSE","Change in body weight frome baseline to end of the study. [3 months] | BMI [baseline and 3 months] | HbA1c [baseline and 3 months] | Blood glucose level. [3 months.] | Beta cell function. [baseline and 3 months] | Insulin sensitivity. [baseline and 3 months]",null,null,null,null],["NCT07401992","Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis","SEMAPSO","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","62","Psoriasis (PsO); Obesity & Overweight; Diabetes Mellitus - Type 2","DRUG:Semaglutide (Rybelsus®); DRUG:Placebo","Hospital Universitario Dr. Jose E. Gonzalez","2026-01-15","2027-02-28","FALSE","Effect of GLP-1 Receptor Agonists on SCD-1 Activity [Baseline to Week 12]",null,null,"YES",null],["NCT07709910","A Trial of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","382","Participants With Obesity and Knee Osteoarthritis","DRUG:Ribupatide Injection; DRUG:Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2026-07","2028-11","FALSE","Change from baseline in WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain score after 68 weeks of treatment [after 68 weeks of continuous treatment, assessed every few weeks] | Percentage change from baseline in body weight after 68 weeks of treatment [after 68 weeks of continuous treatment, assessed every few weeks]",null,null,"UNDECIDED",null],["NCT07765160","Clinical Trials of IBI3040 in Healthy Participants and Overweight or Obese Participants",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","96","Healthy Participants; Overweight or Obese Participants","DRUG:SAD: subcutaneous injection in the abdomen; DRUG:MAD: subcutaneous injection in the abdomen","Innovent Biologics (Suzhou) Co. Ltd.","2026-08-30","2027-11-10","FALSE","SAD: The incidence rate of adverse events (AE) [through study completion, an average of 60 days] | SAD: The incidence rate of serious adverse events (SAE) [through study completion, an average of 60 days] | SAD: Number of subjects with clinically significant changes in physical examination results [through study completion, an average of 60 days] | SAD: Number of subjects with clinically significant changes in vital signs [through study completion, an average of 60 days] | SAD: Number of participants with abnormal laboratory tests results [through study completion, an average of 60 days] | SAD: Number of subjects with clinically significant changes in twelve-lead electrocardiogram [through study completion, an average of 60 days] | MAD: The incidence rate of adverse events (AE) [through study completion, an average of 20 weeks] | MAD: The incidence rate of serious adverse events (SAE) [through study completion, an average of 20 weeks] | MAD: Number of subjects with clinically significant changes in physical examination results [through study completion, an average of 20 weeks] | MAD: Number of subjects with clinically significant changes in vital signs [through study completion, an average of 20 weeks] | MAD: Number of participants with abnormal laboratory tests results [through study completion, an average of 20 weeks] | MAD: Number of subjects with clinically significant changes in twelve-lead electrocardiogram [through study completion, an average of 20 weeks]",null,null,null,null],["NCT07537088","Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","468","T2DM (Type 2 Diabetes Mellitus); CKD - Chronic Kidney Disease","DRUG:Dulaglutide; DRUG:SGLT2i; DRUG:Finerenone","First Affiliated Hospital of Wannan Medical College","2026-05","2027-04","FALSE","Urine Albumin-to-Creatinine Ratio（UACR） [Change in UACR from baseline at Week 26]",null,null,"UNDECIDED",null],["NCT06732960","A Study of the Efficacy and Safety of Efsubaglutide Alfa in Overweight or Obesity Patients","LIGHT","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","50","Overweight or Obesity","BIOLOGICAL:Efsubaglutide Alfa; OTHER:Placebo","Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","2024-04-21","2024-11-18","FALSE","Weight [Baseline, 4 weeks after the target dose] | Adverse Event [Adverse events occurring within 4 weeks of the last dose from baseline]",null,null,"NO","OTHER:YN011-W201"],["NCT06097390","A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","121","Healthy Participants","DRUG:Semaglutide","Novo Nordisk A/S","2023-09-28","2024-02-22","FALSE","Adjusted AUC0-24h,sema; adjusted area under the semaglutide plasma concentration-time curve [From 0 to 24 hours after dosing on day 80 and 90]",null,null,"YES","OTHER:U1111-1289-1040"],["NCT05606913","A Study of IBI362 in Participants With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","731","Type 2 Diabetes","DRUG:dulaglutide; DRUG:IBI362","Innovent Biologics (Suzhou) Co. Ltd.","2023-01-06","2024-01-26","FALSE","HbA1c change from baseline at week 28 [Baseline, 28 weeks]","DERIVED:41407860",null,null,null],["NCT07081178","A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).","WeGoReal","TERMINATED","OBSERVATIONAL",null,null,null,"100","Obesity","DRUG:Semaglutide","Novo Nordisk A/S","2025-08-08","2025-12-18","FALSE","Change in relative body weight [From baseline to month 6 and month 9]",null,null,"YES","OTHER:U1111-1314-8335"],["NCT07539584","Adiponectin in Patients With Metabolic Disorders",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","130","Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD); Type 2 Diabetes Mellitus (T2DM)","DRUG:SGLT2 inhibitor; DRUG:GLP-1 RA","Moscow Regional Research and Clinical Institute (MONIKI)","2022-03-01","2024-04-08","FALSE","Change in serum HMW-adiponectin levels [Baseline and 6 months]",null,null,"NO",null],["NCT04513704","A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","156","Healthy Volunteers Type 2 Diabetes","DRUG:Oral Semaglutide","Novo Nordisk A/S","2020-08-28","2021-04-20","FALSE","Area under the semaglutide plasma concentration - time curve during a dosing interval after the 10th dosing (AUC0-24h,sema,day10) [From 0 to 24 hours after the 10th dosing (day 10)]","DERIVED:36932262",null,"YES","OTHER:U1111-1243-9641; REGISTRY:2019-004569-42; NIH:2019"],["NCT01562678","Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","28","Diabetes; Effects of Liraglutide Administration on Brain Activity; Weight Loss; Hunger","DRUG:Liraglutide; DRUG:Placebo","Beth Israel Deaconess Medical Center","2012-03","2014-05","TRUE","Change Between Highly Desirable vs. Less Desirable Food Cues in the Effect Size of Cortical Activation During Food Visualization [18 days of Liraglutide or placebo treatment]","DERIVED:36375643; DERIVED:26831302",null,null,null],["NCT06039826","A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","46","Overweight","DRUG:LY3437943; DRUG:Ethinyl Estradiol; DRUG:Drospirenone","Eli Lilly and Company","2023-09-12","2024-07-11","FALSE","Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time zero to 24 Hours Postdose (AUC0-24) of Ethinyl Estradiol [Predose on Day 1 up to 144 days postdose] | PK: Maximum Observed Concentration (Cmax) of Ethinyl Estradiol [Predose on Day 1 up to 144 days postdose] | PK: Time of Maximum Observed Concentration (Tmax) of Ethinyl Estradiol [Predose on Day 1 up to 144 days postdose] | PK: Area Under the Concentration Versus Time Curve from Time zero to 24 Hours Postdose (AUC0-24) of Drospirenone [Predose on Day 1 up to 144 days postdose] | PK: Maximum Observed Concentration (Cmax) of Drospirenone [Predose on Day 1 up to 144 days postdose] | PK: Time of Maximum Observed Concentration (Tmax) of Drospirenone [Predose on Day 1 up to 144 days postdose]",null,null,"NO","OTHER:J1I-MC-GZBV"],["NCT06858839","Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight","MARITIME-1","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","3853","Obesity","DRUG:Maridebart Cafraglutide; DRUG:Placebo","Amgen","2025-03-12","2027-01-21","FALSE","Percent Change From Baseline in Body Weight at Week 72 [Baseline and Week 72]",null,null,"YES","EUDRACT_NUMBER:2024-515524-36"],["NCT03239119","The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus",null,"UNKNOWN","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","456","Type2 Diabetes Mellitus","BIOLOGICAL:rE-4 5 mcg; BIOLOGICAL:rE-4 10 mcg; BIOLOGICAL:Placebo 5 mcg; BIOLOGICAL:Placebo 10 mcg","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","2017-11-30","2018-12-30","FALSE","Change in HbA1c from Baseline to Week 30 [Baseline (Day 1) to Week 30]",null,null,"NO",null],["NCT06287437","HRS9531 Controls Weight Regain in Obese Subjects",null,"UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","72","Obesity","DRUG:HRS9531; DRUG:HRS9531 placebo","Shanghai Zhongshan Hospital","2024-01-01","2025-06-30","FALSE","Percent Change in Body Weight from 24 weeks [36 weeks]",null,null,null,null],["NCT05779644","Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus",null,"UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","NONE","300","Metformin; Obesity, Abdominal; Diabetes Mellitus, Type 2; Abdominal Fat; Non-Alcoholic Fatty Liver Disease; Metabolism Disorder, Glucose; Metabolism Disorder, Lipid","DRUG:Liraglutide; DRUG:Semaglutide; DRUG:Metformin","RenJi Hospital","2023-02-23","2025-02-23","FALSE","Blood glucose [The twelfth week of treatment] | Blood insulin [The twelfth week of treatment] | Total cholesterol [The twelfth week of treatment] | Triglyceride [The twelfth week of treatment] | Lipoprotein [The twelfth week of treatment] | Weight [The twelfth week of treatment] | Abdominal fat distribution [The twelfth week of treatment]",null,null,"NO",null],["NCT04154072","A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","255","Parkinson Disease","DRUG:NLY01; DRUG:Vehicle","Neuraly, Inc.","2020-02-27","2023-02-14","FALSE","Change in Unified Parkinson's Disease Rating Scale in combined score of Parts II and III from baseline to 36 weeks [36 weeks]","DERIVED:38101901",null,"UNDECIDED",null],["NCT07465965","A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","60","Overweight; Obesity","DRUG:Semaglutide Nasal Spray; DRUG:Placebo; DRUG:Semaglutide Injection","Shanghai World Leader Pharmaceutical Co., Ltd.","2026-03-02","2026-08-21","FALSE","Maximum Plasma Concentration (Cmax) [Day 1 to Day 36 after administration] | Time to maximum concentration(Tmax) [Day 1 to Day 36 after administration] | Area under the concentration-time curve from time 0 to time t (AUC0-t) [Day 1 to Day 36 after administration] | Area under the concentration-time curve from time 0 to infinity(AUC0-∞) [Day 1 to Day 36 after administration] | Percentage of AUC extrapolated(AUC%Extrap) [Day 1 to Day 36 after administration] | Elimination half-life / Terminal half-life(t1/2) [Day 1 to Day 36 after administration] | Apparent volume of distribution during terminal phase, adjusted for bioavailability (Vz/F) [Day 1 to Day 36 after administration] | Apparent clearance, adjusted for bioavailability(CL/F) [Day 1 to Day 36 after administration] | Terminal elimination rate constant(λz) [Day 1 to Day 36 after administration] | Absolute bioavailability(F) [Day 1 to Day 36 after administration] | Incidence and severity of treatment emergent adverse events (TEAEs) [Day 1 to Day 36 after administration] | 12-Lead-ECGs(Electrocardiograms ) [Day 1 to Day 36 after administration] | Temperature [Day 1 to Day 36 after administration] | Pulse [Day 1 to Day 36 after administration] | Respiratory rate [Day 1 to Day 36 after administration] | Blood pressure [Day 1 to Day 36 after administration] | Urinalysis [Day 1 to Day 36 after administration] | Blood biochemistry [Day 1 to Day 36 after administration] | Thyroid function [Day 1 to Day 36 after administration] | Virology test [Day 1 to Day 36 after administration] | Urine pregnancy test [Day 1 to Day 36 after administration] | Physical examination, includes: head, ears, eyes, nose and throat, skin, lymph nodes, neck, chest, abdomen, heart, cardiovascular, musculoskeletal system/extremities, neurological system and body weight. [Day 1 to Day 4 after administration] | Hemoglobin [Day 1 to Day 36 after administration] | Hematocrit [Day 1 to Day 36 after administration] | Red blood cell count [Day 1 to day 36] | White blood cell count [Day 1 to day36] | Platelet count [Day 1 to day 36] | Neutrophil percentage [day 1 to day 36] | Eosinophil percentage [day 1 to day 36] | Basophil percentage [day 1 to day 36] | Monocyte percentage [day 1 to day 36] | Lymphocyte percentage [day 1 to day 36] | Activated partial thromboplastin time [Day 1 to day 36] | Prothrombin time [day 1 to day 36] | Fibrinogen [day 1 to day 36] | Thrombin time [day 1 to day 36]",null,null,"NO",null],["NCT00569907","Observational Study of Interstitial Glucose Monitoring With Continuous Glucose Monitoring to Track Patients Treated With Exenatide",null,"COMPLETED","OBSERVATIONAL",null,null,null,"18","Diabetes Mellitus Type 2",null,"HealthPartners Institute","2007-01","2009-05","FALSE",null,"BACKGROUND:3552508; BACKGROUND:15504997; BACKGROUND:15855572; BACKGROUND:16373894",null,null,null],["NCT06670209","A Phase I Clinical Study to Evaluate the Effect of GZR18 Injection on the Pharmacokinetics of Oral Metformin Hydrochloride Tablets in Overweight/Obese Subjects",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1",null,"NONE","32","Type 2 Diabetes","DRUG:GZR18 and metformin","Gan and Lee Pharmaceuticals, USA","2024-10-30","2025-03-19","FALSE","Cmax,ss [24 hours] | AUC0-tau [24 hours]",null,null,null,null],["NCT07757087","A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Overweight or Obesity, Compared to a Low-calorie Diet or Placebo",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","120","Overweight; Obesity","DRUG:NNC0487-0111; DRUG:Placebo; BEHAVIORAL:LED","Novo Nordisk A/S","2026-08-03","2028-09-18","FALSE","Change in sleeping metabolic rate (SMR) [Baseline (week 0) to week 12-26]",null,null,"YES","OTHER:U1111-1324-2934; OTHER:2025-522744-40; NIH:2025"],["NCT01508858","Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal Women",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","21","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo; DRUG:levonorgestrel / ethinylestradiol","Novo Nordisk A/S","2006-11","2007-04","FALSE","AUC of ethinylestradiol [] | AUC of levonorgestrel []","RESULT:25504028",null,null,"EUDRACT_NUMBER:2006-003904-21"],["NCT06700538","A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus",null,"RECRUITING","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","QUADRUPLE","180","Obesity","DRUG:ARO-INHBE; DRUG:Placebo; DRUG:Tirzepatide","Arrowhead Pharmaceuticals","2024-12-04","2027-09-17","FALSE","Number of Participants with Treatment-Emergent Adverse Events (TEAEs) [Up to Day 365]",null,null,"NO",null],["NCT07668765","GLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity","GLP-PROCT","NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"100","Morbid Obesity; Anorectal Diseases; Drug-Related Side Effects and Adverse Reactions; Constipation; Diarrhea","DRUG:GLP-1 receptor agonist therapy","Gazi University","2026-08","2027-04","FALSE","Incidence of newly developed proctologic disease [3 months]","BACKGROUND:26177483; RESULT:39649679; RESULT:33625476",null,"NO",null],["NCT01621178","A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)","AWARD-7","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","577","Type 2 Diabetes; Chronic Kidney Disease","DRUG:Dulaglutide; DRUG:Insulin glargine; DRUG:Insulin lispro","Eli Lilly and Company","2012-07","2016-06","TRUE","Change From Baseline in Hemoglobin A1c (HbA1c) [Baseline, 26 Weeks]","DERIVED:39963952; DERIVED:29910024",null,"YES","OTHER:H9X-MC-GBDX; EUDRACT_NUMBER:2012-000829-44"],["NCT06066515","A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight","SYNCHRONIZE™-1","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","726","Obesity","COMBINATION_PRODUCT:survodutide; COMBINATION_PRODUCT:Placebo","Boehringer Ingelheim","2023-11-25","2025-12-02","FALSE","Percentage change in body weight from baseline to Week 76 [Baseline and at Week 76] | Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76 [Baseline and at Week 76]","DERIVED:42253238; DERIVED:41187967",null,"YES","REGISTRY:U1111-1288-9400; REGISTRY:2022-502529-17-00"],["NCT01541215","Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes","Ellipse™","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","135","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo; DRUG:metformin","Novo Nordisk A/S","2012-11-13","2017-11-15","TRUE","Change in HbA1c (Glycosylated Haemoglobin) [Week 0, week 26]","BACKGROUND:31034184; DERIVED:33634589","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/15/NCT01541215/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/15/NCT01541215/SAP_001.pdf","YES","EUDRACT_NUMBER:2011-002605-29; OTHER:P/288/2010; OTHER:U1111-1121-8743; REGISTRY:CTRI/2013/10/004082"],["NCT02974244","Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal Insulins",null,"COMPLETED","OBSERVATIONAL",null,null,null,"7000","Type 2 Diabetes","DRUG:exenatide once weekly; DRUG:basal insulin","AstraZeneca","2014-10-28","2014-10-28","FALSE","Changes from baseline in HbA1c (%) [one year post-index] | Changes from baseline in weight (kg) [one year post-index]",null,null,null,null],["NCT03862716","Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira","REMITiDegLira","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","159","Type 2 Diabetes Mellitus","DRUG:IDegLira; DRUG:insulin degludec; DRUG:Metformin; BEHAVIORAL:Lifestyle Therapy","Population Health Research Institute","2019-04-23","2022-06-15","FALSE","Proportion of participants achieving drug-free diabetes remission [28 weeks after randomization]",null,null,null,null],["NCT06977438","GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward","GLOW","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","1020","Obesity, Childhood","DRUG:Semaglutide","University of Minnesota","2026-10-15","2031-01-31","FALSE","Body Mass Index (BMI) Reduction [24 months]",null,null,"YES",null],["NCT06247748","Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","28","Diabetes Mellitus, Type 2; Overweight","DRUG:Exendin-4 Fc fusion protein (JY09) injection; DRUG:Metformin Hydrochloride tablet; DRUG:Rosuvastatin calcium tablets; DRUG:Digoxin tablet","Beijing Dongfang Biotech Co., Ltd.","2023-10-19","2024-04-15","FALSE","The Metformin Peak Concentration (Cmax ) [During a dosing interval (0-36 hours) after the last of 7 repeated doses of metformin without JY09 exposure (Day 4) and at JY09 steady state (Day 88)] | Area under the Metformin blood concentration-time curve [During a dosing interval (0-36 hours) after the last of 7 repeated doses of metformin without JY09 exposure (Day 4) and at JY09 steady state (Day 88)] | The Rosuvastatin Peak Concentration (Cmax ) [From time 0 to 96 hours after a single dose of Rosuvastatin without JY09 exposure (Day 8) and at JY09 steady state (Day 95)] | Area under the Rosuvastatin blood concentration-time curve [From time 0 to 96 hours after a single dose of Rosuvastatin without JY09 exposure (Day 8) and at JY09 steady state (Day 95)] | The Digoxin Peak Concentration (Cmax ) [From time 0 to 168 hours after a single dose of Digoxin without JY09 exposure (Day 15) and at JY09 steady state (Day 102)] | Baseline-corrected difference of Corrected QT interval after multiple subcutaneous injections of JY09 injection [From time 0 to 72 hours after a single dose of JY09 (Day 22) and at JY09 steady state (Day 92)]",null,null,"NO",null],["NCT01392573","A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes","DUAL™ II","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","413","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide; DRUG:insulin degludec","Novo Nordisk A/S","2011-11-28","2012-10-01","TRUE","Change From Baseline in HbA1c (Glycosylated Haemoglobin) [Week 0, week 26]","BACKGROUND:28332144; BACKGROUND:28063135; RESULT:25114296; RESULT:26894800; RESULT:28282219; RESULT:30383495; DERIVED:39963952",null,null,"EUDRACT_NUMBER:2011-002336-72; OTHER:U1111-1121-4897"],["NCT06764056","Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)","METAfoie","NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","120","Metabolic Associated Fatty Liver Disease; Metabolic Associated-dysfunction Steatohepatitis (MASH); Obesity","DRUG:semaglutide; OTHER:Diet","Institut universitaire de cardiologie et de pneumologie de Québec, University Laval","2025-01","2026-05","FALSE","Liver Steatosis [From enrollment to the end of the clinical trial at 12 months (for 4 visits)] | Liver Stiffness [From enrollment to the end of the clinical trial at 12 months (for 4 visits)]",null,null,"NO",null],["NCT07036172","Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","460","Obesity Control","DRUG:HDM1702; DRUG:Wegovy ®","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2025-01-03","2026-04","FALSE","The percentage change in body weight from baseline to week 44 [week 44]",null,null,null,null],["NCT05516966","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","64","Diabetes Mellitus, Type 2","DRUG:HRS9531; DRUG:Placebo; DRUG:Dulaglutide Injection","Fujian Shengdi Pharmaceutical Co., Ltd.","2022-10-12","2023-05-24","FALSE","Incidence of Adverse Events (Safety and Tolerability) [Screening period up to Day 62]",null,null,"UNDECIDED",null],["NCT06495931","Study on Drug Interaction of HRS-1780 Tablets, Henagliflozin Tablets, Metformin Tablets and HRS-7535 Tablets in Healthy Human",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","24","Type 2 Diabetes Mellitus","DRUG:HRS-1780 tablets; DRUG:HR20033 tablets; DRUG:HRS-7535 tablets","Shandong Suncadia Medicine Co., Ltd.","2024-07-15","2024-08-13","FALSE","PK parameters：Cmax [0 hour to 24 hours after the last dosing] | PK parameters：AUC0-t [0 hour to 24 hours after the last dosing] | PK parameters：AUC0-∞ [0 hour to 24 hours after the last dosing]",null,null,"UNDECIDED",null],["NCT03842202","A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","72","Overweight; Obesity","DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2019-02-15","2019-11-04","FALSE","AUC0-5h,para: the area under the paracetamol concentration-time curve from 0 to 5 hours at steady state [0 to 5 hours after standardised meal (day 142)]","RESULT:33269530",null,"YES","OTHER:U1111-1215-9915; REGISTRY:2018-002497-42; NIH:2018"],["NCT01550653","Liraglutide Effects on Memory in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","40","Healthy","DRUG:liraglutide; DRUG:Placebo","University of Luebeck","2012-05","2013-12","FALSE","Change from Baseline in the immediate and delayed recall of a declarative memory task (word list recall) at time points indicated in \"time frame\" section. [Day -7 (immediate Recall 1), Day 0 (Delayed Recall 1), Day 1 (Immediate Recall 2), Day 7 (Delayed Recall 2), Day 28 (Immediate Recall 3), Day 35 (Delayed Recall 3)] | Change from baseline in the immediate and delayed recall of an Episodic Memory Task (story recall) at the time points indicated in the \"Time Frame\" - section. [Day -7 (immediate Recall 1), Day 0 (Delayed Recall 1), Day 28 (Immediate Recall 2), Day 35 (Delayed Recall 2)] | Change from baseline in performance on a two-dimensional object location task on day 1 and day 35. [Day -7, Day 1, Day 35] | Change from baseline in performance on a working-memory task on day 1 and day 35. [Day -7, Day 1, Day 35] | Change from baseline in immediate and delayed recall of a procedural memory task at the time points indicated in the \"Time Frame\" - section. [Day -7 (immediate Recall 1), Day 0 (Delayed Recall 1), Day 28 (Immediate Recall 2), Day 35 (Delayed Recall 2)]",null,null,null,null],["NCT05663515","A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs","EXCEED","RECRUITING","OBSERVATIONAL",null,null,null,"24000","Pancreatic Cancer","DRUG:Exenatide; DRUG:Non-GLP-1 RA based glucose lowering drugs","AstraZeneca","2024-09-30","2026-10-01","FALSE","Incidence rate of primary diagnosis of pancreatic cancer among exenatide exposed population [Follow-up starts from the index date to the study completion, an average of 1.5 years or less] | Hazard ratio of primary diagnosis of pancreatic cancer among exenatide exposed population [Follow-up starts from thr index date to the study completion, an average of 1.5 years or less]",null,null,"YES",null],["NCT06352424","A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","SINGLE","23","Obesity","DRUG:BI 456906; DRUG:BI 1820237; DRUG:Placebo for BI 1820237; DRUG:Placebo for BI 456906","Boehringer Ingelheim","2024-04-30","2025-02-24","FALSE","Blood Oxygen Level Dependent (BOLD) signal changes following treatment with single dose of BI 1820237 alone, BI 456906 alone, and combination of BI 1820237 + BI 456906 versus placebo [32 days plus up to 8 weeks wash-out for each sequence, up to 51 weeks]",null,null,"NO","REGISTRY:2023-506233-30-01; REGISTRY:U1111-1293-4672; NIH:2023"],["NCT07160257","A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","56","Type 2 Diabetes Mellitus","DRUG:Maridebart cafraglutide; DRUG:Placebo","Amgen","2025-08-05","2026-11-15","FALSE","Change from Baseline in M-value from Hyperinsulinemic-euglycemic Clamp at Week 25 [Baseline and Week 25]",null,null,"YES",null],["NCT05158244","Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","34","Type 2 Diabetes Mellitus","DRUG:PF-07081532; DRUG:Placebo","Pfizer","2021-12-22","2022-06-15","TRUE","Number of Participants With Treatment-emergent Adverse Events (All Causalities) [Baseline up to at least 28 days after last dose of study intervention (77 days)] | Number of Participants With Treatment-emergent Adverse Events (Treatment Related) [Baseline up to at least 28 days after last dose of study intervention (77 days)] | Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality) [Baseline up to 7-14 days after last dose of study drug (maximum: 56 days)] | Number of Participants With Pre-specified Categorical Post-Baseline Vital Signs Data [Baseline up to 14 days after last dose of study intervention (maximum: 56 days)] | Number of Participants With Pre-specified Categorical Post-Baseline Electrocardiogram (ECG) Data [Baseline up to 14 days after last dose of study intervention (maximum: 56 days)]","DERIVED:38751362","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/44/NCT05158244/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/44/NCT05158244/SAP_001.pdf","NO",null],["NCT02104037","Liraglutide in Spinal Fluid","LIRA-CSV","COMPLETED","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","8","Liraglutide Blood-brain Transfer","PROCEDURE:Lumbar puncture","Mikkel Christensen","2012-01","2013-12","FALSE","cerebrospinal fluid concentration of liraglutide [time 60 minutes]",null,null,null,null],["NCT02638805","Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","136","Diabetes Mellitus, Type 2","DRUG:ITCA 650 Osmotic Mini Pump 20/60 mcg/day; DRUG:ITCA 650 Osmotic Mini Pump 60 mcg/day; DRUG:Metformin; DRUG:Liraglutide","Intarcia Therapeutics","2015-12","2017-10","FALSE","Number (percentage) and severity of treatment-emergent adverse events (TEAEs) of nausea and/or vomiting [From Randomization to 34 weeks]",null,null,"NO",null],["NCT03059719","Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","SINGLE","36","Type II Diabetes Mellitus","BIOLOGICAL:Exenatide injection(Byetta); BIOLOGICAL:PB-119 injection","PegBio Co., Ltd.","2015-04-08","2016-09-30","FALSE","Incidence of treatment-emergent AE (safety and tolerability) [the change form base line lab values at 3 months]",null,null,"NO",null],["NCT03552757","Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity","STEP 2","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","1210","Obesity; Overweight","DRUG:Semaglutide 1.0 mg; DRUG:Semaglutide 2.4 mg; DRUG:Placebo I (Semaglutide); DRUG:Placebo II (Semaglutide)","Novo Nordisk A/S","2018-06-04","2020-03-24","TRUE","Change in Body Weight (%) - Semaglutide 2.4 mg Versus Placebo [Baseline (week 0) to week 68] | Participants Who Achieve (Yes/no): Body Weight Reduction ≥5% - Semaglutide 2.4 mg Versus Placebo [At week 68]","BACKGROUND:32441473; RESULT:33667417; DERIVED:40980163; DERIVED:39226070; DERIVED:38698650; DERIVED:36801984; DERIVED:30122305","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/57/NCT03552757/Prot_002.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/57/NCT03552757/SAP_003.pdf","YES","OTHER:U1111-1200-8148; OTHER:2017-003414-10; NIH:2017"],["NCT05172999","Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia",null,"COMPLETED","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","NONE","30","Atypical Endometrial Hyperplasia; Obesity; Fertility Issues","DEVICE:levonorgestrel-releasing intrauterine system; DRUG:Polyethylene Glycol Loxenatide","Fudan University","2022-01-08","2025-12-30","FALSE","Pathological complete response (CR) rates [From date of randomization until the date of CR, assessed up to 32 weeks.]",null,null,null,null],["NCT06603571","A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","367","Obesity; Overweight","DRUG:LY3841136; DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2024-09-20","2026-07-01","FALSE","Percent Change from Baseline in Body Weight [Baseline, Week 48]",null,null,"YES","OTHER:W8M-MC-LAA2; OTHER:W8M-MC-CWMM Master Protocol"],["NCT04641312","A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","67","Healthy; Type 2 Diabetes","DRUG:LY3457263; DRUG:Dulaglutide; DRUG:Placebo","Eli Lilly and Company","2020-11-25","2021-12-21","FALSE","Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline through Day 42]","DERIVED:42829171",null,"NO","EUDRACT_NUMBER:2020-001828-34; OTHER:J1R-MC-GZFA"],["NCT07462663","SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer","SHAPE-ENDO","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","80","Endometrial Cancer; Endometrial Cancer Stage I; Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I; Atypical Endometrial Hyperplasia; Endometrial Intraepithelial Neoplasia; Obesity & Overweight; BMI>40; Obesity; Obesity Grade III","DRUG:GLP-1 Receptor Agonist; DEVICE:Levonorgestrel IUD (Lng-IUD); DRUG:Oral Progestins; BEHAVIORAL:Dietetic-Nutritional intervention; BEHAVIORAL:Structured Exercise and Prehabilitation Program; PROCEDURE:Endometrial Biopsy With or Without Hysteroscopy; PROCEDURE:Radiologic Surveillance (MRI and Transvaginal Ultrasound); PROCEDURE:Standar upfront Surgery","Hospital Universitari de Bellvitge","2027-01","2031-04","FALSE","Recruitment Rate [From study opening to end of recruitment, up to 36 months.] | Acceptance of Randomization Rate [At baseline, before randomization.] | Participant Retention Rate [From randomization to surgery and 30 days postoperatively, up to 14 months.] | Adherence to the Assigned Intervention [From randomization to surgery and 30 days postoperatively, up to 14 months.] | Completion of the SHAPE-ENDO Multimodal Strategy [From randomization to week 28 or week 54.] | Proportion of SHAPE-ENDO Participants Reaching Surgery Without Tumor Progression [From randomization to surgery, up to 54 weeks.] | Incidence of Serious Adverse Events, Tumor Progression, and Study Discontinuation [From randomization to surgery and 30 days postoperatively, up to 14 months.]","BACKGROUND:40744042; BACKGROUND:36326317; BACKGROUND:38764577; BACKGROUND:27654262; BACKGROUND:29266019; BACKGROUND:27901412; BACKGROUND:39429275; BACKGROUND:40768192; BACKGROUND:36216945; BACKGROUND:33755728; BACKGROUND:33667417; BACKGROUND:17096437; BACKGROUND:35314087; BACKGROUND:40316173; BACKGROUND:34238643; BACKGROUND:30193337; BACKGROUND:33397713; BACKGROUND:23021687; BACKGROUND:25791635",null,"UNDECIDED",null],["NCT01237314","The Impact of Food on Blood Sugar in People With Type 2 Diabetes","REACT2","COMPLETED","OBSERVATIONAL",null,null,null,"46","Type 2 Diabetes",null,"HealthPartners Institute","2010-11","2013-05","FALSE","4-hour glycemic response at 3 time points [4 hours]",null,null,null,null],["NCT01596504","Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","142","Type 2 Diabetes Mellitus","DRUG:Lixisenatide (AVE0010); DRUG:Liraglutide; DRUG:Insulin Glargine; DRUG:Metformin","Sanofi","2012-05","2013-07","TRUE","Change From Baseline to Day 56 in Plasma Glucose Corrected Area Under The Plasma Concentration-Time Curve (AUC) From Time 0.5 Hours to 4.5 Hours [0.5 (prior to standardized breakfast), 0.67, 0.84, 1, 1.5, 2, 2.5, 3.5, 4.5 hours on Day -3 (baseline); 0.5 (prior to standardized breakfast), 0.67, 0.84, 1, 1.5, 2, 2.5, 3.5, 4.5 hours post study drug administration on Day 56]","RESULT:25887358",null,null,"EUDRACT_NUMBER:2012-000027-40; OTHER:U1111-1124-1364"],["NCT03426085","The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes",null,"UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","44","Autonomic Nervous System Diseases; Sweat Gland Diseases; Diabetic Neuropathy With Neurologic Complication","DRUG:Liraglutide 6 mg Solution for Injection; OTHER:Placebo","Eastern Virginia Medical School","2016-05","2020-04","FALSE","Sudomotor Function [One Year]",null,null,null,null],["NCT05195944","Semaglutide vs Sitagliptin",null,"ENROLLING_BY_INVITATION","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","58","Liver Transplant; Complications; Diabetes Mellitus; NASH - Nonalcoholic Steatohepatitis; NAFLD","DRUG:Semaglutide Treatment; DRUG:Sitagliptin 100mg","University Health Network, Toronto","2022-10-26","2026-12","FALSE","Change in HbA1c level [Baseline to 26 weeks] | Change in body weight (kg) [Baseline to week 26]",null,null,"NO","REGISTRY:U1111-1268-1934"],["NCT05766358","Role Of Metabolic Adaptation In Weight Regain","EXPEND-FU","COMPLETED","OBSERVATIONAL",null,null,null,"27","Weight Loss; Weight Gain; Obesity","BEHAVIORAL:Intensive lifestyle change therapy; DRUG:Tirzepatide","Pennington Biomedical Research Center","2022-10-06","2024-05-24","FALSE","Body weight [24 months]",null,null,null,null],["NCT05897398","SEMASEARCH, Retrospective/Prospective Cohort Nested at ATUc/AP2 WEGOVY®","SEMASEARCH","COMPLETED","OBSERVATIONAL",null,null,null,"1100","Obesity; Bariatric Surgery; Binge Eating Disorder; Syndromic Obesity; Sarcopenic Obesity; Iatrogenic Obesity; Psychotropic Drugs","OTHER:Data collection; OTHER:Blood sampling; OTHER:Questionnaires","Hospices Civils de Lyon","2024-06-10","2025-06-10","FALSE","Weight trends in patients included in the SEMASEARCH cohort at initiation and 12 months of treatment with WEGOVY®. [At initiation of treatment and 12 month of treatment]","DERIVED:41224657",null,"UNDECIDED",null],["NCT00747968","The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET",null,"COMPLETED","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","TRIPLE","8","Type 2 Diabetes","DRUG:Byetta, Exenatide","University of Aarhus","2010-02","2010-11","FALSE","steady glucose metabolism in the heart and brain during hyperglycemia with GLP-1-analogue infusion compared to placebo. [oct. 2008 - oct 2010]","DERIVED:22544917",null,null,null],["NCT01572740","Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","257","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo; DRUG:insulin","Novo Nordisk A/S","2012-04-05","2012-11-01","TRUE","Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 16 [Week 0, Week 16]","RESULT:27182042; RESULT:29277968",null,null,"OTHER:U1111-1122-4320; OTHER:JapicCTI-121802"],["NCT02408705","Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","14","Type 1 Diabetes Mellitus","DRUG:Liraglutide; DRUG:Placebo; DRUG:Mixed Meal Tolerance Test with paracetamol","Medical University of Graz","2015-01","2016-05","FALSE","Area under the curve of the endogenous glucose production from (=EGP) from begin of the hypoglycaemic clamp 5.5 mmol/L period until the end of recovery period (4.0 mmol/L), calculated from stable isotope labelled plasma glucose [After 12 weeks and 2 days of treatment in each treatment period (day 86 and day 198)]","DERIVED:35833597",null,null,null],["NCT02906930","Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only","PIONEER 1","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","703","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2016-09-20","2017-10-30","TRUE","Change in HbA1c [Week 0, week 26]","BACKGROUND:30993900; BACKGROUND:31168921; RESULT:31186300; RESULT:34472698; RESULT:35373893; RESULT:35653556; DERIVED:36056351; DERIVED:32998732; DERIVED:32267058; DERIVED:31903692","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/30/NCT02906930/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/30/NCT02906930/SAP_001.pdf","YES","EUDRACT_NUMBER:2015-005622-19; OTHER:U1111-1177-5112; OTHER:JapicCTI-163384; NIH:2015"],["NCT06408532","The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","256","Diabetes Mellitus, Type 2","DRUG:IDegLira; DRUG:Premixed insulin","Peking University People's Hospital","2024-04-30","2024-10-30","FALSE","Hemoglobin A1c (HbA1c) [From baseline to the end of the study (week 0-week 14 ± 7days).]",null,null,"NO",null],["NCT03017352","Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetic Cases","MAG1C","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","108","Diabetes Mellitus, Type 1","DRUG:Exenatide; DRUG:Placebos","Filip Krag Knop","2016-12","2019-06","FALSE","Change in HbA1c [6 months]","BACKGROUND:29950475; DERIVED:32135138",null,null,null],["NCT07323134","The Effect of Semaglutide on the Intestinal Flora in Obesity",null,"NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"40","Obesity","DRUG:Semaglutide Injection","Beijing Chao Yang Hospital","2026-02-01","2026-08-01","FALSE","The composition of the gut microbiota changes relative to the baseline [Baseline,4weeks,8weeks,12weeks]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/34/NCT07323134/Prot_000.pdf",null,null],["NCT06045221","A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin","ACHIEVE-3","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","1698","Type 2 Diabetes","DRUG:Orforglipron; DRUG:Semaglutide","Eli Lilly and Company","2023-09-22","2025-08-22","TRUE","Change From Baseline in Hemoglobin A1c (HbA1c) [Non-inferiority of 36 mg Orforglipron Versus 14 mg Semaglutide and 12 mg Orforglipron Versus 7 mg Semaglutide] [Baseline, Week 52]","DERIVED:41765029","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/21/NCT06045221/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/21/NCT06045221/SAP_001.pdf","YES","OTHER:J2A-MC-GZGU; OTHER:U1111-1290-6014"],["NCT04965506","A Study of IBI362 in Chinese Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","252","Type 2 Diabetes","DRUG:IBI362; OTHER:placebo; OTHER:Dulaglutide","Innovent Biologics (Suzhou) Co. Ltd.","2021-09-06","2022-04-28","FALSE","The change in HbA1c from baseline to 20 weeks [Baseline,20 weeks]","DERIVED:37943529",null,"NO",null],["NCT03770728","Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea","AMPLITUDE-S","TERMINATED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","312","Type 2 Diabetes Mellitus","DRUG:Efpeglenatide SAR439977; DRUG:Placebo; DRUG:Background therapy: Metformin alone or in combination with SU","Sanofi","2019-08-01","2020-11-28","TRUE","Change From Baseline to Week 30 in HbA1c [Baseline to Week 30]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/28/NCT03770728/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/28/NCT03770728/SAP_001.pdf","NO","OTHER:U1111-1205-1291"],["NCT04788511","Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity","STEP-HFpEF","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","529","Obesity","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2021-03-16","2023-04-18","TRUE","Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) [From baseline (week 0) to end of treatment (week 52)] | Change in Body Weight [From baseline (week 0) to end of treatment (week 52)]","BACKGROUND:37635157; RESULT:37622681; DERIVED:39222642; DERIVED:38739118; DERIVED:38599221; DERIVED:37993201; DERIVED:37952180","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/11/NCT04788511/Prot_002.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/11/NCT04788511/SAP_003.pdf","YES","OTHER:U1111-1243-4358; REGISTRY:2019-004452-11; NIH:2019"],["NCT02059564","A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus",null,"UNKNOWN","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","44","Diabetes Mellitus","DRUG:HM11260C; DRUG:Placebo; DRUG:Victoza","Hanmi Pharmaceutical Company Limited","2013-12","2014-10","FALSE","PK profile of acetaminophen [13 weeks]","DERIVED:34172436",null,null,null],["NCT07229170","Changes in Taste and Eating Habits Associated With GLP-1 Agonists in Weight Loss Patients","GLP1-TASTE","RECRUITING","OBSERVATIONAL",null,null,null,"150","Obesity & Overweight; Taste Alterations; Weight Loss; Eating Behavior Changes",null,"San Raffaele Telematic University","2025-12-01","2027-01-01","FALSE","Change in taste perception and food preferences [From baseline to 12 weeks after GLP-1 agonist treatment]","BACKGROUND:33567185",null,"UNDECIDED",null],["NCT07387094","A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","140","OSA - Obstructive Sleep Apnea; Obesity","DRUG:XW003 injection; DRUG:placebo with matching volume","Hangzhou Sciwind Biosciences Co., Ltd.","2026-02-09","2027-12-16","FALSE","Change from baseline in Apnea-Hypopnea Index (AHI) [at week 48]",null,null,"NO",null],["NCT05313529","LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes","LIGHT-MCI","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","396","Type 2 Diabetes Mellitus; Mild Cognitive Impairment","DRUG:Liraglutide; DRUG:Empagliflozin; DRUG:Linagliptin","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","2022-10-08","2025-12-31","FALSE","Mild cognitive impairment (MCI) remission rate [The core study spans from baseline to 48 weeks]","RESULT:31221697; RESULT:29500313; RESULT:35263425; DERIVED:40840993","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/29/NCT05313529/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/29/NCT05313529/SAP_002.pdf","YES",null],["NCT02020616","A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes",null,"TERMINATED","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","TRIPLE","60","Type 2 Diabetes Mellitus","DRUG:LY3053102; DRUG:Exenatide ER; DRUG:Placebo; DRUG:Metformin","Eli Lilly and Company","2013-12","2015-02","TRUE","Change From Baseline in Hemoglobin A1c (HbA1c) at 12-Week Endpoint [Baseline, Week 12]",null,null,"YES","OTHER:I6I-MC-LMRB"],["NCT04209049","A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","33","Overweight; Obesity","DRUG:NNC0174-0833","Novo Nordisk A/S","2020-01-15","2021-01-05","FALSE","Area under the plasma NNC0174-0833 concentration-time curve after a single dose [From baseline (Visit 2, Day 1, pre-dose) until completion of the end of trial visit (Visit 7, Day 36)]","DERIVED:42228334",null,"YES","OTHER:U1111-1228-9001"],["NCT01798706","Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients","GetGoal-O","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","350","Type 2 Diabetes","DRUG:Lixisenatide (AVE0010); DRUG:Placebo; DRUG:Antidiabetic background therapy","Sanofi","2013-06","2015-02","TRUE","Absolute Change in HbA1c From Baseline to Week 24 [Baseline, Week 24]","RESULT:28188240; DERIVED:39963952",null,null,"EUDRACT_NUMBER:2012-003292-19; OTHER:U1111-1132-9156"],["NCT07662213","A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus","Eluminate-2","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","1200","Type 2 Diabetes Mellitus","DRUG:Elecoglipron; DRUG:Semaglutide","AstraZeneca","2026-07-06","2028-05-23","FALSE","Change from baseline in Hemoglobin A1c (HbA1c) [Baseline to Week 52]",null,null,"YES","CTIS:2025-523933-24-00; NIH:2025"],["NCT01144338","Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","14752","Type 2 Diabetes Mellitus","DRUG:Exenatide Once Weekly; DRUG:Placebo","AstraZeneca","2010-06-18","2017-04-21","TRUE","Primary Efficacy Outcome MACE Events [Time to first event. Information collected during study period (anticipated to be up to 7.5 years).] | Primary Safety Outcome MACE Events [Time to first event. Information collected during study period (anticipated to be up to 7.5 years).]","DERIVED:41906117; DERIVED:39963952; DERIVED:39358806; DERIVED:39086032; DERIVED:38922488; DERIVED:35761271; DERIVED:34813910; DERIVED:32098501; DERIVED:31882409; DERIVED:31806653; DERIVED:31752517; DERIVED:31640705; DERIVED:31542942; DERIVED:31010875; DERIVED:30371301; DERIVED:29693361; DERIVED:28910237; DERIVED:28454792; DERIVED:26995376; DERIVED:22566747","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/38/NCT01144338/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/38/NCT01144338/SAP_001.pdf",null,"OTHER:MB001-002; OTHER:BCB109"],["NCT07390110","Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)",null,"COMPLETED","OBSERVATIONAL",null,null,null,"25664","Type 2 Diabetes; Heart Failure","DRUG:Oral semaglutide; DRUG:Sitagliptin","Brigham and Women's Hospital","2026-01-24","2026-06-30","FALSE","Composite of worsening heart failure event (exacerbated symptoms of heart failure resulting in hospitalization, intravenous diuretic therapy in an urgent care setting) or all-cause mortality. [Through study completion until the first of outcome, disenrollment, end of study period, discontinuation (45 days grace and risk window), switch between the arms, start of any other GLP-1-RA including injectable semaglutide.] | Worsening heart failure event (exacerbated symptoms of heart failure resulting in hospitalization, intravenous diuretic therapy in an urgent care setting). [Through study completion until the first of outcome, disenrollment, end of study period, discontinuation (45 days grace and risk window), switch between the arms, start of any other GLP-1-RA including injectable semaglutide.]",null,"Study Protocol and Statistical Analysis Plan: Study Protocol with Statistical Analysis Plan Amendment 1|https://cdn.clinicaltrials.gov/large-docs/10/NCT07390110/Prot_SAP_001.pdf; Study Protocol: Study Protocol with Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/10/NCT07390110/Prot_000.pdf; Study Protocol: Study Protocol with Statistical Analysis Plan Amendment 2|https://cdn.clinicaltrials.gov/large-docs/10/NCT07390110/Prot_002.pdf",null,null],["NCT07307235","Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents",null,"RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","1316","Type 2 Diabetes","DRUG:iGlarLixi (insulin glargine/lixisenatide); DRUG:standard of care (basal insulin or premixed insulin, excluding any GLP-1 receptor agonist-containing drugs)","Shanghai Zhongshan Hospital","2025-12-13","2027-06-30","FALSE","hemoglobin A1c (HbA1c) change [from baseline to week 24]",null,null,null,null],["NCT03591718","A Study to Test Different Doses of BI 456906 in Patients With Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","131","Obesity","DRUG:BI 456906; DRUG:Placebo","Boehringer Ingelheim","2018-07-26","2020-04-20","FALSE","Cumulative number [N (%)] of patients withdrawn from up-titration by up-titration scheme [Up to 132 days]","DERIVED:36527386",null,"UNDECIDED","EUDRACT_NUMBER:2018-000250-22; NIH:2018"],["NCT00566813","Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression",null,"COMPLETED","INTERVENTIONAL","PHASE1; PHASE2","NON_RANDOMIZED","NONE","10","Diabetes Mellitus, Type 1","DRUG:Islet Cell Transplant; DRUG:Islet Cell Transplant plus","University of Illinois at Chicago","2004-11","2010-07-05","TRUE","Number of Participants With Adverse Events Including Laboratory Abnormalities at the End of Study Participation [15 months after the last transplant] | Number of Participants With Insulin Independence at End of Study Participation [End of 15 Month Study Participation/Follow-up] | Number of Participants With HbA1c Less Than or Equal to 6.5 & Free of Severe Hypoglycemic Events [At end of 15 month study participation]","RESULT:18444920",null,"NO",null],["NCT06361823","Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment",null,"UNKNOWN","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","74","Idiopathic Intracranial Hypertension","DRUG:Semaglutide; DIETARY_SUPPLEMENT:Low calorie diet","Capital Medical University","2024-05-01","2024-12-01","FALSE","Intracranial pressure [12 weeks] | Adverse reactions [12 weeks]",null,null,"NO",null],["NCT00976391","A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","586","Diabetes Mellitus, Type 2","BIOLOGICAL:albiglutide + insulin glargine; DRUG:insulin glargine + preprandial lispro insulin","GlaxoSmithKline","2009-09","2011-10","TRUE","Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 26 [Baseline and Week 26]","DERIVED:24898300",null,"YES",null],["NCT03574597","Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity","SELECT","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","17604","Overweight; Obesity","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2018-10-24","2023-06-21","TRUE","Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke [From randomisation (week 0) up to 240 weeks]","RESULT:32916609; RESULT:33567185; RESULT:37952131; DERIVED:42747817; DERIVED:42663544; DERIVED:42610271; DERIVED:41928037; DERIVED:41433034; DERIVED:41138739; DERIVED:40156748; DERIVED:39882599; DERIVED:39608381; DERIVED:39480988; DERIVED:39222642; DERIVED:39217559; DERIVED:39181597; DERIVED:38796653; DERIVED:38740993; DERIVED:36738088; DERIVED:35373878; DERIVED:35175229; DERIVED:34693515","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/97/NCT03574597/Prot_002.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/97/NCT03574597/SAP_003.pdf","YES","REGISTRY:2017-003380-35; OTHER:U1111-1200-5564; NIH:2017"],["NCT05498610","A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","24","Diabetes Mellitus, Type 2","DRUG:NNC0480 0389; DRUG:Semaglutide","Novo Nordisk A/S","2022-08-11","2022-10-12","FALSE","AUC0-∞,NNC0480-0389,SD Area under the NNC0480-0389 plasma concentration-time curve from time 0 to infinity after a single dose (SD) [From pre-dose (day 1) to completion of the post-dose follow-up visit (day 43)] | Cmax,NNC0480-0389,SD Maximum plasma concentration of NNC0480-0389 after a single dose [From pre-dose (day 1) to completion of the post-dose follow-up visit (day 43)]",null,null,"YES","OTHER:U1111-1264-4516"],["NCT06595797","A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Polycystic Ovary Syndrome",null,"UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","144","Obese Subjects With Polycystic Ovary Syndrome (PCOS)","DRUG:HRS9531; DRUG:HRS9531placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2024-09","2025-12","FALSE","Percentage change in body weight from baseline at 32 weeks of treatment [0week, 4week ,8week, 12week, 16week, 20week , 24week, 28week, 32week]",null,null,"UNDECIDED",null],["NCT06449235","Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh",null,"UNKNOWN","INTERVENTIONAL","PHASE4","NON_RANDOMIZED","NONE","938","Type2diabetes","DRUG:Omarigliptin; DRUG:Sulphonylureas; DRUG:Metformin; DRUG:Other DPP4-i; DRUG:Thiazolidinediones; DRUG:Alpha-Glucosidase Inhibitor; DRUG:Glucagon-Like Peptide-1; DRUG:Receptor Agonists (GLP1RA); DRUG:SGLT2 inhibitors","Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","2024-09","2025-04","FALSE","Glycemic Control as Measured by HbA1c Levels [Baseline assessment. Follow-up visits at 14 days, 3 months, and 6 months post-enrollment.]",null,null,"UNDECIDED","OTHER:BADAS-ERC/EC/24/13"],["NCT00064714","Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","47","Diabetes Mellitus","DRUG:AC2993 (exenatide); DRUG:daclizumab (immunosuppressive)","AstraZeneca","2003-07","2008-03","FALSE","Change in basal C-peptide level [baseline and 6 months]","BACKGROUND:11244033; BACKGROUND:1935920; BACKGROUND:11742411; DERIVED:19808924",null,null,"OTHER:03-DK-0245"],["NCT02231658","Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion",null,"TERMINATED","INTERVENTIONAL","PHASE1","RANDOMIZED","SINGLE","109","Diabetes Mellitus","DRUG:Liraglutide; DRUG:Lixisenatide","Profil Institut für Stoffwechselforschung GmbH","2015-07-16","2018-07-23","FALSE","Change from baseline (week -1) in the number of reflux episodes [24 hours after 10 weeks of treatment]","DERIVED:32647054",null,null,null],["NCT04174755","Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV","SWIFT","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","80","Obesity; HIV-1-infection","DRUG:Semaglutide Injectable Product; BEHAVIORAL:Standard of care","University College Dublin","2022-06-22","2027-01","FALSE","Changes in total body weight (in Kg) [28 weeks]","DERIVED:35039057",null,"NO",null],["NCT07567378","CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry","CARTIZ","NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"30","Psoriatic Arthritis; Osteoarthitis; Knee; Diabetes (DM); Type 2 Diabetes Mellitus (T2DM); Obesity (Disorder); Insulin Resistance Syndrome; Metabolic Syndrome; Heart Failure; Preserved Ejection Fraction; Coronary Artery Disease; Atrial Fibrillation (AF); Non Alcholic Fatty Liver Disease; Sarcopenia; Pericardium","DRUG:Tirzepatide","JULIO GRANADOS MONTIEL","2026-05","2027-11","FALSE","ACR20 response rate at Week 4 in the Mechanistic Analysis Set [week 4] | Proportion of Week-4 ACR20 response mediated by biomarker panel in the Mechanistic Analysis Set [Week 4]","RESULT:41944220; RESULT:32154773; RESULT:30170852; RESULT:28701474; RESULT:41666927; RESULT:38878772; RESULT:41903163; RESULT:41928037; RESULT:41406444; RESULT:40903131; RESULT:42010357; RESULT:39566869",null,"YES","OTHER:CARTIZ-2026-001; OTHER:64/019,134; OTHER:64/031,635; OTHER:64/039,918; OTHER:64/043,606"],["NCT06380426","A Multicenter Pharmacoepidemiological Cohort on Real Life Use of Semaglutide in Adolescents or Adults With Monogenic Obesity","ObGeSema","RECRUITING","OBSERVATIONAL",null,null,null,"175","Monogenic Obesity",null,"Assistance Publique - Hôpitaux de Paris","2024-09-19","2027-04-30","FALSE","Change in weight and Body Mass Index (BMI) [From baseline (T0) to T12]",null,null,"YES","OTHER:IDRCB : 2023-A02003-42"],["NCT03819153","A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease","FLOW","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","3533","Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2019-06-17","2024-01-09","TRUE","Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2; Initiation of Chronic Renal Replacement Therapy; Renal Death; CV Death [From Week 0 up to Week 234]","BACKGROUND:36651820; DERIVED:42233552; DERIVED:41728915; DERIVED:41706532; DERIVED:41422027; DERIVED:41207620; DERIVED:39963952; DERIVED:39480988; DERIVED:39222642; DERIVED:39217553; DERIVED:38914124; DERIVED:38862303; DERIVED:38785209; DERIVED:35441935","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/53/NCT03819153/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/53/NCT03819153/SAP_001.pdf","YES","OTHER:U1111-1217-6259; REGISTRY:2018-002878-50; REGISTRY:JapicCTI-194843; NIH:2018"],["NCT01299012","Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus",null,"COMPLETED","OBSERVATIONAL",null,null,null,"30","Type 1 Diabetes Mellitus","DRUG:Liraglutide","University at Buffalo","2010-10","2013-02","FALSE","Improved Blood Glucose comtrol in Type 1 Diabetes Patients with Liraglutide [20 weeks]",null,null,null,null],["NCT00713830","GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea","GETGOAL-S","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","859","Diabetes Mellitus, Type 2","DRUG:Lixisenatide (AVE0010); DRUG:Placebo; DEVICE:Pen auto-injector; DRUG:Sulfonylurea; DRUG:Metformin","Sanofi","2008-07","2011-01","TRUE","Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 [Baseline, Week 24]","RESULT:24650952; DERIVED:27319011; DERIVED:27267268; DERIVED:27252787",null,null,"OTHER:EudraCT 2007-005881-11"],["NCT07152756","Impact of a One-Week Discontinuation of Semaglutide on Gastric Retention and Endoscopic Mucosal Visibility Scores",null,"NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"418","Gastric Retention","PROCEDURE:Esophagogastroduodenoscopy","Fudan University","2025-09-15","2028-09-15","FALSE","Rate of gastric retention [immediately after the esophagogastroduodenoscopy]",null,null,"YES",null],["NCT05162183","Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data",null,"COMPLETED","OBSERVATIONAL",null,null,null,"3474","Diabetes","DRUG:Glimepiride; DRUG:Liraglutide","Brigham and Women's Hospital","2019-09-01","2021-09-01","FALSE","Relative Hazard of change in HbA1c from baseline to 26 weeks of treatment (end of follow-up) [26-week follow-up window with a median follow-up time of 99 [84, 148] days]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/83/NCT05162183/Prot_SAP_000.pdf",null,null],["NCT06257966","A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","600","Type2 Diabetes Mellitus","DRUG:Exendin-4 Fc fusion protein injection(1.2mg）; DRUG:Exendin-4 Fc fusion protein injection（2.4mg）; DRUG:Dulaglutide; DRUG:Metformin","Beijing Dongfang Biotech Co., Ltd.","2024-07-17","2026-10-01","FALSE","HbA1c [Baseline, Week 26]",null,null,"NO",null],["NCT06023095","A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","24","Overweight; Obesity","DRUG:LY3502970; DRUG:Placebo","Eli Lilly and Company","2023-09-21","2024-07-29","TRUE","Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline through Week 18 (Cohort 1) & Week 26 (Cohort 2)]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/95/NCT06023095/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/95/NCT06023095/SAP_001.pdf","NO","OTHER:J2A-GH-GZGX"],["NCT07218354","Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)","CRAVE","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","622","Alcohol Use Disorder","DRUG:Semaglutide; DRUG:Placebo","VA Office of Research and Development","2026-07-28","2029-03-31","FALSE","Two-level reduction in the World Health Organization (WHO) risk drinking level assessed in the last 28 days of intervention [Change from baseline (after randomization) to change in the last 28 days of the intervention]",null,null,"YES",null],["NCT07555730","AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","400","Overweight or Obesity; Type 2 Diabetes; Weight Loss Maintenance","BEHAVIORAL:AI assisted multi-domain lifestyle intervention; DRUG:Tirzepatide","Huazhong University of Science and Technology","2026-04-30","2028-09-30","FALSE","Body weight change (kg) [Change from randomization (week 20) to week 72]",null,null,"NO",null],["NCT03029351","GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes","1981","TERMINATED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","15","Type2 Diabetes; Kidney Diseases","DRUG:Exenatide Extended Release for Inj Susp 2 MG; DRUG:Placebo","University at Buffalo","2017-01-10","2019-07","TRUE","Change From Baseline in Urinary Albuminuria Levels [baseline and 52 weeks]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/51/NCT03029351/Prot_SAP_002.pdf","NO",null],["NCT02895672","GLP-1/Basal Insulin Combination Therapy",null,"COMPLETED","OBSERVATIONAL",null,null,null,"150","Type 2 Diabetes Mellitus","DRUG:GLP-1 therapy","Albany College of Pharmacy and Health Sciences","2016-08","2016-11","FALSE","A1C [12 months]",null,null,"UNDECIDED",null],["NCT06313528","A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","85","Obesity","DRUG:LY3437943; OTHER:Placebo","Eli Lilly and Company","2024-03-20","2025-08-26","FALSE","Change from Baseline in Total Calorie Intake at Lunch and Dinner (Combined) [Baseline up to Week 17 (inclusive)]",null,null,"NO","OTHER:J1I-MC-GZBW"],["NCT03619330","Testosterone Replacement Therapy and Liraglutide Effects on Weight Loss in Hypogonadism.",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","30","Hypogonadism; Obesity","DRUG:liraglutide; DRUG:Testosterone","University Medical Centre Ljubljana","2014-12","2015-08","FALSE","The main outcome was improvements of symptoms related to hypogonadism [Patients were screened and asked for symptoms at the beginning and every 4 weeks for 16 weeks of the study.] | The main outcome was change testosterone level. [Patient's blood was drawn at the base point and every four weeks during 16 weeks of clinical trial.] | the main outcome was change in gonadotropin levels. [Patient's blood was drawn at the base point and every four weeks during 16 weeks of clinical trial.]",null,null,null,null],["NCT07835360","Body Composition Changes After Initiation of GLP-1 Receptor Agonists in Adults With Obesity or Type 2 Diabetes",null,"RECRUITING","OBSERVATIONAL",null,null,null,"200","Obesity (Disorder); Type 2 Diabetes Mellitus",null,"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","2026-07-10","2029-07","FALSE","Change in Appendicular Lean Mass [Baseline, 24 weeks, and 52 weeks] | Change in Appendicular Skeletal Muscle Index (ASMI) [Baseline, 24 weeks, and 52 weeks]","BACKGROUND:41079186; BACKGROUND:41951734; BACKGROUND:38717042; BACKGROUND:31897524; BACKGROUND:39996356; BACKGROUND:41877354; BACKGROUND:41358900; BACKGROUND:41358882; BACKGROUND:38346789; BACKGROUND:35344001; BACKGROUND:40196933; BACKGROUND:41914150; BACKGROUND:41931049; BACKGROUND:41698129",null,"NO",null],["NCT01169779","Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin","GetGoal-M-Asia","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","391","Type 2 Diabetes Mellitus","DRUG:Lixisenatide (AVE0010); DRUG:Placebo; DEVICE:Pen auto-injector; DRUG:Metformin; DRUG:Sulfonylurea","Sanofi","2010-07","2011-12","TRUE","Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 [Baseline, Week 24]","RESULT:24639432; DERIVED:27252787",null,null,"OTHER:U1111-1116-8938"],["NCT01174810","Exendin-4 as a Treatment for Parkinson's Disease - Pilot Study",null,"UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","40","Parkinson's Disease","DRUG:Exenatide","University College, London","2010-07","2013-03","FALSE","Change from baseline to 12 months & 14 months between patients on active Exenatide treatment and PD controls in respect of their UPDRS-off-medication motor subscore. []","DERIVED:23728174",null,null,"EUDRACT_NUMBER:2009-018137-37; NIH:2009"],["NCT04777396","A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)","EVOKE","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","1840","Early Alzheimer's Disease","DRUG:Semagludtide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2021-05-18","2025-09-16","FALSE","Change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score [From baseline (week 0) to week 104]","DERIVED:41865758; DERIVED:39780249; DERIVED:38901446",null,"YES","OTHER:U1111-1259-2929; OTHER:2023-506919-18; NIH:2023"],["NCT02803918","A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","SINGLE","23","Type 2 Diabetes Mellitus","DRUG:Lixisenatide (AVE0010); DRUG:Placebo; DRUG:Basal Insulin; DRUG:Metformin","Sanofi","2017-05-17","2020-01-27","FALSE","Number of patients with adverse events (AEs) [Up to 10 weeks] | Number of patients with treatment-emergent adverse events (TEAEs) [Up to 10 weeks] | Number of patients with anti-lixisenatide antibodies [Up to 10 weeks]","DERIVED:35411611",null,"YES","OTHER:U1111-1176-6142"],["NCT07282613","A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes","REIMAGINEYOUNG","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","80","Diabetes Mellitus, Type 2","DRUG:CagriSema (Cagrilintide B and Semaglutide I); DRUG:Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)","Novo Nordisk A/S","2026-08-04","2029-09-07","FALSE","Change in glycated haemoglobin (HbA1c) [From baseline (week 0) to end of double-blinded treatment (week 26)]",null,null,"YES","OTHER:U1111-1307-6786; OTHER:2024-514432-24"],["NCT07822061","AMAZE 10: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People in Japan With Excess Body Weight Lose Weight","AMAZE 10","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","400","Overweight; Obesity","DRUG:NNC0487-0111; DRUG:Placebo (matched to NNC0487-0111)","Novo Nordisk A/S","2026-09-07","2029-02-05","FALSE","Relative change in body weight [From baseline (week 0) to week 84]",null,null,"YES","OTHER:U1111-1313-7707"],["NCT01518101","Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications","PREFER","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","62","Type 2 Diabetes","DRUG:Vildagliptin/ Metformin; DRUG:Liraglutide; DRUG:Metformin","Novartis Pharmaceuticals","2012-01","2012-10","FALSE","Proportion of patients preferring each treatment regimen [At week 24]","RESULT:26301063",null,null,"EUDRACT_NUMBER:2011-003818-16"],["NCT07163650","Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery",null,"RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","60","Obesity; Weight Loss; Metabolic Surgery","DRUG:Efsubaglutide Alfa Injection; BEHAVIORAL:Diet and exercise guidelines","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","2025-09-16","2026-11-30","FALSE","Change in %TWL from baseline to endpoint [24 weeks from enrollment]",null,null,"NO",null],["NCT01508897","Comparison of Two Liraglutide Formulations in Healthy Volunteers",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","SINGLE","22","Diabetes; Healthy","DRUG:liraglutide","Novo Nordisk A/S","2004-05-28","2004-06-30","FALSE","Area under the Curve (AUC) (0-t) [] | Cmax, maximum concentration []",null,null,null,null],["NCT07619508","Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes.",null,"COMPLETED","OBSERVATIONAL",null,null,null,"100000","Obesity; Overweight","DRUG:Tirzepatide; DRUG:Semaglutide","Brigham and Women's Hospital","2026-02-10","2026-06-01","FALSE","Composite of all-cause mortality, myocardial infarction, or stroke. [1 day after prescription fill of exposure or comparator until outcome, end of data, end of study period, death, discontinuation (45 day grace, risk-window), nursing home admission, augmentation/additional exposure or switch to comparator or other GLP1-RA]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/08/NCT07619508/Prot_000.pdf",null,null],["NCT05696847","A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","28","Obesity","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2023-02-07","2025-01-16","TRUE","Percentage of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) [Baseline through Week 14]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/47/NCT05696847/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/47/NCT05696847/SAP_001.pdf","NO","OTHER:I8F-MC-GPHV"],["NCT06961643","Investigation of Pharmacokinetics and Safety of HRS-7535 in Subjects With Hepatic Impairment and Normal Hepatic Function",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","24","Diabetes Mellitus","DRUG:HRS-7535 Tables","Shandong Suncadia Medicine Co., Ltd.","2025-06-05","2026-01-22","FALSE","The maximum plasma concentration of HRS-7535 (Cmax) [Post-dose at day 1 to day 4.] | Area under the concentration curve from time 0 to the last quantifiable concentration (AUC0-t) [Post-dose at day 1 to day 4.] | Area under the concentration curve from time 0 to extrapolated infinite time (AUC0-inf) [Post-dose at day 1 to day 4.]",null,null,"UNDECIDED",null],["NCT04495140","Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","6","Healthy Volunteer","DRUG:[14C]PF-06882961, 50 mg; DRUG:PF-06882961, 50 mg and [14C]PF-06882961, 100 ug","Pfizer","2020-07-22","2020-10-15","FALSE","Total recovery of radioactivity in urine and feces, following oral administration of [14C] PF-06882961 in period 1 [Baseline through approximately hour 312 (day 14). Period 1 is 14 days]",null,null,"NO","EUDRACT_NUMBER:2019-002584-10; NIH:2019"],["NCT03768518","GLP-1 Receptor Expression in CHI","GLP-1-CHI","UNKNOWN","OBSERVATIONAL",null,null,null,"40","Congenital Hyperinsulinism","DIAGNOSTIC_TEST:68Ga-exendin-4 PET/CT","Radboud University Medical Center","2018-02-07","2019-02-01","FALSE","Expression and distribution of GLP-1R in pancreas of children with CHI [1 year]",null,null,null,null],["NCT03829891","Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","60","Type 2 Diabetes Mellitus","DRUG:Beinaglutide; DRUG:glargine","Xijing Hospital","2018-08-07","2019-12-31","FALSE","The proportion and rate of the fasting blood glucose control. [Baseline and week 16] | Proportion of patients with glycosylated hemoglobin < 7%. [Baseline and week 16] | Changes of blood sugar variation . [Baseline and week 16]","DERIVED:37864379",null,null,null],["NCT05872620","A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes","ATTAIN-2","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","1613","Obesity; Overweight; Type 2 Diabetes","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2023-06-05","2025-08-08","TRUE","Percent Change From Baseline in Body Weight [Baseline, Week 72]","DERIVED:42577069; DERIVED:41275875","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/20/NCT05872620/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/20/NCT05872620/SAP_001.pdf","YES","OTHER:J2A-MC-GZGQ; OTHER:2022-502837-24-00; OTHER:U1111-1289-8799"],["NCT04903509","A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","SINGLE","95","Healthy","DRUG:BI 1820237; DRUG:Placebo; DRUG:Saxenda®; DRUG:Paracetamol-ratiopharm®","Boehringer Ingelheim","2021-06-08","2022-08-26","FALSE","Percentage of subjects with drug-related adverse events [up to 48 days]",null,null,"NO","EUDRACT_NUMBER:2021-000327-13"],["NCT06541509","Mechanisms of Semaglutide Therapy in Heart Failure Patients","SEMAHEART","UNKNOWN","INTERVENTIONAL","PHASE1; PHASE2",null,"NONE","10","Heart Failure; Obesity","DRUG:Semaglutide","University Medical Centre Ljubljana","2024-07-10","2025-07-10","FALSE","Interleukin-6 (IL-6) [4 months] | Interleukin-8 (IL-8) [4 months] | Tumor Necrosis Factor-alpha (TNF-α) [4 months] | Interferon-gamma (IFN-γ) [4 months] | B-type Natriuretic Peptide (BNP) [4 months] | C-reactive Protein (CRP) [4 months] | Hemoglobin A1C (HgA1C) [4 months] | Complete Blood Count (CBC) [4 months] | Comprehensive Metabolic Panel (Chem 7) [4 months] | Liver Function Tests (LFT) [4 months] | Body mass index [4 months]",null,null,"NO",null],["NCT07850765","Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets",null,"COMPLETED","OBSERVATIONAL",null,null,null,"1260","Overweight; Obesity","DRUG:Semaglutide","Novo Nordisk A/S","2026-08-28","2026-08-31","FALSE","Change in Food Noise Questionnaire (FNQ) score [At data capture (Day 1)] | Change in Body Weight [At data capture (Day 1)] | Health-Related Quality of Life Measured by EQ-5D-5L [At data capture (Day 1)] | Health Status Measured by EQ Visual Analogue Scale (EQ-VAS) [At data capture (Day 1)] | Medication Adherence Measured by Adelphi Adherence Questionnaire (ADAQ) [At data capture (Day 1)] | Number of Participant Satisfaction With Wegovy [At data capture (Day 1)] | Change in Body Mass Index (BMI) [At data capture (Day 1)] | Percent Change in Body Weight [At data capture (Day 1)] | Number of Participants with Achievement of Weight-Loss Target [At data capture (Day 1)] | Number of Participants who Concern About Future Weight Gain [At data capture (Day 1)] | Impact of Wegovy on Weight-Related Burden [At data capture (Day 1)] | Impact of Wegovy on Daily Life and Health Behaviours [At data capture (Day 1)]",null,null,"YES",null],["NCT01617434","The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","451","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2012-09","2013-10","TRUE","Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 26 [Week 0 to Week 26]","RESULT:26179619; RESULT:26582052",null,null,"EUDRACT_NUMBER:2011-002696-41; OTHER:U1111-1121-9874"],["NCT03586830","A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","196","Obesity and Diabetes Mellitus, Type 2","DRUG:JNJ-64565111 Dose Level 1; DRUG:JNJ-64565111 Dose Level 2; DRUG:JNJ-64565111 Dose Level 3; DRUG:Placebo","Janssen Research & Development, LLC","2018-06-26","2019-04-05","TRUE","Percent Change From Baseline in Body Weight at Week 12 [Baseline, Week 12] | Number of Participants With Treatment Emergent Adverse Events (TEAEs) [Up to 16 Weeks]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/30/NCT03586830/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/30/NCT03586830/SAP_001.pdf",null,"OTHER:64565111OBE2002"],["NCT07563699","Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus",null,"RECRUITING","INTERVENTIONAL","PHASE1; PHASE2","NON_RANDOMIZED","NONE","24","Diabete Type 2","DRUG:SG Depot 2 mg; DRUG:SG Depot 4 mg; DRUG:SG Depot 6 mg; DRUG:SG Depot 8 mg","Mapi Pharma Ltd.","2026-08-09","2028-05","FALSE","The rate of treatment-associated adverse events (AEs) [Through study completion, up to 28 weeks for each subject] | Plasma concentration of semaglutide [Through study completion, up to 28 weeks for each subject]",null,null,"NO",null],["NCT06959784","Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)",null,"ENROLLING_BY_INVITATION","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","142","Diabetes Mellitus; Cardiovascular Diseases; Cerebrovascular Disease","DRUG:semaglutide; DRUG:Metformin","China-Japan Friendship Hospital","2024-01-01","2026-12-31","FALSE","Cardiovascular and cerebrovascular event risk score [One-year follow-up] | Major Adverse Cardiovascular Events [Baseline and every 12 weeks until 96 weeks] | Cerebrovascular disease events [Baseline and every 12 weeks until 96 weeks]",null,null,null,"OTHER_GRANT:2024-1-4064"],["NCT07467447","Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight","GZBF","RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","SINGLE","300","Obesity","DRUG:Retatrutide (LY3437943); DRUG:Placebo; BEHAVIORAL:Standardized diet and physical activity counseling throughout the study.","Hudson Biotech","2026-02-15","2027-03-14","FALSE","Mean percent change in body weight from randomization/baseline to Week 24. [24 weeks]",null,null,null,null],["NCT06630585","GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes","AID-JUNCT","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","42","Type 1 Diabetes (T1D)","DRUG:Tirzepatide","University of Bern","2025-02-14","2026-06","FALSE","Change TIR [At week 16 of treatment.]",null,null,"NO",null],["NCT05467514","Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3",null,"NONE","35","Diabetes Mellitus, Type 1","DRUG:Liraglutide","David Sanchez Garcia","2022-07-01","2023-02-28","FALSE","To assess the effect of liraglutide on carotid intima media thickness in patients with type 1 diabetes mellitus. [Baseline and 6 months]",null,null,"UNDECIDED",null],["NCT04199728","Use of a GLP-1R Agonist to Treat Opioid Use Disorder",null,"COMPLETED","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","QUADRUPLE","27","Opiate Substitution Treatment; Opioid-Related Disorders","DRUG:Liraglutide Pen Injector; DRUG:Placebo","Milton S. Hershey Medical Center","2021-10-18","2023-09-13","TRUE","Change in Self-reported Cue-elicited Drug Craving as Measured by Visual Analog Scale (VAS) [Baseline (Day 1), End of the target drug dose (Day 19)] | Change in Ambient Drug Craving Over Time as Measured by Visual Analog Scale (VAS) [Baseline (Day 1), Treatment Days (Days 2-19)]","DERIVED:39061093","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/28/NCT04199728/Prot_SAP_000.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/28/NCT04199728/ICF_001.pdf","NO","NIH:1UG3DA050325-01"],["NCT04061200","Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria","EmpaSema","UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","80","Type 2 Diabetes With Renal Manifestations","DRUG:Semaglutide, 1.34 mg/mL; OTHER:Placebo, 1,34 mg/mL; DRUG:Empagliflozin 25 MG","Steno Diabetes Center Copenhagen","2019-11-01","2021-07-01","FALSE","Albuminuria [From randomisation to week 52]","DERIVED:39963952; DERIVED:38770818",null,"NO","NIH:2019"],["NCT07629401","Pre-approval Expanded Access of Retatrutide (LY3437943)",null,"AVAILABLE","EXPANDED_ACCESS",null,null,null,null,"Obesity; Obesity-related Complications","DRUG:Retatrutide","Eli Lilly and Company",null,null,"FALSE",null,null,null,null,"REGISTRY:J1I-MC-Y001"],["NCT01077323","A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents",null,"COMPLETED","OBSERVATIONAL",null,null,null,"363766","Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies); Healthy Subjects (Treated With no Diabetes Therapies)","DRUG:exenatide; DRUG:Other antidiabetic therapies; OTHER:No diabetes therapy","AstraZeneca","2004-09","2008-03","TRUE","Incidence Rates Per 100,000 Person-Years of Likely Acute Pancreatitis (During \"Current Use\" Period) - Time on Drug Analysis [43 months] | Incidence Rates Per 100,000 Person-Years of Likely Acute Pancreatitis (Among \"Recent Use\" Period) - Time on Drug Analysis [43 months] | Incidence Rates Per 100,000 Person-Years of Likely Acute Pancreatitis (During \"Past Use\" Period) - Time on Drug Analysis [43 months]",null,null,null,null],["NCT00753896","Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin",null,"COMPLETED","INTERVENTIONAL","PHASE3",null,"NONE","134","Type 2 Diabetes","DRUG:exenatide","AstraZeneca","2008-10","2009-07","TRUE","Percentage of Patients Experiencing Adverse Events [Baseline to Week 52] | Assessment of Event Rate of Treatment-Emergent Hypoglycemic Events [Baseline to Week 52]","DERIVED:23031623",null,null,null],["NCT05093205","STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","35","Healthy Adults","DRUG:PF-06882961; DRUG:Atorvastatin; DRUG:Midazolam; DRUG:Levonorgestrel & Ethinyl Estradiol","Pfizer","2021-10-25","2022-07-06","TRUE","(Part A) Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) of Atorvastatin in Periods 1, 4, and 7 [For Part A Periods 1, 4, and 7: At 0 (prior to atorvastatin dose), 0.5, 1, 1.5, 2, 4, 6, 9, 12, 24, 36, 48, 72 hours (only Periods 1 & 4) post atorvastatin dose on Day 1 of each period.] | (Part A) AUCinf of Midazolam in Periods 2, 5, and 8 [For Part A Periods 2, 5, and 8: At 0 (prior to midazolam dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hours (only for Periods 2 & 5) post midazolam dose on Day 1 of each period.] | (Part B) AUCinf of Levonorgestrel in Periods 1, 3 and 5 [For Part B Periods 1, 3, 5: At 0 (prior to levonorgestrel dose), 0.5, 1, 1.5, 2, 4, 8, 12, 24, 48, 72, 96, 120 hours post levonorgestrel dose on Day 1 of each period.] | (Part B) AUCinf of Ethinyl Estradiol in Periods 1, 3 and 5 [For Part B Periods 1, 3, 5: At 0 (prior to EE dose), 0.5, 1, 1.5, 2, 4, 8, 12, 24, 48, 72, 96, 120 hours post EE dose on Day 1 in Periods 1, 3, 5 of each period.]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/05/NCT05093205/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/05/NCT05093205/SAP_001.pdf","NO",null],["NCT03480022","Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS","SAXAPCOS","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","88","Pre Diabetes; Polycystic Ovary Syndrome; Obesity Android","DRUG:Liraglutide Pen Injector [Saxenda]; DRUG:Placebo Liraglutide Pen Injector","Woman's","2018-09-26","2021-02-22","TRUE","Absolute Body Weight (BW) [32 weeks of treatment] | Free Androgen Index (FAI) [32 weeks of treatment]","DERIVED:35710599","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/22/NCT03480022/Prot_SAP_001.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/22/NCT03480022/ICF_000.pdf","NO",null],["NCT06287307","Semaglutide 2.4mg for Low Responders After Bariatric Surgery","SEABAR","UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","152","Obesity; Obesity, Morbid; Weight Gain","OTHER:Placebo; DRUG:Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]","Zuyderland Medisch Centrum","2024-05","2026-02","FALSE","Weight change from start study at 3 months post operative until 15 months later [15 months] | Difference between placebo group and treatment group in weight change [15 months]","BACKGROUND:26641646; BACKGROUND:26868660; BACKGROUND:29207379; BACKGROUND:25590212; BACKGROUND:26887340; BACKGROUND:24622719; BACKGROUND:23163728; BACKGROUND:24149519; BACKGROUND:29340677; BACKGROUND:22215166; BACKGROUND:19370590; BACKGROUND:23996349; BACKGROUND:35842505; BACKGROUND:22920966; BACKGROUND:28791623; BACKGROUND:24708909; BACKGROUND:24776071; BACKGROUND:30768766; BACKGROUND:26371721; BACKGROUND:33625476; BACKGROUND:33567185; BACKGROUND:33755728",null,"NO",null],["NCT03486392","A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","474","Obesity","DRUG:JNJ-64565111 Dose Level 1; DRUG:JNJ-64565111 Dose Level 2; DRUG:JNJ-64565111 Dose Level 3; DRUG:Liraglutide; DRUG:Placebo","Janssen Research & Development, LLC","2018-03-26","2019-03-08","TRUE","Percent Change From Baseline in Body Weight at Week 26 [Baseline, Week 26] | Number of Participants With Treatment Emergent Adverse Events (TEAEs) [Up to Week 30]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/92/NCT03486392/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/92/NCT03486392/SAP_001.pdf",null,"OTHER:64565111OBE2001; EUDRACT_NUMBER:2017-003616-39; NIH:2017"],["NCT07811895","Dual GIP/GLP-1 Receptor Agonist in Obese Women Before Frozen Embryo Transfer",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","1510","Tirzepatide; Frozen Embryo Transfer; Obesity","DRUG:Dual GIP/GLP-1 receptor agonist","RenJi Hospital","2026-09","2029-12","FALSE","Good birth outcome rate [at delivery]",null,null,"YES",null],["NCT06422039","Bioavailability and Food Effects of HRS-7535 Tablets With Different Formulating Processes in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","24","Type 2 Diabetes Mellitus","DRUG:HRS-7535(D) Tablets; DRUG:HRS-7535(C) Tablets","Shandong Suncadia Medicine Co., Ltd.","2024-05-23","2024-08-06","FALSE","PK parameters：Cmax [0 hour to 72 hours after the last dosing] | PK parameters：AUC0-t [0 hour to 72 hours after the last dosing] | PK parameters：AUC0-∞ [0 hour to 72 hours after the last dosing] | Relative bioavailability of HRS-7535 (D) tablets compared to HRS-7535 (C) tablets following a high-fat meal [0 hour to 72 hours after the last dosing] | Relative bioavailability of HRS-7535 (D) tablets under both fasting and fed (high fat meal) status [0 hour to 72 hours after the last dosing]",null,null,"UNDECIDED",null],["NCT06109311","A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor","ACHIEVE-5","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","546","Type 2 Diabetes","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2023-11-10","2025-09-15","TRUE","Change From Baseline in Hemoglobin A1c (HbA1c) [Baseline, Week 40]","DERIVED:42251769","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/11/NCT06109311/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/11/NCT06109311/SAP_001.pdf","YES","OTHER:J2A-MC-GZGW; OTHER:U1111-1294-2797; OTHER:2023-507280-18-00; NIH:2023"],["NCT03158805","Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","60","Bipolar Disorder; Obesity","DRUG:LIRAGLUTIDE; OTHER:Placebo","Lindner Center of HOPE","2017-04-26","2022-10-11","TRUE","Percent Change in Body Weight [40 week]","DERIVED:38227621","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/05/NCT03158805/Prot_SAP_000.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/05/NCT03158805/ICF_001.pdf","NO",null],["NCT06489457","The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity","SEMAT","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","25","Type 2 Diabetes Mellitus; Obesity; Functional Hypogonadism","DRUG:Semaglutide; DRUG:Testosterone Undecanoate","University Medical Centre Ljubljana","2020-09-20","2023-05-11","FALSE","Change in semen volume from baseline and between the treatment arms [Baseline and 24 weeks] | Change in sperm concentration from baseline and between the treatment arms [Baseline and 24 weeks] | Change in total motility of sperm from baseline and between the treatment arms [Baseline and 24 weeks] | Change in normal sperm forms from baseline and between the treatment arms [Baseline and 24 weeks] | Change in total number of sperm from baseline and between the treatment arms [Baseline and 24 weeks]","DERIVED:39511836",null,"NO","OTHER:0120-26/2020/13"],["NCT05071898","Pharmacogenetics of Response to GLP1R Agonists","PORT","RECRUITING","INTERVENTIONAL","PHASE1",null,"NONE","600","Obesity; Diabetes Type 2","DRUG:Semaglutide Pen Injector [Ozempic]","University of Maryland, Baltimore","2022-04-11","2027-04-30","FALSE","First phase insulin secretion [Measured both at baseline and after completing 6 weeks of semaglutide therapy] | Second phase insulin secretion [Measured both at baseline and after completing 6 weeks of semaglutide therapy] | Rate of glucose disappearance [Measured both at baseline and after completing 6 weeks of semaglutide therapy]","DERIVED:37264484",null,"YES",null],["NCT05804162","A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","107","Obesity","DRUG:Cagrilintide; DRUG:Cagrilintide Placebo; DRUG:Moxifloxacin; DRUG:Moxifloxacin Placebo","Novo Nordisk A/S","2023-04-12","2023-08-12","FALSE","Change From Baseline in Fridericia Heart Rate Corrected QT Interval (QTcF) At 12, 24, 48 and 72 Hours Post-Second Dose of Cagrilintide/Cagrilintide Placebo at the 4.5 mg Dose Level [From pre-last dose on Day 52 to 12, 24, 48 and 72 hours post-last dose on Day 55]","RESULT:39279639",null,"YES","OTHER:U1111-1249-3834; EUDRACT_NUMBER:2022-002357-25"],["NCT05225974","A Randomized Phase 1 Study of Liralutide Injection in Healthy Chinese Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","32","Therapeutic Equivalency","DRUG:Liraglutide injection; DRUG:Liraglutide injection(Victoza®)","The Affiliated Hospital of Qingdao University","2021-07-16","2021-07-30","FALSE","Peak Plasma Concentration (Cmax) [40 days] | Area under the plasma concentration versus time curve (AUC)0-t [40 days] | Area under the plasma concentration versus time curve (AUC)0-∞ [40 days]",null,null,null,null],["NCT07787936","GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry","GLIDE-HF","NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"150","Heart Failure With Preserved Ejection Fraction; Obesity; Diastolic Heart Failure; Pulmonary Hypertension; Iron Deficiency","DRUG:GLP-1 / GIP receptor agonist","Miedziowe Centrum Zdrowia SA","2027-01-01","2031-01-01","FALSE","Trajectory of exercise E/e' over time in GLP-1/GIP-exposed patients [Baseline, 12, 24, and 52 weeks]",null,null,"NO","OTHER:Ethics"],["NCT00354536","In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","SINGLE","60","Diabetes Mellitus, Type 2","DRUG:GSK716155 subcutaneous injections; BIOLOGICAL:placebo injection","GlaxoSmithKline","2006-02","2006-09","FALSE","blood plasma levels of GSK716155 [on days 2 & 9]","DERIVED:25387217",null,"YES",null],["NCT07101939","A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)","PROACT","RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","120","Obesity; Muscle Loss","DRUG:(S)-pindolol benzoate; DRUG:Semaglutide; DRUG:Placebo to (S)-pindolol benzoate","Actimed Therapeutics Ltd","2025-06-23","2027-03","FALSE","The change in lean body mass (LBM) in patients receiving one of two doses of ACM-001.1 whilst also receiving semaglutide. [20 weeks] | The change in lean body mass (LBM) grams/4 weeks over 20 weeks following semaglutide treatment. [20 weeks]",null,null,"UNDECIDED",null],["NCT06931028","A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","260","Sleep Apnea; Obstructive; Obesity","OTHER:placebo; DRUG:IBI362","Innovent Biologics (Suzhou) Co. Ltd.","2025-06-12","2027-05-07","FALSE","Change from Baseline in Apnea-Hypopnea Index (AHI) [Week 48]",null,null,"NO",null],["NCT02533453","A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.","Bydureon","COMPLETED","INTERVENTIONAL","PHASE4",null,"NONE","110","Type 2 Diabetes Mellitus","BIOLOGICAL:Bydureon","AstraZeneca","2016-01-28","2016-12-07","TRUE","Percentage of Participants With Adverse Events(AEs) and Serious Adverse Event(SAEs) [baseline and 12/24 weeks]",null,null,null,null],["NCT02941367","Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan","LixiRam","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","184","Diabetes Mellitus, Type 2","DRUG:Lixisenatide (AVE0010); DRUG:Sulfonylurea; DRUG:metformin; DRUG:basal insulin","Sanofi","2017-02-23","2017-08-04","FALSE","Percentage of patients with at least 1 documented symptomatic hypoglycemia event (plasma glucose ≤70 mg/dL; 3.9 mmol/L) [Approximately 30 days (from start to end of Ramadan holy month)]","DERIVED:37435938; DERIVED:32302665",null,"YES","OTHER:U1111-1172-3026"],["NCT05503927","A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy",null,"ENROLLING_BY_INVITATION","OBSERVATIONAL",null,null,null,"2701","Pregnancy; Obesity; Overweight","OTHER:No Intervention","Novo Nordisk A/S","2020-02-01","2027-08-15","FALSE","Number of Infants with Major Congenital Malformation (MCM) [Birth up to 1 year of age]",null,null,"YES","OTHER:U1111-1273-4411"],["NCT06143956","A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","1481","Obesity; Overweight","DRUG:LY3305677; DRUG:LY3841136; DRUG:Tirzepatide; DRUG:LY3549492; DRUG:LY3532226; DRUG:Placebo","Eli Lilly and Company","2023-11-17","2027-09","FALSE","Number of Participants Allocated to Each ISA [Baseline to Week 6]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/56/NCT06143956/Prot_000.pdf","YES","OTHER:W8M-MC-CWMM; OTHER:W8M-MC-OXA1; OTHER:W8M-MC-LAA1; OTHER:W8M-MC-LAA2; OTHER:W8M-MC-GN01; OTHER:W8M-MC-GN02; OTHER:W8M-MC-MC01"],["NCT06420739","The Semaglutide Study",null,"ACTIVE_NOT_RECRUITING","OBSERVATIONAL",null,null,null,"100","Fasting","DIAGNOSTIC_TEST:Gastric Ultrasound","University Health Network, Toronto","2024-03-25","2025-11-30","FALSE","Incidence of full stomach. [Pre-Surgical fasting duration per guideline]",null,null,"NO",null],["NCT07325500","Incretin Microdosing for Cardiometabolic Health in People With HIV","REINFORCE","RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","30","Weight Gain","DRUG:Dose escalation to 2 mg semaglutide weekly then semaglutide microdosing at 0.5 mg weekly; DRUG:Dose escalation to 2 mg semaglutide weekly then no semaglutide","The University of Texas Health Science Center, Houston","2026-02-12","2028-05-31","FALSE","Percent weight regain from weeks 12-60 (microdosing period) [from week 12 to week 60]",null,null,"NO","NIH:1R01DK142171-01A1"],["NCT07429032","The Effect of AMG 133 on Gastric Emptying",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","57","Overweight or Obesity","DRUG:AMG 133; DRUG:Placebo; DRUG:Acetaminophen","Amgen","2025-04-17","2025-11-26","FALSE","Maximum Observed Plasma Concentration (Cmax) for Acetaminophen [Days 1, 3, 8, 17, 31, 59, 64, and 86] | Time to Cmax (Tmax) for Acetaminophen [Days 1, 3, 8, 17, 31, 59, 64, and 86] | Area Under the Plasma Concentration-time Curve (AUC) from Time Zero to Time of Last Quantifiable Concentration (AUClast) for Acetaminophen [Days 1, 3, 8, 17, 31, 59, 64, and 86] | AUC from Time Zero to Infinity (AUCinf) for Acetaminophen [Days 1, 3, 8, 17, 31, 59, 64, and 86] | AUC from Time Zero to 5 Hours (AUC5hr) for Acetaminophen [Days 1, 3, 8, 17, 31, 59, 64, and 86]",null,null,"YES",null],["NCT04847557","A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","731","Obesity; Heart Failure With Preserved Ejection Fraction (HFpEF)","DRUG:Tirzepatide; OTHER:Placebo","Eli Lilly and Company","2021-04-20","2024-07-02","TRUE","Change From Baseline in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) [Baseline, Week 52] | First Occurrence of the Composite Endpoint of Heart Failure (HF) Outcomes [Baseline Up To 160 weeks]","DERIVED:42417681; DERIVED:40903131; DERIVED:40701669; DERIVED:40162940; DERIVED:39566869; DERIVED:39556714; DERIVED:39555826; DERIVED:39551891; DERIVED:38699780","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/57/NCT04847557/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/57/NCT04847557/SAP_001.pdf","YES","OTHER:I8F-MC-GPID"],["NCT05628311","A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","319","Type 2 Diabetes","OTHER:placebo; DRUG:IBI362","Innovent Biologics (Suzhou) Co. Ltd.","2023-01-06","2023-10-25","FALSE","HbA1c change from baseline at week 24 [Baseline, 24 weeks]",null,null,"NO",null],["NCT05766709","A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","53","Non-alcoholic Steatohepatitis","DRUG:NNC0194-0499; DRUG:Semaglutide; DRUG:NNC0194-0499/Semaglutide A (40/3.20 mg/mL); DRUG:NNC0194-0499/Semaglutide A (40/0.33mg/mL)","Novo Nordisk A/S","2023-03-02","2024-01-05","FALSE","AUC 0-168 hour (h), 0499, steady state (SS): Area under the NNC0194-0499 concentration time curve during a dosing interval (0-168 hours) at steady state after dosing of NNC0194-0499 in combination with semaglutide [Day 134 (pre-dose) to Day 141 (168 hours post-dose)] | AUC 0-168h,sema,SS: Area under the semaglutide concentration time curve during a dosing interval (0-168 hours) at steady state after dosing of NNC0194-0499 in combination with semaglutide [Day 134 (pre-dose) to Day 141 (168 hours post-dose)] | Cmax, 0499, SS: Maximum concentration of NNC0194-0499 at steady state after dosing of NNC0194-0499 in combination with semaglutide [Day 134 (pre-dose) to Day 141 (168 hours post-dose)] | Cmax,sema, SS: Maximum concentration of semaglutide at steady state after dosing of NNC0194-0499 in combination with semaglutide [Day 134 (pre-dose) to Day 141 (168 hours post-dose)]",null,null,"YES","OTHER:U1111-1285-5065"],["NCT04466904","Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM",null,"COMPLETED","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","DOUBLE","42","Type 2 Diabetes","DRUG:IBI362; DRUG:Placebo; DRUG:Dulaglutide","Innovent Biologics (Suzhou) Co. Ltd.","2020-09-12","2021-05-28","FALSE","To assess the number and incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of IBI362 compared with placebo [From the first dose of study drug to week 19]","DERIVED:35750681",null,null,null],["NCT06003465","A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","57","Healthy","DRUG:LY3437943; DEVICE:Test; DEVICE:Reference","Eli Lilly and Company","2023-08-29","2024-02-08","FALSE","Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3437943 [Predose up to 43 days postdose] | PK: Area Under the Plasma Concentration Versus Time Curve from Zero to T, Last Time Point (AUC[0-tlast]) of LY3437943 [Predose up to 43 days postdose] | PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3437943 [Predose up to 43 days postdose]",null,null,"NO","OTHER:J1I-MC-GZBX"],["NCT07172867","A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM",null,"WITHDRAWN","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","0","Diabetes Mellitus, Type 2; Obesity","DRUG:HT-6184; DRUG:HT-6184 Matching Placebo; DRUG:Semaglutide 1 mg","Halia Therapeutics, Inc.","2026-01-06","2026-01-23","FALSE","Assess glycemic control using HbA1c (%) [From first dose through End of Study (up to 12 weeks per participant)] | Assess weight loss using body weight measurements [From first dose through End of Study (up to 12 weeks per participant)]",null,null,"NO",null],["NCT07187830","Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD","ADIPOLIVE","RECRUITING","OBSERVATIONAL",null,null,null,"52","Chronic Kidney Disease in Type 2 Diabetes; Obesity & Overweight",null,"University of Alberta","2026-02-23","2027-12-15","FALSE","Correlation between kidney disease progression and cardiometabolic changes [From enrollment to the end of follow-up at 12 months]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/30/NCT07187830/Prot_SAP_000.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/30/NCT07187830/ICF_002.pdf","UNDECIDED",null],["NCT05573230","A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","32","Healthy","DRUG:Midazolam; DRUG:LY3502970; DRUG:Cyclosporine","Eli Lilly and Company","2022-10-17","2023-01-17","TRUE","Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3502970 [Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 96 hours postdose] | PK: Maximum Observed Concentration (Cmax) of LY3502970 [Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 96 hours postdose]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/30/NCT05573230/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/30/NCT05573230/SAP_001.pdf","NO","OTHER:J2A-MC-GZGL"],["NCT06409130","Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","270","Alcohol-related Liver Disease","DRUG:NNC0194-0499; DRUG:Semaglutide; DRUG:NNC0194-0499 placebo; DRUG:Semaglutide placebo (Group A); DRUG:Cagrilintide + semaglutide; DRUG:Cagrilintide; DRUG:Cagrilintide placebo; DRUG:Semaglutide placebo (Group B)","Novo Nordisk A/S","2024-05-20","2025-11-21","FALSE","Change in Enhanced Liver Fibrosis (ELF) [From week 0 to week 28]",null,null,"YES","OTHER:U1111-1295-6713; OTHER:2023-508170-28; NIH:2023"],["NCT07795164","Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH","PERFORMA","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","1800","Metabolic Dysfunction-Associated Steatohepatitis (MASH)","DRUG:Pemvidutide; OTHER:Placebo","Altimmune, Inc.","2026-07-30","2028-12","FALSE","Clinical Outcome Event [Baseline through end of study (approximately Month 60)] | Histological Response: MASH resolution [Baseline through Week 52] | Histological Response: Fibrosis improvement [Baseline through Week 52]",null,null,"YES",null],["NCT06983171","Semaglutide Effectiveness in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease in the Real World Practice",null,"ACTIVE_NOT_RECRUITING","OBSERVATIONAL",null,null,null,"70","MAFLD",null,"Center of target therapy","2025-04-02","2028-09-12","FALSE","Evaluate the impact of semaglutide therapy on liver morphological changes based on liver histology using the NAFLD Activity Score (NAS). [154 weeks] | Evaluate the impact of semaglutide therapy on the degree of steatosis change based on Controlled Attenuation Parameter (CAP score) [154 weeks] | Evaluate the impact of semaglutide therapy on the degree and distribution of fat infiltration in the liver based on MR spectroscopy data [154 weeks] | Evaluate the impact of semaglutide therapy on changes in liver elasticity based on elastography data [154 weeks]",null,null,"UNDECIDED",null],["NCT04781998","Is Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry?",null,"COMPLETED","INTERVENTIONAL","PHASE4",null,"NONE","24","Mental Disorder; Metabolic Disturbance; Feasibility; Overweight and Obesity; Liraglutide","DRUG:liraglutide 3 mg (Saxenda®) once-daily","Anders Fink-Jensen, MD, DMSci","2021-07-01","2022-07-21","FALSE","The primary endpoint is the number of \"completers\" [26 weeks]",null,null,"NO",null],["NCT07417306","A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","912","Type 2 Diabetes","DRUG:HDM1005 1; DRUG:HDM1005 2; DRUG:Mazdutide","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2026-03-27","2027-08-30","FALSE","Change from baseline in Hemoglobin A1c (HbA1c) [Baseline, Week 40]",null,null,"NO",null],["NCT00763451","GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","GETGOAL-F1","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","484","Diabetes Mellitus, Type 2","DRUG:Lixisenatide (AVE0010); DRUG:Placebo; DEVICE:Pen auto-injector; DRUG:Metformin","Sanofi","2008-09","2011-01","TRUE","Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 [Baseline, Week 24]","RESULT:24117597; DERIVED:39963952; DERIVED:24236828",null,null,"EUDRACT_NUMBER:2008-001002-16; NIH:2008"],["NCT07096739","Tolerance of a High Protein Nutrition Shake in Individuals on GLP-1",null,"COMPLETED","INTERVENTIONAL",null,null,"NONE","20","GLP-1 Concentration","DIETARY_SUPPLEMENT:High protein shake","Kate Farms Inc","2025-08-01","2025-09-19","FALSE","Composite GI symptoms score (CSS) [7 days]","DERIVED:42388893",null,"NO",null],["NCT02152371","A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes","AWARD-9","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","300","Diabetes Mellitus, Type 2","DRUG:Dulaglutide; DRUG:Placebo; DRUG:Insulin Glargine; DRUG:Metformin","Eli Lilly and Company","2014-05","2015-10","TRUE","Change From Baseline to 28 Weeks in Hemoglobin A1c (HbA1c) [Baseline, 28 Weeks]","DERIVED:29430801; DERIVED:29110972",null,"YES","OTHER:H9X-MC-GBDI; EUDRACT_NUMBER:2012-004229-25"],["NCT01444898","Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome",null,"COMPLETED","INTERVENTIONAL",null,null,"NONE","10","Prader-Willi Syndrome","DRUG:Exenatide","Children's Hospital Los Angeles","2012-03","2013-05","TRUE","Change in Weight [6 months] | % Change in Body Mass Index (BMI) [6 months] | Change in BMI Z-Score [6 months] | Change in HbA1c (%) [6 months] | Change in Insulin Levels [6 months] | Change in Leptin [6 months] | Change in Acy Ghr [6 months] | Change in Pancreatic Peptide (PP) [6 months] | Appetite Scores [6 months]","BACKGROUND:16876568; BACKGROUND:14693421; BACKGROUND:20424341; BACKGROUND:11739476; BACKGROUND:12091883; BACKGROUND:15292322; BACKGROUND:20332357; BACKGROUND:17192476; BACKGROUND:21227526; RESULT:27071367",null,"UNDECIDED",null],["NCT00508287","Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","36","Type 2 Diabetes","DRUG:BMS-686117; DRUG:Byetta; DRUG:Placebo","Bristol-Myers Squibb","2007-08","2007-11","FALSE","Safety: incidence of adverse events [from subject enrollment to study discharge]",null,null,null,null],["NCT02001363","Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury",null,"UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","90","Acute Myocardial Infarction","DRUG:liraglutide (Novo Nordisk, Bagsværd, Denmark); DRUG:liraglutide placebo (Novo Nordisk)","Chen Wei Ren, MD","2013-11","2016-03","FALSE","the salvage index measured by cardiac magnetic resonance [3 months after primary percutaneous coronary intervention]","BACKGROUND:18819705; BACKGROUND:21920963; BACKGROUND:19136619; RESULT:19151200; DERIVED:28286967; DERIVED:27940956",null,null,"OTHER:ChinaPLAGH"],["NCT07165158","The Effect of Semaglutide on Bone Health",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","150","Osteoporosis; Osteoporosis Fracture; T2DM","DRUG:semaglutide combined with metformin","The First Affiliated Hospital of Xiamen University","2025-09-15","2026-12-31","FALSE","lumbar bone mineral density [From enrollment to the end of treatment at 12 months]",null,null,null,null],["NCT01253304","A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","26","Diabetes Mellitus, Type 2","DRUG:LY2189265","Eli Lilly and Company","2010-11","2011-11","TRUE","Pharmacokinetics: Maximum Observed Concentration (Cmax) [Predose to 336 hours postdose] | Pharmacokinetics: Time of Maximum Concentration (Tmax) [Predose to 336 hours postdose] | Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to the Last Quantifiable Concentration (AUC[0-tlast]) [Predose to 336 hours postdose] | Pharmacokinetics: AUC From Time Zero to Infinity (AUC[0-infinity]) [Predose to 336 hours postdose] | Pharmacokinetics: Apparent Terminal Elimination Half-life (t1/2) [Predose to 336 hours postdose] | Pharmacokinetics: Apparent Total Plasma Clearance (CL/F) [Predose to 336 hours postdose] | Pharmacokinetics: Apparent Volume of Distribution (Vz/F) [Predose to 336 hours postdose]",null,null,null,"OTHER:H9X-EW-GBDO"],["NCT01599338","Impact of Liraglutide on Sensory Perception, Sensory Specific Satiety, Liking and Wanting in Type 2 Diabetic Patients",null,"COMPLETED","INTERVENTIONAL",null,null,"NONE","30","Type 2 Diabetes Mellitus; Overweight","DRUG:Liraglutide","Centre Hospitalier Universitaire Dijon","2011-01","2011-01","FALSE","Change in liking and wanting for protein, lipid and glucid foods [3 months] | Change in sensory specific satiety for protein, lipid and glucid foods [3 months] | Change in gustative detection thresholds for sweet, bitter and salty tastes [3 months] | Change in appetite, desire to eat, pleasure in eating [3 months]",null,null,null,"EUDRACT_NUMBER:2010-022618-19"],["NCT01001104","A Study of LY2189265 in Japanese Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","145","Diabetes Mellitus, Type 2","DRUG:LY2189265; DRUG:Placebo","Eli Lilly and Company","2009-10","2010-12","TRUE","Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 12 Weeks [Baseline, 12 weeks]",null,null,null,"OTHER:H9X-JE-GBCZ"],["NCT00642538","A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","20","Diabetes Mellitus, Type 2","DRUG:MKC253 Inhalation Powder; DRUG:Technosphere Inhalation Powder; DRUG:subcutaneous injection","Mannkind Corporation","2008-02","2008-09","FALSE","AUC 0-240 min post-prandial serum glucose [240 minutes]",null,null,null,"OTHER:EudraCT #: 2007-003430-42"],["NCT05989711","IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)","IMPACT","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","212","Non-Alcoholic Steatohepatitis (NASH)","DRUG:Pemvidutide; DRUG:Placebo","Altimmune, Inc.","2023-07-27","2025-11-25","FALSE","Proportion of subjects achieving NASH resolution (NAFLD activity score [NAS], ballooning = 0; lobular inflammation = 0, 1) with at least a 2-point reduction in NAS without worsening of fibrosis [24 weeks] | Proportion of subjects achieving at least 1 stage improvement in liver fibrosis without worsening of NASH (defined as no change in the NAS, ie, the sum score for ballooning, inflammation, and steatosis) [24 weeks] | Incidence of Treatment Emergent Adverse Events [52 weeks]","DERIVED:41237796",null,null,null],["NCT07668414","A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide","AMAZE 7","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","650","Overweight; Obesity","DRUG:Zenagamtide; DRUG:Semaglutide; DRUG:Placebo (matched to semaglutide); DRUG:Placebo (matched to zenagamtide)","Novo Nordisk A/S","2026-09-22","2028-10-10","FALSE","Relative change in body weight [From week 0 to week 84]",null,null,"YES","OTHER:U1111-1313-7968"],["NCT02845219","A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","25","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:SNAC; DRUG:Microgynon®","Novo Nordisk A/S","2016-07","2016-12","FALSE","Area under the ethinylestradiol plasma concentration-time curve during a dosing interval (0-24 hours) at steady state [On day 8 (OC alone), day 24 (OC with SNAC) and day 82 (OC with oral semaglutide at steady state)] | Area under the levonorgestrel plasma concentration-time curve during a dosing interval (0-24 hours) at steady state [On day 8 (OC alone), day 24 (OC with SNAC) and day 82 (OC with oral semaglutide at steady state)]","DERIVED:33782832",null,null,"EUDRACT_NUMBER:2015-004232-35; OTHER:U1111-1174-7914; NIH:2015"],["NCT06671587","iGlarLixi CGM Study in Chinese T2D Individuals After OADs","China Soli-CGM","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","678","Type 2 Diabetes (T2D)","DRUG:iGlarLixi (insulin glargine/lixisenatide); DRUG:Gla-100 (insulin glargine)","Sanofi","2024-12-10","2026-09-18","FALSE","Superiority of mean change in the percentage of TIR [3.9-10.0 mmol/L (70-180 mg/dL)] [from baseline to Week 20]",null,null,"YES","REGISTRY:U1111-1306-6660"],["NCT07035093","A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain","TRIUMPH-7","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","586","Obesity; Overweight; Chronic Low Back Pain (CLBP)","DRUG:Retatrutide; DRUG:Placebo","Eli Lilly and Company","2025-05-29","2027-09","FALSE","Change from Baseline in Pain Intensity Per Numeric Rating Scale [Baseline, up to 72 weeks] | Percent Change from Baseline in Body Weight [Baseline, up to 72 weeks]",null,null,"YES","OTHER:J1I-MC-GZQD; CTIS:2024-517431-43-00"],["NCT03235375","A Study to Evaluate Pharmacokinetics, Safety and Tolerability of MEDI0382 in Renal Impairment Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","37","Renal Insufficiency","DRUG:MEDI0382","MedImmune LLC","2017-10-27","2018-04-24","FALSE","Maximum Observed Concentration of MEDI0382 (Cmax) [0-48 hours] | Area under the Concentration Time Curve (AUC) of MEDI0382 [0-48 hours]","DERIVED:37140727",null,null,null],["NCT05788601","Dapiglutide for the Treatment of Obesity","DREAM","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","54","Obesity; Inflammation","DRUG:Dapiglutide; DRUG:Placebo","University Hospital, Gentofte, Copenhagen","2023-04-27","2024-04-24","FALSE","Percentage change in body weight (kg) [From week 0 (baseline) to week 12 (end of treatment)]","DERIVED:41768273","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/01/NCT05788601/Prot_000.pdf","NO","OTHER:2022-501649-54-00"],["NCT07820722","Assessing Heart and Brain Metabolism in Type II Diabetes Mellitus Patients Using Carbon-13 MRI",null,"NOT_YET_RECRUITING","INTERVENTIONAL","EARLY_PHASE1","NON_RANDOMIZED","NONE","32","Diabete Type 2","DRUG:C13 Hyperpolarized pyruvate injection","Sunnybrook Health Sciences Centre","2026-10-01","2029-08-01","FALSE","Change in the 13C-pyruvate [At baseline and during the second MRI scan] | Changes in 13C-lactate [At baseline and during the second MRI scan] | Change in 13C-bicarbonate [At Baseline and during the second MRI scan]",null,null,"NO",null],["NCT07109700","A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","216","Type 2 Diabetes","DRUG:HDM1005 1; DRUG:HDM1005 2; DRUG:HDM1005 3; DRUG:HDM1005 4; DRUG:Placebo; DRUG:Dulaglutide 1.5 MG","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2025-04-30","2026-01-31","FALSE","Change from baseline in Hemoglobin A1c (HbA1c) [Baseline, Week 20]",null,null,"NO",null],["NCT00394030","Injection Site Study In Patients With Type 2 Diabetes Mellitus (T2DM) And Healthy Volunteers",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","63","Diabetes Mellitus, Type 2","DRUG:GSK716155 subcutaneous injections","GlaxoSmithKline","2006-10-16","2007-03-20","FALSE","Pharmacokinetic measurements for different injection sites after one dose. [Pre-dose, 6, 24, 48, 96, 216, 312, 480, 672 and 984 hours]","DERIVED:25387217",null,"YES",null],["NCT05441267","A Study of Cardiovascular Events iN Diabetes Plus","ASCEND PLUS","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","21296","Diabetes Mellitus, Type 2","DRUG:Semaglutide Oral Tablet; DRUG:Placebo oral tablet","University of Oxford","2023-03-13","2028-08-17","FALSE","Time to the first occurrence of a Major Adverse Cardiovascular Events (MACE+) [Scheduled treatment period (anticipated median follow-up period of 5-years)]",null,null,"YES",null],["NCT02496611","Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","100","Severe Obesity","DRUG:Weight loss with pharmacotherapy; DRUG:Weight loss without pharmacotherapy","University of Minnesota","2015-12","2020-08-14","TRUE","Body Mass Index [52 weeks]","DERIVED:42281167; DERIVED:35537665; DERIVED:35403350; DERIVED:27496270","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/11/NCT02496611/Prot_SAP_000.pdf",null,null],["NCT07767175","A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","142","Overweight; Obesity","DRUG:NNC0721-8060; DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2026-08-12","2027-09-23","FALSE","Part A: Number of treatment emergent adverse events (TEAE) [From Day 1 to Day 36] | Part B: Number of treatment emergent adverse events (TEAE) [From Day 1 to Day 57] | Part C: Change from baseline in body weight [From Day 1 to Day 85]",null,null,"YES","OTHER:U1111-1334-3077"],["NCT05788328","A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants",null,"TERMINATED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","16","Healthy","DRUG:Dabigatran etexilate (DE); DRUG:Rosuvastatin; DRUG:PF-07081532","Pfizer","2023-03-27","2023-09-11","TRUE","Area Under the Concentration-Time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of Total Dabigatran in Period 1, 4 and 7 [Pre-dose (0 hour), 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours post dose of DE on Day 1 of Period 1, 4 and 7] | Area Under the Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUClast) of Total Dabigatran in Period 1, 4 and 7 [Pre-dose (0 hour), 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours post dose of DE on Day 1 of Period 1, 4 and 7] | AUCinf of Rosuvastatin in Period 2, 5 and 8 [Pre-dose (0 hour), 1, 2, 3, 4, 5, 6, 8, 10, 14, 24, 48, 72 and 96 hours post dose of ROSU on Day 1 of Period 2, 5 and 8] | AUClast of Rosuvastatin in Period 2, 5 and 8 [Pre-dose (0 hour), 1, 2, 3, 4, 5, 6, 8, 10, 14, 24, 48, 72 and 96 hours post dose of ROSU on Day 1 of Period 2, 5 and 8]","DERIVED:42053447","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/28/NCT05788328/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/28/NCT05788328/SAP_001.pdf","NO",null],["NCT02249871","Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","54","Diabetes; Healthy","DRUG:semaglutide; DRUG:Omeprazole","Novo Nordisk A/S","2014-09-24","2015-04-01","FALSE","Area under the semaglutide plasma concentration time curve [From time 0 to 24 hours after the 10th daily dose]","RESULT:29897249; DERIVED:33969456",null,null,"EUDRACT_NUMBER:2013-005513-12; OTHER:U1111-1151-5077"],["NCT07633639","GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity",null,"RECRUITING","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","200","Obesity","COMBINATION_PRODUCT:LSG-Semaglutide group; COMBINATION_PRODUCT:LSG-Mazdutide group; COMBINATION_PRODUCT:LSG-Tirzepatide group; PROCEDURE:LSG group","China-Japan Friendship Hospital","2026-05-01","2028-05-01","FALSE","Percentage of weight loss. [Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.]",null,null,null,null],["NCT01620489","Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","279","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2012-06-14","2013-08-20","TRUE","Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in HbA1c (%) (Glycosylated Haemoglobin) [Week 0, Week 26]","RESULT:26681713; RESULT:30663196; DERIVED:39963952; DERIVED:29729957",null,null,"EUDRACT_NUMBER:2011-002968-24; OTHER:U1111-1122-3303"],["NCT05302596","Semaglutide Use in Elderly Obese Patients",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","16","Obesity; Aging","DRUG:Semaglutide Pen Injector","State University of New York at Buffalo","2022-09-01","2023-10-23","TRUE","Body Composition as Total Fat Mass/ Total Fat-free Mass Ratio [16 weeks] | Body Weight [16 weeks]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/96/NCT05302596/Prot_SAP_000.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/96/NCT05302596/ICF_001.pdf","NO","NIH:UL1TR001412"],["NCT04809220","A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes","AWARD-JPN","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","591","Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose Metabolism Disorders; Metabolic Disease; Endocrine System Diseases; Hypoglycemic Agents; Type 2 Diabetes Mellitus (T2DM)","DRUG:Dulaglutide; DRUG:Oral antihyperglycemics","Eli Lilly and Company","2021-04-13","2022-10-01","TRUE","Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 [Baseline, Week 26]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/20/NCT04809220/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/20/NCT04809220/SAP_001.pdf","YES","OTHER:H9X-JE-GBGQ"],["NCT00803920","Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide",null,"COMPLETED","OBSERVATIONAL",null,null,null,"8","Type 2 Diabetes Mellitus",null,"HealthPartners Institute","2006-12","2008-02","FALSE","Characterize glucose control using periodic CGM in subjects participating in protocol 2993LAR-105 at the International Diabetes Center study site. [2 week periods of time - 3 times during study:]",null,null,null,null],["NCT03199261","A Study of Pharmacokinetic Comparison of Two Recombinant Exendin-4 Formulations in Chinese Healthy Male Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","24","Type 2 Diabetes","DRUG:rE-4 Injection; DRUG:rE-4 Freeze-dried Powder","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","2016-12-23","2017-01-21","FALSE","Bioequivalency between the 2 formulations of rE-4 [before injection and 0.25,0.5,0.75,1.0,1.5，2.0,3.0,4.0,6.0,8.0hour post-injection]",null,null,"NO",null],["NCT05804513","The Effect of Lixisenatide on the Effect of Pituitary Hormones",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","10","Healthy; Type 1 Diabetes","DRUG:Placebo; DRUG:Lixisenatide 10 micrograms (50 micrograms/ml in 3 ml) Pen Injector","University of Tartu","2023-04-17","2023-10-31","FALSE","Growth hormone area under the curve. [0-150 minutes after study drug administration]",null,null,null,null],["NCT01776788","Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","156","Diabetes Mellitus, Type 2","DRUG:insulin lispro injection, exenatide injection; DRUG:insulin lispro injection","The First Affiliated Hospital of Xiamen University","2012-08","2015-02","FALSE","the glycemic remission rate in different groups [one year]",null,null,null,null],["NCT04876027","GLP-1 RAs in Patients With Polycystic Ovary Syndrome (PCOS)",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","68","Polycystic Ovary Syndrome","DRUG:GLP-1 RAs; OTHER:calorie restricted diet","Shanghai 10th People's Hospital","2021-05-15","2022-04-30","FALSE","the change in visceral adipose tissue [until achievement of the weight loss target,an average of 12 weeks]",null,null,"NO",null],["NCT06825182","Current Status of Islet Alpha Cell Function in Patients with Type 2 Diabetes",null,"RECRUITING","INTERVENTIONAL","PHASE3",null,"NONE","1000","Type 2 Diabetes Mellitus","DRUG:Outpatient newly diagnosed type 2 diabetes subjects; DRUG:Inpatient newly diagnosed type 2 diabetes subjects","Nanjing First Hospital, Nanjing Medical University","2024-11-07","2025-08-01","FALSE","Glucagon levels [19 months]",null,null,"NO",null],["NCT01484262","Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2",null,"COMPLETED","OBSERVATIONAL",null,null,null,"1344","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:insulin","Novo Nordisk A/S","2011-11-14","2014-10-31","FALSE","Diabetes-related quality of life assessed by ADDQoL (Audit of Diabetes-Dependent Quality of Life) [At the end of the observational period (52 weeks)]","RESULT:30157532",null,null,"OTHER:U1111-1123-5044"],["NCT01388361","Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin","BEGIN™","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","413","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec; DRUG:insulin aspart; DRUG:liraglutide","Novo Nordisk A/S","2011-09","2012-07","TRUE","Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin) [week 0, week 26]","RESULT:24443830",null,null,"EUDRACT_NUMBER:2011-001493-25; OTHER:U1111-1120-2782"],["NCT02313220","Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight","Dapalost","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","50","Obesity","DRUG:Dapagliflozin; DRUG:Exenatide; DRUG:Placebo","Uppsala University","2014-12","2016-03","FALSE","Body weight (kg) [From randomization to 24 weeks]",null,null,null,"EUDRACT_NUMBER:2014-003432-39; NIH:2014"],["NCT06440980","A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","533","Healthy; Obese; Overweight; Obesity","DRUG:Orforglipron","Eli Lilly and Company","2024-06-24","2025-06-02","TRUE","Part B: Pharmacokinetics (PK): Steady-state Area Under the Concentration Time Curve From Time Zero to the End of the Dosing Interval, Tau (AUC[0-tau]) of LY3502970 on Day 7 [Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose on Day 7 for each dosing treatment period (1 period=7 days)] | Part B: PK: Steady-state Maximum Observed Concentration (Cmax) of LY3502970 on Day 7 [Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose on Day 7 for each dosing treatment period (1 period=7 days)]","DERIVED:41994902","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/80/NCT06440980/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/80/NCT06440980/SAP_001.pdf","NO","OTHER:J2A-MC-GZPI"],["NCT05705388","POSE2.0 With GLP-1 Agonist for Obesity Management",null,"UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","NONE","50","Obesity","DEVICE:POSE2.0 Endoscopic Gastric Remodeling; DRUG:Liraglutide injection","Emirates Health Services (EHS)","2023-01-16","2025-01-03","FALSE","Mean percent total body weight loss at 6 months in each arm of the study [6 months] | Percentage of subjects with ≥5 percent total body weight loss at 6 months in each arm at 6 months [6 months] | The incidence, frequency, and severity of adverse events related to treatment with the device and procedure as well as medication will be reported. [at 6 months]",null,null,"NO",null],["NCT01910194","Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","39","Diabetes Mellitus","DRUG:Luyxumia versus Lantus","Profil Institut für Stoffwechselforschung GmbH","2013-12","2014-10","FALSE","AUCISEC(0-10min) [Within 0 to 10 min after iv glucose challenge]",null,null,null,null],["NCT02420262","A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","506","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide; DRUG:insulin glargine; DRUG:insulin aspart","Novo Nordisk A/S","2015-07-26","2016-10-05","TRUE","Change in HbA1c (Glycosylated Haemoglobin) [Week 0, Week 26]","RESULT:29483185; DERIVED:32107930; DERIVED:31705547",null,null,"EUDRACT_NUMBER:2014-003621-18; OTHER:U1111-1160-6923; REGISTRY:REec-2015-1682; NIH:2014"],["NCT06649045","A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight","ATTAIN-OSA","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","712","OSA; Overweight or Obesity","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2024-10-22","2026-07-21","FALSE","Change from Baseline in Apnea-Hypopnea Index (AHI) [Baseline to Week 52]","DERIVED:42383207",null,"YES","OTHER:J5P-MC-GZRA; OTHER:J5P-MC-GZ01; OTHER:J5P-MC-GZ02"],["NCT04771273","A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","295","Non-alcoholic Steatohepatitis (NASH)","DRUG:Survodutide; DRUG:Placebo","Boehringer Ingelheim","2021-04-27","2023-11-09","TRUE","Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Actual Maintenance Treatment [At baseline and at 48 weeks.] | Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Planned Maintenance Treatment [At baseline and after 48 weeks of treatment.]","DERIVED:38847460","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/73/NCT04771273/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/73/NCT04771273/SAP_001.pdf","YES","EUDRACT_NUMBER:2020-002723-11"],["NCT05680129","A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","623","T2DM; Type 2 Diabetes Mellitus","DRUG:Ecnoglutide high dosage; DRUG:Ecnoglutide low dosage; DRUG:Dulaglutide; DRUG:Metformin","Hangzhou Sciwind Biosciences Co., Ltd.","2023-01-10","2024-07-03","FALSE","Change from baseline in HbA1c [Baseline, week 32]","DERIVED:40854315",null,"NO",null],["NCT06559527","A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","42","Diabetes Mellitus, Type 2; Obesity; Overweight","DRUG:NNC0487-0111","Novo Nordisk A/S","2024-08-20","2025-02-24","FALSE","AUC0111,0-∞,SD: Area under the NNC0487-0111 plasma concentration-time curve from time 0 to infinity after a single dose [From baseline (Visit 2, Day 1, pre-dose) until completion of the end of study visit (Visit 9, Day 28)]","DERIVED:42443140",null,"YES","OTHER:U1111-1298-6886; OTHER:2023-509961-19; NIH:2023"],["NCT07280403","Effect of a Low-carbohydrate Diet on Weight Loss in People Using the Injectable GLP-1 Agonist Semaglutide for Weight Loss",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","60","Weight Loss","BEHAVIORAL:Low Carbohydrate; BEHAVIORAL:Low Fat","INQUIS Clinical Research","2024-09-12","2025-10-14","FALSE","Body weight [12 weeks]",null,null,"NO",null],["NCT06235086","A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","632","Type 2 Diabetes Mellitus","DRUG:TG103; DRUG:Dulaglutide","CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","2024-04-08","2026-02-03","FALSE","Changes in glycosylated hemoglobin (HbA1c) from baseline at 28 weeks of treatment [Baseline through Week28]",null,null,null,null],["NCT04324229","Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes","Liragest","ACTIVE_NOT_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","80","Gestational Diabetes","DRUG:Liraglutide 6 MG/ML [Victoza]; DRUG:Placebos","Turku University Hospital","2020-02-07","2024-09-30","FALSE","Incidence of type 2 diabetes [from year 1 to 5]",null,null,"UNDECIDED",null],["NCT07143227","A Study of XW003 Injection in Chinese Adolescents With Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","48","Obese Adolescents; Obesity","DRUG:XW003 injection; DRUG:placebo with matching volume","Hangzhou Sciwind Biosciences Co., Ltd.","2025-08-25","2026-04-18","FALSE","Number and severity of adverse events [week 20]",null,null,"NO",null],["NCT00849056","Safety and Efficacy of Albiglutide in Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","310","Diabetes Mellitus, Type 2","BIOLOGICAL:albiglutide; DRUG:placebo","GlaxoSmithKline","2009-01","2011-11","TRUE","Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52 [Baseline and Week 52]","DERIVED:28683300",null,"YES",null],["NCT05963022","A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","206","Type 2 Diabetes","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2023-08-21","2024-10-09","TRUE","Change From Baseline in Hemoglobin A1c (HbA1c) [Baseline, Week 40]","DERIVED:42296968","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/22/NCT05963022/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/22/NCT05963022/SAP_001.pdf","YES","OTHER:I8F-MC-GPIU"],["NCT06804603","A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","124","Obesity","DRUG:Tradipitant; DRUG:Placebo","Vanda Pharmaceuticals","2025-02-25","2025-10-06","FALSE","Proportion of participants with at least 1 vomiting episode per week in the tradipitant group compared to the placebo group as measured by a daily symptom diary. [1 week]",null,null,"NO",null],["NCT04601740","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice","PIONEER REAL","COMPLETED","OBSERVATIONAL",null,null,null,"145","Diabetes Mellitus, Type 2","DRUG:Oral Semaglutide","Novo Nordisk A/S","2020-11-17","2022-12-19","FALSE","Change in Glycated haemoglobin (HbA1c ) [From baseline (week 0) to End of Study visit (V3) (week 34-44)]","DERIVED:39535683; DERIVED:38861137",null,"YES","OTHER:U1111-1240-4249"],["NCT01357850","A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","82","Heart Failure, Congestive","DRUG:GSK716155; DRUG:Placebo","GlaxoSmithKline","2010-09-15","2012-09-18","TRUE","Change From Baseline in Myocardial Glucose Utilization as Assessed by [18F]Fluoro-2-deoxy-glucose Positron Emission Tomography (FDG-PET) Imaging [Baseline and Week 13] | Change From Baseline in Myocardial Efficiency (Work Performed/Myocardial Oxygen Consumption [MVO2]) Assessed at Rest [Baseline and Week 13] | Change From Baseline in Peak Oxygen Uptake (Peak VO2) as Assessed by Bicycle Cardiopulmonary Exercise Testing [Baseline and Week 13]","DERIVED:27039125",null,"YES",null],["NCT07057310","Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women",null,"ENROLLING_BY_INVITATION","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","30","Obesity; Menopause","DRUG:semaglutide or tirzepatide; BEHAVIORAL:Lifestyle modification intervention","Mayo Clinic","2025-05-01","2026-12-31","FALSE","Physical Function Measure: Short Physical Performance Battery (SPPB) score. [24 weeks] | Physical Function Measure: Modified Clinical Test of Sensory Interaction in Balance (mCTSIB) performed on the Rehabilitation Artificial Physical Intelligence Database (RAPID) foot pressure mat [24 weeks] | Physical Function Measure: Standing Chest Throw Test with a 2-kg Weighted Ball using Motion Sensor Technology (MST) [24 weeks] | Physical Function Measure: Chair-to-Stand Tests using Motion Sensor Technology (MST) [24 weeks] | Physical Function Measure: Six-Minute Walk Test (6MWT) [24 weeks] | Physical Function Measure: Hand Grip Strength using a Hydraulic Hand Dynamometer [24 weeks] | Physical Function Measure: Short Form-12 (SF-12) Health Survey [24 weeks] | Physical Function Measure: Patient-Reported Outcomes Measurement Information System (PROMIS) - Fatigue and Physical Function Domains [24 weeks] | Aging Biomarkers: Cellular Senescence Markers in Plasma [24 weeks] | Difference between biological and chronological age [24 weeks] | Vascular Function Assessment: Reactive Hyperemia Index (RHI) using EndoPAT [24 weeks]",null,null,"NO",null],["NCT07756359","Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)","PROP-ZEP","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","20","Pouch, Ileal; Pouches, Ileoanal; Bowel Diseases, Inflammatory","DRUG:Tirzepatide; DRUG:Loperamide; DRUG:Diphenoxylate/Atropine","University of North Carolina, Chapel Hill","2026-09","2027-09","FALSE","Proportion of patients achieving a decrease of the average daily bowel frequency by 30% at week 12 (Week 16 if applicable) [Week 12 (Week 16 if applicable)]","BACKGROUND:37385275; BACKGROUND:25916224; BACKGROUND:35568303; BACKGROUND:36777426; BACKGROUND:29104126; BACKGROUND:3393032; BACKGROUND:38125203; BACKGROUND:18573211; BACKGROUND:14684584; BACKGROUND:16401690; BACKGROUND:10383499; BACKGROUND:10930365; BACKGROUND:17934776; BACKGROUND:12730861; BACKGROUND:17567869; BACKGROUND:8170189; BACKGROUND:12794576; BACKGROUND:35362902; BACKGROUND:28853727; BACKGROUND:39038228; BACKGROUND:37975591; BACKGROUND:40560215; BACKGROUND:36082341; BACKGROUND:39536238; BACKGROUND:35658024; BACKGROUND:40024571; BACKGROUND:29848084; BACKGROUND:8406148; BACKGROUND:27506537; BACKGROUND:30965026; BACKGROUND:35868334; BACKGROUND:40073325; BACKGROUND:38668926; BACKGROUND:27875281; BACKGROUND:21557790; BACKGROUND:23511332; BACKGROUND:10486365; BACKGROUND:10194525; BACKGROUND:9175210; BACKGROUND:31359088; BACKGROUND:28648835; BACKGROUND:25485516; BACKGROUND:26470783; BACKGROUND:10816636; BACKGROUND:14501509; BACKGROUND:28301429; BACKGROUND:17225210; BACKGROUND:30698715; BACKGROUND:28426474; BACKGROUND:34774224; BACKGROUND:38128971; BACKGROUND:37481117; BACKGROUND:10522727; BACKGROUND:36822736; BACKGROUND:34798336; BACKGROUND:24983982",null,"YES",null],["NCT07619989","Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor Agonists",null,"RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","24","Obesity & Overweight","DEVICE:transcutaneous auricular vagus nerve stimulation; DEVICE:Sham","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","2026-08-01","2027-06-01","FALSE","Percent Change in Body Weight From Baseline [Baseline, 4 weeks, 8 weeks, 12 weeks]",null,null,"NO",null],["NCT07295223","Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)","GALACTUS","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","44","Acute Myocardial Infarction With ST Elevation","DRUG:Dapagliflozin 10 MG Oral Tablet; DRUG:Semaglutide (Rybelsus®)","Instituto Mexicano del Seguro Social","2025-12-30","2026-08","FALSE","Inflammatory markers (high-sensitivity PCR) [24 weeks.] | Inflammatory markers (interleukin 6) [24 weeks]",null,null,"NO",null],["NCT06972459","A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","800","Obesity; Overweight","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2025-05-15","2027-08","FALSE","Percent Change from Baseline in Body Weight [Baseline, Week 72]",null,null,"YES","CTIS:2025-521098-14-00; OTHER:J2A-MC-GZP1; OTHER:J2A-MC-GZPO; NIH:2025"],["NCT01588418","Acute Effect of Exenatide on Brain Glucose Metabolism",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","15","Impaired Glucose Tolerance (IGT); Diabetes","DRUG:Exenatide; DRUG:Placebo","The University of Texas Health Science Center at San Antonio","2010-07","2015-07","TRUE","Effect of Exenatide on Brain (Total Gray Matter) Glucose Metabolism [120 minutes after exenatide or placebo injection]","RESULT:26116695; RESULT:27639082",null,"NO",null],["NCT04417582","Life Style Modification Medical and Surgical Management in Patients With Obesity",null,"UNKNOWN","OBSERVATIONAL",null,null,null,"1000","Obesity; Weight Change, Body; Obesity; Endocrine; Obesity, Metabolically Benign","PROCEDURE:bariatric surgey","Marmara University","2020-01-01","2023-12-01","FALSE","weight loss [6 months interval] | metabolic improvement [6 months interval] | metabolic improvement [6 month]",null,null,"UNDECIDED",null],["NCT04763564","Efficacy of Liraglutide Therapy in Patients With IPAA",null,"TERMINATED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","8","Pouchitis; Irritable Pouch Syndrome","DRUG:Liraglutide Pen Injector; DRUG:Placebo Pen Injector","University of North Carolina, Chapel Hill","2022-03-22","2023-10-16","TRUE","Mean % Reduction of Bowel Frequency in Percent of the Mean 7-day Bowel Frequency After 4 Weeks of Therapy on Liraglutide vs Placebo Compared to Baseline . [Baseline, Week 4 (treatment period 1) and week 10 (treatment period 2)]","RESULT:38668926","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/64/NCT04763564/Prot_SAP_000.pdf","YES","OTHER:U1111-1252-6589"],["NCT04109508","A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","278","Healthy Volunteers; Type 2 Diabetes","DRUG:Oral semaglutide","Novo Nordisk A/S","2019-10-02","2020-12-24","FALSE","AUC0-24h,sema,SS; area under the semaglutide plasma concentration-time curve during a dosing interval at steady state [From 0 to 24 hours after the last dosing of oral semaglutide low, medium and high dose on days 28, 56 and 84, respectively]",null,null,"YES","OTHER:U1111-1233-0878; REGISTRY:2019-002010-40; NIH:2019"],["NCT06577090","Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo","CBeyond","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","136","Obesity","BIOLOGICAL:Nimacimab injection; BIOLOGICAL:Nimacimab placebo injection; COMBINATION_PRODUCT:semaglutide injection; BIOLOGICAL:Nimacimab 300 mg injection","Skye Bioscience, Inc.","2024-08-22","2026-11-20","FALSE","Percent change in body weight (main study) [From Baseline to Week 26] | Nature, frequency and severity of AEs (study extension) [Baseline through Week 38 of study extension (approximately 10 months of participation)]",null,null,null,null],["NCT06924697","Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Stimulation on Smoking Consumption in Type 2 Diabetes Patients",null,"ENROLLING_BY_INVITATION","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","46","Diabetes Mellitus, Type 2; Nicotine Dependence, Cigarettes","DRUG:Application of GLP-1RAs drugs; DRUG:DPP-4i group","Shanghai East Hospital","2025-06-21","2026-01-11","FALSE","Fagerstrom Test of Nicotine Dependence (FTND) scores [From enrollment to the end of treatment at 24 weeks.At weeks 0 and 24]","RESULT:19165417; RESULT:28305512; RESULT:17712795; RESULT:23955804; RESULT:22343430; RESULT:24036244; RESULT:36876428; RESULT:24622281; RESULT:33849845; RESULT:31443244; RESULT:1370102; RESULT:9468652; RESULT:8367459; RESULT:11738084; RESULT:8426779; RESULT:8374438; RESULT:11206655; RESULT:26388413; RESULT:23219318; RESULT:19750233; RESULT:37115584; RESULT:37114375; RESULT:24361023; RESULT:21379566; RESULT:30110591; RESULT:23698590; RESULT:26971098; RESULT:29724163; RESULT:28101646; RESULT:11298764; RESULT:36215990; DERIVED:41704542",null,"YES",null],["NCT01885208","Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes","SUSTAIN™ 3","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","813","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:exenatide","Novo Nordisk A/S","2013-12-02","2015-07-13","TRUE","Change From Baseline in HbA1c (Glycosylated Haemoglobin) [Week 0, week 56]","BACKGROUND:30938762; BACKGROUND:30865526; RESULT:29246950; RESULT:29687620; RESULT:29748996; RESULT:29766634; RESULT:29862621; RESULT:29907893; RESULT:30535837; RESULT:30615985; RESULT:30047216; DERIVED:36056351; DERIVED:32998732; DERIVED:32827435; DERIVED:32193837; DERIVED:31903692; DERIVED:31769496; DERIVED:31215727",null,null,"EUDRACT_NUMBER:2012-004826-92; OTHER:U1111-1135-8647"],["NCT01790308","Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","100","Diabetes Mellitus, Type 2","DRUG:CSII; DRUG:Liraglutide","Sun Yat-sen University","2013-02","2014-12","FALSE","the percentage of the patients who maintain glucose control 1 year after short intensive therapy [1 year]",null,null,null,null],["NCT07156591","Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention",null,"NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"460","Gastric Retention","PROCEDURE:Esophagogastroduodenoscopy","Fudan University","2025-09-15","2028-09-15","FALSE","Rate of gastric retention [immediately after the esophagogastroduodenoscopy]",null,null,"YES",null],["NCT00560417","Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","339","Diabetes Mellitus, Type 2","DRUG:Insulin Lispro Protamine Suspension; DRUG:Insulin Glargine","Eli Lilly and Company","2007-11","2009-12","TRUE","Change From Baseline in Hemoglobin A1C (HbA1c) at Endpoint (Last Observation Carried Forward [LOCF]) [Baseline, Endpoint (LOCF) up to 24 weeks]",null,null,null,"OTHER:F3Z-US-IOPB"],["NCT01373450","Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","12","Type 2 Diabetes Mellitus","DRUG:Oxyntomodulin; DRUG:Liraglutide 0.6 mg; DRUG:Liraglutide 1.2 mg; DRUG:Placebo for Oxyntomodulin; DRUG:Placebo for Liraglutide","Merck Sharp & Dohme LLC","2011-06","2011-07","TRUE","Change From Baseline in Time-weighted Average of Glucose Measured by Area Under the Curve (AUC) After a Single Dose of Oxyntomodulin (OXM) [Baseline and during GGI at time points 0, 20, 40, 60, 80, 100, 120, 140, 160 and 165 minutes] | Change From Baseline in Maximum Ambient Glucose Concentration (Gmax) After a Single Dose of OXM [Baseline and up to 160 minutes after start of GGI] | Change From Baseline in Beta Cell Sensitivity to Glucose (Φ) After a Single Dose of OXM [Baseline and up to160 minutes after start of GGI]","DERIVED:29545266; DERIVED:27072496",null,null,null],["NCT02118376","Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status",null,"UNKNOWN","INTERVENTIONAL",null,null,"NONE","20","Obesity","DRUG:Exenatide","Shanghai 10th People's Hospital","2014-08","2014-12","FALSE","Dual energy X-ray absorptiometry [3 month]","DERIVED:28376799",null,null,null],["NCT02455076","Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","150","Type 2 Diabetes","DRUG:Exenatide; DRUG:Glargine; DRUG:Rapid-acting insulin analogs","Emory University","2015-09","2018-03","TRUE","Mean Daily Blood Glucose Concentration Inpatient [Duration of hospital stay, an expected average of 10 days.] | Change in HbA1c Concentration Inpatient [12 weeks from discharge.]","DERIVED:30679302","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/76/NCT02455076/Prot_SAP_000.pdf",null,null],["NCT06041217","A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range","STEP12","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","242","Overweight; Obesity","DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2023-09-15","2025-04-02","TRUE","Change in Body Weight (%) [Baseline (week 0), end of treatment (week 44)] | Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal to (≥) 5% (Yes/No) [At end of treatment (week 44)]","DERIVED:42575111","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/17/NCT06041217/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/17/NCT06041217/SAP_001.pdf","YES","OTHER:U1111-1273-4538"],["NCT00993720","Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","NONE","30","Diabetes Mellitus","DRUG:Liraglutide; OTHER:continuous insulin therapy","Hvidovre University Hospital","2009-10","2010-10","FALSE","insulin-dose [4 weeks]","DERIVED:21593296",null,null,"NIH:2009"],["NCT04881760","A Study of LY3437943 in Participants Who Have Obesity or Are Overweight",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","338","Obesity; Overweight","DRUG:LY3437943; DRUG:Placebo","Eli Lilly and Company","2021-05-20","2022-05-16","TRUE","Mean Percent Change From Baseline in Body Weight [Baseline, Week 24]","DERIVED:42608321; DERIVED:41201783; DERIVED:38858523; DERIVED:37366315","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/60/NCT04881760/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/60/NCT04881760/SAP_001.pdf","YES","OTHER:J1I-MC-GZBF"],["NCT04524832","Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy People",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","290","Diabetes Mellitus, Type 2","DRUG:Oral semaglutide","Novo Nordisk A/S","2020-09-29","2022-02-25","FALSE","Area under the semaglutide plasma concentration - time curve during a dosing interval at steady state (AUC0-24h,sema,SS) [From 0 to 24 hours after the last dosing of oral semaglutide 25 mg on visit 8, day 84] | Area under the semaglutide plasma concentration-time curve during a dosing interval at steady state (AUC0-24h,sema,SS) [From 0 to 24 hours after the last dosing of oral semaglutide 50 mg on visit 10, day 112]",null,null,"YES","OTHER:U1111-1242-2643; REGISTRY:2019-004157-80; NIH:2019"],["NCT05579249","A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","500","Obesity","DRUG:Semaglutide; DRUG:Orlistat; DRUG:Phentermine/Topiramate; DRUG:Naltrexone/Bupropion; DRUG:Liraglutide","Novo Nordisk A/S","2023-01-19","2024-11-27","TRUE","Number of Participants Who Achieved Greater Than or Equal to (≥) 10.0 Percent (%) Body Weight Reduction (Yes/no) [At end of treatment (week 52)]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/49/NCT05579249/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/49/NCT05579249/SAP_001.pdf","YES","OTHER:U1111-1263-7301"],["NCT00882050","Intravenous Exenatide (Byetta) During Surgery",null,"COMPLETED","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","DOUBLE","104","Euglycemia; Hypoglycemia; Hyperglycemia","DRUG:Exenatide 0.27 ng/kg/min; DRUG:Exenatide 0.41 ng/kg/min; DRUG:Placebo","Thomas Jefferson University","2009-03","2016-04","TRUE","The Primary Objective is to Determine the Ability of Intravenous Exenatide to: Maintain Intraoperative Euglycemia in Subjects With Initial Blood Glucose < 126 mg/dL in Surgical Subjects as Compared to Placebo, [Baseline and 90 minutes after starting infusion;]",null,null,null,null],["NCT07088718","Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data","DUP-SURPASS","COMPLETED","OBSERVATIONAL",null,null,null,"44671","Type 2 Diabetes; Major Adverse Cardiac Events; Cardiovascular (CV) Risk","DRUG:Tirzepatide; DRUG:Dulaglutide","Brigham and Women's Hospital","2024-10-01","2025-07-30","FALSE","First occurence of MACE (all-cause mortailty, myocardial infarction, or death) [1 day after cohort entry date until the first of outcome or censoring, up to 365 days]","DERIVED:41207920","Study Protocol and Statistical Analysis Plan: Amendment 1 to Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/18/NCT07088718/Prot_SAP_002.pdf; Study Protocol and Informed Consent Form: Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/18/NCT07088718/Prot_ICF_000.pdf; Study Protocol and Statistical Analysis Plan: Amendment 2 to Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/18/NCT07088718/Prot_SAP_003.pdf",null,null],["NCT04531176","EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial","EMPOWER-T2D","TERMINATED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","74","Type 2 Diabetes; Obesity","OTHER:Weight Management Program (WMP); OTHER:Traditional care; DRUG:Phentermine / Topiramate Extended Release Oral Capsule; DRUG:naltrexone/bupropion extended-release; DRUG:liraglutide 3.0 mg; DRUG:Orlistat","The Cleveland Clinic","2020-09-01","2022-08-15","TRUE","Mean Change in Body Weight Between Baseline and 12 Months [12 Months] | Mean Change in A1C [12 Months]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/76/NCT04531176/Prot_SAP_001.pdf","NO",null],["NCT06331286","The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity",null,"UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","NONE","60","Bipolar Disorder; Obesity; Cognition","DRUG:dulaglutide injection","First Affiliated Hospital of Zhejiang University","2023-09-01","2024-12-31","FALSE","weight [Baseline, the end of Week 12 and the end of Week 24] | Concentration of blood glucose in blood [Baseline, the end of Week 12 and the end of Week 24] | Concentration of total cholesterol in blood [Baseline, the end of Week 12 and the end of Week 24] | Concentration of high density lipoprotein in blood [Baseline, the end of Week 12 and the end of Week 24] | Concentration of low density lipoprotein in blood [Baseline, the end of Week 12 and the end of Week 24] | Concentration of triglyceride in blood [Baseline, the end of Week 12 and the end of Week 24] | CBCT test results [Baseline, the end of Week 12 and the end of Week 24]",null,null,"NO",null],["NCT07041983","24-h Energy Expenditure and Anti-obesity Medication","SEM-TIR","ENROLLING_BY_INVITATION","OBSERVATIONAL",null,null,null,"30","Obesity","DRUG:anti obesity medication","University of Pisa","2025-07-01","2026-06-01","FALSE","change in 24h energy expenditure after 6 months of treatment [Baseline and 6 months after treatment initiation]",null,null,null,"OTHER_GRANT:539901_2019_Santini_PRIN2017"],["NCT04159766","A Study With NLY01 in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","20","Type2 Diabetes; Diabetes Mellitus, Type 2","DRUG:NLY01; DRUG:Placebo","Neuraly, Inc.","2019-10-16","2020-12-04","FALSE","Number of participants with Treatment Emergent Adverse Events [35 days] | Number of Incidences of Adverse Events [35 days] | Plasma glucose [24 hours] | Change in serum insulin [24 hours] | Change in plasma glucagon [24 hours]",null,null,null,null],["NCT07254572","Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes","CASCADES","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","300","Coronary Artery Disease; PreDiabetes","DRUG:Semaglutide 14 MG [Rybelsus]; DRUG:Dapagliflozin (Forxiga); DRUG:Metformin; BEHAVIORAL:Optimal Medical Therapy (OMT) And Lifestyle Intervention","National Institute of Cardiology, Warsaw, Poland","2025-07-10","2029-08-01","FALSE","Evaluation of the effect of GLP-1 analogue treatment on coronary artery disease progression AND Evaluation of the effect of flozin treatment on the progression of coronary artery disease (CO-PRIMARY ENDPOINTS) [24 months]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/72/NCT07254572/Prot_SAP_000.pdf","NO",null],["NCT01507272","Safety and Tolerability of Liraglutide in Healthy Male Volunteers",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","34","Diabetes; Healthy","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","1999-03","1999-12","FALSE","AUC (area under the curve) []","RESULT:12145241; RESULT:12791417",null,null,null],["NCT03297879","Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients With Newly Diagnosed Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE4","NON_RANDOMIZED","NONE","230","Type2 Diabetes","DRUG:Exenatide or metformin hydrochloride","Beijing Chao Yang Hospital","2013-01-01","2016-02-28","FALSE","The change of HbA1c [baseline and 12 weeks]","DERIVED:35432194; DERIVED:29358950",null,null,null],["NCT06567327","A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","82","Obesity","DRUG:Danuglipron; DRUG:Atorvastatin; DRUG:Rosuvastatin","Pfizer","2024-08-28","2025-03-16","FALSE","Steady-state area under the concentration-time profile from time zero to 24 hours (AUC24) for danuglipron [Predose to 24 hours post danuglipron administration] | Steady-state maximum observed concentration (Cmax) for danuglipron [Predose to 24 hours post danuglipron administration] | Steady-state time to reach maximum observed concentration (Tmax) for danuglipron [Predose to 24 hours post danuglipron administration] | Area under the concentration-time curve from time zero extrapolated to infinite time (AUCinf), as data permit, for atorvastatin [Predose to 72 hours post atorvastatin administration] | Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) for atorvastatin (only if AUCinf is not reportable) [Predose to 72 hours post atorvastatin administration] | Area under the concentration-time curve from time zero extrapolated to infinite time (AUCinf), as data permit, for rosuvastatin [Predose to 96 hours post rosuvastatin administration] | Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) for rosuvastatin (only if AUCinf is not reportable) [Predose to 96 hours post rosuvastatin administration]",null,null,"NO","REGISTRY:NCT06567327"],["NCT01870297","A Study of LY3025876 in Participants With Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","72","Type 2 Diabetes Mellitus","DRUG:LY3025876; DRUG:Placebo; DRUG:Liraglutide","Eli Lilly and Company","2013-06","2014-12","TRUE","Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Predose on Day 1 up to Day 56 in each Part]",null,null,null,"OTHER:I6D-MC-SMRB"],["NCT01147627","Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","416","Diabetes Mellitus, Type 2; Newly Diagnosed","DRUG:exenatide injection; DRUG:Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R; DRUG:Pioglitazone","Sun Yat-sen University","2010-08","2012-08","TRUE","the Comparison Between Treatment Groups of the Changes From Baseline in HbA1c at 48 Weeks [48 weeks]",null,null,null,null],["NCT03288740","A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","36","Diabetes; Diabetes Mellitus, Type 2","DRUG:Semaglutide 0.5 mg; DRUG:Placebo (semaglutide 0.5 mg); DRUG:Semaglutide 1.0 mg; DRUG:Placebo (semaglutide 1.0 mg)","Novo Nordisk A/S","2017-09-21","2018-07-10","FALSE","Area under the semaglutide plasma concentration time curve at steady state (semaglutide 0.5 mg) [0-168 hours after last administration of semaglutide] | Area under the semaglutide plasma concentration time curve at steady state (semaglutide 1.0 mg) [0-168 hours after last administration of semaglutide]","RESULT:33159658",null,"YES","OTHER:U1111-1149-6572"],["NCT07415954","A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","270","Diabetes Mellitus, Type 2","DRUG:NNC0662-0419; DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2026-04-17","2027-09-03","FALSE","Change in glycated haemoglobin (HbA1c) (week 16) [From baseline (week 0) to week 16] | Change in HbA1c (week 28) [From baseline (week 0) to week 28] | Change in HbA1c (week 40) [From baseline (week 0) to week 40]",null,null,"YES","OTHER:U1111-1324-0310; OTHER:2025-523260-20; NIH:2025"],["NCT00460941","A Titration Study of a Glucagon-Like Peptide-1 (GLP-1) Analogue in Patients With Type 2 Diabetes Treated With Metformin.",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","133","Diabetes Mellitus Type 2","DRUG:Placebo; DRUG:Taspoglutide 20mg; DRUG:Taspoglutide 20mg-30mg; DRUG:Taspoglutide 20mg-40mg","Hoffmann-La Roche","2007-04","2008-01","FALSE","Percentage of patients withdrawn because of gastrointestinal effects [Week 9]","DERIVED:20536952",null,null,null],["NCT07216651","WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults",null,"COMPLETED","OBSERVATIONAL",null,null,null,"20","Obesity & Overweight",null,"Closed Loop Medicine","2025-09-23","2026-02-27","FALSE","Percentage of participants who persisted on semaglutide treatment over the study period [3 months]",null,null,"UNDECIDED",null],["NCT05360537","Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","100","Diabetes Mellitus, Type 2","DRUG:Insulin Degludec / Liraglutide Injectable Product; DRUG:Insulin Glargine","University of Palermo","2021-04-01","2021-12-01","FALSE","Change of Time in Range % at 7 days, at 1 and 6 months [7 days, 1 months and 6 months] | Change of hypoglycemic events [7 days, 1 months and 6 months] | Change from Baseline Reactive Hyperemia Index at 3 and 9 months [7 days, 1 months and 6 months]",null,null,null,null],["NCT02518945","Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","26","Type 1 Diabetes Mellitus","DRUG:Dapagliflozin; DRUG:Insulin; DRUG:Liraglutide; DRUG:Dapagliflozin placebo","University at Buffalo","2015-08","2015-12","TRUE","Absolute Change After 12 Weeks From Baseline in Mean HbA1c With Addition of Dapagliflozin Compared to Placebo. [12 weeks]","DERIVED:27490915",null,null,null],["NCT02713477","Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","20","Type 2 Diabetes Mellitus","DRUG:Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010; DRUG:Insulin glargine HOE901; DRUG:Placebo","Sanofi","2016-04","2016-06","FALSE","Measurement of plasma glucose concentrations [1 day (D1) in each treatment period]","RESULT:31050109",null,null,"OTHER:U1111-1176-6235"],["NCT07156539","A Phase 3 Study of HS-20094 in Patients With T2DM",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","546","Type 2 Diabetes","DRUG:HS-20094 Injection; DRUG:Dulaglutide Injection","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2025-09-30","2027-03-30","FALSE","Change in HbA1c [Week 0 to Week 44]",null,null,null,null],["NCT02654665","Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults","CGH-LiNASH","UNKNOWN","INTERVENTIONAL","PHASE3","NON_RANDOMIZED","NONE","36","Non-alcoholic Fatty Liver Disease (NAFLD); Weight Loss; Non-alcoholic Steatohepatitis (NASH)","BEHAVIORAL:Lifestyle modification; DRUG:Liraglutide","Changi General Hospital","2014-03","2017-12","FALSE","Improvement in NASH [12 months]","DERIVED:30721572",null,"YES",null],["NCT07817875","Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","150","Obesity","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2026-09-25","2029-12","FALSE","Percent Change from Baseline in Body Mass Index (BMI) [Baseline, Week 84]",null,null,"YES","OTHER:J4M-MC-PW02; OTHER:J4M-MC-PWMP Master Protocol; CTIS:2025-522020-27-00; NIH:2025"],["NCT07617155","GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis","RECAP-GLP1","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","396","Hypertriglyceridemia Induced Acute Pancreatitis; Recurrent Acute Pancreatitis; Pancreatitis Relapsing; Hypertriglyceridemia","DRUG:Semaglutide; DRUG:Placebo (Normal Saline)","Peking Union Medical College Hospital","2026-09","2028-09","FALSE","Proportion of participants with recurrent hypertriglyceridemia-induced acute pancreatitis [Within 18 months after randomization]","BACKGROUND:21479777; BACKGROUND:32245906; BACKGROUND:40681200; BACKGROUND:28682990; BACKGROUND:24172179; BACKGROUND:38759844; BACKGROUND:26143191; BACKGROUND:32084455; BACKGROUND:38346789; BACKGROUND:35344001; BACKGROUND:34305810; BACKGROUND:23440284; BACKGROUND:37796527; BACKGROUND:28473337; BACKGROUND:28476871; BACKGROUND:36568085; BACKGROUND:36335196; BACKGROUND:10197564; BACKGROUND:39332263; BACKGROUND:28244632; BACKGROUND:28283565; BACKGROUND:31750601; BACKGROUND:28941314; BACKGROUND:29989767; BACKGROUND:27322530; BACKGROUND:30629026; BACKGROUND:36697323; BACKGROUND:30094622; BACKGROUND:40550999; BACKGROUND:24717803; BACKGROUND:25269432; BACKGROUND:29923163; BACKGROUND:33567185; BACKGROUND:26132939; BACKGROUND:33977495; BACKGROUND:38241775; BACKGROUND:8538742; BACKGROUND:9374685; BACKGROUND:15271645",null,"NO",null],["NCT06254014","A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","270","Type 2 Diabetes Mellitus","DRUG:Exendin-4 Fc fusion protein injection; DRUG:Placebo","Beijing Dongfang Biotech Co., Ltd.","2024-07-10","2026-05-01","FALSE","HbA1c [Baseline, Week 26]",null,null,"NO",null],["NCT06396416","Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2",null,"RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","60","Obesity; Chronic Kidney Disease","DRUG:Semaglutide; BEHAVIORAL:Virtual Weight Management Coaching","Western University, Canada","2024-09-26","2026-09-30","FALSE","Feasibility of Recruitment [12 months]","DERIVED:42580835",null,"YES",null],["NCT01154933","Exeantide in Type 2 Diabetes on Insulin",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","SINGLE","24","Type 2 Diabetes","DRUG:exenatide 5 mcg; DRUG:exenatide 10 mcg; DRUG:placebo","University at Buffalo","2008-04","2011-11","TRUE","Fasting Insulin [after 24 hours fast at baseline and 12 weeks]","DERIVED:29346597",null,null,null],["NCT04604496","STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","SINGLE","24","Hepatic Impairment; Healthy Volunteers","DRUG:PF-06882961 20MG","Pfizer","2020-12-30","2022-01-10","TRUE","Maximum Plasma Concentration (Cmax) [Predose (0 hours), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36 and 48 hours post dose on Day 1.] | Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) [Predose (0 hours), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36 and 48 hours post dose on Day 1.] | Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) [Predose (0 hours), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36 and 48 hours post dose on Day 1.] | Fraction of Unbound Drug in Plasma (fu) [Predose (0 hours), and 4 hours post dose on Day 1.]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/96/NCT04604496/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/96/NCT04604496/SAP_001.pdf","NO",null],["NCT03684642","Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin","AMPLITUDE-D","TERMINATED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","908","Type 2 Diabetes Mellitus","DRUG:Efpeglenatide; DRUG:Dulaglutide; DRUG:Background therapy Metformin","Sanofi","2018-09-26","2020-10-13","TRUE","Change From Baseline to Week 56 in HbA1c [Baseline to Week 56]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/42/NCT03684642/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/42/NCT03684642/SAP_001.pdf","NO","EUDRACT_NUMBER:2017-002956-10; OTHER:U1111-1205-3150; NIH:2017"],["NCT02787551","Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","LixiLan-G","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","514","Type 2 Diabetes Mellitus","DRUG:Insulin glargine/lixisenatide fixed ratio combination; DRUG:liraglutide; DRUG:exenatide; DRUG:exenatide extended-release; DRUG:albiglutide; DRUG:dulaglutide; DRUG:Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)","Sanofi","2016-07-06","2018-05-25","TRUE","Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 26: Core Period [Baseline, Week 26] | Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 52: Single Arm Extension Period [Baseline, Week 52]","DERIVED:35332216; DERIVED:35257461; DERIVED:34894329; DERIVED:33468520; DERIVED:31530665","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/51/NCT02787551/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/51/NCT02787551/SAP_001.pdf","YES","OTHER:2014-004850-32; OTHER:U1111-1168-4639; NIH:2014"],["NCT07271251","A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","267","Type 2 Diabetes","DRUG:Oral semaglutide","Novo Nordisk A/S","2025-12-01","2026-06-29","FALSE","Change in glycated haemoglobin (HbA1c). [From baseline (week 0) to end of treatment (week 20)]",null,null,"YES","OTHER:U1111-1321-8272"],["NCT04601753","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Sweden, as Part of Local Clinical Practice","PIONEER REAL","COMPLETED","OBSERVATIONAL",null,null,null,"194","Diabetes Mellitus, Type 2","DRUG:Oral Semaglutide","Novo Nordisk A/S","2020-11-12","2023-03-03","FALSE","Change in Glycated haemoglobin (HbA1c ) [From baseline (week 0) to End of Study visit (V3) (week 34-44)]","DERIVED:41986942; DERIVED:39535683; DERIVED:39052163",null,"YES","OTHER:U1111-1240-4039"],["NCT05597202","Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes","DOTAFLAME","UNKNOWN","INTERVENTIONAL","PHASE4",null,"NONE","22","Type 2 Diabetes","DRUG:Semaglutide, 2.0 mg/mL","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","2023-01-01","2024-03","FALSE","Difference in coronary 68Ga-Dotatate uptake after treatment. [6 months]",null,null,"NO",null],["NCT06716216","A Study of BGM0504 in Participants with Type 2 Diabetes",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","537","Type 2 Diabetes Mellitus (T2DM)","DRUG:Drug: 5 mg BGM0504 Administered SC; DRUG:Drug:10 mg BGM0504 Administered SC; DRUG:Drug: Semaglutide Administered SC","BrightGene Bio-Medical Technology Co., Ltd.","2024-11-29","2026-03-20","FALSE","Change From Baseline in Hemoglobin A1c (HbA1c) [Week 0 to Week 32]",null,null,null,null],["NCT01725126","To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","53","Obesity","DRUG:GSK2890457; DRUG:Metformin; DRUG:Placebo; DRUG:Liraglutide","GlaxoSmithKline","2013-02-10","2013-09-12","TRUE","Number of Participants With Any Adverse Event (AE), Serious Adverse Event (SAE) or Death During Part A [Up to Follow-up (8 weeks)] | Number of Participants With Any AE, SAE or Death During Part B and Part C [Up to Follow-up (8 weeks)] | Number of Participants With Any Hypoglycemic Events During Part A [Up to Follow-up (8 weeks)] | Number of Participants With Any Hypoglycemic Events During Part B and Part C [Up to Follow-up (8 weeks)] | Change From Baseline in Clinical Chemistry Parameters of Alkaline Phosphatase (ALP), ALT, Aspartate Aminotransferase (AST) and Gamma Glutamyltransferase (GGT) During Double-blind Treatment Period of Part A [Baseline (Day 1, Randomization) up to Day 42] | Change From Baseline in Clinical Chemistry Parameters of ALP, ALT, AST and GGT During the Double-blind Treatment Period of Part B and C [Baseline (Day -1) up to Day 42] | Change From Baseline in Clinical Chemistry Parameters of Electrolytes, Glucose Phosphorus Inorganic and Urea/Blood Urea Nitrogen (BUN) During the Double-blind Treatment Period of Part A [Baseline (Day 1, Randomization) up to Day 42] | Change From Baseline in Clinical Chemistry Parameters of Electrolytes, Glucose Phosphorus Inorganic, BUN and Cholesterol During the Double-blind Treatment Period of Part B and C [Baseline (Day -1) up to Day 42] | Change From Baseline in Clinical Chemistry Parameters of Direct Bilirubin, Total Bilirubin, Creatinine and Uric Acid During the Double-blind Treatment Period of Part A [Baseline (Day 1, Randomization) up to Day 42] | Change From Baseline in Clinical Chemistry Parameters of Direct Bilirubin, Total Bilirubin, Creatinine and Uric Acid During the Double-blind Treatment Period of Part B and C [Baseline (Day -1) up to Day 42] | Change From Baseline in Clinical Chemistry Parameters of Albumin and Total Protein During the Double-blind Treatment Period of Part A [Baseline (Day 1, Randomization) up to Day 42] | Change From Baseline in Clinical Chemistry Parameters of Albumin and Total Protein During the Double-blind Treatment Period of Part B and C [Baseline (Day -1) up to Day 42] | Change From Baseline in Clinical Chemistry Parameters of Insulin During the Double-blind Treatment Period of Part A [Baseline (Day 1, Randomization) up to Day 42] | Change From Baseline in Clinical Chemistry Parameters of Insulin During the Double-blind Treatment Period of Part B and C [Baseline (Day -1) up to Day 42] | Change From Baseline in Clinical Chemistry Parameters of Amylase and Lipase the Double-blind Treatment Period of Part B of Study [Baseline (Day -1) and Day 42] | Change From Baseline in Clinical Chemistry Parameter of Triiodothyronine (T3) Uptake During the Double-blind Treatment Period of Part B and C [Baseline (Day -1) and Day 42] | Change From Baseline in Clinical Chemistry Parameters of Total Thyroxine and Total T3 During the Double-blind Treatment Period of Part B and C [Baseline (Day -1) and Day 42] | Change From Baseline in Clinical Chemistry Parameters of Thyroid Stimulating Hormone During the Double-blind Treatment Period of Part B and C [Baseline (Day -1) up to Day 42] | Change From Baseline in Hematology Parameters of Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, White Blood Cell (WBC) Count During the Double-blind Treatment Period of Part A [Baseline (Day 1, Randomization) up to Day 42] | Change From Baseline in Hematology Parameters of Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, WBC Count During the Double-blind Treatment Period of Part B and C [Baseline (Day -1) up to Day 42] | Change From Baseline in Hematology Parameters of Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) During the Double-blind Treatment Period of Part A [Baseline (Day 1, Randomization) up to Day 42] | Change From Baseline in Hematology Parameters of Hemoglobin and MCHC During the Double-blind Treatment Period of Part B and C [Baseline (Day -1) up to Day 42] | Change From Baseline in Hematology Parameters of Red Blood Cell (RBC) Count and Reticulocytes During the Double-blind Treatment Period of Part A [Baseline (Day 1, Randomization) up to Day 42] | Change From Baseline in Hematology Parameters of RBC Count and Reticulocytes During the Double-blind Treatment Period of Part B and C [Baseline (Day -1) up to Day 42] | Change From Baseline in Hematology Parameter of Hematocrit During the Double-blind Treatment Period of Part A [Baseline (Day 1, Randomization) up to Day 42] | Change From Baseline in Hematology Parameter of Hematocrit During the Double-blind Treatment Period of Part B and C [Baseline (Day -1) up to Day 42] | Change From Baseline in Hematology Parameter of Mean Corpuscle Hemoglobin (MCH) During the Double-blind Treatment Period of Part A [Baseline (Day 1, Randomization) up to Day 42] | Change From Baseline in Hematology Parameter of MCH During the Double-blind Treatment Period of Part B and C [Baseline (Day -1) up to Day 42] | Change From Baseline in Hematology Parameter of Mean Corpuscle Volume (MCV) During the Double-blind Treatment Period of Part A [Baseline (Day 1, Randomization) up to Day 42] | Change From Baseline in Hematology Parameter of MCV During the Double-blind Treatment Period of Part B and C [Baseline (Day -1) up to Day 42] | Number of Participants With Abnormal Urinalyisis Dipstick and Microscopic Results During the Double-blind Treatment Period of Part A [Up to Day 42] | Number of Participants With Abnormal Urinalyisis Dipstick and Microscopic Results During the Double-blind Treatment Period of Part B [Up to Day 42] | Number of Participants With Abnormal Urinalyisis Dipstick and Microscopic Results During the Double-blind Treatment Period of Part C [Up to Day 42] | Mean Specific Gravity Values of Urine During the Double-blind Treatment Period of Part A [Up to Day 42] | Mean Specific Gravity Values of Urine During the Double-blind Treatment Period of Part B and C [Up to Day 42] | Mean pH Values of Urine During the Double-blind Treatment Period of Part A [up to Day 42] | Mean pH Values of Urine During the Double-blind Treatment Period of Part B and C [Up to Day 42] | Change From Baseline in Vital Sign Parameter of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) During the Double-blind Treatment Period of Part A [Baseline (Day 1, Randomization) up to Day 42] | Change From Baseline in Vital Sign Parameter of SBP and DBP During the Double-blind Treatment Period of Part B and C [Baseline (Day -1) up to Day 42] | Change From Baseline in Vital Sign Parameter of Heart Rate (HR) During the Double-blind Treatment Period of Part A [Baseline (Day 1, Randomization) up to Day 42] | Change From Baseline in Vital Sign Parameter of HR During the Double-blind Treatment Period of Part B and C [Baseline (Day -1) up to Day 42] | Change From Baseline in Electrocardiogram (ECG) Intervals During Part A [Baseline (Day 1, Randomization) up to Follow-up (Day 56)] | Change From Baseline in ECG Intervals During Part B and C [Baseline (Day -1) up to Follow-up (Day 56)] | Change From Baseline in the Overall Gastrointestinal (GI) Symptoms Rating Scale (GSRS) Score During the Double-blind Treatment Period of Part A [Baseline (Day 1, Randomization) up to Day 42] | Change From Baseline in the Overall GSRS Score During the Double-blind Treatment Period of Part B and C [Baseline (Day -2) up to Day 41] | Change From Baseline in In-clinic Body Weight During the Double-blind Treatment Period of Part B and C [Baseline (Day -1 and Day 1) up to Day 42] | Percent Change From Baseline in In-clinic Body Weight During the Double-blind Treatment Period of Part B and C [Baseline (Day -1 and Day 1) up to Day 42] | Change From Baseline in Weighted Mean Glucose Area Under the Curves From Time 0 to 24 Hours (AUC [0-24 Hours]) During the Double-blind Treatment Period of Part B and C [Baseline (Day -1) and Day 42] | Change From Baseline in Fasting Glucose During the Double-blind Treatment Period of Part B and C [Baseline (Day -1) and Day 42 of Part B and C] | Change From Baseline in Fasting Insulin and Weighted Mean Insulin AUC (0-4 Hour) and AUC (0-24 Hour) During the Double-blind Treatment Period of Part B and C [Baseline (Day -1) and Day 42] | Change From Baseline in Glycated Hemoglobin (HbA1c) During the Double-blind Treatment Period of Part B and C [Baseline (Day -1) and Day 42] | Change From Baseline in Homeostasis Model of Assessment-Insulin Resistance (HOMA-IR]) During the Double-blind Treatment Period of Part B and C [Baseline (Day -1) and Day 42] | Change From Baseline in Matsuda Index During the Double Blind-treatment Period of Part B and C [Baseline (Day -1) and Day 42] | Change From Baseline in Fasting Plasma Glucose (Safety Laboratory) Values During the Double-blind Treatment Period of Part B and C [Baseline (Day -1) up to Follow-up (Day 56)]","DERIVED:27093610",null,"YES",null],["NCT06350812","A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","DOUBLE","32","Obesity","DRUG:PB-119; DRUG:Placebo","PegBio Co., Ltd.","2024-05-27","2024-11-16","FALSE","Incidence of Treatment-Emergent Adverse Events [From the first dosing (Day 1 ) of study drug until completion of the post treatment follow-up visit (24 week)]",null,null,"NO",null],["NCT04892199","Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","104","Metabolic Disturbance; Schizophrenia; Type 2 Diabetes; Clozapine; GLP-1; Olanzapine","DRUG:Semaglutide, 1.34 mg/mL; DRUG:Semaglutide-placebo","Anders Fink-Jensen, MD, DMSci","2021-09-01","2026-03-01","FALSE","The primary endpoint is the change from baseline in glycated haemoglobin A1c (HbA1c). [26 weeks]","DERIVED:41335431; DERIVED:36720576","Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/99/NCT04892199/SAP_000.pdf","YES",null],["NCT06037252","A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","414","Type 2 Diabetes; Obesity","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2023-09-21","2026-01-08","FALSE","Percent Change From Baseline in Body Weight [Baseline (Week 0), Week 44]",null,null,"YES","OTHER:I8F-MC-GPIT; OTHER:2023-504561-24-00; NIH:2023"],["NCT05877547","A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","381","Non-alcoholic Fatty Liver Disease; Fatty Liver, Nonalcoholic; NAFLD; Nonalcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis","DRUG:Efinopegdutide; DRUG:Semaglutide; DRUG:Placebo","Merck Sharp & Dohme LLC","2023-06-23","2025-12-29","FALSE","Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis At Week 52 [Week 52] | Percentage of Participants Who Experienced an Adverse Event (AE) [Up to 60 weeks] | Percentage of Participants Discontinuing Study Medication Due to an AE [Up to 52 weeks]",null,null,"YES","REGISTRY:2022-502647-35-00; OTHER:MK-6024-013; REGISTRY:jRCT2031230187; REGISTRY:U1111-1285-0933"],["NCT01029873","QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma",null,"TERMINATED","INTERVENTIONAL","PHASE1; PHASE2","NON_RANDOMIZED","NONE","22","Metastatic Melanoma","DRUG:Cisplatin; BIOLOGICAL:ALT-801","Altor BioScience","2010-02","2011-11","TRUE","To Evaluate the Safety of ALT-801-cisplatin Regimen by the Number of Participants With AEs. [Up to 12 months] | To Assess the Objective Response (OR) Which Includes CR and PR [3 months] | To Assess the Clinical Benefit (CB) of the ALT-801-Cisplatin Regimen Which Includes CR, PR and SD [3 months] | To Determine the MTD of the ALT-801-Cisplatin Regimen Determined by Number of Participants With DLTs [7 weeks]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/73/NCT01029873/Prot_SAP_000.pdf",null,"NIH:R44CA097550"],["NCT04074161","Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity","STEP 8","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","338","Overweight; Obesity","DRUG:Semaglutide; DRUG:Placebo (semaglutide); DRUG:Liraglutide; DRUG:Placebo (liraglutide)","Novo Nordisk A/S","2019-09-11","2021-03-27","TRUE","Change From Baseline (Week 0) to Week 68 in Body Weight (%) (Semaglutide 2.4 mg Versus Liraglutide 3.0 mg) [Baseline (week 0), week 68]","RESULT:34775881; RESULT:35015037; DERIVED:35791625","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/61/NCT04074161/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/61/NCT04074161/SAP_001.pdf","YES","OTHER:U1111-1233-0977"],["NCT07135245","Improved Treatment and Monitoring of Alzheimer's Disease",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","180","Alzheimer Disease (AD)","DRUG:Semaglutide (Rybelsus®) combined with other interventions; OTHER:Placebo; DRUG:Semaglutide (Rybelsus®)","Rune Skovgaard Rasmussen","2026-01-01","2030-09-30","FALSE","The Montreal Cognitive Assessment [At inclusion, and 52 and 78 weeks.]",null,null,"UNDECIDED",null],["NCT07239570","A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease","CKD-bioMatch","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","125","Chronic Kidney Disease(CKD)","DRUG:Dapagliflozin; DRUG:Semaglutide; DRUG:Finerenone","Peter Rossing","2025-06-20","2028-06","FALSE","Chronic eGFR slope [From week 26 to 104]",null,null,"NO","NIH:2023"],["NCT06252623","Exenatide For Reducing the Reinforcing Effects of Cocaine",null,"WITHDRAWN","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","0","Cocaine Use Disorder","DRUG:Exenatide; DRUG:Placebo","Christopher D. Verrico","2024-08-01","2026-03-01","FALSE","Proportion of up to 10 active cocaine doses [6 weeks] | Subjective Effects [6 weeks]",null,null,"NO",null],["NCT02793154","An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects",null,"TERMINATED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","4","Diabetes Mellitus, Type 2","DRUG:Exenatide; DRUG:Albiglutide","GlaxoSmithKline","2016-09-26","2017-03-16","TRUE","Part A: Distribution of Average Power by Frequency Region [Up to Day 4] | Part A: Ratios of Average Power Post- WLT/Pre-WLT by Frequency Region [Up to Day 4] | Part A: Percentage of Time With the Dominant EGG Frequencies in the Four Frequency Ranges of Bradygastria, Normal, Tachygastria and Duodenal [Up to Day 4] | Part A: Number of Par. With Shifts in Gastric Rhythm Status [Up to 12 days] | Part A: Number Par. by Gastric Rhythm Status [Up to 12 days] | Part A: Average Dominant Frequency [Up to Day 4] | Part A: Assessment of Nausea by Visual Analogue Scale (VAS) Score [Day 4] | Part A: Time to Half-gastric Emptying [Up to Day 5] | Part A: Rate of [13]C Dose Excreted in Breath [Day 5] | Part A: Gastroparesis Cardinal Symptom Index -Daily Diary (GCSI-DD) Score [Up to Day 5] | Part A: The Volume of Water Ingested During EGG [Up to Day 4] | Part A: Assessment of Stomach Fullness, Hunger, Bloating and Abdominal Pain by VAS Score [Day 4] | Part A: Assessment of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) as a Measure of Safety [Up to 12 days] | Part A: Assessment of Heart Rate (HR) as a Measure of Safety [Up to 12 days] | Part A: Basophils, Eosinophil, Lymphocytes, Monocytes, Platelet Count, Total Neutrophils, White Blood Cell (WBC) Level at Indicated Time Points [Day 5] | Part A: Red Blood Cell (RBC) Count at Indicated Time Points [Day 5] | Part A: Hemoglobin Level at Indicated Time Points [Day 5] | Part A: Hematocrit Level at Indicated Time Points [Day 5] | Part A: Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT) Levels at Indicated Time Points [Day 5] | Part A: Glucose, Calcium, Magnesium, Potassium, Sodium, Phosphorus Inorganic, Chloride, Urea/Blood Urea Nitrogen (BUN) Levels [Day 5] | Part A: Creatinine, Direct Bilirubin, Total Bilirubin, Indirect Bilirubin Levels at Indicated Time Points [Day 5] | Part A: Estimated Glomerular Filtration Rate at Indicated Time Points [Day 5] | Part A: Total Protein, Albumin Levels at Indicated Time Points [Day 5] | Part A: Albumin Level in Urine at Indicated Time Points [Day 5] | Part A: Concentration of Creatinine in Urine at Indicated Time Points [Day 5] | Part A: Number of Par. With Presence of Ketones, Occult Blood, Glucose, Nitrates and Leukocyte Esterase in Urine at Indicated Time Points [Day 5] | Part A: Presence RBC and WBC in Urine Assessed by Microscopy [Day 5] | Part A: Specific Gravity of Urine at Indicated Time Points [Day 5] | Part A: Potential of Hydrogen (pH) of Urine at Indicated Time Points [Day 5] | Part A: Number of Par. With Adverse Events (AEs) and Serious AEs (SAEs) [Up to 12 days] | Part A: Number of Par. With Nausea AEs Presenting Outside the Timing of the WLT and GCSI-DD [Up to 12 days] | Part B: Distribution of Average Power by Frequency Region [Up to 8 weeks] | Part B: Ratios of Average Power Post- WLT/Pre-WLT by Frequency Region [Up to 8 weeks] | Part B: Percentage of Time With the Dominant EGG Frequencies in the Four Frequency Ranges of Bradygastria, Normal, Tachygastria and Duodenal [Up to 8 weeks] | Part B: Assessment of Nausea by VAS Score [Up to 8 weeks]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/54/NCT02793154/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/54/NCT02793154/SAP_001.pdf","NO",null],["NCT02449603","Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","150","Type 2 Diabetes Mellitus","DRUG:Exenatide; DRUG:Biphasic insulin Aspart 30","Xijing Hospital","2015-11","2018-04","FALSE","Change of mean amplitude of glycemic excursions [from baseline to Week 16]","DERIVED:32856226; DERIVED:27009108",null,null,null],["NCT00517283","A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","SINGLE","17","Type 2 Diabetes Mellitus","DRUG:exenatide and placebo; DRUG:Exenatide and placebo","AstraZeneca","2005-01","2005-06","FALSE","To detect the mean difference in half gastric emptying time for a solid meal between any treatment and placebo [up to 12 hours post meal consumption]",null,null,null,null],["NCT01518166","Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","70","Diabetes; Healthy","DRUG:liraglutide; DRUG:placebo; DRUG:atorvastatin; DRUG:lisinopril; DRUG:griseofulvin; DRUG:digoxin","Novo Nordisk A/S","2006-05","2007-04","FALSE","Area under the curve of atorvastatin [] | Area under the curve of lisinopril [] | Area under the curve of griseofulvin [] | Area under the curve of digoxin []","RESULT:26426736",null,null,"EUDRACT_NUMBER:2006-000175-15"],["NCT03889496","Quantitative GLP-1 Receptor Imaging Correlated to ex Vivo Distribution of In-111-exendin","GLP1-ex-vivo","TERMINATED","INTERVENTIONAL",null,null,"NONE","12","Diabetes Mellitus","RADIATION:indium-111-exendin SPECT/CT","Radboud University Medical Center","2015-11-16","2021-06-14","FALSE","Correlation between the tracer uptake (counts) and beta cell mass (mg) [4 years]","DERIVED:39405026",null,"NO",null],["NCT07244003","Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control","MESSAGE","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","430","T2DM (Type 2 Diabetes Mellitus)","DRUG:Metformin; DRUG:Triple Therapy of Other Oral Antidiabetic Drugs; DRUG:ganagliflozin; DRUG:liraglutide","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2025-03-29","2027-12-31","FALSE","The change of HbA1c compared to the baseline [from baseline to week 24]",null,null,null,null],["NCT07775846","QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","820","Type 2 Diabetic Kidney Disease","DRUG:empagliflozin; DRUG:Finerenone; DRUG:Mazdutide; DRUG:Finerenone Placebo; DRUG:Mazdutide Placebo; DRUG:Angiotensin Receptor Blocker (ARB)","Huijie Zhang","2026-09-01","2029-02-28","FALSE","Relative Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Month 6 [Baseline and Month 6]",null,null,"YES",null],["NCT07621640","Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study)","BAT-Sema","NOT_YET_RECRUITING","INTERVENTIONAL",null,null,"NONE","80","Obesity; Metabolic Syndrome; Brown Adipose Tissue","DRUG:Semaglutide (Wegovy®); PROCEDURE:¹⁸FDG-PET/CT with cold stimulation; PROCEDURE:Liver MRI (PDFF + MRE)","Hallym University","2026-06","2028-02","FALSE","Correlation between baseline BAT metabolic activity (SUVmean and BAT volume on ¹⁸FDG-PET/CT) and percentage body weight loss at 24 weeks of semaglutide treatment [Baseline to 24 weeks]",null,null,"NO","OTHER_GRANT:RS-2026-25483260"],["NCT02147925","Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects","LIGHT-ON","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","75","Non-alcoholic Fatty Liver Disease","DRUG:Liraglutide combined with metformin; DRUG:Insulin glargine combined with metformin; DRUG:Sitagliptin combined with metformin","Sun Yat-sen University","2014-08","2017-04","FALSE","Intrahepatic lipids (IHL) [26-week]",null,null,null,null],["NCT00241423","Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","30","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:Placebo","AstraZeneca","2005-10","2007-06","FALSE","Time-averaged serum glucose during a 24-hour period [Every half-hour to hour for 24 hours]","DERIVED:18394265",null,null,null],["NCT06000891","A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570",null,"TERMINATED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","84","Safety and Tolerability","DRUG:ZP7570; DRUG:Placebo","Zealand Pharma","2023-09-15","2025-02-11","FALSE","Incidence of treatment emergent adverse events (TEAEs) [Day 1 to Day 127 in Part 1. Day 1 to Day 232 in Part 2]",null,null,"NO","EUDRACT_NUMBER:2022-500614-26"],["NCT01856790","Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes",null,"COMPLETED","INTERVENTIONAL","EARLY_PHASE1",null,"NONE","15","Type 1 Diabetes","DEVICE:ePID closed loop system; DRUG:liraglutide","Jennifer Sherr","2013-02","2015-11","TRUE","Peak Post-prandial Venous Glucose Levels [48 hours]",null,null,null,null],["NCT07281196","Semaglutide Effects on Sleep Apnea in Patients With Type 2 Diabetes/Obesity and Comorbid Obstructive Sleep Apnea",null,"COMPLETED","OBSERVATIONAL",null,null,null,"15","Sleep Apnea Syndrome (OSAS)","DRUG:Semaglutide Subcutaneous Injection","Shanghai Fengxian District Central Hospital","2025-01-01","2025-12-31","FALSE","Changes in Apnea-Hypopea Index (AHI) [Baseline and 1 week]",null,null,"NO",null],["NCT00630825","A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus","EGO","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","262","Diabetes Mellitus Type 2","DRUG:LY2189265; DRUG:Placebo","Eli Lilly and Company","2008-04","2009-01","TRUE","Change From Baseline in Glycosylated Hemoglobin (HbA1c) in Overweight and Obese Participants With Type 2 Diabetes Mellitus [Baseline, 16 weeks]",null,null,null,"OTHER:H9X-MC-GBCJ"],["NCT00667732","How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics","MEXELIN","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","41","Type 2 Diabetes","DRUG:exenatide; DRUG:placebo","Oregon Health and Science University","2007-03","2009-10","TRUE","The Percentage of Intent to Treat Participants Randomized and Treated in Each Arm Who Had Lab-measured A1c <6.5% at 24 Weeks of Treatment [After 24 weeks of randomized treatment]",null,null,null,null],["NCT06849843","A Study of 3mg Once Every Two Weeks Administration of Efsubaglutide Alfa Injection in Type 2 Diabetes Patients.",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","59","Type2 Diabetes","DRUG:Efsubaglutide Alfa Injection","Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","2024-12-18","2025-05-29","FALSE","HbA1c [12 weeks]",null,null,null,null],["NCT06706284","Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes",null,"RECRUITING","INTERVENTIONAL","PHASE4","NON_RANDOMIZED","SINGLE","50","Spinal Cord Injuries; Type 2 Diabetes","DRUG:Semaglutide Injectable Product; OTHER:Placebo","Marzieh Salehi","2025-04-11","2028-09-01","FALSE","Glucose tolerance [Baseline to 24 weeks] | Insulin action [Baseline to 24 weeks]",null,null,"YES","NIH:R01DK140144-02"],["NCT00938158","A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","75","Diabetes Mellitus, Type 2","BIOLOGICAL:albiglutide","GlaxoSmithKline","2009-08-05","2011-04-12","FALSE","The primary objective is to characterize the PK of albiglutide in subjects with type 2 diabetes and varying degrees of renal impairment, including subjects requiring hemodialysis, and in age, gender and BMI-matched subjects. [42 days]","DERIVED:25387217; DERIVED:24918790",null,"YES",null],["NCT05912621","Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","66","Obesity; Overweight and Obesity; Overweight","DRUG:Tirzepatide","Stanford University","2023-11-09","2028-06","FALSE","Change in Adipocyte Size [Baseline and Week 22] | Change in Adipocyte Fat Storage Capacity [Baseline and Week 22] | Assess changes in Regional Fat [Baseline, week 6, and week 22] | Change from baseline on the 2-stage Steady State Plasma Glucose test [Baseline, week 6, and week 22]",null,null,null,null],["NCT07136714","Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity","SEMAMOOD","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","116","Major Depressive Disorder","DRUG:Semaglutide Injectable Product; DRUG:Placebo","Nordsjaellands Hospital","2025-09-11","2027-09","FALSE","Change in depressive symptoms [From baseline to 26 weeks of treatment]",null,null,"YES","CTIS:2024-511734-13-04"],["NCT06282458","Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt","QUALITY","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","168","Muscle Loss; Obesity","DRUG:Enobosarm; DRUG:Semaglutide","Veru Inc.","2024-04-29","2025-04-11","FALSE","The primary endpoint for the study is the percentage change from baseline in total lean body mass at 112 days. [Day 112]",null,null,"NO",null],["NCT01664247","The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","346","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec; DRUG:placebo; DRUG:liraglutide","Novo Nordisk A/S","2012-10-01","2013-12-31","TRUE","Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%) [Week 0, week 26]","RESULT:26990378",null,null,"EUDRACT_NUMBER:2011-004665-32; OTHER:U1111-1124-6612"],["NCT06153758","Study to Learn How Different Forms of The Study Medicine Called Danuglipron Are Taken up Into the Blood In Healthy Adults",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","33","Healthy Participants; Healthy Subjects","DRUG:Danuglipron","Pfizer","2023-11-27","2024-09-30","FALSE","Parts A, C and D only: Area under the concentration-time curve from time zero extrapolated to infinite time (AUCinf), as data permit, for danuglipron in the fasted state [Predose to 48 hours post danuglipron administration] | Parts A, C and D only: Maximum observed concentration (Cmax) for danuglipron in the fasted state [Predose to 48 hours post danuglipron administration] | Parts A, C and D only: Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) for danuglipron (only if AUCinf is not reportable) in the fasted state [Predose to 48 hours post danuglipron administration] | Part B only: Dose normalized area under the concentration-time curve from time zero extrapolated to infinite time (AUCinf,dn), as data permit, for danuglipron in the fasted state [Predose to 48 hours post danuglipron administration] | Part B only: Dose normalized maximum observed concentration (Cmax,dn) for danuglipron in the fasted state [Predose to 48 hours post danuglipron administration] | Part B only: Dose normalized area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast,dn) for danuglipron (only if AUCinf,dn is not reportable) in the fasted state [Predose to 48 hours post danuglipron administration]",null,null,"NO",null],["NCT00422058","The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","564","Metabolism and Nutrition Disorder; Obesity","DRUG:liraglutide; DRUG:orlistat; DRUG:placebo","Novo Nordisk A/S","2007-01-10","2007-09-13","TRUE","Mean Change From Baseline in Body Weight at Week 20 [Week 0, week 20]","RESULT:21844879; RESULT:19853906; RESULT:23942319; RESULT:28473337; RESULT:28386912; RESULT:28950422",null,null,"EUDRACT_NUMBER:2006-004481-13"],["NCT06132204","Pharmacokinetic and Safety Studies of HRS-7535 in Subjects With Moderate Renal Insufficiency and Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","16","Type 2 Diabetes","DRUG:HRS-7535 Tablets","Shandong Suncadia Medicine Co., Ltd.","2023-12-21","2024-03-13","FALSE","PK parameters of HRS-7535: Cmax [0 hour to 48 hour after administration] | PK parameters of HRS-7535: AUC0-t [0 hour to 48 hour after administration] | PK parameters of HRS-7535: AUC0-inf [0 hour to Infinity hour after administration]",null,null,"UNDECIDED",null],["NCT03260881","Liraglutide Effects on Epicardial Fat Inflammatory Genes",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","38","Type2 Diabetes; Coronary Artery Disease","DRUG:Liraglutide Pen Injector [Victoza]; DRUG:matching liraglutide-placebo pre-filled pens","University of Miami","2018-09-01","2024-09-05","TRUE","EAT Inflammation [Up to 12 weeks]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/81/NCT03260881/Prot_SAP_000.pdf","NO",null],["NCT01046721","Study Looking at Cardiovascular Effects of Exenatide, Its Blood Pressure Lowering Effect and Its Mechanisms",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","TRIPLE","8","Type 2 Diabetes","DRUG:Exenatide; DRUG:Saline","University of Nottingham","2009-09","2012-12","FALSE","superior mesenteric (SMA) blood flow [0, 30, 60, 90, 120, 150, & 180 min after meal]","RESULT:22320349",null,"NO",null],["NCT06975111","Focusing on the Menopausal Transition to Improve Mid-Life Women's Health",null,"RECRUITING","INTERVENTIONAL","PHASE2; PHASE3","NON_RANDOMIZED","NONE","200","Menopause; Menopause Hot Flashes; Menopause Related Conditions; Cardiovascular","DRUG:Metformin; DRUG:semaglutide; DRUG:Anti-hypertensives; DRUG:Lipid Lowering Medication; BEHAVIORAL:Life style intervention; DRUG:Fezolinetant; DRUG:Hormonal therapy","University of Colorado, Denver","2026-03-01","2029-10-31","FALSE","Epigenetic aging measurements of \"PhenoAge\" [Up to 2 years] | Epigenetic aging measurements of \"GrimAge\" [Up to 2 years]","BACKGROUND:1285753; BACKGROUND:26551272; BACKGROUND:19470968; BACKGROUND:20082925; BACKGROUND:33651741; BACKGROUND:33210602; BACKGROUND:32080740; BACKGROUND:31496122; BACKGROUND:33470142; BACKGROUND:39480425; BACKGROUND:32439010; BACKGROUND:37900422; BACKGROUND:38178979; BACKGROUND:35041662; BACKGROUND:33764994; BACKGROUND:25259787; BACKGROUND:26789348; BACKGROUND:35797481; BACKGROUND:34415665; BACKGROUND:33706956; BACKGROUND:32770384; BACKGROUND:18663170; BACKGROUND:22990755; BACKGROUND:30401549; BACKGROUND:31568098",null,"UNDECIDED","OTHER:U1111-1322-1036"],["NCT03325387","A Study of Multiple Doses of LY3305677 in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","56","Healthy","DRUG:LY3305677; DRUG:Placebo","Eli Lilly and Company","2017-10-27","2018-08-03","FALSE","Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline through 115 days]",null,null,null,"OTHER:I8P-MC-OXAB"],["NCT00103935","Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","45","Type 2 Diabetes Mellitus","DRUG:placebo; DRUG:Exenatide LAR","AstraZeneca","2005-02","2005-10","FALSE","Assess the safety, tolerability, and pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC) injection in subjects with type 2 diabetes (T2DM) [Time intervals: 0 min to 12 hours on Day 1 for a duration of 12 hours, from Day 1; 0 mininutes to Week 1 for a duration of 168 hours, and from Week 14 to Week 15 for a duration of 168 hours]","DERIVED:21142268",null,null,null],["NCT05896384","A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","32","Healthy","DRUG:BI 456906; DRUG:Microgynon®","Boehringer Ingelheim","2023-12-21","2025-02-14","FALSE","Area under the concentration-time curve of ethinylestradiol in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) [up to Week 29] | Maximum measured concentration of ethinylestradiol in plasma (Cmax) [up to Week 29] | Area under the concentration-time curve of levonorgestrel in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) [up to Week 29] | Maximum measured concentration of levonorgestrel in plasma (Cmax) [up to Week 29]",null,null,"NO","REGISTRY:2022-503146-53-00"],["NCT03936049","Replication of the LEADER Diabetes Trial in Healthcare Claims",null,"COMPLETED","OBSERVATIONAL",null,null,null,"168690","Diabetes","DRUG:Liraglutide; DRUG:DPP-4 inhibitor","Brigham and Women's Hospital","2017-09-22","2021-02-18","FALSE","Relative hazard of composite outcome of Stroke, MI, and Mortality [Through study completion (a median of 154-188 days)]","DERIVED:33327727","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/49/NCT03936049/Prot_SAP_003.pdf",null,null],["NCT07838740","A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","270","Obese Adults","DRUG:VK2735 Drug; DRUG:Placebo","Viking Therapeutics, Inc.","2025-11-18","2027-05","FALSE","Evaluate the Safety and Tolerability VK2735 [33 weeks]",null,null,"NO",null],["NCT02718950","Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans","i-LAB","UNKNOWN","INTERVENTIONAL","PHASE3",null,"NONE","20","Obesity; Type 2 Diabetes Mellitus","DRUG:Liraglutide 3.0 mg","University of Campinas, Brazil","2016-06","2017-03","FALSE","Evaluate the effect of liraglutide administration on brown adipose tissue (BAT) activation in humans [2 weeks]",null,null,"NO","REGISTRY:U1111-1178-4180"],["NCT04012255","A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity",null,"TERMINATED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","29","Overweight; Obesity","DRUG:Semaglutide (administered by DV3396 pen); DRUG:Semaglutide (administered by PDS290 pen)","Novo Nordisk A/S","2019-07-15","2019-08-30","FALSE","AUC0-168h,2.4mg,SS: Area under the semaglutide concentration time curve following the last administration of semaglutide s.c. 2.4 mg [0-168 hours (Day 141-148) after last 2.4 mg dose] | Cmax,2.4mg,SS: Maximum observed semaglutide concentration following the last administration of semaglutide s.c. 2.4 mg [0-168 hours (Day 141-148) after last 2.4 mg dose]",null,null,"YES","OTHER:U1111-1221-9644; REGISTRY:2018-003923-13; NIH:2018"],["NCT07078838","Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","40","Endometrial Cancer; Endometrial Intraepithelial Neoplasia; Grade 1 Endometrial Endometrioid Carcinoma","DRUG:Tirzepatide","UNC Lineberger Comprehensive Cancer Center","2027-01","2029-03","FALSE","Anti-proliferative effect of Tirzepatide [At 4th week (during surgery)]",null,null,null,"NIH:U01CA281026"],["NCT07000955","Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","TRIPLE","98","Obesity","DRUG:Tirzepatide; DRUG:Placebo; DRUG:IBI362","Innovent Biologics (Suzhou) Co. Ltd.","2025-06-17","2026-09-30","FALSE","The Incidence of adverse events and serious adverse events during the treatment period [week 44] | The suicidal ideation and behavior of subjects evaluated by Columbia-Suicide Severity Rating Scale (C-SSRS) [week 44] | The incidence rates of Adverse Event of Special Interest [week 44] | The value of systolic and diastolic pressures [week 44] | The RR interval, PR interval, heart rate, QT interval, Fridericia-corrected QT interval, and any abnormal reporting results of 12-lead electrocardiogram [week 44] | Any adverse event evaluated by laboratory examinations [week 44] | The value of pulse rate [week 44]",null,null,null,null],["NCT07095517","Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors","PROSPECT","RECRUITING","INTERVENTIONAL","PHASE1",null,"NONE","20","Colorectal Cancer Prevention; Colorectal Adenoma","DRUG:Tirzepatide","Massachusetts General Hospital","2026-02-24","2027-03-31","FALSE","Change in Urinary PGE-M [From enrollment to the end of treatment at 24 weeks]",null,null,"YES","NIH:1OT2CA297680-01; OTHER_GRANT:CGCATF-2023/100036"],["NCT03861052","A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes","SURPASS J-mono","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","636","Type 2 Diabetes","DRUG:Tirzepatide; DRUG:Dulaglutide","Eli Lilly and Company","2019-05-07","2021-03-10","TRUE","Change From Baseline in Hemoglobin A1c (HbA1c) [Baseline, Week 52]","DERIVED:40711720; DERIVED:39951042; DERIVED:38310163; DERIVED:37843771; DERIVED:35914543; DERIVED:35210595","Study Protocol: Clinical Study Protocol Amendment Version (a)|https://cdn.clinicaltrials.gov/large-docs/52/NCT03861052/Prot_000.pdf; Study Protocol: Clinical Study Protocol Addendum Version (1)|https://cdn.clinicaltrials.gov/large-docs/52/NCT03861052/Prot_001.pdf; Statistical Analysis Plan: Statistical Analysis Plan Version 2|https://cdn.clinicaltrials.gov/large-docs/52/NCT03861052/SAP_002.pdf; Statistical Analysis Plan: Statistical Analysis Plan Addendum Version 2|https://cdn.clinicaltrials.gov/large-docs/52/NCT03861052/SAP_003.pdf","YES","OTHER:I8F-JE-GPGO"],["NCT06554054","A Study of GZR18 Tablet in Chinese Healthy Subjects",null,"UNKNOWN","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","92","Diabetes Mellitus, Type 2","DRUG:GZR18","Gan and Lee Pharmaceuticals, USA","2024-04-01","2024-12-09","FALSE","AE and SAE [22 days and 35 days] | Relative bioavailability of GZR18 tablet [22 days and 35 days] | ADA and NAb [22 days and 35 days]",null,null,null,null],["NCT05492305","Glucagon-like Peptide 1 (GLP1) Receptor Agonists and Mental Health",null,"UNKNOWN","OBSERVATIONAL",null,null,null,"20","Diabetes Mellitus; Obesity; Mental Health Issue","DRUG:GLP-1 receptor agonist","King's College London","2022-09","2023-06","FALSE","subjective effect of GLP1 receptor agonist on mental health [12-16 weeks]",null,null,"NO",null],["NCT02611232","Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults",null,"UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","42","Type 1 Diabetes","DRUG:Victoza®; DRUG:Placebo","University of Oulu","2015-12","2024-06","FALSE","FPIR (first phase insulin response) [From baseline to 26 and 104 weeks]","DERIVED:35797241",null,null,"EUDRACT_NUMBER:2014-003667-37; OTHER_GRANT:3-SRA-2014-301-M-R; OTHER:U1111-1176-6062; NIH:2014"],["NCT07614412","SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes.","SHIELD-T1D","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","240","Type 1 Diabetes Mellitus","DRUG:Recombinant Zoster Vaccine (Shingrix; RZV); DRUG:Semaglutide (Ozempic®); DRUG:Placebo (saline injection)","Ministry of Health, Saudi Arabia","2027-01-01","2028-01-31","FALSE","Change in 2-hour stimulated C-peptide Area Under the Curve (AUC) during a Mixed Meal Tolerance Test (MMTT) [Baseline and 12 months]",null,null,null,null],["NCT07292519","Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB)",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","46","Alcohol Use Disorder (AUD); Overweight or Obese; Comorbidities and Coexisting Conditions","DRUG:Tirzepatide; BEHAVIORAL:Take Control CBT Module; OTHER:Placebo","South West Sydney Local Health District","2026-01-15","2027-05-15","FALSE","Heavy Drinking Days [12 weeks (measured at baseline, during the final 4 weeks of treatment [weeks 5 - 8], end of treatment [week 9], and follow-up [week 12]).]",null,null,"NO",null],["NCT02759107","A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","142","Healthy; Type 2 Diabetes Mellitus (T2DM)","DRUG:Tirzepatide; DRUG:Placebo; DRUG:Dulaglutide","Eli Lilly and Company","2016-05-11","2017-06-26","TRUE","Number of Participants With One or More Serious Adverse Event(s) (SAEs) [Baseline through Day 43 (Part A) and Day 57 (Part B and C)]","DERIVED:30473097","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/07/NCT02759107/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/07/NCT02759107/SAP_001.pdf","YES","OTHER:I8F-MC-GPGA"],["NCT02931344","Biomarkers in Obese Patients With Knee Osteoarthritis; Weight Loss","BIO-LOSEIT-I","UNKNOWN","INTERVENTIONAL",null,null,"NONE","200","Osteoarthrtis; Obesity","DIETARY_SUPPLEMENT:Dietary Supplement: Dietary Supplement: Intensive dietary intervention","Henrik Gudbergsen","2016-11","2019-01","FALSE","Change in collagen II degradation fragment α-C2M [Week -8 to 0]",null,null,"NO",null],["NCT07684144","Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","950","Obesity; Overweight; Diabetes Mellitus, Type 2","DRUG:Maridebart Cafraglutide; DRUG:Placebo","Amgen","2026-07-29","2027-12-26","FALSE","Percent Change in Body Weight from Baseline of the Parent Trial (20210184) [Baseline of parent trial (20210184) to Week 48 of current trial] | Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) [Baseline of current trial up to 60 weeks]",null,null,"YES","CTIS:2025-524788-19-00; OTHER:U1111-1332-0531; NIH:2025"],["NCT06732245","Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","224","Obesity and Overweight","DRUG:NA-931; DRUG:Tirzepatide; DRUG:NA-931 150 mg + no Tirzepatide","Biomed Industries, Inc.","2026-08-15","2027-08-15","FALSE","Change from baseline in body weight at 48 weeks [48 weeks]",null,null,"NO",null],["NCT07866066","Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes","MARITIME-T2D-3","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","1300","Diabetes Mellitus, Type 2","DRUG:Maridebart cafraglutide; DRUG:Semaglutide","Amgen","2026-11-02","2028-09-04","FALSE","Change from Baseline in Hemoglobin A1c (HbA1c) at Week 68 [Non-inferiority] [Baseline to Week 68]",null,null,"YES","CTIS:2025-523772-22-00; NIH:2025"],["NCT05649137","A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","512","Obesity; Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2023-01-04","2024-10-28","TRUE","Relative Change in Body Weight [Baseline (week 0), End of treatment (week 72)] | Number of Participants Who Achieve Body Weight Reduction Greater Than or Equal to (>=) 5% (Yes/no) [At week 72]","DERIVED:40961953","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/37/NCT05649137/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/37/NCT05649137/SAP_001.pdf","YES","EUDRACT_NUMBER:2022-002235-60; OTHER:U1111-1279-0359"],["NCT05184322","XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","87","Obesity; Type 2 Diabetes Mellitus","DRUG:T2026; DRUG:Placebo; DRUG:Oral ecnoglutide tablet","Sciwind Biosciences APAC CO Pty. Ltd.","2022-04-12","2024-07-13","FALSE","Number and percentage of treatment emergent adverse events (TEAEs) and serious adverse events (SAE) [Up to 98 days]",null,null,"NO",null],["NCT07605572","Impact of GLP-1 Receptor Agonists on Dry Eye Disease in Patients With Type 2 Diabetes Mellitus and Obesity","GALENOS","RECRUITING","OBSERVATIONAL",null,null,null,"100","Dry Eye Disease (DED); Diabete Mellitus; GLP-1; Ocular Surface; Diabetes Type 2; Cornea",null,"Attikon Hospital","2026-03-01","2026-12-31","FALSE","Changes in Ocular Parameters [All ophthalmological will be assessed at two time points: t0: Baseline assessment, before initiation of GLP-1 RA or GLP-1 RA/GIP therapy. t1: Follow-up assessment, 6-months after the intervention period, to evaluate changes ocular surface.]","BACKGROUND:34310488",null,"NO",null],["NCT02043054","Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)","LYDIA","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","90","Type 2 Diabetes Mellitus; Cardiovascular Disease","DRUG:Liraglutide; DRUG:Sitagliptin","University of Leicester","2013-12-16","2017-09-02","FALSE","Change in peak early diastolic strain rate measured by cardiac MRI [Change from baseline peak end diastolic strain rate at 26 weeks]","DERIVED:27440110",null,null,"EUDRACT_NUMBER:2012-002422-78; REGISTRY:U1111-1131-8802"],["NCT03987451","A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","71","Non-alcoholic Steatohepatitis","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2019-06-18","2021-04-22","TRUE","Percentage of Participants With At Least One Stage of Liver Fibrosis Improvement With No Worsening of Non-Alcoholic Steatohepatitis (NASH) After 48 Weeks [Week 48]","BACKGROUND:36934740","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/51/NCT03987451/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/51/NCT03987451/SAP_001.pdf","YES","OTHER:U1111-1224-4062; REGISTRY:2018-004484-31; NIH:2018"],["NCT01515553","Bioequivalence of Two Liraglutide Formulations in Healthy Volunteers",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","22","Diabetes; Healthy","DRUG:liraglutide","Novo Nordisk A/S","2007-01","2007-04","FALSE","Area under the curve (0-t) [] | Cmax, maximum concentration []",null,null,null,"EUDRACT_NUMBER:2006-004283-31"],["NCT02036372","Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus","PILGRIM","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","150","Diabetes Mellitus Type II","DRUG:Liraglutide; DRUG:Insulin bolus; DRUG:GIK infusion","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","2014-01","2017-01","FALSE","Median glucose [1 hour after surgery]","DERIVED:25419179",null,null,null],["NCT07301437","RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","120","Overweight and Obese Adults","DRUG:liraglutide monotherapy; DRUG:liraglutide combined with orlistat","The Fourth Affiliated Hospital of Zhejiang University School of Medicine","2026-05-01","2027-08-31","FALSE","weight loss [6 months]",null,null,null,null],["NCT01928329","A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","79","Type I Diabetes","DRUG:Exenatide (Bydureon®); DRUG:Placebo","Yale University","2013-09","2018-06","TRUE","Change From Baseline in HbA1c Levels [6 months]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/29/NCT01928329/Prot_SAP_000.pdf",null,null],["NCT02060383","Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","249","Cushing's Disease; Acromegaly","DRUG:Pasireotide s.c.; DRUG:Sitagliptin; DRUG:Liraglutide; DRUG:Insulin; DRUG:Pasireotide LAR; DRUG:Metformin","Novartis Pharmaceuticals","2014-05-23","2018-02-05","TRUE","Change in HbA1c From Randomization to Approximately 16 Weeks [Randomization, 16 weeks]","DERIVED:34275099; DERIVED:27405306","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/83/NCT02060383/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/83/NCT02060383/SAP_001.pdf","YES","EUDRACT_NUMBER:2012-002916-16"],["NCT06461377","The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy",null,"RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","50","Type 2 Diabetes; Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)","DRUG:Glucagon-like peptide-1 receptor agonist：Semaglutide","The First Affiliated Hospital with Nanjing Medical University","2024-06-13","2026-12-31","FALSE","heart rate variability（HRV） [baseline and 12 weeks later]","BACKGROUND:16014401; BACKGROUND:25685280; BACKGROUND:12716821; BACKGROUND:37397902; BACKGROUND:37021204; BACKGROUND:31552598; BACKGROUND:24567799; BACKGROUND:32497872; BACKGROUND:26254961; BACKGROUND:34317590; BACKGROUND:34793438; BACKGROUND:19259827; BACKGROUND:20460434; BACKGROUND:33292149; BACKGROUND:33804063",null,null,null],["NCT07319975","Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","48","Obesity","DRUG:Semaglutide; DRUG:Tirzepatide; BEHAVIORAL:Tirzepatide+Exercise; BEHAVIORAL:Semaglutide+Exercise","Istanbul Galata University","2025-12-29","2026-10","FALSE","Body fat-muscle ratios (Body composition) [Three months]",null,null,"NO",null],["NCT05890976","Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)","OASIS 3","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","200","Overweight; Obesity","DRUG:Semaglutide; DRUG:Semaglutide Placebo","Novo Nordisk A/S","2023-05-30","2025-01-16","FALSE","Relative Change in Body Weight [From baseline (week 0) to end of treatment (week 44)] | Number of Participants Who Achieve (Yes/No): Body Weight Reduction Greater Than or Equal to 5 Percent [At end of treatment (week 44)]",null,null,"YES","OTHER:U1111-1266-2400"],["NCT05929079","A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight","TRIUMPH-2","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","1152","Type 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apnea","DRUG:Retatrutide; DRUG:Placebo","Eli Lilly and Company","2023-07-11","2026-06-16","FALSE","Percent Change from Baseline in Body Weight [Baseline, Week 80] | Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 Subset [Baseline, Week 80]","DERIVED:42810372",null,"YES","OTHER:J1I-MC-GZBK; OTHER:J1I-MC-GSA2; OTHER:2023-503658-11-00; NIH:2023"],["NCT07793019","IBI3042 Study in Healthy Participants and Overweight or Obese Participants",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","104","Overweight; Healthy Participants; Obesity","DRUG:Orforglipron; DRUG:Matching Placebo; DRUG:IBI3042","Innovent Biologics (Suzhou) Co. Ltd.","2026-09-07","2027-09-06","FALSE","Number of Participants With Adverse Events (Part A) [through study completion, an average of 29 days] | Number of Participants With Abnormal Physical Examination Findings (Part A) [through study completion, an average of 29 days] | Number of Participants With Clinically Significant Abnormal Vital Signs (Part A) [through study completion, an average of 29 day] | Number of Participants With Clinically Significant Abnormal Laboratory Tests (Part A) [through study completion, an average of 29 days] | Number of Participants With Clinically Significant Abnormal Twelve?Lead Electrocardiogram Readings (Part A) [through study completion,an average of 29 days] | Number of Participants With Adverse Events (Part B) [through study completion, an average of 113 days] | Number of Participants With Abnormal Physical Examination Findings (Part B) [through study completion, an average of 113 days] | Number of Participants With Clinically Significant Abnormal Vital Signs (Part B) [through study completion, an average of 113 days] | Number of Participants With Clinically Significant Abnormal Laboratory Tests (Part B) [through study completion, an average of 113 days] | Number of Participants With Clinically Significant Abnormal Twelve?Lead Electrocardiogram Readings (Part B) [through study completion, an average of 113 days]",null,null,null,null],["NCT07223242","Tailored Exercise Training Study Among Adults With HFpEF","TEXPEF","RECRUITING","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","NONE","120","HFpEF - Heart Failure With Preserved Ejection Fraction; Diabetic Cardiomyopathies","BEHAVIORAL:Moderate-intensity continuous training (MCT); BEHAVIORAL:Resistance training; DRUG:Weight loss","University of Texas Southwestern Medical Center","2025-02-18","2026-12-30","FALSE","Peak Exercise Oxygen Uptake (VO2peak) [Baseline, 3months, 6months, and 9months] | Short Physical Performance Battery (SPPB) [Baseline, 3months, 6months, and 9months]",null,null,null,null],["NCT04657939","Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes","Lean-DM","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","57","Diabetes Mellitus, Type 2","DRUG:Liraglutide; DRUG:Pioglitazone","University of Leeds","2020-12-01","2022-10-31","FALSE","Change in myocardial perfusion after treatment [40 weeks]","DERIVED:39084829",null,null,"OTHER_GRANT:18/0005908; OTHER:19/WM/0365"],["NCT02516657","Liraglutide in Adolescents With Type 1 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3",null,"NONE","5","Type 1 Diabetes","DRUG:Liraglutide","University at Buffalo","2012-05","2022-08-03","TRUE","Mean Weekly Blood Glucose [Visit 1 (Before Liraglutide) at baseline (Day 0) vs. Visit 2 (After Liraglutide) on Day 7;]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/57/NCT02516657/Prot_SAP_000.pdf","NO",null],["NCT03036800","Saxenda in Obesity Services (STRIVE Study)","STRIVE","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","392","Obesity; Weight Loss; Diabetes Mellitus","DRUG:Saxenda; OTHER:Specialist Obesity Management Services","University of Leicester","2017-11-28","2021-02-28","TRUE","Weight Loss of ≥15% From Baseline (Complete Cases) [52 weeks] | Weight Loss of ≥15% From Baseline (Intention to Treat) [52 weeks] | Weight Loss of ≥15% From Baseline (Per Protocol) [52 weeks] | Weight Loss of ≥15% From Baseline (Per Protocol Without Excluded Concomitant Medications) [52 weeks]","DERIVED:38803628; DERIVED:32060156","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/00/NCT03036800/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/00/NCT03036800/SAP_001.pdf","NO",null],["NCT06068946","VK2735 for Weight Management Phase 2","VENTURE","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","176","Weight Loss","BIOLOGICAL:VK2735; BIOLOGICAL:Placebo","Viking Therapeutics, Inc.","2023-08-31","2024-02-27","FALSE","Percent (relative) change from baseline to Week 13 in body weight [13 weeks]","DERIVED:41508550",null,null,null],["NCT02194595","Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)","PREVAIL","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","105","Type 2 Diabetes","DRUG:Basal insulin and exenatide; DRUG:Basal insulin only; DRUG:Basal insulin and bolus insulin","Mount Sinai Hospital, Canada","2014-09","2021-12","FALSE","Mean beta-cell function over the 8-week treatment period, measured using the Insulin Secretion-Sensitivity Index-2 (ISSI-2) [8 weeks]","DERIVED:36894921",null,null,null],["NCT02104739","Effects of Antidiabetic Medications on the Postprandial State in Prediabetes",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","21","Prediabetes; Obesity","DRUG:Exenatide; DRUG:Saxagliptin; DRUG:Exenatide extended-release (ER); OTHER:Placebo","The University of Texas Health Science Center, Houston","2014-04","2017-03","TRUE","Monocyte NfkB Levels as Detected by Western Blotting [baseline] | Monocyte NfkB Levels as Detected by Western Blotting [2 hours after ingestion of meal]","DERIVED:32228379","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/39/NCT02104739/Prot_SAP_000.pdf",null,null],["NCT06874751","Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World","SCORE","COMPLETED","OBSERVATIONAL",null,null,null,"45456","Overweight; Obesity; Atherosclerotic Cardiovascular Disease (ASCVD)","OTHER:No treatment given","Novo Nordisk A/S","2024-12-06","2025-03-28","FALSE","Revised 5-Point Major Adverse Cardiovascular Events (MACE-5) (time-to-event) [Index date, earliest of revised MACE-5 and end of follow-up, up to 30 months] | Revised 3-Point Major Adverse Cardiovascular Events (MACE-3) (time-to-event) [Index date, earliest of revised MACE-3 and end of follow-up, up to 30 months]","DERIVED:40926360",null,"YES","OTHER:U1111-1318-9978"],["NCT05140694","Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","135","Metabolic-associated Fatty Liver Disease; Type 2 Diabetes","DRUG:Empagliflozin; DRUG:Dulaglutide; DRUG:Empagliflozin and Dulaglutide","Seoul National University Bundang Hospital","2023-12-01","2024-06-30","FALSE","Changes of HbA1c level [baseline, week 12, week 24] | Changes of CAP score [baseline, week 24]",null,null,null,null],["NCT06120556","Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes",null,"COMPLETED","OBSERVATIONAL",null,null,null,"130","Diabetes Mellitus, Type 2","DRUG:GLP-1 receptor agonist","Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari","2023-06-10","2023-10-31","FALSE","Difference in HbA1c change from baseline (%) among SIDD, SIRD, MARD, MOD subtypes [Difference in HbA1c change from baseline will be evaluated at first follow-up visit (occurring 6-12 months from GLP-1RA initiation)]","BACKGROUND:29503172; BACKGROUND:32699108; BACKGROUND:31047901",null,"YES",null],["NCT07156331","Research on Effects of Drugs on Body Composition and Function With Imaging in Diabetes","REBUILD","NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"20","Type 2 Diabetes",null,"Kristin Clemens","2025-10-01","2027-10-01","FALSE","Change in skeletal muscle mass at 1-year [Change from baseline to 12 months] | Change in Timed Up-and-Go (TUG) at 1-year [Change from baseline to 12 months] | Change in Gait Speed at 1-year [Change from baseline to 12 months] | Change in Handgrip Strength at 1-year [Change from baseline to 12 months]",null,null,"NO",null],["NCT00537719","Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","SINGLE","34","Diabetes Mellitus, Type 2","DRUG:GSK716155; DRUG:Placebo","GlaxoSmithKline","2007-12-07","2008-04-04","FALSE","Change from baseline of the time to 50% gastric emptying (gastric emptying t½) of the solid and liquid components of a meal at 72 hours after dosing in healthy volunteers. [3 Days]","DERIVED:25387217",null,"YES",null],["NCT06659679","Emulating the PIONEER6 Diabetes Trial Using Healthcare Claims",null,"COMPLETED","OBSERVATIONAL",null,null,null,"26126","Diabetes Mellitus, Type 2","DRUG:New use of oral semaglutide; DRUG:New initiation of sitagliptin","Brigham and Women's Hospital","2024-10-24","2025-03-06","FALSE","Major adverse cardiac event (MACE), including myocardial infarction, stroke, and all cause death [Through study completion (1 day after cohort entry date until the first of outcome or censoring)]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/79/NCT06659679/Prot_SAP_002.pdf",null,null],["NCT07701005","Non-Invasive Hepatic and Metabolic Index Changes After Incretin Therapy in Overweight/Obesity","GLP-NIT","COMPLETED","OBSERVATIONAL",null,null,null,"154","Steatosis of Liver; Metabolic Liver Injury; Obesity; Overweight; Insulin Resistance","DRUG:Semaglutide; DRUG:Tirzepatide","Goztepe Prof Dr Suleyman Yalcın City Hospital","2024-01-01","2026-03-30","FALSE","Change in Fibrosis-4 Index (FIB-4) [Baseline and follow-up (median 23.7 weeks; minimum 12 weeks)] | Change in AST-to-Platelet Ratio Index (APRI) [Baseline and follow-up (median 23.7 weeks; minimum 12 weeks)] | Change in Hepatic Steatosis Index (HSI) [Baseline and follow-up (median 23.7 weeks; minimum 12 weeks)] | Change in Triglyceride-Glucose (TyG) Index [Baseline and follow-up (median 23.7 weeks; minimum 12 weeks)]",null,null,"NO",null],["NCT04081337","A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","55","Obesity","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2020-07-09","2022-05-26","TRUE","Change From Baseline to Week 18 in Sleep Metabolic Rate (SMR) [Baseline, Week 18]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/37/NCT04081337/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/37/NCT04081337/SAP_001.pdf","NO","OTHER:I8F-MC-GPGU"],["NCT07112872","A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","330","Type 2 Diabetes Mellitus","DRUG:RO7795081; DRUG:Semaglutide; DRUG:Placebo","Hoffmann-La Roche","2025-08-19","2028-02-05","FALSE","RO7795081 vs. Placebo: Change in Glycated Hemoglobin (HbA1c) from Baseline at Week 30 [Baseline to Week 30]",null,null,"YES","CTIS:2024-520322-11-00"],["NCT07483801","DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies","DECODE","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","112","Cardiovascular Diseases","DRUG:semaglutide; DRUG:Tirzepatide","Cambridge University Hospitals NHS Foundation Trust","2026-03","2027-04","FALSE","Sub-study 1A:Change in forearm blood flow parameters after infusion of semaglutide (Ratio) [2-2.5 months from screening to follow-up] | Sub-study 1A:Change in forearm blood flow parameters after infusion of semaglutide (Absolute flow) [2-2.5 months from screening to follow-up] | Sub-study 1A: Change in forearm blood flow parameters after infusion of semaglutide (Percentage Change) [2-2.5 months from screening to follow-up] | Sub-study 1B: Change in forearm blood flow parameters after infusion of tirzepatide (Absolute flow) [2-2.5 months from screening to follow-up] | Sub-study 1B: Change in forearm blood flow parameters after infusion of tirzepatide (Ratio) [2-2.5 months from screening to follow-up] | Sub-study 1B: Change in forearm blood flow parameters after infusion of tirzepatide (Percent Change) [2-2.5 months from screening to follow-up] | Sub-study 1C: Change in forearm blood flow parameters after infusion of semaglutide or tirzepatide or saline (Absolute flow) [2-2.5 months from screening to follow-up] | Sub-study 1C: Change in forearm blood flow parameters after infusion of semaglutide or tirzepatide or saline (Ratio) [2-2.5 months from screening to follow-up] | Sub-study 1C: Change in forearm blood flow parameters after infusion of semaglutide or tirzepatide or saline (Percentage change) [2-2.5 months from screening to follow-up] | Sub-study 2A: Changes in cardiovascular haemodynamic variables after administration of semaglutide (Blood pressure) [2-2.5 months from screening to follow-up] | Sub-study 2A: Changes in cardiovascular haemodynamic variables after administration of semaglutide (Heart rate) [2-2.5 months from screening to follow-up] | Sub-study 2A: Changes in cardiovascular haemodynamic variables after administration of semaglutide (Cardiac output) [2-2.5 months from screening to follow-up] | Sub-study 2A: Changes in cardiovascular haemodynamic variables after administration of semaglutide (Vascular resistance) [2-2.5 months from screening to follow-up] | Sub-study 2B: Changes in cardiovascular haemodynamic variables after administration of tirzepatide (Blood pressure) [2-2.5 months from screening to follow-up] | Sub-study 2B: Changes in cardiovascular haemodynamic variables ) after administration of tirzepatide (Heart rate) [2-2.5 months from screening to follow-up] | Sub-study 2B: Changes in cardiovascular haemodynamic variables after administration of tirzepatide (Cardiac output) [2-2.5 months from screening to follow-up] | Sub-study 2B: Changes in cardiovascular haemodynamic variables after administration of tirzepatide (Vascular resistance) [2-2.5 months from screening to follow-up] | Sub-study 2C: Changes in cardiovascular haemodynamic variables after administration of semaglutide or tirzepatide or saline (Blood pressure) [2-2.5 months from screening to follow-up] | Sub-study 2C: Changes in cardiovascular haemodynamic variables after administration of semaglutide or tirzepatide or saline (Heart rate) [2-2.5 months from screening to follow-up] | Sub-study 2C: Changes in cardiovascular haemodynamic variables after administration of semaglutide or tirzepatide or saline (Cardiac output) [2-2.5 months from screening to follow-up] | Sub-study 2C: Changes in cardiovascular haemodynamic variables after administration of semaglutide or tirzepatide or saline (Vascular resistance) [2-2.5 months from screening to follow-up]",null,null,"UNDECIDED",null],["NCT01509742","Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","19","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2001-04","2001-11","FALSE","Area under the Curve (AUC) glucagon []",null,null,null,null],["NCT00894322","A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension",null,"COMPLETED","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","SINGLE","65","Type 2 Diabetes Mellitus","DRUG:exenatide once weekly; OTHER:Placebo","AstraZeneca","2009-04","2009-08","TRUE","Area Under the Curve (AUC) for Single Dose of 10 mg Exenatide (Cohort 1) in Healthy Participants in the Pharmacokinetic Evaluable Population [Day 1, Week 12] | Maximum Concentration (Cmax) for Single Dose of 10 mg Exenatide (Cohort 1) in Healthy Participants in the Pharmacokinetic Evaluable Population [Day 1, Week 12] | Time to Maximum Concentration (Tmax) for Single Dose of 10 mg Exenatide (Cohort 1) in Healthy Participants in the Pharmacokinetic Evaluable Population [Day 1, Week 12] | Number of Participants With Treatment Emergent Adverse Events (TEAEs), Injection Site TEAEs, Serious Adverse Events (SAEs), Deaths, and Withdrawals Due to AEs in Cohort 1 and Cohort 2 in Intent to Treat (ITT) Population [Day 1 to Week12] | Number of Participants With Concomitant Medications in Cohort 1 and Cohort 2 in ITT Population [Day 1 to 12 weeks] | Mean Change From Baseline to End of Study in Sitting Diastolic and Systolic Blood Pressure in Cohorts 1 and 2 in ITT Population [Day 1 to Week 12] | Mean Change From Baseline to End of Study in Sitting Heart Rate in Cohorts 1 and 2 in ITT Population [Day 1 to Week 12] | Number of Participants With Hematology and Serum Chemistry Laboratory Values of Potential Clinical Importance in Cohorts 1 and 2 in ITT Population [Day 1 to Week 12] | Antibody Titers for Participants With Treatment Emergent Positive Antibodies to Exenatide in Participants Who Received Exenatide in Cohorts 1 and 2 [Day 1 to Week 12] | Area Under the Curve (AUC) for 2 mg Exenatide (Cohort 2) in Participants With Diabetes in the Pharmacokinetic Evaluable Population [Week 10-11; Weeks 10 - 12] | Average Exenatide Concentration (Cave) of 2 mg Exenatide (Cohort 2) in Participants With Diabetes in the Pharmacokinetic Evaluable Population [Week 10 - Week 11; Week 10 - Week 12] | Maximum Concentration (Cmax) for 2 mg Exenatide (Cohort 2) in Participants With Diabetes in the Pharmacokinetic Evaluable Population [Week 10, Weeks 10-11, Weeks 10-12] | Time to Maximum Concentration (Tmax) of 2 mg Exenatide (Cohort 2) in Participants With Diabetes in Pharmacokinetic Evaluable Population [Week 10, Weeks 10-11, Weeks 10-12]",null,null,null,null],["NCT03951753","A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","117","Diabetes Mellitus, Type 2","DRUG:Tirzepatide; DRUG:Semaglutide; DRUG:Placebo","Eli Lilly and Company","2019-06-28","2021-04-08","TRUE","Change From Baseline in Total Clamp Disposition Index (cDI) [Baseline, Week 28]","DERIVED:36857477; DERIVED:35468322","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/53/NCT03951753/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/53/NCT03951753/SAP_001.pdf","NO","OTHER:I8F-MC-GPGT; EUDRACT_NUMBER:2018-003343-37; NIH:2018"],["NCT06335134","A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","57","Healthy Volunteers","DRUG:XW003 injection; DRUG:Metformin; DRUG:Warfarin; DRUG:Rosuvastatin; DRUG:Digoxin","Hangzhou Sciwind Biosciences Co., Ltd.","2023-07-14","2024-01-08","FALSE","Pharmacokinetics of metformin: AUC0-inf [up to 101 days] | Pharmacokinetics of S-warfarin and R-warfarin: AUC0-inf [up to 114 days] | Pharmacokinetics of rosuvastatin: AUC0-inf [up to 102 days] | Pharmacokinetics of digoxin: AUC0-inf [up to 112days]",null,null,"NO",null],["NCT04862234","Perioperative Stress Hyperglycemia in General and Vascular Surgery Patients",null,"TERMINATED","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","16","Hyperglycemia Stress","DRUG:Dulaglutide; DRUG:Placebo; DEVICE:Continuous glucose monitor (CGM), blinded","Emory University","2021-08-06","2023-06-22","TRUE","Percentage of Time in Target Glucose Range (70-140 mg/dL) by CGM [During hospitalization (up to 5 days postoperatively)]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/34/NCT04862234/Prot_SAP_000.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/34/NCT04862234/ICF_001.pdf","YES","NIH:K23DK122199"],["NCT02944500","Saxenda: Underlying Mechanisms and Clinical Outcomes",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","28","Obesity","DRUG:liraglutide; OTHER:Placebo","Beth Israel Deaconess Medical Center","2016-11","2027-06","FALSE","BOLD response to food cues [5 weeks]","DERIVED:41513169; DERIVED:36375643; DERIVED:31672146",null,"NO",null],["NCT05260021","A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both","SURPASS-PEDS","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","99","Type2 Diabetes; Diabetes Mellitus; Diabetes Mellitus, Type 2; T2D; T2DM (Type 2 Diabetes Mellitus); Glucose Metabolism Disorders; Endocrine System Diseases; Metabolic Disease","DRUG:Tirzepatide Dose 1; DRUG:Tirzepatide Dose 2; DRUG:Placebo","Eli Lilly and Company","2022-04-13","2024-07-30","TRUE","Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) [Baseline, Week 30]","DERIVED:40975112","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/21/NCT05260021/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/21/NCT05260021/SAP_001.pdf","YES","OTHER:I8F-MC-GPGV; EUDRACT_NUMBER:2021-003612-31"],["NCT07035704","Prevent and Reverse Obesity in Children, Adolescents and Young Adults","PasGras","NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","200","Overweight (BMI &gt; 25)","DIETARY_SUPPLEMENT:MeD enriched with mushrooms; DIETARY_SUPPLEMENT:MeD enriched the Lebanese herbal mixture Za'atar; DIETARY_SUPPLEMENT:MeD Diet + semaglutinine or compatible treatment+ Za'atar or Mushroom (to be defined)","piero portincasa","2025-09-15","2027-01-30","FALSE","Weight (Kg) [one year]","BACKGROUND:35163038; BACKGROUND:32312770; BACKGROUND:31817104; BACKGROUND:34063068; BACKGROUND:33490935; BACKGROUND:32823983; BACKGROUND:32326636; BACKGROUND:31960952; BACKGROUND:32098159; BACKGROUND:35625660; BACKGROUND:32020441; BACKGROUND:28521687; BACKGROUND:26758061; BACKGROUND:25194180; BACKGROUND:29100895; BACKGROUND:34629256; BACKGROUND:35269779; BACKGROUND:35052763; BACKGROUND:35514242",null,"NO",null],["NCT01558271","A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","492","Type 2 Diabetes Mellitus","DRUG:LY2189265; DRUG:Placebo; DRUG:Liraglutide","Eli Lilly and Company","2012-03","2013-10","TRUE","Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks [Baseline, 26 weeks]","DERIVED:29264713; DERIVED:28606095",null,null,"OTHER:H9X-JE-GBDP"],["NCT05173714","Sit Less, Interact and Move More (SLIMM) 2 Study",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","156","Chronic Kidney Diseases; Obesity","BEHAVIORAL:SLIMM; BEHAVIORAL:Standard Resistance Training; BEHAVIORAL:Guided Resistance Training; DRUG:Placebo; DRUG:Semaglutide","Srinvasan Beddhu","2021-12-01","2026-12-31","FALSE","Average Change in Sedentary Duration at Months 8, 10 and 12 from Randomization [Randomization to 12 Months]",null,null,"NO","NIH:1R01DK128640-01"],["NCT03560336","A Regulatory Post-marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda®(Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea.",null,"COMPLETED","OBSERVATIONAL",null,null,null,"758","Obesity; Overweight","DRUG:Liraglutide","Novo Nordisk A/S","2018-07-05","2020-12-02","FALSE","Incidence of adverse events (AEs) by preferred term (PT) [From baseline to week 13 (± 3 weeks)] | Incidence of adverse events (AEs) by preferred term (PT) [From baseline to week 26 (± 3 weeks)]",null,null,"YES","OTHER:U111-1199-8606"],["NCT01789086","A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","21","Metabolism and Nutrition Disorder; Obesity","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2013-02","2014-05","FALSE","Number of treatment emergent adverse events (TEAEs) [From the time of first dosing (Day 0) and until completion of follow-up visit (up to 6 weeks' treatment and 5-14 days subsequent follow-up period)]","RESULT:27979579",null,null,"EUDRACT_NUMBER:2012-000038-20; OTHER:U1111-1126-8119"],["NCT01951651","Effect of Exenatide on Liver and Heart Fat and Inflammation",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","24","Type 2 Diabetes Mellitus","DRUG:Exenatide; DRUG:Glipizide","Baylor College of Medicine","2010-04","2012-10","TRUE","Myocardial Fat Content [6 months] | Hepatic Fat Content [6 months]",null,null,null,null],["NCT06439277","A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","300","Obesity; Weight Gain","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2024-06-03","2027-10","FALSE","Percent Change from Baseline in Body Mass Index (BMI) [Baseline, Week 72] | A Composite Endpoint of Normalization or Clinically Significant Improvement in At Least 2 Predefined Weight-Related Comorbidities Present at Screening Without Development of New Predefined Comorbidity or Worsening of Existing Predefined Comorbidity [Baseline, Week 72]",null,null,"YES","OTHER:I8F-MC-GPIX"],["NCT02767596","Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog",null,"TERMINATED","INTERVENTIONAL","PHASE4",null,"NONE","2","Diabetes Mellitus Type 2","DRUG:Lixisenatide; DRUG:Basal insulins","Laniado Hospital","2016-07-12","2017-02","FALSE","Change in hemoglobin A1c [16 weeks] | Change in body weight [16 weeks]",null,null,"NO",null],["NCT07285902","A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","572","Obesity","DRUG:HRS9531 injection; DRUG:Semaglutide Injection","Fujian Shengdi Pharmaceutical Co., Ltd.","2025-12-25","2027-03","FALSE","Percentage change from baseline in body weight after 52 weeks of treatment [52 weeks]",null,null,"UNDECIDED",null],["NCT04029272","Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","80","Polycystic Ovary Syndrome","DRUG:Metformin; DRUG:Exenatide 2 MG","Peking Union Medical College Hospital","2019-07-20","2020-02-28","FALSE","Change in body weight [Patient's body weight was measured at the baseline and after 12 weeks of clinical trial]","DERIVED:40843067; DERIVED:34732660",null,"NO",null],["NCT05421338","A Study in Healthy Men to Test How BI 456906 is Processed in the Body",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","6","Healthy","DRUG:BI 456906 (C-14)","Boehringer Ingelheim","2022-07-04","2022-11-17","FALSE","Fraction of [14C]-radioactivity excreted in urine expressed as percentage of the administered dose over the time interval from 0 to the last quantifiable time point (fe_urine, 0-tz) [up to 7 weeks] | Fraction of [14C]-radioactivity excreted in faeces expressed as percentage of the administered dose over the time interval from 0 to the last quantifiable time point (fe_faeces, 0-tz) [up to 7 weeks]",null,null,"NO","EUDRACT_NUMBER:2021-006690-28"],["NCT01632163","Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","447","Type 2 Diabetes Mellitus","DRUG:Lixisenatide (AVE0010); DRUG:Placebo","Sanofi","2012-10","2015-05","FALSE","Change in HbA1c [from baseline to week 24]","DERIVED:36809495; DERIVED:28742225",null,null,"OTHER:U1111-1124-1213"],["NCT05564104","A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","32","Hepatic Impairment; Healthy Volunteers","DRUG:Cagrilintide","Novo Nordisk A/S","2023-04-05","2024-09-06","FALSE","Part A: AUC 0-infinity (∞), single dose (SD), cagri: The area under the cagrilintide plasma concentration-time curve fromtime 0 to infinity after a single dose [From 00 hours (pre-dose), 04, 08, 12, 18, 24, 30, 36, 48, 54, 60, 72, 84, 96, 120, 168, 336, 504, 672 to 840 hours (post dose)]","DERIVED:42228334",null,"YES","OTHER:U1111-1271-9259; EUDRACT_NUMBER:2022-000138-41"],["NCT05296733","A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","82","Healthy; Liver Diseases; Obesity","DRUG:BI 456906","Boehringer Ingelheim","2022-04-27","2023-12-29","FALSE","Part A: Area under the concentration-time curve of BI 456906 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) [Up to 360 hours] | Part A: Maximum measured concentration of BI 456906 in plasma (Cmax) [Up to 360 hours] | Part B: Percentage of patients treated who experience treatment-emergent adverse event [Up to Day 218]","DERIVED:38857788",null,"NO","EUDRACT_NUMBER:2021-006247-10"],["NCT07347080","A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus","CR059101","RECRUITING","INTERVENTIONAL","EARLY_PHASE1",null,"NONE","9","T2DM","DRUG:Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059））","The First Affiliated Hospital of Henan University of Science and Technology","2026-01-20","2026-08-31","FALSE","Incidence of Treatment-Emergent Adverse Events (TEAEs) [From the first dosing (Day 1 ) of study drug until completion of the post treatment follow-up visit(Day 36)]",null,null,"YES",null],["NCT06911203","A Study of BGM0504 in Participants With Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","96","Obesity","DRUG:BGM0504; DRUG:Tirzepatide","BrightGene Bio-Medical Technology Co., Ltd.","2025-04-09","2026-01-14","FALSE","Change From Baseline in Body Weight [Week 0, Week 26]",null,null,null,null],["NCT07521631","Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","372","Obesity","DRUG:HDM1005 dose level 1; DRUG:HDM1005 dose level 2; DRUG:HDM1005 dose level 3; DRUG:Tirzepatide","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2026-03-31","2027-02-04","FALSE","Primary Outcome [week 40]",null,null,"NO",null],["NCT01126580","A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","807","Diabetes Mellitus, Type 2","DRUG:Metformin; DRUG:LY2189265; DRUG:Placebo (oral); DRUG:Placebo (subcutaneous)","Eli Lilly and Company","2010-05","2011-11","TRUE","Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c) [Baseline, 26 weeks]","DERIVED:32501595; DERIVED:27161178; DERIVED:26691396; DERIVED:24842985",null,null,"OTHER:H9X-MC-GBDC; REGISTRY:CTRI/2010/091/003036"],["NCT07282041","Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis","RADIANT","RECRUITING","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","SINGLE","130","Intracranial Atherosclerosis; Stroke, Ischemic","DRUG:Dulaglutide","National University of Singapore","2025-12-17","2030-12-01","FALSE","To evaluate whether GLP1 RA (Dulaglutide) therapy would improveme cerebral vasodilatory reserve by at least 4 points in patients with severe stenosis of ICA or MCA [within 1 year]",null,null,"NO",null],["NCT07720466","Salivary Function and Dental Changes During GLP-1 Therapy",null,"NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"40","Obesity; Dental Erosion; Saliva Collection; Saliva Altered","PROCEDURE:Unstimulated Whole Saliva Collection; PROCEDURE:Salivary Analysis; PROCEDURE:Oral Examination and BEWE Assessment; PROCEDURE:Standardized Intraoral Photography","Bilecik Seyh Edebali Universitesi","2026-08-17","2026-10-21","FALSE","Change in salivary calcium concentration [Baseline and 3 months]","BACKGROUND:40699237; BACKGROUND:38206684; BACKGROUND:41463424",null,"YES",null],["NCT03492580","A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease",null,"COMPLETED","OBSERVATIONAL",null,null,null,"714582","Diabetes Mellitus, Type 2; Cardiovascular Diseases","DRUG:Canagliflozin; DRUG:Empagliflozin; DRUG:Dapagliflozin; DRUG:Dipeptidyl Peptidase-4 (DPP-4) Inhibitors; DRUG:Glucagon-like Peptide-1 (GLP-1) Agonist; DRUG:Anti-hyperglycemic Agents (AHA); DRUG:Thiazolidinediones (TZD); DRUG:Sulfonylureas (SU); DRUG:Insulin","Janssen Research & Development, LLC","2018-02-22","2018-04-06","FALSE","Number of Hospitalizations for Heart Failure [Approximately 4-years] | Number of Participants with Below Knee Lower Extremity Amputation Events [Approximately 4-years]",null,null,null,"OTHER:RRA-20250"],["NCT06817356","A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","308","Alcohol Use Disorder","DRUG:Mazdutide; DRUG:Placebo","Eli Lilly and Company","2025-02-06","2026-03-19","FALSE","Behaviors Associated with Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method [Baseline, Week 28]",null,null,"YES","OTHER:I8P-MC-OXAH"],["NCT05815680","A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","48","Overweight Subjects; Obese Subjects","DRUG:metformin; DRUG:digoxin; DRUG:IBI362; DRUG:warfarin; DRUG:atorvastatin","Innovent Biologics (Suzhou) Co. Ltd.","2023-04-06","2023-08-18","FALSE","Maximum observed metformin plasma concentration at steady state [up to 116 days] | Area under the metformin plasma concentration-time curve [up to 116 days] | Maximum observed warfarin plasma concentration at steady state [up to 116 days] | Area under the warfarin plasma concentration-time curve [up to 116 days] | Maximum observed atorvastatin plasma concentration at steady state [up to 116 days] | Area under the atorvastatin plasma concentration-time curve [up to 116 days] | Maximum observed digoxin plasma concentration at steady state [up to 116 days] | Area under the digoxin plasma concentration-time curve [up to 116 days]",null,null,null,null],["NCT07868354","A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1",null,"NONE","60","Overweight; Obesity; Type 2 Diabetes","DRUG:Tirzepatide; DRUG:Zenagamtide","Novo Nordisk A/S","2026-10-08","2028-09-07","FALSE","Number of treatment emergent adverse events (TEAE) [From first administration of zenagamtide day 1 to day 57]",null,null,"YES","OTHER:U1111-1330-4403"],["NCT05445232","A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","32","Obesity","DRUG:LY3437943; DRUG:Midazolam; DRUG:Warfarin; DRUG:Caffeine","Eli Lilly and Company","2022-07-08","2023-02-24","FALSE","Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Midazolam [Predose up to 24 hours postdose] | PK: Maximum Observed Concentration (Cmax) of Midazolam [Predose up to 24 hours postdose] | PK: AUC[0-∞] of Warfarin [Predose up to 96 hours postdose] | PK: Cmax of Warfarin [Predose up to 96 hours postdose] | PK: AUC[0-∞] of Caffeine [Predose up to 48 hours postdose] | PK: Cmax of Caffeine [Predose up to 48 hours postdose]",null,null,"NO","OTHER:J1I-MC-GZBI"],["NCT03061214","Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)","SUSTAIN","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","868","Diabetes; Diabetes Mellitus, Type 2","DRUG:Semaglutide 0.5 mg; DRUG:Semaglutide 1.0 mg; DRUG:Sitagliptin placebo; DRUG:Sitagliptin; DRUG:Semaglutide placebo 0.5 mg; DRUG:Semaglutide placebo 1.0 mg","Novo Nordisk A/S","2017-08-28","2019-03-14","TRUE","Change in HbA1c [Week 0, week 30]","RESULT:33074557; DERIVED:38236431","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/14/NCT03061214/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/14/NCT03061214/SAP_001.pdf","YES","OTHER:U1111-1149-0432; REGISTRY:CTR20161003"],["NCT05669755","REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels","REDEFINE 3","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","7101","Cardiovascular Disease","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2023-03-01","2027-09-01","FALSE","Time to first occurrence of 3-point major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke [From baseline (week 0) to end of study (up to 242 weeks or more)]","DERIVED:42838477",null,"YES","OTHER:U1111-1270-0943; EUDRACT_NUMBER:2021-005855-35; REGISTRY:jRCT2031220672"],["NCT04109547","A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes","PIONEER 11","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","521","Diabetes Mellitus, Type 2","DRUG:Oral semaglutide; DRUG:Placebo","Novo Nordisk A/S","2019-10-01","2021-09-23","TRUE","Change From Baseline in Glycosylated Haemoglobin (HbA1c) [Baseline (Week 0), Week 26]","DERIVED:38985162","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/47/NCT04109547/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/47/NCT04109547/SAP_001.pdf","YES","OTHER:U1111-1188-1173; REGISTRY:2018-002590-22; NIH:2018"],["NCT06584916","A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","376","Obesity; Overweight","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2024-09-13","2025-11-21","FALSE","Percent Maintenance of Body Weight Reduction Achieved in SURMOUNT-5 [Week 52]","DERIVED:42120723",null,"YES","OTHER:J2A-MC-GZPN"],["NCT01511185","Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","20","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2001-02","2001-10","FALSE","AUC (area under the curve) of Insulin Secretion Rate (ISR) over the 90-216 mg/dL glucose interval []","RESULT:12829647",null,null,null],["NCT05893043","A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","18","Healthy Volunteers","DRUG:GSBR-1290; OTHER:Placebo","Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics","2023-04-24","2023-06-28","FALSE","Number of Participants With Adverse Events (AEs) and Serious AEs [From start of study drug up to End of study (EOS) (up to Day 42)] | Number of Participants Based on Severity of AEs [From start of study drug up to EOS (up to Day 42)] | Number of Participants With Clinically Significant Change From Baseline in Vital Signs [Baseline up to EOS (Day 42)] | Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters [Baseline up to EOS (Day 42)] | Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters [Baseline up to EOS (Day 42)]",null,null,"YES",null],["NCT03611582","Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program","STEP 3","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","611","Overweight; Obesity","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2018-08-01","2020-03-18","TRUE","Change in Body Weight (%) [Baseline (week 0) to week 68] | Participants Who Achieve (Yes/no): Body Weight Reduction More Than or Equal to 5% [After 68 weeks]","BACKGROUND:32441473; RESULT:33625476; DERIVED:39226070; DERIVED:38698650; DERIVED:36801984; DERIVED:35724304; DERIVED:30122305","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/82/NCT03611582/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/82/NCT03611582/SAP_001.pdf","YES","OTHER:U1111-1200-8199"],["NCT05567796","A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight","REDEFINE 1","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","3400","Obesity","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo cagrilintide; DRUG:Placebo semaglutide","Novo Nordisk A/S","2022-11-01","2024-10-30","FALSE","CagriSema versus placebo: Relative change in body weight [From baseline (week 0) to end of treatment (week 68)] | CagriSema versus placebo: Achievement of greater than or equal to (>=) 5% weight reduction [From baseline (week 0) to end of treatment (week 68)]","DERIVED:41328546; DERIVED:40544433",null,"YES","OTHER:Universal Trial Number (UTN); EUDRACT_NUMBER:2020-005435-75"],["NCT03444142","Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","30","Diabetes Mellitus, Type 2","DRUG:Exenatide LAR; DRUG:Dulaglutide","University of Guadalajara","2017-11-17","2021-11-30","FALSE","Heart rate: nighttime, daytime and 24-h [Baseline to Week 4] | Systolic blood pressure, daytime, night and 24 h [Baseline to Week 4] | Diastolic blood pressure, daytime, night and 24 h [Baseline to Week 4] | Blood pressure [Baseline to Week 4]",null,null,null,null],["NCT07803705","Efficacy of Mazdutide on Fatty Pancreas",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","QUADRUPLE","194","Fatty Pancreas; Overweight; Obesity","DRUG:mazdutide; OTHER:Placebo matching mazdutide","Tongji Hospital","2026-11-15","2028-06-30","FALSE","Percentage change in Intrapancreatic Fat Deposition (IPFD) from baseline [From baseline to Week 48]",null,null,"NO",null],["NCT06050577","The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","64","Type 2 Diabetes; Osteopenia","DRUG:oral Semaglutide/Rybelsus; DRUG:Placebo","Odense University Hospital","2024-06-07","2027-01-15","FALSE","Procollagen type 1 N-terminal propeptide (P1NP) [Baseline and 52 weeks]",null,null,"NO",null],["NCT06517212","Tirzepatide Weight Loss for MRD+ Early Breast Cancer","TRIM-EBC","RECRUITING","INTERVENTIONAL","PHASE2",null,"NONE","48","Breast Cancer; Breast Neoplasms; Breast Cancers","DRUG:Tirzepatide","Baylor Research Institute","2024-11-26","2029-08-31","FALSE","ctDNA efficacy [2 years] | distant disease-free survival efficacy [2 years]",null,null,null,null],["NCT04616027","STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","42","Diabetes Mellitus, Type 2; Renal Impairment; Healthy","DRUG:PF-06882961 20 mg","Pfizer","2021-01-13","2022-02-18","TRUE","Maximum Observed Plasma Concentration (Cmax) of Plasma PF-06882961 [0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3] | Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Plasma PF-06882961 [0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3] | Area Under the Plasma Concentration-Time Profile From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of Plasma PF-06882961 [0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3] | Fraction Unbound (fu) of Plasma PF-06882961 [0 (pre dose), 4 hours (post dose) on Day 1]","DERIVED:37840155","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/27/NCT04616027/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/27/NCT04616027/SAP_001.pdf","NO",null],["NCT04186494","Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","30","Sleep Apnea, Obstructive","DRUG:Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml; DEVICE:Continuous positive airway pressure treatment; COMBINATION_PRODUCT:Liraglutide and CPAP","St Vincent's University Hospital, Ireland","2019-12-02","2021-12-31","FALSE","Insulin resistance [6 months]","DERIVED:38096106",null,"NO",null],["NCT00754988","A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","666","Diabetes Mellitus Type 2","DRUG:Metformin; DRUG:Placebo (matching sitagliptin); DRUG:Placebo (matching taspoglutide); DRUG:Sitagliptin; DRUG:Taspoglutide","Hoffmann-La Roche","2008-10","2011-03","FALSE","Mean changes in HbA1c [24 weeks]",null,null,null,"OTHER:2008-001854-42; NIH:2008"],["NCT05829460","Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia",null,"WITHDRAWN","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","0","Endometrial Hyperplasia","DRUG:Semaglutide; DRUG:Placebo; DRUG:LNG-IUD (Progestin); BEHAVIORAL:Telemedicine behavioral weight program","Washington University School of Medicine","2025-03-12","2030-04-30","FALSE","Number of patients with endometrial hyperplasia free biopsy with uterine preservation [At 2 years (or exit from study)]",null,null,"NO",null],["NCT07592546","Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss","THRIVE","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","NON_RANDOMIZED","NONE","240","Class I/II Obesity","DRUG:semaglutide","Alain Dagher","2026-08-01","2028-12-01","FALSE","Serum C-reactive Protein (CRP) [Baseline & Change from Baseline] | Serum Pro-inflammatory Cytokines (Interleukin-6, TNF-α, Interleukin-1β, and IL-1 Receptor Antagonist) [Baseline & Change from Baseline] | Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) [Baseline & Change from Baseline] | Fasting Plasma Glucose [Baseline & Change from Baseline] | Glycated Hemoglobin A1c (HbA1c) [Baseline & Change from Baseline] | Serum Leptin [Baseline & Change from Baseline] | Serum Ghrelin [Baseline & Change from Baseline] | Serum Adiponectin [Baseline & Change from Baseline] | Fasting Serum Insulin [Baseline & Change from Baseline] | Serum Glucagon-Like Peptide-1 (GLP-1) [Baseline & Change from Baseline] | Serum C-peptide [Baseline & Change from Baseline] | Serum Lipid Panel (Total Cholesterol, HDL Cholesterol, LDL Cholesterol, Triglycerides, and Non-Esterified Fatty Acids [NEFA]) [Baseline & Change from Baseline] | Serum Apolipoprotein B (ApoB) [Baseline & Change from Baseline] | Red Blood Cell Phospholipid Fatty Acid Composition [Baseline & Change from Baseline] | Cerebral Blood Flow as Measured by Pseudo-Continuous Arterial Spin Labeling (pCASL) MRI [Baseline & Change from Baseline] | Oxygen Extraction Fraction (OEF) as Measured by Quantitative Susceptibility Mapping (QSM) and T2* MRI [Baseline & Change from Baseline] | Cerebral Metabolic Rate of Oxygen (CMRO₂) as Measured by QSM and T2* MRI [Baseline & Change from Baseline] | Cortical Thickness as Measured by Structural MRI [Baseline & Change from Baseline] | Grey Matter Volume as Measured by Structural MRI [Baseline & Change from Baseline] | Grey Matter Surface Area as Measured by Structural MRI [Baseline & Change from Baseline] | White Matter Fractional Anisotropy (FA) as Measured by Diffusion Tensor Imaging (DTI) [Baseline & Change from Baseline] | White Matter Mean Diffusivity (MD) as Measured by Diffusion Tensor Imaging (DTI) [Baseline & Change from Baseline] | White Matter Microstructure as Measured by NODDI (intracellular volume fraction [ICVF], isotropic volume fraction [ISOVF], and Orientation Dispersion Index [ODI]) [Baseline & Change from Baseline] | White Matter Hyperintensity Volume as Measured by FLAIR MRI [Baseline & Change from Baseline] | Cerebrovascular Reactivity (CVR) as Measured by BOLD fMRI with End-Tidal CO₂ (EtCO₂) Challenge [Baseline & Change from Baseline] | Neuroinflammation proxy as Measured by T2* relaxation times [Baseline & Change from Baseline] | Neuromelanin Contrast Ratio in the Substantia Nigra as Measured by Neuromelanin-Sensitive MRI [Baseline & Change from Baseline] | Intracranial Artery Lumen Diameter as Measured by Time-of-Flight MRA [Baseline & Change from Baseline] | Body Mass Index (BMI) [Baseline & Change from Baseline] | Waist Circumference, Hip Circumference [Baseline & Change from Baseline] | Waist-to-height ratio, Waist-to-hip ratio [Baseline & Change from Baseline] | Visceral Adipose Tissue as Measured by MRI [Baseline & Change from Baseline] | Subcutaneous Adipose Tissue as Measured by MRI [Baseline & Change from Baseline] | Body Composition [Baseline & Change from Baseline]",null,null,"YES",null],["NCT07223983","Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","SINGLE","4","Alcohol Use Disorder; Weight Loss; Bariatric Surgery Patients","DRUG:Semaglutide 1.0 mg","Yale University","2026-03-26","2027-02","FALSE","Percent weight change [Baseline, Week 12, 6-month follow-up] | Mean drinks per calendar day to assess alcohol use [Baseline, Week 4, Week 8, Week 12, 6-month follow-up] | Mean drinks per drinking day to assess Alcohol use [Baseline, Week 4, Week 8, Week 12, 6-month follow-up] | Mean number of heavy drinking days to assess Alcohol use [Baseline, Week 4, Week 8, Week 12, 6-month follow-up] | Mean number of drinking vs abstinent days to assess Alcohol use [Baseline, Week 4, Week 8, Week 12, 6-month follow-up]","BACKGROUND:39937469",null,"NO",null],["NCT02140983","Effects of Liraglutide on Hippocampal Structure and Function in Aging Adults With Prediabetes","LGT","COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","41","Insulin Resistance; Dementia","DRUG:Liraglutide; DRUG:Placebo","Stanford University","2013-08","2017-02","FALSE","Cognitive Outcomes [Change from Baseline to 3 months] | OGTT [Change from Baseline to 3 months]",null,null,null,null],["NCT03986008","Effects of Benaglutide on Weight and Gut Microbiota in Obese Patients",null,"UNKNOWN","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","60","Obesity","DRUG:Benaglutide; DRUG:Liraglutide","Xiangya Hospital of Central South University","2019-12-01","2021-12-23","FALSE","Weight Change at 3 months [baseline and 3 months] | Gut microbiota composition [3 months]",null,null,"NO",null],["NCT05946148","Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)","NAMELS-18","COMPLETED","OBSERVATIONAL",null,null,null,"78","Non-Alcoholic Fatty Liver Disease; Liver Steatosis","DRUG:Empagliflozin; DRUG:Dulaglutide; DRUG:Control Rx","National and Kapodistrian University of Athens","2018-06-01","2021-05-31","FALSE","Liver Fat Fraction reduction [52 weeks] | >30% Liver Fat Fraction reduction [52 weeks]",null,null,"YES",null],["NCT06692348","A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","86","Healthy","DRUG:Orforglipron","Eli Lilly and Company","2024-12-13","2025-06-09","FALSE","Pharmacokinetics (PK): Steady-state Area Under the Concentration Versus Time Curve (AUC) of Orforglipron (Fasted State) [Week 3 Through Week 16] | PK: Steady-state Maximum Concentration (Cmax) of Orforglipron (Fasted State) [Week 3 Through Week 16] | PK: Steady-state AUC of Orforglipron (Fed State) [Week 3 Through Week 16] | PK: Steady-state Cmax of Orforglipron (Fed State) [Week 3 Through Week 16]",null,null,"NO","OTHER:J2A-JE-GZPM"],["NCT06771115","Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","175","Obesity","DRUG:Placebo; DRUG:VTX3232 30 mg; DRUG:Placebo in combination with semaglutide; DRUG:VTX3232 30 mg in combination with semaglutide","Zomagen Biosciences Ltd.","2025-01-07","2025-09-10","TRUE","Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) [From the first dose of study treatment to Week 16]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/15/NCT06771115/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/15/NCT06771115/SAP_001.pdf","UNDECIDED","OTHER:J7V-MC-EOBA"],["NCT06072963","COMMETS- Combination MCI Metabolic Syndrome",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","80","Alzheimer Disease; Mild Cognitive Impairment; Metabolic Syndrome","DRUG:Semaglutide; DRUG:Intranasal insulin; OTHER:Semaglutide placebo; OTHER:Intranasal insulin placebo","Rutgers, The State University of New Jersey","2024-01-30","2027-12-01","FALSE","Cognitive change - The effect of the combination of Semaglutide and intranasal insulin on cognitive functioning. [12 months] | Neuroimaging outcome -- The effect of the combination of Semaglutide and intranasal insulin on cerebral blood flow (CBF). [6 months] | Neuroimaging outcome -- The effect of the combination of Semaglutide and intranasal insulin on brain glucose intake. [6 months]","BACKGROUND:26711459; BACKGROUND:27350397; BACKGROUND:32982937; BACKGROUND:31189511; BACKGROUND:31924562; BACKGROUND:32562683; BACKGROUND:12821276; BACKGROUND:19237574; BACKGROUND:32568367; BACKGROUND:28372335; BACKGROUND:34101779; BACKGROUND:34756135; BACKGROUND:34039508; BACKGROUND:30917904; BACKGROUND:30182156; BACKGROUND:33903177; BACKGROUND:21911655; BACKGROUND:18765651; BACKGROUND:30383799; BACKGROUND:29955655; BACKGROUND:30868154; BACKGROUND:25150735; BACKGROUND:33044181; BACKGROUND:28432077; BACKGROUND:9191756; BACKGROUND:3662782; BACKGROUND:18367931; BACKGROUND:23687103; BACKGROUND:27488909; BACKGROUND:27255817; BACKGROUND:32588967; BACKGROUND:33585983; BACKGROUND:30984815; BACKGROUND:30760178; BACKGROUND:35079029; BACKGROUND:18430999; BACKGROUND:34305810; BACKGROUND:36871874; BACKGROUND:29687620; BACKGROUND:22015237; BACKGROUND:35482079; BACKGROUND:31022213; BACKGROUND:17848936; BACKGROUND:33222922; BACKGROUND:12925848; BACKGROUND:8563978; BACKGROUND:30944040; BACKGROUND:30635783; BACKGROUND:33831607; BACKGROUND:33849249; BACKGROUND:33461618; BACKGROUND:29959217; BACKGROUND:23332364; BACKGROUND:33887983; BACKGROUND:32716707; BACKGROUND:34636161; BACKGROUND:16112245; BACKGROUND:32296731",null,"NO",null],["NCT04189848","Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","104","Healthy Volunteers; Diabetes Mellitus, Type 2; Overweight; Obesity","DRUG:Semaglutide; DRUG:Dulaglutide","Novo Nordisk A/S","2019-12-03","2020-01-29","TRUE","Intensity of Injection Site Pain [1 minute after each injection (Day 1)]","RESULT:33591618","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/48/NCT04189848/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/48/NCT04189848/SAP_001.pdf","YES","REGISTRY:2019-83003844-57; OTHER:U1111-1241-0348; NIH:2019"],["NCT07107334","A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia",null,"RECRUITING","INTERVENTIONAL","PHASE2",null,"NONE","20","Endometrioid Endometrial Adenocarcinoma","DRUG:Glucagon-like peptide 1 receptor agonist","University of Florida","2026-04-07","2028-11","FALSE","Time from start of GLP-1RA to clearance of staging hysterectomy [12 months] | Time from start of GLP-1RA to clearance for pregnancy pursuit [12 months] | Endometrial pathologic response [6 months after beginning GLP-1RA treatment] | Endometrial pathologic response [12 months after beginning GLP-1RA treatment]",null,null,null,null],["NCT03993132","A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes",null,"COMPLETED","OBSERVATIONAL",null,null,null,"26774","Diabetes Mellitus, Type 2","DRUG:Empagliflozin; DRUG:Liraglutide","Boehringer Ingelheim","2018-10-01","2022-06-16","TRUE","Incidence Rate of Expanded Major Adverse Cardiovascular Event (MACE) Composite Outcome - OT Analysis [From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years.] | Incidence Rate of Expanded Major Adverse Cardiovascular Event (MACE) Composite Outcome - ITT Analysis [From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years.]","DERIVED:36315384","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/32/NCT03993132/Prot_SAP_000.pdf","NO",null],["NCT01652716","Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes","DURATION-NEO-1","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","377","Diabetes Mellitus, Type 2","DRUG:Exenatide once weekly suspension; DRUG:Exenatide twice daily","AstraZeneca","2013-01","2014-08","TRUE","Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28 [Baseline to Week 28]","DERIVED:33037036; DERIVED:28685973",null,null,"OTHER:MB001-003"],["NCT07767552","Mazdutide for Remission of Type 2 Diabetes: Multicentre, Double Blind, Randomised, Placebo Controlled Trial",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","TRIPLE","249","Diabetes Mellitus, Type 2","DRUG:Mazdutide; DRUG:Placebo","Yanbing Li","2026-09-30","2028-08-30","FALSE","Proportion of Participants Achieving Normal Glucose Regulation (NGR) at Week 44 [Baseline, 44 weeks]",null,null,"NO",null],["NCT06772532","A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the Body",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","30","Healthy","COMBINATION_PRODUCT:BI 456906 - Formulation A; DRUG:BI 456906 - Formulation B; DRUG:BI 456906 - Formulation C","Boehringer Ingelheim","2025-02-10","2025-05-29","FALSE","Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) [Up to 22 days] | Maximum measured concentration of the analyte in plasma (Cmax) [Up to 22 days]",null,null,"NO","REGISTRY:2024-516529-30-00; REGISTRY:U1111-1310-7283"],["NCT01938235","Exenatide for Myocardial Protection During Reperfusion Study","EMPRES","UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","198","Myocardial Infarction","DRUG:Exenatide; DRUG:Placebo","University Health Network, Toronto","2014-02","2017-07","FALSE","Ratio of final infarct size at 3 months over area at risk at 72 hours post randomization (using cMRI) [3 months]",null,null,"UNDECIDED","OTHER:9427-D0416-21C"],["NCT02461589","Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","706","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2015-09-21","2016-10-13","TRUE","Change in HbA1c (Glycosylated Haemoglobin) [Week 0, week 26]","RESULT:30026333",null,null,"EUDRACT_NUMBER:2014-003196-39; OTHER:U1111-1159-4923; NIH:2014"],["NCT02958085","Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","96","Metabolism and Nutrition Disorder; Obesity","DRUG:NNC0174-0833; DRUG:Placebo","Novo Nordisk A/S","2016-11-04","2018-01-24","FALSE","Number of treatment emergent adverse events (TEAEs) [From time of first dosing (Day 1) to the post-treatment follow-up visit (Day 99)]",null,null,null,"OTHER:U1111-1131-7209"],["NCT00154401","Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","177","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2005-01","2005-10","FALSE","HbA1c [after 14 weeks treatment]","RESULT:18201212; RESULT:19183322; RESULT:17372153; RESULT:18435773; RESULT:25504028",null,null,null],["NCT02773381","A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","15","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2016-06-02","2018-10-19","FALSE","Area under the serum glucose concentration-time curve [At 12 weeks of treatment]","RESULT:33184979",null,null,"EUDRACT_NUMBER:2015-003998-14; OTHER:U1111-1174-1070; NIH:2015"],["NCT06821919","Impact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps)","NETs","RECRUITING","OBSERVATIONAL",null,null,null,"70","Diabetes Mellitus; Kidney Disease",null,"Western Galilee Hospital-Nahariya","2024-05-13","2030-12-30","FALSE","NETosis marker- citrullinated histone H3 (citH3) [Before treatment, 1,2 , 3, 6 and 12 months after starting anti-diabetic drugs or immunosuppression] | NETosis marker- Myeloperoxidase [Before treatment, 1,2,3,6 and12 moths after treatment.] | NETosis marker- Neutrophil elastase (NE) [Before treatment, 1,2 , 3, 6 and 12 months after starting anti-diabetic drugs or immunosuppression] | NETosis marker: Peptidylarginine deiminase 4-PAD4 [Before treatment, 1,2 , 3, 6 and 12 months after starting anti-diabetic drugs or immunosuppression]",null,null,"YES",null],["NCT06565611","A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity","BMT-801","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","108","Obesity","DRUG:bremelanotide; DRUG:tirzepatide","Palatin Technologies, Inc","2024-08-05","2025-02-05","FALSE","Percent change in body weight between treatment arms [Change from the baseline (Visit 2/Day 1) to Visit 10 (Day 57)]",null,null,"NO",null],["NCT02300844","Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","54","Metabolism and Nutrition Disorder; Obesity","DRUG:NNC0174-0833; DRUG:placebo","Novo Nordisk A/S","2014-12-01","2016-03-21","FALSE","Number of treatment emergent adverse events (TEAEs) [From the time of dosing (Day 1) until completion of the post treatment follow-up visit (Day 43-50)]",null,null,null,"OTHER:U1111-1131-7160"],["NCT06606821","The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease","IDEAL-COR","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","124","Coronary Artery Disease; Coronary Microvascular Dysfunction; Overweight or Obesity; Stable Angina Pectoris; Chronic Coronary Artery Disease; Atherosclerosis Cardiovascular Disease","DRUG:Tirzepatide; DRUG:Placebo","Tina Vilsbøll","2024-10-01","2027-03-20","FALSE","Lipid core burden index [Between-group difference in change from baseline to week 52 in participants treated with tirzepatide vs placebo:]","BACKGROUND:35658024; BACKGROUND:34724592; BACKGROUND:30473097; BACKGROUND:30293770; BACKGROUND:34170647; BACKGROUND:31422062; BACKGROUND:31401015; BACKGROUND:36507646; BACKGROUND:31189511; BACKGROUND:30291013; BACKGROUND:27295427; BACKGROUND:27633186; BACKGROUND:21525448; BACKGROUND:9440661; BACKGROUND:29228169; BACKGROUND:31448673; BACKGROUND:20061546; BACKGROUND:32052833; BACKGROUND:32437302; BACKGROUND:26685971; BACKGROUND:18188451; BACKGROUND:24355497; BACKGROUND:14679176; BACKGROUND:25577445; BACKGROUND:26242984; BACKGROUND:25537494; BACKGROUND:33693121; BACKGROUND:28881268; BACKGROUND:27989886; BACKGROUND:23644090; BACKGROUND:35718858; BACKGROUND:27115820; BACKGROUND:32746822; BACKGROUND:23288155; BACKGROUND:10807742; BACKGROUND:31378814; BACKGROUND:33309175; BACKGROUND:25182248; BACKGROUND:24060894",null,"YES","CTIS:2023-505270-15-00; NIH:2023"],["NCT02898506","Incretin-based Therapy in Late Preclinical Type 1 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","13","Type 1 Diabetes","DRUG:Victoza®; DRUG:Placebo","University of Oulu","2016-03","2021-06","FALSE","FPIR (1+3min serum insulin level after iv glucose infusion) [12 months]","DERIVED:35797241",null,null,"EUDRACT_NUMBER:2014-004761-25; OTHER:U1111-1177-0704; OTHER_GRANT:3-SRA-2014-301-M-R; NIH:2014"],["NCT04657016","A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program","SURMOUNT-3","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","579","Obesity; Overweight","DRUG:Tirzepatide; OTHER:Placebo","Eli Lilly and Company","2021-03-29","2023-04-20","TRUE","Percent Change From Baseline in Body Weight [Baseline, 72 Weeks] | Percentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction [Week 72]","DERIVED:41885866; DERIVED:41640675; DERIVED:41537305; DERIVED:41187013; DERIVED:40717199; DERIVED:37840095","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/16/NCT04657016/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/16/NCT04657016/SAP_001.pdf","YES","OTHER:I8F-MC-GPHM"],["NCT06650007","the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","218","Diabetes Mellitus, Type 2","DRUG:HRS9531 Injection; DRUG:HRS9531 Placebo Injection","Fujian Shengdi Pharmaceutical Co., Ltd.","2024-11-08","2026-01-21","FALSE","Change in HbA1c [from baseline to 36 weeks treatment]",null,null,"UNDECIDED",null],["NCT06161844","Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","506","Type 2 Diabetes Mellitus","DRUG:semaglutide injection (HD1916); DRUG:Ozempic®","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","2024-02-23","2025-05-14","FALSE","Change from baseline to week 32 in glycosylated haemoglobin (HbA1c) [Week 32]",null,null,"NO",null],["NCT01392898","Liraglutide and Insulin Therapy in Patients With Type 2 Diabetes","ELEGANT","UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","NONE","50","Type 2 Diabetes Mellitus","DRUG:liraglutide; DRUG:Insulin","Radboud University Medical Center","2012-02","2014-05","FALSE","Body weight change (measured body weight at 26 weeks minus baseline body weight) [26 weeks (26 weeks - baseline)]","DERIVED:24947583",null,null,null],["NCT01235819","Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","20","Type 1 Diabetes","DRUG:Insulin; DRUG:Sitagliptin; DRUG:Exenatide","Command Hospital, India","2010-11","2011-09","FALSE","change in insulin requirement [one year]","DERIVED:23490599",null,"NO",null],["NCT06557811","Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction","SemaFatCard","UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","88","Diabetic Patients; Acute Myocardial Infarction","DRUG:Semaglutide","University of Sao Paulo General Hospital","2024-09-01","2024-09-01","FALSE","Measurement of pericardial adipose tissue at 180 days [180 days] | Measurement of the fat attenuation index at 180 days [180 days] | Measurement of the perivascular adipose tissue attenuation index at 180 days [180 days]","BACKGROUND:28814394; BACKGROUND:24272604; BACKGROUND:29675684; BACKGROUND:29704210; BACKGROUND:28721155; BACKGROUND:29167227; BACKGROUND:28246237; BACKGROUND:26886418; BACKGROUND:28253918; BACKGROUND:14633821; BACKGROUND:20363161; BACKGROUND:29098638; BACKGROUND:26560351; BACKGROUND:26328952; BACKGROUND:25925354; BACKGROUND:25850659; BACKGROUND:16940192; BACKGROUND:28444175; BACKGROUND:30287946; BACKGROUND:28701474; BACKGROUND:33778665; RESULT:28762019","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/11/NCT06557811/Prot_SAP_000.pdf",null,null],["NCT03712098","Daily Liraglutide for Nicotine Dependence","DAL","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","40","Smoking Cessation; Weight, Body","DRUG:Liraglutide; DRUG:Placebo; BEHAVIORAL:Smoking Cessation Counseling","Rebecca Ashare","2018-11-29","2022-05-25","TRUE","Number of Participants With 7-day Point Prevalence Smoking Abstinence at 12 Weeks Post-Target Quit Date [Week 18] | Number of Participants With 7-day Point Prevalence Smoking Abstinence at 26 Weeks Post-Target Quit Date [Week 32]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/98/NCT03712098/Prot_SAP_000.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/98/NCT03712098/ICF_002.pdf","NO",null],["NCT01832532","A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks",null,"COMPLETED","INTERVENTIONAL","PHASE1; PHASE2","NON_RANDOMIZED","NONE","34","Sleep Apnea; Sleep Disordered Breathing","DRUG:liraglutide","Children's Hospital Medical Center, Cincinnati","2013-04","2015-12","TRUE","Change in Apnea Hypopnea Index (AHI) From Baseline [Baseline and 4 weeks]",null,null,"UNDECIDED","NIH:UL1RR026314"],["NCT00676338","Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","820","Type 2 Diabetes Mellitus","DRUG:exenatide once weekly; DRUG:metformin; DRUG:sitagliptin; DRUG:pioglitazone","AstraZeneca","2008-11","2010-07","TRUE","Change in HbA1c From Baseline to Week 26 [Baseline, Week 26] | Percentage of Patients Achieving HbA1c <=7% at Week 26 [Baseline, Week 26]","DERIVED:32306296; DERIVED:23748507; DERIVED:23748506; DERIVED:23522121; DERIVED:22210563",null,null,null],["NCT06608433","Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function","PIANO","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","TRIPLE","22","Healthy Volunteer Study; HPA; Cortisol Deficiency; Adrenal Insufficiency","DRUG:semaglutide; DRUG:Placebo","University Hospital, Basel, Switzerland","2025-01-16","2025-10-31","FALSE","Change in serum cortisol after Rybelsus vs. Placebo [within 210 minutes after the intake of the study drug]",null,null,"NO",null],["NCT03375463","A Study of Tirzepatide (LY3298176) in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","52","Healthy","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2017-12-19","2018-12-27","TRUE","Pharmacokinetics (PK) Part A: Area Under the Concentration Versus Time Curve [AUC (0-∞)] of Tirzepatide [Part A: Predose, 8, 12, 24, 48, 72, 96, 120, 144, 168, 336, 480, 816-864 hours postdose] | PK Part A: Maximum Observed Drug Concentration (Cmax) of Tirzepatide [Part A: Predose, 8, 12, 24, 48, 72, 96, 120, 144, 168, 336, 480 and 816-864 hours postdose] | PK Part B: Area Under the Concentration Versus Time Curve [AUC (0-∞)] of Tirzepatide [Part B: Predose, 0.08 hours (h), 0.16h, 0.5h, 1h, 2h, 4h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h, 336h, 816h-864h and >=70 days post dose]",null,"Study Protocol: GPGE 05 Protocol Addenda (1)|https://cdn.clinicaltrials.gov/large-docs/63/NCT03375463/Prot_000.pdf; Study Protocol: GPGE 05 Protocol (a)|https://cdn.clinicaltrials.gov/large-docs/63/NCT03375463/Prot_001.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/63/NCT03375463/SAP_002.pdf","NO","OTHER:I8F-MC-GPGE"],["NCT01876849","An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3",null,"NONE","275","Type 2 Diabetes Mellitus","DRUG:exenatide","AstraZeneca","2003-12","2008-07","FALSE","Long-term safety of twice-daily exenatide treatment, as defined by the occurrence of adverse events. [128 weeks (average treatment period)]",null,null,null,null],["NCT07836140","A Study Comparing the Effects of BGM0504 Injection and Semaglutide Injection on Obese Subjects.",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","60","Obesity / Overweight","DRUG:semaglutide; DRUG:BGM0504 Administered SC","Second Affiliated Hospital of Soochow University","2024-04-22","2025-04-25","FALSE","HOMA2-β index [Target dose at week 16] | HOMA2-IR [Target dose at week 16] | MFI [Target dose at week 16]",null,null,"NO",null],["NCT07605052","A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","50","Overweight; Obesity","DRUG:Cagrilintide B; DRUG:Cagrilintide D","Novo Nordisk A/S","2026-05-20","2026-08-19","FALSE","AUCss: area under the total cagrilintide concentration-time curve at steady state after 5th dosing of cagrilintide [From Pre-dose at Day 29 to Day 36] | Cmax,ss: maximum observed concentration of total cagrilintide at steady state after 5th dosing of cagrilintide [From Pre-dose at Day 29 to Day 36]",null,null,"YES","OTHER:U1111-1336-5994"],["NCT03347968","Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","22","Healthy Volunteers","BIOLOGICAL:MEDI0382; DRUG:Warfarin; DRUG:Esmolol","MedImmune LLC","2017-11-27","2018-04-09","FALSE","Maximum international normalized ratio (INRmax) [Days 2-8 and Days 27-33] | Change in heart rate from resting after a 9-minute excercise treadmill test (Bruce Protocol, first 3 stages) [Days 1 and 26]",null,null,null,null],["NCT02201550","Study of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide",null,"COMPLETED","OBSERVATIONAL",null,null,null,"9","Type 2 Diabetes Mellitus",null,"Hvidovre University Hospital","2013-02","2014-04","FALSE","Change in number of specific immune cells in blood detected by flow cytometry [Before and 12 weeks after initiation of liraglutide treatment]",null,null,null,null],["NCT07707778","Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV",null,"ENROLLING_BY_INVITATION","INTERVENTIONAL","PHASE4","NON_RANDOMIZED","NONE","60","Human Immunodeficiency Virus (HIV); Metabolic Dysfunction Associated Steatotic Liver Disease; Dyslipidaemia; Diabetes Mellitus; Obesity & Overweight; Metabolic Syndrome","DRUG:Tirzepatide","National Taiwan University Clinical Trial Center","2026-06-25","2027-12","FALSE","Second generation epigenetic aging clock [Baseline, week 33, week 57] | Third generation epigenetic aging clock [Baseline, week 33, week 57]",null,null,"NO",null],["NCT06575738","Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents","PRESSURE","RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","SINGLE","40","Obesity; Adolescent Obesity; Body-Weight Trajectory; Weight Loss Trajectory; Bariatric Surgery; Anti-obesity Agents","DRUG:Injectable semaglutide or injectable tirzepatide; BEHAVIORAL:Standard postoperative care","University of Colorado, Denver","2024-10-11","2027-09-01","FALSE","Observational phase: Change in fasting glucagon-like peptide-1 (GLP1), measured by blood levels [Baseline, 6 months postoperatively] | Observational phase: Change in stimulated glucagon-like peptide-1 (GLP1), measured by blood levels [Baseline, 6 months postoperatively] | Observational phase: Change in insulin sensitivity (IS), measured by fasting blood insulin levels [Baseline, 6 months postoperatively] | Observational phase: Change in percent fat free mass (FFM), measured by whole body dual-energy X-ray absorptiometry (DXA) [Baseline, 6 months postoperatively] | Observational phase: Change in resting metabolic rate (RMR), measured by canopy indirect calorimetry [Baseline, 6 months postoperatively] | Observational phase: Change in 24 hour systolic blood pressure (BP), measured by ambulatory BP monitor [Baseline, 6 months postoperatively] | Observational phase: Change in indexed left ventricular mass (g/m to the 2.7th power), measured by echocardiogram [Baseline, 6 months postoperatively] | Intervention phase: Change in BMI [Baseline, 26 weeks]",null,null,null,"NIH:5K23HL163480-02"],["NCT05419726","Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.",null,"RECRUITING","OBSERVATIONAL",null,null,null,"20","Obesity","DRUG:Semaglutide Injectable Product (not provided by the study)","University of California, Los Angeles","2023-02-01","2026-01-01","FALSE","change in supraclavicular temperature with cold exposure [20weeks] | change in caloric intake [20weeks] | basal metabolic rate [20 weeks]","BACKGROUND:31337027; BACKGROUND:33261539; BACKGROUND:19357406; BACKGROUND:25677914; BACKGROUND:24954193; BACKGROUND:29802209; BACKGROUND:24917578; BACKGROUND:29650350; BACKGROUND:22933116; BACKGROUND:35069450; BACKGROUND:29847161; BACKGROUND:15277417; BACKGROUND:32127340; BACKGROUND:22446097; BACKGROUND:22735035; BACKGROUND:31982480; BACKGROUND:14530470; BACKGROUND:22677567; BACKGROUND:17873125; BACKGROUND:24238856",null,"NO",null],["NCT01610934","The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)",null,"COMPLETED","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","QUADRUPLE","15","Maturity-onset Diabetes of the Young","DRUG:liraglutide; DRUG:Glimepiride","University Hospital, Gentofte, Copenhagen","2012-08","2013-08","FALSE","Fasting Plasma Glucose [14 weeks]","DERIVED:24929431",null,null,"EUDRACT_NUMBER:2012-000592-17"],["NCT06893211","Effect of Tirzepatide on Brown Adipose Tissue in Obesity","TABFAT","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","SINGLE","34","Obesity","DRUG:Tirzepatide; DRUG:Placebo","University Medical Centre Ljubljana","2025-03-18","2025-11-29","FALSE","Change in Brown Adipose Tissue Activity and Volume [Baseline to Week 24] | Change in Molecular Markers of Browning in Subcutaneous White Adipose Tissue [Baseline to Week 24]","DERIVED:40847412",null,"YES",null],["NCT05745701","A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","16","Healthy","DRUG:PF-07081532; DEVICE:Cyclosporine; DRUG:Itraconazole","Pfizer","2023-02-22","2023-05-29","TRUE","Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Lotiglipron When Administered Alone and With Itraconazole or Cyclosporine [Pre-dose of lotiglipron and at 0.5, 1, 2, 4, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120, and 144 (for Period 3 only) hours post dose of lotiglipron on Day 1 of Periods 1 and 2 and on Day 4 of Period 3.]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/01/NCT05745701/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/01/NCT05745701/SAP_001.pdf","NO",null],["NCT07509307","AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain","AMAZE 6","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","400","Obesity; Overweight; Osteoarthritis, Knee","DRUG:NNC0487-0111; DRUG:Placebo (matched to NNC0487-0111)","Novo Nordisk A/S","2026-04-20","2028-08-14","FALSE","Relative change in body weight [From baseline (week 0) to week 80] | Change in Western Ontario and McMaster Universities Osteoarthritis Index Numerical Rating Scale (NRS) 3.1 (24-hour) (WOMAC) pain score [From baseline (week 0) to week 80]",null,null,"YES","OTHER:U1111-1313-6954; OTHER:2024-520445-23"],["NCT02928471","Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Loss","IM-LOSEIT-I","COMPLETED","OBSERVATIONAL",null,null,null,"200","Osteoarthritis; Obesity","DIETARY_SUPPLEMENT:Intensive dietary intervention","Henrik Gudbergsen","2016-11","2019-02","FALSE","Change in the degree of inflammation in the knee-joint (DCE-MRI) [Week -8 to 0]",null,null,null,null],["NCT06754163","Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients","STEP@STAH","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE4",null,"NONE","20","Obesity and Obesity-related Medical Conditions; Psychiatric Disorders","DRUG:Semaglutide in combination with a healthy lifestyle intervention (diet and exercise)","St Andrew's Healthcare","2025-01-01","2027-07-31","FALSE","Weight [36 months] | Body mass index [36 months] | Waist circumference [36 months] | Blood pressure [36 months] | Heart rate [36 months]","DERIVED:41364787",null,"YES",null],["NCT06010004","A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes","ACHIEVE-J","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","401","Type 2 Diabetes","DRUG:Orforglipron","Eli Lilly and Company","2023-09-28","2025-06-05","TRUE","Number of Participants With Treatment Emergent Adverse Events (TEAEs) [Baseline to Week 54]","DERIVED:42607698","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/04/NCT06010004/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/04/NCT06010004/SAP_001.pdf","YES","OTHER:J2A-JE-GZPE"],["NCT04538352","Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D","TRANSITION-T2D","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","60","Type 2 Diabetes","DRUG:Semaglutide; DRUG:Insulin Degludec; DRUG:Insulin aspart","The Cleveland Clinic","2021-01-18","2023-03-31","TRUE","Mean Change in HbA1C ≤ 7.5% [26 weeks]","RESULT:39532398","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/52/NCT04538352/Prot_SAP_000.pdf","NO",null],["NCT06632444","LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","1800","Metabolic Dysfunction Associated Steatohepatitis (MASH); Liver Fibrosis","COMBINATION_PRODUCT:Survodutide; COMBINATION_PRODUCT:Placebo","Boehringer Ingelheim","2024-10-14","2031-12-27","FALSE","Part 1: Resolution of MASH without worsening of liver fibrosis on MASH Clinical Research Network (CRN) fibrosis score [Baseline and at Week 52.] | Part 1: At least a 1-point improvement in fibrosis stage with no worsening of MASH [Baseline and at Week 52.] | Part 2: Time to first occurrence of any of components of the composite endpoint consisting of progression to cirrhosis, all-cause mortality, liver transplant, hepatic decompensation event(s), worsening of MELD score to ≥15, progression to CSPH [Up to 7 years.]",null,null,"YES","REGISTRY:2024-513739-25-00; REGISTRY:U1111-1306-9071"],["NCT07441252","A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","180","Overweight or Obesity and Elevated Liver Fat","DRUG:Maridebart cafraglutide; DRUG:Placebo","Amgen","2026-03-05","2027-08-25","FALSE","Percent Change from Baseline in Liver Fat Content by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) at Week 52 [Baseline and Week 52] | Percent Change from Baseline in Body Weight at Week 52 [Baseline and Week 52]",null,null,"YES",null],["NCT06909006","Semaglutide Treatment in Type 1 Diabetes","OBES1TY","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","122","Obesity in Diabetes; Obesity/Therapy; Type 1 Diabetes Mellitus (T1DM); Insulin Sensitivity/Resistance; Semaglutide; Lipidomics; Metabolomics; Weight Loss; Glycemic Control for Diabetes Mellitus","DRUG:Semaglutide 2.4mg; DRUG:Semaglutide placebo","Nordsjaellands Hospital","2025-10","2028-06","FALSE","Body weight [74 weeks]",null,null,"YES",null],["NCT02754817","A Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus",null,"COMPLETED","OBSERVATIONAL",null,null,null,"611","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide","Novo Nordisk A/S","2016-04-26","2016-10-20","FALSE","Change in HbA1c (Hemoglobin A1c) [week 0, week 26]","RESULT:29205856",null,null,"OTHER:U1111-1176-6538"],["NCT04287179","SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes","SUSTAIN SWITCH","WITHDRAWN","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","0","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2020-03-09","2020-11-16","FALSE","Change in glycosylated haemoglobin (HbA1c) [From baseline (week 0) to week 12]",null,null,"YES","OTHER:U1111-1242-5426; REGISTRY:2019-004234-42; NIH:2019"],["NCT05443191","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice","PIONEER REAL","COMPLETED","OBSERVATIONAL",null,null,null,"50","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2022-10-20","2023-04-27","FALSE","Change in Glycated haemoglobin (HbA1c ) [From baseline (week 0) to End of Study visit (V3) (week 34-44)]",null,null,"YES","OTHER:U1111-1240-3808"],["NCT01254123","Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial)","EXAMI","UNKNOWN","INTERVENTIONAL","PHASE3","RANDOMIZED","SINGLE","40","Patients With a First Acute Myocardial Infarction to be Treated With Primary Percutaneous Coronary Intervention (PCI).","DRUG:Exenatide infusion; DRUG:Placebo infusion.","Amsterdam UMC, location VUmc","2009-11",null,"FALSE","Safety of GLP-1 receptor agonist Exenatide infusion compared to placebo in patients with an acute myocardial infarction undergoing primary PCI []","DERIVED:28286967; DERIVED:22067476",null,null,null],["NCT04605861","The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","414","Obese; Overweight","DRUG:Liraglutide; DRUG:Placebo","Shanghai Zhongshan Hospital","2020-08-18","2022-12-31","FALSE","The percentage of body weight loss [through study completion, an average of 32 weeks] | The proportion of body weight loss ≥ 5 percent [through study completion, an average of 32 weeks]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/61/NCT04605861/Prot_SAP_000.pdf","NO",null],["NCT07622810","BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","352","Obesity & Overweight","DRUG:Bofanglutida; DRUG:Semaglutide","Carnot Laboratories","2026-09","2027-12","FALSE","Percent Change in Body Weight From Baseline to Week 36 [Baseline to Week 36]",null,null,"NO",null],["NCT06939088","Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder","DUALPSYCHIATRY","RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","108","Alcohol Use Disorder; Alcohol Abuse/Dependence; Alcohol Dependence; Alcoholism; Schizophrenia Disorders; Schizophrenia and Disorders With Psychotic Features; Schizophrenia and Schizophrenia Spectrum Psychosis; Schizophrenia","DRUG:Tirzepatide; DRUG:Placebo","Anders Fink-Jensen, MD, DMSci","2025-05-05","2028-08-01","FALSE","Change in heavy drinking days [From baseline to 16 weeks of treatment]",null,null,"YES","REGISTRY:U1111-1312-8134; REGISTRY:2024-518608-28-00"],["NCT06297603","Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","320","Type 2 Diabetes","DRUG:Retatrutide; DRUG:Placebo","Eli Lilly and Company","2024-03-15","2026-10","FALSE","Change from Baseline in Hemoglobin A1c (HbA1c) (%) [Baseline, Week 52]",null,null,"YES","OTHER:J1I-MC-GZQA"],["NCT06027567","The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure","IIH:DUAL","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","38","Idiopathic Intracranial Hypertension; Intracranial Pressure; Obesity; Pseudotumor Cerebri Syndrome; Papilledema; Weight Loss","DRUG:Semaglutide; DIETARY_SUPPLEMENT:Very Low Calorie Diet; BEHAVIORAL:Dietician counselling","Rigmor Højland Jensen","2022-09-02","2025-01-28","FALSE","Weight [8 weeks] | Intracranial pressure [8 weeks]",null,null,"NO",null],["NCT03919929","Treating PCOS With Semaglutide vs Active Lifestyle Intervention","TEAL","COMPLETED","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","NONE","60","PCOS; Adolescent Obesity; NAFLD","DRUG:Semaglutide 3mg and 7mg [Rybelsus]; OTHER:Weight loss diet","University of Colorado, Denver","2019-05-03","2023-10-03","TRUE","Change in Hepatic Fat Fraction [Baseline and 12 weeks] | Change in Weight [Baseline and 12 weeks]","DERIVED:42014131","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/29/NCT03919929/Prot_SAP_000.pdf","NO","NIH:1R01DK120612-01A1"],["NCT05611957","A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","29","Healthy; Renal Insufficiency","DRUG:LY3437943","Eli Lilly and Company","2022-11-16","2023-09-05","FALSE","Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3437943 [Predose up to 31 days postdose] | PK: Maximum observed concentration (Cmax) of LY3437943 [Predose up to 31 days postdose]",null,null,"NO","OTHER:J1I-MC-GZBL"],["NCT00943501","Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","21","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2009-11","2011-09","FALSE","Number and type of adverse events [up to 8 weeks]","RESULT:25036533; RESULT:25603819",null,null,"OTHER:U1111-1111-9256; EUDRACT_NUMBER:2010-021057-39"],["NCT05768945","Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors",null,"COMPLETED","OBSERVATIONAL",null,null,null,"742670","Diabetes","DRUG:Semaglutide; DRUG:DPP-4 inhibitor","Brigham and Women's Hospital","2022-11-30","2023-07-07","TRUE","Time to Dementia Onset [Median follow up times: 1) 98 days (exp), 134 days (ref) 2) 118 days (exp), 132 days (ref) 3) 90 days (exp), 308 days (ref) 4) 99 days (exp), 135 days (ref)]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/45/NCT05768945/Prot_SAP_000.pdf",null,null],["NCT07284875","Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes","KaiNETIC-1","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","2530","Obesity; Overweight","DRUG:Ribupatide; DRUG:Placebo","Kailera","2025-12-18","2028-02","FALSE","Dose 3 and 4 versus Placebo: Percent Change From Baseline in Body Weight at Week 76 [Baseline, Week 76]",null,null,"NO","CTIS:2025-523486-17-00; NIH:2025"],["NCT01147731","A Drug Interaction Study With Albiglutide and Warfarin",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","16","Diabetes Mellitus, Type 2","BIOLOGICAL:warfarin plus albiglutide","GlaxoSmithKline","2010-06-04","2010-09-09","FALSE","The pharmacokinetic parameters (AUC and Cmax) of R and S-warfarin isomers with and without albiglutide [52 days]","BACKGROUND:23322139; DERIVED:25387217",null,"YES",null],["NCT07121153","A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants When Injected Under the Skin.",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","36","Overweight; Obesity","DRUG:NNC0487-0111 A; DRUG:Placebo A","Novo Nordisk A/S","2025-08-11","2025-12-20","FALSE","Number of treatment emergent adverse events (TEAEs) [From NNC0487-0111 administration (Day 1) to completion of the end of study visit (Day 23)]",null,null,"YES","OTHER:U1111-1311-5582"],["NCT01297062","A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","94","Healthy Subjects","DRUG:Exenatide; DRUG:Moxifloxacin; DRUG:Placebo comparator","AstraZeneca","2011-02","2011-04","TRUE","Comparison of Least Squares (LS) Mean Changes From Baseline in Population-based Corrected QT Intervals (QTcP) Between Exenatide and Placebo on Day 1 Averaged Over 1300h, 1400h, 1500h (Target Steady State Exenatide Concentration of 200 pg/mL) [Baseline, Day 1] | Comparison of LS Mean Changes From Baseline in QTcP Intervals Between Exenatide and Placebo on Day 2 Averaged Over 1300h, 1400h, 1500h (Target Steady State Exenatide Concentration of 300 pg/mL) [Baseline, Day 2] | Comparison of LS Mean Changes From Baseline in QTcP Intervals Between Exenatide and Placebo on Day 3 Averaged Over 1300h, 1400h, 1500h (Target Steady State Exenatide Concentration of 500 pg/mL) [Baseline, Day 3]",null,null,null,null],["NCT03350191","A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","13","Type 2 Diabetes Mellitus","DRUG:SAR425899; DRUG:[68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer); DRUG:[68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)","Sanofi","2017-12-20","2018-06-07","FALSE","Glucagon receptor occupancy [Day 1 and Day 20]","DERIVED:34503957",null,"YES","OTHER:2017-001789-23; NIH:2017"],["NCT07859150","Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE)",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","104","Morbid Obesity","DRUG:Semaglutide weekly injection; DRUG:Placabo","General Committee of Teaching Hospitals and Institutes, Egypt","2026-10","2029-04","FALSE","Mean percentage change in body weight from randomization [week 0 to week 68]",null,null,"YES",null],["NCT07206290","Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease","ARTIST-CKD","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","120","Chronic Kidney Disease","DRUG:Survodutide (BI 456906); DRUG:Placebo","University Medical Center Groningen","2026-03-02","2027-11-30","FALSE","Change in first morning void UACR [From baseline to week 32/36]",null,null,"NO","CTIS:2025-523184-37-00; NIH:2025"],["NCT00909597","A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","756","Diabetes Mellitus Type 2","DRUG:pioglitazone; DRUG:taspoglutide","Hoffmann-La Roche","2009-05","2010-11","FALSE","Absolute change from baseline in HbA1c [24 weeks]",null,null,null,"OTHER:2009-009157-24; NIH:2009"],["NCT05607680","A Study of IBI362 in Participants With Obesity or Overweight",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","610","Obesity Or Overweight","DRUG:Placebo; DRUG:IBI362","Innovent Biologics (Suzhou) Co. Ltd.","2022-11-14","2023-08-21","FALSE","Percent Change from Baseline in Body Weight [Baseline, Week 32] | Percentage of Participants who Achieve ≥5% Body Weight Reduction [Week 32]","DERIVED:40421736",null,null,null],["NCT02092896","Liraglutide as add-on to Insulin in Type 1 Diabetes","T1DMLIRA","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","40","Diabetes; Diabetes Mellitus, Type 1","DRUG:Liraglutide; DRUG:Placebo","Hvidovre University Hospital","2013-03","2014-10","FALSE","Change from baseline in HbA1c (glycosylated haemoglobin) [Week 0, week 12] | Changes from baseline in EEG and cognitive performances [week 0, week 12] | Change from baseline in gastric emptying rate [week 0, week 12]","DERIVED:26486191",null,null,"EUDRACT_NUMBER:2012-002526-67"],["NCT00313001","Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","373","Diabetes; Diabetes Mellitus, Type 2","DRUG:biphasic insulin aspart; DRUG:exenatide","Novo Nordisk A/S","2006-04","2007-07","FALSE","Superiority as assessed by HbA1c reduction [at 24 weeks]","RESULT:19210140",null,null,null],["NCT03371862","Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)","SLIPS","WITHDRAWN","INTERVENTIONAL","PHASE2",null,"NONE","0","Short Bowel Syndrome","DRUG:Liraglutide Pen Injector [Victoza]","Imperial College London","2017-10-20","2020-08-06","FALSE","Improvement in parenteral support [20 weeks post start of drug]",null,null,"UNDECIDED",null],["NCT02683746","Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","308","Diabetes Mellitus, Type 2","DRUG:Lyophilized albiglutide DCC pen injector; DRUG:Lyophilized albiglutide DCC pen injector matching placebo; DRUG:Albiglutide liquid auto-injector; DRUG:Albiglutide liquid auto-injector matching placebo","GlaxoSmithKline","2016-03-16","2017-04-03","TRUE","Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 [Baseline and Week 26]","BACKGROUND:31004676","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/46/NCT02683746/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/46/NCT02683746/SAP_001.pdf","YES",null],["NCT02745470","Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","30","Diabetes Mellitus","DRUG:Lixisenatide; OTHER:Placebo","Seoul National University Hospital","2016-02","2016-12","FALSE","Difference of BOLD (Blood oxygenation level-dependent) signal in hypothalamus [10min (40 min after injection)] | Whole brain connectivity [20min (50 min after injection)]",null,null,"UNDECIDED",null],["NCT06937086","Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study","COMMIT-UC","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","350","Ulcerative Colitis; Obesity or Overweight","DRUG:Mirikizumab; DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2025-06-26","2028-04","FALSE","Percentage of Participants Who Simultaneously Achieve Clinical Remission and at Least 10% Weight Reduction [Week 52]",null,null,"YES","CTIS:2024-520209-38-00; OTHER:I6T-MC-AMCD"],["NCT04504370","Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects","PB119","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","273","Type 2 Diabetes Mellitus (T2DM)","DRUG:GLP-1 receptor agonist; DRUG:Placebo","PegBio Co., Ltd.","2020-04-27","2022-03-30","FALSE","Change in HbA1c [week 1, week 25]","DERIVED:38948164",null,"NO",null],["NCT03182296","Visualizing Beta Cells in Patients With a History of Gestational Diabetes",null,"UNKNOWN","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","24","Gestational Diabetes","RADIATION:68Ga-NODAGA-exendin-4 PET/CT","Radboud University Medical Center","2016-11-10","2026-01-01","FALSE","Pancreatic uptake of 68Ga-NODAGA-exendin-4 [1 year]",null,null,"NO",null],["NCT00877890","A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","254","Type 2 Diabetes Mellitus","DRUG:exenatide once weekly; DRUG:exenatide twice daily","AstraZeneca","2009-03","2009-10","TRUE","Change in HbA1c From Baseline to Week 24 [Day 1, Week 24]","RESULT:21307137; DERIVED:27146799; DERIVED:23748506; DERIVED:23039868; DERIVED:22236356",null,null,null],["NCT07382024","Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation","TREAT-AF","NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","200","Atrial Fibrillation Ablation; Persistent Atrial Fibrillation; Obesity & Overweight","DRUG:Tirzepatide; OTHER:Standard Care (in control arm)","National Taiwan University Hospital","2026-06-16","2027-12-31","FALSE","Atrial fibrillation burden at 3 months after catheter ablation [3 months after catheter ablation (7-day ECG patch monitoring period)]",null,null,"NO",null],["NCT02501161","A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus","DUAL™ VIII","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","1012","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide; DRUG:insulin glargine","Novo Nordisk A/S","2016-01-31","2018-10-03","TRUE","Time From Randomisation to Inadequate Glycaemic Control and Need for Treatment Intensification [Weeks 0-104 + 7 days follow-up-1 + 30 days follow-up-2]","RESULT:31189519; DERIVED:36710452","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/61/NCT02501161/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/61/NCT02501161/SAP_001.pdf",null,"EUDRACT_NUMBER:2014-005639-15; OTHER:U1111-1165-3914; NIH:2014"],["NCT06761703","A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss","COSMOS-DIGITAL","COMPLETED","OBSERVATIONAL",null,null,null,"200","Obesity","DEVICE:TAP® Micro Select Device (Touch Activated Phlebotomy)","Amgen","2024-11-14","2025-01-06","FALSE","Number of Participants with Self-blood Draw Received by Central Laboratory [30 days]",null,null,"YES",null],["NCT06352411","A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","42","Healthy; Renal Impairment","COMBINATION_PRODUCT:BI 456906","Boehringer Ingelheim","2024-05-15","2025-09-16","FALSE","Area under the concentration-time curve of BI 456906 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) [up to Day 29] | Maximum measured concentration of BI 456906 in plasma (Cmax) [up to Day 29]",null,null,"NO","REGISTRY:2023-508557-13-00; REGISTRY:U1111-1298-3135; NIH:2023"],["NCT02210871","Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","44","Diabetes; Diabetes Mellitus, Type 2; Hepatic Impaired","DRUG:semaglutide","Novo Nordisk A/S","2014-08-07","2015-06-03","FALSE","Area under the semaglutide plasma concentration-time curve [Day 1 - day 36]","RESULT:29205786",null,null,"OTHER:U1111-1149-3924; EUDRACT_NUMBER:2009-011673-33; NIH:2009"],["NCT06635057","A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan","T-RAM","COMPLETED","INTERVENTIONAL","PHASE4",null,"NONE","166","Type 2 Diabetes","DRUG:Tirzepatide","Eli Lilly and Company","2024-10-11","2026-04-15","FALSE","Change from Baseline in Hemoglobin A1c (HbA1c) [Baseline (20 to 8 weeks Before Ramadan), Week 4-8 from Start of Ramadan (SoR)]",null,null,"YES","OTHER:I8F-MC-GPIY"],["NCT05152277","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","90","Type 2 Diabetes","DRUG:HRS9531; OTHER:placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2021-12-06","2022-08-24","FALSE","Number of Adverse Events [Start of Treatment to end of study (approximately 7 weeks or 9 weeks)]","DERIVED:42764407",null,"UNDECIDED",null],["NCT01296412","Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","653","Diabetes Mellitus, Type 2","DRUG:sitagliptin; DRUG:liraglutide; DRUG:glimepiride; DRUG:metformin","Merck Sharp & Dohme LLC","2011-03-11","2012-02-29","TRUE","Change From Baseline in Hemoglobin A1c (A1C) [Baseline and Week 26]","DERIVED:23604551",null,"YES",null],["NCT07469800","Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","336","Overweight; Obesity; Hypertensive","DRUG:IBI362; DRUG:Placebo","Innovent Biologics (Suzhou) Co. Ltd.","2026-04-23","2026-08-01","FALSE","To evaluate the effect of IBI362 on mean sitting systolic blood pressure (msSBP) compared with placebo at Week 16 of treatment. [Week 16]",null,null,null,null],["NCT07284901","Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes","KaiNETIC-2","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","1270","Obesity With Diabetes; Overweight With Diabetes","DRUG:Ribupatide; DRUG:Placebo","Kailera","2026-01-12","2028-03-27","FALSE","Doses 3 and 4 of Ribupatide Versus Placebo: Percent Change From Baseline in Body Weight at Week 76 [Baseline, Week 76] | Doses 3 and 4 of Ribupatide Versus Placebo: Change From Baseline in HbA1c at Week 76 [Baseline, Week 76]",null,null,"NO","CTIS:2025-523510-87-00; NIH:2025"],["NCT07229157","Effect of Maridebart Cafraglutide on the Heart's Electrical Activity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","81","Overweight; Obesity","DRUG:Maridebart Cafraglutide; DRUG:Moxifloxacin; DRUG:Placebo for Maridebart Cafraglutide; DRUG:Placebo for Moxifloxacin","Amgen","2025-10-22","2026-08-27","FALSE","Change from Baseline in QTcF for Maridebart Cafraglutide [Up to Day 171]",null,null,"YES",null],["NCT07055607","A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice","PILLAR","ENROLLING_BY_INVITATION","OBSERVATIONAL",null,null,null,"1250","Obesity","DRUG:Semaglutide","Novo Nordisk A/S","2025-05-01","2028-08-15","FALSE","Absolute change in body weight (kilograms [kg]) [From baseline (0 months) to the end of observation (24 months)] | Percentage change in body weight (percentage [%]) [From baseline (0 months) to the end of observation (24 months)]",null,null,"YES","OTHER:U1111-1308-1428"],["NCT01715428","Liraglutide and Cardio-Metabolic Risk Markers",null,"COMPLETED","OBSERVATIONAL",null,null,null,"300","Type-2 Diabetes",null,"University of Palermo","2012-06","2015-12","FALSE","carotid intima-media thickness [every four months for a total period of 2 years]","DERIVED:35167051; DERIVED:33210276; DERIVED:27912784; DERIVED:26195184; DERIVED:25393640; DERIVED:24559258",null,null,null],["NCT05794581","A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","32","Type 1 Diabetes","DRUG:CT-868; DRUG:Placebo; DRUG:Victoza","Carmot Therapeutics, Inc.","2023-03-21","2024-03-06","FALSE","To assess area under the curve (AUC) in glucose metabolism during MMTT [Baseline up to 4 days]",null,null,"NO",null],["NCT07144098","Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver Function",null,"RECRUITING","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","24","Obesity/Overweight","DRUG:GZR18 injection","Gan & Lee Pharmaceuticals.","2025-08-12","2026-07-12","FALSE","Cmax:Maximum plasma concentration. [through study completion, an average of 36 days] | AUC0-last:Area under the plasma concentration-time curve at 0 h to last observation time-point after a single dose. [through study completion, an average of 36 days] | AUC0-inf:Area under the plasma concentration-time curve at 0 h to infinity after a single dose. [through study completion, an average of 36 days]",null,null,null,null],["NCT06916065","A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","188","Overweight; Obesity","DRUG:Eloralintide and Tirzepatide; DRUG:Eloralintide","Eli Lilly and Company","2025-04-09","2026-01-19","FALSE","Cohorts A and B: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Eloralintide and Tirzepatide [Day 106 Predose to Approximately Week 26] | Cohorts A and B: PK: Maximum Concentration (Cmax) of Eloralintide and Tirzepatide [Day 106 Predose to Approximately Week 26] | Cohorts C and D: PK: AUC of Eloralintide and Tirzepatide [Baseline Up to Approximately Week 11] | Cohorts C and D: PK: Cmax of Eloralintide and Tirzepatide [Baseline Up to Approximately Week 11] | Cohorts E and F: PK: AUC of Eloralintide [Day 8 Predose Up to Approximately Week 12] | Cohorts E and F: PK: Cmax of Eloralintide [Day 8 Predose Up to Approximately Week 12] | Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline Up to Approximately Week 26]",null,null,"NO","OTHER:J3R-MC-YDAE"],["NCT07734792","Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial","TOPAZ","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","SINGLE","726","Acute Ischemic Stroke (AIS)","DRUG:Tirzepatide; OTHER:Standard Medical Care (SMC)","yifang zhu","2026-09-20","2028-05-31","FALSE","The primary efficacy outcome: Proportion of patients achieving an excellent functional outcome [90 ± 7 days after randomization] | The primary safety outcome: All-cause mortality [90 ± 7 days]","RESULT:40886075; RESULT:34647404; RESULT:41392086; RESULT:39536238; RESULT:34170647; RESULT:37952131; RESULT:29402504; RESULT:40702450; RESULT:27296974; RESULT:35259929; RESULT:36372278; RESULT:41500725; RESULT:29364767; RESULT:29129157; RESULT:26898852; RESULT:25671797; RESULT:31662037; RESULT:30878104; RESULT:28052979","Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/92/NCT07734792/SAP_001.pdf","NO",null],["NCT00845507","Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","54","Weight Gain","DRUG:Exenatide; DRUG:Placebo","University of Cincinnati","2008-12","2015-07","TRUE","Change in Weight From Baseline to Endpoint. [16 Weeks]","DERIVED:40203970",null,null,null],["NCT01825148","GLP-1 Receptor Targeting in Diabetic and Healthy Individuals","GLP-1-CPOP","COMPLETED","OBSERVATIONAL",null,null,null,"20","Type 1 Diabetes","OTHER:radiolabeled Exendin","Radboud University Medical Center","2012-12","2014-05","FALSE","pancreatic uptake of radiolabeled Exendin [7 days]","DERIVED:24488022",null,null,"EUDRACT_NUMBER:2012-000619-10"],["NCT06884293","A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","479","Overweight; Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)","DRUG:IBI362; DRUG:semaglutide","Innovent Biologics (Suzhou) Co. Ltd.","2025-05-09","2026-12-31","FALSE","percentage change in body weight from baseline [at Week 48] | percentage change in liver fat content from baseline measured by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF) [at Week 48]",null,null,"NO",null],["NCT01212133","A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India","Lead-In","COMPLETED","OBSERVATIONAL",null,null,null,"1386","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2010-11","2012-04","FALSE","The number of serious adverse drug reactions (SADRs) during the study period [during 26 weeks of treatment]","RESULT:27867889",null,null,"OTHER:U1111-1114-9324"],["NCT06415214","Efficacy and Safety of HRS-7535 Tablets in Adults With Diabetic Kidney Disease in Type 2 Diabetes","SOLID-DKD","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","281","Diabetic Kidney Disease, Type 2 Diabetes","DRUG:Placebo; DRUG:HRS-7535","Shandong Suncadia Medicine Co., Ltd.","2024-06-21","2025-07-15","FALSE","Ratio of UACR at week 16 to UACR at baseline [at Week 16]","DERIVED:42472282",null,"UNDECIDED",null],["NCT01740921","GLP-1 and Microvascular Function in Type 2 Diabetes","GLP-1ADDS","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","39","Type 2 Diabetes","DRUG:Liraglutide; OTHER:diet; DRUG:Aspirin","Royal Devon and Exeter NHS Foundation Trust","2011-01","2015-12","FALSE","change of baseline skin maximum hyperaemia at 4 months [baseline and 4 months]","BACKGROUND:28049736",null,null,"OTHER:10/H0106/29"],["NCT07379333","A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","118","Type 2 Diabetes","DRUG:HM11260C; DRUG:Placebo","Hanmi Pharmaceutical Company Limited","2026-04-13","2027-11","FALSE","Change in HbA1c at 36 weeks compared to baseline [baseline, 36 weeks]",null,null,null,null],["NCT02660047","Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent","MAGNA VICTORIA","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","51","Diabetes Mellitus Type 2; Metabolic Syndrome; Cardiovascular Disease; Diastolic Dysfunction; Fatty Liver","DRUG:Liraglutide; DRUG:Liraglutide - Placebo","Leiden University Medical Center","2015-08","2018-03-09","FALSE","Stroke volume [0 and 26 weeks] | Ejection Fraction [0 and 26 weeks] | Cardiac output [0 and 26 weeks] | Cardiac index [0 and 26 weeks] | Peak ejection rate [0 and 26 weeks] | Early peak filling rate [0 and 26 weeks] | Early deceleration peak [0 and 26 weeks] | Atrial peak filling rate [0 and 26 weeks] | Early deceleration peak / Atrial peak filling rate (E/A ratio) [0 and 26 weeks] | Peak mitral annulus longitudinal motion [0 and 26 weeks] | Left ventricular filling pressure (= early peak filling rate / peak mitral annulus longitudinal motion) [0 and 26 weeks]","DERIVED:39963952; DERIVED:39641307; DERIVED:36262060; DERIVED:33293204; DERIVED:31288820",null,null,null],["NCT06139055","A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants",null,"UNKNOWN","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","70","Healthy Volunteers","DRUG:GSBR-1290 (Capsule/Tablet); DRUG:GSBR-1290; DRUG:Placebo; DRUG:Placebo (Capsule/Tablet)","Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics","2023-10-02","2024-03","FALSE","Part 1: Analysis of Maximum Observed Plasma Concentration (Cmax) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate Pharmacokinetic (PK) Parameters [From start of study drug up to Day 10] | Part 1: Analysis of Time to Maximum Observed Plasma Concentration (Tmax) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters [From start of study drug up to Day 10] | Part 1: Analysis of Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters [From start of study drug up to Day 10] | Part 1: Analysis of Area Under the Plasma Concentration-time Curve From 0 to infinity (AUC0-inf) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters [From start of study drug up to Day 10] | Part 1: Analysis of Apparent Terminal Elimination Half-life (t1/2) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters [From start of study drug up to Day 10] | Part 1: Analysis of Total Apparent Body Clearance (CL/F) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters [From start of study drug up to Day 10] | Part 1: Analysis of Apparent Volume of Distribution (Vz/F) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters [From start of study drug up to Day 10] | Part 2: Number of Participants With Adverse Events (AEs) and Serious AEs [From start of study drug up to End of study (EOS) in Part 2 (up to Day 98)] | Part 2: Number of Participants With Severity of AEs [From start of study drug up to EOS in Part 2 (up to Day 98)] | Part 2: Number of Participants With Clinically Significant Change From Baseline in Vital Signs [From start of study drug up to EOS in Part 2 (up to Day 98)] | Part 2: Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters [From start of study drug up to EOS in Part 2 (up to Day 98)] | Part 2: Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters [From start of study drug up to EOS in Part 2 (up to Day 98)]",null,null,"YES",null],["NCT07481747","Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)","SURMOUNT-1","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","2539","Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities","DRUG:Tirzepatide; DRUG:Placebo; BEHAVIORAL:Reduced-calorie diet","Hudson Biotech","2026-02-02","2027-02-14","FALSE","Mean percent change in body weight from randomization [72 Weeks] | Percentage of participants achieving ≥5% body weight reduction from randomization [72 Weeks]",null,null,null,null],["NCT06686134","Comprehensive Clinical Evaluation Study of GLP-1RA",null,"RECRUITING","OBSERVATIONAL",null,null,null,"492","T2DM",null,"LI YAN","2024-07-01","2025-12-31","FALSE","HbA1c compliance rate [4, 8, 12, and 16 weeks after the start of medication] | Weight reduction from baseline [4, 8, 12, and 16 weeks after the start of medication]","RESULT:29397376",null,null,null],["NCT05680155","A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","211","T2DM; Type 2 Diabetes Mellitus","DRUG:Ecnoglutide; DRUG:Placebo","Hangzhou Sciwind Biosciences Co., Ltd.","2022-12-29","2024-06-12","FALSE","Change from baseline in HbA1c [Baseline, Week 24]","DERIVED:41501026",null,"NO",null],["NCT01505673","Adding Liraglutide to High Dose Insulin: Breaking the Cycle",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","71","Type 2 Diabetes Mellitus; Obesity","DRUG:Liraglutide; DRUG:Saline","Ildiko Lingvay","2012-01","2016-06","TRUE","Glycemic Control Measured by HbA1c [6-months]","DERIVED:27273731; DERIVED:26909799",null,null,null],["NCT01451905","GLP-1 Receptors in Normal Skin and Skin From Patients With Psoriasis",null,"UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","QUADRUPLE","12","Reduction of Psoriasis Following Liraglutide Therapy in Terms of PASI and DLQI","DRUG:Liraglutide; DRUG:Placebo","University Hospital, Gentofte, Copenhagen","2011-08","2012-12","FALSE","Changes in PASI and DLQI [2 months]",null,null,null,null],["NCT01557166","Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","359","Metabolism and Nutrition Disorder; Obesity; Obstructive Sleep Apnoea","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2012-06-07","2013-06-01","TRUE","Change From Baseline in Apnoea-hypopnoea Index (AHI) [Week 0, Week 32]","RESULT:27482610; RESULT:27817208; RESULT:27005405; RESULT:28473337; RESULT:28386912; RESULT:28950422",null,null,"OTHER:U1111-1126-6260"],["NCT05035082","A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)","REALYSE","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","1018","Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:oral glucose-lowering medications (commercially available)","Novo Nordisk A/S","2021-09-01","2025-06-18","TRUE","Change in Glycated Haemoglobin (HbA1c) [Week 0, year 1]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/82/NCT05035082/Prot_002.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/82/NCT05035082/SAP_003.pdf","YES","OTHER:U1111-1253-2577"],["NCT04027023","Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus",null,"UNKNOWN","INTERVENTIONAL","PHASE4",null,"NONE","9","Diabetes Mellitus, Type 2","DRUG:Diabetes mellitus Type 2 De-escalation treatment (DET)","Sciema UG","2019-10-30","2021-04-30","FALSE","impact of a temporary personalized poly-pharmaceutical treatment on the disease stage in patients with type 2 diabetes [12 weeks]",null,null,"NO",null],["NCT00381342","Safety and Efficacy of Exenatide as Monotherapy",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","233","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:placebo","AstraZeneca","2006-09","2007-09","FALSE","Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 24 [Baseline, Week 24]","RESULT:18803987; DERIVED:22913891; DERIVED:22236356",null,null,null],["NCT03062774","Continuous Multiple Dose PB-119 Injection in Health Volunteers",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","36","Type2 Diabetes Mellitus","BIOLOGICAL:PB-119 injection","PegBio Co., Ltd.","2014-11-15","2016-09-13","FALSE","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [Change from Baseline lab value at 50 days]","DERIVED:33576936",null,"NO",null],["NCT01232946","Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","30","Type 2 Diabetes","DRUG:liraglutide; DRUG:insulin detemir; DRUG:liraglutide plus insulin detemir","Indiana University","2012-01","2017-09-08","TRUE","Myocardial Glucose Uptake [3 months] | Myocardial Fatty Acid Oxidation Rate [3 months] | Myocardial Fatty Acid Esterification Rate [3 months]","DERIVED:30020461","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/46/NCT01232946/Prot_SAP_000.pdf","NO",null],["NCT07588984","GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study","FLOURISH","NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"2310","Obesity & Overweight; Weight Loss; Preventative Health; Body Weight; Cardiovascular Disease Risk Factor","BEHAVIORAL:Noom Weight; BEHAVIORAL:Free Tier; BEHAVIORAL:Education-only control; DRUG:Semaglutide; DRUG:Tirzepatide; DRUG:Microdose semaglutide; DRUG:Microdose tirzepatide","Noom Inc.","2026-04-30","2029-05","FALSE","Change in Body Weight [Monthly, Baseline through Month 12 (and Months 18 & 24 for FLOURISH GLP-1 arms)] | Change in fasting glucose [Baseline, Month 2, Month 4, Month 8, Month 12] | Change in HbA1c [Baseline, Month 2, Month 4, Month 8, Month 12] | Change in LDL cholesterol [Baseline, Month 2, Month 4, Month 8, Month 12] | Change in HDL cholesterol [Baseline, Month 2, Month 4, Month 8, Month 12] | Change in total cholesterol [Baseline, Month 2, Month 4, Month 8, Month 12] | Change in triglycerides [Baseline, Month 2, Month 4, Month 8, Month 12] | Change in Body Composition [Monthly, Baseline through Month 12 ((and Months 18 & 24 for FLOURISH GLP-1 arms)] | GLP-1 Side Effect Profile [Baseline (pre-treatment), Monthly through Month 12]",null,null,"NO",null],["NCT05762744","Pharmacogenomics of GLP1 Receptor Agonists",null,"TERMINATED","INTERVENTIONAL","PHASE1","RANDOMIZED","SINGLE","63","Type 2 Diabetes","DRUG:Exenatide Injection (before the first FSIGT); DRUG:Exenatide injection before the second FSIGT)","University of Maryland, Baltimore","2016-06-01","2018-11-30","TRUE","Exenatide Effect on First Phase Insulin Secretion [0-10 minutes] | Exenatide Effect on Glucose Disappearance Rate [25-50 minutes]","BACKGROUND:37264484; DERIVED:38700326","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/44/NCT05762744/Prot_SAP_000.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/44/NCT05762744/ICF_001.pdf","YES",null],["NCT00360334","A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","235","Type 2 Diabetes","DRUG:exenatide; DRUG:insulin glargine","AstraZeneca","2006-06","2008-04","TRUE","Percent of Patients Who Achieved HbA1c ≤ 7.4% With Minimal Weight Gain (≤ 1kg) [26 weeks]","RESULT:19930005; DERIVED:22913891",null,null,null],["NCT02505334","A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","635","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2015-07-21","2017-05-02","TRUE","Change in Glycosylated Haemoglobin (HbA1c) (Week 26) [Week 0, Week 26]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/34/NCT02505334/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/34/NCT02505334/SAP_001.pdf","YES","OTHER:U1111-1164-5462; REGISTRY:JapicCTI-152975"],["NCT06820047","Sleeve Gastrectomy vs. Lifestyle & Medications: Impact on BMI Trajectory and Target Attainment in a Matched Cohort Study",null,"COMPLETED","OBSERVATIONAL",null,null,null,"190","Obesity and Obesity-related Medical Conditions","PROCEDURE:Laparoscopic sleeve gastrectomy; OTHER:Obesity pharmacotherapy","University of Roma La Sapienza","2022-05-01","2023-07-01","FALSE","Weight modifications [12 months]","DERIVED:42219275",null,"YES",null],["NCT06546384","GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease","GLP-1 RA","NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","64","Adiposity; Fatty Liver; Alcohol Use Disorder","DRUG:Semaglutide; BEHAVIORAL:Weight reduction recommendations (nutritional and exercise)","Insel Gruppe AG, University Hospital Bern","2026-11-01","2026-12-31","FALSE","Proportion of patients achieving total alcohol abstinence (measured by negative PEth test) [From inclusion date (baseline) until end of the study, total duration 16 weeks per patient]",null,null,"NO","NIH:2023"],["NCT01511198","Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","223","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:metformin","Novo Nordisk A/S","2001-02","2001-10","FALSE","Body weight []","RESULT:16026367; RESULT:25504028",null,null,null],["NCT07176663","Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure","Tirzepatide","NOT_YET_RECRUITING","INTERVENTIONAL",null,null,"NONE","15","Obesity","DRUG:Tirzepatide","Shahid Beheshti University of Medical Sciences","2026-02-01","2026-04-01","FALSE","weight loss [kilogram of weight loss measured by same scale one and three month after injection]",null,null,"NO",null],["NCT04817644","A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","14","Diabetes Mellitus, Type 2","DRUG:Oral semaglutide","Novo Nordisk A/S","2021-09-10","2023-05-26","FALSE","Area under the semaglutide milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,sema,D10,milk) [From 0 to 24 hours after the 10th dosing (day 10)] | Area under the salcaprozate sodium (SNAC) milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,SNAC,D10,milk) [From 0 to 24 hours after the 10th dosing (day 10)]",null,null,"YES","OTHER:U1111-1253-4467"],["NCT07207148","People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists",null,"RECRUITING","OBSERVATIONAL",null,null,null,"100","Multiple Sclerosis","DRUG:GLP-1; DRUG:Ocrelizumab (US)","Northwestern University","2025-11-15","2028-04-01","FALSE","PIRA [From enrollment to the end of study at 72 weeks.]","BACKGROUND:37499338; BACKGROUND:28002688; BACKGROUND:6685237; BACKGROUND:38103230; BACKGROUND:36584570; BACKGROUND:39030327; BACKGROUND:39626095; BACKGROUND:38598572; BACKGROUND:37952131; BACKGROUND:33567185; BACKGROUND:31079537; BACKGROUND:33465039; BACKGROUND:37371254; BACKGROUND:36319190","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/48/NCT07207148/Prot_000.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/48/NCT07207148/ICF_001.pdf","NO",null],["NCT05548647","Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects","STABLE Wt Loss","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","120","Obesity","BEHAVIORAL:Behavioral Treatment; DRUG:Placebo; DRUG:Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]","University of Pennsylvania","2022-07-26","2025-05-12","TRUE","Study 1 Ad Libitum Energy Intake (kcal) During a Buffet Lunch Meal (4 Hrs After Standardized Breakfast) [S1: Change from baseline to weeks 20, 40, and 60] | Study 2 Ad Libitum Energy Intake (kcal) During a Buffet Lunch Meal (4 Hrs After Standardized Breakfast) [S2: Endpoint comparison at week 72]","DERIVED:42323166; DERIVED:38655793","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/47/NCT05548647/Prot_SAP_000.pdf","UNDECIDED",null],["NCT07693608","An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder","TRI-MR","ENROLLING_BY_INVITATION","INTERVENTIONAL","PHASE2",null,"NONE","45","Obesity; Methamphetamine Use Disorder; Cocaine Use Disorder; Stimulant Use Disorders","DRUG:Tirzepatide","University of Texas Southwestern Medical Center","2026-08-19","2030-02-01","FALSE","Effect of tirzepatide on self-reported use of stimulants [32 weeks]",null,null,"NO",null],["NCT07657676","Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity",null,"RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","116","Obesity & Overweight; Coronary Heart Disease","DRUG:Mazdutide; DRUG:Placebo","China National Center for Cardiovascular Diseases","2026-09-14","2027-12-31","FALSE","Change in total non-calcified plaque volume (NCPV) by CCTA from baseline to 52 weeks [Baseline and 52 weeks]",null,null,"NO",null],["NCT07299084","A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","40","Diabetes Mellitus, Type 2; Overweight; Obesity","DRUG:Tirzepatide","Eli Lilly and Company","2026-01-14","2026-11","FALSE","Percentage of Participants with Lack of Gastric Content Retention Post-Solid Test Meal [Baseline, Day 171 (at 6, 8, 12, 18 and 24 hours after baseline or Day 170 solid test meal)]",null,null,"NO","OTHER:I8F-MC-GPJE"],["NCT06935838","Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV",null,"COMPLETED","INTERVENTIONAL","PHASE2",null,"NONE","12","Obesity and Overweight; HIV; Chronic Inflammation","DRUG:Tirzepatide","University of Hawaii","2025-11-12","2026-06-02","FALSE","Change in Baseline Body Weight [12 weeks]","BACKGROUND:28435757; BACKGROUND:38417572; BACKGROUND:29082920; BACKGROUND:25590212; BACKGROUND:32753461; BACKGROUND:35658024; BACKGROUND:38501237; BACKGROUND:19072098; BACKGROUND:34631899; BACKGROUND:38278941; BACKGROUND:37569635; BACKGROUND:39448830; BACKGROUND:38466272",null,null,"NIH:U54GM138062"],["NCT07625774","Renal Efficacy and Safety of the Novel Oral Small-Molecule GLP-1RA HRS-7535 Evaluated in Participants With Chronic Kidney Disease","RENEW-CKD","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","3690","Chronic Kidney Disease","DRUG:HRS-7535; DRUG:Placebo","Shandong Suncadia Medicine Co., Ltd.","2026-07","2031-05","FALSE","Time to first occurrence of any of the following renal composite endpoint events [Up to approximately 4.8 years]",null,null,"UNDECIDED",null],["NCT00791479","Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","167","Diabetes Mellitus, Type 2","DRUG:LY2189265 and Lifestyle Measures; DRUG:Placebo solution and Lifestyle Measures","Eli Lilly and Company","2008-12","2010-01","TRUE","Change From Baseline in Glycosylated Hemoglobin (HbA1c) [Baseline, 12 weeks]","BACKGROUND:22804250",null,null,"OTHER:H9X-MC-GBCK; REGISTRY:CTRI/2009/091/000105"],["NCT02954627","Ultrasound Assessment of the Carotid Intimal Medial Thickness in Obese Subjects; Weight Loss","CIMT-LOSEIT-I","COMPLETED","OBSERVATIONAL",null,null,null,"200","Osteoarthritis; Obesity","DIETARY_SUPPLEMENT:Dietary Supplement: Intensive dietary intervention","Henrik Gudbergsen","2016-11","2019-02","FALSE","Change in the mean posterior wall common carotid intima-media thickness in mm [Week -8 to 0] | Change in the mean posterior wall common carotid intima-media thickness in mm [Week -8 to 52]",null,null,null,null],["NCT02970942","Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","320","Hepatobiliary Disorders; Non-alcoholic Steatohepatitis","DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2016-11-30","2020-02-13","TRUE","Percentage of Participants With Non- Alcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis After 72 Weeks (Yes/No) [After 72 weeks]","RESULT:33185364; DERIVED:40985232; DERIVED:40980163; DERIVED:38112484; DERIVED:38058795; DERIVED:37328931; DERIVED:33039693","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/42/NCT02970942/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/42/NCT02970942/SAP_001.pdf","YES","EUDRACT_NUMBER:2016-000685-39; OTHER:U1111-1179-7464; NIH:2016"],["NCT05670379","Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant","LIBERATE-1","COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","24","Overweight and Obesity; Type2diabetes","COMBINATION_PRODUCT:Exenatide Implant; DRUG:Bydureon BCise (exenatide extended release); DRUG:Semaglutide, 1.0 mg/mL","Vivani Medical, Inc","2024-12-20","2025-08-21","FALSE","Area under the plasma concentration-time curve (AUC) [9 weeks] | Maximum plasma concentration observed (Cmax) [9 weeks] | Time to maximum plasma concentration observed (Tmax) [9 weeks] | Adverse events [9 weeks]",null,null,"NO",null],["NCT07392151","Reversal to Normoglycemia by Treating Prediabetes",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","158","Prediabetes; Chronic Coronary Syndrome","DRUG:Intensified medical follow-up and glucose-lowering drugs; OTHER:No intervention","Michael Mæng","2026-02","2029-10","FALSE","Presence of a composite of retinopathy, nephropathy, neuropathy, and MASLD [Baseline] | Incidence of normoglycemia defined as HbA1c <39 mmol/mol [1-year follow-up]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/51/NCT07392151/Prot_SAP_000.pdf",null,"NIH:2025"],["NCT04596631","A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes","PIONEER TEENS","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","132","Diabetes Mellitus, Type 2","DRUG:Oral semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2020-11-02","2025-04-29","TRUE","Change From Baseline (Week 0) to Week 26 in Glycosylated Haemoglobin (HbA1c)- Percentage Point [Baseline (Week 0), Week 26] | Change From Baseline (Week 0) in HbA1c to Week 26- Millimoles Per Mole (mmol/Mol) [Baseline (Week 0), Week 26]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/31/NCT04596631/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/31/NCT04596631/SAP_001.pdf","YES","OTHER:U1111-1218-1527; REGISTRY:2018-002952-34; NIH:2018"],["NCT07065383","Rebalancing the Fat Content of the Heart and Muscles","Re-CHARM","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","60","Diabetes Mellitus Type 2","DRUG:Semaglutide administration plus dietary counselling and physical activity encouragement; DRUG:Semaglutide plus a personalised and supervised program of resistance and endurance training","University of Aberdeen","2025-08-01","2028-07-31","FALSE","1H-magnetic resonance spectroscopy [From enrollment to the end of treatment at the end of 12 weeks]","BACKGROUND:27553599; BACKGROUND:34675928; BACKGROUND:11177194; BACKGROUND:13428781; BACKGROUND:18393289; BACKGROUND:9094069; BACKGROUND:30586731; BACKGROUND:15161807; BACKGROUND:29203776; BACKGROUND:28266779; BACKGROUND:33567185; BACKGROUND:37952131; BACKGROUND:27633186; BACKGROUND:35296869; BACKGROUND:18319352; BACKGROUND:11739435; BACKGROUND:20299618; BACKGROUND:22547801; BACKGROUND:21873552; BACKGROUND:26438611; BACKGROUND:18497461; BACKGROUND:15734832; BACKGROUND:21327867; BACKGROUND:3292505; BACKGROUND:30131397",null,"NO",null],["NCT02147431","A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","38","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2014-05-21","2015-05-20","FALSE","Change in mean glucagon concentration during hypoglycaemia (change from target level 5.5 mmol/L to nadir (target 2.5 mmol/L)) [After 12 weeks 2 days of treatment in each treatment period (Day 87 and Day 213)]","RESULT:29893488",null,null,"EUDRACT_NUMBER:2013-002751-15; OTHER:U1111-1144-7019"],["NCT02417142","Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","70","Schizophrenia; Schizoaffective Disorder","DRUG:Exenatide; DRUG:Placebo","University of Massachusetts, Worcester","2014-09","2019-07","TRUE","Negative Symptoms as Measured by the Scale for the Assessment of Negative Symptoms (SANS) Total Score [Baseline, Week 6, Week 12, Week 18 and Week 24]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/42/NCT02417142/Prot_002.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/42/NCT02417142/SAP_001.pdf",null,null],["NCT03007329","Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.","EXENDA","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","34","Steatosis, Liver; Type2 Diabetes","DRUG:Exenatide; DRUG:Exenatide matching Placebo; DRUG:Dapagliflozin","Medical University of Vienna","2017-03-08","2019-11-26","FALSE","change in hepatic lipid content measured with magnetic resonance spectroscopy in % [baseline - week 24]","RESULT:33464703",null,null,null],["NCT02673931","GLP-1 and Hyperoxia for Organ Protection in Heart Surgery","GLORIOUS","UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","QUADRUPLE","1400","Coronary Disease; Shock, Cardiogenic; Renal Failure; Stroke; Brain Injury; Aortic Valve Disease","DRUG:Byetta (Lilly, Exenatide); DRUG:Conoxia (AGA, oxygen); DRUG:20% Human Albumin","Copenhagen University Hospital, Rigshospitalet","2016-02","2024-09","FALSE","Time in days to the first occurring of the following co-primary end-points throughout the follow-up period [Minimum 12 months]","DERIVED:40975689; DERIVED:40265262; DERIVED:34740932",null,"NO",null],["NCT07150962","Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","168","Overweight or Obesity","DRUG:HRS-9531 Tablet","Fujian Shengdi Pharmaceutical Co., Ltd.","2025-10-15","2026-02","FALSE","Area under the curve from Time Zero to Time of last quantifiable concentration (AUCtau) [From Day 14 to Day 15.] | Adverse event (AE) [Screening period up to Day 35.] | Serious adverse event (SAE) [Screening period up to Day 35.]",null,null,"UNDECIDED",null],["NCT06401746","Body Surface Gastric Mapping in Patients on Semaglutide",null,"COMPLETED","OBSERVATIONAL",null,null,null,"9","Semaglutide-Induced Gastric Motility; Gastroparesis","DEVICE:Gastric Alimetry","University of Western Sydney","2024-05-01","2025-03-13","TRUE","Change in Overall BSGM BMI-adjusted Amplitude on Drug Compared to Baseline. [Baseline, Month 2 (On Drug)]","BACKGROUND:36130019; BACKGROUND:37782524; BACKGROUND:36534985; RESULT:41952406","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/46/NCT06401746/Prot_SAP_000.pdf","NO",null],["NCT04314622","A Study of Supaglutide in Chinese Type 2 Diabetes Patients",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","40","Diabetes Mellitus, Type 2","DRUG:Supaglutide; DRUG:Placebo","Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","2020-04-14","2020-10-25","FALSE","HbA1c [Baseline, 7 weeks, 17weeks] | Adverse Events [Baseline , through 12 weeks for part A; Baseline, through 17 weeks for part B] | Vital Sign [Baseline , through 12 weeks for part A; Baseline, through 17 weeks for part B] | Laboratory Tests [Baseline , through 12 weeks for part A; Baseline, through 17 weeks for part B] | 12-lead ECGs [Baseline , through 12 weeks for part A; Baseline, through 17 weeks for part B] | Immunogenicity Tests [Baseline , through 12 weeks for part A; Baseline, through 17 weeks for part B]","DERIVED:39961992",null,"NO",null],["NCT02073929","LIPT - Liraglutide in Polycystic Ovary Syndrome","LIPT","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","72","Polycystic Ovary Syndrome; Cardiovascular Disease","DRUG:Liraglutide for 26 weeks; DRUG:placebo","Jens Faber","2014-03","2015-12","TRUE","Change in Endogenous Thrombin Potential (ETP) [at time 0 and 26 weeks]","DERIVED:28681988",null,null,null],["NCT06579105","Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.","SOLSTICE","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","406","Diabetes Mellitus, Type 2","DRUG:Placebo (placebo matching AZD5004 film-coated tablet); DRUG:AZD5004; DRUG:Semaglutide","AstraZeneca","2024-10-08","2025-12-19","FALSE","Change in HbA1c [Baseline to Week 26]","DERIVED:42259343",null,"YES","REGISTRY:2024-512562-34-00"],["NCT03341429","Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response","BARIOPTIMISE","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","70","Obesity","DRUG:Liraglutide Pen Injector [Saxenda]; DRUG:Placebo","University College, London","2018-08-22","2019-11-28","FALSE","%WL [24 weeks]","BACKGROUND:19890430; BACKGROUND:23548858; BACKGROUND:24149519; BACKGROUND:25239175; BACKGROUND:27222547; BACKGROUND:22968072; BACKGROUND:23161525; BACKGROUND:25840670; BACKGROUND:22907795; BACKGROUND:27429019; BACKGROUND:25917783; BACKGROUND:25379859; BACKGROUND:24913243; BACKGROUND:25566743; BACKGROUND:23419600; BACKGROUND:24472033; BACKGROUND:27005405; BACKGROUND:23912365; DERIVED:37494014",null,"YES",null],["NCT02349802","Autoinjector Device Assessment Study","BCB119","COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","3052","Healthy Subjects","DRUG:Auto-injector with exenatide suspension; DRUG:Syringe with exenatide suspension","AstraZeneca","2013-02","2013-12","FALSE","Number of device-related failure injections [10 week study]",null,null,null,null],["NCT02910570","Changes in Skin Autoflouresence Following Weight Loss and Maintenance Using Liraglutide in Knee Osteoarthritis",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","150","Osteoarthritis, Knee","DRUG:Liraglutide 3 mg (Saxenda); DRUG:Liraglutide 3 mg placebo","Parker Research Institute","2016-11","2019-02","FALSE","Change in advanced glycation end products in the skin [week 0 to 52]",null,null,null,null],["NCT07630454","Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF","TEAR-AF-HFpEF","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","602","Atrial Fibrillation; Heart Failure With Preserved Ejection Fraction (HFpEF); Tirzepatide","DRUG:Tirzepatide; BEHAVIORAL:Structured Lifestyle Intervention","Yunlong Wang","2026-08-01","2029-08-01","FALSE","Number of Participants With Recurrence of atrial fibrillation, atrial flutter, or atrial tachycardia [Day 91 through Week 52 after catheter ablation]",null,null,"YES",null],["NCT05433584","A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes","SURPASS-EARLY","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","780","Type 2 Diabetes","DRUG:Tirzepatide; DRUG:Antihyperglycemic medication","Eli Lilly and Company","2022-08-01","2025-10-21","FALSE","Change from Baseline in Hemoglobin A1c (HbA1c) [Baseline, Week 104]","DERIVED:42184419",null,"YES","OTHER:I8F-MC-GPHE; EUDRACT_NUMBER:2022-000130-42; OTHER:2022-5010733-40-00; REGISTRY:U1111-1282-0263"],["NCT01677104","The Microvascular Function of GLP-1 and Its Analogues",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","TRIPLE","63","Type 2 Diabetes; Obesity","DRUG:GLP-1; DRUG:Placebo","Katarina Kos","2012-08","2014-07","FALSE","skin blood flow [3 hours]","DERIVED:31203378",null,null,"OTHER:1204620"],["NCT04504396","Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","620","Type 2 Diabetes Mellitus (T2DM)","DRUG:GLP-1 receptor agonist; DRUG:Placebo","PegBio Co., Ltd.","2020-06-23","2022-09-15","FALSE","Change in HbA1c [week 1, week 25]",null,null,"NO",null],["NCT00838903","Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","1049","Diabetes Mellitus, Type 2","BIOLOGICAL:albiglutide; DRUG:sitagliptin; DRUG:glimepiride; DRUG:metformin; BIOLOGICAL:placebo albiglutide; DRUG:placebo sitagliptin; DRUG:placebo glimepiride","GlaxoSmithKline","2009-02","2012-01","TRUE","Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 104 [Baseline and Week 104]","DERIVED:28683300",null,"YES",null],["NCT01508923","Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","17","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2001-05","2002-02","FALSE","24-hour glucose profiles after three fixed meals []","RESULT:15111485",null,null,null],["NCT00622323","Post Marketing Surveillance Study of Byetta ™ (Exenatide) Use Among Filipino Patients",null,"COMPLETED","OBSERVATIONAL",null,null,null,"41","Type 2 Diabetes Mellitus",null,"AstraZeneca","2008-02","2009-09","FALSE","To determine the proportion of patients experiencing an adverse event and a list of the experienced adverse events, that would occur among Filipino patients with type 2 diabetes and inadequate glycemic control treated with exenatide [12 weeks]",null,null,null,"OTHER:H8O-PH-B006"],["NCT04990024","The Effect of Different Diets on Arterial Stiffness in Obese Patients on Semaglutide",null,"UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","NONE","60","Obesity; Weight Loss","OTHER:Dietary Intervention Med Diet; OTHER:Dietary Intervention HP/LC Diet","American University of Beirut Medical Center","2021-07-01","2025-09-15","FALSE","cfPWV measurement and pulse wave analysis (PWA) using SphygmoCorCvMS V9 (AtCor Medical) [6 months after enrollment]",null,null,null,null],["NCT07599046","Fecal Microbiota Transplantation (FMT) Combined With Calorie-Restricted Diet and Semaglutide in Patients With Obesity and Type 2 Diabetes",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","20","Obesity Type 2 Diabetes Mellitus","BIOLOGICAL:Fecal microbiota transplantation (FMT); DRUG:Semaglutide (1 Mg Dose); BEHAVIORAL:Calorie-restricted diet","Eighth Affiliated Hospital, Sun Yat-sen University","2026-04-30","2027-01-30","FALSE","Percent change in body weight [From enrollment to the end of treatment at 24 weeks]",null,null,"NO",null],["NCT05822609","Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes","RT1D","RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","60","Diabetic Kidney Disease; Type 1 Diabetes","DRUG:Semaglutide; OTHER:Placebo","University of Washington","2024-04-05","2027-06","FALSE","Change in urine albumin excretion [Baseline to 26 weeks]","DERIVED:40693871",null,"YES",null],["NCT02496221","A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","20","Diabetes Mellitus, Type 2","DRUG:Albiglutide 50 mg; DRUG:Placebo; DRUG:CCK (Kinevac)","GlaxoSmithKline","2015-06-11","2015-10-13","TRUE","Maximum Absolute Value of Gallbladder Ejection Fraction (Emax GEF) During Cholecystokinin (CCK) Infusion, as a Measure of Maximum Effect [Day 4 in each treatment period] | Area Under the Effect Curve for Gallbladder Ejection Fraction (AUEC GEF) [Day 4 in each treatment period] | Time at Which the Maximum Effect (Emax GEF) Occurred (TEMAXEF) During the CCK Infusion [Day 4 in each treatment period] | Maximum Gallbladder Ejection Fraction Value During CCK Infusion [Day 1 and Day 4 in each treatment period] | Area Under the Effect Curve for Gallbladder Volume (AUEC VL) [Day 4 in each treatment period] | Maximum Absolute Change From Baseline in Value of Gallbladder Volume (Emax VL) During CCK Infusion, as a Measure of Maximum Effect [Day 4 in each treatment period] | Time at Which the Maximum Effect (Emax VL) Occurred (TEmax VL) During the CCK Infusion [Day 4 in each treatment period] | Maximum Change From Baseline in Main Pancreatic Duct Diameter During CCK Infusion [Day 4 in each treatment period] | Maximum Change From Baseline in Common Bile Duct Diameter During CCK Infusion [Day 4 in each treatment period]","DERIVED:28543352",null,"YES",null],["NCT00650546","Role of Exenatide in NASH-a Pilot Study","NAFLD","COMPLETED","INTERVENTIONAL","PHASE2; PHASE3",null,"NONE","8","Nonalcoholic Fatty Liver Disease","DRUG:Exenatide","Indiana University","2006-08","2010-08","TRUE","Number of Patients With Improvement in Liver Histology After Treatment With Exenatide [between baseline and 24-28 weeks after initiating treatment] | Change in NAS [Between baseline and 28 weeks of treatment with exenatide, sub q, 5-10 mcq.]","BACKGROUND:16012941; BACKGROUND:15017611; BACKGROUND:12843147; BACKGROUND:14752837; BACKGROUND:15017657; BACKGROUND:14512888; BACKGROUND:1700785; BACKGROUND:1313797; BACKGROUND:9020121; BACKGROUND:10027577; RESULT:21131943",null,null,"NIH:U01DK061737"],["NCT02843399","Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy",null,"COMPLETED","OBSERVATIONAL",null,null,null,"15498","Diabetes Mellitus Type 2",null,"AstraZeneca","2016-08-15","2016-12-15","FALSE","Diabetes-related HCRU/costs [Up to 12 months]",null,null,null,null],["NCT05952882","Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility",null,"UNKNOWN","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","188","Polycystic Ovary Syndrome; Obesity; Infertility, Female","DRUG:Liraglutide + Metformin; DRUG:Metformin","Mỹ Đức Hospital","2023-11-01","2025-12-31","FALSE","Absolute Body Weight (BW) [12 weeks of treatment] | Change in Percent Body Weight [12 weeks of treatment]","RESULT:27459230; RESULT:14688154; RESULT:22767467; RESULT:31733195; RESULT:11527911; RESULT:2670645; RESULT:34583840; RESULT:31238940; RESULT:18068166; RESULT:17980364; RESULT:26401593; RESULT:28961722; RESULT:24581574; RESULT:30033227; RESULT:24151290; RESULT:19056992; RESULT:18364705; RESULT:19841045; RESULT:33552465; RESULT:31031702; RESULT:32442310; RESULT:31229399; RESULT:28681988; RESULT:24362411; RESULT:28479118; RESULT:29703793; RESULT:28760517",null,null,null],["NCT01021527","A Study to Assess the Effects of Exenatide on Insulin Secretion Rates Using a Graded Infusion of Intravenous Glucose (0000-099)(COMPLETED)",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","SINGLE","12","Healthy","OTHER:Comparator: Treatment A; DRUG:Comparator: Treatment B; DRUG:Comparator: Treatment C; PROCEDURE:Comparator: graded glucose infusion","Merck Sharp & Dohme LLC","2008-02","2008-03","FALSE","beta-cell glucose sensitivity (slope of the relationship between insulin secretion rate and glucose) [0-160 minutes after start of infusion]",null,null,null,"OTHER:099; OTHER:2009_697"],["NCT07768813","A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","44","Healthy; Obesity","COMBINATION_PRODUCT:Survodutide formulation A; DRUG:Survodutide formulation B2","Boehringer Ingelheim","2026-09-02","2026-12-08","FALSE","Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) [Up to Day 22] | Maximum measured concentration of the analyte in plasma (Cmax) [Up to Day 22] | Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) [Up to Day 22]",null,null,"NO","REGISTRY:U1111-1337-6323; REGISTRY:2026-526307-30-00"],["NCT04032197","A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","101","Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2019-08-12","2022-12-16","FALSE","Change in maximum target-to-background ratio (TBR) for 18F-fluorodeoxyglucose (FDG) in the carotid arteries [From baseline (from 41 days before randomisation) to week 26]","DERIVED:40345413",null,"YES","OTHER:U1111-1215-4058; REGISTRY:2018-002289-38; NIH:2018"],["NCT07628127","A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","332","Obesity; Overweight","DRUG:VRB-103; OTHER:Placebo; DRUG:VRB-101","Verdiva Bio Dev Limited","2026-07-06","2028-03","FALSE","Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) [Screening up to End of Study (Arm 1: Day 29, Arm 2: Week 10, and Arm 3: Week 20)] | Number of Participants with Adverse Events of Special Interest (AESIs) [Screening up to End of Study (Arm 1: Day 29, Arm 2: Week 10, and Arm 3: Week 20)] | Change in Columbia-Suicide Severity Rating Scale (C-SSRS) from Baseline [Screening up to Day 8 (Arm 1) or End of Treatment (Arm 2: Week 7 and Arm 3: Week 17)] | Change in Patient Health Questionnaire-9 (PHQ-9) Scores from Baseline [Screening up to End of Study (Arm 1: Day 29, Arm 2: Week 10, and Arm 3: Week 20)]",null,null,"NO",null],["NCT04307797","Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes","COCONUT","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","10","Type 2 Diabetes; Obesity","DRUG:0.9% Sodium-chloride; DRUG:Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min; DRUG:Glucagon 12.5ng/kg/min and 0.9% saline; DRUG:Glucagon 12.5ng/kg/min","Cambridge University Hospitals NHS Foundation Trust","2022-01-18","2022-10-07","FALSE","Part A - Myocardial glucose uptake [Comparison between scans over a maximum period of 16 weeks] | Part A - Global longitudinal strain / global circumferential strain / global radial strain [Comparison between scans over a maximum period of 16 weeks] | Part A - Ejection fraction [Comparison between scans over a maximum period of 16 weeks] | Part A - Stroke volume [Comparison between scans over a maximum period of 16 weeks] | Part A - Cardiac output [Comparison between scans over a maximum period of 16 weeks] | Part B - Changes in phosphocreatine/adenosine (PCr/ATP) radio [Comparison between scans over a maximum period of 16 weeks] | Part B - Changes in absolute concentrations of PCr and ATP defined by AHA 17- segment territory as a measure of cardiac energy status (determined by 31P-MRS) [Comparison between scans over a maximum period of 16 weeks]",null,null,"NO",null],["NCT00359762","Exenatide Versus Glimepiride in Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","1029","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:glimepiride","AstraZeneca","2006-09","2011-03","TRUE","Number of Patients With Treatment Failure [Baseline to end of Period II (up to 4.5 years)] | Time to Treatment Failure [Baseline to end of Period II (up to 4.5 years)]","DERIVED:26338040; DERIVED:25846577; DERIVED:22683137",null,null,null],["NCT06467604","CRAVE Study: Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users",null,"ACTIVE_NOT_RECRUITING","OBSERVATIONAL",null,null,null,"7","Obesity","BEHAVIORAL:Surveys; OTHER:Indirect Calorimetry; OTHER:Body composition; OTHER:Anthropometrics","University of California, Davis","2024-11-01","2027-03-12","FALSE","Change in Food Craving Score [Baseline, Midpoint (8-12 weeks), End of study (24 + 2 weeks)]","DERIVED:42440974",null,"NO",null],["NCT04261933","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY)","SURE GERMANY","COMPLETED","OBSERVATIONAL",null,null,null,"789","Diabetes Mellitus, Type 2","DRUG:semaglutide","Novo Nordisk A/S","2020-02-13","2021-05-25","FALSE","Change in Glycated Haemoglobin A1c (HbA1c) [Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38)] | Change in HbA1c [Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38)]","BACKGROUND:36809678",null,"YES","OTHER:U1111-1241-6291"],["NCT02597049","A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus","AWARD-10","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","424","Type 2 Diabetes Mellitus","DRUG:Dulaglutide; DRUG:Placebo; DRUG:SGLT2 inhibitor; DRUG:Metformin","Eli Lilly and Company","2015-11","2017-02","TRUE","Change From Baseline in Hemoglobin A1c (HbA1c) at 24 Weeks (Treatment-regimen Estimand) [Baseline, Week 24] | Change From Baseline in the HbA1c at 24 Weeks (Efficacy Estimand) [Baseline, Week 24]","DERIVED:36894938; DERIVED:29483060","Study Protocol: GBGE (a) Protocol|https://cdn.clinicaltrials.gov/large-docs/49/NCT02597049/Prot_000.pdf; Study Protocol: GBGE (b) Protocol|https://cdn.clinicaltrials.gov/large-docs/49/NCT02597049/Prot_001.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/49/NCT02597049/SAP_002.pdf","YES","OTHER:H9X-MC-GBGE; EUDRACT_NUMBER:2015-002095-24; NIH:2015"],["NCT01478074","ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia",null,"WITHDRAWN","INTERVENTIONAL","PHASE1",null,"NONE","0","Acute Myeloid Leukemia","DRUG:G-CSF; DRUG:Cytarabine; DRUG:Fludarabine; BIOLOGICAL:Donor Natural Killer (NK) cells; BIOLOGICAL:ALT-801","Altor BioScience","2011-11","2013-10","FALSE","Maximum tolerated dose of NK cells [18 months] | Safety of delivering NK cells and ALT-801 in combination with FLAG [6 months after study completes accrual]",null,null,null,null],["NCT01969149","Exenatide for Stress Hyperglycemia","ExSTRESS","COMPLETED","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","NONE","110","Stress Hyperglycemia","DRUG:Exenatide; DRUG:Insulin","Centre Hospitalier Universitaire de Besancon","2015-01","2015-12","FALSE","Percentage of patients spending more than 50 % of the time in the glycemic target range (100 to 140 mg/dl) [48 hours]","BACKGROUND:15650975; BACKGROUND:20097589; BACKGROUND:24247476; DERIVED:30384842",null,null,null],["NCT01515579","Comparison of Two Liraglutide Formulations in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","22","Diabetes; Healthy","DRUG:liraglutide","Novo Nordisk A/S","2006-04","2006-06","FALSE","Area under the curve (0-t) [] | Cmax, maximum concentration []",null,null,null,"EUDRACT_NUMBER:2005-005948-68; NIH:2005"],["NCT07411560","A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","100","Overweight; Obese","DRUG:Glucose-dependent Insulinotropic Polypeptide (GIP); DRUG:Cagrilintide; DRUG:Placebo GIP","Novo Nordisk A/S","2026-02-09","2027-01-26","FALSE","Number of Treatment Emergent Adverse Events (TEAEs) nausea, vomiting and diarrhoea [From first investigational medicinal products (IMP) administration (visit 2, day 1 or visit 9, day 74) to the end of treatment visit (Visit 2, day 16 or Visit 9, day 89)]",null,null,"YES","OTHER:U1111-1324-3573"],["NCT07772960","Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes","SEMA AUD","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","90","Alcohol Use Disorder (AUD); Obesity (BMI Equal to or >30)","OTHER:Placebo; DRUG:Semaglutide 1.0 mg; DRUG:Semaglutide 2.0 mg","Yale University","2026-10-01","2031-10-31","FALSE","Alcohol use days [20 weeks]","BACKGROUND:42101823",null,"YES","NIH:R01AA032779"],["NCT07096908","Tirzepatide Use in People With Obesity and Type 1 Diabetes",null,"RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","60","Type1diabetes; Obesity","DRUG:Tirzepatide; DRUG:Placebo","Dasman Diabetes Institute","2025-07-31","2028-02-25","FALSE","Bodyweight [76 weeks]","DERIVED:42097660",null,"UNDECIDED",null],["NCT05564117","Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range","OASIS 4","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","307","Overweight; Obesity","DRUG:Semaglutide; DRUG:Placebo semaglutide","Novo Nordisk A/S","2022-10-11","2024-04-18","TRUE","Percentage Change in Body Weight [Baseline (week 0), end of treatment (week 64)] | Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal to (≥) 5% (Yes/No) [At end of treatment (week 64)]","DERIVED:40934115","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/17/NCT05564117/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/17/NCT05564117/SAP_001.pdf","YES","OTHER:U1111-1271-9056; EUDRACT_NUMBER:2021-006534-40"],["NCT05230589","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Saudi Arabia, as Part of Local Clinical Practice","PIONEER REAL","COMPLETED","OBSERVATIONAL",null,null,null,"194","Diabetes Mellitus, Type 2","DRUG:Oral semaglutide","Novo Nordisk A/S","2022-04-25","2023-03-13","FALSE","Change in Glycated haemoglobin (HbA1c ) [From baseline (week 0) to End of Study visit (V3) (week 34-44)]",null,null,"YES","OTHER:U1111-1240-3898"],["NCT01911468","Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","36","PCOS; Obesity","DRUG:metformin; DRUG:liraglutide; DRUG:metformin and liraglutide","University Medical Centre Ljubljana","2011-11","2012-10","FALSE","The main outcome was change in body weight. [Patient's body weight was mesured at the base point and every four weeks during 12 weeks of clinical trial.]","DERIVED:25330463",null,null,null],["NCT07456774","A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China","SPOTLIGHT","ENROLLING_BY_INVITATION","OBSERVATIONAL",null,null,null,"100000","Type 2 Diabetes",null,"Novo Nordisk A/S","2026-02-13","2026-08-31","FALSE","Time to 3P major adverse cardiovascular events [From index date to the first composite 3P MACE (stroke, myocardial infarction, all-cause death) event or censoring event (up to 36 months)] | Time to 5P MACE [From index date to the first composite 5P MACE (stroke, myocardial infarction, all-cause death, heart failure hospitalization, coronary revascularization) event or censoring event (up to 36 months)] | Time to stroke [From index date to the first stroke event or censoring event (up to 36 months)] | Time to myocardial infarction (MI) [From index date to the first MI event or censoring event (up to 36 months)] | Time to heart failure (HF) [From index date to the first HF event or censoring event (up to 36 months)] | Time to composite renal event [From index date to first composite renal (kidney failure: dialysis/transplantation/eGFR <15, ≥50% eGFR reduction from baseline, or kidney-related/cardiovascular death) or censoring event (up to 36 months)] | Time to renal disease-related hospitalization [From index date to the first renal disease-related hospitalization or censoring event (up to 36 months)] | Incidence rate of 3P MACE [From index date to the first composite 3P MACE (stroke, myocardial infarction, all-cause death) event or censoring event (up to 36 months)] | Incidence rate of 5P MACE [From index date to the first composite 5P MACE (stroke, myocardial infarction, all-cause death, heart failure hospitalization, coronary revascularization) event or censoring event (up to 36 months)] | Incidence rate of stroke [From index date to the first stroke event or censoring event (up to 36 months)] | Incidence rate of myocardial infarction [From index date to the first MI event or censoring event (up to 36 months)] | Incidence rate of heart failure [From index date to the first HF event or censoring event (up to 36 months)] | Incidence rate of composite renal event [From index date to first composite renal (kidney failure: dialysis/transplantation/eGFR <15, ≥50% eGFR reduction from baseline, or kidney-related/cardiovascular death) or censoring event (up to 36 months)] | Incidence rate of renal disease-related hospitalization [From index date to the first renal disease-related hospitalization or censoring event (up to 36 months)]",null,null,"YES",null],["NCT07610174","Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves","SYNCARDIA-HF","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","SINGLE","160","Heart Failure; Heart Valve Prosthesis","DRUG:semaglutide; DRUG:Dapagliflozin (10mg Tab)","Kafrelsheikh University","2025-06-02","2026-04-29","FALSE","Change from Baseline in Left Ventricular Global Longitudinal Strain (LV-GLS) assessed by echocardiography [Baseline and 12 weeks]",null,null,"YES",null],["NCT07724340","A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","150","Adults With Overweight/Obesity and Type 2 Diabetes","DRUG:AT673 low dose; DRUG:AT673 high dose; DRUG:Placebo","Antag Therapeutics","2026-06-19","2027-02","FALSE","Body weight [13 weeks]",null,null,"NO",null],["NCT01191268","A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","884","Diabetes Mellitus, Type 2","DRUG:Insulin Glargine; DRUG:LY2189265; DRUG:Insulin Lispro","Eli Lilly and Company","2010-11","2012-02","TRUE","Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c) [Baseline, 26 weeks]","DERIVED:29430801; DERIVED:27161178; DERIVED:26691396; DERIVED:26009229",null,null,"OTHER:H9X-MC-GBDD"],["NCT05442450","Efficacy of Oral Semaglutide in Overweight or Obesity","OSO","UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","116","Obesity; Weight Loss","DRUG:oral semaglutide","Asian Institute of Gastroenterology, India","2022-07-10","2023-06-30","FALSE","The proportion of patients achieving a reduction in body weight of 5% or more from baseline [seven months]","DERIVED:41066034",null,"NO",null],["NCT01517568","Metabolism and Excretion of Liraglutide in Healthy Male Volunteers",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","7","Diabetes; Healthy","DRUG:liraglutide [3H]","Novo Nordisk A/S","2006-11","2006-12","FALSE","Profile and identity of the major metabolites of tritium labelled liraglutide in plasma, urine, and faeces [] | Total recovery of tritium, [3H]-liraglutide and metabolites in urine and faeces []","RESULT:20709939",null,null,"EUDRACT_NUMBER:2006-002293-22"],["NCT07554417","Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","20","GLP - 1; Obesity & Overweight; Muscle Loss; Exercise Intervention; Dietary Assessment","DRUG:Semaglutide; BEHAVIORAL:Dietary Counseling; BEHAVIORAL:Exercise","William Marsh Rice University","2026-04-06","2026-06-29","FALSE","Change in Skeletal Muscle Mass [Baseline to 12 weeks]",null,null,"YES",null],["NCT03331289","Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","107","Diabetes Mellitus, Type 2","DRUG:Placebo; DRUG:Exenatide; DRUG:Dapagliflozin; DRUG:Exenatide and Dapagliflozin","The University of Texas Health Science Center at San Antonio","2018-02-28","2022-03-31","TRUE","Change in EGP From Baseline to Post-oral Glucose Load. [From baseline [-35 to 0min] to the last hour post-glucose load [240-300 minutes]]","DERIVED:35235659","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/89/NCT03331289/Prot_SAP_000.pdf","YES","NIH:R01DK107680"],["NCT00518115","Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","361","Diabetes Mellitus, Type 2","DRUG:Albiglutide (GSK716155) or exenatide","GlaxoSmithKline","2007-04","2008-05","TRUE","Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16 [Baseline and Week 16]","BACKGROUND:19592625; DERIVED:25387217",null,"YES",null],["NCT02545738","Antiproteinuric Effects of Liraglutide Treatment","LIRALBU","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","32","Diabetic Kidney Disease","DRUG:Liraglutide; DRUG:placebo","Steno Diabetes Center Copenhagen","2015-04","2016-05","FALSE","Change in albuminuria [24 weeks]","DERIVED:39963952; DERIVED:38449081; DERIVED:37752566; DERIVED:27753201",null,null,"NIH:2014"],["NCT06047548","A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","441","Overweight; Obesity","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2023-09-20","2026-01-20","FALSE","Percent Maintenance of Body Weight (BW) Reduction Achieved during the 60-Week Weight Loss Period [Week 112]","DERIVED:42119587; DERIVED:40916045",null,"YES","OTHER:I8F-MC-GPIQ"],["NCT07221214","GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV","GL1DER HIV RCT","RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","200","HIV; Alcohol; Smoking Cigarette; Cardiovascular Disease Prevention","DRUG:Semaglutide (Rybelsus®); DRUG:Placebo","Vanderbilt University Medical Center","2026-04-17","2029-10-31","FALSE","Average drinks/week past 30 days at 3 months [3 Months]",null,null,"NO","NIH:1P60AA032176"],["NCT04878393","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Japan, as Part of Local Clinical Practice","PIONEER REAL","COMPLETED","OBSERVATIONAL",null,null,null,"650","Diabetes Mellitus, Type 2","DRUG:Oral semaglutide","Novo Nordisk A/S","2021-04-30","2023-02-09","FALSE","Change in glycated haemoglobin (HbA1c) [From baseline (week 0) to End of Study visit (Visit 3) (week 34-44)] | Number of adverse event (AEs) [From baseline (week 0) to End of Study visit (Visit 3) (week 34-44)]","RESULT:38711208",null,"YES","OTHER:U1111-1247-5339"],["NCT04305587","Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","66","Diabetes Mellitus Type 2","DRUG:PF-07081532; OTHER:Placebo; DRUG:Clopidogrel","Pfizer","2020-03-16","2021-07-14","TRUE","Number of Participants With Treatment Emergent Treatment-Related Adverse Events [From the first dose up to 28-35 days after last administration of study intervention (that is a maximum of 63 days from first dose for Part A and a maximum of 77 days from first dose for Part B and Part C)] | Number of Participants With Laboratory Abnormalities [From Baseline to 7-14 days following last dose administration (that is a maximum of 42 days from baseline for Part A and a maximum of 56 days from baseline for Part B and Part C)] | Number of Participants With Vital Signs Abnormalities [From Baseline to 7-14 days following last dose administration (that is a maximum of 42 days from baseline for Part A and a maximum of 56 days from baseline for Part B and Part C)] | Number of Participants With Abnormal Electrocardiogram (ECG) [From Baseline to 7-14 days following last dose administration (that is a maximum of 42 days from baseline for Part A and a maximum of 56 days from baseline for Part B and Part C)]","DERIVED:38751362","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/87/NCT04305587/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/87/NCT04305587/SAP_001.pdf","NO",null],["NCT05891587","Semaglutide Therapy for Alcohol Reduction - Tulsa","STAR-T","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","80","Alcohol Use Disorder","DRUG:Semaglutide; DRUG:Placebo","Oklahoma State University Center for Health Sciences","2023-07-07","2025-07-30","FALSE","Change in alcohol drinks per drinking day. [Baseline (Week 1) to post-medication (Week 13)]",null,null,"YES",null],["NCT01514487","Comparison of Three Liraglutide Formulations in Healthy Volunteers",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","24","Diabetes; Healthy","DRUG:liraglutide","Novo Nordisk A/S","2005-01-13","2005-03-30","FALSE","Area under the Curve (0-t) [] | Cmax, maximum concentration []",null,null,null,null],["NCT07715929","Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients","TEAR-AF","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","710","Atrial Fibrillation; Obesity & Overweight; Catheter Ablation","DRUG:Tirzepatide; BEHAVIORAL:Structured Lifestyle Intervention","Yunlong Wang","2026-09-01","2029-09-01","FALSE","Number of Participants With Recurrence of Atrial Fibrillation, Atrial Flutter, or Atrial Tachycardia [Day 91 through Week 52 after catheter ablation]",null,null,"YES",null],["NCT07303556","Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs","ICDDTKZ26","ACTIVE_NOT_RECRUITING","INTERVENTIONAL",null,"NON_RANDOMIZED","QUADRUPLE","120","Heart Failure; Diabete Type 2; Arterial Hypertension","DRUG:Tirzepatide (Mounjaro); DRUG:dapagliflozin, empagliflozin, metformin","Nazarbayev University","2024-12-18","2025-07-01","FALSE","Change in NT-proBNP levels from baseline to Week 24 [Baseline to Week 24]",null,"Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/56/NCT07303556/ICF_001.pdf",null,null],["NCT05671653","A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range",null,"TERMINATED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","32","Obesity","DRUG:PF-07081532; DRUG:Semaglutide","Pfizer","2023-01-19","2023-11-03","TRUE","Cohort 1: Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Midazolam in Periods 1, 4 and 7 [For Cohort 1 Periods 1, 4, and 7: At 0 (prior to midazolam dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24 hours post midazolam dose on Day 1 of each period] | Cohort 1: Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Omeprazole in Periods 1, 4 and 7 [For Cohort 1 Periods 1, 4, and 7: At 0 (prior to omeprazole dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24 hours post midazolam dose on Day 1 of each period] | Cohort 1: AUClast of Levonorgestrel (LE) in Periods 2, 5,and 8 [For Cohort 1 Periods 2, 5, and 8: At 0 (prior to LE dose), 0.75, 2, 4, 8, 12, 24, 48, 72, 96 and 120 hours post LE dose on Day 1 of each period] | Cohort 1: AUCinf of Ethinyl Estradiol (EE) in Periods 2, 5,and 8 [For Cohort 1 Periods 2, 5, and 8: At 0 (prior to EE dose), 0.75, 2, 4, 8, 12, 24, 48, 72, 96 and 120 hours post LE dose on Day 1 of each period] | Cohort 2: AUCinf of Midazolam in Period 1 and 3 [For Cohort 2 Periods 1 and 3: At 0 (prior to midazolam dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24 hours post midazolam dose on Day 1 of each period]","DERIVED:42053447","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/53/NCT05671653/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/53/NCT05671653/SAP_001.pdf","NO","REGISTRY:NCT05671653"],["NCT02829502","The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke","EGRABIS1","UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","30","Ischemic Stroke","DRUG:Byetta; DRUG:Normosaline","Christina Kruuse","2016-08","2023-08","FALSE","Changes in the mean flow velocity in the middle cerebral arteries and in cortical oxigination. [Up till 3 hours]",null,null,"NO","EUDRACT_NUMBER:2016-001219-18; NIH:2016"],["NCT06976853","Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","60","Crohn Disease (CD)","DRUG:Tirzepatide; DRUG:Standard of care treatment","Washington University School of Medicine","2025-05-13","2028-05","FALSE","Proportion and number of participants who have treatment emergent adverse events, serious adverse events, discontinuation of study intervention due to adverse events and injection-site reactions by CTCAE v4.0 [From enrollment to the end of treatment at month 7] | Number of participants who achieve various doses of Tirzepatide at increments of 2.5 mg, up to 15 mg [From enrollment to the end of treatment at month 7] | Proportion and number of participants with endoscopic remission as defined by SES-CD < 4 with no ulcer subscore >1. [From enrollment to the end of treatment at month 7]",null,null,null,null],["NCT07188545","Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)","DASH-CKMH","ACTIVE_NOT_RECRUITING","OBSERVATIONAL",null,null,null,"23280000","Cardiovascular Kidney Metabolic Syndrome","DRUG:Intervention; DRUG:Active Comparator","Ohio State University","2025-09-15","2029-06-30","FALSE","3-Point major adverse cardiovascular event (3P-MACE) [Up to 5 years]",null,null,"NO",null],["NCT04897802","Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","42","Hypopituitarism; Central Diabetes Insipidus; Panhypopituitarism; Psychological Disorder; Social Isolation; Hypothalamic Diseases; Pituitary Diseases; Oxytocin Deficiency","DRUG:Experimental: GLP1-RA (exenatide) administration; DRUG:Control: Placebo administration","Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","2021-09-13","2024-04-30","FALSE","Change in oxytocin concentration (pg/mL) [Baseline blood exam (timepoint 0) and further blood collections after 15, 30, 45, 60, 90 and 120 minutes after baseline blood collection]",null,null,null,null],["NCT05819853","Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome","RESTORE","RECRUITING","INTERVENTIONAL","PHASE3","NON_RANDOMIZED","NONE","80","PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries; Obese","DRUG:Semaglutide Injectable Product (Wegovy and/or Ozempic)","University of Colorado, Denver","2023-11-03","2028-02-01","FALSE","Change in ovulation frequency before and after semaglutide in females with PCOS [14 months]",null,null,"NO","NIH:R01HD108340"],["NCT00712673","GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","GETGOAL-M","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","680","Diabetes Mellitus, Type 2","DRUG:Lixisenatide (AVE0010); DRUG:Placebo; DEVICE:Pen auto-injector; DRUG:Metformin","Sanofi","2008-06","2011-03","TRUE","Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 [Baseline, Week 24]","RESULT:23536584; DERIVED:39963952; DERIVED:27319011; DERIVED:27267268",null,null,"OTHER:EudraCT 2007-005880-80"],["NCT00641056","Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","467","Type 2 Diabetes Mellitus","DRUG:Exenatide Once Weekly; DRUG:Insulin Glargine","AstraZeneca","2008-04","2009-05","TRUE","Change in HbA1c From Baseline to Week 26 [Baseline, Week 26]","RESULT:22357185; DERIVED:32306296; DERIVED:24731672; DERIVED:23748506; DERIVED:23522121; DERIVED:22236356; DERIVED:20609969",null,null,null],["NCT04305002","Exenatide Treatment in Parkinson's Disease",null,"UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","60","Parkinson Disease","DRUG:Exenatide; DRUG:Placebo","Center for Neurology, Stockholm","2020-01-21","2023-10-10","FALSE","FDG-PET network analysis [21 months]",null,null,"UNDECIDED",null],["NCT02527200","Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","56","Metabolism and Nutrition Disorder; Obesity","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2015-11-09","2020-11-04","TRUE","Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 16 Weeks [Week 0, Week 16] | Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 52 Weeks [Week 0, Week 52]","RESULT:36181471","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/00/NCT02527200/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/00/NCT02527200/SAP_001.pdf","YES","EUDRACT_NUMBER:2014-004415-37; OTHER:U1111-1162-7884; OTHER:NL54145.078.15; NIH:2014"],["NCT01255163","A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease",null,"TERMINATED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","57","Alzheimer's Disease; Mild Cognitive Impairment","DRUG:Exendin-4 SC; DRUG:Placebo SC","National Institute on Aging (NIA)","2010-11-21","2016-11-18","TRUE","Number of Participants With Incidence of Nausea [18 months]","BACKGROUND:21147038; BACKGROUND:22476196; DERIVED:36671553; DERIVED:31518224; DERIVED:27871675",null,null,"OTHER:10-AG-0423"],["NCT03144271","Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","58","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:semaglutide; DRUG:Placebo","Novo Nordisk A/S","2007-06-11","2007-10-08","FALSE","Number of Adverse Events [After 24-33 days]",null,null,"YES","EUDRACT_NUMBER:2007-000303-15; OTHER:U1111-1193-6996"],["NCT06820476","A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral Dosing",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","29","Overweight; Obesity","DRUG:NNC0487-0111; DRUG:Placebo (NNC0487-0111)","Novo Nordisk A/S","2025-02-09","2025-05-14","FALSE","Number of treatment emergent adverse events (TEAEs) [From first NNC0487-0111 administration (Day 1) to completion of the end-of-study visit (Day 31)]",null,null,"YES","OTHER:U1111-1289-3164"],["NCT05662189","Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus",null,"RECRUITING","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","70","Type1diabetes; Type2diabetes; Pre Diabetes; Hyperinsulinism","DRUG:68Ga-exendin-4; OTHER:mixed meal test","Azienda Ospedaliero-Universitaria di Parma","2022-03-15","2025-07","FALSE","BCF x M [through study completion, an average of 3 months after enrolment] | pancreatic beta cell mass (BCM) [through study completion, an average of 3 months after enrolment] | pancreatic beta cell function (BCF) [through study completion, an average of 3 months after enrolment]",null,null,null,null],["NCT07513168","Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults",null,"RECRUITING","INTERVENTIONAL","PHASE4",null,"NONE","60","Obesity; Weight Reduction; Cardiometabolic Risk Factors","DRUG:Locally available low-dose semaglutide (0.25 mg, 0.5 mg, 1 mg)","Asian Institute Of Medical Sciences","2025-08-01","2026-08-30","FALSE","Percentage Change in Body Weight [Baseline to 24 weeks]","BACKGROUND:31689026; BACKGROUND:41295856; BACKGROUND:41773123; BACKGROUND:40804463; BACKGROUND:40978842; BACKGROUND:38017205; BACKGROUND:33977495; BACKGROUND:40196933; BACKGROUND:38851997; BACKGROUND:38976257; BACKGROUND:33625476; BACKGROUND:35441470; BACKGROUND:36578889; BACKGROUND:33755728; BACKGROUND:34706925; BACKGROUND:34942372; BACKGROUND:38740993; BACKGROUND:36216945; BACKGROUND:38015216; BACKGROUND:36254579; BACKGROUND:38679221",null,"YES",null],["NCT01006889","Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease",null,"COMPLETED","INTERVENTIONAL","PHASE4",null,"NONE","24","Nonalcoholic Fatty Liver Disease; Type 2 Diabetes Mellitus","DRUG:Exenatide","University of Florida","2008-01","2009-12","TRUE","Hepatic Steatosis [6 months]",null,null,null,null],["NCT01146678","Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","22","Type 1 Diabetes Mellitus","DRUG:Insulin glargine HOE901; DRUG:Lixisenatide AVE0010","Sanofi","2010-06","2010-09","FALSE","Area under the plasma lixisenatide concentration curve (LIX-AUClast) [1 day (D1 to D2) in the first treatment period and 1 day (D1 to D2) during the second treatment period] | Lixisenatide maximum plasma/serum peak concentration (LIX-Cmax) [1 day (D1 to D2) in the first treatment period and 1 day (D1 to D2) during the second treatment period]",null,null,null,"EUDRACT_NUMBER:2010-019228-30; OTHER:U1111-1116-8960"],["NCT06400615","Study That Tests AD109 in Patients Taking GLP-1 Drugs",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","40","OSA","DRUG:AD109","Apnimed","2024-05-20","2024-12-26","FALSE","Primary Objective (Adverse Events) [6 weeks]",null,null,null,null],["NCT04263415","The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","30","PCOS; Semaglutide; Taste, Altered; Tongue Tissue Transcriptome; Gastric Emptying; Central Neural Response","DRUG:Semaglutide; OTHER:Placebo","University Medical Centre Ljubljana","2019-11-02","2020-05-08","FALSE","to investigate the effect of semaglutide on taste perception as change in taste sensitivity detected by chemical gustometry evaluated with \"Taste strips\" test [Changes in taste perception from baseline up to the end of 12th week.] | CO-PRIMARY END-POINT : to investigate alteration of transcriptomic profile of human tongue tissue as changes in expression level from baseline to follow up after 12 weeks of treatment, measured by RNA sequencing [Change in transcriptomic profile from baseline up to the end of 12th week.]","DERIVED:34281590",null,"NO",null],["NCT01648582","A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus","AWARD-CHN2","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","774","Type 2 Diabetes Mellitus","DRUG:Dulaglutide; DRUG:Insulin glargine; DRUG:Metformin; DRUG:Sulfonylureas","Eli Lilly and Company","2012-07","2014-08","TRUE","Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks [Baseline, 26 Weeks]","DERIVED:34580638; DERIVED:34453682; DERIVED:33161492; DERIVED:32857293; DERIVED:32621083; DERIVED:32277401; DERIVED:31950036; DERIVED:31228090",null,"YES","OTHER:H9X-CR-GBDK"],["NCT06716424","A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE4",null,"NONE","105","Type 2 Diabetes","DRUG:iGlarLixi (insulin glargine/lixisenatide)","Sanofi","2025-01-06","2026-06-12","FALSE","Percentage of participants with treatment emergent adverse events (TEAEs) including serious adverse events (SAEs) [From Day 1 to Week 25]",null,null,"YES","REGISTRY:U1111-1303-3494"],["NCT07128082","The Long COVID Treatment Trial","LOCITT","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","1000","Long COVID","DRUG:Tirzepatide; DRUG:Placebo","Scripps Translational Science Institute","2025-10-30","2026-12","FALSE","Primary Objective 1: Changes in fatigue severity score, measured by Fatigue Severity Scale (FSS) [12 months]",null,null,"NO",null],["NCT00518882","Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes","LEAD-6","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","467","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:exenatide","Novo Nordisk A/S","2007-08","2008-04","TRUE","Change in Glycosylated A1c (HbA1c) at Week 26 [week 0, week 26]","RESULT:19245711; RESULT:19491536; RESULT:19515413; RESULT:20332351; RESULT:21388442; RESULT:21450987; RESULT:22018679; RESULT:22055210; RESULT:22193143; RESULT:21883806; RESULT:22862847; RESULT:23010561; RESULT:23186975; RESULT:25504028; RESULT:26936426; DERIVED:24561125",null,null,"EUDRACT_NUMBER:2006-006092-21"],["NCT05051579","A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","272","Obesity; Overweight and Obesity","DRUG:LY3502970; DRUG:Placebo","Eli Lilly and Company","2021-09-29","2022-08-25","TRUE","Percent Change From Baseline in Body Weight in LY3502970 and Placebo [Baseline, Week 26]","DERIVED:40481478; DERIVED:37351564","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/79/NCT05051579/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/79/NCT05051579/SAP_001.pdf","YES","OTHER:J2A-MC-GZGI; EUDRACT_NUMBER:2021-002805-88"],["NCT06411210","Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","54","Diabetes type1; Obesity","DRUG:Semaglutide Pen Injector; DRUG:Placebo","Yale University","2024-07-16","2028-04-30","FALSE","Change in VAT/(VAT+SAT) from baseline to 12 months [baseline and 12 months] | Change in hepatic insulin resistance from baseline to 12 months [baseline and 12 months] | Change in triglycerides from baseline to 12 months [baseline and 12 months]",null,null,"NO","NIH:1R01DK134398-01A1"],["NCT04615910","A GLP-1 Receptor PET Imaging Substudy Within the VER-A-T1D Trial Investigating the Effects on Beta Cell Mass","Ver-A-image","UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","SINGLE","30","Diabetes Mellitus","RADIATION:68Ga-NODAGA-exendin-4 PET/CT","Radboud University Medical Center","2021-07-01","2025-04-01","FALSE","Pancreatic 68Ga-exendin uptake [Change from time of inclusion to 12 months into treatment]",null,null,"NO",null],["NCT06207877","A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","62","Obesity","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2024-02-23","2024-10-16","FALSE","Relative change in energy intake during ad libitum lunch, evening meal and snackbox [Baseline to Day 156]",null,null,"YES","OTHER:U1111-1286-0585; OTHER:2023-504792-24-00; NIH:2023"],["NCT03182231","GLP1-imaging Before and After Bariatric Surgery",null,"UNKNOWN","INTERVENTIONAL","PHASE1; PHASE2",null,"NONE","12","Diabetes Mellitus, Type 2; Bariatric Surgery Candidate","RADIATION:68Ga-NODAGA-exendin-4 PET/CT","Radboud University Medical Center","2016-10-07","2023-07-01","FALSE","Pancreatic uptake of 68Ga-NODAGA-exendin-4 [4 years]",null,null,"NO",null],["NCT06506175","A Clinical Study to Evaluate the Effect of Different Dosing Conditions on the Pharmacokinetics of HRS9531 Tablets in Healthy Participants",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","100","Weight Management; Type 2 Diabetes","DRUG:HRS9531 tablets","Fujian Shengdi Pharmaceutical Co., Ltd.","2026-07","2026-09","FALSE","AUCtau [0-24 hours after the 10th dosing.]",null,null,"UNDECIDED",null],["NCT02100475","A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification","DUAL™","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","31","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide; DRUG:insulin aspart","Novo Nordisk A/S","2014-04","2015-04","TRUE","Change From Baseline in HbA1c (Glycosylated Haemoglobin) [Week 0, week 26]",null,null,null,"EUDRACT_NUMBER:2013-002878-47; OTHER:U1111-1145-0183"],["NCT04889157","A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","20","Diabetes Mellitus, Type 2","DRUG:PF-06882961; DRUG:Placebo","Pfizer","2021-07-07","2022-02-17","TRUE","Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC24) of PF-06882961 10 mg Single Dose on Day 1 [Pre-dose, 1, 2, 4, 6, 8, 10, 12, 14, 24 hours post dose on Day 1] | Maximum Observed Concentration (Cmax) of PF-06882961 10 mg Single Dose on Day 1 [Pre-dose, 1, 2, 4, 6, 8, 10, 12, 14, 24 hours post dose on Day 1] | AUC24 of PF-06882961 in Participants Received 40 mg BID, 80 mg BID, and 120 mg BID PF-06882961 [Pre-dose, 1, 2, 4, 6, 8, 10, 12, 14, 24 hours post dose on Day 21 (40 mg BID), 35 (80 mg BID), and 56 (120 mg BID)] | Maximum Observed Concentration, Steady State (Cmax,ss) of PF-06882961 in Participants Received 40 mg BID, 80 mg BID, and 120 mg BID PF-06882961 [Pre-dose, 1, 2, 4, 6, 8, 10, 12, 14, 24 hours post dose on Day 21 (40 mg BID), 35 (80 mg BID), and 56 (120 mg BID)]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/57/NCT04889157/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/57/NCT04889157/SAP_001.pdf","NO",null],["NCT00308139","Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","303","Type 2 Diabetes Mellitus","DRUG:exenatide, long acting release; DRUG:exenatide","AstraZeneca","2006-04","2008-07","TRUE","Change in HbA1c From Baseline to Week 30 [Day -3, Week 30] | Sub-study Relative Bioavailability of Exenatide When Administered Using the Exenatide Once Weekly Dual Chambered Pen and the Exenatide Once Weekly Single Dose Tray (Single Dose Tray-11 Weekly Doses Switch to Dual Chamber Pen-11 Weekly Dose) [Week 22]","DERIVED:30600137; DERIVED:27525540; DERIVED:25744115; DERIVED:23748506; DERIVED:23358123; DERIVED:23166441; DERIVED:22236356; DERIVED:21529363; DERIVED:20215461; DERIVED:18782641",null,null,"OTHER:MB001-010"],["NCT02488057","Improving Beta Cell Function in Mexican American Women With Prediabetes",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","360","Pre-Diabetes","DRUG:Liraglutide; BEHAVIORAL:Weight loss","Ohio State University","2016-05","2019-03","FALSE","Beta Cell Function [3 months]","BACKGROUND:20675976; BACKGROUND:11815482; BACKGROUND:18834430; BACKGROUND:18388888; BACKGROUND:15111485; BACKGROUND:17468345; BACKGROUND:20876408; BACKGROUND:16755277; BACKGROUND:18332269; BACKGROUND:20413733",null,"YES",null],["NCT06726577","TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis",null,"RECRUITING","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","TRIPLE","60","Amyotrophic Lateral Sclerosis","DRUG:TP04HN106; DRUG:Saline","Talengen Institute of Life Sciences, Shenzhen, P.R. China.","2026-06-04","2027-01","FALSE","Amyotrophic Lateral Sclerosis Rating Scale (ALSFRS-R) [Baseline, 10th week]",null,null,null,null],["NCT01619345","Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","27","Diabetes; Healthy","DRUG:semaglutide","Novo Nordisk A/S","2012-06","2012-08","FALSE","Anatomical location (stomach or proximal small bowel) of tablet at complete tablet erosion (CTE) [Assessed 0-4 hours post dose]",null,null,null,"EUDRACT_NUMBER:2011-004162-14; OTHER:U1111-1123-7450"],["NCT03955575","Treatment of Bile Acid Malabsorption With Liraglutide","BAM-LIRA","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","52","Bile Acid Malabsorption","DRUG:Liraglutide 6 MG/ML; DRUG:Colesevelam","Filip Krag Knop","2019-03-07","2021-03-10","FALSE","Change in stool fequency [7 weeks]",null,null,"NO",null],["NCT07493057","Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","140","Obstructive Sleep Apnea (OSA)","DRUG:Placebo; DRUG:GZR18 injection","Gan & Lee Pharmaceuticals.","2026-04-27","2027-11-14","FALSE","Change from baseline in Apnea-Hypopnea Index (AHI) after 52 weeks of treatment [52 weeks]",null,null,null,null],["NCT06388187","A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","300","Obesity","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2024-06-24","2026-04-22","FALSE","Relative change in body weight [From baseline (week 0) to end of treatment (week 68)] | Achievement of ≥5% weight reduction [From baseline (week 0) to end of treatment (week 68)]",null,null,"YES","OTHER:U1111-1298-3451; OTHER:2023-509273-24; NIH:2023"],["NCT02380521","Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE4",null,"NONE","60","Type 2 Diabetes Mellitus","DRUG:Exenatide once weekly (BYDUREON™)","University of Palermo","2015-01","2016-07","FALSE","Subclinical atherosclerosis (as measured by cIMT) in patients with T2DM treated with exenatide once weekly [Change from baseline to 8 months of the treatment]","BACKGROUND:18782641; BACKGROUND:20580422; BACKGROUND:20609969; BACKGROUND:22210563; BACKGROUND:21307137; BACKGROUND:23141817",null,null,null],["NCT05429593","A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","152","Healthy Volunteers","DRUG:Semaglutide; DRUG:Dapagliflozin; DRUG:Semaglutide/dapagliflozin","Novo Nordisk A/S","2022-06-22","2023-03-10","FALSE","AUC0-24h,sema,ss: area under the semaglutide plasma concentration-time curve during a dosing interval (0 to 24 hours) at steady state [From 0 to 24 hours on day 49 and 84 in Part 1] | AUC0-24h,dapa,ss: area under the dapagliflozin plasma concentration-time curve during a dosing interval (0 to 24 hours) at steady state [From 0 to 24 hours on day 49 and 98 in Part 2]",null,null,"YES","OTHER:U1111-1266-4254; OTHER:2022-500007-52-00"],["NCT02674893","Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes","GLP1 et Goût","TERMINATED","INTERVENTIONAL","PHASE4",null,null,"48","Type 2 Diabetes; Overweight","DRUG:Liraglutide; OTHER:Observation alone","Centre Hospitalier Universitaire Dijon","2014-02-04","2016-08-31","FALSE","Modifications in wanting [Up to 3 months]","RESULT:31405666",null,null,null],["NCT06548945","A Phase I Study of GZR18 Injection in Obese/Overweight Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","16","Overweight and Obesity","DRUG:GZR18; OTHER:Placebo","Gan and Lee Pharmaceuticals, USA","2023-04-25","2023-08-14","FALSE","TEAE [50 days] | Anti-Drug Antibody (ADA) and Neutralizing Antibody (Nab) [50 days]",null,null,null,null],["NCT01952145","A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus","DUAL™ V","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","557","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide; DRUG:insulin glargine","Novo Nordisk A/S","2013-09-20","2014-11-04","TRUE","Change From Baseline in HbA1c (Glycosylated Haemoglobin) [Week 0, week 26]","RESULT:26934259; RESULT:28294641; RESULT:28281218; RESULT:28417535; RESULT:28643425; RESULT:29276398; RESULT:30383495; DERIVED:39963952; DERIVED:36710452; DERIVED:31705547",null,null,"EUDRACT_NUMBER:2012-004413-14; OTHER:U1111-1135-1003"],["NCT01988545","GLP-1's Effect on Cardiac Parameters and Mesenteric Blood Flow",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","8","Healthy","OTHER:1,5 nmol/kg,GLP-1 sc injection; OTHER:1,5 nmol/kg GLP-1 9-36amide, sc injection; OTHER:Exendin-4 ;10 ug,sc injection; OTHER:saline","Zealand University Hospital","2013-11-01","2014-06","FALSE","blood flow [with in 120 minutes]",null,null,null,null],["NCT01766245","A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","28","Diabetes; Healthy","DRUG:semaglutide","Novo Nordisk A/S","2012-12","2013-05","FALSE","Area under the plasma semaglutide concentration curve [0-4 weeks after a single dose s.c. semaglutide administration] | Cmax, the maximum plasma semaglutide concentration [20-40 hours after a single dose s.c. semaglutide administration]",null,null,null,"EUDRACT_NUMBER:2012-002212-20; OTHER:U1111-1130-3931"],["NCT07042672","Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity","BETTER-GLP1","RECRUITING","OBSERVATIONAL",null,null,null,"80","Binge Eating Disorder Associated With Obesity; Binge Eating Disorder; Eating Disorder Binge; Eating Disorders; GLP-1; CBT; Obesity &Amp; Overweight","DRUG:GLP-1; BEHAVIORAL:CBTe Group Therapy","Haukeland University Hospital","2025-07-01","2027-11-05","FALSE","Change in EDE-Q Global Score From Baseline to 12 Months [Baseline and 12 months]",null,null,"NO","NIH:2025"],["NCT01399645","Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes","LIRAINS","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","SINGLE","35","Nonalcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; Type 2 Diabetes","DRUG:Liraglutide-metformin vs insulin-metformin","Centre hospitalier de l'Université de Montréal (CHUM)","2011-05","2014-06","FALSE","To determine liver fat fraction evolution induced by liraglutide and insulin [12 weeks]","DERIVED:25813773",null,null,null],["NCT00931372","Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2","RESTORE","COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","22","Diabetes Mellitus, Type 2","DRUG:Lixisenatide (AVE0010); DRUG:Placebo","Sanofi","2009-06","2009-08","FALSE","Area under the insulin secretion curve [within 10 minutes after I.V. glucose challenge]",null,null,null,"OTHER:EudraCT:2008-003242-28"],["NCT07793929","A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide",null,"RECRUITING","INTERVENTIONAL","PHASE1",null,"NONE","32","End Stage Renal Disease; Renal Impairment; Obesity; Overweight","DRUG:Ribupatide","Kailera","2026-09-08","2028-02-08","FALSE","Maximum Observed Plasma Concentration (Cmax) of Ribupatide [Predose up to 816 hours postdose on Day 35] | Area Under Concentration Time Curve From Time Zero to Time of the Last Measurable Concentration (AUC0-t) of Ribupatide [Predose up to 816 hours postdose on Day 35] | Area Under Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Ribupatide [Predose up to 816 hours postdose on Day 35]",null,null,null,null],["NCT06699329","A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","38","Healthy","DRUG:Enlicitide Decanoate; DRUG:Semaglutide","Merck Sharp & Dohme LLC","2024-01-22","2024-05-24","FALSE","Area Under the Concentration-Time Curve from Time 0 to 24 hours (AUC0-24hrs) of Enlicitide Decanoate [At designated timepoints (up to 24 hours postdose)] | Area Under the Concentration-Time Curve from Time 0 to 24 hours (AUC0-24hrs) of Semaglutide [At designated timepoints (up to 24 hours postdose)] | Maximum Plasma Concentration (Cmax) of Enlicitide Decanoate [At designated timepoints (up to approximately 2 weeks postdose)] | Maximum Plasma Concentration (Cmax) of Semaglutide [At designated timepoints (up to approximately 2 weeks postdose)] | Time to Maximum Plasma Concentration (Tmax) of Enlicitide Decanoate [At designated timepoints (up to approximately 2 weeks postdose)] | Time to Maximum Plasma Concentration (Tmax) of Semaglutide [At designated timepoints (up to approximately 2 weeks postdose)]",null,null,"YES","OTHER:MK-0616-023"],["NCT04175665","Real-world Health Outcomes in Canadian Patients Using Semaglutide",null,"COMPLETED","OBSERVATIONAL",null,null,null,"1133","Type 2 Diabetes","DRUG:Semaglutide","LMC Diabetes & Endocrinology Ltd.","2020-01-06","2020-02-09","FALSE","Change in HbA1c [3 to 6 months]",null,null,"NO",null],["NCT07282769","Semaglutide (Wegovy) Treatment for Trichotillomania",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2",null,"NONE","10","Trichotillomania (Hair-Pulling Disorder); Trichotillomania; Hair Pulling Disorder; Hair Pulling; Hair-Pulling Disorder","DRUG:Semaglutide","University of Chicago","2026-06","2027-02","FALSE","NIMH Trichotillomania Severity Scale [From screening to 1 week after last dose of study drug]",null,null,"NO",null],["NCT06901245","Tirzepatide in PWS, HO and GNSO",null,"RECRUITING","INTERVENTIONAL","PHASE4","NON_RANDOMIZED","NONE","36","Prader-Willi Syndrome; Hypothalamic Obesity; Obesity/Therapy","DRUG:Tirzepatide","Grace Kim","2025-05-01","2026-06","FALSE","Change in weight [48 weeks]",null,null,"NO","OTHER_GRANT:I8F-NS-I001"],["NCT02057172","Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","254","Type 2 Diabetes","DRUG:HM11260C; DRUG:liraglutide; DRUG:Placebo","Hanmi Pharmaceutical Company Limited","2014-01","2014-10","FALSE","Change in baseline in glycosylated haemoglobin (HbA1c) at 12 weeks [Up to 127 days]","DERIVED:31320446",null,null,null],["NCT06818292","Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists","GLPsy","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","10","Healthy","BIOLOGICAL:Liraglutide; BIOLOGICAL:Placebo","Nils Opel","2024-10-21","2024-12-06","FALSE","Neuropsychology: Processing speed [Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months] | Neuropsychology: Attention [Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months] | Neuropsychology: Memory [Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months] | Neuropsychology: Verbal Fluency [Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months] | MR spectroscopy [Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months] | Exploratory Proteomics of Autophagy Processes I [Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months] | Exploratory Proteomics of Autophagy Processes II [Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months]",null,null,null,null],["NCT06260722","Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","1250","Diabetes Mellitus, Type 2","DRUG:Retatrutide; DRUG:Semaglutide","Eli Lilly and Company","2024-02-21","2026-08-27","FALSE","Change from Baseline in Hemoglobin A1c (HbA1c) (%) [Baseline, Week 80]",null,null,"YES","OTHER:J1I-MC-GZBZ"],["NCT07677865","GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation","GLP1-AD-TTE","COMPLETED","OBSERVATIONAL",null,null,null,"213891","Alzheimer Disease; Diabetes Mellitus Type 2; Obesity & Overweight","DRUG:GLP-1 Receptor Agonists; DRUG:DPP-4 Inhibitors","West China Hospital","2007-01-01","2024-12-31","FALSE","Incidence of Alzheimer's Disease [Up to 10 years (from index date of medication initiation to date of first AD diagnosis, death, or end of follow-up, whichever occurs first).]",null,null,"YES",null],["NCT04575194","Study of the Cardiometabolic Effects of Obesity Pharmacotherapy",null,"UNKNOWN","INTERVENTIONAL","PHASE4","NON_RANDOMIZED","NONE","40","Obesity; Blood Pressure","DRUG:Liraglutide 6 MG/ML [Saxenda]; DRUG:Naltrexone-Bupropion Combination","National and Kapodistrian University of Athens","2020-09-08","2022-09-30","FALSE","Changes in blood pressure [3 and 6 months]","DERIVED:37418844",null,"NO",null],["NCT05929066","A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight","TRIUMPH-1","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","2335","Obesity; Overweight; Osteoarthritis, Knee; Obstructive Sleep Apnea","DRUG:Retatrutide; DRUG:Placebo","Eli Lilly and Company","2023-07-10","2026-04-06","FALSE","Percent Change From Baseline in Body Weight [Baseline, Week 80] | Change from Baseline in Apnea-Hypopnea Index (AHI) Events Per Hour for GSA1 Subset [Baseline, Week 80] | Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score for GOA1 Subset [Baseline, Week 80] | Percent Change from Baseline in Body Weight in Participants in Extension Subset [Baseline, Week 104]","DERIVED:42814954",null,"YES","OTHER:J1I-MC-GZBJ; OTHER:J1I-MC-GOA1; OTHER:J1I-MC-GSA1; OTHER:2023-503657-35-00; NIH:2023"],["NCT06301256","Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe HS Hidradenitis Suppurativa",null,"UNKNOWN","INTERVENTIONAL",null,null,"NONE","20","Hidradenitis Suppurativa","DRUG:TIRZEPATIDE","Florida Academic Centers Research and Education, LLC","2024-03-11","2025-03-11","FALSE","Hidradenitis Suppurativa Clinical Response (HiSCR) 50% [24 Weeks]",null,null,"NO",null],["NCT01857895","Feasibility Study of Exenatide by Continuous Subcutaneous Infusion",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","10","Obesity","DRUG:Exenatide","GlaxoSmithKline","2013-05-16","2013-11-01","FALSE","Characterization of interruptions or deviations from prescribed exenatide infusion in Part A [2 days] | Characterization of interruptions or deviations from prescribed exenatide infusion in Part B [8 days] | Infusion rate adjustments when nausea/vomiting occurs in Part B [8 days] | Number of participants with adverse events (AEs) in Part A [17 days] | Number of participants with AEs in Part B [23 days] | Laboratory parameter assessment in Part A [17 days] | Laboratory parameter assessment in Part B [23 days] | Vital sign assessment in Part A [17 days] | Vital sign assessment in Part B [23 days]","DERIVED:26160357",null,"YES",null],["NCT04982575","Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","92","Diabetes Mellitus, Type 2","DRUG:Semaglutide 2.4 mg; DRUG:Cagrilintide 2.4 mg; DRUG:Placebo (semaglutide); DRUG:Placebo (cagrilintide)","Novo Nordisk A/S","2021-08-02","2022-07-07","TRUE","Change in Glycated Haemoglobin (HbA1c): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide) [Week 0, Week 32]","BACKGROUND:37364590","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/75/NCT04982575/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/75/NCT04982575/SAP_001.pdf","YES",null],["NCT03309241","First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","25","Healthy Subjects","DRUG:PF-06882961; OTHER:Placebo","Pfizer","2017-10-17","2018-02-21","FALSE","Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Seriousness and Relationship to Treatment [First dose of study drug up to 28 days after last dose of study drug]",null,null,"NO",null],["NCT04046822","Effect of Liraglutide on Microbiome in Obesity",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","70","Obesity; Weight Loss; Microbiome","DRUG:Liraglutide 6 MG/ML [Saxenda]; DRUG:Placebo","Federico II University","2019-01-09","2020-01-09","FALSE","Change in gut microbiome composition assessed by Firmicutes-to-Bacteroidetes ratio using Quantitative polymerase chain reaction (PCR) [Change from baseline in gut microbiome composition at weeks 5 (visit 7)]","BACKGROUND:15831718; BACKGROUND:26912499; BACKGROUND:27048547; BACKGROUND:28648835; BACKGROUND:15505215",null,"NO",null],["NCT02251431","Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","57","Type 2 Diabetes Mellitus; Chronic Kidney Disease; Left Ventricular Diastolic Dysfunction","DRUG:BYDUREON; DRUG:Placebo","Baylor Research Institute","2015-11","2019-12","TRUE","Galectin-3 [38 weeks] | ST2 [38 weeks] | NGAL [38 weeks] | KIM-1 [38 weeks] | L-FABP [38 weeks] | IL-18 [38 weeks] | Alpha GST [38 weeks] | Troponin I [38 weeks] | Pi GST [38 weeks] | NAG [38 weeks] | Cystatin-C [38 weeks] | BNP [38 weeks] | ACR [38 weeks]","BACKGROUND:17239676; BACKGROUND:21802579; BACKGROUND:1080957; BACKGROUND:20929995; BACKGROUND:22249510; BACKGROUND:23482076; BACKGROUND:20620723","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/31/NCT02251431/Prot_SAP_000.pdf",null,"OTHER_GRANT:D5551L00004/ISSEXEN0013"],["NCT03010475","A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","41","Diabetes; Healthy","DRUG:Furosemide; DRUG:Rosuvastatin; DRUG:SNAC; DRUG:Semaglutide","Novo Nordisk A/S","2017-01-05","2017-06-04","FALSE","Area under the furosemide plasma concentration-time curve [day 1, day 7, day 54] | Area under the rosuvastatin plasma concentration-time curve [day 2, day 8, day 55]","DERIVED:33782832",null,"YES","EUDRACT_NUMBER:2015-003908-23; OTHER:U1111-1173-8618; NIH:2015"],["NCT06323161","A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin","REIMAGINE 3","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","274","Type 2 Diabetes","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2024-03-26","2025-09-09","FALSE","Change in Glycated Haemoglobin (HbA1c) [From baseline (week 0) to end of treatment (week 40)]","DERIVED:42251856",null,"YES","OTHER:U1111-1283-0754; OTHER:2022-502679-43"],["NCT07357766","A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight",null,"WITHDRAWN","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","0","Overweight; Obesity","DRUG:Cagrisema; DRUG:Placebo CagriSema","Novo Nordisk A/S","2026-06-22","2027-11-29","FALSE","Relative change in body weight [From baseline (week 0) to end of treatment (week 44)]",null,null,"YES","OTHER:U1111-1317-0133; OTHER:2024-520448-41"],["NCT03798054","Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)","Lixilan-O-AP","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","878","Type 2 Diabetes Mellitus","DRUG:Insulin glargine/Lixisenatide (HOE901/AVE0010); DRUG:Insulin glargine (HOE901); DRUG:Lixisenatide (AVE0010); DRUG:Metformin; DRUG:SGLT2 inhibitor","Sanofi","2019-02-15","2021-03-01","FALSE","Change in HbA1c [From Baseline to Week 24]","BACKGROUND:35441412; DERIVED:36999231",null,"YES","OTHER:U1111-1190-7669"],["NCT05041673","Anti-diabetic Drugs and Fatty Liver Management",null,"UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","NONE","120","Fatty Liver, Nonalcoholic; Diabetes Mellitus, Type 2","DRUG:Metformin","Alexandria University","2021-02-23","2021-09-30","FALSE","Change in steatosis as measured using CAP score (fibroscan) and MRI [12 months]",null,null,"YES",null],["NCT06808802","To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","30","Healthy","DRUG:Retatrutide; DRUG:Metoprolol","Eli Lilly and Company","2025-02-03","2025-04-15","FALSE","Pharmacokinetics (PK): Area Under Concentration From Time Zero to Infinity (AUC[0-∞]) of Metoprolol [Day 1 to Day 3] | Pharmacokinetics (PK): AUC (0-∞) of Metoprolol with Retatrutide [Day 9 to Day 11] | PK: Maximum Concentration (Cmax) of Metoprolol [Day 1 to Day 3] | PK: Cmax of Metoprolol with Retatrutide [Day 9 to Day 11]",null,null,"NO","OTHER:J1I-MC-GZQE"],["NCT01517412","Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","451","Type 2 Diabetes Mellitus","DRUG:Lixisenatide (AVE0010); DEVICE:Self-injector pen device (OptiClik®); DRUG:Metformin","Sanofi","2012-02","2013-05","TRUE","Change in HbA1c From Baseline to Week 24 [Baseline, Week 24]","RESULT:25012990",null,null,"EUDRACT_NUMBER:2011-002416-85; OTHER:U1111-1118-0841"],["NCT02863328","Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus","PIONEER 2","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","822","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:empagliflozin","Novo Nordisk A/S","2016-08-10","2017-08-01","TRUE","Change in HbA1c [Week 0, week 26]","RESULT:31530666; RESULT:35064550; RESULT:35373893; DERIVED:37178435; DERIVED:36056351; DERIVED:32827435; DERIVED:32267058; DERIVED:31903692","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/28/NCT02863328/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/28/NCT02863328/SAP_001.pdf",null,"EUDRACT_NUMBER:2015-005209-36; OTHER:U1111-1176-6006; NIH:2015"],["NCT02451527","The Pharmacokinetic Study of the Combination of Digoxin and Polythylene Glycol Loxenatide Injection in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","16","Healthy","DRUG:Digoxin; DRUG:PEX168","First Affiliated Hospital Xi'an Jiaotong University","2015-05","2015-09","FALSE","Composite of pharmacokinetic (PK) parameters of digoxin with and without PEX168 in plasma and urine (cmax, t 1/2) [Day 1 through Day 44]",null,null,null,null],["NCT07292441","Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss","GZR18-BWM-303","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","500","Overweight or Obesity","DRUG:GZR18 injection; OTHER:Placebo","Gan & Lee Pharmaceuticals.","2026-01-22","2027-09","FALSE","Percent change (%) from baseline in body weight [from Week 0 (W0) to Week 24 (W24)]",null,null,null,null],["NCT01458210","A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","22","Diabetes Mellitus, Type 2","DRUG:Ortho-Cyclen; BIOLOGICAL:Dulaglutide","Eli Lilly and Company","2011-10","2012-02","TRUE","Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) at Steady State of Ortho-Cyclen - Norelgestromin (NGMN) [Day 21 during Periods 1 and 2: Pre-dose and up to 24 hours post-dose] | Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Ortho-Cyclen - Norelgestromin (NGMN) [Day 21 during Periods 1 and 2: Pre-dose and up to 24 hours post-dose] | Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Ortho-Cyclen - Norelgestromin (NGMN) [Day 21 Periods 1 and 2: Pre-dose and up to 24 hours post-dose] | Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) at Steady State of Ortho-Cyclen - Ethinyl Estradiol (EE) [Day 21 during Periods 1 and 2: Pre-dose and up to 24 hours post-dose] | Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Ortho-Cyclen - Ethinyl Estradiol (EE) [Day 21 during Periods 1 and 2: Pre-dose and up to 24 hours post-dose] | Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Ortho-Cyclen - Ethinyl Estradiol (EE) [Day 21 during Periods 1 and 2: Pre-dose and up to 24 hours post-dose]","DERIVED:28357715",null,null,"OTHER:H9X-MC-GBCQ"],["NCT07009860","RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","121","Alcohol-associated Liver Disease","DRUG:Pemvidutide; OTHER:Placebo","Altimmune, Inc.","2025-06-16","2027-09-30","FALSE","Relative (%) reduction in liver stiffness by VCTE compared to baseline [Week 48 and 24]",null,null,"YES",null],["NCT05959096","A Study of LY3437943 in Healthy Participants With a High Body Mass Index",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","85","Healthy","DRUG:LY3437943","Eli Lilly and Company","2023-07-18","2024-07-25","FALSE","Part A: Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3437943 [Predose on Day 1 up to 43 days postdose (Part A)] | Part A: PK: Maximum Concentration (Cmax) of LY3437943 [Predose on Day 1 up to 43 days postdose (Part A)]",null,null,"NO","OTHER:J1I-MC-GZBS"],["NCT06118203","Semaglutide Use in Acute Pulmonary Embolism",null,"COMPLETED","OBSERVATIONAL",null,null,null,"18","Pulmonary Embolism","DRUG:Semaglutide","Imperial College London","2022-01-02","2023-03-04","FALSE","Endothelial biomarker measurement [4 weeks]","DERIVED:41536961",null,null,null],["NCT02235961","Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","163","Metabolism and Nutrition Disorder; Obesity","DRUG:NNC9204-0530; DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2014-09-04","2016-07-06","FALSE","Number of treatment emergent adverse events recorded [From time of dosing of NNC9204-0530 (Day 1) until completion of the follow-up visit (Day 21-27)]",null,null,null,"REGISTRY:U1111-1151-0761"],["NCT07836270","A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","192","Adolescents With Obesity; Adolescents With Overweight & Weight-related Comorbidities","DRUG:Ecnoglutide Injection; DRUG:placebo with matching volume","Hangzhou Sciwind Biosciences Co., Ltd.","2026-10-31","2028-06-08","FALSE","Percent change in Body Mass Index (BMI) [Baseline, week 40]",null,null,"NO",null],["NCT07220473","Tirzepatide to Slow Biological Aging",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","90","Aging; LONGEVITY 1","DRUG:Zepbound","The University of Texas Medical Branch, Galveston","2026-02-27","2027-11","FALSE","Change in DNA Methylation-Based Biological Age [Immediately before and after the study visit at Weeks 4, 12, and 24]",null,null,"NO",null],["NCT07847515","Effects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese Patients",null,"NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"80","Obesity / Overweight","DRUG:Tirzepatide","Nanjing First Hospital, Nanjing Medical University","2027-02-01","2027-06","FALSE","Changes in Gut Microbiota Characteristics [Baseline (0 week) and 3 months]",null,null,"NO",null],["NCT03520062","The Effect of Liraglutide on Pancreatic Hormones and Its Size","LIRAP","COMPLETED","INTERVENTIONAL",null,null,"NONE","14","Obesity","DRUG:Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml","Nicolai Jacob Wewer Albrechtsen","2017-08-15","2019-04-30","FALSE","Volumetric Changes of the Pancreas [6 weeks]",null,null,"UNDECIDED",null],["NCT07654361","Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","3600","Obesity; Overweight; Chronic Weight Management","DRUG:Aleniglipron; DRUG:Placebo","Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics","2026-07-13","2028-09","FALSE","Percent change in body weight from Baseline [Baseline and Week 76]",null,null,"YES",null],["NCT07770282","Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","600","Schizophrenia Disorder; Metabolic Syndrome; Antipsychotic-induced Weight Gain; Cardiovascular Risk; Insulin Resistance","DRUG:Semaglutide + TAU; DRUG:Placebo + TAU","All India Institute of Medical Sciences, Bhubaneswar","2026-12-01","2030-07-30","FALSE","Change in QRISK3 (QResearch Cardiovascular Risk Prediction Algorithm Version 3),10-year cardiovascular risk score [Baseline to Week 24]","BACKGROUND:24763306; BACKGROUND:10553730; BACKGROUND:18466668; BACKGROUND:20692814; BACKGROUND:22207632; BACKGROUND:17909124",null,"NO",null],["NCT00744224","PREDnisolone-induced Beta-cell Dysfunction Prevented by EXenatide","PREDEX","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","8","Glucocorticoid-induced Glucometabolic Abnormalities; Glucocorticoid-induced Beta-cell Dysfunction","DRUG:Placebo; DRUG:Prednisolone; DRUG:Prednisolone and Exenatide","Amsterdam UMC, location VUmc","2009-02","2010-01","FALSE","To assess whether a single day infusion of the GLP-1 RA exenatide, as compared to placebo, reverses GC-induced impairment of glucose metabolism in healthy males, quantified as glucose tolerance (AUCgluc) during a standardized mixed-meal test [Single-day treatment]","DERIVED:21216851",null,null,null],["NCT06851962","Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.","EPHIC-DIA2","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","92","Diabetes Mellitus Type 2","DRUG:Metformin; DRUG:Dulaglutide; DRUG:Semaglutide 1.0 mg; DRUG:Empagliflozin (BI 10773); DRUG:Canagliflozin; DRUG:Dapagliflozin; DRUG:pioglitazone; DRUG:Sitagliptin; DRUG:Vildagliptin (Galvus); DRUG:linagliptin","Fundación para la Investigación del Hospital Clínico de Valencia","2025-05-26","2026-06-30","FALSE","Comparison of HbA1c ≤7% goal at Week 24 between Pharmacogenetic-Guided and Standard Treatment in Type 2 Diabetes [From baseline to the end of treatment at 24 weeks]",null,null,null,"CTIS:2025-520686-46-00; NIH:2025"],["NCT02560376","68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis",null,"UNKNOWN","INTERVENTIONAL","EARLY_PHASE1",null,"NONE","100","Insulinoma; Nesidioblastosis","DRUG:68Ga-NOTA-exendin-4","Peking Union Medical College Hospital","2014-02","2016-12","FALSE","Standardized uptake value of 68Ga-NOTA-exendin-4 PET/CT in Diagnosis of Insulinoma and Nesidioblastosis [1 year]",null,null,null,"NIH:ZIAEB000073"],["NCT02324842","Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","45","Type 2 Diabetes Mellitus","DRUG:Canagliflozin; DRUG:Liraglutide","The University of Texas Health Science Center at San Antonio","2014-11","2018-03-28","TRUE","HbA1c at 4 Months [Approximately 4 months] | Fasting Plasma Glucose (FPG) at 4 Months [Baseline to Approximately 4 months]","DERIVED:32745202; DERIVED:32220916","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/42/NCT02324842/Prot_SAP_000.pdf",null,"OTHER:HSC20140322H"],["NCT07220759","Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide","RENEW 2","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","330","Overweight; Obesity; Type 2 Diabetes","DRUG:Cagrilintide; DRUG:Placebo (matched to Cagrilintide)","Novo Nordisk A/S","2025-11-05","2027-05-12","FALSE","Relative change in body weight [From baseline (week 0) to end of treatment (week 64)]",null,null,"YES","OTHER:U1111-1314-9328; OTHER:2024-519531-41"],["NCT05316662","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice",null,"COMPLETED","OBSERVATIONAL",null,null,null,"187","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2022-04-06","2024-04-06","FALSE","Change in HbA1c [From baseline (week 0) to End of Study visit (V3) (week 34-44)]",null,null,"YES","OTHER:U1111-1240-4396"],["NCT06720246","Impact of Bariatric Surgery and Liraglutide on Cognitive-Behavioral Markers of Long-Term Weight Loss in Obesity","Balance","RECRUITING","OBSERVATIONAL",null,null,null,"50","Obesity and Overweight",null,"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio","2024-06-26","2027-05-01","FALSE","Reaction times (approach bias) [Baseline and after treatment (2-4 months)] | Accuracy (inhibition) [Baseline and after treatment (2-4 months)]",null,null,"NO","OTHER_GRANT:RC2024"],["NCT03419624","The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients",null,"TERMINATED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","13","Obesity; Diabetes Mellitus, Type 2","DRUG:Dapagliflozin 10mg; DRUG:Exenatide 2 mg [Bydureon]; DRUG:Placebo Oral Tablet; DRUG:Placebo injection; DRUG:Insulin; DRUG:Metformin, if taken before","Universitätsklinikum Hamburg-Eppendorf","2018-02-19","2019-04-01","FALSE","Change in HbA1c from baseline (week 0) to week 28 [28 weeks]","BACKGROUND:26213556; BACKGROUND:22431673; BACKGROUND:22608371; BACKGROUND:22517736; BACKGROUND:22526604; BACKGROUND:24251534; BACKGROUND:18165348; BACKGROUND:24741511; BACKGROUND:18613325; BACKGROUND:21307137; BACKGROUND:20609969; BACKGROUND:11815510; BACKGROUND:25436106; BACKGROUND:27651331",null,"NO",null],["NCT01076842","Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","75","Diabetes Type 2","DRUG:Insulin-Levemir; DRUG:Exenatide-Bayetta; DRUG:Insulin-Levemir and Exenatide-Bayetta; DEVICE:SenseWear Pro3® armband; DEVICE:DexCom CGM","Novo Nordisk A/S","2008-04","2011-04","FALSE","The primary endpoint is the improvement in A1C goal measured in mean reduction in A1c levels over 24 weeks. [1 month]",null,null,null,null],["NCT03279731","Binge Eating Liraglutide Intervention","BELIEVE","TERMINATED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","36","Binge-Eating Disorder","DRUG:Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml; DRUG:Placebo","Kelly Allison","2017-09-29","2019-09-30","TRUE","Binge Episodes [baseline and 17 weeks (or last observation carried forward)]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/31/NCT03279731/Prot_SAP_000.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/31/NCT03279731/ICF_001.pdf","NO",null],["NCT04019561","A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","74","Non-alcoholic Fatty Liver Disease (NAFLD); Non-alcoholic Steatohepatitis (NASH)","DRUG:MEDI0382 high dose; DRUG:Placebo for MEDI0382 high dose; DRUG:MEDI0382 low dose; DRUG:Placebo for MEDI0382 low dose","MedImmune LLC","2019-09-23","2021-05-06","TRUE","Safety (Including Hepatic Safety) and Tolerability of MEDI0382 Compared With Placebo: Number of Participants With TEAE and SAE [Day 1 - Day 161]","DERIVED:38729399","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/61/NCT04019561/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/61/NCT04019561/SAP_003.pdf","YES",null],["NCT07304141","Pharmacological Treatment - An Overview of Its Role in Managing Childhood Obesity",null,"COMPLETED","OBSERVATIONAL",null,null,null,"128","Obesity (Disorder); Child Obesity","OTHER:Liraglutide 3 mg (Saxenda)","Göteborg University","2023-12-20","2025-12-12","FALSE","Change in Body Mass Index Standard Deviation Score (BMI SDS) over time [The primary outcome, change in BMI SDS, will be evaluated at -12 months (pre-baseline), at baseline (0 months), and at +3-6, +12, and +18 months following treatment initiation.]",null,null,"NO",null],["NCT03961256","Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","9","Pre Diabetes","DRUG:Exenatide SR","Mayo Clinic","2019-05-09","2021-10-18","TRUE","Progression From Prediabetes to Diabetes [12 months after transplantation]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/56/NCT03961256/Prot_SAP_000.pdf","NO",null],["NCT02461914","Evaluate the Pharmacokinetics of Warfarin When Coadministered With PEX168 in Healthy Adult Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","16","Healthy","DRUG:PEX168; DRUG:Warfarin","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2015-08-01","2015-12-12","FALSE","Composite measure the plasma concentrations of warfarin [Baseline to Day51]",null,null,"NO",null],["NCT03713684","Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)","AMPLITUDE-L","TERMINATED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","370","Type 2 Diabetes Mellitus","DRUG:Efpeglenatide SAR439977; DRUG:Placebo; DRUG:Background therapy","Sanofi","2018-11-09","2020-11-20","TRUE","Change From Baseline to Week 30 in HbA1c [Baseline to Week 30]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/84/NCT03713684/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/84/NCT03713684/SAP_001.pdf","NO","OTHER:U1111-1189-5009"],["NCT06309992","A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","218","Obesity; Non-Alcoholic SteatoHepatitis (NASH)","COMBINATION_PRODUCT:Survodutide; COMBINATION_PRODUCT:Placebo","Boehringer Ingelheim","2024-04-02","2025-10-09","FALSE","Relative reduction in liver fat content of at least 30% from baseline to Week 48 (yes/no) assessed by magnetic resonance imaging proton density fat fraction (MRI-PDFF) [%] [at baseline, at week 48] | Relative change (%) in body weight [kg] from baseline to Week 48 [at baseline, at week 48]","DERIVED:39967239",null,"YES","REGISTRY:2023-505303-23-00; REGISTRY:U1111-1299-9925; NIH:2023"],["NCT07671248","Tirzepatide in the Treatment of Cannabis Use Disorder",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3",null,"NONE","15","Cannabis Use Disorder, Moderate; Cannabis Use Disorder, Severe","DRUG:Tirzepatide","McMaster University","2026-08-01","2028-07-31","FALSE","Tolerability of Tirzepatide-Assisted-Psychotherapy for Cannabis Use Disorder. [From baseline to 12-week endpoint.] | Feasibility of Tirzepatide-Assisted-Psychotherapy for Cannabis Use Disorder. [From baseline to 12-week endpoint.]",null,null,"UNDECIDED",null],["NCT00833716","Effect of Renal Impairment on the Pharmacokinetics of NN9535",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","62","Diabetes; Diabetes Mellitus, Type 2; Renal Impairment","DRUG:semaglutide","Novo Nordisk A/S","2009-02-02","2010-07-26","FALSE","AUC of NN9535 [at 21 days]","RESULT:28349386",null,null,null],["NCT01003184","Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","222","Type 2 Diabetes Mellitus","DRUG:exenatide once weekly; DRUG:insulin detemir","AstraZeneca","2009-10","2011-07","TRUE","Percentage of Patients Achieving Glycosylated Hemoglobin (HbA1c) Concentration ≤7.0% With Weight Loss (≥1.0 kg) at Endpoint (Week 26) [Baseline, Week 26]","DERIVED:32306296",null,null,null],["NCT04529278","Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients","LIRADIAL","UNKNOWN","INTERVENTIONAL","PHASE2",null,"NONE","18","Diabetes Mellitus, Type 2; Hemodialysis; Obese","DRUG:Liraglutide","Fondation Hôpital Saint-Joseph","2021-01-18","2023-01-17","FALSE","Weight Loss at Week 26 [Week 26]","RESULT:24911038; RESULT:24742478; RESULT:28493926; RESULT:19926371; RESULT:22383694; RESULT:18931095; RESULT:30122305; RESULT:19853906; RESULT:28854085; RESULT:26283739; RESULT:25526642; RESULT:29726082",null,null,null],["NCT01215968","A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","38","Diabetes Mellitus, Type 2","BIOLOGICAL:LY2189265; DRUG:Placebo","Eli Lilly and Company","2010-09","2011-07","TRUE","Time Required for 50% of Radioactivity To Be Emptied From the Stomach by Scintigraphy [Days 3, 10,17, 24 and 31]",null,null,null,"EUDRACT_NUMBER:2009-017305-11; OTHER:H9X-EW-GBDM; NIH:2009"],["NCT06301191","The Effect of Semaglutide on Cardiovascular Markers and Liver Function",null,"UNKNOWN","OBSERVATIONAL",null,null,null,"50","Diabetes Type 2","DRUG:Semaglutide, 1.0 mg/mL; DRUG:Dipeptidyl Peptidase 4 inhibitor","Attikon Hospital","2022-03-01","2023-03-01","FALSE","Comparison of arterial stiffness markers difference among treatment groups [12 months] | Comparison of endothelial glycocalyx thickness difference among treatment groups [12 months] | Comparison of liver stiffness difference among treatment groups [12 months]",null,null,null,null],["NCT01473147","Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic Patients","AGAC2","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","51","Type 2 Diabetes Mellitus","DRUG:Exenatide; DRUG:Normal saline","Chang Gung Memorial Hospital","2011-10","2013-06","FALSE","Mean amplitude of glycaemic excursions (MAGE) [During 6-day treatment course]",null,null,null,null],["NCT02207348","Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","24","Metabolism and Nutrition Disorder; Obesity","DRUG:liraglutide","Novo Nordisk A/S","2014-08","2014-09","FALSE","Area under the liraglutide plasma concentration time curve from 0 to last quantifiable observation (tz) after single dose [0-72 hours following administration of 0.6 mg liraglutide] | Maximum observed liraglutide plasma concentration after single dose [0-72 hours following administration of 0.6 mg liraglutide]",null,null,null,"EUDRACT_NUMBER:2014-000216-34; OTHER:U1111-1152-1391; NIH:2014"],["NCT04559815","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice","PIONEER REAL","COMPLETED","OBSERVATIONAL",null,null,null,"194","Diabetes Mellitus, Type 2","DRUG:Oral Semaglutide","Novo Nordisk A/S","2020-10-21","2022-09-14","FALSE","Change in Glycated haemoglobin (HbA1c) [From baseline (week 0) to End of Study visit (V3) (week 34-44)]","DERIVED:39535683; DERIVED:38468125",null,"YES","OTHER:U1111-1240-3985"],["NCT01767389","Glucagon-like Peptide (GLP) Utilization and Safety",null,"COMPLETED","OBSERVATIONAL",null,null,null,"1","Diabetes Mellitus, Type 2","OTHER:The GLP-1 receptor agonist users; OTHER:DPP-4 inhibitor users; OTHER:Other ADA users","GlaxoSmithKline","2012-09","2013-12","FALSE","For treatment utilization patterns: adherence will be assessed. [6 years] | For treatment utilization patterns: source of the index ADA (add-on, switch or new therapy) will be assessed. [6 years] | For treatment utilization patterns: treatment modification (discontinuation of the index ADA, switching of the index and concomitant ADA, and add-on therapy) will be assessed. [6 years]",null,null,null,"OTHER:WEUSKOP6477"],["NCT03987074","Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","109","Nonalcoholic Steatohepatitis","DRUG:Semaglutide; DRUG:Firsocostat; DRUG:Cilofexor","Gilead Sciences","2019-07-29","2020-07-13","TRUE","Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) [First dose date up to Week 24 plus 30 days] | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities [First dose date up to 24 weeks plus 30 days]","DERIVED:35439567","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/74/NCT03987074/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/74/NCT03987074/SAP_001.pdf","NO",null],["NCT05978713","A Study of Tirzepatide (LY3298176) in Healthy Lactating Females",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","11","Healthy","DRUG:Tirzepatide","Eli Lilly and Company","2023-07-31","2024-03-12","TRUE","Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of Tirzepatide in Breastmilk From Zero to Infinity (AUC [0-∞]) [Predose, 3, 6, 9, 12, 16, 24, 36, 48, 72, 96, 120, 168, 336, 504, 672 hours post-dose]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/13/NCT05978713/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/13/NCT05978713/SAP_001.pdf","NO","OTHER:I8F-MC-GPIN"],["NCT07163624","UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study","T2DM","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","211","Type 2 Diabetes Mellitus (T2DM)","DRUG:UBT251 Injection 2.0 mg and UBT251 Injection Placebo; DRUG:UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo; DRUG:UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo; DRUG:UBT251 Injection 6.0 mg and UBT251 Injection Placebo; DRUG:Semaglutide Injection (Ozempic®)","The United Bio-Technology (Hengqin) Co., Ltd.","2025-03-22","2025-11-21","FALSE","Change From Baseline in HbA1c at Week 24 [Baseline to week 24]",null,null,"YES","OTHER:CTR20250029"],["NCT01056549","Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","15","Hyperlipidemia","DRUG:exenatide","University Health Network, Toronto","2010-01","2011-09","FALSE","The objective is to examine the change in apoB48 production rate after one subcutaneous injection of exenatide, under conditions of a pancreatic clamp and a steady state fed state. [over 10 hours]","DERIVED:22492091",null,null,null],["NCT05990374","Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years",null,"UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","TRIPLE","100","Diabetes","DRUG:Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc","Nanjing First Hospital, Nanjing Medical University","2023-08-01","2024-01-01","FALSE","Effects of different GLP-1 on blood glucose [1,2,3,4 year]","DERIVED:40607222",null,null,null],["NCT06515418","Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over","STRIDES","TERMINATED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","204","Obesity","DRUG:Oral Azelaprag (BGE-105); DRUG:Oral Placebo for Azelaprag (BGE-105); DRUG:Tirzepatide; DRUG:Tirzepatide Placebo","BioAge Labs, Inc.","2024-06-27","2025-02-06","FALSE","Mean Percent Change in Body Weight (Azelaprag Once per Day) [Week 24] | Mean Percent Change in Body Weight (Azelaprag Twice per Day) [Week 24]",null,null,"NO",null],["NCT07092618","Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation",null,"RECRUITING","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","NONE","150","Longevity; GLP-1; Geroscience; Aging","DRUG:Metformin; DRUG:Rapamycin; DRUG:Naltrexone; DIETARY_SUPPLEMENT:Vitamin C","AgelessRx","2024-12-17","2025-08","FALSE","Evaluate the effectiveness of metformin in maintaining GLP1-induced weight loss in participants weaning off of Ozempic or Wegovy (or compounded semaglutide equivalent) [6 months] | Evaluate the effectiveness of metformin + rapamycin in maintaining GLP1-induced weight loss in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent) [6 months] | Evaluate the effectiveness of metformin + LDN in maintaining GLP1-induced weight loss in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent) [6 months]",null,null,"YES",null],["NCT01769378","Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)","AWARD-8","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","300","Type 2 Diabetes Mellitus","DRUG:Placebo; DRUG:Dulaglutide; DRUG:Glimepiride","Eli Lilly and Company","2013-01","2014-12","TRUE","Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 24 Weeks [Baseline, 24 Weeks]","DERIVED:36894938",null,null,"OTHER:H9X-MC-GBDG"],["NCT00872378","The Effects of Exenatide After Gastric Restriction","AGREE","UNKNOWN","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","TRIPLE","28","Morbid Obesity","DRUG:Exenatide; DRUG:Placebo","Advanced Specialty Care","2009-02","2010-12","FALSE","To describe change in body weight in non-diabetic morbidly obese patients after laparoscopic adjustable gastric banding (LAGB) with twice daily exenatide plus lifestyle modification plan or placebo plus lifestyle modification plan. [52 weeks]",null,null,null,null],["NCT05443568","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice","PIONEER REAL","COMPLETED","OBSERVATIONAL",null,null,null,"155","Diabetes Mellitus, Type 2","DRUG:Oral semaglutide","Novo Nordisk A/S","2023-03-09","2024-11-16","FALSE","Change in HbA1c (Glycated haemoglobin) [From baseline (week 0) to End of Study visit (V3) (week 34-44)]",null,null,"YES","OTHER:U1111-1240-4321"],["NCT06954090","Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study","SIGNAL","ENROLLING_BY_INVITATION","INTERVENTIONAL","PHASE4","NON_RANDOMIZED","NONE","50","Type 2 DM; Type 2 DM /Diabetic Nephropathy; Albuminuria","DRUG:Semaglutide, 1.34 mg/mL; DRUG:Finerenone Oral Tablet; DRUG:Dapagliflozin (DAPA)","Steno Diabetes Center Copenhagen","2025-11-20","2026-11-30","FALSE","Proteomic feasibility [2 weeks from sampling] | Evaluation of medical treatment [3 weeks from sampling]",null,null,"NO","CTIS:2024-518682-95-00"],["NCT00434954","Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","494","Type 2 Diabetes Mellitus","DRUG:exenatide twice daily (BID); DRUG:premixed insulin aspart twice daily (BID)","AstraZeneca","2007-02","2009-06","TRUE","Change in Glycosylated Hemoglobin (HbA1c) [Baseline and 26 weeks] | Incidence of Hypoglycemia (Percentage of Participants With at Least One Hypoglycemic Episode) [26 weeks]","DERIVED:22913891; DERIVED:21285388",null,null,null],["NCT02084654","Exenatide and Weight Loss for Diabetes Prevention",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","66","Pre Diabetes; Insulin Resistance","DRUG:Exenatide 5 and 10 mcg 2 times a day; DRUG:placebo","Stanford University","2007-11","2012-10","FALSE","First-phase insulin response [7 months]",null,null,"NO",null],["NCT04034524","Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin",null,"UNKNOWN","OBSERVATIONAL",null,null,null,"20000","Diabetes Mellitus, Type 2","DRUG:GLP-1 receptor agonist; DRUG:Insulin","Brigham and Women's Hospital","2019-05-01","2020-12-31","FALSE","Time until first composite CV event (myocardial infarction, stroke) [Through Study Completion, an estimated average of 1 year]",null,null,null,null],["NCT02750410","A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","159","Type 2 Diabetes","DRUG:Dulaglutide; DRUG:Placebo","Eli Lilly and Company","2016-08","2018-06-18","TRUE","Change From Baseline in Hemoglobin A1c (HbA1c) [Baseline, Week 16]","DERIVED:31994009; DERIVED:31758520","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/10/NCT02750410/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/10/NCT02750410/SAP_001.pdf","YES","OTHER:H9X-JE-GBGF"],["NCT02344186","Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","12","Type 2 Diabetes","DRUG:Liraglutide","Temple University","2014-05","2022-12-31","FALSE","Changes in unfolded protein response markers [baseline, 6 months, 9 months]",null,null,null,null],["NCT06987669","Gastric Emptying in Healthy Volunteers and GLP-1 Agonist Users","aGLP1-GUS","NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"155","Diabetes Type 2; Obesity and Overweight","DIAGNOSTIC_TEST:Gastric Ultrasound","Clinica Alemana de Santiago","2025-05-17","2026-12-31","FALSE","Number of patients with each Grade ( stomach content characteristics) according Perlas et al [24 hours tops since the starting of the clear fluid diet]",null,null,null,"OTHER:2024-100"],["NCT06581120","GLP_1 RA Ultrasound Study",null,"ENROLLING_BY_INVITATION","OBSERVATIONAL",null,null,null,"100","Glucagon Like Peptide-1 (GLP-1; Delayed Gastric Emptying; Risk of Aspiration; Diabetes; Morbid Obesity","DRUG:Glucagon-Like Peptide-1 receptor agonists; DIAGNOSTIC_TEST:Point of Care Gastric Ultrasound","Children's Hospital Medical Center, Cincinnati","2024-07-08","2026-07","FALSE","Aspiration Risk determined by POGUS [Two years]",null,null,"NO",null],["NCT06426446","Monitoring Patients With Severe Obesity Treated With Wegovy® Using Connected Device: Real-world Data","TELE-SEMA","UNKNOWN","INTERVENTIONAL",null,null,"NONE","80","Obesity","DEVICE:Withings Body Comp Pro","Assistance Publique - Hôpitaux de Paris","2024-06-01","2025-06-01","FALSE","The relative difference in weight loss achieved at 6 months of treatment at the maximum tolerated dose ((weight after 6 months of treatment at the maximum tolerated dose - baseline weight) / baseline weight) [6 months]","BACKGROUND:34238998; BACKGROUND:21654630; BACKGROUND:31383618; BACKGROUND:33567185; BACKGROUND:36200477; BACKGROUND:32213703; BACKGROUND:36655300; BACKGROUND:35230650; BACKGROUND:34183269; BACKGROUND:36187123; BACKGROUND:35383100; BACKGROUND:21303642; BACKGROUND:30622090; BACKGROUND:32814459",null,"YES",null],["NCT03631186","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)",null,"COMPLETED","OBSERVATIONAL",null,null,null,"215","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2018-09-12","2019-12-18","FALSE","Change in Glycated Haemoglobin A1c (HbA1c) [Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)] | Change in HbA1c [Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)]","RESULT:34217773; DERIVED:35383100",null,"YES","OTHER:U1111-1207-6039"],["NCT02963922","Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin","SCALE™ Insulin","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","396","Metabolism and Nutrition Disorder; Obesity","DRUG:Liraglutide 3.0 mg; DRUG:Placebo","Novo Nordisk A/S","2017-02-06","2018-09-10","TRUE","Change in Body Weight (%) [Week 0, week 56] | Participants Losing at Least 5% of Baseline Body Weight [Week 56]","RESULT:32139381","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/22/NCT02963922/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/22/NCT02963922/SAP_001.pdf","YES","OTHER:U1111-1177-4903; EUDRACT_NUMBER:2015-005619-33; NIH:2015"],["NCT07154719","GLP-1R Actions on Muscle and the Skeleton","GRAMS","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","50","Musculoskeletal Abnormalities; Obesity; Sarcopenic Obesity; Osteoporosis; Drug Effect","DRUG:Tirzepatide; BEHAVIORAL:Lifestyle toolkit","Pennington Biomedical Research Center","2025-10-09","2027-02-01","FALSE","Changes in fat free mass (FFM) using DXA imaging. FFM equals all body composition that is not fat mass. This includes bone, skeletal muscle, organs, water and all connective tissues. The unit of measurement is in kilograms (kg) at baseline, 3 and 6 mo. [Baseline and time 3, and 6 months.]","BACKGROUND:10778870; BACKGROUND:33951361; BACKGROUND:35658024; BACKGROUND:39344838",null,"YES",null],["NCT05486065","A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","245","Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2022-08-08","2023-10-12","TRUE","Change in Glycated Haemoglobin (HbA1c) [Baseline (week 0) and End of treatment (week 40)]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/65/NCT05486065/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/65/NCT05486065/SAP_001.pdf","YES","OTHER:U1111-1271-9209; EUDRACT_NUMBER:2022-000882-41"],["NCT06222437","Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy",null,"WITHDRAWN","INTERVENTIONAL","PHASE1",null,"NONE","0","Polycystic Ovary Syndrome","DRUG:Semaglutide","Methodist Health System","2026-02","2026-02","FALSE","Number of appropriate weekly dose [4 weeks] | Number of days on therapy [4 weeks]",null,null,"NO",null],["NCT03457012","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice","SURE CANADA","COMPLETED","OBSERVATIONAL",null,null,null,"462","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2018-03-29","2019-12-19","FALSE","Change in Glycated Haemoglobin A1c (HbA1c) [Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28-38)] | Change in HbA1c [Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28-38)]","RESULT:34142429; DERIVED:35383100",null,"YES","OTHER:U1111-1205-5853"],["NCT01175473","Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","148","Type 2 Diabetes Mellitus","DRUG:Lixisenatide (AVE0010); DEVICE:Pen auto-injector; DRUG:Liraglutide; DEVICE:Pre-filled pen injector; DRUG:Metformin","Sanofi","2010-08","2010-11","TRUE","Change From Baseline in Area Under the Plasma Glucose Concentration Curve From Time 0.5 Hours to 4.5 Hours (GLU-AUC0:30-4:30h) at Day 28 [0.5 (8:00 clock time; prior to standardized breakfast), 0.75, 1, 1.5, 2, 2.5, 3.5, 4.5 hours on Day -1 (baseline), 0.5 (prior to standardized breakfast), 0.75, 1, 1.5, 2, 2.5, 3.5, 4.5 hours post study drug administration on Day 28]","RESULT:23368510",null,null,"EUDRACT_NUMBER:2009-017666-23; OTHER:U1111-1116-9040; NIH:2009"],["NCT07653477","Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)","UNIGUIDE-2","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","956","Type 2 Diabetes","DRUG:UBT251 Injection 2.0 mg group; DRUG:UBT251 Injection 4.0 mg group; DRUG:UBT251 Injection 6.0 mg group; DRUG:Semaglutide Injection","The United Bio-Technology (Hengqin) Co., Ltd.","2026-09-07","2028-02-29","FALSE","HbA1c [Week 40]",null,null,"NO",null],["NCT04873050","Treatment to Regress to Normoglycemia in Women with a Recent History of GDM","SWEET","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","102","Pre Diabetes; Postpartum Disorder","DRUG:Semaglutide Pen Injector [Ozempic]; DRUG:Placebo semaglutide pen injector","Woman's","2022-01-13","2026-01-01","FALSE","Regression to normoglycemia [After 24 weeks of full-dose treatment]",null,null,"NO",null],["NCT00993304","A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 Diabetics",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","20","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2009-10","2010-12","FALSE","AUC0-8h (triglyceride), the area under the triglyceride-concentration-time curve in the interval 0-8 hours following a meal with a high fat content [after 3 weeks of treatment]","RESULT:23683069; RESULT:26225223; DERIVED:25603819",null,null,"EUDRACT_NUMBER:2008-003229-18; OTHER:U1111-1111-9161; NIH:2008"],["NCT05819138","Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes","T1-DISCO","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","60","Diabetes Mellitus, Type 1","DRUG:Semaglutide Pen Injector; DRUG:Placebo","University of Colorado, Denver","2023-06-21","2027-10-01","FALSE","Change in Ascending Aortic Pulse Wave Velocity (AA PWV) [Baseline, month 8] | Change in Carotid and Femoral Artery Pulse Wave Velocity (CF-PWV) [Baseline, month 8] | Change in Carotid and Radial Artery Pulse Wave Velocity (CR-PWV) [Baseline, month 8]",null,null,"NO","NIH:R01HL165433"],["NCT01509755","Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2",null,null,"196","Diabetes; Diabetes Mellitus, Type 2","DRUG:placebo; DRUG:liraglutide; DRUG:glimepiride","Novo Nordisk A/S","2000-10","2001-10","FALSE","HbA1c (glycosylated haemoglobin) []","RESULT:15161785; RESULT:25504028",null,null,null],["NCT05006885","ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","95","Non-Alcoholic Fatty Liver Disease","DRUG:ALT-801; OTHER:Placebo","Altimmune, Inc.","2021-09-30","2022-08-17","FALSE","The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs) [Up to Day 110]","DERIVED:39002641",null,null,null],["NCT03292185","A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","24","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide; DRUG:insulin degludec; DRUG:liraglutide","Novo Nordisk A/S","2017-09-29","2018-01-02","FALSE","Area under the serum insulin degludec concentration time curve [From 0 to last quantifiable observation after single dose of insulin degludec/liraglutide and insulin degludec, assessments from 0 hours to 120 hours] | Area under the plasma liraglutide concentration time curve [from 0 to last quantifiable observation after single dose of insulin degludec/liraglutide and liraglutide, assessments from 0 hours to 72 hours]",null,null,"YES","OTHER:U1111-1155-0990"],["NCT04823208","A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","64","Diabetes Mellitus, Type 2","DRUG:LY3437943; DRUG:Placebo","Eli Lilly and Company","2021-05-24","2022-06-23","FALSE","Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline through Day 106]",null,null,"NO","OTHER:J1I-JE-GZBC"],["NCT03737240","IDegLira HIGH Trial",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","145","Diabetes Mellitus","DRUG:IDegLira; DRUG:Insulin Degludec (U-100); DRUG:Insulin Aspart","Emory University","2019-01-15","2022-07-08","TRUE","Change in Hemoglobin A1c (HbA1c) [Baseline, Week 26]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/40/NCT03737240/Prot_SAP_000.pdf",null,null],["NCT07117240","Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes",null,"ENROLLING_BY_INVITATION","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","100","Steroid-Induced Diabetes; Steroid-Induced Hyperglycemia; Diabetes","DRUG:lixisenatide + glargine; DRUG:Intensive insulin therapy","Medical University of Warsaw","2025-07-10","2028-02-09","FALSE","Glucose monitoring index and Time in range [From enrollment to 6 months]",null,null,"NO",null],["NCT00701935","Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin",null,"TERMINATED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","80","Diabetes Mellitus","DRUG:placebo; DRUG:exenatide","AstraZeneca","2008-08","2012-01","TRUE","Percentage Change in Abdominal Visceral Fat From Baseline to 6 Months [baseline, 6 months]",null,null,null,null],["NCT05236517","A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","60","Obesity","DRUG:Semaglutide D Dose 1; DRUG:Semaglutide D Dose 2; DRUG:Semaglutide D Dose 3; DRUG:Semaglutide C Dose 4; DRUG:Semaglutide C Dose 5 (50 mg); DRUG:Placebo (Semaglutide C); DRUG:Placebo ( Semaglutide D)","Novo Nordisk A/S","2022-02-08","2022-09-29","FALSE","Relative change in energy intake during ad libitum lunch [Baseline to Day 140]","RESULT:39082206",null,"YES","EUDRACT_NUMBER:2021-003341-38; OTHER:U1111-1266-4375"],["NCT01514149","Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy",null,"TERMINATED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","73","Type 2 Diabetes Mellitus (T2DM)","DRUG:CJC-1134-PC Injection; DRUG:Weekly placebo for CJC-1134-PC Injection","ConjuChem","2011-09","2012-05","TRUE","Glycosylated Hemoglobin Change From Baseline (CFB) to Week 18 [CFB to Week 18]",null,null,null,null],["NCT05064735","Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","407","Obesity","DRUG:semaglutide 2.4 mg; DRUG:semaglutide 2.4 mg (placebo)","Novo Nordisk A/S","2021-10-01","2023-07-24","TRUE","Percentage Change in Body Weight [Baseline (week 0), end of treatment (week 68)] | Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score [Baseline (week 0), end of treatment (week 68)]","RESULT:39476339","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/35/NCT05064735/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/35/NCT05064735/SAP_002.pdf","YES","OTHER:U1111-1246-5824; EUDRACT_NUMBER:2020-000204-11"],["NCT01403025","Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes",null,"COMPLETED","OBSERVATIONAL",null,null,null,"4121","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2011-07-19","2015-12-28","FALSE","The incidence of SADRs (Serious Adverse Drug Reactions) [After 36 months]",null,null,null,"OTHER:U1111-1120-7575; REGISTRY:JapicCTI-111559"],["NCT03928379","A Study of LY3305677 in Participants With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","24","Diabetes Mellitus, Type 2","DRUG:LY3305677; DRUG:Placebo","Eli Lilly and Company","2019-10-27","2021-07-08","FALSE","Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug [Baseline through 24 weeks]",null,null,"NO","OTHER:I8P-MC-OXAD; EUDRACT_NUMBER:2018-004779-11; NIH:2018"],["NCT02146079","A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","44","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2014-05-21","2014-10-20","FALSE","Area under the plasma semaglutide concentration-time curve [During a dosing interval (0-168 hours) at steady state]","RESULT:29536338",null,null,"OTHER:U1111-1147-6660; REGISTRY:JapicCTI-142550"],["NCT05925959","Preoperative Weight Loss for Open Abdominal Wall Reconstruction",null,"RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","258","Abdominal Wall Hernia","OTHER:Preoperative Weight Management Program","Benjamin T. Miller","2023-06-19","2027-06-01","FALSE","Abdominal core health-specific quality of life at 1 year [1 year]","DERIVED:40434485",null,"NO",null],["NCT04019197","Effects of Semaglutide in HIV-Associated Lipohypertrophy",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","108","HIV/AIDS; Lipohypertrophy; Obesity","DRUG:Semaglutide Injectable Product; DRUG:Placebo","Case Western Reserve University","2019-05-16","2024-04-30","TRUE","Effects of Semaglutide on Quantity of Abdominal Fat (Total, Subcutaneous, Visceral) at Week 32 Compared to Baseline [32 weeks] | Effects of Semaglutide on Quantity of Fat (Total Body Fat, Limb Fat, Trunk Fat) at Week 32 Compared to Baseline [32 weeks] | Effects of Semaglutide on Quantity of Ectopic Fat (Total Pericardial Fat) at Week 32 Compared to Baseline [32 weeks]","DERIVED:42752515; DERIVED:41098140; DERIVED:40160348; DERIVED:38964353","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/97/NCT04019197/Prot_SAP_000.pdf","YES","NIH:R01DK121619"],["NCT02849080","Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.","PIONEER 7","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","504","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:sitagliptin","Novo Nordisk A/S","2016-09-20","2018-02-28","TRUE","Participants Who Achieve HbA1c <7.0% (53 mmol/Mol) ADA Target (Yes/no) [Week 52]","RESULT:31189520; RESULT:33318068; RESULT:35373893; DERIVED:33660198; DERIVED:32998732; DERIVED:32267058; DERIVED:31903692","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/80/NCT02849080/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/80/NCT02849080/SAP_001.pdf","YES","EUDRACT_NUMBER:2015-005593-38; OTHER:U1111-1177-5103; NIH:2015"],["NCT06859268","A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity","TRIUMPH-6","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","643","Obesity","DRUG:Retatrutide; DRUG:Placebo","Eli Lilly and Company","2025-03-05","2028-04","FALSE","Percent Change from Baseline in Body Weight [Week 0, Week 116]",null,null,"YES","OTHER:J1I-MC-GZQB"],["NCT07782359","Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib","NSCLC","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1",null,"NONE","30","Lung Cancer","DRUG:Tirzepatide","University of Chicago","2026-10","2030-06","FALSE","Body weight changes [1 year post treatment start] | Lipid changes [1 year post treatment start] | Change in Cmax [1 year post treatment start] | Change in Tmax [1 year post treatment start] | Bioavailability [1 year post treatment start]",null,null,null,null],["NCT01722240","Liraglutide in Type 1 Diabetes","1966","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","69","Type 1 Diabetes","DRUG:Liraglutide 1.8mg; DRUG:Placebo","University at Buffalo","2012-11-01","2019-01-01","TRUE","HbA1c (%) [52 Weeks]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/40/NCT01722240/Prot_SAP_000.pdf",null,"NIH:1R01DK092653-01A1"],["NCT03835013","Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers","COCOA","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","26","Cardiovascular Diseases","DRUG:Saline 0.9%; DRUG:Glucagon (25ng/kg/min); DRUG:Glucagon (50ng/kg/min); DRUG:Exenatide","Cambridge University Hospitals NHS Foundation Trust","2019-02-11","2021-11-01","FALSE","Changes in haemodynamic parameters following intravenous infusion of 0.9% saline, glucagon, exenatide and their combination. [Comparison between 2 hour infusion visit 1-2 (Part A) / 1 hour infusion visit 1-4 (Part B), over a maximum period of 15 weeks]",null,null,null,"OTHER:18/EM/0417; OTHER:250402"],["NCT02750930","Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects",null,"TERMINATED","INTERVENTIONAL","PHASE4",null,"NONE","8","Diabetes Mellitus, Type 2","DRUG:Albiglutide; DEVICE:Auto-injector","GlaxoSmithKline","2016-10-07","2017-03-21","TRUE","Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [Up to Week 34] | Number of Participants With Physical Examination Abnormalities [Up to Week 34] | Number of Participants With Hematology Values of Potential Clinical Importance (PCI) [Up to Week 34] | Number of Participants With Clinical Chemistry Parameters of PCI [Up to Week 34] | Number of Participants With Clinically Significant Urinalysis Abnormalities by Dipstick Method [Up to 26 weeks] | Number of Participants With Pulse Rate Values of PCI [Up to Week 34] | Number of Participants With Systolic and Diastolic Blood Pressure of PCI [Up to Week 34] | Number of Participants With Clinically Significant Findings for 12-lead ECG [Up to Week 34] | Number of Participant With Positive Results of Anti-albiglutide Antibody Production Over Time [Up to Week 34]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/30/NCT02750930/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/30/NCT02750930/SAP_001.pdf",null,null],["NCT03244800","A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","65","Type 2 Diabetes Mellitus","DRUG:MEDI0382; DRUG:Placebo","MedImmune LLC","2017-09-04","2018-01-23","TRUE","Cohort 1: Percent Change From Baseline in Plasma Glucose Area Under the Concentration-time Curve From Time 0 to 4 Hours (AUC0-4h) by Mixed-meal Tolerance Test (MMTT) to Day 49 [Zero minutes before and 15, 30, 45, 60, 90, 120, 180, and 240 minutes after consumption of the standardised liquid meal] | Cohort 1: Percent Change From Baseline in Body Weight to Day 50 [Day 1 through Day 50]","DERIVED:40665896; DERIVED:31608926","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/00/NCT03244800/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/00/NCT03244800/SAP_001.pdf","NO",null],["NCT06908694","Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy","GAINPCCONTROL","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE4",null,"NONE","20","Prostate Cancer","DRUG:Semaglutide Pen Injector","Hamilton Health Sciences Corporation","2025-07-02","2027-10-31","FALSE","Number of Serious Adverse Events [12 months] | Number of Adverse Events leading to Drug Discontinuation [6 months] | Measure of Weight [12 months] | Measure of Waist Circumference [12 months] | Measure of Blood Pressure [12 months] | Concentration of HbA1c [12 months] | Concentration of Lipids [12 months] | Concentration of PSA [12 months] | Concentration of Creatinine [12 months] | Calculation of estimated glomerular rate [12 months] | Number of Clinical Outcomes [12 months]",null,null,"NO",null],["NCT06865365","Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","72","Obesity, Adolescent","DRUG:Liraglutide daily (0.6-3.0mg, highest tolerable dose) additional to dietological measures and lifestyle optimization suggestions; BEHAVIORAL:Dietologic measures and lifestyle optimization for weight loss","Medical University of Vienna","2025-05-01","2027-02-01","FALSE","% total weight loss [body weight and bmi will be assessed immediately when admission to the study is done as reference value and at at time of operation, which is 6 months after admission to the study, as outcome value]",null,null,"NO",null],["NCT02794402","Double-blinded, 6 Months Study With Bydureon® or Placebo in Adolescents With Obesity to Explore Changes in BMI","Combat-JUDO","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","44","Obesity","DRUG:Exenatide; BEHAVIORAL:Placebo","Uppsala University","2015-09","2016-09","FALSE","BMI SDS (Body Mass Index Standard Deviation Score) [6 months]","DERIVED:38027106",null,null,"NIH:2015"],["NCT07797036","Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","NONE","226","Gestational Diabetes Mellitus (GDM); Metabolic Syndrome","DRUG:Semaglutide (Wegovy) weekly injection","University of Massachusetts, Worcester","2027-09-01","2030-09-01","FALSE","Metabolic Syndrome [6 months after randomization]",null,null,"NO","OTHER:U1111-1346-0976"],["NCT02320045","Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","38","Renal Insufficiency","DRUG:ITCA 650 (Exenatide in osmotic mini pump)","Intarcia Therapeutics","2014-11","2015-07","FALSE","24-h Area under the Curve at steady state (AUCt,ss) [Approximately 67 Days]",null,null,null,null],["NCT05048719","A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","383","Type 2 Diabetes","DRUG:LY3502970; DRUG:Dulaglutide; DRUG:Placebo","Eli Lilly and Company","2021-09-15","2022-09-30","TRUE","Change From Baseline in HbA1c in LY3502970 as Compared to Placebo [Baseline, Week 26]","DERIVED:40481478; DERIVED:37369232","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/19/NCT05048719/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/19/NCT05048719/SAP_001.pdf","YES","OTHER:J2A-MC-GZGE; EUDRACT_NUMBER:2021-002806-29"],["NCT04979130","Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)","SIB","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","69","Type 2 Diabetes; Chronic Inflammation; Intestinal Permeability","DRUG:Semaglutide; DRUG:Placebo","University of Colorado, Denver","2022-01-01","2024-10-16","FALSE","Differences in lactulose mannitol ratio (LMR) test as a measure of intestinal permeability between treatment groups [Week 16 (visit 6)]",null,null,null,null],["NCT05816057","A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","476","Diabetes Mellitus, Type 2","BIOLOGICAL:semaglutide injection","Hangzhou Jiuyuan Gene Engineering Co. Ltd.,","2022-07-25","2023-07-25","FALSE","The observed mean change in Glycosylated Haemoglobin A1c (HbA1c) values from baseline after 32 weeks of treatment. [32 weeks]",null,null,"NO",null],["NCT03136484","Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes","SUSTAIN 8","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","788","Diabetes; Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Canagliflozin; DRUG:Placebo (canagliflozin); DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2017-03-15","2018-10-16","TRUE","Change in HbA1c [Week 0, week 52]","RESULT:31540867; RESULT:31897524; DERIVED:39963952; DERIVED:37178435; DERIVED:32827435","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/84/NCT03136484/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/84/NCT03136484/SAP_001.pdf","YES","EUDRACT_NUMBER:2016-000989-35; OTHER:U1111-1180-3651; NIH:2016"],["NCT06854614","Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)","STAY-LEAN","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","150","Obesity","OTHER:Comprehensive weight loss; OTHER:Enhanced lifestyle changes; DRUG:Tirzepatide; DRUG:Naltrexone-Bupropion; DRUG:Phentermine-Topiramate; DRUG:Semaglutide (Wegovy®)","The Cleveland Clinic","2025-03-01","2027-04-28","FALSE","Weight change [month 9 to month 21]",null,null,"NO",null],["NCT01508949","Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","35","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2001-06","2002-03","FALSE","Change in weight []","RESULT:15277417",null,null,null],["NCT04971785","Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)","WAYFIND","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","457","Nonalcoholic Steatohepatitis","DRUG:Semaglutide (SEMA); DRUG:Cilofexor (CILO)/Firsocostat (FIR); DRUG:PTM SEMA; DRUG:PTM CILO/FIR","Gilead Sciences","2021-08-09","2024-11-12","TRUE","Percentage of Participants Who Achieved ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 72 in Semaglutide (SEMA) + Cilofexor/Firsocostat (CILO/FIR) Fixed Dose Combination (FDC) Versus Placebo Groups [Week 72]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/85/NCT04971785/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/85/NCT04971785/SAP_001.pdf","NO","EUDRACT_NUMBER:2021-001445-12; REGISTRY:jRCT2071210112"],["NCT07276763","Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Retention",null,"NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"16509","Gastric Retention","OTHER:No Intervention: Observational Cohort","Fudan University","2025-12-10","2025-12-15","FALSE","Proportion of gastric retention [Immediately at study initiation]",null,null,"YES",null],["NCT06864026","A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE4",null,"NONE","200","Psoriatic Arthritis; Overweight or Obesity","DRUG:Tirzepatide","Eli Lilly and Company","2025-03-06","2027-08","FALSE","Percentage of Participants Achieving Normalized Functioning Health Assessment Questionnaire - Disability Index (HAQ-DI) ≤0.5 at 12 Months of Therapy [12 Months] | Percentage of Participants Achieving at Least a 10% Weight Loss at 12 Months of Therapy [12 Months]",null,null,"YES","OTHER:I1F-MC-RHDE"],["NCT06672939","A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","150","Obesity; Overweight","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2024-11-18","2027-12","FALSE","Percent Change from Baseline in Body Mass Index (BMI) [Baseline, Week 72]",null,null,"YES","OTHER:J4M-MC-PW01; OTHER:J4M-MC-PWMP Master Protocol; CTIS:2024-514081-40-00"],["NCT07228741","Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity",null,"RECRUITING","INTERVENTIONAL","PHASE2",null,"NONE","20","Acute Lymphoblastic Leukemia; Obesity","DRUG:Tirzepatide; BEHAVIORAL:Resistance Exercise; BEHAVIORAL:Lifestyle Counseling","St. Jude Children's Research Hospital","2026-04-23","2027-11","FALSE","To evaluate the effectiveness for weight loss of the combined intervention using once weekly Tirzepatide plus remote, supervised, tailored resistance exercise. [28 weeks (assessed baseline and Week 28)]",null,null,null,"OTHER:NCI-2026-00106"],["NCT05501483","Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes","DiaSpax","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","60","Type 2 Diabetes","DRUG:Pioglitazone 45 mg; DRUG:Empagliflozin 25 MG; DRUG:Semaglutide 7 MG","Karolinska Institutet","2023-02-08","2026-09-01","FALSE","Changes in fat cell lipolysis after 6 months of treatment [Baseline and after six months intervention]",null,null,"NO","OTHER_GRANT:2022-00792 and 2024-03434; EUDRACT_NUMBER:2021-002367-21"],["NCT07218445","The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity",null,"RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","40","Obesity; Menopause Hot Flashes","DRUG:Tirzepatide; DRUG:Placebo","Mayo Clinic","2026-04-08","2027-09-18","FALSE","Change in Vasomotor Symptoms Frequency [Baseline, 24 weeks] | Change in Vasomotor Symptom Severity [Baseline, 24 weeks] | Aging Biomarkers: Cellular Senescence Markers in Plasma [24 weeks] | Difference between biological and chronological age [24 weeks]",null,null,"NO",null],["NCT00976937","24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","319","Type 2 Diabetes Mellitus","DRUG:Lixisenatide (AVE0010); DRUG:Lixisenatide Placebo; DEVICE:Pen auto-injector; DRUG:Sitagliptin; DRUG:Sitagliptin Placebo; DRUG:Metformin","Sanofi","2009-08","2011-03","TRUE","Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% and at Least 5% Weight Loss From Baseline at Week 24 [Week 24]",null,null,null,"OTHER:EudraCT:2008-007 334-22"],["NCT05784402","A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","264","Healthy Participants","DRUG:Semaglutide J; DRUG:Semaglutide C","Novo Nordisk A/S","2023-03-16","2024-02-23","FALSE","AUC0-24h,semaglutide,SS; area under the semaglutide plasma concentration-time curve during a dosing interval at steady state [From 0 to 24 hours after dosing on days 77, 112 and 147]",null,null,"YES","OTHER:U1111-1279-6289"],["NCT02650206","Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","56","Diabetes Mellitus, Type 2; Diabetes Mellitus, Type II; Diabetes Mellitus, Adult-Onset; Inflammation","DRUG:Victoza (liraglutide) with dietician monitoring; OTHER:Placebo with dietician monitoring","Stanford University","2015-01","2019-09-27","FALSE","Macrophage polarization: % M2 macrophages in adipose tissue and peripheral blood according to positivity for cell surface markers (measured by flow cytometry). [30 months]",null,null,null,null],["NCT05356104","GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)","GAPP-SVD","RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","SINGLE","110","Cerebral Small Vessel Disease","DRUG:GLP-1 receptor agonist","Chinese University of Hong Kong","2022-05-25","2027-05","FALSE","Change of Brain Peak Width of Skeletonized Mean Diffusivity [Baseline and week 78]",null,null,"NO",null],["NCT05895643","Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?","SEMALCO","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","108","Alcohol Abuse; Alcohol Addiction; Alcohol Dependence; Alcohol Use Disorder","DRUG:Semaglutide Injectable Product; DRUG:Placebo","Psychiatric Centre Rigshospitalet","2023-06-13","2025-07-31","FALSE","Change in heavy drinking days [From baseline to 26 weeks of treatment]","DERIVED:42070571; DERIVED:40123107; DERIVED:39779270","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/43/NCT05895643/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/43/NCT05895643/SAP_002.pdf","YES","REGISTRY:U1111-1286-6919"],["NCT05965908","Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","183","Polycystic Ovary","DRUG:liraglutide; DRUG:Metformin","Beni-Suef University","2024-08-01","2025-11-30","FALSE","Insulin Resistance (HOMA-IR) [6-months]",null,null,"YES",null],["NCT01516476","Study of RO6807952 in Patients With Diabetes Mellitus Type 2",null,"TERMINATED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","2","Diabetes Mellitus Type 2","DRUG:Placebo; DRUG:RO6807952; DRUG:liraglutide","Hoffmann-La Roche","2011-11","2012-01","FALSE","Change in hemoglobin A1c (HA1c) [Baseline and 12 weeks]",null,null,null,null],["NCT05078255","The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","TRIPLE","61","Type 2 Diabetes; Obesity","DRUG:Semaglutide 1.34 MG/ML [Ozempic]; DRUG:Glucose-dependent insulinotropic polypeptide (GIP); OTHER:Semaglutide 1.34 mg/ml placebo; OTHER:GIP placebo","Asger Lund, MD","2022-01-27","2025-01-06","FALSE","Mean glucose levels (assessed by blinded continuous glucose monitoring (CGM)) [14-day mean glucose levels during the last 14 days of the intervention period as compared to 14-day mean glucose levels during the last 14 days of the run-in period.]","DERIVED:42173109; DERIVED:36849212",null,null,null],["NCT03625778","A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","51","Obesity","DRUG:MEDI0382; DRUG:Placebo","MedImmune LLC","2018-08-14","2019-08-25","FALSE","Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) for Cohorts 1, 2, and 3 [From Day 1 through 28 days after the last dose of study drug (approximately 13, 18, and 22 weeks for Cohorts 1, 2, and 3, respectively)] | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs for Cohorts 1, 2, and 3 [From Day 1 through 28 days after the last dose of study drug (approximately 13, 18, and 22 weeks for Cohorts 1, 2, and 3, respectively)] | Number of Participants With Abnormal Vital Signs and Physical Examinations Reported as TEAEs for Cohorts 1, 2, and 3 [From Day 1 through 28 days after the last dose of study drug (approximately 13, 18, and 22 weeks for Cohorts 1, 2, and 3, respectively)] | Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs for Cohorts 1, 2, and 3 [From Day 1 through 28 days after the last dose of study drug (approximately 13, 18, and 22 weeks for Cohorts 1, 2, and 3, respectively)] | Change in Blood Pressure from Baseline to End of Dosing as Measured by Telemetry for Cohort 1 [From Baseline (Day -1) through end of dosing (Day 63)] | Change in Respiratory Rate from Baseline to End of Dosing as Measured by Telemetry for Cohort 1 [From Baseline (Day -1) through end of dosing (Day 63)] | Change in Pulse Rate from Baseline to End of Dosing as Measured by Telemetry for Cohort 1 [From Baseline (Day -1) through end of dosing (Day 63)] | Change in Temperature from Baseline to End of Dosing as Measured by Telemetry for Cohort 1 [From Baseline (Day -1) through end of dosing ( Day 63)]",null,null,"YES",null],["NCT05841238","A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","52","Healthy; Obese","DRUG:LY3502970","Eli Lilly and Company","2023-04-26","2023-09-14","TRUE","Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to the 24 Hour Time Point (AUC[0-24]) of LY3502970 in Fasted State - Part A: Periods 1-9, 11 and Part B: Periods 12-13 [Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 20, and 24 hours post-dose on Day 7 of each treatment period in Part A: Periods 1-9, 11 and Part B: Periods 12-13] | PK: Maximum Observed Concentration (Cmax) of LY3502970 in Fasted State - Part A: Periods 1-9, 11 and Part B: Periods 12-13 [Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 20, and 24 hours post-dose on Day 7 of each treatment period in Part A: Periods 1-9, 11 and Part B: Periods 12-13] | PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 in Fasted State - Part A: Periods 1-9, 11 and Part B: Periods 12-13 [Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 20, and 24 hours post-dose on Day 7 of each treatment period in Part A: Periods 1-9, 11 and Part B: Periods 12-13]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/38/NCT05841238/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/38/NCT05841238/SAP_001.pdf","NO","OTHER:J2A-MC-GZGN"],["NCT05377333","A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","94","Diabetes Mellitus, Type 2","DRUG:LY3457263; DRUG:Placebo; DRUG:Dulaglutide","Eli Lilly and Company","2022-06-02","2023-11-22","FALSE","Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Predose up to 16 weeks]",null,null,"NO","OTHER:J1R-MC-GZFB"],["NCT06363747","The Medically Reproducing Bariatric Surgery (MRB) II Study",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","NONE","50","Type 2 Diabetes; Obesity","OTHER:Very Low Calorie Diet","Durham VA Medical Center","2024-06-24","2025-11-03","FALSE","Glycemic Control [baseline, week 12, week 24, week 48]","BACKGROUND:29756388; BACKGROUND:30421863; BACKGROUND:33226607; BACKGROUND:27230990; BACKGROUND:12900694; BACKGROUND:22419108; BACKGROUND:25011946; BACKGROUND:15172919; BACKGROUND:20071471; BACKGROUND:4044780; BACKGROUND:23610060; BACKGROUND:3360564; BACKGROUND:23530013; BACKGROUND:17259489; BACKGROUND:19822830; BACKGROUND:23911112; BACKGROUND:27295427; BACKGROUND:22449317; BACKGROUND:18945920; BACKGROUND:17304084; BACKGROUND:20627709; BACKGROUND:22443306; BACKGROUND:35146601; BACKGROUND:10938048; BACKGROUND:18719634; BACKGROUND:9135939; BACKGROUND:17671237; BACKGROUND:21293452",null,"YES",null],["NCT06184633","DUTCH Weight Control in Atrial Fibrillation Study","DUTCH-WAIST","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","280","Atrial Fibrillation; Obesity; Weight Loss","DRUG:Semaglutide 3.2 MG/ML; DRUG:Placebo","Rijnstate Hospital","2024-07-21","2027-04-10","FALSE","The primary efficacy clinical endpoint of the trial is assessed at 12 months by a 7 point scale. Only the worst clinical outcome will be retained as the primary efficacy outcome [At 1 year follow-up]",null,null,null,null],["NCT04998032","A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients On Metformin Treatment(SUPER-2)",null,"COMPLETED","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","DOUBLE","620","Type2 Diabetes","BIOLOGICAL:supaglutide injection+metformin; OTHER:placebo+metformin","Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","2021-10-12","2023-06-15","FALSE","HbA1c [12 weeks for phase IIb; 24weeks and 52 weeks for phase III]","DERIVED:42103705; DERIVED:40991141; DERIVED:39961992",null,"NO",null],["NCT05689099","A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","20","Diabetes Mellitus, Type 2; Healthy Participants","DRUG:Semaglutide B, 1.34 mg/mL; DRUG:Semaglutide B, 0.68 mg/mL","Novo Nordisk A/S","2023-01-17","2023-05-30","FALSE","AUC0-last,sema 0.5mg: Area under the semaglutide concentration time curve from time 0 until last quantifiable measurement after single dose of subcutaneous semaglutide 0.5 mg [0-840 hours after a single dose of s.c. semaglutide 0.5 mg] | Cmax,sema,0.5mg: maximum observed semaglutide concentration-time after single dose of subcutaneous semaglutide 0.5 mg administration [0-840 hours after a single dose of s.c. semaglutide 0.5 mg]",null,null,"YES","OTHER:U1111-1280-1368"],["NCT02765399","The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","23","Type 2 Diabetes","DRUG:Liraglutide; DRUG:Placebo","Helsinki University Central Hospital","2015-02-01","2019-02-28","TRUE","Change in Liver Fat Content [Baseline and after 16 weeks] | Plasma Triglyceride (TG) Area Under Curve (AUC) [Baseline and after 16 weeks] | Body Weight [Baseline and after 16 weeks] | Change in HbA1c Level [Baseline and after 16 weeks] | Change in fP-glucose Level [Baseline and after 16 weeks] | Change in Insulin Level [Baseline and after16 weeks] | Change in Matsuda Index [Baseline and after 16 weeks] | Change in VAT Area [Baseline and after 16 weeks] | Change in SAT Area [Baseline and after 16 weeks] | Change in ApoCIII Level [Baseline and after 16 weeks]","BACKGROUND:221537; BACKGROUND:10480510; BACKGROUND:12730556; RESULT:30073766; RESULT:33502078; RESULT:30779243","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/99/NCT02765399/Prot_SAP_000.pdf","NO",null],["NCT07832084","Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s","OFF-RAMP","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","60","Obesity & Overweight; Cardiometabolic Health Indicators","DRUG:GLP-1 dose reduction; DRUG:non-GLP weight loss medication; DRUG:Maintenance of GLP-1 dose; BEHAVIORAL:Resistance exercise regimen; BEHAVIORAL:Lifestyle/nutrition counseling","Jing Luo","2026-11-01","2027-04-30","FALSE","Feasibility of recruitment and retention [Completion of participation, up to 12 months.]",null,null,"YES","NIH:1R01DK148666"],["NCT04093752","A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","917","Type 2 Diabetes","DRUG:Tirzepatide; DRUG:Insulin Glargine","Eli Lilly and Company","2019-12-09","2021-11-01","TRUE","Mean Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) [Baseline, Week 40]","DERIVED:38494574; DERIVED:37231074","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/52/NCT04093752/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/52/NCT04093752/SAP_001.pdf","YES","OTHER:I8F-MC-GPHO"],["NCT07797335","AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications","AMBITION 7","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","1778","Type 2 Diabetes; Cardiovascular Risk","DRUG:Zenagamtide; DRUG:Insulin glargine U-100","Novo Nordisk A/S","2026-08-24","2028-07-31","FALSE","Non-inferiority of zenagamtide versus insulin glargine: change in haemoglobin A1c (HbA1c) [From baseline (week 0) to week 52]",null,null,"YES","OTHER:U1111-1333-6446; OTHER:2026-525209-11"],["NCT06605703","A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","226","Obesity; Overweight","BEHAVIORAL:WW Clinic; DRUG:Bupropion-Naltrexone; DRUG:Bupropion-Naltrexone-Metformin","WW International Inc","2024-09-18","2026-02-05","FALSE","Percent body weight change at 12 weeks [Baseline, 12 weeks]",null,null,null,null],["NCT03876015","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK)","SURE UK","COMPLETED","OBSERVATIONAL",null,null,null,"215","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2019-05-01","2020-08-12","FALSE","Change in Glycated Haemoglobin A1c (HbA1c) [Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)] | Change in HbA1c [Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)]","DERIVED:35383100; DERIVED:34562237",null,"YES","OTHER:U1111-1199-9050"],["NCT06269120","SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary",null,"COMPLETED","OBSERVATIONAL",null,null,null,"243","Type 2 Diabetes","DRUG:Oral Semaglutide","Novo Nordisk A/S","2024-09-30","2026-05-05","FALSE","Glycated haemoglobin (HbA1c ) reduction greater than or equal to (≥) 0.5%-point and body weight reduction ≥ 5% [From Baseline to end of study (week 32)]",null,null,"YES","OTHER:U1111-1290-8109"],["NCT01425580","Liraglutide and Heart Failure in Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","62","Congestive Heart Failure; Type 2 Diabetes Mellitus","DRUG:liraglutide; DRUG:glimepiride; DRUG:Metformin","Thomas Nystrom","2012-01","2016-08","FALSE","Left ventricle longitudinal function and/or functional reserve during rest and/or after exercise using tissue Doppler echocardiography [18 weeks]","DERIVED:37349083; DERIVED:34920733; DERIVED:29548934",null,null,"EUDRACT_NUMBER:2010-022695-31"],["NCT02161588","A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","48","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2014-06","2014-11","FALSE","Area under the semaglutide plasma concentration-time curve [During a dosing interval (0-24 hours) at steady state]",null,null,null,"OTHER:U1111-1148-4141; OTHER:JapicCTI-142572"],["NCT07794579","A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity","ATTAIN-NOW","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","2001","Overweight; Prediabetic State; Prehypertension; Obesity, Abdominal","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2026-08-26","2029-08","FALSE","Time to Onset of Obesity Related Complications or Class 1 Obesity [Baseline to Week 104]",null,null,"YES","OTHER:J2A-MC-GZVA; CTIS:2026-526175-35-00"],["NCT01720446","Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes","SUSTAIN™ 6","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","3297","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2013-02-21","2016-03-15","TRUE","Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke [Time from randomisation up to end of follow-up (scheduled at week 109)]","BACKGROUND:30851070; RESULT:27633186; RESULT:29178519; RESULT:29907893; RESULT:30615985; RESULT:31167654; DERIVED:39963952; DERIVED:39520501; DERIVED:37620807; DERIVED:35582947; DERIVED:35484580; DERIVED:35332654; DERIVED:33606902; DERIVED:32998732; DERIVED:32744418; DERIVED:32643857; DERIVED:32372454; DERIVED:32227613; DERIVED:31903692; DERIVED:31769496; DERIVED:29693361",null,null,"EUDRACT_NUMBER:2012-002839-28; OTHER:U1111-1131-7227"],["NCT01976858","A Phase I Study of 8-week Continuous Treatment With Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","50","Type 2 Diabetes","DRUG:PEX168","Jiangsu HengRui Medicine Co., Ltd.","2011-06","2011-09","FALSE","To determine serum concentrations of PEX168 [8 weeks]",null,null,null,null],["NCT03745885","A Study of the Efficacy and Safety of Supaglutide in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","48","Diabetes Mellitus, Type 2","DRUG:Supaglutide injection; DRUG:Placebo","Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","2018-12-04","2019-06-10","FALSE","Pharmacokinetic：Cmax of Supaglutide [baseline and up to 29 days after formal dose] | Pharmacokinetic: Tmax of Supaglutide [baseline and up to 29 days after formal dose] | Pharmacokinetic: AUC0-t of Supaglutide [baseline and up to 29 days after formal dose] | Pharmacokinetic: t½ of Supaglutide [baseline and up to 29 days after formal dose]","DERIVED:39961992",null,"NO",null],["NCT02442791","GLP-1 Analogs for Neuroprotection After Cardiac Arrest","GLIP1","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","QUADRUPLE","120","Cardiac Arrest; Coma","DRUG:Byetta (Lilly, Exenatide); OTHER:20% Human Albumin","Jesper Kjaergaard","2014-06","2016-06","FALSE","Feasibility: Over 90% initiation of study drug infusion [4 hours from return of spontaneous circulation] | Efficacy assessed by Area under the Neuron-specific Enolase curve [72 hours from admission]","RESULT:27838646; DERIVED:35546563; DERIVED:29189347; DERIVED:27363489",null,null,null],["NCT07487103","Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","478","Type 2 Diabetes","DRUG:QLG1091; DRUG:Rybelsus","Qilu Pharmaceutical Co., Ltd.","2026-05-01","2026-12","FALSE","Change in HbA1c [Week 26]",null,null,null,null],["NCT01602913","Type II Diabetes Mellitus in Patients Exposed to Pravastatin and Paroxetine",null,"COMPLETED","OBSERVATIONAL",null,null,null,"1","Depression, Postpartum","DRUG:Pravastatin alone; DRUG:Paroxetine alone; DRUG:Pravastatin and paroxetine combined","GlaxoSmithKline","2011-12","2012-05","FALSE","Incidence of T2DM defined as having at least 2 diagnostic codes indicating T2DM after the index date, or 1 diagnostic code and 1 prescription of oral anti-diabetic medications or insulin (or Byetta and Victoza) after the index date [Up to ten years]",null,null,null,"OTHER:WEUSKOP5966"],["NCT00715624","GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin","GETGOAL-L","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","496","Diabetes Mellitus, Type 2","DRUG:Lixisenatide (AVE0010); DRUG:Placebo; DRUG:Basal Insulin; DRUG:Metformin; DEVICE:Pen auto-injector","Sanofi","2008-07","2011-02","TRUE","Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 [Baseline, Week 24]","RESULT:23628617; DERIVED:36809495; DERIVED:31956422; DERIVED:25130920",null,null,"EUDRACT_NUMBER:2007-005886-36"],["NCT06333080","The Effect of Adherence to Oral Semaglutide on Glycaemic Control in People With Type 2 Diabetes Treated With Metformin","DIACRON","TERMINATED","OBSERVATIONAL",null,null,null,"1","Diabetes Mellitus, Type 2",null,"Aalborg University Hospital","2023-11-01","2025-07-29","FALSE","Time-in-Range (TIR) [Change from baseline to three-month assessment]","DERIVED:40986866",null,null,null],["NCT05259033","A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)","COMBINE 2","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","683","Diabetes Mellitus, Type 2","DRUG:IcoSema; DRUG:Semaglutide 1 mg","Novo Nordisk A/S","2022-04-11","2023-12-13","TRUE","Change From Baseline in Glycosylated Haemoglobin (HbA1c) [Baseline (week 0), (week 52)]","DERIVED:42557064; DERIVED:39820580","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/33/NCT05259033/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/33/NCT05259033/SAP_001.pdf","YES","OTHER:U1111 1260 8268; EUDRACT_NUMBER:2020 005308 21"],["NCT03233178","Measurement of Alanine Aminotransaminase (ALT) Following Initiation of Antidiabetic Agents in Patients With Type 2 Diabetes in a Real-world Clinical Setting: a Retrospective Cohort Study","ALT","COMPLETED","OBSERVATIONAL",null,null,null,"4000","T2DM (Type 2 Diabetes Mellitus); Fatty Liver; NAFLD","OTHER:Non-interventional","LMC Diabetes & Endocrinology Ltd.","2017-01","2017-06","FALSE","Change in ALT in patients with T2DM initiating SGLT2 inhibitors, Liraglutide or Sitagliptin compared to control [1 year]","DERIVED:30149145",null,"NO",null],["NCT06790160","Study of Patients Being Treated With Anti-obesity Medication",null,"ACTIVE_NOT_RECRUITING","OBSERVATIONAL",null,null,null,"100","Obesity and Overweight",null,"Texas Tech University","2025-01-31","2028-03","FALSE","Change in Total Lean Soft Tissue [From baseline assessment to last available time point (follow-up assessments conducted ~6 months and ~17 months after baseline).] | Change in Appendicular Lean Soft Tissue [From baseline assessment to last available time point (follow-up assessments conducted ~6 months and ~17 months after baseline).] | Change in Total Fat Mass [From baseline assessment to last available time point (follow-up assessments conducted ~6 months and ~17 months after baseline).] | Change in Handgrip Strength [From baseline assessment to last available time point (follow-up assessments conducted ~3, ~6, and ~17 months after baseline).]",null,null,"NO",null],["NCT06654960","Influence of HRS9531 on Pharmacokinetics of Metformin in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","20","Type 2 Diabetes","DRUG:HRS9531 injection; DRUG:Metformin Hydrochloride tablets","Fujian Shengdi Pharmaceutical Co., Ltd.","2024-11-05","2024-12-26","FALSE","Area under the concentration versus time curve (AUC) of metformin from dosing time (0) to tau (dosing interval) (AUCtau) after 3.5 days. [Start of treatment up to 12 hours.]",null,null,"UNDECIDED",null],["NCT06723691","Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","57","Type 2 Diabetes","DRUG:Acetaminophen; DRUG:Metformin; DRUG:Warfarin; DRUG:Atorvastatin; DRUG:Digoxin; DRUG:HRS9531","Fujian Shengdi Pharmaceutical Co., Ltd.","2024-12-18","2025-06-09","FALSE","Area under the acetaminophen plasma concentration-time curve [From time 0 to 24 hours after a single dose.] | Maximum observed acetaminophen concentration [From time 0 to 24 hours after a single dose.] | Time of maximum observed acetaminophen concentration [From time 0 to 24 hours after a single dose.] | Area under the metformin plasma concentration-time curve [From time 0 to 12 hours after the last of 7 repeated doses.] | Area under the S-warfarin plasma concentration-time curve [From time 0 to 168 hours after a single dose.] | Area under the atorvastatin plasma concentration-time curve [From time 0 to 72 hours after a single dose.] | Area under the digoxin plasma concentration-time curve [From time 0 to 120 hours after a single dose.]",null,null,"UNDECIDED",null],["NCT07434050","A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","140","OSA - Obstructive Sleep Apnea; Obesity","DRUG:XW003 injection; DRUG:placebo with matching volume","Hangzhou Sciwind Biosciences Co., Ltd.","2026-03-02","2028-06-19","FALSE","Change from baseline in Apnea-Hypopnea Index (AHI) [at week 48]",null,null,null,null],["NCT02975297","Exenatide Once Weekly for Smoking Cessation",null,"COMPLETED","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","TRIPLE","84","Smoking Cessation","DRUG:Exenatide; DRUG:NRT; BEHAVIORAL:Counseling; DRUG:Placebo","The University of Texas Health Science Center, Houston","2016-07","2020-01-03","TRUE","Number of Participants Who Self-Reported Abstinence and Who Were Biochemically Verified as Abstinent Via Expired CO Level of ≤ 5ppm [6 weeks] | Post-quit Craving as Assessed by the Questionnaire of Smoking Urges [6 weeks] | Withdrawal Symptoms as Assessed by the Wisconsin Smoking Withdrawal Scale [6 weeks] | Cue-induced Craving for Cigarettes Following Virtual Reality Exposure as Assessed by the Questionnaire of Smoking Urges [1 week] | Cue-induced Craving for Cigarettes Following Virtual Reality Exposure as Assessed by the Questionnaire of Smoking Urges [3 weeks]","BACKGROUND:29480848; DERIVED:33831213","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/97/NCT02975297/Prot_SAP_000.pdf","NO","OTHER:CCTS Research Scholar Award"],["NCT07602699","Multi-Site Trial of Tirzepatide for Smoking Cessation",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","300","Smoking Cessation; Smoking Behaviors","DRUG:Tirzepatide; OTHER:Placebo","University of Southern California","2026-06-05","2028-03","FALSE","7-day point prevalence abstinence [From baseline through 16 weeks of treatment (final assessment at Week 17 visit) and at 6 months after the target quit date (assessed at Week 27 visit)]",null,null,"YES","NIH:U01DA064384"],["NCT07770152","Semaglutide in Youth With Autism Spectrum Disorder","GLP1","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","NON_RANDOMIZED","NONE","42","Autism Spectrum Disorder; Obesity","DRUG:Glucagon-like peptide-1 receptor agonist：Semaglutide; BEHAVIORAL:Lifestyle Management (LSM) Counseling","Children's Hospital Medical Center, Cincinnati","2026-09-01","2028-09-01","FALSE","Number of Participants With Percent Change in BMI (kg/m2) [12 months] | Number of Participants With Change in Skeletal Muscle Mass (SMM) [12 months]",null,null,"NO",null],["NCT07820358","Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer","SWIFT","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2",null,"NONE","48","Endometrial Atypical Hyperplasia; Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia; Endometrial Cancer Stage I; Endometrial Cancer; Fertility-Sparing Treatment (FST); Obesity & Overweight","DRUG:Semaglutide (Wegovy) weekly injection; DEVICE:LNG-IUD (Progestin); BEHAVIORAL:Structured Weight Loss Program","The Methodist Hospital Research Institute","2027-01-01","2028-12-31","FALSE","Pathological Response Rate [6 months]","BACKGROUND:41329840; BACKGROUND:28476021; BACKGROUND:21270604; BACKGROUND:21324431; BACKGROUND:33470656; BACKGROUND:40839273; BACKGROUND:38967919; BACKGROUND:33567185; BACKGROUND:34669205; BACKGROUND:37927533; BACKGROUND:39388742; BACKGROUND:32805208; BACKGROUND:33762086",null,"YES",null],["NCT06693843","A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity","ACCESS","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","230","Obesity, Overweight, or Chronic Weight Management","DRUG:Aleniglipron or Placebo; DRUG:Aleniglipron","Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics","2024-10-28","2025-10-24","FALSE","Percent change in body weight from Baseline to Week 36 [Baseline and week 36] | TEAEs and SAEs [Baseline and week 72] | AESI [Baseline and week 72] | Evaluate the safety and tolerability of participants with abnormal laboratory values, including hematology, serum chemistry, and coagulation [Baseline and week 72] | Evaluate long-term safety and tolerability of aleniglipron as measured through electrocardiograms (including, but not limited to, the measurements of ventricular HR, PR interval, QRS duration, QT interval, and QTcF) [Baseline and week 72] | Evaluate the safety and tolerability of participants with abnormal vital signs, including blood pressure, heart rate, and temperature [Baseline and week 72]","DERIVED:42249138",null,"YES",null],["NCT00948168","Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE4","NON_RANDOMIZED","NONE","34","Type 2 Diabetes Mellitus","DRUG:exenatide (Byetta)","Cliniques universitaires Saint-Luc- Université Catholique de Louvain","2008-07","2009-07","FALSE","Improvement in HbA1c [6 months]",null,null,null,null],["NCT06852391","JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity","JOULE-MARS","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","74","Obesity (Disorder)","DRUG:Semaglutide Pen Injector; BEHAVIORAL:Behavioural Lifestyle Program (BLP)","McMaster University","2025-06-18","2027-12-31","FALSE","Measurement of Adaptive thermogenesis [6, 12 months]",null,null,"UNDECIDED",null],["NCT06994338","Tirzepatide for Alcohol Use Disorder",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","42","Alcohol Use Disorder; Obesity and Overweight; Alcohol","DRUG:Tirzepatide; DRUG:Placebo injections","University of Southern California","2025-10-06","2026-08-31","FALSE","Number of heavy drinking days [Last 4 weeks of treatment (Weeks 5-8)]",null,null,"YES","NIH:1R21AA031892-01"],["NCT02321878","Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)",null,"COMPLETED","OBSERVATIONAL",null,null,null,"1092","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2014-12-15","2017-06-16","FALSE","Number of AEs (adverse events) [Week 0-52]",null,null,null,"OTHER:U1111-1157-6701"],["NCT01615978","Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","15","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2003-12","2004-03","FALSE","24-hour profiles of serum calcitonin [] | 24-hour profiles of Ca2+ (ionised calcium) [] | 24-hour profiles of PTH (Parathyroid Hormone) [] | Adverse events []",null,null,null,null],["NCT02621489","Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects","Rebuild","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","38","Atherosclerosis; Diabetes; Restenosis","DRUG:Bydureon; DRUG:Humulin kwickpen; DRUG:Metformin","Karolinska Institutet","2015-12","2022-08","FALSE","The degree of non-covered stent struts by Bydureon add on to Insulin over that of Insulin as analyzed by optical coherence tomography (OCT). [12 weeks]","RESULT:25966620; RESULT:23343509; RESULT:20452396; RESULT:22390929; RESULT:15353407; RESULT:23241323; RESULT:20630463; DERIVED:38066597",null,"NO",null],["NCT04733508","Glucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 Diabetes","GLP1R-T2D","UNKNOWN","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","28","Diabetes Mellitus; Diabetes Mellitus, Type 2","DRUG:111In-DTPA-exendin-4; DRUG:IRDye800CW-exendin-4","Radboud University Medical Center","2019-11-01","2022-06-01","FALSE","Pancreatic exendin uptake 111In-DTPA exendin-4 [111In-DTPA-exendin-4 injection will be performed a day before planned surgery, and uptake will be determined using ex vivo SPECTof the resected tissue one day after surgery] | Pancreatic exendin uptake 111In-DTPA exendin-4 [111In-DTPA-exendin-4 injection will be performed a day before planned surgery, and uptake will be determined with tissue autoradiography immediately after resection] | Beta cell function [The glucose tolerance test will be performed within a week before planned surgery] | Blood glucose levels [Blood glucose levels will be continuously monitored a week prior to surgery] | HbA1C levels [HbA1C levels will be determined within a week before planned surgery] | Pancreatic exendin uptake IRDye800CW-exendin-4 [IRDye800CW-exendin-4 injection will be performed a day before planned surgery, and uptake will be determined using microscopy in the excised tissue] | Gene expression [Gene expression will be determined in the excised pancreatic tissue immediately after resection]","DERIVED:39405026",null,"UNDECIDED",null],["NCT06435676","A Study of Single and Multiple Doses HRS9531 Tablets in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","72","Overweight or Obesity; Type 2 Diabetes","DRUG:HRS9531; DRUG:Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2024-06-04","2024-10-08","FALSE","SAD Stage: Number of Adverse Events [36 days] | MAD Stage: Number of Adverse Events [63 days]",null,null,"UNDECIDED",null],["NCT05437848","Chinese Multiple Dose Escalation (MDE) High Dose Study","COTA China PK","COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","16","Diabetes","DRUG:Experimental: Cotadutide; OTHER:Placebo","AstraZeneca","2022-02-25","2022-12-12","FALSE","Incidence of treatment-emergent adverse events (TEAEs) [Baseline until the follow-up period (28 days post last dose), 98 days in total] | Incidence of treatment-emergent serious adverse events (TESAEs) [Baseline until the follow-up period (28 days post last dose), 98 days in total] | Number of Participants With Abnormal Electrocardiograms (ECGs) Reported as TEAEs [Baseline until the follow-up period (28 days post last dose), 98 days in total] | Number of participants with abnormal vital signs reported as TEAEs [Baseline until the follow-up period (28 days post last dose), 98 days in total] | Number of Participants With Abnormal Physical Examinations Reported as TEAEs [Baseline until the follow-up period (28 days post last dose), 98 days in total] | Area under the concentration-time curve (AUC) during the dosing interval (AUCtau) [Day 1 of Up-titration treatment period through 3 days post lost dose, total of up to 73 days.] | Maximum observed concentration (Cmax) [Day 1 of Up-titration treatment period through 3 days post lost dose, total of up to 73 days.] | Time to Cmax (tmax) [Day 1 of Up-titration treatment period through 3 days post lost dose, total of up to 73 days.] | Trough plasma concentration (Ctrough) [Day 1 of Up-titration treatment period through 3 days post lost dose, total of up to 73 days.] | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs [Baseline until the follow-up period (28 days post last dose), 98 days in total]",null,null,"YES",null],["NCT07466017","A Study of CS060380 Tablets in Patients With MASH and Obesity",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","130","Metabolic Dysfunction-associated Steatohepatitis (MASH); Obesity","DRUG:semaglutide; DRUG:CS060380; DRUG:Placebo","Cascade Pharmaceuticals, Inc","2026-04-02","2027-04-30","FALSE","Percentage change in liver fat content from baseline to Week 36 (MRI-PDFF) [Baseline, Week 36]","BACKGROUND:33185364",null,"NO","OTHER:2024LP01824; OTHER:CS060380-MASH-CN-II-03"],["NCT06901349","A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes",null,"WITHDRAWN","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","0","Obesity; Overweight","DRUG:Bimagrumab; DRUG:Tirzepatide; DRUG:Bimagrumab Placebo; DRUG:Tirzepatide Placebo","Eli Lilly and Company","2025-05-23","2025-06-10","FALSE","Percent Change from Baseline in Body Weight [Baseline, Week 36]",null,null,"YES","OTHER:J4Z-MC-GIDI"],["NCT05857085","Novel Therapeutics and Endothelial Dysfunction in T1DM Patients","ENDIS","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","90","Endothelial Dysfunction; Diabetes Mellitus, Type 1; Biomarkers; Endothelial Progenitor Cells; SGLT 2 Inhibitors; Incretins; Glucose Excursions; FMD; FPF; Arterial Stiffness","DRUG:Semaglutide Pen Injector [Ozempic]; DRUG:Empagliflozin 10 MG","General and Teaching Hospital Celje","2021-12-15","2022-03-10","FALSE","evaluation of endothelial function by flow mediated dilation (FMD) of brachial artery [12 weeks] | evaluation of endothelial function by strain gauge plethysmography as change in forearm blood flow [12 weeks] | evaluation of arterial stiffness with peak wave velocity ( PWV) [12 weeks]",null,null,"NO",null],["NCT05598008","Effects of Glucagon-like-Peptide-1 Analogues on Sexuality","Desire PLUS","COMPLETED","OBSERVATIONAL",null,null,null,"85","Sexual Desire",null,"University Hospital, Basel, Switzerland","2022-11-25","2025-10-24","FALSE","Change in the German short version of the Sexual Desire Inventory (SDI-2) total score to assess sexual functioning [At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)]",null,null,null,null],["NCT05024032","A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)","SURMOUNT-CN","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","210","Obesity; Overweight; Metabolism and Nutrition Disorder","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2021-09-01","2022-12-27","TRUE","Mean Percent Change From Baseline in Body Weight [Baseline, Week 52] | Percentage of Participants Who Achieve ≥5% Body Weight Reduction [Week 52]","DERIVED:38819983","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/32/NCT05024032/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/32/NCT05024032/SAP_001.pdf","YES","OTHER:I8F-MC-GPIA"],["NCT07096063","Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk","TIRZSEMA-CVOT","COMPLETED","OBSERVATIONAL",null,null,null,"887132","Type 2 Diabetes; Overweight; Cardiovascular (CV) Risk","DRUG:Tirzepatide; DRUG:Dulaglutide; DRUG:Semaglutide; DRUG:Sitagliptin","Brigham and Women's Hospital","2024-10-01","2025-07-15","FALSE","Composite of all-cause mortality, myocardial infarction or stroke (Tirzepatide vs. dulaglutide) [1 day after cohort entry date until the first of outcome or censoring, up to 365 days] | Composite of all-cause mortality, myocardial infarction or stroke (Injectable semaglutide vs sitagliptin) [1 day after cohort entry date until the first of outcome or censoring, up to 365 days] | Composite of all-cause mortality, myocardial infarction or stroke (Tirzepatide vs injectable semaglutide) [1 day after cohort entry date until the first of outcome or censoring, up to 365 days]","DERIVED:41207920","Study Protocol and Statistical Analysis Plan: Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/63/NCT07096063/Prot_SAP_001.pdf; Study Protocol and Statistical Analysis Plan: Amendment to Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/63/NCT07096063/Prot_SAP_002.pdf",null,null],["NCT06986993","Impact of Semaglutide on Tobacco Use and Related Health Behaviors","ONSET","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","40","Tobacco Use","DRUG:Semaglutide; DRUG:Placebo","University of Oklahoma","2024-07-01","2028-05-30","FALSE","Cigarette smoking [12 weeks]",null,null,"NO",null],["NCT05328843","Study to Evaluate the Pharmacokinetic Characteristics of Pegylated Exenatide Injection (PB-119) in Subjects With Different Degrees of Renal Insufficiency and Matched Subjects With Normal Renal Function",null,"UNKNOWN","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","24","Type2Diabetes","DRUG:PB119","PegBio Co., Ltd.","2022-05-01","2022-10-01","FALSE","Primary PK parameters: AUC0-inf [Up to 336 h(Day15) post-dose] | Primary PK parameters: AUC0-t [Up to 336 h(Day15) post-dose] | Primary PK parameters: Cmax [Up to 336 h(Day15) post-dose]",null,null,"UNDECIDED",null],["NCT02473809","The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function","LIRABONE","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","60","Diabetes Complications; Osteoporosis","DRUG:Liraglutide; DRUG:Placebo","University of Aarhus","2015-08","2017-10","FALSE","Change in collagen I cross-linked C-terminal telopeptide measured in serum [Days 0, 7, 28, 90, 180]","BACKGROUND:7479679; BACKGROUND:23023946; BACKGROUND:17925191; BACKGROUND:17068657; BACKGROUND:18039776; BACKGROUND:21372151; BACKGROUND:25074632",null,"UNDECIDED",null],["NCT02128932","Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes","SUSTAIN™ 4","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","1089","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:insulin glargine","Novo Nordisk A/S","2014-08-04","2015-09-03","TRUE","Change in HbA1c From Baseline [Week 0, week 30]","BACKGROUND:30865526; RESULT:28344112; RESULT:28526920; RESULT:29687620; RESULT:29766634; RESULT:29862621; RESULT:30615985; DERIVED:32998732; DERIVED:32193837; DERIVED:31903692; DERIVED:31769496; DERIVED:31215727",null,null,"EUDRACT_NUMBER:2013-004392-12; OTHER:U1111-1146-0211; REGISTRY:NL47781.018.14"],["NCT04660643","A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss","SURMOUNT-4","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","783","Obesity; Overweight","DRUG:Tirzepatide; OTHER:Placebo","Eli Lilly and Company","2021-03-29","2023-04-25","TRUE","Percent Change From Randomization in Body Weight at Week 88 [Randomization (Week 36), Week 88]","DERIVED:41885866; DERIVED:41640675; DERIVED:41284285; DERIVED:41187013; DERIVED:40903801; DERIVED:40717199; DERIVED:39800653; DERIVED:38078870","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/43/NCT04660643/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/43/NCT04660643/SAP_001.pdf","YES","OTHER:I8F-MC-GPHN"],["NCT05813249","Semaglutide in Nonalcoholic Fatty Liver Disease",null,"COMPLETED","INTERVENTIONAL","PHASE4","NON_RANDOMIZED","NONE","180","Non-alcoholic Fatty Liver Disease","DRUG:Rybelsus Oral Product; DRUG:Ozempic Injectable Product; DRUG:Tocopherol and/or Actos","Zagazig University","2023-02-15","2024-02-15","FALSE","NAFLD regression [48 weeks]",null,null,"NO",null],["NCT03914326","A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes","SOUL","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","9651","Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2019-06-17","2024-08-23","TRUE","Number of Participants From Randomization to First Occurrence of a Major Adverse Cardiovascular Event (MACE), a Composite Endpoint Consisting of: Cardiovascular (CV) Death/Non-fatal Myocardial Infarction/Non-fatal Stroke [From randomisation (week 0) up to week 265]","DERIVED:41879791; DERIVED:41627802; DERIVED:41380027; DERIVED:41099689; DERIVED:40162642; DERIVED:40156843; DERIVED:39963952","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/26/NCT03914326/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/26/NCT03914326/SAP_001.pdf","YES","REGISTRY:2018-003141-42; OTHER:U1111-1218-5368; NIH:2018"],["NCT06548997","A Phase I Study of GZR18 Injection in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","57","Type 2 Diabetes; Overweight and Obesity","DRUG:GZR18; OTHER:Placebo","Gan and Lee Pharmaceuticals, USA","2021-12-02","2022-10-20","FALSE","TEAE [after 28/35 days of treatment]",null,null,null,null],["NCT07071974","A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","16","Healthy","COMBINATION_PRODUCT:BI 456906 formulation A; DRUG:BI 456906 formulation B2","Boehringer Ingelheim","2025-07-28","2025-10-07","FALSE","AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) [Up to 22 days.] | Cmax (maximum measured concentration of the analyte in plasma) [Up to 22 days.]",null,null,"NO","REGISTRY:2025-521419-37-00; REGISTRY:U1111-1319-7116; NIH:2025"],["NCT00013910","NNC 90-1170 Mechanism of Action: A Double-Blind, Randomized, Single-Center, Placebo-Controlled, Crossover Study to Examine Beta-Cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","30","Diabetes Mellitus, Non-Insulin-Dependent","DRUG:NNC 90-1170","National Center for Research Resources (NCRR)",null,null,"FALSE",null,null,null,null,null],["NCT04431713","Exenatide Once-weekly as a Treatment for Multiple System Atrophy","MSA","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","50","Multiple System Atrophy","DRUG:Exenatide Pen Injector [Bydureon]","University College, London","2020-09-16","2024-03-22","TRUE","Change in UMSARS Score (Parts I+II) From Baseline [Baseline and 48 weeks]","BACKGROUND:27713036; BACKGROUND:26851597; BACKGROUND:30640362; BACKGROUND:29843254; BACKGROUND:28781108; BACKGROUND:23728174; BACKGROUND:24662192; BACKGROUND:28334990; BACKGROUND:20580422; BACKGROUND:21307137; BACKGROUND:25496749; BACKGROUND:26500843; BACKGROUND:19356970; BACKGROUND:20014118; BACKGROUND:18782641; BACKGROUND:24571751; BACKGROUND:25587949; BACKGROUND:24727096; BACKGROUND:22236356; BACKGROUND:18725592; BACKGROUND:24529527; BACKGROUND:26025783; BACKGROUND:24507091; BACKGROUND:26511102; BACKGROUND:28653373; BACKGROUND:25545629; BACKGROUND:25498732; BACKGROUND:22476197; BACKGROUND:15452868; BACKGROUND:17222116; BACKGROUND:23391524; DERIVED:41321006","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/13/NCT04431713/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/13/NCT04431713/SAP_001.pdf","NO","EUDRACT_NUMBER:2020-000122-26"],["NCT02325960","A Comparison of Exenatide and Insulin Glargine",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","44","Type 2 Diabetes","DRUG:exenatide; DRUG:Insulin glargine","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","2015-01","2016-07","FALSE","Mean amplitude of glycemic excursions (MAGE) change from baseline by continuous glucose monitoring system (CGMS) [1±3day；112±3d]","DERIVED:30302121",null,"UNDECIDED",null],["NCT07642635","Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","QUADRUPLE","30","Duchenne Muscular Dystrophy (DMD)","DRUG:Semaglutide (Rybelsus®); OTHER:Placebo","Vanderbilt University Medical Center","2026-09-01","2030-09","FALSE","Muscle Volume Index (MVI) [Week 0 (baseline), week 24 (end of RCT), week 64 (end of study)]",null,null,"NO",null],["NCT00729326","Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","83","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:sitagliptin; DRUG:placebo","AstraZeneca","2008-08","2009-10","TRUE","Change in Time-averaged Glucose During a 24 Hour Period [baseline and 8 Weeks]",null,null,null,null],["NCT05073835","Semaglutide 2.4 mg in Patients With Poor Weight-loss","BARI-STEP","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","70","Obesity; Diabetes; Metabolic Syndrome","DRUG:Semaglutide 3 mg; DRUG:Placebo","University College, London","2022-11-01","2025-03","FALSE","Weight loss [68 weeks]","DERIVED:42174253",null,"UNDECIDED",null],["NCT02070510","A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","52","Diabetes; Healthy","DRUG:semaglutide; DRUG:lisinopril; DRUG:warfarin; DRUG:placebo","Novo Nordisk A/S","2014-02-27","2014-08-20","FALSE","Area under the S-warfarin concentration-time curve [From dosing to infinity calculated from a 0-168 hours S-warfarin concentration-time-curve based on 18 sampling time points] | Area under the R-warfarin concentration-time curve [From dosing to infinity calculated from a 0-168 hours S-warfarin concentration-time-curve based on 18 sampling time points] | Area under the lisinopril concentration-time curve [From dosing to infinity calculated from a 0-60 hours lisinopril concentration-time-curve based on 13 sampling time points]","BACKGROUND:30945118",null,null,"EUDRACT_NUMBER:2013-001087-39; OTHER:U1111-1140-3741"],["NCT01761318","Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients","MAGNA VICTORIA","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","50","Diabetes Mellitus Type 2; Metabolic Syndrome; Cardiovascular Disease; Diastolic Dysfunction; Fatty Liver","DRUG:Liraglutide; DRUG:Liraglutide - Placebo","Leiden University Medical Center","2013-11","2016-03","FALSE","Stroke volume [0 and 26 weeks] | Ejection Fraction [0 and 26 weeks] | Cardiac output [0 and 26 weeks] | Cardiac index [0 and 26 weeks] | Peak ejection rate [0 and 26 weeks] | Early peak filling rate [0 and 26 weeks] | Early deceleration peak [0 and 26 weeks] | Atrial peak filling rate [0 and 26 weeks] | Early deceleration peak / Atrial peak filling rate (E/A ratio) [0 and 26 weeks] | Peak mitral annulus longitudinal motion [0 and 26 weeks] | Left ventricular filling pressure (= early peak filling rate / peak mitral annulus longitudinal motion) [0 and 26 weeks]","BACKGROUND:15111519; BACKGROUND:16123478; BACKGROUND:20609967; BACKGROUND:22991697; BACKGROUND:9742976; BACKGROUND:22723560; BACKGROUND:7484905; BACKGROUND:11997279; BACKGROUND:19805654; BACKGROUND:15171747; BACKGROUND:17698735; BACKGROUND:15591516; BACKGROUND:22949540; BACKGROUND:18786482; BACKGROUND:18029455; BACKGROUND:22586279; BACKGROUND:12840659; BACKGROUND:11707564; BACKGROUND:19930006; BACKGROUND:15883751; BACKGROUND:19540343; BACKGROUND:17976835; BACKGROUND:19195607; BACKGROUND:18427132; BACKGROUND:15313949; BACKGROUND:14981009; BACKGROUND:17719327; BACKGROUND:17174230; BACKGROUND:18708025; BACKGROUND:15582729; BACKGROUND:15353407; BACKGROUND:11897280; BACKGROUND:16776751; BACKGROUND:16374859; BACKGROUND:12875772; BACKGROUND:18628354; BACKGROUND:19915017; BACKGROUND:19815124; BACKGROUND:17885193; BACKGROUND:18430773; BACKGROUND:19349323; BACKGROUND:18819705; BACKGROUND:19317822; DERIVED:39963952; DERIVED:39641307; DERIVED:36262060; DERIVED:33293204; DERIVED:32127340; DERIVED:31690988; DERIVED:31292457; DERIVED:31039778",null,null,"EUDRACT_NUMBER:2012-001623-12"],["NCT02249910","Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","32","Diabetes; Healthy","DRUG:semaglutide; DRUG:metformin; DRUG:digoxin; DRUG:placebo","Novo Nordisk A/S","2014-09-18","2015-03-06","FALSE","Area under the metformin plasma concentration-time curve [During a dosing interval (0 to12 hours) at steady state] | Area under the digoxin plasma concentration-time curve [From time 0 to infinity after single dose]","BACKGROUND:30945118",null,null,"EUDRACT_NUMBER:2013-004820-12; OTHER:U1111-1150-0801"],["NCT05652647","A Study to Understand How the Study Medicine (PF-07081532) is Processed and Eliminated in Healthy Men",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","6","Healthy Participants","DRUG:Oral [14C]PF-07081532; DRUG:Oral PF-07081532 and IV [14C]PF-07081532","Pfizer","2022-12-21","2023-03-15","TRUE","Total Recovery of Radioactivity in Urine, Feces and Both Routes Combined, as Percentage of Orally Administered Radioactive Dose of [14C]PF-07081532 [360 hours] | Relative Abundance of [14C]PF-07081532 and Its Metabolites in Plasma After A Single Oral Dose of [14]PF-07081532 in Period 1 [Pre-dose (0 hours [hrs]) and 0.5 hrs, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, 24 hrs, 36 hrs, 48 hrs, and 72 hrs post Period 1 Day 1 dosing] | Relative Abundance of [14C]PF-07081532 and Its Metabolites in Urine and Feces After A Single Oral Dose of [14]PF-07081532 in Period 1 [96 hours for urine samples and 144 hours for feces samples]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/47/NCT05652647/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/47/NCT05652647/SAP_001.pdf","NO",null],["NCT01029886","Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","912","Type 2 Diabetes Mellitus","DRUG:exenatide once weekly; DRUG:liraglutide","AstraZeneca","2010-01","2011-01","TRUE","Change in HbA1c From Baseline to Week 26 [Baseline, Week 26]","DERIVED:23748506; DERIVED:23141817",null,null,null],["NCT04143802","A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","72","Diabetes Mellitus, Type 2","DRUG:LY3437943; DRUG:Dulaglutide; DRUG:Placebo","Eli Lilly and Company","2019-12-18","2020-12-28","FALSE","Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline through Day 106]","DERIVED:36354040",null,"NO","OTHER:J1I-MC-GZBB"],["NCT01455870","A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","535","Type 2 Diabetes","DRUG:ITCA 650 60 mcg/day; DRUG:sitagliptin","Intarcia Therapeutics","2013-05","2015-07","FALSE","Change in HbA1c between Week 52 and Day 0 [52 weeks]",null,null,null,null],["NCT04184622","A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight","SURMOUNT-1","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","2539","Overweight; Obesity","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2019-12-04","2022-04-01","TRUE","Percent Change From Baseline in Body Weight (Primary Treatment Period) [Baseline, Week 72] | Percentage of Participants Who Achieve ≥5% Body Weight Reduction (Primary Treatment Period) [Week 72]","DERIVED:42831032; DERIVED:42348366; DERIVED:42233927; DERIVED:41885866; DERIVED:41612966; DERIVED:41537305; DERIVED:41187013; DERIVED:40717199; DERIVED:40677091; DERIVED:40659850; DERIVED:40550133; DERIVED:40512543; DERIVED:39800653; DERIVED:39536238; DERIVED:39497468; DERIVED:39084707; DERIVED:38314555; DERIVED:37700443; DERIVED:35658024","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/22/NCT04184622/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/22/NCT04184622/SAP_001.pdf","YES","OTHER:I8F-MC-GPHK"],["NCT06049329","A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","36","Obesity","DRUG:NNC0487-0111; DRUG:Placebo (NNC0487-0111)","Novo Nordisk A/S","2023-09-14","2023-12-15","FALSE","Number of treatment emergent adverse events (TEAE) [From pre-dose on Day 1 until completion of the end of study visit Day 31]",null,null,"YES","OTHER:U1111-1284-5901"],["NCT06701305","A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015)",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","48","Healthy","DRUG:Efinopegdutide; DRUG:Placebo; DRUG:Acetaminophen","Merck Sharp & Dohme LLC","2024-06-13","2025-02-18","FALSE","Part 1: Number of Participants Who Experience an Adverse Event (AE) [Up to approximately 35 days] | Part 1: Number of Participants Who Discontinue Study Treatment Due to an AE [Up to approximately 35 days] | Part 1: Maximum Plasma Concentration (Cmax) of Efinopegdutide [Pre-dose and at designated time points up to 35 days post dose] | Part 1: Time to Maximum Plasma Concentration (Tmax) of Efinopegdutide [Pre-dose and at designated time points up to 35 days post dose] | Part 1: Area Under the Concentration-Time Curve from Time 0 to Last Measurable Concentration (AUC0-last) of Efinopegdutide [Pre-dose and at designated time points up to 35 days post dose] | Part 1: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Efinopegdutide [Pre-dose and at designated time points up to 35 days post dose] | Part 1: Apparent Terminal Half-life (t1/2) of Efinopegdutide [Pre-dose and at designated time points up to 35 days post dose] | Part 1: Apparent Clearance (CL/F) of Efinopegdutide [Pre-dose and at designated time points up to 35 days post dose] | Part 1: Apparent volume of distribution during terminal phase (Vz/F) of Efinopegdutide [Pre-dose and at designated time points up to 35 days post dose] | Part 2: Number of Participants Who Experience an Adverse Event (AE) [Up to approximately 184 days] | Part 2: Number of Participants Who Discontinue Study Treatment Due to an AE [Up to approximately 184 days] | Part 2: Cmax of Efinopegdutide [At designated time points up to approximately 184 days] | Part 2: Tmax of Efinopegdutide [At designated time points up to approximately 184 days] | Part 2: Area Under the Concentration-Time Curve from Time 0 to the End of the Dosing Interval (AUC0-tau) of Efinopegdutide [At designated time points up to approximately 184 days] | Part 2: t1/2 of Efinopegdutide [At designated time points up to approximately 184 days] | Part 2: Vz/F of Efinopegdutide [At designated time points up to approximately 184 days] | Part 2: Concentration Immediately Before the Next Dose is Administered (Ctrough) of Efinopegdutide [At designated time points up to approximately 184 days]",null,null,"YES","OTHER:MK-6024-015"],["NCT05502562","A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India","PIONEER REAL","COMPLETED","OBSERVATIONAL",null,null,null,"388","Diabetes Mellitus, Type 2","DRUG:Oral semaglutide","Novo Nordisk A/S","2023-02-24","2024-06-03","FALSE","Change in Glycated haemoglobin A1c (HbA1c) [From baseline (week 0) to End of Study visit (V3) (week 34-44)]","DERIVED:41229720",null,"YES","OTHER:U1111-1270-0826"],["NCT07094568","Tirzepatide vs Liraglutide in Bone","TiLi-BONE","RECRUITING","OBSERVATIONAL",null,null,null,"72","Obesity (Disorder)",null,"National and Kapodistrian University of Athens","2025-05-23","2026-12-30","FALSE","Change in serum CTX concentration [Baseline and 3 months after intervention initiation]","RESULT:27940448; RESULT:22966732; RESULT:16047519; RESULT:33265078; RESULT:24744505; RESULT:38937532; RESULT:22989867; RESULT:9563372; RESULT:37305679; RESULT:32087616; RESULT:21184054; RESULT:36510335; RESULT:38634081; RESULT:39770498; RESULT:26043228; RESULT:31870634; RESULT:30955181; RESULT:35581617; RESULT:29805533; RESULT:37832035; RESULT:39481534; RESULT:30806583; RESULT:34988627; RESULT:31301138; RESULT:26012544; RESULT:28631236; RESULT:39790440; RESULT:25105997; RESULT:34948466; RESULT:39744530; RESULT:37925778; RESULT:33409277; RESULT:32877973; RESULT:23902935; RESULT:35255597; RESULT:28585193",null,"NO",null],["NCT06742710","Liraglutide Treatment in Obese Infertile PCOS Women","LITOP","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","890","PCOS; Obesity; Infertility","DRUG:Liraglutide and metformin; DRUG:Metformin","Peking University Third Hospital","2025-05-22","2029-05-30","FALSE","Live birth rate associated with single cycle frozen embryo transfer [At delivery]",null,null,"UNDECIDED",null],["NCT06888167","Food (Poly)Phenol Metabotypes and Beta-cell Mass and Function.","META-BETA","RECRUITING","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","40","Healthy Volunteer","OTHER:Study setting","Azienda Ospedaliero-Universitaria di Parma","2024-10-14","2025-12-31","FALSE","Specific metabotypes (MTs) that associate with different pancreatic beta-cell mass and function (BCFxM). [through study completion, an average of 3 months after enrolment]","RESULT:25211370; RESULT:37442376; RESULT:34503957",null,null,null],["NCT02231684","Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","42","Diabetes; Healthy","DRUG:semaglutide","Novo Nordisk A/S","2014-09","2015-01","FALSE","Area under the semaglutide plasma concentration curve [From day 0-day 35/840 hours]",null,null,null,"EUDRACT_NUMBER:2013-004566-34; OTHER:U1111-1149-3980"],["NCT06243536","The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","60","Type 2 Diabetes; Overweight; Disordered Eating Behaviors","DRUG:Semaglutide; DRUG:standard of care","University Hospital Sestre Milosrdnice","2024-02-01","2024-12-31","FALSE","Eating Attitude Test (EAT-26) questionnaire score [EAT-26 questionnaire will be assessed at the beginning of the trial and at the end of the trial after 12 weeks.]","BACKGROUND:31518657; BACKGROUND:19336687; BACKGROUND:29168047; BACKGROUND:27575047; BACKGROUND:36305323; BACKGROUND:26301188; BACKGROUND:31516703; BACKGROUND:33762313; BACKGROUND:33950566; BACKGROUND:25745131; BACKGROUND:25841588; BACKGROUND:11728508; BACKGROUND:34486393; BACKGROUND:21157325; BACKGROUND:33989649; BACKGROUND:24245943; BACKGROUND:7852887; BACKGROUND:30372907; BACKGROUND:33068776; BACKGROUND:17498508; BACKGROUND:34922690; BACKGROUND:8770921; BACKGROUND:29617641; BACKGROUND:28461695; BACKGROUND:29407005; BACKGROUND:25870084; BACKGROUND:25330463; BACKGROUND:32289741; BACKGROUND:27527911; BACKGROUND:27208320; BACKGROUND:34286894; BACKGROUND:36722623; BACKGROUND:27443001; BACKGROUND:34248838; BACKGROUND:6961471; BACKGROUND:16682865; BACKGROUND:31177185",null,"NO",null],["NCT06672549","A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)","ADVANCE","RECRUITING","INTERVENTIONAL","PHASE3",null,"NONE","125","Obesity; Overweight","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2024-11-18","2027-02","FALSE","Number of Participants Allocated to Each ISA [Baseline to Week 72]",null,null,"YES","OTHER:J4M-MC-PWMP"],["NCT04097600","A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","274","Healthy Volunteers; Type 2 Diabetes","DRUG:Oral semaglutide","Novo Nordisk A/S","2019-09-30","2020-12-16","FALSE","AUC0-24h,sema,SS; area under the semaglutide plasma concentration-time curve during a dosing interval at steady state [From 0 to 24 hours after the last dosing of oral semaglutide low, medium and high dose on days 28, 56 and 84, respectively]",null,null,"YES","OTHER:U1111-1226-6257; REGISTRY:2019-000279-17; NIH:2019"],["NCT07553299","A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities",null,"TERMINATED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","8","Obesity; Overweight; Weight Maintenance","DRUG:VRB-101; DRUG:Placebo","Verdiva Bio Dev Limited","2026-06-12","2026-09-11","FALSE","To identify the dose of VRB-101 for weight maintenance [Baseline to End of Treatment (Week 17)]",null,null,"UNDECIDED",null],["NCT06060392","Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus","Sema-Lit","RECRUITING","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","50","Liver Transplant; Complications; Diabete Mellitus","DRUG:Semaglutide Pill","Medanta, The Medicity, India","2023-10-30","2025-09-02","FALSE","Change in liver fat content [Baseline to 24 weeks]","RESULT:33185364; RESULT:35439567; RESULT:19938117; RESULT:22025886; RESULT:22554256; RESULT:22431131; RESULT:25482832",null,"NO",null],["NCT07803744","A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","18","Diabetes Mellitus, Type 1; Overweight; Obesity","DRUG:Tirzepatide; DRUG:Acetaminophen; DRUG:Placebo","Eli Lilly and Company","2026-09-11","2026-12","FALSE","Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Acetaminophen [Predose on Day 1 through 36 hours post dose] | PK: Area Under the Concentration Versus Time Curve from Time Zero to Time t (AUC0-tlast) of Acetaminophen [Predose on Day 1 through 36 hours post dose] | PK: Maximum Observed Drug Concentration (Cmax) of Acetaminophen [Predose on Day 1 through 36 hours post dose]",null,null,"NO","OTHER:I8F-MC-GPJI"],["NCT07010432","The Role of the Amylin Analogue Cagrilintide in Bone Metabolism","RAMBO","RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","144","Obesity","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo cagrilintide; DRUG:Placebo semaglutide","Novo Nordisk A/S","2025-06-12","2028-05-03","FALSE","Relative change in volumetric bone mineral density (vBMD) of the total hip assessed by quantitative computed tomography (QCT) [From baseline to end of treatment (week 68)]",null,null,"YES","OTHER:U1111-1313-0864; OTHER:2024-517883-49"],["NCT01934816","Incretin and KATP Channels",null,"TERMINATED","INTERVENTIONAL",null,"RANDOMIZED","TRIPLE","2","Healthy Subjects","OTHER:Intradermal injections of GLP-1 and its analogues","Katarina Kos","2013-06","2015-01","FALSE","Change in skin blood flow to GLP-1 and its analogues [6 weeks]",null,null,null,"REGISTRY:1308823; OTHER:13/SW/0010"],["NCT07554638","Incretin Therapies in Obesity-related HFpEF",null,"RECRUITING","INTERVENTIONAL","PHASE4",null,"NONE","50","Heart Failure, Diastolic; Heart Failure With Preserved Ejection Fraction; Obesity","DRUG:Tirzepatide","Columbia University","2026-08-07","2029-04","FALSE","Plasma volume [12 months]",null,null,"NO",null],["NCT01620476","Safety and Tolerability of Liraglutide in Healthy Japanese Volunteers",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","24","Diabetes; Healthy","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2003-09","2004-03","FALSE","Area under the plasma liraglutide curve []",null,null,null,null],["NCT02964247","LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","303","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2017-03-03","2018-05-04","TRUE","Change in HbA1c [Week 0, Week 26]","RESULT:31984646; DERIVED:34132018","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/47/NCT02964247/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/47/NCT02964247/SAP_001.pdf","YES","OTHER:U1111-1184-8086"],["NCT03292315","Once Weekly GLP-1 in Persons With Spinal Cord Injury",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","5","Spinal Cord Injuries; Insulin Resistance; Pre Diabetes; Obesity","DRUG:Semaglutide 1MG Injection [Ozempic]; OTHER:No Intervention","James J. Peters Veterans Affairs Medical Center","2018-10-16","2020-03-01","FALSE","Body Weight [Baseline, Week 13, Week 26] | Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) [Baseline, Week 13, Week 26] | Homeostatic Model Assessment of Beta-Cell Function (HOMA-B) [Baseline, Week 13, Week 26]","DERIVED:37158751",null,"NO",null],["NCT06775093","Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","392","Polycystic Ovary Syndrome; Obesity; Infertility, Female","DRUG:GLP-1 receptor agonist; DRUG:Metformin; BEHAVIORAL:healthy lifestyle education","Peking University Third Hospital","2025-03-01","2026-12-31","FALSE","Live birth rate [18 months]",null,null,"UNDECIDED",null],["NCT07204249","Glutide for Ending Methamphetamine","GEM","RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","162","Methamphetamine-dependence","DRUG:Semaglutide; DRUG:Placebo","San Francisco Department of Public Health","2026-02-26","2030-02-15","FALSE","Ratio of eligible to enrolled participants [14 months] | Proportion of on-time injections [20 months] | Past month methamphetamine use at baseline vs. week 12 [12 weeks] | Rate of study-drug discontinuation [12 weeks] | Reduced methamphetamine use [12 weeks]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/49/NCT07204249/Prot_SAP_000.pdf",null,null],["NCT02229240","Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus",null,"WITHDRAWN","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","0","Diabetes Mellitus, Type 2","DRUG:Albiglutide; DRUG:Matching albiglutide placebo","GlaxoSmithKline","2015-08","2015-12","FALSE","Percentage of subjects with severe or documented symptomatic hypoglycemia through Week 26 [Up to Week 26] | Change from baseline in glycosylated hemoglobin (HbA1c) at Week 26 [Week 26]",null,null,null,null],["NCT05193578","Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes","HISTORI","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","154","Schizophrenia; Prediabetic State","DRUG:Semaglutide, 1.34 mg/mL; OTHER:Placebo","Jan Frystyk","2022-01-01","2024-03-18","FALSE","HbA1c (mmol/mol) [30 weeks]","DERIVED:41555458; DERIVED:40900607; DERIVED:38503415","Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/78/NCT05193578/SAP_003.pdf","YES",null],["NCT06449625","Semaglutide in Auto-HSCT","PROTECT","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","40","Intestinal Mucositis; Inflammation; Chemotherapeutic Toxicity","DRUG:Semaglutide Pen Injector [Ozempic]; DRUG:Placebo","Klaus Gottlob Müller","2024-08-12","2026-12-31","FALSE","gastrointestinal mucositis severity [from day of stem cell infusion (day 0) to week +3]","DERIVED:39384243",null,"NO","CTIS:2022-502139-20-00"],["NCT06173778","Semaglutide for Post-Smoking Cessation Weight Management",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","197","Obesity; Overweight; Cigarette Smoking","DRUG:semaglutide 2.4mg; DRUG:Placebo; DRUG:Nicotine Replacement Therapy (NRT, nicotine patch); BEHAVIORAL:Brief Smoking Cessation Counseling","The University of Texas Health Science Center, Houston","2024-04-23","2028-05-25","FALSE","Change in Body Weight Percent [Baseline to Week 28]","DERIVED:40554081",null,"NO",null],["NCT03743025","Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients",null,"TERMINATED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","28","Stress Hyperglycemia","DRUG:Dulaglutide Injection; OTHER:Saline Injection","Emory University","2019-03-08","2023-05-02","TRUE","Number of Participants With Blood Glucose Levels (BG) > 140 mg/dl During Post Operative Period [During the hospital stay (up to 12 days postoperatively)]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/25/NCT03743025/Prot_SAP_001.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/25/NCT03743025/ICF_000.pdf","NO","NIH:1K23GM128221-01A1"],["NCT03787225","A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","66","Obesity; Overweight","DRUG:NNC0174-0833; DRUG:Placebo (NNC0174-0833)","Novo Nordisk A/S","2019-01-07","2019-06-04","FALSE","AUC0-∞,AM833: the area under the NNC0174-0833 plasma concentration-time curve from time 0 to infinity after single dose [From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)]",null,null,"YES","OTHER:U1111-1219-7303"],["NCT02973321","A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","296","Type 2 Diabetes Mellitus","DRUG:SAR425899; DRUG:Placebo; DRUG:Liraglutide; DRUG:Metformin","Sanofi","2016-12-02","2017-12-27","TRUE","Change From Baseline in HbA1c to Week 26 [Baseline, Week 26]","DERIVED:33822469; DERIVED:31679129","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/21/NCT02973321/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/21/NCT02973321/SAP_001.pdf","YES","EUDRACT_NUMBER:2016-001328-77; OTHER:U1111-1179-4786; NIH:2016"],["NCT06962280","A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight","SURPASS-T1D-2","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","465","Type 1 Diabetes; Obesity; Overweight","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2025-05-12","2026-11","FALSE","Change from Baseline in Hemoglobin A1c (HbA1c) [Baseline, Week 40]",null,null,"YES","OTHER:I8F-MC-GPJD; CTIS:2024-519685-51-00"],["NCT01907854","Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin","LIRA-SWITCH™","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","407","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:sitagliptin; DRUG:placebo","Novo Nordisk A/S","2013-12-02","2015-06-15","TRUE","Change in HbA1c (Glycosylated Haemoglobin) [From baseline to week 26]","RESULT:27381275",null,null,"EUDRACT_NUMBER:2012-004931-22; OTHER:U1111-1136-2073; REGISTRY:CTRI/2014/05/004623"],["NCT03523273","Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","136","Obesity","DRUG:Liraglutide; DRUG:Placebo","Michael Camilleri, MD","2017-11-29","2021-08-31","TRUE","Gastric Emptying of Solids (T1/2) [5 weeks] | Gastric Emptying of Solids (T1/2) [16 weeks]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/73/NCT03523273/Prot_SAP_000.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/73/NCT03523273/ICF_001.pdf",null,"NIH:R56DK067071; NIH:UL1TR000135"],["NCT06439056","Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","12","Type 2 Diabetes","DRUG:NEX-22A, a prolonged release formulation of liraglutide","Nanexa AB","2024-05-27","2025-07-18","FALSE","To evaluate the PK profile of liraglutide after single ascending doses of NEX-22A in subjects with stable type 2 diabetes [From administration of study drug until 36 days]",null,null,"NO",null],["NCT06914141","Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction","DUP-TIRZSEMA","COMPLETED","OBSERVATIONAL",null,null,null,"28118","Diabetes Mellitus, Type 2; HFpEF - Heart Failure With Preserved Ejection Fraction","DRUG:Tirzepatide; DRUG:Semaglutide","Brigham and Women's Hospital","2025-01-14","2025-06-01","FALSE","Composite of all-cause mortality or heart failure hospitalization [Through study completion (1 day after cohort entry date until the first of outcome or censoring)]","DERIVED:40886075","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/41/NCT06914141/Prot_SAP_000.pdf",null,null],["NCT04050553","A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","42","Diabetes Mellitus, Type 2; Hypoglycemia","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2020-02-24","2022-01-25","TRUE","Change in Mean Glucagon Concentration During Induced Hypoglycemia From Target Plasma Glucose (PG) Concentration of 100 Milligrams Per Deciliter (mg/dL) to a Nadir Target of 45 mg/dL [Week 12 in each study period: Baseline and up to 30 minutes after reaching the nadir glucose level.]","DERIVED:40964167","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/53/NCT04050553/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/53/NCT04050553/SAP_001.pdf","NO","OTHER:I8F-MC-GPHG; EUDRACT_NUMBER:2019-001360-29; NIH:2019"],["NCT06727331","Study of Tirzepatide for Recovery and Alcohol Use Management","STREAM","RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","20","Alcohol Use Disorder (AUD)","DRUG:Tirzepatide; OTHER:Saline Placebo","Brigham and Women's Hospital","2025-09-15","2027-03-01","FALSE","Cue-induced Cravings for Alcohol [Baseline visit and 5 weeks after baseline visit.] | Incidence and Severity of Adverse Events [Epic monitoring throughout the trial and PRISE administered at study weeks 2-5 (visits 3-6).]",null,null,"UNDECIDED",null],["NCT01206101","Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation",null,"TERMINATED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","3","Diabetes; Diabetes Mellitus, Type 1","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2012-03-21","2013-06-03","TRUE","Proportion Of Insulin-independent Subjects After Receiving Only One (Single-Donor) Islet Cell Transplant [At week 52 after initial transplantation]",null,null,null,"EUDRACT_NUMBER:2009-013090-18; OTHER:U1111-1114-8952; NIH:2009"],["NCT01128894","A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","841","Diabetes Mellitus, Type 2","BIOLOGICAL:albiglutide; DRUG:liraglutide","GlaxoSmithKline","2010-05","2011-09","TRUE","Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 32 [Baseline and Week 32]","DERIVED:24703047",null,"YES",null],["NCT06719011","A Study on How NNC0174-1213 Works in People With Overweight or Obesity.",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","178","Obesity; Overweight","DRUG:NNC0174-1213 A; DRUG:Cagrilintide B; DRUG:Placebo A (NNC0174 1213 A)","Novo Nordisk A/S","2024-12-03","2026-07-20","FALSE","Part A: Number of treatment emergent adverse events (TEAE) reported by participants exposed to NNC0174 1213 [From NNC0174 1213 administration (Day 1) to completion of the end of study visit (Day 46)] | Part B: Number of treatment emergent adverse events (TEAE) [From first administration (Day 1) to completion of the end of study visit (Day 67)]",null,null,"YES","OTHER:U1111-1308-5620"],["NCT06246799","Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","256","Type 2 Diabetes (Adult Onset)","DRUG:Tirzepatide; DRUG:Pioglitazone; DRUG:Sitagliptin; DRUG:Metformin HCI XR","The University of Texas Health Science Center at San Antonio","2024-11-07","2029-04-30","FALSE","number of subjects achieving HbA1c <6.5% at 6 months (Efficacy) [6 months] | Number of subjects failing to achieving HbA1c <6.5% Long-term [month 60]",null,null,"YES","NIH:R01DK097554"],["NCT06717698","A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","465","Chronic Kidney Disease","DRUG:NNC0519-0130; DRUG:Placebo; DRUG:Semaglutide","Novo Nordisk A/S","2024-12-02","2026-09-01","FALSE","Change in urinary albumin-to-creatinine ratio (UACR) at week 12 [From baseline (week 0) to end of a given maintenance dose period (week 12)] | Change in urinary albumin-to-creatinine ratio (UACR) at week 24 [From baseline (week 0) to end of a given maintenance dose period (week 24)] | Change in urinary albumin-to-creatinine ratio (UACR) at week 36 [From baseline (week 0) to end of a given maintenance dose period (week 36)]",null,null,"YES","OTHER:U1111-1302-5591; OTHER:2024-510846-15"],["NCT05418907","Exendin PET/CT for Imaging of Paragangliomas","ENTRAP","UNKNOWN","OBSERVATIONAL",null,null,null,"10","Paraganglioma","RADIATION:68Ga-NODAGA-exendin-4 PET/CT","Radboud University Medical Center","2022-06-01","2024-12-01","FALSE","detection rate of PGL's using 68Ga-exendin-4 PET/CT [1 year]",null,null,"UNDECIDED",null],["NCT06739044","Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","494","Type 2 Diabetes","DRUG:Ozempic®; DRUG:HDG1901","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2023-09-20","2024-10-11","FALSE","Change in HbA1c from baseline [Week 32]",null,null,"NO",null],["NCT07755085","GLP-1s in Hip and Knee Arthroplasty",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","100","Arthritis; Obesity & Overweight; GLP - 1","DRUG:GLP-1 Receptor Agonists + Behavioral modification; BEHAVIORAL:Behavioral + placebo","Nova Scotia Health Authority","2026-10-01","2028-06-01","FALSE","Incidence of Wound Complication after Joint Arthroplasty [90 days]","BACKGROUND:38857711",null,"YES",null],["NCT07254715","Effect of Itopride on Semaglutide Gastroparesis",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","60","Semaglutide-Induced Gastric Motility; Anesthesia","DRUG:Itopride HCI 50 mg; DRUG:Placebo","Ain Shams University","2026-01-01","2026-07-30","FALSE","Residual gastric contents [on day 7]",null,null,"NO",null],["NCT04216589","Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)",null,"COMPLETED","INTERVENTIONAL","PHASE2",null,"NONE","51","HIV Infections; Non-Alcoholic Fatty Liver Disease","DRUG:Semaglutide","National Institute of Allergy and Infectious Diseases (NIAID)","2021-02-19","2023-03-16","TRUE","Change (Absolute) in IHTG (%) [Measured at pre-entry and Week 24]","DERIVED:42014432; DERIVED:41299212; DERIVED:41256006; DERIVED:39046173","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/89/NCT04216589/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/89/NCT04216589/SAP_001.pdf","YES","REGISTRY:38453"],["NCT04560998","A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes","STRIDE","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","792","Diabetes Mellitus, Type 2; Peripheral Arterial Disease","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2020-10-01","2024-06-05","TRUE","Change in Maximum Walking Distance on a Constant Load Treadmill Test [Baseline (week 0), end of treatment (week 52)]","DERIVED:40169145","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/98/NCT04560998/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/98/NCT04560998/SAP_001.pdf","YES","REGISTRY:2019-003399-38; OTHER:U1111-1238-7071; NIH:2019"],["NCT04941521","Exenatide for Treating Cocaine Use Disorder",null,"COMPLETED","INTERVENTIONAL","PHASE1; PHASE2",null,"NONE","3","Cocaine Use Disorder","DRUG:Exenatide 2 mg [Bydureon]; BEHAVIORAL:Drug Counseling","The University of Texas Health Science Center, Houston","2021-06-24","2021-11-17","TRUE","Feasibility as Assessed by Number of Participants Who Completed Treatment [Week 6] | Drug Safety as Assessed by Total Number of Adverse Events Reported During Treatment [From Week 1 to Week 6] | Clinical Effect of Exenatide as Assessed by Cocaine Use During Treatment as Indicated by Number of Participants With Cocaine-positive Urine Drug Screen Results [From Week 1 to Week 6]","DERIVED:37579116","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/21/NCT04941521/Prot_SAP_000.pdf","NO",null],["NCT07660848","A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","160","Metabolic Dysfunction-Associated Steatohepatitis (MASH)","DRUG:HRS-4729 Injection; DRUG:HRS9531 Injection; DRUG:HRS-4729 Injection Placebo; DRUG:HRS9531 Injection Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2026-08-14","2028-03","FALSE","Percent Change from Baseline in Liver Fat Content by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) [Baseline, Week 32]",null,null,"UNDECIDED",null],["NCT01739049","Influence of Appetite Related Hormones in Binge Eating Behaviour Among the Overweight and Obese",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","42","Binge Eating Behaviour","DRUG:Liraglutide; BEHAVIORAL:Diet and Exercise","Universiti Kebangsaan Malaysia Medical Centre","2012-11","2013-10","FALSE","Reduction in binge eating scale score [12 weeks]","DERIVED:25870084",null,"NO",null],["NCT07310563","A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","59","Overweight; Obesity","DRUG:AMG 133; DRUG:Ondansetron","Amgen","2024-12-10","2025-05-09","FALSE","Maximum Observed Plasma Concentration (Cmax) of AMG 133 [Up to Day 120] | Area Under the Plasma Concentration-time Curve (AUC) from Time Zero to Time of Last Quantifiable Concentration (AUClast) of AMG 133 [Up to Day 120] | AUC from Time Zero to Infinity (AUCinf) of AMG 133 [Up to Day 120]",null,null,"YES",null],["NCT07732738","Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.","BS-GLP","RECRUITING","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","400","Obesity","COMBINATION_PRODUCT:BS-GLP1RA group; PROCEDURE:BS group","China-Japan Friendship Hospital","2025-01-01","2027-12-30","FALSE","the Percentage of weight loss [1 year]",null,null,null,null],["NCT02877355","Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","55","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide","Novo Nordisk A/S","2016-08-22","2017-11-24","FALSE","Area under the semaglutide plasma concentration-time curve [From 0 to 24 hours after the 10th dosing]","DERIVED:33969456",null,"YES","EUDRACT_NUMBER:2015-004534-10; OTHER:U1111-1175-5246; NIH:2015"],["NCT03767543","Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)","LixilanOne CAN","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","265","Type 2 Diabetes Mellitus","DRUG:INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010","Sanofi","2019-03-11","2020-10-23","FALSE","Change in glycated hemoglobin (HbA1c)% [Baseline to Week 26]","DERIVED:36574199; DERIVED:35670659",null,"YES","OTHER:U1111-1215-0238"],["NCT06788626","Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment","GALLOP2","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","SINGLE","390","Acute Ischemic Stroke; Large Vessel Occlusion; Neuroprotective Drugs; Endovascular Treatment","DRUG:Semaglutide 0.5 mg; OTHER:Standard medical treatment","Wei Hu","2025-02","2028-02","FALSE","The ordinal shift of modified Rankin Scale [90±14 days after procedure]",null,null,"NO",null],["NCT07607587","Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","114","Obesity; Overweight","DRUG:Cagrilintide; DRUG:Placebo (matched to Cagrilintide)","Novo Nordisk A/S","2026-05-29","2027-11-19","FALSE","Percentage of participants on standard dose or higher dose (yes/no) of cagrilintide and placebo [At week 26]",null,null,"YES","OTHER:U1111-1325-8511"],["NCT07720414","Effects of GLP-1 RAs on Human Lactation Outcomes",null,"RECRUITING","OBSERVATIONAL",null,null,null,"18","Lactation; Weight Loss","DRUG:Injected GLP-1 Receptor Agonists and Dual Agonists","University of Colorado, Denver","2026-07","2028-06","FALSE","Hourly milk production rate [From one week before until a maximum of 2 months after beginning GLP-1RA treatment. This timeframe will restart if their dosage is increased.] | Milk macronutrient composition [From one week before until a maximum of 2 months after beginning GLP-1RA treatment. This timeframe will restart if the dosage is increased.]",null,null,"YES",null],["NCT02770885","Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia (The GOLD-Study)","GOLD","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","50","Primary Polydipsia","DRUG:Dulaglutide; DRUG:Placebo","University Hospital, Basel, Switzerland","2016-03","2019-05-17","FALSE","Fluid intake in ml [8 hours]","DERIVED:35134170; DERIVED:34473645",null,"NO",null],["NCT00551343","Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","20","Prader-Willi Syndrome","DRUG:Exenatide","Garvan Institute of Medical Research","2007-10","2008-09","FALSE","satiety hormones [1 day]",null,null,null,"OTHER:X07-0178"],["NCT05232708","A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","18","Healthy Volunteers (Diabetes Mellitus, Type 2)","DRUG:Semaglutide B, 1.34 mg/mL; DRUG:Semaglutide D, 1.0 mg/mL","Novo Nordisk A/S","2022-01-19","2022-08-30","FALSE","AUC0-last,sema 0.5mg: Area under the semaglutide concentration-time curve from time 0 until last quantifiable measurement after single dose of s.c. semaglutide 0.5 mg [0-840 hours after a single dose of s.c. semaglutide 0.5 mg] | Cmax,sema,0.5mg: maximum observed semaglutide concentration-time after single dose of s.c. semaglutide 0.5 mg administration [0-840 hours after a single dose of s.c. semaglutide 0.5 mg]",null,null,"YES","EUDRACT_NUMBER:2021-003216-25; OTHER:U1111-1266-4076"],["NCT06828055","VK2735 for Weight Management Phase 2 (Venture Oral Dosing)",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","280","Weight Loss","DRUG:Placebo; DRUG:VK2735","Viking Therapeutics, Inc.","2024-12-18","2025-06-24","FALSE","Percent (relative) change from baseline in body weight after 13 weeks of treatment [13 Weeks]",null,null,null,null],["NCT02284009","Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","67","Diabetes Mellitus, Type 1","BIOLOGICAL:Albiglutide weekly injection; BIOLOGICAL:Placebo weekly injection; BIOLOGICAL:Insulin","GlaxoSmithKline","2014-10-10","2017-10-18","TRUE","Mean Change From Baseline in Time Normalized Stimulated (From Mixed Meal Tolerance Test [MMTT]) 2-hour Plasma C-peptide Area Under the Curve (AUC) at Week 52 [Baseline and Week 52]","BACKGROUND:32219329","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/09/NCT02284009/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/09/NCT02284009/SAP_001.pdf","YES",null],["NCT02394314","A Phase 1, Single Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy Volunteers",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","362","Healthy Volunteers","DRUG:MEDI0382; DRUG:Placebo","MedImmune LLC","2015-02","2015-08","FALSE","Number of subjects with adverse events as a measure of safety and tolerability of MEDI0382 [28 days post dosing] | Number of subjects with Adverse events as a measure of safety and tolerability of MEDI0382 [28 days post dosing]",null,null,null,null],["NCT07842640","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","84","Chronic Weight Management","DRUG:ASC35 Injection B, for subcutaneous use; DRUG:ASC35 Placebo Injection B, for subcutaneous use; DRUG:Tirzepatide","Ascletis Pharma (China) Co., Limited","2026-08-27","2027-06","FALSE","Adverse events [Baseline and Day 141]",null,null,"NO",null],["NCT04478708","Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","110","Obesity","BIOLOGICAL:maridebart cafraglutide; DRUG:Placebo","Amgen","2020-08-07","2022-11-18","TRUE","Number of Participants With Treatment-emergent Adverse Events (TEAEs) [Part A: 150 days; Part B: 207 days; Part C Cohort 12: 193 days; Part C Cohort 13: 207 days]","BACKGROUND:38316982","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/08/NCT04478708/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/08/NCT04478708/SAP_001.pdf","YES",null],["NCT01794143","A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes","GRADE","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","7850","Type 2 Diabetes; Comparative Effectiveness of Glycemia-lowering Medications","DRUG:Sulfonylurea (glimepiride); DRUG:DPP-4 inhibitor (sitagliptin); DRUG:GLP-1 receptor agonist (liraglutide); DRUG:Insulin (glargine)","GRADE Study Group","2013-05","2021-04-30","TRUE","Time to HbA1c>=7%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication [Quarterly for 4 to 7 years] | HbA1c>=7%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication [Quarterly, 4-7 years]","BACKGROUND:36631123; BACKGROUND:34786739; BACKGROUND:36549905; BACKGROUND:31647326; BACKGROUND:29956365; BACKGROUND:26336199; BACKGROUND:25329662; BACKGROUND:26400875; RESULT:40986645; RESULT:40751289; RESULT:40424051; RESULT:40388190; RESULT:40267365; RESULT:39998948; RESULT:39977640; RESULT:39951058; RESULT:39546502; RESULT:39312277; RESULT:38416773; RESULT:38344820; RESULT:38333889; RESULT:38354481; RESULT:38285957; RESULT:38252886; RESULT:38252848; RESULT:38227900; RESULT:38211595; RESULT:38194519; RESULT:38190619; RESULT:38190625; RESULT:37756542; RESULT:37394014; RESULT:37368512; RESULT:37329282; RESULT:37213109; RESULT:37094945; RESULT:36999229; RESULT:36549506; RESULT:36129997; RESULT:36129996; RESULT:40315175; RESULT:34971663; RESULT:35061024; RESULT:34780485; RESULT:34285097; RESULT:34556408; RESULT:33766761; RESULT:34531242; RESULT:33752962; RESULT:33288412; RESULT:33334808; RESULT:32450102; RESULT:32139384; RESULT:31391203; RESULT:31393176; RESULT:31368793; RESULT:28213915; RESULT:23690531; DERIVED:41282760; DERIVED:39963952; DERIVED:38837240","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/43/NCT01794143/Prot_002.pdf; Statistical Analysis Plan: Manuscript - Microvascular and Cardiovascular Outcomes (OP2)|https://cdn.clinicaltrials.gov/large-docs/43/NCT01794143/SAP_005.pdf; Statistical Analysis Plan: GRADE Study|https://cdn.clinicaltrials.gov/large-docs/43/NCT01794143/SAP_001.pdf; Statistical Analysis Plan: Manuscript - Long Term Differences in Metabolic Status (OP1)|https://cdn.clinicaltrials.gov/large-docs/43/NCT01794143/SAP_004.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/43/NCT01794143/ICF_003.pdf",null,"NIH:1U01DK098246-01"],["NCT00035984","Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","734","Diabetes Mellitus, Non-Insulin-Dependent","DRUG:AC2993; DRUG:Placebo","AstraZeneca","2002-05","2003-08","FALSE","Change in HbA1c from Baseline to Week 30 [Baseline (Day 1) to Week 30]","RESULT:15855571; DERIVED:22913891; DERIVED:22236356",null,null,null],["NCT07226778","Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","348","Overweight; Obesity","DRUG:Maridebart Cafraglutide","Amgen","2025-10-10","2026-05-28","FALSE","Area Under the Plasma Concentration Time Curve from Time Zero to Infinity (AUCinf) of Maridebart Cafraglutide [Up to Day 120] | Area Under the Plasma Concentration Time Curve from Time Zero to Time of Last Quantifiable Concentration (AUClast) of Maridebart Cafraglutide [Up to Day 120] | Maximum Observed Plasma Concentration (Cmax) of Maridebart Cafraglutide [Up to Day 120]",null,null,"YES",null],["NCT07738276","Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity","DUAL-HFrEF","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","60","Heart Failure and Reduced Ejection Fraction; Obesity & Overweight; Tirzepatide","DRUG:Tirzepatide; DRUG:Placebo","Shahid Beheshti University of Medical Sciences","2026-07-18","2027-06-11","FALSE","Change in 6-Minute Walk Distance [Baseline and 6 months after intervention start]","BACKGROUND:3283935; BACKGROUND:18193044; BACKGROUND:18159244; BACKGROUND:34811547; BACKGROUND:38632048; BACKGROUND:37932236; BACKGROUND:39551891; BACKGROUND:39556714; BACKGROUND:39555826; BACKGROUND:37952180; BACKGROUND:38819334; BACKGROUND:37622681",null,null,null],["NCT03439943","Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease","LixiPark","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","156","Parkinson Disease","DRUG:Lixisenatide; DRUG:placebo","University Hospital, Toulouse","2018-06-13","2021-04-15","FALSE","Change from baseline to end-point (M12) in the MDS-UPDRS III motor (Movement Disorder Society-Unified Parkinson's disease rating scale) [12 month]","RESULT:38598572",null,null,null],["NCT02058160","Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes","LixiLan-L","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","736","Type 2 Diabetes","DRUG:Insulin glargine/lixisenatide (HOE901/AVE0010); DRUG:Insulin glargine (HOE901); DRUG:Metformin (Background Drug)","Sanofi","2014-01","2015-07","TRUE","Change in Glycated Hemoglobin (HbA1c) From Baseline to Week 30 [Baseline, Week 30]","RESULT:27650977; DERIVED:31848983; DERIVED:31359368; DERIVED:31114694; DERIVED:30550345; DERIVED:30218434; DERIVED:29974618; DERIVED:29923298; DERIVED:29143919; DERIVED:28386990",null,null,"EUDRACT_NUMBER:2013-003132-79; OTHER:U1111-1148-4351"],["NCT07849348","Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","QUADRUPLE","266","Obesity; Chronic Kidney Disease; Albuminuria","DRUG:Finerenone; DRUG:Finerenone Placebo; DRUG:Semaglutide","Peking University People's Hospital","2026-09","2027-02","FALSE","Change From Baseline in Urinary Albumin-to-Creatinine Ratio (UACR) at Week 24 [Baseline to Week 24]",null,null,"UNDECIDED",null],["NCT06492135","A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","30","Overweight; Obesity","DRUG:survodutide","Boehringer Ingelheim","2024-08-12","2025-04-15","FALSE","AUC0-168 (area under the concentration-time curve of survodutide in plasma over the time interval from 0 to 168h) [up to 7 days] | Cmax (maximum measured concentration of survodutide in plasma) after the first dose [up to 7 days] | Cmax (maximum measured concentration of survodutide in plasma) after multiple doses [up to 7 days]",null,null,"NO",null],["NCT00111540","Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3",null,"NONE","456","Diabetes Mellitus, Type 2","DRUG:exenatide","AstraZeneca","2002-11","2006-09","FALSE","Change in HbA1c (glycosylated hemoglobin) from Visit 1 to each protocol visit [Day 1, Weeks 2, 4, 8, 15, 22, 30, 38, 46 and every 12 weeks while on study (78 week target)] | Change in body weight from Visit 1 to each protocol visit [Day 1, Weeks 2, 4, 8, 15, 22, 30, 38, 46 and every 12 weeks while on study (78 week target)] | Change in fasting plasma glucose from Visit 1 to each protocol visit [Day 1, Weeks 2, 4, 8, 15, 22, 30, 38, 46 and every 12 weeks while on study (78 week target)] | Change in lipids from Visit 1 to each protocol visit [Day 1, Weeks 2, 4, 8, 15, 22, 30, 38, 46 and every 12 weeks while on study (78 week target)]","RESULT:16776751; RESULT:17379054; RESULT:18053320; DERIVED:22236356; DERIVED:17705687",null,null,null],["NCT03593668","Effect and Safety of Benaglutide or Metformin in Patients With Simple Obesity Who Have Inadequate Weight Control",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","60","Obesity; Drug","DRUG:Metformin; DRUG:Benaglutide","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","2017-12-30","2019-10","FALSE","Changes in body weight [Change from Baseline after 12 weeks treatment]",null,null,null,null],["NCT05893576","A Relative Bioavailability Study of HRS9531 in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","50","Type 2 Diabetes","DRUG:HRS9531","Fujian Shengdi Pharmaceutical Co., Ltd.","2023-05-15","2023-09-04","FALSE","Area Under the Concentration versus time curve (AUC) of HRS953 [Start of treatment up to Day 43] | Maximum Concentration (Cmax) of HRS9531 [Start of Treatment up to Day 43] | Calculate the ratio of bioavailability between the new formulation and original formulation of HRS9531 according to the equation F (relative bioavailability) =AUCT·DR/AUCR·DT×100% [Start of Treatment up to Day 43]",null,null,"UNDECIDED",null],["NCT05971940","A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone","ACHIEVE-1","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","559","Type 2 Diabetes","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2023-08-09","2025-04-03","TRUE","Change From Baseline in HbA1c [Baseline, Week 40]","DERIVED:40544435","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/40/NCT05971940/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/40/NCT05971940/SAP_001.pdf","YES","OTHER:J2A-MC-GZGT; OTHER:U1111-1290-5157"],["NCT07820111","Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","159","Obese Diabetics; Obese Non Diabetic","DRUG:Dulaglutide 1.5 MG/ML; DRUG:Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution; DRUG:Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physician; DRUG:Dulaglutide 0.75mg subcutaneous injection; DRUG:Semaglutide 1.0 mg; DRUG:Tirzepatide (Flexible titration)","Zagazig University","2025-10-18","2026-03-17","FALSE","change in body weight at 3 and 6 months [6-MONTH STUDY PERIOD]",null,"Study Protocol, Statistical Analysis Plan, and Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/11/NCT07820111/Prot_SAP_ICF_000.pdf","YES",null],["NCT06751589","A Study of a Weight Loss Intervention in People With Endometrial Cancer",null,"RECRUITING","INTERVENTIONAL","EARLY_PHASE1",null,"NONE","36","Endometrial Cancer","DRUG:Tirzepatide","Memorial Sloan Kettering Cancer Center","2024-12-19","2027-12","FALSE","percentage of patients that complete treatment [1 year]",null,null,"YES",null],["NCT07609160","Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","108","Obesity; Sarcopenia; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities","OTHER:Resistance exercise; OTHER:Lifestyle recommendations","Acibadem University","2026-11-01","2027-11-30","FALSE","Change in muscle thickness [Baseline, 12 weeks, 24 weeks] | Muscle echo intensity [Baseline, 12 weeks, 24 weeks]",null,null,"NO","OTHER:Grant proposal submitted"],["NCT05328726","Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","24","Diabetes Mellitus, Type 2","DRUG:GZR-18; OTHER:Placebo","Gan and Lee Pharmaceuticals, USA","2022-03-08","2023-02-09","FALSE","Dose limiting toxicity [Up to 31 days]",null,null,null,null],["NCT03789578","A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","30","Diabetes Mellitus, Type 2","DRUG:NNC0148-0287sema; DRUG:Semaglutide; DRUG:NNC0148-0287","Novo Nordisk A/S","2019-01-17","2019-10-10","FALSE","AUCI287, 0-tz, area under the serum insulin 287 concentration-time curve from 0 hours to last quantifiable observation after a single dose [0-840 hours] | AUCSema,0-tz, area under the plasma semaglutide concentration-time curve from 0 hours to last quantifiable observation after a single dose [0-840 hours]","RESULT:39488821",null,"YES","OTHER:U1111-1204-8233; REGISTRY:2017-004538-27; NIH:2017"],["NCT07693426","Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","36","Adolescence Obesity","DRUG:Efsubaglutide Alfa 5 mg QW; DRUG:Efsubaglutide Alfa 10 mg QW; DRUG:Efsubaglutide Alfa 20 mg QW; DRUG:Efsubaglutide Alfa placebo","Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","2026-07-16","2027-04-30","FALSE","Safety and tolerability: incidence of TEAEs, SAEs, and AESI [Throughout the study (up to Week 18)] | Pharmacokinetic (PK) characteristics at steady state following multiple doses [Throughout the study (up to Week 18)]",null,null,"NO",null],["NCT07293325","Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity",null,"RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","66","Adults With Simple Obesity","DRUG:Semaglutide; DRUG:Tirzepatide; DRUG:Metformin","Second Affiliated Hospital, Zhejiang University, School of Medicine","2025-06-02","2027-04-02","FALSE","Change in DNA methylation-based biological age measured by iWatchAge [Baseline and Week 24]",null,null,null,null],["NCT05016882","Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","698","Non-alcoholic Steatohepatitis","DRUG:NNC0194 0499 50 mg/mL; DRUG:Placebo (NNC0194-0499); DRUG:Semaglutide 3 mg/mL; DRUG:Semaglutide placebo; DRUG:NNC0174 0833 10 mg/mL; DRUG:NNC0174 0833 placebo","Novo Nordisk A/S","2021-08-31","2024-12-17","FALSE","Improvement in liver fibrosis and no worsening of NASH (Yes/No) [From baseline (week 0) to week 52]","DERIVED:42456707",null,"YES","OTHER:U1111-1255-5551; EUDRACT_NUMBER:2020-003566-39"],["NCT07187856","Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","80","Type 2 Diabetes Mellitus (T2DM)","DRUG:PG-102; DRUG:Placebo; DRUG:Semaglutide","ProGen. Co., Ltd.","2026-01","2026-09","FALSE","Absolute change in HbA1c From Baseline at Week 24 [24 weeks]",null,null,null,null],["NCT02170324","GLP-1 Agonism Stimulates Browning of Subcutaneous White Adipose Tissue in Obesity Men",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","20","Obesity","DRUG:Exenatide; DRUG:Placebo","Xiang Guang-da","2014-06","2015-07","FALSE","The expression of brown adipose related genes in subcutaneous white adipose tissue [3 months]",null,null,null,null],["NCT01597531","Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding",null,"TERMINATED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","1","Type 2 Diabetes; Gastric Banding","DRUG:Liraglutide; DRUG:Orlistat; DRUG:Liraglutide + Orlistat","East Carolina University","2012-06","2014-06","FALSE","Type 2 diabetes remission [baseline, 1 and 4 months post-randomization]","BACKGROUND:19272486",null,null,null],["NCT07017270","Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis","GUARD-1","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","100","Kidney Disease, Chronic; Diabetes; Dialysis; End Stage Kidney Disease (ESRD)","DRUG:Semaglutide Pen","Unity Health Toronto","2025-11-27","2027-07","FALSE","Adherence of Study Intervention [26 weeks]",null,null,"NO",null],["NCT02255266","Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice",null,"COMPLETED","OBSERVATIONAL",null,null,null,"1788","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2015-03-26","2015-11-16","FALSE","Frequency of patients achieving HbA1c reduction of at least 1%-point [Week 0, week 52]","RESULT:29270781",null,null,"OTHER:U1111-1143-9842"],["NCT01722266","Liraglutide in the Treatment of Type 1 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","72","Type 1 Diabetes","DRUG:Liraglutide; DRUG:Placebo","University at Buffalo","2012-11-01","2014-04-01","TRUE","Change in Mean Weekly Glucose Concentrations [12 Weeks]","BACKGROUND:23807520; BACKGROUND:21646283; BACKGROUND:20207828; BACKGROUND:19808924; BACKGROUND:17180352; BACKGROUND:18996824; BACKGROUND:17379054; BACKGROUND:20109994; BACKGROUND:21856595; BACKGROUND:20841306; BACKGROUND:20019672; BACKGROUND:20404854; DERIVED:27208343",null,null,null],["NCT07083154","Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","420","Dementia, Mild; Mild Cognitive Impairment; Type 2 Diabetes","DRUG:Mazdutide; DRUG:Placebo","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","2025-09-27","2029-08-01","FALSE","Integrated Alzheimer's Disease Rating Scale (iADRS) Score Change [From Baseline to Week 76]",null,null,"YES",null],["NCT05202353","A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","SINGLE","29","Obesity","DRUG:BI 456906; DRUG:Semaglutide","Boehringer Ingelheim","2024-11-01","2027-01-06","FALSE","Percentage of glucagon (GCG) receptors occupancy in the liver using Positron emission tomography (PET) imaging at End of Treatment (EOT) visit [up to Week 17]",null,null,"NO","EUDRACT_NUMBER:2021-000363-76; CTIS:2024-515417-17-00"],["NCT00516074","A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","54","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:placebo","AstraZeneca","2007-09","2008-04","TRUE","Change in Mean 24-hour Heart Rate From Baseline to Endpoint [12 weeks]","DERIVED:20109208",null,null,null],["NCT03811574","STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity","STEP 6","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","401","Overweight; Obesity","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2019-01-21","2020-11-20","TRUE","Change in Body Weight (%) [Baseline (week 0), week 68] | Number of Participants Who Achieve (Yes/no): Body Weight Reduction More Than or Equal to 5% [At week 68]","RESULT:33667417; DERIVED:40189961; DERIVED:35131037","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/74/NCT03811574/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/74/NCT03811574/SAP_001.pdf","YES","OTHER:U1111-1201-1629"],["NCT07732218","Efficacy of Once Weekly Semaglutide in Patients With Type 2 Diabetes: a Non Randomized Clinical Trial",null,"COMPLETED","INTERVENTIONAL","PHASE4",null,"NONE","95","Type 2 Diabetes","DRUG:Semaglutide (Ozempic®)","Rehman Medical Institute - RMI","2022-07-04","2023-03-30","FALSE","Change in Glycated hemoglobin [baseline and 16 week] | Changes in Glycated Hemoglobin [Baseline and week 16]",null,null,"NO",null],["NCT03648554","Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST)","REALIST","UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","93","Diabetes Mellitus, Type 2; NASH - Nonalcoholic Steatohepatitis","DRUG:dulaglutide (TRULICITY®) 1.5 mg; OTHER:reinforced dietary monitoring","Central Hospital, Nancy, France","2019-09-01","2023-09-30","FALSE","Responder's proportion difference between the two groups (dulaglutide (TRULICITY®) on top of dietary reinforcement vs. dietary reinforcement alone) [after 52 weeks of treatment]",null,null,"NO","OTHER:PSS2018/REALIST-GUERCI/AS; NIH:2018"],["NCT03034941","Short Term Weight Loss With Liraglutide and Metformin in Infertile Obese PCOS Patients",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","35","Obesity; PCOS","DRUG:Metformin; DRUG:Liraglutide + metformin","University Medical Centre Ljubljana","2014-04","2016-12","FALSE","The main outcome was change in BMI [Patient's BMI was measured at the beginning and every four weeks during 12 weeks of clinical trial.]","BACKGROUND:24362411; BACKGROUND:18692801; BACKGROUND:21500991",null,"YES",null],["NCT05668936","A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants",null,"TERMINATED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","31","Non-alcoholic Steatohepatitis","DRUG:Cotadutide; DRUG:Cotadutide-placebo; DRUG:Moxifloxacin; DRUG:Moxifloxacin-placebo","AstraZeneca","2023-01-03","2023-03-10","FALSE","Time-matched change-from-baseline Fridericia's correction of QT interval (QTcF) [Up to Day 92]",null,null,"YES","EUDRACT_NUMBER:2022-002479-12"],["NCT05230615","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice","PIONEER REAL","COMPLETED","OBSERVATIONAL",null,null,null,"458","Diabetes Mellitus, Type 2","DRUG:Oral semaglutide","Novo Nordisk A/S","2022-04-01","2023-10-31","FALSE","Change in HbA1c (Glycated haemoglobin) [From baseline (week 0) to End of Study visit (V3) (week 34-44)]","DERIVED:40128506; DERIVED:39535683",null,"YES","OTHER:U1111-1240-3945"],["NCT06256523","A Study of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM)",null,"COMPLETED","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","DOUBLE","72","Type 2 Diabetes","DRUG:GZR18; OTHER:Placebo","Gan and Lee Pharmaceuticals, USA","2022-06-29","2023-09-28","FALSE","Number of adverse events and serious adverse events [29 weeks] | Changes from baseline in hemoglobin A1c (HbA1c) at the end of the study [26 weeks]","DERIVED:42320483",null,null,null],["NCT01156779","Study to Evaluate Safety and PK/PD of DA-3091 in Healthy Male Subjects","SR-Exenatide","COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","31","Diabetes Mellitus","DRUG:SR-exenatide","Dong-A Pharmaceutical Co., Ltd.","2010-07","2012-04","FALSE","Assessment of safety [84 days]",null,null,null,null],["NCT03315780","A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","12","Type 2 Diabetes","DRUG:Dulaglutide; DRUG:Placebo","Eli Lilly and Company","2017-10-28","2018-02-28","TRUE","Change From Baseline in Glucose Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC[0-4h]) [Baseline, 4 Weeks]","DERIVED:30949907","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/80/NCT03315780/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/80/NCT03315780/SAP_001.pdf","YES","OTHER:H9X-JE-GBGK"],["NCT06994650","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","140","Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy","DRUG:HRS9531; DRUG:Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2025-08-13","2026-12","FALSE","The change of AHI form baseline after 52 weeks of treatment [52 weeks]",null,null,"UNDECIDED",null],["NCT03689374","A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes","SUSTAIN 11","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","2274","Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Insulin aspart; DRUG:Insulin glargine U100","Novo Nordisk A/S","2018-10-01","2021-02-22","TRUE","Change From Baseline in Glycated Haemoglobin (HbA1c) [Baseline (week 0), week 52]","RESULT:35546450","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/74/NCT03689374/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/74/NCT03689374/SAP_001.pdf","YES","OTHER:U1111-1200-0164; REGISTRY:2017-003219-20; NIH:2017"],["NCT07570810","Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","TRIPLE","30","Type 2 Diabetes; Obesity; Non-alcoholic Fatty Liver Disease","DRUG:CS0159; DRUG:CS0159 placebo; DRUG:Semaglutide","Shanghai Jiao Tong University School of Medicine","2026-06-01","2026-11-30","FALSE","Percentage change in body weight relative to baseline [Baseline to 12 weeks] | Changes in energy expenditure [Baseline to 12 weeks]",null,null,"NO",null],["NCT02254291","A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes","SUSTAIN™","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","308","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:sitagliptin","Novo Nordisk A/S","2014-10-02","2015-11-11","TRUE","Number of Treatment Emergent Adverse Events (TEAEs) [Weeks 0-30]","RESULT:28786547; DERIVED:32998732",null,null,"OTHER:U1111-1140-5334; REGISTRY:JapicCTI-142663"],["NCT07728318","Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","52","Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight","OTHER:Tirzepatide + Standard Therapy (Intervention Group); OTHER:Standard Oral Antidiabetic Drugs (OADs)","Akhtar Saeed Medical and Dental College","2026-08-12","2027-01-12","FALSE","Change in Glycemic Control (HbA1c) [Baseline, 3 months, and 6 months] | Change in Body Weight [Baseline and monthly up to 6 months]",null,null,"UNDECIDED",null],["NCT01117350","Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure","EAGLE","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","978","Diabetes Mellitus, Type 2","DRUG:Insulin glargine; DRUG:Liraglutide; DRUG:Metformin","Sanofi","2010-07","2012-10","TRUE","Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) <7% at the End of the Comparative Period [week 12, week 24]",null,null,null,"EUDRACT_NUMBER:2010-018437-21; OTHER:U1111-1116-9684"],["NCT05114590","Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus","Soli-CGM","COMPLETED","INTERVENTIONAL","PHASE4",null,"NONE","124","Type 2 Diabetes Mellitus","DRUG:Insulin glargine/Lixisenatide","Sanofi","2022-01-27","2023-03-28","TRUE","Change From Baseline to Week 16 in the Percentage of Time in Range [70 to 180 Milligram Per Deciliter (mg/dL)] [Baseline (Days -14 to -1) and Week 16]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/90/NCT05114590/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/90/NCT05114590/SAP_001.pdf","YES","REGISTRY:U1111-1261-7399"],["NCT05530577","Effects of Semaglutide on Nicotine Intake",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","24","Tobacco Use Disorder; Nicotine Addiction","DRUG:Semaglutide; DRUG:Sham/placebo","University of North Carolina, Chapel Hill","2022-10-07","2024-05-13","TRUE","Change in Nicotine Self-Administration [Baseline (Week 0) to post-medication (Week 8)] | Change in Nicotine Reinstatement Duration [Baseline (Week 0) to post-medication (Week 8)]","DERIVED:42189538","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/77/NCT05530577/Prot_SAP_002.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/77/NCT05530577/ICF_000.pdf","YES","NIH:R21DA047663-02"],["NCT07796477","A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","240","T2DM (Type 2 Diabetes Mellitus)","DRUG:SYH2069 Injection (group 1); DRUG:SYH2069 Injection (group 2); DRUG:SYH2069 Injection (group 3); DRUG:SYH2069 Injection (group 4); DRUG:SYH2069 Injection placebo; DRUG:Tirzepatide Injection 15mg","CSPC Ouyi Pharmaceutical Co., Ltd.","2026-11-06","2027-09-28","FALSE","Change from baseline in Hemoglobin A1c (HbA1c) [Baseline，Week 28]",null,null,null,null],["NCT06057077","Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus",null,"UNKNOWN","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","SINGLE","120","Type 1 Diabetes","DRUG:Semaglutide weekly injection","Ministry of Health, Saudi Arabia","2024-01-01","2024-12-31","FALSE","change in HA1c and mounts of insulin of basal and bolus which will be taken daily is the same or decreased after one year of follow up [Time Frame: one year]","RESULT:27048952; DERIVED:39206389",null,"NO",null],["NCT06374875","Fibrosis Lessens After Metabolic Surgery","FLAMES","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","120","Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD); Non-Alcoholic Fatty Liver Disease; Metabolic Dysfunction-Associated Steatohepatitis (MASH); Liver Fibrosis; Obesity","PROCEDURE:Metabolic surgery; DRUG:Incretin-Based Therapy","The Cleveland Clinic","2024-07-11","2029-05-31","FALSE","Improvement of at least 1 fibrosis stage of the Kleiner fibrosis classification and no worsening of MASH in the repeat liver biopsy. [Through study completion, 2 years]",null,null,"YES",null],["NCT06124807","A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","179","Obesity; Overweight and Obesity","DRUG:Mazdutide; DRUG:Placebo","Eli Lilly and Company","2023-11-17","2025-01-22","TRUE","Percent Change From Baseline in Body Weight at Week 32 [Baseline, Week 32]","DERIVED:42628555","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/07/NCT06124807/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/07/NCT06124807/SAP_001.pdf","YES","OTHER:W8M-MC-OXA1; OTHER:CWMM Master Protocol"],["NCT07613437","GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial","GLICH","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","200","Intracerebral Hemorrhage","DRUG:Semaglutide, 0.5 mg/mL","Chinese University of Hong Kong","2026-06-15","2028-06-14","FALSE","Edema extension distance on Day 7 [Day 7]",null,null,"NO",null],["NCT00974272","Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","39","Type 2 Diabetes Mellitus; Impaired Glucose Tolerance","DRUG:Exenatide; OTHER:Normal Saline","Carl T. Hayden VA Medical Center","2006-08","2008-11","FALSE","Triglyceride concentration in serum [Before and up to 8-hours post-injection]","DERIVED:20557887; DERIVED:20200309",null,null,null],["NCT00082407","Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","505","Diabetes Mellitus, Type 2","DRUG:exenatide; DRUG:biphasic insulin aspart","AstraZeneca","2003-11","2008-07","TRUE","Change in Glcosylated Hemoglobin (HbA1c) [baseline, week 52]","RESULT:17160407; DERIVED:22913891; DERIVED:22236356",null,null,null],["NCT00546728","The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","50","Impaired Glucose Tolerance","DRUG:Exenatide; DRUG:Metformin","St. Paul Heart Clinic","2007-10","2011-07","TRUE","Change in Reactive Hyperemic Index Over the 3-month Treatment Period [Change from baseline to 3 months]","DERIVED:22681705",null,null,null],["NCT02305381","Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes","SUSTAIN™ 5","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","397","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2014-12-01","2015-11-21","TRUE","Change in HbA1c (Glycosylated Haemoglobin) [Week 0, week 30]","BACKGROUND:30865526; RESULT:29688502; RESULT:29687620; RESULT:29766634; RESULT:29862621; RESULT:30615985; DERIVED:32998732; DERIVED:31903692; DERIVED:31769496; DERIVED:31215727",null,null,"EUDRACT_NUMBER:2013-004502-26; OTHER:U1111-1149-3738; OTHER:JapicCTI-142729"],["NCT07728383","A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity",null,"RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","40","Obesity & Overweight","DRUG:Semaglutide 6 mg liquid emulsion formulation; DRUG:Wegovy® (semaglutide) Tablet; DRUG:Placebo liquid emulsion formulation","Gila Therapeutics, Inc.","2026-06-17","2027-05","FALSE","Percent body weight change from baseline [24 weeks]",null,null,"NO",null],["NCT05689372","Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea",null,"ENROLLING_BY_INVITATION","OBSERVATIONAL",null,null,null,"600","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2026-02-02","2026-11-30","FALSE","Number (incidence) of adverse events (AEs) [From baseline (week 0) to 26 weeks]",null,null,"YES","OTHER:1111-1243-9580"],["NCT05111912","Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","206","Obesity","DRUG:XW003; DRUG:Saxenda","Sciwind Biosciences APAC CO Pty. Ltd.","2021-11-30","2022-11-16","FALSE","Percentage change in participants body weight (%) from the Baseline [Week 26]",null,null,"NO",null],["NCT07309094","Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","ADIPO-CKD","RECRUITING","OBSERVATIONAL",null,null,null,"250","Chronic Kidney Disease stage3; Chronic Kidney Disease stage4; Chronic Kidney Disease Stage 1; Chronic Kidney Disease Stage 2; Obesity; Diabetes Mellitus, Type 2","DRUG:GLP-1 receptor agonist; DRUG:SGLT2 inhibitor; DRUG:Tirzepatide; DRUG:Other drugs","Cardenal Herrera University","2023-09-15","2027-07-31","FALSE","Ultrasonography change in perirenal adipose tissue thickness [16 months] | Change in estimated glomerular filtration rate [16 months]","BACKGROUND:38378894; BACKGROUND:26386043; BACKGROUND:19776173; BACKGROUND:38785209; BACKGROUND:31373167; BACKGROUND:34113631; BACKGROUND:30898362; BACKGROUND:19896746; BACKGROUND:32444271; BACKGROUND:34441451; BACKGROUND:33008306; BACKGROUND:28765150; BACKGROUND:32061315; BACKGROUND:30340847; BACKGROUND:36908289",null,"NO",null],["NCT01281228","The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes","Braini-Ex","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","48","Diabetes Mellitus; Diabetes Mellitus, Type 2; Obesity","DRUG:exenatide; DRUG:exenatide + exendin (9-39); DRUG:placebo","Amsterdam UMC, location VUmc","2011-09","2013-10","FALSE","Differences in neuronal activity in CNS reward and satiety circuits [1 hour]","DERIVED:25071023",null,null,"EUDRACT_NUMBER:2010-023635-42"],["NCT07438444","A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE4",null,"NONE","344","Diabetes Mellitus, Type 2; Obesity; Overweight","DRUG:Tirzepatide","Eli Lilly and Company","2026-02-27","2027-07","FALSE","Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration [Baseline through Week 46]",null,null,"YES","OTHER:I8F-IN-GPIZ"],["NCT07760532","Comparing Facial Aging Between Identical Twins With 3D Imaging",null,"NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"200","Facial Skin Aging; Facial Volume Loss; Wrinkle Appearance","DRUG:GLP-1 Receptor Agonists","Ponsky Facial Aesthetics And Plastic Surgery, Llc","2026-08-08","2026-09","FALSE","Within-pair difference in quantitative three-dimensional facial surface measurements [Day 1 (single study visit; all data collected at enrollment)]","BACKGROUND:19337100",null,"NO","OTHER:2026-0412"],["NCT06475586","Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","30","Psoriasis Vulgaris; Diabetes Type 2","DRUG:Semaglutide","University of Banja Luka","2023-05-03","2024-03-01","FALSE","clinical characteristics of patients with psoriasis [up to 12 weeks] | Determine BMI Body Mass Index [up to 12 weeks] | Serum values of TNFa, IL-1b, IL-6, IL-17 and IL-23 [up to12 weeks] | Correlation between the course and prognosis of the disease after the treatment [up to 12 weeks] | Change in HgbA1C, [up to 12 weeks] | lipid status, change in Total cholesterol (TC), low-density lipoprotein(LDL), high-density lipoprotein (HDL) and triglicerides [up to 12 weeks] | fasting insulin [up to 12 weeks] | Change in inflammation marker level: CRP, [up to 12 weeks] | fasting glycemia [up to 12 weeks] | urate [up to 12 weeks]","RESULT:34463640; RESULT:33068776","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/86/NCT06475586/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/86/NCT06475586/SAP_001.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/86/NCT06475586/ICF_002.pdf","YES",null],["NCT06651177","Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder","TAB","RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","310","Opioid Use Disorder; Opioid Use Disorder, Moderate; Opioid Use Disorder, Severe","DRUG:Tirzepatide; OTHER:Placebo","T. John Winhusen, PhD","2026-01-29","2027-09-30","FALSE","6-month retention in BUP treatment [6 months]",null,null,"YES","NIH:UG1DA013732"],["NCT07533175","AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight","AMAZE 2","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","630","Diabetes Mellitus; Overweight; Obesity","DRUG:NNC0487-0111; DRUG:Placebo (matched to NNC0487-0111)","Novo Nordisk A/S","2026-04-13","2028-08-07","FALSE","Relative change in body weight [From baseline (week 0) to (week 84)]",null,null,"YES","OTHER:U1111-1313-6325; OTHER:2024-520441-23"],["NCT06482411","Risk Factors Affect Weight Loss Outcomes After Treatment.","WRRFA","COMPLETED","OBSERVATIONAL",null,null,null,"3602","Weight Regain",null,"E-DA Hospital","2024-06-27","2025-10-22","FALSE","The proportion of failure weight loss [Month 6, Year 1, Year 1.5, Year 2]",null,null,null,null],["NCT04885634","Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients","SOCRATES-AF","WITHDRAWN","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","0","Atrial Fibrillation; Overweight and Obesity","DRUG:Semaglutide Injectable Product; DRUG:Placebo","Axel Brandes","2022-10","2024-01","FALSE","Number of Participants to Complete Recruitment [Up to 68 weeks, until end of treatment] | Number of Participants to Complete Follow-up [Up to 75 weeks, until final follow-up] | Total Resource Requirement [Up to 75 weeks, until final follow-up]",null,null,"NO","EUDRACT_NUMBER:2021-002017-34"],["NCT06256419","Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM",null,"RECRUITING","INTERVENTIONAL",null,null,"NONE","300","Type 2 Diabetes Mellitus; Susceptibility, Genetic","DRUG:GLP-1 receptor agonist; DRUG:responders group and nonresponders group","The Affiliated Hospital of Xuzhou Medical University","2024-01-01","2028-01-31","FALSE","Change from baseline HbA1c and baseline weight at 6 month [6 month after GLP-1 RA treatment] | To identify and evaluate the variable factors influencing GLP-1 RA efficacy [1 month after sample integration] | Genotype identification in patients with T2DM [1 month after sample collecting]",null,null,"NO",null],["NCT00623545","Bioenergetic Alterations After Exenatide Administration",null,"COMPLETED","INTERVENTIONAL","PHASE4",null,"NONE","28","Healthy","DRUG:Exenatide","University of Wisconsin, Madison","2008-01","2010-04","TRUE","Change in Energy Intake Measured Before Treatment and at the End of Treatment. [3 months]","RESULT:20152707; DERIVED:22735035",null,null,null],["NCT01455857","A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","460","Type 2 Diabetes","DRUG:ITCA 650; OTHER:ITCA placebo","Intarcia Therapeutics","2013-03","2014-08","FALSE","Change in HbA1c [39 weeks]","DERIVED:29242349",null,null,null],["NCT06131372","A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","626","Chronic Kidney Disease; Type 2 Diabetes; Obesity","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2024-04-01","2025-09-24","FALSE","Change in urinary albumin-to-creatinine ratio (UACR) [From baseline (week 0) to end of treatment (week 26)]",null,null,"YES","OTHER:U1111-1291-5907; EUDRACT_NUMBER:2023-505857-42; NIH:2023"],["NCT05677867","A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","20","Overweight; Obesity","DRUG:Formulation A (PF-07081532 20 mg plus 60 mg); DRUG:Formulation B (PF-07081532 80 mg)","Pfizer","2023-01-18","2023-03-14","TRUE","Pharmacokinetics Parameter - Area Under the Concentration-Time Curve to Infinity (AUCinf) of PF-07081532 [Pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post dose on Day 1 of Period 1 and Period 2] | Pharmacokinetics Parameter - Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07081532 [Pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post dose on Day 1 of Period 1 and Period 2] | Pharmacokinetics Parameter - Maximum Observed Concentration (Cmax) of PF-07081532 [Pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post dose of Day 1 Period 1 and Period 2.]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/67/NCT05677867/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/67/NCT05677867/SAP_001.pdf","NO",null],["NCT07640139","Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes",null,"ENROLLING_BY_INVITATION","OBSERVATIONAL",null,null,null,"125000","Obesity","DRUG:Incretin-based therapies (GLP-1 and GLP-1/GIP)","Indiana University","2026-01-01","2029-12-31","FALSE","Change in subject body weight. [6 months periods from 2018 to 2029] | Change in subject body mass index (BMI). [6 months periods from 2018 to 2029] | Change in obesity and overweight classification. [6 months periods from 2018 to 2029]",null,null,"NO","OTHER:26469"],["NCT04643301","Liraglutide for Low-responders After Bariatric Surgery","LIBAR","WITHDRAWN","INTERVENTIONAL",null,null,"NONE","0","Obesity; Obesity, Morbid","DRUG:Liraglutide Pen Injector","Zuyderland Medisch Centrum","2020-12-21","2021-12-31","FALSE","%TWL (%TWL) [6 months]",null,null,"UNDECIDED",null],["NCT03604419","Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","214","Type 2 Diabetes Mellitus (T2DM)","DRUG:PB-119 100 μg+ Glucophage®; DRUG:PB-119 150 μg+ Glucophage®; DRUG:PB-119 200 μg+ Glucophage®; DRUG:PB-119 placebo + Glucophage®","PegBio Co., Ltd.","2018-06-13","2019-07-23","FALSE","The change from baseline value of HbA1c will be compared between treatments [From Baseline to end of treatment (up to Week 12)]","DERIVED:30957581",null,"NO",null],["NCT06298799","GENETIC VARIABILITY TO GLP1 TREATMENT","GLP1 treatment","UNKNOWN","INTERVENTIONAL",null,null,"NONE","400","Type 2 Diabetes; Obesity","GENETIC:DNA Sequencing and Analysis; GENETIC:differential expression analysis with RNA-sequencing (RNA seq) experiments","GENGE","2023-10-01","2025-01-01","FALSE","Genetic variants and miRNA expressions associated with changes in BMI. [12 months]",null,null,"NO",null],["NCT06083675","Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes",null,"WITHDRAWN","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","0","Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Empagliflozin; DRUG:Metformin","Novo Nordisk A/S","2024-01-26","2025-01-24","FALSE","Change in glycated haemoglobin (HbA1c) [From randomisation (week 0) to week 52]",null,null,"YES","OTHER:U1111-1291-4976"],["NCT00696657","A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","415","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:placebo; DRUG:liraglutide","Novo Nordisk A/S","2008-06-03","2009-02-05","TRUE","HbA1c [After 12 weeks of treatment.]","DERIVED:26358288",null,null,"EUDRACT_NUMBER:2007-003956-12"],["NCT00835848","Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI","POSTCON II","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","100","Myocardial Infarction","DRUG:Exenatide; DRUG:Saline","Copenhagen University Hospital, Rigshospitalet","2009-01","2009-12","FALSE","Infarct size by MRI [3 months]","DERIVED:28286967; DERIVED:22496084; DERIVED:21920963",null,null,null],["NCT02773368","A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus","DUALTM IX","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","420","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide; DRUG:insulin glargine","Novo Nordisk A/S","2016-05-23","2017-09-26","TRUE","Change in HbA1c (Glycosylated Haemoglobin) [Week 0, Week 26]","RESULT:30761720","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/68/NCT02773368/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/68/NCT02773368/SAP_001.pdf",null,"EUDRACT_NUMBER:2015-001596-48; OTHER:U1111-1168-9343; OTHER:REec-2016-2248; NIH:2015"],["NCT07870538","A Neuropsychobiological Approach to Optimize Patient Selection for GLP-1-based Pharmacotherapy for Weight Management Across the Binge Eating Spectrum","SEM-BEAT","RECRUITING","INTERVENTIONAL","PHASE4",null,"NONE","96","Obesity & Overweight","DRUG:Semaglutide 3,2 mg/ml","Universitaire Ziekenhuizen KU Leuven","2026-08-26","2028-12","FALSE","Change in Body Mass Index (BMI) after semaglutide treatment [From enrollment to the end of treatment at 6 months] | Change in Binge Eating Scale (BES) score after semaglutide treatment [From enrollment to the end of treatment at 6 months]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/38/NCT07870538/Prot_000.pdf",null,"EUDRACT_NUMBER:2026-526016-36"],["NCT07523633","Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder","HASHTAG","RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","100","Cannabis Use Disorder; Cannabis Use Disorders; Cannabis Abuse; Cannabis Dependence; Cannabis Addiction","DRUG:semaglutide; DRUG:Placebo","Anders Fink-Jensen, MD, DMSci","2026-04-30","2028-04-30","FALSE","Cannabis consumption [From baseline to week 20.]",null,null,"YES","REGISTRY:U1111-1327-8749; REGISTRY:2025-524163-21; NIH:2025"],["NCT03671733","Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients",null,"UNKNOWN","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","150","Obesity","DRUG:Liraglutide; DRUG:Exenatide; DRUG:Exenatide Microspheres for Injection","Xiangya Hospital of Central South University","2018-09-01","2022-09-01","FALSE","Weight Change at 3 months [baseline , 3 months]",null,null,null,null],["NCT02501850","The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)","EGLIPA","UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","40","Diabetes Mellitus Type 2","DRUG:Liraglutide; DRUG:metformin","Hospital Universitari Vall d'Hebron Research Institute","2014-10","2015-07","FALSE","Change in blood levels of Lipoprotein (a) (Lp(a)) [Baseline and two months]","BACKGROUND:15793200; BACKGROUND:12964817; BACKGROUND:21500721",null,null,null],["NCT02777073","Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes","1974","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","43","Type 1 Diabetes","DRUG:Victoza; DRUG:Placebo; DRUG:Dapagliflozin 10mg Tab","University at Buffalo","2016-03-01","2016-12-01","TRUE","Difference in Ketone Bodies Formation After Single Dose of Liraglutide and Dapagliflozin [8 hours]",null,null,"NO",null],["NCT06841445","Efficacy and Safety of HRS9531 Tablet in Obese Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","166","Chronic Management of Body Weight","DRUG:HRS9531 Tablet; DRUG:HRS9531 Tablet placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2025-04-07","2026-01-08","FALSE","Percentage Change from baseline in body weight after 26 weeks of treatment [after 26 weeks of treatment]",null,null,"UNDECIDED",null],["NCT02417103","Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid",null,"TERMINATED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","2","Obesity","DRUG:GLP-1 (Liraglutide); DRUG:Placebo","Universitätsklinikum Hamburg-Eppendorf","2011-12","2016-09","FALSE","weight reduction [4 years]",null,null,null,null],["NCT06824051","A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","120","Obesity; Overweight","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2025-02-17","2026-01-26","FALSE","Percent Change from Baseline in Visceral Adipose Tissue (VAT) [Baseline, Week 36]",null,null,"NO","OTHER:J2A-MC-GZPQ"],["NCT06807970","Optimization of Obesity for Total Knee Replacement With Glucagon-like Peptide-1 Receptor Agonist","NPO-OOPS-TKR","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","EARLY_PHASE1","RANDOMIZED","DOUBLE","54","Osteoarthritis (OA) of the Knee","DRUG:Glucagon-like peptide-1 receptor agonists (GLP 1 RA); OTHER:Control (Standard treatment)","The University of Hong Kong","2025-09-01","2027-07-01","FALSE","Visual analogue scale and analgesic consumption [As part of the standard of care when undergoing TKR, patients are routinely assessed at enrolment, 1 month and same day before surgery, and at 6 weeks,3 months, 6 months and 12 months post-surgery.]",null,null,"NO",null],["NCT00331851","Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes","LEAD-5","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","584","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:insulin glargine; DRUG:metformin; DRUG:glimepiride","Novo Nordisk A/S","2006-05","2007-04","FALSE","HbA1c [after 26 weeks of treatment]","RESULT:19245711; RESULT:19491536; RESULT:19688338; RESULT:19878259; RESULT:21450987; RESULT:22055210; RESULT:22193143; RESULT:21883806; RESULT:22862847; RESULT:23010561; RESULT:23186975; RESULT:25323312; RESULT:25504028; DERIVED:24561125",null,null,null],["NCT05579977","Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity",null,"TERMINATED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","902","Diabetes Mellitus; Obesity","DRUG:PF-07081532; OTHER:Placebo; DRUG:Rybelsus","Pfizer","2022-10-27","2023-07-14","TRUE","Placebo-adjusted, Change From Baseline in Percentage of Glycated Hemoglobin (HbA1c) at Week 32: Cohort 1 (Type 2 Diabetes Mellitus) [Baseline (result closest prior to dosing on Day 1), Week 32] | Placebo-adjusted, Percent Change From Baseline in Body Weight at Week 32: Cohort 2 (Obesity) [Baseline (result closest prior to dosing on Day 1), week 32]","DERIVED:39952695; DERIVED:39415344","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/77/NCT05579977/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/77/NCT05579977/SAP_001.pdf","YES","EUDRACT_NUMBER:2022-002834-15"],["NCT07169942","Aleniglipron Phase 2 Body Composition Study",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","71","Obesity, Overweight, or Chronic Weight Management","DRUG:aleniglipron or placebo","Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics","2025-08-15","2026-08","FALSE","Percent change in total body fat mass by DXA [Baseline and week 44]",null,null,"YES",null],["NCT00044694","Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","156","Diabetes Mellitus, Non-Insulin-Dependent","DRUG:Placebo 0.01 mL; DRUG:Placebo 0.02 mL; DRUG:Placebo 0.03 mL; DRUG:Placebo 0.04 mL; DRUG:AC2993 2.5 mcg; DRUG:AC2993 5.0 mcg; DRUG:AC2993 7.5 mcg; DRUG:AC2993 10.0 mcg","AstraZeneca","2002-08","2003-05","FALSE","Change in HbA1c (glycosylated hemoglobin) from Baseline to Day 28 [Baseline (Day 1) to Day 28]","DERIVED:17705687",null,null,null],["NCT04153929","A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","413","Diabetes Mellitus, Type 2","DRUG:BI 456906; DRUG:Placebo; DRUG:Semaglutide","Boehringer Ingelheim","2020-04-30","2021-10-08","TRUE","Absolute Change in HbA1c From Baseline to 16 Weeks [At baseline and at Week 17 (16 weeks after treatment start).]","DERIVED:42331726; DERIVED:38095657","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/29/NCT04153929/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/29/NCT04153929/SAP_001.pdf","YES","EUDRACT_NUMBER:2019-002390-60; NIH:2019"],["NCT07370922","Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","SINGLE","80","Transfusion Dependent Beta Thalassemia","DRUG:Dulaglutide 0.75Mg/0.5Ml Inj Pen; DRUG:control group (insulin)","Ain Shams University","2024-11-22","2025-11-22","FALSE","Change in glycemic variability using continuous glucose monitoring after 6 months. [6 months]","DERIVED:42618811",null,"NO",null],["NCT04440345","Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","DOUBLE","60","Overweight or Obesity","DRUG:IBI362; DRUG:Placebo","Innovent Biologics (Suzhou) Co. Ltd.","2020-06-16","2021-06-16","FALSE","Number of treatment adverse events [From the time of first dosing (Day 1 ) until completion of the post treatment follow-up visit (20 week)]","DERIVED:36247927; DERIVED:34430840",null,null,null],["NCT06403761","Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","158","Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Cagrilintide; DRUG:Placebo semaglutide; DRUG:Placebo cagrilintide","Novo Nordisk A/S","2024-05-06","2025-12-28","FALSE","To compare the effect of CagriSema versus placebo: Change in M-value in hyperinsulinaemic euglycaemic clamp (HEC) [Baseline to week 28]",null,null,"YES","OTHER:U1111-1300-1930; OTHER:2023-509483-20; NIH:2023"],["NCT06934655","Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","SINGLE","150","Pediatric Obesity; Metabolic and Bariatric Surgery; Semaglutide","DRUG:Semaglutide 2.4 mg","Children's Hospital Los Angeles","2026-09-01","2030-11-01","FALSE","Percent Body Mass Index [From enrollment to the end of the end of the study at 24 months]",null,null,"YES","NIH:1R01DK144100-01A1"],["NCT07298915","The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)","EXER-MED","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","24","Obesity & Overweight","DRUG:Tirzepatide; BEHAVIORAL:Exercise","University of Virginia","2026-08","2026-12","FALSE","Weight [Baseline and 16 Weeks]",null,null,"NO",null],["NCT03011008","Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","20","Type 1 Diabetes Mellitus; Autoimmune Diabetes","DRUG:Liraglutide; DRUG:Insulin","Second Xiangya Hospital of Central South University","2017-01","2020-12","FALSE","Mean amplitude of glycemic excursions (MAGE) [1 year]","BACKGROUND:24003936; BACKGROUND:26997114; BACKGROUND:21715000",null,null,null],["NCT04893148","Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","40","Type 2 Diabetes Mellitus; Glucose, High Blood","DRUG:IGlarLixi; DRUG:Dulaglutide","Chungbuk National University Hospital","2020-05-26","2021-12-30","FALSE","Changes in glycated hemoglobin (HbA1c) [Baseline, week 12]",null,null,null,null],["NCT06390501","The Effect of Weekly Semaglutide Treatment on Energy Expenditure",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","60","Obesity; Drug","DRUG:Semaglutide; DRUG:Placebo","Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences","2024-04-01","2025-08-15","FALSE","Changes of Total Energy Expenditure Assessed by Doubly Labeled Water Analysis [From baseline at week 0 to week 24] | Changes of Energy Expenditure Assessed by Chamber [From baseline at week 0 to week 24] | Changes of Resting Energy Expenditure [From baseline at week 0 to week 24] | Changes of Physical Activity [From baseline at week 0 to week 24]",null,null,null,null],["NCT03015519","A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus",null,"WITHDRAWN","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","0","Diabetes Mellitus, Type 2","DRUG:Albiglutide; DRUG:Placebo","GlaxoSmithKline","2017-08-14","2020-04-20","FALSE","Area under the curve (AUC) of albiglutide: Part A [Up to 28 days post-dose] | Maximum Plasma Concentration (Cmax) of albiglutide: Part A [Up to 28 days post-dose] | Apparent clearance (CL/F) of albiglutide: Part A [Up to 28 days post-dose] | Apparent volume of distribution (V/F) of albiglutide: Part A [Up to 28 days post-dose] | Number of subjects with adverse events (AEs): Part A [Up to Week 8 post dose] | Change from Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 24: Part B [Up to Week 24] | Time to reach maximum plasma concentration (tmax) of albiglutide: Part A [Up to 28 days post-dose] | Time to reach half of the maximum plasma concentration (t1/2) of albiglutide: Part A [Up to 28 days post-dose]",null,null,null,null],["NCT06271200","Strategic Lifestyle Intervention for Metabolic Syndrome (SLIM-MET)",null,"RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","200","Metabolic Syndrome","OTHER:Strategic lifestyle and drug interventions; OTHER:Control","National Health Research Institutes, Taiwan","2024-03-14","2027-10-10","FALSE","Change in the metabolic syndrome severity score (Z score) after reduction > 5% body weight from baseline to 24 weeks [24 weeks]","BACKGROUND:11315831; BACKGROUND:17167477; BACKGROUND:20863953; BACKGROUND:16344402; BACKGROUND:34769303; BACKGROUND:16873794; BACKGROUND:17258085; BACKGROUND:33276457; BACKGROUND:30641809; BACKGROUND:26998259; BACKGROUND:24222017; BACKGROUND:28455679; BACKGROUND:28412520; BACKGROUND:12196436; BACKGROUND:37137283; BACKGROUND:28521334; BACKGROUND:17284728; BACKGROUND:31180809; BACKGROUND:31881139; BACKGROUND:26411343; BACKGROUND:32270927; BACKGROUND:32986097; BACKGROUND:14684394; BACKGROUND:24290837",null,"NO",null],["NCT07850063","ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","600","Obesity; Metabolic Dysfunction-associated Steatotic Liver Disease","COMBINATION_PRODUCT:Survodutide; COMBINATION_PRODUCT:Placebo matching survodutide","Boehringer Ingelheim","2026-10-23","2029-04-29","FALSE","Composite average Z-score (dimensionless) at Week 76 of cardiac structural and functional parameters [At week 76]",null,null,"YES","REGISTRY:1111-1339-5364; REGISTRY:2026-527091-88-00"],["NCT02641899","Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","33","Healthy","DRUG:ITCA 650 20/60 mcg/day; DRUG:Acetaminophen; DRUG:Atorvastatin; DRUG:Lisinopril; DRUG:Warfarin; DRUG:Digoxin","Intarcia Therapeutics","2015-12","2016-03","FALSE","Area under the concentration-time curve from time zero to the last measurable concentration [AUC(0-last)]) of acetaminophen alone and in the presence of ITCA 650. [time zero to 10 weeks] | Maximum plasma concentration ([Cmax]) of acetaminophen alone and in the presence of ITCA 650 [time zero to 10 weeks] | Area under the concentration-time curve (AUC(0-last)) of atorvastatin, lisinopril, digoxin, R-warfarin, and S-warfarin each alone and in the presence of ITCA 650. [time zero to 10 weeks] | Cmax of atorvastatin, lisinopril, digoxin, R-warfarin, and S-warfarin each alone and in the presence of ITCA 650. [time zero to 10 weeks]",null,null,"NO",null],["NCT07073417","A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","163","Obesity; Weight Management","DRUG:XW003 injection; DRUG:semaglutide injection","Hangzhou Sciwind Biosciences Co., Ltd.","2025-07-28","2027-02-27","FALSE","Percentage change in body weight relative to baseline [week 48]",null,null,null,null],["NCT00259896","In-patient Study in Patients With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","30","Type 2 Diabetes Mellitus; Diabetes Mellitus, Type 2","DRUG:exenatide","GlaxoSmithKline","2005-10",null,"FALSE","Pharmacodynamic measurements during 7 days of dosing. []",null,null,null,null],["NCT02058940","Intravenous Exenatide in Patients With Acute Brain Injury",null,"COMPLETED","INTERVENTIONAL","PHASE4",null,"NONE","8","Brain Injuries","DRUG:Exenatide","University of North Carolina, Chapel Hill","2015-08","2017-08","TRUE","Percentage of Critically Ill Patients With Acute Brain Injury Achieving Pre-specified Feasibility Criteria [Over 48 hours from infusion initiation]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/40/NCT02058940/Prot_SAP_000.pdf",null,"OTHER_GRANT:Astra Zeneca Pharmaceuticals; OTHER_GRANT:Medtronic MiniMed, Inc"],["NCT01612468","Liraglutide in Type 1 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","100","Diabetes Mellitus, Type 1; Overweight","DRUG:Liraglutide; DRUG:Placebo","Steno Diabetes Center Copenhagen","2012-06","2015-02","FALSE","Change in HbA1c [24 week]","DERIVED:26656289; DERIVED:25838513",null,null,null],["NCT05056246","Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","34","Healthy Participants","DRUG:AMG 133","Amgen","2021-09-10","2022-04-08","TRUE","Maximum Observed Plasma Concentration (Cmax) of Intact AMG 133 [Day 1 pre-dose and 24, 48, 72, 96, 120, 144, 168, 336, 504, 672, 1008, 1344, 1680, 2184, and 2856 hours post-dose] | Cmax of Total AMG 133 [Day 1 pre-dose and 24, 48, 72, 96, 120, 144, 168, 336, 504, 672, 1008, 1344, 1680, 2184, and 2856 hours post-dose] | Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast) of Intact AMG 133 [Day 1 pre-dose and 24, 48, 72, 96, 120, 144, 168, 336, 504, 672, 1008, 1344, 1680, 2184, and 2856 hours post-dose] | AUClast of Total AMG 133 [Day 1 pre-dose and 24, 48, 72, 96, 120, 144, 168, 336, 504, 672, 1008, 1344, 1680, 2184, and 2856 hours post-dose] | Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Intact AMG 133 [Day 1 pre-dose and 24, 48, 72, 96, 120, 144, 168, 336, 504, 672, 1008, 1344, 1680, 2184, and 2856 hours post-dose] | AUCinf of Total AMG 133 [Day 1 pre-dose and 24, 48, 72, 96, 120, 144, 168, 336, 504, 672, 1008, 1344, 1680, 2184, and 2856 hours post-dose]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/46/NCT05056246/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/46/NCT05056246/SAP_001.pdf","YES",null],["NCT03115424","Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","46","Obesity","DRUG:Saxenda; DRUG:Placebos; PROCEDURE:RYGB","Mayo Clinic","2017-06-22","2023-10-04","TRUE","Weight [baseline and 36 months]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/24/NCT03115424/Prot_SAP_001.pdf","NO",null],["NCT02641990","Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","28","Healthy Adult Premenopausal Female Volunteers","DRUG:ITCA 650 20/60 mcg/day, ITCA placebo; DRUG:ITCA placebo, ITCA 650 20/60 mcg/day","Intarcia Therapeutics","2015-12","2016-02","FALSE","Area under the plasma concentration-time curve at steady state (AUCss) for ethinyl estradiol and levonorgestrel [from baseline to 13 weeks] | Maximum steady state plasma concentration (Cmax,ss) for ethinyl estradiol and levonorgestrel [from baseline to 13 weeks]",null,null,"NO",null],["NCT03534310","Weight Loss With Intensive Lifestyle Modifications Plus Bariatric Surgery Versus Liraglutide 3 mg","LETHE","COMPLETED","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","75","Obesity","DRUG:LIRAGLUTIDE 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML); OTHER:lifestyle modification; OTHER:sleeve gastrectomy","Catholic University of the Sacred Heart","2015-11-02","2017-01-31","FALSE","Change of baseline BMI [1 year]",null,null,null,null],["NCT07225816","Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)",null,"RECRUITING","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","71","Obesity","DRUG:Liraglutide; DRUG:Oral Semaglutide; DRUG:Semaglutide","Novo Nordisk A/S","2025-11-07","2026-12-13","FALSE","Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of subcutaneous (s.c.) liraglutide once daily (Yes/No) [6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 7, Day 40] | Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of oral semaglutide once daily (Yes/No) [6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 11, Day 161] | Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of s.c. semaglutide once weekly (Yes/No) [6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 7, Day 141]",null,null,"YES","OTHER:U1111-1323-7355"],["NCT03070704","Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India",null,"WITHDRAWN","OBSERVATIONAL",null,null,null,"0","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide","Novo Nordisk A/S","2017-08-16","2019-03-01","FALSE","Incidence of treatment emergent Adverse Events (AEs) [Year 0-1]",null,null,"YES","OTHER:U1111-1185-0871"],["NCT07718126","Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)","PRIME","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","60","Metabolic Dysfunction-Associated Steatohepatitis; Hepatic Steatosis; Living Liver Donors","DRUG:Mazdutide; DRUG:Placebo (Normal Saline); BEHAVIORAL:Lifestyle Optimization","West China Hospital","2026-09-01","2029-02-28","FALSE","Proportion of Participants Achieving Resolution of MASLD Without Worsening of Liver Fibrosis (ROM) [From randomization (Week 0) to Week 12]",null,null,"YES",null],["NCT03130426","Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi","REMIT-iGL","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","161","Type 2 Diabetes Mellitus","DRUG:iGlarLixi; DRUG:Insulin Glargine; DRUG:Metformin; BEHAVIORAL:Lifestyle therapy","Population Health Research Institute","2017-06-27","2019-06-30","FALSE","The first occurrence of diabetes relapse [64 weeks of follow-up]",null,null,"NO",null],["NCT05341089","A Study of Two Different Formulations of LY3502970 in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","39","Healthy","DRUG:LY3502970","Eli Lilly and Company","2022-05-17","2022-09-01","TRUE","Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 in Formulation 1 and Formulation 2 [Test Period 1 (Day 28) and Test Period 2 (Day 35): Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours postdose] | PK: Area Under the Plasma Concentration-Time Curve (AUC) From 0 to 24 Hours (AUC (0-24)) of LY3502970 in Formulation 1 and Formulation 2 [Test Period 1 (Day 28) and Test Period 2 (Day 35): Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours postdose] | PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 in Formulation 1 and Formulation 2 [Test Period 1 (Day 28) and Test Period 2 (Day 35): Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours postdose]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/89/NCT05341089/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/89/NCT05341089/SAP_001.pdf","NO","OTHER:J2A-MC-GZGH"],["NCT07325435","Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists","Beta","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","60","Type 2 Diabetes (T2DM)","DRUG:SGLT-2 inhibitor; DRUG:GLP1-RA","MaryAnn Banerji","2024-12-21","2027-12-31","FALSE","Change in Stimulated C-peptide Index during an Oral Glucose Tolerance Test is a measure of Beta Cell Function and will be measuresd at baseline and at 16 weeks after treatment with GLP-1 Receptor Agonist or SGLT2-Inhibitor [Baseline, 16 weeks]","BACKGROUND:31741440; BACKGROUND:32745202; BACKGROUND:17163361; BACKGROUND:12388151; BACKGROUND:11815483; BACKGROUND:33334808; BACKGROUND:19336687; BACKGROUND:8194658; BACKGROUND:8593939; BACKGROUND:30407535; BACKGROUND:7859931",null,"NO","OTHER_GRANT:New York Community Trust"],["NCT00886626","GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","12","Obesity, Morbid","DRUG:Exenatide","University of Minnesota","2009-05","2011-02","TRUE","Change in Body Mass Index (BMI) [3-month]","DERIVED:22076596",null,null,null],["NCT06952530","A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","487","Hypertension","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2025-04-30","2027-09","FALSE","Change from Baseline in office Systolic Blood Pressure (SBP) [Baseline to Week 36]",null,null,"YES","OTHER:J2A-MC-GZL2; OTHER:J2A-MC-GZPL"],["NCT00781937","Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","422","Metabolism and Nutrition Disorder; Obesity","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2008-10-30","2010-09-01","TRUE","Mean Percentage Change in Fasting Body Weight From Baseline [Week 0, week 56] | Percentage of Subjects Who Maintained Their run-in Fasting Weight Loss From Week 0 [Week 0, week 56] | Percentage of Subjects Who Lost More Than or Equal to 5% of Fasting Body Weight From Week 0 [Week 0, week 56]","RESULT:27482610; RESULT:27817208; RESULT:23812094; RESULT:26418188; RESULT:28473337; RESULT:28386912; RESULT:28950422",null,null,null],["NCT01507337","Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","32","Diabetes; Healthy","DRUG:liraglutide","Novo Nordisk A/S","2004-04","2004-06","FALSE","Area under the liraglutide plasma concentration time curve (AUC 0-t) []","RESULT:16707410",null,null,null],["NCT07677995","Free Fatty Acid Effects In Type 2 Diabetes",null,"ENROLLING_BY_INVITATION","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","60","Type 2 Diabetes; Cardiovascular Disease; Omega-3 Fatty Acids","DIETARY_SUPPLEMENT:Omega-3 Fatty Acids; DRUG:Semaglutide 0.25 mg; DIETARY_SUPPLEMENT:Placebo","University of Ulster","2026-09","2026-12","FALSE","To evaluate the change in fasting glucose from baseline after 28 days of treatment, compared to each treatment group and placebo. [From baseline to 28 days of treatment]",null,null,null,"OTHER_GRANT:TA/PPA/25/215037"],["NCT07825857","Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder","T-STEM","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","228","Methamphetamine Use Disorder","DRUG:Tirzepatide; DRUG:Placebo (saline)","University of Texas Southwestern Medical Center","2026-10-01","2031-07-01","FALSE","Treatment response [26 weeks]",null,null,"YES",null],["NCT03888157","A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical Routine","VIEW-Iran","COMPLETED","OBSERVATIONAL",null,null,null,"839","Diabetes Mellitus, Type 2","DRUG:Liraglutide","Novo Nordisk A/S","2019-03-10","2020-10-21","FALSE","Change in glycated haemoglobin A1c (HbA1c) (percentage) [Week 0, week 26] | Change in HbA1c (mmol/mol) [Week 0, week 26]",null,null,"YES","OTHER:U1111-1213-4238"],["NCT07115069","Comparison of Body Composition Changes With Weight Loss Interventions","REFORM","ACTIVE_NOT_RECRUITING","OBSERVATIONAL",null,null,null,"60","Obesity","DRUG:GLP-1 receptor agonist; PROCEDURE:Gastric Bypass Surgery (laparoscopic); PROCEDURE:Gastric Bypass Surgery (robotic)","Vanderbilt University Medical Center","2025-08-09","2027-06","FALSE","Skeletal Muscle Loss [6 months] | Skeletal Muscle Loss [12 months] | Patient Assessment of Upper Gastrointestinal Disorders Symptoms Questionnaire [6 months] | Patient Assessment of Upper Gastrointestinal Disorders Symptoms Questionnaire [12 months]",null,null,"YES","OTHER:U16066"],["NCT05586802","Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome","KLIN-HEALTH","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","150","Klinefelter Syndrome","DRUG:Anastrozole; DRUG:Semaglutide; DRUG:human chorionic gonadotropin; DRUG:Testosterone gel","Georgios Papadakis","2023-03-21","2027-04-30","FALSE","Design 1 : sperm retrieval rate at mTESE biopsy [mTESE biopsy 26 weeks after hormonal intervention] | Design 2 : change in insulin resistance index (HOMA-IR) [From baseline to week 26 of intervention]",null,null,"YES",null],["NCT07364175","A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults","SOLUTION-Pilot","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","60","Hypertension; Obesity & Overweight","DRUG:Tirzepatide; DRUG:Anti-Hypertensive medications","Cambridge University Hospitals NHS Foundation Trust","2026-01","2027-01","FALSE","Ambulatory systolic blood pressure [Baseline to week 24]",null,null,"YES",null],["NCT07272837","Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass","GLIMMER","RECRUITING","OBSERVATIONAL",null,null,null,"50","Type 2 Diabetes; Obesity; Semaglutide; GLP-1; Diabetes",null,"University of Alberta","2026-05-15","2027-12-31","FALSE","Changes in skeletal and cardiac muscle mass [12 months]",null,null,"NO",null],["NCT07866183","Trial of Innovative Fat-loss Focused Approaches in Patients With Class I Obesity: a Comparative Study","TIFFANY","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","120","Class I Obesity","DRUG:Tirzepatide; DEVICE:Transcutaneous auricular vagus nerve stimulation","National Medical Research Center for Therapy and Preventive Medicine","2026-06-29","2027-06","FALSE","Percentage reduction in body weight [Baseline, Week 8, Week 16, and Week 24.] | Percentage reduction in waist-to-height ratio [Baseline, Week 8, Week 16, and Week 24] | Percentage reduction in epicardial adipose tissue thickness [Baseline and Week 24.] | Percentage reduction in visceral adipose tissue [Baseline and Week 24]",null,null,"NO",null],["NCT06613854","Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes","E-SEMPA","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","90","Type 2 Diabetes Mellitus (T2DM)","DRUG:Oral semaglutide; DRUG:Empagliflozin 10 mg","University Medical Centre Ljubljana","2024-10-01","2027-09","FALSE","Time in Range (TIR) [Period of 14 days prior to last study visit (week 26)]",null,null,"NO","OTHER:0120-70/2024-2711-3"],["NCT03383068","Research of Intensive Metabolic Intervention Before Pregnancy in PCOS","PCOS","UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","160","PCOS; Impaired Glucose Tolerance","DRUG:Acarbose 100 MG; DRUG:Exenatide; DRUG:Orlistat; DRUG:Metformin","RenJi Hospital","2018-01-01","2018-12-31","FALSE","Improvement of pregnant rate after intensive metabolic intervention [up to 24 weeks]",null,null,"NO",null],["NCT05254314","Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)","GATA-3","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","100","Asthma","DRUG:Semaglutide Pen Injector 2.4mg weekly; OTHER:Placebo","Vanderbilt University Medical Center","2022-10-11","2026-09-28","FALSE","The efficacy of semaglutide on asthma control questionnaire-7 score in subjects with symptoms, persistent asthma and obesity. [Baseline to week 12] | The impact of semaglutide once weekly on serum periostin in subjects with symptomatic, persistent asthma and obesity. [Baseline to week 4]","DERIVED:41567689",null,null,"NIH:U01AI155299"],["NCT06148649","Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","234","Type 2 Diabetes","DRUG:HEC88473, Placebo, Dulaglutide","Dongguan HEC Biopharmaceutical R&D Co., Ltd.","2023-12-10","2025-02-27","FALSE","Change from baseline of HbA1c at week 12 [Baseline to week 12]",null,null,"NO",null],["NCT07670884","A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","675","Chronic Management of Body Weight","DRUG:HRS9531 Tablet; DRUG:HRS9531 Tablet Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2026-07-24","2027-10-31","FALSE","Percentage change from baseline in body weight after 52 weeks of treatment [After 52 weeks of treatment.] | Proportion of subjects with weight loss of ≥ 5% from baseline in body weight after 52 weeks of treatment [After 52 weeks of treatment.]",null,null,"UNDECIDED",null],["NCT07247084","A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)",null,"RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","3000","Obesity","DRUG:Tirzepatide; OTHER:Standard of Care","Eli Lilly and Company","2025-11-24","2029-07","FALSE","Percent Change from Baseline in Body Weight [Baseline, 24 months]","DERIVED:42297568",null,"YES","OTHER:I8F-MC-GPJF"],["NCT06361238","Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","260","Delirium, Postoperative","DRUG:Liraglutide injection; DRUG:Placebo injection","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","2024-11-19","2027-03-31","FALSE","The incidence of delirium [One day before surgery and within the first seven days after surgery.]",null,null,"NO",null],["NCT06015893","Semaglutide Therapy for Alcohol Reduction (STAR)",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","63","Addiction; Alcohol Use Disorder","BEHAVIORAL:Take Control; DRUG:Semaglutide","National Institute on Drug Abuse (NIDA)","2023-10-17","2027-03-31","FALSE","Determine whether semaglutide, compared to placebo, reduces alcohol drinking. [Difference in number of standard alcohol-containing drinks consumed / week (Drinks Per Week, DPW) from baseline to end of the study.]","BACKGROUND:26308095; BACKGROUND:28323117; BACKGROUND:21950636; BACKGROUND:26080318; BACKGROUND:33424537; BACKGROUND:37192005; BACKGROUND:36001436; BACKGROUND:35906358; BACKGROUND:34532853",null,"UNDECIDED","OTHER:001603-DA"],["NCT05950516","Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes",null,"UNKNOWN","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","478","Type 2 Diabetes","DRUG:Semaglutide; DRUG:Semaglutide Pen Injector [Ozempic]","Qilu Pharmaceutical Co., Ltd.","2023-07-10","2024-11-24","FALSE","Change in HbA1c [Week 33]",null,null,"NO",null],["NCT07141914","A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World",null,"COMPLETED","OBSERVATIONAL",null,null,null,"285327","Overweight; Obesity; Heart Failure (HF); Atherosclerotic Cardiovascular Disease (ASCVD); Primary Prevention","OTHER:No treatment given","Novo Nordisk A/S","2025-08-29","2025-12-19","FALSE","Revised 5-Point Major Adverse Cardiovascular Events (MACE-5) (time-to-event) [Index date, earliest of revised MACE-5 and end of follow-up; up to 42 months] | Revised 3-point Major Adverse Cardiovascular Events MACE-3 (time-to-event) [Index date, earliest of revised MACE-3 and end of follow-up; up to 42 months]",null,null,"YES","OTHER:U1111-1326-1795"],["NCT07684235","Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","3200","Obesity; Overweight","DRUG:Maridebart cafraglutide; DRUG:Placebo","Amgen","2026-07-23","2027-12-26","FALSE","Percent Change in Body Weight from Baseline of the Parent Trial (20210181) [Baseline of parent trial (20210181) to Week 48 of current trial] | Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) [Baseline of current trial up to 60 weeks]",null,null,"YES",null],["NCT06745284","A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","64","Obesity","DRUG:Survodutide; DRUG:Semaglutide","Boehringer Ingelheim","2025-03-26","2027-01-08","FALSE","Absolute change in sleeping metabolic rate (SMR) (measured in a whole room calorimeter) from baseline to first visit a participant reached at least 10% weight loss [at baseline, up to 36 weeks]",null,null,"YES","REGISTRY:U1111-1309-3679"],["NCT00744926","A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","373","Diabetes Mellitus Type 2","DRUG:placebo; DRUG:taspoglutide","Hoffmann-La Roche","2008-08","2010-04","FALSE","Absolute change from baseline in HbA1c [24 weeks]",null,null,null,"OTHER:2008-001765-28; NIH:2008"],["NCT03466567","A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","21","Diabetes; Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Probenecid; DRUG:Ciclosporin","Novo Nordisk A/S","2018-03-15","2018-07-10","FALSE","AUC0-tz,SNAC,SD, area under the SNAC plasma concentration-time curve from time 0 to time of the last quantifiable concentration after a single dose of oral semaglutide [0-48 hours] | Cmax,SNAC,SD, maximum observed SNAC plasma concentration on the concentration-time curve after a single dose of oral semaglutide [0-48 hours]",null,null,"YES","OTHER:U1111-1197-9088; REGISTRY:2017-002498-21; NIH:2017"],["NCT05548231","A Study of LY3437943 in Chinese Participants With Obesity Or Overweight",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","32","Overweight; Obesity","DRUG:LY3437943; DRUG:Placebo","Eli Lilly and Company","2022-10-24","2023-07-27","FALSE","Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline through Week 20]",null,null,"NO","OTHER:J1I-MC-GZBE"],["NCT01575301","DIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R Agonists","DIRECTGLP","COMPLETED","INTERVENTIONAL",null,null,"NONE","411","Diabetes","DRUG:Exenatide, Liraglutide","University of Dundee","2011-03","2015-07","FALSE","Change in HbA1c between baseline and 6 months [6 months]",null,null,null,null],["NCT01475734","Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","44","Diabetes Mellitus, Type 2","BIOLOGICAL:albiglutide; BIOLOGICAL:placebo","GlaxoSmithKline","2011-12","2012-07","TRUE","Glucagon Concentration (Nanomoles Per Liter [Nmol/L]) During the Hypoglycemic Periods of the Glucose Clamp Procedure [Day 4]","DERIVED:25387217; DERIVED:25263215",null,"YES",null],["NCT01974544","Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines","PRODIGIES","UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","NONE","150","Type 2 Diabetes","DRUG:Best medical treatment; PROCEDURE:gastric bypass; PROCEDURE:sleeve gastrectomy; DRUG:General interventions for all groups: blood presure; DRUG:General interventions for all groups: dysilipidemia; BEHAVIORAL:General interventions for all groups: lifestyle","Pontificia Universidad Catolica de Chile","2013-05","2015-12","FALSE","Change in the microvascular complications of type 2 diabetes, specifically diabetic kidney disease [baseline at 1 month before the intervention and 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 month after intervention] | Change in the microvascular complications of type 2 diabetes, specifically Retinopathy. [baseline at 1 month before the intervention, 12 y 24 month after intervention] | Change in the microvascular complications of type 2 diabetes, specifically peripheral and sympathic neuropathy. [baseline at 1 month before the intervention, 12, 24 y 36 month]",null,null,null,null],["NCT06186622","A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","50","Healthy; Obese; Overweight","DRUG:Orforglipron; DRUG:Simvastatin; DRUG:Digoxin; DRUG:Rosuvastatin; DRUG:Acetaminophen; DRUG:Midazolam; DRUG:Sodium Bicarbonate","Eli Lilly and Company","2024-01-02","2024-07-10","TRUE","Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC[0-∞]) of Simvastatin and Its Metabolite Simvastatin Acid Following Simultaneous Administration of Orforglipron Capsule Formulation (Cohort 1 and 2) [Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours (h) post-dose; Day 98 (Cohort 1) and Day 93 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose] | PK: AUC [0-∞] of Simvastatin and Its Metabolite Simvastatin Acid Following Staggered Administration of Orforglipron Capsule Formulation (Cohort 1 and 2) [Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 104 (Cohort 1) and Day 99 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose] | PK: AUC [0-∞] of Simvastatin and Its Metabolite Simvastatin Acid After Sodium Bicarbonate Coadministration (Cohort 1 and 2) [Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 7 (Cohort 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose] | PK: AUC [0-∞] of Digoxin (Cohort 1 and 2) [Day 2 (For Cohort 1 and 2): Pre-dose, 0.5, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, and 120h post-dose ; Day 99 (Cohort 1) and Day 94 (Cohort 2): Pre-dose, 0.5, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, and 120h post-dose] | PK: AUC [0-∞] of Rosuvastatin (Cohort 1 Only) [Day 8 (Cohort 1 only): Pre-dose, 0.5, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 60, and 72h post-dose; Day 105 (Cohort 1 only): Pre-dose, 0.5, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 60, and 72h post-dose] | PK: AUC [0-∞] of Acetaminophen (Cohort 1 Only) [Day 10 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose; Day 14 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose; Day 107 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose] | PK: AUC [0-∞] of Midazolam and Its Metabolite 1'-Hydroxymidazolam (Cohort 1 Only) [Day 12 (Cohort 1 only): Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, and 24h post-dose; Day 109 (Cohort 1 only): Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, and 24h post-dose] | PK: Maximum Observed Concentration (Cmax) of Simvastatin and Its Metabolite Simvastatin Acid Following Simultaneous Administration of Orforglipron Capsule Formulation (Cohort 1 and 2) [Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 98 (Cohort 1) and Day 93 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose] | PK: Cmax of Simvastatin and Its Metabolite Simvastatin Acid Following Staggered Administration of Orforglipron Capsule Formulation (Cohort 1 and 2) [Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 104 (Cohort 1) and Day 99 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose] | PK: Cmax of Simvastatin and Its Metabolite Simvastatin Acid After Sodium Bicarbonate Coadministration (Cohort 1 and 2) [Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 7 (Cohort 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose] | PK: Cmax of Digoxin (Cohorts 1 and 2) [Day 2 (For Cohort 1 and 2): Pre-dose, 0.5, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, and 120h post-dose; Day 99 (Cohort 1) and Day 94 (Cohort 2): Pre-dose, 0.5, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, and 120h post-dose] | PK: Cmax of Rosuvastatin (Cohort 1 Only) [Day 8 (Cohort 1 only): Pre-dose, 0.5, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 60, and 72h post-dose; Day 105 (Cohort 1 only): Pre-dose, 0.5, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 60, and 72h post-dose] | PK: Cmax of Acetaminophen (Cohort 1 Only) [Day 10 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose; Day 14 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose; Day 107 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose] | PK: Cmax of Midazolam and Its Metabolite 1'-Hydroxymidazolam (Cohort 1 Only) [Day 12 (Cohort 1 only): Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, and 24h post-dose; Day 109 (Cohort 1 only): Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, and 24h post-dose]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/22/NCT06186622/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/22/NCT06186622/SAP_001.pdf","NO","OTHER:J2A-MC-GZPG"],["NCT01147692","A Drug Interaction Study of Simvastatin and Albiglutide",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","40","Diabetes Mellitus, Type 2","BIOLOGICAL:simvastatin plus albiglutide","GlaxoSmithKline","2010-05-19","2010-08-27","FALSE","The effect of albiglutide on the pharmacokinetics of simvastatin [42 days]","DERIVED:25387217",null,"YES",null],["NCT07817251","Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","210","Diabetes Mellitus, Type 2","DRUG:CagriSema","Novo Nordisk A/S","2026-09-16","2027-06-09","FALSE","Number of treatment emergent adverse events (TEAEs) [From baseline (Week 0) to end of treatment (Week 16)]",null,null,"YES","OTHER:U1111-1332-8482"],["NCT07846865","Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative Effectiveness Trial","TIRZE-PAP","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","NONE","256","Sleep Apnoea; Obesity & Overweight; Sleep Apnea Syndrome, Obstructive","DEVICE:Continuous Positive Airway Pressure; DRUG:Tirzepatide","Woolcock Institute of Medical Research","2026-10-01","2028-12-01","FALSE","Breathing Disturbance Index (BDI) [The mean BDI measured over 28 nights of monitoring is calculated for baseline (Weeks -4 to 0) and follow-up (Weeks 48 to 52)]",null,null,"YES",null],["NCT05702905","Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","75","PCOS (Polycystic Ovary Syndrome); Semaglutide","DRUG:Metformin Hydrochloride 500 MG; DRUG:Semaglutide, 1.34 mg/mL; DRUG:Semaglutide, 1.34 mg/mL and Metformin Hydrochloride 500 MG; BEHAVIORAL:calorie-restricted diet; BEHAVIORAL:physical exercise","Peking University First Hospital","2023-05-09","2024-12-31","FALSE","Percentage change in bodyweight at 12 weeks for semaglutide versus metformin [at the end of 12 weeks of treatment] | Achievement of weight reduction of at least 5% at 12 weeks for semaglutide versus metformin [at the end of 12 weeks of treatment]","RESULT:24362411; RESULT:25885106; RESULT:29703793; RESULT:31229399; RESULT:32442310; RESULT:36060969; RESULT:35951627; RESULT:34455568; RESULT:28834553; RESULT:34732660; RESULT:35829765","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/05/NCT05702905/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/05/NCT05702905/SAP_001.pdf","NO",null],["NCT00097500","Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","69","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:Insulin glargine; DRUG:Metformin","AstraZeneca","2004-09","2009-12","TRUE","Beta-cell Function After 52 Weeks of Therapy [Baseline (week -2) and 52 weeks]","RESULT:19196887; DERIVED:39963952; DERIVED:31078666; DERIVED:21868779; DERIVED:20494360",null,null,null],["NCT07281937","A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities","EVOLVE-2","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","206","Obesity; Overweight","DRUG:VRB-101; DRUG:Placebo","Verdiva Bio Dev Limited","2025-11-25","2026-07-23","FALSE","Mean percent change from baseline in body weight [From Baseline (Day 0) up to Week 21]",null,null,"NO",null],["NCT00603239","Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","165","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:placebo","AstraZeneca","2008-01","2009-07","TRUE","Change in Glycosylated Hemoglobin (HbA1c) [baseline and 26 weeks]","RESULT:20977576; DERIVED:22913891",null,null,null],["NCT01104701","A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","121","Type 2 Diabetes","DRUG:exenatide once weekly; DRUG:exenatide once monthly suspension","AstraZeneca","2010-05","2010-12","TRUE","Mean Change in HbA1c From Baseline to End of Treatment (Week 20) - Evaluable Population [Baseline (Day 1) to 20 weeks]","DERIVED:27436275",null,null,null],["NCT05249881","\"Efficacy of Once Weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan.\"",null,"UNKNOWN","INTERVENTIONAL","EARLY_PHASE1",null,"NONE","300","Diabetes Mellitus, Type 2; Weight Change, Body","DRUG:Semaglutide Pen Injector","Aga Khan University","2022-03-10","2022-12","FALSE","Change in glycemic Index in Diabetes mellitus type-2 Patients [3 months]",null,null,"NO",null],["NCT06633783","A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","370","Obesity","DRUG:Semaglutide","Hangzhou Jiuyuan Gene Engineering Co. Ltd.,","2024-10-30","2026-05-30","FALSE","Change in body weight [From baseline at week 0 to week 44]",null,null,"NO",null],["NCT02617654","Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","18","Type 1 Diabetes","DRUG:Liraglutide; DRUG:Placebo for liraglutide","Per-Ola Carlsson","2015-11","2020-09","FALSE","The effect of 52 weeks of treatment with liraglutide 1.8 mg/day, compared to placebo, on stimulated C-peptide concentrations in patients with long-standing type 1 diabetes and residual insulin production [52 weeks]",null,null,null,null],["NCT05881837","Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","249","Overweight or Obesity","DRUG:HRS9531 injection; DRUG:HRS9531 injection Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2023-06-13","2024-10-13","FALSE","Percentage change in body weight [Week 0, Week 24]",null,null,"UNDECIDED",null],["NCT04561245","ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","100","Obesity; Nonalcoholic Steatohepatitis","DRUG:ALT-801; OTHER:Placebo","Altimmune, Inc.","2020-11-10","2021-10-29","FALSE","The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs) [Part 1 SAD Cohorts: up to Day 26; Part 2 MAD Cohorts: up to Day 42] | Pharmacokinetic (PK): Maximum observed concentration (Cmax) of ALT-801 [Baseline, Day 26] | Pharmacokinetic (PK): Area Under the Concentration (AUC) vs Time Curve of ALT-801 [Baseline to Day 26] | Change in body weight [Baseline to Week 6] | Pharmacodynamic (PD): Change from baseline in magnetic resonance derived proton density fat fraction (MRI-PDFF) [Baseline to Week 6]",null,null,"NO","OTHER:Pemvidutide"],["NCT06861439","GLP-1s to Enhance Lasting Optimal Weight","GLOW","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE4",null,"NONE","40","Obesity","DRUG:Tirzepatide","Wake Forest University Health Sciences","2025-07-07","2027-10-30","FALSE","Change in total body lean mass [Baseline to Month 9] | Change in total body lean mass [Month 9 to Month 21] | Change in appendicular lean mass [Baseline to Month 9] | Change in appendicular lean mass [Month 9 to Month 21] | Change in total body fat mass [Baseline to Month 9] | Change in total body fat mass [Month 9 to Month 21] | Change in total hip bone mineral density [Baseline to Month 9] | Change in total hip bone mineral density [Month 9 to Month 21] | Change in lumbar spine bone mineral density [Baseline to Month 9] | Change in lumbar spine bone mineral density [Month 9 to Month 21] | Change in 400 meter walk time [Baseline to Month 9] | Change in 400 meter walk time [Month 9 to Month 21] | Change in lower extremity physical performance score [Baseline to Month 9] | Change in lower extremity physical performance score [Month 9 to Month 21] | Change in leg strength [Baseline to Month 9] | Change in grip strength [Baseline to Month 9] | Change in grip strength [Month 9 to Month 21] | Change in leg strength [Month 9 to Month 21]",null,null,"NO",null],["NCT05303857","Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes","SEMA","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","107","Diabetes Mellitus, Type 2","DRUG:Semaglutide Pen Injector; DRUG:Placebo","University of Erlangen-Nürnberg Medical School","2022-03-03","2023-12-15","FALSE","Central (aortic) pulse pressure assessed by Sphygmocor XCEL [16 weeks]",null,null,"NO",null],["NCT05479591","A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia","GLIDE","WITHDRAWN","OBSERVATIONAL",null,null,null,"0","Diabetes Mellitus, Type 2","DRUG:IDegLira","Novo Nordisk A/S","2022-07-30","2023-04-30","FALSE","Change in Glycated Haemoglobin A1c (HbA1c) [From baseline to end of study (week 36 ± 6 weeks)]",null,null,"YES","OTHER:U1111-1271-8967"],["NCT04972396","Pemvidutide (ALT-801) DDI Study in Healthy Volunteers",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","40","NASH - Nonalcoholic Steatohepatitis","DRUG:Pemvidutide; DRUG:Metformin; DRUG:Atorvastatin; DRUG:Warfarin; DRUG:Digoxin; DRUG:Ethinylestradiol and Levonorgestrel","Altimmune, Inc.","2021-09-15","2022-05-15","FALSE","Area Under the Plasma Concentration Versus Time Curve (AUC) of metformin and atorvastatin/warfarin and digoxin in presence of steady state ALT-801 [Baseline and Day 36] | Area Under the Plasma Concentration Versus Time Curve (AUC) of ethinylestradiol and levonorgestrel in presence of steady state ALT-801 [Baseline and Day 43]",null,null,null,"OTHER:Pemvidutide; OTHER:ALT-801"],["NCT03659682","GLP1R in Parkinson's Disease","GIPD","UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","120","Parkinson Disease","DRUG:Semaglutide","Oslo University Hospital","2019-01-02","2024-12-31","FALSE","Motor Function [48 months]",null,null,"UNDECIDED",null],["NCT06660173","A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","409","Type 2 Diabetes Mellitus (T2DM)","DRUG:Maridebart Cafraglutide; DRUG:Placebo","Amgen","2024-11-07","2025-10-06","FALSE","Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c) [Baseline to Week 24]",null,null,"YES","CTIS:2024-513539-25-00"],["NCT02981069","Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","90","Diabetes Mellitus, Type 2","DRUG:Dapagliflozin; DRUG:Exenatide; DRUG:Placebo","The University of Texas Health Science Center at San Antonio","2017-12-15","2022-07-14","TRUE","Change in Endogenous Glucose Production (EGP) After Acute Exposure to a Single Dose and Again After 16 Weeks of Treatment [ACUTE [after a single dose of each study drug or placebo]] | Change in Endogenous Glucose Production (EGP) After 16 Weeks of Treatment With Each Study Drug. [16 weeks]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/69/NCT02981069/Prot_SAP_001.pdf",null,null],["NCT01930188","Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes","SUSTAIN™ 2","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","1231","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:sitagliptin; DRUG:placebo","Novo Nordisk A/S","2013-12-02","2015-10-12","TRUE","Change in HbA1c (Glycosylated Haemoglobin) From Baseline [Week 0, week 56]","BACKGROUND:30938762; BACKGROUND:30865526; RESULT:28385659; RESULT:29748996; RESULT:29766634; RESULT:29764222; RESULT:29862621; RESULT:29907893; RESULT:30615985; DERIVED:37178435; DERIVED:32998732; DERIVED:32827435; DERIVED:32193837; DERIVED:31903692; DERIVED:31769496; DERIVED:31215727",null,null,"EUDRACT_NUMBER:2012-004827-19; OTHER:U1111-1135-8730; OTHER:132366; REGISTRY:CTRI/2014/05/004626"],["NCT03529123","Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","247","Type 2 Diabetes Mellitus","DRUG:INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010); DRUG:INSULIN GLARGINE (HOE901); DRUG:Metformin; DRUG:Insulin Glulisine (HMR1964)","Sanofi","2018-06-19","2019-11-25","FALSE","Change in HbA1c [From baseline to Week 24]",null,null,"YES","OTHER:U1111-1200-1162"],["NCT06862908","A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","141","Obesity; Heart Failure With Preserved Ejection Fraction (HFPEF); Heart Failure With Mildly Reduced Ejection Fraction","OTHER:placebo; DRUG:IBI362","Innovent Biologics (Suzhou) Co. Ltd.","2025-03-26","2026-09-24","FALSE","Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) [From baseline (week 0) to week 36] | Body weight change from baseline at week 36 [From baseline (week 0) to week 36]",null,null,null,null],["NCT01507038","Safety and Efficacy of YH14617 in Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","84","Diabetes Mellitus","DRUG:YH14617; DRUG:Placebo","Yuhan Corporation","2011-12","2015-01","FALSE","Change from baseline in HbA1c at week 12 [Baseline, Week 12]",null,null,null,null],["NCT04878406","A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","24","Healthy Volunteers Type 2 Diabetes","DRUG:NNC0480-0389; DRUG:Placebo (NNC0480-0389); DRUG:Semaglutide; DRUG:Placebo (Semaglutide)","Novo Nordisk A/S","2021-05-18","2021-07-20","FALSE","Number of treatment emergent adverse events (TEAEs) [From time of dosing (day 1) until completion of the follow-up visit (day 43)]",null,null,"YES","OTHER:U1111-1263-7182"],["NCT07745504","A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight","RENEW 4","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","285","Overweight; Obesity","DRUG:Cagrilintide; DRUG:Placebo cagrilintide; DRUG:Placebo semaglutide","Novo Nordisk A/S","2026-08-04","2027-05-18","FALSE","Relative change in body weight [From baseline (week 0) to end of treatment (week 26)]",null,null,"YES","OTHER:U1111-1328-5168; OTHER:2025-524249-29; NIH:2025"],["NCT04972721","SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial","SELECT-LIFE","COMPLETED","OBSERVATIONAL",null,null,null,"3439","Overweight; Obesity","OTHER:No treatment given","Novo Nordisk A/S","2023-09-01","2025-08-25","FALSE","Time to all-cause death [From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months)] | Time to first occurrence of a composite consisting of: All-cause death, non-fatal myocardial infarction and non-fatal stroke [From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months)] | Time to first occurrence of non-fatal myocardial infarction [From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months)] | Time to first occurrence of non-fatal stroke [From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months)] | Time to diagnosis of type 2 diabetes [From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months)] | Time to first occurrence of any type of cancer [From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months)] | Time to first occurrence of a composite of obesity related cancer defined by WHO [From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months)] | Time to first occurrence of knee replacement [From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months)] | Time to first occurrence of bariatric surgery [From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months)] | Time to first occurrence of anti-obesity medical treatment [From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months)] | Time to first occurrence of use of continuous positive airways pressure (CPAP) device [From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months)] | Total number of myocardial infarctions [From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months)] | Total number of strokes [From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months)] | Change in body weight from V-EOT (is the end of treatment visit in SELECT) to biannual assessments, (year 1-10) [From V-EOT (is the end of treatment visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to120 months)] | Change in Patient reported quality of life questionnaire (EQ-5D-5L) from V-EOT (is the end of treatment visit in SELECT) to biannual assessments, (year 1-10) [From V-EOT (is the end of treatment visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to120 months)] | Total Days of hospitalisation from P-FU (is the end of trial visit in SELECT) to biannual assessments, (year 1-10) [From P-FU(is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to120 months)]",null,null,"YES","OTHER:U1111-1255-5644"],["NCT03363906","A Study of Dulaglutide in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","27","Healthy","DRUG:Dulaglutide (Reference); DRUG:Dulaglutide (Test)","Eli Lilly and Company","2017-12-07","2018-06-06","TRUE","Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Dulaglutide [Periods 1 and 2: Day 1 - 8 and Day 15: Predose, 24, 48, 72,96,120,144,168, and 336 hours post dose; Follow Up: Day 28] | PK: Maximum Observed Drug Concentration (Cmax) of Dulaglutide [Periods 1 and 2: Day 1 - 8 and Day 15: Predose, 24, 48, 72,96,120,144,168, and 336 hours post dose; Follow Up : Day 28]",null,"Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/06/NCT03363906/SAP_000.pdf; Study Protocol|https://cdn.clinicaltrials.gov/large-docs/06/NCT03363906/Prot_001.pdf","NO","OTHER:H9X-MC-GBGM"],["NCT01890993","Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe",null,"COMPLETED","OBSERVATIONAL",null,null,null,"952","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2013-08","2014-06","FALSE","Change in HbA1c (glycosylated haemoglobin) [Baseline (anytime within 3 months before therapy initiation), month 12 (+/-2)]",null,null,null,"OTHER:U1111-1142-2764; OTHER:ENCEPP/SDPP/8135"],["NCT01149421","A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","755","Diabetes Mellitus, Type 2","DRUG:LY2189265; DRUG:Placebo","Eli Lilly and Company","2010-06","2011-09","TRUE","Change From Baseline to 16 Weeks in Mean 24-hour Systolic Blood Pressure (SBP) [Baseline, 16 weeks]","DERIVED:36894938",null,null,"OTHER:H9X-MC-GBDN; REGISTRY:CTRI/2010/091/001444"],["NCT07547878","Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)","RAPID-CKD","ENROLLING_BY_INVITATION","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","64","Chronic Kidney Disease; Type 2 Diabetes","DRUG:Finerenone; DRUG:Semaglutide; DRUG:Lotensin; DRUG:Capoten; DRUG:Enalapril; DRUG:Monopril; DRUG:Lisinopril; DRUG:Univasc; DRUG:Aceon; DRUG:Accupril; DRUG:Altace; DRUG:Mavik; DRUG:Edarbi; DRUG:Atacand; DRUG:Avapro; DRUG:Cozaar; DRUG:Benicar; DRUG:Micardis; DRUG:Diovan; DRUG:Invokana; DRUG:Farxiga; DRUG:Jardiance; DRUG:Ertugliflozin; DRUG:Brenzavvy; DRUG:Sotagliflozin","Baylor Research Institute","2026-04-08","2029-03-31","FALSE","On-study retention rate at 6 months [6 months] | Sustained decline in eGFR ≥30% [6 months] | Change in UACR [6 months]","BACKGROUND:35529086; BACKGROUND:20853156; BACKGROUND:14531770; BACKGROUND:39688924; BACKGROUND:38785209; BACKGROUND:31142441; BACKGROUND:34423370; BACKGROUND:34950508; BACKGROUND:33580784; BACKGROUND:37217188; BACKGROUND:40042835; BACKGROUND:37952217; BACKGROUND:39090593; BACKGROUND:36148880; BACKGROUND:39916475; BACKGROUND:26264780; BACKGROUND:35072048; BACKGROUND:38490803; BACKGROUND:37408009; BACKGROUND:38142396; BACKGROUND:34779091; BACKGROUND:31146814; BACKGROUND:37409564; BACKGROUND:36339664; BACKGROUND:38445950; BACKGROUND:34529313; BACKGROUND:28597606; BACKGROUND:34655282; BACKGROUND:40327845; BACKGROUND:35935070; BACKGROUND:28828479; BACKGROUND:22169081; BACKGROUND:39218030; BACKGROUND:39145789; BACKGROUND:18362259",null,"YES",null],["NCT05517226","Pharmacokinetics of Cotadutide in Participants With Hepatic Impairment",null,"TERMINATED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","24","Hepatic Impairment","COMBINATION_PRODUCT:Cotadutide","AstraZeneca","2022-09-06","2023-02-27","FALSE","Maximum observed plasma (peak) drug concentration [Cmax] [Day 1 to Day 3] | Area under plasma concentration time curve from zero to infinity (AUCinf) [Day 1 to Day 3] | Area under the plasma concentration-curve from time zero to last quantifiable concentration (AUClast) [Day 1 to Day 3] | Time to reach peak or maximum observed concentration or response following drug administration (tmax) [Day 1 to Day 3] | Terminal half-life (t½λz) [Day 1 to Day 3] | Apparent total body clearance (CL/F) [Day 1 to Day 3] | Apparent volume of distribution based on the terminal phase (Vz/F) [Day 1 to Day 3]",null,null,"YES",null],["NCT05669599","Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","592","Obesity; Overweight; Type 2 Diabetes Mellitus","BIOLOGICAL:Maridebart Cafraglutide; DRUG:Placebo","Amgen","2023-01-18","2024-10-08","FALSE","Percent Change From Baseline to Week 52 in Body Weight [Baseline and Week 52]","BACKGROUND:40549887",null,"YES","CTIS:2023-510470-13-00; NIH:2023"],["NCT06847399","Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder","LIBERATE","RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","105","Obesity and Overweight; Binge Eating Disorder","DRUG:Tirzepatide; DRUG:Lisdexamfetamine Dimesylate; BEHAVIORAL:Guided self-help cognitive behavioral therapy; DRUG:Placebo (oral); DRUG:Placebo (injection)","Johns Hopkins University","2025-09-17","2027-12-01","FALSE","Percent initial weight loss [Baseline to 52 weeks] | Change in the Number of Binge-eating episodes [Baseline to 52 weeks]",null,null,null,null],["NCT04639414","Combined Active Treatment in Type 2 Diabetes With NASH","COMBAT_T2_NASH","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","192","Type 2 Diabetes; Non-alcoholic Steatohepatitis (NASH); Non-alcoholic Fatty Liver Disease (NAFLD)","DRUG:Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector; DRUG:Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide; DRUG:Placebo matching empagliflozin and placebo pen injector matching semaglutide","German Diabetes Center","2021-03-26","2025-01-31","FALSE","Histological resolution of NASH without worsening of fibrosis [from baseline to 48 weeks]",null,null,"NO","EUDRACT_NUMBER:2019-001987-31; NIH:2019"],["NCT06214741","A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","307","Obesity; Overweight","DRUG:survodutide; DRUG:Placebo matching BI 456906","Boehringer Ingelheim","2024-02-06","2025-07-29","FALSE","Percentage change in body weight from baseline to Week 52 [At baseline and at Week 52.] | Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 52 [At baseline and at Week 52.]","DERIVED:42599381",null,"YES","REGISTRY:U1111-1295-9567"],["NCT03861039","A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","443","Type 2 Diabetes Mellitus","DRUG:Tirzepatide; DRUG:Oral antihyperglycemic medication (OAM)","Eli Lilly and Company","2019-03-30","2021-01-26","TRUE","Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline through Week 52]","DERIVED:40711720; DERIVED:35914542","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/39/NCT03861039/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/39/NCT03861039/SAP_001.pdf","YES","OTHER:I8F-JE-GPGP"],["NCT01923181","Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","632","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:oral placebo","Novo Nordisk A/S","2013-12-02","2014-12-11","TRUE","Change in HbA1c (Glycosylated Haemoglobin) [Week 0, week 26]","RESULT:29049653","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/81/NCT01923181/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/81/NCT01923181/SAP_001.pdf",null,"EUDRACT_NUMBER:2012-004994-16; OTHER:U1111-1136-4716"],["NCT01473953","Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","31","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:liraglutide-depot; DRUG:placebo","Novo Nordisk A/S","2011-10","2012-03","TRUE","Number of Treatment Emergent Adverse Events (TEAEs) [Day 0 and up to 21 days after treatment]",null,null,null,"OTHER:U1111-1123-0547"],["NCT03002675","Exenatide and Brown Adipose Tissue","exe01","UNKNOWN","INTERVENTIONAL","PHASE4",null,"NONE","24","Obesity","DRUG:Bydureon","Ingrid Jazet","2016-08","2018-06","FALSE","The effect of exenatide on BAT activity and energy expenditure in healthy young South Asian compared to white Caucasian men [End of the study, up to 21 months]","DERIVED:31982480",null,null,null],["NCT05161429","BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","BESTMED","UNKNOWN","OBSERVATIONAL",null,null,null,"550000","Diabetes Mellitus, Type 2","DRUG:DPP4; DRUG:GLP-1 receptor agonist; DRUG:Basal Insulin; DRUG:SLGT2; DRUG:SU","Brigham and Women's Hospital","2021-07-01","2024-06-30","FALSE","4-point major adverse cardiac events (MACE) [Follow-up begins 30 days after enrollment and ends at the earliest of a) the first study outcome; b) study end or c) loss to follow-up. Maximum duration of follow-up will be 10.5 years.] | 3-point major adverse cardiac events (MACE) [Follow-up begins 30 days after enrollment and ends at the earliest of a) the first study outcome; b) study end or c) loss to follow-up. Maximum duration of follow-up will be 10.5 years.]","BACKGROUND:9603539; BACKGROUND:8266381; BACKGROUND:10371227",null,"NO",null],["NCT05419856","Safety, Tolerability and Pharmacokinetics of Intraarticular 4P004 Single Dose in Patient With KL 2-4 Osteoarthritic Knee","LASARE","COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","34","Knee Osteoarthritis","DRUG:4P-004; DRUG:Placebo","4Moving Biotech","2022-08-09","2023-10-31","TRUE","Safety and Tolerability of Single IA Administration of 4P-004 at Escalating Doses in Participants With Knee OA. [Day 1-Day 28]","BACKGROUND:35091584","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/56/NCT05419856/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/56/NCT05419856/SAP_001.pdf","NO",null],["NCT06052566","A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","22","Non-alcoholic Steatohepatitis; Hepatic Impairment","DRUG:Efinopegdutide","Merck Sharp & Dohme LLC","2023-11-21","2024-12-05","TRUE","Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Efinopegdutide [At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35] | Area Under the Curve From Time 0 to Last Sampling Time (AUC0-last) of Efinopegdutide [At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35] | Maximum Plasma Concentration (Cmax) of Efinopegdutide [At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35] | Time to Maximum Concentration (Tmax) of Efinopegdutide [At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35] | Apparent Terminal Half-life (t/12) of Efinopegdutide [At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35] | Apparent Total Clearance (CL/F) of Efinopegdutide [At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35] | Apparent Volume of Distribution (Vz/F) of Efinopegdutide [At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/66/NCT06052566/Prot_SAP_000.pdf","YES","REGISTRY:MK-6024-014"],["NCT01686945","Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","107","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2012-09-19","2013-04-08","FALSE","Number of treatment emergent adverse events (TEAEs) recorded [From the time of first dosing and until completion of the post treatment follow-up visits (Day 90 to 104)]","RESULT:30566096; DERIVED:30565096",null,null,"EUDRACT_NUMBER:2012-000361-20; OTHER:U1111-1127-4408"],["NCT07213323","Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment","PROBIO-GLP1","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","50","Obesity &Amp; Overweight; Digestive Disorders","DIETARY_SUPPLEMENT:Probiotics (Natural product); OTHER:Placebo","Hospices Civils de Lyon","2026-08-05","2027-12-05","FALSE","Assessment of the Limitation of the impairment in digestive quality of life during the dose escalation of GLP1-RA (semaglutide or tirzepatide) [Every 5 weeks]",null,null,null,"OTHER:2025-A01248-41"],["NCT02911818","Lifestyle Modification and Liraglutide","MODEL","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","150","Obesity","BEHAVIORAL:CMS-recommended lifestyle counseling; DRUG:Liraglutide 3.0mg; OTHER:Portion-Controlled Diet; DRUG:Placebo Oral Tablet; DRUG:Phentermine 15 MG; BEHAVIORAL:Extension Study CMS-recommended lifestyle counseling","University of Pennsylvania","2016-09","2018-11","TRUE","Percent Change in Baseline Weight [Randomization and 52 weeks] | Extension Study Primary Outcome: Percent Change in Re-randomization Weight [Re-randomization and 12 weeks]","DERIVED:30926955; DERIVED:30902750; DERIVED:30421856","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/18/NCT02911818/Prot_SAP_000.pdf","NO",null],["NCT07599410","A Research Study to Investigate the Efficacy and Safety of HRS9531 Tablets in Participants With Type 2 Diabetes Mellitus",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","240","T2DM","DRUG:HRS9531 Tablet; DRUG:HRS9531 Tablet placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2026-07-14","2027-05","FALSE","Change in glycated hemoglobin (HbA1c) relative to baseline [Week 20.]",null,null,"UNDECIDED",null],["NCT00393718","Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","400","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:glibenclamide; DRUG:placebo","Novo Nordisk A/S","2006-11","2007-11","TRUE","Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment [after 24 weeks of treatment]","RESULT:20199137; RESULT:24843595; RESULT:23010561; DERIVED:21209033",null,null,null],["NCT02584582","The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate","ALFA-1","UNKNOWN","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","NONE","10","Type 1 Diabetes","DRUG:Liraglutide; DRUG:Exenatide; PROCEDURE:Liquid meal test; OTHER:No drug (Baseline day)","Hvidovre University Hospital","2015-07","2015-11","FALSE","Glucagon concentration (postprandial) [4 hours]",null,null,null,null],["NCT06149260","Subcutaneous Semaglutide in Systemic Scleroderma",null,"UNKNOWN","INTERVENTIONAL","PHASE1",null,"NONE","10","Scleroderma, Systemic; Fibrosis; Semaglutide","DRUG:Semaglutide Pen Injector","Second Xiangya Hospital of Central South University","2024-02-29","2024-08-29","FALSE","Change in modified Rodnan skin score (mRSS) at week 24 [Baseline and 24 weeks]",null,null,"NO",null],["NCT01821846","Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus",null,"COMPLETED","OBSERVATIONAL",null,null,null,"64","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2013-11-20","2017-03-08","FALSE","The incidence of SADRs (Serious Adverse Drug Reactions) [Up to 6 months]",null,null,null,"OTHER:U1111-1132-2221"],["NCT05822830","A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities","SURMOUNT-5","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","751","Obesity; Overweight","DRUG:Tirzepatide; DRUG:Semaglutide","Eli Lilly and Company","2023-04-21","2024-11-13","TRUE","Percent Change From Baseline in Body Weight [Baseline, Week 72]","DERIVED:42434924; DERIVED:41865857; DERIVED:40980721; DERIVED:40353578","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/30/NCT05822830/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/30/NCT05822830/SAP_001.pdf","YES","OTHER:I8F-MC-GPHJ; OTHER:U1111-1283-5404"],["NCT07280221","WEgovy Real World Assessment of Weight Loss in Korea",null,"ENROLLING_BY_INVITATION","OBSERVATIONAL",null,null,null,"500","Obesity","DRUG:Semaglutide","Novo Nordisk A/S","2025-11-10","2027-10-31","FALSE","Percentage change in body weight [From baseline (week 0) to 24 weeks]",null,null,"YES","OTHER:U1111-1306-1595"],["NCT05394519","A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight","REDEFINE 2","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","1200","Overweight; Obesity; Type 2 Diabetes Mellitus","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo cagrilintide; DRUG:Placebo semaglutide","Novo Nordisk A/S","2023-02-01","2025-01-28","FALSE","Relative change in body weight [From baseline (week 0) to end of treatment (week 68)] | Achievement of greater than or equal to (≥) 5% weight reduction [From baseline (week 0) to end of treatment (week 68)]","DERIVED:40544432",null,"YES","OTHER:U1111-1267-4287; EUDRACT_NUMBER:2021-005121-24; REGISTRY:jRCT2031220671"],["NCT05646199","Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)",null,"UNKNOWN","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","NONE","60","Polycystic Ovary Syndrome","DRUG:Metformin; DRUG:Semaglutide Injectable Product","University of Hull","2025-03-01","2025-09-30","FALSE","Weight loss (kg) [28 weeks]","BACKGROUND:23818329; BACKGROUND:12057712; BACKGROUND:18182456; BACKGROUND:17925334; BACKGROUND:26431698; BACKGROUND:23727939; BACKGROUND:22552687; BACKGROUND:17537782; BACKGROUND:18583464; BACKGROUND:18410553",null,"NO",null],["NCT06534411","A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both","REIMAGINE 5","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","1023","Diabetes Mellitus, Type 2","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Tirzepatide","Novo Nordisk A/S","2024-11-05","2026-06-02","FALSE","Change in Glycated Haemoglobin (HbA1c) [From baseline (week 0) to end of treatment (week 60)] | Relative Change in Body Weight [From baseline (week 0) to end of treatment (week 60)]",null,null,"YES","OTHER:U1111-1300-2590; OTHER:2023-509600-15; NIH:2023"],["NCT04615871","Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19","SEMPATICO","UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","SINGLE","400","Covid19; Myocardial Injury","DRUG:semaglutide","Vladimír Džavík","2021-09-10","2022-03-31","FALSE","Composite of death or mechanical ventilation [28 days after randomization]",null,null,"NO",null],["NCT02016911","Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","56","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:semaglutide","Novo Nordisk A/S","2013-12-12","2015-01-12","FALSE","Area under the semaglutide plasma concentration curve [From time 0 to 24 hours after the 10th dosing]","RESULT:29693715; DERIVED:33969456",null,null,"EUDRACT_NUMBER:2013-000550-21; OTHER:U1111-1139-1272"],["NCT07551492","A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","9262","Atherosclerotic Cardiovascular Disease","DRUG:HRS9531; DRUG:HRS9531 placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2026-05-29","2031-05-24","FALSE","The time from randomization to the first occurrence of the MACE-3 composite endpoint [approximately up to 61 months of treatment]",null,null,"UNDECIDED",null],["NCT06299098","A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation","COURAGE","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","1005","Obesity","DRUG:Trevogrumab-Part A; DRUG:Trevogrumab-Part B and Part C; DRUG:Garetosmab; DRUG:Semaglutide; DRUG:Matching Placebo-Part A; DRUG:Matching Placebo-Trevogrumab; DRUG:Matching Placebo-Garetosmab","Regeneron Pharmaceuticals","2024-03-13","2026-06-16","FALSE","Incidence of treatment-emergent adverse events (TEAEs) [Baseline to week 7] | Severity of TEAEs [Baseline to week 7] | Percent change in total fat mass [Baseline to week 26] | Percent change in total lean mass [Baseline to week 26] | Percent change in body weight [Baseline to week 26] | Percent change in total fat mass [Baseline to week 52] | Percent change in total lean mass [Baseline to week 52] | Percent change in body weight [Baseline to week 52]",null,null,"YES",null],["NCT06937099","Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight","COMMIT-CD","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","290","Crohn's Disease; Obesity or Overweight","DRUG:Mirikizumab; DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2025-06-26","2028-05","FALSE","Percentage of Participants Who Simultaneously Achieve Clinical Remission by Crohn's Disease Activity Index (CDAI), Endoscopic Remission, and at least 10% Weight Reduction [Week 52]",null,null,"YES","CTIS:2024-520210-21-00; OTHER:I6T-MC-AMCE"],["NCT06659744","Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims",null,"COMPLETED","OBSERVATIONAL",null,null,null,"158310","Diabetes Mellitus, Type 2","DRUG:New use of semaglutide injection; DRUG:New initiation of sitagliptin","Brigham and Women's Hospital","2024-10-24","2025-03-06","FALSE","Major adverse cardiac event (MACE), including myocardial infarction, stroke, and all cause death [Through study completion (1 day after cohort entry date until the first of outcome or censoring)]","DERIVED:41207920","Study Protocol and Statistical Analysis Plan: Study Protocol for Three-Stage Project|https://cdn.clinicaltrials.gov/large-docs/44/NCT06659744/Prot_SAP_004.pdf; Study Protocol and Statistical Analysis Plan: Study Protocol for Two-Stage Project|https://cdn.clinicaltrials.gov/large-docs/44/NCT06659744/Prot_SAP_002.pdf; Study Protocol and Statistical Analysis Plan: Amendment to Study Protocol for Two-Stage Project|https://cdn.clinicaltrials.gov/large-docs/44/NCT06659744/Prot_SAP_005.pdf",null,null],["NCT01363609","Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes","LIBRA","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","50","Obesity; Type 2 Diabetes","DRUG:Liraglutide treatment 12 weeks; DRUG:insulin glargine treatment; DRUG:GLP-1 receptor antagonist","Amsterdam UMC, location VUmc","2011-10","2015-01","FALSE","food-stimuli related neuronal activity in reward and satiety circuits as represented by BOLD fMRI signal change from baseline (%) [approximately 3 years]","DERIVED:29025878; DERIVED:26385462",null,null,null],["NCT07446439","A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","280","Nausea and Vomiting; Obesity","DRUG:Tradipitant; DRUG:Placebo","Vanda Pharmaceuticals","2026-03-27","2026-12-01","FALSE","Proportion of participants with at least 1 vomiting episode per week in the tradipitant group compared to the placebo group as measured by a daily symptom diary. [1 week]",null,null,"NO",null],["NCT01667900","A Study of Dulaglutide in Chinese Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","58","Diabetes Mellitus, Type 2; Healthy Volunteers","DRUG:Dulaglutide; DRUG:Placebo","Eli Lilly and Company","2012-08","2014-06","TRUE","Pharmacokinetics: Maximum Concentration (Cmax) of Dulaglutide [Pre-dose and 12, 24, 48, 72, 96, 168, and 336 hours post-dose] | Pharmacokinetics: Time of Maximum Observed Concentration (Tmax) of Dulaglutide [Pre-dose and 12, 24, 48, 72, 96, 168, and 336 hours post-dose] | Pharmacokinetics: Area Under the Concentration-time Curve From Time Zero to 336 Hours Postdose (AUC[0-336]) of Dulaglutide [Pre-dose and 12, 24, 48, 72, 96, 168, and 336 hours post-dose] | Pharmacokinetics: Half-life of Dulaglutide [Pre-dose and 12, 24, 48, 72, 96, 168, and 336 hours post-dose]","DERIVED:34787823",null,null,"OTHER:H9X-EW-GBDL"],["NCT06077864","A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","5531","Obesity","COMBINATION_PRODUCT:survodutide; COMBINATION_PRODUCT:Placebo","Boehringer Ingelheim","2023-11-20","2026-06-01","FALSE","Time to first occurrence of any of the adjudicated components of the composite endpoint consisting of: CV death, non-fatal stroke, non-fatal MI, ischaemia related coronary revascularisation, or HFE (to demonstrate non-inferiority) [up to Week 114]","DERIVED:39453356",null,"YES","REGISTRY:2022-502442-27-00; REGISTRY:U1111-1289-0174"],["NCT06200467","A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","110","Overweight; Obesity","COMBINATION_PRODUCT:BI 456906; COMBINATION_PRODUCT:Placebo to BI 456906; DRUG:Moxifloxacin; DRUG:Placebo to moxifloxacin","Boehringer Ingelheim","2024-03-13","2025-10-22","FALSE","Time-matched QTcI change from baseline (ΔQTcI) collected at the same time points as the BI 456906 plasma concentrations up to a maximum of 30 weeks after first drug administration of BI 456906 / BI 456906-placebo [up to 30 weeks.]",null,null,"NO","REGISTRY:2023-506375-10-00; OTHER:U1111-1295-4369; NIH:2023"],["NCT02351232","The Lira Pump Trial",null,"COMPLETED","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","QUADRUPLE","44","Type 1 Diabetes","DRUG:Liraglutide; DRUG:Placebo","Hvidovre University Hospital","2015-02","2016-10","FALSE","Change in HbA1c [6 months]","RESULT:31696598",null,null,"EUDRACT_NUMBER:2014-002285-76; NIH:2014"],["NCT04148209","Study of Single Ascending Doses of PF-07081532 in Healthy Adult Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","22","Healthy","DRUG:PF-07081532; DRUG:Placebo","Pfizer","2019-11-05","2020-03-17","FALSE","Percentage of participants with adverse events [From screening until follow-up call (28-35 days after the last dose of investigational product)] | Percentage of participants with safety laboratory test results above/below certain threshold [Days -1, 2 and 4 of each period and at follow-up visit (7-14 days after the last dose of investigational product)] | Percentage of participants with vital signs above/below certain threshold [Days 1-4 of each period and at follow-up visit (7-14 days after the last dose of investigational product)] | Percentage of participants with 12-lead electrocardiogram (ECG) results above/below certain threshold [Days 1-4 of each period and at follow-up visit (7-14 days after the last dose of investigational product)]",null,null,"NO","EUDRACT_NUMBER:2019-003012-30; NIH:2019"],["NCT04839393","A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","27","Healthy Volunteer","DRUG:PF-06882961 followed by PF-06882961/PF-06865571; DRUG:PF-06882961/PF-06865571 followed by PF-06882961; DRUG:PF-06882961 + PF-06865571","Pfizer","2021-04-05","2021-10-10","TRUE","Part A: PF-06882961 Maximum Observed Concentration (Cmax) [0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16 and 24 hours post-dose on Day 1] | Part A: PF-06882961 Area Under the Plasma Concentration-time Profile From Time 0 to the Time 24 Hours Post-dose (AUC24) [0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16 and 24 hours post-dose on Day 1] | Part B: PF-06865571 Cmax on Day 1 and Day 47 [0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24 and 48 hours post-dose] | Part B: PF-06865571 Area Under the Plasma Concentration-time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) on Day 1 and Day 47 [0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24 and 48 hours post-dose] | Part B: PF-06865571 Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) on Day 1 and Day 47 [0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24 and 48 hours post-dose] | Part B: PF-06882961 Cmax on Day 46 and Day 61 [0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose] | Part B: PF-06882961 Area Under the Plasma Concentration-time Profile From Time 0 to the Time 12 Hours Post-dose (AUC12) on Day 46 and Day 61 [0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/93/NCT04839393/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/93/NCT04839393/SAP_001.pdf","NO",null],["NCT06215196","Effectiveness and Safety of Semaglutide Combined With Dietary Fiber (Soloways) in Adults With Overweight or Obesity","ESSENCE","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","TRIPLE","81","Overweight and Obesity","DIETARY_SUPPLEMENT:Fiber Supplement Group; OTHER:placebo","S.LAB (SOLOWAYS)","2023-04-14","2023-06-28","FALSE","Percentage change in body weight from baseline [180 days] | Achievement of a reduction in body weight of 5% or more from baseline. [180 days]",null,null,null,null],["NCT07527910","A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","204","Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","DRUG:ALN-PNP; DRUG:Tirzepatide; DRUG:Placebo","Regeneron Pharmaceuticals","2026-05-22","2030-03-15","FALSE","Percent change in liver fat [From baseline at week 24] | Percent change in liver fat [From baseline at week 48]",null,null,"YES",null],["NCT02650596","Effects of GLP-1 on Chronic Heart Failure",null,"UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","68","Heart Failure","DRUG:GLP-1; DRUG:Placebo","Shi Yang","2016-01","2018-02","FALSE","left ventricular ejection fraction measured by 3D echocardiography [3 months]","BACKGROUND:19195607; RESULT:26573925; RESULT:26542491",null,null,null],["NCT06373146","A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","392","Obesity","DRUG:Tirzepatide; DRUG:Mibavademab; DRUG:Tirzepatide-Placebo; DRUG:Mibavademab-Placebo","Eli Lilly and Company","2024-04-24","2025-12-15","FALSE","Mean Percent Change from Baseline in Body Weight [Baseline, Week 48]",null,null,"YES","OTHER:I8F-MC-GPIV"],["NCT01302327","GLP Analogs for Diabetes in Wolfram Syndrome Patients",null,"WITHDRAWN","INTERVENTIONAL",null,null,"NONE","0","Diabetes Mellitus Associated With Genetic Syndrome; Wolfram Syndrome","DRUG:Exenatide","Hadassah Medical Organization","2011-03-01","2013-03-01","FALSE","beta cell function [3 months]","DERIVED:27459537",null,null,null],["NCT06164873","A Study of IBI362 9 mg in Chinese Adults With Obesity",null,"UNKNOWN","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","462","Obesity","DRUG:IBI362; DRUG:Placebo","Innovent Biologics (Suzhou) Co. Ltd.","2023-12-27","2025-06-27","FALSE","Percent Change from Baseline in Body Weight [Week 60] | Proportion of Participants who Achieve ≥5% Body Weight Reduction [Week 60]","DERIVED:42251595",null,"NO",null],["NCT00870194","A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","255","Type 2 Diabetes Mellitus","DRUG:exenatide and sitagliptin; DRUG:exenatide and placebo","AstraZeneca","2009-03","2010-04","TRUE","Change in HbA1c (Percent) [Baseline to 20 Weeks]","DERIVED:22375612",null,null,null],["NCT07846956","NAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World Study",null,"NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"28","Non-arteritic Anterior Ischemic Optic Neuropathy Obesity; Obesity","DRUG:GLP-1 Receptor Agonist Therapy","Istanbul Saglik Bilimleri University","2026-09-21","2026-11-30","FALSE","Occurrence of NAION [Baseline (GLP-1 RA initiation) to final recorded eye examination, up to 14 months]","BACKGROUND:38958939; BACKGROUND:37013752; BACKGROUND:37454782; BACKGROUND:39863057; RESULT:36700417",null,"UNDECIDED",null],["NCT05872022","A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy",null,"ENROLLING_BY_INVITATION","OBSERVATIONAL",null,null,null,"728","Pregnancy; Obesity; Overweight","OTHER:No Intervention","Novo Nordisk A/S","2023-07-05","2032-10-31","FALSE","Number of Infants with Major Congenital Malformation (MCM) [From date of conception (DOC) to pregnancy outcome for foetal losses or 12 months of infant age for live births]",null,null,"YES","OTHER:U1111-1273-4336"],["NCT07225829","A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis","INFLAM MOTION","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","129","Knee Osteoarthritis; Synovitis of Knee","DRUG:4P004; DRUG:Placebo (NaCl 0.9%)","4Moving Biotech","2025-06-17","2026-08-31","FALSE","Change from Baseline at Week 4 in the weekly average of Target Knee (TK) daily pain intensity using the WOMAC (Western Ontario and McMaster Universities Arthritis Index) Pain subscore [Baseline and Week 4]",null,null,"UNDECIDED","CTIS:2024-518916-38-00"],["NCT01272973","Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","96","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2011-01","2011-07","FALSE","Frequency of adverse events (AEs) [from the first trial related activity (screening visit) and until completion of the post treatment follow-up visit 91-105 days after first dose]",null,null,null,"OTHER:U1111-1118-0257; EUDRACT_NUMBER:2010-019951-23"],["NCT06283641","Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.",null,"COMPLETED","OBSERVATIONAL",null,null,null,"300","Obesity","DRUG:Liraglutide","Novo Nordisk A/S","2024-04-08","2025-01-13","FALSE","Incidence of adverse events (AEs) by preferred term (PT) [From baseline (week 0) to week 26]",null,null,"YES","OTHER:U1111-1289-9747"],["NCT05268237","Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus",null,"RECRUITING","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","DOUBLE","15","Diabete Type 2","DRUG:Liraglutide; DRUG:Placebo","Biolingus","2023-04-25","2025-12","FALSE","Incidence, nature and severity of adverse events [Through study completion, an average of 6 weeks]",null,null,"NO",null],["NCT03322631","A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","48","Type 2 Diabetes Mellitus","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2017-11-15","2018-05-29","TRUE","Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline through Day 85]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/31/NCT03322631/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/31/NCT03322631/SAP_001.pdf","NO","OTHER:I8F-JE-GPGC"],["NCT00736229","Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients",null,"COMPLETED","INTERVENTIONAL","PHASE4",null,"NONE","40","Hyperglycemia; Acute Coronary Syndromes; Myocardial Infarction","DRUG:Exenatide","Saint Luke's Health System","2008-08","2011-06","TRUE","Median Glucose Values From Steady State Through 48 Hours or Until Discharge. [1-48 hours] | Time to Steady State [Start of infusion through 48 hours or until discharge]","RESULT:23186969",null,null,null],["NCT05110794","A Multiple-Dose Study of LY3502970 in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","34","Healthy","DRUG:LY3502970","Eli Lilly and Company","2021-11-05","2022-02-10","TRUE","PK: Maximum Observed Concentration (Cmax) of LY3502970 [PK: Day 28: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24h Postdose (Test Period 1); Day 35: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 2)] | PK: Area Under the Concentration-time Curve From 0 to 24 Hour (AUC0-24) of LY3502970 [PK: Day 28: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 1); Day 35: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 2)] | Time to Maximum Observed Concentration (Tmax) of LY3502970 [PK: Day 28: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 1); Day 35: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 2)]","DERIVED:38402332","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/94/NCT05110794/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/94/NCT05110794/SAP_001.pdf","NO","OTHER:J2A-MC-GZGJ"],["NCT05936151","A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","146","Overweight or Obesity; CKD; Type 2 Diabetes","DRUG:Retatrutide; DRUG:Placebo","Eli Lilly and Company","2023-07-20","2025-10-01","FALSE","Change from Baseline in Glomerular Filtration Rate (mGFR) [Baseline, Week 24]","DERIVED:41160422",null,"YES","OTHER:J1I-MC-GZBU; OTHER:2023-504583-42-00; NIH:2023"],["NCT06918405","Efficacy and Safety of Tirzepatide for Weight Management",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3",null,"NONE","440","Obesity and Obesity-related Medical Conditions","DRUG:Tirzepatide","Chittagong Medical College","2025-01-01","2026-06-30","FALSE","Change in body weight (kg) [52 weeks]",null,null,"UNDECIDED",null],["NCT07251556","GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","40","Psoriasis Arthritis","DRUG:Semaglutide 0.5 mg; DRUG:Semaglutide 1.0 mg; DRUG:Semaglutide 0.25 mg; OTHER:No intervention","Chinese University of Hong Kong","2025-12-01","2027-01-01","FALSE","Difference in the proportion of subjects with CIMT between the semaglutide group and control group over a period of 24 weeks. [24 weeks]",null,null,null,null],["NCT02477969","Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin",null,"UNKNOWN","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","587","Type 2 Diabetes Mellitus","DRUG:PEX168(100µg); DRUG:PEX168(200µg); DRUG:Placebo; DRUG:Metformin","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2014-02-27","2016-06-22","FALSE","HbA1c [Baseline to Week24]",null,null,"NO",null],["NCT07457424","Direct Measurement of Microstructure of Ingestive Behaviour After Initiation of GLP-1 Receptor Agonist Treatment at Maximum Dose (DIGRAT)","DIGRAT","ACTIVE_NOT_RECRUITING","OBSERVATIONAL",null,null,null,"140","Metabolic Disease; Obesity & Overweight","DRUG:semaglutide 1 mg weekly injection","University College Dublin","2022-02-17","2026-08-31","FALSE","Energy Intake from Liquid Meal Consumption [At baseline, 4 weeks, 12 weeks, 24 weeks, 52 weeks] | Macrostructure of Ingestive Behaviour (Rate of Energy Intake) [At baseline, 4 weeks, 12 weeks, 24 weeks, 52 weeks] | Macrostructure of Ingestive Behaviour (Meal Duration) [At baseline, 4 weeks, 12 weeks, 24 weeks, 52 weeks] | Macrostructure of Ingestive Behaviour (Number of Sucks) [At baseline, 4 weeks, 12 weeks, 24 weeks, 52 weeks] | Microstructure of Ingestive Behaviour (Suck Energy Intake) [At baseline, 4 weeks, 12 weeks, 24 weeks, 52 weeks] | Microstructure of Ingestive Behaviour (Suck Duration) [At baseline, 4 weeks, 12 weeks, 24 weeks, 52 weeks] | Microstructure of Ingestive Behaviour (Suck Rate) [At baseline, 4 weeks, 12 weeks, 24 weeks, 52 weeks] | Microstructure of Ingestive Behaviour (Suck Maximal Rate) [At baseline, 4 weeks, 12 weeks, 24 weeks, 52 weeks] | Microstructure of Ingestive Behaviour (Burst Number) [At baseline, 4 weeks, 12 weeks, 24 weeks, 52 weeks] | Microstructure of Ingestive Behaviour (Burst Duration) [At baseline, 4 weeks, 12 weeks, 24 weeks, 52 weeks] | Microstructure of Ingestive Behaviour (Burst Energy Intake) [At baseline, 4 weeks, 12 weeks, 24 weeks, 52 weeks] | Microstructure of Ingestive Behaviour (Burst Rate) [At baseline, 4 weeks, 12 weeks, 24 weeks, 52 weeks] | Microstructure of Ingestive Behavior (Number of Sucks per Burst) [At baseline, 4 weeks, 12 weeks, 24 weeks, 52 weeks] | Microstructure of Ingestive Behaviour (Inter-Burst Intervals) [At baseline, 4 weeks, 12 weeks, 24 weeks, 52 weeks] | Microstructure of Ingestive Behaviour (Inter-Sucks Intervals) [At baseline, 4 weeks, 12 weeks, 24 weeks, 52 weeks]","BACKGROUND:35620756; BACKGROUND:37667550; BACKGROUND:38154576; BACKGROUND:34369388; BACKGROUND:35134394; BACKGROUND:35233038; BACKGROUND:38485648; BACKGROUND:33759396; BACKGROUND:35998250; BACKGROUND:40780185; BACKGROUND:34486393",null,"NO",null],["NCT05716724","O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait","O-SEMA-Fast","COMPLETED","OBSERVATIONAL",null,null,null,"288","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2023-01-25","2023-07-09","FALSE","Change in glycated haemoglobin (HbA1c) [From participant enrolment visit (0 to 8 weeks before Ramadan) to end of follow-up visit (0 to 8 weeks after Ramadan)]","DERIVED:40016571",null,"YES","OTHER:U1111-1280-0404"],["NCT01592279","GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","124","Uncontrolled Type 1 Diabetic Patients","DRUG:liraglutide; DRUG:Insulin injections","Hadassah Medical Organization","2012-06","2014-06","FALSE","The primary end point is the change in HbA1C relative to baseline after 3 months treatment with liraglutide in uncontrolled type 1 diabetic patients. The expected change is 1% reduction from baseline. [the change in HbA1C relative to baseline after 3 months treatment with liraglutide in uncontrolled type 1 diabetic patients.]",null,null,null,null],["NCT05285397","Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.",null,"UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","60","Morbid Obesity","DRUG:Liraglutide Pen Injector [Saxenda]","General Committee of Teaching Hospitals and Institutes, Egypt","2022-03-10","2022-09","FALSE","Percentage Total weight loss [6 months] | Percentage Excess body weight loss [6 months]","BACKGROUND:32656729",null,"UNDECIDED",null],["NCT01954147","Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus",null,"UNKNOWN","INTERVENTIONAL","PHASE1; PHASE2","NON_RANDOMIZED","NONE","100","Type 2 Diabetes","DRUG:GLP-1; BIOLOGICAL:SC; OTHER:Standard Medical Treatment","Diabetes Care Center of Nanjing Military Command","2013-10","2014-10","FALSE","HbA1C [1 year]","DERIVED:27143183",null,null,null],["NCT02920385","A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects.",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","45","Diabetes; Healthy","DRUG:Semaglutide; DRUG:SNAC; DRUG:Levothyroxine; DRUG:Placebo","Novo Nordisk A/S","2016-10-10","2017-04-26","FALSE","Baseline-corrected area under the total T4 serum concentration-time curve from 0 to 48 hours after a single dose of levothyroxine [On day 1 (levothyroxine administered alone), on day 38 (levothyroxine co-administered with SNAC) and on day 89 (levothyroxine co-administered with oral semaglutide)] | Area under the semaglutide plasma concentration-time curve during a dosing interval (0-24 hours) at steady state [On day 88 (oral semaglutide administered alone) and on day 139 (oral semaglutide co-administered with placebo tablets)]",null,null,"YES","EUDRACT_NUMBER:2015-005558-36; OTHER:U1111-1177-2807; NIH:2015"],["NCT01179048","Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results","LEADER®","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","9341","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2010-08-31","2015-12-17","TRUE","Time From Randomisation to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) [from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)]","BACKGROUND:30851070; BACKGROUND:30900349; RESULT:27295427; RESULT:26855018; RESULT:26864124; RESULT:27320184; RESULT:27274772; RESULT:24176437; RESULT:25275271; RESULT:25656058; RESULT:28476871; RESULT:28854085; RESULT:29279300; RESULT:29627109; RESULT:29760228; RESULT:29898902; RESULT:29903847; RESULT:29947247; RESULT:30072400; RESULT:30354517; RESULT:30566006; RESULT:30566004; RESULT:30260088; RESULT:30392095; RESULT:30508430; DERIVED:41198855; DERIVED:39963952; DERIVED:35332654; DERIVED:34704120; DERIVED:33504496; DERIVED:32744418; DERIVED:32647053; DERIVED:32643857; DERIVED:32372454; DERIVED:32366578; DERIVED:32164886; DERIVED:32132141; DERIVED:31959650; DERIVED:31721979; DERIVED:31399438; DERIVED:31282028; DERIVED:29693361",null,null,"EUDRACT_NUMBER:2009-012201-19; OTHER:U1111-1113-7090; OTHER:CTR20130003; NIH:2009"],["NCT01516255","Effect of Liraglutide on Heart Frequency in Healthy Volunteers",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","64","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo; DRUG:moxifloxacin; PROCEDURE:electrocardiogram (ECG)","Novo Nordisk A/S","2006-07","2006-11","FALSE","Maximum time-matched mean difference between the baseline subtracted QTci intervals []","RESULT:19737980",null,null,null],["NCT01512108","Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","363","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:oral anti-diabetic drug","Novo Nordisk A/S","2012-01-10","2013-04-26","TRUE","Incidence of Treatment Emergent Adverse Events (AEs) [Week 0 to Week 52 + 7 days]","RESULT:26816604; RESULT:28984041",null,null,"OTHER:U1111-1121-3457; REGISTRY:JapicCTI-121744"],["NCT02911948","A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs","DUAL™ II Japan","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","210","Diabetes; Diabetes Mellitus, Type 2","DRUG:Insulin degludec/liraglutide; DRUG:Insulin degludec","Novo Nordisk A/S","2016-09-21","2017-11-17","TRUE","Change in Glycosylated Haemoglobin (HbA1c) [week 0, week 26]","RESULT:31423685; RESULT:33595901; DERIVED:31760599","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/48/NCT02911948/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/48/NCT02911948/SAP_001.pdf",null,"OTHER:U1111-1178-3453; OTHER:JapicCTI-163385"],["NCT07628985","BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","374","Type 2 Diabetes Mellitus (T2DM)","BIOLOGICAL:Bofanglutide; BIOLOGICAL:Semaglutide","Carnot Laboratories","2026-09","2027-10","FALSE","Change in Hemoglobin A1c (HbA1c) From Baseline at Week 30 [Baseline to Week 30]","BACKGROUND:35718129; BACKGROUND:40028667",null,"NO",null],["NCT07809568","Real-World Outcomes of Tirzepatide in Pakistani Adults With Obesity, Prediabetes, and Type 2 Diabetes","TRIBUTE-PK","NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"330","Prediabetes or Overweight; Obesity Type 2 Diabetes Mellitus; Obesity & Overweight",null,"Universiti Sains Malaysia","2026-10-01","2027-12-28","FALSE","Percentage change in body weight (obesity and prediabetes cohorts) [Baseline to Week 26] | Change in HbA1c (type 2 diabetes cohort) [Baseline to Week 26]",null,null,"UNDECIDED","OTHER_GRANT:R504-LR-GAL008-2600000333-B158"],["NCT02887625","Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM",null,"UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","NONE","410","Type 2 Diabetes","DRUG:Pioglitazone plus exenatide; DRUG:insulin glargine and insulin aspart","Dr. Muhammad Abdulghani","2015-02","2017-05","FALSE","HbA1c [3 years]","DERIVED:28096223",null,"NO",null],["NCT07202247","Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","60","Prostate Carcinoma; Recurrent Prostate Carcinoma","DRUG:Antiandrogen Therapy; BEHAVIORAL:Behavioral Intervention; PROCEDURE:Biospecimen Collection; PROCEDURE:Cardiac Computerized Tomographic Angiography; PROCEDURE:Computed Tomography; OTHER:Electronic Health Record Review; OTHER:Internet-Based Intervention; BEHAVIORAL:Lifestyle Counseling; OTHER:Medical Device Usage and Evaluation; OTHER:Nutritional Intervention; OTHER:Questionnaire Administration; RADIATION:Radiation Therapy; OTHER:Referral; DRUG:Semaglutide; OTHER:Short-Term Fasting; DRUG:Tirzepatide","City of Hope Medical Center","2025-11-05","2028-04-09","FALSE","Changes in the 10-year risk of cardiovascular disease [At completion of 6 months of androgen deprivation therapy (ADT) and at 12 months follow up after completion of ADT] | Changes in the 10-year risk of cardiovascular disease [At completion of 6 months of ADT and at 12 months follow up after completion of ADT]",null,null,null,"REGISTRY:NCI-2025-06197; OTHER:25332; NIH:P30CA033572"],["NCT01373216","Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass","Executive","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","SINGLE","38","Coronary Artery Disease; Decreased Left Ventricular Function","DRUG:Exenatide","Charles University, Czech Republic","2011-06","2014-05","FALSE","Cardiac function - echocardiographic parameters [90 days after administration of exenatide]","DERIVED:28581209",null,null,null],["NCT03160261","Effect of Exenatide on Cortisol Secretion",null,"COMPLETED","INTERVENTIONAL","PHASE4",null,"NONE","10","Healthy","DRUG:Exenatide Injection","University of Tartu","2017-09-07","2017-12-28","FALSE","Cortisol peak [every 30 minutes during 2 hours after injection]","DERIVED:36800161",null,"NO",null],["NCT06518837","Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer","FITWISE","RECRUITING","INTERVENTIONAL","PHASE2",null,"NONE","40","Hormone Receptor-Positive Breast Cancer; HER2-Negative Breast Cancer","DRUG:Tirzepatide","Rutgers, The State University of New Jersey","2024-10-30","2027-09-30","FALSE","Weight Loss Reduction with Tirzepatide during Adjuvant Treatment for HR+/Her2- Breast Cancer (Measured by Body Weight Reduction) [Through study completion, total of two years.]",null,null,"NO",null],["NCT04591626","A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes","AWARD-CHN3","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","291","Type 2 Diabetes Mellitus","DRUG:Dulaglutide; DRUG:Placebo; DRUG:Insulin Glargine","Eli Lilly and Company","2020-12-07","2022-04-28","TRUE","Change From Baseline in Hemoglobin A1c (HbA1c) [Baseline, Week 28]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/26/NCT04591626/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/26/NCT04591626/SAP_001.pdf","YES","OTHER:H9X-MC-GBGO"],["NCT06967389","Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity","MODERN","RECRUITING","OBSERVATIONAL",null,null,null,"50","Obesity and Overweight; Obese Adolescents; Weight Management; Weight Loss; Cardiovascular Disease Risk Factor","DRUG:Ozempic®","John Bauer","2025-06-12","2027-07","FALSE","Change in medication use [Enrollment, 6 months post enrollment, 12 months +/- 2 months post enrollment] | Change in Lipid Profile [Enrollment, 6 months post enrollment, 12 months +/- 2 months post enrollment] | Change in C-reactive protein [Enrollment, 6 months post enrollment, 12 months +/- 2 months post enrollment] | Change in Tumor necrosis factor [Enrollment, 6 months post enrollment, 12 months +/- 2 months post enrollment] | Change in Interleukin-6 [Enrollment, 6 months post enrollment, 12 months +/- 2 months post enrollment] | Change in Adiponectin [Enrollment, 6 months post enrollment, 12 months +/- 2 months post enrollment] | Change in Soluble Intercellular Adhesion Marker [Enrollment, 6 months post enrollment, 12 months +/- 2 months post enrollment] | Changes in Renin-Angiontensin-Alsosterone System biomarkers profiling [Enrollment, 6 months post enrollment, 12 months +/- 2 months post enrollment] | Change in Systolic Blood pressure [Enrollment, 6 months post enrollment, 12 months +/- 2 months post enrollment] | Change in Diastolic Blood pressure [Enrollment, 6 months post enrollment, 12 months +/- 2 months post enrollment] | Change in ambulatory blood pressure [Enrollment, 6 months post enrollment, 12 months +/- 2 months post enrollment] | Change in Cardiac structure [Enrollment, 6 months post enrollment, 12 months +/- 2 months post enrollment] | Change in Cardiac function (Ejection Fraction) [Enrollment, 6 months post enrollment, 12 months +/- 2 months post enrollment] | Change in Cardiac function (Stroke Volume (SV) [Enrollment, 6 months post enrollment, 12 months +/- 2 months post enrollment] | Change in Cardiac function (Cardiac Output (CO) [Enrollment, 6 months post enrollment, 12 months +/- 2 months post enrollment] | Change in Cardiac function (Wall motion) [Enrollment, 6 months post enrollment, 12 months +/- 2 months post enrollment] | Change in Cardiac function (Valve motion) [Enrollment, 6 months post enrollment, 12 months +/- 2 months post enrollment]",null,null,"YES",null],["NCT07505303","MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","151","Adult Obesity; Weight Management","DRUG:ECC4703; DRUG:Placebo; DRUG:Semaglutide","Eccogene","2026-03-23","2026-10-15","FALSE","Percentage Change in Body Weight from Baseline (Week 9) to Week 20 [Baseline (Week 9) to Week 20] | Proportion of Participants Achieving ≥5% Reduction in Body Weight from Baseline (Week 9) to Week 20 [Baseline (Week 9) to Week 20] | Absolute Change in Liver Fat Content as Measured by MRI-PDFF in Participants With Hepatic Steatosis [Baseline (Week 9) to Week 20] | Percentage Change in Liver Fat Content as Measured by MRI-PDFF in Participants With Hepatic Steatosis [Baseline (Week 9) to Week 20] | Proportion of Participants With ≥30% Relative Reduction in Liver Fat Content as Measured by MRI-PDFF [Baseline (Week 9) to Week 20]",null,null,"NO",null],["NCT02577848","GLP-1 on Non-ST-Segment Elevation Myocardial Infarction",null,"UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","90","Myocardial Infarction","DRUG:GLP-1; DRUG:Placebo","Chinese PLA General Hospital","2015-10","2016-10","FALSE","left ventricular ejection fractions [at 3 months]","BACKGROUND:23991622; BACKGROUND:17392556; BACKGROUND:21920963; BACKGROUND:23564922; BACKGROUND:15356213",null,null,null],["NCT02109315","Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.","DIAB-01","WITHDRAWN","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","0","Type 1 Diabetes Mellitus","DRUG:Vitamine C; DRUG:Liraglutide 6 mg","Anna Cruceta","2014-05","2015-05","FALSE","Endothelial dysfunction (Flow mediated dilation): Endothelial function is assessed measuring flow-mediated vasodilation (FMD) of the brachial artery. [8 weeks]",null,null,null,null],["NCT07539415","A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","72","Obesity & Overweight; Type 2 Diabetes","DRUG:DWRX5003; DRUG:DWC202502; DRUG:DWC202503; OTHER:DWRX5003P","Daewoong Pharmaceutical Co. LTD.","2026-05-06","2026-10-27","FALSE","AUC 0-t [Pre-dose (0 hour) up to 672 hours post-dose] | Cmax [Pre-dose (0 hour) up to 672 hours post-dose]",null,null,"NO",null],["NCT02160990","Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","20","Obesity","DRUG:Exenatide; DRUG:Placebo","Mayo Clinic","2014-06","2015-03","TRUE","Gastric Emptying Half-time (T 1/2) of Solids [time frame is 30 days after the initiation of dose.]","RESULT:26542264",null,"NO","NIH:R01DK067071; NIH:UL1TR000135"],["NCT01270191","The Effects of Short-Term Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","160","Type 2 Diabetes","DRUG:Exenatide; DRUG:Humulin-N","Taipei Veterans General Hospital, Taiwan","2010-11","2014-12","FALSE","the time of glycemic remission and remission rate [at one year] | The time of monotherapy failure and monotherapy failure rate [5 years]","DERIVED:42290292",null,null,null],["NCT05371496","Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","81","Cardiomyopathy; Heart Failure With Preserved Ejection Fraction (HFpEF); Obesity","DRUG:Semaglutide; DRUG:Placebo; BEHAVIORAL:Counselling on healthy lifestyle intervention","Mayo Clinic","2022-09-06","2026-07-17","FALSE","Pulmonary Capillary Wedge Pressure (PCWP) [Baseline, 12 months]",null,"Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/96/NCT05371496/ICF_000.pdf","NO",null],["NCT01795248","The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","105","Gestational Diabetes Mellitus","DRUG:Liraglutide; DRUG:Placebo","Tina Vilsboll","2012-07","2019-09","FALSE","Change in glucose tolerance [from baseline to 52 wks, 53 wks, 260 wks, and 261 wks]","BACKGROUND:10842653; BACKGROUND:14968296; BACKGROUND:16009062; BACKGROUND:17928588; BACKGROUND:9742976; BACKGROUND:8623813; BACKGROUND:14634573; BACKGROUND:9704245; BACKGROUND:15111544; BACKGROUND:20682697; BACKGROUND:12027921; BACKGROUND:11776065; BACKGROUND:9715377; BACKGROUND:21153530; BACKGROUND:19853906; BACKGROUND:21844879; BACKGROUND:10702749; BACKGROUND:9449682; DERIVED:24176797",null,null,"EUDRACT_NUMBER:2012-001371-37"],["NCT05916560","A Study of LY3437943 in Participants With Impaired and Normal Liver Function",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","43","Healthy; Hepatic Insufficiency","DRUG:LY3437943","Eli Lilly and Company","2023-07-13","2025-03-02","FALSE","Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3437943 [Predose up to 30 days postdose] | PK: Maximum observed concentration (Cmax) of LY3437943 [Predose up to 30 days postdose]",null,null,"NO","OTHER:J1I-MC-GZBT"],["NCT02476760","Incretin-based Drugs and Acute Pancreatitis",null,"COMPLETED","OBSERVATIONAL",null,null,null,"1417914","Diabetes Mellitus, Type 2","DRUG:DPP-4 inhibitors; DRUG:GLP-1 analogs; DRUG:Insulins; DRUG:Biguanides; DRUG:Sulfonylureas; DRUG:Thiazolidinediones; DRUG:Alpha-glucosidase inhibitors; DRUG:Meglitinides","Canadian Network for Observational Drug Effect Studies, CNODES","2014-03","2015-04","FALSE","Hospitalization for acute pancreatitis [Patients were followed from the date of study cohort entry until hospitalization for incident acute pancreatitis, censoring, or for up to 87 months.]","RESULT:27479930",null,null,null],["NCT02928679","Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance","IM-LOSEIT-II","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","150","Osteoarthritis; Obesity","DRUG:Liraglutide 3 mg (Saxenda); DRUG:Liraglutide 3 mg placebo","Henrik Gudbergsen","2016-11","2019-02-20","FALSE","Change in the degree of inflammation in the knee-joint (DCE-MRI) [Week 0 to 52]",null,null,"NO",null],["NCT01319240","Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","24","Diabetes; Healthy","DRUG:insulin degludec; DRUG:insulin degludec/liraglutide; DRUG:liraglutide","Novo Nordisk A/S","2011-03","2011-05","FALSE","The area under insulin degludec concentration-time curve [from 0-infinity hours after trial product administration] | The area under liraglutide concentration-time curve [from 0-infinity hours after trial product administration]",null,null,null,"EUDRACT_NUMBER:2010-021190-36; OTHER:U1111-1119-2417"],["NCT06774079","Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients",null,"RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","24","Crohn Disease","DRUG:Tirzepatide; BEHAVIORAL:Mediterranean diet","University of Miami","2025-03-05","2027-03-05","FALSE","Change in percentage of participants retained [Baseline, 12 weeks] | Number of patients who adhere to diet measured by 24 hour dietary recall [Up to 12 weeks] | Number of patients who adhere to medications measured by self report [Up to 12 weeks]",null,null,"NO",null],["NCT07706088","Effect of Tirzepatide on Diabetic Peripheral Sensorimotor Neuropathy","T-DPN","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","40","Neuropathy, Small Fiber; Diabete Mellitus","DRUG:Tirzepatide 2.5mg weekly; DRUG:all standard of care to diabetic patient besides tirzepatide","Post Graduate Institute of Medical Education and Research, Chandigarh","2026-07","2028-07-01","FALSE","To assess the percent change in CNFD compared to baseline [6 months]",null,null,null,null],["NCT00500370","A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","163","Obesity","DRUG:exenatide; DRUG:placebo","AstraZeneca","2007-06","2008-02","TRUE","Change in Body Weight [24 weeks]","DERIVED:20332357",null,null,null],["NCT04621227","Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","16","Obesity","DRUG:PF-06882961; DRUG:Rosuvastatin; DRUG:Midazolam","Pfizer","2020-12-15","2021-05-13","TRUE","Area Under the Plasma Concentration-time Profile From Time 0 to Last Quantifiable Concentration (AUClast) of Rosuvastatin in Periods 1, 4 and 7 [At 0 (prior to rosuvastatin dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, and 72 hours post rosuvastatin dose on Day 1 in Periods 1, 4, and 7] | AUClast of Midazolam in Periods 2, 5 and 8 [At 0 (prior to midazolam dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours post midazolam dose on Day 1 in Periods 2, 5, and 8]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/27/NCT04621227/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/27/NCT04621227/SAP_001.pdf","NO",null],["NCT06438146","LIROH - Liraglutide for Obesity in HIV","LIROH","UNKNOWN","INTERVENTIONAL","PHASE4",null,"NONE","40","Obesity; HIV Infections","DRUG:Liraglutide","Brigham and Women's Hospital","2024-05-02","2025-05","FALSE","Proportion of participants who screen and enroll among those approached [Measured at screening] | Time to reach study enrollment target [Measured at enrollment] | Study retention rate at 12 weeks [Measured at Visit 4 at 12 weeks] | Study retention rate at 24 weeks [Measured at End of Study at 24 weeks] | Rate of adherence to treatment over 12 weeks [Measured at Visit 4 at 12 weeks] | Embedded qualitative interviews regarding the acceptability of liraglutide for obesity management [Measured at End of Study at 24 weeks]","BACKGROUND:31339677; BACKGROUND:33010240; BACKGROUND:37632604; BACKGROUND:37437159; BACKGROUND:36962629; BACKGROUND:35015037; BACKGROUND:33625476; BACKGROUND:33567185; BACKGROUND:30990252; BACKGROUND:32072466",null,"YES","NIH:K23DK125162"],["NCT00943917","Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","155","Type 2 Diabetes","OTHER:ITCA 650; DRUG:Exenatide Injection; OTHER:Ex Inj/ITCA 650","Intarcia Therapeutics","2009-08","2010-08","TRUE","Mean Change in HbA1c (Per Protocol) [Day 0 and Week 12] | Mean Change in HbA1c (ITT) [Day 0 to Week 12] | Mean Change in HbA1c (Per Protocol) [Day 0 to Week 24] | Mean Change in HbA1c (ITT) [Day 0 to Week 24] | Mean Change in HbA1c (Per Protocol) [Day 0 to Week 48] | Mean Change in HbA1c (ITT) [Day 0 to Week 48]","DERIVED:23645886",null,null,null],["NCT04535960","Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: \"NATRIURETIC\" Trial","NATRIURETIC","UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","36","Type 2 Diabetes Mellitus","DRUG:Empagliflozin 25 MG + Liraglutide 1.8 MG; DRUG:Liraglutide 1.8 MG + Empagliflozin 25 MG","University Health Network, Toronto","2019-01-24","2023-10","FALSE","Proximal tubular natriuresis [up to 12 weeks]",null,null,"NO",null],["NCT06758583","A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","30","Overweight and Obesity","DRUG:Dapiglutide 7.5 mg","Zealand Pharma","2024-12-23","2025-04-12","FALSE","To compare pharmacokinetics of a single dose administration of 7.5 mg dapiglutide [Trial Day 1 to 28]",null,null,"NO","EUDRACT_NUMBER:2024-516901-21"],["NCT05132088","Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity","OASIS 2","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","201","Overweight and Obesity","DRUG:semaglutide 50 mg; DRUG:placebo (semaglutide)","Novo Nordisk A/S","2021-11-16","2023-07-11","TRUE","Percent Change From Baseline in Body Weight [Baseline (week 0), week 68] | Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 5% (Yes/No) [At week 68]","DERIVED:40758358","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/88/NCT05132088/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/88/NCT05132088/SAP_001.pdf","YES","OTHER:U1111-1258-7561"],["NCT01394341","Liraglutide Treatment to Patients With Severe Renal Insufficiency",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","40","Type 2 Diabetes Mellitus; End-stage Renal Disease","DRUG:Liraglutide","Bo Feldt-Rasmussen","2011-09","2013-10","FALSE","Plasma liraglutide concentration (pmol/L) [12 weeks]","DERIVED:39963952; DERIVED:26283739; DERIVED:23624993",null,null,"EUDRACT_NUMBER:2010-021922-36"],["NCT07354880","Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart Disease","TEACH","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","30","Obesity & Overweight; Adult Congenital Heart Disease","DRUG:Treatment with tirzapatide; DRUG:Treatment with placebo","University Medical Centre Ljubljana","2026-01-20","2027-06-30","FALSE","Change in exercise capacity after 6 months of treatment with tirzepatide. [From enrollment (visit 1) to the end of the treatment at 6 months (visit 6).] | Change in left ventricular systolic function after 6 months of treatment with tirzepatide. [From enrollment (visit 1) to the end of the treatment at 6 months (visit 6).] | Change in cholesterol levels after 6 months of treatment with tirzepatide. [From enrollment (visit 1) to the end of the treatment at 6 months (visit 6).]",null,null,"YES",null],["NCT02014740","Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","100","Type 2 Diabetes; Overweight; Obesity","DRUG:Liraglutide; DRUG:Metformin","University of Miami","2014-03","2017-03","TRUE","Echocardiographic Epicardial Fat Thickness [6 months]","DERIVED:28124506","Study Protocol, Statistical Analysis Plan, and Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/40/NCT02014740/Prot_SAP_ICF_000.pdf",null,null],["NCT07497880","Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","306","Obesity; Overweight","DRUG:KAI-7535; DRUG:Placebo","Kailera","2026-04-06","2027-07-07","FALSE","Percent Change from Baseline in Body Weight at Week 44 for Participants Without Diabetes Mellitus [Baseline, Week 44]",null,null,"NO",null],["NCT00099320","Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","182","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:Placebo","AstraZeneca","2004-05","2005-08","FALSE","Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 16, and if measured, any visits in between [Baseline, Week 4, Week 8, Week 12, Week 16] | Change from Baseline to Week 16 in fasting serum glucose (FSG) and glucose [Baseline, Week 16]","DERIVED:22236356; DERIVED:17404349",null,null,null],["NCT01107717","Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","318","Diabetes","DRUG:metformin\\pioglitazone\\exenatide; DRUG:metformin, glyburide and glargine","The University of Texas Health Science Center at San Antonio","2009-01","2023-02-03","TRUE","HbA1c Level [at the end of the study (3 years)]","RESULT:33273042; DERIVED:40288809","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/17/NCT01107717/Prot_SAP_000.pdf","YES","NIH:5R01DK103841-03"],["NCT06738979","A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","408","Obesity","DRUG:TQF3510 (Semaglutide Injection); DRUG:Wegovy®","Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","2025-03-20","2026-03-07","FALSE","Percentage (%) of body weight loss [Baseline to week 44]",null,null,null,null],["NCT05759897","A 16 Week Study of HRS-7535 in Adults With Type 2 Diabetes Mellitus",null,"UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","180","Type 2 Diabetes","DRUG:HRS-7535; DRUG:Placebo","Shandong Suncadia Medicine Co., Ltd.","2023-02-28","2023-12-21","FALSE","Mean Change From Baseline in HbA1c at Week 16 [at Week 16]]","DERIVED:42234428",null,"UNDECIDED",null],["NCT02092597","Safety Evaluation of Adverse Reactions in Diabetes","SAFEGUARD","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","42","Type 2 Diabetes Mellitus","DRUG:Exenatide; DRUG:Linagliptin; DRUG:Gliclazide","Charles University, Czech Republic","2013-10","2015-10","FALSE","Heart rate [90 days after treatment initiation] | Gastric evacuation velocity [90 days after treatment initiation] | Blood pressure [90 days after treatment initiation] | Left ventricular ejection fraction [90 days after treatment initiation] | Intimomedial thickness [90 days after treatment initiation] | Pulse wave velocity [90 days after treatment initiation] | Glomerular filtration rate [90 days after treatment initiation] | Tubular function [90 days after treatment initiation] | KIM-1 [90 days after treatment initiation] | Exocrine pancreas function [90 days after treatment initiation]",null,null,null,null],["NCT02557620","Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","113","Diabetes; Healthy","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2015-09","2016-04","FALSE","Area under the semaglutide concentration-time curves [At steady-state from 0 to168 hours after dosing on day 78]",null,null,null,"EUDRACT_NUMBER:2014-005171-84; OTHER:U1111-1164-2741; NIH:2014"],["NCT05514535","A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","573","Diabetes Mellitus, Type 2; Obesity","DRUG:Semaglutide; DRUG:Insuline glargine U100 (reduced); DRUG:Insuline glargine U100 (titrated)","Novo Nordisk A/S","2022-08-29","2025-03-05","TRUE","Change in Glycated Haemoglobin (HbA1c) [Noninferiority] [From baseline (week 0) to end of treatment (week 40)]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/35/NCT05514535/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/35/NCT05514535/SAP_001.pdf","YES","OTHER:U1111-1267-0312; EUDRACT_NUMBER:2021-004392-13"],["NCT03182192","GLP1R-imaging in Hypoglycemia",null,"UNKNOWN","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","12","Hypoglycemia","RADIATION:68Ga-NODAGA-exendin-4 PET/CT","Radboud University Medical Center","2016-04-01","2024-07-01","FALSE","Uptake of 68Ga-exendin in the pancreas of patients [1 year]",null,null,"NO",null],["NCT06132477","Impact GLP-1 Agonists Following Bariatric",null,"RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","150","Morbid Obesity; Metabolic Syndrome; Diabetes Mellitus; Hypertension; Obstructive Sleep Apnea of Adult","DRUG:GLP-1 receptor agonist","University of Missouri-Columbia","2024-02-01","2028-07","FALSE","Effect of GLP1-RA on weight loss [6 months] | Effect of GLP1-RA on circulating bile acids and metabolites [6 months] | Effector of GLP1-RA on gut microbiome diversity [6 months] | Effect of GLP1-RA on satiety and hunger [6 months] | Effect of GLP1-RA on Glycemic control [6 months]","BACKGROUND:28406283; BACKGROUND:32163341; BACKGROUND:25412152; BACKGROUND:24679060; BACKGROUND:28352941; BACKGROUND:32198618; BACKGROUND:28938270; BACKGROUND:29730732; BACKGROUND:36441488; BACKGROUND:25595383; BACKGROUND:35317659; BACKGROUND:28266779; BACKGROUND:21844879; BACKGROUND:36478039; BACKGROUND:27219496; BACKGROUND:34016530; BACKGROUND:36321278; BACKGROUND:36765019; BACKGROUND:36502288; BACKGROUND:30315341; BACKGROUND:26511102; BACKGROUND:33518159; BACKGROUND:35105664; BACKGROUND:29339445; BACKGROUND:34084153; BACKGROUND:22673227; BACKGROUND:33434516; BACKGROUND:34920733; BACKGROUND:31666597; BACKGROUND:34822391; BACKGROUND:36542005; BACKGROUND:32656729; BACKGROUND:29551470; BACKGROUND:32785814; BACKGROUND:27038046; BACKGROUND:33011630; BACKGROUND:31502183",null,"UNDECIDED",null],["NCT06657209","Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide",null,"RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","104","Diabetes Mellitus, Type 2; Diabetes; Type 2 Diabetes; Pre Diabetes","PROCEDURE:Insulin resistance testing; PROCEDURE:OGTT; PROCEDURE:Fat biopsy; RADIATION:DXA scan; PROCEDURE:MRI; PROCEDURE:1H-MRS; DRUG:Tirzepatide; DRUG:Pioglitazone","Stanford University","2025-01-13","2027-12-15","FALSE","Insulin resistance in normal weight women with diabetes compared to those with no diabetes [Baseline measures comparison between the groups] | Adipocyte function in women with normal weight diabetes as compared with those without diabetes [Baseline comparisons] | Fat storage in women with normal weight diabetes compared to those without diabetes [Baseline comparisons between the groups]",null,null,"NO",null],["NCT01620463","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese Volunteers",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","32","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2002-12","2003-03","FALSE","Body weight [] | Vital signs (Blood pressure) [] | Vital signs (Pulse rate) [] | ECG (ElectroCardioGram) [] | Adverse events []",null,null,null,null],["NCT01250834","LY2189265 and Atorvastatin Interaction Study",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","27","Healthy Volunteers","DRUG:Atorvastatin; BIOLOGICAL:LY2189265","Eli Lilly and Company","2010-12","2011-03","TRUE","Pharmacokinetics of Atorvastatin: Maximum Plasma Concentration (Cmax) [Pre-dose to 56 hours post-dose] | Pharmacokinetics of Atorvastatin: Area Under the Curve (AUC) [Pre-dose to 56 hours post-dose]","DERIVED:28357715",null,null,"OTHER:H9X-MC-GBCP; EUDRACT_NUMBER:2010-021657-39"],["NCT02928614","Biomarkers in Obese Patients With Knee Osteoarthritis; Weight Maintenance","BIO-LOSEIT-II","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","150","Osteoarthritis; Obesity","DRUG:Liraglutide 3 mg (Saxenda); DRUG:Liraglutide 3 mg placebo","Henrik Gudbergsen","2016-11","2019-02","FALSE","Change in collagen II degradation fragment α-C2M [Week 0 to 52]",null,null,null,null],["NCT05209165","Semaglutide to Reduce Atrial Fibrillation Burden",null,"SUSPENDED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","132","Atrial Fibrillation; Obesity; Overweight","DRUG:Semaglutide; DRUG:Placebo","San Francisco Veterans Affairs Medical Center","2023-05","2027-05","FALSE","Atrial fibrillation burden [52 weeks]",null,null,"NO",null],["NCT02962492","An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","TRIPLE","70","Evaluate Ketogenic Stress","DRUG:Exenatide/Exenatide extended release; DRUG:Dapagliflozin; DRUG:Placebo","University at Buffalo","2016-11-01","2021-02-01","TRUE","Change in Beta-hydroxybutyrate Levels in Blood [12 weeks]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/92/NCT02962492/Prot_SAP_000.pdf","NO",null],["NCT06649344","A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","884","Type 2 Diabetes","DRUG:HRS9531 Injection; DRUG:Semaglutide Injection","Fujian Shengdi Pharmaceutical Co., Ltd.","2024-10-31","2026-07-18","FALSE","Change in HbA1c [Week 0 to Week 36]",null,null,"UNDECIDED",null],["NCT07242534","Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.","SEQ","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","62","Infertility; Obesity","DRUG:Semaglutide; OTHER:No pre-treatment","Fundacion Dexeus","2026-01-19","2027-02","FALSE","Number of good quality blastocysts (GQB) [Assessed once per participant, from oocyte retrieval (Day 0) to Day 5 of embryo culture, when embryos reach blastocyst stage.]","BACKGROUND:33257906; BACKGROUND:38444070; BACKGROUND:26097395; BACKGROUND:36635080; BACKGROUND:38810863; BACKGROUND:30910544; BACKGROUND:31260047; BACKGROUND:36551163; BACKGROUND:30763543; BACKGROUND:21806596; BACKGROUND:37427372; BACKGROUND:38339186; BACKGROUND:29221938; BACKGROUND:29703793; BACKGROUND:29523133; BACKGROUND:37762856; BACKGROUND:39696822; BACKGROUND:40142784; BACKGROUND:33567185",null,"UNDECIDED","CTIS:2025-522525-34-00; NIH:2025"],["NCT03131687","A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","318","Type 2 Diabetes Mellitus","DRUG:tirzepatide; DRUG:Dulaglutide; DRUG:Placebo","Eli Lilly and Company","2017-05-24","2018-08-01","TRUE","Change From Baseline to Week 26 in Hemoglobin A1c (HbA1c) Bayesian Dose Response [Baseline, Week 26]","DERIVED:35210595; DERIVED:34608929; DERIVED:32291277; DERIVED:30293770","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/87/NCT03131687/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/87/NCT03131687/SAP_001.pdf","YES","OTHER:I8F-MC-GPGB; EUDRACT_NUMBER:2016-004179-33; NIH:2016"],["NCT02607865","Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes","PIONEER 3","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","1864","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:sitagliptin; DRUG:placebo","Novo Nordisk A/S","2016-02-15","2017-02-14","TRUE","Change in HbA1c: Week 26 [Week 0, week 26]","RESULT:30903796; RESULT:34472698; RESULT:35064550; RESULT:35373893; DERIVED:37178435; DERIVED:33660198; DERIVED:32998732; DERIVED:32267058; DERIVED:31903692","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/65/NCT02607865/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/65/NCT02607865/SAP_001.pdf","YES","EUDRACT_NUMBER:2015-001351-71; OTHER:U1111-1168-4339; OTHER:JAPIC; NIH:2015"],["NCT07575399","Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","300","Obesity or Overweight","DRUG:Maridebart Cafraglutide","Amgen","2026-05-11","2028-01-03","FALSE","Percent Change from Baseline in Body Weight at Week 68 [Week 68]",null,null,"YES",null],["NCT04969939","A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","120","Obesity","DRUG:Semaglutide 2.4 mg and NNC0165-1875 2.0 mg; DRUG:Semaglutide 2.4 mg and placebo 2.0 mg; DRUG:Semaglutide 2.4 mg and NNC0165-1875 1.0 mg; DRUG:Semaglutide 2.4 mg and placebo 1.0 mg","Novo Nordisk A/S","2021-07-15","2022-12-06","TRUE","Part 1: Number of Treatment-emergent Adverse Events (TEAEs) [Part 1: From time of dosing (day 1) to follow-up (week 24)] | Part 2b: Percentage Change in Body Weight [Part 2: Randomisation (week 32), end of treatment (week 48)]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/39/NCT04969939/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/39/NCT04969939/SAP_001.pdf","YES","OTHER:U1111-1254-9046"],["NCT03899402","Triple Therapy in T1DM",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","DOUBLE","78","Type 1 Diabetes Mellitus","DRUG:Insulin; DRUG:Semaglutide; DRUG:Dapagliflozin; DRUG:Placebo to Dapagliflozin","State University of New York at Buffalo","2019-05-01","2026-01-31","FALSE","Change in HbA1c following dapagliflozin [6 months]","DERIVED:42473259","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/02/NCT03899402/Prot_000.pdf","NO","OTHER:1987"],["NCT07059377","Semaglutide for Smoking Cessation in Patients With Diabetes","GLP1-SC","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","100","Diabetes Mellitus, Type 2; Nicotine Addiction; Tobacco Dependence","DRUG:Semaglutide; DRUG:Nicotine replacement","Ottawa Heart Institute Research Corporation","2026-02-13","2026-12","FALSE","Project success [12 months]",null,null,"NO",null],["NCT02119819","A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","420","Diabetes Mellitus, Type 2","DRUG:LY2944876; DRUG:Exenatide extended-release; DRUG:Placebo; DRUG:Metformin","OPKO Health, Inc.","2014-04","2015-08","TRUE","Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12 [Baseline, Week 12]","DERIVED:30957581",null,"YES","EUDRACT_NUMBER:2013-003552-21; OTHER:I7I-MC-XNAA"],["NCT07497399","Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis","TAG-MS","RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","120","Multiple Sclerosis","DRUG:NLY01; DRUG:Placebo","Johns Hopkins University","2026-04-28","2030-01","FALSE","Change in normalized (for head size) brain parenchymal volume (nBPV) [Baseline, week 48, and week 96]",null,null,"YES",null],["NCT02930265","Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy",null,"UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","QUADRUPLE","400","Ischemic Cardiomyopathy","DRUG:Liraglutide","Chinese PLA General Hospital","2016-09","2018-02","FALSE","main adverse cardiovascular events [Followed up for 6 months after enrolled in the study]","BACKGROUND:19552923; BACKGROUND:19195607; BACKGROUND:19151200; BACKGROUND:27295427; BACKGROUND:22544917; BACKGROUND:21920963; BACKGROUND:26849684; BACKGROUND:26573925; BACKGROUND:26542491; BACKGROUND:21586690; BACKGROUND:18819705; BACKGROUND:18931095; BACKGROUND:19289857; BACKGROUND:23835684; BACKGROUND:27038735",null,"NO",null],["NCT04944992","A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","145","Nonalcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis","DRUG:Efinopegdutide 20 mg/mL; DRUG:Semaglutide 1.34 mg/mL","Merck Sharp & Dohme LLC","2021-08-04","2022-10-19","TRUE","Mean Relative Reduction From Baseline in Liver Fat Content (LFC) Measured by Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF), Evaluated by Blinded Independent Central Review (BICR) After 24 Weeks [Baseline and up to ~24 Weeks] | Percentage of Participants Who Experienced an Adverse Event (AE) [Up to ~29 weeks] | Percentage of Participants Who Discontinued Study Intervention Due to an AE [Up to ~24 weeks]","RESULT:37355043","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/92/NCT04944992/Prot_SAP_000.pdf","YES","OTHER:MK-6024-001; EUDRACT_NUMBER:2020-005136-30"],["NCT03492697","A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","12","Healthy Subjects","DRUG:PF-06882961 Immediate Release Tablet; DRUG:PF-06882961 Controlled Release Tablet (long); DRUG:PF-06882961 Controlled Release Tablet (short); DRUG:PF-06882961 Immediate Release Solution","Pfizer","2018-04-30","2018-07-18","FALSE","Maximum Observed Plasma Concentration (Cmax) for PF-06882961 [0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 24, 28, 32, 36 and 48 hours post dose in each period] | Time to Maximum Observed Plasma Concentration (Tmax) for PF-06882961 [0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 24, 28, 32, 36 and 48 hours post dose in each period] | Area under the curve from time zero to last quantifiable concentration for PF-06882961 (AUClast) [0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 24, 28, 32, 36 and 48 hours post dose in each period] | Area under the curve from time zero to extrapolated infinite time for PF-06882961 (AUCinf), as data permit [0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 24, 28, 32, 36 and 48 hours post dose in each period] | Observed Plasma Concentration for PF-06882961 at 24 hours post-dose (C24) [24 hours post dose in each period] | Plasma Decay Half-Life (t1/2) for PF-06882961, as data permit [0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 24, 28, 32, 36 and 48 hours post dose in each period] | Apparent clearance (CL/F) for PF-06882961, as data permit [0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 24, 28, 32, 36 and 48 hours post dose in each period] | Peak-to-trough (PTR) ratio for PF-06882961 [0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 24, 28, 32, 36 and 48 hours post dose in each period]",null,null,"NO",null],["NCT07783854","A Randomized Controlled Study of Dose-tapering Regimen of Semaglutide for Weight-Loss Maintenance in Adults With Overweight or Obesity",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","72","Obesity & Overweight","DRUG:Semaglutide Dose-Tapering Regimen; DRUG:Semaglutide Maintenance-Dose Regimen","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","2026-09-01","2027-12-30","FALSE","Percentage change in body weight from baseline to week 24 [Baseline (Week 0) to Week 24]",null,null,"NO",null],["NCT00318422","Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes","LEAD-1","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","1041","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:rosiglitazone; DRUG:glimepiride","Novo Nordisk A/S","2006-05","2007-05","FALSE","HbA1c [after 26 weeks of treatment]","RESULT:19245711; RESULT:19317822; RESULT:19491535; RESULT:19491536; RESULT:19878259; RESULT:21450987; RESULT:22055210; RESULT:22193143; RESULT:21209033; RESULT:21883806; RESULT:22862847; RESULT:23010561; RESULT:23186975; RESULT:25504028; DERIVED:24561125",null,null,"EUDRACT_NUMBER:2005-003414-15; NIH:2005"],["NCT05364931","A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis","PROXYMO-ADV","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","54","Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis","DRUG:Cotadutide; DRUG:Placebo","AstraZeneca","2022-07-14","2024-04-19","TRUE","Number of Participants With Adverse Events (AEs). [First dose on Day 1 until the follow-up period, 28 days post last dose, up to approximately 52 weeks.] | Number of Participants With Abnormal Vital Signs. [First dose on Day 1 until the follow-up period, 28 days post last dose, up to approximately 52 weeks.] | Number of Participants With Abnormal Laboratory Assessments [First dose on Day 1 until the follow-up period, 28 days post last dose, up to approximately 52 weeks.] | Number of Participants With Treatment Emergent Abnormality in 12-lead Electrocardiogram (ECG). [First dose on Day 1 until the follow-up period, 28 days post last dose, up to approximately 52 weeks.] | Number of Treatment-induced Anti-Drug Antibody (ADA) Participants [First dose on Day 1 until the follow-up period, 28 days post last dose, up to approximately 52 weeks.] | Titer of Treatment-induced Anti-Drug Antibody (ADA) [From first dose on Day 1 until the follow-up period, 28 days post last dose (from randomization up to approximately 52 weeks).]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/31/NCT05364931/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/31/NCT05364931/SAP_001.pdf","YES","EUDRACT_NUMBER:2021-005484-53"],["NCT05438186","INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records","INSPIRE Turkey","WITHDRAWN","OBSERVATIONAL",null,null,null,"0","Obesity","DRUG:Liraglutide","Novo Nordisk A/S","2022-09-01","2022-09-30","FALSE","Relative change in body weight [At 52th week after treatment initiation]",null,null,"YES","OTHER:U1111-1259-8749"],["NCT01817569","Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)",null,"COMPLETED","OBSERVATIONAL",null,null,null,"2948","Type 2 Diabetes",null,"AstraZeneca","2011-02-13","2019-10-03","FALSE","Adverse event incidence. [3 years]",null,null,null,"REGISTRY:EUPAS19606"],["NCT03189953","68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH","GLP-1-AHH","COMPLETED","INTERVENTIONAL","PHASE1; PHASE2",null,"NONE","56","Insulinoma","RADIATION:68Ga-NODAGA-exendin 4 PET/CT","Radboud University Medical Center","2015-04","2021-01","FALSE","Tumor visualization by 68Ga-NODAGA-exendin-4 PET/CT and standard imaging [1 year]",null,null,null,"EUDRACT_NUMBER:2014-003167-38; OTHER_GRANT:602812; NIH:2014"],["NCT01460069","The Effect of Glucagon Like Peptide (GLP)-1 in Psoriasis",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","QUADRUPLE","20","Psoriasis","DRUG:liraglutide; DRUG:Placebo","Annesofie Faurschou","2011-10","2013-05","FALSE","PASI (psoriasis area and severity index) [Baseline and after 2 months] | DLQI (dermatology life quality index) [Baseline and after 2 months]",null,null,null,null],["NCT03374956","Individualized Obesity Pharmacotherapy",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","193","Obesity","DRUG:Phentermine-Topiramate; DRUG:Liraglutide; DRUG:Naltrexone/bupropion; DRUG:Phentermine","Mayo Clinic","2017-12-11","2022-05-26","TRUE","Change in Total Body Weight [baseline to 12 weeks]","DERIVED:33759389","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/56/NCT03374956/Prot_SAP_001.pdf","NO",null],["NCT04017832","A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes","PIONEER 12","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","1441","Diabetes Mellitus, Type 2","DRUG:Oral semaglutide; DRUG:Sitagliptin; DRUG:Placebo (oral semaglutide); DRUG:Placebo (sitagliptin)","Novo Nordisk A/S","2019-07-29","2021-10-27","TRUE","Change From Baseline to Week 26 in Glycated Haemoglobin (HbA1c) (%) [From baseline to week 26]","DERIVED:38985161","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/32/NCT04017832/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/32/NCT04017832/SAP_001.pdf","YES","OTHER:U1111-1188-1256; REGISTRY:2018-002589-38; NIH:2018"],["NCT00755287","A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","1072","Diabetes Mellitus Type 2","DRUG:insulin glargine; DRUG:metformin; DRUG:taspoglutide","Hoffmann-La Roche","2008-11","2010-12","FALSE","Absolute change from baseline in HbA1c [24 weeks]","DERIVED:22937895",null,null,"OTHER:2008-001855-23; NIH:2008"],["NCT06326047","A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","299","Diabetes Mellitus, Type 2","DRUG:NNC0519-0130; DRUG:Placebo; DRUG:Trizepatide","Novo Nordisk A/S","2024-03-18","2025-09-19","FALSE","Change in Glycated haemoglobin (HbA1c) [From baseline (week 0) to 12 weeks on a given maintenance dose]",null,null,"YES","OTHER:U1111-1291-9196; REGISTRY:jRCT2031230704"],["NCT03989232","A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes","SUSTAIN FORTE","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","961","Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2019-06-19","2020-09-18","TRUE","Change in HbA1c [Week 0, week 40]","RESULT:34293304","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/32/NCT03989232/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/32/NCT03989232/SAP_002.pdf","YES","OTHER:U1111-1224-5162; REGISTRY:2018-004529-96; NIH:2018"],["NCT04187300","A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","68","Overweight; Obesity","DRUG:Semaglutide","Novo Nordisk A/S","2019-12-16","2020-09-23","FALSE","AUC0-168h,2.4mg,SS, Area under the semaglutide concentration time curve [0-168 hours (Day 141-148) after last 2.4 mg dose] | Cmax,2.4mg,SS, Maximum observed semaglutide concentration [0-168 hours (Day 141-148) after last 2.4 mg dose]",null,null,"YES","OTHER:U1111-1236-7697; REGISTRY:2019-002909-21; NIH:2019"],["NCT06289504","A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","34","Obesity","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Atorvastatin; DRUG:Warfarin","Novo Nordisk A/S","2024-02-27","2024-10-16","FALSE","AUC0-72hours,atorv,SD: Area under the atorvastatin plasma concentration-time curve from time 0 to 72 hours after a single dose of atorvastatin without CagriSema exposure and at CagriSema steady state [Day 1 (pre-dose to 72 hours post-dose) and day 171 (pre-dose to 72 hours post-dose)] | AUC0-168hours,S-war,SD: Area under the S-warfarin plasma concentration-time curve from time 0 to 168 hours after a single dose of warfarin without CagriSema exposure and at CagriSema steady state [Day 8 (pre-dose to 168 hours post-dose) and day 178 (pre-dose to 168 hours post-dose)]",null,null,"YES","OTHER:U1111-1295-4056"],["NCT01394952","Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)","REWIND","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","9901","Cardiovascular Disease; Diabetes Mellitus, Type 2","DRUG:Dulaglutide; DRUG:Placebo","Eli Lilly and Company","2011-07-22","2018-08-21","TRUE","Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) [From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)]","DERIVED:41988866; DERIVED:39963952; DERIVED:36897834; DERIVED:36723445; DERIVED:35996147; DERIVED:35546279; DERIVED:35446415; DERIVED:35043140; DERIVED:34563178; DERIVED:34153269; DERIVED:33537745; DERIVED:33239067; DERIVED:32562683; DERIVED:31924562; DERIVED:31189511; DERIVED:31189509; DERIVED:29693361; DERIVED:28573765","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/52/NCT01394952/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/52/NCT01394952/SAP_001.pdf","YES","OTHER:H9X-MC-GBDJ"],["NCT00806520","Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control",null,"COMPLETED","OBSERVATIONAL",null,null,null,"16","Type 2 Diabetes",null,"HealthPartners Institute","2008-04","2011-08","FALSE",null,null,null,null,null],["NCT07407348","A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","80","Healthy; Obesity; Overweight","COMBINATION_PRODUCT:Formulation A; COMBINATION_PRODUCT:Formulation B6","Boehringer Ingelheim","2026-03-11","2027-01-26","FALSE","Area under the concentration-time curve of survodutide in plasma at steady state over a uniform dosing interval tau (AUC tau,ss) [Up to 239 days.] | Maximum measured concentration of survodutide in plasma at steady state over a uniform dosing interval tau (Cmax,ss) [Up to 239 days.]",null,null,"NO","REGISTRY:U1111-1323-8960"],["NCT02503943","Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","90","Type 2 Diabetes; Overweight; Obesity; Masked Hypertension","DRUG:\"Liraglutide\" and \"Mitiglinide\"; DRUG:\"Metformin\" and \"Mitiglinide\"; DRUG:\"Mitiglinide\"","Third Affiliated Hospital of Third Military Medical University","2015-05","2016-09","FALSE","Blood Pressure change [Baseline,4 weeks,8 weeks,12 weeks,16 weeks,20 weeks,up to 24 weeks] | Lipid profile (triglyceride, total cholesterol, LDL-c; HDL-c; mmol/L) change [Baseline,4 weeks,8 weeks,12 weeks,16 weeks,20 weeks,up to 24 weeks]",null,null,null,null],["NCT07313813","A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus","GBGT","COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","20","Type 2 Diabetes Mellitus (T2DM)","DRUG:Dulaglutide","Eli Lilly and Company","2025-12-29","2026-08-13","FALSE","Percentage of Fasting Participants with Lack of Gastric Content Retention Post-Solid Test Meal [Day 116 (at 6, 8, 12, 18 and 24 hours after baseline or Day 115 solid test meal)]",null,null,"NO","OTHER:H9X-MC-GBGT"],["NCT06974825","A Study of BGM0504 in Chinese Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","67","Type 2 Diabetes","DRUG:BGM0504 Administered SC; DRUG:Semaglutide Administered SC; DRUG:Placebo Administered SC","BrightGene Bio-Medical Technology Co., Ltd.","2023-08-30","2024-08-13","FALSE","Change From Baseline in Hemoglobin A1c (HbA1c) [Week 0 to Week 12]",null,null,null,null],["NCT01511159","Comparison of Liraglutide Inhaled Into the Lungs Compared to Liraglutide Injected Under the Skin in Healthy Male Volunteers",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","32","Diabetes; Healthy","DRUG:liraglutide; DRUG:placebo; DRUG:insulin human","Novo Nordisk A/S","2001-10","2001-12","FALSE","Ratio of the areas under the plasma NN 90-1170 curves []",null,null,null,null],["NCT04235959","A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","24","Diabetes Mellitus, Type 2","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2020-10-21","2021-08-17","TRUE","Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. [Baseline up to 43 Weeks]","DERIVED:37285081","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/59/NCT04235959/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/59/NCT04235959/SAP_001.pdf","NO","OTHER:I8F-MC-GPHT"],["NCT00845182","Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function","PIO-EX","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","43","Type 2 Diabetes; Healthy; Impaired Glucose Tolerance","DRUG:Pioglitazone; DRUG:Exenatide; DRUG:Pioglitazone and Exenatide","The University of Texas Health Science Center at San Antonio","2007-06","2010-07","TRUE","Effect of Pioglitazone, Exenatide and Combined Pioglitazone and Exenatide on Body Weight [baseline and 6 months] | HbA1c [baseline and 6 months]","DERIVED:27624579",null,null,null],["NCT02054897","Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes","SUSTAIN™1","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","388","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2014-02-03","2015-05-08","TRUE","Change in HbA1c (Glycosylated Haemoglobin) [Week 0, week 30]","BACKGROUND:30047216; BACKGROUND:30938762; BACKGROUND:30865526; RESULT:28110911; RESULT:29687620; RESULT:29748996; RESULT:29766634; RESULT:29862621; RESULT:29907893; RESULT:30615985; DERIVED:32998732; DERIVED:31903692; DERIVED:31769496",null,null,"EUDRACT_NUMBER:2013-000632-94; OTHER:U1111-1139-3090; REGISTRY:JapicCTI-142442"],["NCT03311724","A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","111","Type 2 Diabetes","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2017-10-19","2018-04-24","TRUE","Change From Baseline in Haemoglobin A1c (HbA1c) [Baseline, 3 Months]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/24/NCT03311724/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/24/NCT03311724/SAP_001.pdf","YES","OTHER:I8F-MC-GPGF"],["NCT00099333","Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","49","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:Insulin","AstraZeneca","2004-02","2005-08","FALSE","Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 16 [Baseline, Week 16]","DERIVED:22236356; DERIVED:17595353",null,null,null],["NCT05153564","A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","27","Diabetes Mellitus, Type 2","DRUG:Semaglutide 1.34 mg/mL; DRUG:Semaglutide 3.0 mg/mL; DRUG:NNC0480-0389 10 mg/mL; DRUG:NNC0480-0389 30 mg/mL; DRUG:Microgynon®","Novo Nordisk A/S","2021-12-13","2022-08-13","FALSE","Area under the ethinylestradiol plasma concentration time curve during a dosing interval (0 to 24 hours) at steady state (AUC0-24h,EE,SS) [From pre-dose to 24 hours after last dosing of oral contraceptive on day 8 and day 100] | Area under the levonorgestrel plasma concentration time curve during a dosing interval (0 to 24 hours) at steady state (AUC0-24h,LN,SS) [From pre-dose to 24 hours after last dosing of oral contraceptive on day 8 and day 100]",null,null,"YES","EUDRACT_NUMBER:2021-003060-27; OTHER:U1111-1266-3910"],["NCT02908087","Incretin-based Therapy in Early Diagnosed Type 1 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","13","Type 1 Diabetes","DRUG:Victoza® (liraglutide); DRUG:Placebo","University of Oulu","2016-03","2021-05","FALSE","Serum C-peptide AUC [From baseline to 26 and 52 weeks]","DERIVED:35797241",null,null,"EUDRACT_NUMBER:2014-004760-37; OTHER_GRANT:3-SRA-2014-301-M-R; OTHER:U1111-1177-0661; NIH:2014"],["NCT02905864","Liraglutide 3 mg for Knee Osteoarthritis","LOSEIT","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","150","Osteoarthritis; Obesity","DRUG:Liraglutide 3 mg (Saxenda); DRUG:Liraglutide 3 mg placebo","Henrik Gudbergsen","2016-11","2019-02","FALSE","Change in body weight [Week 0 to 52] | KOOS pain subscale [Week 0 to 52]","DERIVED:39877802; DERIVED:33471039; DERIVED:32165240; DERIVED:31061017",null,"NO",null],["NCT02243098","Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","31","Diabetes; Healthy","DRUG:semaglutide; DRUG:digoxin; DRUG:atorvastatin","Novo Nordisk A/S","2014-09-16","2015-04-07","FALSE","Area under the atorvastatin plasma concentration-time curve [From time 0 to 72 hours after a single dose] | Area under the digoxin plasma concentration-time curve [From time 0 to 120 hours after a single dose]","RESULT:28349387",null,null,"EUDRACT_NUMBER:2013-001288-22; OTHER:U1111-1140-8551"],["NCT07872033","Aleniglipron Hepatic Impairment Study",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","36","Hepatic Impairment","DRUG:Aleniglipron","Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics","2026-10","2027-08","FALSE","PK parameters including but not limited to AUC0-t [Baseline to Day 5 (Part 1)] | PK parameters including but not limited to AUC0-inf [Baseline to Day 5 (Part 1)] | PK parameters including but not limited to Cmax [Baseline to Day 5 (Part 1)] | PK parameters including but not limited to AUC0-t [Baseline to Day 5 (Part 2)] | PK parameters including but not limited to AUC0-inf [Baseline to Day 5 (Part 2)] | PK parameters including but not limited to Cmax [Baseline to Day 5 (Part 2)]",null,null,"NO",null],["NCT02527993","Treatment of Hypoglycemia Following Gastric Bypass Surgery",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","11","Hypoglycemia; Obesity; Surgery","DRUG:Glucobay (acarbose); DRUG:Januvia (sitagliptin); DRUG:Verapamil HEXAL (verapamil); DRUG:Victoza (liraglutide); DRUG:Signifor (pasireotide); DEVICE:Continuous glucose monitoring (CGM); DIETARY_SUPPLEMENT:Meal tolerance test (MTT)","Zealand University Hospital","2015-10","2017-04-08","FALSE","Changes in blood glucose (mmol/L) assessed by continuous glucose monitoring (CGM). [6 days CGM will be performed at week 1, 3, 5, 7 and 11.]","DERIVED:31907828",null,null,null],["NCT07650149","Genetic, Microbiological and Behavioral Factors in Obesity","OPTIMIZE-GEN","RECRUITING","OBSERVATIONAL",null,null,null,"200","Obesity & Overweight; Obesity; Genetics","DIAGNOSTIC_TEST:genetic polymorphism; DIAGNOSTIC_TEST:gut microbiome","Jan Kochanowski University","2026-05-23","2027-05","FALSE","weight change [1 and 6 months]",null,null,"UNDECIDED",null],["NCT03730662","A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk","SURPASS-4","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","2002","Type 2 Diabetes Mellitus","DRUG:Tirzepatide; DRUG:Insulin Glargine","Eli Lilly and Company","2018-11-20","2021-01-22","TRUE","Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) [Baseline, Week 52]","DERIVED:39531161; DERIVED:37668888; DERIVED:37526908; DERIVED:36152639; DERIVED:35210595; DERIVED:34672967","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/62/NCT03730662/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/62/NCT03730662/SAP_001.pdf","YES","OTHER:I8F-MC-GPGM; EUDRACT_NUMBER:2018-002618-11; NIH:2018"],["NCT07046273","Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","496","Type 2 Diabetes (T2DM)","DRUG:F027; DRUG:Ozempic®","Shandong New Time Pharmaceutical Co., LTD","2025-08-01","2028-08-01","FALSE","Change in HbA1c from baseline [Week 32]",null,null,"UNDECIDED",null],["NCT06811324","Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults",null,"RECRUITING","INTERVENTIONAL","PHASE2",null,"NONE","20","Obesity Prevention; Sarcopenia in Elderly; Cardiovascular Function; GLP - 1; Weight Loss","DRUG:Tirzepatide","The University of Texas Health Science Center at San Antonio","2026-04-01","2027-04-01","FALSE","Appendicular lean muscle mass [6 months] | Muscle Strength [6 months] | Lower Extremity Functional Capacity [6 months]","BACKGROUND:36508493; BACKGROUND:24764133; BACKGROUND:34562568; BACKGROUND:30048806; BACKGROUND:37840095; BACKGROUND:38829659; BACKGROUND:34170647; BACKGROUND:35949358; BACKGROUND:38271277; BACKGROUND:39265590; BACKGROUND:38937282; BACKGROUND:30427277; BACKGROUND:35977298",null,"YES",null],["NCT06588296","Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight","TOGETHER-PsA","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","279","Psoriatic Arthritis; Obesity","DRUG:Ixekizumab; DRUG:Tirzepatide","Eli Lilly and Company","2024-09-24","2025-11-18","FALSE","Percentage of Participants Who Simultaneously Achieved American College of Rheumatology (ACR) ACR50 and at Least a 10% Weight Reduction [Baseline up to Week 36]","DERIVED:41903163",null,"YES","OTHER:I1F-MC-RHDB"],["NCT01845259","Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?","GREAT","UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","103","Impaired Glucose Tolerance Associated With Drugs","DRUG:Liraglutide; DRUG:Liraglutide Placebo","Psychiatric Centre Rigshospitalet","2013-04","2016-03","FALSE","Glucose tolerance [Baseline - 16 weeks]","DERIVED:28601891; DERIVED:25023888; DERIVED:24667381",null,null,"EUDRACT_NUMBER:2013-000121-31; REGISTRY:U1111-1128-3404"],["NCT04657003","A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight","SURMOUNT-2","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","938","Type 2 Diabetes; Overweight; Obesity","DRUG:Tirzepatide; OTHER:Placebo","Eli Lilly and Company","2021-03-29","2023-03-16","TRUE","Percent Change From Baseline in Body Weight [Baseline, Week 72] | Percentage of Participants Who Achieve ≥5% Body Weight Reduction From Baseline [Week 72]","DERIVED:42348366; DERIVED:41537305; DERIVED:40512543; DERIVED:40120035; DERIVED:37385275","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/03/NCT04657003/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/03/NCT04657003/SAP_001.pdf","YES","OTHER:I8F-MC-GPHL"],["NCT06324461","GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery","GLUMINS","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","372","Myocardial Injury","DRUG:Dulaglutide 0.75mg subcutaneous injection","The University of Hong Kong","2024-03-20","2028-12-31","FALSE","Proportion of patients with MINS [Within 72 hours after surgery]",null,null,"UNDECIDED",null],["NCT05810597","A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","65","Healthy","DRUG:Tirzepatide; DEVICE:Single Dose Pen; DEVICE:Multi-use Prefilled Pen","Eli Lilly and Company","2023-04-03","2023-07-17","TRUE","Pharmacokinetics (PK): Maximum Concentration (Cmax) of Tirzepatide [Predose, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 336, and 480 hours post Day 1 dose and on Day 36 of each study period.] | PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Time t, Where t is the Last Time Point With a Measurable Concentration (AUC[0-t]) of Tirzepatide [Predose, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 336, and 480 hours post Day 1 dose and on Day 36 of each study period.] | PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Tirzepatide [Predose, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 336, and 480 hours post Day 1 dose and on Day 36 of each study period.]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/97/NCT05810597/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/97/NCT05810597/SAP_001.pdf","NO","OTHER:I8F-MC-GPIP"],["NCT00811460","A Study of Taspoglutide in Type 2 Diabetic Patients",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","18","Diabetes Mellitus Type 2","DRUG:Placebo; DRUG:taspoglutide","Hoffmann-La Roche","2008-11","2009-08","FALSE","Incremental area under insulin concentration time curve relative to basal insulin concentration [First 10 minutes after glucose bolus]",null,null,null,"OTHER:2008-003582-97; NIH:2008"],["NCT01037582","A Two Part Trial Investigating the Safety of NN9924 in Healthy Male Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","155","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:NN9924 (oral); DRUG:placebo; DRUG:NN9924 (s.c.); DRUG:NN9924 (i.v.)","Novo Nordisk A/S","2009-12-17","2010-05-07","FALSE","Number and severity of adverse events (AEs) recorded [from dosing to Day 22]","DERIVED:30565096",null,null,"EUDRACT_NUMBER:2009-012366-31; OTHER:U1111-1112-7564; NIH:2009"],["NCT03555994","A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","51","Type 2 Diabetes Mellitus","DRUG:MEDI0382; DRUG:Placebo; DRUG:Liraglutide","MedImmune LLC","2018-05-31","2021-04-14","TRUE","Change in Hepatic Glycogen Concentration Adjusted for Liver Volume as Measured by MRS at T = 4 Hours Post Standardised Morning Meal From Baseline (Day -1) to the End of 28 Days of Treatment (Part A Only) [Day -1 to Day 28] | Percentage Change in Fasting Hepatic Glycogen Concentration Adjusted for Liver Volume as Measured by MRS at T = 24 Hours Post Standardised Morning Meal From Baseline (Day -1) to the End of 35 Days of Treatment (Day 36) (Part B) [Day -1 to Day 36]","DERIVED:38066113","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/94/NCT03555994/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/94/NCT03555994/SAP_001.pdf","YES","EUDRACT_NUMBER:2017-005081-22; NIH:2017"],["NCT06003153","GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH","GLUCOSE-MGH","RECRUITING","INTERVENTIONAL","PHASE4",null,"NONE","125","Genetic Predisposition; Metabolic Diseases; Type 2 Diabetes","DRUG:oral semaglutide; OTHER:Mixed Meal Tolerance Test (MMTT)","Massachusetts General Hospital","2024-03-12","2027-05-31","FALSE","Insulin response to oral semaglutide treatment [15 days]",null,null,null,"NIH:K23DK131345"],["NCT01455441","The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","40","Type 2 Diabetes","OTHER:Training and liraglutide; OTHER:Training and placebo","Tina Vilsboll","2011-10","2013-06","FALSE","HbA1c [16 weeks]",null,null,null,null],["NCT02664441","Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity","ECHO","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","42","Hypothalamic Obesity","DRUG:Exenatide; DRUG:placebo","Seattle Children's Hospital","2016-03","2020-03-16","TRUE","Percent Change of Body Mass Index (BMI) as Calculated by the Formula: Body Weight in kg Divided by Height in Meters². [From baseline to 36 weeks]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/41/NCT02664441/Prot_SAP_000.pdf","NO",null],["NCT01670994","QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma",null,"TERMINATED","INTERVENTIONAL","PHASE1; PHASE2","NON_RANDOMIZED","NONE","6","Relapsed or Refractory Multiple Myeloma","BIOLOGICAL:ALT-801","Altor BioScience","2012-08-14","2015-09-09","TRUE","Number of Participants With Treatment-Related Adverse Events [7 weeks]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/94/NCT01670994/Prot_SAP_000.pdf","NO",null],["NCT02308254","Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy People","Lixi","UNKNOWN","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","DOUBLE","30","Diabetes Mellitus; Gastroparesis","DRUG:Lixisenatide; DRUG:Placebo","Royal Adelaide Hospital","2013-11","2016-04","FALSE","Blood Pressure [4.5 hours per study]","BACKGROUND:10764704; BACKGROUND:15695321; BACKGROUND:9374685; BACKGROUND:16492694; BACKGROUND:11841992; BACKGROUND:16407380; BACKGROUND:23423907; BACKGROUND:23627775; BACKGROUND:22432104; BACKGROUND:15983224; BACKGROUND:21391833; BACKGROUND:7825766; BACKGROUND:11904109; BACKGROUND:22129616; BACKGROUND:9505868; BACKGROUND:11956353; BACKGROUND:1937669; BACKGROUND:9831697; BACKGROUND:8952007; BACKGROUND:19801363; BACKGROUND:16271921; BACKGROUND:22738299; BACKGROUND:1244564; BACKGROUND:11207870; BACKGROUND:19553500; BACKGROUND:18175750; BACKGROUND:9491357; BACKGROUND:3049214; BACKGROUND:8672740; BACKGROUND:9652470; BACKGROUND:1518974; DERIVED:35460043",null,null,null],["NCT01917656","Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes","LIRA-Ramadan™","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","343","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:metformin; DRUG:sulphonylurea","Novo Nordisk A/S","2014-01-09","2014-09-01","TRUE","Change in Fructosamine From Start of Ramadan to End of Ramadan [Day -1, day 29]","RESULT:27376711; DERIVED:37435938",null,null,"OTHER:U1111-1132-9716"],["NCT03668470","Dulaglutide and Insulin MicrosecretiON in Type 1 Diabetes","DIAMOND GLP1","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","45","Adult Subjects With Type1Diabetes and Insulin Microsecretion","DRUG:Dulaglutide; DRUG:Placebo","Hospices Civils de Lyon","2019-01-31","2021-02-03","FALSE","HbA1c level [after 24 weeks of treatment]",null,null,"UNDECIDED",null],["NCT04683237","Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia",null,"WITHDRAWN","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","NONE","0","Atypical Endometrial Hyperplasia; Obese; Fertility Issues","DRUG:Liraglutide Injection; DRUG:Megestrol Acetate 160 MG","Xiaojun Chen","2021-03-20","2025-11-30","FALSE","Pathological complete response (CR) rates [From date of randomization until the date of CR, assessed up to 28 weeks.]",null,null,"NO",null],["NCT06564441","A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","34","Overweight; Obesity","COMBINATION_PRODUCT:Survodutide; DRUG:Bupropion; DRUG:Caffeine; DRUG:Midazolam","Boehringer Ingelheim","2024-10-01","2025-12-16","FALSE","Area under the concentration-time curve of bupropion in plasma over the time interval from 0 extrapolated to infinity (AUC 0-∞) [Up to week 32] | Area under the concentration-time curve of the caffeine in plasma over the time interval from 0 extrapolated to infinity (AUC 0-∞) [Up to week 32] | Area under the concentration-time curve of midazolam in plasma over the time interval from 0 extrapolated to infinity (AUC 0-∞) [Up to week 32] | Maximum measured concentration of bupropion in plasma (Cmax) [Up to week 32] | Maximum measured concentration of caffeine in plasma (Cmax) [Up to week 32] | Maximum measured concentration of midazolam in plasma (Cmax) [Up to week 32]",null,null,"NO","REGISTRY:2024-512332-29-00; REGISTRY:U1111-1307-0132"],["NCT03611322","A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","54","Diabetes Mellitus, Type 2","DRUG:Semaglutide, 0.25 mg; DRUG:Semaglutide, 0.5 mg; DRUG:Semaglutide, 1.0 mg; DEVICE:DV3372; DEVICE:PDS290 pen-injector","Novo Nordisk A/S","2018-08-08","2019-01-07","FALSE","AUC0-last,sema,Week5: the area under the plasma semaglutide concentration-time curve from 0 until last quantifiable measurement after first maintenance dose of subcutaneous semaglutide 1 mg administration following a four week escalation period [0-840 hours (5 weeks)] | Cmax,sema,Week5: the maximum plasma semaglutide concentration after first maintenance dose of subcutaneous semaglutide 1 mg administration following a four week escalation period [0-840 hours (5 weeks)]",null,null,"YES","OTHER:U1111-1206-9372; REGISTRY:2017-005127-25; NIH:2017"],["NCT07695454","Imaging in Semaglutide Study",null,"RECRUITING","OBSERVATIONAL",null,null,null,"10","Type 2 Diabetes; BMI Greater Than 30","RADIATION:31P-MRS and MRI","The Cleveland Clinic","2026-07-30","2026-12-30","FALSE","Effects of semaglutide therapy on patients muscle mitochondrial function as quantified using phosphorous MR spectroscopy. [6 months] | Effects of semaglutide therapy on patients muscle fatty infiltration measured by MR relaxation time (T1, T2 and T1rho) mapping. [6 months] | Effects of semaglutide therapy on patients measured by hand grip. [6 months] | Effects of semaglutide therapy on patients measured by MRI. [6 months] | Effects of semaglutide therapy on patients muscle composition measured by MR relaxation time (T1, T2 and T1rho) mapping. [6 months] | Effects of semaglutide therapy on patients muscle composition measured by MR water-fat imaging. [6 months] | Effects of semaglutide therapy on patients muscle fatty infiltration measured by MR water-fat imaging. [6 months] | Effects of semaglutide therapy on patients muscle fatty infiltration measured by MR relaxation time (T1, T2 and T1rho) mapping [6 months]",null,null,"NO",null],["NCT00707031","GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","GETGOAL-X","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","639","Diabetes Mellitus, Type 2","DRUG:Lixisenatide (AVE0010); DEVICE:Pen auto-injector; DRUG:Exenatide; DEVICE:Prefilled pen injector; DRUG:Metformin","Sanofi","2008-06","2010-11","TRUE","Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 [Baseline, Week 24]","RESULT:23698396; DERIVED:39963952",null,null,"EUDRACT_NUMBER:2007-005883-28"],["NCT06507475","Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes","REALISED","COMPLETED","OBSERVATIONAL",null,null,null,"209","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2024-09-07","2024-12-20","FALSE","Change in Glycated Haemoglobin (HbA1c) [Baseline (week 0), end of study (week 26)]",null,null,"YES","OTHER:U1111-1294-2999"],["NCT06246175","A Study of HRS9531 in Participants With Impaired Kidney Function and Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","32","Type 2 Diabetes","DRUG:HRS9531","Fujian Shengdi Pharmaceutical Co., Ltd.","2024-02-28","2025-09-02","FALSE","Area Under the Concentration Versus Time Curve (AUC) of HRS9531 From Time Zero to T(last) (AUC0-t) [Start of Treatment up to Day 29] | Maximum Concentration of HRS9531 (Cmax) [Start of Treatment up to Day 29] | Area Under the Concentration Versus Time Curve (AUC) of HRS9531 From Time Zero to Infinity (AUC0-inf) [Start of Treatment up to Day 29]",null,null,"UNDECIDED",null],["NCT07226765","Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy","MARITIME-OSA-2","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","250","Obstructive Sleep Apnea","DRUG:Maridebart cafraglutide; DRUG:Placebo","Amgen","2025-11-25","2027-08-30","FALSE","Change in Apnea-hypopnea Index (AHI) from baseline at Week 52 [At Week 52]",null,null,"YES",null],["NCT03994549","A Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570",null,"COMPLETED","INTERVENTIONAL","EARLY_PHASE1","RANDOMIZED","TRIPLE","64","Healthy","DRUG:Dual GLP-1/GLP-2 Receptor agonists","Zealand Pharma","2019-06-14","2020-11-02","FALSE","Safety - Incidence of adverse events (AEs) [From time zero to 28 days after dosing]",null,null,"NO","EUDRACT_NUMBER:2019-001128-36; NIH:2019"],["NCT07850050","SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","600","Obesity","COMBINATION_PRODUCT:Survodutide; COMBINATION_PRODUCT:Placebo","Boehringer Ingelheim","2026-10-31","2028-07-26","FALSE","Percentage change in body weight from baseline to Week 52 [At baseline and Week 52]",null,null,"YES","REGISTRY:U1111-1338-2684; REGISTRY:2026-527092-29-00"],["NCT02749890","Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan","LIXILAN JP-O1","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","321","Type 2 Diabetes Mellitus","DRUG:Insulin glargine/Lixisenatide (HOE901/AVE0010); DRUG:Lixisenatide (AVE0010); DRUG:Oral anti-diabetic drugs","Sanofi","2016-05-09","2018-05","FALSE","Change from baseline in HbA1c [Baseline, 26 weeks]","RESULT:32295808",null,null,"OTHER:U1111-1176-8357"],["NCT05582096","A Study of LY3457263 in Obese Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","38","Overweight; Obesity","DRUG:LY3457263; DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2022-11-11","2023-06-08","FALSE","Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline up to 11 weeks]",null,null,"NO","OTHER:J1R-MC-GZFC"],["NCT04008290","The Effect of Liraglutide on the GIT","LIRHV","UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","15","Obesity","DRUG:0.6 mg Liraglutide; DRUG:Placebo","Universitaire Ziekenhuizen KU Leuven","2020-04-01","2021-04-01","FALSE","MMC activity compared between placebo and treatment with liraglutide [The catheter will be placed 1 hour before the subcutaneous administration. Antroduodenal contractility will be measured for 5 hours after liraglutide or placebo injection.]",null,null,null,null],["NCT04200625","Semaglutide vs Dulaglutide on Epicardial Adipose Tissue",null,"COMPLETED","OBSERVATIONAL",null,null,null,"80","Epicardial Fat",null,"University of Miami","2019-09-24","2019-12-09","FALSE","Epicardial Fat thickness [12 weeks]",null,null,"NO",null],["NCT06085482","A Phase I Study of LY3502970 in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","10","Healthy","DRUG:LY3502970; DRUG:[14C]-LY3502970","Eli Lilly and Company","2023-10-19","2024-01-05","TRUE","Pharmacokinetics (PK): Absolute Bioavailability of LY3502970 [Pre-oral dose, 0.5, 1, 2, 4, 6, 6.5, 7, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120 hours post-oral dose; 0 (immediately after IV dosing), 2, 5, 10, 15 minutes and 0.5, 1, 2, 4, 6, 10, 18, 30, 42, 66, 90, 114, 138, 162, 186 hours post-IV dose.]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/82/NCT06085482/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/82/NCT06085482/SAP_001.pdf","NO","OTHER:J2A-MC-GZGO"],["NCT00359879","Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","377","Type 2 Diabetes","DRUG:exenatide","AstraZeneca","2006-09","2007-07","FALSE","Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 12 [Baseline, Week 12]","DERIVED:18662495",null,null,null],["NCT01357889","Pharmacokinetics/Pharmacodynamics of Albiglutide",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","283","Diabetes Mellitus, Type 2","BIOLOGICAL:albiglutide (GSK716155)","GlaxoSmithKline","2011-07","2012-10","TRUE","Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to Infinity (0-inf) of Albiglutide in the Bioequivalence (BE) Phase [Pre-dose at Baseline; 24 hours (hr), 48 hr, 96 hr, 216 hr, 312 hr, 480 hr, and 672 hr post-dose] | Maximum Observed Plasma Concentration (Cmax) of Albiglutide in the BE Phase [Pre-dose at Baseline; 24 hr, 48 hr, 96 hr, 216 hr, 312 hr, 480 hr, and 672 hr post-dose]","DERIVED:25387217",null,"YES",null],["NCT02548585","A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","QUADRUPLE","113","Type 2 Diabetes Mellitus","DRUG:MEDI0382; DRUG:Placebo","MedImmune LLC","2015-12-09","2017-02-24","TRUE","Percent Change From Baseline in Mixed-meal Test (MMT) Glucose Area Under the Concentration-time Curve From Time 0 to 4 Hours to the End of Treatment (EOT) (Cohort 4) [0 minutes before; and 15, 30, 45, 60, 90, 120, 180, and 240 minutes post standardized meal intake (SMI) on Baseline (Day -1) and EOT (Day 41)] | Change From Baseline in Body Weight to the EOT (Cohort 4) [Baseline (Day 1) and EOT (Day 42)]","DERIVED:38403793; DERIVED:29945727","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/85/NCT02548585/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/85/NCT02548585/SAP_001.pdf",null,null],["NCT07297589","Epicardial Cardiac Fat-CT (EPIC-CT)","EPIC-CT","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","SINGLE","136","STEMI - ST Elevation Myocardial Infarction; Epicardial Fat","DRUG:Dapagliflozin 10 MG Oral Tablet; DRUG:Semaglutide (Rybelsus®)","Instituto Mexicano del Seguro Social","2025-12-30","2027-01","FALSE","Epicardial fat [12 months]",null,null,null,null],["NCT07587710","A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in People With Reduced Liver Function and Normal Liver Function",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","35","Overweight; Obesity","DRUG:NNC0487-0111","Novo Nordisk A/S","2026-05-13","2027-12-01","FALSE","AUC0-∞: The area under the NNC0487-0111 plasma concentration-time curve from time 0 to infinity after a single dose [From pre-dose on Day 1 up to Day 28]",null,null,"YES","OTHER:U1111-1320-4875; OTHER:2025-521647-20; NIH:2025"],["NCT02014259","Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","71","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:semaglutide","Novo Nordisk A/S","2013-12-11","2014-10-24","FALSE","Area under the semaglutide plasma concentration time curve [From time 0 to 24 hours after the 10th dosing]","RESULT:29623579",null,null,"EUDRACT_NUMBER:2013-000682-36; OTHER:U1111-1139-4281"],["NCT00839527","A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","685","Diabetes Mellitus, Type 2","DRUG:placebo to match albiglutide; BIOLOGICAL:albiglutide; DRUG:metformin; DRUG:glimepiride; DRUG:pioglitazone; DRUG:placebo to match pioglitazone","GlaxoSmithKline","2009-02","2012-01","TRUE","Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52 [Baseline and Week 52]","DERIVED:28683300; DERIVED:25387217; DERIVED:24918790",null,"YES",null],["NCT05751720","Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue",null,"UNKNOWN","INTERVENTIONAL","PHASE1; PHASE2",null,"NONE","30","Non-Alcoholic Fatty Liver Disease; Non-alcoholic Steatohepatitis; Type 2 Diabetes; Liver Fat","DRUG:GIP/GLP-1a","Dr Adnan Agha","2023-10-01","2024-10","FALSE","change in liver stiffness in terms of kPa [12 months] | Change in Liver fat quantification [12 months]","BACKGROUND:26677985; BACKGROUND:27017224",null,"UNDECIDED",null],["NCT07417618","INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)","INTERCEPT","COMPLETED","OBSERVATIONAL",null,null,null,"60000","Type 2 Diabetes; Overweight; ASCVD","DRUG:Dulaglutide; DRUG:Semaglutide; DRUG:Tirzepatide; DRUG:Sitagliptin","Brigham and Women's Hospital","2026-01-27","2026-06-19","FALSE","Composite of myocardial infarction, stroke, or all-cause mortality (with ASCVD) [Through study completion until first of outcome, disenrollment, end of study period, 365 days after cohort entry, discontinuation (45 days grace and risk window), switch between study arms, nursing home admission, or start of any other GLP-1-RA or DPP4i] | Composite of myocardial infarction, or stroke (with ASCVD) [Through study completion until first of outcome, disenrollment, end of study period, 365 days after cohort entry, discontinuation (45 days grace and risk window), switch between study arms, nursing home admission, or start of any other GLP-1-RA or DPP4i] | Composite of myocardial infarction, stroke, or all-cause mortality (without ASCVD) [Through study completion until first of outcome, disenrollment, end of study period, 365 days after cohort entry, discontinuation (45 days grace and risk window), switch between study arms, nursing home admission, or start of any other GLP-1-RA or DPP4i] | Composite of myocardial infarction, or stroke (without ASCVD) [Through study completion until first of outcome, disenrollment, end of study period, 365 days after cohort entry, discontinuation (45 days grace and risk window), switch between study arms, nursing home admission, or start of any other GLP-1-RA or DPP4i]",null,"Study Protocol and Statistical Analysis Plan: Study Protocol|https://cdn.clinicaltrials.gov/large-docs/18/NCT07417618/Prot_SAP_000.pdf; Study Protocol: Study Protocol Amendment|https://cdn.clinicaltrials.gov/large-docs/18/NCT07417618/Prot_001.pdf",null,null],["NCT06616961","Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3",null,"NONE","480","Obesity; Type 2 Diabetes Mellitus (T2DM)","DRUG:Semaglutide Pen","Popular Medical College Hospital","2024-11-01","2025-02","FALSE","Body Weight (kg) [26 weeks]",null,null,"NO",null],["NCT07249554","Combination Therapy for Alcohol Use Disorder",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","45","Alcohol Use Disorder","DRUG:Placebo; DRUG:Glucagon-Like Peptide-1 Agonist (GLP-1); DRUG:Naltrexone (oral tablets)","Johns Hopkins University","2026-11","2028-07","FALSE","Participant-reported Adverse Events [14 days]",null,null,"NO",null],["NCT00679042","Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3",null,"NONE","21","Type 1 Diabetes Mellitus","BIOLOGICAL:Islets of Langerhans transplantation","CellTrans Inc.","2007-09-05","2017-07-19","TRUE","Treatment Emergent Adverse Events [From first islet transplant through one year after last transplant (maximum 3 infusions possible), an average of 1 year] | Number of Subjects Reaching the Efficacy Goal [One year after islet transplant]","DERIVED:39735417; DERIVED:29779835","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/42/NCT00679042/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/42/NCT00679042/SAP_001.pdf","NO",null],["NCT01916174","A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","50","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:insulin degludec/liraglutide","Novo Nordisk A/S","2013-08","2013-11","FALSE","Area under the serum IDeg concentration time curve after single dose [Assessed from 0 to 120 hours] | Maximum observed serum IDeg concentration after single dose [Assessed from 0-120 hours] | Area under the plasma liraglutide concentration time curve after single dose [Assessed from 0-72 hours] | Maximum observed plasma liraglutide concentration after single dose [Assessed from 0-72 hours]",null,null,null,"EUDRACT_NUMBER:2012-005468-93; OTHER:U1111-1137-3809"],["NCT01181986","The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","76","Type 2 Diabetes Mellitus","DRUG:Exenatide SC; DRUG:Exenatide IV; DRUG:Placebo SC; DRUG:Exendin-9; DRUG:Placebo IV","Carl T. Hayden VA Medical Center","2010-08","2012-12","TRUE","Reactive Hyperemia Index (RHI) [0, 2, 4, 6 and 8 hours on Day 11 (Sub-study 1); 0 and 120 minutes on test Days 1, 2 & 3 (Sub-study 2)]",null,null,null,null],["NCT02783196","Effect of Liraglutide on Clock Genes","LIR-CG","UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","TRIPLE","14","Type 2 Diabetes","DRUG:Liraglutide; DRUG:Placebo","Tel Aviv University","2016-07","2016-12","FALSE","Clock Gene expression [Up to 95 days]",null,null,"NO",null],["NCT06555146","Semaglutide's Effect on Renal Hemodynamics and Function in Patients With Type 2 Diabetes Mellitus and Nephropathy","Sema-RMA","UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","15","Diabetes Mellitus, Type 2; Kidney Disease, Chronic","DRUG:Semaglutide, 0.5 mg/mL; DRUG:Placebo, Saline","Bispebjerg Hospital","2024-08","2025-03","FALSE","Total blood flow [Measured during 30 minutes of MRI. One measurement will be done on each study day, a total of 4 measurements for each participant, over the span of the study (approximately 1 year).] | Regional renal perfusion [Measured during 30 minutes of MRI. One measurement will be done on each study day, a total of 4 measurements for each participant, over the span of the study (approximately 1 year)]","DERIVED:39963952",null,null,null],["NCT02229383","Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","464","Diabetes Mellitus","DRUG:Exenatide; DRUG:Exenatide matching placebo","AstraZeneca","2014-09-06","2016-08-29","TRUE","Change in HbA1c From Baseline to Week 28 [Baseline to Week 28]","DERIVED:32306296; DERIVED:29473704",null,null,"EUDRACT_NUMBER:2014-003502-33; NIH:2014"],["NCT05144984","A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","500","Diabetes Mellitus, Type 2","DRUG:NNC0480-0389; DRUG:Semaglutide; DRUG:Placebo (NNC080-0389); DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2021-11-29","2023-02-13","TRUE","Change From Baseline in Glycosylated Haemoglobin (HbA1c) [Baseline (week 0), (week 34)]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/84/NCT05144984/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/84/NCT05144984/SAP_001.pdf","YES","OTHER:U1111-1259-2741; EUDRACT_NUMBER:2020-004863-14; OTHER:jRCT2031210474"],["NCT06619015","Tailoring Obesity Treatment Trial","TOTT","WITHDRAWN","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","TRIPLE","0","Obesity; Appetite Regulation; PreDiabetes","DRUG:Pramlintide Acetate 1 MG/ML; DRUG:Semaglutide Pen Injector; DRUG:Sodium Chloride 0.9% Inj","Esbjerg Hospital - University Hospital of Southern Denmark","2025-04-01","2025-04-01","FALSE","Change in kilocalorie (kCal) consumption at ad libitum meal test, from baseline, to after 26 weeks of semaglutide of which the last two weeks is with the addition of either pramlintide or placebo [From baseline at the start of the study(week 0), to the end of the study after 26 weeks]",null,null,null,"CTIS:2024-510802-10-00"],["NCT06987513","RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","100","Alcohol Use Disorder (AUD)","DRUG:Pemvidutide; OTHER:Placebo","Altimmune, Inc.","2025-05-15","2026-07-30","FALSE","Change from baseline in the average number of heavy drinking days per week [Baseline to Weeks 21-24]",null,null,"YES",null],["NCT03550378","A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well Tolerated",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","41","Type II Diabetes Mellitus; Renal Insufficiency","DRUG:MEDI0382; DRUG:Placebo","MedImmune LLC","2018-06-29","2019-02-04","TRUE","Percent Change From Baseline in Plasma Glucose Area Under the Concentration Time-curve From Time 0 to 4 Hours (AUC0-4 Hrs) as Measured by Mixed-meal Tolerance Test (MMTT) to Day 32 [Zero minutes before and 15, 30, 45, 60, 90, 120, 180, and 240 minutes after consumption of the standardised meal on Day -5 (Baseline) and Day 32]","DERIVED:39963952; DERIVED:35403793","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/78/NCT03550378/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/78/NCT03550378/SAP_001.pdf","YES","EUDRACT_NUMBER:2018-000019-26; NIH:2018"],["NCT04016974","A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","32","Healthy Volunteers; Diabetes Mellitus, Type 2","DRUG:Oral semaglutide; DRUG:Placebo","Novo Nordisk A/S","2019-10-08","2021-01-23","FALSE","AUC0-24h,sema,SS, area under the semaglutide concentration-time curve during a dosing interval (0-24 hours) at steady state [After the last dose of oral semaglutide at dose levels of 3 mg on day 28 and 7 mg on day 56, and after the last 3 daily doses of oral semaglutide at dose level 14 mg on day 82, 83 and 84]","RESULT:38808476",null,"YES","OTHER:U1111-1186-6753"],["NCT05537233","ADJUnct Semaglutide Treatment in Type 1 Diabetes","ADJUST-T1D","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","115","Type 1 Diabetes; Obesity","DRUG:Semaglutide; DRUG:Placebo","Viral N. Shah","2023-04-11","2024-08-06","TRUE","Proportion of Adults With T1D Achieving Composite Outcome (CGM-measured Time in Range (TIR)>70% With Time Below Range (TBR) of <4% and Reduction in Body Weight by 5%) at 26 Weeks in the Semaglutide Group Compared to Placebo Group [26 weeks]","DERIVED:40550013","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/33/NCT05537233/Prot_SAP_001.pdf","NO",null],["NCT01800968","Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)","FIGHT","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","300","Acute Heart Failure","DRUG:Liraglutide; DRUG:Placebo","Duke University","2013-04","2015-10","TRUE","Global Ranking of Predefined Events [Randomization to 180 days]","DERIVED:35654972; DERIVED:32362166; DERIVED:30120812; DERIVED:27483064",null,null,"NIH:5U10HL084904-09"],["NCT07241390","A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","7140","Atherosclerosis Cardiovascular Disease; Chronic Kidney Disease","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2025-12-01","2031-08","FALSE","Time to First Occurrence of Composite Endpoint of Major Cardiovascular Events [Baseline up to end of study (about 5 years)]",null,null,"YES","OTHER:J2A-MC-GZPW; CTIS:2025-523123-22-00; NIH:2025"],["NCT06363487","Semaglutide and Cognition in Healthy Volunteers","OxSENSE","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","TRIPLE","70","Cognitive Change","DRUG:Semaglutide, 0.5 mg/mL; OTHER:Placebo, 0.9% NaCl 1.5mL","University of Oxford","2024-06-06","2024-12-11","FALSE","Reward (learning) [6-7 days] | Reward (effort-based) [6-7 days] | Reward (primary) [6-7 days]","BACKGROUND:31855395; BACKGROUND:34003475; BACKGROUND:28386912; BACKGROUND:31153593; BACKGROUND:27721184; BACKGROUND:26137918; BACKGROUND:15229059; BACKGROUND:28153641; BACKGROUND:31938879; BACKGROUND:30695707; BACKGROUND:16929307; BACKGROUND:24747776; BACKGROUND:3676376; BACKGROUND:19755572; BACKGROUND:13539317; BACKGROUND:37330165",null,"UNDECIDED",null],["NCT06267092","A Study of How CagriSema Works on Appetite in People With Excess Body Weight",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","164","Overweight; Obesity","OTHER:No treatment given; DRUG:Cagrilintide and Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2024-02-15","2025-04-07","FALSE","Change in mean postprandial appetite score based on visual analogue scale (VAS) [Baseline to week 24]",null,null,"YES",null],["NCT07819227","Optimizing Albuminuria Treatment in CKD With Finerenone and Semaglutide","FINESSE-CKD","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","41","Chronic Kidney Disease","DRUG:Finerenone (BAY 94-8862); DRUG:Semaglutide 14 MG [Rybelsus]; DRUG:Finerenone and Semaglutide","University Medical Center Groningen","2025-02-11","2026-08-31","FALSE","Proportion of patients with ≥30% reduction in urinary albumin:creatinine ratio (UACR) from baseline during monotherapy with finerenone or semaglutide or combined treatment with finerenone-semaglutide. [From baseline to the end of study (Week 37)]",null,null,"NO","CTIS:2023-506434-69-00; NIH:2023"],["NCT01542242","Liraglutide Use in Prader-Willi Syndrome",null,"TERMINATED","INTERVENTIONAL","PHASE4",null,"NONE","1","Diabetes Mellitus Type 2; Prader Willi Syndrome","DRUG:Liraglutide","Vancouver General Hospital","2012-02","2013-03","FALSE","Hemoglobin A1C [Change from baseline in A1C at 12 months]","BACKGROUND:21388446; BACKGROUND:21632815",null,null,null],["NCT00975286","24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine","GetGoal-Duo1","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","446","Type 2 Diabetes Mellitus","DRUG:Lixisenatide (AVE0010); DRUG:Placebo; DRUG:Insulin glargine; DEVICE:Pen auto-injector; DRUG:Metformin; DRUG:Thiazolidinedione (TZD)","Sanofi","2009-10","2011-08","TRUE","Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 [Baseline, Week 24]","RESULT:23564915; DERIVED:36809495; DERIVED:31956422; DERIVED:29974618; DERIVED:25130920; DERIVED:23628617",null,null,"OTHER:EudraCT : 2008-007335-40"],["NCT06836037","A Clinical Study of Efinopegdutide (MK-6024) in Healthy Chinese Volunteers (MK-6024-011)",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","56","Healthy","DRUG:Efinopegdutide; DRUG:Placebo","Merck Sharp & Dohme LLC","2022-09-05","2023-02-02","FALSE","Number of Participants Who Experience an Adverse Event (AE) [Up to approximately 112 days] | Number of Participants Who Discontinue Study Treatment Due to an AE [Up to approximately 78 days] | Maximum Plasma Concentration (Cmax) of Efinopegdutide- single dose [At designated time points up to 35 days] | Time to Maximum Plasma Concentration (Tmax) of Efinopegdutide- single dose [At designated time points up to 35 days] | Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Efinopegdutide- single dose [At designated timepoints up to 35 days] | Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-inf) of Efinopegdutide- single dose [At designated timepoints up to 35 days] | Terminal half life (t1/2) of Efinopegdutide- single dose [At designated timepoints up to 35 days] | Apparent Clearance (CL) of Efinopegdutide- single dose [At designated timepoints up to 35 days] | Volume of Distribution (Vz) of Efinopegdutide- single dose [At designated timepoints up to 35 days] | Maximum Plasma Concentration (Cmax) of Efinopegdutide- multiple dose [At designated time points up to 112 days] | Minimum Plasma Concentration (Cmin) of Efinopegdutide- multiple dose [At designated time points up to 112 days] | Time to Maximum Plasma Concentration (Tmax) of Efinopegdutide- multiple dose [At designated time points up to 112 days] | Terminal half life (t1/2) of Efinopegdutide- multiple dose [At designated timepoints up to 112 days] | Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Efinopegdutide-multiple dose [At designated timepoints up to 112 days] | Apparent Clearance (CL) of Efinopegdutide- multiple dose [At designated timepoints up to 112 days] | Volume of Distribution at Steady State (Vss) of Efinopegdutide- multiple dose [At designated timepoints up to 112 days] | Area Under the Concentration-Time Curve to the end of the dosing period (AUC 0-tau)of Efinopegdutide- multiple dose [At designated timepoints up to 78 days]",null,null,"YES","OTHER:MK-6024-011; REGISTRY:2020-005136-30"],["NCT01700075","Physical and Chemical Study of Atherosclerosis Mechanisms","PCSAM","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","97","Myocardial Infarction; Coronary Artery Diseases; Diabetes Mellitus, Type 2; Atherosclerosis of Femoral Artery","DRUG:Conventional treatment; DIETARY_SUPPLEMENT:Weight loss treatment","Nazarbayev University","2009-01","2009-12","FALSE","full recovery from atherosclerotic diseases [for 12 months]","DERIVED:26608649",null,null,null],["NCT07668401","AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight","AMAZE 13","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","400","Obesity; Overweight","DRUG:Zenagamtide; DRUG:Placebo ( matched to Zenagamtide)","Novo Nordisk A/S","2027-01-07","2029-01-11","FALSE","Relative change in body weight [From baseline (week 0) to week 80]",null,null,"YES","OTHER:U1111-1335-9475"],["NCT06778967","A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus","Optimum 2","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","1100","Type 2 Diabetes Mellitus (T2DM)","DRUG:GZR18; DRUG:semaglutide","Gan & Lee Pharmaceuticals.","2025-02-13","2026-12-11","FALSE","Change from Baseline in Hemoglobin A1c (HbA1c)(%) [Baseline, Week 44]",null,null,null,null],["NCT07091500","Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity",null,"RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","40","Obesity; Skeletal Muscle; Brain Connectivity","BEHAVIORAL:Exercise training; DRUG:Semaglutide; BEHAVIORAL:Therapy Cessation","Washington University School of Medicine","2025-08-11","2028-08-01","FALSE","Physical function [Baseline, after 52 weeks of intervention, and 52 weeks after stopping the intervention] | Body composition [Baseline, after 52 weeks of intervention, and 52 weeks after stopping the intervention]",null,null,null,null],["NCT05390307","Obesity Treatment to Improve Diabetes","OTID","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","60","Type 1 Diabetes","DRUG:Liraglutide / Semaglutide; DRUG:Dapagliflozin; DRUG:Liraglutide or Semaglutide / Dapagliflozin; DRUG:Liraglutide or Semaglutide / Dapagliflozin plus intensive weight loss nutrition; OTHER:Usual care","Dasman Diabetes Institute","2023-04-01","2024-01-01","FALSE","Weight [26 weeks]","DERIVED:38365744","Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/07/NCT05390307/SAP_000.pdf",null,null],["NCT04575844","Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome","ZQL008","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","80","Metabolic Syndrome","DRUG:Liraglutide; OTHER:Exercise training; DRUG:Liraglutide + Exercise training","University of Virginia","2020-11-01","2027-04-30","FALSE","Microvascular Blood Volume - change from baseline [24 weeks]","BACKGROUND:28237263; BACKGROUND:27295427; BACKGROUND:21610226; BACKGROUND:15161743; BACKGROUND:17720897; BACKGROUND:19996061; BACKGROUND:19567533; BACKGROUND:21047922; BACKGROUND:12791603; BACKGROUND:16644702; BACKGROUND:11078458; BACKGROUND:23397463; BACKGROUND:15298982; BACKGROUND:3301899; BACKGROUND:21289242; BACKGROUND:16633338; BACKGROUND:15084712; BACKGROUND:23002035; BACKGROUND:17823371; BACKGROUND:23519745; BACKGROUND:24608437; BACKGROUND:16682488; BACKGROUND:17563063; BACKGROUND:23899560; BACKGROUND:15213062; BACKGROUND:24450403; BACKGROUND:19237429; BACKGROUND:17711996; BACKGROUND:23684008; BACKGROUND:10600857; BACKGROUND:10843167; BACKGROUND:14966043; BACKGROUND:11916935; BACKGROUND:12107720; BACKGROUND:21617098; BACKGROUND:16489128; BACKGROUND:15616022; BACKGROUND:14981009",null,null,"NIH:R01DK125330"],["NCT03881995","Effects of Insulin Glargine and Lixisenatide on the Brain","Lixibrain01","TERMINATED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","1","Diabetes Mellitus, Type 2","DRUG:IGlarLixi; DRUG:Insulin Glargine 100 UNT/ML","University Hospital Tuebingen","2019-03-18","2020-06-29","FALSE","Brain insulin sensitivity [Change from baseline brain insulin sensitivity at 12 weeks]",null,null,"NO","EUDRACT_NUMBER:2018-003557-21; NIH:2018"],["NCT07518121","A Bridging Study of Efsubaglutide Alfa in Healthy Adults in Brazil","BRIDGE-BR","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","48","Diabete Type 2","DRUG:Efsubaglutide Alfa Injection; DRUG:Placebo","Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","2026-06-01","2026-08-01","FALSE","Maximum Observed Plasma Concentration (Cmax) of YN-011 [Predose through Day 29] | Time to Maximum Observed Plasma Concentration (Tmax) of YN-011 [Predose through Day 29] | Area Under the Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t) of YN-011 [Predose through Day 29] | Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of YN-011 [Predose through Day 29] | Terminal Elimination Half-Life (t1/2) of YN-011 [Predose through Day 29]",null,null,"NO",null],["NCT00983021","Safety and Tolerability of NN9068 in Healthy Male Volunteers",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","24","Diabetes; Healthy","DRUG:insulin degludec/liraglutide; DRUG:insulin degludec; DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2009-09","2009-12","FALSE","Number and severity of adverse events, number and severity of local tolerability issues at the injection site, number and severity of hypoglycaemic episodes [assessed 0-96 hours after trial product administration]","RESULT:25998481",null,null,"EUDRACT_NUMBER:2009-011269-95; OTHER:U1111-1111-8859; NIH:2009"],["NCT05767255","Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue",null,"UNKNOWN","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","66","Diabetes Mellitus, Type 2 Treated With Insulin","DRUG:insulin degludec + liraglutide; DRUG:Insulin Glargine - Insulin Aspart","Hospital Universitario San Ignacio","2022-12-01","2023-08-30","FALSE","To compare the percentage of hypoglycemia [4 weeks]","DERIVED:40760249",null,"NO",null],["NCT01472640","The Effect of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","QUADRUPLE","240","Hyperglycemia; Chronic Heart Failure","DRUG:liraglutide; DRUG:placebo","Flyvbjerg, Allan, DMSc","2011-11","2015-09","FALSE","Change in Left ventricular function from visit 1 to week 24, measured by Ecco [24 weeks]","DERIVED:28770459; DERIVED:24844271",null,null,"EUDRACT_NUMBER:2011-002468-26"],["NCT00572689","Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes",null,"WITHDRAWN","INTERVENTIONAL","PHASE4","NON_RANDOMIZED","NONE","0","Gestational Diabetes","DRUG:Exenatide; GENETIC:Buccal/blood Sample Collection","Georgetown University","2013-08","2015-08","FALSE","glycemic control through insulin, glucose, c-peptide and glucagon assays [duing testing days]",null,null,null,"OTHER:202-801-2636"],["NCT06064006","A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","125","Obesity; Overweight","DRUG:NNC0487-0111; DRUG:Placebo (NNC0487-0111)","Novo Nordisk A/S","2023-09-15","2024-11-27","FALSE","PART A: Number of treatment emergent adverse events (TEAE) [From pre-dose on Day 1 until completion of the end of study visit, up to Day 25] | PARTS B to E: Number of treatment emergent adverse events (TEAE) [From pre-dose on Day 1 until completion of the end of study visit (V37) up to Day 270]","DERIVED:40550231",null,"YES","OTHER:U1111-1289-3282"],["NCT04487743","Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities",null,"UNKNOWN","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","300","Obesity","DRUG:Liraglutide; DRUG:placebo","Xiangya Hospital of Central South University","2020-05-09","2022-06","FALSE","Mean Change From Baseline in Fasting Body Weight [Week 0, Week 28] | Percentage of Subjects Losing at Least 5% of Baseline Fasting Body Weight. [Week 28]",null,null,null,"OTHER_GRANT:HDSJ19LLLT"],["NCT04515576","A Study of LY3493269 in Participants With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","56","Diabetes Mellitus, Type 2","DRUG:LY3493269; DRUG:Dulaglutide; DRUG:Placebo","Eli Lilly and Company","2020-08-25","2021-03-09","TRUE","Number of Participants With One or More Treatment-Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline through final follow-up at Day 57]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/76/NCT04515576/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/76/NCT04515576/SAP_001.pdf","NO","OTHER:J1X-MC-GZHC"],["NCT01269047","Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","37","Type 1 Diabetes","DRUG:Pramlintide; DRUG:Exenatide; DRUG:Insulin","Albert Einstein College of Medicine","2009-08","2016-08","TRUE","Post-prandial Blood Glucose Concentration in Both Pramlintide and Exenatide Treated Groups in Acute and Chronic Setting, Compared to Insulin Monotherapy in Type 1 Diabetes Mellitus. [6 months]",null,null,null,"NIH:R01DK077166"],["NCT01879917","Liraglutide in Newly Onset Type 1 Diabetes.","NewLira","COMPLETED","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","TRIPLE","65","Diabetes Mellitus, Type 1","DRUG:Liraglutide; DRUG:Placebo","Hvidovre University Hospital","2014-02","2018-08","FALSE","Beta-cell function [52 weeks]",null,null,null,"EUDRACT_NUMBER:2012-005317-39; OTHER:U1111-1137-3221"],["NCT03011021","Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes",null,"UNKNOWN","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","NONE","40","Type1 Diabetes Mellitus; Autoimmune Diabetes","DRUG:Liraglutide; BIOLOGICAL:UCB-Treg; DRUG:Insulin","Second Xiangya Hospital of Central South University","2017-01","2025-06","FALSE","Adverse effects [2 years]","BACKGROUND:23263503; BACKGROUND:22348606; BACKGROUND:20952687; BACKGROUND:24003936; BACKGROUND:26997114; BACKGROUND:27285580",null,null,null],["NCT02963935","Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting","SCALE™ IBT","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","282","Metabolism and Nutrition Disorder; Obesity","DRUG:liraglutide; DRUG:placebo; BEHAVIORAL:CMS Intensive Behavior Therapy","Novo Nordisk A/S","2017-02-06","2018-05-23","TRUE","Change in Body Weight (%) [Week 0, week 56] | Proportion of Subjects Losing at Least 5% of Baseline Body Weight at Week 56 [Week 56]","RESULT:32090517","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/35/NCT02963935/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/35/NCT02963935/SAP_001.pdf","YES","OTHER:U1111-1177-5059"],["NCT00950677","The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes","T2DM","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","16","Type 2 Diabetes","DRUG:Byetta (exenatide); DRUG:Symlin (pramlintide)","Baylor College of Medicine","2009-07","2011-05","FALSE","Glucose [4 hours]",null,null,"NO","NIH:K23DK075931"],["NCT06896981","Semaglutide in Women With Polycystic Ovary Syndrome and Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","NONE","31","Polycystic Ovary Syndrome (PCOS) Women; Obesity","DRUG:Metformin with Semaglutide","Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","2025-01-01","2025-10-31","FALSE","Weight [12 weeks] | Body mass index [12 weeks] | Waist circumference [12 weeks] | Hip circumference [12 weeks] | Blood pressure [12 weeks] | Acanthosis nigricans [12 weeks] | Fasting plasma glucose [12 weeks] | Fasting insulin [12 weeks] | Homeostasis model assessment of insulin resistance [12 weeks] | Total cholesterol [12 weeks] | HDL-cholesterol [12 weeks] | LDL-cholesterol [12 weeks] | Triglyceride [12 weeks]",null,null,"NO",null],["NCT06662383","A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity","TRIUMPH-5","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","800","Obesity","DRUG:Retatrutide; DRUG:Tirzepatide","Eli Lilly and Company","2024-11-01","2026-11","FALSE","Percent Change from Baseline in Body Weight [Baseline, Week 80]",null,null,"YES","OTHER:J1I-MC-GZBP; CTIS:2024-511450-49-00"],["NCT07858331","Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access","PIVOT","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","880","Obesity; Chronic Kidney Disease; Chronic Renal Disease; CKD","DRUG:Semaglutide; BEHAVIORAL:Virtual Weight Management Coaching","Kristin Clemens","2027-01-01","2029-01-01","FALSE","Change in Body Weight [Baseline to 26 weeks +/- 14 days]",null,null,"NO",null],["NCT02020629","Study on Lixisenatide and Counterregulation to Hypoglycemia",null,"COMPLETED","INTERVENTIONAL","PHASE4",null,"NONE","18","Type 2 Diabetes","DRUG:Lixisenatide","Lund University","2013-12","2014-08","FALSE","Glucagon response to hypoglycemia [30 min]","DERIVED:26537183",null,null,"EUDRACT_NUMBER:2012-004959-36"],["NCT07243171","A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity",null,"RECRUITING","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","QUADRUPLE","126","Overweight and/or Obesity; Weight Management","DRUG:ecnoglutide tablets; DRUG:placebo with matching dosage","Hangzhou Sciwind Biosciences Co., Ltd.","2025-11-18","2027-01-05","FALSE","The incidence and severity of adverse events [up to day 204]",null,null,"NO",null],["NCT05569772","Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes","SERENA","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","252","Glucose Intolerance After a Recent History of Gestational Diabetes","DRUG:Semaglutide Pen Injector; DRUG:Semaglutide placebo","Universitaire Ziekenhuizen KU Leuven","2023-09-14","2030-03","FALSE","Development of T2DM [by 160 weeks]","RESULT:42493207",null,"YES","OTHER:2022-502082-22-00"],["NCT03693430","Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity","STEP 5","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","304","Overweight; Obesity","DRUG:Semaglutide; DRUG:Placebo (Semaglutide)","Novo Nordisk A/S","2018-10-05","2021-01-29","TRUE","Percentage Change From Baseline (Week 0) to Week 104 in Body Weight [From Baseline (Week 0) to Week 104] | Number of Participants Who Achieved (Yes/no): Body Weight Reduction More Than or Equal to 5% [At Week 104]","BACKGROUND:32441473; BACKGROUND:36655300; DERIVED:39226070; DERIVED:37605636; DERIVED:36216945","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/30/NCT03693430/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/30/NCT03693430/SAP_001.pdf","YES","REGISTRY:2017-003726-32; OTHER:U1111-1202-1740; NIH:2017"],["NCT01300260","Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","32","Diabetes Mellitus, Type 2","BIOLOGICAL:LY2189265; DRUG:Placebo; DRUG:Insulin; DRUG:Glucose; DRUG:Glucagon","Eli Lilly and Company","2011-02","2011-08","TRUE","Maximum Insulin Concentration (Cmax) - First Phase Response [0-10 minutes after dextrose bolus on Day 3 postdose] | Area Under the Insulin Concentration-time Curve (AUC) - First Phase Response [0-10 minutes after dextrose bolus on Day 3 postdose] | Maximum Insulin Concentration (Cmax) - Second Phase Response [10-180 minutes after dextrose bolus on Day 3 postdose] | Insulin Area Under the Curve (AUC) - Second Phase Response [10-180 minutes after dextrose bolus on Day 3 post dose]",null,null,null,"OTHER:H9X-MC-GBCI"],["NCT02918279","Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","251","Metabolism and Nutrition Disorder; Obesity","DRUG:Liraglutide; DRUG:Placebo","Novo Nordisk A/S","2016-09-29","2019-02-14","TRUE","Change in BMI SDS (Week 0, Week 56) [Week 0, week 56]","RESULT:32233338; DERIVED:37264767","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/79/NCT02918279/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/79/NCT02918279/SAP_001.pdf",null,"EUDRACT_NUMBER:2014-004353-14; OTHER:U1111-1162-7101; NIH:2014"],["NCT05424003","Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","50","NAFLD","DRUG:Semaglutide Pen Injector; DRUG:Placebo","University of Virginia","2024-02-22","2026-08-01","FALSE","Change in weight [Baseline to week 72]",null,null,"NO",null],["NCT00294723","To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c","LEAD-3","TERMINATED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","746","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:glimepiride; DRUG:placebo","Novo Nordisk A/S","2006-02","2008-11","TRUE","Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 52 [week 0, week 52] | Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 104 [week 0, week 104] | Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 156 [week 0, week 156]","RESULT:18819705; RESULT:19245711; RESULT:19491536; RESULT:19878259; RESULT:19930006; RESULT:20590735; RESULT:21450987; RESULT:22055210; RESULT:22193143; RESULT:22174428; RESULT:21883806; RESULT:22862847; RESULT:23010561; RESULT:23186975; RESULT:25504028; RESULT:26574791; RESULT:26936426; DERIVED:24561125; DERIVED:21209033",null,null,null],["NCT02721888","Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism","LIRA-NAFLD/LIP","TERMINATED","INTERVENTIONAL","PHASE4",null,"NONE","127","Type 2 Diabetes","DRUG:Liraglutide; DRUG:MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy); BIOLOGICAL:Blood sample; OTHER:Kinetic substudy (10 patients)","Centre Hospitalier Universitaire Dijon","2012-07-10","2019-10-02","FALSE","Effect of liraglutide on fatty liver content evaluated by proton-spectroscopy (1H-spectroscopy and lipoprotein kinetics, in patients with type 2 diabetes [Before and after 6 month-treatment with liraglutide (1.2 mg/day)] | Effects of liraglutide on Very Low Density Lipoprotein 1 (VLDL1) apolipoprotein B (apoB) production rate [Before and after 6 month-treatment with liraglutide (1.2 mg/day)] | Effects of liraglutide on Very Low Density Lipoprotein 2 (VLDL2) apolipoprotein B (apoB) production rate [Before and after 6 month-treatment with liraglutide (1.2 mg/day)] | Effects of liraglutide on Intermediate Density Lipoprotein (IDL) apolipoprotein B (apoB) production rate [Before and after 6 month-treatment with liraglutide (1.2 mg/day)] | Effects of liraglutide on Low Density Lipoprotein (LDL) apolipoprotein B (apoB) production rate [Before and after 6 month-treatment with liraglutide (1.2 mg/day)] | Effects of liraglutide on High Density Lipoprotein (HDL) apolipoprotein A1 (apoA1) production rate [Before and after 6 month-treatment with liraglutide (1.2 mg/day)] | Effects of liraglutide on Very Low Density Lipoprotein 1 (VLDL1) apolipoprotein B (apoB) fractional catabolic rate [Before and after 6 month-treatment with liraglutide (1.2 mg/day)] | Effects of liraglutide on Very Low Density Lipoprotein 2 (VLDL2) apolipoprotein B (apoB) fractional catabolic rate [Before and after 6 month-treatment with liraglutide (1.2 mg/day)] | Effects of liraglutide on Intermediate Density Lipoprotein (IDL) apolipoprotein B (apoB) fractional catabolic rate [Before and after 6 month-treatment with liraglutide (1.2 mg/day)] | Effects of liraglutide on Low Density Lipoprotein (LDL) apolipoprotein B (apoB) fractional catabolic rate [Before and after 6 month-treatment with liraglutide (1.2 mg/day)] | Effects of liraglutide on High Density Lipoprotein (HDL) apolipoprotein A1 (apoA1) fractional catabolic rate [Before and after 6 month-treatment with liraglutide (1.2 mg/day)]","RESULT:30026275; DERIVED:37143040; DERIVED:33531418",null,null,null],["NCT06797869","A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","142","Diabetes Mellitus, Type 2; Diabetic Peripheral Neuropathy","DRUG:CagriSema (Cagrilintide B and Semaglutide I); DRUG:Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)","Novo Nordisk A/S","2025-01-29","2026-06-26","FALSE","Change in weekly average Pain Intensity-Numerical Rating Scale (PI-NRS) [From baseline (week 0) to end of treatment (week 32)]",null,null,"YES","OTHER:U1111-1306-9422; OTHER:2023-509662-38; NIH:2023"],["NCT02072096","A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)","IMPERIUM","TERMINATED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","192","Diabetes Mellitus, Type 2","DRUG:Glimepiride; DRUG:Metformin; DRUG:Pioglitazone; DRUG:Acarbose; DRUG:Linagliptin; DRUG:Sitagliptin; DRUG:Liraglutide; DRUG:Insulin Glargine; DRUG:Exenatide once weekly (QW); DRUG:Exenatide twice daily (BID)","Eli Lilly and Company","2014-02","2015-10","TRUE","Percentage of Participants Achieving and Maintaining Individualized Glycated Hemoglobin A1c (HbA1c) Targets Without Clinically Significant Hypoglycemia [Baseline to last participant visit (up to 72 weeks)]","DERIVED:28671753",null,"YES","OTHER:F3Z-MC-IOQL; EUDRACT_NUMBER:2013-001473-24"],["NCT05034783","[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients",null,"UNKNOWN","INTERVENTIONAL","EARLY_PHASE1",null,"NONE","20","Insulinoma","DRUG:[68Ga]Ga-HBED-CC-exendin-4; DRUG:[68Ga]Ga-NOTA-exendin-4","Peking Union Medical College Hospital","2021-10-01","2022-10-13","FALSE","Metabolic parameters [through study completion, an average of 1 year]","DERIVED:39499011",null,null,null],["NCT07743983","A Study of BGM0504 in Early T2DM With Obesity",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","372","Type 2 Diabetes (T2DM)","DRUG:BGM0504; DRUG:semaglutide","BrightGene Bio-Medical Technology Co., Ltd.","2026-09-17","2028-09-30","FALSE","Proportion of Participants Achieving HbA1c < 7.0% and Body Weight Reduction ≥ 10% from Baseline [Week 52]",null,null,null,null],["NCT04537923","A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin","SURPASS-6","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","1428","Type 2 Diabetes","DRUG:Tirzepatide; DRUG:Insulin Lispro (U100)","Eli Lilly and Company","2020-10-19","2022-10-11","TRUE","Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) [Baseline, Week 52]","DERIVED:41961454; DERIVED:37786396","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/23/NCT04537923/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/23/NCT04537923/SAP_001.pdf","YES","OTHER:I8F-MC-GPHD; EUDRACT_NUMBER:2020-000284-23"],["NCT07843862","A Study of HRS-4729 Injection in Participants With Type 2 Diabetes",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","240","Type 2 Diabetes","DRUG:HRS-4729 Injection; DRUG:Mazdutide; DRUG:Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2026-10","2027-04","FALSE","Change From Baseline in HbA1c [Baseline, Week 28]",null,null,"UNDECIDED",null],["NCT07336862","Bariatric Surgery Combined With GLP-1 Receptor Agonists Study","BS-GLP","RECRUITING","INTERVENTIONAL","PHASE1; PHASE2","NON_RANDOMIZED","NONE","200","Obesity","COMBINATION_PRODUCT:BS-GLP group; PROCEDURE:BS group","China-Japan Friendship Hospital","2024-01-01","2027-12","FALSE","the Percentage of weight loss [1 year]",null,null,null,null],["NCT01628445","Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin","SAIL","TERMINATED","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","52","Type 2 Diabetes","DRUG:liraglutide; DRUG:placebo injection","University of Manitoba","2012-08","2015-11","FALSE","Change in A1c [Baseline to 24 wks]",null,null,null,null],["NCT04373967","Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes",null,"UNKNOWN","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","424","Type 2 Diabetes","DRUG:Victoza®.; DRUG:Metformin Hydrochloride; DRUG:TQZ2451","Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","2020-04-29","2021-12-01","FALSE","glycated hemoglobin (HbA1c) [week 0,week 26]",null,null,null,null],["NCT03596177","A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","28","Diabetes Mellitus, Type II; Obesity","DRUG:MEDI0382; DRUG:Placebo","MedImmune LLC","2018-09-26","2019-12-22","TRUE","Percent Change in Body Weight From Baseline to Day 59 [Baseline (Day 17) and Day 59]","DERIVED:38562018","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/77/NCT03596177/Prot_002.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/77/NCT03596177/SAP_003.pdf",null,null],["NCT06639464","Semaglutide for Helping Opioid Recovery","SHORE","RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","46","Opioid Use Disorder","DRUG:Semaglutide; OTHER:Placebo","Brigham and Women's Hospital","2025-06-02","2027-09-01","FALSE","Cue-induced Cravings for Opioids [Baseline, 6 weeks, and 13 weeks after baseline visit] | Relapse to Illicit Opioid Use [Weekly from baseline to end of study at 14 weeks]",null,null,"UNDECIDED",null],["NCT07621419","Study of Adult Patients Residing in Argentina Diagnosed With Type 2 Diabetes Treated With a New Formulation of Semaglutide, Both Oral and Subcutaneous, in a Real-world Setting at 3 Months, 6 Months, and 1 Year of Follow-up, Quantifying the Reduction in Glycated Hemoglobin","SEMA-REAL ARG","RECRUITING","OBSERVATIONAL",null,null,null,"145","Diabetes Mellitus","DRUG:semaglutide","Hospital Italiano de Buenos Aires","2025-08-04","2027-12-31","FALSE","Change in glycated hemoglobin (HbA1c) levels from baseline to 3, 6, and 12 months of follow-up. [Baseline, 3 months, 6 months, and 12 months.]","BACKGROUND:11873004; BACKGROUND:35897259; BACKGROUND:40775843; BACKGROUND:39651989; BACKGROUND:39316289; BACKGROUND:31186300; BACKGROUND:34993760",null,"NO",null],["NCT06234111","Semaglutide and Physical Activity for Obesity and Multimorbidity",null,"ACTIVE_NOT_RECRUITING","OBSERVATIONAL",null,null,null,"35","Obesity Morbid; Multimorbidity; Obesity","COMBINATION_PRODUCT:Semaglutide 2.4 mg, total diet replacement, behavioural intervention","Hvidovre University Hospital","2024-02-20","2026-10","FALSE","Habitual physical activity [Baseline (± 2 weeks), 4 months (± 2 weeks) and 24 months (± 2 weeks).]",null,null,"NO",null],["NCT01345734","Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes","Lead-Ph","COMPLETED","OBSERVATIONAL",null,null,null,"1056","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2011-09-01","2013-07-26","FALSE","Incidence of serious adverse drug reactions (SADRs) [Week 0, week 26]","RESULT:33442116",null,null,"OTHER:U1111-1119-8803"],["NCT01676116","The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy","DUAL™ III","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","438","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide; DRUG:liraglutide; DRUG:exenatide","Novo Nordisk A/S","2012-08-29","2014-03-11","TRUE","Change in Glycosylated Haemoglobin (HbA1c) From Baseline (Randomisation, Visit 2) [Week 0, week 26]","RESULT:27943107; RESULT:30383495; DERIVED:39963952",null,null,"EUDRACT_NUMBER:2012-000209-63; OTHER:U1111-1127-1321"],["NCT02692716","A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes","PIONEER 6","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","3183","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2017-01-17","2018-09-25","TRUE","Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE) Composite Endpoint Consisting of: Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke [Maximum treatment duration is dependent on event rates and is estimated to be no longer than 19 months + 5 weeks of follow-up period.]","RESULT:29263194; RESULT:30284349; RESULT:31185157; RESULT:34277983; RESULT:35484580; RESULT:35373893; DERIVED:39963952; DERIVED:39520501; DERIVED:37620807; DERIVED:35582947; DERIVED:33606902; DERIVED:32998732; DERIVED:32267058; DERIVED:31903692","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/16/NCT02692716/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/16/NCT02692716/SAP_001.pdf",null,"EUDRACT_NUMBER:2015-003563-10; OTHER:U1111-1173-0750; OTHER:NL56580.091.16; NIH:2015"],["NCT07297238","Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","20","Short Bowel Syndrome (SBS); Intestinal Failure","DRUG:GLP-1 Receptor Agonists","Jinling Hospital, China","2026-01-24","2026-05-27","FALSE","Serum Biomarkers of Intestinal Barrier Function [the initiation of enrollment and upon completion of the 28-days treatment period]","BACKGROUND:23086829; BACKGROUND:27542128; BACKGROUND:36206837; BACKGROUND:26470783; BACKGROUND:23511332; BACKGROUND:27875281; BACKGROUND:25311444; BACKGROUND:30170779; BACKGROUND:25441588; BACKGROUND:26635320; BACKGROUND:34620351; BACKGROUND:27440772; BACKGROUND:37639741; BACKGROUND:36796121",null,"NO",null],["NCT05936138","A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment.",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","24","Renal Insufficiency; Healthy","DRUG:LY3502970","Eli Lilly and Company","2023-07-13","2024-04-11","TRUE","Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-∞) of LY3502970 [Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours postdose] | PK: Area Under the Concentration Versus Time Curve From Time Zero to Last Time Point (AUC0-tlast) of LY3502970 [Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours postdose] | PK: Maximum Observed Concentration (Cmax) of LY3502970 [Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours postdose]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/38/NCT05936138/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/38/NCT05936138/SAP_001.pdf","NO","OTHER:J2A-MC-GZPC"],["NCT06642584","A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","90","Healthy Volunteers Type 2 Diabetes","DRUG:Semaglutide B; DRUG:Semaglutide J; DRUG:Semaglutide L; DRUG:Semaglutide M; DRUG:Semaglutide N","Novo Nordisk A/S","2024-10-15","2025-07-10","FALSE","Adjusted AUC(sema); adjusted area under the semaglutide plasma concentration-time curve [From 0 to 24 hours after dosing on Days 122 and 132.] | Adjusted Cmax,(sema); adjusted maximum observed semaglutide plasma concentration [From 0 to 24 hours after dosing on Days 122 and 132.] | Adjusted tmax,sema; time to adjusted maximum observed semaglutide plasma concentration [From 0 to 24 hours after dosing on Days 122 and 132.] | t½,sema; the terminal half-life of semaglutide [From 0 to 840 hours after dosing on Day 132.]",null,null,"YES","OTHER:U1111-1304-9627"],["NCT04374578","Effect of Dulaglutide on Glycemic Variability in Patients With Type 2 Diabetes","DIVE","COMPLETED","OBSERVATIONAL",null,null,null,"100","Type 2 Diabetes","DRUG:Dulaglutide 1.5 MG/ML","Shanghai Zhongshan Hospital","2020-05-08","2021-01-31","FALSE","Effect on glycemic variability [one months]",null,null,"NO",null],["NCT02607306","A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.","DUAL™ I Japan","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","819","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide; DRUG:insulin degludec; DRUG:liraglutide","Novo Nordisk A/S","2015-11-18","2017-12-15","TRUE","Change From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Non-inferiority of IDegLira vs IDeg and Superiority of IDegLira vs Lira [Week 0, Week 52]","RESULT:31407845; RESULT:33595901","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/06/NCT02607306/Prot_SAP_000.pdf","YES","OTHER:U1111-1170-1332; OTHER:JapicCTI-153089"],["NCT06501326","Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","102","Non-alcoholic Fatty Liver Disease; Obesity","DRUG:Liraglutide; DRUG:Orlistat","Affiliated Hospital of Nantong University","2023-11-01","2024-10-31","FALSE","Body weight [Three months] | FABP4 [Three months] | BMI [Three months] | lipid indices [Three months] | LSM [Three months] | CAP [Three months]",null,null,"NO",null],["NCT04515849","A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","248","Type 2 Diabetes Mellitus; Chronic Kidney Diseases","DRUG:Cotadutide 100 micrograms; DRUG:Cotadutide 300 micrograms; DRUG:Cotadutide 600 micrograms; DRUG:Semaglutide; DRUG:Placebo","AstraZeneca","2020-08-31","2022-03-08","TRUE","The Primary Endpoint Was Percentage Change in UACR of Cotadutide at Different Dose Levels Compared to Placebo After 14 Weeks [Baseline to the end of 14 weeks of dosing]","RESULT:39218393; DERIVED:40344607; DERIVED:39963952","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/49/NCT04515849/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/49/NCT04515849/SAP_001.pdf","YES","EUDRACT_NUMBER:2020-000255-12"],["NCT07779343","OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management Programme","OBESIAL","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","300","Obesity Difficult Airway Airway Management; Obesity Adult Onset; Obesity and Cardiovascular Risk; Obesity Type 2 Diabetes Mellitus","DRUG:Semaglutide (Wegovy) weekly injection; BEHAVIORAL:Behavioral Treatment; OTHER:Weight loss","University of Health Sciences, Algeria","2026-01-22","2028-01-23","FALSE","Percentage of Participants Achieving ≥5% Weight Loss at Month 18 [18 months follow-up]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/43/NCT07779343/Prot_SAP_000.pdf","UNDECIDED","OTHER:MCHA-MED-2026/01"],["NCT06976619","The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","SINGLE","60","Type 1 Diabetes; Type 2 Diabetes","DRUG:Liraglutide Pen Injector; OTHER:Saline Injections","Mayo Clinic","2025-10-03","2028-10-30","FALSE","Effect of exendin 9-39 on fasting glucagon secretion rate before and after liraglutide treatment [The change in fasting glucagon secretion rate (saline vs. exendin 9-39) in the baseline study will be compared with the change in fasting glucagon secretion rate (saline vs. exendin 9-39) after 30 days of treatment with liraglutide (post-liraglutide)] | Effect of exendin 9-39 on glucagon secretion rate during hyperglycemia before and after liraglutide [The change in glucagon secretion rate during hyperglycemia (saline vs. exendin 9-39) in the baseline study will be compared with the change (saline vs. exendin 9-39) after 30 days of treatment with liraglutide (post-liraglutide)]",null,null,"NO",null],["NCT06066528","A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight","SYNCHRONIZE™-2","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","755","Obesity; Diabetes Mellitus, Type 2","COMBINATION_PRODUCT:Survodutide; COMBINATION_PRODUCT:Placebo","Boehringer Ingelheim","2023-11-27","2025-12-12","FALSE","Percentage change in body weight from baseline to Week 76 [Baseline and at Week 76] | Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76 [Baseline and at Week 76]","DERIVED:42820639; DERIVED:41216778",null,"YES","REGISTRY:2022-502531-18-00; REGISTRY:U1111-1289-0247"],["NCT04680767","A Study of LY3502970 in Healthy Male Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","6","Healthy","DRUG:[¹⁴C]-LY3502970","Eli Lilly and Company","2021-03-29","2021-07-03","TRUE","Feces Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered [0, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, and 384 hours (h) postdose] | Urinary Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered [0, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, and 384 hours (h) postdose]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/67/NCT04680767/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/67/NCT04680767/SAP_001.pdf","NO","OTHER:J2A-MC-GZGF"],["NCT05681299","Effects of GH and Lirglutide on AgRP",null,"RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","40","Healthy; Growth Hormone Deficiency","DRUG:growth hormone and lirglutide; DRUG:growth hormone; DRUG:liraglutide; DRUG:Placebo","Columbia University","2023-05-01","2028-04-30","FALSE","AgRP change in GH vs. placebo arms [Baseline to weeks 1, 2, 3 of each study arm.] | AgRP change in GH vs. GH + liraglutide arms [Baseline to weeks 1, 2, 3 of each study arm.]",null,null,"NO",null],["NCT07391267","Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","90","Chronic Kidney Diseases; MAFLD","DRUG:Semaglutide Oral Tablet; OTHER:Placebo; OTHER:Standard medical treatment","Institute of Liver and Biliary Sciences, India","2026-02-01","2028-12-31","FALSE","Time to first occurrence of a composite primary outcome event defined as persistent eGFR decline of greater than or equal to 50 percentage from trial start, reaching ESRD, death from kidney disease or death from cardiovascular disease. [3 months, 6 months, 12 months,18 months and 24 months]",null,null,null,null],["NCT02453711","Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","957","Metabolism and Nutrition Disorder; Obesity","DRUG:semaglutide; DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2015-10-01","2017-03-30","TRUE","Relative Change in Body Weight (%) [Week 0, Week 52]","BACKGROUND:30993900; RESULT:30122305","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/11/NCT02453711/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/11/NCT02453711/SAP_001.pdf",null,"EUDRACT_NUMBER:2014-001540-38; OTHER:U1111-1155-4660; NIH:2014"],["NCT07400107","AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight","AMAZE 8","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","1000","Obesity; Overweight; Diabetes Mellitus, Type 2","DRUG:NNC0487-0111; DRUG:Semaglutide; DRUG:Placebo (matched to NNC0487-0111); DRUG:Placebo (matched to semaglutide)","Novo Nordisk A/S","2026-05-20","2028-12-12","FALSE","Relative change in body weight [From baseline (week 0) to week 84]",null,null,"YES","OTHER:U1111-1313-8017; OTHER:2024-520446-31"],["NCT00375492","Effect on Weight Loss of Exenatide Versus Placebo",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","196","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:placebo","AstraZeneca","2006-09","2008-02","TRUE","Change From Baseline in Body Weight [Baseline, Week 24]","DERIVED:22913891",null,null,null],["NCT06542874","A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","448","Type 2 Diabetes (T2D)","DRUG:NNC0487-0111 subcutanous; DRUG:Placebo (NNC0487-0111 subcutanous); DRUG:NNC0487-0111 oral; DRUG:Placebo (NNC0487-0111 oral)","Novo Nordisk A/S","2024-08-07","2025-10-01","FALSE","Change in HbA1c [From baseline (week 0) to end of treatment (week 36)]","DERIVED:42532080; DERIVED:42532079",null,"YES","OTHER:U1111-1296-9708; OTHER:2023-509412-28; NIH:2023"],["NCT06182618","Retrospective Analysis for Patients With Metabolic Syndrome",null,"UNKNOWN","OBSERVATIONAL",null,null,null,"400","Metabolic Syndrome","OTHER:dietary, semaglutide or/and metformin","Second Affiliated Hospital, Zhejiang University, School of Medicine","2023-06-01","2024-01-01","FALSE","weight [0month/1month/2months/3 months]","DERIVED:39540270",null,null,null],["NCT07729332","Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","60","Obesity","DRUG:Phentermine Pill; DRUG:Orforglipron","Massachusetts General Hospital","2026-11-01","2031-07-31","FALSE","Percent change in body weight [6 months]",null,null,"UNDECIDED",null],["NCT01326871","A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer",null,"COMPLETED","INTERVENTIONAL","PHASE1; PHASE2","NON_RANDOMIZED","NONE","68","Transitional Cell Carcinoma of Bladder; Urethra Cancer; Ureter Cancer; Malignant Tumor of Renal Pelvis","DRUG:Cisplatin; DRUG:Gemcitabine; BIOLOGICAL:ALT-801","Altor BioScience","2011-09-06","2016-04-11","TRUE","Maximum Tolerated Dose (MTD) and/or the Recommended Dose (RD) for Dose Expansion of ALT-801 in Combination With Cisplatin and Gemcitabine or ALT-801 in Combination With Gemcitabine Alone [8 weeks] | Number of Participants With Adverse Events [8 weeks] | Objective Response Rate in Treated Patients [12 weeks]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/71/NCT01326871/Prot_SAP_000.pdf",null,null],["NCT05756764","Anti-obesity Pharmacotherapy and Inflammation",null,"ACTIVE_NOT_RECRUITING","OBSERVATIONAL",null,null,null,"30","Obesity","DRUG:Semaglutide; DRUG:Phentermine-Topiramate combination; DRUG:Phentermine; DRUG:Tirzepatide; DRUG:Topiramate; DRUG:Diethylpropion; DRUG:Naltrexone/Bupropion; DRUG:Liraglutide","Louisiana State University Health Sciences Center in New Orleans","2023-06-01","2026-01-30","FALSE","weight loss [baseline and 24 weeks] | MDSC in peripheral blood [baseline and 24 weeks] | Levels of lipids in circulation [baseline and 24 weeks]",null,null,"YES","NIH:U24DK132740"],["NCT01798264","Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","44","Type 2 Diabetes","DRUG:ITCA 650 (exenatide in DUROS)","Intarcia Therapeutics","2009-02","2009-05","TRUE","Number of Subjects With Study Drug-Related Adverse Events [4 weeks]","DERIVED:23578605",null,null,null],["NCT07195994","A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes",null,"RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","90","Prediabetes / Type 2 Diabetes","DIETARY_SUPPLEMENT:AMPK Charge+®; DIETARY_SUPPLEMENT:AMPK Charge+® with semaglutide","QuickSilver Scientific","2026-02-05","2026-09","FALSE","The difference in change in fasting blood glucose between AMPK Charge+® and AMPK Charge+® with semaglutide [Day 0 to 84] | The difference in change in fasting insulin between AMPK Charge+® and AMPK Charge+® with semaglutide [Day 0 to 84] | The difference in change in hemoglobin A1c (HbA1c) between AMPK Charge+® and AMPK Charge+® with semaglutide [Day 0 to 84]",null,null,null,null],["NCT01093729","A Study of HM11260C in Healthy Male Subject",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","41","Healthy","DRUG:HM11260C","Hanmi Pharmaceutical Company Limited","2010-02","2010-10","FALSE","Safety [1, 2, 3, 4, 5, 7, 9, 16, 22, 30, 36, 43, 57, 84 Day]",null,null,null,null],["NCT05564039","A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)","SURPASS-SWITCH","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","282","Type 2 Diabetes","DRUG:Tirzepatide; DRUG:Dulaglutide","Eli Lilly and Company","2022-11-30","2024-07-15","TRUE","Change From Baseline in HbA1c [Baseline, Week 40]","DERIVED:41912265; DERIVED:40183678","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/39/NCT05564039/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/39/NCT05564039/SAP_001.pdf","YES","OTHER:I8F-MC-GPIH; OTHER:2022-500101-41-00"],["NCT02616003","Preoperative Condition in Giant Obese Patients",null,"COMPLETED","INTERVENTIONAL","PHASE4",null,"NONE","50","Morbid Obesity; Bariatric Surgery Candidate","DRUG:Liraglutide; OTHER:Aminosteril hepa 8%; DIETARY_SUPPLEMENT:Caloric diet with 1000 kcal","Sana Klinikum Offenbach","2014-04","2018-01","FALSE","Operability [21 days]","RESULT:25202976; RESULT:24681814; RESULT:26132939; RESULT:26007339; RESULT:17360978; RESULT:22535285; DERIVED:35871930",null,null,null],["NCT04143945","A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","104","Healthy Volunteers Diabetes Mellitus, Type 2; Healthy Volunteers Overweight; Healthy Volunteers Obesity","DRUG:Semaglutide (administered by DV3396 pen); DRUG:Semaglutide (administered by PDS290 pen)","Novo Nordisk A/S","2019-10-28","2020-01-04","TRUE","Intensity of Injection Site Pain [After 1 minute of each injection (Day 1)]","DERIVED:35434913","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/45/NCT04143945/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/45/NCT04143945/SAP_001.pdf","YES","REGISTRY:2019-003654-83; OTHER:U1111-1239-7955; NIH:2019"],["NCT03811561","A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes","FOCUS","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","1500","Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2019-05-08","2027-11-07","FALSE","Presence of at least 3 steps Early Treatment Diabetic Retinopathy Study (ETDRS) subject level progression. [Year 5]","DERIVED:38197991",null,"YES","OTHER:U1111-1201-6256; REGISTRY:2017-003619-20; NIH:2017"],["NCT01982630","Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","87","Diabetes Mellitus","DRUG:MK-8521; DRUG:Liraglutide; DRUG:Placebo","Merck Sharp & Dohme LLC","2013-11-07","2014-10-03","TRUE","Number of Participants Experiencing Adverse Events (AEs) in Part 1 [Up to approximately 42 days] | Number of Participants Experiencing Adverse Events (AEs) in Part 2 [Up to approximately 57 days] | Number of Participants Discontinuing Study Drug Due to Adverse Events (AEs) in Part 1 [Up to approximately 14 days] | Number of Participants Discontinuing Study Drug Due to Adverse Events (AEs) in Part 2 [Up to approximately 29 days] | Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 7 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 1 [Baseline (predose Day 1) and up to 24 hours post Day 7 dose] | Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 7 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 2 [Baseline (predose Day 1) and up to 24 hours post Day 7 dose] | Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 14 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 1 [Baseline (predose Day 1) and up to 24 hours post Day 14 dose] | Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 14 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 2 [Baseline (predose Day 1) and up to 24 hours post Day 14 dose] | Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 19 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 2 [Baseline (predose Day 1) and up to 24 hours post Day 19 dose] | Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 24 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 2 [Baseline (predose Day 1) and up to 24 hours post Day 24 dose] | Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 29 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 2 [Baseline (predose Day 1) and up to 24 hours post Day 29 dose] | Change From Baseline in Peak Heart Rate (PHR) at Day 7 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2 [Baseline (predose Day 1) and up to 24 hours post Day 7 dose] | Change From Baseline in Peak Heart Rate (PHR) at Day 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2 [Baseline (predose Day 1) and up to 24 hours post Day 14 dose] | Change From Baseline in Peak Heart Rate (PHR) at Day 19 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2 [Baseline (predose Day 1) and up to 24 hours post Day 19 dose] | Change From Baseline in Peak Heart Rate (PHR) at Day 24 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2 [Baseline (predose Day 1) and up to 24 hours post Day 24 dose] | Change From Baseline in Peak Heart Rate (PHR) at Day 29 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2 [Baseline (predose Day 1) and up to 24 hours post Day 29 dose] | Change From Baseline in Resting Morning Heart Rate (RMHR) After the Day 7 Dose for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2 [Baseline (predose Day 1) and Day 8 (24 hours after Day 7)] | Change From Baseline in Resting Morning Heart Rate (RMHR) After the Day 14 Dose for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2 [Baseline (predose Day 1) and Day 15 (24 hours after Day 14)] | Change From Baseline in Resting Morning Heart Rate (RMHR) After the Day 19 Dose for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2 [Baseline (predose Day 1) and Day 20 (24 hours after Day 19)] | Change From Baseline in Resting Morning Heart Rate (RMHR) After the Day 24 Dose for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2 [Baseline (predose Day 1) and Day 25 (24 hours after Day 24)] | Change From Baseline in Resting Morning Heart Rate (RMHR) After the Day 29 Dose for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2 [Baseline (predose Day 1) and Day 30 (24 hours after Day 29)] | Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24hr) of MK-8521 on Days 1, 7, and 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1 [Predose and 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Days 1, 7, and 14] | Maximum Concentration (Cmax) of MK-8521 on Days 1 and 7 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1 [Predose and 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Days 1 and 7] | Maximum Concentration (Cmax) of MK-8521 on Day 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1 [Predose and 1, 2, 4, 6, 8, 10, 12, 16, 24, 72, 96, and 120 hours post-dose on Day 14] | Trough Concentration (Ctrough) of MK-8521 on Days 1, 7, and 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1 [Predose on Days 2, 7, and 14] | Time to Maximum Concentration (Tmax) of MK-8521 on Days 1 and 7 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1 [Predose and 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Days 1 and 7] | Time to Maximum Concentration (Tmax) of MK-8521 on Day 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1 [Predose and 1, 2, 4, 6, 8, 10, 12, 16, 24, 72, 96, and 120 hours post-dose on Day 14] | Apparent Terminal Half Life (t1/2) of MK-8521 on Days 1 and 7 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1 [Predose and 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Days 1 and 7] | Apparent Terminal Half Life (t1/2) of MK-8521 on Day 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1 [Predose and 1, 2, 4, 6, 8, 10, 12, 16, 24, 72, 96, and 120 hours post-dose on Day 14] | Accumulation Ratio of the Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24hr) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1 [Predose and 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Days 1 and 7] | Accumulation Ratio of the Maximum Concentration (Cmax) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1 [Predose and 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Days 1 and 7] | Accumulation Ratio of the Trough Concentration (Ctrough) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1 [Predose on Days 2 and 7] | Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24hr) of MK-8521 on Days 1, 7, and 14 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2 [Predose and 1, 2, 6, 10, 16, and 24 hours postdose on Days 1, 7, and 14] | Accumulation Ratio of the Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24hr) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2 [Predose and 1, 2, 6, 10, 16, and 24 hours post-dose on Days 1 and 7]",null,null,"YES",null],["NCT02972645","A Study of LY3305677 in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","66","Healthy","DRUG:LY3305677; DRUG:Placebo","Eli Lilly and Company","2016-12-05","2017-07-14","FALSE","Number of Participants with One or More Serious Adverse Event(s) (SAEs) considered by the Investigator to be Related to Study Drug Administration [Baseline to Study Completion (approximately 16 weeks)]",null,null,null,"OTHER:I8P-MC-OXAA"],["NCT07868939","Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","560","Weight Loss","DRUG:VK2735 Oral; DRUG:Placebo Comparator","Viking Therapeutics, Inc.","2026-10-16","2028-10","FALSE","Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily [68 weeks]",null,null,"NO",null],["NCT07417631","Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.",null,"COMPLETED","OBSERVATIONAL",null,null,null,"300000","Type 2 Diabetes","DRUG:Dulaglutide; DRUG:Sitagliptin","Brigham and Women's Hospital","2026-02-03","2026-06-15","FALSE","Time to first occurrence of myocardial infarction, stroke, or all-cause mortality [From cohort entry through first occurrence of outcome, disenrollment, end of the study period, treatment discontinuation +45-day grace/risk window, treatment switch between arms, nursing home admission, start of another GLP-1 RA, assessed up to 1 year.]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/31/NCT07417631/Prot_000.pdf",null,null],["NCT03495102","A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes","AWARD-11","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","1842","Diabetes Mellitus, Type 2","DRUG:Dulaglutide","Eli Lilly and Company","2018-04-05","2019-05-28","TRUE","Change in Hemoglobin A1c (HbA1c) From Baseline [Baseline, Week 36]","DERIVED:36894938; DERIVED:35546790; DERIVED:33397768","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/02/NCT03495102/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/02/NCT03495102/SAP_001.pdf","YES","OTHER:H9X-MC-GBGL; EUDRACT_NUMBER:2017-003490-33; NIH:2017"],["NCT07581145","Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients","SEMAFOOT2","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","52","Foot Ulcer Due to Type 2 Diabetes Mellitus","DRUG:Semaglutide, 1.34 mg/mL; DRUG:Placebo","Ole Lander Svendsen","2026-04-24","2028-12","FALSE","Proportion of clinical healed index foot ulcer at week 20 [20 weeks]",null,null,"NO","CTIS:2023-504913-65-01; OTHER:U1111-1282-3930; NIH:2023"],["NCT02467790","Polyethylene Glycol Loxenatide Pharmacokinetics Study in Subjects With Normal and Insufficiency Renal Function",null,"UNKNOWN","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","24","Type 2 Diabetes Mellitus","DRUG:PEX168","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2015-02","2016-03","FALSE","Pharmacokinetic index [Baseline to Day31]","DERIVED:31396983",null,null,null],["NCT07812597","A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","210","Obesity","DRUG:zovaglutide Arm 1; DRUG:zovaglutide Arm 2; DRUG:semaglutide","Beijing QL Biopharmaceutical Co.,Ltd","2026-10-12","2028-01-13","FALSE","Proportion of participants achieving successful switch from semaglutide 2.4 mg to zovaglutide after randomization [from week 20 (randomization) to week 36]",null,null,null,null],["NCT06858878","Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight","MARITIME-2","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","1105","Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight","DRUG:Maridebart cafraglutide; DRUG:Placebo","Amgen","2025-03-17","2027-01-21","FALSE","Percent Change from Baseline in Body Weight at Week 72 [Baseline and Week 72]",null,null,"YES",null],["NCT06478550","A Research Study to Understand How People With Type 2 Diabetes Take Ozempic® and if the Ozempic®App Helps Them Stay on This Treatment",null,"COMPLETED","OBSERVATIONAL",null,null,null,"304","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2024-06-26","2025-04-23","FALSE","Persistency of semaglutide s.c. treatment in PSS app with connectivity vs control arm (Yes/No) (HCP reported) [At Visit 2 (week 16)]",null,null,"YES","OTHER:U1111-1286-4221"],["NCT07677891","Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","60","Type 2 Diabetes","DRUG:PG-102(MG12); DRUG:Dulaglutide","ProGen. Co., Ltd.","2026-10","2027-05","FALSE","Change in HbA1c from Baseline at Week 32 [[Time Frame: Baseline to Week 32]]",null,null,null,null],["NCT01270789","LIraglutide and Beta-cell RepAir (LIBRA) Study","LIBRA","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","63","Type 2 Diabetes","DRUG:Liraglutide; DRUG:placebo","Mount Sinai Hospital, Canada","2011-01","2013-12","FALSE","Preservation of beta-cell function measured by Insulin Secretion-Sensitivity Index-2 (ISSI-2) [48-weeks]","DERIVED:30503831; DERIVED:28472325; DERIVED:27547422; DERIVED:26230296; DERIVED:26079776; DERIVED:25495067; DERIVED:25249651; DERIVED:24550219; DERIVED:24129396",null,null,null],["NCT07339423","AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight","AMAZE 1","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","1150","Obesity","DRUG:NNC0487-0111; DRUG:Placebo (matched to NNC0487-0111)","Novo Nordisk A/S","2026-02-24","2029-06-26","FALSE","Relative change in body weight [From baseline (week 0) to week 84]",null,null,"YES","OTHER:U1111-1313-6262; OTHER:2024-520440-42"],["NCT05469126","A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","26","Healthy","DRUG:LY3502970; DRUG:Clarithromycin","Eli Lilly and Company","2022-08-01","2022-11-03","TRUE","Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Infinity AUC(0-∞) of LY3502970 [Period 1: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours Day 1 postdose; Period 2: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 168 and 240 hours Day 21 postdose] | PK: Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of LY3502970 [Period 1: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours Day 1 postdose; Period 2: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 168 and 240 hours Day 21 postdose] | PK: Maximum Observed Concentration (Cmax) of LY3502970 [Period 1: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours Day 1 postdose; Period 2: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 168 and 240 hours Day 21 postdose]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/26/NCT05469126/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/26/NCT05469126/SAP_001.pdf","NO","OTHER:J2A-MC-GZGM"],["NCT02472717","Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study","PLAQUE","WITHDRAWN","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","0","Psoriatic Arthritis; Psoriasis; Impaired Glucose Tolerance; Type 2 Diabetes","DRUG:liraglutide; OTHER:Placebo","University Health Network, Toronto","2015-05","2016-10","FALSE","The change in the proportion of patients achieving an ACR 20% improvement response in patients with psoriatic arthritis receiving liraglutide for 12 weeks compared to placebo [Baseline to 12 weeks, liraglutide compared to placebo]",null,null,null,null],["NCT01089569","Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","60","Type 2 Diabetes","DRUG:Exenatide; DRUG:Insulin Glargine","HealthPartners Institute","2010-04","2013-05","TRUE","HbA1c Change [baseline to final visit (32 weeks)]","BACKGROUND:18473688; BACKGROUND:19454385",null,"NO",null],["NCT07135141","Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity","SMART","NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","TRIPLE","256","Severe Obesity","DRUG:Sleeve gastrectomy plus early mazdutide initiation; DRUG:Sleeve gastrectomy followed with early mazdutide placebo initation","Beijing Friendship Hospital","2025-09-30","2027-09-30","FALSE","the rate of excess weight loss(EWL%) compared to baseline [At 48th week post procedure]",null,null,"YES",null],["NCT05757531","A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","7","Healthy","DRUG:[¹⁴C]-LY3437943","Eli Lilly and Company","2023-03-17","2023-06-23","FALSE","Urinary Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered [Predose up to 63 days post dose] | Fecal Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered [Predose up to 63 days post dose]",null,null,"NO","OTHER:J1I-MC-GZBG"],["NCT01960179","Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3",null,"NONE","361","Type 2 Diabetes Mellitus","DRUG:lixisenatide AVE0010","Sanofi","2013-11","2015-03","FALSE","Safety over 24 and 52 weeks assessed by treatment emergent adverse event (TEAE), vital signs, 12-lead electrocardiogram (ECG), and laboratory data. [from baseline to 24 weeks and 52 weeks]",null,null,null,"OTHER:U1111-1134-2695"],["NCT05013229","A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","679","Diabetes Mellitus, Type 2","DRUG:IcoSema; DRUG:Insulin glargine; DRUG:insulin aspart","Novo Nordisk A/S","2021-11-30","2023-11-14","FALSE","Change in HbA1c [From baseline week 0 (V2) to week 52 (V54)]","DERIVED:42557064; DERIVED:42306490; DERIVED:40482670",null,null,"OTHER:U1111-1260-8295; EUDRACT_NUMBER:2020-005309-18; REGISTRY:jRCT2051210127"],["NCT06728124","A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","630","Obesity/Overweight","DRUG:GZR18; OTHER:Placebo","Gan & Lee Pharmaceuticals.","2024-12-30","2026-05","FALSE","Percent change in weight from baseline (%) [From Week 0 to Week 48]",null,null,null,null],["NCT07171723","Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment","SILENCED","COMPLETED","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","DOUBLE","24","Obesity &Amp; Overweight","BIOLOGICAL:Liver-Expressed Antimicrobial Peptide 2 (LEAP2); OTHER:Placebo (saline)","University Hospital, Gentofte, Copenhagen","2025-09-01","2026-08-12","FALSE","Food intake [290 to 310 minutes]",null,null,"UNDECIDED",null],["NCT07728669","Digital Dietary Intervention for Patients Receiving GLP-1 Receptor Agonist Therapy","NutriSteppe","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","120","Type 2 Diabetes Mellitus (T2DM); Obesity (Disorder); Overweight; Metabolic Syndrome","BEHAVIORAL:NutriSteppe Digital Dietary Intervention","Kazakh Academy of Nutrition","2026-07-20","2026-11","FALSE","Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12 [Baseline and Week 12]",null,null,"YES","OTHER_GRANT:AP26102783"],["NCT03632759","Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D",null,"COMPLETED","INTERVENTIONAL","EARLY_PHASE1","NON_RANDOMIZED","NONE","16","Type 1 Diabetes Mellitus","DRUG:Liraglutide; DRUG:Golimumab","Carla Greenbaum, MD","2018-08-15","2021-11-09","FALSE","Proportion of individuals with peak MMTT stimulated C-peptide >0.017 pmol/mL. [0-to-8 weeks]","DERIVED:38096190",null,"UNDECIDED",null],["NCT01364584","Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes","Exenatide","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","23","Type 2 Diabetes","DRUG:Exenatide; DRUG:Placebo","University of Colorado, Denver","2010-10","2014-12","TRUE","Peak Oxygen Consumption (VO2 Peak) [Baseline and 3 months]",null,null,null,null],["NCT07257484","Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors",null,"RECRUITING","INTERVENTIONAL","PHASE4",null,"NONE","30","Obesity (Disorder); Breast Cancer","DRUG:Tirzepatide","Weill Medical College of Cornell University","2026-06-08","2027-12-03","FALSE","Percentage of participants completing week 24 visit with all required assessments [24 weeks]",null,null,"NO","NIH:KL2TR002385"],["NCT07294950","Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination","REST","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","98","Obesity (Disorder); Weight Change; Blood Pressure Monitoring; Appetite Regulation","DRUG:Gradual dose reduction of semaglutide; DRUG:Abrupt cessation of semaglutide","Mount Sinai Hospital, Canada","2026-02-01","2028-09","FALSE","Differences in changes in body weight between each study group [32 weeks]","DERIVED:42507673",null,"NO",null],["NCT03586843","A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","52","Obesity","DRUG:JNJ-64565111","Janssen Research & Development, LLC","2018-06-29","2019-03-17","FALSE","Part A: Maximum Observed Serum Concentration of JNJ-64565111 (Cmax) [Predose, 4, 8, 12, 24, 36, 48, 72, 96, 144, 192, 384, 672 and 984 hours postdose; at End of study (EOS): 7-14 days after Day 42 of Treatment Period 3 (approximately up to 26 weeks)] | Part A: Area Under the Serum Concentration Time Curve From Time 0 to Infinite Time (AUC [0-infinity]) [Predose, 4, 8, 12, 24, 36, 48, 72, 96, 144, 192, 384, 672 and 984 hours postdose; at EOS: 7-14 days after Day 42 of Treatment Period 3 (approximately up to 26 weeks)] | Part A: Area Under the Serum Concentration Time Curve From Time 0 to Time of the Last Measurable Concentration (AUC [0-last]) [Predose, 4, 8, 12, 24, 36, 48, 72, 96, 144, 192, 384, 672 and 984 hours postdose; at EOS: 7-14 days after Day 42 of Treatment Period 3 (approximately up to 26 weeks)] | Part B: Number of Participants with Gastrointestinal Adverse Events as a Measure of Safety and Tolerability of JNJ-64565111 [Approximately up to 6 weeks]",null,null,null,"OTHER:64565111OBE1001"],["NCT07275697","Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study","WAIT","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","200","Atrial Fibrillation (AF); Obesity & Overweight","DRUG:Semaglutide 2.4 mg; BEHAVIORAL:Standard medical treatment","Emma Svennberg","2026-03-23","2028-12-30","FALSE","Arrhythmia-free survival at 12 months after catheter ablation, excluding the 3-month blanking period, with recurrence defined as any ILR-detected AF, atrial flutter, or atrial tachycardia ≥30 seconds. [12 months post-ablation]",null,null,"NO","CTIS:2025-524182-25-00; NIH:2025"],["NCT04779697","GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","96","Obesity","DRUG:GLP-1 analogue - semaglutide; OTHER:Placebo","Yale University","2021-02-01","2024-11-19","TRUE","Change in Craving Score [Average change in avg FCI craving score from week 0 to end of treatment (week 12) computed as avg FCI score at week 12 - avg FCI score at Week 0.] | Change in Hunger Score [Average change in hunger VAS rating from week 0 and end of study week 12 (week 12 VAS - Week 0 VAS)] | Change in Food Intake [Change in FST total calorie energy density (totalcalED)from FST at week 0 and FST during treatment at week 12 (week 12 FST - Week 0 FST totalcalED change)]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/97/NCT04779697/Prot_SAP_000.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/97/NCT04779697/ICF_001.pdf",null,"NIH:2R01DK099039-06"],["NCT05347147","A Trial to Determine the Efficacy and Safety of Presendin in IIH","IIH EVOLVE","TERMINATED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","14","Idiopathic Intracranial Hypertension","DRUG:Presendin; DRUG:Placebo","Invex Therapeutics Ltd.","2022-11-18","2023-09-18","TRUE","Change in ICP From Baseline to Week 24 Measured by Lumbar Puncture (LP), Where a Higher LP Value Indicates Greater ICP [Baseline to Week 24]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/47/NCT05347147/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/47/NCT05347147/SAP_001.pdf","NO",null],["NCT06393348","Efficacy and Safety of HRS-7535 Tablets in T2DM Subjects Poorly Controlled With Metformin and SGLT2i.",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","155","Type 2 Diabetes","DRUG:HRS-7535; DRUG:Placebo","Shandong Suncadia Medicine Co., Ltd.","2024-05-17","2024-11-15","FALSE","Change in HbA1c from baseline at Week 16 [Week 16]",null,null,"UNDECIDED",null],["NCT06323174","A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise","REIMAGINE 1","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","189","Type 2 Diabetes","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2024-03-19","2025-10-01","FALSE","Change in glycated haemoglobin (HbA1c) [From baseline (week 0) to end of treatment (week 40)]","DERIVED:42251860",null,"YES","OTHER:2022-502677-42; OTHER:U1111-1283-0404"],["NCT05029076","Human Bioequivalence Test of Liraglutide Injection",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","28","Type 2 Diabetes","DRUG:Liraglutide injection; DRUG:Victoza","Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","2019-05-21","2019-06-01","FALSE","Maximum (peak) plasma drug concentration(Cmax) [0 hour（pre-dose,within 60mins） to 72hours after administration on day1 and day 15.] | Time to reach maximum (peak) plasma concentration following drug administration (Tmax) [0 hour（pre-dose,within 60mins） to 72hours after administration on day1 and day 15.] | Area under the plasma concentration-time curve from time zero to time t (AUC0-t) [0 hour（pre-dose, within 60 mins） to 72 hours after administration on day1 and day 15.] | Terminal disposition rate constant/terminal rate constant (λz) [0 hour（pre-dose, within 60 mins） to 72 hours after administration on day1 and day 15.] | Elimination half-life (t1/2) [0 hour（pre-dose, within 60 mins） to 72 hours after administration on day1 and day 15.] | Apparent total clearance of the drug from plasma after oral administration (CL/F) [0 hour（pre-dose, within 60 mins） to 72 hours after administration on day1 and day 15.] | Apparent volume of distribution after non-intravenous administration (Vd/F) [0 hour（pre-dose, within 60 mins） to 72 hours after administration on day1 and day 15.] | Bioavailability (systemic availability of the administered dose) [0 hour（pre-dose, within 60mins） to 72 hours after administration on day1 and day 15.] | Adverse Event, Serious Adverse Event and Drug Combination [up to day 15]","DERIVED:36883362",null,null,null],["NCT06449703","A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects",null,"UNKNOWN","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","44","Healthy","DRUG:insulin degludec/liraglutide; DRUG:Xultophy®","Tonghua Dongbao Pharmaceutical Co.,Ltd","2024-05-06","2024-06-16","FALSE","Maximum observed plasma insulin degludec concentration [0 hours to 120 hours] | Maximum observed plasma liraglutide concentration [0 hours to 72 hours] | Area under the plasma insulin degludec concentration time curve [From 0 to last quantifiable observation after single dose of insulin degludec/liraglutide, assessments from 0 hours to 120 hours] | Area under the plasma liraglutide concentration time curve [From 0 to last quantifiable observation after single dose of insulin degludec/liraglutide, assessments from 0 hours to 72 hours] | Area under the plasma insulin degludec concentration time curve from 0 to infinity after single dose [0 hours to 120 hours] | Area under the plasma liraglutide concentration time curve from 0 to infinity after single dose [0 hours to 72 hours]",null,null,"NO",null],["NCT07808879","Comparison of [68Ga]Ga-HBED-CC-PEG6-Exendin-4 and [68Ga]Ga-HBED-CC-Exendin-4 PET/CT for Insulinoma Localization","HBED-CC-PEG6-E","RECRUITING","INTERVENTIONAL",null,null,"NONE","20","Insulinoma","DIAGNOSTIC_TEST:[68Ga]Ga-HBED-CC-PEG6-exendin-4 PET/CT; DIAGNOSTIC_TEST:[68Ga]Ga-HBED-CC-exendin-4 PET/CT","Peking Union Medical College Hospital","2026-10-01","2027-08-31","FALSE","Diagnostic performance comparison between two GLP-1R PET tracers for insulinoma localization [Up to 2 months after subjects complete both PET/CT scans and obtain pathological biopsy/surgical results]",null,null,"NO","OTHER_GRANT:2025-PUMCH-D-003"],["NCT06465186","A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","85","Non-alcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; NAFLD; Metabolic Dysfunction-associated Steatotic Liver Disease; Metabolic Dysfunction-associated Steatohepatitis","COMBINATION_PRODUCT:Efinopegdutide; COMBINATION_PRODUCT:Placebo","Merck Sharp & Dohme LLC","2024-07-12","2026-08-03","FALSE","Change from Baseline in Liver Fat Content (LFC) at Week 28 [Baseline and 28 weeks] | Percentage of Participants Who Experienced an Adverse Event (AE) [Up to approximately 36 weeks] | Percentage of Participants Discontinuing Study Medication Due to an AE [Up to approximately 28 weeks]",null,null,"YES","REGISTRY:2024-510923-20-00; OTHER:MK-6024-017; REGISTRY:jRCT2031240217; REGISTRY:U1111-1302-7589"],["NCT03204396","Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues","SKIP","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","256","Glucagon-like Peptide-1; Smoking Cessation; Weight Change, Body; Craving","DRUG:Dulaglutide; DRUG:0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl])","University Hospital, Basel, Switzerland","2017-06-26","2022-07-30","FALSE","Point prevalence abstinence rate at week 12 [12 weeks]","DERIVED:40037282; DERIVED:38371479; DERIVED:38264360; DERIVED:37991022; DERIVED:37081574; DERIVED:36874396","Study Protocol and Statistical Analysis Plan: Substudy \"SKIP-Energy\"|https://cdn.clinicaltrials.gov/large-docs/96/NCT03204396/Prot_SAP_000.pdf; Study Protocol: Appendix 4_SKIP Energy_V1_13_10_17|https://cdn.clinicaltrials.gov/large-docs/96/NCT03204396/Prot_001.pdf; Study Protocol: Appendix 5_SKIP_Substudy fMRI|https://cdn.clinicaltrials.gov/large-docs/96/NCT03204396/Prot_002.pdf","NO","NIH:2017"],["NCT07702461","Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists",null,"RECRUITING","OBSERVATIONAL",null,null,null,"300","Obesity & Overweight; Diabetes (DM)","DRUG:Glucagon-Like Peptide-1 Agonist (GLP-1)","Ohio State University","2026-06-12","2026-10","FALSE","Change in Resistance Training Status Before Versus Since GLP-1 Receptor Agonist Initiation [Day 1]","BACKGROUND:39043396; BACKGROUND:33239350; BACKGROUND:41843416; BACKGROUND:36841762; BACKGROUND:38629387; BACKGROUND:38937282; BACKGROUND:35237446",null,"UNDECIDED",null],["NCT03060980","Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin",null,"TERMINATED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","245","Diabetes Mellitus, Type 2","DRUG:ITCA 650 20/60 mcg/day; DRUG:Empagliflozin (oral); DRUG:Glimepiride (oral)","Intarcia Therapeutics","2017-03-03","2018-01-26","FALSE","Reduction in glycosylated hemoglobin A1c [Randomization to 69 weeks] | Reduction in weight [Randomization to 69 weeks]",null,null,"NO",null],["NCT00085969","Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","99","Diabetes Mellitus, Type 2","DRUG:Placebo 0.04 mL twice daily; DRUG:Placebo 0.04 mL once daily; DRUG:Placebo 0.08 mL once daily; DRUG:B - Exenatide 10 mcg twice daily; DRUG:C - Exenatide 10 mcg once daily; DRUG:Exenatide 20 mcg once daily","AstraZeneca","2003-09","2004-01","FALSE","Change in HbA1c (glycosylated hemoglobin) from Baseline to Day 28 [Baseline, Day 28]","DERIVED:17705687",null,null,null],["NCT00254254","A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","SINGLE","13","Type 2 Diabetes Mellitus","DRUG:Exenatide - Exenatide - Placebo; DRUG:Exenatide - Placebo - Exenatide; DRUG:Placebo - Exenatide - Exenatide","AstraZeneca","2006-02","2007-02","FALSE","To assess the pharmacokinetics of exenatide [Three day-long (8 hour) assessments over a 5-week period] | To assess the pharmacodynamics of exenatide [Three day-long (8 hour) assessments over a 5-week period] | Number of adverse events [Visit 2 through Visit 4]","DERIVED:19446153",null,null,null],["NCT03341013","A Pilot Study Investigating Bioequivalence Between a Single Dose of Formulation 2 and Formulation 3 of MEDI0382",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","24","Type 2 Diabetes Mellitus","DRUG:MEDI0382 Formulation 2; DRUG:MEDI0382 Formulation 3","MedImmune LLC","2017-11-30","2018-01-29","FALSE","Area under the drug concentration curve [48 hours] | Maximum observed plasma concentration of MEDI0382 [48 hours]",null,null,null,null],["NCT07654062","Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)","DREAM-PRE","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","150","Prediabetes; Impaired Fasting Glucose; Impaired Glucose Tolerance (Prediabetes)","DRUG:Mazdutide; DRUG:Placebo; BEHAVIORAL:Standardized Lifestyle Intervention","Shandong Provincial Hospital","2026-07","2028-06","FALSE","Proportion of Participants Achieving Normal Glucose Regulation (NGR) at Week 24 [Week 24]","BACKGROUND:33567185; BACKGROUND:38907683; BACKGROUND:26132939; BACKGROUND:41407860; BACKGROUND:41407859; BACKGROUND:28655017; BACKGROUND:31036503; BACKGROUND:38092790; BACKGROUND:37943529",null,"NO","OTHER:SWYX:NO. 2026-1026"],["NCT04039503","A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin","SURPASS-5","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","475","Type 2 Diabetes","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2019-08-30","2020-12-22","TRUE","Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) [Baseline, Week 40]","DERIVED:41961454; DERIVED:39531161; DERIVED:37668888; DERIVED:37526908; DERIVED:35210595; DERIVED:35133415","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/03/NCT04039503/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/03/NCT04039503/SAP_001.pdf","YES","OTHER:I8F-MC-GPGI; EUDRACT_NUMBER:2019-000860-99; NIH:2019"],["NCT04916470","Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes","STEP HFpEF DM","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","617","Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Placebo (Semaglutide)","Novo Nordisk A/S","2021-06-15","2023-10-11","FALSE","Change in KCCQ (Kansas City Cardiomyopathy Questionnaire) clinical summary score [From baseline (week 0) to end of treatment (week 52)] | Change in body weight [From baseline (week 0) to end of treatment (week 52)]","BACKGROUND:37294245; DERIVED:41045908; DERIVED:40956259; DERIVED:39848268; DERIVED:39222642; DERIVED:39217567; DERIVED:39217565; DERIVED:39217564; DERIVED:38913004; DERIVED:38913003; DERIVED:38739118; DERIVED:38599221; DERIVED:38587233",null,"YES","OTHER:U1111-1257-5069; EUDRACT_NUMBER:2020-004170-22"],["NCT04741074","Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy","RAISE-KT","TERMINATED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","15","CKD; Diabetic Kidney Disease; Type 2 Diabetes Mellitus in Obese; Obesity; Severe Obesity","DRUG:Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution; DRUG:Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution","Geisinger Clinic","2021-07-23","2023-01-31","TRUE","Kidney Transplant Eligibility [Ascertained at the end of 9 months]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/74/NCT04741074/Prot_SAP_000.pdf","YES","REGISTRY:Universal Trial Number"],["NCT01753362","Liraglutide In Overweight Patients With Type 1 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","84","Type 1 Diabetes","DRUG:liraglutide; DRUG:placebo","University at Buffalo","2012-12","2017-12","TRUE","HbA1c [26 weeks]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/62/NCT01753362/Prot_SAP_000.pdf",null,null],["NCT01638260","GLP-1 and Non-exercise Activity Thermogenesis in RHZ",null,"TERMINATED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","22","Type 2 Diabetes Mellitus","DRUG:Liraglutide; BEHAVIORAL:NEAT","Maastricht University Medical Center","2012-10","2013-11","FALSE","Change in HbA1c from baseline and end of treatment (26 weeks) and end of follow-up (52 weeks) [6 times, screening, week 0, week 13-26-39-52] | Change in weight from baseline and end of treatment (26 weeks) and end of follow-up (52 weeks) [6 times, screening, week 0, week 13-26-39-52]",null,null,null,null],["NCT07382388","A Real-World Study on the Impact of Weight Loss on Treatment Efficacy in Overweight/Obese Patients With Plaque Psoriasis",null,"NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"70","Psoriasis","COMBINATION_PRODUCT:Weight loss and psoriasis treatment; COMBINATION_PRODUCT:psoriasis treatment","Peking University Third Hospital","2026-01-28","2027-12-31","FALSE","Proportion of PASI<3 at Week 24 [Week 24]",null,null,null,null],["NCT07700030","High-protein plUs reSistance Training in gLucagon-like pEptide 1 Receptor Agonist Users (HUSTLE)",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","32","Weight Loss","OTHER:High protein diet; BEHAVIORAL:Resistance Training (RT) Programs","NYU Langone Health","2026-07","2027-11","FALSE","Changes in lean Skeletal Muscle Mass (SMM) quadriceps [Baseline, Month 6] | Changes in lean Skeletal Muscle Mass (SMM) rhomboids [Baseline, Month 6] | Changes in 3-Repetition Maximum (3RM) Bench Press [Baseline, Month 6] | Changes in 3-Repetition Maximum (3RM) Leg Press [Baseline, Month 6]",null,null,"NO",null],["NCT00917267","A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","691","Type 2 Diabetes Mellitus","DRUG:exenatide once weekly; DRUG:exenatide twice daily","AstraZeneca","2009-07","2010-09","TRUE","Change in HbA1c From Baseline to Week 26. [Baseline, Week 26]","DERIVED:24843650; DERIVED:24843631",null,null,null],["NCT05931367","A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee","TRIUMPH-4","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","445","Obesity; Overweight; Osteo Arthritis Knee","DRUG:Retatrutide; DRUG:Placebo","Eli Lilly and Company","2023-08-01","2025-11-14","FALSE","Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score [Baseline, Week 68] | Percent Change from Baseline in Body Weight [Baseline, Week 68]",null,null,"YES","OTHER:J1I-MC-GZBN; OTHER:2023-503660-17-00; NIH:2023"],["NCT00744367","A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","326","Diabetes Mellitus Type 2","DRUG:metformin; DRUG:pioglitazone; DRUG:placebo; DRUG:taspoglutide","Hoffmann-La Roche","2008-10","2010-11","FALSE","Absolute change from baseline in HbA1c [24 weeks]",null,null,null,"OTHER:2008-001744-39; NIH:2008"],["NCT06972992","A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","28","Chronic Weight Management","DRUG:ASC47 +Semaglutide; DRUG:Placebo+Semaglutide","Ascletis Pharma (China) Co., Limited","2025-04-18","2025-09-22","FALSE","Adverse events [up to 71 days]",null,null,null,null],["NCT01061775","Effects of Exenatide on Hypothalamic Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1; PHASE2",null,"NONE","19","Hypothalamic Obesity","DRUG:Exenatide","Children's Hospitals and Clinics of Minnesota","2010-01","2013-07","TRUE","BMI Change [24 weeks] | Waist to Height Ratio (WHtR) [24 weeks]",null,null,"NO",null],["NCT00135330","An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","137","Diabetes Mellitus, Type 2","DRUG:exenatide; DRUG:rosiglitazone","AstraZeneca","2005-10","2008-07","TRUE","Change in ASIiAUC During a Hyperglycemic Clamp Test. [20 weeks]","DERIVED:22236356; DERIVED:20107105",null,null,null],["NCT07613307","A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting","ACHIEVE-RAM","RECRUITING","INTERVENTIONAL","PHASE3",null,"NONE","130","Diabetes Mellitus, Type 2; Diabetes Melletus; Glucose Metabolism Disorders; Metabolic Disorders; Nutritional and Metabolic Diseases; Endocrine System Diseases; Feeding Behavior; Behavior; Fasting; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptide Receptors; Receptors, G-Protein-Coupled; Receptors, Cell Surface; Membrane Proteins; Proteins; Receptors, Peptide","DRUG:Orforglipron","Eli Lilly and Company","2026-07-15","2027-05","FALSE","Change from Baseline in Hemoglobin A1C (HbA1c) [Baseline, up to 8 Weeks after Start of Ramadan]",null,null,"YES","OTHER:J2A-MC-GZPV"],["NCT05822544","Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","564","Healthy Subjects; Obesity; Type 2 Diabetes","DRUG:TLC-6740 Oral Solution; OTHER:Placebo Oral Solution; DRUG:TLC-6740 Tablet; DRUG:Drug Metabolizing Enzyme; DRUG:Tirzepatide; OTHER:Placebo Tablet","OrsoBio, Inc","2023-04-22","2026-09","FALSE","Incidence of TLC-6740 treatment-emergent adverse events [Through study completion: up to Day 15 (Parts A, C); Day 24 (Parts B, C); Day 22 (Part D); Day 49 (Part E); Day 168 (Parts F, G) of the study] | PK of TLC-6740 AUC [Through study completion: up to Day 15 (Parts A, C); Day 24 (Parts B, C); Day 22 (Part D); Day 49 (Part E); Day 168 (Parts F, G) of the study] | PK of TLC-6740 Cmax [Through study completion: up to Day 15 (Parts A, C); Day 24 (Parts B, C); Day 22 (Part D); Day 49 (Part E); Day 168 (Parts F, G) of the study] | PK of TLC-6740 tmax [Through study completion: up to Day 15 (Parts A, C); Day 24 (Parts B, C); Day 22 (Part D); Day 49 (Part E); Day 168 (Parts F, G) of the study] | PK of TLC-6740 t1/2 [Through study completion: up to Day 15 (Parts A, C); Day 24 (Parts B, C); Day 22 (Part D); Day 49 (Part E); Day 168 (Parts F, G) of the study] | PK of TLC-6740 CL/F [Through study completion: up to Day 15 (Parts A, C); Day 24 (Parts B, C); Day 22 (Part D); Day 49 (Part E); Day 168 (Parts F, G) of the study]",null,null,null,null],["NCT04196231","Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)","BEYOND","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","258","Type 2 Diabetes","DRUG:IDegLira; DRUG:IGlarLixi; DRUG:Insulin/Canaglifozin; DRUG:Insulin/Dapaglifozin; DRUG:Insulin/Empaglifozin; DRUG:Basal Bolus","University of Campania Luigi Vanvitelli","2019-11-27","2020-09-30","FALSE","Hba1c change [6 months, 9 months, 12 months] | Proportions of patients with significant HbA1c change [Baseline, 3 months, 6 months, 9 months, 12 months, 18 months]","BACKGROUND:31715201; DERIVED:37787888; DERIVED:33883195",null,"NO",null],["NCT05226000","Pharmacokinetics of Benaglutide Injection in Overweight/Obese Adults",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","16","Overweight/Obese Adults","DRUG:Benaglutide Injection","The Affiliated Hospital of Qingdao University","2020-07-07","2020-12-01","FALSE","Peak Plasma Concentration (Cmax) [80 days] | Area under the plasma concentration versus time curve (AUC)0-t [80 days] | Area under the plasma concentration versus time curve (AUC)0-∞ [80 days] | elimination half-life time(T1/2) [80 days] | The total clearance(CL) [80 days]",null,null,null,null],["NCT06993792","A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","1400","Obesity; Overweight; Type 2 Diabetes","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2025-05-15","2027-08","FALSE","Number of Participants Allocated to Each Study [Baseline to Week 4]",null,null,"YES","CTIS:2025-521098-14-00; OTHER:J2A-MC-GZPO; OTHER:J2A-MC-GZP1; OTHER:J2A-MC-GZP2; NIH:2025"],["NCT02456428","Incretin-based Drugs and the Risk of Heart Failure",null,"COMPLETED","OBSERVATIONAL",null,null,null,"1499650","Type 2 Diabetes Mellitus","DRUG:DPP-4 inhibitors; DRUG:GLP-1 analogs; DRUG:Insulins; DRUG:Biguanides; DRUG:Sulfonylureas; DRUG:Thiazolidinediones; DRUG:Alpha-glucosidase inhibitors; DRUG:Meglitinides","Canadian Network for Observational Drug Effect Studies, CNODES","2014-03","2015-05","FALSE","Hospitalization for incident heart failure [Patients were followed from the date of study cohort entry until hospitalization for incident heart failure, censoring, or for up to 87 months.]","RESULT:27007958",null,null,null],["NCT01269034","New Onset Type 1 Diabetes: Role of Exenatide",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","13","Type 1 Diabetes","DRUG:Exenatide; DRUG:Rapid and long acting insulin; DRUG:long acting insulin + rapid acting + 1.25 mcg Exenatide","Albert Einstein College of Medicine","2010-12","2017-01-31","TRUE","The Role of Exenatide as Compared to Insulin Monotherapy in Reducing Postprandial Hyperglycemia. [February 2013]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/34/NCT01269034/Prot_000.pdf",null,"NIH:3R01DK077166-05S1"],["NCT02075281","Effect of LAPS-Exendin on Body Weight in Obese Population",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","297","Obesity","BIOLOGICAL:HM11260C; BIOLOGICAL:Placebo","Hanmi Pharmaceutical Company Limited","2014-02","2015-01","FALSE","Change from baseline in body weight at 20 weeks [20 weeks from baseline]",null,null,null,null],["NCT06856928","Impact of Antiobesity Medications on Appetite and Appetite-related Hormones and Metabolites.",null,"NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"16","Obesity; Drug","OTHER:Meal Challenge","University of Colorado, Denver","2025-03","2026-12","FALSE","Participant Recruitment [6-10 weeks] | Meal test tolerability [6-10 weeks] | Rate of protocol completion [6-10 weeks]",null,null,"NO",null],["NCT04998136","Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","150","Obesity","DRUG:Semaglutide 2.4 mg; DRUG:Placebo (semaglutide 2.4 mg)","Novo Nordisk A/S","2022-08-15","2023-10-16","TRUE","Change in Body Weight (%) : In-trial Observation Period [Baseline (week 0), end of treatment (week 44)] | Change in Body Weight (%) : On-treatment Observation Period [Baseline (week 0), end of treatment (week 44)] | Number of Participants Achieved More Than or Equal to (≥) 5 Percent (%) Body Weight Reduction (Yes/no) : In-trial Observation Period [At week 44] | Number of Participants Achieved More Than or Equal to (≥) 5 Percent (%) Body Weight Reduction (Yes/no) : On-treatment Observation Period [At week 44]","DERIVED:40825340","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/36/NCT04998136/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/36/NCT04998136/SAP_001.pdf","YES","OTHER:U1111-1265-5285"],["NCT05435677","A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or Together",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","20","Diabetes Mellitus, Type 2","DRUG:IcoSema; DRUG:insulin icodec; DRUG:semaglutide","Novo Nordisk A/S","2022-06-22","2023-04-25","FALSE","AUCIco,0-tz:Area under the serum insulin icodec concentration-time curve after a single dose [From 0 hours to tz hours after IMP administration (day 1) where tz is the time of the last quantifiable concentration] | Dose-normalised AUCSema,0-tz: Area under the plasma semaglutide concentration-time curve after a single dose divided by dose [From 0 hours to tz hours after IMP administration (day 1) where tz is the time of the last quantifiable concentration]","DERIVED:41051695",null,"YES","OTHER:U1111-1262-1959"],["NCT00344851","Exenatide and Metformin Therapy in Overweight Women With PCOS",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","60","Polycystic Ovary Syndrome","DRUG:metformin, exenatide or combined (metformin & exenatide )","Metabolic Center of Louisiana Research Foundation","2006-06",null,"FALSE","- Menstrual Cyclicity ( # menses/ 24 weeks) [every 4 weeks]","DERIVED:18460557",null,null,null],["NCT00688701","GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy","GETGOAL-MONO","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","361","Diabetes Mellitus, Type 2","DRUG:Lixisenatide (AVE0010); DRUG:Placebo; DEVICE:Pen auto-injector","Sanofi","2008-05","2009-12","TRUE","Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 [Baseline, Week 12]","RESULT:22432104; DERIVED:38770818",null,null,"OTHER:EudraCT 2007-005887-29"],["NCT00809705","A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","60","Diabetes Mellitus Type 2","DRUG:Placebo; DRUG:taspoglutide","Hoffmann-La Roche","2008-12","2009-10","FALSE","Tmax, log (AUC), log(Cmax)of paracetamol [Days -1, 1, 5, 29, 33, 78 and 82]",null,null,null,"OTHER:2008-003575-47; NIH:2008"],["NCT06221969","A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","1024","Type 2 Diabetes","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Tirzepatide","Novo Nordisk A/S","2024-01-16","2026-03-04","FALSE","Change in glycated haemoglobin (HbA1c) [From baseline (week 0) to end of treatment (week 68)] | Relative change in body weight [From baseline (week 0) to end of treatment (week 68)]",null,null,"YES","OTHER:U1111-1282-5561; OTHER:2023-503789-21-00; NIH:2023"],["NCT05812183","Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity",null,"WITHDRAWN","INTERVENTIONAL","PHASE4","NON_RANDOMIZED","SINGLE","0","Dyspnea; Quality of Life","DEVICE:Bariatric surgery; DRUG:Medical weight loss","University of California, Los Angeles","2023-07-09","2025-02-12","FALSE","Dyspnea [12 months]",null,null,"NO",null],["NCT06921486","The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","QUADRUPLE","1003","Obesity and Overweight","DRUG:Phase IIb：Efsubaglutide Alfa 5 mg QW; DRUG:Phase IIb：Efsubaglutide Alfa 10 mg QW; DRUG:Phase IIb：Efsubaglutide Alfa 20 mg QW; DRUG:Phase IIb：Efsubaglutide Alfa 20 mg Q2W; DRUG:Phase IIb：Placebo; DRUG:Phase III：Recommended Phase 3 Dose High Dose; DRUG:Phase III：Recommended Phase 3 Dose Low Dose; DRUG:Phase III：Placebo","Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","2025-03-31","2026-08-31","FALSE","Percentage change in body weight from baseline [Phase IIb (18 weeks) , Phase III (30 weeks)] | Proportion of subjects with ≥5% reduction in body weight from baseline [Phase III (30 weeks)]",null,null,"NO","OTHER:YN011-W202; OTHER:YN011-W303"],["NCT02584075","Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function",null,"UNKNOWN","INTERVENTIONAL","PHASE4",null,"NONE","100","Coronary Endothelial Function","DRUG:Byetta (Exenatide); DRUG:Glucophage ( Metformin Hydrochloride)","Beijing Chao Yang Hospital","2015-11","2017-11","FALSE","Coronary endothelial function [the change of coronary endothelial function(baseline, 12 weeks)]",null,null,null,null],["NCT02315001","Liraglutide to Improve corONary Haemodynamics During Exercise streSS","LIONESS","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","26","Ischaemic Heart Disease; Coronary Heart Disease; Chronic Stable Angina","DRUG:Liraglutide; OTHER:Placebo","King's College London","2014-01","2015-03","FALSE","Change in rate pressure product at 0.1 mV ST-segment depression [Following consecutive exercise treadmill tests performed at Week 2, Week3, Week 5 and Week 6 of a 6-week study protocol] | Change in degree of ST-segment depression at peak exercise [Following consecutive exercise treadmill tests performed at Week 2, Week3, Week 5 and Week 6 of a 6-week study protocol]","BACKGROUND:25848859; DERIVED:33579317",null,null,"OTHER_GRANT:FS/11/70/28917"],["NCT07429045","A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","44","Overweight and Obesity","DRUG:AMG 133","Amgen","2025-03-11","2025-11-21","FALSE","Maximum Observed Concentration (Cmax) of AMG 133 [Up to Day 120] | Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of AMG 133 [Up to Day 120] | AUC From Time 0 Extrapolated to Infinity (AUCinf) of AMG 133 [Up to Day 120]",null,null,"YES",null],["NCT02276196","Effect of LIXIsenatide on the Renal System","ELIXIRS","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","40","Diabetic Kidney Disease; Diabetic Nephropathy; Diabetes Mellitus; Glucagon-Like Peptide 1","DRUG:Lixisenatide; DRUG:Insulin glulisine","Amsterdam UMC, location VUmc","2014-09","2016-04","FALSE","Changes from baseline following 8-week treatment with a glucagon-like peptide(GLP)-1 receptor agonist versus insulin glulisine on renal hemodynamics, measured as glomerular filtration rate (GFR) / effective renal plasma flow (ERPF) [8 weeks]","DERIVED:28449402",null,null,null],["NCT04232969","Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease","Exenatide-PD3","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","194","Parkinson's Disease","DRUG:Exenatide extended release 2mg (Bydureon)","University College, London","2020-01-20","2024-02-24","FALSE","Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part 3 [96 weeks]","DERIVED:39919773; DERIVED:34049922",null,"NO",null],["NCT04451837","Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","200","Type2 Diabetes","DRUG:Semaglutide; DRUG:Dapagliflozin","Region Skane","2020-09-10","2021-12-15","FALSE","Hba1c [6 months]","DERIVED:38177805",null,"NO",null],["NCT04731272","GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","30","Cystic Fibrosis; Pancreatic Insufficiency; Abnormal Glucose Tolerance; Diabetes","DRUG:Dulaglutide 0.75Mg/0.5Ml Inj Pen","University of Pennsylvania","2021-07-16","2027-06-30","FALSE","Early-phase insulin secretion [18 weeks]",null,null,"YES",null],["NCT03546205","A Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Participants With Varying Degrees of Renal Function",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","40","Kidney Failure, Chronic","DRUG:JNJ-64565111","Janssen Research & Development, LLC","2018-06-06","2018-12-17","FALSE","Maximum Observed Serum Analyte Concentration (Cmax) of JNJ-64565111 [Predose, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 984 hours postdose] | Area Under the Serum Analyte Concentration-Time Curve from Time Zero to Last Measurable (not Below Quantification Limit) Concentration (AUC[0-last]) of JNJ-64565111 [Predose, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 984 hours postdose] | Area Under the Serum Analyte Concentration-Time Curve from Time Zero to Infinite Time (AUC[0-infinity]) of JNJ-64565111 [Predose, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 984 hours postdose]",null,null,null,"OTHER:64565111OBE1003"],["NCT04001231","Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus",null,"WITHDRAWN","INTERVENTIONAL","PHASE1",null,"NONE","0","Type 2 Diabetes","DRUG:Exenatide Once-Weekly Suspension","AstraZeneca","2020-06-30","2021-07-02","FALSE","Plasma concentrations versus time profile of exenatide [Blood sample will be collected on Visit 3-6 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 7-17 (pre-dose). Visit 18-22 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 23-29 (once/visit).] | Cmax [Blood sample will be collected on Visit 3-6 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 7-17 (pre-dose). Visit 18-22 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 23-29 (once/visit).] | tmax [Blood sample will be collected on Visit 3-6 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 7-17 (pre-dose). Visit 18-22 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 23-29 (once/visit).] | AUC(0-8h) [Blood sample will be collected on Visit 3-6 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 7-17 (pre-dose). Visit 18-22 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 23-29 (once/visit).] | AUC(0-168h) [Blood sample will be collected on Visit 3-6 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 7-17 (pre-dose). Visit 18-22 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 23-29 (once/visit).] | AUCτ,ss [Blood sample will be collected on Visit 3-6 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 7-17 (pre-dose). Visit 18-22 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 23-29 (once/visit).] | Cav,ss [Blood sample will be collected on Visit 3-6 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 7-17 (pre-dose). Visit 18-22 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 23-29 (once/visit).] | λ z [Blood sample will be collected on Visit 3-6 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 7-17 (pre-dose). Visit 18-22 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 23-29 (once/visit).] | t½ [Blood sample will be collected on Visit 3-6 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 7-17 (pre-dose). Visit 18-22 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 23-29 (once/visit).] | CL/F [Blood sample will be collected on Visit 3-6 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 7-17 (pre-dose). Visit 18-22 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 23-29 (once/visit).] | Vss/F [Blood sample will be collected on Visit 3-6 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 7-17 (pre-dose). Visit 18-22 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 23-29 (once/visit).] | Rac [Blood sample will be collected on Visit 3-6 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 7-17 (pre-dose). Visit 18-22 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 23-29 (once/visit).] | Ctrough [Blood sample will be collected on Visit 3-6 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 7-17 (pre-dose). Visit 18-22 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 23-29 (once/visit).]",null,null,"UNDECIDED",null],["NCT06779929","Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes",null,"COMPLETED","OBSERVATIONAL",null,null,null,"70000","Type 2 Diabetes","DRUG:Tirzepatide; DRUG:Dulaglutide; DRUG:Semaglutide","Brigham and Women's Hospital","2024-11-01","2025-12-01","FALSE","Composite CV outcome [From treatment initiation to end of follow up, up to 48 months.]","BACKGROUND:37758044; RESULT:41778928",null,null,null],["NCT07060456","Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","300","Type 2 Diabetes","DRUG:HRS9531; DRUG:Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2025-07-25","2027-02","FALSE","Change in HbA1c [from baseline to Week 40]",null,null,"UNDECIDED",null],["NCT07747805","GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD","GLIMR COPD","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","30","COPD; Obesity & Overweight; Sarcopenia","DRUG:Tirzepatide","The Cleveland Clinic","2026-08-28","2028-08-15","FALSE","Change in FEV1 [12 months]","BACKGROUND:31020810; BACKGROUND:37647574",null,"NO","OTHER_GRANT:Mandel MAG0024"],["NCT01768559","Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients","GetGoal-Duo-2","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","894","Type 2 Diabetes","DRUG:Lixisenatide (AVE0010); DRUG:Insulin glulisine QD; DRUG:Insulin glulisine TID; DRUG:Insulin Glargine (Mandatory background drug); DRUG:Metformin (Background drug)","Sanofi","2013-01","2014-12","TRUE","Change in HbA1c From Baseline to Week 26 [Baseline, Week 26] | Change in Body Weight From Baseline to Week 26 [Baseline, Week 26]","RESULT:27222510; DERIVED:31848983; DERIVED:29974618",null,null,"EUDRACT_NUMBER:2012-004096-38; OTHER:U1111-1131-4936"],["NCT06500143","Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery","RESIDUAL","COMPLETED","OBSERVATIONAL",null,null,null,"94","Gastric Retention","DIAGNOSTIC_TEST:Gastric ultrasound","Ciusss de L'Est de l'Île de Montréal","2024-10-09","2025-02-28","FALSE","Increased residual gastric content [Preoperative (day of surgery)]","DERIVED:42265610",null,null,null],["NCT02274740","Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients",null,"TERMINATED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","2","Type II Diabetes Mellitus","DRUG:LIXISENATIDE AVE0010; DRUG:metformin","Sanofi","2015-04","2015-08","FALSE","Change in plasma triglycerides after 10 weeks of treatment area under-the-time concentration curve between 0 and 480 minutes (AUC0-480 min) [After 10 weeks of treatment]",null,null,null,"OTHER:U1111-1153-3774"],["NCT04004988","A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","47","Healthy","DRUG:Tirzepatide; DEVICE:Prefilled syringe (PFS); DEVICE:Auto-injector (AI)","Eli Lilly and Company","2019-08-19","2019-12-16","TRUE","Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Infinity (AUC0toinf) [Predose, 8hours(h), 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h, 336h , 480h, 864h postdose] | PK: Maximum Observed Plasma Concentration (Cmax) of Tirzepatide [Predose, 8hours(h), 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h, 336h , 480h, 864h postdose]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/88/NCT04004988/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/88/NCT04004988/SAP_001.pdf","NO","OTHER:I8F-MC-GPGS"],["NCT04707313","A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","628","Obesity","DRUG:Placebo (Cohorts 1 and 2); DRUG:PF-06882961 (Cohorts 1 and 2); DRUG:Placebo (Cohort 3); DRUG:PF-06882961 (Cohort 3)","Pfizer","2021-01-29","2023-09-13","TRUE","Cohorts 1 and 2: Percent Change From Baseline in Body Weight at End of Treatment at Week 26 [Baseline, Week 26] | Cohort 3: Percent Change From Baseline in Body Weight at End of Treatment at Week 32 [Baseline, Week 32]","DERIVED:40539310","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/13/NCT04707313/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/13/NCT04707313/SAP_001.pdf","YES","EUDRACT_NUMBER:2020-001312-19"],["NCT05577728","Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data",null,"COMPLETED","OBSERVATIONAL",null,null,null,"2316","Diabetes Mellitus, Type 2","DRUG:New use of semaglutide injection; DRUG:New initiation of \"standard of care\" (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral)","Brigham and Women's Hospital","2021-07-01","2022-10-31","FALSE","Long-term glycemic control defined as proportion of patients who will achieve an HbA1c of less than 7.0% (53.0 mmol/mol) [At year 1]","DERIVED:41161770","Study Protocol and Statistical Analysis Plan: Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/28/NCT05577728/Prot_SAP_000.pdf",null,null],["NCT06632457","LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","1590","Metabolic Dysfunction Associated Steatohepatitis","COMBINATION_PRODUCT:Survodutide; COMBINATION_PRODUCT:Placebo matching survodutide","Boehringer Ingelheim","2024-11-12","2029-06-05","FALSE","Time to first occurrence of any component of the composite clinical endpoint (at EoS) consisting of: all-cause mortality, liver transplant, hepatic decompensation events, worsening of MELD score to ≥15 and progression to CSPH [up to 4.5 years.]",null,null,"YES","REGISTRY:2024-513741-36-00; REGISTRY:U1111-1307-0227"],["NCT07858864","GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes","GLP1-SARCO","RECRUITING","OBSERVATIONAL",null,null,null,"42","Obesity; Sarcopenia","DRUG:GLP-1 receptor agonist (e.g., semaglutide, tirzepatide) - prescribed by the treating physician as standard care; the study does not assign or alter treatment.","Istanbul Saglik Bilimleri University","2026-05-30","2026-11-30","FALSE","Change in SARC-F (Strength, Assistance in walking, Rise from a chair, Climb stairs, and Falls) total score [Baseline (GLP-1 RA initiation) and 3 months]","BACKGROUND:36700417; BACKGROUND:31565876; BACKGROUND:37188932; RESULT:37186680",null,"UNDECIDED",null],["NCT05292911","Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","64","Non-Alcoholic Fatty Liver Disease","DRUG:ALT-801; OTHER:Placebo","Altimmune, Inc.","2022-03-09","2022-10-31","FALSE","The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs) [Up to Day 110]","DERIVED:41113119",null,null,null],["NCT01272219","Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","3731","Metabolism and Nutrition Disorder; Obesity","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2011-06-01","2013-03-18","TRUE","Change From Baseline in Fasting Body Weight [Week 0, Week 56] | Proportion of Subjects Losing at Least 5% of Baseline Fasting Body Weight. [At Week 56] | Proportion of Subjects Losing More Than 10% of Baseline Fasting Body Weight [At 56 weeks] | Proportion of Subjects With Onset of Type 2 Diabetes [At 160 weeks]","RESULT:27198973; RESULT:27193270; RESULT:27482610; RESULT:27804269; RESULT:27817208; RESULT:26833744; RESULT:26132939; RESULT:26418188; RESULT:26744025; RESULT:28237263; RESULT:28462892; RESULT:28386912; RESULT:28950422; RESULT:29045079; RESULT:29145215; DERIVED:39316288; DERIVED:35975210",null,null,"EUDRACT_NUMBER:2008-001049-24; OTHER:U1111-1118-7871; NIH:2008"],["NCT07559500","Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","176","Alcohol Use Disorder (AUD)","DRUG:Tirzepatide; DRUG:Placebo; DRUG:[11C]raclopride plus drug; DRUG:[11C]NNC-112","National Institute on Alcohol Abuse and Alcoholism (NIAAA)","2026-05-20","2031-12-31","FALSE","Part 1 (n=5 healthy volunteers): We will assess the reproducibility of striatal dopamine (DA) measures in response to iv methylphenidate (MP) using PET/MR combined scanning and the bolus infusion protocol in healthy controls. [We aim to have each subject (n=5) complete all study procedures within 60 days.] | Part 2 (n=88, 44 healthy volunteers and 44 AUD) : Effects of Tirzepatide on striatal dopamine D1R and D2R availability; striatal DA increase; brain reactivity to MP and to food and alcohol cues in AUD and in healthy controls. [We aim to have each subject complete study procedures within 90 days, but this could take longer. AUD participants will undergo a Follow Up phone call about 1 month after imaging scans are complete.]",null,null,"UNDECIDED","OTHER:002447-AA"],["NCT02403284","The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","97","Insulin Resistance","DRUG:Liraglutide; DRUG:Sugar Pill","Phoenix VA Health Care System","2013-03","2021-04-28","FALSE","Whole Body Insulin Sensitivity (insulin suppression test) [3 weeks]",null,null,"NO","OTHER:1593855"],["NCT01075282","A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)","AWARD-2","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","810","Diabetes Mellitus, Type 2","DRUG:Insulin Glargine; DRUG:LY2189265; DRUG:Metformin; DRUG:Glimepiride","Eli Lilly and Company","2010-02","2012-05","TRUE","Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c) [Baseline, 52 weeks]","DERIVED:27161178; DERIVED:26691396; DERIVED:26089386",null,null,"OTHER:H9X-MC-GBDB"],["NCT07781371","A Retrospective Real-World Cohort Study","SCALA-TK-CM","ACTIVE_NOT_RECRUITING","OBSERVATIONAL",null,null,null,"100000","Obesity; Type 2 Diabetes (T2D); Prediabetes; Cardiovascular Disease (CVD); Dyslipidemia; Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD); Chronic Kidney Disease (CKD)","OTHER:No treatment given","Novo Nordisk A/S","2026-08-20","2026-11-02","FALSE","Index and yearly prevalence of major cardiometabolic diseases (percentage) [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025), and at the end of each calendar year] | Index and yearly prevalence of major cardiometabolic diseases: binary (yes/no) [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025), and at the end of each calendar year] | Overlap of major cardiometabolic diseases (percentage) [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Overlap of major cardiometabolic diseases: binary (yes/no) [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Age distribution [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Age distribution: Number of participants [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Gender distribution [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Gender distribution: binary (yes/no) [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | BMI distribution [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | BMI distribution: number of participants [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Medical history of interest: percentage of events [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Smoking status: percentage of participants [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Systolic and diastolic blood pressure (BP) [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of C reactive protein (CRP)/high sensitive (hs)-CRP [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of CRP/hs-CRP: binary (under and above 2 mg/L) [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of ferritin [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of transferrin [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of serum creatinine [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of estimated glomerular filtration rate (eGFR) [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of creatinine clearance (CrCl) [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of serum albumin levels [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of albuminuria [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of albumin-to-creatinine ratio (ACR) [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of platelets [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of neutrophils [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of lymphocytes [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of monocytes [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of troponin T (TnT)/high sensitive (hs)-TnT [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of troponin I (TnI)/high sensitive (hs)-TnI [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of fasting glucose [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of hemoglobin (Hb) [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of hemoglobin A1c (HbA1c) [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of triglycerides [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of total cholesterol [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of low-density lipoprotein cholesterol (LDL-c) [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of high-density lipoprotein cholesterol (HDL-c) [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of lipoprotein A (LpA) [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of alanine transaminase (ALT) [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of aspartate transaminase (AST) [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of FIB-4 score [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of N-terminal pro-Btype natriuretic peptide (NTproBNP) levels [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of thyroid-stimulating hormone (TSH) levels [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of follicle-stimulating hormone (FSH) levels [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of luteinizing hormone (LH) levels [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of progesterone levels [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of estrogen levels [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)] | Laboratory assessment of testosterone levels [Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)]",null,null,"YES","OTHER:U1111-1341-4025"],["NCT07058155","Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease","OPTIMAL","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","70","Liver Cirrhoses; Portal Hypertension Related to Cirrhosis; Severe Obesity; TIPS","PROCEDURE:Transjugular Intrahepatic Portosystemic Shunt (TIPS); PROCEDURE:Sleeve Gastrectomy; DRUG:Anti-Obesity Pharmacotherapy (Class Effect); BEHAVIORAL:Lifestyle Counseling - Diet & Physical-Activity Program","The Cleveland Clinic","2025-12-17","2029-02-01","FALSE","Change in SF-36 Physical Component Summary (PCS) Score From Baseline to 6 Months [At 6 months after treatment initiation (Day 0 = TIPS placement date or start of medical management).]",null,null,"NO",null],["NCT01855490","Study of the Acute Metabolic Effect of Exenatide in Type 1 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","17","Type 1 Diabetes","DRUG:Exenatide","Yale University","2012-01","2013-07","FALSE","Effect of exenatide on metabolic responses to an oral (as a mixed meal) or intravenous glucose challenge in subjects with established T1D with or without residual insulin production. [Each patients is estimated to finish the study within 4-6 weeks]",null,null,null,null],["NCT07463846","A Study to Evaluate ALN-2232 in Participants With Obesity",null,"RECRUITING","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","TRIPLE","156","Obesity","DRUG:ALN-2232; DRUG:Placebo; DRUG:Tirzepatide","Alnylam Pharmaceuticals","2026-03-02","2027-04-28","FALSE","Part A: Frequency of Adverse Events (AEs) [Up to 12 months] | Part B: Percent Change from Baseline in Body Weight [Baseline up to Month 6] | Part C: Percent Change from Baseline in Body Weight [Baseline up to Month 6]",null,null,"YES",null],["NCT02465515","Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","9463","Diabetes Mellitus","BIOLOGICAL:Albiglutide 30 mg; BIOLOGICAL:Albiglutide 50 mg; BIOLOGICAL:Albiglutide matching placebo","GlaxoSmithKline","2015-07-01","2018-02-20","TRUE","Time to First Occurrence of Major Adverse Cardiovascular Events (MACE) During Cardiovascular (CV) Follow-up Time Period [Median of 1.65 person years for CV follow-up time period]","DERIVED:41906117; DERIVED:39963952; DERIVED:38317618; DERIVED:34281607; DERIVED:30291013; DERIVED:30015066; DERIVED:29693361","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/15/NCT02465515/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/15/NCT02465515/SAP_001.pdf",null,"EUDRACT_NUMBER:2014-001824-32; NIH:2014"],["NCT04208620","Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes Melitus",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","16","Type 2 Diabetes","DRUG:Placebo; DRUG:Cotadutide","AstraZeneca","2020-01-21","2020-07-08","FALSE","Incidence of treatment-emergent adverse events (TEAEs) [Baseline until the follow-up period, 28 days post-last dose] | Incidence of treatment-emergent serious adverse events (TESAEs) [Baseline until the follow-up period, 28 days post-last dose] | Clinically important changes in 12-lead electrocardiogram (ECG) [Baseline until the follow-up period, 28 days post-last dose] | Vital signs as measured by pulse rate (bpm) [Baseline until the follow-up period, 28 days post-last dose] | Vital signs as measured by blood pressure (mmHg) [Baseline until the follow-up period, 28 days post-last dose] | ABPM (Ambulatory blood pressure monitoring) to measure pulse rate (bpm) and blood pressure (mmHg) [Baseline until the follow-up period, 28 days post-last dose] | Physical examination (abnormality to be reported as part of adverse events) [Baseline until the follow-up period, 28 days post-last dose] | Clinical laboratory evaluations [Baseline until the follow-up period, 28 days post-last dose]",null,null,"YES",null],["NCT00971659","Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","48","Type 2 Diabetes","DRUG:insulin glargine + exenatide + preexisting metformin; DRUG:insulin glargine + sitagliptin + preexisting metformin; DRUG:insulin glargine + preexisting metformin","Profil Institut für Stoffwechselforschung GmbH","2008-01","2008-09","FALSE","the unadjusted 6-hour postprandial blood glucose excursion (AUCBG0-6h) following ingestion of a standardized breakfast [after 4 weeks of treatment]","DERIVED:20357372",null,null,null],["NCT01406262","Albiglutide Thorough ECG Study in Healthy Volunteers",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","94","Diabetes Mellitus, Type 2","BIOLOGICAL:Albiglutide; DRUG:Moxifloxacin","GlaxoSmithKline","2011-07-06","2011-12-29","FALSE","QTc interval [6 weeks]","DERIVED:25387217",null,"YES",null],["NCT05134662","ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","55","Type 2 Diabetes","DRUG:ALT-801; OTHER:Placebo","Altimmune, Inc.","2022-02-01","2023-02-03","FALSE","The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs) [Up to Day 110] | Changes from baseline in area under the curve of serum glucose, C-peptide, and insulin [Baseline to Day 85] | Changes from baseline in fasting serum glucose and insulin as measured by Homeostasis Model Assessment for Insulin Resistance 2 (HOMA-IR2) [Baseline to Day 85]",null,null,null,null],["NCT05005741","The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","120","Diabetes Mellitus, Type 2; Overweight or Obesity","DRUG:Beinaglutide; DRUG:Dulaglutide","Second Xiangya Hospital of Central South University","2021-05-01","2023-12-31","FALSE","haemoglobin A1c(HbA1c) [From baseline to 16 week.]",null,null,"NO",null],["NCT05706506","A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)",null,"COMPLETED","INTERVENTIONAL","PHASE4",null,"NONE","152","Type 2 Diabetes; Diabetes Mellitus, Type 2","DRUG:Tirzepatide","Eli Lilly and Company","2023-03-08","2023-10-31","TRUE","Change From Baseline in Hemoglobin A1c (HbA1c) [Baseline, Week 12]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/06/NCT05706506/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/06/NCT05706506/SAP_001.pdf","YES","OTHER:I8F-MC-GPIL; EUDRACT_NUMBER:2022-002708-18"],["NCT05646706","A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)","STEP UP","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","1407","Obesity","DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2023-01-04","2024-10-30","TRUE","Semaglutide 7.2 mg Versus Placebo: Relative Change in Body Weight [Baseline (week 0), End of treatment (week 72)] | Semaglutide 7.2 mg Versus Placebo: Number of Participants Who Achieve Body Weight Reduction Greater Than or Equal to (>=) 5% (Yes/no) [At week 72]","DERIVED:42764399; DERIVED:40961952","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/06/NCT05646706/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/06/NCT05646706/SAP_001.pdf","YES","OTHER:U1111-1274-4259; EUDRACT_NUMBER:2022-000790-94"],["NCT04612517","A Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570",null,"COMPLETED","INTERVENTIONAL","EARLY_PHASE1","RANDOMIZED","TRIPLE","40","Healthy","DRUG:ZP7570; DRUG:Placebo","Zealand Pharma","2020-10-26","2021-08-30","FALSE","Safety and Tolerability - Incidence of treatment emergent adverse events as assessed by type and severity [From time 0 to 51 days after first dosing (29 days after fourth dosing) ]]",null,null,null,"EUDRACT_NUMBER:2019-001129-29; NIH:2019"],["NCT07361874","IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion","IMPACT-MACS","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","75","Mild Autonomous Cortisol Secretion (MACS); Autonomous Cortisol Secretion (ACS); Subclinical Cushing's; Mild Autonomous Cortisol Excess","PROCEDURE:Intervention 1: Adrenalectomy; DRUG:Intervention 2: Semaglutide","University of Texas Southwestern Medical Center","2026-03-05","2030-05-31","FALSE","Change in Insulin Sensitivity (M-value), mg/kg/min [Baseline to Week 26]","BACKGROUND:33593680; BACKGROUND:34260734; BACKGROUND:34978855; BACKGROUND:33065059; BACKGROUND:37318239; BACKGROUND:20588242; BACKGROUND:31900474; BACKGROUND:16699294",null,"YES","NIH:1K23DK142038-01A1"],["NCT02008682","The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","368","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:sitagliptin","Novo Nordisk A/S","2013-12","2014-11","TRUE","Change From Baseline in Glycosylated Haemoglobin (HbA1c) [Week 0, week 26]","RESULT:27060930",null,null,"OTHER:U1111-1139-0016"],["NCT01664624","Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","40","Type 2 Diabetes","DRUG:Roflumilast; DRUG:Alogliptin; DRUG:Exenatide; DRUG:Placebo to roflumilast; DRUG:Placebo to alogliptin","AstraZeneca","2012-07","2012-11","TRUE","Change From Baseline in Postprandial Area Under the Curve From Time 0 to 8 Hours (AUC[0-8]) for Active Glucagon-like Peptide-1 [Baseline and Day 11; samples were taken at -15 min and -5 min (pre-meal), and 15 min, 30 min, and 1, 2, 3, 4, 6, and 8 hours (post-meal).]",null,null,null,"REGISTRY:U1111-1128-6945"],["NCT07649759","Mindfulness-Based Nutrition Group Therapy as an Adjunct to GLP-1 Treatment of Obesity","MBNGT","ACTIVE_NOT_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","40","Obesity & Overweight; Emotional Eating Behaviour; Mindful Eating Intervention","BEHAVIORAL:Mindfulness-based nutritional group therapy (MBNGT)","Bern University of Applied Sciences","2026-02-01","2026-08","FALSE","Recruitment rate [From start of recruitment to completion of recruitment] | Retention rate [From randomization to week 16 (±2-weeks)] | Adherence [At week 16 (±2-weeks)] | Completeness of questionnaire data [At baseline and week 16 (±2-weeks)] | Acceptability of the intervention [At week 16 (±2-weeks)] | Session Attendance [At week 16 (±2-weeks)] | Randomization Acceptance and Attrition [At week 16 (±2-weeks)]","BACKGROUND:27658995; BACKGROUND:31368631; BACKGROUND:29076610",null,"NO",null],["NCT07037459","Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity","MARITIME-HF","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","5056","Heart Failure With Preserved Ejection Fraction; Heart Failure With Mildly Reduced Ejection Fraction; Obesity","DRUG:Maridebart cafraglutide; DRUG:Placebo","Amgen","2025-06-25","2028-06-30","FALSE","Time to First Occurrence of a Composite Endpoint Consisting of: CV Death or HF Events [Up to approximately 35 months]",null,null,"YES",null],["NCT01060059","Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 Diabetes",null,"COMPLETED","OBSERVATIONAL",null,null,null,"888","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:basal insulin","AstraZeneca","2010-04","2012-05","TRUE","Percentage of Patients Who Achieved Glycemic Target of HbA1c ≤ 7.0% With Minimal Weight Gain (≤ 1 Kg) at Month 12. [Baseline, Month 12]",null,null,null,null],["NCT03707990","A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","88","Obesity and Overweight","DRUG:NNC0165-1875; DRUG:Placebo (NNC0165-1875); DRUG:Semaglutide","Novo Nordisk A/S","2018-10-15","2019-08-13","FALSE","Number of treatment emergent adverse events (TEAEs) [Day 1-36]",null,null,"YES","OTHER:U1111-1212-3615"],["NCT01971242","Trial of Exenatide for Parkinson's Disease","EXENATIDE-PD","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","60","Parkinson's Disease","DRUG:Exenatide; OTHER:Placebo","University College, London","2014-06","2016-05","FALSE","Efficacy [60 weeks]","DERIVED:28781108",null,"NO",null],["NCT01524770","A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual Syringe",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","50","Diabetes Mellitus, Type 2","BIOLOGICAL:Dulaglutide","Eli Lilly and Company","2012-03","2012-06","TRUE","Pharmacokinetics: Area Under the Concentration Curve (AUC[0-336]) for Dulaglutide [Predose to 336 hours postdose] | Pharmacokinetics: Maximum Concentration (Cmax) for Dulaglutide [Predose to 336 hours postdose]",null,null,null,"OTHER:H9X-MC-GBDT"],["NCT01624259","A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes","AWARD-6","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","599","Type 2 Diabetes","DRUG:LY2189265; DRUG:Liraglutide; DRUG:Metformin","Eli Lilly and Company","2012-06","2013-11","TRUE","Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c) [Baseline, 26 Weeks]","DERIVED:27161178; DERIVED:26691396; DERIVED:25018121",null,null,"OTHER:H9X-MC-GBDE; EUDRACT_NUMBER:2011-003810-18"],["NCT06137469","Assessment of Gastric Emptying by SHR20004 in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","28","Type 2 Diabetes Mellitus","DRUG:Acetaminophen/SHR20004; DRUG:Acetaminophen/Placebo","Jiangsu HengRui Medicine Co., Ltd.","2023-12-26","2024-03-16","FALSE","Pharmacokinetics parameters of acetaminophen after a single dose of 1.0 g was measured after administration of the standardized meal.：(AUC0-300min) [Based on pre-dose to 300 min post-dose sampling times on Day 1 and Day 31]",null,null,"UNDECIDED",null],["NCT07457437","Function and Lean Mass Preservation With Resistance Exercise During a GLP-1RA Treatment","FLEX","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","60","Muscle Mass and Strength; Obesity & Overweight; Physical Function","OTHER:Progressive Resistance Exercise Training Program; OTHER:Habitual physical activity guidelines","University of Exeter","2026-04-01","2027-12-01","FALSE","Skeletal Muscle Mass [Skeletal muscle mass will be plotted over time and we will compare the pre , mid and post values (weeks 0, 10 and 20) to see if there was a change in both groups.] | Muscle Thickness (Ultrasound) [Muscle thickness in millimetres will be plotted over time (week 0, 4, 8, 10, 12, 16, 20) and compared between the two groups. Muscle thickness will also be measure at two separate time points during a follow up study at week 40 and 72 weeks from week 0.]","BACKGROUND:39480197; BACKGROUND:28166780; BACKGROUND:39996356; BACKGROUND:31565876; BACKGROUND:35658024",null,"UNDECIDED",null],["NCT04238962","A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","111","Overweight; Obesity","DRUG:Semaglutide (administered by DV3396 pen-injector); DRUG:Semaglutide (administered by PDS290 pen-injector)","Novo Nordisk A/S","2020-02-03","2020-10-20","FALSE","AUC0-last,sema,2mg: Area under the semaglutide concentration time curve from time 0 until last quantifiable measurement after one dose of s.c. semaglutide 2 mg administration following a 6-week dose escalation period [0-840 hours after one dose of s.c. semaglutide 2 mg] | Cmax,sema,2mg: Maximum observed semaglutide concentration after one dose of s.c. semaglutide 2 mg administration following a 6-week dose escalation period [0-840 hours after one dose of s.c. semaglutide 2 mg]",null,null,"YES","OTHER:U1111-1239-1473; REGISTRY:2019-003477-25; NIH:2019"],["NCT04854083","Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes","MitoSema","UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","50","Type2 Diabetes","DRUG:Semaglutide, 1.34 mg/mL; DRUG:Placebo","Kirsi Pietiläinen","2022-02-17","2025-08","FALSE","HbA1c [from baseline to 12 months]",null,null,null,null],["NCT02084251","Clinical Trial for PB-119 in Healthy Subjects (Phase I)",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"DOUBLE","70","Type II Diabetes","DRUG:PB-119","PegBio Co., Ltd.","2014-02","2014-11","FALSE","Safety/Adverse Event Outcome Measure [Up to 3 weeks]","DERIVED:32006325",null,null,null],["NCT01436201","A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","24","Diabetes Mellitus, Type 2","DRUG:Digoxin; BIOLOGICAL:Dulaglutide","Eli Lilly and Company","2011-09","2011-11","TRUE","Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Digoxin [Predose (Digoxin) and up to 24 hours postdose on Days 7, 10, and 17] | Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Digoxin [Predose (Digoxin) and up to 24 hours postdose on Days 7, 10, and 17] | Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Digoxin [Predose (Digoxin) and up to 24 hours postdose on Days 7, 10, and 17]","DERIVED:28357715",null,null,"OTHER:H9X-MC-GBCR"],["NCT07517042","ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management",null,"RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","QUADRUPLE","420","Obesity; Weight Control","DRUG:Mazdutide; BEHAVIORAL:Intensive Lifestyle Intervention","Shanghai Zhongshan Hospital","2026-06-10","2028-12","FALSE","Percentage change of body weight [From randomization to Week 52]",null,null,"YES",null],["NCT04379856","Proof of Concept Study in Patients With Short Bowel Syndrome",null,"UNKNOWN","INTERVENTIONAL","PHASE1; PHASE2","NON_RANDOMIZED","NONE","12","Short Bowel Syndrome","DRUG:NM-002","9 Meters Biopharma, Inc.","2020-06-23","2020-12-11","FALSE","To assess the safety and tolerability of repeated doses of NM002 three different dose levels [56 days]",null,null,"NO",null],["NCT01098461","Dose Ranging Study of Albiglutide in Japanese Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","215","Diabetes Mellitus, Type 2","BIOLOGICAL:albiglutide; BIOLOGICAL:placebo","GlaxoSmithKline","2010-04","2011-05","TRUE","Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16 [Baseline and Week 16]","DERIVED:25387217; DERIVED:24552155",null,"YES",null],["NCT02931370","Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Loss","US-LOSEIT-I","COMPLETED","OBSERVATIONAL",null,null,null,"200","Osteoarthritis; Obesity","DIETARY_SUPPLEMENT:Dietary Supplement: Intensive dietary intervention","Henrik Gudbergsen","2016-11","2019-02","FALSE","Change in the degree of inflammation in the knee-joint (Greyscale-score) [Week -8 to 0]",null,null,"NO",null],["NCT00477581","A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","102","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:sitagliptin","AstraZeneca","2007-05","2007-09","FALSE","Effect of Exenatide on postprandial glucose [28 days]","DERIVED:18786299",null,null,null],["NCT05755360","DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy","DOORS","COMPLETED","OBSERVATIONAL",null,null,null,"291","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2023-02-21","2024-10-21","FALSE","Absolute change in glycated haemoglobin (HbA1c) (percentage [%]-point) [From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks)] | Absolute change in glycated haemoglobin (HbA1c) (millimoles per mole [mmol/mol]) [From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks)]",null,null,"YES","OTHER:U1111-1274-4674"],["NCT04862923","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in the United Kingdom, as Part of Local Clinical Practice","PIONEER REAL","COMPLETED","OBSERVATIONAL",null,null,null,"336","Diabetes Mellitus, Type 2","DRUG:Oral semaglutide","Novo Nordisk A/S","2021-05-12","2023-08-31","FALSE","Change in glycated haemoglobin (HbA1c) [From baseline (week 0) to End of Study visit (Visit 3) (week 34-44)]","RESULT:39316289; DERIVED:39535683",null,"YES","OTHER:U1111-1240-3705"],["NCT07099742","Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)",null,"NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"364","Obesity","DRUG:Tirzepatide; BEHAVIORAL:Life Style Modification","Dr. Md. Alimur Reza","2026-11","2027-10","FALSE","Percentage change in body weight at Week 24 in both treatment groups. [Baseline to 24 Weeks] | Percentage of participants withdrawn from the study due to adverse events by Week 24 [Up to Week 24]","BACKGROUND:37152942; BACKGROUND:36498958; BACKGROUND:37840095; BACKGROUND:35658024",null,"NO",null],["NCT06914154","Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data","DUP-SUMMIT","COMPLETED","OBSERVATIONAL",null,null,null,"11265","Diabetes Mellitus, Type 2; Heart Failure With Preserved Ejection Fraction (HFPEF)","DRUG:Tirzepatide; DRUG:Placebo","Brigham and Women's Hospital","2025-01-14","2025-06-01","FALSE","Composite of all-cause mortality or heart failure hospitalisation. [Through study completion (1 day after cohort entry date until the first of outcome or censoring)] | Composite of all-cause mortality or heart failure hospitalization. [Through study completion (1 day after cohort entry date until the first of outcome or censoring)]","DERIVED:40886075","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/54/NCT06914154/Prot_SAP_001.pdf",null,null],["NCT01843127","A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","SINGLE","24","Type 2 Diabetes Mellitus","DRUG:Ranolazine; DRUG:Placebo; DRUG:Exenatide","Gilead Sciences","2013-04","2013-09","FALSE","Area under the concentration-time curve (AUC) of plasma glucagon during the standard meal test (SMT) [Days 5, 10, and 14]",null,null,null,null],["NCT04050670","A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","54","Healthy","DRUG:Tirzepatide","Eli Lilly and Company","2019-09-13","2020-04-03","TRUE","Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of Tirzepatide From Time Zero to Infinity (AUC[0-∞]) [Predose, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 336, 480 hours post dose] | PK: Maximum Concentration (Cmax) of Tirzepatide [Predose, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 336, 480 hours post dose]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/70/NCT04050670/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/70/NCT04050670/SAP_001.pdf","NO","OTHER:I8F-MC-GPHI"],["NCT04228354","A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","28","Healthy Volunteers; Overweight; Obesity","DRUG:Semaglutide","Novo Nordisk A/S","2020-01-29","2020-06-01","FALSE","Area under the semaglutide plasma concentration curve from 0 to tz [0-840 hours] | Maximum semaglutide plasma concentration [0-840 hours]",null,null,"YES","OTHER:U1111-1241-6257; REGISTRY:2019-004020-37; NIH:2019"],["NCT02847403","Long-acting Exenatide and Cognitive Decline in Dysglycemic Patients","DRINN","UNKNOWN","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","40","Dysglycemia; Cognitive Deficit","DRUG:Exenatide; OTHER:placebo","Azienda Ospedaliero-Universitaria di Parma","2016-02","2019-07","FALSE","Improvement of ADAS-cog Alzheimer's Disease Assessment Scale defined by ADAS-cog score at 16 (V2) and at 32 weeks (V3) compared to baseline [16 and 32 weeks]","BACKGROUND:17125767; BACKGROUND:12925848; BACKGROUND:23973293; BACKGROUND:23728174",null,"YES","NIH:2015"],["NCT06904105","A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","556","Overweight; Obesity","DRUG:HRS-7535 Tablets; DRUG:HRS-7535 Placebo Tablets","Shandong Suncadia Medicine Co., Ltd.","2025-04-10","2026-04-17","FALSE","Percentage change in body weight relative to the baseline [44th week after administration.] | Proportion of participants with a body weight reduction of ≥ 5% relative to the baseline [44th week after administration.]",null,null,"UNDECIDED",null],["NCT02299388","To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","11","Diabetes Mellitus, Non-Insulin-Dependent; Hypertensive Disease","DRUG:Liraglutide or Placebo","Tulane University School of Medicine","2014-10","2016-11","TRUE","Change in Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitors. [Baseline and 8 Weeks]",null,null,null,null],["NCT02079870","Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","30","Diabetes; Metabolism and Nutrition Disorder; Obesity","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2014-03-06","2015-01-07","FALSE","Ad libitum energy intake during a lunch meal (following a standardised breakfast meal) [After 12 weeks of treatment]","RESULT:28266779; RESULT:28941314",null,null,"EUDRACT_NUMBER:2013-000012-24; OTHER:U1111-1138-2039"],["NCT05305794","Effect of Weekly GLP1 Agonist Treatment in \"Double Diabetes\"","TOLEDDO","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","76","Double Diabetes","DRUG:Insulin + semaglutide treatment; DRUG:Usual insulin treatment; BIOLOGICAL:Biological check-up","Centre Hospitalier Universitaire Dijon","2022-07-12","2028-08","FALSE","Percentage of time spent within glycemic target range (0.70-1.80 g/l) [Change from baseline at Day 180]",null,null,null,null],["NCT06069622","Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment",null,"RECRUITING","OBSERVATIONAL",null,null,null,"30","Overweight and Obesity","DIAGNOSTIC_TEST:24-hour ambulatory blood pressure; DIETARY_SUPPLEMENT:Liberal salt diet","Brigham and Women's Hospital","2023-11-01","2026-10-01","FALSE","Blood pressure response to GLP-1 RA treatment [20 weeks] | Weight loss response to GLP-1 RA treatment [20 weeks]",null,null,"NO",null],["NCT07319286","Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes Mellitus",null,"ENROLLING_BY_INVITATION","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","NONE","50","Menstrual Irregularities; Type1 Diabetes Mellitus; Glucagon-Like Peptide-1 Receptor Agonists; Female Reproductive Health","DRUG:Dulaglutide","Ain Shams University","2025-08-04","2026-12","FALSE","Frequency of Self-Reported Menstrual Irregularities [Baseline]","RESULT:39518671",null,"NO",null],["NCT01455922","A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes",null,"WITHDRAWN","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","0","Type 2 Diabetes","DRUG:ITCA 650; DRUG:glimepiride","Intarcia Therapeutics","2013-02","2014-07","FALSE","Change in HbA1c [52 weeks]",null,null,null,null],["NCT02303730","Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","76","Diabetes Mellitus, Type 2; Non-alcoholic Fatty Liver Disease","DRUG:Exenatide; DRUG:insulin glargine","Fudan University","2015-03","2017-11","FALSE","Change in liver fat content（%） measured by MRS [baseline and 24 weeks]","BACKGROUND:25039675; BACKGROUND:20225248; BACKGROUND:21957486; BACKGROUND:20019672; BACKGROUND:23236362; BACKGROUND:21131943; BACKGROUND:21660077; BACKGROUND:24823873; BACKGROUND:17090752; BACKGROUND:22686416; DERIVED:37524110",null,"NO",null],["NCT07104500","VK2735 for Weight Management Phase 3","VANQUISH 1","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","4500","Weight Loss","DRUG:VK2735","Viking Therapeutics, Inc.","2025-06-23","2027-07-01","FALSE","Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment [78 Weeks]",null,null,null,null],["NCT02022254","Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","24","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:semaglutide; DRUG:placebo; DRUG:metformin; DRUG:warfarin","Novo Nordisk A/S","2013-12-17","2014-08-28","FALSE","Area under the metformin plasma concentration-time curve [During a dosing interval (0-12 hours) after the last of 7 repeated doses of metformin without semaglutide exposure (Day 4) and at semaglutide steady state (Day 104)] | Area under the S-warfarin plasma concentration-time curve [From time 0 to 168 hours after a single dose of warfarin without semaglutide exposure (Day 11) and at semaglutide steady state (Day 111)] | Area under the R-warfarin plasma concentration-time curve [From time 0 to 168 hours after a single dose of warfarin without semaglutide exposure (Day 11) and at semaglutide steady state (Day 111)]","RESULT:28349387",null,null,"EUDRACT_NUMBER:2012-005072-33; OTHER:U1111-1136-6442"],["NCT01794429","Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue","TAO","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","45","Obesity; Metabolic Syndrome X; Drug-induced Obesity; Schizophrenia","DRUG:Exenatide; DRUG:Placebo","Bjorn H. Ebdrup","2013-02","2015-06","FALSE","Weight loss [3 months]","DERIVED:28260235; DERIVED:27717222; DERIVED:24401727",null,null,null],["NCT07478653","MODERN-Dental: Pediatric Obesity, Cardiometabolic Risks, And Periodontal Disease",null,"RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","50","Obesity; Dental Care for Children","PROCEDURE:Dental Cleaning and Oral Hygiene Instruction (OHI); BEHAVIORAL:Oral Hygiene Instruction (OHI)","Oelisoa Andriankaja","2026-08-31","2028-07-31","FALSE","Change in gingival index [Baseline, 6 months, 12 months] | Change in probing depth [Baseline, 6 months, 12 months] | Change in BOP (Bleeding on probing) [Baseline, 6 months, 12 months] | Change in Plaque Index [Baseline, 6 months, 12 months] | Change in Clinical Attachment Level (CAL) [Baseline, 6 months, 12 months] | Change in Gingival Margin Position (GM) [Baseline, 6 months, 12 months] | Number of participants with Supragingival and Subgingival Calculus [Baseline, 6 months, 12 months] | Change in Gingival Crevicular Fluid (GCF) [Baseline, 6 months, 12 months] | Change in Bacterial Subgingival Biofilm [Baseline, 6 months, 12 months] | Change in levels of Interleukin-1 beta (IL-1β) [Baseline, 6 months, 12 months] | Change in levels of Tumor Necrosis Factor-alpha [Baseline, 6 months, 12 months] | Change in levels of Interleukin-6 (IL-6) [Baseline, 6 months, 12 months] | Change in levels of C-reactive protein (CRP) [Baseline, 6 months, 12 months] | Change in levels of Soluble intercellular adhesion molecule-1 (sICAM-1) [Baseline, 6 months, 12 months] | Change in levels of Soluble vascular cell adhesion molecule-1 (sVCAM-1) [Baseline, 6 months, 12 months] | Change in levels of endocan [Baseline, 6 months, 12 months] | Change in levels of Vascular Endothelial Growth Factor A (VEGF-A) [Baseline, 6 months, 12 months] | Change in Oral Microbiome [Baseline, 6 months, 12 months] | Change in active oral microbiome (RNA sequencing) [Baseline, 6 months, 12 months]",null,null,null,null],["NCT06497595","Lifestyle Intervention to Reduce the Risk of Sarcopenia in Adults With Diabetes & Obesity Treated With Semaglutide","STAY-STRONG","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","60","Type 2 Diabetes Mellitus in Obese","BEHAVIORAL:Wegovy (2.4 Mg Dose) + exercise & nutrition; OTHER:Wegovy (2.4 Mg Dose) + usual care","Sheba Medical Center","2025-05-11","2027-09-30","FALSE","Thigh muscle volume (TMV) [26 weeks]",null,null,null,null],["NCT01511692","Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","43","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo; DRUG:glimepiride","Novo Nordisk A/S","2005-11","2007-09","FALSE","The energy intake at a standardised buffet meal with a preload paradigm quantified using Foodworks 2.10 []","RESULT:22446097",null,null,"EUDRACT_NUMBER:2006-000377-30"],["NCT07021937","Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity","PLASTIC","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","120","Obesity/Therapy","DRUG:Semaglutide 1.7mg subcutaneous; DRUG:Placebo","University of Colorado, Denver","2026-06-15","2031-04-30","FALSE","blood oxygen-level dependent signal [From enrollment to the end of trial at 32 weeks] | meal kilocalories (kcal) [From enrollment to the end of trial at 32 weeks] | visual analogue scale (VAS) score for hunger [From enrollment to the end of trial at 32 weeks] | visual analogue scale (VAS) for desire to eat [From enrollment to end of trial at 32 weeks] | visual analogue scale (VAS) score for fullness [From enrollment to end of trial at 32 weeks] | visual analogue scale (VAS) score for amount participant feels they can eat [From enrollment to end of trial at 32 weeks]",null,null,"NO","OTHER:Pending"],["NCT00382239","A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","153","Type 2 Diabetes Mellitus","DRUG:exenatide (LY2148568); DRUG:Placebo","AstraZeneca","2006-09","2007-05","FALSE","Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 12 [Baseline, Week 12]","RESULT:19194050; DERIVED:22236356",null,null,null],["NCT03707171","Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3","NON_RANDOMIZED","NONE","30","Type 2 Diabetes Mellitus","DRUG:Liraglutide; DRUG:placebo","Third Military Medical University","2018-10-01","2019-02-01","FALSE","Changes of cognitive function assessed by cognitive function scale after 12 weeks. [Baseline,4weeks,8weeks，12weeks(End of Trial)]","DERIVED:34250817",null,null,null],["NCT05623839","A Study of LY3305677 in Participants With Obesity Or Overweight",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","32","Overweight; Obesity","DRUG:LY3305677; DRUG:Placebo","Eli Lilly and Company","2022-11-16","2023-06-27","FALSE","Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline through Week 20]","DERIVED:40832785",null,"NO","OTHER:I8P-MC-OXAG"],["NCT02686177","Effect of GLP-1 on Angiogenesis","ANGIOSAFE 1","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","50","Type 2 Diabetes","DRUG:Liraglutide; DRUG:Metformin or sulfonylurea","Assistance Publique - Hôpitaux de Paris","2016-05-18","2017-08-08","FALSE","Difference of ANGPTL4 concentration at 4 weeks of treatment from baseline in Liraglutide and control group [At 1 month]","DERIVED:31589290",null,"NO","OTHER:2015-002930-35; NIH:2015"],["NCT06201819","Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery",null,"COMPLETED","INTERVENTIONAL","PHASE4",null,"NONE","37","Weight Loss; Bariatric Surgery Candidate; Obesity, Morbid","DRUG:Liraglutide injection","Hospital Civil Juan I. Menchaca","2022-12-18","2023-03-18","FALSE","Preoperative weight changes [3 months]",null,null,"YES",null],["NCT04822181","Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)","ESSENCE","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","1205","Non-alcoholic Steatohepatitis","DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2021-04-01","2029-04-25","FALSE","Part 1: Resolution of steatohepatitis and no worsening of liver fibrosis (Yes/No) [From randomisation (week 0) to week 72] | Part 1: Improvement in liver fibrosis and no worsening of steatohepatitis (Yes/No) [From randomisation (week 0) to week 72] | Part 2: Cirrhosis-free survival (Yes/No) [From randomisation (week 0) to week 240]","RESULT:39412509; DERIVED:42663669; DERIVED:40305708; DERIVED:39392766; DERIVED:36738088",null,"YES","OTHER:U1111-1244-3678; REGISTRY:2019-004594-44; REGISTRY:jRCT2031210033; NIH:2019"],["NCT05390892","PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes","PRECIDENTD","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","6000","Type2Diabetes; ASCVD","DRUG:SGLT2 inhibitor; DRUG:GLP-1 receptor agonist","Brigham and Women's Hospital","2022-09-26","2029-03-01","FALSE","Total (first and recurrent) cardiovascular, kidney, and death events [Through study completion, with an average follow up of approximately 3 years]","DERIVED:41456635",null,"YES",null],["NCT02492763","A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)",null,"TERMINATED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","176","Type II Diabetes Mellitus","DRUG:MK-8521; DRUG:Placebo; DRUG:Liraglutide; DRUG:Metformin","Merck Sharp & Dohme LLC","2015-07-27","2017-04-18","TRUE","Change From Baseline in Hemoglobin A1C (A1C) at Week 12 [Baseline and Week 12] | Number of Participants With an Adverse Event (AE) [Up to Week 14] | Number of Participants Who Discontinued Study Treatment Due to an AE [Up to Week 12] | Number of Participants With an AE of Symptomatic Hypoglycemia [Up to Week 14] | Change From Baseline in Heart Rate at Week 12 [Baseline and Week 12]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/63/NCT02492763/Prot_SAP_000.pdf","YES","OTHER:MK-8521-004"],["NCT06827002","Effect of Aqueous Extracts of Cissus Quadrangularis and Dichrostachys Glomerata on GLP-1 Concentration and DPP-4 Activity in Overweight and Obese Adults",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","DOUBLE","248","Obesity and Overweight; Appetite Regulation","DRUG:Dichrostachys glomerata; DRUG:Cissus quadrangularia; DRUG:Dextrin; DRUG:Semaglutide (Rybelsus®)","University of Yaounde 1","2023-03-29","2026-02-23","FALSE","Effect of DGE and CQE on participants GLP-1 level [Baseline (Week 0), Week 4, Week 8, Week 12 and Week 16] | Effect of DGE and CQE on participants DPP4 activity [Baseline (Week 0), Week 4, Week 8, Week 12 and Week 16]","BACKGROUND:4337382; BACKGROUND:26288659; BACKGROUND:26177483; BACKGROUND:27659407; BACKGROUND:23622135; BACKGROUND:28450900; BACKGROUND:15655721; BACKGROUND:24323912","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/02/NCT06827002/Prot_SAP_001.pdf","YES","OTHER_GRANT:JAOF122025; OTHER:N°2014/08/488/CE/CNERSH/SP; OTHER:BTC-JIRB2023-084"],["NCT04537637","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark, as Part of Local Clinical Practice","PIONEER REAL","COMPLETED","OBSERVATIONAL",null,null,null,"99","Diabetes Mellitus, Type 2","DRUG:Oral Semaglutide","Novo Nordisk A/S","2020-08-28","2023-05-08","FALSE","Change in Glycated haemoglobin (HbA1c ) [From baseline (week 0) to End of Study visit (V3) (week 34-44)]","DERIVED:42592768; DERIVED:39535683",null,"YES","OTHER:U1111-1240-4198"],["NCT06643728","A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","252","Obesity; Overweight","DRUG:Bimagrumab; DRUG:Tirzepatide; DRUG:Bimagrumab Placebo; DRUG:Tirzepatide Placebo","Eli Lilly and Company","2024-10-21","2026-01-16","FALSE","Percent Change from Baseline in Body Weight [Baseline, Week 24]",null,null,"YES","OTHER:J4Z-MC-GIDF"],["NCT00299871","Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","542","Type 2 Diabetes","DRUG:LIXISENATIDE (AVE0010)","Sanofi","2006-02","2007-08","FALSE","HbA1c levels at baseline and endpoint (at 13 weeks). []","RESULT:20722676",null,null,null],["NCT05933499","Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","63","Obesity","DRUG:Bimagrumab; DRUG:Tirzepatide; DIETARY_SUPPLEMENT:Calcium/Vitamin D; BEHAVIORAL:Lifestyle and nutrition counseling","Massachusetts General Hospital","2025-11-05","2028-12-31","FALSE","Change in number of kilograms of lean mass by dual-energy x-ray absorptiometry [52 weeks]",null,null,null,null],["NCT07340437","Clinical Study of 18F-Exendin-4 in Insulinoma",null,"COMPLETED","OBSERVATIONAL",null,null,null,"20","Insulinoma",null,"Sichuan Provincial People's Hospital","2023-02-01","2025-10-31","FALSE","Correlation between clinical indicators and PET/CT results [2 years]",null,null,null,null],["NCT05031871","Pharmacokinetics of HR17031 Injection in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","24","Type 2 Diabetes Mellitus","DRUG:HR17031 injection ；INS068 injection；SHR20004 injection","Jiangsu HengRui Medicine Co., Ltd.","2021-09-02","2021-11-19","FALSE","Cmax：Maximum observed concentration [Day1 to Day 26] | AUC0-t ：Area under the curve from the time of dosing time to the last measurable (positive) concentration； [Day1 to Day 26] | AUC0-inf：Area under the curve from time 0 to infinity； [Day1 to Day 26]",null,null,"UNDECIDED",null],["NCT04865744","The Effect of Semaglutide on Pituitary Function",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","10","Healthy","DRUG:Semaglutide 7 MG Oral Tablet; DRUG:Placebo; DRUG:Semaglutide 14 MG Oral Tablet","University of Tartu","2021-05-19","2021-09-23","FALSE","Growth hormone peak [60, 90, 120, 150, 180 and 240 minutes after study medication administration]",null,null,"NO",null],["NCT03642600","The Gut Microbiome in Women With Polycystic Ovary Syndrome",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","21","PCOS; Obesity; Metabolic Syndrome","DIETARY_SUPPLEMENT:dietary advice plus myo-inositol and folic acid; DRUG:dietary advice plus Liraglutide Pen Injector","Universitaire Ziekenhuizen KU Leuven","2019-02-28","2020-02-01","FALSE","weight loss [32 weeks]",null,null,"NO",null],["NCT05443334","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice","PIONEER REAL","COMPLETED","OBSERVATIONAL",null,null,null,"465","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2022-07-28","2024-07-04","FALSE","Change in HbA1c [From baseline (week 0) to End of Study visit (V3) (week 34-44)]","DERIVED:40555703",null,"YES","OTHER:U1111-1240-4149"],["NCT02483299","Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary Syndrome",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","40","PCOS; Obesity","DRUG:Metformin; DRUG:Glucophage tablets and Victoza","University Medical Centre Ljubljana","2014-01","2015-04","FALSE","Change in body weight [up to 12 weeks of clinical trial] | The number of good responders to combined treatment regarding body weight [up to 12 weeks of clinical trial]",null,null,null,null],["NCT05694221","Drug Drug Interaction (DDI) Between Supaglutide and Digoxin or Metformin",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","34","Healthy Volunteers","DRUG:Supaglutide injection; DRUG:Digoxin; DRUG:Metformin","Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","2023-03-20","2023-06-06","FALSE","Group A: Plasma Cmax of digoxin [39 Days] | Group A: Plasma AUC0-last of digoxin [39 Days] | Group A: Plasma AUC0-inf of digoxin [39 Days] | Group B: Plasma Cmax,ss of Metformin [34 Days] | Group B: Plasma AUC0-tau of Metformin [34 Days]","DERIVED:40587051",null,"NO",null],["NCT05347758","A Phase I Single- and Multiple- Ascending Dose and Food Effect Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7535 in Healthy Subjects",null,"UNKNOWN","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","106","Healthy Subjects","DRUG:HRS-7535; DRUG:Placebo","Shandong Suncadia Medicine Co., Ltd.","2022-05-01","2022-09-18","FALSE","Number of adverse Events [Day-2 to last follow-up]",null,null,"UNDECIDED",null],["NCT06162715","GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial","GRABS-0","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","NONE","30","Severe Obesity; Obesity; BMI Greater Than 30","DRUG:Tirzepatide; OTHER:Standard of Care post-gastric bypass","Vanderbilt University Medical Center","2024-10-30","2027-01-01","FALSE","Weight loss [baseline to 24 weeks] | Gastrointestinal symptoms [baseline to 24 weeks]","DERIVED:42712125","Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/15/NCT06162715/ICF_000.pdf","YES",null],["NCT00761540","To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or Placebo",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","37","Diabetes; Healthy","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2008-10","2008-12","FALSE","AUC 0-24h (last dosing day): Area under the plasma liraglutide curve from 0 to 24 hours after last dosing. [After 21 days of treatment]","RESULT:21273395",null,null,null],["NCT07179120","Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","SINGLE","180","Obesity-related Male Infertility","DRUG:Semaglutide (Rybelsus®); DRUG:Tirzepatide; BEHAVIORAL:Standardized Lifestyle Intervention","First Affiliated Hospital of Wenzhou Medical University","2026-05-01","2026-08-12","FALSE","Change from Baseline in Sperm Concentration (million/mL) at Week 32 of Intervention [Baseline and Week 32]",null,null,"NO",null],["NCT05412004","Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea","SURMOUNT-OSA","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","469","Obstructive Sleep Apnea; Obesity","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2022-06-21","2024-03-12","TRUE","Change From Baseline in Apnea-Hypopnea Index (AHI) [Baseline, Week 52]","DERIVED:42774617; DERIVED:42675225; DERIVED:41793578; DERIVED:41540105; DERIVED:41135142; DERIVED:40774158; DERIVED:38912654; DERIVED:38547961","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/04/NCT05412004/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/04/NCT05412004/SAP_001.pdf","YES","OTHER:I8F-MC-GPIF; OTHER:I8F-MC-GPI1; OTHER:I8F-MC-GPI2; EUDRACT_NUMBER:2021-004552-41"],["NCT01501084","Effects of the GLP-1 Exenatide on Satiety in Lean and Obese Women",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","34","Obesity","DRUG:Exenatide; DRUG:Normal saline .2cc subcutaneous injection","University of California, Los Angeles","2011-12","2012-12","FALSE","Resting State networks in the brain [one year]",null,null,"YES",null],["NCT07065552","Tirzepatide in Obesity-Driven Endometrial Cancer",null,"RECRUITING","INTERVENTIONAL","EARLY_PHASE1",null,"NONE","20","Endometrial Cancer; Obesity","DRUG:Tirzepatide","UNC Lineberger Comprehensive Cancer Center","2026-04-27","2028-07","FALSE","Change in Proliferation [Baseline - Up to 6 weeks]",null,null,null,null],["NCT02058147","Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM","LixiLan-O","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","1170","Type 2 Diabetes","DRUG:Insulin glargine/lixisenatide Fixed Ratio Combination; DRUG:Insulin glargine (HOE901); DRUG:Lixisenatide (AVE0010); DRUG:Metformin","Sanofi","2014-02","2015-06","TRUE","Change in HbA1c From Baseline to Week 30 [Baseline, Week 30]","RESULT:27527848; DERIVED:35101326; DERIVED:31124299; DERIVED:31114694; DERIVED:30550345; DERIVED:29974618; DERIVED:29923298; DERIVED:28432746",null,null,"EUDRACT_NUMBER:2013-003131-30; OTHER:U1111-1148-4334"],["NCT05813925","A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","331","Obesity or Overweight","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo Semaglutide","Novo Nordisk A/S","2023-04-03","2025-01-17","FALSE","Relative Change in Body Weight [From baseline (week 0) to end of treatment (week 68)]","DERIVED:42009015",null,"YES","OTHER:U1111-1277-3764; REGISTRY:jRCT2031220734"],["NCT05996874","A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","121","Healthy Participants","DRUG:Semaglutide","Novo Nordisk A/S","2023-08-12","2024-04-18","FALSE","AUC0-24h,sema,Day10: Area under the semaglutide plasma concentration-time curve during a dosing interval after the 10th dosing [From 0 to 24 hours after dosing on day 10]",null,null,"YES","OTHER:U1111-1281-4819; EUDRACT_NUMBER:2022-002848-52"],["NCT03347890","Reward Mechanisms in Obesity","LIRAOB","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","70","Obesity","DRUG:Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml or Placebo","Zoltan Pataky","2018-03-05","2020-03-18","FALSE","Change of Bold Oxygenation Level Dependent (BOLD) signal (%) in brain regions involved in the reward system [16 weeks]",null,null,"NO","REGISTRY:U1111-1194-9675; NIH:2017"],["NCT01866748","Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","170","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2013-05","2014-04","FALSE","Part A: Number of treatment emergent adverse events (TEAEs) [Day -1 to Day 24] | Part B: Number of treatment emergent adverse events (TEAEs) [Recorded from the time of first dosing (Visit 3, Day -1 to day +2) and until completion of the post treatment follow-up visit (Visit 18, Day 90-104)]",null,null,null,"EUDRACT_NUMBER:2012-003199-38; OTHER:U1111-1132-4190"],["NCT01147718","A Drug Interaction Study of Albiglutide and Digoxin",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","30","Diabetes Mellitus, Type 2","BIOLOGICAL:digoxin plus albiglutide","GlaxoSmithKline","2010-06-11","2010-11-29","FALSE","The pharmacokinetic parameters of digoxin with and without albiglutide [38 days]","BACKGROUND:23322139; DERIVED:25387217",null,"YES",null],["NCT00838916","A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","779","Diabetes Mellitus, Type 2","BIOLOGICAL:albiglutide; DRUG:insulin glargine","GlaxoSmithKline","2009-02","2012-01","TRUE","Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52 [Baseline and Week 52]","DERIVED:28683300; DERIVED:25387217; DERIVED:25208756; DERIVED:24918790",null,"YES",null],["NCT03500484","Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.",null,"TERMINATED","INTERVENTIONAL","EARLY_PHASE1","RANDOMIZED","SINGLE","13","Obesity, Childhood; Neural Development","DRUG:Liraglutide","Yale University","2018-06-06","2020-06-25","TRUE","Brain Response in Obese Young Adults Who Drink Sugar Sweetened Beverages. [1 week] | Change in Brain Response in Obese Young Adults Who Drink Sugar Sweetened Beverages. [1 week and 12 weeks]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/84/NCT03500484/Prot_SAP_000.pdf",null,null],["NCT06715514","Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Diabetes","DECLARED-CT","ACTIVE_NOT_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","96","Menopause; Type 2 Diabetes","DRUG:GLP-1 Receptor Agonist; DRUG:Menopausal Hormone Therapy","Lia Bally","2025-02-18","2026-12-17","FALSE","Change in HbA1C [12 Weeks]",null,null,"YES","OTHER_GRANT:10000574; REGISTRY:2024-01882"],["NCT01234649","Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","153","Gestational Diabetes Mellitus; Type 2 Diabetes Mellitus; Metabolic Syndrome; Impaired Glucose Tolerance; Disorder of Glucose Regulation","DRUG:Metformin XR plus placebo; DRUG:Metformin XR plus liraglutide","Woman's","2011-08-11","2019-04-24","TRUE","Insulin Secretion-Sensitivity Index (IS-SI) [84 weeks of treatment]","DERIVED:32046931","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/49/NCT01234649/Prot_SAP_000.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/49/NCT01234649/ICF_001.pdf","NO",null],["NCT00765817","Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","261","Type 2 Diabetes","DRUG:placebo; DRUG:exenatide","AstraZeneca","2008-10","2010-01","TRUE","Change in Glycosylated Hemoglobin (HbA1c) [baseline and 30 weeks]","DERIVED:24621255; DERIVED:23043166; DERIVED:22913891; DERIVED:22432107; DERIVED:21138825",null,null,null],["NCT05996848","A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight","REDEFINE 6","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","300","Obesity or Overweight","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo Semaglutide; DRUG:Placebo Cagrilintide","Novo Nordisk A/S","2023-08-15","2025-01-06","FALSE","CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in body weight [From baseline (week 0) to end of treatment (week 44)] | CagriSema 2.4 mg/2.4 mg versus placebo: Number of participants who achieve (yes/no): Body weight reduction greater than or equal to 5% [From baseline (week 0) to end of treatment (week 44)]",null,null,"YES","OTHER:U1111-1267-4364"],["NCT03353948","The Effect of a Liraglutide on IVF in Obese PCOS",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","30","Polycystic Ovary Syndrome; Obesity; Infertility, Female","DRUG:MET; DRUG:COMBI","University Medical Centre Ljubljana","2014-09-01","2016-05-31","FALSE","IVF pregnancy rates [14 days] | BMI [Patient's BMI was measured at the beginning and every four weeks during 12 weeks of clinical trial. ]] | Cumulative pregnancy rates [The pregnancies were collected by phone interview after one year]","BACKGROUND:24362411; DERIVED:35834645",null,"UNDECIDED",null],["NCT06948435","A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","487","Hypertension; Overweight or Obesity","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2025-04-30","2027-09","FALSE","Change from Baseline in office Systolic Blood Pressure (SBP) [Baseline to Week 36]",null,null,"YES","OTHER:J2A-MC-GZL1; OTHER:J2A-MC-GZPL"],["NCT00324363","Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","466","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:Placebo","AstraZeneca","2006-01","2007-04","FALSE","To test the hypothesis that exenatide (before morning and evening meals) produces a greater decrease in HbA1c than placebo in patients with type 2 diabetes and inadequate glycemic control taking metformin alone or metformin and sulfonylureas. [16 weeks]","DERIVED:22236356; DERIVED:19019476",null,null,null],["NCT03848793","A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","128","Diabetes Mellitus, Type 2","DRUG:HS-20004","Jiangsu HengRui Medicine Co., Ltd.","2019-03-06","2020-06-04","FALSE","HbA1c [16 weeks treatment]",null,null,"NO",null],["NCT07153471","A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee","ATTAIN-OA PAIN","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","SINGLE","800","Osteoarthritis","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2025-09-15","2028-04","FALSE","Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score [Baseline, Week 72]",null,null,"YES","CTIS:2025-522631-34-00; OTHER:J2A-MC-GZPT; OTHER:J2A-MC-GZT1; OTHER:J2A-MC-GZT2; NIH:2025"],["NCT00658021","Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","122","Type 2 Diabetes","DRUG:Placebo; DRUG:Exenatide","AstraZeneca","2008-05-30","2019-04-18","TRUE","Adjusted Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 28 [Baseline (Day 1) and Week 28] | Number of Participants With Post-Treatment Adverse Events of Special Interest (AESI) During Safety Follow-up Period [From 1 day after the Week 28/ED visit to 3 years after Week 28/ED visit.]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/21/NCT00658021/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/21/NCT00658021/SAP_001.pdf","YES","OTHER:H8O-MC-GWBQ"],["NCT06042153","DIALYSIS-TIR Study",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","43","Type 2 Diabetes; End Stage Renal Disease on Dialysis","DRUG:Semaglutide; DRUG:Placebo","University of Texas Southwestern Medical Center","2023-12-05","2027-09","FALSE","Change in TIR (70-180 mg/dl) [Baseline, 52 weeks]",null,null,"NO",null],["NCT07758231","Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics","TAP","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1",null,"NONE","5","GLP-1; Alcohol","DRUG:Acute Ethanol Dose","University of Wisconsin, Madison","2026-10","2027-03","FALSE","Maximum Ethanol Concentration (Cmax) [prior to dosing (-25 minutes), start of dosing (0 minutes), 15 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 240 minutes, 300 minutes, 350 minutes] | Time to Maximum Ethanol Concentration (Tmax) [prior to dosing (-25 minutes), start of dosing (0 minutes), 15 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 240 minutes, 300 minutes, 350 minutes] | Ethanol Elimination Rate: Blood samples [prior to dosing (-25 minutes), start of dosing (0 minutes), 15 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 240 minutes, 300 minutes, 350 minutes] | Ethanol Elimination Rate: Breath tests [prior to dosing (-25 minutes), 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 240 minutes, 300 minutes, 350 minutes] | Ethanol Elimination Rate: Urine samples [prior to dosing (-25 minutes), 60 minutes, 120 minutes, 180 minutes, 240 minutes, 300 minutes]",null,null,"YES","OTHER:Protocol Version 7/20/26; OTHER:Pharmacy | Pharmacy Practice; OTHER:ICTR TBCR Pilot Award"],["NCT01507311","Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","11","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","1999-09","1999-12","FALSE","Insulin secretory burst mass []","RESULT:11812750",null,null,null],["NCT07676331","Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial","CLARA","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","168","Hormone-receptor-positive Breast Cancer; Early Breast Cancer","DRUG:Tirzepatide; DRUG:Letrozole (Aromatase Inhibitors)","Universitaire Ziekenhuizen KU Leuven","2026-08-01","2028-03-01","FALSE","Ki67 proliferation marker [From enrollment till time of surgery (4-5 weeks)]",null,null,"NO","EUDRACT_NUMBER:2026-525820-76"],["NCT01301092","A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","30","Diabetes Mellitus, Type II","BIOLOGICAL:LY2189265","Eli Lilly and Company","2011-02","2011-08","TRUE","Dose Normalized Area Under the Concentration Time Curve (AUC) of LY2189265: Subcutaneous (SC) to Intravenous (IV) [Predose up to 336 hours postdose] | Maximum Concentration (Cmax) of LY2189265: Subcutaneous (SC) to Intravenous (IV) [Predose up to 336 hours postdose]",null,null,null,"OTHER:H9X-MC-GBDR"],["NCT06396429","To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","567","Overweight or Obesity","DRUG:HRS9531 injection; DRUG:Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2024-05-13","2025-07-07","FALSE","Percentage change from baseline in weight after 48 weeks of treatment [Baseline, Week 48] | Proportion of subjects with weight loss of≥5% from baseline after 48 weeks of treatment [Week 48]",null,null,"UNDECIDED",null],["NCT06890611","A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","125","Healthy","DRUG:Bimagrumab; DRUG:Tirzepatide; DRUG:Bimagrumab + Tirzepatide Coformulation","Eli Lilly and Company","2025-03-25","2025-09-26","FALSE","Pharmacokinetics (PK): Maximum Concentration (Cmax) of Bimagrumab Test Material [Predose through Week 13] | PK: Cmax of Bimagrumab Reference Material [Predose through Week 13] | PK: Cmax of Bimagrumab Coadministered with Tirzepatide [Predose through Week 13] | PK: Cmax of Tirzepatide Coadministered with Bimagrumab [Predose through Week 16] | PK: Cmax of Bimagrumab Coformulated with Tirzepatide [Predose through Week 16] | PK: Cmax of Tirzepatide Coformulated with Bimagrumab [Predose through Week 16] | PK: Area Under the Curve from Zero to Infinity AUC (AUC(0-∞)) of Bimagrumab Test Material [Predose through Week 13] | PK: AUC(0-∞) of Bimagrumab Reference Material [Predose through Week 13] | PK: AUC(0-∞) of Bimagrumab Coadministered with Tirzepatide [Predose through Week 13] | PK: AUC(0-∞) of Tirzepatide Coadministered with Bimagrumab [Predose through Week 16] | PK: AUC(0-∞) of Bimagrumab Coformulated with Tirzepatide [Predose through Week 16] | PK: AUC(0-∞) of Tirzepatide Coformulated with Bimagrumab [Predose through Week 16]",null,null,"NO","OTHER:J4Z-MC-GIDG"],["NCT06950684","Impact of Protein Supplementation and Resistance Training on Body Composition, Functional Parameters, Metabolic Adaptation, and Nitrogen Balance in Adults Aged 45 Years and Older With Overweight or Obesity Receiving Incretin-based Medications","PRIME","NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","180","Obesity; Overweight (BMI &gt; 25); Weight Loss","DIETARY_SUPPLEMENT:Whey Protein Supplement; BEHAVIORAL:Resistance Training Program","Assuta Medical Center","2025-07-01","2028-07-01","FALSE","Change in Fat Mass (kg) [Baseline, 3 months, 6 months.] | Change in Fat Mass Percentage (%) [Baseline, 3 months, 6 months.] | Change in Lean Body Mass (kg) [Baseline, 3 months, 6 months.] | Change in Skeletal Muscle Mass (kg) [Baseline, 3 months, 6 months.] | Change in Body Mass Index (BMI) [Baseline, 3 months, 6 months.]",null,null,"UNDECIDED","OTHER_GRANT:1001829006"],["NCT07832799","Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous Dose",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","340","Overweight; Obesity","DRUG:Maridebart Cafraglutide","Amgen","2026-10-12","2027-03-23","FALSE","Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUCinf) of Maridebart Cafraglutide [Up to Day 120] | Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration of Maridebart Cafraglutide [Up to Day 120] | Maximum Observed Concentration (Cmax) of Maridebart Cafraglutide [Up to Day 120]",null,null,"YES",null],["NCT04873245","Lifestyle Counseling and Medication for Adolescent Weight Management","QUEST","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","120","Obesity, Childhood","BEHAVIORAL:Intensive Behavioral Program; DRUG:Semaglutide and Behavioral Program","University of Minnesota","2022-03-15","2026-06-29","FALSE","Change in body mass index [56 weeks]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/45/NCT04873245/Prot_SAP_000.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/45/NCT04873245/ICF_001.pdf","YES",null],["NCT01755572","Blood Pressure Outcomes With Liraglutide Therapy","BOLT","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","22","Type 2 Diabetes; Systolic Hypertension","DRUG:Liraglutide; DRUG:Placebo","Mount Sinai Hospital, Canada","2013-01","2014-01","FALSE","Change in plasma ANP level at 1 Day [Change from Baseline compared in plasma ANP following 1 dose of liraglutide (0.6 mg) compared to crossover treatment with placebo at the 2-hour timepoint] | Change in plasma ANP level at 21 Days [Change from Baseline in plasma ANP following 21 days of liraglutide (titrated to 1.8 mg) compared to crossover treatment with placebo at the 2-hour timepoint]","RESULT:25414155",null,null,null],["NCT03804411","Prognostic Predictors of Response to Hypoglycemic Therapy",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","800","Diabetes Mellitus, Type 2","DRUG:Automatic system guided treatment; DRUG:Standard treatment","Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","2017-08-01","2020-03","FALSE","HbA1c [baseline and 3, 12, and 24 months after intervention] | Body mass index [baseline and 3, 12, and 24 months after intervention]",null,null,null,null],["NCT07245771","Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity",null,"RECRUITING","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","QUADRUPLE","104","Obesity &Amp; Overweight","DRUG:RN3161; DRUG:Placebo Control; DRUG:Tirzepatide","Ikaria Bioscience Pty Ltd","2025-11-04","2027-02-15","FALSE","Blood Pressure [180 Days] | ECG PR interval [180 days] | Physical Examination [180 days] | Blood Chemistry Laboratory [180 days] | Adverse Events [180 days] | Heart Rate [180 days] | ECG QRS Complex [180 days] | ECG QT interval [180 days] | Blood Hematology Laboratory [180 days] | Blood Coagulation Laboratory [180 days]",null,null,"YES",null],["NCT07374445","Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery",null,"COMPLETED","INTERVENTIONAL","PHASE4","NON_RANDOMIZED","NONE","100","Obesity; Weight Loss; Bariatric Surgery","DRUG:Liraglutide injection; BEHAVIORAL:Diet and exercise guidelines","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","2023-09-01","2025-06-01","FALSE","Change in %TWL from baseline to endpoint across patient groups [48 weeks from enrollment]",null,null,"NO",null],["NCT07859137","Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or Higher",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","100","Morbid Obesity","DRUG:Semaglutide weekly injection; DRUG:Placebo","General Committee of Teaching Hospitals and Institutes, Egypt","2026-10","2028-11","FALSE","Mean operative difficulty score [At the time or during surgery]",null,null,"YES",null],["NCT07046819","Tirzepatide in MetALD",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","120","Metabolic Alcohol-associated Liver Disease; Alcohol Use Disorder","DRUG:Tirzepatide; OTHER:Placebo","National Institute on Alcohol Abuse and Alcoholism (NIAAA)","2026-06-11","2027-07-30","FALSE","Metabolic improvement from baseline as measured by percentage reduction of body weight and reduction in liver steatosis from baseline as measured by percentage reduction in Fibroscan controlled attenuation parameter (CAP) score. [Change from baseline to week 12]","BACKGROUND:30473097",null,"YES","OTHER:002246-AA"],["NCT01572753","Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","161","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:semaglutide","Novo Nordisk A/S","2012-04-12","2012-09-08","FALSE","AUC 0-24h; Area under the semaglutide concentration curve from time 0-24 hours after the 10th dosing [0-24hrs after the 10th dosing]","DERIVED:34080123; DERIVED:33969456",null,null,"EUDRACT_NUMBER:2010-019653-17; OTHER:U1111-1120-6776"],["NCT06582875","Glucagon-Like Peptide-1 Receptor Agonist in ADPKD",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","126","Autosomal Dominant Polycystic Kidney; Obesity","DRUG:Tirzepatide; OTHER:Placebo","University of Colorado, Denver","2025-03-06","2029-06-30","FALSE","Change in height-Adjusted Total kidney volume [Baseline, 12-months]","DERIVED:41385299; DERIVED:41348481",null,"YES","NIH:R01DK138915-01A1"],["NCT07559136","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","48","Overweight and Obesity","DRUG:HRS9531 injection；Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2026-06-12","2027-02","FALSE","Adverse Events (AEs) [up to Week 28]",null,null,"UNDECIDED",null],["NCT03970044","Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","67","Diabetes Mellitus, Type 2","DRUG:Exenatide 2 MG; DRUG:Dapagliflozin 10 MG","Consano Clinical Research, LLC","2019-07-02","2021-06-01","FALSE","MAGE [14 weeks]",null,null,"NO",null],["NCT02138045","Treatment of Diabetic Neuropathy With Liraglutide","TODINELI","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","QUADRUPLE","39","Diabetes Mellitus, Type 1; Type 1 Diabetes Mellitus","DRUG:Placebo treatment; DRUG:Liraglutide treatment","Aalborg University Hospital","2014-05","2017-02","FALSE","RIII withdrawal reflex activity (using standard electromyography) [After 6 months of treatment with Liraglutide] | Evoked brain potentials (using standard electroencephalographic brain imaging). [After 6 months of treatment with Liraglutide]","DERIVED:34918951; DERIVED:32571684; DERIVED:32501945; DERIVED:31338868",null,null,null],["NCT06914895","A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight","SURPASS-T1D-1","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","905","Type 1 Diabetes; Obesity; Overweight","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2025-04-25","2026-11","FALSE","Change from Baseline in Hemoglobin A1c (HbA1c) [Baseline, Week 40]",null,null,"YES","OTHER:I8F-MC-GPJA; CTIS:2024-519684-17-00"],["NCT06897475","A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","200","Type 2 Diabetes","DRUG:LY3457263; DRUG:Placebo","Eli Lilly and Company","2025-03-28","2027-05","FALSE","Change from Baseline in Hemoglobin A1c (HbA1c) [Baseline, Week 24]",null,null,"YES","CTIS:2024-520328-27-00; OTHER:J1R-MC-GZFD"],["NCT02730377","Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes","LIRA-PRIME","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","1991","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:alpha-glucosidase inhibitors; DRUG:DPP-4 inhibitors; DRUG:meglitinides; DRUG:SGLT-2 inhibitors; DRUG:sulphonylurea; DRUG:thiazolidinediones","Novo Nordisk A/S","2016-03-28","2019-08-05","TRUE","Time to Inadequate Glycaemic Control [Weeks 26-104]","BACKGROUND:30828917; DERIVED:39963952","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/77/NCT02730377/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/77/NCT02730377/SAP_001.pdf","YES","EUDRACT_NUMBER:2015-002417-29; OTHER:U1111-1170-7035; NIH:2015"],["NCT02447601","Evaluate the Pharmacokinetics of Simvastatin When Coadministered With PEX168 in Healthy Adult Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","16","Type 2 Diabetes Mellitus","DRUG:PEX168; DRUG:Simvastatin","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2015-03-30","2015-05-14","FALSE","Plasma concentrations of simvastatin and simvastatin acid. [Baseline to Day34]",null,null,"NO","OTHER:PEX168-Ik"],["NCT04525300","Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities",null,"UNKNOWN","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","300","Obesity","DRUG:Liraglutide; DRUG:placebo","Xiangya Hospital of Central South University","2020-05-24","2022-06","FALSE","The composition of the gut microbiota from baseline to end of treatment. [week 28]",null,null,null,null],["NCT05205928","Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care","SEMA-AP","COMPLETED","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","TRIPLE","28","Type 1 Diabetes; Diabetes Mellitus, Type 1","DRUG:Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy","McGill University Health Centre/Research Institute of the McGill University Health Centre","2022-10-02","2024-04-15","FALSE","Percentage of time of plasma glucose levels spent in target range (semaglutide vs placebo) [4 weeks]","DERIVED:39794615","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/28/NCT05205928/Prot_SAP_000.pdf","YES",null],["NCT05478707","Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes","MCD-1","RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","47","Diabetes Mellitus, Type 1; Endothelial Dysfunction","DRUG:Dulaglutide; DRUG:Placebo","AdventHealth Translational Research Institute","2023-10-05","2028-06-30","FALSE","Microvascular blood volume (MBV) [At baseline and after 14 weeks of treatment.]","BACKGROUND:20739685; BACKGROUND:30129464; BACKGROUND:30657336; BACKGROUND:22362823; BACKGROUND:25899581; BACKGROUND:26936306; BACKGROUND:21610226; BACKGROUND:32776829; BACKGROUND:21346068; BACKGROUND:20339920; BACKGROUND:26265791; BACKGROUND:34075130; BACKGROUND:24130351; BACKGROUND:23564922; BACKGROUND:33123598; BACKGROUND:19654321; BACKGROUND:31888883; BACKGROUND:24401231; BACKGROUND:24552454; BACKGROUND:27039125; BACKGROUND:17711996; BACKGROUND:27436611; BACKGROUND:29310645; BACKGROUND:22732108; BACKGROUND:27295427; BACKGROUND:27633186; BACKGROUND:30291013; BACKGROUND:31189511; BACKGROUND:1348845; BACKGROUND:31110479; BACKGROUND:30270019; BACKGROUND:23052062; BACKGROUND:29038314; BACKGROUND:16109070; BACKGROUND:33219433; BACKGROUND:28386795; BACKGROUND:33184152; BACKGROUND:28817231; BACKGROUND:24742660; BACKGROUND:22511259; BACKGROUND:9490243; BACKGROUND:15161743; BACKGROUND:16644702; BACKGROUND:22167126; BACKGROUND:20952670; BACKGROUND:32955366; BACKGROUND:26293127; BACKGROUND:27506222; BACKGROUND:27493132; BACKGROUND:30281094; BACKGROUND:33259257; BACKGROUND:29371269; BACKGROUND:34339111; BACKGROUND:32661106; BACKGROUND:26739816; BACKGROUND:26082639; BACKGROUND:11842075; BACKGROUND:19672102",null,null,null],["NCT02049034","Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","8","Type 2 Diabetes","OTHER:Lixisenatide; OTHER:Placebo","University of Surrey","2014-01","2016-01","FALSE","Postprandial glucose kinetics [Two years]","DERIVED:30215735",null,"NO","EUDRACT_NUMBER:2013-002826-22"],["NCT04909333","Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia","FAST","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","29","Endogenous Hyperinsulinism","DRUG:Exenatide; DRUG:0.9% saline solution","University Hospital, Basel, Switzerland","2021-04-29","2024-04-30","FALSE","time to symptomatic hypoglycemia after exenatide test compared to placebo [within 4 hours after injection]","DERIVED:40747712",null,null,null],["NCT05553093","Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes",null,"RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","150","Type 2 Diabetes Mellitus","DRUG:Tirzepatide; DRUG:Insulin Glargine","Nanjing First Hospital, Nanjing Medical University","2022-03-15","2023-12-31","FALSE","blood sugar changes [40 weeks] | blood lipid changes [40 weeks] | Brain function [40 weeks]",null,null,null,null],["NCT03021187","Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin","PIONEER 8","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","731","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2017-02-02","2018-01-18","TRUE","Change in HbA1c (Week 26) [Week 0, week 26]","RESULT:31530667; DERIVED:33660198; DERIVED:32998732; DERIVED:32267058; DERIVED:31903692","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/87/NCT03021187/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/87/NCT03021187/SAP_001.pdf","YES","EUDRACT_NUMBER:2016-000988-16; OTHER:U1111-1180-3637; OTHER:JapicCTI-173508; NIH:2016"],["NCT06820099","Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failure and Obesity",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","225","Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity","DRUG:HRS-7535 tablet; DRUG:HRS-7535 tablet placebo","Shandong Suncadia Medicine Co., Ltd.","2025-04-10","2026-12","FALSE","The percentage change from baseline in body weight. [At week 36.]",null,null,"UNDECIDED",null],["NCT03151005","The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","70","Polycystic Ovary Syndrome (PCOS); Overweight; Obesity","DRUG:Metformin-GLP-1 Receptor Agonist; DRUG:Metformin-Oral Contraceptive(OC)","Xinqiao Hospital of Chongqing","2017-07-01","2021-04-01","TRUE","Assessment of Reproductive Functions [12 weeks]","RESULT:28646699; RESULT:12046553; RESULT:24389146; RESULT:26426951; RESULT:14688154; RESULT:22777527; RESULT:20471009; RESULT:29569621; RESULT:28463030; RESULT:28860713; RESULT:30459598; DERIVED:37653215","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/05/NCT03151005/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/05/NCT03151005/SAP_001.pdf","YES",null],["NCT07737522","Myocardial Metabolic Flux in Pulmonary Arterial Hypertension",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2",null,"NONE","32","Pulmonary Arterial Hypertension","DRUG:GLP-1 agonist","Imperial College London","2026-10-01","2028-10-01","FALSE","Change in the phosphocreatine-to-adenosine triphosphate (31PCr/ATP) ratio between baseline and follow up in response to treatment with GLP-1 agonist [12 weeks]",null,null,null,null],["NCT00734474","A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin",null,"COMPLETED","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","QUADRUPLE","1202","Diabetes Mellitus, Type 2","DRUG:LY2189265; DRUG:Sitagliptin; DRUG:Placebo solution; DRUG:Placebo tablet; DRUG:Metformin","Eli Lilly and Company","2008-08","2011-06","TRUE","Glycosylated Hemoglobin (HbA1c) Change From Baseline [Baseline, 52 weeks]","DERIVED:36894938; DERIVED:28755389; DERIVED:27161178; DERIVED:26691396; DERIVED:25912221; DERIVED:24762094; DERIVED:23294774",null,null,"OTHER:H9X-MC-GBCF; REGISTRY:CTRI/2009/091/000969"],["NCT04185350","Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma",null,"UNKNOWN","INTERVENTIONAL","EARLY_PHASE1",null,"NONE","60","Insulinoma","DRUG:68Ga-NOTA-MAL-Cys39-exendin-4","Nanjing First Hospital, Nanjing Medical University","2019-05-05","2020-04-05","FALSE","Standardized uptake value [1 year]",null,null,null,null],["NCT07221591","A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","100","Healthy","COMBINATION_PRODUCT:survodutide","Boehringer Ingelheim","2025-11-05","2026-07-28","FALSE","Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ (AUCτ,ss) [up to 232 days] | Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmax,ss) [up to 232 days]",null,null,"NO","CTIS:2025-522325-35-00; REGISTRY:U1111-1322-4700; NIH:2025"],["NCT02655770","Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","40","Diabetes Mellitus Type 2; Diastolic Dysfunction; Cardiac MRI; Myocardial Perfusion","DRUG:Liraglutide; DRUG:Placebo","Copenhagen University Hospital, Rigshospitalet","2016-02","2019-12","FALSE","Change in diastolic properties as assessed by CMR. [Measured in week 18 and compared to baseline.]","BACKGROUND:4835750; BACKGROUND:7351930; BACKGROUND:9498536; BACKGROUND:1486584; BACKGROUND:18071071; BACKGROUND:20117433; BACKGROUND:16386668; BACKGROUND:20466848; BACKGROUND:16305055; BACKGROUND:22246377",null,null,"EUDRACT_NUMBER:2015-000410-22; NIH:2015"],["NCT05630586","Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke","ASSET","RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","SINGLE","380","Acute Ischemic Stroke","DRUG:Semaglutide; OTHER:Standard care","Aarhus University Hospital","2023-04-12","2025-09","FALSE","Modified Ranking Scale [90 (+/- 14) days]",null,null,"NO","OTHER:EUCT number: 2022-501072-25-02"],["NCT04552470","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06882961 in Japanese Adults With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","37","Type 2 Diabetes Mellitus","DRUG:Placebo; DRUG:PF-06882961","Pfizer","2020-10-26","2021-03-25","TRUE","Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) [Day 1 of dosing up to approximately 4 weeks after last dose (up to maximum of approximately 12 weeks)] | Number of Participants With Clinical Laboratory Abnormalities [Day 1 of dosing up to approximately 4 weeks after last dose (up to maximum of approximately 12 weeks)] | Number of Participants With Absolute Vital Signs (SBP, DBP and Pulse Rate) Values; Increased and Decreased Vital Signs (SBP, DBP) Values From Time-Matched Baseline [Baseline (1 Day before dosing) up to last dose (maximum up to Week 8)] | Number of Participants With Absolute Electrocardiogram (ECG) Values and Increased ECG Values From Time-Matched Baseline [Baseline (1 Day before dosing) up to last dose (maximum up to Week 8)]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/70/NCT04552470/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/70/NCT04552470/SAP_001.pdf","NO",null],["NCT05369390","A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","144","Obesity","DRUG:NNC0487-0111 A; DRUG:NNC0487-0111 B; OTHER:Placebo B (NNC0487-0111 B); OTHER:Placebo A (NNC0487-0111 A)","Novo Nordisk A/S","2022-05-11","2024-01-09","FALSE","Number of treatment emergent adverse events (TEAE) [Part A: From pre-dose on Day 1 to 22 days; Part B: From pre-dose on Day 1 to 31 days; Part C and D: From pre-dose on Day 1 to 105 days]","DERIVED:40550229",null,"YES","OTHER:U1111-1270-0852"],["NCT06391710","HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","203","Heart Failure With Preserved Ejection Fraction","DRUG:HRS9531; DRUG:Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2024-05-06","2026-01","FALSE","Change in KCCQ (Kansas City Cardiomyopathy Questionnaire) clinical summary score [From baseline (week 0) to week 36] | Change in body weight [From baseline (week 0) to week 36]",null,null,"UNDECIDED",null],["NCT06830343","The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","66","Overweight or Obesity","DRUG:SYH9017; DRUG:Placebo; DRUG:Wegovy ®","CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","2025-02-27","2026-08-01","FALSE","Incidence of AEs following single-dose administration of SYH9017 Description: [up to 49 days after the dosing] | Incidence of AEs following multiple doses administration of SYH9017AEs of SYH 9017 following multiple doses [up to 140 days after the last dosing]",null,null,null,null],["NCT06221696","Preventing Weight Regain Post-Semaglutide Treatment With Active Fiber Supplement (Soloways)","PWR-FAST","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","TRIPLE","160","Overweight and Obesity","DIETARY_SUPPLEMENT:Active Fiber Supplement Group; OTHER:Placebo Group","S.LAB (SOLOWAYS)","2023-06-12","2023-11-23","FALSE","Percentage of weight regain from baseline [180 days]",null,null,null,null],["NCT03824002","Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","92","Diabetes Mellitus","DRUG:Dulaglutide; DRUG:Aspart insulin; DRUG:Glargine; DRUG:Metformin; DRUG:Repaglinide","University of Palermo","2017-04-01","2017-10-01","FALSE","Change from Baseline Reactive Hyperemia Index at 3 and 9 months [0 months, 3 months and 9 months]","DERIVED:39963952",null,null,null],["NCT02696148","A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","24","Metabolism and Nutrition Disorder; Obesity","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2016-03-14","2017-04-13","FALSE","Number of treatment emergent adverse events [From the time of first dosing and until completion of follow-up visit (59-108 days after first dosing)]","RESULT:30653847",null,"YES","OTHER:U1111-1162-9171; EUDRACT_NUMBER:2014-004454-34; NIH:2014"],["NCT01919489","Liraglutide Hospital Discharge Trial",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","273","Type 2 Diabetes","DRUG:Liraglutide + OADs; DRUG:Glargine + OADs","Emory University","2014-03","2020-08-30","TRUE","Glycemic Control at Hospital Discharge and 6 Months Follow up [Hospital discharge, 6 months (26 weeks)]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/89/NCT01919489/Prot_SAP_000.pdf",null,"REGISTRY:(UTN) U1111-1139-2991"],["NCT06914102","Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data","DUP-STEP-HFpEF","COMPLETED","OBSERVATIONAL",null,null,null,"58387","Diabetes Mellitus, Type 2; HFpEF - Heart Failure With Preserved Ejection Fraction","DRUG:Semaglutide; DRUG:Placebo","Brigham and Women's Hospital","2025-01-14","2025-06-01","FALSE","Composite of all-cause mortality or heart failure hospitalization [Through study completion (1 day after cohort entry date until the first of outcome or censoring)]","DERIVED:40886075","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/02/NCT06914102/Prot_SAP_001.pdf",null,null],["NCT02284230","The Effect of Liraglutide in Patients With Prediabetes and Kidney Failure","LiRA2","WITHDRAWN","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","0","Kidney Failure, Chronic; Prediabetic State","DRUG:Liraglutide; DRUG:Placebo","Bo Feldt-Rasmussen","2014-12","2015-08","FALSE","Plasma glucose during oral glucose tolerance test at week 26 [The trial visit of week 26]",null,null,null,null],["NCT01940965","Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","NON_RANDOMIZED","NONE","294","Type 2 Diabetes Mellitus","DRUG:lixisenatide AVE0010; DRUG:biguanide; DRUG:TZD; DRUG:alpha-GI; DRUG:glinide","Sanofi","2013-09","2015-07","FALSE","Safety over 52 weeks assessed by treatment emergent adverse event (TEAE), vital signs, 12-lead electrocardiogram (ECG), and laboratory data [52 weeks]",null,null,null,"OTHER:U1111-1129-8754"],["NCT03115099","A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","80","Diabetes Mellitus, Type 2","DRUG:LY3325656; DRUG:Placebo; DRUG:Liraglutide; DRUG:Sitagliptin","Eli Lilly and Company","2017-05-31","2018-04-05","FALSE","Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline through approximately 12 weeks and 5 weeks after first administration of study drug in Parts A and B, respectively]",null,null,null,"OTHER:I8U-MC-DMBA"],["NCT03648281","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN)",null,"COMPLETED","OBSERVATIONAL",null,null,null,"333","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2018-08-24","2020-01-10","FALSE","Change in Glycated Haemoglobin A1c (HbA1c) [Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)] | Change in HbA1c [Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)]","RESULT:34183269; DERIVED:35383100",null,"YES","OTHER:U1111-1204-5181"],["NCT06500130","Effects of Liraglutide on Body Surface Gastric Mapping",null,"COMPLETED","INTERVENTIONAL",null,null,"NONE","22","Gastroparesis; Functional Dyspepsia; Chronic Nausea and Vomiting Syndrome; Healthy","DEVICE:Body Surface Gastric Mapping","Alimetry","2024-05-30","2024-10-30","FALSE","Change in overall postprandial BSGM Gastric Alimetry Rhythm Index (GA-RI) on treatment compared to baseline. [2 weeks]",null,null,"NO",null],["NCT02244164","Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.",null,"TERMINATED","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","5","Type 2 Diabetes; Incretinomimetics; Pancreas","DRUG:Incretinomimetics; DRUG:DPP-4 inhibitors","Erasme University Hospital","2014-10","2023-02-13","FALSE","Volumetric measurement of the pancreas [1 year]","RESULT:17098089; RESULT:17622601; RESULT:23524641; RESULT:23645885",null,null,null],["NCT02586831","Diabetes Islet Preservation Immune Treatment","DIPIT","WITHDRAWN","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","TRIPLE","0","Diabetes Mellitus, Type 1; Hypoglycemia; Autoimmune Diseases; Diabetes Mellitus","DRUG:Anti-Thymocyte Globulin (ATG); DRUG:Interleukin 2; DRUG:Exenatide; DRUG:Adalimumab; OTHER:ATG Placebo; OTHER:IL-2 Placebo; OTHER:Adalimumab Placebo; OTHER:Exenatide Placebo","Camillo Ricordi and Jay Skyler","2024-06-01","2024-06-01","FALSE","Simulated C-peptide AUC [1 Year Visit] | Proportion of regulatory T cells [1 Year Visit]","BACKGROUND:25998292; BACKGROUND:21193733",null,"NO",null],["NCT05510245","A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction",null,"TERMINATED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","18","Type 2 Diabetes; Renal Impairment","DRUG:PF-07081532","Pfizer","2022-08-29","2023-07-20","TRUE","Maximum Observed Concentration (Cmax) for PF-07081532 Following a Single Oral Dose of PF-07081532 20 mg in Participants With Varying Degrees of Renal Impairment [Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96, 120, 144 hours post dose on Day 1] | Unbound Cmax (Cmax,u) for PF-07081532 Following a Single Oral Dose of PF-07081532 20 mg in Participants With Varying Degrees of Renal Impairment [Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96, 120, 144 hours post dose on Day 1] | Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) for PF-07081532 Following a Single Oral Dose of PF-07081532 20 mg in Participants With Varying Degrees of Renal Impairment [Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96, 120, 144 hours post dose on Day 1] | Unbound AUCinf (AUCinf,u) for PF-07081532 Following a Single Oral Dose of PF-07081532 20 mg in Participants With Varying Degrees of Renal Impairment [Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96, 120, 144 hours post dose on Day 1] | Unbound Fraction (fu) for PF-07081532 Following a Single Oral Dose of PF-07081532 20 mg in Participants With Varying Degrees of Renal Impairment [Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96, 120, 144 hours post dose on Day 1]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/45/NCT05510245/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/45/NCT05510245/SAP_001.pdf","NO",null],["NCT06745128","Tirzepatide for Obesity and Meth Use Disorder",null,"COMPLETED","INTERVENTIONAL","PHASE2",null,"NONE","35","Obesity; Methamphetamine Use Disorder","DRUG:Tirzepatide","University of Texas Southwestern Medical Center","2025-02-03","2026-02-12","FALSE","Effect of tirzepatide on self-reported use of methamphetamine [36 weeks]","BACKGROUND:39049203; BACKGROUND:39535805; BACKGROUND:38320504; BACKGROUND:18237386; BACKGROUND:37253796; BACKGROUND:19874165; BACKGROUND:16996138; BACKGROUND:3395719",null,"NO",null],["NCT04617275","A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","151","Diabetes; Obesity","DRUG:PF-06882961; OTHER:Placebo","Pfizer","2021-01-06","2021-11-17","TRUE","Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity [Baseline through follow-up (Day 112)]","DERIVED:37311722","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/75/NCT04617275/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/75/NCT04617275/SAP_001.pdf","YES","OTHER:GLP-1Ra Ph 2 Titration Study"],["NCT00766857","Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart Failure",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","27","Type 2 Diabetes Mellitus; Congestive Heart Failure","DRUG:exenatide; DRUG:Insulin glargine","Amsterdam UMC, location VUmc","2009-05","2012-12","FALSE","Cardiac Magnetic Resonance (CMR) will be used to assess global cardiac function (LV ejection fraction). [week -2 and week 11]","DERIVED:28526033",null,null,"OTHER:EudraCT: 2008-005325-10"],["NCT03086330","Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus","SUSTAIN 9","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","302","Diabetes; Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2017-03-15","2018-07-04","TRUE","Change in HbA1c [Week 0, week 30]","RESULT:30833170","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/30/NCT03086330/Prot_SAP_000.pdf","YES","EUDRACT_NUMBER:2016-000904-27; OTHER:U1111-1180-1213; REGISTRY:JapicCTI-173542; NIH:2016"],["NCT07812636","Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer","TIDE","NOT_YET_RECRUITING","INTERVENTIONAL","EARLY_PHASE1",null,"NONE","15","Grade 1 Endometrial Endometrioid Carcinoma; Endometrial Intraepithelial Neoplasia; Metabolic Comorbidities","DRUG:Tirzepatide","Milton S. Hershey Medical Center","2026-11-01","2028-05-01","FALSE","Pathologic Response at 6 months from Cycle 1 Day 1 [At the end Cycle 6 Day 28 (Approximately 6 months from Cycle 1 Day 1with each cycle approximately 28 days)]",null,null,null,null],["NCT05203237","Phase 1 Study to Evaluate the Safety and Tolerability of VK2735",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","92","Weight Loss; NASH","BIOLOGICAL:VK2735; BIOLOGICAL:Placebo; DRUG:VK2735 Placebo; DRUG:VK2735 Drug","Viking Therapeutics, Inc.","2021-12-14","2024-11-04","FALSE","Incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious AEs (TESAEs) [8 days]",null,null,"NO",null],["NCT07653412","Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.","Diagenix","RECRUITING","OBSERVATIONAL",null,null,null,"220","Obesity (Disorder); Anti-obesity Agents; Precision Medicine","DRUG:Semaglutide or Tirzepatide","National and Kapodistrian University of Athens","2026-04-22","2027-01-30","FALSE","Percentage weight loss at 6 months [6 months]","RESULT:30104762; RESULT:35658024; RESULT:33567185; RESULT:16415884; RESULT:25471927; RESULT:17434869; RESULT:30124842; RESULT:25673413",null,"NO",null],["NCT07824895","Mazdutide for Weight Management and Gout in Adults With Obesity",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4",null,"NONE","30","Gout; Obesity (BMI>30); Hyperuricemia; Metabolic Syndrome","DRUG:Mazdutide","Hongwei Jiang","2026-09-15","2027-12-31","FALSE","Annualized Flare Rate (AFR) [Baseline to Week 52；Unit of Measure: Flares per person-year]",null,null,"YES",null],["NCT02098395","The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes","ADJUNCT TWO™","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","835","Diabetes; Diabetes Mellitus, Type 1","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2014-05","2015-04","TRUE","Change From Baseline in Glycosylated Haemoglobin (HbA1c) [Week 0, Week 26]","RESULT:27493132; RESULT:27493232; DERIVED:39717993; DERIVED:34463425",null,null,"EUDRACT_NUMBER:2012-005778-74; OTHER:U1111-1138-0619; REGISTRY:NL47705.060.14; REGISTRY:REec-2014-0884"],["NCT06482112","Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","124","Metabolic Dysfunction-Associated Steatotic Liver Disease; Non-alcoholic Fatty Liver Disease; Nonalcoholic Fatty Liver Disease; Liver Disease","DRUG:Efinopegdutide","Merck Sharp & Dohme LLC","2024-07-29","2025-06-27","TRUE","Mean Relative Reduction From Baseline in Liver Fat Content at Week 28 [Baseline and Week 28] | Percentage of Participants Who Experienced an Adverse Event (AE) [Up to Week 32] | Percentage of Participants Who Discontinued Study Intervention Due to an AE [Up to Week 28]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/12/NCT06482112/Prot_SAP_000.pdf","YES","OTHER:MK-6024-016"],["NCT06131437","A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","809","Obesity","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Tirzepatide","Novo Nordisk A/S","2023-11-27","2025-12-08","FALSE","To confirm non-inferiority of CagriSema versus tirzepatide: Relative change in body weight [From baseline (week 0) to end of treatment (week 84)]",null,null,"YES","OTHER:U1111-1292-4835"],["NCT03548935","STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity","STEP 1","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","1961","Metabolism and Nutrition Disorder; Overweight or Obesity","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2018-06-04","2020-03-30","TRUE","Change in Body Weight (%) [Baseline (week 0) to week 68] | Participants Who Achieve 5 or More Percent Body Weight Reduction (Yes/no) [After week 68]","BACKGROUND:32441473; RESULT:33567185; DERIVED:40980163; DERIVED:39316288; DERIVED:39226070; DERIVED:38698650; DERIVED:36876594; DERIVED:36801984; DERIVED:36200477; DERIVED:35724304; DERIVED:35441470; DERIVED:30122305","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/35/NCT03548935/Prot_002.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/35/NCT03548935/SAP_003.pdf","YES","OTHER:U1111-1200-8053; REGISTRY:2017-003436-36; NIH:2017"],["NCT06192108","A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin","ACHIEVE-2","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","962","Type 2 Diabetes","DRUG:Orforglipron; DRUG:Dapagliflozin","Eli Lilly and Company","2024-01-10","2025-09-26","FALSE","Change from Baseline in Hemoglobin A1c: (HbA1c) [Baseline, Week 40]","DERIVED:42259339",null,"YES","OTHER:J2A-MC-GZGV; OTHER:2023-507206-13-00; OTHER:U1111-1296-1507; NIH:2023"],["NCT07227948","Repurposing Semaglutide for the Treatment of Cocaine Use Disorder",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","75","Cocaine Use Disorder","DRUG:Semaglutide; DRUG:Placebo; BEHAVIORAL:cognitive behavioral therapy (CBT).","The University of Texas Health Science Center, Houston","2026-01-15","2029-01-28","FALSE","Amplitude of the Late Positive Potential (LPP) in microvolts in response to visual stimuli on the Picture Viewing Task. [End of Treatment (Week 15)] | Intensity of demand as assessed by the amount of cocaine purchased and consumed as assessed by cocaine purchasing task [End of Treatment (Week 15)] | Cocaine craving as assessed by the score on the Cocaine Cravings Questionnaire [End of Treatment (Week 15)] | Proportion of cocaine negative urine drug screens (UDS) during the final two weeks of treatment [From Week 13 to Week 14]","DERIVED:42161545",null,"NO","NIH:R01DA062720-01"],["NCT01513525","Comparison of Liraglutide Injected at Three Different Injection Sites in Healthy Volunteers",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","21","Diabetes; Healthy","DRUG:liraglutide","Novo Nordisk A/S","2007-02","2007-05","FALSE","Area under the Curve (AUC) of liraglutide for each injection site []","RESULT:20671294",null,null,"EUDRACT_NUMBER:2006-004670-27"],["NCT04687514","Effects of Glucagon-Like Peptide-1 Analogs on Sexuality","DESIRE","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","26","Sexual Functioning","DRUG:Dulaglutide; DRUG:Placebo","University Hospital, Basel, Switzerland","2021-05-05","2022-09-05","FALSE","Change in sexual functioning, assessed with the German version of the Massachusetts General Hospital - Sexual Functioning Questionnaire (MGH-SFQ). [at baseline (before start of treatment) and after each week of treatment (V1, V2, V3, V4 and EV1), up to 10 weeks.]",null,null,null,null],["NCT01432938","A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","28","Diabetes Mellitus, Type 2","BIOLOGICAL:dulaglutide; DRUG:Warfarin","Eli Lilly and Company","2011-09","2011-12","TRUE","Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of R-warfarin and S-warfarin [Predose (warfarin) and up to 144 hours postdose on Day 1 for Treatment 1 (warfarin alone) and on Day 3 for Treatment 2 (warfarin in combination with dulaglutide)] | Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of R-warfarin and S-warfarin [Predose (warfarin) and up to 144 hours postdose on Day 1 for Treatment 1 (warfarin alone) and on Day 3 for Treatment 2 (warfarin in combination with dulaglutide)] | Pharmacokinetics: Time to Maximum Concentration (Tmax) of R-warfarin and S-warfarin [Predose (warfarin) and up to 144 hours postdose on Day 1 for Treatment 1 (warfarin alone) and on Day 3 for Treatment 2 (warfarin in combination with dulaglutide)]","DERIVED:28357715",null,null,"OTHER:H9X-MC-GBCS"],["NCT04166773","A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)","SYNERGY-NASH","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","190","Nonalcoholic Steatohepatitis","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2019-11-19","2023-12-11","TRUE","Percentage of Participants With Absence of Nonalcoholic Steatohepatitis (NASH) With no Worsening of Fibrosis on Liver Histology [Week 52]","DERIVED:38856224","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/73/NCT04166773/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/73/NCT04166773/SAP_001.pdf","YES","OTHER:I8F-MC-GPHR; EUDRACT_NUMBER:2019-001550-26; NIH:2019"],["NCT06009653","Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity","TRZ","WITHDRAWN","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","0","Obesity; Metabolic Disease","BEHAVIORAL:Standard Care; BEHAVIORAL:Culturally-tailored dietary and behavioral intensive lifestyle intervention; DRUG:Placebo; DRUG:Tirzepatide","Washington University School of Medicine","2023-09-13","2024-05-29","FALSE","Change in body weight [After 24 weeks of intervention] | Change in body weight [After 52 weeks of intervention]",null,null,null,"NIH:P50MD017344"],["NCT03520972","Dose-finding of PB-119 Administered Subcutaneously Once-weekly Versus Placebo in Drug-naïve T2DM Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","251","Type 2 Diabetes Mellitus","DRUG:PB-119 75ug; DRUG:PB-119 150ug; DRUG:PB-119 200ug; DRUG:placebo","PegBio Co., Ltd.","2018-06-05","2019-07-29","FALSE","Change of glycosylated hemoglobin(HbA1c) [12 weeks]","DERIVED:33687487; DERIVED:30957581",null,null,null],["NCT06217848","The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study",null,"UNKNOWN","INTERVENTIONAL","EARLY_PHASE1",null,"NONE","50","Panhypopituitarism; Craniopharyngioma; Hypothalamic Obesity","DRUG:Saxenda","Seoul National University Hospital","2022-11-28","2024-02-08","FALSE","Change in weight [3 month]",null,null,null,null],["NCT00456885","The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","41","Obesity; Impaired Glucose Tolerance","DRUG:exenatide; DRUG:Placebo","Beth Israel Deaconess Medical Center","2007-04","2010-09","TRUE","Change in Weight [16 weeks after the beginning of each treatment] | Change in Body Mass Index [16 weeks from the start of each treatment period.]","RESULT:22040840",null,null,"OTHER:BFA912"],["NCT05966272","Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","199","Type 2 Diabetes","DRUG:HRS9531 injection; DRUG:HRS9531 injection Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2023-08-12","2024-09-24","FALSE","Change From Baseline in HbA1c after 20 weeks of treatment [Week 0 to Week 20]",null,null,"UNDECIDED",null],["NCT06499857","Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation","SEMINAL-AF","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","200","Overweight or Obesity; Atrial Fibrillation","DRUG:Semaglutide; DRUG:Placebo","University of Chicago","2025-04-14","2027-12","FALSE","Time to first AF event detected by routine outpatient monitoring [Baseline to Week 68] | Change from baseline in AF burden detected by routine outpatient monitoring. [Baseline to Week 68]",null,null,"NO",null],["NCT00612794","A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","30","Type 2 Diabetes","DRUG:exenatide once weekly; DRUG:placebo","AstraZeneca","2007-09","2008-05","FALSE","To assess the safety and tolerability of exenatide administered once weekly by subcutaneous (SC) injection in subjects with type 2 diabetes mellitus. [10 weeks]","DERIVED:19706990",null,null,null],["NCT07203677","Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT)",null,"COMPLETED","OBSERVATIONAL",null,null,null,"49065","Type2 Diabetes Mellitus; Atherosclerotic Cardiovascular Disease","DRUG:Initiation of tirzepatide; DRUG:Initiation of sitagliptin","Brigham and Women's Hospital","2025-09-19","2025-10-15","FALSE","Major adverse cardiovascular events [1 day after cohort entry date until the first of outcome or censoring, up to 365 days]","DERIVED:42556854","Study Protocol and Statistical Analysis Plan: Amendment 2 to Study Protocol with Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/77/NCT07203677/Prot_SAP_002.pdf; Study Protocol and Statistical Analysis Plan: Amendment 3 to Study Protocol with Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/77/NCT07203677/Prot_SAP_003.pdf; Study Protocol and Statistical Analysis Plan: Amendment to Study Protocol with Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/77/NCT07203677/Prot_SAP_001.pdf; Study Protocol: Study Protocol with Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/77/NCT07203677/Prot_000.pdf",null,null],["NCT03498001","Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging","LICAS-MR","COMPLETED","INTERVENTIONAL",null,null,"NONE","42","Type II Diabetes","DRUG:GLP-1 agonists; PROCEDURE:Cardiac MRI; OTHER:Follow up by phone","Centre Hospitalier Universitaire Dijon","2018-04-16","2023-06-06","FALSE","Change from Baseline Concentration of intramyocardial triglycerides at 6 months [Month 6]","RESULT:39900263",null,null,null],["NCT03235219","A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","39","Diabetes Mellitus, Type 2","DRUG:JNJ-64565111; DRUG:Placebo","Janssen Research & Development, LLC","2017-08-01","2018-02-19","FALSE","Number of Participants With Adverse Events as a Measure of Safety and Tolerability [Up to Day 72]",null,null,null,"OTHER:64565111EDI1002"],["NCT01644500","A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus","AWARD-CHN1","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","737","Type 2 Diabetes Mellitus","DRUG:Dulaglutide; DRUG:Glimepiride; DRUG:Placebo as Capsules; DRUG:Placebo as SC Injection","Eli Lilly and Company","2012-07","2014-08","TRUE","Change From Baseline in HbA1c at 26 Weeks [Baseline, 26 Weeks]","DERIVED:32857293; DERIVED:32621083; DERIVED:32277401; DERIVED:32219675; DERIVED:31183384",null,"YES","OTHER:H9X-JE-GBCG"],["NCT06256536","A Study of GZR18 Injection in Chinese Obese/Overweight Patients",null,"COMPLETED","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","DOUBLE","60","Obesity; Overweight","DRUG:GZR18; OTHER:Placebo","Gan and Lee Pharmaceuticals, USA","2022-07-14","2023-10-22","FALSE","Incidence of adverse events and serious adverse events [38 weeks] | Changes in weight from baseline to the end of treatment [35 weeks]","DERIVED:41956096",null,null,null],["NCT06974851","A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","140","Bstructive Sleep Apnea (OSA) and Obesity","DRUG:HRS9531; DRUG:HRS9531placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2025-07-25","2026-12","FALSE","Percentage Change in AHI from Baseline at Week 52 of Treatment [52week]",null,null,"UNDECIDED",null],["NCT07044401","A Single-dose Study to Investigate the Effect of Injection Site on KAI-9531 Relative Bioavailability in a Range of Body Mass Indices",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","51","Healthy Volunteers","DRUG:KAI-9531","Kailera","2025-07-14","2025-11-13","FALSE","Maximum Observed Concentration (Cmax) of KAI-9531 [Treatment Period 1, 2 and 3: Pre-dose and up to 672 hours post-dose] | Area Under the Concentration-time Curve From 0 to Time of Last Quantifiable Concentration (AUC0-t) of KAI-9531 [Treatment Period 1, 2 and 3: Pre-dose and up to 672 hours post-dose] | Area Under the Concentration-time Curve From 0 to Infinity (AUC0-inf) of KAI-9531 [Treatment Period 1, 2 and 3: Pre-dose and up to 672 hours post-dose]",null,null,"NO",null],["NCT06910839","Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity",null,"TERMINATED","INTERVENTIONAL","PHASE1",null,"NONE","21","Overweight; Obesity","DRUG:PF-07976016; DRUG:PF-06882961","Pfizer","2025-03-13","2025-05-01","FALSE","Steady state area under the concentration-time profile for PF-07976016 [From 0 Hours to 24 Hours following steady-state dose] | Steady state maximum observed concentration (Cmax) for PF-07976016 [From 0 Hours to 24 Hours following steady-state dose] | Steady state area under the concentration-time profile danuglipron [From 0 Hours to 24 Hours following steady-state dose] | Steady state maximum observed concentration (Cmax) for danuglipron [From 0 Hours to 24 Hours following steady-state dose]",null,null,"NO",null],["NCT03672812","The Use of Liraglutide in Brain Death",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","50","Brain Death","DRUG:Liraglutide","Hospital de Clinicas de Porto Alegre","2018-09-01","2019-12-10","FALSE","change inflammation [from 6 hours to 24 hours]",null,null,"UNDECIDED",null],["NCT02298192","A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms","DUAL™ VI","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","420","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide","Novo Nordisk A/S","2014-11-21","2015-12-23","TRUE","Change From Baseline in HbA1c [Week 0, week 32]","RESULT:28124817",null,null,"EUDRACT_NUMBER:2012-004625-25; OTHER:U1111-1135-6634"],["NCT03606057","A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","188","Healthy","DRUG:JNJ-64565111; DRUG:Moxifloxacin; DRUG:JNJ-64565111-matching Placebo; DRUG:Moxifloxacin-matching Placebo","Janssen Research & Development, LLC","2018-07-13","2019-02-08","FALSE","Placebo-Corrected Change from Baseline in QT Interval Corrected for Individual Heart Rate (QTcI) on Day 26 Time-Matched Time Points [Baseline and Day 26] | Change from Time-Matched Baseline in QTc Interval [Up to Day 27] | Change from Time-Matched Baseline in Heart Rate (HR) [Up to Day 27] | Change from Time-Matched Baseline in QRS Interval [Up to Day 27] | Change from Time-Matched Baseline in PR Interval [Up to Day 27]",null,null,null,"OTHER:64565111OBE1002"],["NCT07673900","Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","62","Overweight and/or Obesity","COMBINATION_PRODUCT:VX-201; DRUG:semaglutide SC","Terrestrial Bio, Inc.","2026-06-15","2027-02-10","FALSE","Type, incidence, and severity of treatment emergent adverse events (TEAEs), including assessment of application site skin sensitivity, vital signs, electrocardiograms (ECGs), and clinical laboratory results) [From enrollment until approximately 5 weeks after the last dose of study drug]",null,null,"NO",null],["NCT07040592","Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide","HARP","RECRUITING","INTERVENTIONAL","PHASE2",null,"NONE","30","Alcohol Use Disorder (AUD); HIV","DRUG:semaglutide","Yale University","2026-01-15","2027-06-30","FALSE","Proportion of participants who complete enrollment and duration of sessions [12 weeks] | Number of sessions completed [12 weeks] | Adherence to Medication [12 weeks] | Safety of study assessed by adverse event reporting [12 weeks]",null,null,"NO","NIH:1P01AA029545-01"],["NCT07374328","Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus","TRED","RECRUITING","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","SINGLE","240","Type 2 Diabetes","DRUG:Semaglutide (1 Mg Dose); DRUG:Sitagliptin (DPP4 inhibitor)","Second Affiliated Hospital of Guangzhou Medical University","2025-06-01","2026-05-31","FALSE","Diabetes remission rate [From enrollment to the end of follow-up at 11 months]",null,null,null,null],["NCT00353834","The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","72","Type 2 Diabetes Mellitus","DRUG:Exenatide; DRUG:Glargine Insulin","Joslin Diabetes Center","2006-08","2010-09","TRUE","The Primary Endpoint Was the Change in FMD at the End of the Study Compared to Baseline Measurements in Subjects Treated With Exenatide Compared to Subjects Treated With Lantus. [Baseline and End of Study]",null,null,null,null],["NCT00530309","Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED",null,"40","Diabetes Mellitus, Type 2","DRUG:GSK716155 for injection; DRUG:Placebo","GlaxoSmithKline","2007-08-01","2008-04-17","FALSE","Plasma concentrations and PD parameters over time and at the end of study [Up to Week 9]","BACKGROUND:19863477; DERIVED:25387217",null,"YES",null],["NCT04389775","To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants","XW003","COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","64","Type 2 Diabetes Mellitus; Obesity; Nonalcoholic Steatohepatitis","DRUG:Cohort A; DRUG:Placebo A; DRUG:Cohort B; DRUG:Placebo B","Sciwind Biosciences APAC CO Pty. Ltd.","2020-03-29","2021-09-29","FALSE","Number of treatment emergent adverse events (TEAEs) [From administration of XW003 on Day 1 to the last follow-up visit]","DERIVED:37364710",null,"NO","REGISTRY:ACTRN12620000344998"],["NCT06820281","Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes","TIRTLE2","RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","44","Type 1 Diabetes Mellitus","DRUG:Tirzepatide 2.5mg weekly; DRUG:Placebo injection (normal saline)","Victor Chang Cardiac Research Institute","2026-07-07","2027-12-31","FALSE","Whole-body insulin sensitivity [6 weeks]","BACKGROUND:41264593",null,"YES",null],["NCT03617081","First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","40","Diabetes Mellitus, Type 2","DRUG:NNC0113-2023; DRUG:Placebo (NNC0113-2023)","Novo Nordisk A/S","2018-08-09","2018-12-13","FALSE","Number of treatment emergent adverse events (TEAEs) [From time of dosing (day 1) until completion of the follow-up visit (day 43)]",null,null,"YES","OTHER:U1111-1209-3837"],["NCT05294536","A Pharmacokinetic Study Comparing the Liraglutide Injection (RD12014) and Victoza® in Healthy Chinese Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","50","Type 2 Diabetes","DRUG:Liraglutide injection,RD12014; DRUG:Liraglutide injection,Victoza","Sunshine Lake Pharma Co., Ltd.","2020-06-22","2020-07-20","FALSE","Maximum (peak) plasma drug concentration(Cmax) [0 hour（pre-dose,within 30mins） to 72 hours after administration] | Area under the plasma concentration-time curve from time zero to time t (AUC0-t) [0 hour（pre-dose,within 30mins） to 72 hours after administration]","DERIVED:35871497",null,null,null],["NCT04067999","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice","SURE SPAIN","COMPLETED","OBSERVATIONAL",null,null,null,"230","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2019-08-05","2021-07-19","FALSE","Change in Glycated Haemoglobin A1c (HbA1c) (measured in percent) [Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)] | Change in Glycated Haemoglobin A1c (HbA1c) (measured in mmol/mol) [Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)]",null,null,"YES","OTHER:U1111-1217-3546"],["NCT00717457","A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","1189","Diabetes Mellitus Type 2","DRUG:exenatide; DRUG:taspoglutide","Hoffmann-La Roche","2008-07","2011-03","FALSE","Change in HbA1c [24 weeks]","DERIVED:23139373",null,null,"OTHER:2008-001856-36; NIH:2008"],["NCT07509112","Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study","SHIFT","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2",null,"NONE","40","Methamphetamine Use Disorder","DRUG:12 weeks of weekly subcutaneous semaglutide injection","Kirby Institute","2026-09","2027-01","FALSE","Efficacy Outcome (exploratory) [12 weeks]",null,null,"NO",null],["NCT07018544","A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea",null,"ENROLLING_BY_INVITATION","OBSERVATIONAL",null,null,null,"840","Obesity and Overweight","OTHER:semaglutide","Novo Nordisk A/S","2024-11-19","2027-02-28","FALSE","Number (incidence) of AEs [From Visit 1 (baseline, 0 week) to Visit 4 (22 weeks < ~ ≤ 30 weeks)]",null,null,"YES","OTHER:U1111-1281-9419"],["NCT07777575","Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide","RESIST","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","150","Obesity (BMI>30)","DRUG:Dual GIP/GLP-1 Receptor Agonist Tirzepatide; BEHAVIORAL:Resistance Training","Technical University of Munich","2026-09-07","2027-05-31","FALSE","Change in contractile thigh muscle volume (mL), as assessed by magnetic resonance imaging (MRI) [From baseline to the end of treatment at 24 weeks]",null,null,"NO","CTIS:2026-526200-69-00"],["NCT03101930","Cardiovascular Effects of GLP-1 Receptor Activation",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","329","Obesity; PreDiabetes","DRUG:Liraglutide; DRUG:Sitagliptin; OTHER:hypocaloric diet; DRUG:Placebos; DRUG:Exendin (9-39)","Vanderbilt University Medical Center","2017-05-01","2021-06-24","TRUE","Change in Flow-mediated Dilation [Baseline to 2 and 14 weeks] | Urine Albumin-to-creatinine Ratio [Baseline to 13 weeks] | Change in Plasminogen Activator Inhibitor-1 [Baseline to 2 and 14 weeks]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/30/NCT03101930/Prot_SAP_000.pdf","YES",null],["NCT02475499","Incretin-based Drugs and Pancreatic Cancer",null,"COMPLETED","OBSERVATIONAL",null,null,null,"886172","Diabetes Mellitus, Type 2","DRUG:DPP-4 inhibitors; DRUG:GLP-1 analogs; DRUG:Sulfonylureas; DRUG:Biguanides; DRUG:Thiazolidinediones; DRUG:Alpha-glucosidase inhibitors; DRUG:Meglitinides","Canadian Network for Observational Drug Effect Studies, CNODES","2014-03","2015-04","FALSE","Incident pancreatic cancer [Patients were followed from the date of study cohort entry until hospitalization for incident pancreatic cancer, censoring, or for up to 79 months.]","RESULT:26888382",null,null,null],["NCT05067621","Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","60","Type 2 Diabetes Mellitus; Impaired Glucose Tolerance; Non-Alcoholic Fatty Liver Disease; Obesity, Childhood","DRUG:Semaglutide Pen Injector; DRUG:Placebo","Yale University","2023-07-17","2026-12","FALSE","Change in Oral Disposition Index (oDI) [Baseline and 6 months] | Change in Protein Density Fat Fraction (PDFF) [Baseline and 6 months]",null,null,"NO","NIH:2R01DK111038-06A1"],["NCT07501832","Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Receiving Positive Airway Pressure (PAP) Therapy",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","140","Obstructive Sleep Apnea (OSA)","DRUG:GZR18 injection; DRUG:Placebo","Gan & Lee Pharmaceuticals.","2026-03-27","2028-09-28","FALSE","Change from baseline in Apnea-Hypopnea Index (AHI) after 52 weeks of treatment [52 weeks]",null,null,null,null],["NCT00978393","A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","49","Metabolism and Nutrition Disorder; Obesity","DRUG:liraglutide","Novo Nordisk A/S","2009-09-16","2011-06-08","FALSE","Gastric emptying measured as AUC0-300min of paracetamol postprandial concentration profiles during a standardised meal test with intake of 1.5 g paracetamol [after 35 days of treatment]","RESULT:23999198",null,null,"EUDRACT_NUMBER:2008-003228-44; OTHER:U1111-1111-9119; NIH:2008"],["NCT03645421","Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","61","Type 2 Diabetes","DRUG:MEDI0382 100 μg; DRUG:MEDI0382 200 μg; DRUG:MEDI0382 300 μg; DRUG:PlaceboA; DRUG:MEDI0382 50 ug; DRUG:PlaceboB","AstraZeneca","2018-08-10","2019-01-17","TRUE","Mean Change From Baseline in 24-Hour Heart Rate at Days 20 and 48 [Baseline (Day -1) and Days 20 and 48.] | Mean Change From Baseline in 24-Hour Systolic and Diastolic Blood Pressure (BP) at Days 20 and 48 [Baseline (Day -1) and Days 20 and 48.] | Mean Percentage Change From Baseline in Glucose Area Under the Plasma Concentration Curve (AUC[0-4h]) as Measured by a Standardised Mixed-Meal Test (MMT) at Day 48 [Baseline (Day -1) and Day 48: 15 minutes before standardised meal, and then at 15, 30, 45, 60, 90, 120, 180 and 240 minutes (+/-5 minutes) after consumption of the standardised meal.] | Mean Percentage Change From Baseline in Body Weight at Day 48 [Baseline (Day -1) and Day 48.] | Mean Change From Baseline in Heart Rate Measured by Electrocardiogram (ECG) at Day 48. [Baseline (Day -1) and Days 1, 6, 13, 20 and 48: predose and 6 hours (+/-15 minutes) postdose.] | Number of Patients Who Experienced Adverse Events (AEs) [Day 1 up to 14 days after the last dose of IP (approximately 9 weeks).]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/21/NCT03645421/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/21/NCT03645421/SAP_001.pdf",null,null],["NCT00849017","Safety and Efficacy Study of Albiglutide in Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","309","Diabetes Mellitus, Type 2","BIOLOGICAL:albiglutide; BIOLOGICAL:albiglutide uptitration; BIOLOGICAL:placebo","GlaxoSmithKline","2009-01","2011-11","TRUE","Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52 [Baseline and Week 52]","DERIVED:28683300; DERIVED:26577795; DERIVED:25387217; DERIVED:24918790",null,"YES",null],["NCT06256549","A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus",null,"UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","272","Type 2 Diabetes","DRUG:GZR18; DRUG:Semaglutide","Gan and Lee Pharmaceuticals, USA","2023-08-09","2024-07-20","FALSE","Compared with Semaglutide, the changes of HbA1c compared with baseline after continuous administration of GZR18 injection for 24 weeks [24 weeks]","DERIVED:42372276",null,null,null],["NCT06691243","Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV","STAC","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","40","Cocaine Use Disorder; HIV","DRUG:Semaglutide; DRUG:Placebo","University of Maryland, Baltimore","2025-08-07","2027-01","FALSE","Safety of semaglutide in patients with cocaine use disorder (CUD) with and without HIV [16 weeks] | Tolerability of semaglutide in patients with cocaine use disorder (CUD) with and without HIV [16 weeks]",null,null,"YES","OTHER:75N90024C00036"],["NCT03574584","A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","37","Metabolism and Nutrition Disorders; Overweight or Obesity","DRUG:NNC0165-1562; DRUG:Semaglutide; DRUG:Placebo (NNC0165-1562)","Novo Nordisk A/S","2018-06-18","2019-07-27","FALSE","Number of treatment emergent adverse events (TEAEs) [Week 0-25]",null,null,"YES","OTHER:U1111-1191-5147"],["NCT00039026","Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","377","Diabetes Mellitus, Non-Insulin-Dependent","DRUG:AC2993; DRUG:Placebo","AstraZeneca","2002-02","2003-08","FALSE","Change in HbA1c from Baseline to Week 30 [Baseline (Day 1) to Week 30]","RESULT:15504997; DERIVED:22913891; DERIVED:22236356",null,null,null],["NCT07030621","Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial","STARS","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","436","Acute Ischemic Stroke","DRUG:Semaglutide 0.5 mg; DRUG:Normal Saline","RenJi Hospital","2025-07-01","2027-07-31","FALSE","mRS at 90-days [90 days postoperatively]","RESULT:37231200; RESULT:27633186; RESULT:34519040; RESULT:40426210; RESULT:35387495; RESULT:35767089; RESULT:36475464; RESULT:35138767; RESULT:19372447; RESULT:32668115; RESULT:31662037; RESULT:34487721",null,"NO",null],["NCT01664676","Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","11","Type 2 Diabetes Mellitus","DRUG:Liraglutide; DRUG:Placebo-liraglutide","University of Aarhus","2012-12","2014-02","FALSE","Glomerular Filtration Rate (51Cr-EDTA plasma clearance) [10-15 hours post-dose]",null,null,null,"EUDRACT_NUMBER:2012-003577-26"],["NCT05659368","Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1",null,"UNKNOWN","INTERVENTIONAL","PHASE2",null,"NONE","10","Wolfram Syndrome","DRUG:Tirzepatide","Ospedale San Raffaele","2024-01-01","2024-10","FALSE","changing in endogenous insulin production [[Time Frame: month 6±1, month 12±1]] | changing in insulin production [[Time Frame: month 6±1, month 12±1]]",null,null,null,"EUDRACT_NUMBER:2022-003853-70; OTHER_GRANT:PNRR-MR1-2022-12375914"],["NCT05793450","Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","20","Renal Impairment","DRUG:IBI362","Innovent Biologics (Suzhou) Co. Ltd.","2023-05-05","2023-09-18","FALSE","Pharmacokinetics (PK): Maximum Concentration (Cmax) of IBI362 [Predose through 1344 hours postdose] | PK: Area Under the Concentration Versus Time Curve (AUC) of IBI362 [Predose through 1344 hours postdose]",null,null,null,null],["NCT07317115","Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes","MAGvMED","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","20","Obesity (Disorder); Obesity & Overweight; Type 2 Diabetes (T2DM)","DEVICE:Magnet System; DRUG:Semaglutide","GT Metabolic Solutions, Inc.","2026-03-18","2027-06","FALSE","Functional improvement of T2D: HbA1c [Day 360]",null,null,"NO",null],["NCT07428525","A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","36","Hepatic Impairment","DRUG:AMG 133","Amgen","2025-03-14","2026-02-26","FALSE","Maximum Observed Plasma Concentration (Cmax) of AMG 133 [Up to Day 120] | Area Under the Plasma Concentration-time Curve (AUC) from Time Zero to Time of Last Quantifiable Concentration (AUClast) of AMG 133 [Up to Day 120] | AUC from Time Zero to Infinity (AUCinf) of AMG 133 [Up to Day 120]",null,null,"YES",null],["NCT04867785","A Study of LY3437943 in Participants With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","281","Type 2 Diabetes","DRUG:LY3437943; DRUG:Dulaglutide; DRUG:Placebo","Eli Lilly and Company","2021-05-13","2022-07-08","TRUE","Change From Baseline in Hemoglobin A1c (HbA1c) [Baseline, 24 Weeks]","DERIVED:42608321; DERIVED:40609566; DERIVED:37385280","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/85/NCT04867785/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/85/NCT04867785/SAP_001.pdf","YES","OTHER:J1I-MC-GZBD"],["NCT02987348","Clinical Outcomes of Exenatide Versus Basal Insulin",null,"COMPLETED","OBSERVATIONAL",null,null,null,"18000","Type 2 Diabetes","DRUG:exenatide once weekly; DRUG:exenatide twice daily; DRUG:basal insulin","AstraZeneca","2015-06-30","2015-06-30","FALSE","Changes from baseline in HbA1c (%) [6, 12 and 24 months] | Changes from baseline in weight (kg) [6, 12 and 24 months] | Changes from baseline in composite outcomes of HbA1c<=7.0% and weight reduction [6, 12 and 24 months]","BACKGROUND:28218819",null,null,null],["NCT07728812","Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy","PhenoRXPrag","NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","424","Obesity & Overweight","GENETIC:Genetic Test; DRUG:Anti-Obesity Medication (AOM) treatment","Phenomix Sciences","2026-09-01","2028-07-01","FALSE","Total Body Weight Loss (TBWL) at 6 Months % [6-Months]",null,null,"NO",null],["NCT06492330","Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","62","Metabolic Dysfunction-Associated Steatohepatitis (MASH); Obesity; Diabetes Mellitus, Type 2","DRUG:CS0159; DRUG:CS0159 placebo","Shanghai Jiao Tong University School of Medicine","2024-07-19","2025-02-28","FALSE","Percentage change in body weight relative to baseline [Baseline to 16 weeks]",null,null,null,null],["NCT03856047","Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","706","Overweight; Obesity","DRUG:NNC0174-0833; DRUG:Placebo (NNC0174-0833); DRUG:Liraglutide 3.0 mg; DRUG:Placebo (Liraglutide 3.0 mg)","Novo Nordisk A/S","2019-03-01","2020-03-02","TRUE","Change in Body Weight (%) [From baseline (week 0) to week 26]","RESULT:34798060","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/47/NCT03856047/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/47/NCT03856047/SAP_001.pdf","YES","OTHER:U1111-1214-0429; REGISTRY:2018-001945-14; NIH:2018"],["NCT00799435","Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure",null,"TERMINATED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","2","Diabetes Mellitus, Type 2; Heart Failure, Diastolic","DRUG:Exenatide","Baylor College of Medicine","2009-07","2012-04","TRUE","Change in Aortic Stiffness, as Measured by the Change in the Mean Aortic Pulse Wave Velocity [Measured at Week 12]",null,null,"NO","NIH:1K01HL092585; NIH:1K01HL092585-01; OTHER:H-22906"],["NCT00905255","GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)","GETGOAL-MONO","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","69","Diabetes Mellitus, Type 2","DRUG:Lixisenatide (AVE0010); DEVICE:Pen auto-injector","Sanofi","2009-05","2011-01","TRUE","Overview of Adverse Event Profile (Treatment Emergent Adverse Events) of the One-Step and Two-Step Titration Arms Assessed Through Adverse Events Collection and Vital Signs, Electrocardiogram (ECG) and Laboratory Monitoring [First dose of study drug up to 3 days after the last dose of study drug at Week 24 or early withdrawal]","RESULT:26342556",null,null,null],["NCT07357415","A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight","TRIUMPH-9","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","600","Obesity; Overweight","DRUG:Retatrutide","Eli Lilly and Company","2026-01-24","2028-10","FALSE","Percent Change from Baseline in Body Weight [Baseline, Week 104]",null,null,"YES","OTHER:J1I-MC-GZQL"],["NCT03819790","The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians","VARIATION 2 SA","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","119","Diabetes Mellitus, Type 2","DRUG:Basal insulin glargine and lixisenatide; DRUG:Basal insulin Basaglar/Lantus + gliclazide MR; DRUG:Metformin","LMC Diabetes & Endocrinology Ltd.","2018-10-02","2019-11-19","FALSE","Time in range at week 13 [7 days] | Time in range within 12-hours (6 AM -6 PM) at week 13 [7 days]","BACKGROUND:9742976; BACKGROUND:27659408; BACKGROUND:24428469; BACKGROUND:24731666; BACKGROUND:15331551; BACKGROUND:15111485; BACKGROUND:9449682; BACKGROUND:28724168; BACKGROUND:26642233; BACKGROUND:24898300; BACKGROUND:25011946; BACKGROUND:25562265; BACKGROUND:18784090; BACKGROUND:25409370; BACKGROUND:15197140; BACKGROUND:18650371; BACKGROUND:27913575; BACKGROUND:20403888; BACKGROUND:26260346; BACKGROUND:23317344; BACKGROUND:28803820; DERIVED:35752566",null,"NO",null],["NCT03618160","A Study to Assess the Safety, Tolerability and Pharmacokinetics of Subcutaneous (SC) Injections of JNJ-64565111 in Healthy Male Japanese Participants and to Assess Pharmacokinetics Following Subcutaneous Injections of JNJ-64565111 in Healthy Male Caucasian Participants",null,"TERMINATED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","42","Healthy","DRUG:JNJ-64565111; DRUG:Placebo","Janssen Pharmaceutical K.K.","2018-08-06","2019-06-21","FALSE","Part 1 and Part 3: Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability [Up to Day 35] | Part 1: Maximum Observed Serum Concentration (Cmax) of JNJ-64565111 [Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose] | Part 1: Actual Sampling Time to Reach Maximum Observed Serum Concentration (Tmax) of JNJ-64565111 [Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose] | Part 1: Area Under Serum Concentration Curve From Time 0 to Time of the Last Measurable Concentration (AUC[0-Last]) of JNJ-64565111 [Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose] | Part 1: Area Under the Serum Concentration-Time Curve From Time 0 to Infinity (AUC[0-Infinity]) of JNJ-64565111 [Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose] | Part 1: Apparent Terminal Elimination Half-Life (t1/2) of JNJ-64565111 [Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose] | Part 1: Apparent Volume of Distribution (V/F) of JNJ-64565111 [Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose] | Part 1: Total Apparent Clearance (CL/F) of JNJ-64565111 [Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose] | Part 2: Number of Participants With AEs as a Measure of Safety and Tolerability [Up to Day 72] | Part 2: Maximum Observed Serum Concentration (Cmax) of JNJ-64565111 [Day 1: Predose, 8, 24, 48, 72, 120 hours postdose; Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose] | Part 2: Actual Sampling Time to Reach Maximum Observed Serum Concentration (Tmax) of JNJ-64565111 [Day 1: Predose, 8, 24, 48, 72, 120 hours postdose; Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose] | Part 2: Apparent Terminal Elimination Half-Life (t1/2) of JNJ-64565111 [Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose] | Part 2: Apparent Volume of Distribution (V/F) of JNJ-64565111 [Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose] | Part 2: Total Apparent Clearance (CL/F) of JNJ-64565111 [Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose] | Part 2: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of JNJ-64565111 [Day 1: Predose, 8, 24, 48, 72, 120, 168 hours postdose; Day 22: 72, 96, 144, 168 hours postdose] | Part 2: Observed Serum Concentration Just Prior to the Beginning or the End of a Dosing Interval (Ctrough) of JNJ-64565111 [Day 8: Predose ; Day 15: Predose; Day 22: Predose, 168 hours postdose] | Part 2: Average Concentration Over the Dosing Interval Tau (T) at Steady State (Caverage,ss) of JNJ-64565111 [Day 22: Predose, 72, 96, 144, 168 hours postdose] | Part 2: Observed Accumulation Index (AR-AUC) of JNJ-64565111 [Day 1: Predose, 8, 24, 48, 72, 120, 168 hours postdose; Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose]",null,null,null,"OTHER:64565111NAS1001"],["NCT07511543","Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy","LEAST","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","SINGLE","100","Ischemic Stroke","DRUG:Semaglutide","Population Health Research Institute","2026-10-31","2028-10-31","FALSE","Feasibility - Recruitment [From site activation until the end of recruitment (approximately 24 months)]",null,null,"YES",null],["NCT02640118","The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects","Px-Lixi","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","24","Diabetes After Total Pancreatectomy","DRUG:Lixisenatide; DRUG:Lixisenatide-Placebo; OTHER:Standardized liquid meal","University Hospital, Gentofte, Copenhagen","2015-08","2016-07","FALSE","PPG excursions measured as incremental area under curve (iAUC) [-120,-45,-30,-15,0,5,10,15,20,25,30,40,50,60,70,80,90,105,120,135,150,180 minutes]","DERIVED:32394228",null,"UNDECIDED",null],["NCT02432976","Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients","ExeQOL","COMPLETED","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","NONE","64","Quality of Life","DRUG:Exenatide; DRUG:Insulin","Centre Hospitalier Universitaire de Besancon","2015-05","2017-01","FALSE","Variation of the SF-36 score value at 3-months [3 months]","BACKGROUND:15650975; BACKGROUND:20097589; BACKGROUND:7775992; BACKGROUND:17174230; BACKGROUND:17719327",null,"NO",null],["NCT01336023","Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes","DUAL™ I","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","1663","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide; DRUG:insulin degludec; DRUG:liraglutide","Novo Nordisk A/S","2011-05-23","2012-05-24","TRUE","Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26. [Week 0, week 26]","BACKGROUND:28332144; RESULT:26443290; RESULT:26894800; RESULT:25190523; RESULT:25980900; RESULT:25998481; RESULT:28282219; RESULT:28417535; DERIVED:39963952",null,null,"OTHER:U1111-1119-1174; EUDRACT_NUMBER:2010-021560-15"],["NCT02302976","GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","13","Cocaine Dependence","DRUG:cocaine hydrochloride; DRUG:exenatide; DRUG:placebo","Yale University","2014-11","2018-08-01","FALSE","Mean cocaine inter-infusion interval [3 hours]",null,null,null,"NIH:1R21DA040914-01A1"],["NCT06856291","Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance","TRIM-IR","COMPLETED","OBSERVATIONAL",null,null,null,"40","Obesity and Obesity-related Medical Conditions; Obesity and Overweight; Insulin Sensitivity/Resistance; Semaglutide",null,"ETH Zurich","2025-03-15","2026-09-06","FALSE","Change in body weight (%) [16 weeks]",null,null,"UNDECIDED",null],["NCT03175120","A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)","DUAL™ II China","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","453","Diabetes; Diabetes Mellitus, Type 2","DRUG:Insulin degludec/liraglutide; DRUG:Insulin degludec","Novo Nordisk A/S","2017-05-26","2019-03-05","TRUE","Change in HbA1c [Week 0, week 26]",null,"Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/20/NCT03175120/SAP_000.pdf; Study Protocol|https://cdn.clinicaltrials.gov/large-docs/20/NCT03175120/Prot_001.pdf","YES","OTHER:U1111-1154-6732; REGISTRY:CTR20060909"],["NCT04829903","Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","QUADRUPLE","116","Type 2 Diabetes Treated With Insulin; Obesity; Adolescent Obesity","DRUG:Dulaglutide; DRUG:Liraglutide","Corporacion Parc Tauli","2020-01-02","2021-03-29","FALSE","Glycemic level [24 weeks for the duration of the study] | BMI [24 weeks for the duration of the study] | Adverse effects [24 weeks for the duration of the study]",null,null,"NO",null],["NCT06982859","A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","95","Diabetes Mellitus; Insulin Sensitivity","DRUG:Retatrutide; DRUG:Semaglutide; DRUG:Placebo","Eli Lilly and Company","2025-06-02","2027-01","FALSE","Change from Baseline in Total Clamp Disposition Index (cDI) for Comparison of Retatrutide With Placebo [Baseline, Week 28]",null,null,"NO","OTHER:J1I-MC-GZQG; CTIS:2024-518470-13-00"],["NCT07790861","A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems","ATTAIN-CN","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","192","Obesity; Overweight","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2026-12","2028-03","FALSE","Mean Percent Change From Baseline in Body Weight [Baseline, Week 48]",null,null,"YES","OTHER:J2A-GH-GZVC"],["NCT02963766","A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes","AWARD-PEDS","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","154","Type 2 Diabetes","DRUG:Dulaglutide; DRUG:Placebo","Eli Lilly and Company","2016-12-29","2021-06-12","TRUE","Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses) at Week 26 [Baseline, Week 26]","DERIVED:39963952; DERIVED:35658022","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/66/NCT02963766/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/66/NCT02963766/SAP_001.pdf","YES","OTHER:H9X-MC-GBGC; EUDRACT_NUMBER:2016-000361-22; NIH:2016"],["NCT00496860","Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","26","Progressive Metastatic Malignancies","BIOLOGICAL:ALT-801","Altor BioScience","2007-05","2009-10","TRUE","The Safety and Toxicity of ALT-801 in Patients With Progressive Metastatic Malignancies [18 months] | The Maximum-tolerated Dose (MTD) of ALT-801 [18 months]","DERIVED:21994418",null,null,null],["NCT07191873","Tirzepatide in Idiopathic Intracranial Hypertension Trial","TIIHT","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","60","Idiopathic Intracranial Hypertension (IIH)","DRUG:Tirzepatide; DRUG:Tirzepatide Placebo","Duke University","2026-08-25","2027-08","FALSE","Change in intracranial pressure in Idiopathic Intracranial Hypertension (IIH) patients [From enrollment to end of treatment at 12 months]","BACKGROUND:25449938; BACKGROUND:24296367; BACKGROUND:26888960; BACKGROUND:33472926; BACKGROUND:30356129",null,"NO",null],["NCT07262762","Spartina® (Tirzepatide) Effectiveness and Safety Evaluation",null,"COMPLETED","OBSERVATIONAL",null,null,null,"175","Obesity & Overweight",null,"Cinnagen","2025-11-11","2026-06-20","FALSE","Proportion of patients with ≥5% weight loss [day 0, 180]",null,null,null,null],["NCT03596450","Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","1278","Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Standard of care","Novo Nordisk A/S","2018-07-13","2022-06-09","TRUE","Number of Participants With Glycosylated Haemoglobin (HbA1c) Less Than 7.0 Percentage (%) (53 Millimoles Per Mole [mmol/Mol]) at Year 1 (Yes/No) [At year 1]","DERIVED:41093600; DERIVED:37137527","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/50/NCT03596450/Prot_002.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/50/NCT03596450/SAP_003.pdf","YES","OTHER:U1111-1207-6474"],["NCT06989203","Protein Supplementation Intervention on Body Weight",null,"RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","140","Obesity; Weight Loss; Protein Supplementation","BEHAVIORAL:General lifestyle and nutritional education; BEHAVIORAL:Calorie-restricted balanced diet; DRUG:semaglutide; DIETARY_SUPPLEMENT:Dietary protein supplementation","Chinese Academy of Sciences","2025-06-10","2026-12-31","FALSE","Change in Body Weight (kg) from Baseline to Week 12 [Baseline and Week 12]",null,null,null,null],["NCT06934642","Effect of Tirzepatide on Markers of MASLD in Patients With Obesity",null,"RECRUITING","INTERVENTIONAL","EARLY_PHASE1",null,"NONE","8","MASLD; Obesity","DRUG:Tirzepatide","University of New Mexico","2025-06-30","2026-10","FALSE","Biomarkers associated with MASLD [12 months]",null,null,"NO",null],["NCT05333003","Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity","Sema","ACTIVE_NOT_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","92","Schizophrenia Spectrum Disorders","DRUG:Semaglutide; OTHER:Placebo","Centre for Addiction and Mental Health","2022-05-25","2026-08","FALSE","Weight change [32 weeks]",null,null,null,null],["NCT01779362","RISE Adult Medication Study","RISE Adult","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","267","Prediabetes; Type 2 Diabetes","DRUG:Metformin; DRUG:Liraglutide; DRUG:Glargine; DRUG:Placebo","RISE Study Group","2013-04","2019-02","TRUE","ß-cell Response Measured by Hyperglycemic Clamp [3-months after medication washout (Month 15)] | Insulin Sensitivity, M/I [3-months after a medication washout]","BACKGROUND:24194506; BACKGROUND:28493515; DERIVED:36938582; DERIVED:35894078; DERIVED:34274407; DERIVED:34135015; DERIVED:34131048; DERIVED:34131047; DERIVED:33436401; DERIVED:32501595; DERIVED:31301210; DERIVED:31178434; DERIVED:31178433; DERIVED:29941498; DERIVED:29941497","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/62/NCT01779362/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/62/NCT01779362/SAP_001.pdf","YES","NIH:5U01DK094406-02"],["NCT03010683","Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","60","Type 2 Diabetes Mellitus; Coronary Artery Disease","DRUG:Liraglutide; DRUG:Metformin","University of Athens","2015-11","2017-06","TRUE","Differences in Pulse Wave Velocity at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R. [Baseline, 3 months, 6 months and 12 months] | Differences in Augmentation Index at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R. [Baseline, 3 months, 6 months, and 12 months.] | Differences in Coronary Flow Reserve at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R. [Baseline, 3 months, 6 months, and 12 months.] | Differences in Endothelial Glycocalyx Thickness at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R. [Baseline, 3 months, 6 months, and 12 months.]","DERIVED:32501595; DERIVED:29310645","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/83/NCT03010683/Prot_SAP_000.pdf","NO",null],["NCT03038620","Impact of Liraglutide 3.0 on Body Fat Distribution",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","235","Obesity, Visceral; Cardiovascular Diseases; Fat Disorder","DRUG:Liraglutide; DRUG:Placebo","University of Texas Southwestern Medical Center","2017-01","2020-10-13","TRUE","Relative Percent Reduction in Visceral Adipose Tissue Mass Measured by MRI [Baseline, 40 weeks]","BACKGROUND:19853906; BACKGROUND:21844879; BACKGROUND:18340209; BACKGROUND:21121834; BACKGROUND:22949540; BACKGROUND:25253227; BACKGROUND:24345592; BACKGROUND:18356555; BACKGROUND:21865361; BACKGROUND:17549449; BACKGROUND:17707180; BACKGROUND:24582192; BACKGROUND:16182882; BACKGROUND:25538311; BACKGROUND:23687099; BACKGROUND:22990274; BACKGROUND:25190234; BACKGROUND:23929898; BACKGROUND:23850922; BACKGROUND:23812094; BACKGROUND:26768490; BACKGROUND:25808071; BACKGROUND:25343445; BACKGROUND:24871333; BACKGROUND:15810802; DERIVED:34358471","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/20/NCT03038620/Prot_001.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/20/NCT03038620/SAP_002.pdf","NO",null],["NCT03929679","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)","SURE NL","COMPLETED","OBSERVATIONAL",null,null,null,"218","Diabetes Mellitus, Type 2","DRUG:semaglutide","Novo Nordisk A/S","2019-05-28","2020-11-24","FALSE","Change in Glycated Haemoglobin A1c (HbA1c) [Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38)]","RESULT:36542260",null,"YES","OTHER:U1111-1222-5565"],["NCT05147896","Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients","SAMAS","UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","TRIPLE","100","Diabetes Mellitus, Type 2; Atherosclerosis","DRUG:Semaglutide Oral Tablet","University Medical Centre Ljubljana","2022-05-01","2023-05-01","FALSE","Change in morphological arterial wall characteristics [1 year] | Change in functional arterial wall characteristics [1 year] | Change in structural arterial wall characteristics [1 year]","DERIVED:35258841",null,"NO",null],["NCT04979611","The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma",null,"UNKNOWN","INTERVENTIONAL","PHASE1",null,"NONE","60","Insulinoma","DRUG:68Ga-NOTA-exendin-4","First Affiliated Hospital of Fujian Medical University","2020-08-01","2025-08-01","FALSE","Standard uptake value (SUV) [From right after tracer injection to 1-hours post-injection]",null,null,null,null],["NCT03421119","Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes",null,"UNKNOWN","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","300","Diabetes Mellitus, Type 2","DRUG:Liraglutide 6 MG/ML Pen Injector; DRUG:Metformin; DRUG:Sulfonylurea/non-sulfonylurea insulin secretagogues","Cinnagen","2019-06-20","2019-12-01","FALSE","HbA1c [26 weeks]","BACKGROUND:18931095; BACKGROUND:19317822; BACKGROUND:19289857; BACKGROUND:19688338; BACKGROUND:19515413; DERIVED:37707701",null,"UNDECIDED",null],["NCT05035095","Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)","OASIS 1","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","667","Obesity; Overweight","DRUG:Oral semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2021-09-13","2023-03-24","TRUE","Percentage Change in Body Weight [Baseline (week 0), end-of-treatment (week 68)] | Number of Participants Who Achieved Weight Loss Greater Than or Equal (≥) 5% (Yes/No) [At end-of-treatment (week 68)]","BACKGROUND:37385278","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/95/NCT05035095/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/95/NCT05035095/SAP_001.pdf","YES","OTHER:U1111-1253-1670; EUDRACT_NUMBER:2020-002953-11"],["NCT01784965","Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","69","Pre-diabetes; Older Adults","DRUG:liraglutide; DRUG:Placebo","Stanford University","2009-12","2012-12","TRUE","Change in Weight Reported at 14 Weeks [Baseline and 14 weeks]","DERIVED:24326527; DERIVED:23835684",null,"NO",null],["NCT03434119","Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents","LixiLan-D","TERMINATED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","241","Type 2 Diabetes Mellitus","DRUG:Insulin glargine/Lixisenatide; DRUG:Insulin glargine (HOE901); DRUG:Background therapy","Sanofi","2018-02-20","2019-01-07","TRUE","Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 [Baseline, Week 26]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/19/NCT03434119/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/19/NCT03434119/SAP_001.pdf","YES","OTHER:U1111-1200-1891"],["NCT07573163","Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","34","Mild Autonomous Cortisol Secretion (MACS); Adrenalectomy; Status","DRUG:Tirzepatide; OTHER:Standard medical treatment","Alaa Sada","2026-07-27","2028-07-31","FALSE","Change in systolic blood pressure [Baseline and 12 months]","BACKGROUND:37700437; BACKGROUND:39084707; BACKGROUND:19632967; BACKGROUND:37801655; BACKGROUND:35799460; BACKGROUND:32206602; BACKGROUND:38137336; BACKGROUND:38649778; BACKGROUND:33017843; BACKGROUND:33528757; BACKGROUND:29963828; BACKGROUND:34978855; BACKGROUND:34260734; BACKGROUND:31900474; BACKGROUND:35976622; BACKGROUND:33065059; BACKGROUND:37318239",null,"NO",null],["NCT06974487","A Phase I Study to Evaluate the PK and PD Profiles of GZR102 Injection Versus GZR4 Injection and GZR18 Injection Given Separately in Chinese Adult Overweight Subjects",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","30","Type 2 Diabetes","DRUG:GZR102 injection; DRUG:GZR4 injection; DRUG:GZR18 injection","Gan & Lee Pharmaceuticals.","2025-05-08","2025-09-30","FALSE","AUC0-t [Day 36 (end of period)]",null,null,null,null],["NCT01237197","Exenatide in Extreme Pediatric Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","26","Obesity","DRUG:Exenatide; DRUG:Placebo","University of Minnesota","2010-10","2012-05","TRUE","Percent Change From Baseline in Body Mass Index at 3-months [Baseline and 3-months]","DERIVED:23380890",null,null,null],["NCT04537624","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice","PIONEER REAL","COMPLETED","OBSERVATIONAL",null,null,null,"194","Diabetes Mellitus, Type 2","DRUG:Oral Semaglutide","Novo Nordisk A/S","2020-08-24","2023-01-11","FALSE","Change in Glycated haemoglobin (HbA1c ) [From baseline (week 0) to End of Study visit (V3) (week 34-44)]","RESULT:38240875; DERIVED:39535683",null,"YES","OTHER:U1111-1240-4102"],["NCT00782418","A Study to Compare Methodologies for Assessing Glucose-Dependent Insulin Secretion (0000-104)(COMPLETED)",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","27","The Methodology Assessment of Glucose Dependent Insulin Secretion","DRUG:Comparator: exenatide; DRUG:Comparator: Placebo","Merck Sharp & Dohme LLC","2008-09","2009-02","TRUE","Change From Baseline in Insulin Secretion Rate (ISR) Normalized to Ambient Plasma Glucose [Steady-state of HGC: 90 - 120 minutes post dose; highest glucose infusion rate of GGI: 120 - 160 minutes post dose] | Change From Baseline in C-peptide Concentration [Pre and Post glucose infusion] | Change From Baseline in Insulin Concentration [Pre and Post glucose infusion]","RESULT:27072496",null,null,"OTHER:2008_568"],["NCT01724060","Effects of Obesity Treatments on Food Preferences and Metabolism","FPS","COMPLETED","OBSERVATIONAL",null,null,null,"80","Obesity; Type 2 Diabetes Mellitus",null,"Imperial College London","2012-09","2017-10","TRUE","Change in Energy Intake From Baseline [Change at 12 months]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/60/NCT01724060/Prot_SAP_000.pdf","NO",null],["NCT05931380","A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease","ATTAIN-J","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","238","Obesity","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2023-07-31","2025-06-19","TRUE","Percent Change From Baseline in Body Weight at Week 72 [Baseline, Week 72] | Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline [Baseline to Week 72]",null,"Study Protocol: Amendment (b)|https://cdn.clinicaltrials.gov/large-docs/80/NCT05931380/Prot_000.pdf; Study Protocol: Errata to Amendment (b)|https://cdn.clinicaltrials.gov/large-docs/80/NCT05931380/Prot_001.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/80/NCT05931380/SAP_002.pdf","YES","OTHER:J2A-JE-GZPD"],["NCT00813020","A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","44","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide","Novo Nordisk A/S","2009-01","2009-04","FALSE","AUC0-8 (NN9535), the area under the plasma NN9535 plasma-concentration-time curve in the interval 0-8 after investigational medicinal product administration [a 28 day time period]",null,null,null,"EUDRACT_NUMBER:2008-004990-17; NIH:2008"],["NCT07859189","Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric Surgery",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","100","Morbid Obesity","DRUG:Semaglutide weekly injection; DRUG:Placebo","General Committee of Teaching Hospitals and Institutes, Egypt","2026-10","2028-10","FALSE","Percentage total weight loss [at 12 months]",null,null,"YES",null],["NCT06326060","A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","354","Obesity","DRUG:NNC0519-0130; DRUG:Placebo; DRUG:Tirzepatide","Novo Nordisk A/S","2024-03-18","2025-04-10","FALSE","Relative change in body weight [From baseline (week 0) to end of treatment (week 36)]",null,null,"YES","OTHER:U1111-1291-9210; REGISTRY:jRCT2051230198"],["NCT04844918","A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease","SURMOUNT-J","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","267","Obesity","DRUG:Tirzepatide; OTHER:Placebo","Eli Lilly and Company","2021-05-10","2023-06-24","TRUE","Mean Percent Change in Body Weight [Baseline, 72 Weeks] | Percentage of Participants Who Achieve ≥5% Body Weight Reduction [Week 72]","DERIVED:42287159; DERIVED:42108080; DERIVED:41290555; DERIVED:40031941","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/18/NCT04844918/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/18/NCT04844918/SAP_001.pdf","YES","OTHER:I8F-JE-GPHZ"],["NCT01931982","Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes.","EGOFIP","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","20","Type 2 Diabetes; Microvascular Dysfunction","DRUG:Victoza","Bispebjerg Hospital","2013-05","2014-04","FALSE","Change in coronary flow reserve (CFR) [CFR is measured at baseline and after 10 weeks of intervention]","DERIVED:25896352",null,null,"EUDRACT_NUMBER:2012-005013-38"],["NCT07349641","A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2",null,"NONE","55","Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia; FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma","OTHER:Medical Device Usage and Evaluation; DRUG:Tirzepatide","National Cancer Institute (NCI)","2026-11-01","2029-10-31","FALSE","Weighted pathological complete response (pCR) [At 26 weeks]",null,null,"YES","REGISTRY:NCI-2026-00081; OTHER:MDA24-19-01; NIH:P30CA016672; NIH:UG1CA242609"],["NCT06803888","Bariatric Surgery vs. Semaglutide vs. Tirzepatide",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","140","Obesity and Obesity-related Medical Conditions","PROCEDURE:Bariatric Surgery; DRUG:Semaglutide; DRUG:Tirzepatide","Ali Aminian","2025-01-29","2027-07-01","FALSE","Mean percentage total body weight loss at Week 52 [Baseline to Week 52 after treatment initiation]",null,null,"NO",null],["NCT00845559","The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young Adults",null,"WITHDRAWN","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","0","Obesity; Insulin Resistance; Impaired Glucose Tolerance; Cardiovascular Disease","DRUG:Exenatide","Yale University","2008-08","2010-03","FALSE","Whether treatment with exenatide attenuates post-prandial glycemic excursions as assessed by oral glucose tolerance testing (OGTT) and continuous monitoring system (CGMS) technology. [OGTT (Pre- and post-intervention), CGMS (Pre-intervention, 2-months and post-intervention)]",null,null,null,null],["NCT01973231","Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes","LIRA-LIXI™","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","404","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:lixisenatide","Novo Nordisk A/S","2013-10","2014-11","TRUE","Change in Glycosylated Haemoglobin (HbA1c) From Baseline [Week 0, week 26]","RESULT:27311491; DERIVED:28124820",null,null,"EUDRACT_NUMBER:2012-004984-27; OTHER:U1111-1136-3644"],["NCT07739537","PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses","PATHS-T2D","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4",null,"NONE","100","Diabete Type 2; Pharmacogenomic Drug Interaction","DRUG:Orforglipron","Massachusetts General Hospital","2026-10-01","2029-09-30","FALSE","Physiologic characterization by MMTT [1 day] | The acute drug challenges [12 days]",null,null,"NO","NIH:1R01DK148455-01"],["NCT06976372","A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","120","Overweight; Obesity","DRUG:AMG 133","Amgen","2024-08-20","2024-12-27","FALSE","Maximum Concentration (Cmax) of AMG 133 [Up to Day 99] | Area Under the Plasma Concentration-time Curve from Time Zero to the Last Quantifiable Concentration (AUClast) of AMG 133 [Day 29] | Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of AMG 133 [Day 29] | Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCtau) of AMG 133 [Day 1 and Day 15]",null,null,"YES",null],["NCT04773977","Clinical Study of IBI362 in Healthy Chinese Male Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","24","Overweight/Obesity","DRUG:IBI362 liquid formulation; DRUG:IBI362 lyophilized powder","Innovent Biologics (Suzhou) Co. Ltd.","2021-03-03","2021-03-09","FALSE","Evaluate the PK parameters of IBI362 in healthy Chinese male subjects [From the first dose of study drug until 8 weeks]",null,null,null,null],["NCT06445075","Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese","EMBRAZE","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","102","Overweight and Obesity","DRUG:Apitegromab; DRUG:Placebo; DRUG:Tirzepatide","Scholar Rock, Inc.","2024-05-21","2025-03-04","FALSE","Change from Baseline in total Lean Body Mass (kg) at 24 weeks [Baseline and 24 weeks]","DERIVED:42260100",null,"YES",null],["NCT07232719","A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight","TRIUMPH-8","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","250","Obesity; Overweight","DRUG:Retatrutide; DRUG:Placebo","Eli Lilly and Company","2025-11-17","2027-07","FALSE","Percent Change from Baseline in Body Weight [Baseline, Week 56]",null,null,"YES","OTHER:J1I-MC-GZQJ"],["NCT05659537","A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India",null,"COMPLETED","INTERVENTIONAL","PHASE4",null,"NONE","212","Diabetes Mellitus, Type 2","DRUG:Dulaglutide","Eli Lilly and Company","2022-12-29","2024-01-16","TRUE","Number of Participants With One or More Adverse Events (AEs) - Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Deaths [Baseline through Follow-up (up to 28 weeks)] | Number of Participants With One or More Hypoglycemic Events, Including Severe Hypoglycemic Events. [Baseline through Follow-up (up to 28 weeks)] | Percentage of Participants Reporting AEs and SAEs From Baseline to Week 24 [Baseline through Week 24] | Number of Participants With One or More Gastrointestinal (GI) AEs From Baseline to Week 24 [Baseline through Week 24]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/37/NCT05659537/Prot_002.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/37/NCT05659537/SAP_001.pdf","YES","OTHER:H9X-IN-GBGR"],["NCT05574439","Young Adults With Early-onset Obesity Treated With Semaglutide","RESETTLE","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","246","Obesity, Adolescent","BEHAVIORAL:TCOC treatment; DRUG:Semaglutide 3 mg/ml; DRUG:Placebo (Semaglutide 3 mg/ml)","Signe Torekov","2022-05-30","2026-04-01","FALSE","Change in BMI (weight in kg/height in m^2) [Change from baseline to end-of-treatment (68 weeks)]","BACKGROUND:28604169; BACKGROUND:29617589; BACKGROUND:21063014; BACKGROUND:27423262; BACKGROUND:28738325; BACKGROUND:28264043; BACKGROUND:23181919; BACKGROUND:24733029; BACKGROUND:26714769; BACKGROUND:24251641; BACKGROUND:21362122; BACKGROUND:21401851; BACKGROUND:9449682; BACKGROUND:25677912; BACKGROUND:26976129; BACKGROUND:25287751; BACKGROUND:33951361; BACKGROUND:29207396; BACKGROUND:35970829; BACKGROUND:32921795; BACKGROUND:27222505; BACKGROUND:29861388; BACKGROUND:35015037","Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/39/NCT05574439/SAP_001.pdf",null,"EUDRACT_NUMBER:2019-002274-31; NIH:2019"],["NCT07443956","Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis","COMBAT-PsA","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","45","Psoriatic Arthritis (PsA); Obesity & Overweight","DRUG:Ixekizumab; DRUG:Tirzepatide","NHS Greater Glasgow and Clyde","2026-03-09","2028-02","FALSE","Correlation of molecular changes in biopsies (skin, synovial and adipose) with weight loss [12 weeks]","BACKGROUND:31209855; BACKGROUND:22586165; BACKGROUND:22562978; BACKGROUND:17698691; BACKGROUND:33147607; BACKGROUND:36264448; BACKGROUND:34076348; BACKGROUND:31292564; BACKGROUND:34300360; BACKGROUND:37667975; BACKGROUND:33423070; BACKGROUND:34453579; BACKGROUND:40090785; BACKGROUND:15708927",null,"YES",null],["NCT03172494","A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)","DUAL™ I China","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","720","Diabetes; Diabetes Mellitus, Type 2","DRUG:Insulin degludec/liraglutide; DRUG:Insulin degludec; DRUG:Liraglutide","Novo Nordisk A/S","2017-05-26","2019-06-14","TRUE","Change in HbA1c [Week 0, week 26]","RESULT:35762390","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/94/NCT03172494/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/94/NCT03172494/SAP_001.pdf","YES","OTHER:U1111-1154-6671; REGISTRY:CTR20170004"],["NCT00960661","A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","1036","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:insulin lispro; DRUG:Metformin; DRUG:Insulin/ Glargine","AstraZeneca","2009-09","2012-08","TRUE","Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 30 [Baseline, 30 weeks]","RESULT:25011946",null,null,null],["NCT01511172","Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","145","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:metformin; DRUG:placebo; DRUG:glimepiride","Novo Nordisk A/S","2002-08","2002-12","FALSE","Fasting plasma/serum glucose []","RESULT:17039422; RESULT:25504028",null,null,null],["NCT01843075","Evaluating Liraglutide in Alzheimer's Disease","ELAD","UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","204","Alzheimer's Disease","DRUG:Liraglutide; DRUG:Placebo","Imperial College London","2014-01","2019-12","FALSE","The change in cerebral glucose metabolic rate [12 months]","DERIVED:41326666; DERIVED:30944040; DERIVED:27871675",null,"NO",null],["NCT05040971","Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes","STEP 10","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","207","Obesity","DRUG:Semaglutide 2.4 mg; DRUG:Placebo","Novo Nordisk A/S","2021-09-06","2023-01-06","TRUE","Change in Body Weight (Percentage [%]) [From randomisation (week 0) to end of treatment (week 52)] | Participants With Change to Normoglycemia [At week 52]","RESULT:39089293","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/71/NCT05040971/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/71/NCT05040971/SAP_001.pdf","YES","OTHER:U1111-1253-1956; EUDRACT_NUMBER:2020-002939-29"],["NCT06948422","A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","974","Hypertension","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2025-04-30","2027-09","FALSE","Number of Participants Allocated to Each ISA [Week -8 to Week 0]","DERIVED:42830762",null,"YES","OTHER:J2A-MC-GZPL; OTHER:J2A-MC-GZL1; OTHER:J2A-MC-GZL2"],["NCT02205528","A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","108","Diabetes; Diabetes Mellitus Type 2","DRUG:Liraglutide; DRUG:Metformin; DRUG:Placebo; DRUG:NNC0090-2746","Novo Nordisk A/S","2014-08-18","2015-09-15","FALSE","Change in HbA1c [Day 1; Week 8]","RESULT:28768173",null,null,"OTHER:U1111-1189-5627"],["NCT07619495","Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk",null,"COMPLETED","OBSERVATIONAL",null,null,null,"120000","Type 2 Diabetes Mellitus; Obesity; Overweight","DRUG:Semaglutide; DRUG:Dulaglutide","Brigham and Women's Hospital","2026-01-20","2026-06-01","FALSE","Composite of all-cause mortality, myocardial infarction, or stroke. [1 day after cohort entry until outcome, disenrollment, end of study period, death, 365 days after cohort entry, discontinuation (45 days grace and risk window), switch between study arms, nursing home admission, or start of any other GLP-1-RA]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/95/NCT07619495/Prot_000.pdf",null,null],["NCT06716307","A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","18","Obesity","DRUG:CagriSema (cagrilintide B and semaglutide I); DRUG:CagriSema A","Novo Nordisk A/S","2024-12-02","2025-03-28","FALSE","AUC0-∞,cagri,0.25 milligram (mg)/0.25mg,SD: Area under the cagrilintide concentration-time curve after a single dose 0.25 mg/0.25 mg CagriSema A in PDS290 pen-injector or CagriSema in DV3384 pen-injector [From 0 hours (pre-dose) to 1176 hours (post-dose)] | Cmax,cagri,0.25mg/0.25mg,SD: Maximum concentration of cagrilintide after a single dose 0.25 mg/0.25 mg CagriSema A in PDS290 pen-injector or CagriSema in DV3384 pen-injector [From 0 hours (pre-dose) to 1176 hours (post-dose)] | AUC0-∞,sema,0.25mg/0.25mg,SD: Area under the semaglutide concentration-time curve after a single dose 0.25 mg/0.25 mg CagriSema A in PDS290 pen-injector or CagriSema in DV3384 pen-injector [From 0 hours (pre-dose) to 1176 hours (post-dose)] | Cmax,sema,0.25mg/0.25mg,SD: Maximum concentration of semaglutide after a single dose 0.25 mg/0.25 mg CagriSema A in PDS290 pen-injector or CagriSema in DV3384 pen-injector [From 0 hours (pre-dose) to 1176 hours (post-dose)]",null,null,"YES","OTHER:U1111-1309-7476"],["NCT06589765","A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","810","Type 2 Diabetes","DRUG:HRS-7535 tablet; DRUG:dapagliflozin tablet","Shandong Suncadia Medicine Co., Ltd.","2024-09-27","2026-05-29","FALSE","Change from baseline in HbA1c at 32 weeks of treatment [at 32 weeks]","DERIVED:42834229",null,"UNDECIDED",null],["NCT00635492","CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy",null,"COMPLETED","OBSERVATIONAL",null,null,null,"2515","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:any human insulin or analog insulin(s) given in any regimen by subcutaneous injection","AstraZeneca","2008-01","2011-12","TRUE","Estimates of Probability to Remain on Initial Injectable Treatment at 12 and 24 Months. [Month 24]","DERIVED:33049248; DERIVED:24369764",null,null,null],["NCT07178145","Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction",null,"RECRUITING","INTERVENTIONAL","PHASE4","NON_RANDOMIZED","NONE","192","Heart Failure Preserved Ejection Fraction; Epicardial Adipose Tissue","DRUG:GLP-1RA","University of Virginia","2025-11-20","2029-09","FALSE","Epicardial adipose tissue (EAT) fatty acid composition (FAC) [Baseline, 3 months (self-control period), and 9-months (6 months post semaglutide treatment)]","BACKGROUND:31120821; BACKGROUND:37797885; BACKGROUND:37325396; BACKGROUND:39323040; BACKGROUND:35726367; BACKGROUND:30548522; BACKGROUND:30006022; BACKGROUND:26527483; BACKGROUND:30368904; BACKGROUND:21868182; BACKGROUND:22334300; BACKGROUND:32844500; BACKGROUND:18509197; BACKGROUND:35714617; BACKGROUND:37814776; BACKGROUND:38878970; BACKGROUND:30684282; BACKGROUND:22777847; BACKGROUND:18777528; BACKGROUND:36870978; BACKGROUND:31177816; BACKGROUND:37021018; BACKGROUND:30402702; BACKGROUND:33720759; BACKGROUND:28837682; BACKGROUND:29233634; BACKGROUND:28914752; BACKGROUND:31782934; BACKGROUND:29258509; BACKGROUND:34890762; BACKGROUND:19056664; BACKGROUND:26971994; BACKGROUND:29773163; BACKGROUND:31202119; BACKGROUND:28640452; BACKGROUND:35296869",null,"UNDECIDED",null],["NCT07622992","Preoperative Optimization With Tirzepatide, Ketogenic Diet, or Standard Care Before One Anastomosis Gastric Bypass Surgery","OPTI-OAGB","NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"96","Obesity (BMI > 35) and Diabetes Mellitus; Obesity (BMI > 35) and Dyslipemia; Obesity (BMI > 35) and High Blood Pressure",null,"Mario Musella MD","2027-01-01","2029-07-01","FALSE","Percentage of Total Weight Loss at 1 Year Post-Surgery [1 year]",null,null,"YES",null],["NCT00044668","Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination",null,"COMPLETED","INTERVENTIONAL","PHASE3","NON_RANDOMIZED","NONE","155","Diabetes Mellitus, Type 2","DRUG:AC2993","AstraZeneca","2002-08","2005-09","FALSE","Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 24, Week 52, and to each intermediate visit [Baseline, and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52] | Change in concentrations of fasting plasma glucose and lipids from Baseline Visit 2 (Day 1) to Week 24, to Week 52, and to each intermediate visit [Baseline, and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52]","DERIVED:22608106; DERIVED:22236356",null,null,null],["NCT07355738","Bioequivalence Study of GZR18 Injection Before and After CMC Change",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","138","Obesity&T2D","DRUG:GZR18 injection A; DRUG:GZR18 injection B","Gan & Lee Pharmaceuticals.","2026-01-09","2026-05-20","FALSE","the maximum concentration (Cmax) [Day1-Day36] | the area under the concentration-time curve during a dosing interval (AUC0-t) [Day1-Day36] | the area under the concentration-time curve from the time of dosing extrapolated to infinity (AUC0-∞) [Day1-Day36]",null,null,null,null],["NCT06191848","Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)","STOP KNEE-OA","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","352","Obesity; Knee Osteoarthritis; Osteoarthritis, Knee","DRUG:Tirzepatide; DRUG:Placebo","University of Melbourne","2024-11-19","2027-05","FALSE","Percentage of patients who undergo knee replacement in the target joint [within 72 weeks of randomization]","DERIVED:40992788","Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/48/NCT06191848/SAP_000.pdf","YES",null],["NCT01507285","Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","24","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","1999-08","1999-11","FALSE","Area under the Curve []","RESULT:11935150",null,null,null],["NCT07847593","Probiotics in Obese Patients Treated With Semaglutide","ProSem","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","QUADRUPLE","102","Obesity (Disorder); GLP-1 Receptor Agonist Treatment; Probiotic Intervention; Diabetes Mellitus Type 2","DIETARY_SUPPLEMENT:Four-strain probiotic formulation; DIETARY_SUPPLEMENT:Maltodextrin (Placebo)","Nordic Biotic Sp. z o.o.","2025-07-09","2026-07-15","FALSE","Gastrointestinal adverse event incidence proportion during semaglutide treatment [During the 12-week semaglutide treatment and dose-escalation period] | Prevalence of gastrointestinal adverse events during semaglutide treatment [During the 12-week semaglutide treatment and dose-escalation period]",null,null,"NO",null],["NCT03598621","A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","68","Diabetes Mellitus, Type 2","DRUG:Semaglutide, 0.5 mg/mL; DRUG:Semaglutide, 1.0 mg/mL; DRUG:Semaglutide, 1.34 mg/mL; DRUG:Semaglutide, 2.0 mg/mL; DEVICE:DV3372, 0.5 mg/mL; DEVICE:DV3372, 1.0 mg/mL; DEVICE:PDS290; DEVICE:NovoPen®4","Novo Nordisk A/S","2018-07-23","2019-01-17","FALSE","AUC0-last,sema,SD, the area under the plasma semaglutide concentration curve from time 0 until last quantifiable measurement after a single dose subcutaneous semaglutide administration [0-840 hours (5 weeks)] | Cmax,sema,SD, the maximum plasma semaglutide concentration after a single dose subcutaneous semaglutide administration [0-840 hours (5 weeks)]",null,null,"YES","OTHER:U1111-1200-8075; REGISTRY:2017-003437-29; NIH:2017"],["NCT02490176","Effects of Glucagon Like Peptide-1 on Haemodynamic Parameters",null,"UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","50","Heart Failure","DRUG:liraglutide; DRUG:placebo","Chinese PLA General Hospital","2015-07","2016-07","FALSE","a change in cardiac output measured by pulse indicator continuous cardiac output (PiCCO) technology [7 days after treatment]","BACKGROUND:18688814; BACKGROUND:18724013; BACKGROUND:19195607; BACKGROUND:21920963; BACKGROUND:19151200; BACKGROUND:14981009; BACKGROUND:21263372",null,null,null],["NCT05220917","Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","CER-4-T2D","ACTIVE_NOT_RECRUITING","OBSERVATIONAL",null,null,null,"781430","Cardiovascular Events; Type2 Diabetes; Renal Disease","DRUG:SGLT2 inhibitor; DRUG:DPP-4 inhibitor; DRUG:GLP-1RA; DRUG:2nd generation SU","Brigham and Women's Hospital","2021-08-01","2026-05-31","FALSE","MACE [through study completion, an average of 1 year] | Modified MACE [through study completion, an average of 1 year] | Hospitalization for Heart Failure (HHF) Hospitalization for Heart Failure (HHF) [through study completion, an average of 1 year]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/17/NCT05220917/Prot_SAP_001.pdf",null,null],["NCT04074174","Research Study to Investigate the Effect of NNC0174-0833 on a Birth Control Pill in Women Who Are Not Able to Become Pregnant",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","31","Overweight; Obesity","DRUG:NNC0174-0833; DRUG:Oral contraceptive (OC) tablets; DRUG:Acetaminophen","Novo Nordisk A/S","2019-09-12","2020-03-06","FALSE","AUC0-24h,EE,SS area under the ethinylestradiol concentration-time curve during a dosing interval (0-24 hours) at steady state [Day 8 (predose to 24 hours post-dose) and Day 79 (predose to 24 hours post-dose)] | AUC0-24h,LN,SS area under the levonorgestrel concentration-time curve during a dosing interval (0-24 hours) at steady state [Day 8 (predose to 24 hours post-dose) and Day 79 (predose to 24 hours post-dose)]",null,null,"YES","OTHER:U1111-1228-4219"],["NCT07711548","Can Two Dietary Interventions Maintain Weight Loss for 12 Months After GLP-1 Therapy in Adults With Overweight/Obesity?","DIET-SLIM","NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","292","Obesity & Overweight; Weight Loss Maintenance","BEHAVIORAL:NutriAct plus; BEHAVIORAL:Rescue VLCD","Knut Mai","2027-03","2030-02","FALSE","weight in kg [body weight in kg after weight loss (3 to 5 months) and dietary intervention (12 months)]",null,null,"UNDECIDED",null],["NCT05751226","A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","SINGLE","88","Healthy; Obesity","DRUG:BI 1820237; DRUG:semaglutide; DRUG:Placebo; DRUG:BI 456906","Boehringer Ingelheim","2023-04-11","2024-08-01","FALSE","Percentage of treatment-emergent adverse events [Up to 180 days]",null,null,"NO","EUDRACT_NUMBER:2022-002733-34"],["NCT04940078","A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","40","Obesity & Overweight","DRUG:Cagrilintide; DRUG:semaglutide; DRUG:Cagrilintide and semaglutide","Novo Nordisk A/S","2021-07-07","2022-01-19","FALSE","AUC0-168h,cagri,2.4/2.4mg,SS area under the cagrilintide concentration-time curve during a dosing interval (0-168 hours) at steady state after last dosing of cagrilintide 2.4 mg in combination with semaglutide 2.4 mg [Day 148 (pre-dose) to Day 155 (168 hours post-dose)] | Cmax,cagri,2.4/2.4mg,SS maximum concentration of cagrilintide at steady state after last dosing of cagrilintide 2.4 mg in combination with semaglutide 2.4 mg [Day 148 (pre-dose) to Day 155 (168 hours post-dose)] | AUC0-168h,sema,2.4/2.4mg,SS area under the semaglutide concentration-time curve during a dosing interval (0-168 hours) at steady state after last dosing of semaglutide 2.4 mg in combination with cagrilintide 2.4 mg [Day 148 (pre-dose) to Day 155 (168 hours post-dose)] | Cmax,sema,2.4/2.4mg,SS maximum concentration of semaglutide at steady state after last dosing of semaglutide 2.4 mg in combination with cagrilintide 2.4 mg [Day 148 (pre-dose) to Day 155 (168 hours post-dose)]",null,null,"YES","OTHER:U1111-1250-7789"],["NCT06344247","Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease",null,"UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","NONE","48","Obesity; Chronic Kidney Diseases","DRUG:RAS inhibitors：Losartan®️/Valsartan®️; DRUG:dapagliflozin：Forxiga®️; DRUG:simagliptin：Forxiga®️","RenJi Hospital","2023-09-01","2025-09-01","FALSE","Change of 24-hour urine protein quantification [4、12、24、36、48 WEEK]",null,null,"NO",null],["NCT06937749","A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","165","Metabolic Dysfunction-associated Steatohepatitis (MASH)","DRUG:Placebo; DRUG:IBI362","Innovent Biologics (Suzhou) Co. Ltd.","2025-07-01","2026-04-30","FALSE","Percentage of Participants With MASH resolution With no Worsening of Fibrosis on Liver Histology [Baseline, Week 60]",null,null,null,null],["NCT06297616","A Study of LY3841136 in Japanese Participants With Obesity or Overweight",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","128","Obesity; Overweight","DRUG:LY3841136; DRUG:LY3841136-Placebo; DRUG:Tirzepatide; DRUG:Tirzepatide-Placebo","Eli Lilly and Company","2024-04-15","2025-11-21","FALSE","Part A: Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration at Week 22 [Baseline through Week 22] | Part B: Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration at Week 34 [Baseline through Week 34]",null,null,"NO","OTHER:J3R-JE-YDAB"],["NCT07732426","Effects of Semaglutide on Brain Dopamine Responses to Food Cues in Adults With Obesity and Food Addiction Tendencies",null,"RECRUITING","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","30","Food Addiction Tendency; Obesity; Overweight","DRUG:Semaglutide","Seoul National University Hospital","2026-07-15","2028-02-29","FALSE","Change in Dopamine Binding Potential During the Look, Smell, and Drink Period [Group A: At Baseline (Day 0) and 8 weeks (±3 days) after starting semaglutide. Group B: At 8 weeks (±3 days) after starting semaglutide and 8 weeks after semaglutide discontinuation.]",null,null,"NO",null],["NCT04122716","Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet","S-LITE","UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","215","Obesity","DRUG:Liraglutide; BEHAVIORAL:Exercise","Signe Torekov","2016-09","2019-11","FALSE","Body weight change (kg) [Change from baseline to end-of-treatment (52 weeks)]","BACKGROUND:11234459; BACKGROUND:28480197; BACKGROUND:24222017; BACKGROUND:27219496; BACKGROUND:16476868; BACKGROUND:27465384; BACKGROUND:27605038; BACKGROUND:26916363; BACKGROUND:23302544; BACKGROUND:25197563; BACKGROUND:20167668; BACKGROUND:20345430; BACKGROUND:11684524; BACKGROUND:15925949; BACKGROUND:20935667; BACKGROUND:7632212; BACKGROUND:26976129; BACKGROUND:25287751; BACKGROUND:24438736; BACKGROUND:19127177; BACKGROUND:17054187; BACKGROUND:22436841; BACKGROUND:16464906; BACKGROUND:23494259; BACKGROUND:26139859; BACKGROUND:28790922; BACKGROUND:16526835; BACKGROUND:18663167; BACKGROUND:16002825; BACKGROUND:9449682; BACKGROUND:18353723; BACKGROUND:26284720; BACKGROUND:26132939; BACKGROUND:23812094; BACKGROUND:24507240; BACKGROUND:16285994; BACKGROUND:12829649; BACKGROUND:11812755; BACKGROUND:12626436; BACKGROUND:21818123; BACKGROUND:30052921; BACKGROUND:28688914; BACKGROUND:20068138; BACKGROUND:22722451; BACKGROUND:23186644; BACKGROUND:29283509; BACKGROUND:24362727; BACKGROUND:22013105; BACKGROUND:28049736; BACKGROUND:20424219; BACKGROUND:27295427; BACKGROUND:27633186; DERIVED:42342869; DERIVED:41579235; DERIVED:40998556; DERIVED:39530599; DERIVED:38544798; DERIVED:36841762; DERIVED:36472579; DERIVED:35970829; DERIVED:35580859; DERIVED:33951361","Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/16/NCT04122716/SAP_001.pdf",null,"EUDRACT_NUMBER:2015-005585-32; OTHER:H-16027082; NIH:2015"],["NCT07411378","Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.","OBA","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","164","Muscle Wasting; Obesity & Overweight; Obesity","DRUG:BIO101; OTHER:Placebo; DRUG:Semaglutide","Biophytis","2026-07","2027-06","FALSE","Change from baseline in the knee extension strength at 21 weeks [Baseline and 21 weeks]",null,null,null,null],["NCT04152915","A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","68","Healthy Volunteers; Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2019-11-25","2020-05-25","FALSE","AUC0-last,sema,1mg: Area under the semaglutide concentration time curve from time 0 until last quantifiable measurement after one dose of s.c. semaglutide 1 mg administration following a 6-week dose escalation period [0-840 hours after one dose of s.c. semaglutide 1 mg] | Cmax,sema,1mg: Maximum observed semaglutide concentration after one dose of s.c. semaglutide 1 mg administration following a 6-week dose escalation period [0-840 hours after one dose of s.c. semaglutide 1 mg]",null,null,"YES","OTHER:U1111-1235-3506; REGISTRY:2019-002588-92; NIH:2019"],["NCT02089256","Effect of Repeated Administration of Liraglutide on Insulinogenic Indices",null,"COMPLETED","INTERVENTIONAL","PHASE4",null,"NONE","10","Healthy","DRUG:Liraglutide","University of Tartu","2014-06","2015-03","FALSE","Change in the glucose-sensitivity of the beta cells [baseline, first dose, after 3-weeks on treatment]","DERIVED:36800161; DERIVED:28379427; DERIVED:27300475",null,null,null],["NCT01476475","Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","323","Type 2 Diabetes Mellitus","DRUG:Insulin glargine /lixisenatide Fixed Ratio Combination; DRUG:Insulin glargine; DRUG:Metformin (Background drug)","Sanofi","2011-11","2012-12","TRUE","Change in HbA1c From Baseline to Week 24 [Baseline, Week 24]","RESULT:27284114",null,null,"EUDRACT_NUMBER:2011-002090-36; OTHER:U1111-1121-7111"],["NCT07504172","Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity","TIRZ-DOSE-NL","NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"1700","Overweight , Obesity; Obesity (Disorder)","DRUG:Tirzepatide","Radboud University Medical Center","2026-04-01","2026-07-01","FALSE","Weight change [Baseline-6 months]","BACKGROUND:41039116; BACKGROUND:39536238; BACKGROUND:35658024",null,"NO",null],["NCT06989177","Probiotic Intervention on Body Weight",null,"RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","140","Obesity; Homeostasis; Weight Loss; Probiotic Intervention","BEHAVIORAL:General lifestyle and nutritional education; BEHAVIORAL:Energy-restricted nutritional and lifestyle intervention; DIETARY_SUPPLEMENT:Placebo; DIETARY_SUPPLEMENT:Probiotic; DRUG:semaglutide","Chinese Academy of Sciences","2025-06-10","2026-12-30","FALSE","Change in Body Weight (kg) from Baseline to Week 12 [Baseline and Week 12]",null,null,null,null],["NCT04667377","A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","387","Obesity","DRUG:BI 456906; DRUG:Placebo","Boehringer Ingelheim","2021-03-08","2022-09-15","TRUE","Percentage Change in Body Weight From Baseline to Week 46 [Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46.]","DERIVED:42331726; DERIVED:39821928; DERIVED:38330987","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/77/NCT04667377/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/77/NCT04667377/SAP_001.pdf","YES","EUDRACT_NUMBER:2020-002479-37"],["NCT06073184","Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium","WE-FiERCE","RECRUITING","INTERVENTIONAL","PHASE2",null,"NONE","71","Endometrial Cancer; Atypical Hyperplasia; Fertility Perservation","DRUG:Wegovy; DRUG:Mirena","GynOncTrials","2026-09-17","2029-02","FALSE","Assessment of Complete Pathologic Response [48 weeks]",null,null,null,null],["NCT03638778","Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","105","Diabetes Mellitus, Type 2","DRUG:Semaglutide 3 mg; DRUG:Semaglutide 7 mg; DRUG:Semaglutide B 3 mg; DRUG:Semaglutide B 7 mg; DRUG:Semaglutide C 3 mg; DRUG:Semaglutide C 7 mg; DRUG:Semaglutide D 3 mg; DRUG:Semaglutide D 7 mg","Novo Nordisk A/S","2018-08-17","2018-12-05","FALSE","AUC0-24h,sema,day10, area under the semaglutide plasma concentration time curve from 0 to 24 hours after the 10th dosing [0 to 24 hours on day 10]",null,null,"YES","OTHER:U1111-1206-6210; REGISTRY:2017-005023-24; NIH:2017"],["NCT00700817","The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","665","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:sitagliptin; DRUG:metformin","Novo Nordisk A/S","2008-06","2009-06","TRUE","Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 26 [Week 0, Week 26] | Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 52 [Week 0, Week 52] | Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 78 [Week 0, Week 78] | Mean Change in Glycosylated Haemoglobin A1c (HbA1c) From Week 52 to Week 78 [Week 52, Week 78]","RESULT:20417856; RESULT:21309842; RESULT:21355967; RESULT:22193143; RESULT:21883806; RESULT:21883438; RESULT:22851600; RESULT:22834986; RESULT:22862847; RESULT:23010561; RESULT:23186975; RESULT:25504028; RESULT:26936426; DERIVED:23537458",null,null,"EUDRACT_NUMBER:2007-003937-17"],["NCT05254418","Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease","GLIMP","COMPLETED","INTERVENTIONAL","PHASE2",null,"NONE","7","Chronic Kidney Diseases","DRUG:dulaglutide injection","Vanderbilt University Medical Center","2022-03-15","2024-05-01","TRUE","Changes in Intermuscular Fat Deposition as Assessed by Magnetic Resonance Imaging (MRI). [16 weeks] | Changes in Skeletal Muscle Mitochondrial Function as Assessed by Phosphocreatine Recovery Time Constant by 31P Magnetic Resonance Spectroscopy (31P-MRS). [16 weeks] | Changes in Physical Performance as Assessed by Systemic Physical Performance Battery Test [16 weeks] | Safety and Feasibility of Dulaglutide Treatment as Evaluated by Subject Interview, Continuous Glucose Monitoring, Adverse Events (AE), Laboratory Tests, Vital Signs, ECG & Allergic/Hypersensitivity Reactions. [16 weeks]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/18/NCT05254418/Prot_002.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/18/NCT05254418/SAP_003.pdf","NO",null],["NCT06541678","A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy Adults.",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","16","Healthy","DRUG:Danuglipron; DRUG:Cyclosporine; DRUG:Itraconazole","Pfizer","2024-12-23","2025-03-10","FALSE","AUCinf (if data permits otherwise AUClast): to estimate the effect of a single dose of cyclosporine on the single-dose PK of a MR formulation of danuglipron in healthy adult participants. [0 to 72 hour postdose] | Cmax: to estimate the effect of a single dose of cyclosporine on the single-dose PK of a MR formulation of danuglipron in healthy adult participants. [0 to 72 hour postdose] | AUCinf (if data permits otherwise AUClast): to estimate the effect of multiple doses of itraconazole on the single-dose PK of a MR formulation of danuglipron in healthy adult participants. [0 to 72 hour postdose] | Cmax: to estimate the effect of multiple doses of itraconazole on the single-dose PK of a MR formulation of danuglipron in healthy adult participants. [0 to 72 hour postdose]",null,null,"NO","REGISTRY:2024-513863-21-00"],["NCT02838589","The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers","EGRABINS1","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","30","Stroke","DRUG:Byetta; DRUG:Isotonic saline","Christina Kruuse","2016-08","2017-02","FALSE","Changes in the mean flow velocity in the middle cerebral arteries and in cortical oxigination . [Up till 3 hours]","DERIVED:36636739",null,"NO","EUDRACT_NUMBER:2016-001221-14; NIH:2016"],["NCT07781150","Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer","MELIA","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","128","Obesity; Overweight; Atypical Endometrial Hyperplasia; Endometrial Carcinoma Stage I; Endometrioid Endometrial Cancer","DRUG:Mazdutide(Dual GLP-1R/GCGR Agonist); DRUG:Placebo; DEVICE:Levonorgestrel-releasing intrauterine system","Tongji Hospital","2026-11-01","2029-06-30","FALSE","Complete response rate of endometrial lesions at 24 week [At 24 weeks after randomization]",null,null,"NO",null],["NCT02292290","Trial for People With Established Type 2 Diabetes During Ramadan","T4R","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","99","Type 2 Diabetes","DRUG:Liraglutide; DRUG:Sulfonylurea or Pioglitazone; DRUG:Maintain dual therapy (Sulf/Pio) as comparator to Liraglutide","University of Leicester","2011-04","2012-12","FALSE","Composite [12 weeks following post Ramadan cinical assessment]",null,null,null,null],["NCT01554618","Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","84","Children and Adolescent With Type 2 Diabetes","DRUG:Exenatide Once Weekly; DRUG:Placebo","AstraZeneca","2011-12-02","2020-05-06","TRUE","Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) to Week 24 (Controlled Assessment Period) [Baseline (Week 0) and Week 24] | Percentage of Patients With On-Treatment Adverse Events (AEs) up to Week 24 (Controlled Assessment Period) [Day 1 (Week 0) up to Week 24, plus up to a maximum of 90 days follow up] | Percentage of Patients Positive for Anti-Drug Antibodies (ADAs) to Exenatide up to Week 24 [Samples were collected on Day 1 (Week 0), Week 4, Week 8, Week 12 and Week 24]","DERIVED:35679098","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/18/NCT01554618/Prot_002.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/18/NCT01554618/SAP_003.pdf","YES",null],["NCT06058585","The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect","CAPTIVATE","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","2000","Chronic Kidney Diseases","DRUG:Finerenone; DRUG:Placebo Finerenone; DRUG:Semaglutide; DRUG:Placebo semaglutide","The George Institute","2024-09-04","2029-12-31","FALSE","Core Primary Outcome Measure [From randomisation to week 108] | MRA Domain Primary Outcome Measure [From week 4 to week 108] | GLP1-RA Domain Primary Outcome Measure [From week 0 to week 108]","DERIVED:42335037; DERIVED:42228487; DERIVED:39661388; DERIVED:39248631",null,"YES","OTHER:U1111-1324-3113"],["NCT04311424","Study of Tirzepatide in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","6","Healthy","DRUG:14C Tirzepatide","Eli Lilly and Company","2020-07-28","2020-10-02","TRUE","Urinary Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered [Pre-dose and up to 63 days post-dose] | Fecal Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered [Pre-dose and up to 63 days post-dose]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/24/NCT04311424/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/24/NCT04311424/SAP_001.pdf","NO","OTHER:I8F-MC-GPHX; EUDRACT_NUMBER:2019-003664-44; NIH:2019"],["NCT02082496","GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations",null,"COMPLETED","INTERVENTIONAL","PHASE2","NON_RANDOMIZED","NONE","50","Obesity","DRUG:Liraglutide","University of Copenhagen","2014-06","2016-04","FALSE","Difference in insulin levels in reponse to GLP-1 RA treatment in obese genetic mutation carriers vs obese controls [4 months intervention]",null,null,null,null],["NCT03798080","Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin","Lixilan-L-CN","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","426","Type 2 Diabetes Mellitus","DRUG:Insulin glargine/Lixisenatide (HOE901/AVE0010); DRUG:Insulin glargine (HOE901); DRUG:Metformin","Sanofi","2019-02-19","2020-12-01","FALSE","Change in HbA1c [From Baseline to Week 30]","BACKGROUND:35762489; DERIVED:39360440; DERIVED:36999231",null,"YES","OTHER:U1111-1190-7781"],["NCT07754045","Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","202","Obesity & Overweight","DRUG:LUM-201; DRUG:Placebo; DRUG:Semagludtide","Lumos Pharma","2027-02-15","2028-02-15","FALSE","Proportion of participants with Short Physical Performance Battery (SPPB) score ≤ 7 at Week 26. [From Day 1 to week 26]",null,null,"UNDECIDED",null],["NCT01435980","Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","60","Type 2 Diabetes","PROCEDURE:Gastric Bypass; DRUG:Exenatide","Wu Qinan","2008-02","2016-01","FALSE","Clinical events [1 year]",null,null,null,null],["NCT06913023","Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus","SPOT-DM","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2; PHASE3",null,"NONE","37","Kidney Transplant Recipient","DRUG:Semaglutide 0.25 mg; DRUG:Semaglutide 0.5 mg; DRUG:Semaglutide 1.0 mg; DRUG:Semaglutide 1.7mg subcutaneous; DRUG:Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]","University Health Network, Toronto","2026-09-05","2029-06-30","FALSE","2-hour OGTT [24 weeks]",null,null,"NO",null],["NCT02960659","Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","NONE","24","Type 2 Diabetes","DRUG:Liraglutide; DRUG:Metformin","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","2017-05-09","2022-05-20","TRUE","Change in Absolute Gluconeogenesis From Baseline to 12 Weeks [Baseline to 12 weeks]","DERIVED:41020378","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/59/NCT02960659/Prot_SAP_000.pdf","YES","OTHER:17-DK-0013"],["NCT04883346","Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy",null,"COMPLETED","INTERVENTIONAL","PHASE2",null,"NONE","34","Obesity; Status Post Sleeve Gastrectomy","DRUG:Liraglutide","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","2021-06-21","2024-03-15","TRUE","Cohen's d (the Standardized Mean Difference) [16 weeks]","BACKGROUND:32233338; BACKGROUND:26132939; BACKGROUND:26544725","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/46/NCT04883346/Prot_SAP_000.pdf; Informed Consent Form: Consent that Parents signed|https://cdn.clinicaltrials.gov/large-docs/46/NCT04883346/ICF_003.pdf; Informed Consent Form: Assent that children signed|https://cdn.clinicaltrials.gov/large-docs/46/NCT04883346/ICF_004.pdf","YES","OTHER:000241-CH"],["NCT07387796","Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation","CLIN-GLP1","RECRUITING","INTERVENTIONAL",null,null,"NONE","40","Drug Discontinuation; Substance Use Disorders; Eating Behavior Changes; Tirzepatide","OTHER:Discontinuation and Reinitiation of Tirzepatide","The University of Texas at Dallas","2026-10","2028-02","FALSE","Change From On-Treatment to Discontinuation and Re-Initiation in Food Cue-Evoked BOLD Response in Reward and Salience Brain Regions [Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation]","BACKGROUND:33559214; BACKGROUND:15085902; BACKGROUND:28370722; BACKGROUND:30597585; BACKGROUND:19500623; BACKGROUND:12900694; BACKGROUND:11126230; BACKGROUND:12203741; BACKGROUND:16168867; BACKGROUND:14613562; BACKGROUND:38094040; BACKGROUND:40730315; BACKGROUND:3981480; BACKGROUND:15510530; BACKGROUND:27002123; BACKGROUND:22329987; BACKGROUND:17187897; BACKGROUND:7351540; BACKGROUND:26866783; BACKGROUND:10702749; BACKGROUND:39828656; BACKGROUND:15001004; BACKGROUND:6668417; BACKGROUND:33796498; BACKGROUND:2748771; BACKGROUND:25009514; BACKGROUND:29588623",null,"NO",null],["NCT07128888","Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection",null,"RECRUITING","INTERVENTIONAL","PHASE1",null,"NONE","60","Obesity or Overweight","DRUG:GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets","Gan & Lee Pharmaceuticals.","2025-11-17","2026-07-05","FALSE","Cmax:Maximum plasma concentration [through study completion,up to 16 weeks] | AUC0-last:Area under the plasma concentration-time curve at 0 h to last observation time-point after a single dose. [through study completion,up to 16 weeks] | AUC0-inf:Area under the plasma concentration-time curve at 0 h to infinity after a single dose. [through study completion,up to 16 weeks]",null,null,null,null],["NCT03385369","A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","32","Safety; Healthy Subjects","DRUG:MEDI0382; DRUG:Placebo","MedImmune LLC","2018-01-05","2018-04-12","FALSE","Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) [Day 1 through Day 29] | Number of Participants With Treatment Emergent Adverse Events of Special Interest (AESIs) [Day 1 through Day 29] | Number of Participants With Abnormal Electrocardiogram (ECG) Reported as TEAEs [Day 1 through Day 29] | Number of Participants With Vital Signs Abnormalities Reported as TEAEs [Day 1 through Day 29] | Number of Participants With Abnormal Laboratory parameters Reported as TEAEs [Day 1 through Day 29]",null,null,"UNDECIDED",null],["NCT07770841","Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight","OASIS 5","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","450","Overweight; Obesity","DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2026-08-12","2028-02-22","FALSE","Relative change in body weight [From baseline (week 0) to week 60]",null,null,"YES","OTHER:U1111-1331-5612; OTHER:2025-524626-18; NIH:2025"],["NCT04251156","Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.","STEP7","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","375","Overweight; Obesity; Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2020-12-08","2022-08-23","TRUE","Change From Baseline in Body Weight (Percentage [%]) [Baseline (week 0), week 44] | Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 5% (Yes/No) [At week 44]","RESULT:38330988","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/56/NCT04251156/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/56/NCT04251156/SAP_001.pdf","YES","OTHER:U1111-1212-2189"],["NCT06174779","A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","448","Obesity","DRUG:HM11260C; DRUG:Placebo","Hanmi Pharmaceutical Company Limited","2024-01-03","2025-08-14","FALSE","The percent change of body weight from baseline [baseline, 40 weeks] | The proportion of subjects achieving body weight loss ≥ 5% from baseline [baseline, 40 weeks]",null,null,null,null],["NCT04865770","A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)","REMODEL","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","106","Diabetes Mellitus, Type 2; Chronic Kidney Disease","DRUG:Semaglutide; DRUG:Placebo (Semaglutide)","Novo Nordisk A/S","2021-04-28","2024-11-21","TRUE","Change in Kidney Oxygenation (Cortex), Blood Oxygenation-level Dependent Magnetic Resonance Imaging (BOLD MRI) (R2*) [Baseline (week 0), End of treatment (week 52)] | Change in Kidney Oxygenation (Medulla), BOLD MRI (R2*) [Baseline (week 0), End of treatment (week 52)] | Change in Global Kidney Perfusion (MRI) [Baseline (week 0), End of treatment (week 52)] | Change in Kidney Inflammation (Cortex), Longitudinal Relaxation Time (T1) Mapping (MRI) [Baseline (week 0), End of treatment (week 52)] | Change in Kidney Inflammation (Medulla), T1 Mapping (MRI) [Baseline (week 0), End of treatment (week 52)]","DERIVED:42823485; DERIVED:41207620; DERIVED:39963952; DERIVED:39480988","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/70/NCT04865770/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/70/NCT04865770/SAP_001.pdf","YES","OTHER:U1111-1248-7912; EUDRACT_NUMBER:2020-000828-19"],["NCT07055386","A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes Mellitus",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","90","Type 2 Diabetes Mellitus (T2DM)","DRUG:GZR102; DRUG:GZR18","Gan & Lee Pharmaceuticals.","2025-08-07","2026-06-28","FALSE","efficiency endpoint [Week 24]",null,null,null,null],["NCT02650479","Study of the Effects of Intravenous Exenatide on Cardiac Repolarization",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","82","Healthy Adult Male and Female Volunteers","DRUG:Exenatide; DRUG:Placebo; DRUG:Moxifloxacin; DRUG:Palonosetron","Intarcia Therapeutics","2016-01","2016-04","FALSE","Pilot Study: Establishment of mean plasma steady state concentration of 500 pg/mL [35 days] | Core Study: Changes to QTc interval changes (threshold > 10 msec) measurements [56 days]",null,null,"NO",null],["NCT00851773","Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","84","Diabetes; Healthy","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2009-02","2009-10","FALSE","Adverse events [at all scheduled visits (2 - 14) following screening]",null,null,null,"EUDRACT_NUMBER:2008-006325-13; NIH:2008"],["NCT07389941","Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation","SPICE-AF","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","240","Atrial Fibrillation (AF)","DRUG:Semaglutide (SEMA)","University of Luebeck","2026-10","2029-04","FALSE","Freedom from atrial arrhythmia (AF/atrial flutter/atrial tachycardia >30 sec) at 12 months post-ablation (8-week-blanking period) [12 months]",null,null,"NO",null],["NCT00577824","Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","181","Type 2 Diabetes","DRUG:exenatide; DRUG:placebo","AstraZeneca","2008-01","2008-11","TRUE","Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 24 [baseline, 24 weeks]","RESULT:24843486; RESULT:24843529; DERIVED:22913891",null,null,null],["NCT04707469","Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes","PIONEER PLUS","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","1606","Diabetes Mellitus, Type 2","DRUG:Oral semaglutide","Novo Nordisk A/S","2021-01-15","2023-03-07","TRUE","Change From Baseline in Glycated Haemoglobin (HbA1c) (Week 52) [Baseline (week 0), week 52]","RESULT:37385279","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/69/NCT04707469/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/69/NCT04707469/SAP_001.pdf","YES","OTHER:U1111-1247-0210; REGISTRY:2020-000299-39"],["NCT02060266","Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","7","Diabetes; Healthy","DRUG:semaglutide","Novo Nordisk A/S","2014-02-04","2014-04-28","FALSE","Concentration of the major metabolites of [3H]-semaglutide in plasma, urine, and faeces [Up to 9 weeks following a single dose of 0.5 mg [3H]-semaglutide]","RESULT:28323117",null,null,"EUDRACT_NUMBER:2013-001769-18; OTHER:U1111-1142-0810"],["NCT07635953","New Triple Combination Therapy in Newly Diagnosed Type 2 Diabetes",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","296","Diabetes Mellitus","DRUG:Group A (triple combination intensive therapy group); DRUG:Group B (standard therapy group)","Sun Yat-sen University","2026-07-01","2029-07-01","FALSE","Diabetic remission rate [6 months after discontinuation of medication]",null,null,"NO",null],["NCT03232112","Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?","EXALT","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","152","Alcohol Dependence, in Remission; Addiction, Alcohol","DRUG:Exenatide 2 MG Injection; DRUG:BD PosiFlush (saline)","Anders Fink-Jensen, MD, DMSci","2017-08-07","2020-03-15","FALSE","Heavy drinking days [30 days prior to baseline and 30 days prior to final follow up at 26 weeks]","DERIVED:36066977","Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/12/NCT03232112/SAP_000.pdf","YES",null],["NCT03823339","A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates","INTENSIFY","COMPLETED","OBSERVATIONAL",null,null,null,"300","Diabetes Mellitus, Type 2","DRUG:Insulin degludec/liraglutide","Novo Nordisk A/S","2019-01-29","2020-12-14","FALSE","Change in laboratory measured glycosylated haemoglobin A1c (HbA1c) [From baseline [≤12 weeks prior to treatment initiation [week 0]) to end of study (26-34 weeks)]",null,null,"YES","OTHER:U1111-1213-4338"],["NCT03449654","Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes","LIRAFLAME","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","102","Diabetes Mellitus, Type 2","DRUG:Liraglutide; DRUG:Placebo (for liraglutide)","Steno Diabetes Center Copenhagen","2017-10-26","2019-08-16","FALSE","Change in vascular inflammation [baseline to week 26]","DERIVED:37752566; DERIVED:36992761; DERIVED:34518158; DERIVED:34187185",null,"NO",null],["NCT00855439","Evaluation of Exenatide in Patients With Diabetic Neuropathy",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","46","Type 2 Diabetes Mellitus; Diabetic Peripheral Neuropathy","DRUG:Exenatide; DRUG:Glargine","University of Michigan","2008-06","2014-05","TRUE","Confirmed Clinical Neuropathy (CCN) [18 Months]","DERIVED:26264399",null,"NO",null],["NCT03795701","To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","QUADRUPLE","73","Obesity","DRUG:Saxenda®; OTHER:Placebo","Texas Tech University","2019-01-08","2022-05-01","FALSE","Compare the changes of pre-prandial fMRI-FCR in Liraglutide 3.0 vs. Placebo Group [Baseline, Week 4, and Week 16] | Compare the changes of post-prandial fMRI-FCR in Liraglutide 3.0 vs. Placebo Group [Baseline, Week 4, and Week 16] | Compare the changes of energy intake in Liraglutide 3.0 vs. Placebo Group [Baseline, Week 4, and Week 16] | Compare the changes of hunger/satiety in Liraglutide 3.0 vs. Placebo Group [Baseline, Week 4, and Week 16] | Prediction of weight loss in Liraglutide 3.0 group by examine early change in pre-prandial fMRI-FCR [Baseline, Week 4, and Week 16] | Prediction of weight loss in Liraglutide 3.0 group by examine early change in post-prandial fMRI-FCR [Baseline, Week 4, and Week 16]",null,null,null,null],["NCT06446531","Prevention of Progression of Prediabetes, Obesity and CV Risk","Pre-DM","RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","SINGLE","64","Pre-Diabetes; Weight, Body; Cardiovascular Diseases","DRUG:Placebo; DRUG:Rybelsus Tablet; DRUG:Jardiance 25Mg Tablet; DRUG:Metformin; DRUG:Actos","The University of Texas Health Science Center at San Antonio","2024-09-11","2027-07","FALSE","Hemoglobin A1c Level (HBA1c) [Baseline and 6 months]",null,null,"YES",null],["NCT04616339","STUDY TO COMPARE PHARMACOKINETICS (PK) OF SINGLE ORAL DOSES OF DIFFERENT PF-06882961 FORMULATIONS IN PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITY",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","31","Overweight and/or Obesity","DRUG:PF-06882961 100 mg","Pfizer","2020-11-04","2021-07-19","FALSE","Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for Formulations A and B cohort 1 [Day 1 hour (hr) 0, 1, 2, 3, 4, 6, 8, 10, 12, 16, Day 2 hr 24 and 36, Day 3 hr 48 and end of study (Day 28)] | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Formulations A and B cohort 1 [Day 1 hr 0, 1, 2, 3, 4, 6, 8, 10, 12, 16, Day 2 hr 24 and 36 and Day 3 hr 48] | Maximum Observed Plasma Concentration (Cmax) for Formulations A and B cohort 1 [Day 1 hr 0, 1, 2, 3, 4, 6, 8, 10, 12, 16, Day 2 hr 24 and 36 and Day 3 hr 48] | Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for Formulations A and E cohort 2 [Day 1 hour (hr) 0, 1, 2, 3, 4, 6, 8, 10, 12, 16, Day 2 hr 24 and 36, Day 3 hr 48 and end of study (Day 28)] | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Formulations A and E cohort 2 [Day 1 hr 0, 1, 2, 3, 4, 6, 8, 10, 12, 16, Day 2 hr 24 and 36 and Day 3 hr 48] | Maximum Observed Plasma Concentration (Cmax) for Formulations A and E cohort 2 [Day 1 hr 0, 1, 2, 3, 4, 6, 8, 10, 12, 16, Day 2 hr 24 and 36 and Day 3 hr 48]",null,null,"NO","EUDRACT_NUMBER:2020-001016-24"],["NCT07685834","Evaluation of Facial and Neck Skin Laxity With SofWave Treatment in Adults Initiating Tirzepatide for Weight Loss",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","30","Lax Skin","DEVICE:SUPERB","Sofwave Medical LTD","2026-02-27","2027-03-01","FALSE","Improvement in the appearance of lax skin [20 WEEKS POST LAST TREATMENT]",null,null,"UNDECIDED",null],["NCT05136287","SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.","SEVERAL","COMPLETED","OBSERVATIONAL",null,null,null,"140","Weight Loss; Diabetes Mellitus, Type 2; Quality of Life; Safety Issues","DRUG:GLP-1 receptor agonist","Jose Seijas Amigo","2022-02-01","2023-11-15","FALSE","Weight loss [11 months]","BACKGROUND:23882037; BACKGROUND:8366922; BACKGROUND:9742976; BACKGROUND:20609967; BACKGROUND:19545590; BACKGROUND:26378978; BACKGROUND:27295427; BACKGROUND:31189511; BACKGROUND:29397376; BACKGROUND:28249135; BACKGROUND:33567185; BACKGROUND:36520578; DERIVED:42103575; DERIVED:41129847",null,"YES",null],["NCT06725693","Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease",null,"RECRUITING","OBSERVATIONAL",null,null,null,"500","GLP1-R-related Disease; Tumor; Insulinoma; Positron Emission Tomography","DIAGNOSTIC_TEST:18F/68Ga-Exendin 4","Tianjin Medical University","2019-02-01","2027-11-01","FALSE","Standardized uptake value (SUV) [30 days]","DERIVED:40259061",null,"NO",null],["NCT00856609","The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","150","Weight Loss; Obesity","DRUG:Byetta (exenatide); BEHAVIORAL:Weight loss; OTHER:Metabolic Chamber; DRUG:Placebo","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","2009-03-03","2016-09-19","TRUE","Energy Intake [Day 6-7-8 (at baseline) and Day 12-13-14 (3 days after starting study intervention)] | Twenty-four-hour Energy Expenditure [Day 5 and Day 11]","BACKGROUND:17379054; BACKGROUND:15504997; BACKGROUND:17622601; DERIVED:32002540; DERIVED:30651576; DERIVED:29596853",null,null,"OTHER:09-DK-N095"],["NCT00529204","Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease",null,"TERMINATED","INTERVENTIONAL","PHASE2",null,"NONE","1","Diabetes Complications; Fatty Liver","DRUG:exenatide","University of California, Davis","2007-10","2009-07","TRUE","Reduction in Serum ALT From Baseline to 24 Weeks of Exenatide Therapy [24 weeks]","BACKGROUND:17379054",null,null,"OTHER:H80-MC-X006"],["NCT01580514","Myocardial Protection of Exenatide in AMI","EMPIRE","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","127","Myocardial Infarction","DRUG:exenatide BYETTA® (Amylin-Lilly); DRUG:Saline","Kyunghee University Medical Center","2009-09","2011-08","FALSE","Infarct size [1 month]","BACKGROUND:19195607; DERIVED:28286967; DERIVED:23868944",null,null,null],["NCT07314684","GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM","STABLE-GLP1","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","80","T2DM (Type 2 Diabetes Mellitus)","DRUG:semaglutide; DRUG:Standard Treatment (Guideline-Based)","Federico II University","2025-09-08","2027-03-08","FALSE","To evaluate the effects of semaglutide in addition to standard therapy on inflammatory biomarkers compared with standard therapy alone in T2DM patients without ASCVD or severe TOD but with SCORE2-Diabetes ≥10%. [From enrollment to the end of treatment at 52 weeks] | To evaluate the effects of semaglutide in addition to standard therapy on biomarkers of endothelial dysfunction compared with standard therapy alone in T2DM patients without ASCVD or severe TOD but with SCORE2-Diabetes ≥10%. [From enrollment to the end of treatment at 52 weeks]","BACKGROUND:37622663",null,"NO","CTIS:2025-520802-37-00; NIH:2025"],["NCT07816744","Danish Trial of Weight Loss to Reduce Atrial Fibrillation Progression","DANWRAP","NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","480","Atrial Fibrillation (AF); Obesity & Overweight","OTHER:Structured weight loss program including behavioral support and optional meal re-placement or pharmacotherapy with Glucagon-like peptide-1 receptor agonists (GLP1-RA); OTHER:Standard Care (in control arm)","Axel Brandes","2026-10-01","2030-04","FALSE","Hierarchical composite outcome capturing AF progression and AF burden, inte-grating clinical events assessed by blinded adjudication and objective measures of AF burden, assessed by 14-day continuous ECG monitoring [From 4 months to 12 months after enrollment]",null,null,"NO",null],["NCT02802514","A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects",null,"TERMINATED","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","5","Diabetes Mellitus","DRUG:Albiglutide 50mg; DRUG:Albiglutide matching placebo; DRUG:Exenatide 10microgram; DRUG:Exenatide placebo (saline)","GlaxoSmithKline","2016-09-20","2017-08-10","TRUE","Blood Oxygen Level Dependent (BOLD) Signal by Functional Magnetic Resonance Imaging (fMRI) Visual Nauseogenic Task [Up to Week 11] | Regional Cerebral Blood Flow (rCBF) by Functional MRI (fMRI)-Arterial Spin Labeling (ASL) [Up to Week 11] | Glutamate Concentration in Nausea-associated Brain Regions by Magnetic Resonance Spectroscopy (MRS) [Up to Week 11] | Gama-aminobutyric Acid (GABA) Concentration in Nausea-associated Brain Regions by MRS [Up to Week 11]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/14/NCT02802514/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/14/NCT02802514/SAP_001.pdf","NO",null],["NCT02212067","A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","87","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2014-08-11","2015-05-11","FALSE","Area under the serum insulin concentration time curve from 0 to 10 minutes after a 25 g glucose bolus i.v. infusion (IVGTT,intravenous glucose tolerance test) over 2 minutes [Day -1, day 86] | Area under the serum insulin concentration time curve from 10-120 minutes after a 25 g glucose bolus i.v. infusion (IVGTT). [Day -1, day 86]","RESULT:28526920",null,null,"EUDRACT_NUMBER:2013-002173-22; OTHER:U1111-1143-1206"],["NCT06075667","A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","160","Obesity; Overweight","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2023-10-16","2026-06-02","FALSE","Percent Change from Baseline in Body Mass Index (BMI) [Baseline, Week 72]",null,null,"YES","OTHER:I8F-MC-GPHP; OTHER:2023-504413-80-00; NIH:2023"],["NCT06802081","TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation","TIRO-AF","RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","100","Atrial Fibrillation; Obesity","DRUG:Tirzepatide; DRUG:Placebo","The Cleveland Clinic","2025-04-08","2026-12-31","FALSE","AFib burden [Up to 4 weeks]",null,null,"NO",null],["NCT05295875","Efficacy and Safety of ALT-801 in the Treatment of Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","391","Obesity/Overweight","DRUG:ALT-801; OTHER:Placebo","Altimmune, Inc.","2022-03-31","2023-09-28","FALSE","Relative change from baseline in body weight percentage [Baseline to Week 48]",null,null,null,null],["NCT01140893","Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes","EXEPUMP","UNKNOWN","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","QUADRUPLE","110","Type 2 Diabetes","DRUG:Exenatide; DRUG:Placebo","University Hospital, Caen","2010-11","2017-05","FALSE","Change from baseline to 6 months of centrally measured HbA1c [baseline to 6 months]",null,null,null,null],["NCT07564414","A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","2500","Obesity; Type 2 Diabetes","DRUG:Cagrisema; DRUG:Semaglutide","Novo Nordisk A/S","2026-05-21","2028-02-23","FALSE","Relative change in body weight [From randomisation (week 0) to end of treatment (week 72)]",null,null,"YES","OTHER:U1111-1323-0372; OTHER:2025-522488-14; NIH:2025"],["NCT06727838","Study on Drug Interaction of Metformin Tablets and HRS-7535 Tablets in Healthy Human",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","18","Diabetes","DRUG:HRS-7535 tablets; DRUG:Metformin Hydrochloride Extended-release Tablets; DRUG:Metformin Hydrochloride Tablets","Shandong Suncadia Medicine Co., Ltd.","2024-12-31","2025-01-25","FALSE","Maximum plasma concentration (Cmax) [0 hour to 24 hours after the last dosing.] | Area under the plasma concentration-time curve from time zero to the time of last quantifiable analyte concentration (AUC0-t) [0 hour to 24 hours after the last dosing.] | Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-∞) [0 hour to 24 hours after the last dosing.]",null,null,"UNDECIDED",null],["NCT06855147","Mass Balance Study of [14C]HRS9531 in Healthy Male Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","7","Type 2 Diabetes Mellitus; Weight Loss","DRUG:[14C]HRS9531","Fujian Shengdi Pharmaceutical Co., Ltd.","2025-04-21","2025-06-17","FALSE","Maximum concentration (Cmax). [0 to anticipated 64 days.] | Time to reach the maximum concentration (Tmax). [0 to anticipated 64 days.] | Half-life (t1/2). [0 to anticipated 64 days.] | Total radioactive recovery rate in urine. [0 to anticipated 64 days.] | Total radioactive recovery rate in feces. [0 to anticipated 64 days.] | Cumulative radioactive recovery rate in urine. [0 to anticipated 64 days.] | Cumulative radioactive recovery rate in feces. [0 to anticipated 64 days.]",null,null,"UNDECIDED",null],["NCT04184947","Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists",null,"COMPLETED","OBSERVATIONAL",null,null,null,"10000","Type 2 Diabetes","DRUG:SGLT2 inhibitor; DRUG:GLP-1 receptor agonist","University of Padova","2014-03-01","2018-12-31","FALSE","3 point major adverse cardiovascular events (4P-MACE) [3-26 months after index date]","DERIVED:32591373",null,"NO",null],["NCT01572649","Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","24","Type 2 Diabetes Mellitus","DRUG:Lixisenatide (AVE0010); DRUG:Placebo","Sanofi","2012-05","2014-03","FALSE","GLU-AUC 0:30-4:30h: area under the plasma glucose concentration time profile from time of the standardized breakfast start (30 min after IMP injection and pre-meal plasma glucose) until 4 hours later subtracting the pre-meal value [D1 at each period up to 4h30 after study drug injection (8 timepoints)]",null,null,null,"EUDRACT_NUMBER:2011-004584-67; OTHER:U1111-1124-3136"],["NCT07011667","A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","609","Obesity","DRUG:CagriSema (Cagrilintide B and Semaglutide I); DRUG:Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)","Novo Nordisk A/S","2025-06-03","2027-03-01","FALSE","Relative change in body weight [From baseline (week 0) to week 80]",null,null,"YES","OTHER:U1111-1318-6372"],["NCT03954834","A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone","SURPASS-1","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","478","Type 2 Diabetes Mellitus","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2019-06-03","2020-10-05","TRUE","Change From Baseline in Hemoglobin A1c (HbA1c) [Baseline, Week 40]","DERIVED:39531161; DERIVED:37668888; DERIVED:37526908; DERIVED:35210595; DERIVED:34186022","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/34/NCT03954834/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/34/NCT03954834/SAP_001.pdf","YES","OTHER:I8F-MC-GPGK"],["NCT04777409","A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)","EVOKE Plus","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","1840","Early Alzheimer´s Disease","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2021-05-18","2025-09-15","FALSE","Change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score [From baseline (week 0) to week 104]","DERIVED:41865758; DERIVED:41522368; DERIVED:39780249; DERIVED:38901446",null,"YES","OTHER:U1111-1259-2920; OTHER:2023-506918-45; NIH:2023"],["NCT06721507","2024 Tirzepatide-Bariatric Surgery",null,"RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","50","Obesity and Obesity-related Medical Conditions; Bariatric Surgery","DRUG:tirzepatide; BEHAVIORAL:Standard of Care","Marlene Starr","2025-03-27","2026-12-31","FALSE","Change in inflammatory markers c reactive protein (CRP) [Baseline and 3 months post-drug] | Change in inflammatory markers interleukin 6 (IL-6) [Baseline and 3 months post-drug] | Change in inflammatory markers tumor necrosis factor (TNF) [Baseline and 3 months post-drug] | change in inflammatory markers (leptin) [Baseline and 3 months post-drug] | change in inflammatory markers (adiponectin) [Baseline and 3 months post-drug] | change in inflammatory markers renin-angiotensin-aldosterone system (RAAS) [Baseline and 3 months post-drug] | RNA sequencing [at time of surgery]","DERIVED:41643256",null,"NO",null],["NCT03948347","Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus","LAMP","UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","1708","Ischemic Stroke; Transient Ischemic Attack; Type 2 Diabetes Mellitus","DRUG:Liraglutide","First Affiliated Hospital of Jinan University","2019-06-25","2023-12","FALSE","Percentage of patients with the 90-day new stroke events (ischemic or hemorrhagic) [90 days]","DERIVED:42145088; DERIVED:41182740",null,null,null],["NCT01269008","Closed Loop System With Pramlintide Versus Exenatide","Closedloop","COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","13","Type 1 Diabetes","DEVICE:Medtronic ePID 2.0","Albert Einstein College of Medicine","2010-12","2013-01","FALSE","Better meal and post meal sugars on the closed loop device using the study medications. [18 months]",null,null,null,null],["NCT04255433","A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes","SURPASS-CVOT","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","13299","Type 2 Diabetes Mellitus","DRUG:Tirzepatide; DRUG:Dulaglutide","Eli Lilly and Company","2020-05-29","2025-06-12","TRUE","Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] [From randomization (week 0) up to week 259]","DERIVED:41903177; DERIVED:41406444; DERIVED:40746703; DERIVED:35949358","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/33/NCT04255433/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/33/NCT04255433/SAP_001.pdf","YES","OTHER:I8F-MC-GPGN; EUDRACT_NUMBER:2019-002735-28; CTIS:2023-507846-96-00; NIH:2023; NIH:2019"],["NCT02827708","Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment","PIONEER 5","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","324","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2016-09-20","2018-04-10","TRUE","Change in HbA1c [Week 0, week 26]","RESULT:31189517; DERIVED:39963952; DERIVED:36056351; DERIVED:33660198; DERIVED:32998732; DERIVED:32267058; DERIVED:31903692","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/08/NCT02827708/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/08/NCT02827708/SAP_001.pdf","YES","EUDRACT_NUMBER:2015-005326-19; OTHER:U1111-1176-9230; NIH:2015"],["NCT03287076","Trial of EXenatide in Acute Ischaemic Stroke","TEXAIS","UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","SINGLE","350","Acute Ischemic Stroke","DRUG:Exenatide Injection","Neuroscience Trials Australia","2017-11-23","2021-10-04","FALSE","improved neurological outcome [7 days]","DERIVED:38011235",null,"NO","EUDRACT_NUMBER:2018-004325-88; NIH:2018"],["NCT06065540","A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor","REIMAGINE 2","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","2734","Type 2 Diabetes Mellitus","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo cagrilintide; DRUG:Placebo semaglutide","Novo Nordisk A/S","2023-09-27","2025-11-19","FALSE","CagriSema (dose 1) versus semaglutide (dose 1): Change in glycated haemoglobin (HbA1c) [From baseline (week 0) to end of treatment (week 68)]","DERIVED:42251859",null,"YES","OTHER:U1111-1283-0427; EUDRACT_NUMBER:2022-502678-18"],["NCT06410352","Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome",null,"RECRUITING","INTERVENTIONAL","PHASE4","NON_RANDOMIZED","NONE","220","Metabolic Syndrome","DRUG:Semaglutide, Empagliflozin; PROCEDURE:Minigastric bypass; DIETARY_SUPPLEMENT:Analimentary detoxication; BEHAVIORAL:Ramadan fast's weight loss","University Medical Center, Kazakhstan","2024-03-01","2025-09-30","FALSE","Weight [Baseline, 24 weeks] | Body mass index [Baseline, 24 weeks] | Fat mass [Baseline, 24 weeks] | Fat free mass [Baseline, 24 weeks] | blood insulin level [Baseline, 24 weeks] | systolic/diastolic Blood presure [Baseline, 24 weeks] | Fasting blood glucose [Baseline, 24 weeks]",null,null,"NO",null],["NCT04146155","Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","200","Type 2 Diabetes; Peripheral Vascular Disorder Due to Diabetes Mellitus","DRUG:Liraglutide+standard-of-care treatment; OTHER:standard-of-care treatment","Second Affiliated Hospital, Zhejiang University, School of Medicine","2020-05-01","2021-12-31","FALSE","Initial and absolute claudication distance [24 weeks]","DERIVED:34693515",null,"NO",null],["NCT07740291","Tirzepatide Impact Assessment Study","TIA","RECRUITING","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","27","Obesity & Overweight; Cardiometabolic Health Indicators; Addiction; Eating Disorders; Mental Health","DRUG:GLP-1 Receptor Agonist Therapy; BEHAVIORAL:Structured Lifestyle Intervention","Texas Tech University","2025-01-02","2026-11-23","FALSE","Change in Fasting Blood Glucose [Baseline and 3 months] | Change in LDL Cholesterol [Baseline and 3 months] | Change in Triglycerides [Baseline and 3 months] | Change in Fasting Insulin [Baseline and 3 months] | Change in Blood Pressure [Baseline and 3 months] | Change in Disordered Eating [Baseline and 3 months] | Change in Food Addiction [Baseline and 3 months] | Change in Alcohol Use [Time Frame: Baseline and 3 months] | Change in Substance Use [Time Frame: Baseline and 3 months] | Change in Depressive Symptoms and Suicidal Ideation [Time Frame: Baseline and 3 months] | Change in Anxiety [Baseline and 3 months] | Change in Perceived Stress [Baseline and 3 months] | Change in Fatigue [Baseline and 3 months]",null,null,"NO",null],["NCT02129985","Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy","T2DMRS","UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","100","Type 2 Diabetes","DRUG:Exenatide; DRUG:Metformin","xiaolong zhao","2014-02","2015-06","FALSE","time to glycaemic remission [up to 1 year] | remission rate of type 2 diabetes at a year. [up to 1 year]",null,null,null,null],["NCT02207374","A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes","SUSTAIN™","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","601","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:DPP-4 inhibitor","Novo Nordisk A/S","2014-08-04","2016-02-27","TRUE","Number of Treatment Emergent Adverse Events (TEAEs) [Weeks 0-56]","RESULT:29322610; RESULT:29748996; RESULT:29907893; DERIVED:32998732",null,null,"OTHER:U1111-1140-3081; REGISTRY:JapicCTI-142640"],["NCT01051011","A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy",null,"TERMINATED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","370","Diabetes Mellitus Type 2","DRUG:insulin glargine; DRUG:metformin; DRUG:taspoglutide","Hoffmann-La Roche","2010-01","2010-12","FALSE","Glycemic control assessed by HbA1c [week 24]",null,null,null,null],["NCT02090673","Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea",null,"COMPLETED","OBSERVATIONAL",null,null,null,"1711","Diabetes Mellitus Type 2","DRUG:Exenatide","AstraZeneca","2009-02","2014-03","FALSE","The proportion of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) in patients who are treated with Exenatide for type 2 diabetes mellitus [At 12 weeks ± 4 weeks or 24 weeks ± 4 weeks]","DERIVED:29065865",null,null,null],["NCT07104383","VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","1100","Weight Loss","DRUG:VK2735","Viking Therapeutics, Inc.","2025-06-23","2027-07-01","FALSE","Percent change in body weight from baseline to Week 78 in body weight [78 Weeks]",null,null,null,null],["NCT07150975","Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","420","Obesity/Overweight in Adult","DRUG:GZR18; DRUG:Semaglutide(Wegovy® )","Gan & Lee Pharmaceuticals.","2025-09-23","2027-06-30","FALSE","Percentage change in body weight from baseline after 52 weeks (W) of treatment. [From Week 0 to Week 52]",null,null,null,null],["NCT05221229","Outcome of Overweight AF Patients Following Ablation With a Potential Weight Loss Medication ( GOAL-AF )","GOAL-AF","ACTIVE_NOT_RECRUITING","OBSERVATIONAL",null,null,null,"29","Atrial Fibrillation; Recurrence; Overweight and Obesity; Liraglutide","DRUG:Liraglutide plus upstream risk factors modification advice and consultation","University Hospital Birmingham","2022-04-17","2025-06-30","FALSE","Adherence to Liraglutide by AF patients before and after first-time ablation [Time Frame- 13 weeks before and 52 weeks after ablation] [13 weeks before and 52 weeks after ablation] | Number of participants recruited over recruitment period [Time Frame-39 weeks] [39 weeks] | Accelerated weight loss by Liraglutide on AF patients before first-time ablation and during one year follow-up [Time Frame- 13 weeks from recruitment and 52 weeks after ablation] [13 weeks from recruitment and 52 weeks after ablation]","DERIVED:38383462",null,"NO",null],["NCT01524705","FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)","FLAT-SUGAR","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","102","Type 2 Diabetes","DRUG:Insulin Glargine; DRUG:Metformin; DRUG:Prandial insulin; DRUG:Exenatide","University of Washington","2012-08","2014-07","TRUE","Coefficient of Variation at 26 Weeks Minus Coefficient of Variation at Baseline [At baseline, 6 months of intervention]","BACKGROUND:18539917; BACKGROUND:18539916; BACKGROUND:19092145; BACKGROUND:9892587; BACKGROUND:15939816; BACKGROUND:10880413; BACKGROUND:19179212; BACKGROUND:16243403; BACKGROUND:18818862; BACKGROUND:16609090; BACKGROUND:18299315; BACKGROUND:18198229; BACKGROUND:15197140; BACKGROUND:11916939; BACKGROUND:10773760; BACKGROUND:17276798; BACKGROUND:9224218; BACKGROUND:11466120; BACKGROUND:16871239; BACKGROUND:12711737; BACKGROUND:12765959; BACKGROUND:12716809; BACKGROUND:18972096; BACKGROUND:16731998; BACKGROUND:15897298; BACKGROUND:20154025; BACKGROUND:15326314; BACKGROUND:20378541; BACKGROUND:17332893; BACKGROUND:18765395; BACKGROUND:20847305; BACKGROUND:6403580; BACKGROUND:16473512; BACKGROUND:11865066; BACKGROUND:18779236; BACKGROUND:5469118; BACKGROUND:19469677; BACKGROUND:16386091; BACKGROUND:15857227; BACKGROUND:15251625; BACKGROUND:19764834; BACKGROUND:19429875; BACKGROUND:20530784; BACKGROUND:21525493; RESULT:27208320; DERIVED:26068865",null,"YES",null],["NCT03072407","MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","SINGLE","40","Type2 Diabetes Mellitus","BIOLOGICAL:PB-119 injection; BIOLOGICAL:PB-119 injection placebo","PegBio Co., Ltd.","2015-11-24","2016-11-02","FALSE","the number of AEs and the finding from the physical examination, the abnormal lab results [accessed up to 4 weeks]",null,null,"NO",null],["NCT05616013","Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","507","Obesity; Obese; Overweight or Obesity","BIOLOGICAL:Bimagrumab; DRUG:Semaglutide; OTHER:Placebo","Eli Lilly and Company","2022-11-16","2024-05-16","TRUE","Change From Baseline in Body Weight at Week 48 [Baseline, Week 48]","DERIVED:41772149; DERIVED:40230053","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/13/NCT05616013/Prot_002.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/13/NCT05616013/SAP_003.pdf","YES","OTHER:J4Z-MC-GIDA; OTHER:VER201-PH2-031"],["NCT01288326","Observational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes","ROOTS","COMPLETED","OBSERVATIONAL",null,null,null,"254","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2011-02","2013-03","FALSE","Percentage of participants with a decrease in HbA1c (glycosylated haemoglobin A1c) of at least 1% [month 12] | Percentage of participants reaching the treatment target of a HbA1c (glycosylated haemoglobin A1c) decrease of at least 1% [month 12]","RESULT:26004030",null,null,"OTHER:U1111-1116-2199"],["NCT01595789","The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 Diabetes","AddHope2","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","41","Coronary Artery Disease; Diabetes Mellitus, Type 2","DRUG:Liraglutide; DRUG:Placebo","Haugaard, Steen Bendix, M.D., DMSc","2012-05","2014-10","FALSE","Beta-cell function [after 12 weeks of intervention] | LVEF [after 12 weeks of intervention]","DERIVED:33413428; DERIVED:31164926; DERIVED:28129251; DERIVED:27797930; DERIVED:27455835; DERIVED:25031198",null,null,"EUDRACT_NUMBER:2011-005405-78"],["NCT03496298","Effect of Efpeglenatide on Cardiovascular Outcomes","AMPLITUDE-O","TERMINATED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","4076","Type 2 Diabetes Mellitus","DRUG:Efpeglenatide (SAR439977); DRUG:Placebo","Sanofi","2018-04-27","2020-12-10","TRUE","Time to First Occurrence of Major Adverse Cardiovascular Events (MACE): Event Rate Per 100 Participant-years for First Occurrence of Major Cardiovascular (CV) Event - Non-Inferiority Analysis [From Day 1 until the date of first adjudicated and confirmed occurrence of major CV event (maximum duration: up to 31.5 months)]","RESULT:34215025; DERIVED:39963952; DERIVED:36802715; DERIVED:34775781; DERIVED:33026143","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/98/NCT03496298/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/98/NCT03496298/SAP_001.pdf","NO","EUDRACT_NUMBER:2017-002954-35; OTHER:U1111-1186-2533; NIH:2017"],["NCT06894784","A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes","SEMPA","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","36","Diabetes Type 1","DRUG:Intervention Period 1: Semaglutide + Empagliflozin; DRUG:Intervention Period 2: Semaglutide + Empagliflozin Placebo; DRUG:Intervention Period 3: Semaglutide Placebo + Empagliflozin; DRUG:Intervention Period 4: Semaglutide Placebo + Empagliflozin Placebo","McGill University Health Centre/Research Institute of the McGill University Health Centre","2025-04","2027-01","FALSE","Time-in-Range [At days 7, 35, 63 of the titration period and days 3 and 7 of each intervention.]","BACKGROUND:35551290; BACKGROUND:31177185; BACKGROUND:27118163; BACKGROUND:30833170; BACKGROUND:25220191; BACKGROUND:24947583; BACKGROUND:20616619; BACKGROUND:25388240; BACKGROUND:31696598; BACKGROUND:27493132; BACKGROUND:27506222; BACKGROUND:32135138; BACKGROUND:29246950; BACKGROUND:29397376; BACKGROUND:31539622; BACKGROUND:31189511; BACKGROUND:28854085; BACKGROUND:31159279; BACKGROUND:27633186; BACKGROUND:27295427; BACKGROUND:19925391; BACKGROUND:9285204; BACKGROUND:34989070; BACKGROUND:21707956; BACKGROUND:31767182; BACKGROUND:9780839; BACKGROUND:10233049; BACKGROUND:36331522; BACKGROUND:33528904; BACKGROUND:30287422; BACKGROUND:36942888; BACKGROUND:30459245; BACKGROUND:31334145",null,"YES","NIH:2025"],["NCT03799198","Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","200","Obesity","OTHER:Weight Management Program (WMP); DRUG:Medication for chronic weight management (Rx)","Novo Nordisk A/S","2019-01-07","2020-05-22","TRUE","Change in Body Weight [Month 0, month 12]","DERIVED:38573466; DERIVED:34255049","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/98/NCT03799198/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/98/NCT03799198/SAP_001.pdf","YES","OTHER:U1111-1218-8104"],["NCT02055014","Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","72","Type 2 Diabetes; Obesity; Diabesity","DRUG:Liraglutide; DEVICE:Duodenal-jejunal bypass liner - Endobarrier device","Sandwell & West Birmingham Hospitals NHS Trust","2013-07","2017-03","FALSE","Glycated haemoglobin (HbA1c) [24 months]",null,null,null,"REGISTRY:ISRCTN00151053; EUDRACT_NUMBER:2012-004988-42"],["NCT06487832","Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness",null,"RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","60","Normal Weight; Overweight and Obesity; Insulin Sensitivity; Insulin Resistance","OTHER:Subcutaneous GLP1-RA; OTHER:Subcutaneous placebo","University Hospital Tuebingen","2024-07-01","2027-07-31","FALSE","Cerebral response after insulin compared to placebo nasal spray [24 hours after semaglutide or placebo administration]",null,null,"NO",null],["NCT03538743","4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","98","Type 2 Diabetes Mellitus","DRUG:Placebo; DRUG:PF-06882961","Pfizer","2018-06-25","2019-05-23","TRUE","Number of Participants With All-causality and Treatment-related Treatment-emergent Adverse Events (TEAEs) [From baseline to up to 35 days after last dose for a total of approximately 63 days] | Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality [From baseline to up to 14 days after last dose for a total of approximately 42 days] | Number of Participants With Abnormal Vital Signs [From baseline to up to 14 days after last dose for a total of approximately 42 days] | Number of Participants With Abnormal Electrocardiogram (ECG) Interval [From baseline to up to 14 days after last dose for a total of approximately 42 days]","DERIVED:34127852","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/43/NCT03538743/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/43/NCT03538743/SAP_001.pdf","NO",null],["NCT07769047","Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase Inhibitors",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","50","Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8","PROCEDURE:Biospecimen Collection; PROCEDURE:Dual X-ray Absorptiometry; OTHER:Functional Assessment; BEHAVIORAL:Lifestyle Counseling; DRUG:Semaglutide","Mayo Clinic","2026-09-01","2031-07-30","FALSE","Change in PWV between arms (Aim 1) [Baseline to 24 weeks] | Change in protein expression between arms (Aim 2a) [Baseline to 24 weeks] | Significantly enriched biological pathways and gene sets among DEPs (Aim 2b) [Up to 24 weeks]",null,null,null,"NIH:K23HL183845; OTHER:NCI-2026-04536"],["NCT01136798","Impact of Exenatide on Sleep in Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","QUADRUPLE","18","Type 2 Diabetes; Sleep Disordered Breathing","DRUG:Exenatide; DRUG:Placebo","University of Chicago","2010-06-01","2016-09-01","TRUE","Non-REM Slow Wave Sleep [baseline and after 6 weeks of treatment] | Total Amount of Slow Wave Activity [baseline and after 6 weeks of treatment]",null,null,"NO",null],["NCT06762314","Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","114","Diabetes","DRUG:Insulin; DRUG:Semaglutide; DRUG:Empagliflozin","Mostafa Bahaa","2025-01-20","2026-01-20","FALSE","The primary outcome of this trial is the change in glycated haemoglobin from baseline after 3 months of treatment. [3 months]",null,null,null,null],["NCT01416649","Impact of Exenatide on Sleep Duration",null,"COMPLETED","OBSERVATIONAL",null,null,null,"8","Type 2 Diabetes","DRUG:Exenatide","University of Chicago","2011-02-01","2021-04-21","FALSE","Sleep duration and sleep efficiency [at the end of 3 months of treatment with the medication]",null,null,null,null],["NCT06814938","A Study of a Novel Precision Medicine Approach For Obesity",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","135","Obesity","DRUG:Semaglutide; DRUG:Placebo","Mayo Clinic","2025-02-21","2027-12","FALSE","Change in Total Body Weight at 24 weeks [Baseline, 24 weeks]",null,"Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/38/NCT06814938/ICF_000.pdf","NO","NIH:1R44DK138619"],["NCT02635386","EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","SINGLE","119","Polycystic Ovary Syndrome; Obesity","DRUG:Exenatide once weekly (EQW ); DRUG:Dapagliflozin (DAPA); DRUG:EQW plus DAPA; DRUG:Dapagliflozin plus Glucophage (MET ER); DRUG:Phentermine /Topiramate (PHEN/ TPM) ER","Woman's","2016-03-22","2020-07-22","TRUE","Oral Disposition (Insulin Sensitivity-insulin Secretion) Index [24 weeks of treatment]","DERIVED:34097062","Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/86/NCT02635386/ICF_000.pdf; Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/86/NCT02635386/Prot_SAP_002.pdf","NO","OTHER_GRANT:AZ ESR-14-10725"],["NCT05891496","A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","23","Alzheimers Disease","DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2023-06-20","2024-08-19","TRUE","Change in Gene Expression Assessed by Single-cell Ribonucleic Acid Sequencing (scRNAseq) (Cells in Cerebrospinal Fluid [CSF]) [Baseline (week 0), week 12] | Change in Gene Expression Assessed by scRNAseq (Cells in Blood) [Baseline (week 0), week 12]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/96/NCT05891496/Prot_002.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/96/NCT05891496/SAP_003.pdf","YES","OTHER:U1111-1283-8743; EUDRACT_NUMBER:2022-003384-24; OTHER:2023-506825-13; NIH:2023"],["NCT03352869","Research of Exenatide for Overweight/Obese PCOS Patients With IGR",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","183","Polycystic Ovary Syndrome; Overweight and Obesity; Disorder of Glucose Regulation","DRUG:Exenatide; DRUG:Metformin","RenJi Hospital","2017-11-28","2018-07-01","FALSE","Improvement of intravenous blood glucose from impaired glucose regulation to normal glucose regulation [up to 12 weeks]","BACKGROUND:25880805; BACKGROUND:18460557; BACKGROUND:24256515; BACKGROUND:25330463; BACKGROUND:24362411; BACKGROUND:25726702; RESULT:28143456; DERIVED:32995892",null,"UNDECIDED",null],["NCT05119179","Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes",null,"RECRUITING","INTERVENTIONAL","PHASE4",null,"NONE","300","PreDiabetes","DRUG:Semaglutide","The University of Texas Health Science Center, Houston","2021-11-22","2026-10-31","FALSE","Mean change in beta cell responsivity [12 weeks] | Insulin Sensitivity [12 weeks] | Disposition Index [12 weeks] | GLP-1-Induced Potentiation [12 weeks] | Mean change in GLP-1 Area Under the Curve (AUC) [12 weeks] | Gene expression changes for minor variants of eQTLs for TCF7L2 [12 weeks] | Gene expression changes for minor variants of eQTLs for KCNQ1 [12 weeks] | Gene expression changes for minor variants of eQTLs for WFS1 [12 weeks] | Gene expression changes for minor variants of eQTLs for THADA [12 weeks] | Gene expression changes for minor variants of eQTLs for CNR1 [12 weeks] | Gene expression changes for minor variants of eQTLs for CTRB1 [12 weeks] | Gene expression changes for minor variants of eQTLs for CTRB2 [12 weeks] | Gene expression changes for minor variants of eQTLs for GLP1R [12 weeks] | Gene expression changes for minor variants of eQTLs for CHST3 [12 weeks] | Gene expression changes for minor variants of eQTLs for MTNR1B [12 weeks] | Gene expression changes for minor variants of eQTLs for SORCS1 [12 weeks] | Previously unidentified cis-eQTLs associated with change in gene expression due to GLP-1 challenge [12 weeks]",null,null,"NO","NIH:5R01DK127084"],["NCT07313761","A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","349","Overweight and Obesity","DRUG:Maridebart Cafraglutide","Amgen","2025-12-15","2026-07-02","FALSE","Area Under the Plasma Concentration-time Curve (AUC) From Time 0 to Infinity (AUCinf) of AMG 133 [Up to Day 120] | AUC From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of AMG 133 [Up to Day 120] | Maximum Observed Plasma Concentration (Cmax) of AMG 133 [Up to Day 120]",null,null,"YES",null],["NCT05869903","A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities","ATTAIN-1","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","3127","Obesity; Overweight; Overweight or Obesity","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2023-06-05","2025-07-25","TRUE","Percent Change From Baseline in Body Weight (Primary Treatment Period) [Baseline, Week 72]","DERIVED:42750540; DERIVED:42577069; DERIVED:40960239","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/03/NCT05869903/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/03/NCT05869903/SAP_001.pdf","YES","OTHER:J2A-MC-GZGP; OTHER:2022-502839-19-00; OTHER:U1111-1289-8877"],["NCT07056803","Oral vs. Subcutaneous Semaglutide in Type 2 Diabetes Mellitus",null,"COMPLETED","OBSERVATIONAL",null,null,null,"212","Diabetes Mellitus Type 2","DRUG:Oral semaglutide; DRUG:subcutaneous semaglutide","University of Palermo","2024-01-01","2024-06-25","FALSE","Number of participants with HbA1c change [From enrollment to 12 months]",null,null,"YES",null],["NCT05622123","BetaFIT Study: Beta Cell Imaging After Faecal mIcrobiota Transplantation","BetaFIT","UNKNOWN","INTERVENTIONAL","PHASE2",null,"NONE","20","Type 1 Diabetes","DRUG:68Ga-NODAGA-Exendin-4","Radboud University Medical Center","2023-02-23","2024-02-28","FALSE","Correlation between residual beta cell mass and function [1 year]",null,null,null,null],["NCT05227196","A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","546","Healthy Volunteers; Type 2 Diabetes","DRUG:Semaglutide D Dose 1; DRUG:Semaglutide D Dose 2; DRUG:Semaglutide D Dose 3; DRUG:Semaglutide Dose 4; DRUG:Semaglutide Dose 5; DRUG:Semaglutide Dose 6","Novo Nordisk A/S","2022-02-04","2023-06-28","FALSE","AUC0-24h,semaglutide,SS Area under the semaglutide plasma concentration-time curve during a dosing interval at steady state (SS) [24 hours after the dosing of oral semaglutide on days 35/42/49, 70/77/84, 105/112/119 and 140/147/154.] | Cmax,0-24h.semaglutide,SS Maximum semaglutide plasma concentration at steady state [24 hours after the dosing of oral semaglutide on days 35/42/49, 70/77/84, 105/112/119 and 140/147/154.]","DERIVED:39708086",null,"YES",null],["NCT06903923","Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy",null,"RECRUITING","INTERVENTIONAL","PHASE2","NON_RANDOMIZED","NONE","120","Obesity in Children; Bone Strength; GLP - 1; Lifestyle Modification; Bone Density; Obesity","DRUG:GLP-1 receptor agonist; BEHAVIORAL:Lifestyle intervention","University of Virginia","2025-07-31","2030-02-28","FALSE","24-month change in total vBMD at the distal radius [24 months]",null,null,"YES","NIH:R01HD118635"],["NCT04775082","SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","78","Obesity","DRUG:Liraglutide; DRUG:Placebo","Novo Nordisk A/S","2021-03-04","2023-08-01","FALSE","Relative change in BMI (Body mass index) [From baseline (week 0) to week 56]","RESULT:39258838",null,"YES","OTHER:U1111-1247-8226; REGISTRY:2020-000546-34"],["NCT00964262","A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","34","Type 2 Diabetes Mellitus","DRUG:SR Exenatide (PT302); DRUG:Placebo","Peptron, Inc.","2009-08","2010-10","FALSE","To evaluate the safety and pharmacokinetics of SR exenatide (PT302) in healthy subjects after a single subcutaneous injection [8 weeks]","DERIVED:24373998",null,null,null],["NCT07574723","Tirzepatide Titration to Reduce Side Effects in Individuals With Obesity","TiTRE","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","68","Obesity","DRUG:Tirzepatide (Per-label titration); DRUG:Tirzepatide (Flexible titration)","Dasman Diabetes Institute","2026-05-15","2029-05-15","FALSE","Vomiting episodes per patient assessed using the Modified Index of Nausea, Vomiting, and Retching (M-INVR) [From enrollment (at baseline) to the end of treatment at 76 weeks.]",null,null,"NO",null],["NCT04994288","A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients(SUPER-1)",null,"COMPLETED","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","DOUBLE","547","Type2 Diabetes","BIOLOGICAL:Supaglutide injection; OTHER:placebo injection","Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","2021-08-03","2023-06-20","FALSE","HbA1c [12 weeks for phase IIb; 24weeks and 52 weeks for phase III]","DERIVED:41272211; DERIVED:41107649; DERIVED:39961992",null,"NO",null],["NCT04799327","The Effect of SHR20004（Noiiglutide ） on Body Weight in Obese Subjects Without Diabetes",null,"UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","254","Obesity","DRUG:SHR20004; DRUG:placebo","Jiangsu HengRui Medicine Co., Ltd.","2021-03-29","2022-05-15","FALSE","Change from baseline in body weight [Week 0, Week 24]",null,null,null,null],["NCT03548987","Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity","STEP 4","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","902","Metabolism and Nutrition Disorder; Obesity","DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2018-06-04","2020-02-22","TRUE","Change From Randomisation to Week 68 in Body Weight (%) [Randomisation (week 20) to week 68]","BACKGROUND:32441473; RESULT:33755728; DERIVED:38698650; DERIVED:37605636; DERIVED:36200477; DERIVED:35724304; DERIVED:30122305","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/87/NCT03548987/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/87/NCT03548987/SAP_001.pdf","YES","OTHER:U1111-1201-0898; REGISTRY:2017-003473-34; NIH:2017"],["NCT06217887","Efficacy Comparison of Polyethylene Glycol Loxenatide and Gliclazide on the Brain Function in T2DM Patients",null,"UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","NONE","58","Type 2 Diabetes Mellitus; Cognitive Function Abnormal","DRUG:loxenatide Group; DRUG:Gliclazide Group","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","2020-05-10","2024-02","FALSE","Change of olfactory brain activation by fMRI [from baseline to 4-month follow-up]","BACKGROUND:31221697; BACKGROUND:35263425",null,null,null],["NCT05478252","A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","388","Diabetes Mellitus, Type 2","DRUG:Semaglutide J; DRUG:Semaglutide B","Novo Nordisk A/S","2022-08-03","2023-08-09","TRUE","Change in Glycosylated Haemoglobin (HbA1c) [From baseline (week 0) to end of treatment (week 28)]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/52/NCT05478252/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/52/NCT05478252/SAP_001.pdf","YES","OTHER:U1111-1266-2391; EUDRACT_NUMBER:2021-001501-69"],["NCT01590433","Weight Loss With Exenatide Treatment",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","249","Obesity","DRUG:Exenatide; DRUG:Placebo; BEHAVIORAL:Dietary counseling","Jody Dushay","2012-03","2019-01","TRUE","Change in Body Weight [12 weeks]","DERIVED:34867786","Study Protocol, Statistical Analysis Plan, and Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/33/NCT01590433/Prot_SAP_ICF_000.pdf","NO",null],["NCT02648204","Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.","SUSTAIN 7","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","1201","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:Dulaglutide","Novo Nordisk A/S","2016-01-06","2017-04-10","TRUE","Change in HbA1c [Week 0, week 40]","BACKGROUND:30865526; BACKGROUND:30927241; BACKGROUND:31168765; RESULT:29397376; RESULT:29246950; RESULT:29764222; RESULT:29557057; RESULT:30615985; RESULT:30362224; DERIVED:38777128; DERIVED:33199417; DERIVED:31769496; DERIVED:31215727","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/04/NCT02648204/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/04/NCT02648204/SAP_001.pdf",null,"EUDRACT_NUMBER:2014-005375-91; OTHER:U1111-1164-8495; NIH:2014"],["NCT00866658","GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)","GETGOAL-L-ASIA","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","311","Diabetes Mellitus, Type 2","DRUG:Lixisenatide (AVE0010); DRUG:Placebo; DEVICE:Pen auto-injector; DRUG:Sulfonylurea; DRUG:Basal Insulin","Sanofi","2009-03","2010-06","TRUE","Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 [Baseline, Week 24]","RESULT:22564709; DERIVED:31956422; DERIVED:26039935",null,null,null],["NCT02064348","A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","168","Diabetes; Healthy","DRUG:semaglutide; DRUG:placebo; DRUG:moxifloxacin","Novo Nordisk A/S","2014-02-26","2015-04-23","FALSE","QTcI, (Individual heart rate corrected QT (Interval in the ECG: from the start of the QRS complex to the end) interval) based on ECG recordings obtained at 11 time points [0-48 hours after the fourth dose of semaglutide/semaglutide placebo at the 1.5 mg dose level]","RESULT:29799100",null,null,"EUDRACT_NUMBER:2012-005073-31; OTHER:U1111-1136-6455"],["NCT05294458","A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","10","Non-alcoholic Steatohepatitis; Type 2 Diabetes Mellitus (T2DM); Chronic Kidney Disease","DRUG:cotadutide solution for injection","AstraZeneca","2022-03-28","2022-09-12","FALSE","Absolute bioavailability of the high and the low concentration cotadutide SC formulations [Collection of plasma samples from pre-dose to 72 hours post-dose.] | Maximum observed concentration (cmax) [Collection of plasma samples from pre-dose to 72 hours post-dose.] | Relative bioavailability of a high concentration cotadutide SC formulation in comparison to low concentration formulation, in the fasted state [Collection of plasma samples from pre-dose to 72 hours post-dose.]",null,null,"YES","EUDRACT_NUMBER:2021-005442-15"],["NCT01818648","Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome",null,"WITHDRAWN","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","0","Short Bowel Syndrome","DRUG:Exenatide; DRUG:Placebo","Mayo Clinic","2013-03","2014-01","FALSE","Change in 24hr Gastrointestinal and Colonic Transit before and after Exenatide vs placebo [In both arms participants will undergo GI transit measurements on 2 seperate occasions for a total of 24 hours, with a wash out period of 48 hours in between transit studies.]",null,null,null,null],["NCT03182426","Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)",null,"COMPLETED","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","NONE","22","Diabetes Mellitus, Type 1","DRUG:Plerixafor; DRUG:Alemtuzumab; DRUG:Anakinra; DRUG:Etanercept; DRUG:Liraglutide","University of Alberta","2017-08-15","2024-07-15","FALSE","Change of 2-hour mixed meal stimulated C-peptide AUC [Baseline, Month 3, 6, 9, 12, 18 and 24] | Rate of Serious Adverse Event/Medical Event of Special Interest [Within 24 months]",null,null,"UNDECIDED",null],["NCT03361098","DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2","DECREASE","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","65","Type 2 Diabetes Mellitus; Obesity","DRUG:Dapagliflozin 10mg; DRUG:Exenatide; OTHER:placebo exenatide; OTHER:placebo dapagliflozin","Amsterdam UMC, location VUmc","2017-09-18","2019-11-25","FALSE","Differences in neuronal activity in the central reward and satiety circuits in response to food-related stimuli by BOLD fMRI signal [at baseline, after 10 days and after 16 weeks]","BACKGROUND:26815786; BACKGROUND:26769912; BACKGROUND:26672638; BACKGROUND:26385462; BACKGROUND:26331843; BACKGROUND:26094857; BACKGROUND:25071023; BACKGROUND:24323912; BACKGROUND:22402735; BACKGROUND:26180105; BACKGROUND:24463454; BACKGROUND:28345814; BACKGROUND:27651331; BACKGROUND:20423700; BACKGROUND:17566768; BACKGROUND:26403227; BACKGROUND:25943756; BACKGROUND:28869249; BACKGROUND:22332246; DERIVED:35484607; DERIVED:35134184",null,"YES",null],["NCT06387199","Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide","SEMA SMA","RECRUITING","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","QUADRUPLE","26","Type 1 Diabetes; Diabetes Mellitus","DRUG:Semaglutide with 4 meal strategies; DRUG:Placebo with 4 meal strategies","McGill University Health Centre/Research Institute of the McGill University Health Centre","2024-12-01","2027-01","FALSE","Percentage of daytime plasma glucose levels spent in target range (semaglutide vs. placebo) [24 weeks]",null,null,"YES",null],["NCT03141632","Effects of Glucagon Like Peptide 1 (GLP-1) Analogues on Fluid Intake","GATE","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","17","Thirst; Water-Electrolyte Imbalance","DRUG:Dulaglutide; OTHER:Placebo","University Hospital, Basel, Switzerland","2016-10-17","2017-05","FALSE","Fluid intake [8 hours]","DERIVED:35134170",null,"NO",null],["NCT05533632","Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE4",null,"NONE","104","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2022-04-25","2024-01-18","TRUE","Number of Adverse Events (AEs) [From baseline (Day 1) up to 24 weeks]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/32/NCT05533632/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/32/NCT05533632/SAP_001.pdf","YES","OTHER:U1111-1281-5677"],["NCT06621316","A Study of Safety and Tolerability of Multiple Doses of HRS-7535 in Obese Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","QUADRUPLE","74","Overweight or Obesity","DRUG:HRS-7535 Tablet; DRUG:Placebo","Shandong Suncadia Medicine Co., Ltd.","2024-10-30","2025-07-14","FALSE","Number of Adverse Events [24 weeks]",null,null,"UNDECIDED",null],["NCT01899430","Polycystic Ovary Syndrome and Liraglutide",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","32","PCOS; Obesity","DRUG:liraglutide; DRUG:metformin","University Medical Centre Ljubljana","2011-11","2012-10","FALSE","The main outcome was change in body weight. [Patient's body weight was mesured at the base point and every four weeks during 12 weeks of clinical trial.]",null,null,null,null],["NCT06863363","PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese Adults",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","212","Non-diabetic Obesity","DRUG:PEG-rhGH Injection + Semaglutide Injection; DRUG:Semaglutide Injection","Shanghai Zhongshan Hospital",null,null,"FALSE","The change in lean body weight (kg) from baseline [Week 40]",null,null,"UNDECIDED",null],["NCT06704763","A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","27","Healthy","DRUG:Orforglipron; DRUG:Midazolam; DRUG:Quinidine","Eli Lilly and Company","2024-12-06","2025-02-05","TRUE","Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Orforglipron [Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 96 hours post orforglipron dose on days 1, 8] | PK: Maximum Observed Concentration (Cmax) of Orforglipron [Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 96 hours post orforglipron dose on days 1, 8]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/63/NCT06704763/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/63/NCT06704763/SAP_001.pdf","NO","OTHER:J2A-MC-GZPP"],["NCT02832999","Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes","LIRAVIS","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","14","Type 2 Diabetes Mellitus","DRUG:sub cutaneous liraglutide; DRUG:Oral Vildagliptin","Yaounde Central Hospital","2016-01","2016-09","FALSE","Insulin sentivity [2 weeks]",null,null,null,null],["NCT01511393","An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)",null,"ENROLLING_BY_INVITATION","OBSERVATIONAL",null,null,null,"6750","Diabetes; Diabetes Mellitus, Type 2; Medullary Thyroid Carcinoma; Weight Management","OTHER:No treatment given","Novo Nordisk A/S","2012-01","2039-12","FALSE","Annual incidence of MTC in the US to identify any possible increase related to the introduction of liraglutide, exenatide once-weekly, and other GLP-1 receptor agonists into the US market. [Up to 15 years]","DERIVED:33179845",null,"UNDECIDED","OTHER:U1111-1125-4362"],["NCT03456687","Effects of Exenatide on Motor Function and the Brain",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","5","Parkinson's Disease","DRUG:Exenatide","University of Florida","2018-06-05","2020-10-16","FALSE","Change in free-water accumulation in the substantia nigra [Baseline and one-year] | Change in blood oxygen level-dependent(BOLD) signal in the posterior putamen. [Baseline and one-year] | Change in blood oxygen level-dependent(BOLD) signal in M1. [Baseline and one-year] | Change in blood oxygen level-dependent(BOLD) signal in the supplementary motor area(SMA). [Baseline and one-year]",null,null,"NO","NIH:R01NS052318; OTHER:OCR17539"],["NCT07523711","Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","49","Overweight; Obesity","DRUG:COC; DRUG:Maridebart Cafraglutide","Amgen","2026-04-09","2026-11-18","FALSE","Maximum Observed Concentration (Cmax) of COC [Day 1 up to Day 89] | Area Under the Concentration-time Curve (AUC) from Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of COC [Day 1 up to Day 89] | AUC from Time Zero Extrapolated to Infinity (AUCinf) of COC [Day 1 up to Day 89]",null,null,"YES",null],["NCT07859163","Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","100","Morbid Obesity","DRUG:Semaglutide weekly injection; DRUG:Placebo","General Committee of Teaching Hospitals and Institutes, Egypt","2026-10","2029-04","FALSE","Percentage total weight loss [Baseline till 30 months]",null,null,"YES",null],["NCT04172987","A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","40","Healthy","DRUG:Tirzepatide; DRUG:EE/NGM","Eli Lilly and Company","2020-02-26","2021-02-09","TRUE","Period 1 and Period 2, Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) Within 1 Dosing Interval (AUC[0-tau]) of Ethinylestradiol (EE) [Period 1 and Period 2: Predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48 hours postdose] | Period 1 and Period 2, PK: Maximum Concentration (Cmax) of EE [Predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48 hours postdose] | Period 1 and Period 2, PK: Area Under the Concentration Versus Time Curve (AUC) Within 1 Dosing Interval (AUC[0-tau]) of Norelgestromin (NGMN) [Predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48 hours postdose] | Period 1 and Period 2, PK: Cmax of Norelgestromin (NGMN) [Predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48 hours postdose]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/87/NCT04172987/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/87/NCT04172987/SAP_001.pdf","NO","OTHER:I8F-MC-GPGR"],["NCT07169136","Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)",null,"RECRUITING","OBSERVATIONAL",null,null,null,"20","Polycystic Ovarian Syndrome in Adolescent Females; Obesity (Disorder)","DRUG:GLP-1 Receptor Agonists","Nemours Children's Clinic","2025-09-11","2026-12","FALSE","Change in LH pulse frequency after 4 months of GLP-1 agonist use. [Blood sampling will occur at study enrollment and then 4 months post intervention.] | Change in average levels of LH and FSH after 4 months of GLP-1 agonist use. [Blood sampling will occur at study enrollment and then 4 months post intervention.] | Change in average levels of Total testosterone and Estradiol after 4 months of GLP-1 agonist use. [Blood sampling will occur at study enrollment and then 4 months post intervention.] | Change in average levels of progesterone after 4 months of GLP-1 agonist use. [Blood sampling will occur at study enrollment and then 4 months post intervention.] | Change in LH amplitude. [Blood sampling will occur at study enrollment and then 4 months post intervention.]","BACKGROUND:32676541; BACKGROUND:3899825; BACKGROUND:35718216; BACKGROUND:18957503",null,"YES",null],["NCT03225209","Medically Reproducing Bariatric Surgery","MRB","COMPLETED","INTERVENTIONAL","PHASE2",null,"NONE","5","Type 2 Diabetes Mellitus","OTHER:OPTIFAST","Moahad S Dar","2018-01-31","2018-10-23","FALSE","Change in Glycemic control [Change in HbA1c from baseline at week 12 and week 24 will be measured]","BACKGROUND:12900694; BACKGROUND:22419108; BACKGROUND:15172919; BACKGROUND:23610060; BACKGROUND:3360564; BACKGROUND:22449317",null,"NO",null],["NCT02535299","Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 or Metformin Treatment","Par-4；GLP-1","UNKNOWN","INTERVENTIONAL","PHASE4",null,"NONE","200","GLP-1；Metformin；Telomere-telomerase System；Par-4","DRUG:Liraglutide; DRUG:Metformin","Third Military Medical University","2016-06","2018-12","FALSE","physiological parameter:glycosylated hemoglobin A1c [up to 6 months;]",null,null,"UNDECIDED",null],["NCT05468632","A Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE)","MIRAGE","COMPLETED","OBSERVATIONAL",null,null,null,"314","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2022-07-05","2022-07-31","FALSE","Change in glycated haemoglobin (HbA1c) [From baseline (week 0) to end of follow-up (week 30+- 4 weeks)]",null,null,"YES","OTHER:U1111-1273-4429"],["NCT07294898","A Study to Investigate the Effect of a Low-fat Meal and Evening Dosing on KAI-7535 in Participants Living With Obesity or Overweight",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","18","Obesity; Overweight","DRUG:KAI-7535","Kailera","2025-12-15","2026-01-26","FALSE","Time to Maximum Observed Concentration (Tmax) of KAI-7535 [Pre-dose and up to 60 hours post-dose] | Maximum Observed Concentration (Cmax) of KAI-7535 [Pre-dose and up to 60 hours post-dose] | Area Under the Concentration-time Curve From 0 to Time of Last Quantifiable Concentration (AUC0-t) of KAI-7535 [Pre-dose and up to 60 hours post-dose] | Area Under the Concentration-time Curve From 0 to Infinity (AUC0-inf) of KAI-7535 [Pre-dose and up to 60 hours post-dose]",null,null,"NO",null],["NCT07357740","A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes",null,"WITHDRAWN","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","0","Diabetes Mellitus, Type 2","DRUG:CagriSema; DRUG:Placebo CagriSema","Novo Nordisk A/S","2026-08-27","2027-08-25","FALSE","Change in glycated haemoglobin (HbA1c) [Baseline to week 28]",null,null,"YES","OTHER:U1111-1323-3766; OTHER:2025-522570-37; NIH:2025"],["NCT02157974","Liver and Fat Regulation in Overweight Adolescent Girls","APPLE","COMPLETED","INTERVENTIONAL","PHASE2; PHASE3","NON_RANDOMIZED","NONE","92","Hepatic Steatosis; Polycystic Ovarian Syndrome; Obesity","DRUG:Byetta 5Mcg Pen Injection","University of Colorado, Denver","2014-08","2022-12","TRUE","Hepatic Glucose Release [Measured up to 4 months from enrollment]","DERIVED:42014131; DERIVED:31301251; DERIVED:30888398","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/74/NCT02157974/Prot_SAP_000.pdf","NO","NIH:UL1TR001082; NIH:K23DK107871"],["NCT07413913","A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","56","Healthy; Obesity","COMBINATION_PRODUCT:Survodutide formulation A; COMBINATION_PRODUCT:Survodutide formulation B2","Boehringer Ingelheim","2026-03-03","2026-05-28","FALSE","Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) [Up to Day 22] | Maximum measured concentration of the analyte in plasma (Cmax) [Up to Day 22] | Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) [Up to Day 22]",null,null,"NO","REGISTRY:U1111-1314-3577; REGISTRY:2024-519614-30-00"],["NCT02889510","Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","76","Type 2 Diabetes","DRUG:liraglutide; DRUG:placebo","Lecube, Albert, M.D.","2016-10-04","2019-11-18","TRUE","Changes From Baseline on Measurements of Respiratory Function Defined by Forced Expiratory Volume in 1 Second (FEV1) [7 weeks]","BACKGROUND:10960726; BACKGROUND:18056886; BACKGROUND:11282754; BACKGROUND:20882512; BACKGROUND:20217039; BACKGROUND:19262746; BACKGROUND:18285549; BACKGROUND:18579551; BACKGROUND:14988297; BACKGROUND:15526520; DERIVED:34737187","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/10/NCT02889510/Prot_SAP_000.pdf","NO",null],["NCT02172313","Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","78","Diabetes; Healthy","DRUG:semaglutide","Novo Nordisk A/S","2014-06","2014-10","FALSE","Area under the semaglutide plasma concentration time curve [From time 0 to 24 hours after the 10th daily dose]","DERIVED:34080123; DERIVED:33969456",null,null,"EUDRACT_NUMBER:2013-004707-39; OTHER:U1111-1149-8127"],["NCT01625260","A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer",null,"TERMINATED","INTERVENTIONAL","PHASE1; PHASE2","NON_RANDOMIZED","NONE","12","Non-muscle Invasive Bladder Cancer","BIOLOGICAL:ALT-801; DRUG:Gemcitabine","Altor BioScience","2012-03-30","2018-03-08","TRUE","Safety Profile [12 weeks] | Disease Response Rate [From start of study treatment to up to 13 weeks]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/60/NCT01625260/Prot_SAP_000.pdf","NO",null],["NCT03885297","3mg Liraglutide for Overweight or Obesity",null,"COMPLETED","OBSERVATIONAL",null,null,null,"43","Overweight; Obesity; Infertility, Female","DRUG:Saxenda; OTHER:Lifestyle modification; DIAGNOSTIC_TEST:Metabolomics; DIAGNOSTIC_TEST:miRNA","University Hospitals Coventry and Warwickshire NHS Trust","2019-01-18","2020-12-18","FALSE","Weight changes related to treatment [6 months]","BACKGROUND:19136980; BACKGROUND:19333056; BACKGROUND:15372042; BACKGROUND:14744438",null,"NO","REGISTRY:250896"],["NCT01755416","Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","18","Type 1 Diabetes","DRUG:Closed loop with sensor and Insulin; DRUG:Closed loop with sensor, Insulin and Liraglutide","Albert Einstein College of Medicine","2013-01","2015-01","TRUE","Blood Glucose Measures in Subjects on Closed Loop With Insulin and Liraglutide, Compared to the Closed Loop With Insulin Alone [0-1500 min]",null,null,null,null],["NCT00935532","Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","427","Type 2 Diabetes Mellitus","DRUG:exenatide once weekly; DRUG:insulin glargine","AstraZeneca","2009-07","2010-09","TRUE","Change in HbA1c From Baseline to Endpoint (Week 26) [Baseline, Week 26]","DERIVED:32306296; DERIVED:22884767",null,null,null],["NCT04303819","The Effect of Exenatide on Fasting Bile Acids",null,"COMPLETED","OBSERVATIONAL",null,null,null,"38","Type 2 Diabetes Mellitus in Obese","DRUG:Exenatide treatment","Beijing Chao Yang Hospital","2020-01-05","2020-01-28","FALSE","Plasma total bile acids in fasting state [12 weeks]","DERIVED:32539783",null,null,null],["NCT07141030","Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal Function",null,"RECRUITING","INTERVENTIONAL","PHASE1",null,"NONE","32","Obesity/Overweight","DRUG:GZR18 injection","Gan & Lee Pharmaceuticals.","2025-04-11","2025-10-09","FALSE","Cmax:Maximum plasma concentration [through study completion, an average of 36 days] | AUC0-last:Area under the plasma concentration-time curve at 0 h to last observation time-point after a single dose. [through study completion, an average of 36 days] | AUC0-inf:Area under the plasma concentration-time curve at 0 h to infinity after a single dose. [through study completion, an average of 36 days]",null,null,null,null],["NCT02863419","Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus","PIONEER 4","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","711","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2016-08-10","2017-08-19","TRUE","Change in HbA1c (Week 26) [Week 0, week 26]","RESULT:31186120; RESULT:34472698; RESULT:35373893; DERIVED:37775297; DERIVED:33660198; DERIVED:32267058; DERIVED:31903692","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/19/NCT02863419/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/19/NCT02863419/SAP_001.pdf",null,"EUDRACT_NUMBER:2015-005210-30; OTHER:U1111-1176-6029; NIH:2015"],["NCT03841630","A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","45","Healthy","DRUG:LY3437943; DRUG:Placebo","Eli Lilly and Company","2019-03-13","2019-07-25","FALSE","Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline through final follow-up at approximately Day 43]",null,null,"NO","OTHER:J1I-MC-GZBA"],["NCT06519656","Efficacy of Mazdutide for Treating PCOS",null,"COMPLETED","INTERVENTIONAL","PHASE1; PHASE2",null,"NONE","43","Polycystic Ovary Syndrome","DRUG:Mazdutide","Shanghai Zhongshan Hospital","2024-10-21","2026-09-01","FALSE","Free Androgen Index (FAI) [24 weeks]",null,null,"NO",null],["NCT05870462","Semaglutide and Vascular Regeneration","SEMA-VR","UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","100","Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Obesity","DRUG:Semaglutide Pen Injector","Canadian Medical and Surgical Knowledge Translation Research Group","2023-04-29","2024-12","FALSE","Changes in the mean frequency (%) of circulating ALDHhiSSClow primitive progenitor cells in individuals treated with semaglutide versus usual care for 6 months [Baseline to 6 months post-randomization]","BACKGROUND:34849704; BACKGROUND:33554145; BACKGROUND:23973684; BACKGROUND:17098089; RESULT:32306097; RESULT:30847424; RESULT:31477497; RESULT:33205058; RESULT:28110911; RESULT:27633186; RESULT:34425083",null,"NO",null],["NCT04969627","Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","60","Polycystic Ovary Syndrome","DRUG:Metformin; DRUG:Exenatide","Bing He","2021-01-04","2022-01-04","FALSE","Change in body weight [12 weeks]",null,null,null,null],["NCT01455896","A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","4156","Type 2 Diabetes","DRUG:ITCA 650; OTHER:ITCA placebo","Intarcia Therapeutics","2013-03","2016-03","FALSE","time to first occurrence of any event included in the MACE cardiovascular composite endpoint (CV death, non fatal MI, non fatal stroke, or hospitalization for unstable angina), [2 years]","DERIVED:34873344; DERIVED:29693361",null,null,null],["NCT00318461","To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together","LEAD-2","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","1091","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:metformin; DRUG:glimepiride; DRUG:placebo","Novo Nordisk A/S","2006-05","2007-05","TRUE","Change in Glycosylated A1c (HbA1c) at Week 26 [week 0, week 26] | Change in Glycosylated A1c (HbA1c) at Week 104 [week 0, week 104]","RESULT:18931095; RESULT:19245711; RESULT:19491535; RESULT:19491536; RESULT:19878259; RESULT:19930006; RESULT:21450987; RESULT:22055210; RESULT:22193143; RESULT:21883806; RESULT:21883438; RESULT:22985213; RESULT:22862847; RESULT:23010561; RESULT:23186975; RESULT:25504028; DERIVED:24561125; DERIVED:21209033",null,null,null],["NCT01455883","A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes",null,"WITHDRAWN","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","0","Type 2 Diabetes","DRUG:ITCA 650 60 mcg/day; DRUG:glimepiride","Intarcia Therapeutics","2013-02","2014-07","FALSE","Change in HbA1c [52 weeks]",null,null,null,null],["NCT06759701","Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study",null,"RECRUITING","INTERVENTIONAL","EARLY_PHASE1",null,"NONE","30","Diabetes; Prostate Cancer","DRUG:Tirzepatide","M.D. Anderson Cancer Center","2025-07-02","2026-12-31","FALSE","Safety and Adverse Events (AEs) [Through study completion; an average of 1 year]",null,null,null,"OTHER:NCI-2024-10696"],["NCT07571109","AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea","AMAZE 4","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","300","Obesity; Overweight; Obstructive Sleep Apnoea","DRUG:NNC0487-0111; DRUG:Placebo (matched to NNC0487-0111)","Novo Nordisk A/S","2026-05-05","2028-06-26","FALSE","Relative change in body weight [From baseline (week 0) to (week 80)] | Change in apnoea-hypopnoea index (AHI) [From baseline (week 0) to (week 80)]",null,null,"YES","OTHER:U1111-1313-6538; OTHER:2024-520443-16"],["NCT05882032","A Study of LY3502970 in Participants With Impaired and Normal Liver Function",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","29","Healthy; Hepatic Insufficiency","DRUG:LY3502970","Eli Lilly and Company","2023-06-13","2024-11-18","TRUE","Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-∞]) of LY3502970 [Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose on Day 1] | PK: Area Under the Concentration Versus Time Curve From Time Zero to Last Time Point (AUC0-tlast) of LY3502970 [Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose on Day 1] | PK: Maximum Observed Concentration (Cmax) of LY3502970 [Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose on Day 1]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/32/NCT05882032/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/32/NCT05882032/SAP_001.pdf","NO","OTHER:J2A-MC-GZPB"],["NCT01584232","A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","361","Type 2 Diabetes Mellitus","DRUG:LY2189265; DRUG:Insulin glargine; DRUG:Sulfonylureas (SU); DRUG:Biguanide (BG)","Eli Lilly and Company","2012-04","2013-07","TRUE","Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks [Baseline, 26 weeks]","DERIVED:28606095",null,null,"OTHER:H9X-JE-GBDY"],["NCT05892432","Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","50","Alcohol Use Disorder","DRUG:Semaglutide 3 MG [Rybelsus]; DRUG:Semaglutide 7 MG [Rybelsus]; DRUG:Placebo","University of Colorado, Denver","2024-01-11","2025-11-04","FALSE","Change in Cue Craving Visual Analog Score [7 weeks - change between screening and Week 6 visit]",null,null,"YES","NIH:R21AA031146"],["NCT06082063","Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes","Steno1","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","2000","Cardiovascular Diseases; Heart Failure; Type 1 Diabetes; Kidney Failure","DRUG:Aspirin tablet; DRUG:Semaglutide; DRUG:Sotagliflozin; DRUG:Finerenone","Steno Diabetes Center Copenhagen","2024-07-01","2029-07-01","FALSE","MACE + HHF [5 years]","DERIVED:39078403",null,"NO",null],["NCT03883412","Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)","ZQL007","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","60","Type2 Diabetes","OTHER:Exercise; DRUG:Liraglutide","University of Virginia","2019-02-28","2027-06","FALSE","Microvascular Blood Volume - change from baseline [16 weeks]","BACKGROUND:21200015; BACKGROUND:7114231; BACKGROUND:19283361; BACKGROUND:15161743; BACKGROUND:17720897; BACKGROUND:19996061; BACKGROUND:19567533; BACKGROUND:21047922; BACKGROUND:12791603; BACKGROUND:10449437; BACKGROUND:15863720; BACKGROUND:16618833; BACKGROUND:10078557; BACKGROUND:11078458; BACKGROUND:11916937; BACKGROUND:12453905; BACKGROUND:16644702; BACKGROUND:21617098; BACKGROUND:15792994; BACKGROUND:12445887; BACKGROUND:15059773; BACKGROUND:3301899; BACKGROUND:15298982; BACKGROUND:25352432; BACKGROUND:16633338; BACKGROUND:17823371; BACKGROUND:15084712; BACKGROUND:23002035; BACKGROUND:21512146; BACKGROUND:19356447; BACKGROUND:7923674; BACKGROUND:11165969; BACKGROUND:21481871; BACKGROUND:24438856; BACKGROUND:3499255; BACKGROUND:16682488; BACKGROUND:24450403; BACKGROUND:17563063; BACKGROUND:15213062; BACKGROUND:22429614; BACKGROUND:19237429; BACKGROUND:23034699; BACKGROUND:23026425; BACKGROUND:16489128",null,"NO",null],["NCT02917057","Subanalyses of Elderly Type 2 Diabetes Patients or Type 2 Diabetes Patients With Renal Impairment",null,"COMPLETED","OBSERVATIONAL",null,null,null,"6024","Type 2 Diabetes","DRUG:exenatide once weekly; DRUG:basal insulin","AstraZeneca","2015-08-01","2015-08-01","FALSE","Changes from baseline in HbA1c (%) [one year post-index] | Changes from baseline in weight (kg) [one year post-index]","BACKGROUND:29193561",null,null,null],["NCT06533527","Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","69","Diabetes Mellitus, Type 2; Obesity; Gastroparesis","DRUG:GLP-1 medication","The Cleveland Clinic","2024-07-31","2025-05-20","TRUE","Presence of RGV (Residual Gastric Volume) in Stomach [Procedure] | Tracking the Use of Intubation Due to RGV [Procedure] | Aspiration Events Due to RGV (Residual Gastric Volume) [Procedure]","RESULT:36919944; RESULT:36870274; DERIVED:41837981","Study Protocol and Statistical Analysis Plan: Protocol Ver. 5|https://cdn.clinicaltrials.gov/large-docs/27/NCT06533527/Prot_SAP_001.pdf",null,null],["NCT05407961","A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","90","Diabetes Mellitus, Type 2","DRUG:LY3532226; DRUG:Placebo; DRUG:Dulaglutide","Eli Lilly and Company","2022-06-07","2024-01-12","FALSE","Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline up to Week 16] | Part B: Change from Baseline in Total Clamp Disposition Index (cDI) [Baseline up to Week 12]",null,null,"NO","EUDRACT_NUMBER:2021-003257-31; OTHER:J2V-MC-GZLB"],["NCT02743598","Liraglutide for HIV-associated Neurocognitive Disorder",null,"TERMINATED","INTERVENTIONAL","PHASE4",null,"NONE","4","HIV Infection; Diabetes Mellitus Type 2; Obesity; Overweight; Metabolic Syndrome","DRUG:Liraglutide","Temple University","2016-09","2018-06-01","FALSE","Neurocognitive performance- change in global cognitive scores on a standard neuropsychological profile [6 months] | Neurocognitive performance- change in domain averages on a standard neuropsychological profile [6 months]",null,null,"NO",null],["NCT07829198","Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial","TirBaS","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","70","Obesity","DRUG:Tirzepatide; DRUG:Placebo","Universidade do Porto","2027-01","2028-12","FALSE","Percentage Change in Body Weight from Baseline to Week 52 [Baseline (Week 0) to Week 52]",null,null,null,"CTIS:2026-527275-29-00"],["NCT01455909","A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes",null,"WITHDRAWN","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","0","Type 2 Diabetes","DRUG:ITCA 650 60 mcg/day; DRUG:sitagliptin","Intarcia Therapeutics","2013-02","2014-07","FALSE","Change in HbA1c [39 weeks]",null,null,null,null],["NCT07558863","Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes","GLP-1-CAN","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","60","Type 2 Diabetes; Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)","DRUG:GLP-1 Receptor Agonists","The First Affiliated Hospital with Nanjing Medical University","2026-04-01","2028-03-30","FALSE","heart rate variability（HRV） [baseline and 12 weeks later]]","RESULT:33804063; RESULT:33292149; RESULT:20460434; RESULT:19259827; RESULT:34793438; RESULT:34317590; RESULT:26254961; RESULT:32497872; RESULT:24567799; RESULT:31552598; RESULT:37021204; RESULT:37397902; RESULT:12716821; RESULT:25685280; RESULT:16014401",null,"NO",null],["NCT06819488","A Clinical Study of Mass Balance of [14C]HRS-7535",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","6","Type 2 Diabetes Mellitus; Weight Loss","DRUG:[14C]HRS-7535","Shandong Suncadia Medicine Co., Ltd.","2025-02-27","2025-04-16","FALSE","The time of maximum observed concentration (Tmax) [0-120 hours.] | The maximum observed concentration (Cmax) [0-120 hours.] | The terminal half-life (t1/2) [0-120 hours.] | The total body clearance for extravascular administration (CL/F) [0-120 hours.] | The total radioactivity ratio for blood [0-96 hours.] | The total radioactivity ratio for plasma [0-96 hours.]",null,null,"UNDECIDED",null],["NCT07398222","Gastric Content in Fasting Volunteers and in Tirzepatide Users: an Observational and Cross-sectional Study",null,"RECRUITING","OBSERVATIONAL",null,null,null,"30","Full Stomach Status","OTHER:Ultrasonographic evaluation of gastric content","Hospital Israelita Albert Einstein","2026-01-26","2026-03-20","FALSE","Comparison of the prevalence of a full stomach after fasting using gastric ultrasonography in volunteers using tirzepatide versus those not using the medication. [1 day]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/22/NCT07398222/Prot_SAP_000.pdf","UNDECIDED",null],["NCT03479762","In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database",null,"COMPLETED","OBSERVATIONAL",null,null,null,"105","Obesity; Overweight","DRUG:Liraglutide","Novo Nordisk A/S","2018-04-20","2022-09-12","FALSE","Number of patients with a BMI above or equal to 30 kg/m^2 (Saxenda® only) [Less than 6 months before the date of the first prescription] | Number of patients with a BMI above or equal to 27 kg/m^2 and below 30 kg/m^2 and 1 or more comorbidities (Saxenda® only) [Less than 6 months before the date of the first prescription] | Number of patients with a BMI above or equal to 27 kg/m^2 and less than 30 kg/m^2 and no comorbidities (Saxenda® only) [Less than 6 months before the first prescription] | Number of patients with BMI below 27 kg/m^2 (Saxenda® only) [Less than 6 months before the first prescription] | Number of patients with less than 5% weight loss and continuing treatment (Saxenda® only) [Week 0 (first prescription) to week 16; week 24] | Mean weight loss in patients not treated according to stopping rule (Saxenda® only) [Week 0 (first prescription) to week 16; week 24] | Number of patients with a BMI not measured (Saxenda® only) [Less than 6 months before the first prescription] | Number of patients with at least 5% weight loss and continuing treatment (Saxenda® only) [Week 16 - week 24]",null,null,"YES","OTHER:U1111-1185-3276; REGISTRY:EUPAS23369"],["NCT01381926","Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist","CMBD","TERMINATED","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","14","Type 2 Diabetes Mellitus; Bone Remodeling","DRUG:exenatide; DRUG:Saline","University of Alabama at Birmingham","2011-02","2015-08","TRUE","Determine Changes in Bone Resorption Markers During the Treatment With a GLP-1 Receptor Agonist (Exenatide) Compared to Placebo in Patients With T2DM. [Baseline to 20 weeks] | Determine Changes in Bone Turnover Markers by Serum N-Telo Peptide During the Treatment With a GLP-1 Receptor Agonist (Exenatide) Compared to Placebo in Patients With T2DM. [Baseline to 20 weeks] | Determine Changes in Bone Turnover Markers by Tartrate-Resistant Acid Phosphatase 5b (TRACP5b) During the Treatment With a GLP-1 Receptor Agonist (Exenatide) Compared to Placebo in Patients With T2DM. [Baseline to 20 weeks]",null,null,"UNDECIDED",null],["NCT07202884","A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight","RESTRAIN-SUI","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","1000","Urinary Incontinence,Stress","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2025-09-30","2028-03","FALSE","Change from Baseline in Incontinence Episode Frequency (IEF) [Baseline, Week 52]",null,null,"YES","CTIS:2025-522514-23-00; OTHER:J2A-MC-GZPS; OTHER:J2A-MC-GZS1; OTHER:J2A-MC-GZS2; NIH:2025"],["NCT03590626","Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease","D-LIFT","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","60","Non Alcoholic Fatty Liver Disease; Type2 Diabetes Mellitus","DRUG:Dulaglutide","Medanta, The Medicity, India","2019-01-01","2020-01-14","FALSE","Change in liver fat [Baseline to 24 weeks]","BACKGROUND:24842985; RESULT:27916783; RESULT:27732328; RESULT:25018121; RESULT:24742660; RESULT:26089386; RESULT:23383649; RESULT:22025886; RESULT:22554256; RESULT:22431131; RESULT:25482832; DERIVED:32865597",null,null,null],["NCT07037433","Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity","MARITIME-CV","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","12800","Atherosclerotic Cardiovascular Disease; Overweight; Obesity","DRUG:Maridebart Cafraglutide; DRUG:Placebo","Amgen","2025-07-25","2028-06-30","FALSE","Time to First Occurrence of a Composite Endpoint Consisting of: CV Death, Myocardial Infarction (MI), or Ischemic Stroke (3-point Major Adverse Cardiac Events [3-P MACE]) [Up to approximately 35 months] | Time to First Occurrence of a Composite Endpoint Consisting of: All-cause Death, MI, Ischemic Stroke, Coronary Revascularization, or Heart Failure (HF) Event (5-point MACE) [Up to approximately 35 months]",null,null,"YES",null],["NCT03048578","Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","132","Obesity","DRUG:Saxenda; DRUG:Placebo","NYU Langone Health","2017-05-22","2021-03-02","TRUE","Percentage of Participants Losing at Least 5% Enrollment Body Weight Measured Using Cochran-Mantel-Haenszel (CMH) Test [12 Months]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/78/NCT03048578/Prot_SAP_000.pdf",null,null],["NCT07190144","Coronary Flow Reserve Changes After Semaglutide Treatment",null,"COMPLETED","OBSERVATIONAL",null,null,null,"122","The Study Focused on the Vascular Effects of Semaglutide in Both Diabetic and Non-diabetic Patients; Obesity &Amp; Overweight",null,"Ekrem Bilal Karaayvaz","2025-01-07","2025-08-01","FALSE","Number of patients who had acute coronary syndrome [From start of the study to 3 months after]","RESULT:27633186; RESULT:37952131",null,"UNDECIDED",null],["NCT01064687","A Study in Participants With Type 2 Diabetes Mellitus","AWARD-1","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","978","Diabetes Mellitus, Type 2","DRUG:LY2189265; DRUG:Exenatide; DRUG:Placebo; DRUG:Metformin; DRUG:Pioglitazone","Eli Lilly and Company","2010-02","2011-11","TRUE","Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c) [Baseline, 26 weeks]","DERIVED:36894938; DERIVED:27161178; DERIVED:26691396",null,null,"OTHER:H9X-MC-GBDA"],["NCT02735031","Exenatide and Impaired Hypoglycaemic Awareness in Type 1 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","QUADRUPLE","10","Diabetes Mellitus, Type 1; Hypoglycemia","DRUG:Exenatide; DRUG:Placebo","Radboud University Medical Center","2017-02-21","2018-03-28","FALSE","Symptom score in response to insulin-induced hypoglycaemia [30 minutes]",null,null,null,null],["NCT02862431","Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM)",null,"TERMINATED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","24","Diabetes Mellitus, Type 2","DRUG:JNJ-64565111; DRUG:Placebo","Janssen Research & Development, LLC","2016-07-12","2016-11-29","FALSE","Number of Participants With Adverse Events as a Measure of Safety and Tolerability [Up to Day 72]",null,null,null,"OTHER:64565111EDI1001; EUDRACT_NUMBER:2016-001084-37; NIH:2016"],["NCT06648031","Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants","DehydraTECH","COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","148","Type2diabetes","DRUG:Arm 1 - DehydraTECH-CBD alone; DRUG:Arm 2 - DehydraTECH-semaglutide alone; DRUG:Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide; DRUG:Arm 4 - Rybelsus medication (semaglutide) alone; DRUG:Arm 5- Tirzepatide","Lexaria Bioscience Corp.","2024-12-04","2025-07-31","FALSE","Number of participants with treatment-emergent adverse events (TEAEs) and Serious adverse events [Baseline to Day 113 post first dose administration]",null,null,"NO",null],["NCT07589322","Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTs","COMPARE-AT","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","120","Obesity and Metabolic Syndrome","DRUG:Tirzepatide with lifestyle modification; DRUG:Semaglutide with lifestyle modification","Tri-Service General Hospital (TSGH)","2026-03-31","2028-09-30","FALSE","Percent change in total body weight from baseline to 6 months. [Baseline to 6 months] | Total fat to lean mass loss ratio (DXA derived) from baseline to 6 months. [Baseline to 6 months] | Change in metabolic syndrome severity Z score from baseline to 6 months. [Baseline to 6 months.]",null,null,"NO",null],["NCT05313802","A Study of LY3502970 in Healthy Overweight and Obese Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","72","Healthy; Obese","DRUG:LY3502970","Eli Lilly and Company","2022-05-26","2022-09-09","TRUE","Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline up to Day 42]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/02/NCT05313802/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/02/NCT05313802/SAP_001.pdf","NO","OTHER:J2A-MC-GZGK"],["NCT01965496","A Phase I Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","64","Type 2 Diabetes","DRUG:PEX168","Jiangsu HengRui Medicine Co., Ltd.","2012-03","2013-03","FALSE","To assess HbA1C levels after 14 weeks continuous treatment [14 weeks]",null,null,null,null],["NCT07430059","Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant","SLIM-1","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","20","Obesity & Overweight","COMBINATION_PRODUCT:Semaglutide Implant (NPM-139); DRUG:Semaglutide (Wegovy) weekly injection","Vivani Medical, Inc","2026-07","2026-12","FALSE","Area under the plasma concentration-time curve (AUC) [4 weeks] | Maximum plasma concentration (Cmax) [4 weeks] | Time to maximum semaglutide concentration (Tmax) [4 weeks] | Adverse Events [4 weeks]",null,null,"NO",null],["NCT07428746","Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes","GLOW","RECRUITING","INTERVENTIONAL","PHASE3",null,"NONE","20","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Emory University","2026-05-07","2028-11","FALSE","Change in handgrip strength [Baseline, week4, week 8, week12, week 26.]",null,null,"YES","NIH:K12AR084234"],["NCT06857942","A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)",null,"RECRUITING","INTERVENTIONAL","PHASE4",null,"NONE","200","Psoriasis; Overweight or Obesity","DRUG:Tirzepatide","Eli Lilly and Company","2025-03-19","2028-05","FALSE","Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) (0,1) [12 months] | Percentage of Participants Achieving at least 10% Weight Reduction [12 months]",null,null,"YES","OTHER:I1F-MC-RHDD"],["NCT04447859","16-week Flexible vs. 8-week Semaglutide Titration",null,"UNKNOWN","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","100","Diabetes type2","DRUG:Semaglutide; OTHER:label recommended titration","Tel-Aviv Sourasky Medical Center","2020-02-23","2022-05-10","FALSE","Gastrointestinal adverse events (GI-AEs) [16 weeks - from visit one to visit seven (and in each visit alone)]",null,null,null,null],["NCT06256562","A Study of GZR18 Injection in Obese/Overweight Patients",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","340","Obesity; Overweight","DRUG:GZR18; OTHER:Placebo","Gan and Lee Pharmaceuticals, USA","2023-06-08","2024-06-05","FALSE","Percent (%) change from baseline in body weight at the end of the study (W30) [30 weeks]","DERIVED:41760612",null,"NO",null],["NCT06634927","Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","68","Type 2 Diabetes","DRUG:Ozempic®; DRUG:HDG1901","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2024-09-22","2024-11-14","FALSE","AUC0-inf [-60minutes and 6, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 144, 336, 504, 672, 840 hours after administration] | AUC0-t [-60minutes and 6, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 144, 336, 504, 672, 840 hours after administration] | Cmax [-60minutes and 6, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 144, 336, 504, 672, 840 hours after administration]",null,null,null,null],["NCT01787916","52 Week Trial of Liraglutide in Type 1 Diabetes","LIDO","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","15","Type 1 Diabetes","DRUG:Liraglutide; DRUG:Placebos","CHU de Quebec-Universite Laval","2013-04","2015-04","TRUE","Assessment of Changes in Glycemic Control by HbA1c. [Measure changes in HbA1c at 24 and 52 weeks from baseline]","DERIVED:28722271",null,"NO",null],["NCT04407234","A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","36","Overweight; Obesity; Diabetes Mellitus, Type 2","DRUG:Tirzepatide; DRUG:Acetaminophen","Eli Lilly and Company","2020-09-15","2021-01-07","TRUE","Pharmacokinetics (PK): Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of Acetaminophen [Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours post-dose on Day 1, Day 2 and Day 37 , Day 2 and Day 37] | PK: Maximum Observed Drug Concentration (Cmax) of Acetaminophen [Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours post-dose on Day 1, Day 2 and Day 37 , Day 2 and Day 37]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/34/NCT04407234/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/34/NCT04407234/SAP_001.pdf","NO","OTHER:I8F-MC-GPHU"],["NCT07639021","A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","233","Obesity","DRUG:NNC0662-0419; DRUG:Semaglutide; DRUG:NNC0662-0419 Placebo; DRUG:Semaglutide placebo","Novo Nordisk A/S","2026-06-09","2027-06-14","FALSE","Number of gastrointestinal adverse events [From week 0 to week 39]",null,null,"YES","OTHER:U1111-1333-3475"],["NCT00423501","A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","306","Diabetes Mellitus Type 2","DRUG:Placebo; DRUG:taspoglutide","Hoffmann-La Roche","2007-02","2007-11","FALSE","Absolute change from baseline in HbAlc [Week 8]","DERIVED:19366970",null,null,null],["NCT04137328","Clinical Study on the Improvement of Diabetic Neuropathic Pain by Liraglutide",null,"UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","60","Diabetic Neuropathic Pain","DRUG:Liraglutide; DRUG:insulin","Fudan University","2019-11-30","2022-11-30","FALSE","Numerical pain scale (NRS) [3 months]","BACKGROUND:29559450; BACKGROUND:20359765; BACKGROUND:30320508; BACKGROUND:26813032; BACKGROUND:29416128; BACKGROUND:27186361; BACKGROUND:29110715; BACKGROUND:28608285; BACKGROUND:28456941; BACKGROUND:24936731",null,"NO",null],["NCT06176365","A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease","SYNCHRONIZE™JP","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","274","Obesity","DRUG:Survodutide; DRUG:Placebo matching survodutide","Boehringer Ingelheim","2024-01-16","2025-12-03","FALSE","Percentage change in body weight from baseline to Week 76 [at baseline, at week 76] | Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76 [at baseline, at week 76]","DERIVED:42219222",null,"YES",null],["NCT05545800","Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin Therapy",null,"UNKNOWN","INTERVENTIONAL","PHASE3","RANDOMIZED","SINGLE","78","Type 2 Diabetes Mellitus","DRUG:metformin+empagliflozin+insulin glargine; DRUG:IDegLira; DRUG:premixed insulin analogues","Xiangya Hospital of Central South University","2022-09-01","2024-06-01","FALSE","Mean Change From Baseline in HbA1c [Month 0 to 3] | Percentage of patients achieving HbA1c <7% [Month 0 to 3] | Amplitude of glycemic excursions [Month 0 to 3]",null,null,null,null],["NCT07871409","Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight","MARITIME-PEN","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3",null,"NONE","230","Obesity; Overweight","DRUG:Maridebart cafraglutide; DEVICE:Autoinjector","Amgen","2026-10-28","2027-06-16","FALSE","Percentage of Participants Who Successfully Self-inject a Full Dose Among Those Who Attempted Injection at Each Home Administration [Weeks 12, 16, and 20] | Percentage of Participants Who Successfully Self-inject a Full Dose Among All Participants Who Entered the Home Self-administration Phase at Each Scheduled Home Administration [Weeks 12, 16, and 20]",null,null,"YES",null],["NCT04466345","Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","72","Major Depressive Disorder","BIOLOGICAL:Semaglutide; BIOLOGICAL:Placebo","University Health Network, Toronto","2021-10-06","2024-12-27","FALSE","Executive Function Composite Score [16 Weeks]","DERIVED:42054055; DERIVED:41218611",null,"NO",null],["NCT01208012","Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","44","Diabetes Mellitus, Type 2","DRUG:Victoza®","ikfe-CRO GmbH","2010-04","2010-11","FALSE","The difference in increase of retinal blood flow after flicker stimulation of retinal endothelial cells [timepoint 0 and after 6 and 12 weeks]","DERIVED:22288732",null,null,null],["NCT00099619","Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","138","Type 2 Diabetes Mellitus","DRUG:exenatide/insulin glargine; DRUG:insulin glargine/exenatide","AstraZeneca","2004-09","2005-08","FALSE","Change in HbA1c (glycosylated hemoglobin) from the baseline of the first period (16-weeks of exenatide or insulin) to the end of each 16-week period. [Baseline, Week 16, Week 32]","DERIVED:22236356",null,null,null],["NCT07114419","The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity（SPARKLE）",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","200","Obesity and Overweight","DRUG:Efsubaglutide Alfa 20 mg QW; DRUG:Efsubaglutide Alfa 40 mg QW; DRUG:Efsubaglutide Alfa 40 mg Q2W; DRUG:Efsubaglutide Alfa 80 mg QW; DRUG:Efsubaglutide Alfa 80 mg Q4W; OTHER:Placebo","Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","2025-08-25","2026-06-01","FALSE","Percentage change (%) of body weight from baseline after subcutaneous administration of YN-011 for 22 weeks [22 weeks]",null,null,"NO","OTHER:YN012-II-W204-AU"],["NCT02973100","A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","318","Type 2 Diabetes","DRUG:Dulaglutide; DRUG:Placebo","Eli Lilly and Company","2016-12","2017-07-15","TRUE","Change From Baseline in Hemoglobin A1c (HbA1c) [Baseline, Week 18]",null,"Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/00/NCT02973100/SAP_000.pdf; Study Protocol|https://cdn.clinicaltrials.gov/large-docs/00/NCT02973100/Prot_001.pdf","YES","OTHER:H9X-MC-GBGJ; EUDRACT_NUMBER:2016-002494-34; NIH:2016"],["NCT02647944","Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","40","Obesity","DRUG:Liraglutide; DRUG:Placebo","Mayo Clinic","2015-12-18","2016-12-30","TRUE","Gastric Emptying of Solids Half-time (T1/2) at 5 Weeks [5 weeks] | Gastric Emptying of Solids Half-time (T1/2) at 16 Weeks [16 weeks]","BACKGROUND:28958851; DERIVED:42392577; DERIVED:35894080; DERIVED:31665455",null,null,"NIH:R56DK067071; NIH:UL1TR000135"],["NCT07029009","Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)",null,"RECRUITING","INTERVENTIONAL","PHASE2",null,"NONE","50","Maturity Onset Diabetes of the Young","DRUG:Liraglutide","Mansa","2025-05-08","2026-08","FALSE","Blood sugar control - HbA1C [Baseline and 3 months after study treatment initiation] | BMI [baseline, 1 month, 2 months, and final study visit 3 months after study treatment initiation]",null,null,"NO",null],["NCT06605287","The Progress of Diabetes After Supaglutide Treatment in Type 2 Diabetes Patients",null,"UNKNOWN","OBSERVATIONAL",null,null,null,"100","Type 2 Diabetes Mellitus",null,"Nanjing First Hospital, Nanjing Medical University","2023-03-13","2024-12-31","FALSE","The clinical remission rate of diabetes [48 weeks]","DERIVED:41498879",null,"UNDECIDED",null],["NCT06180616","Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity","TZP-T1D","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","40","Type 1 Diabetes Mellitus; Overweight and Obesity","DRUG:Tirzepatide","Royal North Shore Hospital","2026-12","2028-12","FALSE","Body weight [32 weeks]","DERIVED:40962353",null,"YES",null],["NCT00154414","Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","226","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2005-01","2006-05","FALSE","HbA1c [after 14 weeks treatment]","RESULT:18495285; RESULT:25504028",null,null,"REGISTRY:JapicCTI-050131"],["NCT06703021","A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity","ACCESS II","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","85","Obesity; Overweight; Chronic Weight Management","DRUG:aleniglipron or placebo","Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics","2024-12-20","2026-01-12","FALSE","Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) [Baseline and week 44] | Adverse events of special interest [Baseline and week 44] | Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters, including hematology, plasma chemistry, coagulation, and urinalysis [Baseline and week 44] | Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters: Common ECG-related variables will be assessed, including but not limited to : heart rate and QRS duration [Baseline and week 44] | Number of Participants With Clinically Significant Change From Baseline in Vital Signs, including systolic and diastolic Blood Pressure, Heart Rate, Respiratory Rate, and temperature [Baseline and week 44]",null,null,"YES",null],["NCT06484114","Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide","REMAIN-1","ACTIVE_NOT_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","TRIPLE","315","Obesity; Weight Change Trajectory; Weight Change, Body","DEVICE:Revita Duodenal Mucosal Resurfacing (DMR); DEVICE:Sham","Fractyl Health Inc.","2024-09-01","2027-02-15","FALSE","To demonstrate that Revita DMR is superior to sham in percent change in body weight from baseline to week 26 [26 Weeks] | To demonstrate that a majority of Revita DMR participants maintain clinically significant weight loss 52 weeks (1 year) after discontinuing tirzepatide therapy [52 weeks]",null,null,"NO",null],["NCT07834398","Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","150","Non-diabetec Obesity; Obesity (Disorder)","DRUG:Dulaglutide; DRUG:Semagludtide; DRUG:Tirzepatide","Zagazig University","2025-11-14","2026-04-13","FALSE","change in body weight at 3 and 6 months [Baseline, Week 12 (3 months) and Week 24 (6 months)]",null,"Study Protocol, Statistical Analysis Plan, and Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/98/NCT07834398/Prot_SAP_ICF_000.pdf","YES",null],["NCT06283667","Special Use - Results Surveillance on Long-term Use With Wegovy®",null,"ACTIVE_NOT_RECRUITING","OBSERVATIONAL",null,null,null,"1071","Obesity","DRUG:Semaglutide","Novo Nordisk A/S","2024-06-11","2028-01-31","FALSE","Number of Adverse Reactions (ARs) [From baseline (week 0) to end of study (week 104)]",null,null,"YES","OTHER:U1111-1266-3863"],["NCT01785771","A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c",null,"TERMINATED","INTERVENTIONAL","PHASE3",null,"NONE","100","Type 2 Diabetes","DRUG:ITCA 650 (exenatide in DUROS)","Intarcia Therapeutics","2013-05","2018-01","FALSE","Change in HbA1c between Week 39 and Day 0 [39 weeks]","DERIVED:29301824",null,null,null],["NCT02690987","Gut Hormones in Obesity, Nicotine and Alcohol Dependence","GHADD","UNKNOWN","INTERVENTIONAL","EARLY_PHASE1","RANDOMIZED","QUADRUPLE","95","Obesity; Smoking Cessation; Alcoholism","DRUG:Exenatide; BIOLOGICAL:Desacyl ghrelin; BIOLOGICAL:Saline","Imperial College London","2015-08","2019-08-21","FALSE","Functional MRI measure of brain activation during cigarette, alcohol and food picture evaluation task [4 years]","BACKGROUND:21354264; BACKGROUND:24204788; BACKGROUND:24760977; BACKGROUND:1932883; BACKGROUND:8329970; BACKGROUND:23613987; BACKGROUND:24550190; BACKGROUND:25071023; BACKGROUND:23964100",null,"NO","OTHER_GRANT:MR/M007022/1"],["NCT01536665","The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","45","Diabetes; Diabetes Mellitus, Type 1","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2012-02","2012-08","FALSE","Geometric mean glucagon concentration during hypoglycaemia (nadir glucose (target 2.5 mmol/L) ) [At week 4]","RESULT:27282158; RESULT:25855340",null,null,"OTHER:U1111-1123-9882; EUDRACT_NUMBER:2011-004240-22"],["NCT00456300","Role of Exenatide in Type 1 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","11","Type 1 Diabetes","DRUG:Exenatide; DRUG:Insulin","Montefiore Medical Center","2007-03","2009-03","TRUE","Mean Plasma Glucose Area Under the Curve (AUC) for Blood Glucose Concentration in the Exenatide 1.25 mcg or Exenatide 2.5 mcg Treated Groups Along With Insulin, Compared to Insulin Alone [0-120 minutes post-dose]","DERIVED:20332358",null,"NO",null],["NCT02041234","Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","40","Type II Diabetes in Subjects BMI 27 to 32","PROCEDURE:Roux-en-Y Gastric Bypass (RYGB); DRUG:Incretin analogues; DRUG:Xenical; DRUG:SGLT2 inhibitors; DRUG:DPP-4 Inhibitors","Khoo Teck Puat Hospital","2014-02","2020-12","FALSE","Number of subjects achieving HBA1c of 6% without diabetic medication [at 12 month after randomisation] | Number of subjects achieving systolic BP <130mm hg without antihypertension medication [12 months post randomisation] | number of subjects achieving LDL level of <100mg/dl without lipid lowering medication [12 months post randomisation]","BACKGROUND:19370590; BACKGROUND:19272486; BACKGROUND:17715408; BACKGROUND:21480973; BACKGROUND:7677463; BACKGROUND:22449319; BACKGROUND:22449317; BACKGROUND:22723580; DERIVED:35513159",null,"NO",null],["NCT02198209","Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation",null,"WITHDRAWN","INTERVENTIONAL","PHASE4",null,"NONE","0","Type 2 Diabetes","DRUG:Liraglutide","Cedars-Sinai Medical Center","2019-12","2020-07","FALSE","Liver glucokinase activity (acute effect) [12 months] | Liver glucokinase activity (chronic effect) [12 months]",null,null,null,null],["NCT02150707","The Differential Effects of Diabetes Therapy on Inflammation",null,"COMPLETED","OBSERVATIONAL",null,null,null,"17","Diabetic Nephropathy; Type 2 Diabetes","DRUG:Dipeptidyl-Peptidase IV Inhibitors; DRUG:Glucagon-Like Peptide 1","University College Dublin","2014-05","2015-12","FALSE","Monocyte:chemoattractant protein 1 (MCP-1):creatinine ratio [6 months]","BACKGROUND:22608055; BACKGROUND:24362727; BACKGROUND:21206136; BACKGROUND:21284481",null,null,null],["NCT03087032","Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)","LiraGooD","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","164","Type 2 Diabetes Patients; Overweight and Obesity; Hyperglycaemia (Diabetic)","DRUG:Liraglutide; DRUG:insulin glargine","The First Affiliated Hospital of Xiamen University","2019-01-10","2025-01-15","FALSE","the proportion of patients with HbA1c < 7.0% without experiencing hypoglycemia and without weight gain,with a superiority margin of 3% [24 weeks]",null,null,"UNDECIDED",null],["NCT02477865","Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 Patients",null,"UNKNOWN","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","406","Type 2 Diabetes Mellitus","DRUG:PEX168(100µg); DRUG:PEX168(200µg); DRUG:Placebo","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2014-03-23","2016-05-15","FALSE","HbA1c [Baseling to 24 weeks]",null,null,"NO",null],["NCT01272232","Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","846","Metabolism and Nutrition Disorder; Obesity","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2011-06-01","2013-01-01","TRUE","Change (%) From Baseline in Body Weight (Fasting) [Week 0, week 56] | Proportion of Subjects Losing at Least 5% of Baseline Body Weight [at 56 weeks] | Proportion of Subjects Losing More Than 10% of Baseline Body Weight [at 56 weeks]","BACKGROUND:29145215; RESULT:27193270; RESULT:27482610; RESULT:27804269; RESULT:27817208; RESULT:26744025; RESULT:26833744; RESULT:26284720; RESULT:26418188; RESULT:28473337; RESULT:28462892; RESULT:28386912; RESULT:28950422",null,null,"EUDRACT_NUMBER:2008-002199-88; OTHER:U1111-1118-7963; NIH:2008"],["NCT07550816","Drug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants",null,"RECRUITING","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","60","Overweight,Obesity","DRUG:ZT002 injection, metformin, warfarin; DRUG:ZT002 injection, rosuvastatin, digoxin","Beijing QL Biopharmaceutical Co.,Ltd","2026-05-27","2026-12-05","FALSE","Area under the concentration-time curve of metformin within dosing interval (12 hours) at steady state [From Day 4 to Day 5, from Day 112 to Day 113] | Area under the concentration-time curve of S-warfarin from time zero to infinity after single-dose administration [From Day 6 to Day 13, from Day 126 to Day 133] | Area under the concentration-time curve of R-warfarin from time zero to infinity after single-dose administration [From Day 6 to Day 13, from Day 126 to Day 133] | Area under the concentration-time curve of rosuvastatin from time zero to infinity after single-dose administration [From Day 1 to Day 5, from Day 111 to Day 115] | Area under the concentration-time curve of digoxin from time zero to infinity after single-dose administration [From Day 5 to Day 12, from Day 125 to Day 132]",null,null,null,null],["NCT07166081","Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","80","Non-diabetic Overweight or Obese","DRUG:BGM0504; DRUG:Placebo","BrightGene Bio-Medical Technology Co., Ltd.","2025-08-11","2026-01-12","FALSE","Number of treatment adverse events [11 weeks]",null,null,null,null],["NCT07394114","A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","240","Type 2 Diabetes","DRUG:HDM1005 1; DRUG:HDM1005 2; DRUG:HDM1005 injection or placebo","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2026-02-24","2027-08-28","FALSE","Change from baseline in Hemoglobin A1c (HbA1c) [Baseline, Week 36]",null,null,null,null],["NCT04521738","First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to Overweight Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","48","Overweight; Healthy Subjects","DRUG:SAR441255; DRUG:placebo","Sanofi","2019-04-25","2019-09-26","FALSE","Number of participants with adverse events [Screening to Day 28]","DERIVED:34932984",null,"YES","OTHER:U1111-1210-0180"],["NCT07848880","A Phase 2 Study to Evaluate the Efficacy and Safety of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney Disease",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","315","Hypertriglyceridemia","DRUG:DR10624 Injection; DRUG:Placebo","Zhejiang Doer Biologics Co., Ltd.","2026-10","2028-04","FALSE","Percentage change from baseline in fasting serum triglyceride concentration at Week 26 [Baseline up to Week 26 of double-blind treatment period]",null,null,null,null],["NCT05116410","A Study of HS-20094 in Healthy Participants",null,"UNKNOWN","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","68","Type 2 Diabetes","DRUG:HS-20094; DRUG:Placebo","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2021-11-01","2022-10-31","FALSE","Incidence of adverse event (AE), serious adverse event (SAE), AE leading to study discontinuation, AE severity and relation with study drug [Time of Inform Consent Form to Day 29 (SAD) or Day 50 (MAD)]",null,null,"NO",null],["NCT06481085","To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","324","Type 2 Diabetes","DRUG:HDM1002 50 mg; DRUG:HDM1002 100 mg; DRUG:HDM1002 200 mg; DRUG:HDM1002 400 mg; DRUG:HDM1002 200 mg BID; DRUG:Placebo","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2024-06-27","2025-05-30","FALSE","Change From Baseline in HbA1c at Week 12 [Baseline, Week 12]",null,null,"NO",null],["NCT04790006","A Study of TG103 in Subjects With Type 2 Diabetes",null,"UNKNOWN","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","54","Type 2 Diabetes","DRUG:TG103; DRUG:Placebo","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","2021-04","2022-03","FALSE","Safety and tolerability assessed by incidence and severity of adverse events [up to 15 weeks]",null,null,"NO",null],["NCT03374241","A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","41","Obesity","BIOLOGICAL:HM15211 or Placebo","Hanmi Pharmaceutical Company Limited","2018-04-04","2018-09-14","TRUE","Number of Participants With Adverse Events [1 month]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/41/NCT03374241/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/41/NCT03374241/SAP_001.pdf","UNDECIDED",null],["NCT07073170","A Study of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","36","Type 2 Diabetes","DRUG:LY3549492; DRUG:Placebo","Eli Lilly and Company","2025-07-25","2026-01-27","FALSE","Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration [Baseline through Week 14]",null,null,"NO","OTHER:J3H-GH-GZNH"],["NCT06062069","A Study of CT-868 in Type 1 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","111","Overweight; Obese; Type 1 Diabetes Mellitus","DRUG:CT-868; DEVICE:CT-868 Pen Injector; DRUG:CT-868 Pen Injector, Placebo","Carmot Therapeutics, Inc.","2023-10-19","2025-07-09","FALSE","Compare the effect of CT-868 versus placebo on change in HbA1c (%) from baseline [at Day 1 to Week 16]",null,null,"NO",null],["NCT07857265","Mass Balance Study of [14C]DA-302168S in Healthy Chinese Adult Male Participants",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1",null,"NONE","10","Healthy Adult Subjects","DRUG:[14C] DA-302168S","Chendu DIAO Pharmaceutical Group CO., LTD.","2026-11-20","2026-12-20","FALSE","Total recovery of HDM1002 radioactivity in urine and feces, following oral administration of [14C] DA-302168S [Predose up to Day 8 after administration of [14C]DA-302168S] | Identification of Major Metabolites in Human Plasma, Urine, and Feces [Predose up to Day 8 after administration of [14C]DA-302168S]",null,null,"NO",null],["NCT06548932","A Study to Evaluate the Safety, Tolerance, PK and PD Parameters of GZR33 and GZR101 in Healthy Male Adult Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","52","Healthy Subjects","DRUG:GZR33 Injection; DRUG:GZR101 Injection; DRUG:Placebo","Gan and Lee Pharmaceuticals, USA","2022-06-30","2023-02-24","FALSE","Incidence of adverse events (AE) [From Predose to Day14 after a single dose]",null,null,"NO",null],["NCT04020445","Simplification of Complex Insulin Regimens With Preserving Good Glycemic Control in Type 2 Diabetes",null,"COMPLETED","OBSERVATIONAL",null,null,null,"150","HBA1c; Body Weight; Hypoglycemia","OTHER:de-escalation of complex insulin regimens","Bekes County Central Hospital","2016-01-01","2022-01-01","FALSE","Number of participants reaching HbA1c<7% and HbA1c<6.5% [it is checked at baseline and at 3, 6, 9 and 12 months] | change in body weight from baseline to 3, 6, 9 and 12 months [it is checked at baseline and at 3, 6, 9 and 12 months] | change in risk of hypoglycemia from baseline to 3, 6, 9 and 12 months [it is checked at baseline and at 3, 6, 9 and 12 months]","RESULT:31347100",null,"UNDECIDED",null],["NCT05063253","A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes",null,"UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","208","Type 2 Diabetes Mellitus","DRUG:TG103; DRUG:Placebo","CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","2021-10","2024-03","FALSE","Changes in glycosylated hemoglobin (HbA1c) from baseline to week 20 [Baseline through Day 141 (the end of the 20-week treatment)]",null,null,"NO",null],["NCT07741604","A Study Investigating the Safety of RO7795081 and How the Body Processes RO7795081 in People With Normal or Decreased Kidney Functions",null,"RECRUITING","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","60","Renal Impairment","DRUG:RO7795081","Hoffmann-La Roche","2026-09-09","2028-02-01","FALSE","Maximum Plasma Concentration (Cmax) of RO7795081 [At prespecified timepoints from Day 1 to Day 14] | Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Last Measurable Concentration (AUClast) of RO7795081 [At prespecified timepoints from Day 1 to Day 14] | AUC From Time 0 to Infinity (AUCinf) of RO7795081 [At prespecified timepoints from Day 1 to Day 14]",null,null,"NO",null],["NCT04505436","Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)","HM-TRIA-201","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","215","NASH - Nonalcoholic Steatohepatitis","DRUG:HM15211; DRUG:Placebo of HM15211","Hanmi Pharmaceutical Company Limited","2020-07-31","2026-06-26","FALSE","pharmacodynamic (PD) effect of HM15211 [12 months]",null,null,"NO",null],["NCT06948747","A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","49","Healthy Participants","DRUG:AZD5004; DRUG:Rosuvastatin; DRUG:Erythromycin; DRUG:Atorvastatin; DRUG:Simvastatin; DRUG:Repaglinide","AstraZeneca","2025-05-06","2025-10-03","FALSE","Part A, Part B and Part C: Area under concentration time curve from time 0 to infinity (AUCinf) [Part A:Days 1-4, 7-10, 14-17, 21-24, 28-31, 35-38, 42-49 and 55-62 Part B:Days 1, 2, 4-7, 8-11, 15, 16-19, 23, 24, 30, 31, 32, 37, 38-41, 42-45 Part C:Days 1, 2, 9, 10, 11, 18, 19, 25, 26, 27, 33, 34-36] | Part A, Part B and Part C: Area under concentration curve from time 0 to the last quantifiable concentration (AUClast) [Part A:Days 1-4, 7-10, 14-17, 21-24, 28-31, 35-38, 42-49 and 55-62 Part B:Days 1, 2, 4-7, 8-11, 15, 16-19, 23, 24, 30, 31, 32, 37, 38-41, 42-45 Part C:Days 1, 2, 9, 10, 11, 18, 19, 25, 26, 27, 33, 34-36] | Part A, Part B and Part C: Maximum observed drug concentration (Cmax) [Part A:Days 1-4, 7-10, 14-17, 21-24, 28-31, 35-38, 42-49 and 55-62 Part B:Days 1, 2, 4-7, 8-11, 15, 16-19, 23, 24, 30, 31, 32, 37, 38-41, 42-45 Part C:Days 1, 2, 9, 10, 11, 18, 19, 25, 26, 27, 33, 34-36] | Part A, Part B and Part C: Terminal elimination half life (t½λz) [Part A:Days 1-4, 7-10, 14-17, 21-24, 28-31, 35-38, 42-49 and 55-62 Part B:Days 1, 2, 4-7, 8-11, 15, 16-19, 23, 24, 30, 31, 32, 37, 38-41, 42-45 Part C:Days 1, 2, 9, 10, 11, 18, 19, 25, 26, 27, 33, 34-36] | Part A, Part B and Part C: Terminal rate constant (λz) [Part A:Days 1-4, 7-10, 14-17, 21-24, 28-31, 35-38, 42-49 and 55-62 Part B:Days 1, 2, 4-7, 8-11, 15, 16-19, 23, 24, 30, 31, 32, 37, 38-41, 42-45 Part C:Days 1, 2, 9, 10, 11, 18, 19, 25, 26, 27, 33, 34-36] | Part A, Part B and Part C: Time to reach maximum observed concentration (tmax) [Part A:Days 1-4, 7-10, 14-17, 21-24, 28-31, 35-38, 42-49 and 55-62 Part B:Days 1, 2, 4-7, 8-11, 15, 16-19, 23, 24, 30, 31, 32, 37, 38-41, 42-45 Part C:Days 1, 2, 9, 10, 11, 18, 19, 25, 26, 27, 33, 34-36] | Part A, Part B and Part C: Ratio Area under concentration time curve from time 0 to infinity (RAUCinf) [Part A:Days 1-4, 7-10, 14-17, 21-24, 28-31, 35-38, 42-49 and 55-62 Part B:Days 1, 2, 4-7, 8-11, 15, 16-19, 23, 24, 30, 31, 32, 37, 38-41, 42-45 Part C:Days 1, 2, 9, 10, 11, 18, 19, 25, 26, 27, 33, 34-36] | Part A, Part B and Part C: Ratio of Area under concentration curve from time 0 to the last quantifiable concentration (RAUClast) [Part A:Days 1-4, 7-10, 14-17, 21-24, 28-31, 35-38, 42-49 and 55-62 Part B:Days 1, 2, 4-7, 8-11, 15, 16-19, 23, 24, 30, 31, 32, 37, 38-41, 42-45 Part C:Days 1, 2, 9, 10, 11, 18, 19, 25, 26, 27, 33, 34-36] | Part A, Part B and Part C: Ratio of Maximum observed drug concentration (RCmax) [Part A:Days 1-4, 7-10, 14-17, 21-24, 28-31, 35-38, 42-49 and 55-62 Part B:Days 1, 2, 4-7, 8-11, 15, 16-19, 23, 24, 30, 31, 32, 37, 38-41, 42-45 Part C:Days 1, 2, 9, 10, 11, 18, 19, 25, 26, 27, 33, 34-36]",null,null,"YES",null],["NCT06147544","A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-718 Injection in Chinese Obese Subjects.",null,"COMPLETED","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","DOUBLE","36","Obesity","DRUG:PB-718; DRUG:Placebo","PegBio Co., Ltd.","2023-07-06","2024-04-16","FALSE","Incidence of Treatment-Emergent Adverse Events [From the first dosing (Day 1 ) of study drug until completion of the post treatment follow-up visit (20 weeks for cohort 1 and cohort 2 or 26 weeks for cohort 3)]",null,null,"NO",null],["NCT06712836","A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight","VESPER-1","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","239","Obesity; Overweight or Obesity","DRUG:MET097; DRUG:Placebo","Pfizer","2024-10-09","2025-07-03","TRUE","Percent Change From Baseline in Body Weight at Week 28: Part A [Baseline (last non-missing measurement prior to the first dose), Week 28]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/36/NCT06712836/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/36/NCT06712836/SAP_001.pdf","YES","OTHER:C6491004"],["NCT02188303","A Study of LY2944876 in Healthy Japanese and Non-Japanese Participants",null,"TERMINATED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","48","Healthy Volunteers","DRUG:LY2944876; DRUG:Placebo","OPKO Health, Inc.","2014-07","2014-12","TRUE","Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to Be Related to Study Drug Administration [Pre-dose (PRD) through Study Completion (Up to Day 40)]",null,null,null,"OTHER:I7I-EW-XNAB"],["NCT00674466","A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Who Are Currently on Metformin Monotherapy",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","90","Type 2 Diabetes Mellitus","DRUG:1.5 mg or 2.0 mg CJC-1134-PC; DRUG:Placebo","ConjuChem","2008-03","2008-11","TRUE","Reduction of HbA1c From Baseline [Screening and Day 85]",null,null,null,null],["NCT06988553","A Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","45","Obesity or Overweight; Type 2 Diabetes","DRUG:AZD5004; DRUG:Placebo","Eccogene","2025-06-17","2025-11-28","FALSE","Number of participants with adverse events (AEs), serious adverse events (SAEs), adverse event leading to the discontinuation of study intervention (DAEs), death, and Adverse events of special interest (AESIs) [From baseline to week 16.]",null,null,"NO",null],["NCT06577428","A Study of RAY1225 at Different Injection Sites in Participants With Different Body Sizes",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","48","Healthy","DRUG:RAY1225","Guangdong Raynovent Biotech Co., Ltd","2024-07-30","2024-09-29","FALSE","Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of RAY1225 From Time Zero to Infinity (AUC[0-∞]) [DAY1~43] | PK: Maximum Concentration (Cmax) of RAY1225 [DAY1~43]",null,null,null,null],["NCT05943886","A Phase 1 Study of HEC88473 Injection in Healthy Subjects, Obese Subjects and T2DM Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","164","Healthy Subjects; Obesity; T2DM (Type 2 Diabetes Mellitus)","DRUG:HEC88473 injection; DRUG:Placebo","Dongguan HEC Biopharmaceutical R&D Co., Ltd.","2021-08-11","2023-02-17","FALSE","Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) after a single dose of HEC88473 [Baseline to day 15] | Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) after multiple dose of HEC88473 [Baseline to day 43] | Cmax [Predose and postdose 4、8、10、12、14、24、48、72、96、168、216、336 hours] | AUC [Predose and postdose 4、8、10、12、14、24、48、72、96、168、216、336 hours]","DERIVED:40175670; DERIVED:39709140",null,null,null],["NCT07056842","This is an Open-label, Non-randomized Study to Assess the Pharmacokinetics (PK) of VCT220 in Healthy Volunteers When Administered With Rifampin or Itraconazole",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","32","Obesity &Amp; Overweight","DRUG:Rifampin + VCT220; DRUG:Itraconazole + VCT220","Vincentage Pharma Co., Ltd","2025-07-20","2025-08-11","FALSE","Area under plasma concentration-time curve from time zero to infinity (AUC) for VCT220. [1 hour pre-dose on D1 and D11, and 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, 72h post dose] | Area under plasma concentration-time curve from time zero to infinity (AUC) for VCT220 [1 hour pre-dose on D1 and D12, and 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, 72h post dose] | Maximum observed plasma concentration (Cmax) for VCT220 [1 hour pre-dose on D1 and D11, and 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, 72h post dose] | Maximum observed plasma concentration (Cmax) for VCT220 [1 hour pre-dose on D1 and D12, and 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, 72h post dose]",null,null,"NO",null],["NCT06113341","A Research Study in Italy to Understand How the Dose Check App Used With Xultophy® Works in the Treatment of People Living With Type 2 Diabetes",null,"WITHDRAWN","OBSERVATIONAL",null,null,null,"0","Diabetes Mellitus, Type 2","DRUG:IDegLira","Novo Nordisk A/S","2024-11-07","2025-02-23","FALSE","Participant downloaded and actively used the app (Yes/No) [From baseline (week 0) to end of the study (EOS) visit (week 26)]",null,null,"YES","OTHER:U1111-1288-8131"],["NCT06199505","A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","153","Type 2 Diabetes","DRUG:GZR101; DRUG:insulin degledec/insulin aspart","Gan and Lee Pharmaceuticals, USA","2023-11-21","2024-06-28","FALSE","Change in HbA1c [Baseline to week 16]",null,null,null,null],["NCT06562088","A Drug-Drug Interaction (DDI) Study of HDM1002 With Rifampicin and Itraconazole in Healthy Subjects",null,"UNKNOWN","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","40","Healthy Adult Subject","DRUG:HDM1002 and rifampicin; DRUG:HDM1002 and itraconazole","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2024-08-16","2024-11-19","FALSE","AUC[0-∞] of HDM1002 [Cohort 1: Day 1-Day 5 and Day 12-Day 16; Cohort 2: Day 1-Day 5 and Day 9-Day 13] | AUC[0-24 h] of HDM1002 [Cohort 1: Day 1-Day 5 and Day 12-Day 16; Cohort 2: Day 1-Day 5 and Day 9-Day 13] | Cmax of HDM1002 [Cohort 1: Day 1-Day 5 and Day 12-Day 16; Cohort 2: Day 1-Day 5 and Day 9-Day 13] | AUC[0-t] of HDM1002 [Cohort 1: Day 1-Day 5 and Day 12-Day 16; Cohort 2: Day 1-Day 5 and Day 9-Day 13] | Tmax of HDM1002 [Cohort 1: Day 1-Day 5 and Day 12-Day 16; Cohort 2: Day 1-Day 5 and Day 9-Day 13] | t1/2 of HDM1002 [Cohort 1: Day 1-Day 5 and Day 12-Day 16; Cohort 2: Day 1-Day 5 and Day 9-Day 13] | CL/F of HDM1002 [Cohort 1: Day 1-Day 5 and Day 12-Day 16; Cohort 2: Day 1-Day 5 and Day 9-Day 13] | Vz/F of HDM1002 [Cohort 1: Day 1-Day 5 and Day 12-Day 16; Cohort 2: Day 1-Day 5 and Day 9-Day 13]",null,null,null,null],["NCT02653599","A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","174","Type 2 Diabetes Mellitus","DRUG:TTP273; DRUG:Placebo","vTv Therapeutics","2015-12","2016-11","FALSE","Change in HbA1c from baseline at 12 weeks [Day 1 to Week 12]",null,null,null,null],["NCT06613763","A Study of RAY1225 in Participants With Impaired Kidney Function",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","32","Kidney Impairment","DRUG:RAY1225","Guangdong Raynovent Biotech Co., Ltd","2024-09-11","2025-01-10","FALSE","Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of RAY1225 From Time Zero to T (AUC[0-t]) [Baseline through Day 43] | PK: Maximum Concentration of RAY1225 [Baseline through Day 43]",null,null,null,null],["NCT07145151","A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)","MASH","RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","156","Metabolic Dysfunction-associated Steatohepatitis (MASH)","DRUG:UBT251; DRUG:Placebo","The United Bio-Technology (Hengqin) Co., Ltd.","2025-09-30","2027-06-04","FALSE","Percentage of Participants With MASH resolution With no Worsening of Fibrosis on Liver Histology [Baseline, Week 48]",null,null,"NO","OTHER:Approved No.:2023LP01795"],["NCT07311850","Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity","VESPER-4","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","3578","Obesity and Overweight","DRUG:MET097; DRUG:Placebo","Pfizer","2025-12-19","2027-09-21","FALSE","Percent change from baseline in body weight [Baseline (Day 0) to Week 64]",null,null,"YES","OTHER:C6491007; REGISTRY:2025-523974-18-00; OTHER:VESPER-4; NIH:2025"],["NCT07872436","A Study of VCT220 Tablets in Adults With Type 2 Diabetes and Inadequate Blood Glucose Control","VICTOR-DM","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","120","Type 2 Diabetes Mellitus (DM)","DRUG:VCT220 tablets; DRUG:Placebo","Vincentage Pharma Co., Ltd","2026-11-01","2027-07-01","FALSE","Change From Baseline in HbA1c [Baseline (Week0) and Week 16]",null,null,"NO",null],["NCT06555640","A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","79","Severe Hypertriglyceridemia","DRUG:DR10624 Injection; DRUG:Placebo","Zhejiang Doer Biologics Co., Ltd.","2024-08-01","2025-06-30","FALSE","Change of fasting TG [From baseline to Week 12]",null,null,null,null],["NCT06886126","Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","240","Obesity","DRUG:HDM1005 injection or placebo","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2025-02-07","2025-09-23","FALSE","Percentage Change From Baseline in Body Weight at Week 22 [Baseline, Week 22]",null,null,"NO",null],["NCT06857695","A Study to Assess the Mass Balance and ADME of [14C]AZD5004 and the Absolute Bioavailability of AZD5004",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","8","Healthy Participants","DRUG:AZD5004 film-coated tablet; DRUG:[14C]AZD5004 Solution for Infusion; DRUG:[14C]AZD5004 Oral Solution","AstraZeneca","2025-03-06","2025-05-05","FALSE","Absolute bioavailability - Part 1 [Plasma sample collection from pre-dose to 110 hrs post-dose] | Amount of AZD5004 excreted (Ae) - Part 2 [Urine and faecal samples collected from pre-dose until 168 hours post-dose] | Amount of AZD5004 excreted expressed as a percentage of the dose administered (Fe) - Part 2 [Urine and faecal samples collected from pre-dose until 168 hours post dose] | Cumulative amount of AZD5004 excreted (CumAe) - Part 2 [Urine and faecal samples collected from pre-dose until 168 hours post dose] | Cumulative amount of AZD5004 excreted expressed as a percentage of the dose administered (CumFe) - Part 2 [Urine and faecal samples collected from pre-dose until 168 hours post dose]",null,null,"YES",null],["NCT07340320","A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","240","Type II Diabetes Mellitus","DRUG:CX11; OTHER:Placebo","Corxel Pharmaceuticals","2026-02-06","2027-04-16","FALSE","Change in Glycosylated hemoglobin, Type A1C (HbA1c) from baseline [At Week 24]",null,null,"NO",null],["NCT07360275","A Study of VCT220 in Participants With Hypertension and Obesity or Overweight","VICTOR-HTN","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","160","Hypertension","DRUG:VCT220 Tablet; DRUG:VCT220 Placebo Tablet","Vincentage Pharma Co., Ltd","2026-03-01","2026-10-30","FALSE","Change from baseline in office seated systolic blood pressure (SBP) at Week 20 [From baseline to week 20]",null,null,null,null],["NCT07807059","A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment",null,"RECRUITING","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","32","Overweight/Obesity; Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH); Type 2 Diabetes Mellitus","DRUG:HRS-4729","Fujian Shengdi Pharmaceutical Co., Ltd.","2026-09-09","2027-03-15","FALSE","Cmax [assessed up to approximately 4 weeks post-dose;] | AUC0-t [assessed up to approximately 4 weeks post-dose] | AUC0-inf. [assessed up to approximately 4 weeks post-dose]",null,null,"UNDECIDED",null],["NCT07827027","Evaluation of the Bioequivalence of RAY1225 Injection in Healthy Participants",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","68","Basic Science","DRUG:RAY1225","Guangdong Raynovent Biotech Co., Ltd","2026-09-21","2026-11-05","FALSE","Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of RAY1225 From Time Zero to T (AUC[0-t]) [Baseline through Day 43] | PK: Maximum Concentration of RAY1225 [Baseline through Day 43]",null,null,"NO",null],["NCT04973111","A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","32","Diabetes","DRUG:CT-868 as SC Injection; DRUG:Placebo as SC Injection; DRUG:Active Comparator as SC Injection","Carmot Therapeutics, Inc.","2021-07-16","2022-04-22","FALSE","Change in insulin secretion rate and ambient glucose levels [Baseline up to 4 days]",null,null,"NO",null],["NCT06893016","Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","640","Obesity","DRUG:RAY1225; DRUG:Placebo","Guangdong Raynovent Biotech Co., Ltd","2025-06-15","2026-06-15","FALSE","Percent Change From Baseline in Body Weight at Week 52 [Baseline and Week 52] | Number of Participants who Achieved a ≥ 5% Reduction in Body Weight from Baseline at Week 52 [Baseline and Week 52]",null,null,"UNDECIDED",null],["NCT07830329","Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","300","Hidradenitis Suppurativa","DRUG:Olatorepatide; DRUG:Placebo","Regeneron Pharmaceuticals","2026-10-30","2028-11-24","FALSE","Percent change in total Abscess and inflammatory Nodule (AN) count [From baseline to week 52]",null,null,"YES","CTIS:2026-526375-39-00"],["NCT03406377","Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","113","Type 2 Diabetes Mellitus","DRUG:OPK-88003; DRUG:Placebo","OPKO Health, Inc.","2018-04-02","2019-03-08","TRUE","Change in HbA1c in Subjects With Type 2 DM [From baseline to 30 weeks]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/77/NCT03406377/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/77/NCT03406377/SAP_001.pdf",null,null],["NCT06520540","HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects",null,"UNKNOWN","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","72","Glucagon-Like Peptide-1 Receptor Agonists","DRUG:HDM1002 100 mg QD 12weeks; DRUG:HDM1002 200 mg QD 12weeks; DRUG:HDM1002 400 mg QD 12weeks，Q 2W for titration; DRUG:HDM1002 400 mg QD 12weeks，Q 3W for titration; DEVICE:Placebo","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2024-07-28","2024-11-30","FALSE","TEAEs, SAEs, AEs leading to withdrawal, and AEs leading to death, AEs of special interest [Baseline, Week 12]",null,null,"NO",null],["NCT07652047","A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","90","Obesity & Overweight","DRUG:CX11; OTHER:Placebo","Corxel Pharmaceuticals","2026-05-11","2027-03","FALSE","Percentage change in body weight from baseline [Week 26]",null,null,null,null],["NCT01665352","A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","186","Type 2 Diabetes Mellitus","DRUG:TTP054; DRUG:Placebo","vTv Therapeutics","2012-08","2013-05","FALSE","Change from baseline in HbA1c (%) as compared to placebo [Day 1 to Day 84]",null,null,null,null],["NCT06481098","A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","74","Obesity","DRUG:HM15275; DRUG:Placebo of HM15275","Hanmi Pharmaceutical Company Limited","2024-05-28","2025-05-02","FALSE","Part A: Safety and Tolerability [Up to Day 29] | Part B: Safety and Tolerability [Up to Day 57]",null,null,"UNDECIDED",null],["NCT03095807","Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","34","Metabolism and Nutrition Disorder; Obesity","DRUG:NNC9204-1706 A; DRUG:Placebo","Novo Nordisk A/S","2017-03-20","2017-08-31","FALSE","Number of treatment-emergent adverse events (TEAEs) [From the time of dosing (Day 1) and until completion of the post-treatment follow-up visit (Days 10-13)]",null,null,"YES","OTHER:U1111-1177-7821"],["NCT07626515","A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese Participants",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","36","Healthy Participants","COMBINATION_PRODUCT:Enicepatide; COMBINATION_PRODUCT:Placebo","Hoffmann-La Roche","2026-07-02","2027-05-14","FALSE","Incidence and Severity of Adverse Events [Baseline to Safety Follow-Up (27 weeks)] | Number of Participants with Abnormal Clinical Laboratory Parameters as a Shift from Baseline to Maximum Postbaseline Severity Grade [Baseline to Safety Follow-Up (27 weeks)] | Change from Baseline in Pulse Rate [At prespecified time points from Baseline to Safety Follow-Up (27 weeks)] | Change from Baseline in Respiratory Rate [At prespecified time points from Baseline to Safety Follow-Up (27 weeks)] | Change from Baseline in Systolic Blood Pressure [At prespecified time points from Baseline to Safety Follow-Up (27 weeks)] | Change from Baseline in Diastolic Blood Pressure [At prespecified time points from Baseline to Safety Follow-Up (27 weeks)] | Change from Baseline in Body Temperature [At prespecified time points from Baseline to Safety Follow-Up (27 weeks)]",null,null,"NO",null],["NCT07400653","A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","1078","Obesity; Overweight and/or Obesity; Overweight; Diabetes, Type 2; Type 2 Diabetes","DRUG:PF-08653944; OTHER:Placebo","Pfizer","2026-02-24","2027-10-12","FALSE","Percent Change from baseline in body weight [Baseline, Week 64]",null,null,"YES","OTHER:MET097-25-302; REGISTRY:2025-523975-48-00; OTHER:VESPER-5; NIH:2025"],["NCT05110846","A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","103","Obesity; Overweight; Type 2 Diabetes Mellitus","DRUG:Placebo; DRUG:CT-868","Carmot Therapeutics, Inc.","2022-02-22","2023-02-28","FALSE","Change from Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 26 [Baseline and Week 26]",null,null,"NO","OTHER:BP45664"],["NCT07030868","A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes",null,"TERMINATED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","1","Obesity; Overweight; Type 2 Diabetes","DRUG:LY3549492; DRUG:Placebo","Eli Lilly and Company","2025-06-19","2025-07-29","TRUE","Percent Change From Baseline in Body Weight [Baseline, Week 32]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/68/NCT07030868/Prot_000.pdf","YES","OTHER:W8M-MC-GN02; OTHER:W8M-MC-CWMM"],["NCT06194500","A Study of Carbon-14-Labeled [14C]-LY3549492 in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","18","Healthy Male","DRUG:[14C]-LY3549492; DRUG:LY3549492","Eli Lilly and Company","2024-01-03","2024-02-15","FALSE","Urinary Excretion of Total Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose in Part A [Predose up to Day 24 postdose in Part A] | Fecal Excretion of Total Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose in Part A [Predose up to Day 24 postdose in Part A] | Pharmacokinetic (PK): Area Under the Curve (AUC) for Oral Determination of Absolute Bioavailability (F) of LY3549492 in Part B [Predose up to Day 7 postdose in Part B] | PK: AUC for Intravenous (IV) Determination of Absolute Bioavailability (F) of LY3549492 in Part B [Predose up to Day 7 postdose in Part B]",null,null,"NO","OTHER:J3H-MC-GZNC; OTHER:U1111-1293-8652"],["NCT07351058","A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes","Enith2","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","1600","Obesity or Overweight; Type 2 Diabetes Mellitus","COMBINATION_PRODUCT:Placebo; COMBINATION_PRODUCT:Enicepatide","Hoffmann-La Roche","2026-03-23","2028-08-07","FALSE","Percent (%) Change from Baseline in Body Weight at Week 72 [Baseline through Week 72]",null,null,"YES","CTIS:2025-523106-32-00; NIH:2025"],["NCT05491421","A Study of ZT002 in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","32","Type 2 Diabetes Mellitus","DRUG:ZT002; OTHER:Placebo","QL Biopharmaceutical Australia Pty Ltd","2022-09-02","2023-04-28","FALSE","Safety and tolerability of a single escalation dose of ZT002 through the incidence and severity of treatment emergent adverse events in SAD Cohorts. Number of participants with treatment-emergent adverse events. [Up to 71 days] | Safety and tolerability of a single escalation dose of ZT002 through the incidence severity of serious adverse events in SAD Cohorts. Number of participants with serious adverse events. [Up to 71 days] | To assess safety and tolerability of multiple escalation doses of ZT002 in healthy participants with a BMI range of 26 kg/m2 to 40 kg/m2 and a body weight of ≥80 kg through number of participants with treatment emergent adverse events in MAD Cohorts. [up to 85 days] | To assess safety and tolerability of multiple escalation doses of ZT002 in healthy participants with a BMI range of 26 kg/m2 to 40 kg/m2 and a body weight of ≥80 kg through incidence severity of serious adverse events in MAD Cohorts. [Upto 85 days]",null,null,null,null],["NCT06118021","A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","200","Overweight and Obesity","DRUG:HS-20094; DRUG:Placebo","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2023-10-16","2024-08-13","FALSE","Percent Change from Baseline in Body Weight [From Week 0 to Week 24]",null,null,null,null],["NCT07349381","A Food-Effect Study of CX11 in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","32","Obesity & Overweight; Type 2 Diabetes","DRUG:CX11 (VCT220)","Vincentage Pharma Co., Ltd","2026-03-04","2026-06-30","FALSE","Area Under the Concentration-time curve from 0 to 24 hour (AUC0-24) of CX11 (VCT220) [Predose at Day1 up to 35 days postdose] | Maximum Observed Concentration (Cmax) of CX11 (VCT220) [Predose at Day1 up to 35 days postdose] | Time to Maximum Observed Concentration (Tmax) of CX11 (VCT220) [Predose at Day 1 up to 35 days postdose]",null,null,"NO",null],["NCT03376802","A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","24","Type 2 Diabetes Mellitus","DRUG:SAR425899; DRUG:Placebo","Sanofi","2018-04-18","2018-12-27","FALSE","Sleep energy expenditure [Baseline to Day 19]",null,null,"YES","OTHER:U1111-1191-5658"],["NCT07444424","A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","32","Healthy Participants","DRUG:AZD5004; DRUG:Mitiglinide; DRUG:Pioglitazone","AstraZeneca","2026-03-13","2026-07-02","FALSE","Area under concentration-time curve from time 0 to infinity (AUCinf) [Part A: From Day 1 to Day 50; Part B: From Day 1 to Day 70] | Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) [Part A: From Day 1 to Day 50; Part B: From Day 1 to Day 70] | Maximum observed drug concentration (Cmax) [Part A: From Day 1 to Day 50; Part B: From Day 1 to Day 70]",null,null,"YES",null],["NCT05151705","A Trial of HR17031 Injection With Hepatic Insufficiency",null,"UNKNOWN","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","24","Improved Glycemic Control in Patients With Type 2 Diabetes","DRUG:HR17031 injection","Jiangsu HengRui Medicine Co., Ltd.","2021-12-20","2022-06-15","FALSE","Pharmacokinetics parameters of INS068 and SHR20004: Cmax [Based on pre-dose, 2-96 hours post-dose sampling times] | Pharmacokinetics parameters of INS068 and SHR20004: AUC0-t [Based on pre-dose, 2-96 hours post-dose sampling times] | Pharmacokinetics parameters of INS068 and SHR20004: AUC0-inf [Based on pre-dose, 2-96 hours post-dose sampling times]",null,null,"UNDECIDED",null],["NCT07658560","A Study to Evaluate Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without Diabetes",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","200","Overweight or Obese Participants Without Diabetes","DRUG:BGM0504 tablets; DRUG:BGM0504 placebo","BrightGene Bio-Medical Technology Co., Ltd.","2026-06-30","2027-02-28","FALSE","Fasting body weight [20 weeks]",null,null,null,null],["NCT06258148","A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","465","Type 2 Diabetes Mellitus","DRUG:TG103; DRUG:Placebo","CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","2024-04-15","2026-01-23","FALSE","Changes in glycosylated hemoglobin (HbA1c) [Baseline through Week28]",null,null,null,null],["NCT07347808","A Pharmacokinetic Study of VCT220 With Moderate Renal Impairment Patients",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","16","Obesity & Overweight","DRUG:VCT220","Vincentage Pharma Co., Ltd","2025-12-25","2026-01-18","FALSE","Maximum Plasma Concentration (Cmax) of VCT220 [Day 1 at 0 h prior to dosing and at 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0, and 24.0 h (Day 2) ,36.0 h(Day 2) , 48.0 h (Day 3), and 72.0 h (Day 4) after dosing] | Area Under the Plasma Concentration-Time Curve From Time 0 to Last Measurable Concentration (AUC₀-t) of VCT220 [Day 1 at 0 h prior to dosing and at 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0, and 24.0 h (Day 2) ,36.0 h(Day 2) , 48.0 h (Day 3), and 72.0 h (Day 4) after dosing]",null,null,"NO",null],["NCT07828197","A Pharmacokinetic Study of HDM1005 Injection at Different Injection Sites",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","135","Overweight and/or Obesity; Healthy Participants","DRUG:HDM1005","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2026-09-03","2026-10","FALSE","Cmax [Up to Day 29] | AUC(0-t) [Up to Day 29] | AUC(0-∞) [Up to Day 29]",null,null,"NO",null],["NCT07527650","Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","180","Type 2 Diabetes Mellitus; T2DM","DRUG:HM15275; DRUG:Placebo of HM15275","Hanmi Pharmaceutical Company Limited","2026-05-18","2027-10","FALSE","Change in Glycated Hemoglobin (HbA1c) [Up to 41 weeks]",null,null,"NO",null],["NCT07431086","Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","120","Overweight or Obesity","DRUG:Olatorepatide; DRUG:Placebo","Regeneron Pharmaceuticals","2026-03-16","2026-11-13","FALSE","Occurrence of Treatment-Emergent Adverse Events (TEAEs) [Up to approximately 30 weeks] | Severity of TEAEs [Up to approximately 30 weeks] | Maximum plasma Concentration (Cmax) [At week 15 and week 24] | Area Under the Concentration time curve from time 0 to 168 hours (AUC0-168h) [At week 15 and week 24]",null,null,"YES",null],["NCT06929156","A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal Function",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","34","Type 2 Diabetes Mellitus (T2DM); Overweight or Obese","DRUG:BGM0504","BrightGene Bio-Medical Technology Co., Ltd.","2025-05-06","2025-12-25","FALSE","Area Under the Concentration Versus Time Curve (AUC) of BGM0504 From Time Zero to Tlast (AUC0-t) [Start of Treatment up to Day 29] | Maximum Concentration of BGM0504 (Cmax) [Start of Treatment up to Day 29] | Area Under the Concentration Versus Time Curve (AUC) of BGM0504 From Time Zero to Infinity (AUC0-inf) [Start of Treatment up to Day 29]",null,null,null,null],["NCT07794761","A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","180","Obesity","DRUG:Berobenatide; OTHER:Placebo","Pfizer","2026-09-28","2029-03-14","FALSE","Percent change from baseline in body weight [Baseline, Week 72]",null,null,"YES","OTHER:VESPER-JW"],["NCT07058545","A Study of CJC-1134-PC Injection in Antidiabetic Treatment-naive Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","474","Type 2 Diabetes Mellitus - Poor Control","DRUG:CJC-1134-PC Injection; DRUG:Placebo","Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.","2021-04-16","2023-02-20","FALSE","Change from baseline in HbA1c at the end of double-blind treatment period. [Week 25 visit]",null,null,"NO",null],["NCT03744182","A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","66","NAFLD","DRUG:HM15211; DRUG:Placebo of HM15211","Hanmi Pharmaceutical Company Limited","2018-11-01","2020-03-18","TRUE","Number of Participants With Adverse Events [12 weeks] | Incidence of Clinical Renal Function Lab Abnormalities [baseline and 12 weeks] | Vital Signs [baseline and 12 weeks] | 12-lead ECG [baseline and 12 weeks]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/82/NCT03744182/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/82/NCT03744182/SAP_001.pdf",null,null],["NCT04839744","A Comparative Study of TG103 Produced by Two Manufacturing Processes in Chinese Healthy Male Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","24","Healthy Male Subjects","DRUG:TG103 produced by the modified manufacturing process; DRUG:TG103 produced by the original manufacturing process","CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","2021-05-18","2021-06-15","FALSE","Peak Plasma Concentration (Cmax) [Day1-5, 7,9,10, 15, and 28] | Area under the plasma concentration versus time curve (AUC) [Day1-5, 7,9,10, 15, and 28]",null,null,"NO",null],["NCT05021666","A Phase 1, Double-blind, Randomized, Placebo-controlled, Single- and Multiple-dose Escalating Study",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","82","Healthy Subjects","DRUG:Placebo; DRUG:PB 718","PegBio Co., Ltd.","2020-07-29","2022-05-18","FALSE","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [From Group A1 until Group B4. The study duration for each subject in Part A will be approximately 8 weeks. The study duration for each subject in Part B will be approximately 11 weeks.]",null,null,"UNDECIDED",null],["NCT07400679","A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","48","Overweight; Obesity; Healthy","DRUG:PF-08653944","Pfizer","2026-02-04","2026-07-02","FALSE","Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of PF-08653944 [Up to 85 days] | PK: Maximum Observed Concentration (Cmax) of PF-08653944 [Up to 85 days]",null,null,"NO",null],["NCT06742762","A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","16","Renal Impairment","DRUG:AZD5004","AstraZeneca","2024-12-17","2025-04-20","FALSE","AUCinf [Day 1 to Day 5] | AUClast [Day 1 to Day 5] | Cmax [Day 1 to Day 5]",null,null,"YES",null],["NCT07395687","A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","333","Overweight; Obesity","DRUG:UBT251; DRUG:Placebo","Novo Nordisk A/S","2026-02-02","2027-01-14","FALSE","Part A - Number of treatment emergent adverse events (TEAEs) [From baseline (week 0) to end of study (week 33)] | Part B - Relative change in body weight [From baseline (week 0) to end of treatment (week 28)] | Part C- AUC; the area under the UBT251 plasma concentration time curve [From pre-dose on Day 1 until completion of the end of study visit (Day 43)]",null,null,"YES","OTHER:U1111-1324-3831"],["NCT00638716","A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus Who Are Currently on Metformin Monotherapy","DM200-101","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","122","Type 2 Diabetes Mellitus","DRUG:CJC-1134-PC; DRUG:Placebo","ConjuChem","2008-02","2008-11","TRUE","Reduction of HbA1c From Baseline [Screening and Day 85]",null,null,null,null],["NCT06621017","Effect of GLP-1 Analogue ROSE-010 on Appetite in Overweight and Obese Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","40","Obesity; Overweight","DRUG:ROSE-010 99 mcg; DRUG:Placebo; DRUG:ROSE-010 150 mcg","Rose Pharma Inc","2024-09-26","2025-02-27","TRUE","Food Consumption [30 minutes]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/17/NCT06621017/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/17/NCT06621017/SAP_001.pdf","NO",null],["NCT06525935","A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","469","Obesity; Overweight","DRUG:Placebo; DRUG:Enicepatide","Carmot Therapeutics, Inc.","2024-08-16","2025-12-08","FALSE","Percent Change in Body Weight from Baseline to Week 48 [Baseline to Week 48]",null,null,"NO","OTHER:XC45526"],["NCT06226090","A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","314","Obesity; Overweight","DRUG:TG103 7.5 mg; DRUG:Placebo 7.5 mg; DRUG:TG103 15 mg; DRUG:Placebo 15 mg; DRUG:TG103 22.5 mg; DRUG:Placebo 22.5 mg","CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","2024-02-21","2024-09-26","FALSE","Percentage relative change from baseline in body weight at week 24 [From baseline to week 24]",null,null,null,null],["NCT06897202","A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM","VESPER-2","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","133","Obesity in Diabetes; Type 2 Diabetes Mellitus (T2DM)","DRUG:MET097 Injection; DRUG:Placebo","Pfizer","2025-03-14","2025-12-29","FALSE","Percent change from baseline in body weight at Week 28 (Day 197) [Baseline (Week 0) through Week 28 (Day 197)]",null,null,"YES","OTHER:C6491005"],["NCT04812262","A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","255","Overweight and Obesity; Type2 Diabetes; NAFLD","DRUG:DD01; DRUG:Placebo","Neuraly, Inc.","2021-02-24","2022-12-20","FALSE","Number of participants with treatment-related adverse events and serious adverse events [Part A - 43 days] | Number of participants with treatment-related adverse events and serious adverse events (TEAEs) [Part B - 57 days] | Number of participants with clinically significant abnormalities in clinical laboratory values [Part A - 43 days] | Number of participants with clinically significant abnormalities in clinical laboratory values [Part B - 57 days] | Number of participants with clinically significant abnormalities in physical examinations [Part A - 43 days] | Number of participants with clinically significant abnormalities in physical examinations [Part B - 57 days] | Number of participants with clinically significant abnormalities in vital signs [Part A - 43 days] | Number of participants with clinically significant abnormalities in vital signs [Part B - 57 days] | Blood Pressure assessed by 24-hour ambulatory blood pressure monitoring (ABPM) [Part A - 43 days] | Blood Pressure assessed by 24-hour ambulatory blood pressure monitoring (ABPM) [Part B - 57 days] | Heart Rate assessed by 24-hour ambulatory electrocardiography monitoring reader) [Part A - 43 days] | Heart Rate assessed by 24-hour ambulatory electrocardiography monitoring reader) [Part B - 57 days] | Number of participants with clinically significant abnormalities in 12-lead ECGs [Part A - 43 days] | Number of participants with clinically significant abnormalities in 12-lead ECGs [Part B - 57 days]",null,null,"NO",null],["NCT06423872","A SAD Study of ZT002 Injection in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","28","Type 2 Diabetes Mellitus","DRUG:ZT002; OTHER:Placebo","Beijing QL Biopharmaceutical Co.,Ltd","2023-06-19","2023-10-20","FALSE","Safety and tolerability of a single escalation dose of ZT002 through the incidence and severity of treatment emergent adverse events in SAD Cohorts. Number of participants with treatment-emergent adverse events [Up to 50 days] | Safety and tolerability of a single escalation dose of ZT002 through the incidence severity of serious adverse events in SAD Cohorts. Number of participants with serious adverse events. [Up to 50 days]",null,null,null,null],["NCT04838743","GOAL: A Research Study Looking at Long Term Blood Sugar Control in People With Type 2 Diabetes Treated With Xultophy® in Local Clinical Practice in Japan.","GOAL","COMPLETED","OBSERVATIONAL",null,null,null,"244","Diabetes Mellitus, Type 2","DRUG:IDegLira","Novo Nordisk A/S","2021-04-23","2022-10-26","FALSE","Change in local laboratory measured HbA1c (Glycated haemoglobin ) [From baseline (Visit 1) to 26 weeks (Visit 3)]",null,null,"YES","OTHER:U1111-1253-2025; REGISTRY:jRCT1051210008"],["NCT05324462","Glycaemic Control and Other Clinical Parameters in Adult Type 2 Diabetes Patients on Basal Insulin Initiating Treatment With IDegLira in Routine Clinical Practice in Colombia","SPIRIT","COMPLETED","OBSERVATIONAL",null,null,null,"175","Diabetes Mellitus, Type 2","DRUG:IDegLira","Novo Nordisk A/S","2022-03-22","2022-07-15","FALSE","Change in local laboratory measured Glycated Haemoglobin A1c (HbA1c) [From baseline (week 0) to end of study (week 26 plus/minus 6 weeks) after IDegLira initiation]","DERIVED:38717577",null,"YES","OTHER:U1111-1266-5484"],["NCT06839664","A Study of HS-20094 in Chinese Adults With Overweight or Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","604","Overweight; Obesity","DRUG:HS-20094 injection; DRUG:Placebo injection","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2024-11-16","2026-01-04","FALSE","Percent Change from Baseline in Body Weight [Baseline, week 48] | Percentage of Participants Who Achieve weight loss≥ 5% from Baseline [Baseline, week 48]",null,null,null,null],["NCT06938529","A Pharmacokinetic Study of VCT220 in Particicants With Hepatic Injury and Normal Hepatic Function",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","24","Obesity, Overweight","DRUG:VCT220; DRUG:Placebo","Vincentage Pharma Co., Ltd","2025-04-18","2025-07-15","FALSE","Peak Plasma Concentration (Cmax) of VCT220 [Predose up to 72 hours postdose (D1 to D4)] | Area Under the Serum Concentration Curve From Time 0 to the Last Measurable Concentration (AUC0-last) of VCT220 [Predose up to 72 hours postdose (D1 to D4)] | Area Under the Serum Concentration Curve From Time 0 to Infinity(AUC0-inf) of VCT220 [Predose up to 72 hours postdose (D1 to D4)]",null,null,"NO",null],["NCT05299697","A Study of TG103 Injection in Overweight or Obesity",null,"UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","SINGLE","195","Overweight or Obesity","DRUG:TG103 15 mg; DRUG:TG103 22.5 mg; DRUG:Placebo","CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","2022-05-20","2023-06-30","FALSE","Relative change from baseline in body weight at week 24 [From baseline to week 24]",null,null,"NO",null],["NCT06601517","A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.",null,"UNKNOWN","INTERVENTIONAL","PHASE1",null,"NONE","30","Healthy Adult Subject; Overweight Subject","DRUG:Repaglinide; DRUG:Atorvastatin; DRUG:Digoxin; DRUG:Rosuvastatin; DRUG:HDM1002","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2024-10","2025-02","FALSE","AUC[0-∞] [Period 1 and Period 3: Day 1-Day 16] | AUC[0-t] [Period 1 and Period 3: Day 1-Day 16] | Cmax [Period 1 and Period 3: Day 1-Day 16]",null,null,null,null],["NCT06637020","Phase Ib Clinical Study of HDM1005 Injection",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","80","Overweight and Obesity","DRUG:HDM1005 injection or placebo","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2024-06-21","2025-03-28","FALSE","The incidence, severity, and causality of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) [Signing informed until day 57]",null,null,null,null],["NCT03661879","Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","60","Metabolism and Nutrition Disorder; Obesity","DRUG:NNC9204-1706; DRUG:Placebo (NNC9204-1706)","Novo Nordisk A/S","2018-09-12","2019-09-05","FALSE","Number of treatment emergent adverse events (TEAEs) [Days 1-84]","DERIVED:36524539",null,"YES","OTHER:U1111-1208-7677"],["NCT06268145","ECC5004 RBA FE Study in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","14","Type 2 Diabetes Mellitus","DRUG:ECC5004","Eccogene","2024-02-06","2024-03-29","FALSE","ECC5004 PK parameters: AUC0-tlast [Up to day 6] | ECC5004 PK parameters: AUC0-inf [Up to day 6] | ECC5004 PK parameters: Cmax [Up to day 6] | ECC5004 PK parameters: tmax [Up to day 6]",null,null,"NO",null],["NCT07177469","UBT251 Injection Phase II Study (Overweight or Obesity)",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","205","Obesity &Amp; Overweight","DRUG:UBT251 Injection 2.0 mg and UBT251 Injection Placebo; DRUG:UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo; DRUG:UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo; DRUG:UBT251 Injection 6.0 mg and UBT251 Injection Placebo","The United Bio-Technology (Hengqin) Co., Ltd.","2025-03-14","2025-10-22","FALSE","Body Weight [Week 24]","DERIVED:42843337",null,"YES",null],["NCT02941042","A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity.",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","49","Metabolism and Nutrition Disorder; Obesity","DRUG:NNC9204-1177; DRUG:Placebo","Novo Nordisk A/S","2016-10-10","2017-09-30","FALSE","Number of treatment emergent adverse events (TEAEs) [From time of dosing (day 1) until completion of the follow-up visit (day 39)]",null,null,"YES","OTHER:U1111-1173-8190"],["NCT07274644","Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver Disease",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","36","Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus Type 2","DRUG:iGlarLixi; DRUG:IGlar U100","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","2025-03-29","2026-06-30","FALSE","Absolute change from baseline to Week 12 in hepatic fat fraction [Baseline, Week 12]",null,null,"NO",null],["NCT05997576","A Study of TG103 Injection in Non-diabetic Overweight or Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","675","Overweight or Obesity","DRUG:TG103 22.5 mg; DRUG:Placebo","CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","2023-11-22","2025-02-17","FALSE","Proportion of participants with weight loss of ≥ 5% at week 40 [From baseline to week 40] | Relative percentage change from baseline in body weight at week 40 [From baseline to week 40]",null,null,"UNDECIDED",null],["NCT02411825","Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","76","Type 2 Diabetes Mellitus","DRUG:SAR425899; DRUG:placebo; DRUG:metformin","Sanofi","2015-03","2016-01","FALSE","Number of adverse events [28 to 35 days]","DERIVED:31808298; DERIVED:30091218",null,null,"EUDRACT_NUMBER:2014-004216-10; OTHER:U1111-1163-1209; NIH:2014"],["NCT07499050","A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","30","Healthy Volunteers; Overweight or Obesity","DRUG:RO7795081; DRUG:Placebo","Hoffmann-La Roche","2026-03-30","2027-01-09","FALSE","Incidence, Severity, and Causal Relationship to Treatment of Adverse Events [Baseline to Safety Follow-Up (26 weeks)] | Incidence of Abnormal Clinical Laboratory Test Findings [Baseline to Safety Follow-Up (26 weeks)] | Incidence of Abnormal Vital Signs [Baseline to Safety Follow-Up (26 weeks)] | Incidence of Abnormal Electrocardiogram (ECG) Results [Baseline to Safety Follow-Up (26 weeks)] | Incidence of Abnormal Psychiatry Parameters [Baseline to Safety Follow-Up (26 weeks)]",null,null,"NO",null],["NCT04059367","Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy People",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","45","Healthy Volunteers; Overweight; Obesity","DRUG:NNC9204-1177; DRUG:Cocktail of 5 already approved drugs","Novo Nordisk A/S","2019-08-15","2020-01-02","FALSE","Area under the plasma concentration-time curve extrapolated to infinity of the caffeine [From 0 to 24 hours after a single dose of caffeine without NNC9204-1177 exposure (administered on Visit 2, Day 1) and at NNC9204-1177 steady state (administered on Visit 12, Day 78)] | Area under the plasma concentration-time curve extrapolated to infinity of the omeprazole [From 0 to 8 hours after a single dose of omeprazole without NNC9204-1177 exposure (administered on Visit 2, Day 1) and at NNC9204-1177 steady state (administered on Visit 12, Day 78)] | Area under the plasma concentration-time curve extrapolated to infinity of the midazolam [From 0 to 12 hours after a single dose of midazolam without NNC9204-1177 exposure (administered on Visit 2, Day 1) and at NNC9204-1177 steady state (administered on Visit 12, Day 78)] | Area under the plasma concentration-time curve extrapolated to infinity of the s-warfarin [From 0 to 168 hours after a single dose of warfarin without NNC9204-1177 exposure (administered on Visit 2, Day 1) and at NNC9204-1177 steady state (administered on Visit 12, Day 78)] | Area under the plasma concentration-time curve extrapolated to infinity of the dextromethorphan [From 0 to 72 hours after a single dose of dextromethorphan without NNC9204-1177 exposure (administered on Visit 2, Day 1) and at NNC9204-1177 steady state (administered on Visit 12, Day 78)]",null,null,"YES","OTHER:U1111-1232-7100 Trial"],["NCT07156500","A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","204","Type 2 Diabetes","DRUG:HS-20094 Injection; DRUG:HS-20094 Placebo Injection","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2025-09-30","2027-03-30","FALSE","Change in HbA1c [Week 0 to Week 44]",null,null,null,null],["NCT01056107","Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients",null,"COMPLETED","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","QUADRUPLE","52","Irritable Bowel Syndrome Constipation Predominant","DRUG:ROSE-010; DRUG:Placebo","Mayo Clinic","2010-01","2011-12","TRUE","Colonic Transit, Colonic Geometric Center at 24 Hours [24 hours (Visit 3 = Day 1)] | Change Between Postprandial and Fasting Whole Gastric Volume by Technetium-99m (99mTc)-SPECT Imaging (Gastric Accommodation) [approximately 1 hour after 99mTC injection, approximately 30 min after liquid meal (Visit 5 = approximately 2-10 days after Visit 4)] | Half Time (t1/2) of Gastric Emptying of Solids Measured by Scintigraphy (Gastric Transit) [approximately 2 hours after radiolabeled meal is ingested (Visit 2 = Day 0)]","RESULT:22517769",null,null,"NIH:UL1RR024150"],["NCT05378893","A First in Human (FIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DR10624",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","153","Healthy, Obesity, Metabolically","DRUG:DR10624 for injection; DRUG:Placebo","Zhejiang Doer Biologics Co., Ltd.","2022-06-22","2024-10-10","FALSE","Number of participants with one or more treatment-emergent adverse event (TEAE), serious adverse event (SAE) and adverse event of special interest (AESI). [baseline through day 29(part 1)or day 106(part 2)]",null,null,"NO",null],["NCT07767942","UBT251 Injection Phase Ⅲ Study (OSA-NPAP)","UNISHAPE-OSA-1","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","150","Obstructive Sleep Apnea, Obesity","DRUG:UBT251; DRUG:Placebo","The United Bio-Technology (Hengqin) Co., Ltd.","2026-09-18","2028-09","FALSE","Change from baseline in the Apnea-Hypopnea Index (AHI) [Baseline, Week 52]",null,null,"NO",null],["NCT07680829","A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","378","Severe Hypertriglyceridemia","DRUG:DR10624 Subcutaneous Injection; DRUG:Icosapent Ethyl Oral Capsule; DRUG:Matching Placebo Subcutaneous Injection","Zhejiang Doer Biologics Co., Ltd.","2026-08","2030-06","FALSE","Percentage change from baseline in average fasting serum triglyceride concentration at Week 26 [Baseline up to Week 26 of double-blind treatment period]",null,null,null,null],["NCT07710729","A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become Pregnant",null,"RECRUITING","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","40","Overweight; Obesity","DRUG:UBT251; DRUG:Oral contraceptive; DRUG:Acetaminophen","Novo Nordisk A/S","2026-07-17","2027-04-27","FALSE","AUC,EE,SS: The area under the EE plasma concentration time curve during a dosing interval at steady state [From pre-dose on Day 8 up to 157 days] | AUC ,LN,SS: The area under the LN plasma concentration time curve during a dosing interval at steady state [From pre-dose on Day 8 up to 157 days]",null,null,"YES","OTHER:U1111-1332-9333"],["NCT07690826","A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","252","Overweight or Obesity","DRUG:HRS-4729 Injection; DRUG:HRS-4729 Injection;; DRUG:HRS-4729 Injection Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2026-07","2027-03","FALSE","Percent Change From Baseline in Body Weight [Baseline, Week 32]",null,null,"UNDECIDED",null],["NCT07232732","A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","120","Healthy; Obesity; Overweight","DRUG:LY3549492","Eli Lilly and Company","2025-10-27","2026-07-16","FALSE","Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline through end of the Follow-up Period (Week 10)]",null,null,"NO","OTHER:J3H-MC-GZNJ"],["NCT07085468","A Study of LY3549492 in Healthy Weight Adult Participants",null,"TERMINATED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","1","Healthy","DRUG:LY3549492; DRUG:Placebo","Eli Lilly and Company","2025-07-21","2025-08-14","TRUE","Number of Participants With One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration [Baseline through Week 48]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/68/NCT07085468/Prot_SAP_001.pdf","YES","OTHER:J3H-MC-GZNI"],["NCT07787260","A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Not Receiving Positive Airway Pressure (PAP) Therapy",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","200","Obstructive Sleep Apnea (OSA) and Obesity","DRUG:HDM1005; DRUG:Placebo","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2026-08","2028-03","FALSE","Percentage change in body weight from baseline at week 52 [52 week] | Change in AHI from baseline at week 52 [52 week]",null,null,null,null],["NCT03437720","Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver Disease","Restore","WITHDRAWN","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","0","Non-alcoholic Steatohepatitis; Type 2 Diabetes Mellitus","DRUG:SAR425899; DRUG:Placebo","Sanofi","2019-05-23","2021-08-25","FALSE","Resolution of Non-alcoholic steatohepatitis (NASH) [Week 52]",null,null,"YES","EUDRACT_NUMBER:2017-002371-26; OTHER:U1111-1191-5486; NIH:2017"],["NCT06577415","A Study of RAY1225 in Participants With Impaired Liver Function",null,"UNKNOWN","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","24","Hepatic Impairment","DRUG:RAY1225","Guangdong Raynovent Biotech Co., Ltd","2024-08-26","2025-10-31","FALSE","Pharmacokinetics (PK): Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC[0-∞]) of RAY1225 [DAY1~43] | PK: Maximum Observed Drug Concentration (Cmax) of RAY1225 [DAY1~43]",null,null,null,null],["NCT06857617","This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","DOUBLE","120","Obesity and Overweight","BIOLOGICAL:(Part C) MET097; BIOLOGICAL:(Part C) Placebo","Metsera, a wholly owned subsidiary of Pfizer","2024-04-01","2025-01-03","FALSE","(Part C) Percent change from baseline in body weight at Week 12 (Day 85). [Day 1 (Week 0) to Day 85 (Week 12)]",null,null,"UNDECIDED",null],["NCT06716203","A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","207","Type 2 Diabetes Mellitus (T2DM)","DRUG:Drug: 5 mg BGM0504 Administered SC; DRUG:Drug: : 10 mg BGM0504 Administered SC; DRUG:Drug: Placebo Administered SC","BrightGene Bio-Medical Technology Co., Ltd.","2024-12-02","2025-12-29","FALSE","Change From Baseline in Hemoglobin A1c (HbA1c) [Week 0 to Week 32]",null,null,null,null],["NCT07460284","A Mass Balance Study Of 14C-RAY1225 Injection In Healthy Chinese Participants",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1",null,"NONE","8","Basic Science","DRUG:14C-RAY1225","Guangdong Raynovent Biotech Co., Ltd","2026-03-15","2026-10-14","FALSE","Total radioactivity recovery and cumulative recovery in urine and feces in each time period; [DAY1~DAY60] | Radioactivity of each metabolite in urine and feces as a percentage of the total administered dose and the circulating metabolites in plasma as a percentage of the total exposure AUC (%AUC); [DAY1~DAY60]",null,null,"NO",null],["NCT07082114","A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","800","Type 2 Diabetes","DRUG:HDM1002 100 mg; DRUG:HDM1002 200 mg; DRUG:HDM1002 400 mg; DRUG:Dapagliflozin (DAPA)","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2025-07-14","2027-02-16","FALSE","Change From Baseline in HbA1c at Week 40 [Baseline, Week 40]",null,null,"NO",null],["NCT06640647","Phase Ia Clinical Study of HDM1005 Injection",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","65","Obesity and Overweight","DRUG:HDM1005 injection or placebo","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2024-03-19","2024-08-06","FALSE","Safety Outcomes [Signing informed until day 29]",null,null,null,null],["NCT05848440","A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","48","Non-alcoholic Steatohepatitis","DRUG:AZD9550; DRUG:Placebo","AstraZeneca","2023-05-02","2023-11-13","FALSE","Adverse Events (AEs) and Serious Adverse Events (SAEs) [Throughout the study (up to 6 months)]",null,null,"YES","EUDRACT_NUMBER:2022-003308-34"],["NCT06608329","A Relative Bioavailability and Food Effect Study of HDM1002 in Healthy Subjects",null,"UNKNOWN","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","33","Healthy Adult Subject","DRUG:HDM1002","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2024-10","2024-11","FALSE","AUC[0-∞] [Day1-Day17] | AUC[0-t] [Day1-Day17] | Cmax [Day1-Day17] | Tmax [Day1-Day17] | t1/2 [Day1-Day17] | CL/F [Day1-Day17] | Vz/F [Day1-Day17] | F [Day1-Day17]",null,null,null,null],["NCT05292495","A Trial of HR17031 Injection With Renal Insufficiency",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","24","Improved Glycemic Control in Patients With Type 2 Diabetes","DRUG:HR17031 injection","Jiangsu HengRui Medicine Co., Ltd.","2022-10-12","2024-04-10","FALSE","Pharmacokinetics parameters of INS068 and SHR20004: Cmax [Based on pre-dose, 2-96 hours post-dose sampling times] | Pharmacokinetics parameters of INS068 and SHR20004: AUC0-t [Based on pre-dose, 2-96 hours post-dose sampling times] | Pharmacokinetics parameters of INS068 and SHR20004: AUC0-inf [Based on pre-dose, 2-96 hours post-dose sampling times]",null,null,"UNDECIDED",null],["NCT07594847","A Study of HDM1002 Tablets on Cardiac Repolarization in Healthy Subjects",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","72","Healthy Adult Subject","DRUG:HDM1002 200 mg; DRUG:HDM1002 400 mg; DRUG:Placebo; DRUG:Moxifloxacin 400 mg","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2026-03-07","2026-09-25","FALSE","Correlation between HDM1002 Plasma Concentration and ΔΔQTc [From the base line ECG (Day -1) to end of the period, up to 48 hours post-dose]",null,null,"NO",null],["NCT07081958","A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","352","Obesity or Overweight","DRUG:RO7795081; DRUG:Placebo","Hoffmann-La Roche","2025-07-29","2026-04-28","FALSE","Percent Change in Body Weight From Baseline to Week 30 [Baseline to Week 30]",null,null,"YES",null],["NCT06703658","A Study to Investigate Multiple Ascending Doses of AZD5004 in Healthy Japanese Participants and Participants With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","35","Healthy Participants; Type 2 Diabetes","DRUG:AZD5004(Part A); DRUG:Placebo(Part A); DRUG:AZD5004(Part B); DRUG:Placebo(Part B)","AstraZeneca","2024-11-02","2025-03-13","FALSE","PartA: Number of participants with adverse events (AEs) and serious adverse events (SAEs) [From screening (Day -28) to last follow up visit (Day 8)] | PartB: Number of participants with adverse events (AEs) and serious adverse events (SAEs) [From screening (Day -28) to last follow up visit (Day 119 )]",null,null,"YES",null],["NCT06410924","A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","67","NAFLD; NASH","DRUG:DD01; DRUG:Placebo","Neuraly, Inc.","2024-06-13","2025-05-20","FALSE","Proportion of subjects who achieve at least 30% liver fat reduction measured by MRI-PDFF [12 weeks]","DERIVED:42480572",null,null,null],["NCT07508241","A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE1",null,"NONE","22","Obesity; Overweight and/or Obesity; Overweight; Drug Interaction","DRUG:PF-08653944; DRUG:Acetaminophen","Pfizer","2026-03-31","2027-01-27","FALSE","Acetaminophen Pharmacokinetic (PK) Parameters: Maximum observed plasma concentration (Cmax) [Day 1 pre-dose through approximately 11 Weeks after last dose of study intervention.] | Acetaminophen PK parameters: Area under the plasma concentration (AUC) [Day 1 pre-dose through approximately 11 Weeks after last dose of study intervention.] | Acetaminophen PK parameters: Time to Maximum concentration (Tmax) [Day 1 pre-dose through approximately 11 Weeks after last dose of study intervention.]",null,null,"NO","OTHER:MET097-25-106"],["NCT07616037","Efficacy of a GLP-1/FGF21 Dual Agonist for Treating PCOS",null,"RECRUITING","INTERVENTIONAL","PHASE2",null,"NONE","30","PCOS (Polycystic Ovary Syndrome)","DRUG:GLP-1/FGF21 dual agonist (HEC88473)","Shanghai Zhongshan Hospital","2026-06","2027-06","FALSE","Change From Baseline in Free Androgen Index Over 24 Weeks of Treatment [Baseline to Week 24 (assessed at scheduled follow-up visits).]",null,null,"YES",null],["NCT07205900","Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","267","Obese; Obesity","DRUG:HM15275; DRUG:Placebo of HM15275","Hanmi Pharmaceutical Company Limited","2025-12-02","2027-01","FALSE","Percent Change in Body Weight. [Up to 41 weeks]",null,null,"NO",null],["NCT02055547","A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","61","Type 2 Diabetes Mellitus","DRUG:MK-8521 35μg; DRUG:MK-8521 100μg; DRUG:MK-8521 125μg; DRUG:MK-8521 150μg; DRUG:MK-8521 175μg; DRUG:MK-8521 200μg; DRUG:MK-8521 300μg; DRUG:MK-8521 50/72μg; DRUG:MK-8521 72/125μg; DRUG:MK-8521 100/150μg; DRUG:MK-8521 125/150μg; DRUG:Placebo","Merck Sharp & Dohme LLC","2013-05-10","2013-09-17","TRUE","Number of Participants Who Experienced at Least One Adverse Event (AE) (Part 1) [From Day 1 through post-trial visit (Up to 8 weeks)] | Number of Participants Who Discontinued Treatment Due to an AE (Part 1) [Up to 8 weeks (Part 1)] | Area Under the Concentration Time Curve of MK-8521 From 0 to Infinity (AUC0-∞) After a Single Dose (Part 1) [Pre-dose, 0.5, 1, 2, 4, 8, 10, 12, 14, 16, 24, 30, 34, 48, 72, 96, 120 hrs. post-dose (Part 1)] | Peak Plasma Concentration (Cmax) of Participants Treated With a Single Dose of MK-8521 (Part 1) [Pre-dose, 0.5, 1, 2, 4, 8, 10, 12, 14, 16, 24, 30, 34, 48, 72, 96, 120 hrs. post-dose (Part 1)] | Time Taken to Reach Cmax (Tmax) for Plasma Concentration of Participants Treated With a Single Dose of MK-8521 (Part 1) [Pre-dose, 0.5, 1, 2, 4, 8, 10, 12, 14, 16, 24, 30, 34, 48, 72, 96, 120 hrs. post-dose (Part 1)] | Apparent Terminal Half-life (t1/2) for Plasma Concentration of Participants Treated With a Single Dose of MK-8521 (Part 1) [Pre-dose, 0.5, 1, 2, 4, 8, 10, 12, 14, 16, 24, 30, 34, 48, 72, 96, 120 hrs. post-dose (Part 1)] | Number of Participants With an Adverse Event (AE) (Part 2) [From Day 1 through post-trial visit (Up to 7 weeks)] | Number of Participants Who Discontinued Treatment Due to an AE (Part 2) [Up to 7 weeks (Part 2)] | AUC 0-24hr for Plasma Concentration of Participants Treated After Multiple Doses of MK-8521 (Part 2, Panels C, D, and E) [Days 1, 5 and 10 (Part 2) (Panels C, D, E)] | AUC 0-24hr for Plasma Concentration of Participants Treated After Multiple Doses of MK-8521 (Part 2, Panel F) [Days 1, 7 and 14 (Part 2) (Panel F)] | Cmax for Plasma Concentration of Participants Treated With Multiple Doses of MK-8521 (Part 2, Panels C, D, and E) [Days 1, 5 and 10 (Part 2) (Panels C, D, E)] | Cmax for Plasma Concentration of Participants Treated With Multiple Doses of MK-8521 (Part 2, Panel F) [Days 1, 7 and 14 (Part 2) (Panel F)] | Trough Plasma Concentration (Ctrough) of Participants Treated With Multiple Doses of MK-8521 (Part 2, Panels C, D, and E) [Days 1, 5 and 10 (Part 2) (Panels C, D, E)] | Trough Plasma Concentration (Ctrough) of Participants Treated With Multiple Doses of MK-8521 (Part 2, Panel F) [Days 1, 7 and 14 (Part 2) (Panel F)] | Tmax for Plasma Concentration of Participants Treated With Multiple Doses of MK-8521 (Part 2, Panels C, D, and E) [Days 1, 5 and 10 (Part 2) (Panels C, D, E)] | Tmax for Plasma Concentration of Participants Treated With Multiple Doses of MK-8521 (Part 2, Panel F) [Days 1, 7 and 14 (Part 2) (Panel F)] | Apparent Terminal Half-life (t1/2) for Plasma Concentration of Participants Treated With Multiple Doses of MK-8521 (Part 2, Part C, D, and E) [Days 1, 5 and 10 (Part 2) (Panels C, D, E)] | Apparent Terminal Half-life (t1/2) for Plasma Concentration of Participants Treated With Multiple Doses of MK-8521 (Part 2, Part F) [Days 1, 7 and 14 (Part 2) (Panel F)] | Number of Participants With an Adverse Event (AE) (Part 3) [Up to 6 weeks (Part 3)] | Number of Participants Who Discontinued Treatment Due to an AE (Part 3) [Up to 6 weeks (Part 3)] | Average Concentration (Cave) of MK-8521 Corresponding to Slope of Insulin Secretion Rate/Glucose (ISR/G) During Graded Glucose Infusion (GGI) at Tmax After a Single Dose of MK-8521 (Part 3) [From -10 to 160 minutes after GGI on Day 1 (Part 3)]",null,null,"YES","EUDRACT_NUMBER:2013-000083-28; OTHER:MK-8521-002"],["NCT07693777","A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","480","Severe Hypertriglyceridemia (sHTG); Hypertriglyceridemia","BIOLOGICAL:DR10624 Injection; OTHER:Matching Placebo for DR10624","Zhejiang Doer Biologics Co., Ltd.","2026-08-17","2029-02-14","FALSE","Percentage change from baseline in central laboratory-measured fasting serum triglyceride at Week 26 [Baseline to Week 26 of double-blind treatment]",null,null,"NO",null],["NCT07659574","Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1）","UNIGUIDE-1","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","360","Type 2 Diabetes","DRUG:UBT251 Injection 2.0 mg; DRUG:UBT251 Injection 4.0 mg; DRUG:UBT251 Injection 6.0 mg; DRUG:UBT251 Injection Placebo 2.0 mg; DRUG:UBT251 Injection Placebo 4.0 mg; DRUG:UBT251 Injection Placebo 6.0 mg","The United Bio-Technology (Hengqin) Co., Ltd.","2026-09-07","2027-09-24","FALSE","HbA1c [Week 40]",null,null,"NO",null],["NCT06628362","A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","447","Overweight or Obese; Type 2 Diabetes Mellitus (T2DM)","DRUG:Placebo; DRUG:Enicepatide","Carmot Therapeutics, Inc.","2024-11-21","2026-05-29","FALSE","Percent Change in Body Weight from Baseline to Week 36 [Baseline to Week 36] | Change in Glycated Hemoglobin (HbA1c) from Baseline to Week 36 [Baseline to Week 36]",null,null,"NO","OTHER:XC45544"],["NCT06371326","A Study of ZT002 Injection in Participants With Overweight or Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","28","Overweight or Obesity","DRUG:ZT002 Injection; DRUG:Placebo","Beijing QL Biopharmaceutical Co.,Ltd","2023-11-21","2024-04-15","FALSE","Safety and tolerability of a multiple escalation dose of ZT002 through the incidence and severity of treatment emergent adverse events in MAD Cohorts. Number of participants with treatment-emergent adverse events. [up to 270 days] | Safety and tolerability of a multiple escalation dose of ZT002 through the incidence severity of serious adverse events in MAD Cohorts. Number of participants with serious adverse events. [up to 270 days]",null,null,null,null],["NCT07139535","A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","350","T2DM","DRUG:RAY1225; DRUG:placebo","Guangdong Raynovent Biotech Co., Ltd","2025-08-31","2026-12-01","FALSE","Change From Baseline in Hemoglobin A1c (HbA1c) [Baseline,36 Week]",null,null,"NO",null],["NCT06683508","A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","288","Obesity; Overweight","DRUG:LY3549492; DRUG:Placebo","Eli Lilly and Company","2024-11-13","2026-01-07","FALSE","Percent Change from Baseline in Body Weight [Baseline, Week 36]",null,null,"YES","OTHER:W8M-MC-GN01; OTHER:W8M-MC-CWMM"],["NCT07546760","A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234",null,"RECRUITING","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","28","Hepatic Impairment","DRUG:AZD6234; DRUG:AZD9550","AstraZeneca","2026-03-20","2027-02-04","FALSE","PK parameters AUCinf [Day 0 through Day 56] | PK parameters AUClast [Day 0 through Day 56] | PK parameters Cmax [Day 0 through Day 56]",null,null,"YES",null],["NCT07065058","A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","24","Obesity &Amp; Overweight","DRUG:Drug: VCT220, Repaglinide, Rosuvastatin, and Digoxin","Vincentage Pharma Co., Ltd","2025-07-01","2025-07-11","FALSE","Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Repaglinide [1h before dosing, 0.25 h、0.5 h、1 h、1.5 h、2 h、3 h、4 h、6 h、8 h、12 h and 24 h post dosing] | Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Rosuvastatin [1h before dosing, 0.5 h、1 h、2 h、3 h、4 h、6 h、8 h、10 h、12 h、16 h、24 h、48 h、72 h、96 h and 120 h post dosing] | Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Digoxin [1h before dosing, 0.5 h、1 h、2 h、3 h、4 h、6 h、8 h、10 h、12 h、16 h、24 h、48 h、72 h、96 h and 120 h post dosing] | Maximum Observed Concentration (Cmax) of Repaglinide [1h before dosing, 0.25 h、0.5 h、1 h、1.5 h、2 h、3 h、4 h、6 h、8 h、12 h and 24 h post dosing] | Maximum Observed Concentration of Rosuvastatin [1h before dosing, 0.5 h、1 h、2 h、3 h、4 h、6 h、8 h、10 h、12 h、16 h、24 h、48 h、72 h、96 h and 120 h post dosing] | Maximum Observed Concentration (Cmax) of Digoxin [1h before dosing, 0.5 h、1 h、2 h、3 h、4 h、6 h、8 h、10 h、12 h、16 h、24 h、48 h、72 h、96 h and 120 h post dosing]",null,null,"NO",null],["NCT06254274","A Study of RAY1225 in Participants With Type 2 Diabetes",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","210","T2DM (Type 2 Diabetes Mellitus)","DRUG:RAY1225; DRUG:Placebo","Guangdong Raynovent Biotech Co., Ltd","2024-02-26","2025-12-20","FALSE","Change From Baseline in Hemoglobin A1c (HbA1c) [Baseline,Week 26]",null,null,null,null],["NCT07134335","UBT251 Injection Phase II Clinical Study (CKD)",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","180","Obesity &Amp; Overweight; Chronic Kidney Disease","DRUG:UBT251","The United Bio-Technology (Hengqin) Co., Ltd.","2025-09-01","2030-07-11","FALSE","log-transformed urinary albumin:creatinine ratio（UACR） [24 weeks]",null,null,"NO",null],["NCT06973681","A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","120","Overweight or Obesity","DRUG:BGM0504; DRUG:Placebo","BrightGene Bio-Medical Technology Co., Ltd.","2023-10-13","2024-09-13","FALSE","Percentage change in body weight [Week 0 to Week 24]","DERIVED:42755112",null,null,null],["NCT06558708","A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD",null,"UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","60","Type 2 Diabetes","DRUG:GZR101 Injection; DRUG:GZR33 Injection; DRUG:Insulin aspart","Gan and Lee Pharmaceuticals, USA","2024-06-28","2024-12","FALSE","Change in HbA1c [Week 0, week 16]",null,null,"NO",null],["NCT06973720","A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight","VESPER-3","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","268","Obesity; Overweight or Obesity","DRUG:MET097; DRUG:Placebo","Pfizer","2025-04-07","2025-12-16","FALSE","Percent change from baseline in body weight at Week 28 [Baseline (Week 0) through Week 28 (Day 197)]",null,null,"YES","OTHER:C6491006"],["NCT06871761","A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","393","Adult Patients With Type 2 Diabetes","DRUG:HR17031 injection; DRUG:insulin glargine","Jiangsu HengRui Medicine Co., Ltd.","2024-05-08","2025-05-13","FALSE","Changes in HbA1c from baseline to week 26 [from baseline to week 26]",null,null,"UNDECIDED",null],["NCT06293742","ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","48","Type 2 Diabetes Mellitus","DRUG:ECC5004; DRUG:Midazolam; DRUG:Rosuvastatin; DRUG:Digoxin; DRUG:Atorvastatin","Eccogene","2024-02-08","2024-04-15","FALSE","Atorvastatin PK parameters: AUC(0-tlast) [Part B and optional Part D: up to Day 34] | Atorvastatin PK parameters: AUC(0-inf) [Part B and optional Part D: up to Day 34] | Atorvastatin PK parameters: Cmax [Part B and optional Part D: up to Day 34] | Rosuvastatin PK parameters: AUC(0-tlast) [Part A and optional Part C: up to Day 11] | Rosuvastatin PK parameters: AUC(0-inf) [Part A and optional Part C: up to Day 11] | Rosuvastatin PK parameters: Cmax [Part A and optional Part C: up to Day 11] | Digoxin PK parameters: AUC(0-tlast) [Part A and optional Part C: up to Day 11] | Digoxin PK parameters: AUC(0-inf) [Part A and optional Part C: up to Day 11] | Digoxin PK parameters: Cmax [Part A and optional Part C: up to Day 11] | Midazolam PK parameters: AUC(0-tlast) [Part B and optional Part D: up to Day 34] | Midazolam PK parameters: AUC(0-inf) [Part B and optional Part D: up to Day 34] | Midazolam PK parameters: Cmax [Part B and optional Part D: up to Day 34]",null,null,"NO",null],["NCT05814107","Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","94","Type 2 Diabetes; Overweight or Obesity","DRUG:CT-996; DRUG:Placebo","Carmot Australia First Pty Ltd","2023-05-09","2025-11-07","FALSE","Incidence of Treatment-Emergent Adverse Events [From first study drug administration until last safety follow-up (up to 31 days [Part 1] or 58 days [Parts 2 and 3])]",null,null,"NO",null],["NCT06881264","A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","401","Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs","DRUG:HR17031 injection; DRUG:insulin glargine","Jiangsu HengRui Medicine Co., Ltd.","2024-04-30","2025-09-19","FALSE","Change in HbA1c: Changes in HbA1c from baseline to week 26 [week 26]",null,null,"UNDECIDED",null],["NCT05327595","A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM)",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","80","Diabetes Mellitus, Type 2","DRUG:LY3549492; DRUG:Placebo; DRUG:Atorvastatin; DRUG:Midazolam","Eli Lilly and Company","2022-05-09","2024-04-22","FALSE","Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline through final follow-up at approximately Day 49]",null,null,"NO","OTHER:J3H-MC-GZNB; EUDRACT_NUMBER:2021-002220-20"],["NCT06939296","A Research Study of VCT220 in Adult Chinese Participants With Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","840","Obesity; Overweight","DRUG:VCT220; DRUG:Placebo","Vincentage Pharma Co., Ltd","2024-12-24","2025-11-25","FALSE","Percentage change from baseline in body weight [From baseline to week 34] | The proportion of subjects with a body weight reduction ≥5% from baseline [From baseline to week 34]",null,null,null,null],["NCT06579092","Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity","VISTA","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","310","Obesity or Overweight","DRUG:AZD5004; DRUG:Placebo","AstraZeneca","2024-10-08","2025-11-21","FALSE","Percent change in body weight from baseline [26 weeks] | Achieved Weight Loss ≥ 5% From Baseline [26 weeks]","DERIVED:42259337",null,"YES","REGISTRY:2024-513691-18-00"],["NCT04829123","The Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","64","Non-alcoholic Steatohepatitis","DRUG:HEC88473 injection; DRUG:Placebo","Dongguan HEC Biopharmaceutical R&D Co., Ltd.","2021-05-14","2022-03-02","FALSE","Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) after a single dose of HEC88473 [Baseline to day 15] | Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) after multiple dose of HEC88473 [Baseline to day 43] | Cmax [Predose and postdose 4, 8, 10, 12, 14, 24, 48, 72, 96, 168, 216, and 336 hours] | AUC [Predose and postdose 4, 8, 10, 12, 14, 24, 48, 72, 96, 168, 216, and 336 hours]",null,null,"NO",null],["NCT07011797","A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","250","Obesity","DRUG:CX11; OTHER:Placebo","Corxel Pharmaceuticals","2025-06-17","2026-03-23","FALSE","Percentage change in body weight from baseline [At Week 26]",null,null,null,null],["NCT07685808","Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","360","Overweight or Obesity","DRUG:Olatorepatide; DRUG:Placebo","Regeneron Pharmaceuticals","2026-07-28","2028-01-21","FALSE","Occurrence of Treatment-Emergent Adverse Events (TEAEs) [Up to approximately 60 weeks] | Severity of TEAEs [Up to approximately 60 weeks] | Percent change in body weight [From baseline to week 52]",null,null,"YES",null],["NCT06704581","A Study of BGM0504 Injection in Participants with Obesity or Overweight",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","620","Overweight or Obesity","DRUG:5 mg BGM0504 injection; DRUG:10 mg BGM0504 injection administered subcutaneously (SC) once a week; DRUG:15 mg BGM0504 injection; DRUG:BGM0504 placebo","BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.","2024-10-28","2025-11-27","FALSE","Percent Change from Baseline in Body Weight [Baseline,Week 36] | Percentage of Participants Who Achieve≥5% Body Weight Reduction [Baseline,Week 36]",null,null,null,null],["NCT07050134","A Trial to Evaluate the Efficacy and Safety of DR10624 in Patients With Hypertriglyceridemia and Carotid Atherosclerotic Plaque",null,"ENROLLING_BY_INVITATION","INTERVENTIONAL",null,"RANDOMIZED","QUADRUPLE","40","Hypertriglyceridemia; Carotid Atherosclerotic Plaques","DRUG:DR10624 Injection；; DRUG:DR10624 Injection Placebo (referred to as placebo)","Junbo Ge","2025-07-01","2026-12-31","FALSE","Change in carotid intima-media thickness (IMT) from baseline at treatment week 24 (W24). [24weeks]","BACKGROUND:32052833; BACKGROUND:23128470; BACKGROUND:38057786; BACKGROUND:35547006; BACKGROUND:33204386; BACKGROUND:30468503; BACKGROUND:26999484",null,"NO",null],["NCT07519135","A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver Function",null,"RECRUITING","INTERVENTIONAL","PHASE1",null,"NONE","26","Healthy","DRUG:PF-08653944","Pfizer","2026-04-15","2027-07-09","FALSE","Pharmacokinetics (PK): Maximum observed plasma concentration (Cmax) of PF-08653944 [Day 1 pre-dose through approximately 11 Weeks after last dose of study intervention.] | PK: Area under the plasma concentration (AUC) of PF-08653944 [Day 1 pre-dose through approximately 11 Weeks after last dose of study intervention.]",null,null,"NO","OTHER:MET097-25-105"],["NCT07057674","A Study of HS-20094 in Overweight or Obese Participants",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","144","Overweight or Obesity","DRUG:HS-20094 AI pen;; DRUG:HS-20094 MDV pen","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2025-04-16","2026-02-04","FALSE","To evaluate the bioequivalence of HS-20094 MDV pen and AI pen following multiple doses at 15 mg. [From Day 1 to Day 169]",null,null,null,null],["NCT07331389","A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin",null,"RECRUITING","INTERVENTIONAL","PHASE1",null,"NONE","111","Overweight Subject; Healthy Subjects","DRUG:Metformin; DRUG:Empagliflozin; DRUG:Midazolam; DRUG:Valsartan; DRUG:Warfarin; DRUG:HDM1002","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2025-09-24","2026-01-12","FALSE","AUC[0-∞] [through study completion, an average of 11 weeks] | Cmax [through study completion, an average of 11 weeks] | AUC[0-t] [through study completion, an average of 11 weeks]",null,null,null,null],["NCT06924320","A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes",null,"RECRUITING","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","QUADRUPLE","381","Obesity and Obesity-related Medical Conditions","DRUG:MET233 and MET097; OTHER:Placebo; DRUG:MET097","Pfizer","2025-03-06","2026-09-15","FALSE","Occurrence of treatment-emergent adverse events (TEAEs) [Part A (Baseline, Day 85), Part B (Baseline, Day 155), Part C (Baseline, Day 155), Part D (Baseline, Day 218), Part E (Baseline, Day 246), Part G (Baseline, Day 274)]","DERIVED:41747885",null,"NO","OTHER:C6511001; OTHER:MET233/097-24-101"],["NCT07455825","A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","65","Healthy Participants","DRUG:AZD5004","AstraZeneca","2026-03-05","2026-06-01","FALSE","Area under concentration-time curve from time 0 extrapolated to infinity (AUCinf) [From Day 1 to Day 22] | Area under concentration-curve from time 0 to the time of last quantifiable concentration (AUClast) [From Day 1 to Day 22] | Maximum observed concentration (Cmax) [From Day 1 to Day 22]",null,null,"YES",null],["NCT07794397","A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Receiving Positive Airway Pressure (PAP) Therapy",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","200","Obstructive Sleep Apnea (OSA) and Obesity","DRUG:HDM1005; DRUG:Placebo","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2026-09","2028-09","FALSE","Percentage change in body weight from baseline at week 52 [52 week] | Change in AHI from baseline at week 52 [52 week]",null,null,null,null],["NCT07566572","A Study of BGM0504 Tablets in Healthy Chinese Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","144","Chinese Healthy Volunteers","DRUG:BGM0504 tablets","BrightGene Bio-Medical Technology Co., Ltd.","2026-03-26","2026-08-31","FALSE","Pharmacokinetic (PK) endpoint： AUC0-tau,ss [4 weeks] | PK endpoint：Cmax,ss [4 weeks] | PK endpoint：t1/2,ss [4 weeks]",null,null,null,null],["NCT06813781","Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","33","Hepatic Impairment","DRUG:AZD5004","AstraZeneca","2024-12-19","2025-10-02","FALSE","AUCinf [Day 1 to Day 6] | AUClast [Day 1 to Day 6] | Cmax [Day 1 to Day 6]",null,null,"YES",null],["NCT06556641","A Clinical Study of GZR33 and GZR101 in Healthy Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","28","Healthy Subjects","DRUG:GZR33 Injection; DRUG:GZR101 Injection; DRUG:Placebo; DRUG:Insulin Degludec","Gan and Lee Pharmaceuticals, USA","2022-12-17","2023-02-03","FALSE","AUC0-24h [From 0 to 24 hours] | Incidence of adverse events (AE) [From Predose to Day12]",null,null,"NO",null],["NCT07502001","Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1",null,"NONE","42","Overweight; Obesity","DRUG:Acetaminophen; DRUG:Metformin; DRUG:Warfarin; DRUG:Atorvastatin; DRUG:Digoxin; DRUG:HDM1005 injection","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2026-04-08","2026-12-01","FALSE","Area Under the Concentration Time Curve From Time Zero to ∞ [ AUC(0- ∞)] [Up to Day 115] | Maximum observed concentration (Cmax) [Up to Day 115] | Area Under the Concentration Time Curve From Time Zero to t [ AUC(0- t)] [Up to Day 115] | Time of maximum observed concentration (Tmax) [Up to Day 115]",null,null,null,null],["NCT07057271","A Study of CJC-1134-PC Injection in Patients With Type 2 Diabetes With Inadequately Controlled Blood Glucose Level After Metformin Monotherapy or Metformin in Combination With Insulin Secretagogues",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","464","Type 2 Diabetes Mellitus - Poor Control","DRUG:CJC-1134-PC Injection; DRUG:Placebo","Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.","2021-05-27","2023-02-21","FALSE","Change from baseline in HbA1c at the end of double-blind treatment period [Week 25 visit]",null,null,"NO",null],["NCT04758234","A Study of LY3549492 in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","54","Healthy","DRUG:LY3549492; DRUG:Placebo","Eli Lilly and Company","2021-02-22","2022-01-10","FALSE","Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline through final follow-up at approximately Day 76]",null,null,"NO","OTHER:J3H-MC-GZNA"],["NCT03414736","A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","60","Type 2 Diabetes Mellitus","DRUG:SAR425899","Sanofi","2018-01-19","2018-10-05","FALSE","Frequency of gastrointestinal (GI) adverse events (AEs) [Main study: Up to week 8; Six-month study extension period: Up to month 8] | Frequency of GI AEs [Main study: Up to week 8; Six-month study extension period: Up to month 8]",null,null,"YES","OTHER:U1111-1205-1368"],["NCT06714955","Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","30","Non-diabetic Overweight or Obese","DRUG:Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.; DRUG:Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.; DRUG:Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.","BrightGene Bio-Medical Technology Co., Ltd.","2024-10-21","2025-01-21","FALSE","Number of treatment adverse events [10 weeks]",null,null,null,null],["NCT06576401","A Study To Characterize Mass Balance Of [14C] HDM1002 in Chinese Healthy Subjects",null,"UNKNOWN","INTERVENTIONAL","PHASE1",null,"NONE","10","Healthy Adult Subject","DRUG:[14C] HDM1002","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2024-08-27","2024-10","FALSE","Total recovery of HDM1002 radioactivity in urine and feces, following oral administration of [14C] HDM1002 [Predose up to Day 11 after administration of [14C] HDM1002] | Metabolite profiling/identification in plasma, urine, and feces [Predose up to Day 11 after administration of [14C] HDM1002] | Plasma and whole blood AUC[0-t] of radioactivity [Predose up to Day 11 after administration of [14C] HDM1002] | Plasma and whole blood AUC[0-∞] of radioactivity [Predose up to Day 11 after administration of [14C] HDM1002] | Plasma and whole blood Cmax of radioactivity [Predose up to Day 11 after administration of [14C] HDM1002] | Plasma and whole blood Tmax of radioactivity [Predose up to Day 11 after administration of [14C] HDM1002] | Plasma and whole blood t1/2 of radioactivity [Predose up to Day 11 after administration of [14C] HDM1002] | Plasma and whole blood CL/F of radioactivity [Predose up to Day 11 after administration of [14C] HDM1002] | Plasma and whole blood Vz/F of radioactivity [Predose up to Day 11 after administration of [14C] HDM1002] | Percentage of plasma HDM1002 and metabolites in total plasma radioactivity [Predose up to Day 11 after administration of [14C] HDM1002]",null,null,null,null],["NCT04221945","Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","1060","Uterine Cervical Neoplasms","BIOLOGICAL:Pembrolizumab; DRUG:Placebo for pembrolizumab; DRUG:Cisplatin; RADIATION:External Beam Radiotherapy (EBRT); RADIATION:Brachytherapy","Merck Sharp & Dohme LLC","2020-05-12","2025-01-07","TRUE","Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator [Up to approximately 55 months] | Overall Survival (OS) [Up to approximately 55 months]","RESULT:38521086; RESULT:39288779; DERIVED:40592026","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/45/NCT04221945/Prot_SAP_000.pdf","YES","OTHER:MK-3475-A18; OTHER:KEYNOTE-A18; OTHER:ENGOT-cx11; REGISTRY:205189; OTHER:GOG-3047; REGISTRY:2022-501972-25-00; REGISTRY:U1111-1282-6395; EUDRACT_NUMBER:2019-003152-37; NIH:2019"],["NCT05654831","FTIH of ECC5004 in Healthy and Diabetic Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","69","Type 2 Diabetes Mellitus","DRUG:Placebo; DRUG:ECC5004","Eccogene","2022-12-01","2023-11-01","FALSE","Number of participants with adverse events, with abnormal laboratory test results, abnormal ECGs, abnormal vital signs, and abnormal physical examinations [SAD: Up to Day 8 and MAD: Up to Day 35]","DERIVED:39495140",null,"NO",null],["NCT06996886","A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral Formulations",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","16","Healthy Participants","DRUG:AZD5004","AstraZeneca","2025-05-22","2025-07-15","FALSE","Area under concentration-time curve from time 0 to infinity (AUCinf) [Day 1-6, Day 8-13, Day 15-20 and Day 22-27] | Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) [Day 1-6, Day 8-13, Day 15-20 and Day 22-27] | Maximum observed drug concentration (Cmax) [Day 1-6, Day 8-13, Day 15-20 and Day 22-27] | Time to reach maximum observed concentration (tmax) [Day 1-6, Day 8-13, Day 15-20 and Day 22-27] | Half-life (t½) [Day 1-6, Day 8-13, Day 15-20 and Day 22-27] | Apparent total body clearance (CL/F) [Day 1-6, Day 8-13, Day 15-20 and Day 22-27]",null,null,"YES",null],["NCT07785934","Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity",null,"RECRUITING","INTERVENTIONAL","PHASE1",null,"NONE","48","Drug Drug Interaction (DDI); Pharmacokinetics and Pharmacodynamics","DRUG:UBT251; DRUG:Metformin hydrochloride; DRUG:Warfarin Sodium; DRUG:Atorvastatin calcium; DRUG:Digoxin","The United Bio-Technology (Hengqin) Co., Ltd.","2026-05-27","2026-12","FALSE","Area under plasma concentration-time curve of metformin (AUC0-τ) and S-warfarin, R-warfarin (AUC0-t, AUC0-∞) [From time 0 to 30 hours (metformin, post last dose) and 168 hours (S-warfarin, R-warfarin) after respective doses] | Area under plasma concentration-time curve (AUC0-t and AUC0-∞) of atorvastatin and digoxin [From time 0 to 72 hours (atorvastatin) and 120 hours (digoxin) after respective single doses]",null,null,"NO",null],["NCT05579314","XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","127","Type 2 Diabetes Mellitus","DRUG:XW014; DRUG:Placebo","Sciwind Biosciences USA Co., Ltd.","2022-09-26","2024-11-16","FALSE","Number and percentage of treatment emergent adverse events (TEAE) and serious adverse events (SAE) [11 weeks] | Mean change from baseline in clinical laboratory values, vital signs, clinical findings from physical exam and ECG abnormalities [11 weeks]",null,null,"NO",null],["NCT07020884","A Study of ZT002 Injection With Subjects With Overweight or Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","303","Overweight or Obesity","DRUG:ZT002 Injection; DRUG:ZT002 Placebo","Beijing QL Biopharmaceutical Co.,Ltd","2024-08-14","2025-05-07","FALSE","The percentage change from baseline in weight after 24 weeks of treatment. [baseline, 24 weeks]",null,null,null,null],["NCT07017179","This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","16","Obesity/Overweight","DRUG:AZD6234; DRUG:Placebo; DRUG:AZD9550; DRUG:Plocebo; DRUG:AZD6234 in combination with AZD9550","AstraZeneca","2025-05-20","2026-10-23","FALSE","Numbers of participant with Adverse Events (AEs) and Serious adverse events (SAEs) (sub-study 1). [From baseline to Day 141] | Numbers of participant with Adverse Events (AEs) and Serious adverse events (SAEs) (sub-study 2). [From baseline to Day 225]",null,null,null,null],["NCT07362030","Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE1",null,"NONE","32","Obesity","DRUG:RAY1225; DRUG:atorvastatin calcium tablet; DRUG:Metformin Tablets; DRUG:Warfarin Sodium Tablets; DRUG:Digoxin Tablets","Guangdong Raynovent Biotech Co., Ltd","2025-04-14","2025-12-27","FALSE","Pharmacokinetic - Cmax [Day 1~Day 5 and Day 86~Day 107] | Pharmacokinetic -Area under the curve（AUC） [Day 1~Day 5 and Day 86~Day 107]",null,null,null,null],["NCT07024212","Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","110","MASLD","DRUG:DR10624 Injection; DRUG:Placebo","Zhejiang Doer Biologics Co., Ltd.","2025-04-22","2026-06-18","FALSE","Changes of LFC [From baseline to Week 12]",null,null,null,null],["NCT07710768","A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight",null,"RECRUITING","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","44","Obesity; Overweight","DRUG:UBT251; DRUG:Cocktail (Warfarin/Caffeine/Midazolam)","Novo Nordisk A/S","2026-07-15","2027-04-07","FALSE","AUC0-∞,s-warfarin: The area under the plasma s-warfarin concentration-time curve extrapolated to infinity after single dose [From pre-dose on Day 1 up to 156 days] | AUC0-∞,caffeine : The area under the plasma caffeine concentration-time curve extrapolated to infinity after single dose [From pre-dose on Day 1 up to 156 days] | AUC0-∞,midazolam: The area under the midazolam concentration-time curve extrapolated to infinity after single dose [From pre-dose on Day 1 up to 156 days]",null,null,"YES","OTHER:U1111-1332-5554"],["NCT06942936","A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","51","Healthy Participants","DRUG:AZD5004; DRUG:Itraconazole; DRUG:EE/LNG","AstraZeneca","2025-05-28","2026-01-28","FALSE","Part A: Area under concentration-time curve from time zero to infinity (AUCinf) of AZD5004 [Day 1 and Day 10] | Part A: Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) of AZD5004 [Day 1 and Day 10] | Part A: Maximum observed drug concentration (Cmax) of AZD5004 [Day 1 and Day 10] | Part A: Terminal elimination half-life (t1/2λz) of AZD5004 [Day 1 and Day 10] | Part A: Time to reach maximum observed concentration (tmax) of AZD5004 [Day 1 and Day 10] | Part A: Apparent total body clearance (CL/F) of AZD5004 [Day 1 and Day 10] | Part A: Apparent volume of distribution based on the terminal phase (Vz) of AZD5004 [Day 1 and Day 10] | Part B: Area under concentration-time curve from time zero to infinity (AUCinf) of EE/LNG [Day 1, Day 8, Day 50 and Day 78] | Part B: Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) of EE/LNG [Day 1, Day 8, Day 50 and Day 78] | Part B: Maximum observed drug concentration (Cmax) of EE/LNG [Day 1, Day 8, Day 50 and Day 78] | Part B: Terminal elimination half-life (t1/2λz) of EE/LNG [Day 1, Day 8, Day 50 and Day 78] | Part B: Time to reach maximum observed concentration (tmax) of EE/LNG [Day 1, Day 8, Day 50 and Day 78] | Part B: Apparent total body clearance (CL/F) of EE/LNG [Day 1, Day 8, Day 50 and Day 78] | Part B: Apparent volume of distribution based on the terminal phase (Vz) of EE/LNG [Day 1, Day 8, Day 50 and Day 78]",null,null,"YES","OTHER:2024-518467-35-00"],["NCT06500299","Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults",null,"UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","180","Overweight and Obesity","DRUG:HDM1002 100 mg QD; DRUG:HDM1002 200 mg QD 12weeks; DRUG:HDM1002 400 mg QD 12weeks; DRUG:Placebo","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2024-07-15","2024-10-30","FALSE","Percentage Change From Baseline in Body Weight at Week 12 [Baseline, Week 12]",null,null,null,null],["NCT07806851","UBT251 Injection Phase Ⅲ Study (OSA-PAP)","UNISHAPE-OSA-2","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","150","Obstructive Sleep Apnea; Obesity","DRUG:UBT251; DRUG:Placebo","The United Bio-Technology (Hengqin) Co., Ltd.","2026-10-10","2029-03","FALSE","Change from baseline in the Apnea-Hypopnea Index (AHI) [Baseline, Week 52]",null,null,"NO",null],["NCT07775404","A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus","Elecoglipron","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","351","Obesity; Overweight","DRUG:Elecoglipron; DRUG:Placebo","AstraZeneca","2026-08-21","2028-04-06","FALSE","Percent change from baseline to Week 52 in body weight [Week 52] | Participants achieving at least 5% body weight loss at Week 52 [Week 52]",null,null,"YES",null],["NCT07794774","A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","197","Obesity","DRUG:Berobenatide; OTHER:Placebo","Pfizer","2026-09-28","2029-02-21","FALSE","Percent change from baseline in body weight [Baseline, Week 72]",null,null,"YES","OTHER:VESPER-JM"],["NCT06985615","A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic Impairement",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","40","Hepatic Impairment; Healthy Volunteers","DRUG:Single dose of HDM1002 on Day 1","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2025-03-18","2026-01-14","FALSE","Maximum Plasma Concentration (Cmax) [Predose (0 hours), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 and 72 hours post dose.] | Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) [Predose (0 hours), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 and 72 hours post dose.] | Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) [Predose (0 hours), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 and 72 hours post dose.] | Fraction of Unbound Drug in Plasma (fu) [Predose (0 hours), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 and 72 hours post dose.]",null,null,null,null],["NCT07351045","A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes","Enith1","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","2000","Obesity or Overweight","COMBINATION_PRODUCT:Placebo; COMBINATION_PRODUCT:Enicepatide","Hoffmann-La Roche","2026-03-16","2028-07-24","FALSE","Percent (%) Change from Baseline in Body Weight at Week 72 [Baseline through Week 72]",null,null,"YES","CTIS:2025-523104-71-00; NIH:2025"],["NCT06809608","A Study Investigating the Effect of Different Approved Medications on How the Body Processes the Study Compound RO7795081",null,"COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","36","Healthy Participants","DRUG:RO7795081; DRUG:Itraconazole; DRUG:Gemfibrozil; DRUG:Cyclosporine","Hoffmann-La Roche","2025-02-13","2025-05-28","FALSE","Part 1: Maximum Concentration Observed (Cmax) of RO7795081, Administered Alone and in Combination with Itraconazole [Part 1, Period 1: Days 1 to 5 and 7; Part 1, Period 2: Days -4, -1, 1 to 10, 12, 14, 20, and 26] | Part 1: Time to Maximum Concentration Observed (Tmax) of RO7795081, Administered Alone and in Combination with Itraconazole [Part 1, Period 1: Days 1 to 5 and 7; Part 1, Period 2: Days -4, -1, 1 to 10, 12, 14, 20, and 26] | Part 1: Area Under the Concentration-Time Curve from Time 0 to the Last Measurable Concentration (AUClast) of RO7795081, Administered Alone and in Combination with Itraconazole [Part 1, Period 1: Days 1 to 5 and 7; Part 1, Period 2: Days -4, -1, 1 to 10, 12, 14, 20, and 26] | Part 1: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUCinf) of RO7795081, Administered Alone and in Combination with Itraconazole [Part 1, Period 1: Days 1 to 5 and 7; Part 1, Period 2: Days -4, -1, 1 to 10, 12, 14, 20, and 26] | Part 2: Cmax of RO7795081, Administered Alone and in Combination with Gemfibrozil or Cyclosporine [Part 2, Period 1: Days 1 to 5 and 7; Part 2, Period 2: Days -3 to 5, and 7; Part 2, Period 3: Days -1 to 5, and 7; Part 2, Period 4: Days -1 to 5, 7, and 18] | Part 2: Tmax of RO7795081, Administered Alone and in Combination with Gemfibrozil or Cyclosporine [Part 2, Period 1: Days 1 to 5 and 7; Part 2, Period 2: Days -3 to 5, and 7; Part 2, Period 3: Days -1 to 5, and 7; Part 2, Period 4: Days -1 to 5, 7, and 18] | Part 2: AUClast of RO7795081, Administered Alone and in Combination with Gemfibrozil or Cyclosporine [Part 2, Period 1: Days 1 to 5 and 7; Part 2, Period 2: Days -3 to 5, and 7; Part 2, Period 3: Days -1 to 5, and 7; Part 2, Period 4: Days -1 to 5, 7, and 18] | Part 2: AUCinf of RO7795081, Administered Alone and in Combination with Gemfibrozil or Cyclosporine [Part 2, Period 1: Days 1 to 5 and 7; Part 2, Period 2: Days -3 to 5, and 7; Part 2, Period 3: Days -1 to 5, and 7; Part 2, Period 4: Days -1 to 5, 7, and 18]",null,null,"NO","REGISTRY:2024-517360-37-00"],["NCT07013643","A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","100","Healthy Participants","DRUG:AZD6234; DRUG:Ethinyl estradiol/Levonorgestrel (EE/LEVO); DRUG:Acetaminophen (APAP); DRUG:AZD9550","AstraZeneca","2025-06-04","2027-07-09","FALSE","Area under the concentration-time curve from time 0 to infinity (AUCinf) of EE and LEVO [Cohort 1: At predefined intervals from Day -5 up to Day 99; Cohort 2 : At pre-defined interval from Day -5 up to Day 169; Cohort 3: At predefined intervals from Day -5 up to Day 225; Cohort 4: At predefined intervals from Day -5 up to Day 253] | Area under the concentration-time curve from time of dosing to the last measurable concentration (AUClast) of EE and LEVO [Cohort 1: At predefined intervals from Day -5 up to Day 99; Cohort 2 : At pre-defined interval from Day -5 up to Day 169; Cohort 3: At predefined intervals from Day -5 up to Day 225; Cohort 4: At predefined intervals from Day -5 up to Day 253] | Maximum plasma concentration (Cmax) of EE and LEVO [Cohort 1: At predefined intervals from Day -5 up to Day 99; Cohort 2 : At pre-defined interval from Day -5 up to Day 169; Cohort 3: At predefined intervals from Day -5 up to Day 225; Cohort 4: At predefined intervals from Day -5 up to Day 253] | Time to reach maximum drug concentration in plasma (tmax) of EE and LEVO [Cohort 1: At predefined intervals from Day -5 up to Day 99; Cohort 2 : At pre-defined interval from Day -5 up to Day 169; Cohort 3: At predefined intervals from Day -5 up to Day 225; Cohort 4: At predefined intervals from Day -5 up to Day 253] | Elimination half-life (t1/2λz) of EE and LEVO [Cohort 1: At predefined intervals from Day -5 up to Day 99; Cohort 2 : At pre-defined interval from Day -5 up to Day 169; Cohort 3: At predefined intervals from Day -5 up to Day 225; Cohort 4: At predefined intervals from Day -5 up to Day 253]",null,null,"YES",null],["NCT05835752","The Safety, Tolerability and Pharmacokinetic Study of RAY1225",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","68","Obese; Healthy","DRUG:RAY1225; DRUG:Placebo","Guangdong Raynovent Biotech Co., Ltd","2023-05-18","2024-03-01","FALSE","Number and severity of participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events(SAE) [Baseline through Day 29 (Part A)] | Number and severity of participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events(SAE) [Baseline through Day 64 (QW,Part B&C);baseline through Day 71 (Q2W,Part B&C)]",null,null,"NO",null],["NCT07559240","A Pharmacokinetic Study of HDM1005 Injection in Participants With Impaired Renal Function and Healthy Participants",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","30","Overweight; Obese","DRUG:HDM1005","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2026-05-15","2026-06-12","FALSE","Maximum Concentration (Cmax) [Up to Day 29] | Area Under the Concentration Time Curve From Time Zero to t [ AUC(0- t)] [Up to Day 29]",null,null,"NO",null],["NCT05591391","The Efficacy of Mallya in Type 2 Diabetes Transiting From Oral Antidiabetic Drugs to iGlarLixi",null,"UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","NONE","40","Mallya","OTHER:Mallya cap; OTHER:Standard care","Taipei Veterans General Hospital, Taiwan","2022-09-28","2025-06-30","FALSE","Time in range [7 days of CGM data]",null,null,"NO",null],["NCT06982131","A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","40","Overweight; Obesity","DRUG:RO7795081; DRUG:Placebo; DRUG:Rosuvastatin; DRUG:Pitavastatin","Hoffmann-La Roche","2025-06-04","2026-12-07","FALSE","Incidence and Severity of Adverse Events [From the first dose of study treatment until the final visit (up to 111 days)] | Incidence of Abnormal Clinical Laboratory Test Results [From the first dose of study treatment until the final visit (up to 111 days)] | Incidence of Abnormal Vital Sign Assessments [From the first dose of study treatment until the final visit (up to 111 days)] | Incidence of Abnormal Electrocardiogram Parameters [From the first dose of study treatment until the final visit (up to 111 days)] | Maximum Plasma Concentration Observed (Cmax) of Rosuvastatin, Administered Alone and in Combination with RO7795081 [Periods 1 and 4: predose and postdose at prespecified times on Days 1 to 5] | Time to Maximum Plasma Concentration (Tmax) of Rosuvastatin, Administered Alone and in Combination with RO7795081 [Periods 1 and 4: predose and postdose at prespecified times on Days 1 to 5] | Area Under the Plasma Concentration-Time Curve (AUC) from Time 0 to the Last Measurable Concentration (AUClast) of Rosuvastatin, Administered Alone and in Combination with RO7795081 [Periods 1 and 4: predose and postdose at prespecified times on Days 1 to 5] | AUC from Time 0 to Infinity (AUCinf) of Rosuvastatin, Administered Alone and in Combination with RO7795081 [Periods 1 and 4: predose and postdose at prespecified times on Days 1 to 5] | Cmax of Pitavastatin, Administered Alone and in Combination with RO7795081 [Periods 2 and 5: predose and postdose at prespecified times on Days 1 to 4] | Tmax of Pitavastatin, Administered Alone and in Combination with RO7795081 [Periods 2 and 5: predose and postdose at prespecified times on Days 1 to 4] | AUClast of Pitavastatin, Administered Alone and in Combination with RO7795081 [Periods 2 and 5: predose and postdose at prespecified times on Days 1 to 4] | AUCinf of Pitavastatin, Administered Alone and in Combination with RO7795081 [Periods 2 and 5: predose and postdose at prespecified times on Days 1 to 4]",null,null,"NO","CTIS:2024-519277-18-00"],["NCT04945070","INSULIN THERAPY DE-INTENSIFICATION WITH iGlarLixi","IDEAL","UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","96","Type 2 Diabetes Treated With Insulin","DRUG:IGlarLixi; DRUG:MDI - Multiple dose insulin injection","Institute for Clinical and Experimental Medicine","2021-07","2023-01","FALSE","HbA1C [6 months]","DERIVED:38653903",null,null,null],["NCT06555822","A Study to Investigate Multiple Ascending Doses and Relative Bioavailability of AZD5004 in Healthy Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","SINGLE","31","Healthy Participants","DRUG:AZD5004; DRUG:Placebo","AstraZeneca","2024-08-15","2025-03-06","FALSE","Part A: Number of participants with adverse events (AEs) and serious adverse events (SAEs) [From screening (Day -28) to last follow up visit (Day 120)] | Part B: Maximum observed plasma (peak) drug concentration (Cmax) of AZD5004 [From Day 1 (Treatment Period 1) to Day 13 (end of Treatment Period 2)] | Part B: Area under the concentration-curve from time zero to the last quantifiable concentration (AUClast) [From Day 1 (Treatment Period 1) to Day 13 (end of Treatment Period 2)] | Part B: Area under concentration-time curve from time 0 to infinity (AUCinf) [From Day 1 (Treatment Period 1) to Day 13 (end of Treatment Period 2)] | Part B: Time to reach maximum observed concentration (tmax) [From Day 1 (Treatment Period 1) to Day 13 (end of Treatment Period 2)]",null,null,"YES",null],["NCT06869018","A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","92","Healthy; Type 2 Diabetes Mellitus (T2D)","DRUG:LY3549492; DRUG:Placebo","Eli Lilly and Company","2025-05-07","2026-03-02","FALSE","Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Day 1 Through Day 127]",null,null,"NO","OTHER:J3H-JE-GZNG"],["NCT04838405","A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","129","Diabetes","DRUG:CT-388; DRUG:Placebo","Carmot Therapeutics, Inc.","2021-04-29","2024-06-18","FALSE","Incidence of Treatment-Emergent Adverse Events as assessed by self-report [Baseline up to 24 weeks]",null,null,"NO",null],["NCT06086912","A Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different Sites",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","24","Type 2 Diabetes","DRUG:HR17031","Jiangsu HengRui Medicine Co., Ltd.","2023-11-07","2023-12-12","FALSE","After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Area Under the Concentration versus time curve (AUC0-t) [Start of treatment up to Day 26] | After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Area Under the Concentration versus time curve (AUC0-∞) [Start of treatment up to Day 26] | After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Maximum Concentration (Cmax) [Start of treatment up to Day 26]",null,null,"UNDECIDED",null],["NCT07648225","UBT251 Injection Phase Ⅲ Study (Overweight or Obesity)",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","600","Obesity & Overweight","DRUG:UBT251 Injection 4.0 mg; DRUG:UBT251 Injection 6.0 mg; DRUG:UBT251 Injection Placebo 4.0 mg; DRUG:UBT251 Injection Placebo 6.0 mg","The United Bio-Technology (Hengqin) Co., Ltd.","2026-07-31","2027-09-29","FALSE","Body Weight [Week 52]",null,null,"NO",null],["NCT07382908","Bioequivalence Study of BGM0504 Injection",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","144","Overweight/Obesity","DRUG:BGM0504 Injection multi-dose pen; DRUG:BGM0504 Injection single-dose pen","BrightGene Bio-Medical Technology Co., Ltd.","2025-12-23","2026-02-12","FALSE","Peak Plasma Concentration (Cmax) [0 to 672 hours] | Area under the plasma concentration versus time curve (AUC)0-t [0 to 672 hours]",null,null,null,null],["NCT06569355","A Study to Evaluate the Efficacy and Safety of VCT220 in Obesity Chinese Population",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","250","Obesity; Overweight","DRUG:VCT220; DRUG:Placebo","Vincentage Pharma Co., Ltd","2023-12-27","2024-07-13","FALSE","Percentage change in body weight [From baseline (week 1) to week 16]","DERIVED:42595749",null,"NO",null],["NCT07697846","A Study to Investigate the Effects of Zovaglutide (ZT002 Injection) on QTc Interval in Healthy Adults",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","40","Overweight, Obesity","DRUG:ZT002 injection; DRUG:ZT002 injection matching placebo","Beijing QL Biopharmaceutical Co.,Ltd","2026-07-18","2027-01-13","FALSE","Change to baseline- and placebo-corrected QTc interval (ΔΔQTc) [Up to Day 141]",null,null,null,null],["NCT07279194","Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","825","Obesity & Overweight","DRUG:HDM1005 1; DRUG:HDM1005 2; DRUG:Placebo","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2025-10-14","2026-09-20","FALSE","primary outcome [week 40] | Co-primary outcome [week 40]",null,null,null,null],["NCT07230119","A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","755","Overweight , Obesity","DRUG:Zovaglutide dose 1; DRUG:Zovaglutide dose 2; DRUG:Placebo","Beijing QL Biopharmaceutical Co.,Ltd","2026-01-16","2027-05-29","FALSE","Change in body weight(%) [baseline (week 0) to week 52] | Proportion of subjects achieving ≥ 5% weight loss [52 weeks]",null,null,null,null],["NCT03308721","Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","99","Metabolism and Nutrition Disorder; Obesity","DRUG:NNC9204-1177 A 1.0 mg/mL; DRUG:PLACEBO","Novo Nordisk A/S","2017-10-16","2020-01-03","FALSE","Number of treatment emergent adverse events (TEAEs) [Day 1-110]","DERIVED:36524539",null,"YES","OTHER:U1111-1189-1919"],["NCT07823608","A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","258","Apnea; Sleep Disorders; Overweight and/or Obesity","DRUG:Berobenatide; OTHER:Placebo","Pfizer","2026-09-17","2028-04-30","FALSE","Change From Baseline in Apnea-Hypopnea Index (AHI) [baseline, Week 52]",null,null,"YES","OTHER:VESPER-OSA 1"],["NCT03990090","A Study of TG103 in Chinese Healthy Adult Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","32","Healthy","DRUG:TG103; DRUG:Placebo","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","2019-07-29","2020-11-11","FALSE","Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline through Day 28]","DERIVED:37062422",null,"NO",null],["NCT07065032","A Study of ZT002 Injection in Adult Chinese Subjects With Type 2 Diabetes Mellitus (T2DM)",null,"COMPLETED","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","DOUBLE","27","Type 2 Diabetes","DRUG:ZT002 Injection; DRUG:ZT002 Placebo","Beijing QL Biopharmaceutical Co.,Ltd","2024-02-19","2024-07-22","FALSE","Number of treatment emergent adverse events and serious adverse events; Number of participants with injection site reaction. [up to 155days]",null,null,"NO",null],["NCT06254261","A Study of RAY1225 in Participants With Obesity",null,"RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","270","Obesity","DRUG:RAY1225; DRUG:Placebo","Guangdong Raynovent Biotech Co., Ltd","2024-02-21","2025-12-20","FALSE","Change From Baseline in Body Weight [Baseline,Week26]",null,null,"UNDECIDED",null],["NCT07589686","A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight","ZYNERGY","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","486","Obesity or Overweight","DRUG:Petrelintide; COMBINATION_PRODUCT:Enicepatide; DRUG:Petrelintide-matching Placebo; COMBINATION_PRODUCT:Enicepatide-matching Placebo","Hoffmann-La Roche","2026-09-30","2027-11-12","FALSE","Percentage Change in Body Weight between Arms 1 and 6 [From Baseline to Week 40]",null,null,"YES",null],["NCT07443059","A Study of Zovaglutide (ZT002 Injection) in Participants With Impaired Kidney Function and Healthy Participants",null,"RECRUITING","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","40","Overweight , Obesity","DRUG:Zovaglutide","Beijing QL Biopharmaceutical Co.,Ltd","2026-04-13","2026-12-03","FALSE","Area Under the Concentration Versus Time Curve (AUC) of ZT002 From Time Zero to Tlast (AUC0-t). [Start of Treatment up to Day 50] | Maximum Concentration of ZT002 (Cmax) [Start of Treatment up to Day 50] | Area Under the Concentration Versus Time Curve (AUC) of ZT002 From Time Zero to Infinity (AUC0-∞) [Start of Treatment up to Day 50] | Time to maximum concentration (Tmax) [From baseline to Day 50] | Apparent terminal half-life (t1/2) [From baseline to Day 50] | Apparent clearance (CL/F) [From baseline to Day 50] | Incidence and severity of adverse events [Screening period up to Day 50]",null,null,null,null],["NCT07670416","A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","300","Obesity; Overweight; Type 2 Diabetes Mellitus (T2DM)","COMBINATION_PRODUCT:Enicepatide; COMBINATION_PRODUCT:Placebo","Hoffmann-La Roche","2026-07-03","2028-02-24","FALSE","Percent Change From Baseline in Body Weight at Week 52 [Baseline through Week 52]",null,null,"YES",null],["NCT06151964","A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight","CONTEMPO","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","TRIPLE","166","Overweight and Obesity","DRUG:AZD9550; DRUG:placebo; DRUG:AZD9550 and AZD6234","AstraZeneca","2023-09-29","2027-01-29","FALSE","Number and percentage of participants with any AE, SAEs, AEs leading to discontinuation of study intervention, AEs with outcome of death, and AEs leading to withdrawal from study. [Day - 35 to Day 261] | Number and percentage of participants with clinically significant changes from baseline in Vital Sign Parameters. [Day - 35 to Day 261] | Number and percentage of participants with clinically significant changes in ECG parameters. [Day - 35 to Day 261] | Number and percentage of participants with clinically significant changes from baseline in Clinical Laboratory Parameters [Day - 35 to Day 261] | Area Under Concentration-Time Curve of AZD9550 following repeat weekly SC doses [Day 1 to Day 65] | Maximum observed concentration of AZD9550 following repeat weekly SC doses [Day 1 to Day 65] | Half life associated with terminal phase elimination rate constant of AZD9550 following repeat weekly SC doses [Day 1 to Day 65] | Time to maximum observed concentration of AZD9550 following repeat weekly SC doses [Day 1 to Day 65] | Apparent oral clearance of AZD9550 following repeat weekly SC doses [Day 1 to Day 65] | Apparent volume of distribution of AZD9550 following repeat weekly SC doses [Day 1 to Day 65] | Ratio for AUC of AZD9550 following repeat weekly SC doses [Day 1 to Day 65] | Ratio for Cmax of AZD9550 following repeat weekly SC doses [Day 1 to Day 65]",null,null,"YES","REGISTRY:2023-504215-32-00; NIH:2023"],["NCT06862791","A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone","ASCEND","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","377","Obesity or Overweight","DRUG:AZD9550; DRUG:AZD6234; DRUG:Placebo comparator","AstraZeneca","2025-02-18","2026-05-11","FALSE","Percent change in body weight from baseline after 36 weeks of treatment [36 weeks] | Weight loss ≥ 5% from baseline after 36 weeks of treatment [36 weeks]",null,null,"YES","REGISTRY:2024-516176-15-00"],["NCT06920056","A Study of BGM0504 in Overweight or Obese Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","28","Overweight or Obese","DRUG:Paracetamol; DRUG:Metformin Hydrochloride; DRUG:Warfarin; DRUG:BGM0504","BrightGene Bio-Medical Technology Co., Ltd.","2025-03-25","2025-07-25","FALSE","Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC0-t)of Paracetamol [From Day1 to Day72] | Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Paracetamol [From Day1 to Day72] | Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC0-t) of Metformin [From Day4 to Day76] | Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Metformin [From Day4 to Day76] | Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC0-t) of Warfarin [From Day7 to Day84] | Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Warfarin [From Day7 to Day84]",null,null,null,null],["NCT07239973","A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","75","Healthy; Non-diabetic Overweight or Obese","DRUG:BGM0504 tablets; DRUG:Placebo tablets","BrightGene Bio-Medical Technology Co., Ltd.","2025-10-24","2026-03-05","FALSE","Number of treatment adverse events [8 weeks]",null,null,null,null],["NCT05054530","Assessment of the Safety, Tolerability, and Pharmacokinetic of GMA106",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","73","Overweight and Obesity","DRUG:GMA106 Injection; DRUG:GMA106 Matching Placebo","Gmax Biopharm Australia Pty Ltd.","2021-11-11","2023-11-17","FALSE","Nature, incidence and severity of treatment emergent adverse events [up to 150±5 days post injection] | Nature, incidence and severity of treatment emergent adverse events [up to 227±5 days post first injection]",null,null,null,null],["NCT04855292","A Study of TG103 Injection in Overweight/Obese Subjects Without Diabetes",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","48","Diabetes","DRUG:TG103 injection; DRUG:Placebo","CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","2021-07-01","2022-12-01","FALSE","Safety and tolerability assessed by incidence and severity of adverse events [Up to 99 days]","DERIVED:38807146",null,"NO",null],["NCT07193459","Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","360","Type 2 Diabetes","DRUG:HDM1002 200 mg; DRUG:HDM1002 400 mg; DRUG:Placebo","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2025-08-12","2026-10-10","FALSE","Change From Baseline in HbA1c at Week 40 [Week 40]",null,null,"NO",null],["NCT02731664","GLP-1 Inhibits Prandial Antro-duodeno-jejunal Motility in Humans","GLPMOT","COMPLETED","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","SINGLE","12","Functional Gastrointestinal Disorders","BIOLOGICAL:GLP-1; BIOLOGICAL:Intravenous saline","Uppsala University","2012-09","2017-08","FALSE","Motility index (measure of contraction amplitude x duration; area for mmHg x sec) [60 minutes]","BACKGROUND:20584260; BACKGROUND:18945254; RESULT:18298441; DERIVED:29177486",null,"YES",null],["NCT06885021","Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","780","Overweight and Obesity","DRUG:HDM1002 200mg, oral, once daily, 52 weeks; DRUG:HDM1002 400mg, oral, once daily, 52 weeks; DRUG:HDM1002 placebo, oral, once daily, 52 weeks","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2025-03-28","2026-05-30","FALSE","Percentage Change From Baseline in Body Weight [44weeks] | Percentage Change of Participants Achieving Weight Loss ≥ 5% [44weeks]",null,null,"UNDECIDED",null],["NCT03314844","Plasma Glucagon-like Peptide-1 Levels and In-hospital Complications in ST-segment Elevation Myocardial Infarction",null,"COMPLETED","OBSERVATIONAL",null,null,null,"564","STEMI - ST Elevation Myocardial Infarction; Glucagon-like Peptide-1; Bleeding; Complications",null,"Chinese PLA General Hospital","2013-02-01","2015-02-01","FALSE","in-hospital complications [Time Frame: up to 2 week after PCI (until discharge)]",null,null,null,null],["NCT06655740","Safety, Tolerability, and Effectiveness of Duodenal Mucosal RF Vapor Ablation for Insulin Elimination in Type-2 Diabetes","STEAM-IE","ACTIVE_NOT_RECRUITING","INTERVENTIONAL",null,null,"NONE","16","Diabetes Mellitus, Type 2","DEVICE:RF Vapor Ablation","Aqua Medical, Inc.","2024-10-01","2027-06-30","FALSE","Safety Endpoint [1 month] | Efficacy Endpoint [168 days]",null,null,null,null],["NCT07593105","Oat Flakes β-glucan on Glycemic Variability, Pancreatic Reserve, and Dyslipidemia Among Adolescents With Type 1 Diabetes",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","60","Type 1 Diabetes; Nutrition","DIETARY_SUPPLEMENT:Oat Flour","Ain Shams University","2024-10-12","2025-11-12","FALSE","Glycemic control [6 months]",null,null,"NO",null],["NCT07866846","Managing Pasireotide-associated Hyperglycaemia in Acromegaly With Ketogenic Diet","PasiAcroKeto","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","30","Acromegaly Due to Pituitary Adenoma; Hyperglycemia; Ketogenic Diet; Standard Care Control","DIETARY_SUPPLEMENT:Ketogenic diet; DRUG:Diabetes Medication","Leiden University Medical Center","2025-07-29","2027-12-31","FALSE","Hemoglobin A1c (HbA1c) level [At baseline, and 3 months, 7 months, 9, 11 and 13 months after initiation of pasireotide treatment.]",null,null,"YES",null],["NCT00306098","Islet Cell Transplantation Alone in Patients With Type 1 Diabetes Mellitus: Steroid-Free Immunosuppression",null,"COMPLETED","INTERVENTIONAL","PHASE2",null,"NONE","26","Diabetes Mellitus, Type I","DRUG:islets","Rodolfo Alejandro","2000-12","2004-07-04","FALSE","a1c less than 6.5 without severe hypoglycemia [for the duration of islet graft function]","RESULT:15996257; DERIVED:20003758; DERIVED:19005394",null,"NO","NIH:1U42RR016603-01; OTHER:HRSA # 1 R38OT01367-01-00; OTHER_GRANT:No Number"],["NCT06981936","This Randomized Trial Aims to Investigate the Efficacy of Balanced Nutritional Tablets-Comprehensive Multivitamin and Mineral Supplements- in Preventing Micronutrient Deficiencies Among Patients Utilizing GLP-1 RAs for Weight Loss in Comparison to a Placebo Control",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","TRIPLE","150","Micronutrient Deficiencies","DRUG:Balance Tablet; DRUG:Control (placebo)","General Committee of Teaching Hospitals and Institutes, Egypt","2025-05-15","2026-05-21","FALSE","Incidence of vitamin and mineral deficiencies at 12 months, comparing the proportion of participants in each group who develop one or more deficiencies. [From enrollment to the end of treatment at 12 months]",null,null,"YES",null],["NCT05015894","A Research Study Looking Into Blood Levels of the Medicine NNC0480-0389 in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function",null,"COMPLETED","INTERVENTIONAL","PHASE1",null,"NONE","42","Diabetes Mellitus, Type 2","DRUG:NNC0480-0389","Novo Nordisk A/S","2021-08-30","2022-08-02","FALSE","AUC0-∞,NNC0480-0389,SD, area under the NNC0480-0389 plasma concentration time curve after a single dose [From baseline (visit 2, day 1, pre-dose) until completion of the end-of-study visit (visit 11, day 36)]",null,null,"YES","EUDRACT_NUMBER:2021-001450-57; OTHER:U1111-1266-0594"],["NCT02910544","Weight Loss and Physical Activity in Overweight/Obese Individuals With Knee Osteoarthritis",null,"COMPLETED","OBSERVATIONAL",null,null,null,"150","Osteoarthritis, Knee","DIETARY_SUPPLEMENT:Intensive dietary intervention","Parker Research Institute","2016-11","2017-12","FALSE","Change in time spent inactive (minutes) [week -8 to week 0]",null,null,"UNDECIDED",null],["NCT04866667","Observational Study of ASCVD Risks of Type 2 Diabetes in East China",null,"COMPLETED","OBSERVATIONAL",null,null,null,"316","Type 2 Diabetes Mellitus; Arteriosclerotic Cardiovascular Disease; Liraglutide",null,"Zhejiang Provincial People's Hospital","2021-05-01","2023-12-31","FALSE","New-onset cardiovascular events [maximum 2 years]",null,null,"NO",null],["NCT02971722","a Study of JY09 in Chinese Healthy Subjects",null,"UNKNOWN","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","26","Healthy","DRUG:JY09; DRUG:Placebo","Beijing Dongfang Biotech Co., Ltd.","2016-12","2017-05","FALSE","Pharmacokinetics (PK) [Baseline through day29 of period]","BACKGROUND:12975499; BACKGROUND:20152707",null,"NO",null],["NCT06883019","Lecanemab for Early Onset Familial Alzheimer's Disease",null,"RECRUITING","OBSERVATIONAL",null,null,null,"114","Alzheimer Disease",null,"RenJi Hospital","2025-03-13","2027-06-30","FALSE","Chang of CDR-SB score [baseline, 9 month, 18 month]",null,null,"NO",null],["NCT07852988","Pancreatin Added to Standard Antihyperglycemic Therapy in Patients With Type 2 Diabetes",null,"RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","100","Type 2 Diabetes (T2DM)","DRUG:Pancreatin; DRUG:Placebo","Silesian Centre for Heart Diseases","2026-08-01","2027-12-31","FALSE","Glycemic control [3 months] | Time in range [3 months]","BACKGROUND:24670086; BACKGROUND:16954337; BACKGROUND:6997121",null,"YES","OTHER_GRANT:BNW-1-089/N/5/K"],["NCT05597475","GLP1R-imaging in Post-RYGB Hypoglycemia",null,"UNKNOWN","INTERVENTIONAL",null,null,"NONE","24","Obesity; Hypoglycemia Post Gastric Bypass Surgery; Hyperinsulinemic Hypoglycemia","DIAGNOSTIC_TEST:GLP-1R PET","Rijnstate Hospital","2016-11-01","2024-05-30","FALSE","Pancreatic uptake of 68Ga-NODAGA-exendin-4 [baseline]",null,null,null,null],["NCT07495020","The Transit Bipartition With the Use of a Metallic Anastomosis Clip and Circular Fundocorporeal Gastroplication","MACBIPARTFCG","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","90","Type 2 Diabetes Mellitus (T2DM); Obesity & Overweight; Marginal Ulcer (Peptic) or Erosion; Leakage, Anastomotic","PROCEDURE:Laparoscopic transit bipartition with Metallic Anastomotic Clip and Circular Fundocorporeal Gastroplication; PROCEDURE:Laparoscopic transit bipartition (gastroenteroanastomosis and entero-enteric anastomosis) use the Metallic Anastomotic Clip and with sleeve gastrectomy; PROCEDURE:laparoscopic duodenal transit bipartition using the Metallic Anastomotic Clip with circular fundocorporeal gastroplication without gastrectomy","The Society of Bariatric and Metabolic Surgeons of Kazakhstan","2026-04-30","2027-12-31","FALSE","T2DM remission rate [Baseline, 1, 2, 3 year after surgery]",null,null,"NO",null],["NCT06451458","ECHO for Diabetes and Multiple Chronic Conditions Study","E4DMMC","ENROLLING_BY_INVITATION","INTERVENTIONAL",null,"RANDOMIZED","NONE","20","Diabetes Mellitus; Chronic Disease","BEHAVIORAL:ECHO program for DMMC; BEHAVIORAL:Usual care","University of New Mexico","2024-10-16","2027-03-31","FALSE","HbA1c trajectory [At least once every 6 months per Electric Health Record (EHR), during 12 months baseline prior to intervention, during 18 months intervention.] | HbA1c level in control [At least once every 6 months per Electric Health Record (EHR), during 12 months baseline prior to intervention, during 18 months intervention.]","BACKGROUND:21596757; BACKGROUND:29189491; BACKGROUND:21631316; BACKGROUND:29368967; BACKGROUND:27549110; BACKGROUND:30442864",null,"YES","OTHER_GRANT:TE-2022C3-30560"],["NCT02941445","Weight Maintenance With Dipeptidyl Peptidase 4 (DPP4) Inhibitor Sitagliptin in Combination With Metformin After Liragludite Induced Weight Loss",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","24","Polycystic Ovary Syndrome; Body Weight","DRUG:sitagliptin and metformin; DRUG:Metformin","University Medical Centre Ljubljana","2015-10","2016-08","FALSE","Change in body weight. [Patient's body weight was measured at the baseline and after 12 weeks of clinical trial.]",null,null,"NO",null],["NCT07226947","Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment","BICEP","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","100","Obesity; Body Composition","DEVICE:Smartwatch activity and body composition monitor; BEHAVIORAL:General guidance on recommended exercise","Massachusetts General Hospital","2025-11-24","2027-06","FALSE","Lean mass (kg) [6 months]","BACKGROUND:38687506; BACKGROUND:16685058; BACKGROUND:26949037; BACKGROUND:27266673; BACKGROUND:37366315; BACKGROUND:37385275; BACKGROUND:35658024; BACKGROUND:33567185",null,"NO",null],["NCT07833813","Incretin Therapy and Exercise in Type 2 Diabetes","BIOM","NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","110","Type 2 Diabetes Mellitus","BEHAVIORAL:Structured Exercise Program","University of Regina","2026-09","2028-09","FALSE","Change in insulin resistance (HOMA-IR) [Baseline, 8 weeks, and 24 weeks]",null,null,"YES",null],["NCT07314528","Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","42","Rectal Cancer Patients; Obesity &Amp; Overweight; Locally Advanced Rectal Cancer (LARC); Total Neoadjuvant Therapy; GLP-1","DRUG:GLP-1 receptor agonist; DRUG:Total neoadjuvant therapy (TNT)","St. James's Hospital, Ireland","2026-04","2028-09","FALSE","Weight Loss [6 months] | Metabolic Profile of the Tissue [From enrolment to operation within 1 year] | Inflammatory Mediators [From enrolment to surgical resection within 1 year] | GLP-1 effects on mitochondrial fitness [From enrolment to surgical resection within 1 year] | Mapping systemic inflammatory profiles [From enrolment to surgical resection within 1 year] | Mapping circulating immune systems [From enrolment to surgical resection within 1 year] | Mapping tumour resident immune system [From enrolment to surgical resection within 1 year]","RESULT:38888262; RESULT:36294412; RESULT:35565381; RESULT:39093546; RESULT:32923389; RESULT:40437949; RESULT:38893212; RESULT:37085291; RESULT:40140925; RESULT:40285503; RESULT:33567185; RESULT:38967919; DERIVED:41806363",null,"NO",null],["NCT03785236","Visualizing Beta Cells After Islet Transplantation","GLP1-transpl","TERMINATED","OBSERVATIONAL",null,null,null,"13","Type 1 Diabetes Mellitus","RADIATION:68Ga-NODAGA-exendin PET/CT","Radboud University Medical Center","2016-06-06","2021-05-27","FALSE","Hepatic uptake of 68Ga-NODAGA-exendin-4 [1 year]",null,null,"NO",null],["NCT07701460","Assessing Follow up Trajectories in Eating, Routines, and Weight After GLP-1","AFTER-GLP","NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","200","Weight Maintenance","BEHAVIORAL:Digital Behavioral Application","Tufts University","2026-08-01","2028-01-31","FALSE","Percentage of weight loss maintained [12-months]",null,null,"NO",null],["NCT07536516","Measurement of Ocular Blood Flow and Retinal Oxygen Extraction in Diabetic Patients","DM OPF ROXY","RECRUITING","INTERVENTIONAL",null,null,"NONE","20","Diabetes Mellitus","DEVICE:• Laser Speckle Flowgraphy (LSFG); DEVICE:• Optical Coherence Tomography (OCT); DEVICE:• Optical Coherence Tomography Angiography (OCT-A)","Medical University of Vienna","2025-11-28","2026-05-01","FALSE","Ocular blood flow (LSFG) [From enrollment to last study day (=5-11 weeks)]",null,null,null,null],["NCT05177653","Separate and Combined Extrapancreatic Effects of the Incretin Hormones","GA-19","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","13","Pancreatectomy; Hyperglycemia","OTHER:Intravenous infusion","University Hospital, Gentofte, Copenhagen","2022-04-07","2023-03-03","FALSE","Changes in plasma levels of glucose between interventions assessed through frequently blood sampling during the experimental days [Up to two months] | Changes in plasma levels of glucagon (gut-derived) between interventions assessed through frequently blood sampling during the experimental days [Up to two months] | Changes in plasma levels of insulin/C-peptide between interventions assessed through frequently blood sampling during the experimental days [Up to two months] | Changes in plasma triglycerides between interventions assessed through frequently blood sampling during the experimental days. [Up to two months] | Changes in plasma lipoproteins between interventions assessed through frequently blood sampling during the experimental days. [Up to two months] | Changes in brown adipose tissue activity between interventions, assessed by thermographic camera [Up to two months] | Changes in adiponectin in plasma between interventions, assessed through frequently blood sampling during the experimental days. [Up to two months] | Changes in CTX between interventions assessed through frequently blood sampling during the experimental days [Up to two months] | Changes in plasma P1NP between interventions assessed through frequently blood sampling during the experimental days [Up to two months]","DERIVED:41069310",null,"NO",null],["NCT07602803","The Effect of GLP1 Agonists on Weight Loss in BBS Cohort in the UK",null,"COMPLETED","OBSERVATIONAL",null,null,null,"300","Bardet-Biedl Syndrome",null,"The Queen Elizabeth Hospital","2023-01-01","2026-04-01","FALSE","Weight loss change (%) at the end of study date, compared to one at the time zero [From enrolment to the end of treatment at the end of study date up to 18 months]",null,null,"YES",null],["NCT04354090","Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JY09",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","41","Diabetes Mellitus, Type 2","DRUG:JY09","Beijing Dongfang Biotech Co., Ltd.","2018-04-26","2018-12-27","FALSE","Incidence of adverse events and serious adverse events related to JY09 [Up to day 21]",null,null,"NO",null],["NCT01017302","A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","32","Diabetes Mellitus Type 2","DRUG:Placebo; DRUG:RO5095932","Hoffmann-La Roche","2009-12","2011-08","FALSE","Safety and Tolerability of various doses of RO5095932 [Weeks 1-4, 6, 8]",null,null,null,null],["NCT07251803","GLP1 Fasting Status and Gastric Retention Using Gastric Ultrasound",null,"RECRUITING","OBSERVATIONAL",null,null,null,"150","Gastric Retention","DIAGNOSTIC_TEST:Gastric Ultrasound","Medical University of South Carolina","2026-02-03","2026-12-31","FALSE","Pre-operative gastric volume per unit of weight (ml/kg) as assessed by gastric ultrasound. [From enrollment until completion of pre-operative gastric ultrasound (typically within 3 hours of scheduled procedure).]",null,null,"NO",null],["NCT04268862","Metabolic Defects in Prediabetic Kuwaiti Arabs and Indians",null,"UNKNOWN","OBSERVATIONAL",null,null,null,"120","Pathophysiology; Metabolic Glucose Disorders",null,"Dasman Diabetes Institute","2020-03-01","2021-07-15","FALSE","Insulin Resistance [15 months] | Insulin Secretion [15 months] | Beta Cell function [15 months] | Comparison of genetic markers [15 months] | GLP1 Action [15 months]","BACKGROUND:19336687; BACKGROUND:19490820; BACKGROUND:20361178; BACKGROUND:28847910; BACKGROUND:20445742; BACKGROUND:21602457; BACKGROUND:18625114; BACKGROUND:28162956; BACKGROUND:17216279; BACKGROUND:11151758; BACKGROUND:26884438; BACKGROUND:25411437; BACKGROUND:216883; BACKGROUND:27222389; BACKGROUND:14764748",null,null,null],["NCT04815278","NC Works4Health: Reducing Chronic Disease Risks in Socioeconomically Disadvantaged, Unemployed Populations","NCW4H","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","455","Diabetes; Chronic Disease; Psychological Distress","BEHAVIORAL:Immediate Chronic Disease Prevention Program (CDPP); BEHAVIORAL:Workplace Equity, Job and Health Supports Employer Intervention; BEHAVIORAL:Delayed, attenuated Chronic Disease Prevention Program (CDPP)","University of North Carolina, Chapel Hill","2021-09-17","2025-11-30","FALSE","Mean Psychological Distress Scores at Baseline [Baseline (Month 0)] | Mean Psychological Distress Scores at Month 3 [3 Months] | Mean Psychological Distress Scores at Month 6 [Month 6] | Mean Psychological Distress Scores at Month 12 [Month 12] | Weight at Baseline [Baseline (Month 0)] | Weight at Month 3 [Month 3] | Weight at Month 6 [Month 6] | Weight at Month 12 [Month12] | Blood Pressure at Baseline [Baseline (Month 0)] | Blood Pressure at Month 3 [Month 3] | Blood Pressure at Month 6 [Month 6] | Blood Pressure at Month 12 [Month 12]",null,"Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/78/NCT04815278/ICF_000.pdf","YES","NIH:1R01MD012832-01A1"],["NCT07244458","Dietary Peanuts and Nutrition-Related Outcomes",null,"RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","64","Dietary Change; Obesity & Overweight; Food Acceptance","DIETARY_SUPPLEMENT:Peanuts; PROCEDURE:Dual-energy X-ray absorptiometry (DEXA) scans","Ian J. Neeland, MD","2026-04-20","2027-12","FALSE","Change is Satiety as measured by the Hunger and Satiety Visual Analog Scales (VAS) [Baseline, End of study (12 weeks)] | Change in fatigue as measured by the Fatigue Severity VAS-F Survey [Baseline, End of study (12 weeks)] | Change in mood/well-being as measured by the Mental clarity, energy levels, and motivation VAS. [Baseline, End of study (12 weeks)] | Change in dietary quality as measured by Healthy Eating Index (HEI) [Baseline, End of study (12 weeks)] | Change in food enjoyment as measured by the Food Pleasure Scale (FPS) [Baseline, End of study (12 weeks)] | Change in fasting glucose as measured by medical record review [Baseline, End of study (12 weeks)] | Change in HbA1c as measured by medical record review [Baseline, End of study (12 weeks)] | Change in total cholesterol as measured by medical record review [Baseline, End of study (12 weeks)] | Change in LDL-C as measured by medical record review [Baseline, End of study (12 weeks)] | Change in HDL-C as measured by medical record review [Baseline, End of study (12 weeks)] | Change in triglycerides as measured by medical record review [Baseline, End of study (12 weeks)] | Change in physical activity as measured by International Physical Activity Questionnaire (IPAQ) [Baseline, End of study (12 weeks)]",null,null,"NO",null],["NCT07194317","A Feasibility Study to Determine the Most Appropriate Digital Dietary Assessment Tool in Patients With Obesity Initiating GLP-1 Receptor Agonist Treatment","FIDGET","COMPLETED","INTERVENTIONAL",null,null,"NONE","64","Obese Patients","DEVICE:Testing 3 different digital dietary assessment tools in a random order (Nutritics-Libro, MyFood24 and Intake24)","King's College London","2025-09-01","2026-03-13","FALSE","Usability [Following each test period of 1 week] | Usability and context of use [Following each test period of 1 week]]","RESULT:39175746; RESULT:28216582; RESULT:40507092; RESULT:38890501",null,"UNDECIDED",null],["NCT00353587","Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin",null,"COMPLETED","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","DOUBLE","396","Type 2 Diabetes","DRUG:MBX-102; DRUG:Placebo; DRUG:Actos","Gilead Sciences","2006-05","2007-11","FALSE","Evaluate effects of MBX-102 administered orally at doses of 200, 400 and 600 mg daily for 16 weeks, on glucose control, as measured by HbA1c [] | Evaluate safety of MBX-102 with particular emphasis on endpoints of weight gain and edema []",null,null,null,null],["NCT07789106","A Study on Ubiquinol on Fatigue and Muscle Strength in Healthy Adults Taking GLP-1 Agonists","Project Zest","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","90","Obesity & Overweight; GLP - 1; Fatigue Severity Scale; Ubiquinol; Muscle Contraction","DIETARY_SUPPLEMENT:Ubiquinol 100 MG Oral Capsule; DIETARY_SUPPLEMENT:Placebo","StudySetGo","2026-09-01","2027-12-01","FALSE","Self-reported fatigue [9 months]",null,null,"UNDECIDED",null],["NCT02130778","Natriuretic Effect of GLP-1in Healthy Non Obese Subjects",null,"COMPLETED","INTERVENTIONAL","EARLY_PHASE1","NON_RANDOMIZED","SINGLE","15","Sodium Excretion by Urination","DRUG:Synthetic GLP-1 (1.5 pmol/kg/min) dissolved in 500 ml 0.9% saline; OTHER:500 ml 0.9% saline","Clinical Hospital Centre Zagreb","2014-04","2015-10","FALSE","Evidence of the positive effect on natriuresis (level of sodium in urin sample) following the of GLP1 infusion [Within the 10 minutes after the infusion synthetic GLP-1 (1.5 pmol/kg/min) dissolved in 500 ml 0.9% saline]","BACKGROUND:15181098; DERIVED:30298444",null,null,null],["NCT05037045","Effect of Gene Polymorphisms on GLP-1 Receptor Agonists Response in Patients With T2DM",null,"COMPLETED","INTERVENTIONAL",null,null,"NONE","338","Type 2 Diabetes Mellitus","DRUG:GLP-1 receptor agonist","The Affiliated Hospital of Xuzhou Medical University","2019-01-10","2023-10-01","FALSE","Change from baseline HbA1c at 1 month [1 month after GLP-1 RA treatment] | Change from baseline FPG at 1 month [1 month after GLP-1 RA treatment] | Change from baseline PPG at 1 month [1 month after GLP-1 RA treatment] | Change from baseline serum lipids at 1 month [1 month after GLP-1 RA treatment] | Change from baseline HbA1c at 3 month [3 month after GLP-1 RA treatment] | Change from baseline FPG at 3 month [3 month after GLP-1 RA treatment] | Change from baseline PPG at 3 month [3 month after GLP-1 RA treatment] | Change from baseline serum lipids at 3 month [3 month after GLP-1 RA treatment] | Change from baseline HbA1c at 6 month [6 month after GLP-1 RA treatment] | Change from baseline FPG at 6 month [6 month after GLP-1 RA treatment] | Change from baseline PPG at 6 month [6 month after GLP-1 RA treatment] | Change from baseline serum lipids at 6 month [6 month after GLP-1 RA treatment]",null,null,"NO",null],["NCT05521256","A Research Study of a New Medicine NNC0113-6856 in Healthy Males",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","70","Healthy Volunteers; Type 2 Diabetes","DRUG:NNC0113-6856; DRUG:Placebo","Novo Nordisk A/S","2022-08-26","2023-03-27","FALSE","Number of adverse events [From time of dosing (day 1) until completion of the follow-up visit (Day 42)]",null,null,"YES","OTHER:U1111-1270-0813; EUDRACT_NUMBER:2021-005397-26"],["NCT07525037","Chinese, Overweight or Obesity, Real-World Registry Study",null,"NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"10000","Obesity Type 2 Diabetes Mellitus",null,"Chinese PLA General Hospital","2026-05-30","2027-12","FALSE","The treatment model for overweight and obese individuals in China at present. [1 year]",null,null,null,null],["NCT05196958","Interest of GLP1 Analogues in Overweight Type 2 Diabetic Patients With Chronic Inflammatory Bowel Disease","DiagMICI","UNKNOWN","INTERVENTIONAL",null,null,"NONE","20","Inflammatory Bowel Diseases; Diabetes Mellitus, Type 2","OTHER:GLP1 analogues","Fondation Hôpital Saint-Joseph","2022-01-25","2024-01-14","FALSE","Glycemic control [Month 6] | Weight loss [Month 6]","BACKGROUND:24970784; BACKGROUND:31394285; BACKGROUND:27899815; BACKGROUND:26241001; BACKGROUND:31531732; BACKGROUND:30956572; BACKGROUND:32429195; BACKGROUND:18931095; BACKGROUND:30122305; BACKGROUND:19853906; BACKGROUND:31359088",null,null,null],["NCT06790225","Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA)","GINEBRA","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","13","Bone Disease, Metabolic; Diabetes Mellitus, Type 2; Obesity and Obesity-related Medical Conditions","OTHER:Glucose-dependent Insulinotropic Polypeptide (GIP)","Esbjerg Hospital - University Hospital of Southern Denmark","2025-11-10","2026-09-17","FALSE","Serum levels of CTX [During a three day period. With 14-28 days of washout between the two administration methods]",null,null,"NO",null],["NCT06069895","Investigation of Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-6856 in Healthy Participants, Including a Subset of Healthy Japanese Participants",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","170","Healthy Participants","DRUG:NNC0113-6856; DRUG:Placebo","Novo Nordisk A/S","2023-10-04","2025-04-23","FALSE","Number of adverse events (AEs) [From time of first dosing (day 1) until completion of the follow-up visit (day 148)]",null,null,"YES","OTHER:U1111-1284-5743"],["NCT03917238","Beta Cell Imaging During and Shortly After the Honeymoon Phase of T1D","Honeymoon","ACTIVE_NOT_RECRUITING","INTERVENTIONAL",null,null,"NONE","14","Type 1 Diabetes Mellitus","RADIATION:gallium-68-exendin injection followed by PET/CT scan","Radboud University Medical Center","2019-10-11","2026-11-25","FALSE","Pancreatic uptake of gallium-68-NODAGA-exendin-4 [2 years]",null,null,"NO",null],["NCT03936660","A 12 Month Site Randomized Trial in Adults With Type 2 Diabetes Mellitus and History of Cardiovascular Disease","COORDINATE","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","1049","Diabetes Mellitus, Type 2; Cardiovascular Diseases","OTHER:Intense Education Intervention","Duke University","2019-07-25","2022-12-30","TRUE","Number of Participants Prescribed All 3 Groups of Recommended Evidence-based Medications [Up to 12 Months]","BACKGROUND:26981940; BACKGROUND:27295427; BACKGROUND:28545639; BACKGROUND:28859942; BACKGROUND:30559235; BACKGROUND:30559236; DERIVED:38934111; DERIVED:36877177","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/60/NCT03936660/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/60/NCT03936660/SAP_001.pdf","NO",null],["NCT07179796","Digital Physical Activity Program",null,"ENROLLING_BY_INVITATION","OBSERVATIONAL",null,null,null,"300000","Overall Health; Wellbeing; Quality of Life; Mental Health","BEHAVIORAL:Observation","Sword Health, SA","2025-09-09","2035-09","FALSE","Member Progress (PGIC) [Assessed at regular intervals (after 5, 9, 15, and every 6 days with activity until 3 months). Additional follow-up assessments may be undertaken at other times: 3, 6, and 12 months.]",null,null,"NO",null],["NCT06895408","Separate and Combined Extrapancreatic Effects of GIP and GLP-1","GA-19b","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","12","Pancreatectomy; Hyperglycemia","OTHER:Intravenous Infusion","University Hospital, Gentofte, Copenhagen","2025-02-19","2025-07-14","FALSE","Plasma glucose [Up to two months] | Plasma glucagon [Up to two months] | Plasma Insulin/C-peptide [Up to two months] | Plasma triglycerides [Up to two months] | Plasma CTX [Up to two months] | Plasma PINP [Up to two months]","DERIVED:42225304",null,"UNDECIDED",null],["NCT02299050","Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy",null,"COMPLETED","INTERVENTIONAL","PHASE4",null,"NONE","23","Type 2 Diabetes","DRUG:Cycloset","The University of Texas Health Science Center at San Antonio","2014-06","2018-04-30","TRUE","HbA1C [Change from baseline to four to five months] | Glucose Metabolism During Mixed Meal Tolerance Test [Change from baseline to four to five months]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/50/NCT02299050/Prot_SAP_000.pdf",null,null],["NCT07244445","Pistachio Intake and Nutrition-Related Outcomes in Individuals on GLP-1 Therapy",null,"RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","108","Dietary Change; Obesity & Overweight; Food Acceptance","DIETARY_SUPPLEMENT:Pistachios; PROCEDURE:Dual-energy X-ray absorptiometry (DEXA) scans","Ian J. Neeland, MD","2026-01-29","2027-12","FALSE","Change is Satiety as measured by the Hunger and Satiety Visual Analog Scales (VAS) [Baseline, End of study (12 weeks)] | Change in fatigue as measured by the Fatigue Severity VAS-F Survey [Baseline, End of study (12 weeks)] | Change in mood/well-being as measured by the Mental clarity, energy levels, and motivation VAS. [Baseline, End of study (12 weeks)] | Change in dietary quality as measured by Healthy Eating Index (HEI) [Baseline, End of study (12 weeks)] | Change in food enjoyment as measured by the Food Pleasure Scale (FPS) [Baseline, End of study (12 weeks)] | Change in fasting glucose as measured by medical record review [Baseline, End of study (12 weeks)] | Change in HbA1c as measured by medical record review [Baseline, End of study (12 weeks)] | Change in total cholesterol as measured by medical record review [Baseline, End of study (12 weeks)] | Change in LDL-C as measured by medical record review [Baseline, End of study (12 weeks)] | Change in HDL-C as measured by medical record review [Baseline, End of study (12 weeks)] | Change in triglycerides as measured by medical record review [Baseline, End of study (12 weeks)] | Change in physical activity as measured by International Physical Activity Questionnaire (IPAQ) [Baseline, End of study (12 weeks)]",null,null,"NO",null],["NCT00637338","Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus",null,"TERMINATED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","42","Diabetes Mellitus, Type 2","BIOLOGICAL:PF-04603629; BIOLOGICAL:Placebo","Pfizer","2008-04","2008-09","FALSE","To characterize the pharmacokinetics of PF-04603629 in serum after administration of escalating, multiple, subcutaneously injected doses of PF-04603629 to subjects with T2DM. [4 weeks per dose group] | To evaluate the effects of multiple, escalating, subcutaneously injected doses of PF-04603629, on the pharmacodynamic responses of glucose, insulin, C-peptide and glucagon during a mixed meal tolerance test (MMTT). [4 weeks per dose group] | To describe the safety and tolerability of escalating, multiple, subcutaneously injected doses of PF-04603629 administered to subjects with T2DM. [4 weeks per dose group]",null,null,null,null],["NCT07809945","A Study of IBI3046 in Participants With Overweight or Obesity",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","128","Obesity and Overweight","DRUG:IBI3046; DRUG:placebo","Innovent Biologics (Suzhou) Co. Ltd.","2026-09-15","2028-07-16","FALSE","Number of participants with Adverse Event [up to Day 169 for SAD;up to Day 225 for MAD] | Change in systolic blood pressure after dosing in each dose group(Unit of Measure: mmHg) [up to Day 169 for SAD;up to Day 225 for MAD] | Change in diastolic blood pressure after dosing in each dose group(Unit of Measure: mmHg) [up to Day 169 for SAD;up to Day 225 for MAD] | Number of participants with clinically significant abnormal findings in complete physical examination(Unit of Measure: participants) [up to Day 169 for SAD;up to Day 225 for MAD] | Number of participants with clinically significant changes in physical examination results； [up to Day 169 for SAD;up to Day 225 for MAD] | Number of participants with abnormal ECG changes before and after administration in each dose group [up to Day 169 for SAD;up to Day 225 for MAD]",null,null,null,null],["NCT07506356","Investigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors","SAGUSE","RECRUITING","OBSERVATIONAL",null,null,null,"38","Diabete Type 2; Regurgitation; Pulmonary Aspiration During Anaesthetic Induction",null,"University Hospital, Geneva","2026-04-01","2026-12-31","FALSE","A safe gastric volume for anesthesia in diabetic patients treated with GLP-1 analog after a 6 hours fasting period 7 day after the last injection. [1 week]",null,null,"NO","NIH:2025"],["NCT07478198","Study on the Efficacy and Safety of PLLA Injections for Improving Facial Laxity Following GLP-1 Analog Therapy","PLLA-GLP-1","ENROLLING_BY_INVITATION","INTERVENTIONAL",null,null,"NONE","22","Facial Skin Laxity","DEVICE:PLLA injection","Shanghai Punan Hospital of Pudong New District","2025-07-03","2026-08-31","FALSE","WSRS (Wrinkle Severity Rating Scale) Assessment [At screening, before each treatment session, and at 4, 12, 24 and 48 weeks after the final treatment]","BACKGROUND:39098289; BACKGROUND:39339028; BACKGROUND:37786340",null,"UNDECIDED","OTHER:PuNanPLLA-001"],["NCT07557355","A Study of SRSD384 in Overweight or Obese Participants",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1; PHASE2","RANDOMIZED","QUADRUPLE","78","Overweight , Obesity","DRUG:SRSD384 injection; DRUG:Placebo","Sirius Therapeutics Co., Ltd.","2026-06","2027-10","FALSE","Incidence of treatment-emergent adverse events (TEAEs) [168 days]",null,null,"UNDECIDED",null],["NCT07503028","An Exploratory Clinical Study Evaluating Allogeneic iPSC-derived Pancreatic Islet Cells (CRG-002) for the Treatment of Diabetic Patients With Hypoglycemia Unawareness or Severe Hypoglycemic Events",null,"ENROLLING_BY_INVITATION","INTERVENTIONAL","EARLY_PHASE1",null,"NONE","10","T1DM - Type 1 Diabetes Mellitus; Pancreatogenic Diabetes Mellitus","DRUG:CRG002","Celregen Therapeutics","2025-10-17","2028-01-18","FALSE","Safety as assessed by number of adverse events accoridng to CTCAE v 6.0 [Within one year after CRG-002 transplantation]","BACKGROUND:32641151; BACKGROUND:36113507; BACKGROUND:34590174",null,"NO",null],["NCT01406717","Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","360","Type 2 Diabetes Mellitus","DRUG:SPIL1033; DRUG:Placebo","Sun Pharmaceutical Industries Limited","2013-03-01","2015-11-04","TRUE","Change From Baseline to End of Study in Hemoglobin A1c (HbA1c) [24 weeks] | Change From Baseline to End of Study in Fasting Plasma Glucose (FPG) [24 weeks] | Count and Percentage of Subjects Positive for Anti-exenatide Antibodies [24 weeks] | Count and Percentage of Subjects With Potentially Immune-related Treatment-emergent Adverse Events (TEAEs) [24 weeks]",null,null,null,null],["NCT04880005","Digital Individualized and Collaborative Treatment of T2D in General Practice Based on Decision Aid","DICTA","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","400","Diabetes type2","BEHAVIORAL:Clinical decision support; BEHAVIORAL:Digital Lifestyle Coaching; BEHAVIORAL:Integration to Standard Electronic Health Record","University of Southern Denmark","2021-06-01","2025-08-31","FALSE","Change in a binary indicator, composed by a composite endpoint of HbA1c, systolic blood pressure, low-density lipoprotein cholesterol, no smoking, and normal albuminuria [12 months]","BACKGROUND:29172021; BACKGROUND:30852132; BACKGROUND:29627803; BACKGROUND:29229652; BACKGROUND:30291100; BACKGROUND:29530904; BACKGROUND:29666045; BACKGROUND:29980496; BACKGROUND:30860486",null,"YES",null],["NCT07829016","GLP-1 Impacts on Weight Management","GLOW","NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"100","Weight Management; Disordered Eating Behaviors",null,"University of California, San Francisco","2026-10-20","2029-09-01","FALSE","Change in the frequency of Objective Binge Episodes [6 months]",null,null,"NO",null],["NCT00588380","GLP1R Polymorphisms and Response to GLP1",null,"COMPLETED","INTERVENTIONAL",null,null,"NONE","88","Diabetes","DRUG:GLP-1","Mayo Clinic","2007-11","2010-09","TRUE","Insulin Secretion at 150-180 Minutes. [150 - 180 minutes after GLP-1 infusion]","RESULT:20805279",null,null,null],["NCT04135287","Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients",null,"UNKNOWN","INTERVENTIONAL","PHASE4",null,"NONE","315","Diabetes Mellitus, Type 2","DRUG:GLP-1 receptor agonist","Dasman Diabetes Institute","2020-03-01","2023-03-01","FALSE","HbA1c [6 months]",null,null,null,null],["NCT06694558","Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease",null,"RECRUITING","OBSERVATIONAL",null,null,null,"60","Chronic Kidney Disease(CKD); Type 1 Diabetes (T1D)",null,"The Cleveland Clinic","2025-03-01","2026-12-30","FALSE","Number of subjects with proinflammatory monocytes by flow cytometry, higher ER stress, and cytokine levels after monocyte exposure to hyperglycemia compared to euglycemia for 6 hours. [monocyte response to varying glycemic exposure after 6 hrs]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/58/NCT06694558/Prot_SAP_000.pdf","NO","NIH:K12DK133995"],["NCT01856907","Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","36","Disorder of Glucose Regulation","DRUG:Sitagliptin-Metformin; DRUG:Metformin; DRUG:Placebo pill","Woman's","2013-09-28","2017-09-05","TRUE","Normalization of Glucose Levels [16 weeks]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/07/NCT01856907/Prot_SAP_000.pdf","NO",null],["NCT06038734","Using Point-of-Care-Ultrasound (POCUS) to Assess Gastric Contents Among Fasting Pre-operative Patients Taking GLP-1 Agonists.",null,"COMPLETED","OBSERVATIONAL",null,null,null,"108","Delayed Gastric Emptying; Gastroparesis","DIAGNOSTIC_TEST:gastric ultrasound","University of North Carolina, Chapel Hill","2023-11-10","2024-04-17","FALSE","Retained gastric contents [At time of pre-operative assessment]",null,null,"YES",null],["NCT05948969","Transform CV Risk in Diabetes","CVRiD","UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","NONE","750","Type 2 Diabetes","OTHER:Decision support; OTHER:Facilitated referral to a cardiometabolic team-based center","American College of Cardiology","2023-09-01","2024-07-01","FALSE","New prescription of a SGLT2i and/or GLP-1RA [9 months]",null,null,"NO",null],["NCT06600490","Nationwide Utilization of Danish Government Electronic Letter System for Confirming the Effectiveness of Behavioral Nudges in Increasing InFLUenza Vaccine Uptake Among Adults With Chronic Disease",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","308978","Influenza; Behavior and Behavior Mechanisms","BEHAVIORAL:Behavioral Economic Principles","Tor Biering-Sørensen","2024-10-01","2025-01-01","FALSE","Number of participants who received an influenza vaccine [Up to 3 months]","DERIVED:41213006",null,"YES",null],["NCT04626323","Randomized Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease","OBESE-DKD","UNKNOWN","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","60","Diabetes Mellitus, Type 2; Kidney Disease, Chronic; Kidney Injury","PROCEDURE:Roux-en-Y gastric bypass; DRUG:Best medical treatment","Hospital Alemão Oswaldo Cruz","2021-05-25","2024-12","FALSE","Mean differenceGlomerular filtration rate (GFR) [At 12 and 36 months after randomization]","RESULT:20150934; RESULT:11304102; RESULT:23362314; RESULT:19954692; RESULT:28522654; RESULT:22187472; RESULT:21602457; RESULT:11565518; RESULT:11565517; RESULT:30990260; RESULT:21693741; RESULT:26450931; RESULT:24356416; RESULT:21931075; RESULT:16120818; RESULT:27263398; RESULT:11238785; RESULT:16188903; RESULT:20700413; RESULT:19420913; RESULT:18435772; RESULT:15380496; RESULT:7010165; RESULT:11832527; RESULT:18430778; RESULT:23288372; RESULT:8243850; RESULT:12684357; RESULT:15632335; RESULT:29133606; RESULT:31104957; RESULT:28549834; RESULT:28755274; RESULT:20876408; RESULT:28199805; RESULT:25405560; RESULT:24149519; RESULT:27665150; RESULT:31726864; RESULT:30083761; RESULT:30251143; RESULT:29568103; RESULT:31331758; RESULT:29532078; RESULT:27927587; RESULT:29335242; RESULT:25352176; RESULT:30443719; RESULT:18701613; RESULT:31753796; RESULT:27222550; RESULT:27222547; RESULT:27189354; RESULT:26369473; RESULT:22723580; RESULT:19808241; RESULT:28077412; RESULT:15273542; DERIVED:40663401",null,"NO","OTHER:CAAE - 37013420500000070"],["NCT07190794","RESCUE: Discontinuation of GLP-1",null,"TERMINATED","OBSERVATIONAL",null,null,null,"18","Obesity","DEVICE:OverStitch™ or OverStitch NXT™; BEHAVIORAL:Lifestyle Modification","Boston Scientific Corporation","2025-12-17","2026-05-26","FALSE","Percent total body weight loss (TBWL) at 1 year from baseline [12 months]",null,null,"NO",null],["NCT04295005","A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists",null,"COMPLETED","OBSERVATIONAL",null,null,null,"24500","Diabetes Mellitus, Type 2","DRUG:Empagliflozin; DRUG:DPP-4i; DRUG:GLP-1-RA","Boehringer Ingelheim","2020-11-16","2021-09-30","TRUE","Direct Healthcare Cost [Dataset included all adult persons, who were continuously insured between 01 january 2014 until 31 december 2018 (except for death), approximately a 4 year period.] | Healthcare Resource Utilization [Dataset included all adult persons, who were continuously insured between 01 january 2014 until 31 december 2018 (except for death), approximately a 4 year period.]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/05/NCT04295005/Prot_SAP_000.pdf","NO",null],["NCT06850129","Efficacy of a Digital Educational Intervention in Patients With Type 2 Diabetes Mellitus","DDC","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","85","Diabetes Mellitus Type 2","BEHAVIORAL:DIGITAL INTERVENTION","HOSPITAL VITHAS SEVILLA","2020-10-26","2022-10-26","FALSE","weight in Kilograms [From enrollment to the end of treatment at 6 months] | Hba1c in percent (lab result) [From enrollment to the end of treatment at 6 months] | weight and height will be combined to report BMI (Kg/m^2) [From enrollment to the end of treatment at 6 months]","DERIVED:40209213",null,"NO","OTHER:acf93301039dc0d0207316e1a95891"],["NCT06300086","Nationwide Utilization of Danish Government Electronic Letter System for Increasing Guideline-directed Medical Therapy in Chronic Kidney Disease","NUDGE-CKD","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","28388","Chronic Kidney Diseases; Behavior and Behavior Mechanisms","BEHAVIORAL:Electronically delivered nudging letters to patients with CKD; BEHAVIORAL:Electronically delivered nudging letter to associated GPs of patients with CKD","Tor Biering-Sørensen","2024-08-19","2025-02-19","FALSE","Number of participants with any prescription of renin-angiotensin system inhibition and/or sodium-glucose cotransporter 2 inhibitors [within 6 months]","DERIVED:40481660; DERIVED:40174694",null,"YES",null],["NCT07361640","DiaMester Pilot RCT: E-health Lifestyle Program for Type 2 Diabetes","DiaMester","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","99","Diabetes Mellitus, Type 2","BEHAVIORAL:e-health lifestyle program; BEHAVIORAL:Low calorie diet","Oslo University Hospital","2026-01-14","2027-09-30","FALSE","Change in body weight from baseline (weight loss) [Body weight will be assessed at baseline, 3 months, 6 months, 9 months and 12 months.]","BACKGROUND:7866415; BACKGROUND:12716841; BACKGROUND:15735199; BACKGROUND:7555499; BACKGROUND:21479777; BACKGROUND:12900694; BACKGROUND:37808205",null,"NO","OTHER_GRANT:SDAM_FOR555606"],["NCT07385547","Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency",null,"RECRUITING","INTERVENTIONAL","PHASE1",null,"NONE","40","Type II Diabetes Mellitus","DRUG:GL0034","Sun Pharmaceutical Industries Limited","2026-02-25","2026-09","FALSE","Single dose PK exposure parameters: Maximum concentration (Cmax) [From predose through 672 hours post-dose (multiple time points)] | Single dose PK exposure parameters: Area under the plasma concentration-time curve (AUC) from time zero to the time of the last quantifiable concentration (AUC0-t) [From predose through 672 hours post-dose (multiple time points)] | Single dose PK exposure parameters: AUC from time zero extrapolated to infinite time (AUC0-i) [From predose through 672 hours post-dose (multiple time points)]",null,null,null,null],["NCT07755150","A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 Diabetes",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","272","Type 2 Diabetes Mellitus","DRUG:DA-302168S; DRUG:Placebo of DA-302168S","Chendu DIAO Pharmaceutical Group CO., LTD.","2026-08-30","2027-10-20","FALSE","Change from baseline in HbA1c [From baseline (week 1) to week 16]",null,null,"NO",null],["NCT05831085","Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease","DEFINE-DM","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","1500","Coronary Artery Stenosis","PROCEDURE:State-of-the-Art Percutaneous Coronary Intervention; PROCEDURE:standard CABG","Duk-Woo Park, MD","2024-06-14","2029-12-31","FALSE","The event rate of major adverse cardiac or cerebrovascular events [2 years]",null,null,"UNDECIDED",null],["NCT07495904","Effect of GLP-1 Receptor Agonists on Body Composition in Obesity: The Role of Dietary Protein Consumption in Muscle Mass Maintenance","LEAN-PRO GLP-1","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","130","Obesity","BEHAVIORAL:High Protein Dietary Intervention; BEHAVIORAL:Control (Standard Mediterranean Diet Counseling)","Hellenic Mediterranean University","2026-03-30","2028-03-30","FALSE","Change from Baseline in Muscle Mass [Baseline and End of Intervention (up to 24 weeks)]",null,null,"NO","OTHER:Protocol No. 44248"],["NCT03288402","Investigation of the Effects of Diet on the Measurement of Plasma Chromogranin in NET Patients","DIB-NET","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","346","Neuroendocrine Tumors","OTHER:ongoing fasted state, intake of caffeine containing beverages or 5-item English breakfast","University Hospitals Coventry and Warwickshire NHS Trust","2017-02-01","2021-08-10","FALSE","changes in plasma CgA measurements related to intake of food or caffeine containing beverages, as compared to ongoing fasted state [up to 180 min]",null,null,"NO",null],["NCT07270172","The MICRON Study - A Steno 1 Substudy","MICRON","RECRUITING","OBSERVATIONAL",null,null,null,"40","Type 1 Diabetes Mellitus",null,"University of Aarhus","2025-10-27","2028-07","FALSE","Myocardial oxygen consumption [At baseline (0 month), at 6 months and 24 months.] | Renal oxygen consumption [At baseline (0 month), at 6 months and 24 months.]","RESULT:40726451",null,"UNDECIDED",null],["NCT07006272","Cohort Study to Refine the Positioning of Closed-loop Therapy Versus Islet Transplantation in the Management of Patients With Unstable Type 1 Diabetes","STABILOOP","RECRUITING","OBSERVATIONAL",null,null,null,"35","Type 1 Diabetes (T1D)",null,"University Hospital, Grenoble","2025-06-04","2030-12-31","FALSE","Describe Closed Loop (CL) failures at 12 months in patients referred to an expert center for management of unstable diabetes. [12 months]",null,null,"NO",null],["NCT07784127","Whole Gut Motility Abnormalities Following GLP-1 Receptor Agonist (GLP-1RA) Initiation",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,null,"NONE","20","Diabetes","PROCEDURE:Gut motility quantification using a capsule after initiating GLP-1RA therapy","The Cleveland Clinic","2026-12","2028-08","FALSE","Patient reported outcome for gastroparesis symptoms as assessed by Gastroparesis Cardinal Symptom Index (GCSI) Questionnaire [At Baseline and 3 Month Follow Up] | Patient-Reported Severity and Frequency of Gastrointestinal Symptoms as Assessed by Gastrointestinal Symptom Rating Scale (GSRS) Questionnaire [At Baseline and 3 Month Follow Up] | Patient-Reported frequency, duration, and diagnostic criteria for conditions affecting the gastrointestinal tract for colonic motility and function as Assessed by Rome IV Diagnostic Questionnaire [At Baseline and 3 Month Follow Up]",null,null,"UNDECIDED",null],["NCT05037058","China Diabetes Cardiovascular Initiative","CDCV","UNKNOWN","OBSERVATIONAL",null,null,null,"9600","Acute Coronary Syndrome; Diabetes Mellitus","OTHER:Quality improvement activities","Beijing Institute of Heart, Lung and Blood Vessel Diseases","2021-09-01","2023-12-31","FALSE","Proportion of patients receiving dual antiplatelet therapy at arrival (within 24 hours) [Duration of hospital stay, an expected average of 1 week] | Proportion of STEMI patients receiving fibrinolytic therapy within 30 minutes after arrival among those receiving this treatment [Duration of hospital stay, an expected average of 1 week] | Proportion of STEMI patients receiving reperfusion therapy by PCI [Duration of hospital stay, an expected average of 1 week] | Proportion of STEMI patients receiving primary PCI within 90 minutes after arrival among those receiving this treatment [Duration of hospital stay, an expected average of 1 week] | Proportion of NSTE-ACS patients receiving early cardiac troponin measurement (within 6 hours of arrival) [Duration of hospital stay, an expected average of 1 week] | Proportion of NSTE-ACS patients receiving risk stratification at admission [Duration of hospital stay, an expected average of 1 week] | Proportion of NSTE-ACS patients receiving PCI within recommended times for patients with high or intermediate risk [Duration of hospital stay, an expected average of 1 week] | Proportion of patients prescribed dual antiplatelet medications at discharge [Duration of hospital stay, an expected average of 1 week] | Proportion of patients with indications prescribed a beta-blocker at discharge [Duration of hospital stay, an expected average of 1 week] | Proportion of patients prescribed a statin at discharge [Duration of hospital stay, an expected average of 1 week] | Proportion of patients with indications prescribed an ACE-I or ARB at discharge [Duration of hospital stay, an expected average of 1 week] | Proportion of patients that receiving an LDL-C assessment [Duration of hospital stay, an expected average of 1 week] | Proportion of patients with evaluation for LV systolic function by echocardiography [Duration of hospital stay, an expected average of 1 week] | Proportion of smoking patients that receiving smoking cessation advice/counseling [Duration of hospital stay, an expected average of 1 week] | Proportion of patients receiving fasting glucose test at least twice [Duration of hospital stay, an expected average of 1 week] | Proportion of patients receiving HbA1C test [Duration of hospital stay, an expected average of 1 week] | Proportion of patients prescribed a SGLT-2 inhibitor or a GLP-1 receptor agonist at discharge with cardiovascular disease benefit [Duration of hospital stay, an expected average of 1 week] | Proportion of patients with body height and weight measured and documented [Duration of hospital stay, an expected average of 1 week] | Proportion of patients receiving guidance on individualized dietary [Duration of hospital stay, an expected average of 1 week] | Proportion of patients receiving guidance on individualized physical activity [Duration of hospital stay, an expected average of 1 week]",null,null,null,null],["NCT06982378","GLP-1 RA on Liver OMICS in MASLD","OMICS in MASLD","WITHDRAWN","OBSERVATIONAL",null,null,null,"0","NAFLD; Diabetes; Obesity","DRUG:GLP-1 receptor agonist","Medical College of Wisconsin","2026-07-01","2026-07-09","FALSE","Changes in lipidomics profile on use of GLP-1 RA [1 year]",null,null,"NO",null],["NCT04856683","PRecisiOn MEdicine to Target Frailty of Endocrine-metabolic Origin","PROMETEO","UNKNOWN","OBSERVATIONAL",null,null,null,"1100","Frailty",null,"University of Roma La Sapienza","2020-08-10","2023-08","FALSE","Composite Clinical Score [Baseline] | Prediction of frailty [Baseline]","BACKGROUND:27143951; BACKGROUND:28357683; BACKGROUND:27881060; BACKGROUND:29186457; BACKGROUND:27855417; BACKGROUND:29210056; BACKGROUND:29166244; BACKGROUND:28281219; BACKGROUND:24564322; BACKGROUND:23395245; BACKGROUND:29229498; BACKGROUND:15308380; BACKGROUND:9742976; BACKGROUND:18694979; BACKGROUND:27493135; BACKGROUND:23629540; BACKGROUND:28213644; BACKGROUND:27249660; BACKGROUND:29849622; BACKGROUND:20086217; BACKGROUND:25950715; BACKGROUND:23471977; BACKGROUND:22596288; BACKGROUND:14769829; BACKGROUND:22385888; BACKGROUND:21193542; BACKGROUND:15579193; BACKGROUND:11273062; BACKGROUND:25732653; BACKGROUND:26433736; BACKGROUND:29684108; BACKGROUND:14703017; BACKGROUND:28351913; BACKGROUND:26809957; BACKGROUND:11475942; BACKGROUND:15741267; BACKGROUND:25924873; BACKGROUND:28710115; BACKGROUND:19351744; BACKGROUND:22904173; BACKGROUND:17938392; BACKGROUND:16322389; BACKGROUND:17192338; BACKGROUND:25590217; BACKGROUND:12810194; BACKGROUND:22805710; BACKGROUND:8992884; BACKGROUND:10605626; BACKGROUND:15619671; BACKGROUND:27533615; BACKGROUND:15523071; BACKGROUND:16475872; BACKGROUND:16908916; BACKGROUND:18284942; BACKGROUND:18349089",null,null,null],["NCT02882477","Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy",null,"UNKNOWN","INTERVENTIONAL","PHASE2; PHASE3","NON_RANDOMIZED","NONE","20","Diabetes Mellitus; Iron Metabolism Disorders; Gastroduodenal Ulcer; Optic Atrophy; Sensorineural Hearing Loss; Platelet Dysfunction","DRUG:Deferiprone; DRUG:Acetylcysteine; DRUG:Sitagliptin and Metformin","Hadassah Medical Organization","2016-12","2018-05","FALSE","Insulin levels in blood in response to Glucose Challenge - Oral Glucose tolerance test (OGTT ) and Intra venous glucose tolerance test (IVGTT) [5 months] | Platelet aggregation to Adenosine diphosphate (ADP) and Collagen - blood test for Platelet function test [5 months] | Nerve conduction velocity in VEP [5 months] | HBA1C level [5 months] | daily glucose level measurement in the blood using Glucometer two to 5 times daily [5 months] | C-Peptide levels in blood in response to Glucose Challenge - Oral Glucose tolerance test ( OGTT ) and Intra venous glucose tolerance test IVGTT [5 months]","BACKGROUND:25422446; BACKGROUND:17846994; BACKGROUND:24227685; BACKGROUND:24843469; BACKGROUND:25448035; BACKGROUND:23959881; BACKGROUND:19451219; BACKGROUND:20649540; BACKGROUND:23859349; BACKGROUND:9519708; BACKGROUND:17084712; BACKGROUND:19720788",null,"NO",null],["NCT01681550","A Cohort Study of Incretin-based Therapy Combined With Insulin in Type 2 Diabetic Patients for 5 Years",null,"UNKNOWN","INTERVENTIONAL",null,null,"NONE","500","Type 2 Diabetes Mellitus","DRUG:Incretin-based therapy","Nagaoka Red Cross Hospital","2012-10","2018-10","FALSE","Death [Duration varied between individual patients and was as the period of time after treatment with incretin-based therapy combined with insulin.]",null,null,null,null],["NCT02585674","Comparison of MyStar DoseCoach to Routine Titration in Adult Patients With Type 2 Diabetes Mellitus Using Toujeo","AUTOMATIX","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","151","Type 2 Diabetes Mellitus","DRUG:Insulin glargine (U300); DEVICE:MyStar DoseCoach","Sanofi","2015-12","2016-11","FALSE","Percentage of patients reaching fasting SMPG target range 90-130 mg/dL (5.0-7.2 mmol/L) at Week 16 (mean of the last 5 readings recorded over the last 2 weeks) without a severe hypoglycemic episode during the 16-week on-treatment period [Baseline to Week 16]","DERIVED:29895556",null,null,"EUDRACT_NUMBER:2014-004533-13; OTHER:U1111-1165-9001; NIH:2014"],["NCT07602348","Assessment of Retinal-Angio Findings In Patients With Diabetes Type II Treated With Novel Antidiabetic Therapies","ARIADNE","ACTIVE_NOT_RECRUITING","OBSERVATIONAL",null,null,null,"40","Diabetic Retinopathy; GLP-1; SGLT 2 Inhibitors; Endothelial Dysfunction; Microvascular Circulation; Retinal Vascular Diseases",null,"University of Athens","2024-03-01","2026-01-30","FALSE","Changes in Ocular Parameters [Changes from baseline to 12-month follow-up.]",null,null,"NO",null],["NCT04791358","Decision Impact Trial of KidneyIntelX",null,"ACTIVE_NOT_RECRUITING","OBSERVATIONAL",null,null,null,"1500","Diabetic Kidney Disease","DIAGNOSTIC_TEST:KidneyIntelX","Renalytix AI, Inc.","2021-11-01","2026-11-01","FALSE","Blood pressure [12 Months] | HbA1c [12 Months] | ACEi/ARB [12 Months] | SGLT2/ GLP1 [12 Months] | Urine albumin to creatinine ratio [12 Months] | Referrals [12 Months]",null,null,"UNDECIDED",null],["NCT07360457","GLP1 Analogues and the Risk of Osteoarthritis",null,"NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"390","Osteoarthritis","DRUG:GLP-1 analog; DRUG:SGLT2 inhibitor; DRUG:Antidiabetic","Beni-Suef University","2026-02-01","2026-12-01","FALSE","WOMAC score [at Day 1]",null,null,"NO",null],["NCT06913881","Comparative Cardiovascular Effectiveness of GLP-1 RAs vs. Insulin in Early-Onset Type 2 Diabetes",null,"COMPLETED","OBSERVATIONAL",null,null,null,"92100","Type 2 Diabetes Mellitus (T2DM)","DRUG:GLP-1","Karolinska Institutet","2010-01-01","2021-12-31","FALSE","MACE [2010-2021]",null,null,"NO",null],["NCT06003985","Gastric Ultrasound Assessment for Patients Taking GLP1 Agonists",null,"COMPLETED","OBSERVATIONAL",null,null,null,"354","Gastric Ultrasound; Glucagon-like Peptide 1; Point of Care Ultrasound","OTHER:Gastric Ultrasound Exam","Hospital for Special Surgery, New York","2023-08-29","2025-01-31","FALSE","incidence of delayed gastric emptying [This will be measured pre-operatively in the holding room area.]","BACKGROUND:36870274; BACKGROUND:32077010; BACKGROUND:28648835",null,"NO",null],["NCT07708610","Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes",null,"NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"71775","Pneumonia; Type 2 Diabetes Mellitus (T2DM)",null,"Chung Shan Medical University","2026-07-31","2026-08-31","FALSE","Composite outcome (all-cause mortality, invasive mechanical ventilation, or renal replacement therapy) [Within 30 days after the index pneumonia admission]","BACKGROUND:38663919; BACKGROUND:35100355; BACKGROUND:37193038; BACKGROUND:30652541; BACKGROUND:28693043; BACKGROUND:20335814; BACKGROUND:26858290; BACKGROUND:21818162; BACKGROUND:36508210; BACKGROUND:36041749; BACKGROUND:26994063; BACKGROUND:34302745; BACKGROUND:22113526; BACKGROUND:24988558; BACKGROUND:28193610; BACKGROUND:25602997; BACKGROUND:30625066; BACKGROUND:28205683; BACKGROUND:23332146; BACKGROUND:22219349; BACKGROUND:11996618; BACKGROUND:17595354",null,"NO",null],["NCT07550634","Pharmacokinetics and Safety of MDR-001 in Mild and Moderate Hepatic Impairment",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","32","Hepatic Impairment (Mild and Moderate, Child-Pugh Class A and B); Hepatic Insufficiency (MeSH ID: D048550)","DRUG:MDR-001","MindRank AI Ltd","2026-06-01","2026-07-08","FALSE","Primary pharmacokinetic (PK) parameters of MDR-001 [Baseline (Day 1 pre-dose) and at 0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, and 48 hours post-dose on Day 1 (single dose).]",null,null,null,null],["NCT01972893","A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, Following Subcutaneous Administration in Healthy Volunteers","ZYD1","COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","56","Type 2 Diabetes Mellitus","DRUG:ZYD1; DRUG:Placebo","Zydus Lifesciences Limited","2011-02","2012-03","FALSE","To evaluate Safety and tolerability of ZYD1 [21 days]",null,null,null,"OTHER:CTRI/2011/04/001684"],["NCT07854990","Clinical Predictors and Therapeutic Gaps in CKM Syndrome Among Adults With Type 2 Diabetes","CKM-T2D","NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"231","Type 2 Diabetes Mellitus; Cardiovascular-Kidney-Metabolic Syndrome; Diabetic Kidney Disease","DIAGNOSTIC_TEST:clinical and laboratory CKM staging evaluation","Assiut University","2026-10-20","2028-03-20","FALSE","CKM Syndrome Stage Distribution and Clinical Predictors [Single outpatient visit]",null,null,"NO",null],["NCT03665350","Insulin Treatment in Diabetic Older People With Heart Failure.","Insulin-HF","TERMINATED","INTERVENTIONAL","PHASE2","RANDOMIZED","SINGLE","10","Heart Failure; Diabetes Mellitus, Type 2","DRUG:Insulin","Mario Negri Institute for Pharmacological Research","2018-11-08","2019-09-18","FALSE","Change in blood glucose variability [baseline to 12 months.]","BACKGROUND:29222382; BACKGROUND:28751837; BACKGROUND:27799274; BACKGROUND:29488676; BACKGROUND:23613566; BACKGROUND:1120786; BACKGROUND:28017523; BACKGROUND:28455343; BACKGROUND:22686416",null,"UNDECIDED","EUDRACT_NUMBER:2018-001057-26; NIH:2018"],["NCT07623148","GLP-1 RA Cessation and Gastric Ultrasound Findings",null,"COMPLETED","OBSERVATIONAL",null,null,null,"186","Residual Gastric Contents; Delayed Gastric Emptying","OTHER:GLP-1 RA Cessation Interval","Wonkwang University Hospital","2026-07-01","2026-07-20","FALSE","Estimated Gastric Volume Normalized to Body Weight [Immediately before induction of anesthesia on the day of surgery]",null,null,null,null],["NCT06668935","Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring",null,"RECRUITING","OBSERVATIONAL",null,null,null,"800","Diabetes Mellitus","DEVICE:To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists","Abbott Diabetes Care","2024-10-24","2026-10","FALSE","To assess the length of time subjects in each group remain on a GLP-1 or GLP-1/GIP combination drug [210 days]",null,null,"UNDECIDED",null],["NCT02451137","A \"Real World\" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","3304","Diabetes Mellitus, Type 2","DRUG:Insulin glargine, 300 U/ml; DRUG:Insulin glargine, 100 U/ml; DRUG:Insulin detemir; DRUG:Background Therapy","Sanofi","2015-06-16","2018-03-02","TRUE","Percentage of Participants With Individualized Glycated Hemoglobin Target Attainment Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria Without Documented Symptomatic(Blood Glucose <=70 mg/dL [<=3.9 mmol/L]) and/or Severe Hypoglycemia [Baseline to Month 6]","DERIVED:33509703; DERIVED:27690710","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/37/NCT02451137/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/37/NCT02451137/SAP_001.pdf",null,"OTHER:U1111-1168-0354"],["NCT02857764","Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States",null,"COMPLETED","OBSERVATIONAL",null,null,null,"127690","Diabetes Mellitus, Type 2",null,"Janssen Research & Development, LLC","2016-02-15","2017-06-30","FALSE","Incidence of Below-knee Lower Extremity Amputation in Type 2 Diabetes Mellitus (T2DM) Patients Newly Exposed to Sodium-glucose Co-transporter 2 Inhibitors (SGLT2i) Overall and in the Subgroup With High Cardiovascular (CV) Risk [up to 6 years (estimated study duration)] | Incidence of Below-Knee Lower Extremity Amputation in T2DM Patients Newly Exposed To non-SGLT2i Aha Overall And In The Subgroup With High CV Risk [up to 6 years (estimated study duration)] | Incidence of Below-Knee Lower Extremity Amputation in Canagliflozin New Users Versus non-SGLT2i Aha New Users [up to 6 years (estimated study duration)]",null,null,null,"OTHER:RRA-17578"],["NCT07518407","Dietary Insights and Nutritional Education in Adults on GLP-1 Therapy","DINE-GLP1","RECRUITING","INTERVENTIONAL",null,null,"NONE","50","Obesity Type 2 Diabetes Mellitus; Obesity","BEHAVIORAL:SWITCH Diets - Mobile Nutrition Behavioral Intervention","University of South Carolina","2026-04-06","2027-04-01","FALSE","Intervention acceptability, usefulness and ease of use [End of 6-week intervention]",null,null,"UNDECIDED",null],["NCT02954692","A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey","EASE","COMPLETED","INTERVENTIONAL","PHASE4",null,"NONE","112","Type 2 Diabetes Mellitus","DRUG:INSULIN GLARGINE (U300); DRUG:metformin; DRUG:sulfonylurea; DRUG:meglitinides; DRUG:thiazolidinediones; DRUG:alpha-glucosidase inhibitors; DRUG:GLP1 Receptor Agonist; DRUG:Dipeptidyl peptidase-IV (DPP-IV) inhibitors; DRUG:Sodium-glucose transport-2 (SGLT-2) inhibitors","Sanofi","2016-11-30","2017-12-22","FALSE","Mean change from baseline in HbA1c [Baseline, Week 24]",null,null,null,"OTHER:U1111-1183-8755"],["NCT04017221","Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes",null,"COMPLETED","OBSERVATIONAL",null,null,null,"1249636","Diabetes Mellitus, Type 2; Urosepsis; Diabetic Ketoacidosis; Lower Extremity Amputation","DRUG:Sodium-glucose cotransporter 2 (SGLT2) inhibitors; DRUG:Dipeptidyl peptidase-4 (DPP-4) inhibitors; DRUG:Other treatment combinations","Canadian Network for Observational Drug Effect Studies, CNODES","2018-10-01","2019-12-01","FALSE","Incidence rate of urosepsis [Patients will be followed from the date of study cohort entry until hospitalization for urosepsis, death, end of health care coverage, or for up to 64 months, whichever occurs first.] | Incidence rate of diabetic ketoacidosis (DKA) [Patients will be followed from the date of study cohort entry until hospitalization for DKA, death, end of health care coverage, or for up to 64 months, whichever occurs first.] | Incidence rate of lower extremity amputation [Patients will be followed from the date of study cohort entry until occurrence of a lower extremity amputation, death, end of health care coverage, or for up to 64 months, whichever occurs first.]","RESULT:32383792; RESULT:32759360; RESULT:32716707",null,"NO",null],["NCT07702825","Magnetic Resonance Imaging Assessment of Multiorgan Health in Obesity","FIT-YOUNG","RECRUITING","OBSERVATIONAL",null,null,null,"30","Childhood Obesity",null,"Alder Hey Children's NHS Foundation Trust","2026-03-06","2027-12","FALSE","Change in Liver fat measured using quantitative MRI [From enrollment to 9 months]",null,null,null,null],["NCT05297045","A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes",null,"TERMINATED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","17","Type 2 Diabetes Mellitus","DRUG:RGT001-075; OTHER:Placebo","Regor Pharmaceuticals Inc.","2022-03-29","2023-05-30","FALSE","Change in HbA1c from baseline to end of treatment in the modified intent-to-treat population [up to 16 weeks]",null,null,null,null],["NCT07724288","Designing and Implementing a Safety Net Surveillance Program for High Risk CKD","CKD Safety-Net","NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","972","Chronic Kidney Diseases","OTHER:Letter to participants","University of Manitoba","2026-08","2027-06","FALSE","Composite of kidney failure and all-cause mortality [within 12 months of letter mailout]",null,null,"NO",null],["NCT06659159","Effects of Beginning a GLP1-Agonist Therapy on Residual Gastric Content and Gastric Emptying","GLP-1","NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"50","Pulmonary Aspiration During Anaesthetic Induction","DIAGNOSTIC_TEST:Gastric ultrasound","Sascha Battig","2024-11-01","2026-10-31","FALSE","Gastric content [baseline examination at the first endocrinologic appointment the second examination/data collection will be at the regular endocrinologic control examination 6-8 weeks after therapy initiation. Final examination is 5 months after therapy start]",null,null,"NO","OTHER_GRANT:Hirslanden Klinik"],["NCT03526289","GIP/GLP-1 Co-Activity in Subjects With Overweight and Type 2 Diabetes: Lowering of Food Intake","GASOLIN II","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","22","Type 2 Diabetes Mellitus; Overweight and Obesity","BIOLOGICAL:GIP1-42 infusion; OTHER:Saline","University Hospital, Gentofte, Copenhagen","2017-11-08","2018-10-24","FALSE","food intake [time point 300-330 minutes]","DERIVED:31949084",null,"UNDECIDED",null],["NCT07806838","Effects of Dietary Supplements on Muscle Mass and Function While Using GLP-1 Medication",null,"RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","75","Obesity & Overweight; Muscle Mass and Strength; Muscle Function","DIETARY_SUPPLEMENT:Whey Protein Supplementation; DIETARY_SUPPLEMENT:Maltodextrin Placebo Capsules; DIETARY_SUPPLEMENT:Mixed Spice Capsules","University of California, Los Angeles","2026-09-10","2028-09-01","FALSE","Change in Muscle Mass Measured by DEXA [Baseline, 3 months, and 6 months] | Change in Muscle Mass Measured by D3-Creatine Enrichment [Baseline and 6 months]",null,null,null,null],["NCT07595575","The Effects of LEUVATE on Glycemia, Insulinemia, Aminoacidemia, and Protein Synthesis in GLP-1 RA-treated Adults","Leuvate001","NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","QUADRUPLE","8","The Whole-body Protein Synthesis Response to Protein With Amino Acid or Amino Acids","DIETARY_SUPPLEMENT:GLP-1","Nutraceutical Innovations LLC","2026-06-01","2026-08-01","FALSE","Whole-body protein synthesis [5 hours following consumption.]","BACKGROUND:35609328; BACKGROUND:41321015",null,"NO",null],["NCT07546357","AIManage Using an AI-driven CDS and Chatbot",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","16","Diabetes; Obesity; Medication Side Effects","OTHER:AIManage","NYU Langone Health","2026-06-01","2028-03-30","FALSE","Percentage of Patients who Complete Qualitative Measure - Perceived Usefulness [Day 1 (60 minutes)] | Percentage of Patients who Complete Qualitative Measure - Perceived Usability [Day 1 (60 minutes)] | Percentage of Patients who Complete Qualitative Measure - Perceived Use Challenges [Day 1 (60 minutes)] | Percentage of Patients who Complete Qualitative Measure - Perceived Value [Day 1 (60 minutes)]",null,null,"YES","NIH:1R01DK144008"],["NCT07770906","Effect of GLP-1 Receptor Agonists on Periodontal Health and Response to Nonsurgical Periodontal Therapy","GLP1-PERIO","NOT_YET_RECRUITING","INTERVENTIONAL",null,"NON_RANDOMIZED","SINGLE","40","Periodontal Disease; Obesity & Overweight","PROCEDURE:non-surgical periodontal therapy","Cukurova University","2026-09-01","2027-05-01","FALSE","Probing Depth [Baseline, 3 months- 6 months]",null,null,"UNDECIDED",null],["NCT06203275","The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus",null,"UNKNOWN","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","44","Diabetes Mellitus, Type 2","DRUG:Paroxetine; DRUG:Placebo","aya ramadan ashmawy sarhan","2024-01","2025-01","FALSE","The primary outcome is the change in glycated Hemoglobin (HbA1c). [3 months] | Change in HOMA-IR . [3 months]",null,null,null,null],["NCT06478173","Exercise Training and Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","TRIPLE","126","Type2diabetes","BEHAVIORAL:Exercise training","University of the Faroe Islands","2024-08-01","2024-12-20","FALSE","Lean mass (kg) [Change from baseline to end-of-intervention (14 weeks)]","BACKGROUND:24903461; BACKGROUND:27697647; BACKGROUND:32567951; BACKGROUND:29496507; BACKGROUND:27473445; BACKGROUND:27733284; BACKGROUND:23288372; BACKGROUND:28810024; BACKGROUND:22818937; BACKGROUND:29886433; BACKGROUND:28124381; BACKGROUND:24038928; BACKGROUND:26305880; BACKGROUND:24944131; BACKGROUND:25512789; BACKGROUND:26177573; BACKGROUND:16451303; BACKGROUND:26606383; BACKGROUND:28144978; BACKGROUND:20332353; BACKGROUND:26656025; BACKGROUND:31565876; BACKGROUND:30047579; BACKGROUND:29718556; BACKGROUND:29596941; BACKGROUND:29219149",null,"NO","OTHER_GRANT:0358"],["NCT07140289","Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) on Gastric Emptying",null,"ENROLLING_BY_INVITATION","OBSERVATIONAL",null,null,null,"100","Gastric Emptying; Glucagon-Like Peptide-1 Receptor Agonists; Intermittent Fasting; Intraoperative Complication Due to Anesthesia; Respiratory Aspiration of Gastric Contents","DIAGNOSTIC_TEST:Ultrasound of gastric contents","Wael Saasouh, MD","2025-09-01","2027-06-01","FALSE","Gastric cross-sectional area [Preoperatively on the day of surgery (between admission to preoperative testing and start of surgical procedure).]",null,null,"NO",null],["NCT07434791","Goal-Directed Therapy to Reduce Kidney and Cardiovascular Risk in Diabetic Kidney Disease (GOLD-STANDARD)","GOLD-STANDARD","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","100","Diabetic Kidney Disease (DKD); Type 2 Diabetes Mellitus (T2DM); Chronic Kidney Disease","OTHER:Early goal-directed Cardio-Kidney-Metabolic (CKM) care; OTHER:Standard care (Comparison arm)","Sunnybrook Health Sciences Centre","2026-08-26","2028-09","FALSE","Feasibility of the pivotal Randomized Controlled Trial (RCT) [From consent through completion of screening procedures to randomization (maximum 60 days).] | Prescription and Adherence to Guideline-Directed Medical Therapy (GDMT) [12 months after randomization (±45-day window).]","BACKGROUND:39142721; BACKGROUND:32116454; BACKGROUND:36356631; BACKGROUND:22945832; BACKGROUND:7580713; BACKGROUND:37939689; BACKGROUND:33873265; BACKGROUND:32926067; BACKGROUND:37517546; BACKGROUND:37429523; BACKGROUND:35812300; BACKGROUND:35700142; BACKGROUND:38569821; BACKGROUND:33264825; BACKGROUND:30990260; BACKGROUND:34964812; BACKGROUND:36272764; BACKGROUND:41160832; BACKGROUND:38991584; BACKGROUND:39210781; BACKGROUND:23362314; BACKGROUND:10972685; BACKGROUND:7648820; BACKGROUND:34426012",null,"YES",null],["NCT07100691","Gastric Emptying With Metoclopramide in GLP-1 Agonist Patients Undergoing Elective Surgery","GEM-GLP1RA","NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","80","Pulmonary Aspiration During Anaesthetic Induction; Gastric Emptying Time; Preoperative Risk Assessment; Obesity (Disorder)","DRUG:Metoclopramide","Mater Misericordiae University Hospital","2025-08","2026-05","FALSE","Presence of residual gastric content on preoperative gastric ultrasound [On the day of surgery prior to anaesthesia induction]","BACKGROUND:38446466; BACKGROUND:39781571; BACKGROUND:37234409; BACKGROUND:31314613; BACKGROUND:37982170; BACKGROUND:37874648; BACKGROUND:38298102; BACKGROUND:38286487; BACKGROUND:15361474; BACKGROUND:21447489",null,"NO",null],["NCT06839248","Effect of Fasting Recommendations Among Patients Using GLP-1 Receptor Agonists",null,"RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","154","Residual Gastric Contents; Pulmonary Aspiration of Gastric Contents","OTHER:24-hour clear liquid diet; OTHER:Standard fasting guidelines","St Vincent's Hospital Melbourne","2025-06-20","2027-02-01","FALSE","Residual gastric contents [Immediately following fasting intervention]","BACKGROUND:28045707; BACKGROUND:36629465; BACKGROUND:25951832; BACKGROUND:10702749; BACKGROUND:10757584; BACKGROUND:8156248; BACKGROUND:38039763; BACKGROUND:1071419; BACKGROUND:23860442",null,"YES",null],["NCT04272359","Substitution of Sulfonylureas With New Generation of Hypoglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus","Sulfa-Zero","UNKNOWN","OBSERVATIONAL",null,null,null,"138","T2DM (Type 2 Diabetes Mellitus); Diet, Healthy; Renal Function Disorder; Albuminuria","DRUG:Sulfa-zero: possible benefits of the treatment of new generation hypoglycaemic drugs compared to sulphonylureas","University of Milan","2019-05-06","2021-10-06","FALSE","Concentration of the glyco-metabolic parameters [12 months] | Therapeutic adherence [12 months] | Long-term diabetes complications [12 months]","BACKGROUND:18819705; BACKGROUND:17145742; BACKGROUND:24123720; BACKGROUND:15889234; BACKGROUND:15386821; BACKGROUND:22985213; BACKGROUND:23850055; BACKGROUND:21194578; BACKGROUND:25735400; BACKGROUND:25246775; BACKGROUND:24948511; BACKGROUND:15483097; BACKGROUND:23350795; BACKGROUND:11757083; BACKGROUND:992232; BACKGROUND:9742976; BACKGROUND:28497592; BACKGROUND:28223296",null,"UNDECIDED",null],["NCT05542420","A Research Study, Looking at the Characterization of Treatment Intensified (Add on to Metformin) Real-world Adult Population With Type 2 Diabetes Mellitus in India, Pakistan and Thailand.","CONVERGE","COMPLETED","OBSERVATIONAL",null,null,null,"3000","Diabetes Mellitus, Type 2","OTHER:No treatment given","Novo Nordisk A/S","2022-10-19","2023-04-20","FALSE","BMI (body mass index) [6 months prior to Baseline (day 0, defined as the date of first prescription for the most recent antidiabetic medication drug class) (retrospective)] | Most recent blood pressure measurement values [6 months prior to Baseline (day 0, defined as the date of first prescription for the most recent antidiabetic medication drug class) (retrospective)] | The proportion of patients prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RA) [At Baseline (day 0, defined as the date of first prescription for the most recent antidiabetic medication drug class)] | The proportion of patients prescribed cardiovascular disease (CVD) medications [Since the start of medical record]",null,null,"YES","OTHER:U1111-1273-4446"],["NCT04559191","Atheroma Progression and Vulnerability Under Continuous Glucose Monitoring","OPTIMAL","UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","90","Coronary Atherosclerosis","DEVICE:continuous glucose monitoring (CGM)","National Cerebral and Cardiovascular Center, Japan","2019-03-01","2021-12-31","FALSE","the normalized absolute change in total atheroma volume on serial intravascular ultrasound imaging. [from baseline to 12 months]","RESULT:31737515",null,"UNDECIDED",null],["NCT07588750","Retrospective Evaluation of Sibutramine-Topiramate Therapy for Obesity in Real-World Outpatient Practice","SIBUTAMATE","COMPLETED","OBSERVATIONAL",null,null,null,"278","Obesity & Overweight","DRUG:Sibutramine + Topiramate","Falquetomed","2026-06-01","2026-08-01","FALSE","Percent Change in Body Weight [Baseline to 12 months] | Change in Body Mass Index (BMI) [Baseline to 12 months]","RESULT:40691810; RESULT:15536230; RESULT:10102256",null,"NO","OTHER:SIBTOP-2026"],["NCT07499518","Fertility and Polycystic Ovary Syndrome","FERTIOPK","NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"473","Polycystic Ovary Syndrome (PCOS)","OTHER:Questionnaires","Assistance Publique - Hôpitaux de Paris","2026-06-01","2027-06-01","FALSE","Description of the mode of conception [Through study completion, an average of 1 year]",null,null,"YES",null],["NCT01192659","Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes",null,"COMPLETED","OBSERVATIONAL",null,null,null,"16492","Diabetes Mellitus, Type 2",null,"AstraZeneca","2010-05","2015-12","FALSE","To identify risk factors for lymphopenia, defined as an absolute lymphocyte count < 500 cells/μl, or investigator reported lymphopenia, in the SAVOR study population. [60 months]",null,null,null,null],["NCT02015780","Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis",null,"WITHDRAWN","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","0","Type 2 Diabetes Mellitus; Chronic Kidney Disease","DRUG:Fasiglifam; DRUG:Placebo; DRUG:Antihyperglycemic therapy","Takeda","2013-12","2016-01","FALSE","Change from Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16 [Baseline and Week 16]",null,null,null,"OTHER:U1111-1146-5546; EUDRACT_NUMBER:2013-003414-40"],["NCT05362058","A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time","QWINT-2","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","928","Diabetes; Type 2 Diabetes","DRUG:Insulin Efsitora Alfa; DRUG:Insulin Degludec","Eli Lilly and Company","2022-06-03","2024-04-10","TRUE","Change From Baseline in HbA1c at Week 52 [Noninferiority Analysis] [Baseline, Week 52]","DERIVED:42177728; DERIVED:41591636; DERIVED:39254740","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/58/NCT05362058/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/58/NCT05362058/SAP_001.pdf","YES","OTHER:I8H-MC-BDCX; EUDRACT_NUMBER:2021-005891-21"],["NCT07558603","Evaluate the Safety and Efficacy of AGE Serum in Post-menopausal Patients on Hormone Replacement Therapy Taking Glucagon-like Peptide-1 Agonist",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","50","Laxity; Skin","DRUG:On GLP1 plus HRT; DRUG:On GLP1 Only","Goldman, Butterwick, Fitzpatrick and Groff","2026-04-20","2026-08-30","FALSE","Modified Griffith Scale [Baseline, Week 6 and Week12]",null,null,null,null],["NCT07837973","Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss","PRESERVE","RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","220","Overweight , Obesity; Adults","DRUG:ALV-100; DRUG:Placebo","Alveus Therapeutics, Inc.","2026-08-10","2027-08-24","FALSE","Dose response of ALV-100 as assessed by maintenance of weight loss [24 weeks]",null,null,null,null],["NCT07789223","Weight and Metabolic Management Study","WMMS","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","TRIPLE","200","Overweight; Obesity; Weight Maintenance","DIETARY_SUPPLEMENT:elénzia CONTROL®; DIETARY_SUPPLEMENT:Placebo","Elenzia","2026-09-15","2027-02","FALSE","Percentage Change in Body Weight From Baseline to Week 16 [Baseline to Week 16] | Absolute Change in Body Weight From Baseline to Week 16 [Baseline to Week 16]",null,null,"YES",null],["NCT02157298","Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","266","Type 2 Diabetes Mellitus","DRUG:Dapagliflozin 5 mg; DRUG:Placebo tablet","AstraZeneca","2014-06","2015-02","TRUE","Adjusted Mean Change in HbA1c Levels [Baseline to Week 16]",null,null,null,null],["NCT07614230","SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes","SCOPE","RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","144","Type 2 Diabetes Mellitus (T2DM); Coronary Artery Disease; Atherosclerosis","DRUG:Dapagliflozin (DAPA); OTHER:Standard Care (Treatment as Usual)","Junjie Yang","2026-01-01","2027-06-01","FALSE","Progression of Coronary Plaque Volume and Proportion from Baseline to the 18-Month Follow-Up [Baseline to 18 months]",null,null,"NO","OTHER_GRANT:82470342"],["NCT02537834","Tofogliflozin GLP-1 Analogue Combination Trial",null,"COMPLETED","INTERVENTIONAL","PHASE4",null,"NONE","65","Type 2 Diabetes Mellitus","DRUG:Tofogliflozin; DRUG:GLP-1 analogue","Kowa Company, Ltd.","2015-08","2017-07","FALSE","Safety and Tolerability Assessed by Adverse Event and Adverse Drug Reaction [baseline and Week 52] | Change from Baseline in HbA1c at 52 weeks [Week 52]","RESULT:31033218",null,null,"OTHER:TOFOGL07279"],["NCT01568125","Effect of Incretin-related Drugs on Dietary Intake in Japanese Patients With Type 2 Diabetes Mellitus",null,"UNKNOWN","OBSERVATIONAL",null,null,null,"100","Type 2 Diabetes Mellitus","DRUG:Incretin-related drugs","Nagaoka Red Cross Hospital","2010-01","2014-01","FALSE","HbA1c [one year]",null,null,null,null],["NCT01879228","Effect of Chronic Incretin-based Therapy in Cystic Fibrosis",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","TRIPLE","26","Cystic Fibrosis; Pancreatic Insufficiency","DRUG:Sitagliptin; DRUG:Placebo","University of Pennsylvania","2013-06","2019-12","TRUE","Change in Second-phase Insulin Response Derived From the Glucose-potentiated Arginine Test as a Measure of β-cell Sensitivity to Glucose at Baseline and at 6 Months [Baseline and 6 months]","DERIVED:34406395","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/28/NCT01879228/Prot_SAP_000.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/28/NCT01879228/ICF_001.pdf",null,null],["NCT02176681","A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","70","Haemodialyzed, Type 2 Diabetes","DRUG:Vildagliptin (Galvus); DRUG:Insulin","University Hospital, Strasbourg, France","2014-06","2017-10","FALSE","Mean glucose value of CGM [M] to be averaged from day 2 and day 3 of CGM [up to day 3]","RESULT:32048396",null,null,"EUDRACT_NUMBER:2013-004737-33"],["NCT06654219","Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) Agonist Prior to Anesthesia",null,"RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","136","Pulmonary Aspiration","OTHER:GLP-1 RA users with prolonged fasting instructions; OTHER:GLP-1 RA users with standard NPO instructions","The University of Texas Health Science Center, Houston","2025-10-30","2026-12-31","FALSE","Number of participants that show prevalence of increased RGC determined using preoperative GUS [prior to procedure ( within 2 hours before procedure)]",null,null,"NO",null],["NCT06865456","Predictors of Survival of DKD Patients in Assiut University Hospital",null,"NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"129","Chronic Kidney Disease(CKD)",null,"Assiut University","2025-05-01","2026-05-01","FALSE","incidence of CKD in diabetic patients [baseline]",null,null,null,null],["NCT05324241","Laxative Properties of Microencapsulated Lipid (Constipation Study)",null,"UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","31","Constipation","DIETARY_SUPPLEMENT:Fat Microcapsules","University College Dublin","2022-04-15","2023-04-15","FALSE","Completed bowel motion [24 hours]",null,null,"NO",null],["NCT07032311","Digital Behavioral Therapy to Reduce Diabetes and Liver Disease Risk","SIPPA-QH_HHC-2","NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","180","Type 2 Diabetes; Liver Disease","DEVICE:Behavioral Treatment","SIPPA Solutions INC","2026-08-20","2027-10-30","FALSE","Change in Glycated Hemoglobin (HbA1c) [Baseline to 6 months after randomization]","BACKGROUND:35755867",null,"UNDECIDED",null],["NCT06236672","Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease",null,"COMPLETED","OBSERVATIONAL",null,null,null,"348","Type 2 Diabetes; Chronic Kidney Diseases","DRUG:GLP-1 receptor agonist; DRUG:basal insulin","LMC Diabetes & Endocrinology Ltd.","2023-02-15","2023-11-29","FALSE","change in HbA1c (%) [baseline to 26-to-52 weeks follow-up]","DERIVED:39113258",null,"NO",null],["NCT05342545","Decision Support for Detection of Chronic Kidney Disease in Type II Diabetes Mellitus","CKD-DETECT","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","QUADRUPLE","400","Chronic Kidney Diseases; Type2Diabetes","OTHER:Alert-based computerized decision support","Brigham and Women's Hospital","2022-12-01","2024-12-31","FALSE","Frequency of UACR testing order for CKD in patients with T2DM who have not had such testing within the past year [90 days]","DERIVED:42031191",null,"NO",null],["NCT06877572","Weight Loss Management in Endometrial Cancer Survivors","ECS Weight","ACTIVE_NOT_RECRUITING","OBSERVATIONAL",null,null,null,"50","Endometrial Cancer Survivors; Weight Management; Early Stage Endometrial Cancer","BEHAVIORAL:Weight loss with pharmacotherapy; BEHAVIORAL:Weight loss without pharmacotherapy","University of Kansas Medical Center","2025-03-25","2028-10","FALSE","Percentage of participants referred to weight loss clinic who are able to start weight management medications [12 months]","BACKGROUND:37905277; BACKGROUND:36336720; BACKGROUND:24222976; BACKGROUND:21731866; BACKGROUND:34336024; BACKGROUND:36977782; BACKGROUND:36188627; BACKGROUND:31855395; BACKGROUND:36971688; BACKGROUND:23824948; BACKGROUND:36589506; BACKGROUND:22507532; BACKGROUND:29741696; BACKGROUND:19320986; BACKGROUND:27909905; BACKGROUND:27903150; BACKGROUND:12079291; BACKGROUND:35020204",null,"YES",null],["NCT05268081","Specialist Conferences Between General Practitioners and Endocrinologists","STAR","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","25","Diabetes Mellitus, Type 2","OTHER:Virtual specialist conferences","University of Aarhus","2022-01-01","2023-08-30","FALSE","Ischemic heart disease and/or stroke treated with GLP1-RA and SGLT2 inhibitor [Month 12] | Micro/macro-albuminuria treated with ACE-inhibitor or AT2 [Month 12] | LDL>2.5 mmol/L treated with Statins [Month 12] | Questionnaire for the assessment of general practitioners' confidence in managing type-2 diabetes in general [Month 12] | Questionnaire for the assessment of general practitioners' skills in managing type-2 diabetes in general [Month 12] | Questionnaire for the assessment of general practitioners' confidence in managing type-2 diabetes and cardiovascular disease or heart failure [Month 12] | Questionnaire for the assessment of general practitioners' confidence in managing type-2 diabetes and blood pressure [Month 12] | Questionnaire for the assessment of general practitioners' confidence in managing type-2 diabetes and kidney disease [Month 12] | Questionnaire for the assessment of general practitioners' confidence in managing type-2 diabetes and cholesterol [Month 12]","BACKGROUND:36578024; DERIVED:40148532",null,"NO",null],["NCT06657339","National Registry of Obesity Treatment by Endosleeve",null,"NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"354","Obesity","PROCEDURE:Therapeutic endoscopy endosleeve using a gastric suturing device (OverStitch™/Endomina™)","Société Française d'Endoscopie Digestive","2024-12","2029-12","FALSE","Measurement of total weight loss (TWL) in % 5 years afther endosleeve [5 years]",null,null,null,null],["NCT07611201","The Effects of GLP-1 Receptor Agonists on Chemosensory Function and Ingestive Behavior",null,"COMPLETED","OBSERVATIONAL",null,null,null,"90","Obesity; Overweight; Taste Perception; Olfaction; Eating Behavior; Appetite",null,"Purdue University","2025-02-20","2026-05-04","FALSE","Taste Detection Thresholds [During study participation, up to 2 weeks] | Suprathreshold Taste Intensity [During study participation, up to 2 weeks] | Taste Hedonics [During study participation, up to 2 weeks] | Fat Taste Intensity Rating [During study participation, up to 2 weeks] | ArOMa-T Olfactory Test Performance [During study participation, up to 2 weeks] | SCENTinel Olfactory Test Performance [During study participation, up to 2 weeks]","BACKGROUND:31665455; DERIVED:42641845",null,"NO",null],["NCT04151849","Effects of Diabetes Medications on Adrenal Function and Intestinal Microbiota",null,"COMPLETED","OBSERVATIONAL",null,null,null,"23","Type 2 Diabetes","DRUG:GLP-1 receptor agonist; DRUG:SGLT2 inhibitor","University of Tartu","2019-11-07","2023-01-23","FALSE","Urinary aldosterone at 3 months [3 months]",null,null,"NO",null],["NCT06967337","Microsteps Study-Short, Animated Storytelling Video",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","TRIPLE","5431","Behavior, Health","BEHAVIORAL:Microsteps; BEHAVIORAL:Storytelling video; BEHAVIORAL:Instructional Video","Stanford University","2025-06-19","2025-07-07","FALSE","Effects of the written Microsteps, with instructional booster video or storytelling booster video, on behavioral expectation to adopt behavioral nudges, in the immediate and medium-term. [Baseline, immediately post-intervention exposure (up to 24 hours) and 2 weeks post exposure.]","DERIVED:41801203",null,"NO",null],["NCT06740435","Enhancing Telemedicine for T2D",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","50","Type 2 Diabetes","OTHER:Enhanced Telemedicine for Type 2 Diabetes; OTHER:Usual Telemedicine Endocrinology Care for T2D","University of Pittsburgh","2025-02-03","2026-10","FALSE","Recruitment percentage [12 months] | Loss to follow up [6 months]",null,"Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/35/NCT06740435/ICF_000.pdf","YES","NIH:K23DK135794"],["NCT06660134","Strict Weight Management Based on GLP-1 RA for Ablation Outcomes in Overweight or Obese Patients with T2DM and AF",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","174","Type 2 Diabetes Mellitus (T2DM); Atrial Fibrillation (AF)","DRUG:Glucagon-like peptide-1 receptor agonists (GLP 1 RA)","Shanghai Chest Hospital","2021-08-01","2023-12-31","FALSE","Atrial fibrillation (AF), atrial flutter (AFL), or atrial tachycardia events lasting ≥30 seconds occurring from the end of a 3-month blanking period post-procedure up to 12 months of follow-up. [at least 12 months of follow-up, beyond the initial 3-month blanking period]",null,null,"UNDECIDED",null],["NCT02105792","PROMASTER - PROspective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes","PROMASTER","COMPLETED","OBSERVATIONAL",null,null,null,"820","Diabetes","DRUG:second- or third-line glucose-lowering diabetes treatment","Royal Devon and Exeter NHS Foundation Trust","2013-03","2015-05","FALSE","Response to diabetes therapy [Up to 9 months from commencement of new therapy]",null,null,"NO","OTHER:12/SW/0347"],["NCT07575932","A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity","SOLIS-1","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","940","Overweight; Obesity; Overweight and/or Obesity; Overweight or Obesity; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight","DRUG:PF-08653945; DRUG:PF-08653944; DRUG:Placebo","Pfizer","2026-05-11","2027-08-04","FALSE","Percent change from baseline in body weight [Baseline (Week 0) to Week 48]",null,null,"YES","OTHER:SOLIS-1"],["NCT05198284","Prospective Decision Impact Clinical Utility Trial of KidneyIntelX",null,"ACTIVE_NOT_RECRUITING","OBSERVATIONAL",null,null,null,"2000","Diabetic Kidney Disease; Chronic Kidney Diseases; Chronic Kidney Disease Stage 1; Chronic Kidney Disease Stage 2; Chronic Kidney Disease Stage 3","DIAGNOSTIC_TEST:KidneyIntelX","Renalytix AI, Inc.","2021-11-01","2023-12-01","FALSE","Blood pressure [12 Months] | HbA1c [12 Months] | ACEi/ARB [12 Months] | SGLT2/ GLP1 [12 Months] | Urine albumin to creatinine ratio [12 Months] | Referrals [12 Months]",null,null,"UNDECIDED",null],["NCT05662332","A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)","QWINT-1","COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","795","Type 2 Diabetes; T2D","DRUG:Insulin Efsitora Alfa; DRUG:Insulin Glargine","Eli Lilly and Company","2023-01-14","2024-07-19","TRUE","Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] [Baseline, Week 52]","DERIVED:41591636; DERIVED:40548694","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/32/NCT05662332/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/32/NCT05662332/SAP_001.pdf","YES","OTHER:I8H-MC-BDCW"],["NCT07014709","Impact of GLP-1 Receptor Agonists on Patients With IPMN","IPMN-GLP1RA","NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"30","IPMN; IPMN, Pancreatic; GLP-1; Intraductal Papillary Mucinous Neoplasm of Pancreas; Glucagon-Like Peptide-1 Receptor Agonists","DRUG:GLP1 receptor agonist","Hôpital Fribourgeois","2025-05-31","2026-10-31","FALSE","Radiological changes in pancreatic cyst characteristic as described in the Kyoto 2023 Consensus [during the GLP1 RA treatment]","RESULT:38182527; DERIVED:42715243",null,"UNDECIDED",null],["NCT01446003","A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1)",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","31","Hypertension","DRUG:MK-8457; DRUG:Placebo for MK-8457","Merck Sharp & Dohme LLC","2011-10-25","2012-02-18","TRUE","Change From Baseline to Day 10 in 24-hour Mean Ambulatory Systolic Blood Pressure (SBP) [Baseline and Day 10] | Number of Participants Who Experienced at Least One Adverse Event (AE) [Up to 70 days] | Number of Participants Who Discontinued the Study Medication Due to an AE [Up to 70 days]",null,null,"YES",null],["NCT07224880","Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists",null,"COMPLETED","OBSERVATIONAL",null,null,null,"9","glp1 Agonist; Gene Expression; Skin Laxity","DEVICE:ellacor","Cytrellis Biosystems, Inc.","2025-10-14","2026-08-21","FALSE","Safety and Outcomes [study time frame]","BACKGROUND:38841534; BACKGROUND:36262685",null,"NO",null],["NCT07240246","Effect of a Dietary Supplement on Hormones Involved in Appetite Regulation in Overweight and Obese Adults",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","QUADRUPLE","40","GLP-1; Obesity &Amp; Overweight; Dietary Supplement","DIETARY_SUPPLEMENT:Intervention: Dietary Supplement with Plant Extracts; OTHER:Placebo","FFoQSI - Austrian Competence Centre for Feed and Food Quality, Safety & Innovation","2025-10-24","2026-03-11","FALSE","GLP-1 secretion [12 weeks]","BACKGROUND:24614112; BACKGROUND:29850829; BACKGROUND:38027106; BACKGROUND:25852028; BACKGROUND:39082206; BACKGROUND:31767182; BACKGROUND:31002893; BACKGROUND:16022753; BACKGROUND:26641646; BACKGROUND:34082399; BACKGROUND:19390518; BACKGROUND:30226521; BACKGROUND:40004954; BACKGROUND:40094091; BACKGROUND:29776414; BACKGROUND:38717042; BACKGROUND:38302593",null,"NO",null],["NCT05903482","Gastric Volume in Patients on GLP-1 Medications",null,"COMPLETED","OBSERVATIONAL",null,null,null,"70","Diabetes","OTHER:None - observational","Children's Hospital of Philadelphia","2023-06-06","2024-12-31","FALSE","Gastric volume in pediatric patients on GLP-1 RA [Day 1]",null,null,"NO",null],["NCT00843479","The Aging Endocrine Pancreas: Characterization of the Entero-insular Axis Physiology in the Elderly",null,"COMPLETED","OBSERVATIONAL",null,null,null,"24","Diabetes Mellitus, Type 2; Insulin Resistance",null,"University of Campinas, Brazil","2009-06","2010-09","TRUE","Homeostasis Model Assessment Insulin Resistance (HOMA-IR) Index [within 1 month from screening visit] | Glucose Infusion Rate [within 1 month from screening visit] | Adaptive Beta-cell Insulin Production. The Product of Meal Tolerance Test-derived Insulinogenic Index (IGI) for Clamp-derived Insulin Sensitivity Index (ISI) in Normoglycemic Subjects After 65 Years Old in Comparison With Middle-age Normoglycemic Subjects [within 1 month from screening visit] | Distinctive Beta-cell Function From the Arginine Stimulation Test in Normoglycemic Subjects After Sixty-five Years Old in Comparison With Middle-age Normoglycemic Subjects. [within 1 month from screening visit]","DERIVED:24854384",null,null,null],["NCT05535322","Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity",null,"COMPLETED","OBSERVATIONAL",null,null,null,"26944","Type 2 Diabetes; Obesity","DRUG:GLP-1RA; DRUG:SGLT2i; DRUG:Insulin; DRUG:Miscellany","Ana Palanca","2014-01-01","2019-12-31","FALSE","Major acute cardiovascular events [From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first.]","BACKGROUND:29675797; BACKGROUND:28801475; BACKGROUND:29364585; BACKGROUND:27466235; BACKGROUND:31028689; BACKGROUND:28070733; BACKGROUND:31673896; BACKGROUND:21457427; BACKGROUND:27531506; BACKGROUND:30677504; BACKGROUND:30291013; BACKGROUND:31422062; BACKGROUND:28053550; BACKGROUND:32372454; BACKGROUND:28834075; BACKGROUND:32295809; BACKGROUND:32347181; DERIVED:36847952",null,"UNDECIDED",null],["NCT07075341","Healthy Living BEYOND Weight Study",null,"RECRUITING","OBSERVATIONAL",null,null,null,"1000000","Overweight or Obesity","OTHER:None - Observational study","American Heart Association","2025-06-30","2060-12","FALSE","Answer fundamental unanswered questions regarding patient experiences and outcomes related to overweight and obesity. [From enrollment to at least 10 years post enrollment, continuous follow up] | Evaluate the real-world effectiveness of different weight management strategies, within contemporary and diverse patient populations. [From enrollment to at least 10 years post enrollment, continuous follow up] | Create a community of volunteers interested in advancing research on the conditions of overweight/obesity and related weight management strategies. [From enrollment to at least 10 years post enrollment] | To provide an enduring resource of value to individuals living with overweight and obesity. [From enrollment to at least 10 years post enrollment]",null,null,"YES",null],["NCT03912623","Evaluation of the Benefit at 6 Months of a 3 Weeks Spa Treatment in the Type 2 Diabetic Patient.","DIABEO2THERMES","UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","NONE","200","Diabetes Mellitus; Physical Activity; Dietetic Rules; Therapeutic Education","OTHER:SPA Treatment with therapeutic education and physical activity; OTHER:Week end","Association Francaise pour la Recherche Thermale","2019-09-13","2022-03-01","FALSE","HbA1c evolution [6 months]","BACKGROUND:21705069; BACKGROUND:25347226; BACKGROUND:18829362; BACKGROUND:10457741; BACKGROUND:19734131; BACKGROUND:23346190; BACKGROUND:23886461",null,"NO",null],["NCT07670520","Acute Kidney Injury In Care Transitions (ACT): Pragmatic Clinical Trial","ACT","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","2260","Acute Kidney Injury","BEHAVIORAL:Acute Kidney Injury in Care Transitions (ACT); BEHAVIORAL:Usual Care","Mayo Clinic","2026-04-16","2030-03-31","FALSE","Hospital-Free Days [90 days, 180 days, 1 year]",null,null,"YES","NIH:1R01DK145433-01"],["NCT06576375","Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome",null,"UNKNOWN","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","70","Polycystic Ovary Syndrome","DRUG:Dapagliflozin; DRUG:Metformin","Future University in Egypt","2024-09-02","2025-01","FALSE","Fertility parameters- Luteinizing hormone [3-6 months] | Fertility parameters-Follicle-stimulating hormone [3-6 months] | Fertility parameters-Free androgen index [3-6 months] | Fertility parameters-Total testosterone [3-6 months] | Transvaginal ultrasonography [3-6 months] | Menstrual diaries [3-6 months]",null,null,"NO",null],["NCT01096277","Vascular Effects of Sitagliptin in Diabetes Mellitus",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","QUADRUPLE","70","Type 2 Diabetes Mellitus","DRUG:Sitagliptin; DRUG:Placebo; OTHER:Control","Hannover Medical School","2010-10","2011-11","FALSE","Endothelial function [Before and after two week treatment]",null,null,null,"OTHER:MHH_NPH_SS_1/2010"],["NCT02694575","The Impact of Glucose Lowering Therapies on Circulating Endothelial Progenitor Cells and Its Mobilising Factor Stromal Derived Factor-1α in Patients With Type 2 Diabetes","IGLOOS","COMPLETED","OBSERVATIONAL",null,null,null,"241","Diabetes Mellitus, Type 2; Cardiovascular Diseases",null,"University of Leicester","2015-03-01","2017-04-12","FALSE","EPC [Single sample analysis - no time frame]","BACKGROUND:8529508; BACKGROUND:17192355; BACKGROUND:3514343; BACKGROUND:20871975; BACKGROUND:17098089; BACKGROUND:20151774; BACKGROUND:20068138; BACKGROUND:14981009; BACKGROUND:17174230; BACKGROUND:16305055; BACKGROUND:9020076; BACKGROUND:16148285; BACKGROUND:21040691; BACKGROUND:15862417; BACKGROUND:12451003; BACKGROUND:12584367; BACKGROUND:11440984; BACKGROUND:16824855; BACKGROUND:15927972; BACKGROUND:17277037; BACKGROUND:15126524; BACKGROUND:20357375",null,"YES",null],["NCT02671864","Incretin-mimetic Hypoglycemic Drugs and Severe Retinopathy","ANGIOSAFE2","UNKNOWN","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","7200","Type 2 Diabetes","OTHER:1: incretin-based therapy; OTHER:2: other antidiabetic","Assistance Publique - Hôpitaux de Paris","2016-04-11","2022-04-11","FALSE","Prevalence of Severe DR at V1 (inclusion) [at inclusion]","DERIVED:31589290",null,"NO",null],["NCT06665919","The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","TRIPLE","283","Coronary Artery Disease; Clopidogrel Resistance; Coronary Thrombosis; Adverse Cardiac Events; Bleeding; Hospitalisations; Death; Death From Cardiovascular Disease","OTHER:CYP2C19 Genotype-Guided Clopidogrel Treatment; OTHER:CYP2C19 Genotype Guided Antiplatelet Treatment Alternative to Clopidogrel; OTHER:The Conventional Clopidogrel Treatment","Vistamedi Ltd.","2023-06-15","2025-05-15","TRUE","Number of Study Participants Who Died From Any Cause (Death From Any Cause) [within a 12-month of the study follow-up] | Number of Study Participants Who Died From Any Cardiovascular Cause (Death From Cardiovascular Cause) [within a 12-month of the study follow-up] | Number of Study Participants Who Died From Non-cardiovascular Causes (Death From Non-cardiovascular Cause) [within a 12-month of the study follow-up]","BACKGROUND:35016208; BACKGROUND:33551797; BACKGROUND:32678355; BACKGROUND:34936903; BACKGROUND:29700074; BACKGROUND:31479209; BACKGROUND:28854078; BACKGROUND:26108379; BACKGROUND:35699175; BACKGROUND:32243053; BACKGROUND:36082121; BACKGROUND:35155631; BACKGROUND:31116395; BACKGROUND:28110296; BACKGROUND:24067509; BACKGROUND:37345589; BACKGROUND:33515031; BACKGROUND:28294551; BACKGROUND:31758664; BACKGROUND:31664775; BACKGROUND:29615454; BACKGROUND:33140858; BACKGROUND:34903548; BACKGROUND:32821149; BACKGROUND:29540324; BACKGROUND:29102571; BACKGROUND:32027168; BACKGROUND:34995471; BACKGROUND:26431961; BACKGROUND:35860051; BACKGROUND:37045504; BACKGROUND:37045502; BACKGROUND:34154743; BACKGROUND:30998396; BACKGROUND:31928229; BACKGROUND:35034351; BACKGROUND:33568995; BACKGROUND:29799992; BACKGROUND:34670396; BACKGROUND:32840598; BACKGROUND:37961335; BACKGROUND:31316169; BACKGROUND:31202949; BACKGROUND:35132875; BACKGROUND:35402528; BACKGROUND:33763519; BACKGROUND:27026020; BACKGROUND:28886622; BACKGROUND:37632363; BACKGROUND:28923905","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/19/NCT06665919/Prot_SAP_000.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/19/NCT06665919/ICF_001.pdf","YES",null],["NCT07723833","A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","152","Healthy Participants","DRUG:Elecoglipron Reference Formulation Dose A; DRUG:Elecoglipron Test formulation 1 Dose A; DRUG:Elecoglipron Reference Formulation Dose B; DRUG:Elecoglipron Test formulation 1 Dose B; DRUG:Elecoglipron Test formulation 2 Dose A; DRUG:Elecoglipron Test formulation 2 Dose B","AstraZeneca","2026-07-27","2026-11-18","FALSE","Maximum observed drug concentration (Cmax) [At pre-defined intervals from Day 1 to Day 15] | Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) [At pre-defined intervals from Day 1 to Day 15] | Area under concentration-time curve from time 0 to infinity (AUCinf) [At pre-defined intervals from Day 1 to Day 15] | Time to reach maximum observed concentration (tmax) [At pre-defined intervals from Day 1 to Day 15] | Terminal elimination rate constant (λz) [At pre-defined intervals from Day 1 to Day 15] | Terminal elimination half-life (t1/2λz) [At pre-defined intervals from Day 1 to Day 15] | Apparent total body clearance (CL/F) [At pre-defined intervals from Day 1 to Day 15] | Apparent volume of distribution based on the terminal phase (Vz/F) [At pre-defined intervals from Day 1 to Day 15] | Ratio of elecoglipron (test formulation) to elecoglipron (reference formulation) based on AUCinf (R AUCinf) [At pre-defined intervals from Day 1 to Day 15] | Ratio of elecoglipron (test formulation) to elecoglipron (reference formulation) based on AUClast (R AUClast) [At pre-defined intervals from Day 1 to Day 15] | Ratio of elecoglipron (test formulation) to elecoglipron (reference formulation) based on Cmax (R Cmax) [At pre-defined intervals from Day 1 to Day 15]",null,null,"YES",null],["NCT06795360","Weight Changes After Incretin-mimetics",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,null,"NONE","52","Obesity and Obesity-related Medical Conditions","OTHER:discontinuation of weight loss medication","Medical College of Wisconsin","2026-12-01","2031-11-30","FALSE","weight change [3 months] | fasting and post-prandial circulating AgRP [3 months]",null,null,"YES",null],["NCT07031596","Study on the Weight Loss Effects and Mechanisms of Probiotic Preparation Intervention in Weight Cyclers","Probiotic","NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","QUADRUPLE","198","Obesity and Obesity-related Medical Conditions","DIETARY_SUPPLEMENT:WONDERLAB SHAPE100™ Ready-to-Eat Probiotic Food (S100).; DIETARY_SUPPLEMENT:WONDERLAB SHAPE100™ Ready-to-Eat Probiotic Food (S100) + WONDERLAB Weight Management Probiotic Food.; DIETARY_SUPPLEMENT:Placebo","Peking Union Medical College Hospital","2025-06","2026-12","FALSE","Percentage of Participants with >5% Body Weight Loss [From baseline (D0) to end of intervention (D85 ±7 days)]",null,null,"YES",null],["NCT06142006","The Diabetes Staging System in Patient Aligned Care Teams",null,"UNKNOWN","OBSERVATIONAL",null,null,null,"120","Diabetes Mellitus; Type 2 Diabetes","OTHER:Diabetes Staging System (DSS) use among Primary Care Teams","Durham VA Medical Center","2023-09-01","2024-09-01","FALSE","SGLT2i and/or GLP-1 agonist use after DSS EHR template use [Baseline and 6 months after DSS implementation]","BACKGROUND:30568472; BACKGROUND:36700391; DERIVED:41982645",null,"NO",null],["NCT07012642","Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema",null,"RECRUITING","INTERVENTIONAL","EARLY_PHASE1",null,"NONE","110","Lymphedema","DRUG:GLP-1 Receptor Agonists","Advanced Reconstructive Surgery Alliance","2025-04-09","2027-04-09","FALSE","Patient reported quality of life outcome using LLIS [6 months]",null,null,"YES",null],["NCT07223216","Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","80","Obesity","DRUG:BMF-650","Biomea Fusion Inc.","2025-10-23","2026-05","FALSE","Assess safety and tolerability of BMF-650 [6 weeks (Part 1) and 11 weeks (Part 2)]",null,null,"NO",null],["NCT07130396","Impact of Multivitamin (PhytoMulti®) and a Probiotic (UltraFlora® Balance Probiotic) on Gut Health of People Taking GLP-1 Medication",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,null,"NONE","100","GLP-1; Adults","DIETARY_SUPPLEMENT:Multivitamin and a Probiotic","Metagenics, Inc.","2025-11-01","2026-03-31","FALSE","IBS- SSS [From enrollment to the end of treatment at 12 weeks (90 days)]",null,null,"NO",null],["NCT02105324","The Summer Camp Study 2: Blood Glucose Control With a Bi-Hormonal Endocrine Pancreas",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","19","Type 1 Diabetes","DEVICE:Bionic Pancreas; OTHER:Usual Care","Massachusetts General Hospital","2014-06","2014-08","TRUE","Mean Continuous Glucose Monitoring Glucose (CGMG) Values During Days 2 to 5 [Days 2 to 5 of each period] | Percentage of Time Spent With CGMG Concentration < 60 mg/dL During Days 2 to 5 [Days 2 to 5 of each period]","DERIVED:26850709",null,null,null],["NCT07703683","Myokines as Potential Biomarkers and Drivers of Sarcopenia in Metabolic and Endocrine Diseases","SARC-ENDO","RECRUITING","OBSERVATIONAL",null,null,null,"100","Diabetes; Obesity & Overweight; Cushing Syndrome; Metabolic Diseases; Endocrine Diseases; Sarcopenia; Sarcopenic Obesity","DRUG:GLP-1 Receptor Agonists","Cliniques universitaires Saint-Luc- Université Catholique de Louvain","2026-02-19","2056-12-31","FALSE","Prevalence of sarcopenia / sarcopenic obesity [From February 2026 to december 2056]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/83/NCT07703683/Prot_000.pdf","NO",null],["NCT05832151","A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","382","Diabetic Gastroparesis","DRUG:CIN-102 Dose 15mg or 10mg; DRUG:Placebo","CinDome Pharma, Inc.","2023-03-27","2025-11-14","FALSE","Effect of CIN-102 to significantly decrease gastroparesis-related symptoms as compared to baseline based on the composite of the average ANMS GCSI-DD Nausea Sub-Scale and Vomiting Scores [Over the last 2 weeks of the 12-week Treatment Period as compared to baseline]",null,null,"NO",null],["NCT02109978","RetroMASTER - Retrospective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes","RetroMASTER","COMPLETED","OBSERVATIONAL",null,null,null,"562","Diabetes",null,"Royal Devon and Exeter NHS Foundation Trust","2013-04","2015-05","FALSE","Response to diabetes therapy and rate of diabetes progression [Within 9 months from date of recruitment]",null,null,null,"OTHER:12/SW/0348"],["NCT06046560","Diabetes Remote Intervention to improVe Use of Evidence-based Medications","DRIVE","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","200","Cardiovascular Diseases; Diabetes","DRUG:SGLT2 inhibitor, GLP-1 RA; BEHAVIORAL:Education-First","Brigham and Women's Hospital","2021-03-22","2023-07-25","TRUE","Number of Patients With Prescriptions of SGLT2i or GLP1-RA at Any Time [Any time between 0-months (baseline) to 6-months following enrollment]","BACKGROUND:38302335; RESULT:38583146; DERIVED:41610902","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/60/NCT06046560/Prot_001.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/60/NCT06046560/SAP_002.pdf",null,null],["NCT01303315","TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor Agonist Therapy",null,"TERMINATED","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","20","Diabetes Mellitus, Type 2","DEVICE:TANTALUS System","MetaCure (USA), Inc.","2011-01","2011-07","FALSE","Decrees in HbA1c of at least 0.5 points and Weight loss of at least 3% of total body weight after 6 month of treatment [6 month]",null,null,null,"OTHER:Position II"],["NCT07663591","Machine Learning Prediction of Respiratory Muscle Changes and Ventilatory Responses After Incretin-Based Therapy in Obesity",null,"NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"48","Obesity (BMI>30)","OTHER:Incretin-based therapy","Biruni University","2026-07-01","2026-07-01","FALSE","Maximum Inspiratory Pressure (MIP) [Baseline to 3 months]",null,null,"UNDECIDED",null],["NCT07760896","The GLOW Study: GLP-1 and Lifestyle for Optimal Wellness","GLOW","RECRUITING","INTERVENTIONAL",null,null,"NONE","200","Wellness","BEHAVIORAL:WILD 5 Wellness Program","Saundra Jain","2026-09-15","2027-10","FALSE","Change in HERO Wellness Scale Total Score From Baseline to Post-Program [Baseline and end of 30-day intervention]",null,null,"NO",null],["NCT03415139","Finding the Cause for Post-Transplant Diabetes Mellitus After Allogeneic Hematopoietic Cell Transplant",null,"UNKNOWN","OBSERVATIONAL",null,null,null,"120","Diabetes Mellitus; Cancer","DRUG:Oral Glucose Tolerance Test (OGTT); DRUG:2 OGTTs with and without GLP-1 analogue; DRUG:Hyperglycemic clamp procedure","Vanderbilt-Ingram Cancer Center","2019-03-12","2023-04","FALSE","Pre-transplant insulin secretion will be measured as glucose stimulated insulin secretion (GSIS) during a hyperglycemic clamp procedure among patients who do or do not go on to develop PTDM (univariable analysis). [Up to 28 days pre-transplant] | Pre-transplant insulin secretion will be measured as glucose stimulated insulin secretion (GSIS) during a hyperglycemic clamp procedure among patients who do or do not go on to develop PTDM (multivariable analysis). [Up to 28 days pre-transplant] | Post-transplant glucagon secretion will be measured during the oral glucose tolerance test among patients who do or do not develop PTDM (univariable analysis). [Up to 100 days after transplant] | Post-transplant glucagon secretion will be measured during the oral glucose tolerance test among patients who do or do not develop PTDM (multivariable analysis). [Up to 100 days after transplant] | Plasma IL-33 levels will be measured among patients who do or do not develop PTDM (univariable analysis). [Up to 100 days after transplant] | Plasma IL-33 levels will be measured among patients who do or do not develop PTDM (multivariable analysis). [Up to 100 days after transplant]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/39/NCT03415139/Prot_SAP_000.pdf",null,null],["NCT07842393","A Study of IBI3042 in Healthy Adult Participants",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","32","Healthy Volunteers (HV)","DRUG:Investigational Drug: IBI3042; DRUG:Matching Placebo","Fortvita Biologics (USA)Inc.","2026-09-29","2027-02-03","FALSE","Number of Participants With Adverse Events [through study completion, an average of 29 days] | Number of Participants With Clinically Significant Abnormal Vital Signs [through study completion, an average of 29 days] | Number of Participants With Clinically Significant Abnormal 12-lead electrocardiogram [through study completion, an average of 29 days] | Number of Participants With Abnormal General Appearance Findings [through study completion, an average of 29 days] | Number of Participants With Abnormal Respiratory Findings [through study completion, an average of 29 days] | Number of Participants With Abnormal Cardiovascular Findings [through study completion, an average of 29 days] | Number of Participants With Abnormal Abdominal Findings [through study completion, an average of 29 days] | Number of Participants With Abnormal Skin Findings [through study completion, an average of 29 days] | Number of Participants With Abnormal Head and Neck Findings [through study completion, an average of 29 days] | Number of Participants With Abnormal Lymph Node Findings [through study completion, an average of 29 days] | Number of Participants With Abnormal Thyroid Findings [through study completion, an average of 29 days] | Number of Participants With Abnormal Musculoskeletal Findings [through study completion, an average of 29 days] | Number of Participants With Abnormal Neurological Findings [through study completion, an average of 29 days] | Number of Participants With Abnormal Blood Routine Findings [through study completion, an average of 29 days] | Number of Participants With Abnormal Blood Biochemistry Findings [through study completion, an average of 29 days] | Number of Participants With Abnormal Coagulation Findings [through study completion, an average of 29 days] | Number of Participants With Abnormal Urine Routine Findings [through study completion, an average of 29 days] | Number of Participants With Abnormal Calcitonin Findings [through study completion, an average of 29 days] | Number of Participants With Abnormal Glycated Hemoglobin Findings [through study completion, an average of 29 days] | Number of Participants With Abnormal Infection-Related Immunology Findings [through study completion, an average of 29 days] | Number of Participants With Abnormal Thyroid Function Findings [through study completion, an average of 29 days] | Number of Participants With Abnormal Pregnancy Test Findings [through study completion, an average of 29 days]",null,null,null,null],["NCT07550621","Drug-Drug Interaction Study of MDR-001 With Rifampin and Itraconazole in Healthy Adult Participants",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1","NON_RANDOMIZED","NONE","28","Healthy Volunteers (HV)","DRUG:MDR-001; DRUG:Rifampin; DRUG:Itraconazole","MindRank AI Ltd","2026-05-06","2026-05-31","FALSE","Cmax of MDR-001 [Baseline (Day 1 pre-dose) and up to 48 hours post-dose on Day 1 and on co-administration (Day 10 for Part A, Day 7 for Part B).] | AUC0-t of MDR-001 [Baseline (Day 1 pre-dose) and up to 48 hours post-dose on Day 1 and on co-administration (Day 10 for Part A, Day 7 for Part B).] | AUC0-∞ of MDR-001 [Baseline (Day 1 pre-dose) and up to 48 hours post-dose on Day 1 and on co-administration (Day 10 for Part A, Day 7 for Part B).]",null,null,null,null],["NCT03050619","Characteristics of Empagliflozin Initiators",null,"COMPLETED","OBSERVATIONAL",null,null,null,"31908","Type 2 Diabetes","DRUG:Empagliflozin; DRUG:Other SGLT2 inhibitors; DRUG:Other non-insulin GLDs","Boehringer Ingelheim","2016-09-10","2016-10-14","TRUE","Baseline Characteristics of Adults (as Measured by Demographics) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK [Baseline] | Baseline Characteristics of Adults (as Measured by Life Style Factors (Smoking and Alcohol Use)) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK [Baseline] | Baseline Characteristics of Adults (as Measured by Life Style Factors (BMI)) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK [Baseline] | Baseline Characteristics of Adults (as Measured by Life Style Factors (Blood Pressure)) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK [Baseline] | Baseline Characteristics of Adults (as Measured by Glycated Haemoglobin (HbA1c)) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK [Baseline] | Baseline Characteristics of Adults (as Measured by Laboratory Tests) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK [Baseline] | Baseline Characteristics of Adults (as Measured by Estimated Glomerular Filtration Rate (eGFR)) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK [Baseline] | Baseline Characteristics of Adults (as Measured by Creatinine Serum (SCR)) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK [Baseline] | Baseline Characteristics of Adults (as Measured by Comorbidities) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK [Baseline] | Baseline Characteristics of Adults (as Measured by Concomitant Medications) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK [Baseline]",null,null,null,null],["NCT07327281","A Clinical Trial Evaluating TQF3250 Capsules in Healthy Adult Subjects",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","66","Hyperglycemia","DRUG:TQF3250 placebo; DRUG:TQF3250 capsule","Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","2025-12-18","2026-12","FALSE","Number of participants with incidence and severity of all adverse events (AEs), serious adverse events (SAEs), and treatment-emergent adverse events (TEAEs) [Up to 20 days] | Number of participants with abnormal clinical laboratory test indicators [Up to 20 days] | Changes in body temperature after using TQF3250 capsules [Up to 24 hour] | Tolerance assessment: 12-lead electrocardiogram [Up to 20 days] | Changes in pulse/heart rate after use of TQF3250 capsules [Up to 24 hour] | Changes in respiratory rate after using TQF3250 capsules [Up to 24 hour] | Changes in blood pressure after using TQF3250 capsules [Up to 24 hour] | Changes in blood oxygen saturation after using TQF3250 capsules [Up to 24 hour]",null,null,null,null],["NCT07221461","Assess Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality in Patients on Glucagon-like Peptide-1 Agonists",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","NON_RANDOMIZED","NONE","24","Wrinkle","DEVICE:Skinvive","Goldman, Butterwick, Fitzpatrick and Groff","2025-11-01","2026-01-30","FALSE","Global Fine Lines [Screening, Day 30, Day 60] | Overall Hyperpigmentation [Screening, Day 30, Day 60] | Skin Tone Evenness [Screening, Day 30, Day 60] | Skin Firmness [Screening, Day 30, Day 60] | Skin Radiance/ Brightness [Screening, Day 30, Day 60] | Skin Texture Smoothness [Screening, Day 30, Day 60] | Global Wrinkles [Screening, Day 30, Day 60]",null,null,null,null],["NCT07409831","Incretin-based Therapies, Nutrition, and Physical Activity","HARMONY","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","120","Obesity & Overweight; Cardiometabolic Conditions","BEHAVIORAL:Intervention; DRUG:Incretin-Based Treatment","Laval University","2026-07-06","2028-03","FALSE","Changes in muscle mass (bioimpedance scale) [Baseline to 6 months] | Changes in muscular function (handgrip strength) [Baseline to 6 months] | Changes in muscular function (short physical performance battery) [Baseline to 6 months]",null,null,"UNDECIDED",null],["NCT06682351","Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","200","Prediabetes / Type 2 Diabetes","DRUG:Metformin; DRUG:GLP-1A; DIETARY_SUPPLEMENT:MED","Stanford University","2024-11","2027-12","FALSE","Change in HbA1c [At month 0, month 4, month 8, month 11, month 15, month 18]",null,null,"NO",null],["NCT07798284","A Clinical Trial of TQF3250 Capsules in Overweight/Obese Trial Participants With Poor Weight Control Through Simple Lifestyle Intervention",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","80","Overweight/Obesity","DRUG:TQF3250 capsules; DRUG:TQF3250 placebo","Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","2026-09","2027-04","FALSE","Adverse Event [Baseline up to 14 weeks] | Abnormal clinical examination findings [Baseline up to 14 weeks]",null,null,null,null],["NCT05569304","Endoscopic Sleeve Gastroplasty Versus GLP-1 Analogue for Class 1 and 2 Obesity Study","EGG","UNKNOWN","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","66","Obesity","PROCEDURE:Endoscopic sleeve gastroplasty","Sengkang General Hospital","2022-10-07","2025-12-31","FALSE","Total body weight loss [1-year]",null,null,"NO",null],["NCT07611552","Effects of Inulin on Cardiometabolic Risk Factors in Individuals Using Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA ) Medications for Weight Loss",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","QUADRUPLE","600","Obesity & Overweight","DIETARY_SUPPLEMENT:inulin (prebiotics); DIETARY_SUPPLEMENT:Placebo Comparator: maltodextrin","Huazhong University of Science and Technology","2026-06","2026-11","FALSE","change in concentrations of blood lipid levels in millimole per liter (mmol/L). [From enrollment to the end of intervention at 4 months]",null,null,"NO",null],["NCT02227849","Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE4",null,"NONE","71","Type 2 Diabetes Mellitus","DRUG:Canagliflozin (TA-7284); DRUG:GLP-1 analogue","Tanabe Pharma Corporation","2014-08","2016-03","TRUE","Safety and Tolerability Assessed by Adverse Events (Number of Participants Experiencing With Adverse Events) [52 Weeks]","RESULT:29473709",null,null,null],["NCT01000688","Vildagliptin and Endothelium-dependent Vasodilatation",null,"COMPLETED","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","16","Type 2 Diabetes; Endothelial Dysfunction","DRUG:vildagliptin + acarbose; DRUG:acarbose + vildagliptin","Radboud University Medical Center","2010-01","2010-08","FALSE","Forearm vasodilator response to intra-arterial infusion of acetylcholine (endothelium-dependent) following treatment with vildagliptin and following active control with acarbose [8 weeks]","DERIVED:24485397",null,null,null],["NCT07117695","Duke Cardiometabolic Prevention Clinic's Impact on High-risk Cardiovascular Patients With Uncontrolled Risk Factors","DUKE PREVENT","NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","150","ASCVD; Hyperlipidemia; Hypertension","OTHER:Referral to the Duke Cardiometabolic Prevention Clinic","Duke University","2026-10-02","2027-10-27","FALSE","Change in LDL-C [Baseline, 12 months after enrollment] | Change in Systolic Blood Pressure [Baseline, 12 months after enrollment]",null,null,"NO",null],["NCT07842757","Preoperative Gastric Volume and High-Risk Gastric Content in Patients With Type 2 Diabetes Mellitus",null,"NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"120","Type 2 Diabetes Mellitus (DM); Gastric Ultrasound","DIAGNOSTIC_TEST:Preoperative Gastric Ultrasonography; DIAGNOSTIC_TEST:Capillary Fasting Blood Glucose Measurement","Bakirkoy Dr. Sadi Konuk Research and Training Hospital","2026-10-01","2027-04-01","FALSE","Presence of a High-Risk Stomach [On the day of surgery, during the preoperative assessment immediately before anesthesia induction]","RESULT:39663603; RESULT:38654864; RESULT:37883294",null,"UNDECIDED",null],["NCT06988397","Stomach Processing and Emptying Evaluation With Diet and Ultrasound","SPEED-US","NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","60","Gastric Emptying; Preoperative Risk Assessment; Healthy Volunteer Study","BEHAVIORAL:Physical activity after different type of meals","Medical University of Warsaw","2025-06-01","2026-05-01","FALSE","Time to ultrasonographic signs of an empty stomach [after 15 minutes, 3 hours and 6 hours post-meal]","BACKGROUND:24893784; BACKGROUND:3896910; BACKGROUND:19512861; BACKGROUND:28675504; BACKGROUND:24336400; BACKGROUND:28045707",null,"NO",null],["NCT06278285","Effect of Agonist GLP1 on Adipose Tissue in Patients Undergoing Bariatric Surgery","Maigrir_OT","RECRUITING","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","40","Obesity","OTHER:Blood GLP1; OTHER:Blood No treated GLP1","Centre Hospitalier Universitaire de Nice","2024-03-06","2026-09-06","FALSE","Rate of oxytocin [one time (before surgery)]",null,null,"NO",null],["NCT06278207","An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions","FINEROD","RECRUITING","OBSERVATIONAL",null,null,null,"50000","Chronic Kidney Disease; Type 2 Diabetes Mellitus","DRUG:Finerenone (BAY 94-8862)","Bayer","2024-05-15","2026-09-30","FALSE","Participants' characteristics at baseline in a cohort of participants with CKD and T2D who initiate finerenone. [12 months before first prescription/dispensation of finerenone (index date)] | Participants' comorbidities at baseline in a cohort of participants with CKD and T2D who initiate finerenone. [12 months before first prescription/dispensation of finerenone (index date)] | Participants' comedications at baseline in a cohort of participants with CKD and T2D who initiate finerenone. [12 months before first prescription/dispensation of finerenone (index date)]",null,null,"NO",null],["NCT06351358","Evaluation of the Effects of a Biostimulator and Dermal Fillers for Cheek Augmentation and Contour Deficiencies",null,"COMPLETED","INTERVENTIONAL",null,null,"NONE","41","Photoaging; Weight Loss; Skin Laxity; Photodamaged Skin; Volume Deficiency of the Midface","DEVICE:Sculptra treatment; DEVICE:Restylane Treatment","Galderma R&D","2024-02-19","2025-05-31","FALSE","Change in skin hydration from baseline [Baseline, Week 4, Week 8, Week 16 or Week 20] | Change in skin radiance from baseline [Baseline, Week 4, Week 8, Week 16 or Week 20] | Change in skin elasticity from baseline [Baseline, Week 4, Week 8, Week 16 or Week 20] | Change in skin thickness from baseline [Baseline, Week 4, Week 8, Week 16 or Week 20]",null,null,"NO",null],["NCT03108521","SNP Study of DPP-4 and GLP-1R in Chinese People (Including Diabetes Patients)",null,"COMPLETED","INTERVENTIONAL","PHASE4","NON_RANDOMIZED","NONE","119","Diabetes Mellitus","DRUG:Sitagliptin","Sichuan Provincial People's Hospital","2016-04-21","2018-01-04","TRUE","Glycosylated Hemoglobin A1c (HbA1c) [12 weeks later]","BACKGROUND:25962518; BACKGROUND:24353270; BACKGROUND:24140094","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/21/NCT03108521/Prot_SAP_000.pdf","NO",null],["NCT06889454","Cardiovascular and Endothelial Markers During OGTT Before and at Six and Twelve Months Post-treatment in Women With PCOS",null,"RECRUITING","OBSERVATIONAL",null,null,null,"120","PCOS; Hyperinsulinism; Hyperandrogenism; Metabolic Syndrome","DRUG:GLP-1 receptor agonist; DRUG:Oral contraceptive; DRUG:Metformin; OTHER:Lifestyle modification","Attikon Hospital","2024-02-01","2025-02-01","FALSE","Τhe change in Global Longitudinal Strain during Oral glucose Tolerance Test [120 minute of Oral glucose Tolerance Test] | The change in Pulse Wave Velocity during Oral glucose Tolerance Test [120minute of Oral glucose Tolerance Test] | The change in Perfused Boundary Region during Oral glucose Tolerance Test [120minute of Oral glucose Tolerance Test] | The change in Global Longitudinal Strain [six months] | The change in Pulse Wave Velocity [six months] | The change in Perfused Boundary Region [six months] | The change in Metalloproteinase 9 [six months]",null,null,"UNDECIDED",null],["NCT04960514","Prospective Decision Impact Trial of KidneyIntelX",null,"ACTIVE_NOT_RECRUITING","OBSERVATIONAL",null,null,null,"2000","Diabetic Kidney Disease; Chronic Kidney Disease Stage 1; Chronic Kidney Disease Stage 2; Chronic Kidney Disease, Stage 3 (Moderate)","DIAGNOSTIC_TEST:KidneyIntelX","Renalytix AI, Inc.","2021-11-22","2023-12-01","FALSE","Blood pressure [12 Months] | HbA1c [12 Months] | ACEi/ARB [12 Months] | SGLT2/ GLP1 [12 Months] | Urine albumin to creatinine ratio [12 Months] | Referrals [12 Months]",null,null,"UNDECIDED",null],["NCT07216352","Evaluate the Safety and Efficacy of a Topical Serum (AGE Serum) in Improving Visible Signs of Aging",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,null,"NONE","25","Laxity; Skin","OTHER:AGE Serum","Goldman, Butterwick, Fitzpatrick and Groff","2025-10-25","2026-03-30","FALSE","Modified Griffith Scale [Baseline, Week 6 and Week12]",null,null,null,null],["NCT07140055","A Research Study to Evaluate BLX-7006 in Healthy Adults",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","TRIPLE","76","Normal Healthy Volunteer; Safety After Oral Intake","DRUG:BLX-7006; DRUG:Placebo","Biolexis Therapeutics","2025-09","2026-04","FALSE","Number of participants who experienced Adverse Events (AEs) [From first dose through End of Study (up to ~28 days per participant)] | Number of participants who experienced Serious Adverse Events (SAEs) [From first dose through End of Study (up to ~28 days per participant)] | Number of participants who experienced Treatment-Related Adverse Avents (TRAEs) [From first dose through End of Study (up to ~28 days per participant)]",null,null,"NO",null],["NCT07271043","Nutrition+: Effect of a High-Protein Diabetes Formula on Body Composition in Type 2 Diabetes Patients Treated With Incretin Mimetics",null,"RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","60","Type 2 Diabetes","DIETARY_SUPPLEMENT:protein supplement","Joslin Diabetes Center","2026-01-01","2026-11-01","FALSE","Change in lean muscle mass from baseline [Endpoints will be analyzed at three months and six months.]",null,null,"UNDECIDED",null],["NCT07513259","Pre-Diagnosis GLP-1 Receptor Agonist Use and Post-Cancer Mortality in Adults With Obesity and Type 2 Diabetes",null,"COMPLETED","OBSERVATIONAL",null,null,null,"203424","Obesity & Overweight; Diabetes Mellitus Type 2; Neoplasms",null,"Chung Shan Medical University","2018-01-01","2025-10-31","TRUE","All-cause Mortality (Comparison 1) [From obesity-associated cancer diagnosis through 36 months] | All-cause Mortality (Comparison 2) [From obesity-associated cancer diagnosis through 36 months] | All-cause Mortality (Comparison 3) [From obesity-associated cancer diagnosis through 36 months] | All-cause Mortality (Comparison 4) [From obesity-associated cancer diagnosis through 36 months] | All-cause Mortality (Comparison 5) [From obesity-associated cancer diagnosis through 36 months]","BACKGROUND:41196576; BACKGROUND:28390156; BACKGROUND:33775061; BACKGROUND:38785209; BACKGROUND:38113888; BACKGROUND:35021057; BACKGROUND:41178710; BACKGROUND:39289339; BACKGROUND:39357509; BACKGROUND:39810151; BACKGROUND:41034888; BACKGROUND:33301825; BACKGROUND:38386717; BACKGROUND:40437949; BACKGROUND:41178720; BACKGROUND:38967919; BACKGROUND:41359966; BACKGROUND:41387113; BACKGROUND:39992643; BACKGROUND:26994063; BACKGROUND:40903028; BACKGROUND:33591334; BACKGROUND:37169040; BACKGROUND:37562726; BACKGROUND:39989045; BACKGROUND:39961105; BACKGROUND:30897037; BACKGROUND:41453566; BACKGROUND:40839273; BACKGROUND:40281304; BACKGROUND:39171569; BACKGROUND:40374399; BACKGROUND:33189186; BACKGROUND:30215698; BACKGROUND:32061306; BACKGROUND:35818559; BACKGROUND:37311415; BACKGROUND:35988567","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/59/NCT07513259/Prot_SAP_000.pdf","NO",null],["NCT05182359","Pragmatic Impact of Proteomic Risk Stratification in Diabetes Mellitus","PORTRAIT-DM","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","150","Type 2 Diabetes","OTHER:SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) Test and SomaSignal Metabolic Factors test","University Hospitals Cleveland Medical Center","2022-01-26","2023-03-31","FALSE","The relation of prescription rates of cardioprotective medications (SGLT2i or GLP1 RA) to CVD-T2D test risk assessment in the Informed group vs. Uninformed group. [12 weeks]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/59/NCT05182359/Prot_SAP_000.pdf","UNDECIDED",null],["NCT05349955","Effects and Safety of Diabetic GUideline Algorithm Implementation Performed by Primary Care Physicians in the Community","GUARD","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","5600","Type 2 Diabetes; Cardiovascular Complication; Diabetic Kidney Disease","OTHER:Intensive guideline algorithm implementation; OTHER:Conventional guideline algorithm implementation","Shanghai Zhongshan Hospital","2022-11-21","2026-11-30","FALSE","Primary Outcome of Phase 1: Comprehensive management effect of various cardiovascular risk factors in T2D，meeting control targets for a combination of A1c, BP, LDL-C. [18 months since randomization] | Primary Outcome of Phase 2: Composite of 3P MACE and hospitalization for heart failure. [3 years since randomization]","BACKGROUND:31269573; BACKGROUND:9742976; BACKGROUND:15616252; BACKGROUND:26378978; BACKGROUND:30415602; BACKGROUND:28605608; BACKGROUND:33200892; BACKGROUND:32970396; BACKGROUND:30990260; BACKGROUND:27295427; BACKGROUND:31189511; BACKGROUND:27633186; BACKGROUND:31497854; BACKGROUND:33298420; BACKGROUND:34233928; BACKGROUND:27299675",null,"NO",null],["NCT07451938","A Cohort Study on Obese Patients' Multidisciplinary Integrated Health Management","ODHM","COMPLETED","OBSERVATIONAL",null,null,null,"1500","Obesity; Diabete Type 2; Bariatric Surgery","PROCEDURE:Bariatric surgery; OTHER:Non-surgical threapy","China-Japan Friendship Hospital","2017-07-01","2025-07-30","FALSE","Total weight loss [1st, 3rd, 6th and 12th month after intervention, respectively.]",null,null,null,null],["NCT07393360","Effect of a Food for Special Medical Purposes on Muscle Mass Preservation During GLP-1 RAs Weight Loss Treatment","MYO-PRESERVE","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","QUADRUPLE","144","Obesity & Overweight","DIETARY_SUPPLEMENT:Myosave®; OTHER:Placebo","Pharmanutra S.p.a.","2025-12-11","2026-12","FALSE","Change in Appendicular Skeletal Muscle Mass (ASMM) [Baseline, Week 8, Week 16, Week 24]",null,null,null,null],["NCT06851858","Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist","ARAY","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","TRIPLE","69","Endocrinology; Diabetes, Type II; Obesity","DRUG:AZD6234; DRUG:Placebo to match","AstraZeneca","2025-03-12","2026-05-26","FALSE","Percent change in body weight from baseline at Study Week 26 [From baseline to week 26] | Weight loss ≥ 5% from baseline at Study Week 26 [From baseline to week 26]",null,null,"YES",null],["NCT07803185","Evaluation of Anhedonia and Emotional Eating in Individuals Using GLP-1 Receptor Agonists",null,"RECRUITING","OBSERVATIONAL",null,null,null,"60","Obesity; Emotional Eating; Anhedonia",null,"TC Erciyes University","2026-06-01","2026-12-31","FALSE","Change in Dimensional Anhedonia Rating Scale (DARS) Score [Baseline and 6 months]","BACKGROUND:32213216; BACKGROUND:39892489",null,"NO","OTHER:2026/173"],["NCT05275608","Effects of VLCKD in Metabolic Syndrome","KETO-MI","ACTIVE_NOT_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","40","Diabetes Mellitus, Type 2; Non-alcoholic Fatty Liver Disease; Obesity; Metabolic Syndrome","DIETARY_SUPPLEMENT:VLCKD diet with replacing meals; BEHAVIORAL:Hypocaloric mediterranean Diet","Azienda Ospedaliero Universitaria Maggiore della Carita","2022-11-07","2026-01-31","FALSE","Change in weight [Change from Baseline BMI at 15 days, 30 days, 60 days, 90 days] | Change in body circumferences [Change from Baseline circumferences at 15 days, 30 days, 60 days, 90 days] | Change in metabolic control [Change from Baseline blood glucose at 15 days, 30 days, 60 days, 90 days] | Change in metabolic control [Change from Baseline lipid profile at 15 days, 30 days, 60 days, 90 days]","BACKGROUND:29340675; BACKGROUND:30559231; BACKGROUND:30559234; BACKGROUND:32437658; BACKGROUND:8345648; BACKGROUND:12091180; BACKGROUND:22146094; BACKGROUND:27409822; BACKGROUND:31263284; BACKGROUND:31720986; BACKGROUND:29738484; BACKGROUND:31111407; BACKGROUND:9229194; BACKGROUND:27720522; BACKGROUND:25986079; BACKGROUND:33042004; BACKGROUND:24336217; BACKGROUND:28553291; BACKGROUND:28864332; BACKGROUND:32919928; BACKGROUND:16818923; BACKGROUND:28604226; BACKGROUND:27643725; BACKGROUND:23573151; BACKGROUND:7838189; BACKGROUND:27898428; BACKGROUND:26214781; BACKGROUND:24239920; BACKGROUND:12633516; BACKGROUND:29942089; BACKGROUND:24307633; BACKGROUND:27610004; BACKGROUND:21656330; BACKGROUND:22318758; BACKGROUND:30391485; BACKGROUND:24520424; BACKGROUND:25798181; BACKGROUND:21448265; BACKGROUND:32370212; BACKGROUND:27013897; BACKGROUND:33652834; BACKGROUND:33882506; BACKGROUND:25698989; BACKGROUND:30292286; BACKGROUND:28741280; BACKGROUND:1991946; BACKGROUND:25707379; BACKGROUND:31277506; BACKGROUND:34054731; BACKGROUND:24849710; BACKGROUND:29269731; BACKGROUND:28388917; BACKGROUND:27002059; BACKGROUND:34229263; BACKGROUND:18855190; BACKGROUND:24030694",null,null,null],["NCT07437716","Impact Of Laparoscopic Sleeve Gastrectomy On Obesity-Related Comorbidities In Patients Over 65 Years",null,"COMPLETED","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","60","Laparascopic Sleeve Gastrectomy; Obesity & Overweight; Obesity Type 2 Diabetes Mellitus; Obstructive Sleep Apnea (OSA); Hypertension (HTN); Osteo Arthritis of the Knee","PROCEDURE:Laparoscopic Sleeve Gastrectomy (LSG); BEHAVIORAL:Structured Dietary Counseling","Kafrelsheikh University","2023-01-01","2025-03-01","FALSE","Change in weight-related comorbidity status at 12 months [Baseline to 12 months]",null,null,"NO",null],["NCT05578352","The Exploreration of the Management for the Positive IAA in Patients With Type 2 Diabetes After Premix Insulin Therapy",null,"UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","NONE","20","Type 2 Diabetes Mellitus","OTHER:Add oral hyppoglycemia drug; OTHER:Add GLP-1 receptor agonist; OTHER:Change insulin","Nanjing First Hospital, Nanjing Medical University","2022-08-05","2023-01-31","FALSE","Insulin autoimmune antibody [3 month]",null,null,null,null],["NCT06577584","Comparison of Diabetes Patients - Care Trajectory Versus Convention",null,"UNKNOWN","OBSERVATIONAL",null,null,null,"20000","Type 2 Diabetes","OTHER:Follow-up in the Diabetes Care Trajectory; OTHER:Follow-up in the Diabetes Convention","Universitaire Ziekenhuizen KU Leuven","2025-02-01","2025-12","FALSE","HbA1c [Yearly for the entire study period (2009 - 2024)]",null,null,"NO",null],["NCT07639684","Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)","MEASURE","NOT_YET_RECRUITING","INTERVENTIONAL",null,null,"NONE","50","Type 2 Diabetes Mellitus (T2D); Obesity (BMI>30)","DEVICE:ESG with OverStitch","Boston Scientific Corporation","2027-04","2029-07","FALSE","Serious Adverse Events [Through study completion, 12 months post procedure] | Average Change in HbA1c [12 months post procedure]",null,null,null,null],["NCT05818995","Therapeutic Drug Use for CKD Patients",null,"UNKNOWN","OBSERVATIONAL",null,null,null,"10000","Chronic Kidney Disease","DRUG:angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker","Qianfoshan Hospital","2022-07-01","2024-05-31","FALSE","eGFR [October , 2023] | albuminuria [October , 2023]",null,null,null,null],["NCT07787533","Digital Resistance Training for Midlife Women Using GLP-1","PLAN-RT","NOT_YET_RECRUITING","INTERVENTIONAL",null,null,"NONE","15","Women's Health; Obesity & Overweight; Perimenopausal Women; Digital Intervention; Behavior Change; glp1 Agonist; Resistance Exercise","BEHAVIORAL:PLAN-RT 1.0","Louisiana State University and A&M College","2026-11-01","2027-06-30","FALSE","Number of adults screened (Participants) [Weekly throughout recruitment] | Intervention Acceptability (CSQ-8) [Week 12] | Number of Adults Enrolled (Participants) [Weekly throughout recruitment] | Retention Rate (Percentage of enrolled participants) [Week 4, 8, 12]",null,null,"NO",null],["NCT04769765","Feasability of a Care Pathway Integrating Collaborative Tele-expertise to Prevent Recurring Hospitalisations for Diabetic Patients","TELXCODIA","TERMINATED","INTERVENTIONAL",null,null,"NONE","200","Diabetes Mellitus","OTHER:Definition of the Individualized Care Pathway","Centre Hospitalier Universitaire de Nīmes","2022-05-04","2022-10-10","FALSE","Number of patients eligible for the Individualized Care Pathway as well as the basic diabetic program. [At the end of the study period: Month 12 + 5 days] | Number of patients on the basic diabetic program, included in the study, who have completed at least three of the four scheduled follow-up visits. [At the end of the study period: Month 12 + 5 days]",null,null,null,null],["NCT05290506","Linagliptin Response to OGTT in Prediabetes and Type 2 Diabetes Mellitus",null,"COMPLETED","INTERVENTIONAL","PHASE3","NON_RANDOMIZED","NONE","50","PreDiabetes; Type 2 Diabetes","DRUG:Dipeptidyl-Peptidase IV Inhibitors","National University of Malaysia","2020-08-01","2021-03-01","FALSE","change from baseline in glucose after 12-week treatment [baseline to 12 weeks] | change from baseline in HbA1c after 12-week treatment [baseline to 12 weeks] | change from baseline in insulin sensitivity/resistance index after 12-week treatment [baseline to 12 weeks]",null,null,"NO",null],["NCT05284344","The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes",null,"COMPLETED","OBSERVATIONAL",null,null,null,"78","Type 2 Diabetes","DRUG:Anti-Diabetics","University of Adelaide","2021-01-24","2023-12-31","FALSE","Change in Gastric-half emptying time of the 75 g glucose drink [Baseline, 1 month and 3 months in diabetic group] | Gastric-half emptying time of the 75 g glucose drink [Baseline in both diabetic and non-diabetic group]","BACKGROUND:33301790; BACKGROUND:31790715; BACKGROUND:33951363; BACKGROUND:30933282; BACKGROUND:25421372; DERIVED:38698647",null,"NO",null],["NCT07481305","Lifestyle Change Implementation Research Network at PRC at UMass Chan","LCIRN","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","220","GLP - 1","OTHER:Digital Lifestyle Coaching Program","University of Massachusetts, Worcester","2026-07-22","2029-04-30","FALSE","Primary Outcomes [Baseline, 4-, and 8-months] | Healthy Eating Index [Baseline, 4, and 8 months]",null,null,"YES","NIH:U48DP006955"],["NCT04128995","Surgical or Medical Treatment","ST2OMP","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE4","NON_RANDOMIZED","NONE","88","Diabetes Mellitus, Type 2; Pediatric Obesity; Bariatric Surgery Candidate","PROCEDURE:Advanced Medical Therapy and Bariatric Surgery; DRUG:Advanced Medical Therapy; PROCEDURE:Bariatric Surgery","Children's Hospital Medical Center, Cincinnati","2019-12-15","2026-12","FALSE","Glycemic Control [At one year]","DERIVED:34389568",null,"NO",null],["NCT01674972","Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls",null,"COMPLETED","OBSERVATIONAL",null,null,null,"102","Non Alcoholic Fatty Liver Disease; Non Alcoholic Steatohepatitis","OTHER:Oral glucose tolerance test","University Hospital, Basel, Switzerland","2011-01","2012-04","FALSE","Glucagon-like Peptide 1 (GLP-1) secretion in response to oGTT [0, 15, 30, 60, 90, 120 min. after glucose administration]",null,null,null,null],["NCT07234916","Multivitamin Impact on Micronutrient Status in GLP-1 Users: A Randomized Trial","VITAGLP","ENROLLING_BY_INVITATION","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","246","Weight Loss; Nutritional Deficiencies; GLP - 1; Obese Patients","DIETARY_SUPPLEMENT:Multivitamin Supplementation; OTHER:Placebo","Erasmus Medical Center","2025-12-16","2027-03-16","FALSE","serum levels [15 months]","RESULT:38454010; RESULT:33269530; RESULT:39295512; RESULT:39040467; RESULT:36568085; RESULT:31565876; RESULT:39722834; RESULT:39175746; RESULT:39892489",null,"YES","OTHER:ABR 2025 GLP"],["NCT07217743","Assess Impact of Poly-L-lactic Acid on GLP1 Subjects",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","NON_RANDOMIZED","NONE","20","Laxity; Skin","DEVICE:Sculptra Aesthetic","Goldman, Butterwick, Fitzpatrick and Groff","2025-10-27","2026-08-30","FALSE","Physical Global Aesthetic Improvement Scale [Month 3 and Month 9]",null,null,null,null],["NCT04862858","Educational Intervention to Increase Select Guideline-recommended Cardioprotective Medications in Patients With Diabetes",null,"UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","NONE","4197","Diabetes Mellitus, Type 2; Cardiovascular Diseases","OTHER:Educational Intervention","Humana Inc.","2021-08-18","2021-11-30","FALSE","Percentage of individuals who initiate guideline-based SGLT2i or GLP-1 RA medications with cardiovascular benefit, excluding combination products, based on administrative claims data [6-months]","BACKGROUND:33298420; BACKGROUND:33298421; BACKGROUND:32771263","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/58/NCT04862858/Prot_SAP_000.pdf","NO",null],["NCT07627048","Influence of Gut Microbiota on the Development of Type 2 Diabetes Mellitus and Personalization of Diabetes-lowing Therapy","GM","COMPLETED","OBSERVATIONAL",null,null,null,"100","Type 2 Diabetes (T2DM)",null,"Pirogov Russian National Research Medical University","2021-12-01","2021-12-01","FALSE","Number of participants with domination of different bacterial species in the stool analysis [3 months]",null,null,null,null],["NCT07783113","Dietary Supplement for Telogen Effluvium Associated With GLP-1 Receptor Agonist Use","GLP-1","NOT_YET_RECRUITING","INTERVENTIONAL",null,null,"NONE","48","Alopecia","DIETARY_SUPPLEMENT:Dietary Supplement for Hair Loss","Farmoquimica S.A.","2026-10","2027-02","FALSE","Anagen-to-Telogen Hair Ratio (A:T) [Baseline and Day 120]",null,null,"UNDECIDED",null],["NCT07833501","Estradiol Levels According to Body Mass Index in Premenopausal Patients With Breast Cancer","SIMPEC-E2","NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"172","Hormone Receptor-Positive Breast Cancer",null,"D'Or Institute for Research and Education","2026-09-03","2026-12-30","FALSE","Percentage of Participants With Inadequate Estrogen Suppression [At 3 months of treatment (visit window: ±14 days)]","BACKGROUND:31373601; BACKGROUND:21335088; BACKGROUND:39793457; BACKGROUND:38242892; BACKGROUND:26729437",null,"NO",null],["NCT07736911","Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy.",null,"RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","140","GLP-1","DRUG:GLP-1 Stop for 1 week; DRUG:GLP-1 non stop","Fu Jen Catholic University Hospital","2026-06-01","2029-06-01","FALSE","This scoring system is referred to as PEACE (Polprep: Effective Assessment of Cleanliness in Esophagogastroduodenoscopy) [\"From enrollment to the end of treatment at least 30 days]",null,null,"NO",null],["NCT07810998","Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2; PHASE3","RANDOMIZED","DOUBLE","60","Poly Cystic Ovary Syndrome","DRUG:Metformin; DRUG:Dapagliflozin (10mg Tab)","Tanta University","2026-09-10","2027-04-30","FALSE","Fertility parameters- Luteinizing hormone [3-months] | Fertility parameters- Follicle stimulating hormone [3-months] | Fertility parameters-Total testosterone [3-months]",null,null,null,null],["NCT05889637","Gastric Ultrasound Assessment for Preoperative Prandial State of Patients Taking Glucagon-Like Peptide-1 Receptor Agonists",null,"COMPLETED","OBSERVATIONAL",null,null,null,"132","Pulmonary Aspiration","DIAGNOSTIC_TEST:Gastric ultrasound","The University of Texas Health Science Center, Houston","2023-06-06","2023-07-12","FALSE","Number of subjects that are at risk for aspiration [end of ultrasound] | Number of subjects that are at low risk for aspiration [end of ultrasound]",null,null,"NO",null],["NCT07104539","Strength Training Response of Muscle in GLP-1 Users","STRONG-GLP","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","30","Muscle Mass","BEHAVIORAL:Strength Training; OTHER:Wait first, then strength training","Virginia Polytechnic Institute and State University","2025-10-08","2026-12","FALSE","Muscle mass by d3-creatine dilution [Water containing creatine isotope consumed in lab; Urine sample collection on Day 0 and Day 3 at baseline and 14 weeks.] | Balance testing - Percentage of failed recoveries [2-hour testing session in lab at baseline and 14 weeks.]",null,null,null,null],["NCT02844153","Metformin Use in Chronic Kidney Disease: The CKD-Met Study","CKD-Met","UNKNOWN","OBSERVATIONAL",null,null,null,"1000","Type 2 Diabetes; Chronic Kidney Disease","OTHER:modalities of metformin prescription","Hospices Civils de Lyon","2014-03","2018-03","FALSE","Percentage of patients receiving metformin [every January 1st up to 2020]","DERIVED:30145030",null,null,null],["NCT06867718","Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions","COMO-1","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","DOUBLE","267","Obesity or Overweight","DRUG:RGT001-075; DRUG:Placebo Comparator","Regor Pharmaceuticals Inc.","2025-01-24","2025-11-06","FALSE","Percent change from baseline in body weight at Week 36 [Baseline and 36 weeks]",null,null,"UNDECIDED",null],["NCT07465926","Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3","GLP1-SGLT2-CKM","COMPLETED","OBSERVATIONAL",null,null,null,"451036","Cardiovascular-kidney-metabolic Syndrome; Cardiovascular Disease Risk Factor; Kidney Disease; Type 2 Diabetes; Obesity & Overweight","DRUG:GLP-1 receptor agonist; DRUG:SGLT2 inhibitor","Chung Shan Medical University","2017-01-01","2026-01-31","TRUE","All-cause Mortality (Comparison 1) [From index through 36 months] | All-cause Mortality (Comparison 2) [From index through 36 months] | All-cause Mortality (Comparison 3) [From index through 36 months] | All-cause Mortality (Comparison 4) [From index through 36 months]","BACKGROUND:39651970; BACKGROUND:40371589; BACKGROUND:39651975; BACKGROUND:38717747; BACKGROUND:40570007; BACKGROUND:40796935; BACKGROUND:27237061; BACKGROUND:41178710; BACKGROUND:36331190; BACKGROUND:36467859; BACKGROUND:39291205; BACKGROUND:27295427; BACKGROUND:32227432; BACKGROUND:39289339; BACKGROUND:38523127; BACKGROUND:40367988; BACKGROUND:39961105; BACKGROUND:39556396; BACKGROUND:33591334; BACKGROUND:39992643; BACKGROUND:28576404; BACKGROUND:26106189; BACKGROUND:19776173; BACKGROUND:32927478; BACKGROUND:30835273; BACKGROUND:31767182; BACKGROUND:38777402; BACKGROUND:29203583; BACKGROUND:30132036; BACKGROUND:27440829; BACKGROUND:32114848; BACKGROUND:38768620; BACKGROUND:31422062; BACKGROUND:39342059; BACKGROUND:30415602; BACKGROUND:26378978; BACKGROUND:38490803; BACKGROUND:38785209; BACKGROUND:32970396; BACKGROUND:38663919; BACKGROUND:40899949; BACKGROUND:39588897; BACKGROUND:40281304; BACKGROUND:39171569; BACKGROUND:40388382; BACKGROUND:40014670; BACKGROUND:37622663; BACKGROUND:37807920; BACKGROUND:38103820; BACKGROUND:37807924","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/26/NCT07465926/Prot_SAP_000.pdf","NO","OTHER_GRANT:NSTC 113-2314-B-040-026-MY2; OTHER_GRANT:NSTC 114-2622-B-040-001; OTHER_GRANT:CSH-2025-C-012; OTHER_GRANT:CSH-2025-C-023"],["NCT07012317","A Trial to Assess Gastrointestinal Responses to Dietary Fibers in Adults Using Weight Loss Medications",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","QUADRUPLE","50","Gastrointestinal Symptoms; Weight Loss; GLP-1","OTHER:High Fiber Bar with Inulin; OTHER:High Fiber bar with Fiber Blend; OTHER:High Fiber Bar with Resistant Starch type 4; OTHER:Low Fiber Bar","Midwest Center for Metabolic and Cardiovascular Research","2025-05-29","2025-11-24","FALSE","Composite GI Symptom Score [Measured on days 1-10, 25-34, 49-58, and 73-82 where day 1 is the virtual visit date and start of the 3-day baseline. Study product consumption begins on day 4, 28, 52, and 76 and continues for 7 days followed by a 14 day washout period.]",null,null,null,null],["NCT07723820","Glycemic Velocity and Early Retinal Microvascular Change With GLP-1RA Versus SGLT2i Initiation in Type 2 Diabetes (GLIDE)","GLIDE","NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"126","Type 2 Diabetes Mellitus; Diabetic Retinopathy (DR)","DRUG:GLP-1 Receptor Agonists; DRUG:SGLT2 inhibitor","Thammasat University Hospital","2026-09-01","2027-06-01","FALSE","Change in parafoveal deep-capillary-plexus (DCP) vessel density on OCT angiography [Baseline to Month 3]","BACKGROUND:18064739; BACKGROUND:38584180; BACKGROUND:37454782; BACKGROUND:9682700; BACKGROUND:30226298; BACKGROUND:27633186; BACKGROUND:41501669",null,"NO",null],["NCT07336329","Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use","PERIODIC-CGM","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","150","Diabetes Mellitus, Type 2","DEVICE:FreeStyle Libre 2 Continuous Glucose Monitoring","Kangbuk Samsung Hospital","2026-01-02","2026-12-31","FALSE","Change in HbA1c from 3 to 6 months [At 6 months (V3)]",null,null,"YES",null],["NCT06017544","GLP-1RAs) and SGLT2is Combination Therapy and MACEs in Patients with Type 2 Diabetes.",null,"COMPLETED","OBSERVATIONAL",null,null,null,"257","Diabetes Mellitus, Type 2; Myocardial Infarction","PROCEDURE:PCI","University of Campania Luigi Vanvitelli","2017-01-01","2024-06-01","FALSE","MACE [12 months]","DERIVED:38184582",null,"UNDECIDED",null],["NCT07422987","GLP-1RA Effects on Lean Mass and Bone Health in Midlife Women","GLOW","ACTIVE_NOT_RECRUITING","OBSERVATIONAL",null,null,null,"50","Body Composition; Muscle Function; GLP-1; Estrogen Level",null,"University of Kansas Medical Center","2026-02-12","2027-06-30","FALSE","Body weight [Baseline through 6-month visit] | Body composition [Baseline through 6-month visit] | Bone mineral density (BMD) [Baseline through 6-month visit] | Muscle function [Baseline through 6-month visit]",null,null,null,null],["NCT02417012","Lifestyle and Glucose Lowering Medication in T2DM",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","97","Diabetes Mellitus, Type 2","BEHAVIORAL:U-TURN; BEHAVIORAL:Standard care","Copenhagen University Hospital, Rigshospitalet","2015-04","2017-09","FALSE","Change in Hba1c [0, 3, 6, 9, 12 months]","BACKGROUND:16451303; DERIVED:35764194; DERIVED:34431828; DERIVED:33441418; DERIVED:32816096; DERIVED:32007295; DERIVED:28810024; DERIVED:26656025",null,null,null],["NCT07202910","VALidation of Imaging-based Liver Biomarkers in PEDiatric Patients","VALiBi-PED","RECRUITING","OBSERVATIONAL",null,null,null,"550","Hepatic Disorders; Intestinal Failure-associated Liver Disease; Cystic Fibrosis Liver Disease; MAFLD; Pediatric Liver Transplantation",null,"Sahlgrenska University Hospital","2019-03-28","2030-03","FALSE","Diagnostic accuracy of ultrasound-based liver biomarkers (SWE, SWD, ATI) (STUDY 1) [At time of liver biopsy] | Longitudinal change in SWE/SWD/ATI biomarkers before and after treatment with CFTR modulators, (Study 2A - Children with Cystic Fibrosis) [baseline (pretreatment) up to 2 years] | Change in liver biomarkers measured by SWE and SWD during routine ultrasound surveillance post-liver transplantation. (Study 2b) [Up to 1 year] | Detection of early liver damage using SWE, SWD, and ATI (Attenuation Imaging) in children with intestinal failure. (Study 2c) [up to 2 years] | Change in SWE/SWD/ATI biomarkers following obesity treatment (GLP-1 analogues or bariatric surgery) (Study2d) [through study completion, an average of 1 years] | Correlation between ultrasound biomarkers and MR biomarkers . (Study 3) [periprocedurally]",null,null,"NO","OTHER_GRANT:Dnr 2023-01951; OTHER_GRANT:ALFGBG-1005247"],["NCT06661174","A Cohort Study on the Efficacy of Bariatric Surgery for Rapidly Progressing Diabetic Nephropathy","EBSDKD","RECRUITING","OBSERVATIONAL",null,null,null,"100","Bariatric Surgeries; Diabetic Nephropathy","PROCEDURE:Bariatric surgery; OTHER:Non-surgical therapy","China-Japan Friendship Hospital","2023-10-01","2025-10-30","FALSE","Total weight loss [1st, 3rd, 6th and 12th month after intervention, respectively.]",null,null,null,null],["NCT06030726","Nationwide Utilization of Danish Government Electronic Letter System for Confirming the Effectiveness of Behavioral Nudges in Increasing InFLUenza Vaccine Uptake Among Older Adults","NUDGE-FLU-2","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","881373","Influenza; Behavior and Behavior Mechanisms","BEHAVIORAL:Behavioral Economic Principles","Tor Biering-Sørensen","2023-09-14","2024-01-01","FALSE","Number of participants who received an influenza vaccine [Up to 3 months]","DERIVED:41968745; DERIVED:39550717; DERIVED:39215149; DERIVED:38460754",null,"YES",null],["NCT07111494","Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial",null,"RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","22","Psoriatic Arthritis (PsA)","DRUG:GLP-1 agonists; OTHER:Nutrition Counseling","Medical College of Wisconsin","2026-05-01","2026-10-15","FALSE","Change from the baseline Minimal Disease Activity (MDA) Scores at Week 12 and 24 with GLP-1 Agonists vs Nutrition Counseling [Week 12 and 24] | Proportion of Patients who Achieve Disease Activity in Psoriatic Arthritis (DAPSA) Remission with GLP-1 Agonists Vs. Nutrition Counseling at Week 12 and 24 [Week 12 and 24]",null,null,"YES",null],["NCT07127354","The Impact of GLP Medication on Colonoscopy Bowel Preparation Quality",null,"RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","132","GLP - 1; Bowel Preparation for Colonoscopy","DRUG:Continue GLP/GIP","The Cleveland Clinic","2025-08-01","2026-08","FALSE","Rate of inadequate bowel preparation [During Surgery]",null,null,null,null],["NCT07280325","Moxie Self-Management and Education Support Program",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","9000","Chronic Kidney Disease; Diabetes (DM); Heart Disease; Stroke; Chronic Disease","BEHAVIORAL:Moxie SMES Letters; BEHAVIORAL:Facilitated Relay Letter","University of Calgary","2026-06-01","2028-05-01","FALSE","Hospital Readmissions [Within 12 months from randomization.]","BACKGROUND:27671037; BACKGROUND:21300179; BACKGROUND:20407272; BACKGROUND:24275499; BACKGROUND:36309746; BACKGROUND:31202612; BACKGROUND:29929477; BACKGROUND:34965882; BACKGROUND:25010519; BACKGROUND:36871212; BACKGROUND:20734525; BACKGROUND:33234627; BACKGROUND:28827437; BACKGROUND:30762420; BACKGROUND:32213468; BACKGROUND:21733889; BACKGROUND:17426062; BACKGROUND:23983743; BACKGROUND:26209209; BACKGROUND:28658719; BACKGROUND:32056280; BACKGROUND:24744042; BACKGROUND:19339721; BACKGROUND:18359407; BACKGROUND:37807924",null,"NO",null],["NCT07776509","A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus","SELENE 3","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","QUADRUPLE","500","Obesity or Overweight; Weight-Related Comorbidity; With/Without Diabetes Mellitus, Type 2","DRUG:Lenbelintide; DRUG:Placebo","AstraZeneca","2026-08-24","2028-08-09","FALSE","Percent change in body weight from baseline at 68 weeks of treatment [68 weeks]",null,null,"YES","CTIS:2025-523295-23-00; REGISTRY:159494; NIH:2025"],["NCT07629544","A Study of DA-302168S in Participants With Overweight/Obesity","PANDA-1","RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","DOUBLE","840","Overweight and Obesity","DRUG:DA-302168S; DRUG:Placebo","Chendu DIAO Pharmaceutical Group CO., LTD.","2026-06-19","2027-07-09","FALSE","Percentage change from baseline in body weight [From baseline to week 40] | The proportion of subjects with a body weight reduction ≥5% from baseline [From baseline to week 40]",null,null,"NO",null],["NCT04813003","How Altered Gut-Brain-Axis Influences Food Choices: Part 1","BrainFood","COMPLETED","OBSERVATIONAL",null,null,null,"50","Obesity; Food Preferences","OTHER:Functional Brain Imaging and neurobehavioural tasks","Lia Bally","2021-04-12","2022-09-05","FALSE","Representational similarity analysis to assess neural encoding of food attributes [Continuously while participants perform the tasks (during 2.5 hours)] | Nutrient factor weights [Continuously while participants perform the tasks (during 2.5 hours)]",null,null,"UNDECIDED",null],["NCT06987903","Impact of a Perioperative Physical Exercise and Respiratory Physiotherapy Program on the Patient Undergoing Bariatric Surgery","CAPS-OB","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","132","Bariatric Surgery and Physical Activity; Obesity/Therapy; Bariatric Surgery Complications; Bariatric Patients","PROCEDURE:Pre- and post-operative physical exercise programme; PROCEDURE:Pre- and post-operative respiratory physiotherapy","Fundacin Biomedica Galicia Sur","2025-05-07","2028-09-30","FALSE","Total weight loss [From enrollment to the end of intervention at 8 weeks] | Waist circumference [From enrollment to the end of intervention at 8 weeks] | Sex (at birth) [Once at the inclusion]",null,null,"NO",null],["NCT03549754","iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases","iCaReMe","RECRUITING","OBSERVATIONAL",null,null,null,"35000","Type 2 Diabetes; Hypertension; Chronic Kidney Disease; Heart Failure",null,"AstraZeneca","2018-02-17","2030-12-31","FALSE","1. Age of particpants [At Baseline] | 2. Percentage of Participants by Sex [At baseline] | 3. Percentage of Participants by Ethnicity [At Baseline] | 4. Percentage of Participants by Education Level [At Baseline] | 5. Percentage of Participants by Marital Status [At Baseline] | 6. Percentage of Participants with Family History of Cardiovascular and Renal-Metabolic Disease [At Baseline] | 7.Percentage of Participants by Physical Activity Level [At Baseline] | 8. Percentage of Participants by Smoking Status [At Baseline] | 9. Percentage of Participants by Alcohol Consumption [At Baseline] | 10. Body Weight of Participants [At Baseline] | 11. Height of Participants [At Baseline] | 12. Body Mass Index (BMI) of Participants [At Baseline] | 13. Waist Circumference of Participants [At Baseline] | 14. Waist-to-Hip Ratio of Participants [At Baseline] | 15. Waist-to-Height Ratio of Participants [At Baseline] | 16. Percentage of Participants by Cardiac and Renal Functional Measurements Category [At Baseline] | 17. Primary Disease Duration [At Baseline] | 18. Percentage of Participants by Number and Types of Comorbidities [At Baseline] | 19. Percentage of Participants by NYHA Functional Class [At Baseline] | 20. Percentage of Participants by Heart Failure Phenotype [At Baseline] | 21. Percentage of Participants by Heart Failure Etiology [At Baseline] | 22. Percentage of Participants by CKD Etiology [At Baseline] | 23. Percentage of Participants by Hypertension Stage [At Baseline] | 24. Percentage of Participants by Secondary Hypertension Etiology [At Baseline] | 25. Office Systolic and Diastolic Blood Pressure [At Baseline] | 26. Home Blood Pressure Monitoring (HBPM) Systolic and Diastolic Values [At Baseline] | 27. Ambulatory Blood Pressure Monitoring (ABPM) Systolic and Diastolic Values [At Baseline] | 28. Blood HbA1c [Average of 3 years] | 29. Fasting Glucose [Average of 3 years] | 30. Lipid Profile Testing [Average of 3 years] | 31. Serum Creatinine [Average of 3 years] | 32. Estimated Glomerular Filtration Rate (eGFR) [Average of 3 years] | 33. Urine Albumin-to-Creatinine Ratio (UACR) [Average of 3 years] | 34. Serum Electrolyte Values [Avergae of 3 years] | 35. Frequency of HbA1c Testing [Average of 3 years] | 36. Frequency of Fasting Glucose Testing [Average of 3 years] | 37. Frequency of Lipid Profile Testing [Average of 3 years] | 38. Frequency of Serum Creatinine Testing [Average of 3 years] | 39. Frequency of eGFR Assessment [Average of 3 years] | 40. Frequency of Urine Albumin-to-Creatinine Ratio Testing [Average of 3 years] | 41. Echocardiography [Average of 3 years] | 42. Electrocardiogram (ECG) [Average of 3 years] | 43. Participants Receiving Dietary Modification Counseling [Average of 3 years] | 44. Participants Enrolled in Exercise Programs [Average of 3 years] | 45. Participants Receiving Weight Management Interventions [Average of 3 years] | 46. Participants Receiving Smoking Cessation Counseling [Average of 3 years] | 47. Participants Receiving Alcohol Reduction Counseling [Average of 3 years] | 48. Percentage of Participants by Line of Treatment [Average of 3 years] | 49. Percentage of Participants by Drug Class [Average of 3 years] | 50. Percentage of Participants Undergoing Cardiac Surgeries (CABG or PCI) [Average of 3 years] | 51. Percentage of Participants Receiving Dialysis [Average of 3 years] | 52. Percentage of Participants with Cardiac Device Implantation [Average of 3 years] | 53. Mean Duration of Pharmacological Treatments [Average of 3 years] | 54. Drug Dose of Pharmacological Treatments [Average of 3 years] | 55. Number of Primary Care Visits per Participant [Average of 3 years] | 56. Number of Tertiary Care Hospital Visits per Participant [Average of 3 years] | 57. Number of Specialist Care Visits per Participant [Average of 3 years] | 58.Number of Emergency Department Visits per Participant [Average of 3 years] | 59. All-Cause Hospitalizations [Average of 3 years] | 60. Disease-Specific Hospitalizations [Average of 3 years] | 61. All-Cause Emergency Department Visits [Average of 3 years] | 62. Disease-Specific Emergency Department Visits [Average of 3 years] | 63. Length of Hospital Stay [Average of 3 years]","DERIVED:42694927",null,"YES",null],["NCT06388213","Investigation of the Evolution of Gastric Emptying by Gastric Ultra Sonography in Patients Treated With GLP-1 Receptor Agonists on a 7 Days Pausing Period.",null,"UNKNOWN","OBSERVATIONAL",null,null,null,"40","Diabetes Mellitus, Type 2; Anesthesia; Pulmonary Aspiration of Gastric Contents","DEVICE:Gastric Ultrasonography","University Hospital, Geneva","2024-06","2025-06","FALSE","Change of antral cross sectional area in patients pausing 7 days GLP-1 RA treatment. [7 days]",null,null,"UNDECIDED",null],["NCT05734989","Improving Screening and Therapy for Hispanic/Latinx at Risk for CKD",null,"COMPLETED","OBSERVATIONAL",null,null,null,"248","Type 2 Diabetes; Chronic Kidney Diseases","DIAGNOSTIC_TEST:BP; DIAGNOSTIC_TEST:HbA1c; BEHAVIORAL:PCP Guidelines for Screening and Monitoring Hispanic/Latinx patients for CKD","Duke University","2023-05-18","2025-04-04","TRUE","Number of Participants Who Attended or Scheduled a Primary Care Physician (PCP) Visit [up to 3 months after screening] | Number of Participants Who Received Urine Albumin-to-Creatinine Ratio (uACR) Screening [Within three months of T0 (primary care appointment)] | Number of Participants Who Were Prescribed an SGLT2 Inhibitor (SGLT2i) and/or a GLP-1 Receptor Agonist (GLP-1 RA) [Within three months of T0 (primary care appointment)] | Number of Participants Who Were Prescribed a Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) [Within three months of T0 (primary care appointment)]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/89/NCT05734989/Prot_SAP_001.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/89/NCT05734989/ICF_000.pdf","NO",null],["NCT06593314","Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes",null,"RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","800","Heart Failure; Diabetes","BEHAVIORAL:Message with EchoGo; BEHAVIORAL:Standard Message","University of Texas Southwestern Medical Center","2025-08-06","2026-09-15","FALSE","Frequency of prescription of SGLT-2i medication at outpatient clinic visits over 3 months follow-up [3-month follow-up] | Frequency of prescription of SGLT-2i medication at outpatient clinic visits over 6 months follow-up [3-month follow-up]",null,null,"NO",null],["NCT06939517","Acupressure Wristbands for GLP-1RA Related Nausea",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL",null,null,"NONE","35","Nausea","DEVICE:SeaBand","Florencia Ziemke","2024-02-01","2025-03-13","FALSE","Nausea relief [Nausea relief with use of wristbands for every recorded episode, reviewed weekly, for a total of four weeks]",null,null,"NO",null],["NCT05854979","Effects of GLP-1 Agonists on Gastric Volume",null,"COMPLETED","OBSERVATIONAL",null,null,null,"210","Diabetes; Gastric Content Aspiration; Glucagon-like Peptide 1; GLP-1","DIAGNOSTIC_TEST:Gastric Ultrasound","Medical University of South Carolina","2023-08-09","2024-04-15","FALSE","Gastric Volume in RLD Position [From time of enrollment until the start of surgery, assessed up to 4 weeks]",null,null,null,null],["NCT06915090","FIT-COACH: Fitbit Intervention With Coordinated Health Coaching and PCP Support","FIT-COACH","COMPLETED","INTERVENTIONAL",null,null,"NONE","15","GLP - 1; Diabetes; Obesity and Obesity-related Medical Conditions; Cardiovascular Diseases","BEHAVIORAL:Health Coach/Fitbit","University of Massachusetts, Worcester","2025-03-18","2025-09-30","FALSE","Feasibility of enrollment [6-months]",null,null,"YES",null],["NCT02026024","Incretin Based Therapy for Poorly Controlled Type 2 Diabetic Patients","IBCT2","COMPLETED","OBSERVATIONAL",null,null,null,"10","Type 2 Diabetes Mellitus",null,"Chang Gung Memorial Hospital","2013-10","2015-12","FALSE","mean amplitude of glycaemic excursions (MAGE) [3 months]",null,null,null,null],["NCT07585526","Safety and Efficacy of Finerenone in Metabolic Dysfunction Associated Steatotic Liver Disease(MASLD/NAFLD) Related Cirrhosis Patients With Ascites in Prevention of Chronic Kidney Disease.",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","160","MASLD; Chronic Kidney Diseases","DRUG:Finerenone; DRUG:Spironolactone; OTHER:Standard Medical Treatment","Institute of Liver and Biliary Sciences, India","2026-04-15","2028-03-31","FALSE","Incidence of chronic kidney disease (CKD) in patients with MASLD/NAFLD related cirrhosis with clinical ascites at 6 months between both the groups, defined as: [6 months]",null,null,"UNDECIDED",null],["NCT06904846","To Evaluate the Change in Glucose Parameters in Adult Patients With Type 1 or Type 2 Diabetes From Europe Using the iCan o3 CGM System for 60 Days Period","DETECT","ENROLLING_BY_INVITATION","INTERVENTIONAL",null,null,"NONE","70","Diabetes Mellitus; Continuous Glucose Monitoring System","DEVICE:iCan o3 CGM Continuous Glucose Monitoring System","Sinocare","2025-04-23","2026-04-30","FALSE","Improvement of Glycemic control [60 days]",null,null,"NO",null],["NCT07817823","Yeast Protein Supplementation and Muscle Preservation During GLP-1RA-Induced Weight Loss",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","QUADRUPLE","200","Overweight and Obesity in Adults Receiving GLP-1RA Treatment","DIETARY_SUPPLEMENT:Yeast Protein; DIETARY_SUPPLEMENT:Whey Protein; DIETARY_SUPPLEMENT:Yeast Protein/Whey Protein Blend (1:1)","Huazhong University of Science and Technology","2026-09-20","2027-03-30","FALSE","Change in Lean Body Mass From Baseline to Week 12 [Baseline and Week 12]","RESULT:31911785; RESULT:41612951; RESULT:24724774; RESULT:41877354; RESULT:41068996",null,"NO",null],["NCT01967589","Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","82","Diabetes; Healthy","DRUG:NNC0113-0987; DRUG:placebo","Novo Nordisk A/S","2013-10","2014-05","FALSE","Number of treatment emergent adverse events (TEAEs) recorded [From the time of first dosing (Day 0) and until completion of the post-treatment follow-up visit (Day 83-97)]",null,null,null,"EUDRACT_NUMBER:2012-002893-30; OTHER:U1111-1131-8724"],["NCT07455630","Cardiac Function and Biomarkers in Patients With Obesity and Overweight","BEYOND","COMPLETED","OBSERVATIONAL",null,null,null,"30","Obesity & Overweight","DRUG:Weight loss with pharmacotherapy; BEHAVIORAL:Weight loss without pharmacotherapy","TecSalud Investigación Clínica","2023-06-20","2023-09-19","FALSE","Left Ventricular Mass by Cardiac MRI [Baseline, 3 months, 6 months, and 9 months.] | Right Ventricular Mass by Cardiac MRI [Baseline, 3 months, 6 months, and 9 months.] | Left Ventricular Ejection Fraction [Baseline, 3 months, 6 months, and 9 months.] | Right Ventricular Ejection Fraction [Baseline, 3 months, 6 months, and 9 months.] | Diastolic Function Left Ventricle [Baseline, 3 months, 6 months, and 9 months.] | Diastolic Function Right Ventricle [Baseline, 3 months, 6 months, 9 months.]",null,null,"NO",null],["NCT06745544","Impact of Screening and Multicomponent Exercise on Fall Rates, Fractures, and Cardiovascular Health in Diabetes","DiaACTIVE","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","490","Type 2 Diabetes; Osteoporosis; Diabetic Neuropathies; Fall Prevention; Cardiovascular Diseases","OTHER:Rhythm- and Multitask-Based Activity (RYMA) and Activities of Daily Living (ADL)","Aalborg University Hospital","2025-10-01","2026-12-31","FALSE","Reduction in Fall Rates [Measurements will take place at 26 weeks, 52 weeks, 104 weeks, and 5 years post-intervention to evaluate both short- and long-term effects of the intervention.] | Improvement in Bone Mineral Density (BMD) [Measurements will assess changes at 26 weeks, 52 weeks, 104 weeks, and 5 years post-intervention to evaluate sustained benefits.] | Reduction in Cardiovascular Risk and Events [26 weeks, 52 weeks, 104 weeks, and 5 years post-intervention.] | Improvement in Nerve Function [26 weeks, 52 weeks, 104 weeks, and 5 years post-intervention.] | Blood glucose changes [HbA1c measurements will take place at baseline and after 26 weeks, 52 weeks, 104 weeks, and 5 years post-intervention to evaluate both short- and long-term effects of the intervention. CGM will be measures blinded during the 26 weeks RYMA intervention.]","BACKGROUND:16291301; BACKGROUND:37515636; BACKGROUND:26455926; BACKGROUND:33889286; BACKGROUND:15817027; BACKGROUND:29697780; BACKGROUND:32636957; BACKGROUND:33239019; BACKGROUND:32900349; BACKGROUND:33755157; BACKGROUND:30915638",null,"YES","OTHER_GRANT:NNF22SA0079901"],["NCT05781334","Optimizing In-hospital Use of Evidence-based Therapies for Patients With Cardio-Renal-Metabolic Disease","IMPLEMENT-CRM","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","202","Heart Failure; Type 2 Diabetes; Chronic Kidney Diseases","OTHER:Virtual Consult Intervention","Duke University","2023-06-09","2024-08-31","FALSE","Proportion of patients prescribed SGLT2i (sodium glucose co-transporter-2 inhibitors) [hospital discharge (up to approximately 14 days)] | Proportion of patients prescribed SGLT2i (sodium glucose co-transporter-2 inhibitors) [30 days post-discharge (approximately 6 weeks)]",null,null,"NO",null],["NCT07697469","Atrial Cardiomyopathy in Patients With Cardiovascular-Kidney-Metabolic Syndrome: Non-invasive Characterization","ATRIO-CKM","NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"200","Cardiovascular-Kidney-Metabolic Syndrome; Atrial Cardiomyopathy; Atrial Fibrillation; Chronic Kidney Disease; Metabolic Syndrome",null,"Grigore T. Popa University of Medicine and Pharmacy","2026-07-10","2027-10","FALSE","Prevalence of atrial cardiomyopathy (ACM) across CKM syndrome stages [Baseline (single evaluation visit)]",null,null,"YES",null],["NCT03363464","Comparative Effectiveness of Empagliflozin in the US",null,"COMPLETED","OBSERVATIONAL",null,null,null,"230000","Diabetes Mellitus, Type 2","DRUG:Empagliflozin; DRUG:DPP-4 inhibitor; DRUG:GLP-1 receptor agonist","Boehringer Ingelheim","2017-10-16","2026-07-09","FALSE","3-point major adverse cardiovascular events (MACE) [60 months] | Hospitalization for heart failure (specific, based on primary inpatient diagnosis code) [60 months] | Hospitalization for heart failure (broad, based on any inpatient diagnosis code) [60 months] | Modified MACE [60 months] | Composite of MI or stroke hospital admission for heart failure [60 months] | All-cause mortality [60 months]","DERIVED:30955357",null,"NO",null],["NCT07270497","The Effect of Pharmacotherapy With GLP-1 and GIP/GLP-1 Analogs on Changes in Qualitative and Quantitative Parameters of the Diet as Well as Metabolic and Behavioral Parameters in Patients With Excess Body Weight",null,"RECRUITING","OBSERVATIONAL",null,null,null,"100","GLP-1; Nutrition",null,"Medical University of Warsaw","2025-08-15","2026-08-14","FALSE","change in body weight [12 months]",null,null,null,null],["NCT06854952","A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity","FALCON","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","167","Overweight or Obesity","DRUG:TERN-601; OTHER:Matching Placebo","Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","2025-03-07","2025-08-19","TRUE","Percent Change in Body Weight [12 weeks]","DERIVED:42528333","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/52/NCT06854952/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/52/NCT06854952/SAP_001.pdf","NO",null],["NCT06030739","Nationwide Utilization of Danish Government Electronic Letter System for Increasing InFLUenza Vaccine Uptake Among Adults With Chronic Disease",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","299881","Influenza; Behavior and Behavior Mechanisms","BEHAVIORAL:Behavioral Economic Principles","Tor Biering-Sørensen","2023-09-24","2024-01-01","FALSE","Number of participants who received an influenza vaccine [Up to 3 months]","DERIVED:41968745; DERIVED:39606218; DERIVED:39550717; DERIVED:39392741; DERIVED:38460754",null,"YES",null],["NCT07340112","Expression of GLP1 Receptor on Peripheral Blood Mononuclear Cells in Advanced Peripheral Artery Disease: Paving the Way for GLP1R Agonists Treatment in Chronic Limb Threatening Ischemia","EXCEL-CLTI","NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"50","Peripheral Arterial Disease (PAD); Claudication, Intermittent; Chronic Limb-Threatening Ischemia","DIAGNOSTIC_TEST:Analysis of GLP-1 receptor expression","University Hospital, Strasbourg, France","2026-06","2028-06","FALSE","Level of GLP-1 Receptor (GLP-1R) Gene Expression in PBMCs [Day 1 (at the time of the one-time blood sampling)]",null,null,"NO",null],["NCT07770737","Cardioprotective Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Korean Patients With Type 2 Diabetes",null,"NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"100","Type 2 Diabetes Mellitus (T2DM); Cardiovascular Diseases; Stage B Heart Failure",null,"Dongtan Sacred Heart Hospital","2026-09","2027-12-31","FALSE","Time to First Atherosclerotic Cardiovascular Disease Composite Event [From the index date until the first occurrence of acute myocardial infarction or ischemic stroke, loss to follow-up, death, or the end of available database records, whichever occurs first, assessed up to 12 years] | Time to First Hospitalization for Heart Failure [From the index date until the first hospitalization for heart failure, loss to follow-up, death, or the end of available database records, whichever occurs first, assessed up to 12 years] | Change in Echocardiographic Global Longitudinal Strain [Baseline and 6 months after SGLT2 inhibitor initiation]","BACKGROUND:39488646; BACKGROUND:40448135; BACKGROUND:39438942",null,"NO",null],["NCT04964388","Effect of GLP-1 Receptor Agonists on Trabecular Bone Score",null,"TERMINATED","INTERVENTIONAL","PHASE2","NON_RANDOMIZED","NONE","5","Osteoporosis, Postmenopausal; Diabetes Mellitus, Type 2","DRUG:GLP-1 receptor agonist","University of Mississippi Medical Center","2021-11-09","2023-05-01","TRUE","Trabecular Bone Score [12 months after index date]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/88/NCT04964388/Prot_SAP_000.pdf","NO",null],["NCT07444203","Transformative Research in Diabetic Nephropathy 2.0","TRIDENT 2","RECRUITING","OBSERVATIONAL",null,null,null,"200","Diabetic Nephropathies; Kidney Diseases; Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2","DRUG:Sodium-glucose cotransporter 2 inhibitors (SGLT2i); DRUG:Renin-angiotensin-aldosterone system blockade; DRUG:Glucagon-like peptide-1 receptor agonists (GLP 1 RA); DRUG:Mineralocorticoid Receptor Antagonists(MRAs)","University of Pennsylvania","2025-11-12","2027-05-30","FALSE","Change in Kidney Tissue molecular fingerprint [Baseline enrollment to 18 months.]",null,null,null,null],["NCT07182123","GLP1-RA and Periodontitis",null,"NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"30","Periodontitis; Diabetes (DM)",null,"Medical University of Graz","2025-10-24","2026-06","FALSE","Effect of weekly GLP1-RA administration on periodontal clinical parameters (PD, CAL, BOP, furcation involvement, and tooth mobility) measured using a periodontal probe in patients with stage III or IV periodontitis. [From enrollment to the end of treatment at 16 weeks]",null,null,null,null],["NCT05933174","Promoting Alternatives to Sulfonylureas to Improve Patient Safety in Type 2 Diabetes",null,"RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","220","Type2diabetes","OTHER:Prompt-sheet; OTHER:Usual education","University Hospitals Cleveland Medical Center","2023-10-01","2027-06-30","FALSE","Proportion of patients who had a conversation with their primary care provider about SU use and alternatives for their diabetes management [12 months]",null,null,"NO","OTHER_GRANT:Neeland AHA 23SCISA1144816"],["NCT03921242","Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease",null,"COMPLETED","OBSERVATIONAL",null,null,null,"4888","Diabetes Mellitus, Type 2; Renal Insufficiency, Chronic","DRUG:Metformin; DRUG:Sulfonylurea; DRUG:DPP-4 inhibitor; DRUG:SGLT2 inhibitor; DRUG:GLP1 receptor agonist","Weill Medical College of Cornell University","2019-08-01","2023-08-01","FALSE","Incidence of Severe Hypoglycemia Assessed from EMR [18 Months] | Difference in Glycosylated Hemoglobin (HbA1c) level (mmol/mol) [24 Months] | Heterogeneity of Treatment Effect Via Pre-specified Sub-Group Analyses [25 Months]",null,null,"NO",null],["NCT07021443","The Effect of GLP-1 Analogues on Liver Steatosis and Fibrosis in Diabetic and Obese Patients in a Clinical Setting","GLP1_NAFLD","COMPLETED","OBSERVATIONAL",null,null,null,"50","Non-Alcoholic Fatty Liver Disease","OTHER:non-interventional","Universitair Ziekenhuis Brussel","2023-10-09","2023-10-26","TRUE","Serum Markers (sfG) to Follow the Evolution of Liver Damage [From time of infomed consent till 1 year after signing informed consent.] | Fatty Liver Index (FLI) [From time of signing the ICF till 1 year after given informed consent] | FIB-4 Index [From time of signing the ICF till 1 year after given informed consent] | Serum Markers (HbA1c) to Follow the Evolution of Liver Damage [From time of infomed consent till 1 year after signing informed consent.]",null,"Study Protocol|https://cdn.clinicaltrials.gov/large-docs/43/NCT07021443/Prot_000.pdf","NO",null],["NCT05465317","Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease",null,"COMPLETED","OBSERVATIONAL",null,null,null,"62197","Diabetes Mellitus, Type 2","DRUG:Empagliflozin; DRUG:Dipeptidyl Peptidate-4 inhibitors","Boehringer Ingelheim","2022-08-08","2023-05-02","TRUE","Incidence Rate of the Composite Outcome Including 40% Decline in Estimated Glomerular Filtration Rate (eGFR), Incident End-stage Renal Disease (ESRD) and All-cause Death [Starting the day after the index date (date of initiation of empagliflozin or DPP4i) and continuing until the first occurrence of the outcome of interest, or end of study date (date of death, date of study end, 2 years after index date). Up to 2 years.]","DERIVED:39142723","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/17/NCT05465317/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/17/NCT05465317/SAP_001.pdf","NO",null],["NCT07773272","Cardiovascular-kidney-metabolic (CKM)-Guided Therapy for Patients After Acute Coronary Syndrome","SLIM-3","RECRUITING","OBSERVATIONAL",null,null,null,"1215","Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI); Hypercholerolemia; Hypertension; Diabete Mellitus; Cardiovascular Risk Management","DRUG:Rapid ESC-guideline based secondary prevention following myocardial infaction","Zuyderland Medisch Centrum","2026-03-16","2029-03-31","FALSE","MACCE within 2 years after the ACS and PCI [From enrollment to end of 2 year follow-up]",null,null,"UNDECIDED",null],["NCT06101667","Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)","ANGEL-BAO","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","224","Acute Ischemic Stroke; Basilar Artery Occlusion","DRUG:Best medical management; PROCEDURE:Endovascular treatment","Beijing Tiantan Hospital","2023-11-16","2026-02-25","FALSE","Rate of modified Rankin scale 0-3 at 90 (±14) days after randomization [90±14 days after randomization]","DERIVED:42419771",null,"NO",null],["NCT06927401","Evaluate the Detection of Retained Gastric Contents and Assess Safety Using the Flower Capsule Endoscopy in Healthy Individuals and GLP-1 Receptor Agonist Users",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","36","Endoscopy, Digestive System; GLP1-R-related Disease","DEVICE:Flower","Asian Institute of Gastroenterology, India","2025-04-08","2025-06-30","FALSE","Detection of Retained Gastric Contents Using Flower Capsule [Within 1 hour post-capsule ingestion]","BACKGROUND:35663207; BACKGROUND:36870274; BACKGROUND:39071832; BACKGROUND:36752856; BACKGROUND:34019629; BACKGROUND:30443057; BACKGROUND:28879323",null,"NO",null],["NCT05039450","A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)",null,"COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","213","NASH - Nonalcoholic Steatohepatitis","DRUG:EFX; DRUG:Placebo","Akero Therapeutics, Inc","2021-07-30","2023-12-15","TRUE","Main: Change From Baseline in Fibrosis With no Worsening Steatohepatitis Assessed by NASH CRN System [Week 36]","DERIVED:40341827; DERIVED:38447814","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/50/NCT05039450/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/50/NCT05039450/SAP_001.pdf","NO",null],["NCT06167135","Polycystic Ovary Syndrome, Mitochondrial Dysfunction, Obesity, Insulin Resistance Infertility (POMODORI) Cohort","POMODORI","RECRUITING","OBSERVATIONAL",null,null,null,"150","Infertility, Female; Polycystic Ovary Syndrome; Insulin Resistance; Primary Ovarian Insufficiency; Mitochondrial Alteration; Obesity",null,"Semmelweis University","2021-09-10","2033-09-30","FALSE","Serum Glucose and Insulin Levels [One year] | Clinical Pregnancy Rate [One year]",null,null,"NO",null],["NCT02029846","Glycemia in Diabetic Elders Trial",null,"TERMINATED","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","2","Type 2 Diabetes Mellitus","DRUG:Standard Treatment; DRUG:Incretin-Based Treatment","Johns Hopkins University","2013-04","2017-02","TRUE","Time to Achieve Glycemic Target (HbA1c <7.5%). [6 months]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/46/NCT02029846/Prot_SAP_000.pdf",null,null],["NCT04445181","A Study Using the LMC Diabetes Registry to Learn More About Chronic Kidney Disease (CKD) in Canadian Patients With Type 2 Diabetes (T2D)",null,"COMPLETED","OBSERVATIONAL",null,null,null,"14873","Chronic Kidney Disease in Type 2 Diabetes","DRUG:The physician's prescription in routine clinical practice","Bayer","2020-07-01","2020-11-23","FALSE","Proportion of patients with CKD in a large T2D population [Retrospectively analysis between January 1, 2019 and December 31, 2019]","DERIVED:34426012",null,"NO",null],["NCT06273163","Identifying Strategies to Curtail Weight Regain After GLP-1 Receptor Agonist Treatment Cessation",null,"TERMINATED","INTERVENTIONAL",null,"RANDOMIZED","TRIPLE","39","Obesity","OTHER:Medically tailored meals; BEHAVIORAL:Noom®; OTHER:Usual care","University of Texas Southwestern Medical Center","2024-03-05","2025-08-05","FALSE","Intervention Adherence [4-months] | Intervention Satisfaction [4-months]",null,null,"UNDECIDED",null],["NCT07006142","Effect of Prolonged Fasting Time on Gastric Residual Volume in Patients Taking GLP1 Receptor Agonists",null,"RECRUITING","INTERVENTIONAL",null,null,"SINGLE","150","Upper Endoscopy; GLP1-R-related Disease","OTHER:Modified Fasting Guidelines","Mayo Clinic","2025-08-01","2026-12-31","FALSE","Gastric contents [Baseline]",null,null,"NO",null],["NCT07001553","Understanding Acute Dietary Changes After GLP-1 Agonist Treatment: The GLaD Feasibility Study","GLaD","COMPLETED","OBSERVATIONAL",null,null,null,"37","Obesity; Type 2 Diabetes Mellitus (T2DM)",null,"Australian Catholic University","2025-05-28","2026-01-07","FALSE","Feasibility of recruitment [4 months]",null,null,"YES",null],["NCT06438874","Type 2 Diabetes Post Exercise Arterial Stiffness",null,"WITHDRAWN","INTERVENTIONAL",null,null,"NONE","0","Type 2 Diabetes","OTHER:Exercise Test","University of Illinois at Chicago","2024-07","2024-11","FALSE","Arterial stiffness [Baseline and up to 20 minutes post exercise]",null,null,"NO",null],["NCT01827280","Acute and Short-term Chronic Effects of Galvus (Vildagliptin) in Diabetes Type 2 Obese Women",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","40","1- Microvascular Function; 2-oxidative Stress; 3-inflammation","DRUG:Vildagliptin","Rio de Janeiro State University","2013-04","2016-08","FALSE","Change from Baseline in microcirculation function at 30 days [Before and after 30 days]","DERIVED:31462933",null,null,"REGISTRY:BioVasc_2013"],["NCT01408862","Effects of Incretins on Human Platelet Function",null,"COMPLETED","OBSERVATIONAL",null,null,null,"20","Inhibition of Platelet Aggregation by Incretins","OTHER:venous puncture","National Council of Scientific and Technical Research, Argentina","2012-12","2014-08","TRUE","Expression of Glucagon Like Peptide -1 (GLP-1) and Gastric Inhibitory Peptide (GIP) Receptors in Normal Human Platelets [Platelets drawn from a volunteer were evaluated 1 time (in 1-2 days)] | Changes in Basal or Aggregant-induced Platelet Activation (With and Without Glucose Added to the Media, 200 mg/dl, 400 mg/dL) by GLP-1-(7-36)NH2 and Its Metabolite (GLP-1-(9-36)NH2)and a GIP Agonist at Different Concentrations. [Platelets drawn from a volunteer will be evaluated 1 time (in 1-2 days)]",null,null,null,null],["NCT03678727","Effects of Exercise on VLDL-TG Metabolism",null,"COMPLETED","OBSERVATIONAL",null,null,null,"19","NAFLD - Nonalcoholic Fatty Liver Disease; NASH - Nonalcoholic Steatohepatitis",null,"University of Aarhus","2018-12-01","2020-11-10","FALSE","Effects of exercise on VLDL-TG metabolism in individuals with NAFL or NASH [3 years]",null,null,null,null],["NCT07551947","Insulin Resistance as a Predictor of Pulsed Field Ablation Success in Atrial Fibrillation (HOMA-PULSE)","HOMA-PULSE","ENROLLING_BY_INVITATION","OBSERVATIONAL",null,null,null,"120","Atrial Fibrillation; Insulin Resistance; Catheter Ablation; Artificial Intelligence",null,"Nemocnice AGEL Trinec-Podlesi a.s.","2026-04-01","2028-12","FALSE","Rate of Reablation at 4-5 Months [4 to 5 months after primary PFA ablation] | Prevalence of Insulin Resistance in Non-Diabetic AF Patients Undergoing PFA [Baseline (day of ablation)] | Association Between HOMA-IR and Reablation Risk [Baseline HOMA-IR measurement to reablation decision at 4-5 months post-ablation]","BACKGROUND:31439289; BACKGROUND:31558158; BACKGROUND:33933412",null,"UNDECIDED","OTHER:EK KLH_EK_01_HOMA PULSE; OTHER_GRANT:INT2025003"],["NCT07652333","The Effects of Strength Training on Muscle Mass and Mental Health in Adults Taking Obesity Medication","STRONG","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","40","Muscle Composition; Obesity; Quality of Life (QOL)","BEHAVIORAL:Resistance Exercise; DRUG:GLP-1 RAs","University of Pittsburgh","2026-05-25","2027-04-30","FALSE","Change in Body Composition [From Baseline to Week 12] | Change in Quality of Life [From Baseline to Week 12]",null,null,"YES",null],["NCT07701291","Online Group Programme on Mindful Eating During Medication-Supported Weight Loss",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","28","Obesity & Overweight; Emotional Eating; Emotional Eating Behaviour; Online Intervention","BEHAVIORAL:Online Group Intervention on Mindful Eating","Bern University of Applied Sciences","2026-08-15","2027-02-15","FALSE","Recruitment rate [From start of recruitment to completion of recruitment] | Randomization acceptance [At week 16 (±2-weeks)] | Retention rate [At week 16 (±2-weeks)] | Group session attendance & adherence [At week 16 (±2-weeks)] | Data completion [At week 16 (±2-weeks)] | Acceptability of the intervention [At week 16 (±2-weeks)]",null,null,"NO",null],["NCT03455049","The Effect of Andrographis Paniculata to GLP-1, Fasting Insulin, Insulin 2-h Post OGTT, and HOMA-IR",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","73","Increased Insulin","OTHER:Andrographis Paniculata Ext","Universitas Indonesia","2017-10-17","2018-05-02","FALSE","GLP-1 [A measure assesing change from baseline GLP-1 at 14 days.]","BACKGROUND:22357723; DERIVED:35075363",null,"NO",null],["NCT04813146","Role of Synchronized Lifestyle Modification Program on Diabetic Neuropathy Taking Oral Hypoglycemics",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","216","Diabetic Neuropathies","OTHER:SLP; OTHER:SLP along with Physiotherapy; OTHER:Physiotherapy","Riphah International University","2021-02-05","2022-01-30","FALSE","Life style pattern assessment [12 weeks] | Calculation of Body Mass Index [12 weeks] | Measurement of Systolic Blood pressure [12 weeks] | Measurement of Diastolic Blood pressure [12 weeks] | Michigan Neuropathy Screening Instrument [12 weeks] | Peak latency of Sensory Nerves (Sural and Peroneal) [12 weeks] | Amplitude of Sensory Nerves (Sural and Peroneal) [12 weeks] | Velocity of Sensory Nerves [12 weeks] | Onset Latency of Motor Nerves (Peroneal and Tibial) [12 weeks] | Amplitude of Motor Nerves (Peroneal and Tibial) [12 weeks] | Velocity of Motor Nerves (Peroneal and Tibial) [12 weeks] | Assessment of Balance by Berg Balance Scale [12 weeks] | Serum Fasting Blood Glucose [12 weeks] | Serum Total Cholesterol [12 weeks] | Serum Triglycerides [12 weeks] | Serum High Density Lipoproteins (HDL) [12 weeks] | Serum Low Density Lipoproteins [12 weeks] | Serum HbA1c concentration [12 weeks]","BACKGROUND:31685799; BACKGROUND:30796126; BACKGROUND:29650080; BACKGROUND:29709457; BACKGROUND:30785930; BACKGROUND:28055075; BACKGROUND:29606547; BACKGROUND:31555652; BACKGROUND:31688298; BACKGROUND:30783405; BACKGROUND:27660695",null,"NO",null],["NCT07056595","Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial",null,"RECRUITING","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","30","IgA Nephropathy (IgAN)","DRUG:Finerenone","Botkin Hospital","2025-05-21","2026-05-21","FALSE","Median change in albuminuria from baseline [6 months]",null,null,null,null],["NCT04162067","The Current Health Status of Patients Living With Type 1 Diabetes From the LMC Diabetes Patient Registry",null,"COMPLETED","OBSERVATIONAL",null,null,null,"3600","Type1diabetes",null,"LMC Diabetes & Endocrinology Ltd.","2020-01-06","2020-01-20","FALSE","HbA1c [1 day]","DERIVED:32667835",null,"NO",null],["NCT07576777","Hormonal and Microbiota Modulation After Endoscopic Sleeve Gastroplasty","HOVIGAMI-ESG","NOT_YET_RECRUITING","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","40","Obesity (Disorder); Metabolic Disorders","PROCEDURE:Laparoscopic sleeve gastrectomy; PROCEDURE:Endoscopic sleeve gastroplasty","Assistance Publique - Hôpitaux de Paris","2026-05-04","2028-12-04","FALSE","Gastric emptying evolution after endoscopic sleeve gastroplasty versus surgical sleeve [Baseline to 12 months post-intervention]",null,null,"NO",null],["NCT05463705","Addressing Diffusion of Responsibility and Prescribing Burden to Improve Use of Diabetes Medications",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","1580","Diabetes; SGLT-2i and GLP-1RA Therapies; Diffusion of Responsibility; Prescribing Burden","BEHAVIORAL:Intervention to address diffusion of responsibility; BEHAVIORAL:Intervention to address diffusion of responsibility + simplification of prescribing","Brigham and Women's Hospital","2023-05-04","2023-11-22","TRUE","Number of Participants With Prescriptions for SGLT-2i or GLP-1RA Medications Among Eligible Patients in Each Arm [Beginning 3 days before the targeted visit and continuing through 28 days after the visit]","DERIVED:39986337","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/05/NCT05463705/Prot_SAP_000.pdf","NO","NIH:5P30AG064199-02"],["NCT01405261","Trial Investigating the Safety of NNC 0113-0987 in Healthy Male Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","101","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:oral NNC 0113-0987; DRUG:I.v. NNC 0113-0987; DRUG:oral placebo","Novo Nordisk A/S","2011-08","2012-05","FALSE","Overview of Treatment Emergent Adverse Events (AEs) [Up to 25 days after trial product administration]",null,null,null,"OTHER:U1111-1119-1560; EUDRACT_NUMBER:2011-000297-57"],["NCT07744360","A Pilot Study Evaluating the Impact of a Prebiotic Soda on Gastrointestinal Symptoms in Users of GLP-1 Agonists",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","80","GI Symptoms","OTHER:Prebiotic Soda","Olipop, PBC","2026-02-10","2026-05-04","FALSE","Evaluate the impact of a prebiotic soda on gastrointestinal (GI) symptoms in users of GLP-1 agonists [Baseline, week 1, week 2, and week 4]",null,null,"NO",null],["NCT07348718","Rubix LS Diabetic Kidney Disease (DKD) Registry Study",null,"ACTIVE_NOT_RECRUITING","OBSERVATIONAL",null,null,null,"2000","Diabetic Kidney Disease (DKD)","DRUG:Kidney-Protective Therapies Used in Routine Care","Rubix LS","2025-12-15","2026-03-31","FALSE","Annualized Estimated Glomerular Filtration Rate (eGFR) Slope [24 months]",null,null,"UNDECIDED",null],["NCT02446834","Research of Intensive Lifestyle Intervention for PCOS Patients With IGT",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","40","Polycystic Ovary Syndrome","BEHAVIORAL:intensive lifestyle intervention; DRUG:GLP-1 Receptor Agonists; DRUG:Metformin; DRUG:Acarbose","RenJi Hospital","2015-04","2017-12","FALSE","changes of Islet β-cell functions from baseline [up to 12 weeks]",null,null,"UNDECIDED",null],["NCT07747857","A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","72","Type 2 Diabetes Mellitus Combined With Overweight or Obesity","DRUG:TQF3250 capsules; DRUG:TQF3250 placebo","Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","2026-08-25","2027-06","FALSE","Adverse Event [Baseline up to 14 weeks] | Abnormal clinical examination findings [Baseline up to 14 weeks]",null,null,null,null],["NCT07736729","Continuous Wearable Biometric Monitoring in Adults Undergoing Obesity Treatment (SMART-BMI)","SMART-BMI","NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","260","Obesity","BEHAVIORAL:Biometric-informed care; BEHAVIORAL:Control Arm: Standard Care","Jeff Reeves","2026-08-17","2030-12-30","FALSE","Percent Total Body Weight Loss (%TBWL) [52 weeks]","BACKGROUND:29569016; BACKGROUND:32706685; BACKGROUND:38219269; BACKGROUND:35092872; BACKGROUND:40179387; BACKGROUND:33921697; BACKGROUND:32870301; BACKGROUND:39160334; BACKGROUND:34283229; BACKGROUND:27654602",null,"YES","OTHER:#814666"],["NCT07087431","Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health","PROACT 3","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","500","Coronary Artery Disease","BEHAVIORAL:Immediate disclosure of CAD PRS results; BEHAVIORAL:Deferred Disclosure of CAD PRS results","Massachusetts General Hospital","2025-10-15","2026-10-15","FALSE","Change in low-density lipoprotein cholesterol (LDL-C) from baseline to 12 months [12 months]",null,null,"YES","NIH:R01HL164629"],["NCT01033500","Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients",null,"WITHDRAWN","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","0","Islets of Langerhans Transplantation; Diabetes Mellitus, Type 1; Kidney Transplantation","DRUG:Belatacept","University of Wisconsin, Madison","2010-07","2012-12","FALSE","Achieve and consistently maintain insulin independence in simultaneous islet-kidney transplant recipients for one year. [1 year]",null,null,null,null],["NCT04709263","Heart Failure Patients Registry","Priority-HF","COMPLETED","OBSERVATIONAL",null,null,null,"19990","Heart Failure",null,"AstraZeneca","2020-12-21","2024-03-28","FALSE","Mean age [Baseline] | Proportion of men and women [Baseline] | Proportion of patients with negative lifestyle factors [Baseline] | Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different etiology of CHF [Baseline] | Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with a history of HF comorbidities and conditions of special interest [Baseline] | Mean duration of comorbidities listed in previous paragraph (p. 5) (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) [Baseline] | Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different chronic comorbidities [Baseline] | Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with history of COVID-19 [Baseline] | Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with vaccination [Baseline] | Proportion of patients with different types of HF based on LVEF [Baseline] | Proportion of patients with T2DM comorbid with different types of HF based on LVEF [Baseline] | Mean HbA1c (for patients with T2DM) (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF); [Baseline] | Proportions of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different levels of HbA1c (for patients with T2DM) [Baseline] | Mean BMI (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) [Baseline] | Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different BMI levels [Baseline] | Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different functional classes of CHF according to NYHA classification based on patient symptoms of HF [Baseline] | Mean NT-proBNP level (or BNP) [Baseline] | Mean heart rate (HR) (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF); [Baseline] | Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different functional classes of HF according to SHOKS level [Baseline] | Mean SBP (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) [Baseline] | Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with SBP [Baseline] | Mean Diastolic blood pressure (DBP) (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) [Baseline] | Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with DBP [Baseline] | Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with concomitant CKD of different stages [Baseline] | Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with CKD and different levels of albumin-to-creatinine ratio in a spot urine sample [Baseline] | Proportion of patients (in total sample, in subgroups of patients with HFrEF, HFmEF and HFpEF, in sub-subgroups of patients with CKD and without CKD) with concomitant hyperkalemia (K+ level >5,5 mmol/L) [Baseline] | Proportion of patients (in total sample, in subgroups of patients with HFrEF, HFmEF and HFpEF, in sub-subgroups of patients with CKD and without CKD) with concomitant hypokalemia (K+ level <3,5 mmol/L) [Baseline] | Mean LVEF (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) [Baseline] | Mean K+ level (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) [Baseline] | Mean Na+ level (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) [Baseline] | Mean hemoglobin level (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) [Baseline] | Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different rhythm [Baseline] | Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different QRS duration [Baseline] | Proportion of patients receiving different classes of drugs for treatment of HF [Baseline] | Proportion of patients with HFrEF with implantable devices [Baseline] | Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with cardiac surgery and endovascular procedures [Baseline] | Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) receiving dual disease-modifying therapy [Baseline] | Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) receiving triple disease-modifying therapy [Baseline] | Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) receiving quadruple disease-modifying therapy [Baseline] | Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with CHF receiving different classes of glucose lowering drugs and their combinations for T2DM treatment [Baseline]",null,null,"YES",null],["NCT02094521","Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","122","Diabetes; Healthy","DRUG:NNC0113-0987","Novo Nordisk A/S","2014-03","2014-07","FALSE","Area under the NNC0113-0987 plasma concentration time curve [From time 0 to 24 hours after the 10th dosing]",null,null,null,"EUDRACT_NUMBER:2012-003855-13; OTHER:U1111-1133-7097"],["NCT06944353","Improving Diagnostic Safety Through STeatosis Identification, Risk Stratification, and Referral in the ED","STIRRED","ENROLLING_BY_INVITATION","INTERVENTIONAL",null,"RANDOMIZED","NONE","4704","Non-Alcoholic Fatty Liver Disease; Steatosis of Liver; Metabolic Dysfunction-Associated Steatotic Liver Disease","BEHAVIORAL:STIRRED","Northwestern University","2025-12-04","2027-01","FALSE","Effectiveness: New steatotic liver disease-related diagnosis among high-risk patients [120 days post-ED discharge] | Implementation: Intervention fidelity [Baseline at time of intervention delivery]","DERIVED:41407098",null,"YES","AHRQ:R01HS029777"],["NCT05161793","Telemedicine Continuous Remote Monitoring of Adults With Uncontrolled Diabetes Mellitus","TELEMTRRDM","COMPLETED","OBSERVATIONAL",null,null,null,"200","Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2","DEVICE:Tele-Monitor DM","University of Southern California","2022-05-01","2025-05-31","FALSE","CGM - Tele-monitoring effects on HbA1c [12-months]",null,null,"NO",null],["NCT07642921","HFpEF Phenotyping With Echo, Clinical, and Biomarkers","The EPIC-HFpEF","NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"500","Heart Failure With Preserved Ejection Fraction (HFPEF)",null,"University Of Perugia","2026-06-02","2027-06-30","FALSE","Prevalence of HFpEF phenotypes [At Baseline]","BACKGROUND:28434933; BACKGROUND:36917048; BACKGROUND:37137593; BACKGROUND:35363499; BACKGROUND:37622666",null,"NO",null],["NCT05526157","An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice","FINEGUST","COMPLETED","OBSERVATIONAL",null,null,null,"50000","Chronic Kidney Disease; Type 2 Diabetes Mellitus","DRUG:Finerenone (Kerendia, BAY 948862); DRUG:Sodium-glucose cotransporter 2 inhibitors (SGLT2i); DRUG:Glucagon-like peptide-1 receptor agonists (GLP 1 RA); DRUG:Steroidal mineral corticoid receptor antagonists (sMRA); DRUG:Non-steroidal mineral corticoid receptor antagonists (nsMRA)","Bayer","2022-10-01","2024-09-05","FALSE","Descriptive summary of baseline patient characteristics [Baseline study periods I and II] | Descriptive summary of patient comorbidities [Baseline study periods I and II] | Descriptive summary of patient comedications [Baseline study periods I and II]","DERIVED:41364416",null,"NO",null],["NCT04802395","Real World Evidence Clinical Utility Study of KidneyIntelX",null,"RECRUITING","OBSERVATIONAL",null,null,null,"10000","Chronic Kidney Diseases; Diabetic Kidney Disease","DIAGNOSTIC_TEST:KidneyIntelX","Renalytix AI, Inc.","2021-03-02","2026-12-01","FALSE","Referrals [6 Months] | Statins and or ACEi/ARB [6 Months] | HbA1c [6 Months] | SGLT2/ GLP1 [6 Months]",null,null,"UNDECIDED",null],["NCT07646457","Comparative Effectiveness of Western Pharmacotherapy Versus Integrative Western and Traditional Chinese Medicine for Weight Management in Central Taiwan: A Real-World Cohort Study",null,"ACTIVE_NOT_RECRUITING","OBSERVATIONAL",null,null,null,"296","Obesity & Overweight",null,"National Yang Ming Chiao Tung University","2026-04-01","2026-04-28","FALSE","Percentage change in body weight associated with Chinese herbal medicine use [From baseline to end of follow-up (up to 14 months)]",null,null,"NO",null],["NCT07605390","RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)",null,"NOT_YET_RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","600","Chronic Kidney Disease; Type 2 Diabetes","OTHER:Epic-Based Clinician Notification; OTHER:Usual Care","Baylor Research Institute","2026-08","2028-01","FALSE","Initiation of Guideline-Directed Cardio-Kidney Metabolic Therapy [3 months] | Therapy-Specific Initiation Rate [3 months]",null,null,"YES",null],["NCT07676565","Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study","ATT1D","RECRUITING","OBSERVATIONAL",null,null,null,"300","Type 1 Diabetes",null,"Indiana University","2026-03-24","2028-04","FALSE","Change in HbA1c by type of therapy [1 year]",null,null,"UNDECIDED","OTHER_GRANT:ATT1D"],["NCT07104461","Advanced Protein-based Program for Effective Treatment of Appetite Regulation and Obesity","APPETITE","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","12","Appetite and General Nutritional Disorders","OTHER:Oat porridge; DIETARY_SUPPLEMENT:Whey protein isolate; DIETARY_SUPPLEMENT:Potato protein isolate; DIETARY_SUPPLEMENT:Meal replacement shake","University of Westminster","2023-06-09","2024-10-31","FALSE","To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate and meal replacement shake on glucose levels (T30) [Glucose measured 30 minutes post meal consumption] | To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on glucose levels (T60) [Glucose measured 60 minutes post meal consumption] | To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on glucose levels (T120) [Glucose measured 120 minutes post meal consumption] | To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on glucose levels (T180) [Glucose measured 180 minutes post meal consumption] | To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on insulin levels (T30) [Insulin measured 30 minutes post meal consumption] | To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on insulin levels (T60) [Insulin measured 160 minutes post meal consumption] | To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on insulin levels (T120) [Insulin measured 120 minutes post meal consumption] | To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on insulin levels (T180) [Insulin measured 180 minutes post meal consumption] | To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on glucagon-like peptide 1 levels (T30) [Glucagon-like peptide 1 measured 30 minutes post meal consumption] | To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on glucagon-like peptide 1 levels (T60) [Glucagon-like peptide 1 measured 60 minutes post meal consumption] | To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on glucagon-like peptide 1 levels (T120) [Glucagon-like peptide 1 measured 120 minutes post meal consumption] | To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on glucagon-like peptide 1 levels (T180) [Glucagon-like peptide 1 measured 180 minutes post meal consumption] | To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on gastric inhibitory polypeptide (T30) [Gastric inhibitory polypeptide measured 30 minutes post meal consumption] | To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on gastric inhibitory polypeptide (T60) [Gastric inhibitory polypeptide measured 60 minutes post meal consumption] | To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on gastric inhibitory polypeptide (T120) [Gastric inhibitory polypeptide measured 120 minutes post meal consumption] | To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on gastric inhibitory polypeptide (T180) [Gastric inhibitory polypeptide measured 180 minutes post meal consumption] | To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on peptide tyrosine tyrosine levels (T30) [Peptide tyrosine tyrosine measured 30 minutes post meal consumption] | To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on peptide tyrosine tyrosine levels (T60) Markers: peptide tyrosine tyrosine (pmol/L) [Peptide tyrosine tyrosine measured 60 minutes post meal consumption] | To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on peptide tyrosine tyrosine levels (T120) [Peptide tyrosine tyrosine measured 120 minutes post meal consumption] | To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on peptide tyrosine tyrosine levels (T180) [Peptide tyrosine tyrosine measured 180 minutes post meal consumption] | To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on ghrelin levels (T30) [Ghrelin measured 30 minutes post meal consumption] | To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on ghrelin levels (T60) [Ghrelin measured 60 minutes post meal consumption] | To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on ghrelin levels (T120) [Ghrelin measured 120 minutes post meal consumption] | To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on ghrelin levels (T180) [Ghrelin measured 180 minutes post meal consumption] | To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on appetite (T30) [Visual Analogue Scale for Appetite (VAS-A) collected 30 minutes after meal consumption] | To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on appetite (T60) [Visual Analogue Scale for Appetite (VAS-A) collected 60 minutes after meal consumption] | To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on appetite (T120) [Visual Analogue Scale for Appetite (VAS-A) collected 120 minutes after meal consumption] | To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on appetite (T180) [Visual Analogue Scale for Appetite (VAS-A) collected 180 minutes after meal consumption]","BACKGROUND:32175717; BACKGROUND:39605914; BACKGROUND:32292920; BACKGROUND:28244632; BACKGROUND:26884639; BACKGROUND:22510792; BACKGROUND:39547251",null,"NO",null],["NCT03430284","Multifactorial Intervention on Diabetes (MIDiab Study)",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","6300","Diabetes Mellitus, Type 2","BEHAVIORAL:Lifestyle therapy; DRUG:Pharmacotherapy; OTHER:Monitoring and management; OTHER:General treatment","Shandong Provincial Hospital","2018-04-01","2021-12-31","FALSE","Integrated management rate of multiple risk factor in type 2 diabetes [30 months] | Incidence of diabetic vascular complications [30 months] | Control rate of diabetes and diabetic vascular complications [30 months]",null,null,null,null],["NCT07743567","Gestational Response, Outcomes, and Weight After GLP-1 Use","GROW","RECRUITING","OBSERVATIONAL",null,null,null,"400","Pregnant Individuals; Obesity & Overweight; Gestational Weight Gain",null,"University of Kansas Medical Center","2026-04-13","2028-04","FALSE","Gestational weight gain [From the start of pregnancy to delivery.]","BACKGROUND:38787563; BACKGROUND:41284263",null,"NO",null],["NCT02738151","Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist","BRIGHT","COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","929","Diabetes Mellitus, Type 2","DRUG:Insulin glargine, 300U/mL; DRUG:Insulin degludec, 100 U/mL; DRUG:Non-insulin anti-diabetic treatment","Sanofi","2016-05-19","2017-08-15","TRUE","Change From Baseline in HbA1c to Week 24 [Baseline, Week 24]","DERIVED:30104294","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/51/NCT02738151/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/51/NCT02738151/SAP_001.pdf",null,"EUDRACT_NUMBER:2015-005101-36; OTHER:U1111-1177-6327; NIH:2015"],["NCT07625202","Creatine Supplementation During GLP-1a Therapy",null,"RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","QUADRUPLE","40","Sarcopenia","DIETARY_SUPPLEMENT:Dietary supplementation during a 12 week resistance-training program (creatine); DIETARY_SUPPLEMENT:Dietary supplementation during a 12 week resistance-training program (placebo)","University of Saskatchewan","2026-05-25","2027-05-30","FALSE","Change in sit to stand performance (number of times) [12 weeks]",null,null,"NO",null],["NCT05875636","GLP-1 Receptor Agonist Use and Incidence of Retained Gastric Food on Endoscopy",null,"COMPLETED","OBSERVATIONAL",null,null,null,"260","Gastric Content Aspiration","OTHER:Esophagogastroduodenoscopy","Medical University of South Carolina","2023-08-21","2024-08-23","FALSE","Retained gastric food [From time of enrollment until the end of surgery, assessed up to 4 weeks]",null,null,null,null],["NCT04931030","Low Carbohydrate Diet in Diabetic Kidney Disease",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","30","Type 2 Diabetes Mellitus; Diabetic Kidney Disease; Obesity","OTHER:Dietary advice","Universiti Teknologi Mara","2019-03-15","2021-03-05","FALSE","Change from baseline serum Creatinine at 12 weeks [Study end at 12 weeks] | Change from baseline urine microalbuminuria at 12 weeks [Study end at 12 weeks]","BACKGROUND:23760287","Study Protocol, Statistical Analysis Plan, and Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/30/NCT04931030/Prot_SAP_ICF_000.pdf","YES",null],["NCT05214573","Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk",null,"COMPLETED","OBSERVATIONAL",null,null,null,"386301","Type 2 Diabetes; Cardiac Disease","DRUG:Glucagon like peptide 1 receptor agonist; DRUG:Sodium-glucose cotransporter 2 inhibitor; DRUG:Dipeptidyl Peptidase 4 Inhibitor; DRUG:Sulfonylurea","Mayo Clinic","2021-12-01","2023-09-30","TRUE","3-point Major Adverse Cardiovascular Event (MACE) [Retrospective Data between 1/1/2014 - 12/31/2022, up to 8 years, collected over a 2-year period] | Expanded Major Adverse Cardiovascular Events (MACE) and Its Components [Retrospective Data between 1/1/2014 - 12/31/2022, up to 8 years, collected over a 2-year period] | Patient Preferences for Second-line Type 2 Diabetes Medication Treatment Outcomes [1 hour]","DERIVED:42167878; DERIVED:39847346; DERIVED:39729347; DERIVED:38846711","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/73/NCT05214573/Prot_SAP_000.pdf",null,null],["NCT04788836","How Altered Gut-Brain-Axis Influences Food Choices: Part 2 (BrainFood)","BrainFood","COMPLETED","OBSERVATIONAL",null,null,null,"61","Food Preferences; Obesity","OTHER:Questionnaire (Survey and Food Frequency Questionnaire (FFQ)); OTHER:Collection of digital receipts from grocery shopping","Lia Bally","2021-11-01","2025-12-31","FALSE","Changes in food purchase behaviour on the basis of the Healthy Trolley Index (HETI) [Pre-treatment until 5 years after start of obesity treatment] | Changes in food purchase behaviour on the basis of the Grocery Purchase Quality Index (GPQI) [Pre-treatment until 5 years after start of obesity treatment] | Changes in food purchase behaviour on the basis of food groups [Pre-treatment until 5 years after start of obesity treatment] | Changes in food purchase behaviour on the basis of nutrition facts [Pre-treatment until 5 years after start of obesity treatment] | Changes in food purchase behaviour on the basis of the Nutri-Score [Pre-treatment until 5 years after start of obesity treatment] | Food purchase behaviour on the basis of the Healthy Trolley Index (HETI) [Pre-treatment until 5 years after start of obesity treatment] | Food purchase behaviour on the basis of the Grocery Purchase Quality Index (GPQI) [Pre-treatment until 5 years after start of obesity treatment] | Food purchase behaviour on the basis of food groups [Pre-treatment until 5 years after start of obesity treatment] | Food purchase behaviour on the basis of nutrition facts [Pre-treatment until 5 years after start of obesity treatment] | Food purchase behaviour on the basis of the Nutri-Score [Pre-treatment until 5 years after start of obesity treatment]",null,null,"UNDECIDED",null],["NCT05890807","Concordance in Diagnosis of Periodontitis in Diabetic Patients Between an Indirect Method Based on a Photograph of the Oral Cavity and a Direct Method Based on the Clinical Examination of This Oral Cavity (Reference).","PARODIABNOSTIC","COMPLETED","INTERVENTIONAL",null,null,"NONE","145","Diabetes Complications; Periodontal Diseases","DIAGNOSTIC_TEST:Front view photography of the patient's oral cavity with the help of a smartphone in the diabetology department.","Centre Hospitalier Universitaire de Nīmes","2023-03-20","2024-02-29","FALSE","Parodontitis based on a photograph of the patient's oral cavity (indirect method) [Day 0 to day 7] | Parodontitis based on clinical observation of the patient's oral cavity (direct method) [Day 0]",null,null,null,null],["NCT07713901","Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma",null,"ENROLLING_BY_INVITATION","OBSERVATIONAL",null,null,null,"93600000","Medullary Thyroid Carcinoma","OTHER:No treatment given","Novo Nordisk A/S","2025-12-31","2026-12-31","FALSE","Time to first occurence of Medullary Thyroid Carcinoma (MTC) [From day 1 up to 15 years]",null,null,"NO","OTHER:U1111-1341-5652"],["NCT07027995","Food and Fitness With Medicine (FFWM)","FFWM","RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","NONE","200","Cardiovascular Kidney Metabolic Syndrome; Type 2 Diabetes","BEHAVIORAL:Exercise is Medicine (EIM); BEHAVIORAL:Culinary Education; BEHAVIORAL:Food is Medicine; BEHAVIORAL:Nutrition Counseling; BEHAVIORAL:Participant Website","Ohio State University","2026-01-14","2028-11","FALSE","GLP-1 RA discontinuation rates [0, 12, and 24 weeks]",null,null,"NO",null],["NCT03222245","The Effect of Injectable Therapies on Quality of Life in Diabetes",null,"COMPLETED","OBSERVATIONAL",null,null,null,"256","Diabetes",null,"Portsmouth Hospitals NHS Trust","2017-06-30","2022-09-01","FALSE","Change in quality of life [26 weeks]",null,null,"NO",null],["NCT07316816","Stanford Pediatric Healthy Weight Index",null,"RECRUITING","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","120","Obesity & Overweight","OTHER:Remote Monitoring Program","Stanford University","2026-01-05","2030-12","FALSE","Percent Reduction in BMI [baseline through study completion, an average of 4 months] | Body Weight [baseline through study completion, an average of 4 months] | Fasting Glucose [baseline through study completion, an average of 4 months] | Fasting Insulin [baseline through study completion, an average of 4 months] | HbA1c [baseline through study completion, an average of 4 months] | Lipid Panel [baseline through study completion, an average of 4 months] | Liver Enzymes [baseline through study completion, an average of 4 months]",null,null,"NO",null],["NCT06105931","Physiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes",null,"ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE1",null,"NONE","15","type1diabetes; Obesity","BIOLOGICAL:Hyperinsulinemic-euglycemic clamp; OTHER:High Fat Mixed Meal Tolerance Test","Yale University","2023-12-13","2027-08","FALSE","Change in VAT/(VAT+SAT) from baseline to 1 year [baseline and 1 year] | Change in hepatic insulin resistance from baseline to 1 year [baseline and 1 year] | Change in triglycerides from baseline to 1 year [baseline and 1 year]",null,null,"NO","NIH:1R01DK134398-01A1"],["NCT07437911","A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Supplement on Nutrient Gaps and Gut Health Among Individuals Utilizing GLP-1 RAs",null,"RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","TRIPLE","120","Nutrition Intake; Nutrition Status; Gastrointestinal Microbiome; GLP-1","DIETARY_SUPPLEMENT:AG1 - Nutritional Supplement; DIETARY_SUPPLEMENT:Placebo","Athletic Greens International","2026-02","2026-08","FALSE","Nutrient Gaps [90 days]",null,null,null,null],["NCT07269821","Evaluation of a Nutritional Intervention With Dietary Supplements in People Who Have Recently Lost Weight: Effects on Body Composition, Emotional Health, and Gut Microbiota",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","70","GLP-1; Weight Loss Trajectory; Emotional Disorder; Microbiota Balance","DIETARY_SUPPLEMENT:Metabolaid®-based nutraceutical formulation; DIETARY_SUPPLEMENT:Placebo capsules","University of Alicante","2025-07-01","2025-10-31","FALSE","Change in Fat Mass (%) [Baseline and Week 12]",null,null,null,null],["NCT07283978","Real-world Exploration of Digital iNnovation in the Management of Excess Weight","RENEW","ENROLLING_BY_INVITATION","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","580","Obesity; Obesity & Overweight","OTHER:Digital Weight Management Programme","Guy's and St Thomas' NHS Foundation Trust","2025-12-16","2027-11","FALSE","Percentage of weight change at 12 months [Baseline and 12 months] | Quality of Life as a measure to determine cost-effectiveness [Baseline and 12 months]",null,null,"UNDECIDED",null],["NCT06355219","Macrovascular and Microvascular Morbidity and Mortality After Metabolic Surgery Versus Medicines","M6","COMPLETED","OBSERVATIONAL",null,null,null,"3932","Type 2 Diabetes Mellitus; Obesity; Microvascular Disease; Macrovascular Disease; Major Adverse Cardiovascular Events; Nephropathy; Retinopathy; Heart Failure; All Cause Mortality",null,"Ali Aminian","2010-01-01","2022-12-31","FALSE","All-cause Mortality Rate [After surgical or assigned index date to Dec 31, 2022]",null,null,"NO",null],["NCT07636395","Eating Behaviour Before, During, and After Obesity Medication",null,"RECRUITING","OBSERVATIONAL",null,null,null,"30","Obesity Type 2 Diabetes Mellitus; Obesity & Overweight",null,"University College Dublin","2026-05-25","2026-08-25","FALSE","Change in Total Score on the Eating Behavior Patient-Reported Outcomes in Obesity Management Questionnaire [30 months]",null,null,null,null],["NCT07736963","Discontinuation Recommendations for GLP-1 Receptor Agonists Prior to Colonoscopy",null,"RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","240","GLP-1","BEHAVIORAL:GLP-1 not stop for 1 week; BEHAVIORAL:GLP-1 stop for 1 week","Fu Jen Catholic University Hospital","2026-06-01","2027-06-01","FALSE",".Incomplete bowel preparation rate(IBP) through BBPS(Boston Bowel Preparation Scale) [\"From enrollment to the end of Procedure and follow up for 30 days\"]",null,null,"NO",null],["NCT06593704","Proactive Population Health Management of Cardiovascular Disease in Primary Care Using the PROSPERA-program.","PROSPERA","ENROLLING_BY_INVITATION","INTERVENTIONAL",null,"RANDOMIZED","NONE","848","Cardiovascular Diseases","OTHER:PROSPERA-program","Leiden University Medical Center","2025-02-17","2026-10-01","FALSE","The proportion of individuals who have achieved all protocol-defined cardiovascular prevention goals. [At 0 and 18 months]",null,null,"NO","OTHER_GRANT:10140302110018"],["NCT06182852","The Effect of GLP-1 Receptor Agonist on Bone Metabolism in Patients With Diabetes Mellitus",null,"UNKNOWN","OBSERVATIONAL",null,null,null,"330","Diabete Type 2; Bone Metabolism",null,"Nanjing First Hospital, Nanjing Medical University","2024-01-01","2024-12-31","FALSE","Bone metabolism [3、6、9、12month] | Bone mineral density [6、12month] | HbA1c [0、3、6、9、12month]",null,null,null,null],["NCT06927973","Leveraging Exercise Stress Echocardiography for Heart Failure With Preserved Ejection Fraction",null,"COMPLETED","INTERVENTIONAL",null,null,"NONE","30","Chest Pain; Shortness of Breath","DIAGNOSTIC_TEST:Echocardiogram","Duke University","2025-05-30","2025-12-19","FALSE","HFpEF clinic visit at 1 month and 6 months [Within 6 months of participant enrollment] | Confirmed HFpEF diagnosis at 1 month and 6 months [Within 6 months of participant enrollment] | Estimate the prevalence of undiagnosed HFpEF in patients undergoing exercise stress echo using HFpEF probability score and exercise echo filling pressure assessment [Within 6 months of participant enrollment]",null,null,"NO",null],["NCT03566693","Type 2 Diabetes (T2D) Basal Insulin Users: The Mobile Study (MOBILE)","MOBILE","COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","176","Diabetes Mellitus, Type 2","DEVICE:Dexcom G6 CGM System; DEVICE:Blood glucose meter","DexCom, Inc.","2018-07-30","2021-01-04","FALSE","Phase 1: Change in HbA1c [Baseline to Month 8] | Phase 2: Change in CGM time in target range [Month 8 to Month 14]","DERIVED:41192933; DERIVED:34962151; DERIVED:34704817; DERIVED:34588210; DERIVED:34077499",null,"NO",null],["NCT06666049","Gastric POCUS for Airway Management in Patients Using Glucagon-like Peptide-1 Receptor Agonist (Multicentric)","POCUS","RECRUITING","OBSERVATIONAL",null,null,null,"39","Aspiration Pneumonia","DIAGNOSTIC_TEST:Gastric Ultrasound","Clinica Universidad de Navarra, Universidad de Navarra","2024-10-21","2026-11-01","FALSE","Gastric Ultrasound [Immediately prior to induction of anesthesia]",null,null,null,null],["NCT07818226","Effects of GLP-1 Receptor Agonists on Saliva and Oral Health",null,"NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"50","Type 2 Diabetes; Obesity & Overweight; Xerostomia; Dental Caries","DRUG:GLP-1 Receptor Agonists","Kırıkkale University","2026-10-16","2027-07-16","FALSE","Change in Unstimulated Salivary Flow Rate [Baseline (Month 0), Month 3, and Month 6]",null,null,"NO","OTHER_GRANT:2026/142"],["NCT02589626","Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA",null,"COMPLETED","INTERVENTIONAL","PHASE4","RANDOMIZED","DOUBLE","65","Diabetes Mellitus, Type 2","DRUG:empagliflozin 10mg; DRUG:empagliflozin 25 mg; DRUG:Placebo","Boehringer Ingelheim","2015-10-29","2017-06-02","TRUE","Percentage of Patients With Drug-related Adverse Events (AEs) During 52 Weeks of Treatment [52 weeks]","DERIVED:30912033","Study Protocol|https://cdn.clinicaltrials.gov/large-docs/26/NCT02589626/Prot_000.pdf; Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/26/NCT02589626/SAP_001.pdf",null,null],["NCT02291874","Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)",null,"COMPLETED","INTERVENTIONAL","PHASE4",null,"NONE","100","Type 2 Diabetes Mellitus","DRUG:Ipragliflozin","Astellas Pharma Inc","2014-10-08","2016-07-07","FALSE","HbA1c [at 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52-week] | Fasting plasma glucose [at 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52-week]","DERIVED:29926400",null,"YES",null],["NCT06528405","The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease","ESS-AKD","RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","264","Acute Kidney Injury","DRUG:dapagliflozin; OTHER:Other anti-diabetic drug or no anti-diabetic drug; DRUG:empagliflozin; DRUG:canagliflozin","National Taiwan University Hospital","2024-11-21","2027-07","FALSE","Albuminuria [Day 28 and Day 90] | Discontinuation of SGLT2i [Day 0 to Day 90]",null,null,"UNDECIDED",null],["NCT07419854","Restoring Facial Volume After GLP-1 Weight Loss With Radiesse",null,"RECRUITING","INTERVENTIONAL","PHASE4","RANDOMIZED","SINGLE","48","Volume Loss (Soft Tissue Ptosis or Atrophy )","DEVICE:Hyperdiluted Calcium Hydroxylapatite; DEVICE:Calcium hydroxylapatite; DEVICE:Calcium hydroxylapatite with integral lidocaine","Kalpna Kay Durairaj, MD, FACS","2026-02-01","2027-08","FALSE","Change in Cheek Volume, as quantified by Quantificare's LifeViz Software [Up to 6 months] | Change in Jowl Volume, as quantified by Quantificare's LifeViz Software [Up to 6 months] | Change in Nasolabial Fold Depth, as quantified by Quantificare's LifeViz Software [Up to 6 months] | Change in Marionette Line Depth, as quantified by Quantificare's LifeViz Software [Up to 6 months] | Body Mass Index (BMI) [Up to 12 months] | Global Aesthetic Improvement Scale (GAIS) for Global Facial Aesthetic Appearance [Up to 6 months] | Global Aesthetic Improvement Scale (GAIS) for Skin Quality [Up to 6 months] | Global Aesthetic Improvement Scale (GAIS) for Skin Radiance [Up to 6 months]","BACKGROUND:28831339; BACKGROUND:28095536; BACKGROUND:20480786; BACKGROUND:30893178; BACKGROUND:16020207; BACKGROUND:28247924; BACKGROUND:20442101; BACKGROUND:30038511; BACKGROUND:26056483; BACKGROUND:24301235; BACKGROUND:34192299; BACKGROUND:26505542; BACKGROUND:28562435; BACKGROUND:18547186; BACKGROUND:16936543; BACKGROUND:25610523; BACKGROUND:30358631; BACKGROUND:31044123",null,"YES",null],["NCT05694741","A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186",null,"TERMINATED","INTERVENTIONAL","PHASE1","RANDOMIZED","DOUBLE","31","Type 2 Diabetes","DRUG:AZD0186; DRUG:Placebo","AstraZeneca","2022-12-20","2023-05-10","FALSE","Adverse Events (AEs), and Serious Adverse Events (SAEs) [Up to the Follow-up Visit (approximately 6 weeks)]",null,null,"YES",null],["NCT01503112","Predicting Response to Incretin Based Agents in Type 2 Diabetes","PRIBA","COMPLETED","OBSERVATIONAL",null,null,null,"957","Type2 Diabetes","OTHER:No intervention, observational study","Royal Devon and Exeter NHS Foundation Trust","2011-05","2014-04","FALSE","Glycaemic response (HbA1c change post treatment) [6 months]","RESULT:26242184; RESULT:29386249; RESULT:25340784",null,null,null],["NCT06317051","Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)","OPTIMAR","ACTIVE_NOT_RECRUITING","INTERVENTIONAL","PHASE3","RANDOMIZED","TRIPLE","300","HIV Infections; Weight Gain","DRUG:Dapagliflozin 10mg Tab; DRUG:Pitavastatin 4 Mg Oral Tablet; DRUG:Rosuvastatin and Ezetimibe; DRUG:Placebo","Kirby Institute","2024-12-16","2026-07","FALSE","To assess the impact of dapagliflozin vs. placebo on weight reduction [24 weeks] | To assess the impact of pitavastatin vs. rosuvastatin/ezetimibe on low-density lipoproteins (LDL) concentration [24 weeks]","DERIVED:42050587",null,null,null],["NCT07175805","Pelvic Floor Disorder Symptoms in Women Seeking Weight Loss Therapy",null,"NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"200","Lower Urinary Tract Symptoms; Stress Urinary Incontinence; Urge Urinary Incontinence; Overactive Bladder; Pelvic Organ Prolapse; Weight Loss; Fecal Incontinence; Bariatric Surgery; glp1 Agonist","PROCEDURE:Bariatric Surgery; DRUG:GLP1 receptor agonist","Hartford HealthCare","2025-10","2026-10","FALSE","Change in pelvic floor symptoms measured by survey the Urogenital Distress Inventory (UDI) [6 months] | Change in pelvic floor symptoms measured by validated survey the Colorectal-Anal Distress Inventory (CRADI-8). [6 months]",null,null,"NO",null],["NCT07387003","Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes",null,"NOT_YET_RECRUITING","INTERVENTIONAL","PHASE2","RANDOMIZED","NONE","345","Type 2 Diabetes (T2DM)","DRUG:GZR101-80; DRUG:GZR33 or Insulin degludec/Insulin aspart or Insulin aspart30 (NovoRapid®30)","Gan & Lee Pharmaceuticals.","2026-04-10","2027-02-11","FALSE","Change in Hemoglobin A1c (HbA1c) from baseline after 16 weeks of treatment. [Baseline , 16 weeks]",null,null,null,null],["NCT07360262","Gastric Emptying Recovery After GLP-1 RA Cessation",null,"COMPLETED","OBSERVATIONAL",null,null,null,"186","Gastric Emptying; Gastroparesis; Preoperative Care","OTHER:Preoperative gastric ultrasound","Wonkwang University Hospital","2025-11-20","2025-12-10","FALSE","Ultrasound-estimated gastric volume (mL/kg) [Immediately preoperatively (just before induction of anesthesia)]",null,null,null,null],["NCT07628556","Antidiabetic Medications and Risk of Cancer",null,"COMPLETED","OBSERVATIONAL",null,null,null,"74799","Cancer","DRUG:Metformin; DRUG:sulphonylurea; DRUG:DPP-4 inhibitor; DRUG:GLP-1 Receptor Agonists; DRUG:SGLT-2 inhibitor; DRUG:insulin; DRUG:MET + SU; DRUG:MET + DPP-4 inhibitor; DRUG:MET + GLP-1RA; DRUG:MET + SGLT2i; DRUG:MET + INS","University of Pecs","2025-03-15","2025-12-30","FALSE","Overall cancer risk [2016-2022]",null,null,"NO",null],["NCT00432809","Advanced Medical Therapy Versus Advanced Medical Therapy Plus Bariatric Surgery for the Resolution of Type 2 Diabetes",null,"COMPLETED","INTERVENTIONAL",null,"RANDOMIZED","NONE","150","Diabetes Mellitus, Type 2; Obesity","PROCEDURE:Gastric bypass; PROCEDURE:Sleeve Gastrectomy","The Cleveland Clinic","2007-02","2016-02","TRUE","Success Rate of Biochemical Resolution of Diabetes at 12 Months as Measured by HbA1c ≤ 6%. [1 year] | Success Rate of Biochemical Resolution of Diabetes at 12 Months as Measured by HbA1c ≤ 6% With no Diabetes Medications [1 year]","BACKGROUND:16670131; BACKGROUND:14530719; BACKGROUND:17128540; BACKGROUND:9742976; BACKGROUND:9571335; BACKGROUND:12397193; BACKGROUND:7622004; BACKGROUND:12610059; DERIVED:28199805; DERIVED:24679060; DERIVED:23439632; DERIVED:22449319",null,null,null],["NCT04287387","Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents",null,"UNKNOWN","INTERVENTIONAL","PHASE4","RANDOMIZED","NONE","180","Type2 Diabetes Mellitus","DRUG:Glucophage 500Mg Tablet; DRUG:Acarbose Tablets; DRUG:Sitagliptin tablet; DRUG:Dapagliflozin Tablet; DRUG:Pioglitazone Tablets; DRUG:Glimepiride Tablets","Peking Union Medical College Hospital","2020-03-02","2021-03-02","FALSE","Changes from baseline to post-treatment in composition in gut microbiota analyzed by meta-genome sequencing. [Baseline, Week 4, Week 8, Week 12] | Changes from baseline to post-treatment in composition in fasting blood glucose. [Baseline, Week 4, Week 8, Week 12] | Changes from baseline to post-treatment in composition in level of TNF-a. [Baseline, Week 4, Week 8, Week 12] | Changes from baseline to post-treatment in composition in fasting insulin. [Baseline, Week 4, Week 8, Week 12] | Changes from baseline to post-treatment in blood lipid including cholesterol, triglycerides, high-density lipoprotein. [Baseline, Week 4, Week 8, Week 12] | Changes from baseline to post-treatment in composition in 2-hour postprandial blood glucose. [Baseline, Week 4, Week 8, Week 12] | Changes from baseline to post-treatment in composition in level of IL-6. [Baseline, Week 4, Week 8, Week 12] | Changes from baseline to post-treatment in composition in level of IL-8. [Baseline, Week 4, Week 8, Week 12] | Changes from baseline to post-treatment in composition in level of IL-10. [Baseline, Week 4, Week 8, Week 12] | Changes from baseline to post-treatment in composition in level of C-reative protein. [Baseline, Week 4, Week 8, Week 12]",null,null,"NO",null],["NCT07566299","Early GLP-1 Receptor Agonist and SGLT2 Inhibitor Add-On Strategies in Adults With Obesity, Type 2 Diabetes, Cardiovascular-Kidney-Metabolic Syndrome Stage 2-3, and Metabolic Dysfunction-Associated Steatotic Liver Disease",null,"COMPLETED","OBSERVATIONAL",null,null,null,"118805","Obesity Type 2 Diabetes Mellitus; Cardiovascular-kidney-metabolic Syndrome; Metabolic Dysfunction-Associated Steatotic Liver Disease",null,"Chung Shan Medical University","2017-01-01","2026-03-31","TRUE","All-cause Mortality (Comparison 1) [From 90 days after treatment initiation through up to 60 months of follow-up] | All-cause Mortality (Comparison 2) [From 90 days after treatment initiation through up to 60 months of follow-up] | All-cause Mortality (Comparison 3) [From 90 days after treatment initiation through up to 60 months of follow-up] | All-cause Mortality (Comparison 4) [From 90 days after treatment initiation through up to 60 months of follow-up]","BACKGROUND:26858290; BACKGROUND:21586725; BACKGROUND:20335814; BACKGROUND:21818162; BACKGROUND:36041749; BACKGROUND:36508210; BACKGROUND:26994063; BACKGROUND:30652541; BACKGROUND:37193038; BACKGROUND:35100355; BACKGROUND:39210781; BACKGROUND:38663919; BACKGROUND:33396949; BACKGROUND:38856224; BACKGROUND:40305708; BACKGROUND:33185364; BACKGROUND:36331190; BACKGROUND:32970396; BACKGROUND:30990260; BACKGROUND:38785209; BACKGROUND:33031522; BACKGROUND:31535829; BACKGROUND:26378978; BACKGROUND:34425083; BACKGROUND:37952131; BACKGROUND:27633186; BACKGROUND:27295427; BACKGROUND:28432726; BACKGROUND:31852920; BACKGROUND:31279902; BACKGROUND:36727674; BACKGROUND:37363821; BACKGROUND:37807920; BACKGROUND:37807924","Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/99/NCT07566299/Prot_SAP_000.pdf","NO",null],["NCT06953063","A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese Subjects","DA168","COMPLETED","INTERVENTIONAL","PHASE2","RANDOMIZED","QUADRUPLE","250","Overweight and Obesity","DRUG:DA-302168S; DRUG:Placebo of DA-302168S","Chendu DIAO Pharmaceutical Group CO., LTD.","2025-05-15","2025-12-15","FALSE","percentage change in body weight [From baseline (week1) to week16]",null,null,"NO",null],["NCT04621656","Sugar Challenge Study",null,"UNKNOWN","OBSERVATIONAL",null,null,null,"1022","Type 2 Diabetes; Pre-Diabetes; Healthy","COMBINATION_PRODUCT:January Mobile Application (Sugar AI)","January, Inc.","2017-11-01","2020-07-06","FALSE","Assessment of percent of total time monitored that blood glucose is in range 70-180 mg/dL [10 Continuous Days]",null,null,"YES",null],["NCT07484061","Efficacy and Safety of a Drinkable Nutraceutical for Hair Loss in Patients Using GLP-1/GIP Receptor Agonists",null,"RECRUITING","INTERVENTIONAL",null,"RANDOMIZED","DOUBLE","40","Telogen Effluvium","DIETARY_SUPPLEMENT:Drinkable multifactorial food supplement containing vitamins, minerals, amino acids, plant extracts, and other bioactive compounds, formulated to support hair growth and scalp health in women +45.; OTHER:Placebo control","Olistic Research Labs S.L.","2026-03-16","2027-05-31","FALSE","Hair loss [From baseline to Day 180.]","BACKGROUND:29167734",null,"NO",null],["NCT03635671","Diabetic Retinopathy and Subclinical Signs of Disease Transition","DIRECTION","TERMINATED","OBSERVATIONAL",null,null,null,"5","Diabetic Retinopathy","DIAGNOSTIC_TEST:Optical Coherence Tomography Angiography","University of British Columbia","2018-09-01","2019-07-15","FALSE","Perfusion density [6 months]",null,null,"NO",null],["NCT03774095","Effect of Dietary Oils as G-protein-coupled Receptor Agonists on Glucose Tolerance",null,"UNKNOWN","INTERVENTIONAL",null,"RANDOMIZED","SINGLE","10","Type 2 Diabetes Mellitus; Obesity","DIETARY_SUPPLEMENT:Hydrolyzed pine nut oil; DIETARY_SUPPLEMENT:Hydrolyzed pine nut oil and olive oil","Karina Vejrum Sørensen","2018-06-11","2018-12-30","FALSE","Glucose [6 hours] | Insulin [6 hours] | C-peptide [6 hours] | GLP-1 [6 hours] | GIP [6 hours] | Ghrelin [6 hours] | Appetite [6 hours] | Gastrointestinal tolerability [24 hours]",null,null,null,null],["NCT06891287","An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers.",null,"RECRUITING","INTERVENTIONAL","PHASE1","RANDOMIZED","QUADRUPLE","60","Obesity","COMBINATION_PRODUCT:RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity; DRUG:PG-102; OTHER:Placebo","RANI Therapeutics","2025-12-30","2026-12-01","FALSE","To evaluate safety and tolerability of RT-114 by assessing treatment emergent adverse events (TEAEs) [Single dose and 8 weeks of repeat dosing]",null,null,"NO",null],["NCT07404150","Lifestyle Program Focused on Nourishment, Well-Being, and Health Behaviors in Women With Obesity",null,"ENROLLING_BY_INVITATION","OBSERVATIONAL",null,null,null,"60","Obesity and Cardiovascular Risk","OTHER:lifestyle change program","Heather Conradson","2026-01-12","2027-06-15","FALSE","Percent weight change and internalized weight bias (WBIS) [18 months]",null,null,"NO",null],["NCT03965130","The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA",null,"COMPLETED","INTERVENTIONAL","PHASE1","RANDOMIZED","NONE","10","Healthy Participants","BIOLOGICAL:Glucagon; OTHER:Control Study","Yale University","2019-06-05","2022-07-07","TRUE","Rates of Hepatic Mitochondrial Oxidation [5 hours]",null,"Study Protocol and Statistical Analysis Plan|https://cdn.clinicaltrials.gov/large-docs/30/NCT03965130/Prot_SAP_001.pdf; Informed Consent Form|https://cdn.clinicaltrials.gov/large-docs/30/NCT03965130/ICF_002.pdf","NO","OTHER_GRANT:MISP58340"],["NCT07860814","Ultrasound Biomarkers for Assessing Eligibility and Response to Resmetirom Therapy",null,"NOT_YET_RECRUITING","OBSERVATIONAL",null,null,null,"524","Metabolic Dysfunction-steatohepatitis (MASH)",null,"Radnet Management, Inc.","2026-10","2028-10","FALSE","Diagnostic performance of UDFF (ultrasound-derived fat fraction) [Enrollment Day 1 Baseline] | Diagnostic performance of Ultrasound pSWE (point shear wave elastography) [Enrollment Day 1 Baseline]",null,null,"NO",null],["NCT01972542","The Usefulness of Postprandial Triglyceride for Assessment of Cardiovascular Risk",null,"COMPLETED","INTERVENTIONAL",null,"NON_RANDOMIZED","NONE","80","Diabetes; Prediabetes","DIETARY_SUPPLEMENT:Oral fat tolerance test","Seoul National University Bundang Hospital","2013-06","2015-07","FALSE","Changes of Triglyceride [8 hours]",null,null,null,null],["NCT07313384","Dietary Insights and Nutrition Experiences in Adults on GLP-1 Therapy - A Study on Diet Quality Changes in Adults on GLP-1 Therapy","DINE-GLP1","ACTIVE_NOT_RECRUITING","OBSERVATIONAL",null,null,null,"50","Obesity Type 2 Diabetes Mellitus; Obesity (Disorder)","DRUG:GLP-1 Therapy","University of South Carolina","2026-02-11","2026-11-01","FALSE","Change in Healthy Eating Index [Baseline and 12-weeks]",null,null,"UNDECIDED",null],["NCT03249506","Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)",null,"COMPLETED","OBSERVATIONAL",null,null,null,"25358","Diabetes Mellitus, Type 2","DRUG:Canagliflozin; DRUG:Empagliflozin; DRUG:Dapagliflozin; DRUG:Dipeptidyl Peptidase-4 Inhibitor (DPP-4); DRUG:Glucagon-Like Peptide-1 Agonist (GLP-1); DRUG:Thiazolidinedione (TZD); DRUG:Sulfonylureas; DRUG:Insulin","Janssen Research & Development, LLC","2016-05-12","2017-11-01","FALSE","Incidence Rate of the Composite of All-cause Mortality (ACM) or Hospitalization for Heart Failure (HF) [approximately 3 years]",null,null,null,"OTHER:RRA-17640"],["NCT01762644","The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Omeprazole for Insulin Independence Among Recent Onset Type 1 Diabetes Patients","IIT","WITHDRAWN","INTERVENTIONAL","PHASE3","RANDOMIZED","NONE","0","Type 1 Diabetes","DRUG:Oral Cyclosporine and Oral Omeprazole; DRUG:Oral Omeprazole","Perle Bioscience, Inc.","2015-08","2016-05","FALSE","Insulin Independence and Hemoglobin A1c (A1C) < 6.5% [24 weeks]","BACKGROUND:12469360; BACKGROUND:3125434; BACKGROUND:2873396; BACKGROUND:24997559; BACKGROUND:12677149; BACKGROUND:23853103; BACKGROUND:16323002; BACKGROUND:24997558; BACKGROUND:22904177; BACKGROUND:1611143; BACKGROUND:20440520; BACKGROUND:2903105",null,null,"EUDRACT_NUMBER:2015-000105-39; NIH:2015"]]}